PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lin, DH; Tatham, MH; Yu, B; Kim, S; Hay, RT; Chen, Y				Lin, DH; Tatham, MH; Yu, B; Kim, S; Hay, RT; Chen, Y			Identification of a substrate recognition site on Ubc9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYMES; SUMO-1 MODIFICATION; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; ACTIVATING ENZYME; BINDING INTERFACE; PROTEIN SUMO-1; NUCLEAR-BODIES; YEAST SEPTINS	Human Ubc9 is homologous to ubiquitin-conjugating enzymes. However, instead of conjugating ubiquitin, it conjugates a ubiquitin homologue, small ubiquitin-like modifier 1 (SUMO-1), also known as UBL1, GMP1, SMTP3, PIC1, and sentrin. The SUMO-1 conjugation pathway is very similar to that of ubiquitin with regard to the primary sequences of the ubiquitin-activating enzymes (El), the three-dimensional structures of the ubiquitin-conjugating enzymes (E2), and the chemistry of the overall conjugation pathway. The interaction of substrates with Ubc9 has been studied using NMR spectroscopy. Peptides with sequences that correspond to those of the SUMO-1 conjugation sites from p53 and c-Jun both bind to a surface adjacent to the active site Cys(93) of human Ubc9, which has been previously shown to include residues that demonstrate the most significant dynamics on the microsecond to millisecond time scale. Mutations in this region, Q126A, Q130A, A131D, E132A, Y134A, and T135A, were constructed to evaluate the role of these residues in SUMO-1 conjugation. These alterations have significant effects on the conjugation of SUMO-1 with the target proteins p53, E1B, and promyelocytic leukemia protein and define a substrate binding site on Ubc9. Furthermore, the SUMO-1 conjugation site of p53 does not form any defined secondary structure when either free or bound to Ubc9. This suggests that a defined secondary structure at SUMO-1 conjugation sites in target proteins is not necessary for recognition and conjugation by the SUMO-1 pathway.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; Univ St Andrews, Inst Biomol Sci, St Andrews KY16 5ST, Fife, Scotland	City of Hope; Beckman Research Institute of City of Hope; University of St Andrews	Chen, Y (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.		Hay, Ronald/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Tatham, Michael/0000-0001-6986-1691	NIGMS NIH HHS [GM59887] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059887] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P32, DOI 10.1021/bi00052a006; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P1706, DOI 10.3891/acta.chem.scand.11-1706; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DOUGHERTY WG, 1989, VIROLOGY, V172, P145, DOI 10.1016/0042-6822(89)90116-5; Duprez E, 1999, J CELL SCI, V112, P381; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; Giraud MF, 1998, ACTA CRYSTALLOGR D, V54, P891, DOI 10.1107/S0907444998002480; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; HAAS AL, 1982, J BIOL CHEM, V257, P329; Hamilton KS, 2000, J BIOMOL NMR, V18, P319, DOI 10.1023/A:1026773008237; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Liu Q, 1999, BIOCHEMISTRY-US, V38, P1415, DOI 10.1021/bi981840h; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Michaelis L, 1913, BIOCHEM Z, V49, P333; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rost B, 2000, METH MOL B, V143, P71; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; WUTHRICH K, 1986, PROTEIN NMR SPECTROS	55	104	106	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21740	21748		10.1074/jbc.M108418200	http://dx.doi.org/10.1074/jbc.M108418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11877416	hybrid			2022-12-25	WOS:000176286000082
J	Mc Gee, MM; Campiani, G; Ramunno, A; Nacci, V; Lawler, M; Williams, DC; Zisterer, DM				Mc Gee, MM; Campiani, G; Ramunno, A; Nacci, V; Lawler, M; Williams, DC; Zisterer, DM			Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRROLO-1,5-BENZOXAZEPINES INDUCE APOPTOSIS; GERMINAL CENTER KINASE; BINDING PROTEINS RAC1; TRANSCRIPTION FACTOR; NH2-TERMINAL KINASE; GROWTH-FACTOR; BCR-ABL; CDC42; JNK/SAPK; PHOSPHORYLATION	The mitogen-activated protein (MAP) kinase family is activated in response to a wide variety of external stress signals such as UV irradiation, heat shock, and many chemotherapeutic drugs and leads to the induction of apoptosis. A novel series of pyrrolo-1,5-benzoxazepines have been shown to potently induce apoptosis in chronic myelogenous leukemia (CML) cells, which are resistant to many chemotherapeutic agents. In this study we have delineated part of the mechanism by which a representative compound known as PBOX-6 induces apoptosis. We have investigated whether PBOX-6 induces activation of MAP kinase signaling pathways in CML cells. Treatment of K562 cells with PBOX-6 resulted in the transient activation of two JNK isoforms, JNK1 and JNK2. In contrast, PBOX-6 did not activate the extracellular signal-regulated kinase (ERK) or p38. Apoptosis was found to occur independently of the small GTPases Ras, Rac, and Cdc42 but involved phosphorylation of the JNK substrates, c-Jun and ATF-2. Pretreatment of K562 cells with the JNK inhibitor, dicoumarol, abolished PBOX-6-induced phosphorylation of c-Jun and ATF-2 and inhibited the induced apoptosis, suggesting that JNK activation is an essential component of the apoptotic pathway induced by PBOX-6. Consistent with this finding, transfection of K562 cells with the JNK scaffold protein, JIP-1, inhibited JNK activity and apoptosis induced by PBOX-6. JIP-1 specifically scaffolds JNK, MKK7, and members of the mixed-lineage kinase (MLK) family, implicating these kinases upstream of JNK in the apoptotic pathway induced by PBOX-6 in K562 cells.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Univ Siena, Dipartimento Farmacochim Technol, I-53100 Siena, Italy; St James Hosp, Sir Patrick Dun Res Labs, Dept Haematol, Dublin 2, Ireland	Trinity College Dublin; University of Siena; Trinity College Dublin	Zisterer, DM (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.			Campiani, Giuseppe/0000-0001-5295-9529; Zisterer, Daniela/0000-0001-5005-1023				Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Chan-Hui PY, 1998, BIOCHEM J, V336, P599, DOI 10.1042/bj3360599; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; Davis W, 1999, BIOCHEM J, V338, P387, DOI 10.1042/0264-6021:3380387; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Faderl S, 1999, ANN INTERN MED, V131, P207, DOI 10.7326/0003-4819-131-3-199908030-00008; Fernandes RS, 1996, LEUKEMIA, V10, pS17; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Mc Gee MM, 2001, J PHARMACOL EXP THER, V296, P31; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Murasawa S, 2000, J BIOL CHEM, V275, P26856; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Puls A, 1999, J CELL SCI, V112, P2983; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zisterer DM, 1998, BIOCHEM PHARMACOL, V55, P397, DOI 10.1016/S0006-2952(97)00500-5; Zisterer DM, 2000, J PHARMACOL EXP THER, V293, P48	38	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18383	18389		10.1074/jbc.M112058200	http://dx.doi.org/10.1074/jbc.M112058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11856743	Green Submitted, hybrid			2022-12-25	WOS:000175975800018
J	Chen-Hwang, MC; Chen, HR; Elzinga, M; Hwang, YW				Chen-Hwang, MC; Chen, HR; Elzinga, M; Hwang, YW			Dynamin is a minibrain kinase/dual specificity Yak1-related kinase 1A substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; DOWN-SYNDROME; HUMAN HOMOLOG; DYRK PROTEIN; SH3 DOMAIN; FAMILY; GENE; BINDING; AMPHIPHYSIN; PHOSPHORYLATION	The minibrain kinase (Mnbk)/dual specificity Yak 1-related kinase 1A (Dyrk1A) gene is implicated in the mental retardation associated with Down's syndrome. It encodes a proline-directed serine/threonine kinase whose function has yet to be defined. We have used a solid-phase Mnbk/Dyrk1A kinase assay to aid in the search for the cellular Mnbk/Dyrk1A substrates. The assay revealed that rat brain contains two cytosolic proteins, one with a molecular mass of 100 kDa and one with a molecular mass of 140 kDa, that were prominently phosphorylated by Mnbk/Dyrk1A. The 100-kDa protein was purified and identified as dynamin 1. The conclusion was further supported by evidence that a recombinant glutathione S-transferase fusion protein containing dynamin isoform 1aa was phosphorylated by Mnbk/Dyrk1A. In addition to isoform 1aa, Mnbk/Dyrk1A also phosphorylated isoforms lab and 2aa but not human MxA protein when analyzed by the solid-phase kinase assay. Upon Mnbk/Dyrk1A phosphorylation, the interaction of dynamin 1 with the Src homology 3 domain of amphiphysin 1 was reduced. However, when Mnbk/Dyrk1A phosphorylation was allowed to proceed more extensively, the phosphorylation enhanced rather than reduced the binding of dynamin 1 to amphiphysin 1. The result suggests that Mnbk/Dyrk1A can play a dual role in regulating the interaction of dynamin 1 with amphiphysin 1. Mnbk/Dyrk1A phosphorylation also reduced the interaction of dynamin with endophilin 1, whereas the same phosphorylation enhanced the binding of dynamin 1 to Grb2. Nevertheless, the dual function of Mnbk/Dyrk1A phosphorylation was not observed for the interaction of dynamin 1 with endophilin 1 or Grb2. The interactions of dynamin with amphiphysin and endophilin are essential for the formation of endocytic complexes; our results suggest that Mnbk/Dyrk1A may function as a regulator controlling the assembly of endocytic apparatus.	New York State Inst Basic Res Dev Disabil, Dept Mol Biol, Staten Isl, NY 10314 USA; Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan; CUNY, CSI IBR Ctr Dev Neurosci, New York, NY 10016 USA; CUNY, Grad Program Biol, New York, NY 10016 USA	Institute for Basic Research in Developmental Disabilities; National Yang Ming Chiao Tung University; City University of New York (CUNY) System; Institute for Basic Research in Developmental Disabilities; City University of New York (CUNY) System	Hwang, YW (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Mol Biol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	hwang@postbox.csi.cuny.edu			NICHD NIH HHS [HD35870, HD38295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038295, R03HD035870] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; Bahler J, 2001, EMBO J, V20, P1064, DOI 10.1093/emboj/20.5.1064; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; Chen HM, 1997, HUM GENET, V99, P262, DOI 10.1007/s004390050350; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dubnau J, 2001, NATURE, V411, P476, DOI 10.1038/35078077; FERRELL JE, 1991, METHOD ENZYMOL, V200, P430; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Guimera J, 1997, CYTOGENET CELL GENET, V77, P182, DOI 10.1159/000134571; Guimera J, 1996, HUM MOL GENET, V5, P1305, DOI 10.1093/hmg/5.9.1305; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Hofmann TG, 2000, BIOCHIMIE, V82, P1123, DOI 10.1016/S0300-9084(00)01196-2; HORISBERGER MA, 1990, J VIROL, V64, P1171, DOI 10.1128/JVI.64.3.1171-1181.1990; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kola I, 1998, CURR OPIN GENET DEV, V8, P316, DOI 10.1016/S0959-437X(98)80088-9; Lee K, 2000, CANCER RES, V60, P3631; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; McGuire SE, 2001, SCIENCE, V293, P1330, DOI 10.1126/science.1062622; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Ohira M, 1997, GENOME RES, V7, P47, DOI 10.1101/gr.7.1.47; Rahmani Z, 1998, BIOCHEM BIOPH RES CO, V253, P514, DOI 10.1006/bbrc.1998.9803; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shang EY, 2000, MOL REPROD DEV, V55, P372, DOI 10.1002/(SICI)1098-2795(200004)55:4&lt;372::AID-MRD3&gt;3.0.CO;2-A; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Smith DJ, 1997, NAT GENET, V16, P28, DOI 10.1038/ng0597-28; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Song WJ, 1997, BIOCHEM BIOPH RES CO, V231, P640, DOI 10.1006/bbrc.1997.6154; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; SUNG YJ, 1995, BIOCHEMISTRY-US, V34, P3470, DOI 10.1021/bi00010a040; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takenawa T, 1998, CURR TOP MICROBIOL, V228, P325; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; VALTORTA F, 1986, ANAL BIOCHEM, V158, P130, DOI 10.1016/0003-2697(86)90600-7; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; YAMAMOTO R, 1995, HUM MOL GENET, V4, P265, DOI 10.1093/hmg/4.2.265; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200	66	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17597	17604		10.1074/jbc.M111101200	http://dx.doi.org/10.1074/jbc.M111101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877424	hybrid			2022-12-25	WOS:000175685100028
J	Panopoulou, E; Gillooly, DJ; Wrana, JL; Zerial, M; Stenmark, H; Murphy, C; Fotsis, T				Panopoulou, E; Gillooly, DJ; Wrana, JL; Zerial, M; Stenmark, H; Murphy, C; Fotsis, T			Early endosomal regulation of Smad-dependent signaling in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; COATED VESICLE FORMATION; TGF-BETA RECEPTORS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; FYVE-FINGER; PROTEIN-KINASE; RAB5; MEMBRANE; DYNAMIN	Transforming growth factor beta (TGFbeta) receptors require SARA for phosphorylation of the downstream transducing Smad proteins. SARA, a FYVE finger protein, binds to membrane lipids suggesting that activated receptors may interact with downstream signaling molecules at discrete endocytic locations. In the present study, we reveal a critical role for the early endocytic compartment in regulating Smad-dependent signaling. Not only is SARA localized on early endosomes, but also its minimal FYVE finger sequence is sufficient for early endosomal targeting. Expression of a SARA mutant protein lacking the FYVE finger inhibits downstream activin A signaling in endothelial cells. Moreover, a dominant-negative mutant of Rab5, a crucial protein for early endosome dynamics, causes phosphorylation and nuclear translocation of Smads leading to constitutive (i.e. ligand independent) transcriptional activation of a Smad-dependent promoter in endothelial cells. As inhibition of endocytosis using the K44A negative mutant of dynamin and RN-tre did not lead to activation of Smad-dependent transcription, the effects of the dominant-negative Rab5 are likely to be a consequence of altered membrane trafficking of constitutively formed TGFbeta/activin type I/II receptor complexes at the level of early endosomes. The results suggest an important interconnection between early endosomal dynamics and TGFbeta/activin signal transduction pathways.	Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece; Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Biomed Res Inst, Ioannina 45110, Greece	University of Ioannina; University of Oslo; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Max Planck Society; Foundation for Research & Technology - Hellas (FORTH)	Fotsis, T (corresponding author), Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece.		Murphy, Carol/ABE-4282-2021; Stenmark, Harald/B-8868-2008; Wrana, Jeffrey/F-8857-2013	Murphy, Carol/0000-0003-1353-8558; 				Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Breit S, 2000, CANCER RES, V60, P4596; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Leof EB, 2000, TRENDS CELL BIOL, V10, P343, DOI 10.1016/S0962-8924(00)01795-5; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; Peacock AJ, 1999, THORAX, V54, P1107, DOI 10.1136/thx.54.12.1107; Raiborg C, 2001, J CELL SCI, V114, P2255; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stenmark H, 1999, J CELL SCI, V112, P4175; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; Tamaru M, 1999, J BIOL CHEM, V274, P3753, DOI 10.1074/jbc.274.6.3753; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zwaagstra JC, 2001, J BIOL CHEM, V276, P27237, DOI 10.1074/jbc.M100033200	45	115	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18046	18052		10.1074/jbc.M107983200	http://dx.doi.org/10.1074/jbc.M107983200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877415	hybrid			2022-12-25	WOS:000175685100083
J	Reckenfelderbaumer, N; Krauth-Siegel, RL				Reckenfelderbaumer, N; Krauth-Siegel, RL			Catalytic properties, thiol pK value, and redox potential of Trypanosoma brucei tryparedoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; ACTIVE-SITE; DIFFERENTIAL REACTIVITY; CRITHIDIA-FASCICULATA; DEPENDENT SYNTHESIS; CYSTEINE RESIDUES; TRYPANOTHIONE; GLUTATHIONE; PROTEIN; REDUCTASE	The dithiol protein tryparedoxin is a component of the unique trypanothione/trypanothione reductase metabolism of trypanosomatids and is involved in the parasite synthesis of deoxyribonucleotides and the detoxication of hydroperoxides. Tryparedoxin is a highly abundant protein in all life stages of Trypanosoma brucei, the causative agent of African sleeping sickness. As shown here, its functional properties are intermediate between those of classical thioredoxins and glutaredoxins. The redox potential of T. brucei tryparedoxin of -249 mV was determined by protein-protein redox equilibration with Escherichia coli thioredoxin. The trypanothione/tryparedoxin couple is probably the most significant factor determining the cytosolic redox potential of the parasites. The pK value of Cys(40), the first thiol in the WCPPC motif, is 7.2 as derived from the thiolate absorption at 240 nm and the rate of carboxymethylation. Alteration of the active site into that of thioredoxin (CGPC) did not affect the pK value. In contrast, in the mutant with the glutaredoxin motif (CPYC) the pK dropped to less than or equal to4.0. The fact that the pK value of tryparedoxin coincides with the intracellular pH of the parasite may contribute to the reactivity of tryparedoxin in thiol disulfide exchange reactions.	Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Krauth-Siegel, RL (corresponding author), Heidelberg Univ, Biochem Zentrum Heidelberg, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	krauth-siegel@urz.uni-heidelberg.de						Alphey MS, 1999, J BIOL CHEM, V274, P25613, DOI 10.1074/jbc.274.36.25613; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Braun H, 1996, EUR J BIOCHEM, V240, P781, DOI 10.1111/j.1432-1033.1996.0781h.x; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; Debarbieux L, 1998, P NATL ACAD SCI USA, V95, P10751, DOI 10.1073/pnas.95.18.10751; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; FraserLhostis C, 1997, BIOL CHEM, V378, P1039, DOI 10.1515/bchm.1997.378.9.1039; GAN ZR, 1990, ARCH BIOCHEM BIOPHYS, V282, P110, DOI 10.1016/0003-9861(90)90093-E; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Hofmann B, 2001, BIOL CHEM, V382, P459, DOI 10.1515/BC.2001.056; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Ivens AC, 1998, GENOME RES, V8, P135, DOI 10.1101/gr.8.2.135; JENG MF, 1995, BIOCHEMISTRY-US, V34, P10101, DOI 10.1021/bi00032a001; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Keese MA, 1999, FEBS LETT, V447, P135, DOI 10.1016/S0014-5793(99)00296-3; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Krauth-Siegel RL, 1999, PARASITOL TODAY, V15, P404, DOI 10.1016/S0169-4758(99)01516-1; KrauthSiegel RL, 1996, MOL BIOCHEM PARASIT, V80, P203, DOI 10.1016/0166-6851(96)02689-8; Lopez JA, 2000, FREE RADICAL BIO MED, V28, P767, DOI 10.1016/S0891-5849(00)00159-3; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; Mossner E, 1998, PROTEIN SCI, V7, P1233; MOUTIEZ M, 1994, CHEM PHARM BULL, V42, P2641; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Reckenfelderbaumer N, 2000, J BIOL CHEM, V275, P7547, DOI 10.1074/jbc.275.11.7547; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; SNYDER GH, 1987, BIOCHEMISTRY-US, V26, P688, DOI 10.1021/bi00377a005; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; Washburn MP, 1999, BIOCHEMISTRY-US, V38, P268, DOI 10.1021/bi980480v; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1	39	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17548	17555		10.1074/jbc.M112115200	http://dx.doi.org/10.1074/jbc.M112115200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11867629	hybrid			2022-12-25	WOS:000175685100022
J	Andreucci, JJ; Grant, D; Cox, DM; Tome, LK; Prywes, R; Goldhamer, DJ; Rodrigues, N; Bedard, PA; McDermott, JC				Andreucci, JJ; Grant, D; Cox, DM; Tome, LK; Prywes, R; Goldhamer, DJ; Rodrigues, N; Bedard, PA; McDermott, JC			Composition and function of AP-1 transcription complexes during muscle cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN ACTIVATION DOMAIN; C-JUN; MYOGENIC DIFFERENTIATION; PROTEIN-KINASE; TERMINAL DIFFERENTIATION; INHIBITS MYOGENESIS; POSITIVE REGULATION; GENE-EXPRESSION; FOS; MYOBLASTS	The role of activating protein-1 (AP-1) in muscle cells is currently equivocal. While some studies propose that AP-1 is inhibitory for myogenesis, others implicate a positive role in this process. We tested whether this variation may be due to different properties of the AP-1 subunit composition in differentiating cells. Using Western analysis we show that c-Jun, Fra-2, and JunD are expressed throughout the time course of differentiation. Phosphatase assays indicate that JunD and Fra-2 are phosphorylated in muscle cells and that at least two isoforms of each are expressed in muscle cells. Electrophoretic mobility shift assays combined with antibody supershifts indicate the appearance of Fra-2 as a major component of the AP-1 DNA binding complex in differentiating cells. In this context it appears that Fra-2 heterodimerizes with c-Jun and JunD. Studying the c-jun enhancer in reporter gene assays we observed that the muscle transcription factors MEF2A and MyoD can contribute to robust transcriptional activation of the c-jun enhancer. In differentiating muscle cells mutation of the MEF2 site reduces transactivation of the c-jun enhancer and MEF2A is the predominant MEF2 isoform binding to this cis element. Transcriptional activation of an AP-1 site containing reporter gene (TRE-Luc) is enhanced under differentiation conditions compared with growth conditions in C2C12 muscle cells. Further studies indicate that Fra-2 containing A-P-1 complexes can transactivate the MyoD enhancer/promoter. Thus, an A-P-1 complex containing Fra-2 and c-Jun or JunD is consistent with muscle differentiation, indicating that AP-1 function during myogenesis is dependent on its subunit composition.	York Univ, Dept Biol, N York, ON M3J 1P3, Canada; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	York University - Canada; Columbia University; University of Pennsylvania	McDermott, JC (corresponding author), York Univ, Dept Biol, 327 Farquharson LSB,4700 Keele St, N York, ON M3J 1P3, Canada.							ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aurade F, 1997, J CELL SCI, V110, P2771; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Dorman CM, 2000, J BIOL CHEM, V275, P27481; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GROSSI M, 1991, ONCOGENE, V6, P1767; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Kucharczuk KL, 1999, DEVELOPMENT, V126, P1957; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MURUKAMI M, 1997, ONCOGENE, V14, P2435; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Ornatsky OI, 1997, J BIOL CHEM, V272, P33271, DOI 10.1074/jbc.272.52.33271; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCUH AC, 1992, ONCOGENE, V7, P667; Sharma SC, 2000, J BIOL CHEM, V275, P33718, DOI 10.1074/jbc.M003555200; SU HY, 1991, ONCOGENE, V6, P1759; Thepot D, 2000, DEVELOPMENT, V127, P143; THINAKARAN G, 1993, BIOCHEM CELL BIOL, V71, P260, DOI 10.1139/o93-040; THINAKARAN G, 1993, FEBS LETT, V319, P271, DOI 10.1016/0014-5793(93)80561-8	41	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16426	16432		10.1074/jbc.M110891200	http://dx.doi.org/10.1074/jbc.M110891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877423	hybrid			2022-12-25	WOS:000175564500013
J	Cipriano, DJ; Bi, YM; Dunn, SD				Cipriano, DJ; Bi, YM; Dunn, SD			Genetic fusions of globular proteins to the epsilon subunit of the Escherichia coli ATP synthase - Implications for in vivo rotational catalysis and epsilon subunit function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; ROTARY MOTOR; CONFORMATIONAL-CHANGES; MONOCLONAL-ANTIBODIES; BETA-SUBUNITS; CROSS-LINKING; F-ATPASE; F1-ATPASE; COMPLEX; NUCLEOTIDE	The rotational mechanism of ATP synthase was investigated by fusing three proteins from Escherichia coli, the 12-kDa soluble cytochrome b(562), the 20-kDa flavodoxin, and the 28-kDa flavodoxin reductase, to the C terminus of the epsilon subunit of the enzyme. According to the concept of rotational catalysis, because epsilon is part of the rotor a large domain added at this site should sterically clash with the second stalk, blocking rotation and fully inhibiting the enzyme. E. coli cells expressing the cytochrome b(562) fusion in place of wild-type epsilon grew using acetate as the energy source, indicating their capacity for oxidative phosphorylation. Cells expressing the larger flavodoxin or flavodoxin reductase fusions failed to grow on acetate. Immunoblot analysis showed that the fusion proteins were stable in the cells and that they had no effect on enzyme assembly. These results provide initial evidence supporting rotational catalysis in vivo. In membrane vesicles, the cytochrome b(562) fusion caused an increase in the apparent ATPase activity but a minor decrease in proton pumping. Vesicles bearing ATP synthase containing the larger fusion proteins showed reduced but significant levels of ATPase activity that was sensitive to inhibition by dicyclohexylcarbodiimide (DCCD) but no proton pumping. Thus, all fusions to epsilon generated an uncoupled component of ATPase activity. These results imply that a function of the C terminus of epsilon in F1F0 is to increase the efficiency of the enzyme by specifically preventing the uncoupled hydrolysis of ATP. Given the sensitivity to DCCD, this uncoupled ATP hydrolysis may arise from rotational steps of gammaepsilon in the inappropriate direction after ATP is bound at the catalytic site. It is proposed that the C-terminal domain of epsilon functions to ensure that rotation occurs only in the direction of ATP synthesis when ADP is bound and only in the direction of hydrolysis when ATP is bound.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Dunn, SD (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	sdunn@uwo.ca	Dunn, Stanley/D-3418-2013					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1992, ARCH BIOCHEM BIOPHYS, V296, P685, DOI 10.1016/0003-9861(92)90627-9; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1985, J BIOL CHEM, V260, P418; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; Gardner JL, 1999, ARCH BIOCHEM BIOPHYS, V361, P302, DOI 10.1006/abbi.1998.0995; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Hara KY, 2001, J BIOL CHEM, V276, P23969, DOI 10.1074/jbc.M009303200; Hasler K, 1998, FEBS LETT, V426, P301, DOI 10.1016/S0014-5793(98)00358-5; Hausrath AC, 2001, J BIOL CHEM, V276, P47227, DOI 10.1074/jbc.M107536200; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; Hoover DM, 1997, PROTEIN SCI, V6, P2525; Ingelman M, 1997, J MOL BIOL, V268, P147, DOI 10.1006/jmbi.1997.0957; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUKI M, 1988, J BIOL CHEM, V263, P17437; Kuo PH, 1998, FEBS LETT, V426, P217, DOI 10.1016/S0014-5793(98)00337-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHEWS FS, 1979, J BIOL CHEM, V254, P1699; McCarty RE, 2000, ANNU REV PLANT PHYS, V51, P83, DOI 10.1146/annurev.arplant.51.1.83; McLachlin DT, 2000, BIOCHEMISTRY-US, V39, P3486, DOI 10.1021/bi992586b; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; PETERSON PL, 2000, J BIOENERG BIOMEMBR, V32, P4; PRIVE GG, 1994, ACTA CRYSTALLOGR D, V50, P375, DOI 10.1107/S0907444993014301; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Sambrook J., MOL CLONING LAB MANU; Schulenberg B, 1999, J BIOL CHEM, V274, P28351, DOI 10.1074/jbc.274.40.28351; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P279, DOI 10.1006/abbi.1993.1211; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WALKER JE, 2000, BIOCHIM BIOPHYS ACTA, V1458, P2; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	59	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16782	16790		10.1074/jbc.M201349200	http://dx.doi.org/10.1074/jbc.M201349200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875079	hybrid			2022-12-25	WOS:000175564500059
J	Coskun, U; Gruber, G; Koch, MHJ; Godovac-Zimmermann, J; Lemker, T; Muller, V				Coskun, U; Gruber, G; Koch, MHJ; Godovac-Zimmermann, J; Lemker, T; Muller, V			Cross-talk in the A(1)-ATPase from Methanosarcina mazei Go1 due to nucleotide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ATP SYNTHASE; F1 ADENOSINE-TRIPHOSPHATASE; SCATTERING-DATA TREATMENT; MANDUCA-SEXTA MIDGUT; ESCHERICHIA-COLI; ELECTRON-MICROSCOPY; GAMMA-SUBUNIT; MOLECULAR ARCHITECTURE; SYNCHROTRON RADIATION; MASS-SPECTROMETRY	Changes in the A(3)B(3)CDF-complex of the Methanosarcina mazei Gol A(1)-ATPase in response to ligand binding have been studied by small-angle x-ray scattering, protease digestion, fluorescence spectroscopy, matrix-assisted laser desorption ionization time-of-flight mass spectrometry, and CuCl2-induced disulfide formation. The value of the radius of gyration, R-g, increases slightly when MgATP, MgADP, or MgADP + P-i (but not MgAMP-PNP) is present. The nucleotide-binding subunits A and B were reacted with N-4[4- [7-(dimethylamino)-4-methyl]coumarin-3-yl]maleimide, and spectral shifts and changes in fluorescence intensity were detected upon addition of MgAMP-PNP, MgATP, MgADP + P-i, or MgADP. Trypsin treatment of A(1) resulted in cleavage of the stalk subunits C and F, which was rapid in the presence of MgAMP-PNP but slow when MgATP or MgADP were added to the enzyme. When A(1) was supplemented with CuCl2 a clear nucleotide dependence of an A-A-D cross-linking product was generated in the presence of MgADP and MgATP but not when MgAMP-PNP or MgADP + P-i was added. The site of cross-link formation was located in the region of the N and C termini of subunit D. The data suggest that the stalk subunits C, D, and F in A(1) undergo conformational changes during ATP hydrolysis.	Univ Saarland, Fachrichtung Biophys 2 5, D-66421 Homburg, Germany; DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; UCL, Ctr Mol Med, London WC1E 6JJ, England; Univ Munich, Lehrstuhl Mikrobiol, D-80638 Munich, Germany	Saarland University; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of London; University College London; University of Munich	Gruber, G (corresponding author), Univ Saarland, Fachrichtung Biophys 2 5, Univ Bau 76, D-66421 Homburg, Germany.	ggrueber@med-rz.uni-saarland.de	Coskun, Ünal/F-4683-2011; Zimmermann, Jasminka Godovac/E-6863-2010; Mueller, Volker/ABE-4305-2021	Coskun, Ünal/0000-0003-4375-3144; Mueller, Volker/0000-0001-7955-5508				AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Bottcher B, 2000, J MOL BIOL, V296, P449, DOI 10.1006/jmbi.1999.3435; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GOGARTEN JP, 1995, TRENDS ECOL EVOL, V10, P147, DOI 10.1016/S0169-5347(00)89024-2; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; Gruber G, 2001, J EXP BIOL, V204, P2597; Gruber G, 2001, BIOCHEMISTRY-US, V40, P1890, DOI 10.1021/bi002195t; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; Gruber G, 1997, FEBS LETT, V410, P165, DOI 10.1016/S0014-5793(97)00528-0; Gruber G, 2000, J BIOENERG BIOMEMBR, V32, P341, DOI 10.1023/A:1005519801891; Hausrath AC, 2001, J BIOL CHEM, V276, P47227, DOI 10.1074/jbc.M107536200; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Hilario E, 1998, J MOL EVOL, V46, P703, DOI 10.1007/PL00006351; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemker T, 2001, EUR J BIOCHEM, V268, P3744, DOI 10.1046/j.1432-1327.2001.02284.x; LERCH K, 1982, J BIOL CHEM, V257, P6414; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBBEN M, 1988, BIOL CHEM H-S, V369, P1259, DOI 10.1515/bchm3.1988.369.2.1259; Marin I, 2001, J MOL EVOL, V52, P17, DOI 10.1007/s002390010130; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Muller V, 1999, J BIOENERG BIOMEMBR, V31, P15, DOI 10.1023/A:1005451311009; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Perzov N, 2001, FEBS LETT, V504, P223, DOI 10.1016/S0014-5793(01)02709-0; Radermacher M, 1999, FEBS LETT, V453, P383, DOI 10.1016/S0014-5793(99)00739-5; Radermacher M, 2001, J STRUCT BIOL, V135, P26, DOI 10.1006/jsbi.2001.4395; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Roos M, 1998, J BIOL CHEM, V273, P924, DOI 10.1074/jbc.273.2.924; Schafer G, 1999, MICROBIOL MOL BIOL R, V63, P570; SCHAFER G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P232, DOI 10.1016/0005-2728(92)90233-R; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; SVOBODA M, 1995, J MASS SPECTROM, V30, P1562, DOI 10.1002/jms.1190301107; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilms R, 1996, J BIOL CHEM, V271, P18843, DOI 10.1074/jbc.271.31.18843; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	49	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17327	17333		10.1074/jbc.M110407200	http://dx.doi.org/10.1074/jbc.M110407200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11854274	hybrid			2022-12-25	WOS:000175564500129
J	Kongsvik, TL; Honing, S; Bakke, O; Rodionov, DG				Kongsvik, TL; Honing, S; Bakke, O; Rodionov, DG			Mechanism of interaction between leucine-based sorting signals from the invariant chain and clathrin-associated adaptor protein complexes AP1 and AP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; POLARIZED EPITHELIAL-CELLS; SURFACE-PLASMON RESONANCE; CYTOPLASMIC TAIL; MDCK CELLS; STRUCTURAL REQUIREMENTS; IN-VITRO; RAPID INTERNALIZATION; SELECTIVE BINDING; VESICLE FORMATION	The cytoplasmic tail of the invariant chain contains two leucine-based sorting signals, and each of those seems sufficient to route the invariant chain to its intracellular destination in either normal or polarized cells. It is believed that the intracellular routing of the invariant chain is mediated by its interactions with the clathrin-associated adaptor protein complexes AP1 and AP2. We (1) have previously demonstrated the in vitro interactions between the cytoplasmic tail of the invariant chain and AP1/AP2 complexes. These interactions were specific and depended on the critical leucine residues in the invariant chain's sorting signals. In the present study, we decided to investigate the molecular mechanism of these interactions. To this end, we constructed a set of glutathione S-transferase fusion proteins that contained the intact cytoplasmic tail of the invariant chain and its various mutants to define residues important for its interactions with AP1 and AP-2. Our results demonstrated the importance of several residues other than the critical leucine residues for such interactions. A strong correlation between in vitro binding of AP2 to the invariant chain and in vivo internalization of the invariant chain was observed, confirming the primary role of AP2 in recognition of endocytic signals. In addition, we demonstrated different requirements for AP1 and AP2 binding to cytoplasmic tail of the invariant chain, which may reflect that the different sorting pathways mediated by A-P1 and AP2 involve their recognition of the primary structure of the sorting signal.	Univ Oslo, Dept Biol, Div Mol Cell Biol, N-0316 Oslo, Norway; Univ Gottingen, Inst Biochem 2, D-37073 Gottingen, Germany	University of Oslo; University of Gottingen	Bakke, O (corresponding author), Univ Oslo, Dept Biol, Div Mol Cell Biol, POB 1050 Blindern, N-0316 Oslo, Norway.			Bakke, Oddmund/0000-0003-4843-7626				Bakke O, 1999, IMMUNOL REV, V172, P171, DOI 10.1111/j.1600-065X.1999.tb01365.x; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; Boehm M, 2001, EMBO J, V20, P6265, DOI 10.1093/emboj/20.22.6265; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; BREMNES B, 1994, J CELL SCI, V107, P2021; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; FINGERHUT A, 2000, J BIOL CHEM, V275; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Germain RN, 1996, IMMUNOL REV, V151, P5, DOI 10.1111/j.1600-065X.1996.tb00701.x; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kang S, 1998, J BIOL CHEM, V273, P20644, DOI 10.1074/jbc.273.32.20644; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; Odorizzi G, 1997, J BIOL CHEM, V272, P11757, DOI 10.1074/jbc.272.18.11757; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Shi GY, 1998, J CELL BIOL, V143, P947, DOI 10.1083/jcb.143.4.947; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; Simonsen A, 1997, J CELL SCI, V110, P597; Simonsen A, 1998, EUR J CELL BIOL, V76, P25, DOI 10.1016/S0171-9335(98)80014-9; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835	47	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16484	16488		10.1074/jbc.M201583200	http://dx.doi.org/10.1074/jbc.M201583200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11854303	hybrid			2022-12-25	WOS:000175564500021
J	Leung-Pineda, V; Kilberg, MS				Leung-Pineda, V; Kilberg, MS			Role of Sp1 and Sp3 in the nutrient-regulated expression of the human asparagine synthetase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; AMINO-ACID REGULATION; HUMAN LEUKEMIA-CELLS; ENDOPLASMIC-RETICULUM; TRANSCRIPTIONAL REGULATION; SP-FAMILY; GC BOX; ACTIVATION; ELEMENT; AVAILABILITY	The human asparagine synthetase (AS) gene responds to depletion of mammalian cells for either amino acids or carbohydrates. Five specific cis-elements have been implicated: three GC boxes (GC-I, GC-II and GC-III) and two nutrient-sensing response elements (NSRE-1, -2). This study shows that all three GC boxes are required to maintain basal transcription and to obtain maximal induction of the AS gene by amino acid limitation. However, there is not complete redundancy among the three GC boxes, and there is a hierarchy of importance with regard to transcription (GC-III > GC-H > GC-I). In vitro, two GC boxes formed protein-DNA complexes (GC-II and GC-III) with Sp1 and Sp3. Although transcription of the AS gene is elevated by nutrient limitation, the absolute amount of these protein-DNA complexes and the total pools of Sp1 and Sp3 did not increase. A small, but detectable portion of Sp1 was modified by phosphorylation following amino acid deprivation. In vivo, expression of Sp1 and Sp3 in Drosophila SL2 cells increased AS promoter activity. Sp1 expression increased basal transcription but did not cause a further increase when SL2 cells were amino acid-deprived. Sp3 expression enhanced both the basal and the starvation-induced transcription.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.	mkilberg@ufl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Aslanian AM, 2001, BIOCHEM J, V358, P59, DOI 10.1042/0264-6021:3580059; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hutson RG, 1997, AM J PHYSIOL-CELL PH, V272, pC1691, DOI 10.1152/ajpcell.1997.272.5.C1691; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Richards NGJ, 1998, ADV ENZYMOL RAMB, V72, P145; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Whetstine JR, 2001, J BIOL CHEM, V276, P6350, DOI 10.1074/jbc.M008074200	27	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16585	16591		10.1074/jbc.M110972200	http://dx.doi.org/10.1074/jbc.M110972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867623	hybrid			2022-12-25	WOS:000175564500034
J	Maeda, M; Hamada, D; Hoshino, M; Onda, Y; Hase, T; Goto, Y				Maeda, M; Hamada, D; Hoshino, M; Onda, Y; Hase, T; Goto, Y			Partially folded structure of flavin adenine dinucleotide-depleted ferredoxin-NADP(+) reductase with residual NADP(+) binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN-GLOBULE STATE; X-RAY-SCATTERING; INTERMEDIATE STATES; FOLDING UNITS; PROTEIN; APOMYOGLOBIN; MECHANISM; IDENTIFICATION; OXIDOREDUCTASE; FLAVOPROTEINS	Maize ferredoxin-NADP(+) reductase (FNR) consists of flavin adenine dinucleotide (FAD) and NADP(+) binding domains with a FAD molecule bound noncovalently in the cleft between these domains. The structural changes of FNR induced by dissociation of FAD have been characterized by a combination of optical and biochemical methods. The CD spectrum of the FAD-depleted FNR (apo-FNR) suggested that removal of FAD from holo-FNR produced an intermediate conformational state with partially disrupted secondary and tertiary structures. Small angle x-ray scattering indicated that apo-FNR assumes a conformation that is less globular in comparison with holo-FNR but is not completely chain-like. Interestingly, the replacement of tyrosine 95 responsible for FAD binding with alanine resulted in a molecular form similar to apo-protein of the wild-type enzyme. Both apo- and Y95A-FNR species bound to Cibacron Blue affinity resin, indicating the presence of a native-like conformation for the NADP(+) binding domain. On the other hand, no evidence was found for the existence of folded conformations in the FAD binding domains of these proteins. These results suggested that FAD-depleted FNR assumes a partially folded structure with a residual NADP(+) binding domain but a disordered FAD binding domain.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Osaka University	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Hase, Toshiharu/H-9271-2013; Hamada, Daizo/F-3307-2011; Hamada, Daizo/N-1118-2016	Hamada, Daizo/0000-0002-1799-5476				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Arai M, 2000, ADV PROTEIN CHEM, V53, P209; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; Baker D, 2000, NATURE, V405, P39, DOI 10.1038/35011000; Chamberlain AK, 1996, NAT STRUCT BIOL, V3, P782, DOI 10.1038/nsb0996-782; DOBSON CM, 1994, CURR BIOL, V4, P636, DOI 10.1016/S0960-9822(00)00141-X; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; Ferguson N, 1999, J MOL BIOL, V286, P1597, DOI 10.1006/jmbi.1998.2548; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; FERSHT AR, 2000, STRUCTURE MECH PROTE, P543; FINK AL, 1995, ANNU REV BIOPH BIOM, V24, P495, DOI 10.1146/annurev.bb.24.060195.002431; Fischer KF, 2000, J MOL BIOL, V302, P701, DOI 10.1006/jmbi.2000.4049; FORTI G, 1966, BROOKHAVEN SYM BIOL, P195; Genzor CG, 1996, PROTEIN SCI, V5, P1376, DOI 10.1002/pro.5560050716; Glatter O., 1982, SMALL ANGLE X RAY SC; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; HAMADA D, 1993, BIOCHEMISTRY-US, V32, P10351, DOI 10.1021/bi00090a010; HASE T, 1991, PLANT PHYSIOL, V97, P1395, DOI 10.1104/pp.97.4.1395; Hopfner KP, 1998, P NATL ACAD SCI USA, V95, P9813, DOI 10.1073/pnas.95.17.9813; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Kataoka M, 1996, FOLD DES, V1, pR107, DOI 10.1016/S1359-0278(96)00047-8; KATAOKA M, 1995, J MOL BIOL, V249, P215, DOI 10.1006/jmbi.1995.0290; Kojima M, 2000, BIOCHEMISTRY-US, V39, P1364, DOI 10.1021/bi991584o; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; Matsumura T, 1997, PLANT PHYSIOL, V114, P653, DOI 10.1104/pp.114.2.653; Mayr EM, 1997, J MOL BIOL, V269, P260, DOI 10.1006/jmbi.1997.1033; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; Onda Y, 2000, PLANT PHYSIOL, V123, P1037, DOI 10.1104/pp.123.3.1037; Pace C N, 1986, Methods Enzymol, V131, P266; Peng ZY, 2000, ADV PROTEIN CHEM, V53, P1; Phillip S, 1998, EUR J BIOCHEM, V251, P854, DOI 10.1046/j.1432-1327.1998.2510854.x; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; Privalov PL, 1996, J MOL BIOL, V258, P707, DOI 10.1006/jmbi.1996.0280; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; SREERAMA N, 1994, BIOCHEMISTRY-US, V33, P10022, DOI 10.1021/bi00199a028; Steensma E, 1998, J MOL BIOL, V282, P653, DOI 10.1006/jmbi.1998.2045; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; Vallon O, 2000, PROTEINS, V38, P95, DOI 10.1002/(SICI)1097-0134(20000101)38:1<95::AID-PROT10>3.0.CO;2-A; ZANETTI G, 1982, EUR J BIOCHEM, V126, P453, DOI 10.1111/j.1432-1033.1982.tb06801.x; Zitzewitz JA, 1999, BIOCHEMISTRY-US, V38, P10205, DOI 10.1021/bi9909041	46	16	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17101	17107		10.1074/jbc.M112002200	http://dx.doi.org/10.1074/jbc.M112002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872744	hybrid, Green Published			2022-12-25	WOS:000175564500101
J	Chern, MK; Chang, KN; Liu, LF; Tam, TCS; Liu, YC; Liang, YL; Tam, MF				Chern, MK; Chang, KN; Liu, LF; Tam, TCS; Liu, YC; Liang, YL; Tam, MF			Yeast ribosomal protein L12 is a substrate of protein-arginine methyltransferase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; N-METHYLTRANSFERASE; METHYLATION; IDENTIFICATION; BINDING; PRMT1; RNA; OLIGOMERIZATION; INTERACTS; RECEPTOR	Type III protein-arginine methyltransferase from the yeast Saccharomyces cerevisiae (RMT2) was expressed in Escherichia coli and purified to apparent homogeneity. The cytosolic, ribosomal, and ribosome salt wash fractions from yeast cells lacking RMT2 were used as substrates for the recombinant RMT2. Using S-adenosyl-L-methionine as co-substrate, RMT2 methylated a protein in the ribosome salt wash fraction. The same protein in the ribosomal fraction was also methylated by RMT2 after pretreating the sample with endonuclease. Amino acid analysis affirmed that the labeling products were delta-N-monomethylarginines. The methylated protein from the ribosomal or the ribosome salt wash fraction was isolated by two-dimensional gel electrophoresis and identified as ribosomal protein L12 by mass spectrometry. Using synthetic peptides, recombinant L12, and its mutant as substrates, we pinpointed Arg(67) on ribosomal protein L12 as the methyl acceptor. L12 was isolated from wild type yeast cells that have been grown in the presence of S-adenosyl-L-[methyl-H-3]methionine and subjected to amino acid analysis. The results indicate that L12 contains delta-N-monomethylarginines.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Tam, MF (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	mbr405@ccvax.sinica.edu.tw	Liang, Yi-Ling/F-8770-2012	Liang, Yi-Ling/0000-0001-9173-0145				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; ELBARADI TTAL, 1984, EUR J BIOCHEM, V144, P393, DOI 10.1111/j.1432-1033.1984.tb08477.x; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Henry MF, 1996, MOL CELL BIOL, V16, P3668; HILL WE, 1969, J MOL BIOL, V44, P89, DOI 10.1016/0022-2836(69)90406-9; Hwang DDW, 1999, BIOCHEM J, V338, P335, DOI 10.1042/0264-6021:3380335; JUANVIDALES F, 1983, EUR J BIOCHEM, V136, P275, DOI 10.1111/j.1432-1033.1983.tb07738.x; Klein S, 2000, J BIOL CHEM, V275, P3150, DOI 10.1074/jbc.275.5.3150; KRUISWIJK T, 1978, BIOCHEM J, V175, P221, DOI 10.1042/bj1750221; Kzhyshkowska J, 2001, BIOCHEM J, V358, P305, DOI 10.1042/0264-6021:3580305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; Lee JH, 2000, BIOCHEM BIOPH RES CO, V274, P105, DOI 10.1006/bbrc.2000.3049; LHOEST J, 1984, EUR J BIOCHEM, V141, P585, DOI 10.1111/j.1432-1033.1984.tb08233.x; Li G, 1997, ELECTROPHORESIS, V18, P391, DOI 10.1002/elps.1150180313; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LIU LF, 1993, BIOCHEM J, V296, P189, DOI 10.1042/bj2960189; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; PUCCIARELLI MG, 1990, NUCLEIC ACIDS RES, V18, P4409, DOI 10.1093/nar/18.15.4409; RAUE HA, 1991, METHOD ENZYMOL, V194, P453; Rho J, 2001, J BIOL CHEM, V276, P11393, DOI 10.1074/jbc.M008660200; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; THOMPSON J, 1979, EUR J BIOCHEM, V98, P261, DOI 10.1111/j.1432-1033.1979.tb13184.x; VIDALES FJ, 1981, BIOCHEM BIOPH RES CO, V98, P717; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; YEH HI, 1995, BIOCHEM J, V308, P69, DOI 10.1042/bj3080069; Zobel-Thropp P, 1998, J BIOL CHEM, V273, P29283, DOI 10.1074/jbc.273.45.29283	41	44	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15345	15353		10.1074/jbc.M111379200	http://dx.doi.org/10.1074/jbc.M111379200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856739	hybrid			2022-12-25	WOS:000175510400018
J	Guhan, N; Muniyappa, K				Guhan, N; Muniyappa, K			Mycobacterium tuberculosis RecA intein possesses a novel ATP-dependent site-specific double-stranded DNA endonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODED HOMING ENDONUCLEASE; CRYSTAL-STRUCTURE; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; ESCHERICHIA-COLI; RIBOSOMAL-RNA; PI-PFUI; I-CREI; PROTEIN; CLEAVAGE	Mycobacterium tuberculosis recA harbors an intervening sequence in its open reading frame, presumed to encode an endonuclease (PI-MtuI) required for intein homing in inteinless recA allele. Although the protein-splicing ability of PI-MtuI has been characterized, the identification of its putative endonuclease activity has remained elusive. To investigate whether PI-MtuI possesses endonuclease activity, recA intervening sequence was cloned, overexpressed, and purified to homogeneity. Here we show that PI-MtuI bound both single- and double-stranded DNA with similar affinity but failed to cleave DNA in the absence of cofactors. Significantly, PI-MtuI nicked supercoiled DNA in the presence of alternative cofactors but required both Mn2+ and ATP to generate linear double-stranded DNA. We observed that PI-MtuI was able to inflict a staggered double-strand break 24 bp upstream of the insertion site in the inteinless recA allele. Similar to a few homing endonucleases, DNA cleavage by PI-MtuI was specific with an exceptionally long cleavage site spanning 22 bp. The kinetic mechanism of PI-MtuI promoted cleavage supports a sequential rather than concerted pathway of strand cleavage with the formation of nicked double-stranded DNA as an intermediate. Together, these results reveal that RecA intein is a novel Mn2+-ATP-dependent double-strand specific endonuclease, which is likely to be important for homing process in vivo.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Muniyappa, K (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.		Wood, David W/B-2992-2012					Bakshi RP, 2001, J MOL ENDOCRINOL, V26, P193, DOI 10.1677/jme.0.0260193; Belfort M, 1995, J BIOL CHEM, V270, P30237, DOI 10.1074/jbc.270.51.30237; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; BOS JL, 1978, NATURE, V275, P336, DOI 10.1038/275336a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chevalier BS, 2001, NUCLEIC ACIDS RES, V29, P3757, DOI 10.1093/nar/29.18.3757; Chevalier BS, 2001, NAT STRUCT BIOL, V8, P312, DOI 10.1038/86181; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; Datta S, 2000, NUCLEIC ACIDS RES, V28, P4964, DOI 10.1093/nar/28.24.4964; DAVIS EO, 1994, EMBO J, V13, P699, DOI 10.1002/j.1460-2075.1994.tb06309.x; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; DAVIS EO, 1991, J BACTERIOL, V173, P5653, DOI 10.1128/jb.173.18.5653-5662.1991; Derbyshire V, 1997, P NATL ACAD SCI USA, V94, P11466, DOI 10.1073/pnas.94.21.11466; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; DUJON B, 1980, CELL, V20, P185, DOI 10.1016/0092-8674(80)90246-9; Galburt EA, 1999, NAT STRUCT BIOL, V6, P1096, DOI 10.1038/70027; Galburt EA, 2000, J MOL BIOL, V300, P877, DOI 10.1006/jmbi.2000.3874; Gimble FS, 2000, FEMS MICROBIOL LETT, V185, P99; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; Horton NC, 2001, NAT STRUCT BIOL, V8, P290, DOI 10.1038/86149; Ichiyanagi K, 2000, J MOL BIOL, V300, P889, DOI 10.1006/jmbi.2000.3873; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4175, DOI 10.1093/nar/27.21.4175; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kumar RA, 1996, BIOCHEMISTRY-US, V35, P1793, DOI 10.1021/bi9517751; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; Liu XQ, 2000, ANNU REV GENET, V34, P61, DOI 10.1146/annurev.genet.34.1.61; Maxam A M, 1980, Methods Enzymol, V65, P499; Mills KV, 1998, P NATL ACAD SCI USA, V95, P3543, DOI 10.1073/pnas.95.7.3543; MUELLER JE, 1993, NUCLEASES, P111; Noren CJ, 2000, ANGEW CHEM INT EDIT, V39, P450; NORMAN E, 1995, MOL MICROBIOL, V16, P755, DOI 10.1111/j.1365-2958.1995.tb02436.x; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Pelicic V, 1998, MOL MICROBIOL, V28, P413, DOI 10.1046/j.1365-2958.1998.00807.x; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Sambrook J., 2002, MOL CLONING LAB MANU; Saves I, 2001, NUCLEIC ACIDS RES, V29, P4310, DOI 10.1093/nar/29.21.4310; Shingledecker K, 1998, GENE, V207, P187, DOI 10.1016/S0378-1119(97)00624-0; Silva GH, 1999, J MOL BIOL, V286, P1123, DOI 10.1006/jmbi.1998.2519; Vaze MB, 1999, BIOCHEMISTRY-US, V38, P3175, DOI 10.1021/bi9819125; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	45	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16257	16264		10.1074/jbc.M112365200	http://dx.doi.org/10.1074/jbc.M112365200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11850426	hybrid			2022-12-25	WOS:000175510400136
J	Hu, B; Senkler, C; Yang, A; Soto, F; Liang, BT				Hu, B; Senkler, C; Yang, A; Soto, F; Liang, BT			P2X(4) receptor is a glycosylated cardiac receptor mediating a positive inotropic response to ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; EXPRESSION	Although P2X receptors are suggested to play a role in synaptic neurotransmission, the specific physiological role of each P2X receptor subtype remains largely unknown. We used cultured chick embryo ventricular myocytes as a model to study a potential physiological role of the P2X(4) receptor in mediating the positive inotropic effect of ATP. The chick P2X(4) receptor (cP2X(4)R) mRNA was expressed in the heart and the pharmacological features of the ATP-induced positive inotropic response were similar to those of the cP2X(4)R in terms of insensitivity to blockade by known P2 receptor antagonists and the ineffectiveness of adenosine 5'-(alpha,beta-methylene)triphosphate as an agonist. Treatment of myocytes with antisense oligonucleotides specific to the 5' region of cP2X(4)R abrogated the P2 agonist-stimulated Ca-45 influx. Similarly, antisense oligonucleotide treatment also blocked the 2-methylthio-ATP-stimulated increase in contractile amplitude. The data suggest that the native P2X(4) receptor is involved in mediating the P2 agonist-stimulated response in the heart. In characterizing the biochemical property of the P2X(4) receptor, antibody against cP2X(4)R detected a 44-kDa and a 58-kDa protein in the immunoblot. Inhibition of N-linked glycosylation by tunicamycin converted the 58-kDa protein to the 44-kDa protein, suggesting that the 58-kDa protein was a glycosylated P2X(4) receptor. The nonglycosylated 44-kDa P2X(4) receptor was resistant to various detergent/aqueous extraction, consistent with a role of glycosylation in maintaining its detergent solubility and hydrophilicity. Cross-linking the cell surface proteins with N-hydroxysuccinimide-SS-biotin followed by affinity precipitation with streptavidin-conjugated agarose and subsequent immunoblotting with anti-cP2X(4)R showed that only the glycosylated 58-kDa P2X(4) receptor was expressed on the cell surface, indicating an important role of glycosylation for the receptor's localization on the plasma membrane. These data revealed a novel physiologic function of the P2X(4) receptor and suggested the importance of N-linked glycosylation in its cell surface expression and detergent solubility.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Max Planck Inst Expt Med, Abt 300, D-37075 Gottingen, Germany	University of Pennsylvania; University of Pennsylvania; Max Planck Society	Liang, BT (corresponding author), Univ Penn, Med Ctr, Rm 956,BRBII-III,421 Curie Blvd, Philadelphia, PA 19104 USA.	Liangb@mail.med.upenn.edu			NHLBI NIH HHS [R01 HL48225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bisello A, 1996, BIOCHEMISTRY-US, V35, P15890, DOI 10.1021/bi962111+; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Hu B, 2001, FASEB J, V15, P2739, DOI 10.1096/fj.01-0445fje; Khakh BS, 2001, PHARMACOL REV, V53, P107; Kim M, 1997, BIOCHEM BIOPH RES CO, V240, P618, DOI 10.1006/bbrc.1997.7713; Le KT, 1998, NEUROSCIENCE, V83, P177, DOI 10.1016/S0306-4522(97)00365-5; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; PODRASKY E, 1997, AM J PHYSIOL-HEART C, V273, pH2380; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rettinger J, 2000, J BIOL CHEM, V275, P33542, DOI 10.1074/jbc.M002918200; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; Ruppelt A, 1999, PROG BRAIN RES, V120, P81; Soto F, 1997, J MEMBRANE BIOL, V160, P91, DOI 10.1007/s002329900298; Souslova V, 2000, NATURE, V407, P1015, DOI 10.1038/35039526; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; TORDAI A, 1995, BIOCHEM BIOPH RES CO, V206, P857, DOI 10.1006/bbrc.1995.1122; Torres GE, 1998, BIOCHEMISTRY-US, V37, P14845, DOI 10.1021/bi981209g; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425	21	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15752	15757		10.1074/jbc.M112097200	http://dx.doi.org/10.1074/jbc.M112097200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864978	hybrid			2022-12-25	WOS:000175510400072
J	Patrick, SM; Turchi, JJ				Patrick, SM; Turchi, JJ			Xeroderma pigmentosum complementation group A protein (XPA) modulates RPA-DNA interactions via enhanced complex stability and inhibition of strand separation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; CISPLATIN-MODIFIED DNA; DAMAGED DNA; BINDING-PROTEIN; A RPA; MAMMALIAN-CELLS; IN-VITRO; NUCLEASE; RECOGNITION; RECONSTITUTION	Replication protein A (RPA) participates in many cellular functions including DNA replication and nucleotide excision repair. A direct interaction between RPA and the xeroderma pigmentosum group A protein (XPA) facilitates the assembly of a preincision complex during the processing of DNA damage by the nucleotide excision repair pathway. We demonstrate here the formation of a ternary RPA, XPA, and duplex cisplatin-damaged DNA complex as is evident by electrophoretic supershift analysis. The RPA-YPA complex displays modest specificity for damaged versus undamaged duplex DNA, and the RPA-XPA complex displays a greater affinity for binding duplex cisplatin-damaged DNA when compared with the RPA or XPA proteins alone, consistent with previous results. Using DNA denaturation assays, we demonstrate that the role of XPA is in the stabilization of the duplex DNA structure via inhibition of the strand separation activity of RPA. Rapid kinetic analysis indicates that the bimolecular k(on) of the RPA-XPA complex is 2.5-fold faster than RPA alone for binding a duplex cisplatin-damaged DNA. The dissociation rate, k(off), of the RPA-XPA complex is slower than that of the RPA protein alone, suggesting that the XPA protein stabilizes the initial binding of RPA to duplex DNA as well as maintaining the integrity of the duplex DNA. Interestingly, XPA has no effect on the k(on) of RPA for a single-stranded 40-mer DNA.	Wright State Univ, Sch Med, Dept Biochem & Mol Biol, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton	Turchi, JJ (corresponding author), Wright State Univ, Sch Med, Dept Biochem & Mol Biol, 3640 Colonel Glenn Highway, Dayton, OH 45435 USA.		Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NATIONAL CANCER INSTITUTE [R01CA082741] Funding Source: NIH RePORTER; NCI NIH HHS [CA82741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Batty D, 2000, J MOL BIOL, V300, P275, DOI 10.1006/jmbi.2000.3857; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; Branum ME, 2001, J BIOL CHEM, V276, P25421, DOI 10.1074/jbc.M101032200; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CLEAVER JE, 1989, METABOLIC BASIS INHE; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; Hermanson IL, 2000, PROTEIN EXPRES PURIF, V19, P1, DOI 10.1006/prep.2000.1224; Hermanson-Miller IL, 2002, BIOCHEMISTRY-US, V41, P2402, DOI 10.1021/bi0112863; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; Jamieson ER, 2000, BIOCHEMISTRY-US, V39, P8426, DOI 10.1021/bi000342h; Jamieson ER, 1999, J BIOL CHEM, V274, P12346, DOI 10.1074/jbc.274.18.12346; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; Lao Y, 2000, BIOCHEMISTRY-US, V39, P850, DOI 10.1021/bi991704s; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAGAI A, 1995, BIOCHEM BIOPH RES CO, V211, P960, DOI 10.1006/bbrc.1995.1905; Patrick SM, 1999, J BIOL CHEM, V274, P14972, DOI 10.1074/jbc.274.21.14972; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; Patrick SM, 2001, J BIOL CHEM, V276, P22630, DOI 10.1074/jbc.M010314200; REARDON JT, 1993, J BIOL CHEM, V268, P21301; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759; Wakasugi M, 1998, P NATL ACAD SCI USA, V95, P6669, DOI 10.1073/pnas.95.12.6669; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wakasugi M, 2001, J BIOL CHEM, V276, P15434, DOI 10.1074/jbc.M011177200; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	41	65	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16096	16101		10.1074/jbc.M200816200	http://dx.doi.org/10.1074/jbc.M200816200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859086	hybrid			2022-12-25	WOS:000175510400117
J	Quinsey, NS; Whisstock, JC; Le Bonniec, B; Louvain, V; Bottomley, SP; Pike, RN				Quinsey, NS; Whisstock, JC; Le Bonniec, B; Louvain, V; Bottomley, SP; Pike, RN			Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; CONFORMATIONAL CHANGE; ENZYME SPECIFICITY; STRUCTURAL BASIS; BINDING-SITE; THROMBIN; INHIBITION; PROTEINASE; COMPLEX; SERPIN	The control of coagulation enzymes by antithrombin is vital for maintenance of normal hemostasis. Antithrombin requires the co-factor, heparin, to efficiently inhibit target proteinases. A specific pentasaccharide sequence (115) in high affinity heparin induces a conformational change in antithrombin that is particularly important for factor Xa (fXa) inhibition. Thus, synthetic H5 accelerates the interaction between antithrombin and fXa 100-fold as compared with only 2-fold versus thrombin. We built molecular models and identified residues unique to the active site of fXa that we predicted were important for interacting with the reactive center loop of H5-activated antithrombin. To test our predictions, we generated the mutants E37A, E37Q, E39A, E39Q, Q61A, S173A, and F174A in human fXa and examined the rate of association of these mutants with antithrombin in the presence and absence of H5. fXa Q61A interacts with antithrombin alone with a nearly normal k(ass); however, we observe only a 4-fold increase in k(ass) in the presence of H5. The x-ray crystal structure of fXa reveals that Gln(61) forms part of the S1' and S3' pocket, suggesting that the P' region of the reactive center loop of antithrombin is crucial for mediating the acceleration in the rate of inhibition of fXa by H5-activated antithrombin.	Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia; Univ Paris 05, INSERM, U428, F-75270 Paris, France	Monash University; Monash University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Pike, RN (corresponding author), Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, POB 13D, Clayton, Vic 3800, Australia.		Le Bonniec, Bernard/ABA-1366-2020; Le Bonniec, Bernard/S-5756-2016	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363; Pike, Robert/0000-0002-2083-0269; Whisstock, James/0000-0003-4200-5611				Adler M, 2000, BIOCHEMISTRY-US, V39, P12534, DOI 10.1021/bi001477q; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; Brinen LS, 1996, BIOCHEMISTRY-US, V35, P5999, DOI 10.1021/bi9530200; Buller HR, 2000, CIRCULATION, V102, P2726; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; COETZER THT, 1992, IMMUNOL INVEST, V21, P495, DOI 10.3109/08820139209069386; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Futamura A, 2001, BIOCHEMISTRY-US, V40, P6680, DOI 10.1021/bi0029346; Huntington JA, 1998, BIOCHEMISTRY-US, V37, P3272, DOI 10.1021/bi972182o; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kamata K, 1998, P NATL ACAD SCI USA, V95, P6630, DOI 10.1073/pnas.95.12.6630; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESK AM, 1986, BIOSEQUENCES PERSPEC, P23; LOTTENBERG R, 1986, BIOCHIM BIOPHYS ACTA, V874, P326, DOI 10.1016/0167-4838(86)90032-4; MACKAY EJ, 1981, THROMB RES, V21, P375; Maignan S, 2000, J MED CHEM, V43, P3226, DOI 10.1021/jm000940u; MANN KG, 1990, BLOOD, V76, P755; Nar H, 2001, STRUCTURE, V9, P29, DOI 10.1016/S0969-2126(00)00551-7; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P3339; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; Pike RN, 1997, J BIOL CHEM, V272, P19652, DOI 10.1074/jbc.272.32.19652; QIU XY, 1992, BIOCHEMISTRY-US, V31, P11689, DOI 10.1021/bi00162a004; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 1996, EUR J BIOCHEM, V242, P477, DOI 10.1111/j.1432-1033.1996.477rr.x; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P7437, DOI 10.1021/bi962965u; REZAIE AR, 1995, J BIOL CHEM, V270, P16176, DOI 10.1074/jbc.270.27.16176; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; Rezaie AR, 2002, J BIOL CHEM, V277, P1235, DOI 10.1074/jbc.M108544200; Rezaie AR, 2001, BLOOD, V97, P2308, DOI 10.1182/blood.V97.8.2308; Rudolph AE, 1996, J BIOL CHEM, V271, P28601, DOI 10.1074/jbc.271.45.28601; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Sun J, 2001, J BIOL CHEM, V276, P15177, DOI 10.1074/jbc.M006645200; THEUNISSEN HJM, 1993, J BIOL CHEM, V268, P9035; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A; Whisstock JC, 2000, J MOL BIOL, V301, P1287, DOI 10.1006/jmbi.2000.3982; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979	48	21	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15971	15978		10.1074/jbc.M108131200	http://dx.doi.org/10.1074/jbc.M108131200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854268	hybrid			2022-12-25	WOS:000175510400101
J	Tadokoro, R; Fujita, M; Miura, H; Shirahige, K; Yoshikawa, H; Tsurimoto, T; Obuse, C				Tadokoro, R; Fujita, M; Miura, H; Shirahige, K; Yoshikawa, H; Tsurimoto, T; Obuse, C			Scheduled conversion of replication complex architecture at replication origins of Saccharomyces cerevisiae during the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC7 PROTEIN-KINASE; DNA-REPLICATION; S-PHASE; BUDDING YEAST; CHROMOSOME-VI; MCM PROTEIN; IN-VIVO; ASSOCIATION; CDC45P; ACTIVATION	Replication of DNA within Saccharomyces cerevisiae chromosomes is initiated from multiple origins, whose activation follow their own inherent time schedules during the S phase of the cell cycle. It has been demonstrated that a characteristic replicative complex (RC) that includes an origin recognition complex is formed at each origin and shifts between post- and pre-replicative states during the cell cycle. We wanted to determine whether there was an association between this shift in the state of the RC and firing events at replication origins. Time course analyses of RC architecture using UV-footprinting with synchronously growing cells revealed that pre-replicative states at both early and late firing origins appeared simultaneously during late M phase, remained in this state during G, phase, and converted to the post-replicative state at various times during S phase. Because the conversion of the origin footprinting profiles and origin firing, as assessed by two-dimensional gel electrophoresis, occurred concomitantly at each origin, then these two events must be closely related. However, conversion of the late firing origin occurred without actual firing. This was observed when the late origin was suppressed in clb5-deficient cells and a replication fork originating from an outside origin replicated the late origin passively. This mechanism ensures that replication at each chromosomal locus occurs only once per cell cycle by shifting existing pre-RCs to the post-RC state, when it is replicated without firing.	Nara Inst Sci & Technol, Nara 6300101, Japan	Nara Institute of Science & Technology	Obuse, C (corresponding author), Nara Inst Sci & Technol, 8916-5 Takayama, Nara 6300101, Japan.		Obuse, Chikashi/F-5273-2011	Tsurimoto, Toshiki/0000-0001-7597-2216				Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; BREWER BJ, 1993, COLD SPRING HARB SYM, V58, P425, DOI 10.1101/SQB.1993.058.01.049; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; DESHPANDE AM, 1992, MOL CELL BIOL, V12, P4305, DOI 10.1128/MCB.12.10.4305; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; DROUIN R, 1990, CHROMOSOMA, V99, P273, DOI 10.1007/BF01731703; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; Friedman KL, 1997, GENES CELLS, V2, P667, DOI 10.1046/j.1365-2443.1997.1520350.x; Fujita M, 1998, GENES CELLS, V3, P737, DOI 10.1046/j.1365-2443.1998.00226.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KUHNE C, 1993, EMBO J, V12, P3437, DOI 10.1002/j.1460-2075.1993.tb06018.x; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; Masumoto H, 2000, MOL CELL BIOL, V20, P2809, DOI 10.1128/MCB.20.8.2809-2817.2000; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SCHWEITZER B, 1991, YEAST, V7, P265, DOI 10.1002/yea.320070308; SHIRAHIGE K, 1993, MOL CELL BIOL, V13, P5043, DOI 10.1128/MCB.13.8.5043; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Yamashita M, 1997, GENES CELLS, V2, P655, DOI 10.1046/j.1365-2443.1997.1530351.x; YOON HJ, 1993, MOL BIOL CELL, V4, P195, DOI 10.1091/mbc.4.2.195; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	31	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15881	15889		10.1074/jbc.M200322200	http://dx.doi.org/10.1074/jbc.M200322200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11842092	hybrid			2022-12-25	WOS:000175510400090
J	Ramsey, IS; DeFelice, LJ				Ramsey, IS; DeFelice, LJ			Serotonin transporter function and pharmacology are sensitive to expression level - Evidence for an endogenous regulatory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE DOMAIN-I; BIOGENIC-AMINE TRANSPORTERS; NA+CL COTRANSPORT FUNCTION; HUMAN DOPAMINE TRANSPORTER; VOLTAGE-DEPENDENT UPTAKE; OOCYTE MEMBRANE PATCHES; XENOPUS-OOCYTES; NOREPINEPHRINE TRANSPORTERS; RADIATION INACTIVATION; HUMAN-BLOOD	We express mammalian serotonin transporters (SERTs) in Xenopus oocytes by cRNA injection and measure 5-hydroxytryptamine (5-HT) transport and 5-HT-induced current at varying expression levels. Transport and current both increase sigmoidally with the amount of cRNA injected, but current requires similar to5-fold more cRNA to elicit a half-maximal response. Western blots of SERT protein demonstrate that current, but not transport, correlates linearly with the amount of SERT on the plasma membrane. In oocytes co-injected with wild-type SERT and an inactive SERT mutant, transport is similar to SERT alone, but current is attenuated. The charge/transport ratio reports the differential sensitivity of transport and current to increasing SERT cRNA injection and mutant co-expression. Manipulations that alter the charge/transport ratio also perturb substrate and inhibitor recognition. 5-HT, d-amphetamine, cocaine, and paroxetine inhibit transport more potently at lower expression levels; however, 5-HT potency for induction of current is similar at high and low expression. Moreover, the apparent potency of cRNA for transport depends on 5-HT concentration. We postulate that SERT interacts allosterically with an endogenous factor of limited abundance to alter substrate and inhibitor potency and the balance of 5-HT transport and channel-like activity.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University	DeFelice, LJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Ctr Mol Neurosci, Nashville, TN 37232 USA.			De Felice, Louis/0000-0002-4594-3171	NIMH NIH HHS [MH-12393] Funding Source: Medline; NINDS NIH HHS [NS-34075] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034075] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adkins EM, 2001, MOL PHARMACOL, V59, P514, DOI 10.1124/mol.59.3.514; ANGEL I, 1984, FEBS LETT, V171, P280, DOI 10.1016/0014-5793(84)80504-9; Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; Beckman ML, 2001, NEUROPHARMACOLOGY, V40, P526, DOI 10.1016/S0028-3908(00)00191-X; BERGER SP, 1994, MOL PHARMACOL, V46, P726; BLAKELY RD, 1994, J EXP BIOL, V196, P263; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Broer S, 1998, J MEMBRANE BIOL, V164, P71, DOI 10.1007/s002329900394; BRUNS D, 1993, NEURON, V10, P559, DOI 10.1016/0896-6273(93)90159-O; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; CAMMACK JN, 1994, NEURON, V13, P949, DOI 10.1016/0896-6273(94)90260-7; Cao YW, 1997, J NEUROSCI, V17, P2257; CESURA AM, 1983, EUR J PHARMACOL, V96, P235, DOI 10.1016/0014-2999(83)90312-6; Chang AS, 1998, BIOCHEM BIOPH RES CO, V249, P416, DOI 10.1006/bbrc.1998.9158; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COREY JL, 1994, J BIOL CHEM, V269, P14759; DeFelice LJ, 1996, BIOPHYS J, V70, P579, DOI 10.1016/S0006-3495(96)79604-2; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Dowd LA, 1996, MOL PHARMACOL, V49, P465; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; Feighner JP, 1999, J CLIN PSYCHIAT, V60, P18; Galli A, 1999, J NEUROSCI, V19, P6290; Galli A, 1997, J NEUROSCI, V17, P3401; Galli A, 1998, P NATL ACAD SCI USA, V95, P13260, DOI 10.1073/pnas.95.22.13260; Galli A, 1996, P NATL ACAD SCI USA, V93, P8671, DOI 10.1073/pnas.93.16.8671; Gorman JM, 1999, J CLIN PSYCHIAT, V60, P33; Gross E, 2001, J PHYSIOL-LONDON, V531, P597, DOI 10.1111/j.1469-7793.2001.0597h.x; GU H, 1994, J BIOL CHEM, V269, P7124; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Inserte J, 1999, BIOCHEM PHARMACOL, V57, P111, DOI 10.1016/S0006-2952(98)00281-0; Jess U, 1996, FEBS LETT, V394, P44, DOI 10.1016/0014-5793(96)00916-7; KEYES SR, 1982, J BIOL CHEM, V257, P1172; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; Lu CC, 1999, J GEN PHYSIOL, V114, P445, DOI 10.1085/jgp.114.3.445; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; Martens JR, 1999, TRENDS CARDIOVAS MED, V9, P253, DOI 10.1016/S1050-1738(00)00037-2; MELLERUP ET, 1984, EUR J PHARMACOL, V106, P411, DOI 10.1016/0014-2999(84)90730-1; MILNER HE, 1994, BBA-BIOMEMBRANES, V1190, P185, DOI 10.1016/0005-2736(94)90051-5; Ni YG, 2001, J BIOL CHEM, V276, P30942, DOI 10.1074/jbc.M104653200; OREILLY CA, 1988, J BIOL CHEM, V263, P6115; Petersen CI, 1999, NAT NEUROSCI, V2, P605, DOI 10.1038/10158; Plenge P, 1997, PHARMACOL TOXICOL, V80, P197, DOI 10.1111/j.1600-0773.1997.tb00396.x; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; QIAN Y, 1995, J NEUROSCI, V15, P1261; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; RAMAMOORTHY S, 1993, PLACENTA, V14, P449, DOI 10.1016/S0143-4004(05)80465-5; RESHKIN SJ, 1989, AM J PHYSIOL, V256, pE610, DOI 10.1152/ajpendo.1989.256.5.E610; Risso S, 1996, J PHYSIOL-LONDON, V490, P691, DOI 10.1113/jphysiol.1996.sp021178; ROSS SB, 1975, ACTA PHARMACOL TOX, V36, P382; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P5300, DOI 10.1021/bi00617a033; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Sitte HH, 2001, MOL PHARMACOL, V59, P1129, DOI 10.1124/mol.59.5.1129; Sonders MS, 1997, J NEUROSCI, V17, P960; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Su A, 1996, BIOPHYS J, V70, P762, DOI 10.1016/S0006-3495(96)79616-9; Sur C, 1998, J NEUROCHEM, V70, P2545; TALVENHEIMO J, 1980, J BIOL CHEM, V255, P8606; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WALL SC, 1995, MOL PHARMACOL, V47, P544; WHITWORTH TL, 2001, J BIOL CHEM; WOOD MD, 1986, NEUROPHARMACOLOGY, V25, P519, DOI 10.1016/0028-3908(86)90178-4; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	76	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14475	14482		10.1074/jbc.M110783200	http://dx.doi.org/10.1074/jbc.M110783200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11844791	hybrid			2022-12-25	WOS:000175203000018
J	Brigotti, M; Alfieri, R; Sestili, P; Bonelli, M; Petronini, PG; Guidarelli, A; Barbieri, L; Stirpe, F; Sperti, S				Brigotti, M; Alfieri, R; Sestili, P; Bonelli, M; Petronini, PG; Guidarelli, A; Barbieri, L; Stirpe, F; Sperti, S			Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells	FASEB JOURNAL			English	Article						ribosome-inactivating proteins; alkaline-halo assay; AP sites; cytotoxins	RIBOSOME-INACTIVATING PROTEINS; POLYNUCLEOTIDE-ADENOSINE GLYCOSIDASE; ESCHERICHIA-COLI O157-H7; SINGLE-STRANDED-DNA; EUKARYOTIC RIBOSOMES; SENSITIVE METHOD; KINASE-C; APOPTOSIS; RNA; DEATH	Ribosome-inactivating proteins (RIPs) remove a specific adenine from 28S rRNA leading to inactivation of ribosomes and arrest of translation. Great interest as to a possible second physiological substrate for RIPs came from the observation that in vitro RIPs remove adenine from DNA. This paper addresses the problem of nuclear lesions induced by RIPs in human endothelial cells susceptible to the bacterial RIP Shiga toxin 1 and the plant RIP ricin. With both toxins, nuclear DNA damage as evaluated by two independent techniques (alkaline-halo assay and alkaline filter elution) appears early, concomitant with (ricin) or after (Shiga toxin 1) the inhibition of protein synthesis. At this time, the annexin V binding assay, caspase 3 activity, the formation of typical less than or equal to 50 Kb DNA fragments, and changes in morphology associated with apoptosis were negative. Furthermore, a block of translation comparable to that induced by RIPs, but obtained with cycloheximide, did not induce nuclear damage. Such damage is consistent with the enzymatic activity (removal of adenine) of RIPs acting in vitro on RNA-free chromatin and DNA. The results unequivocally indicate that RIPs can damage nuclear DNA in whole cells by means that are not secondary to ribosome inactivation or apoptosis.	Univ Bologna, Dipartimento Patol Sperimentale, I-40126 Bologna, Italy; Univ Parma, Dipartimento Med Sperimentale, Sez Patol Mol & Immunol, I-43100 Parma, Italy; Univ Urbino, Fac Sci Motorie, Catedra Farmacol, I-61029 Urbino, Italy; Univ Urbino, Ist Farmacol & Farmacognosia, I-61029 Urbino, Italy	University of Bologna; University of Parma; University of Urbino; University of Urbino	Brigotti, M (corresponding author), Univ Bologna, Dipartimento Patol Sperimentale, Via S Giacomo 14, I-40126 Bologna, Italy.	brigotti@alma.unibo.it	Alfieri, Roberta R/G-6350-2012; Brigotti, Maurizio/AAB-9007-2022	Brigotti, Maurizio/0000-0001-7429-744X; Sestili, Piero/0000-0001-9412-1660				Alfieri R, 1996, BIOCHEM J, V319, P601, DOI 10.1042/bj3190601; ARAKI S, 1990, BIOCHEM BIOPH RES CO, V172, P1081, DOI 10.1016/0006-291X(90)91557-9; Barbieri L, 1998, MOL MICROBIOL, V29, P661, DOI 10.1046/j.1365-2958.1998.00911.x; Barbieri L, 2000, BBA-PROTEIN STRUCT M, V1480, P258, DOI 10.1016/S0167-4838(00)00077-7; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; BARBIERI L, 1994, NATURE, V372, P624, DOI 10.1038/372624a0; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Barbieri L, 2000, J BIOCHEM-TOKYO, V128, P883, DOI 10.1093/oxfordjournals.jbchem.a022827; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brigotti M, 2001, TOXICON, V39, P341, DOI 10.1016/S0041-0101(00)00135-5; Brigotti M, 1998, NUCLEIC ACIDS RES, V26, P4306, DOI 10.1093/nar/26.18.4306; Brigotti M, 2000, NUCLEIC ACIDS RES, V28, P2383, DOI 10.1093/nar/28.12.2383; CANTONI O, 1984, CARCINOGENESIS, V5, P1207, DOI 10.1093/carcin/5.9.1207; CORCORAN GB, 1994, TOXICOL APPL PHARM, V128, P169, DOI 10.1006/taap.1994.1195; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DONOHUEROLFE A, 1988, METHOD ENZYMOL, V165, P231; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; FERRERAS JM, 1993, BIOCHIM BIOPHYS ACTA, V1216, P31, DOI 10.1016/0167-4781(93)90034-B; GRIFFITHS GD, 1987, J PATHOL, V151, P221, DOI 10.1002/path.1711510310; Hamuro T, 1998, FEBS LETT, V421, P197, DOI 10.1016/S0014-5793(97)01559-7; Hu RG, 2001, J CELL BIOCHEM, V81, P583, DOI 10.1002/jcb.1076; HUANG RCC, 1969, J MOL BIOL, V39, P365, DOI 10.1016/0022-2836(69)90323-4; Hughes JN, 1996, HUM EXP TOXICOL, V15, P443, DOI 10.1177/096032719601500513; Kiyokawa N, 2001, J CELL BIOCHEM, V81, P128, DOI 10.1002/1097-4644(20010401)81:1<128::AID-JCB1029>3.0.CO;2-G; KOHN KW, 1991, PHARMACOL THERAPEUT, V49, P55, DOI 10.1016/0163-7258(91)90022-E; KOHN KW, 1981, DNA REPAIR LAB MAN B, V1, P397; Komatsu N, 1998, J BIOCHEM-TOKYO, V124, P1038, DOI 10.1093/oxfordjournals.jbchem.a022197; LOUISE CB, 1995, INFECT IMMUN, V63, P2766, DOI 10.1128/IAI.63.7.2766-2769.1995; Louise CB, 1997, INFECT IMMUN, V65, P3337, DOI 10.1128/IAI.65.8.3337-3344.1997; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MANGENEY M, 1993, CANCER RES, V53, P5314; Marini M, 1996, BIOCHEM BIOPH RES CO, V229, P910, DOI 10.1006/bbrc.1996.1901; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Nakagawa I, 1999, MOL MICROBIOL, V33, P1190, DOI 10.1046/j.1365-2958.1999.01564.x; Nakao H, 2000, J NAT TOXINS, V9, P299; Nicolas E, 2000, J BIOL CHEM, V275, P31399, DOI 10.1074/jbc.M004505200; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; OBRIG TG, 1988, INFECT IMMUN, V56, P2373, DOI 10.1128/IAI.56.9.2373-2378.1988; Olmo N, 2001, EUR J BIOCHEM, V268, P2113, DOI 10.1046/j.1432-1327.2001.02086.x; Paton JC, 1998, CLIN MICROBIOL REV, V11, P450, DOI 10.1128/CMR.11.3.450; PETRONINI PG, 1987, EXP CELL RES, V172, P450, DOI 10.1016/0014-4827(87)90403-4; Petronini PG, 1996, J CELL PHYSIOL, V169, P175, DOI 10.1002/(SICI)1097-4652(199610)169:1<175::AID-JCP18>3.0.CO;2-C; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; Ramirez CD, 2000, CELL DEATH DIFFER, V7, P548, DOI 10.1038/sj.cdd.4400686; RYD M, 1989, FEBS LETT, V258, P320, DOI 10.1016/0014-5793(89)81684-9; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; Sestili P, 1999, FREE RADICAL BIO MED, V26, P1019, DOI 10.1016/S0891-5849(98)00290-1; SESTILI P, 1995, CARCINOGENESIS, V16, P703, DOI 10.1093/carcin/16.4.703; Sestili P, 1996, FEBS LETT, V396, P337, DOI 10.1016/0014-5793(96)01130-1; SPERTI S, 1986, BIOSCIENCE REP, V6, P1035, DOI 10.1007/BF01141024; Suzuki A, 2000, GENE DEV, V14, P1734; TESH VL, 1991, J INFECT DIS, V164, P344, DOI 10.1093/infdis/164.2.344; URBANI S, 1996, FUND CLIN IMMUNOL, V4, P27; Williams JM, 1997, TOXICOL LETT, V91, P121, DOI 10.1016/S0378-4274(97)03879-4; Yamasaki C, 1999, FEBS LETT, V442, P231, DOI 10.1016/S0014-5793(98)01667-6	56	119	124	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0365	10.1096/fj.01-0521com	http://dx.doi.org/10.1096/fj.01-0521com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874985	Green Submitted			2022-12-25	WOS:000174755900028
J	Ragone, R				Ragone, R			Homocystine solubility and vascular disease	FASEB JOURNAL			English	Article						homocysteine; cystine solubility; redox thiol status	PLASMA HOMOCYSTEINE; PROTEIN-BINDING; REDOX STATUS; AMINOTHIOLS; HOMOCYST(E)INE	There is evidence that mild elevations of tHcy are associated with an increased risk for occlusive vascular disease, thrombosis, and stroke. It is hypothesized here that cellular toxicity could indirectly result from auto-oxidation of homocysteine to homocystine. Elevated levels of total plasma homocysteine could be the primary cause of increased vascular risk, causing endothelial damage through a mechanism similar to that of cystine precipitation, which is known to cause stone formation in cystinosis and cystinuria. In fact, only traces of homocysteine circulate in plasma as the free thiol; the remainder is present as oxidation products. Of these, the symmetric disulfide homocystine is scarcely soluble at neutral pH. Its saturation limit is so close to the concentration of homocysteine in normal plasma that a transient increase of homocysteine levels could lead to precipitation of homocystine microcrystals in the bloodstream. These could damage endothelial tissue, acting as a mechanic primer for subsequent prothrombotic blood vessel alterations.	Univ Naples 2, Dept Biochem & Biophys, CRISCEB, I-80138 Naples, Italy	Universita della Campania Vanvitelli	Ragone, R (corresponding author), Univ Naples 2, Dept Biochem & Biophys, CRISCEB, Via Costantinopoli 16, I-80138 Naples, Italy.	ragone@unina2.it						Borsook H, 1937, J BIOL CHEM, V117, P281; BRENTON DP, 1965, J PEDIATR-US, V67, P58, DOI 10.1016/S0022-3476(65)80304-3; DAngelo A, 1997, BLOOD, V90, P1; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; GUTTORMSEN AB, 1993, CLIN CHEM, V39, P1390; GUTTORMSEN AB, 1994, J NUTR, V124, P1934, DOI 10.1093/jn/124.10.1934; Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9; Jacobsen DW, 1998, CLIN CHEM, V44, P1833; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; LIDE DR, 1999, HDB CHEM PHYSICS; MANSOOR MA, 1993, CLIN CHEM, V39, P980; MANSOOR MA, 1993, METABOLISM, V42, P1481, DOI 10.1016/0026-0495(93)90202-Y; MANSOOR MA, 1992, CLIN CHEM, V38, P1316; MCCULLY KS, 1975, ATHEROSCLEROSIS, V22, P215, DOI 10.1016/0021-9150(75)90004-0; MUDD SH, 1995, NEW ENGL J MED, V333, P325; Schwarzenbach R., 1993, ENV ORGANIC CHEM; Ueland PM, 1996, J NUTR, V126, pS1281, DOI 10.1093/jn/126.suppl_4.1281S	18	21	21	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0401	10.1096/fj.01-0682hyp	http://dx.doi.org/10.1096/fj.01-0682hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874989				2022-12-25	WOS:000174755900032
J	Van Den Steen, PE; Proost, P; Grillet, B; Brand, DD; Kang, AH; Van Damme, J; Opdenakker, G				Van Den Steen, PE; Proost, P; Grillet, B; Brand, DD; Kang, AH; Van Damme, J; Opdenakker, G			Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis	FASEB JOURNAL			English	Article						autoimmunity; gelatinase B; neutrophil; rheumatoid arthritis; glycosylation	T-CELL RECOGNITION; MHC CLASS-II; DENDRITIC CELLS; SYNOVIAL-FLUIDS; IV COLLAGENASE; IDENTIFICATION; INTERLEUKIN-8; PROTEIN; METALLOPROTEINASE; RECRUITMENT	During acute inflammation, leukocytes release proteolytic enzymes including matrix metalloproteinases (MMPs), but the physiopathological mechanisms and consequences of this process are not yet fully understood. Neutrophils, the predominant leukocyte type, produce neutrophil collagenase (MMP-8) and gelatinase B (MMP-9) but not the tissue inhibitors of MMPs. After stimulation, these cells also activate MMPs chemically. In arthritic diseases, neutrophils undergo great chemoattraction to the synovium, are activated by interleukin-8, and are stimulated to release gelatinase B in vivo. Production levels and net activities of gelatinase B were found to be absent in degenerative osteoarthritis but significantly increased in rheumatoid arthritis. The cleavage sites in cartilage type II collagen by gelatinase B were determined by a combination of reverse phase high-performance liquid chromatography, Edman degradation, and mass spectrometry analysis. The analysis revealed the site specificity of proline and lysine hydroxylations and O-linked glycosylation, the cleavage specificities by gelatinase B, and the preferential absence and presence of post-translational modifications at P2' and P5', respectively. Furthermore, gelatinase B leaves the immunodominant peptides intact, which are known from studies with (autoreactive) T cells. Lysine hydroxylation was detected at a critical position for T-cell activation. These data lend support to the thesis that extracellular proteolysis and other post-translational modifications of antigenic peptides may be critical in the establishment and perpetuation of autoimmune processes.	Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Univ Tennessee, Res Serv, Vet Affairs Med Ctr, Memphis, TN 38104 USA	KU Leuven; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Opdenakker, G (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, Minderbroedersstr 10, B-3000 Louvain, Belgium.	Ghislain.Opdenakker@rega.kuleuven.ac.be	Van den Steen, Philippe E/K-5132-2012; Proost, Paul/V-3052-2017; Opdenakker, Ghislain/Q-3130-2017; Opdenakker, Ghislain/V-8562-2019	Van den Steen, Philippe E/0000-0002-7334-9145; Proost, Paul/0000-0002-0133-5545; Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294; Van Damme, Jo/0000-0002-6707-1167; Brand, David/0000-0002-9260-7963				Ahrens D, 1996, ARTHRITIS RHEUM, V39, P1576, DOI 10.1002/art.1780390919; AKAHOSHI T, 1994, LYMPHOKINE CYTOK RES, V13, P113; Andersson EC, 1998, P NATL ACAD SCI USA, V95, P7574, DOI 10.1073/pnas.95.13.7574; Arndt SO, 2000, EMBO J, V19, P1241, DOI 10.1093/emboj/19.6.1241; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bartholome EJ, 2001, J INTERF CYTOK RES, V21, P495, DOI 10.1089/10799900152434367; BRAND DD, 1994, J IMMUNOL, V152, P3088; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CLAGUE RB, 1991, ANN RHEUM DIS, V50, P769, DOI 10.1136/ard.50.11.769; D'Haese A, 2000, J INTERF CYTOK RES, V20, P667, DOI 10.1089/107999000414853; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Gruber BL, 1996, CLIN IMMUNOL IMMUNOP, V78, P161, DOI 10.1006/clin.1996.0025; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; Inaba K, 2000, J EXP MED, V191, P927, DOI 10.1084/jem.191.6.927; ISHIOKA GY, 1992, J IMMUNOL, V148, P2446; Kleifeld O, 2000, J BIOL CHEM, V275, P34335, DOI 10.1074/jbc.M005714200; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; Martinez ON, 2001, AM J GASTROENTEROL, V96, P1665; MASURE S, 1990, BIOCHIM BIOPHYS ACTA, V1054, P317, DOI 10.1016/0167-4889(90)90103-K; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; MICHAELSSON E, 1994, J EXP MED, V180, P745, DOI 10.1084/jem.180.2.745; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; MYERS LK, 1995, IMMUNOLOGY, V84, P509; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; OPDENAKKER G, 1991, LYMPHOKINE CYTOK RES, V10, P317; Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851; OPDENAKKER G, 1994, IMMUNOL TODAY, V15, P103, DOI 10.1016/0167-5699(94)90151-1; PEICHL P, 1991, SCAND J IMMUNOL, V34, P333, DOI 10.1111/j.1365-3083.1991.tb01554.x; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; RAMPART M, 1992, LAB INVEST, V66, P512; Rosloniec EF, 1996, CELL IMMUNOL, V172, P21, DOI 10.1006/cimm.1996.0210; ROSLONIEC EF, 1997, CURRENT PROTOCOLS IM; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15056, DOI 10.1073/pnas.96.26.15056; SEITZ M, 1992, RHEUMATOL INT, V12, P159, DOI 10.1007/BF00274936; SELTZER JL, 1990, J BIOL CHEM, V265, P20409; SHIKHMAN AR, 1994, J IMMUNOL, V152, P4375; SOPATA I, 1995, RHEUMATOL INT, V15, P9, DOI 10.1007/BF00286763; StPierre Y, 1996, CYTOMETRY, V25, P374, DOI 10.1002/(SICI)1097-0320(19961201)25:4<374::AID-CYTO9>3.0.CO;2-D; SUN JP, 1991, EUR J IMMUNOL, V21, P1461, DOI 10.1002/eji.1830210620; Taylor PC, 2000, ARTHRITIS RHEUM-US, V43, P38, DOI 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L; Van Damme J, 1990, Cytokine, V2, P106, DOI 10.1016/1043-4666(90)90004-D; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vergelli M, 1997, EUR J IMMUNOL, V27, P941, DOI 10.1002/eji.1830270421	48	134	137	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0379	10.1096/fj.01-0688com	http://dx.doi.org/10.1096/fj.01-0688com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874987				2022-12-25	WOS:000174755900030
J	Kulesza, CA; Van Buskirk, HA; Cole, MD; Reese, JC; Smith, MM; Engel, DA				Kulesza, CA; Van Buskirk, HA; Cole, MD; Reese, JC; Smith, MM; Engel, DA			Adenovirus E1A requires the yeast SAGA histone acetyltransferase complex and associates with SAGA components Gcn5 and Tra1	ONCOGENE			English	Article						gene regulation; transcription; genetics; yeast; adenovirus	TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME ACETYLATION; GENE ACTIVATION; ADA COMPLEX; PCAF; P300; ONCOPROTEIN; EXPRESSION	The budding yeast Saccharomyces cerevisiae was used as a model system to study the function of the adenovirus E1A oncoprotein. Previously we demonstrated that expression of the N-terminal 82 amino acids of E1A in yeast causes pronounced growth inhibition and specifically interferes with SWI/SNF-dependent transcriptional activation. Further genetic analysis identified the yeast transcription factor Adr1 as a high copy suppressor of E1A function. Transcriptional activation by Adr1 requires interaction with co-activator proteins Ada2 and Gcn5, components of histone acetyltransferase complexes including ADA and SAGA. Analysis of mutant alleles revealed that several components of the SAGA complex, including proteins from the Ada, Spt, and Taf classes were required for E1A-induced growth inhibition. Growth inhibition also depended on the Gcn5 histone acetyltransferase, and point mutations within the Gen5 HAT domain rendered cells E1A-resistant. Also required was SAGA component Tra1, a homologue of the mammalian TRRAP protein which is required for c-myc and E1A induced cellular transformation. Additionally, Gcn5 protein could associate with E1A in vitro in a manner that depended on the N-terminal domain of E1A, and Tra1 protein was co-immunoprecipitated with E1A in vivo. These results indicate a strong requirement for intact SAGA complex for E1A to function in yeast, and suggest a role for SAGA-like complexes in mammalian cell transformation.	Univ Virginia, Sch Med, Dept Microbiol & Canc Ctr, Charlottesville, VA 22908 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Virginia; Princeton University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Engel, DA (corresponding author), Univ Virginia, Sch Med, Dept Microbiol & Canc Ctr, Charlottesville, VA 22908 USA.	dae2s@virginia.edu			NCI NIH HHS [CA60675, CA87620] Funding Source: Medline; NIGMS NIH HHS [5T32GM08136, R01 GM058672-05, R01 GM028920, GM28920, R01 GM058672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060675, R01CA060675, R01CA087620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028920, T32GM008136, R01GM058672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Berk AJ, 1998, COLD SPRING HARB SYM, V63, P243, DOI 10.1101/sqb.1998.63.243; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, J BIOL CHEM, V271, P5237; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DYSON N, 1992, CANCER SURV, V12, P161; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Eckner R, 1996, MOL CELL BIOL, V16, P3454; EISENMANN DM, 1994, GENETICS, V137, P647; FASSLER JS, 1988, GENETICS, V118, P203; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HANDA H, 1987, GENE, V58, P127; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MILLER ME, 1995, ONCOGENE, V11, P1623; Miller ME, 1996, MOL CELL BIOL, V16, P5737; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Peterson CL, 1998, COLD SPRING HARB SYM, V63, P545, DOI 10.1101/sqb.1998.63.545; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Roberts SM, 1997, GENETICS, V147, P451; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; SIMCHEN G, 1984, P NATL ACAD SCI-BIOL, V81, P2431, DOI 10.1073/pnas.81.8.2431; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; VANDENELSEN P, 1983, VIROLOGY, V128, P377; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; WINSTON F, 1984, GENETICS, V107, P179; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	74	22	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1411	1422		10.1038/sj.onc.1205201	http://dx.doi.org/10.1038/sj.onc.1205201			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857084				2022-12-25	WOS:000173861000011
J	Simpson, DJ; Clayton, RN; Farrell, WE				Simpson, DJ; Clayton, RN; Farrell, WE			Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion	ONCOGENE			English	Article						DAP kinase; methylation; homozygous deletion; pituitary tumours	PROGRAMMED CELL-DEATH; DAP-KINASE; DNA METHYLATION; PROMOTER HYPERMETHYLATION; CANCER PATIENTS; LUNG-CANCER; APOPTOSIS; GENES; ADENOMAS; TUMORS	Death Associated Protein kinase (DAP kinase) a novel calmodulin-dependent serine/threonine kinase was first identified as a positive mediator of programmed cell death. Loss of DAP kinase expression was first demonstrated in highly metastatic cells, whilst reexpression of the protein resulted in delayed local tumour growth and a decreased incidence of metastasis. Although loss of DAP kinase expression has been reported in several cell lines derived from human malignancies the mechanisms responsible have not been defined. In this study we have examined 32 sporadic pituitary tumours for expression of the DAP kinase protein and transcript. In addition, we examined the methylation and deletion status of the DAP kinase CpG island as possible mechanisms for the inactivation of the DAP kinase gene. Eleven of 32 (34%) tumours had undetectable DAP kinase expression, by Western blot and/or RT-PCR analysis. Loss of DAP kinase expression was significantly (P=0.004) associated with invasive tumours (10 of 17; 59%) compared to their noninvasive (1 of 15; 7%) counterparts. Of 11 tumours that failed to express DAP kinase, five (45%) showed de novo methylation of the CpG island contained within the promoter region, while four (36%) had evidence of homozygous deletion of this region. Statistical analysis showed that loss of DAP kinase expression was significantly (P= <0.001) associated with methylation or deletion of the DAP kinase CpG island. With two exceptions, none of the remaining tumours or five histologically normal post-mortem pituitaries examined had evidence of methylation or deletion within this region. To our knowledge this is the first report that describes two mutually exclusive mechanisms associated with loss of DAP kinase gene expression. In addition, we also show that loss of the DAP kinase protein and associated genetic aberrations preferentially segregates with tumours that show an invasive phenotype.	Keele Univ, N Staffordshire Hosp, Postgrad Med Sch, Ctr Cell & Mol Med, Stoke On Trent ST4 7QB, Staffs, England	Keele University; University Hospital of North Staffordshire NHS Trust	Farrell, WE (corresponding author), Keele Univ, N Staffordshire Hosp, Postgrad Med Sch, Ctr Cell & Mol Med, Stoke On Trent ST4 7QB, Staffs, England.	w.e.farrell@keele.ac.uk						Bates AS, 1997, J CLIN ENDOCR METAB, V82, P818, DOI 10.1210/jc.82.3.818; Baylin SB, 1998, ADV CANCER RES, V72, P141; BOGGILD MD, 1994, J CLIN ENDOCR METAB, V78, P387, DOI 10.1210/jc.78.2.387; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Costello JF, 1996, CANCER RES, V56, P2405; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Esteller M, 1999, CANCER RES, V59, P67; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farrell WE, 1997, CANCER RES, V57, P2703; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; FEINSTEIN E, 1995, TIBS, P342; Grigg GW, 1996, DNA SEQUENCE, V6, P189, DOI 10.3109/10425179609008443; Hardy J., 1979, RECENT ADV DIAGNOSIS, P375; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jones PA, 1996, CANCER RES, V56, P2463; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; LASTER SM, 1988, J IMMUNOL, V141, P2629; LIN JK, 1992, CANCER RES, V52, P385; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; Nakatsuka S, 2000, LAB INVEST, V80, P1651, DOI 10.1038/labinvest.3780175; NOVELLI F, 1994, J IMMUNOL, V152, P496; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; Simpson DJ, 1999, CANCER RES, V59, P1562; Simpson DJ, 1999, GENE CHROMOSOME CANC, V24, P328; Simpson DJ, 2001, CARCINOGENESIS, V22, P1801, DOI 10.1093/carcin/22.11.1801; Simpson DJ, 2000, CANCER RES, V60, P1211; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Ueki T, 2000, CANCER RES, V60, P1835; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	36	74	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1217	1224		10.1038/sj.onc.1205195	http://dx.doi.org/10.1038/sj.onc.1205195			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850841				2022-12-25	WOS:000173729400009
J	Fekete, RA; Frost, LS				Fekete, RA; Frost, LS			Characterizing the DNA contacts and cooperative binding of F plasmid TraM to its cognate sites at oriT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACTERIAL CONJUGATION; SEX FACTOR; TRANSFER REGION; TRANSFER ORIGIN; HELICASE-I; PROTEIN; GENE; REPRESSION; EXPRESSION	TraM is a DNA binding protein required for conjugative transfer of the self-transmissible IncF group of plasmids, including F, R1, and R100. F TraM binds to three sites in F oriT. two high affinity binding sites, sbmA and sbmB, which are direct repeats of nearly identical sequence involved in the autoregulation of the traM gene; and a lower affinity site, sbmC, an inverted repeat important for transfer, which is situated nearest to the nic, site where transfer originates. TraM bound cooperatively to its binding sites at oriT; the presence of sbmA and sbmB increased the affinity for sbmC 10-fold. Bending of oriT DNA by TraM was minimal, suggesting that TraM, a tetramer, was able to loop the DNA when bound to sbmA and sbmB simultaneously. Hydroxyl radical footprinting of DNA of sbmA and sbmC revealed that TraM contacted the DNA within a region previously delineated by DNase I footprinting. TraM protected the CT bases within the sequence CTAG, which occurred at 12-base intervals on the top and bottom strand of sbmA, most consistently with other protected bases. The footprint on sbmC revealed that the predicted inverted repeats were protected by TraM with a pattern that began at the center of the repeats and radiated outward at 11-12 base intervals toward the 5'-ends of either strand. At high protein concentrations, this pattern extended beyond the footprint defined by DNase 1, suggesting that the DNA was wrapped around the protein forming a nucleosome-like structure, which could aid in preparing the DNA for transfer.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Frost, LS (corresponding author), Univ Alberta, Dept Biol Sci, CW405 Biol Sci Bldg, Edmonton, AB T6G 2E9, Canada.		Frost, Laura/A-2639-2014	Frost, Laura/0000-0002-8433-8230				ABO T, 1995, J BACTERIOL, V177, P4350, DOI 10.1128/jb.177.15.4350-4355.1995; ACHTMAN M, 1971, J BACTERIOL, V106, P529, DOI 10.1128/JB.106.2.529-538.1971; AUSUBEL FM, 1987, CURRENT PROTOCOLS S; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Cabezon E, 1997, MOL GEN GENET, V254, P400, DOI 10.1007/s004380050432; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CARLSON NG, 1993, J MOL BIOL, V230, P1108, DOI 10.1006/jmbi.1993.1229; Chatterjee J, 1996, MOL MICROBIOL, V20, P415, DOI 10.1111/j.1365-2958.1996.tb02628.x; DILAURENZIO L, 1992, MOL MICROBIOL, V6, P2951; DILAURENZIO L, 1995, MOL GEN GENET, V247, P726, DOI 10.1007/BF00290404; DisqueKochem C, 1997, J BACTERIOL, V179, P6133, DOI 10.1128/jb.179.19.6133-6137.1997; Fekete RA, 2000, J BACTERIOL, V182, P4022, DOI 10.1128/JB.182.14.4022-4027.2000; FREIFELDER D, 1982, PHYSICAL BIOCH APPL; FROST L, 1989, MOL GEN GENET, V218, P152, DOI 10.1007/BF00330578; Frost LS, 1998, MICROBIOL-SGM, V144, P2579, DOI 10.1099/00221287-144-9-2579; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FU YHF, 1991, J BACTERIOL, V173, P1012, DOI 10.1128/jb.173.3.1012-1020.1991; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Kupelwieser G, 1998, J MOL BIOL, V275, P81, DOI 10.1006/jmbi.1997.1436; Matson SW, 2001, J BIOL CHEM, V276, P2372, DOI 10.1074/jbc.M008728200; MATSON SW, 1993, J BACTERIOL, V175, P2599, DOI 10.1128/JB.175.9.2599-2606.1993; NELSON WC, 1995, J BIOL CHEM, V270, P28374; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; Penfold SS, 1996, MOL MICROBIOL, V20, P549, DOI 10.1046/j.1365-2958.1996.5361059.x; PENFOLD SS, 1995, THESIS U ALBERTA; Sambrook J., 2002, MOL CLONING LAB MANU; TSAI MM, 1990, J BACTERIOL, V172, P4603, DOI 10.1128/jb.172.8.4603-4609.1990; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; ZIEGELIN G, 1992, J BIOL CHEM, V267, P17279	29	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16705	16711		10.1074/jbc.M111682200	http://dx.doi.org/10.1074/jbc.M111682200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875064	hybrid			2022-12-25	WOS:000175564500049
J	Gonzalez-Guerrico, AM; Cafferata, EG; Radrizzani, M; Marcucci, F; Gruenert, D; Pivetta, OH; Favaloro, RR; Laguens, R; Perrone, SV; Gallo, GC; Santa-Coloma, TA				Gonzalez-Guerrico, AM; Cafferata, EG; Radrizzani, M; Marcucci, F; Gruenert, D; Pivetta, OH; Favaloro, RR; Laguens, R; Perrone, SV; Gallo, GC; Santa-Coloma, TA			Tyrosine kinase c-Src constitutes a bridge between cystic fibrosis transmembrane regulator channel failure and MUC1 overexpression in cystic fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EPITHELIAL-CELLS; CONDUCTANCE REGULATOR; PSEUDOMONAS-AERUGINOSA; DIFFERENTIAL DISPLAY; MESSENGER-RNA; CHLORIDE CHANNEL; CFTR; ACTIVATION; EXPRESSION	Cystic fibrosis (CF), a disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) chloride channel, is associated in the respiratory system with the accumulation of mucus and impaired lung function. The role of the CFTR channel in the regulation of the intracellular pathways that determine the overexpression of mucin genes is unknown. Using differential display, we have observed the differential expression of several mRNAs that may correspond to putative CFTR-dependent genes. One of these mRNAs was further characterized, and it corresponds to the tyrosine kinase c-Src. Additional results suggest that c-Src is a central element in the pathway connecting the CFTR channel with MUC1 overexpression and that the overexpression of mucins is a primary response to CFTR malfunction in cystic fibrosis, which occurs even in the absence of bacterial infection.	Univ Buenos Aires, CONICET, Inst Invest Bioquim, Fdn Campomar, RA-1405 Buenos Aires, DF, Argentina; ANLIS, Ctr Nacl Genet Med, RA-1425 Buenos Aires, DF, Argentina; Univ Vermont, Dept Med, Human Mol Genet Unit, Burlington, VT 05405 USA; Fdn Favaloro, RA-1093 Buenos Aires, DF, Argentina; Hosp Pediat Prof Dr Juan P Garrahan, RA-1425 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; University of Buenos Aires; University of Vermont; Hospital de Pediatria Doctor Juan Garrahan	Santa-Coloma, TA (corresponding author), Univ Buenos Aires, CONICET, Inst Invest Bioquim, Fdn Campomar, Av Patricias Argentinas 435, RA-1405 Buenos Aires, DF, Argentina.		Santa-Coloma, Tomas/I-1254-2019	Santa-Coloma, Tomas/0000-0002-3266-1095; Cafferata, Eduardo G/0000-0001-5089-3757				Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Brocardo MG, 2001, BIOCHEM BIOPH RES CO, V284, P982, DOI 10.1006/bbrc.2001.5066; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cafferata EG, 1996, CELL MOL BIOL, V42, P797; Cafferata EG, 2000, BBA-MOL BASIS DIS, V1500, P241, DOI 10.1016/S0925-4439(99)00105-2; Cafferata EGA, 2001, J BIOL CHEM, V276, P15441, DOI 10.1074/jbc.M010061200; CHAMBERS JA, 1994, J CELL SCI, V107, P413; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COZENS AL, 1992, P NATL ACAD SCI USA, V89, P5171, DOI 10.1073/pnas.89.11.5171; DAHIYA R, 1995, BIOCHEM MOL BIOL INT, V35, P351; Dehm S, 2001, FEBS LETT, V487, P367, DOI 10.1016/S0014-5793(00)02354-1; Esen M, 2001, INFECT IMMUN, V69, P281, DOI 10.1128/IAI.69.1.281-287.2001; Fischer H, 1996, BIOPHYS J, V71, P3073, DOI 10.1016/S0006-3495(96)79501-2; Hwang TC, 1999, TRENDS PHARMACOL SCI, V20, P448, DOI 10.1016/S0165-6147(99)01386-3; Ito Y, 2000, BIOCHEM BIOPH RES CO, V274, P230, DOI 10.1006/bbrc.2000.3125; Koegl M, 1995, ONCOGENE, V11, P2317; Kunzelmann K, 1996, GENE THER, V3, P859; Lei DC, 1996, GENE THER, V3, P427; Lepple-Wienhues A, 2000, CELL PHYSIOL BIOCHEM, V10, P307, DOI 10.1159/000016363; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Lillehoj EP, 2001, AM J PHYSIOL-LUNG C, V280, pL181, DOI 10.1152/ajplung.2001.280.1.L181; Liu XB, 1999, J BIOL CHEM, V274, P25121, DOI 10.1074/jbc.274.35.25121; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Osika E, 1999, EUR RESPIR J, V14, P339, DOI 10.1034/j.1399-3003.1999.14b17.x; Parmley RR, 1998, J CLIN INVEST, V102, P1798, DOI 10.1172/JCI3820; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SCHUSTER A, 1995, EUR ARCH ORTORHINO S, V1, P59; Shestakova EA, 2001, P NATL ACAD SCI USA, V98, P7045, DOI 10.1073/pnas.121146098; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Van Seuningen I, 2001, FRONT BIOSCI-LANDMRK, V6, pD1216; vonOlleschikElbheim L, 1996, J IMMUNOL METHODS, V197, P181, DOI 10.1016/0022-1759(96)00150-0; WAGNER JA, 1992, P NATL ACAD SCI USA, V89, P6785, DOI 10.1073/pnas.89.15.6785; Walsh KB, 1999, BRIT J PHARMACOL, V127, P369, DOI 10.1038/sj.bjp.0702562; Zhang ZR, 2000, J MEMBRANE BIOL, V175, P35, DOI 10.1007/s002320001053	44	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17239	17247		10.1074/jbc.M112456200	http://dx.doi.org/10.1074/jbc.M112456200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872746	hybrid			2022-12-25	WOS:000175564500118
J	Aleksandrov, L; Aleksandrov, AA; Chang, XB; Riordan, JR				Aleksandrov, L; Aleksandrov, AA; Chang, XB; Riordan, JR			The first nucleotide binding domain of cystic fibrosis transmembrane conductance regulator is a site of stable nucleotide interaction, whereas the second is a site of rapid turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; PROTEIN-KINASE-A; ATP-BINDING; SULFONYLUREA RECEPTOR; ABC TRANSPORTERS; P-GLYCOPROTEIN; WILD-TYPE; FOLD; SUBUNIT; PHOSPHORYLATION	As in other adenine nucleotide binding cassette (ABC) proteins the nucleotide binding domains of the cystic fibrosis transmembrane conductance regulator (CFTR) bind and hydrolyze ATP and in some manner regulate CFTR ion channel gating. Unlike some other ABC proteins, however, there are preliminary indications that the two domains of CFTR are nonequivalent in their nucleotide interactions (Szabo, K., Szakacs, G., Hegeds, T., and Sarkadi, B. (1999) J. Biol. Chem. 274,12209-12212; Aleksandrov, L., Mengos, A., Chang, X., Aleksandrov, A., and Riordan, J. R. (2001) J. Biol. Chem. 276, 1291812923). We have now characterized the interactions of the 8-azido-photoactive analogues of ATP, ADP, and 5'-adenyl-beta,gamma-imidodiphosphate (AMP-PNP) with the two domains of functional membrane-bound CFTR. The results show that the two domains appear to act independently in the binding and hydrolysis of 8-azido-ATP. At NBD1 binding does not require a divalent cation. This binding is followed by minimal Mg2+-dependent hydrolysis and retention of the hydrolysis product, 8-azido-ADP, but not as a vanadate stabilized post-hydrolysis transition state complex. In contrast, at NBD2, MgN(3)ATP is hydrolyzed as rapidly as it is bound and the nucleoside diphosphate hydrolysis product dissociates immediately. Confirming this characterization of NBD1 as a site of more stable nucleotide interaction and NBD2 as a site of fast turnover, the non-hydrolyzable N(3)AMP-PNP bound preferentially to NBD1. This demonstration of NBD2 as the rapid nucleotide turnover site is consistent with the strong effect on channel gating kinetics of inactivation of this domain by mutagenesis.	Mayo Fdn & Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Riordan, JR (corresponding author), Mayo Clin Scottsdale, SC Johnson Med Res Ctr, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	riordan@mayo.edu			NIDDK NIH HHS [DK51619] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051619] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aleksandrov AA, 2000, J PHYSIOL-LONDON, V528, P259, DOI 10.1111/j.1469-7793.2000.00259.x; Aleksandrov L, 2001, J BIOL CHEM, V276, P12918, DOI 10.1074/jbc.M100515200; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; CHANG XB, 1993, J BIOL CHEM, V268, P11304; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Duffieux F, 2000, EUR J BIOCHEM, V267, P5306, DOI 10.1046/j.1432-1327.2000.01614.x; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Howell LD, 2000, BIOCHEM BIOPH RES CO, V271, P518, DOI 10.1006/bbrc.2000.2659; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Ikuma M, 2000, P NATL ACAD SCI USA, V97, P8675, DOI 10.1073/pnas.140220597; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KO YH, 1993, J BIOL CHEM, V268, P24330; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Lu NT, 2000, ARCH BIOCHEM BIOPHYS, V375, P7, DOI 10.1006/abbi.1999.1656; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Neville DCA, 1998, BIOCHEMISTRY-US, V37, P2401, DOI 10.1021/bi972021k; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Randak C, 1997, FEBS LETT, V410, P180, DOI 10.1016/S0014-5793(97)00574-7; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Saurin W, 1999, J MOL EVOL, V48, P22, DOI 10.1007/PL00006442; Schultz BD, 1996, J MEMBRANE BIOL, V151, P63, DOI 10.1007/s002329900058; Seibert FS, 1999, BBA-BIOMEMBRANES, V1461, P275, DOI 10.1016/S0005-2736(99)00163-7; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Yike I, 1996, PROTEIN SCI, V5, P89; Zingman LV, 2002, J BIOL CHEM, V277, P14206, DOI 10.1074/jbc.M109452200; Zou XQ, 2001, BIOCHEMISTRY-US, V40, P5579, DOI 10.1021/bi010133c	43	152	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15419	15425		10.1074/jbc.M111713200	http://dx.doi.org/10.1074/jbc.M111713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861646	hybrid			2022-12-25	WOS:000175510400027
J	Camerer, E; Kataoka, H; Kahn, M; Lease, K; Coughlin, SR				Camerer, E; Kataoka, H; Kahn, M; Lease, K; Coughlin, SR			Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR XA; COLI SEPTIC SHOCK; THROMBIN RECEPTOR; ESCHERICHIA-COLI; TISSUE FACTOR; DEPENDENT RELAXATIONS; FACTOR VIIA; RAT AORTA; EXPRESSION; PAR-2	The coagulation protease Factor Xa (Xa)(1) triggers a variety of cellular responses that may be important for inflammatory reactions to tissue injury. Protease-activated receptors (PAR1, PAR2, and PAR4) can mediate Xa signaling in heterologous expression systems. However, other candidate Xa receptors have been described, and the extent to which one or more PARs account for Xa signaling in relevant differentiated cells is unknown. We examined Xa signaling in endothelial cells from wildtype and PAR-deficient mice. Wild-type endothelial cells responded to agonists for PAR1, PAR2, and PAR4. Relative to wild-type, Xa-triggered phosphoinositide hydrolysis was reduced by 60-75% in Par2 -/- endothelial cells, by 20-30% in Par1 -/- endothelial cells, and by similar to90% in Par2 -/- endothelial cells treated with a PARI antagonist. Similar results were obtained when ERK1/2 phosphorylation was used to assess Xa signaling. Thus PAR2 is the main endogenous Xa receptor in these endothelial cell preparations and, together, PAR2 and PAR1 appear to account for similar to90% of endothelial Xa signaling. By contrast, in fibroblasts, PAR1 by itself accounted for virtually all Xa-induced phosphoinositide hydrolysis. This information is critical for the design and interpretation of knockout mouse studies to probe the possible roles of Xa signaling in vivo.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Coughlin, SR (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Rm HSE-1300,513 Parnassus Ave, San Francisco, CA 94143 USA.		Camerer, Eric/K-4161-2017	Camerer, Eric/0000-0002-6271-7125	NHLBI NIH HHS [HL65185, HL44907, HL65590] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907, R01HL065185, R01HL065590] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1995, FASEB J, V9, P860, DOI 10.1096/fasebj.9.10.7615156; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Bono F, 2000, ARTERIOSCL THROM VAS, V20, pE107, DOI 10.1161/01.ATV.20.11.e107; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; Esmon CT, 2000, BLOOD, V95, P1113, DOI 10.1182/blood.V95.4.1113.004k54_1113_1116; Esmon CT, 2001, THROMB HAEMOSTASIS, V86, P51; GAJDUSEK C, 1986, J CELL BIOL, V103, P419, DOI 10.1083/jcb.103.2.419; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Hamilton JR, 2001, CIRC RES, V89, P92, DOI 10.1161/hh1301.092661; Hoffman M, 2001, THROMB HAEMOSTASIS, V85, P958, DOI 10.1055/s-0037-1615947; ISHII K, 1993, J BIOL CHEM, V268, P9780; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kawabata A, 2001, BIOCHEM BIOPH RES CO, V282, P432, DOI 10.1006/bbrc.2001.4597; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Molino M, 1998, ARTERIOSCL THROM VAS, V18, P825, DOI 10.1161/01.ATV.18.5.825; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Nicholson AC, 1996, J BIOL CHEM, V271, P28407, DOI 10.1074/jbc.271.45.28407; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; Papapetropoulos A, 1998, P NATL ACAD SCI USA, V95, P4738, DOI 10.1073/pnas.95.8.4738; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Schaeffer P, 1997, CIRC RES, V81, P824; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Senden NHM, 1998, J IMMUNOL, V161, P4318; Taylor FB, 1998, BLOOD, V91, P1609, DOI 10.1182/blood.V91.5.1609.1609_1609_1615; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TAYLOR FB, 1991, BLOOD, V78, P364; Trejo J, 1996, J BIOL CHEM, V271, P21536, DOI 10.1074/jbc.271.35.21536; Zaman GJR, 2000, BLOOD, V96, P145, DOI 10.1182/blood.V96.1.145.013k34_145_148	41	135	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16081	16087		10.1074/jbc.M108555200	http://dx.doi.org/10.1074/jbc.M108555200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11850418	hybrid			2022-12-25	WOS:000175510400115
J	Potente, M; Michaelis, UR; Fisslthaler, B; Busse, R; Fleming, I				Potente, M; Michaelis, UR; Fisslthaler, B; Busse, R; Fleming, I			Cytochrome P4502C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERIAL SMOOTH-MUSCLE; ARACHIDONIC-ACID; 11,12-EPOXYEICOSATRIENOIC ACID; EPOXYEICOSATRIENOIC ACIDS; SIGNALING PATHWAYS; CORONARY-ARTERIES; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; NH2-TERMINAL KINASE; BINDING PROTEIN	Cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) are important modulators of endothelial cell homeostasis. We investigated the signaling pathway linking the activation of CYP 2C9 to enhanced endothelial. cell proliferation. Overexpression of CYP 2C9 in cultured human endothelial cells markedly increased proliferation. This effect was paralleled by an up-regulation of the G, phase regulatory protein, cyclin D1. The specific CYP 2C9 inhibitor, sulfaphenazole, prevented both the enhanced cell proliferation and up-regulation of cyclin D1. CYP 2C9 overexpression also decreased the activity of the c-Jun N-terminal kinase (JNK). Coexpression of wild type JNK with CYP 2C9 attenuated the CYP 2C9-induced increase in cyclin D1 expression and abolished the CYP 2C9-induced proliferation response. In contrast, cotransfecting dominant negative JNK with CYP 2C9 restored the CYP 2C9-mediated up-regulation of cyclin D1 and proliferation. The inactivation of JNK is linked to its dephosphorylation by dual specificity mitogen-activated protein (MAP) kinase phosphatases (MKPs). Overexpression of CYP 2C9 significantly increased the expression of MKP-1, as did incubation with 11, 12-EET. These data demonstrate that the mitogenic effect of CYP 2C9 is due to the generation of EETs, which promote the MKP-1-mediated dephosphorylation and inactivation of JNK, effects ultimately culminating in the expression of cyclin D1 and endothelial cell proliferation.	Univ Frankfurt Klinikum, Inst Kardiovasc Physiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Fleming, I (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovasc Physiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Fleming, Ingrid/AAB-6123-2022; Fleming, Ingrid/L-1225-2014	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635; Potente, Michael/0000-0002-5689-0036				BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Campbell W B, 2001, Med Sci Monit, V7, P578; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Chen JK, 1999, J BIOL CHEM, V274, P4764, DOI 10.1074/jbc.274.8.4764; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Chen JK, 1998, J BIOL CHEM, V273, P29254, DOI 10.1074/jbc.273.44.29254; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cook SJ, 2000, BIOCHEM SOC T, V28, P233, DOI 10.1042/bst0280233; DAIKH BE, 1994, J PHARMACOL EXP THER, V271, P1427; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Fisslthaler B, 2000, HYPERTENSION, V36, P270, DOI 10.1161/01.HYP.36.2.270; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Fisslthaler B, 2001, HYPERTENSION, V38, P1427, DOI 10.1161/hy1201.096532; Fleming I, 1996, J BIOL CHEM, V271, P11009, DOI 10.1074/jbc.271.18.11009; Fleming I, 2001, PFLUG ARCH EUR J PHY, V442, P511, DOI 10.1007/s004240100565; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Fleming I, 2001, CIRC RES, V89, P753, DOI 10.1161/hh2101.099268; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Hoebel BG, 1998, EUR J PHARMACOL, V346, P115, DOI 10.1016/S0014-2999(98)00118-6; Hofken T, 2000, BIOCHEM BIOPH RES CO, V276, P680, DOI 10.1006/bbrc.2000.3530; Imig JD, 1999, HYPERTENSION, V33, P408, DOI 10.1161/01.HYP.33.1.408; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li PL, 1997, HYPERTENSION, V29, P262, DOI 10.1161/01.HYP.29.1.262; Li PL, 1999, CIRC RES, V85, P349, DOI 10.1161/01.RES.85.4.349; Li PL, 1997, CIRC RES, V80, P877; LIN JHC, 1996, ENDOTHELIUM, V4, P219; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Mancy A, 1996, BIOCHEMISTRY-US, V35, P16205, DOI 10.1021/bi961950t; Muthalif MM, 2001, PROSTAG OTH LIPID M, V65, P33, DOI 10.1016/S0090-6980(01)00112-5; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Pedram A, 2001, ENDOCRINOLOGY, V142, P1578, DOI 10.1210/en.142.4.1578; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Ruiz-Gines JA, 2000, J CARDIOVASC PHARM, V35, P109, DOI 10.1097/00005344-200001000-00014; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Wong PYK, 2000, PROSTAG OTH LIPID M, V62, P321, DOI 10.1016/S0090-6980(00)00079-4	42	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15671	15676		10.1074/jbc.M110806200	http://dx.doi.org/10.1074/jbc.M110806200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867622	hybrid			2022-12-25	WOS:000175510400062
J	Stitham, J; Stojanovic, A; Hwa, J				Stitham, J; Stojanovic, A; Hwa, J			Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; BETA(2)-ADRENERGIC RECEPTOR; LIGAND-BINDING; PULMONARY-HYPERTENSION; TRANSGENIC MICE; PROTEIN; GENE; IDENTIFICATION; MUTATIONS; DOPAMINE	The human prostacyclin receptor (hIP) is a seven transmembrane-spanning G-protein-coupled receptor that plays an important role in vascular homeostasis. Recent genetic analyses (SNP database, NCBI) have revealed the first two polymorphisms within the coding sequence, V25M and R212H. Here we present structure-function characterizations of these polymorphisms at physiological pH (7.4) and at an acidic pH (6.8) that would be encountered during stress such as renal, respiratory, or heart failure. Through a series of competition binding and G-protein activation assays (measured by cAMP production), we determined that the V25M polymorph exhibited agonist binding and G-protein activation similar to wild-type receptor at normal pH (7.4). However, the R212H variant demonstrated a significant decrease in binding affinity at lower pH (R212H at pH 7.4, K-i = 2.2 +/- 1.2 nM; pH 6.8 K-i = 45.6 +/- 12.0 nM). The R212H polymorph also exhibited abnormal activation at both pH 7.4 and pH 6.8 (pH 7.4, R212H EC50 = 2.8 +/- 0.5 nM versus wild-type hIP EC50 = 0.5 +/- 0.1 nM; pH 6.8, R212H EC50 = 3.2 +/- 1.6 nM versus wild-type hIP EC50 = 0.5 +/- 0.2 nM). Polymorphisms of the human prostacyclin receptor potentially may be important predictors of disease progress during biological stressors such as acidosis in which urgent correction of bodily pH may be required to restore normal hemostasis and vasodilation. This study provides the mechanistic basis for further research into genetic risk factors and pharmacogenetics of cardiovascular disease associated with hIP.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	Hwa, J (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.							Bengtsson K, 2001, CIRCULATION, V104, P187, DOI 10.1161/01.CIR.104.2.187; Cravchik A, 1996, J BIOL CHEM, V271, P26013, DOI 10.1074/jbc.271.42.26013; GAUDIN C, 1995, J CLIN INVEST, V95, P1676, DOI 10.1172/JCI117843; Hayes JS, 1999, J BIOL CHEM, V274, P23707, DOI 10.1074/jbc.274.34.23707; Hiratsuka M, 2001, MOL GENET METAB, V73, P298, DOI 10.1006/mgme.2001.3204; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Kam YW, 2001, CELL SIGNAL, V13, P841, DOI 10.1016/S0898-6568(01)00210-8; Kobayashi T, 2000, J BIOL CHEM, V275, P24294, DOI 10.1074/jbc.M002437200; Kobayashi T, 1997, J BIOL CHEM, V272, P15154, DOI 10.1074/jbc.272.24.15154; Liggett SB, 1998, J CLIN INVEST, V102, P1534, DOI 10.1172/JCI4059; Liggett SB, 1997, AM J RESP CRIT CARE, V156, pS156, DOI 10.1164/ajrccm.156.4.12tac-15; Liu ISC, 1996, AM J MED GENET, V61, P277, DOI 10.1002/(SICI)1096-8628(19960122)61:3<277::AID-AJMG14>3.3.CO;2-5; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Nagaya N, 1999, J AM COLL CARDIOL, V34, P1188, DOI 10.1016/S0735-1097(99)00312-5; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; Olschewski H, 2000, ANN INTERN MED, V132, P435, DOI 10.7326/0003-4819-132-6-200003210-00003; Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407; Rana BK, 2001, ANNU REV PHARMACOL, V41, P593, DOI 10.1146/annurev.pharmtox.41.1.593; ROSENTHAL W, 1994, CELL MOL BIOL, V40, P429; Sherry ST, 1999, GENOME RES, V9, P677; Smyth EM, 2000, J BIOL CHEM, V275, P32037, DOI 10.1074/jbc.M003873200; STITHAM J, 2002, IN PRESS MOL PHARM; Tanaka H, 1998, J BIOL CHEM, V273, P11378, DOI 10.1074/jbc.273.18.11378; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; Zhang ZB, 2001, MOL PHARMACOL, V60, P480	27	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15439	15444		10.1074/jbc.M201187200	http://dx.doi.org/10.1074/jbc.M201187200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854299	hybrid			2022-12-25	WOS:000175510400030
J	Terentis, AC; Thomas, SR; Takikawa, O; Littlejohn, TK; Truscott, RJW; Armstrong, RS; Yeh, SR; Stocker, R				Terentis, AC; Thomas, SR; Takikawa, O; Littlejohn, TK; Truscott, RJW; Armstrong, RS; Yeh, SR; Stocker, R			The heme environment of recombinant human indoleamine 2,3-dioxygenase - Structural properties and substrate-ligand interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; HORSERADISH-PEROXIDASE; EFFECTOR INTERACTIONS; TRYPTOPHAN BINDING; SUPEROXIDE ANION; CAVITY STRUCTURE; AXIAL LIGAND; MYOGLOBIN; ENZYME; OXYGEN	Indoleamine 2,3-dioxygenase is a heme enzyme that catalyzes the oxidative degradation of L-Trp and other indoleamines. We have used resonance Raman spectroscopy to characterize the heme environment of purified recombinant human indoleamine 2,3-dioxygenase (hIDO). In the absence of L-Trp, the spectrum of the Fe3+ form displayed six-coordinate, mixed high and low spin character. Addition of L-Trp triggered a transition to predominantly low spin with two Fe-OH- stretching modes identified at 546 and 496 cm(-1), suggesting H-bonding between the NH group of the pyrrole ring of L-Trp and heme-bound OH-. The distal pocket of Fe3+ hIDO was explored further by an exogenous heme ligand, CN-; again, binding of L-Trp introduced strong H-bonding and/or steric interactions to the heme-bound CN-. On the other hand, the spectrum of Fe2+ hIDO revealed a five-coordinate and high spin heme with or without L-Trp bound. The proximal Fe-His stretching mode, identified at 236 cm(-1), did not shift Upon L-Trp addition, indicating that the proximal Fe-His bond strength is not affected by binding of the substrate. The high Fe-His stretching frequency suggests that Fe2+ hIDO has a strong "peroxidase-like" Fe-His bond. Using CO as a structural probe for the distal environment of Fe2+ hIDO revealed that binding of L-Trp in the distal pocket converted IDO to a peroxidase-like enzyme. Binding of L-Trp also caused conformational changes to the heme vinyl groups, which were independent of changes of the spin and coordination state of the heme iron. Together these data indicate that the strong proximal Fe-His bond and the strong H-bonding and/or steric interactions between L-Trp and dioxygen in the distal pocket are likely crucial for the enzymatic activity of hIDO.	Heart Res Inst, Biochem Grp, Camperdown, NSW 2050, Australia; Hokkaido Univ, Dept Pharmacol, Sapporo, Hokkaido 0608638, Japan; Univ Wollongong, Australian Cataract Res Fdn, Wollongong, NSW 2522, Australia; Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	University of Sydney; Heart Research Institute; Hokkaido University; University of Wollongong; University of Sydney; Yeshiva University; Albert Einstein College of Medicine	Stocker, R (corresponding author), Univ New S Wales, Ctr Thrombosis & Vasc Biol, Sydney, NSW 2052, Australia.	r.stocker@unsw.edu.au	Terentis, Andrew/N-9188-2019; Stocker, Roland/AAV-4489-2021	Terentis, Andrew/0000-0001-6137-8275; Stutchbury, Tamantha/0000-0001-9308-4562; Yeh, Syun-Ru/0000-0002-9858-386X	NHLBI NIH HHS [HL65465] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065465] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMUSTAFA J, 1995, J BIOL CHEM, V270, P10449, DOI 10.1074/jbc.270.18.10449; ALMUSTAFA J, 1994, BIOCHEMISTRY-US, V33, P2191, DOI 10.1021/bi00174a028; CADY SG, 1991, ARCH BIOCHEM BIOPHYS, V291, P326, DOI 10.1016/0003-9861(91)90142-6; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; Feis A, 1998, BIOCHEMISTRY-US, V37, P13575, DOI 10.1021/bi981399v; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; Franzen S, 1998, J AM CHEM SOC, V120, P4658, DOI 10.1021/ja973212d; HAYAISHI O, 1977, J BIOL CHEM, V252, P3548; HAYAISHI O, 1985, BIKEN J, V28, P39; HIRATA F, 1977, J BIOL CHEM, V252, P4637; Hirota S, 1996, J PHYS CHEM-US, V100, P15274, DOI 10.1021/jp953190m; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1990, J PHYS CHEM-US, V94, P47, DOI 10.1021/j100364a008; Littlejohn TK, 2000, PROTEIN EXPRES PURIF, V19, P22, DOI 10.1006/prep.2000.1214; NAKAGAWA M, 1977, P NATL ACAD SCI USA, V74, P4730, DOI 10.1073/pnas.74.11.4730; OHNISHI T, 1977, J BIOL CHEM, V252, P4643; Smulevich G, 1998, BIOSPECTROSCOPY, V4, pS3, DOI 10.1002/(SICI)1520-6343(1998)4:5+<S3::AID-BSPY2>3.0.CO;2-R; Smulevich G., 1993, BIOMOLECULAR SPECT A, P163; SONO M, 1980, J BIOL CHEM, V255, P1339; SONO M, 1989, BIOCHEMISTRY-US, V28, P5400, DOI 10.1021/bi00439a013; SONO M, 1989, BIOCHEMISTRY-US, V28, P5392, DOI 10.1021/bi00439a012; SONO M, 1990, BIOCHEMISTRY-US, V29, P1451, DOI 10.1021/bi00458a016; SONO M, 1989, J BIOL CHEM, V264, P1616; SONO M, 1984, BIOCHIM BIOPHYS ACTA, V789, P170, DOI 10.1016/0167-4838(84)90202-4; Southan MD, 1996, MED CHEM RES, V6, P343; Spiro, 1988, BIOL APPL RAMAN SPEC, P1; SUZUKI T, 1992, J MOL BIOL, V228, P698, DOI 10.1016/0022-2836(92)90854-D; Suzuki T, 1998, J PROTEIN CHEM, V17, P817, DOI 10.1023/A:1020782403070; Suzuki T, 1998, COMP BIOCHEM PHYS B, V121, P117, DOI 10.1016/S0305-0491(98)10086-X; TANIGUCHI T, 1979, J BIOL CHEM, V254, P3288; Thomas SR, 1999, REDOX REP, V4, P199, DOI 10.1179/135100099101534927; TONE S, 1990, NUCLEIC ACIDS RES, V18, P367, DOI 10.1093/nar/18.2.367; UCHIDA K, 1985, J BIOL CHEM, V260, P1400; Vogel KM, 2000, INORG CHIM ACTA, V297, P11, DOI 10.1016/S0020-1693(99)00253-4; Wang J., 1996, METHODS NITRIC OXIDE, P427; WITKOP B, 1951, J AM CHEM SOC, V73, P2196, DOI 10.1021/ja01149a080; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; YOSHIDA R, 1987, METHOD ENZYMOL, V142, P188; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	41	85	87	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15788	15794		10.1074/jbc.M200457200	http://dx.doi.org/10.1074/jbc.M200457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867636	hybrid			2022-12-25	WOS:000175510400077
J	Bartolini, F; Bhamidipati, A; Thomas, S; Schwahn, U; Lewis, SA; Cowan, NJ				Bartolini, F; Bhamidipati, A; Thomas, S; Schwahn, U; Lewis, SA; Cowan, NJ			Functional overlap between retinitis pigmentosa 2 protein and the tubulin-specific chaperone cofactor C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED RETINITIS-PIGMENTOSA; NUCLEOTIDE-EXCHANGE FACTOR; GTP-BINDING PROTEIN; ARF FAMILY; SACCHAROMYCES-CEREVISIAE; POSITIONAL CLONING; DELTA-SUBUNIT; N-TERMINUS; GENE; MUTATIONS	Mutations in the X-linked retinitis pigmentosa 2 gene cause progressive degeneration of photoreceptor cells. The retinitis pigmentosa 2 protein (RP2) is similar in sequence to the tubulin-specific chaperone cofactor C. Together with cofactors D and E, cofactor C stimulates the GTPase activity of native tubulin, a reaction regulated by ADP-ribosylation factor-like 2 protein. Here we show that in the presence of cofactor D, RP2 protein also stimulates the GTPase activity of tubulin. We find that this function is abolished by mutation in an arginine residue that is conserved in both cofactor C and RP2. Notably, mutations that alter this arginine codon cause familial retinitis pigmentosa. Our data imply that this residue acts as an "arginine finger" to trigger the tubulin GTPase activity and suggest that loss of this function in RP2 contributes to retinal degeneration. We also show that in Saccharomyces cerevisiae, both cofactor C and RP2 partially complement the microtubule phenotype resulting from deletion of the cofactor C homolog, demonstrating their functional overlap in vivo. Finally, we find that RP2 interacts with GTP-bound ADP ribosylation factor-like 3 protein, providing a link between RP2 and several retinal-specific proteins, mutations in which also cause retinitis pigmentosa.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Aventis Pharma Deutschland, DG Metab Dis Ind Pk Hochst, D-65926 Frankfurt, Germany	New York University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Sanofi-Aventis	Lewis, SA (corresponding author), NYU, Med Ctr, Dept Biochem, 550 1st Ave, New York, NY 10016 USA.	sally.lewis@med.nyu.edu						Amor JC, 2001, J BIOL CHEM, V276, P42477, DOI 10.1074/jbc.M106660200; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOUGHMAN JA, 1980, AM J HUM GENET, V32, P223; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CARLIER MF, 1992, PHILOS T R SOC B, V336, P93, DOI 10.1098/rstb.1992.0048; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; Chapple JP, 2000, HUM MOL GENET, V9, P1919, DOI 10.1093/hmg/9.13.1919; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; Fleming JA, 2000, GENETICS, V156, P69; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Hong JX, 1998, J BIOL CHEM, V273, P15872, DOI 10.1074/jbc.273.25.15872; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; Hoyt MA, 1997, GENETICS, V146, P849; Jacobs S, 1999, FEBS LETT, V456, P384, DOI 10.1016/S0014-5793(99)00759-0; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lewis SA, 1997, TRENDS CELL BIOL, V7, P479, DOI 10.1016/S0962-8924(97)01168-9; Linari M, 1999, P NATL ACAD SCI USA, V96, P1315, DOI 10.1073/pnas.96.4.1315; Linari M, 1999, FEBS LETT, V458, P55, DOI 10.1016/S0014-5793(99)01117-5; Mayer U, 1999, EUR J CELL BIOL, V78, P100, DOI 10.1016/S0171-9335(99)80011-9; McElver J, 2000, PLANT CELL, V12, P1379, DOI 10.1105/tpc.12.8.1379; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; Radcliffe PA, 2000, GENETICS, V156, P93; Radcliffe PA, 2000, FEBS LETT, V468, P84, DOI 10.1016/S0014-5793(00)01202-3; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schwahn U, 1998, NAT GENET, V19, P327, DOI 10.1038/1214; Schwahn U, 2001, HUM MOL GENET, V10, P1177, DOI 10.1093/hmg/10.11.1177; Sharer JD, 1999, J BIOL CHEM, V274, P27553, DOI 10.1074/jbc.274.39.27553; Sharon D, 2000, INVEST OPHTH VIS SCI, V41, P2712; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; STEARNS T, 1990, GENETICS, V124, P251; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; Tian GL, 1999, J BIOL CHEM, V274, P24054, DOI 10.1074/jbc.274.34.24054; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; Vaughan M, 1997, ADV EXP MED BIOL, V419, P315; ZABALA JC, 1992, CELL MOTIL CYTOSKEL, V23, P222, DOI 10.1002/cm.970230306	44	77	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14629	14634		10.1074/jbc.M200128200	http://dx.doi.org/10.1074/jbc.M200128200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847227	hybrid			2022-12-25	WOS:000175203000036
J	Okun, JG; Horster, F; Farkas, LM; Feyh, P; Hinz, A; Sauer, S; Hoffmann, GF; Unsicker, K; Mayatepek, E; Kolker, S				Okun, JG; Horster, F; Farkas, LM; Feyh, P; Hinz, A; Sauer, S; Hoffmann, GF; Unsicker, K; Mayatepek, E; Kolker, S			Neurodegeneration in methylmalonic aciduria involves inhibition of complex II and the tricarboxylic acid cycle, and synergistically acting excitotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SUCCINATE-DEHYDROGENASE; POSSIBLE EXPLANATION; PROPIONIC ACIDEMIA; BOVINE HEART; BRAIN; METABOLISM; OXIDATION; 2-METHYLCITRATE; OXIDOREDUCTASE	Methylmalonic acidurias are biochemically characterized by an accumulation of methylmalonate (MMA) and alternative metabolites. There is growing evidence for basal ganglia degeneration in these patients. The pathomechanisms involved are still unknown, a contribution of toxic organic acids, in particular MMA, has been suggested. Here we report that MMA induces neuronal damage in cultures of embryonic rat striatal cells at a concentration range encountered in affected patients. MMA-induced cell damage was reduced by ionotropic glutamate receptor antagonists, antioxidants, and succinate. These results suggest the involvement of secondary excitotoxic mechanisms in MMA-induced cell damage. MMA has been implicated in inhibition of respiratory chain complex II. However, MMA failed to inhibit complex II activity in submitochondrial particles from bovine heart. To unravel the mechanism underlying neuronal MMA toxicity, we investigated the formation of intracellular metabolites in MMA-loaded striatal neurons. There was a time-dependent intracellular increase in malonate, an inhibitor of complex II, and 2-methylcitrate, a compound with multiple inhibitory effects on the tricarboxylic acid cycle, suggesting their putative implication in MMA neurotoxicity. We propose that neuropathogenesis of methylmalonic aciduria may involve an inhibition of complex II and the tricarboxylic acid cycle by accumulating toxic organic acids, and synergistic secondary excitotoxic mechanisms.	Heidelberg Univ, Dept Pediat, Div Metab & Endocrine Dis, D-69120 Heidelberg, Germany; Heidelberg Univ, Dept Neuroanat, D-69120 Heidelberg, Germany; Heidelberg Univ, Interdisciplinary Ctr Neurosci, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Okun, JG (corresponding author), Univ Childrens Hosp, Div Metab & Endocrine Dis, Neuenheimer Feld 150, D-69120 Heidelberg, Germany.	Juergen_Okun@med.uni-heidelberg.de						ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; ANDO T, 1972, P NATL ACAD SCI USA, V69, P2807, DOI 10.1073/pnas.69.10.2807; ANDO T, 1972, J BIOL CHEM, V247, P2200; BEAL MF, 1993, J NEUROSCI, V13, P4181; BRANDANGE S, 1984, ACTA CHEM SCAND B, V38, P695, DOI 10.3891/acta.chem.scand.38b-0695; Brandt U, 1997, BIOCHEMISTRY-US, V36, P11234, DOI 10.1021/bi970968g; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BRISMAR J, 1994, AM J NEURORADIOL, V15, P1459; CHEEMADHADLI S, 1975, PEDIATR RES, V9, P905, DOI 10.1203/00006450-197512000-00008; COUDE FX, 1979, J CLIN INVEST, V64, P1544, DOI 10.1172/JCI109614; Dawson R.M.C, 1986, DATA BIOCH RES, P356; deMello CF, 1996, BRAIN RES, V721, P120, DOI 10.1016/0006-8993(96)00117-5; DUTRA JC, 1993, J INHERIT METAB DIS, V16, P147, DOI 10.1007/BF00711328; ERECINSKA M, 1990, J GEN PHYSIOL, V95, P591, DOI 10.1085/jgp.95.4.591; Farkas LM, 1997, J NEUROSCI RES, V50, P361; Fato R, 1996, BIOCHEMISTRY-US, V35, P2705, DOI 10.1021/bi9516034; Fenton WA, 2001, METABOLIC MOL BASES, P2165; Fighera MR, 1999, NEUROREPORT, V10, P2039, DOI 10.1097/00001756-199907130-00009; GREENE JG, 1993, J NEUROCHEM, V61, P1151, DOI 10.1111/j.1471-4159.1993.tb03634.x; HALPERIN ML, 1971, J CLIN INVEST, V50, P2276, DOI 10.1172/JCI106725; HEIDENREICH R, 1988, J PEDIATR-US, V113, P1022, DOI 10.1016/S0022-3476(88)80574-2; Horswill AR, 2001, J BIOL CHEM, V276, P19094, DOI 10.1074/jbc.M100244200; Kolker S, 2000, J INHERIT METAB DIS, V23, P355, DOI 10.1023/A:1005631230455; Kolker S, 2000, PEDIATR RES, V47, P495; Kolker S, 2001, J NEUROSCI RES, V66, P666, DOI 10.1002/jnr.10012; Larnaout A, 1998, J INHERIT METAB DIS, V21, P639, DOI 10.1023/A:1005428432730; LEDLEY FD, 1988, AM J HUM GENET, V42, P839; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHONEY MJ, 1975, P NATL ACAD SCI USA, V72, P2799, DOI 10.1073/pnas.72.7.2799; MARTIN JJ, 1988, J NEUROL SCI, V84, P189, DOI 10.1016/0022-510X(88)90124-4; MATSUI SM, 1983, NEW ENGL J MED, V308, P857, DOI 10.1056/NEJM198304143081501; McLaughlin BA, 1998, NEUROSCIENCE, V86, P279, DOI 10.1016/S0306-4522(97)00594-0; Narasimhan P, 1996, J NEUROSCI, V16, P7336; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OBERHOLZ.VG, 1967, ARCH DIS CHILD, V42, P492, DOI 10.1136/adc.42.225.492; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; SORENSEN RG, 1982, J BIOENERG BIOMEMBR, V14, P527, DOI 10.1007/BF00743076; STEWART PM, 1980, J CLIN INVEST, V66, P484, DOI 10.1172/JCI109879; THOMPSON GN, 1989, J PEDIATR-US, V115, P735, DOI 10.1016/S0022-3476(89)80651-1; Trinh BC, 2001, AM J NEURORADIOL, V22, P831; TSIEN RY, 1981, NATURE, V290, P527, DOI 10.1038/290527a0; VANDERMEER SB, 1994, J PEDIATR-US, V125, P903, DOI 10.1016/S0022-3476(05)82005-0; Wajner M, 1997, J INHERIT METAB DIS, V20, P761, DOI 10.1023/A:1005359416197; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052; Yu XM, 1998, NATURE, V396, P469, DOI 10.1038/24877; ZIEGLER D, 1967, METHOD ENZYMOL, V10, P231	47	143	147	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14674	14680		10.1074/jbc.M200997200	http://dx.doi.org/10.1074/jbc.M200997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847233	hybrid			2022-12-25	WOS:000175203000042
J	Ueda, HR; Matsumoto, A; Kawamura, M; Iino, M; Tanimura, T; Hashimoto, S				Ueda, HR; Matsumoto, A; Kawamura, M; Iino, M; Tanimura, T; Hashimoto, S			Genome-wide transcriptional orchestration of circadian rhythms in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CLOCK; TIMELESS; PERIOD; MELANOGASTER; GLUTAMATE; FEEDBACK	Circadian rhythms govern the behavior, physiology, and metabolism of living organisms. Recent studies have revealed the role of several genes in the clock mechanism both in Drosophila and in mammals. To study how gene expression is globally regulated by the clock mechanism, we used a high density oligonuelcotide probe array (GeneChip) to profile gene expression patterns in Drosophila under light-dark and constant dark conditions. We found 712 genes showing a daily fluctuation in mRNA levels under light-dark conditions, and among these the expression of 115 genes was still cycling in constant darkness, i.e. under free-running conditions. Unexpectedly the expression of a large number of genes cycled exclusively under constant darkness. We found that cycling in most of these genes was lost in the arrhythmic Clock (Clk) mutant under light-dark conditions. Expression of periodically regulated genes is coordinated locally on chromosomes where small clusters of genes are regulated jointly. Our findings reveal that many genes involved in diverse functions are under circadian control and reveal the complexity of circadian gene expression in Drosophila.	Univ Tokyo, Grad Sch Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1130033, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Res Labs, Tsukuba, Ibaraki 3058585, Japan; Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8108560, Japan	University of Tokyo; Astellas Pharmaceuticals; Kyushu University	Ueda, HR (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1130033, Japan.		Ueda, Hiroki R/C-5037-2014	Ueda, Hiroki R/0000-0001-8342-9176				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; Chen B, 1999, J COMP PHYSIOL A, V185, P393, DOI 10.1007/s003590050400; Claridge-Chang A, 2001, NEURON, V32, P657, DOI 10.1016/S0896-6273(01)00515-3; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; Crosio C, 2000, NAT NEUROSCI, V3, P1241, DOI 10.1038/81767; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Glossop NRJ, 1999, SCIENCE, V286, P766, DOI 10.1126/science.286.5440.766; Goto S, 2000, NUCLEIC ACIDS RES, V28, P380, DOI 10.1093/nar/28.1.380; Grundschober C, 2001, J BIOL CHEM, V276, P46751, DOI 10.1074/jbc.M107499200; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; LIU Y, 1995, GENE DEV, V9, P1469, DOI 10.1101/gad.9.12.1469; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; MOORE RY, 1993, NEUROSCI LETT, V150, P112, DOI 10.1016/0304-3940(93)90120-A; Mrosovsky N, 1999, CHRONOBIOL INT, V16, P415, DOI 10.3109/07420529908998717; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Pyza E, 1996, J COMP PHYSIOL A, V178, P33, DOI 10.1007/BF00189588; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; So WV, 2000, MOL CELL BIOL, V20, P6935, DOI 10.1128/MCB.20.18.6935-6944.2000; Ueda HR, 2001, J THEOR BIOL, V210, P401, DOI 10.1006/jtbi.2000.2226; Volkner M, 2000, J NEUROCHEM, V75, P1791, DOI 10.1046/j.1471-4159.2000.0751791.x	30	221	226	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14048	14052		10.1074/jbc.C100765200	http://dx.doi.org/10.1074/jbc.C100765200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11854264	hybrid			2022-12-25	WOS:000175096000091
J	Sakuraba, H; Yoshioka, I; Koga, S; Takahashi, M; Kitahama, Y; Satomura, T; Kawakami, R; Ohshima, T				Sakuraba, H; Yoshioka, I; Koga, S; Takahashi, M; Kitahama, Y; Satomura, T; Kawakami, R; Ohshima, T			ADP-dependent glucokinase/phosphofructokinase, a novel bifunctional enzyme from the hyperthermophilic Archaeon Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROCOCCUS-FURIOSUS; PHOSPHOFRUCTOKINASE; PATHWAY	nase homologue has been identified in the hyperthermophilic archaeon Methanococcus jannaschii via genome sequencing. The gene encoded a protein of 462 amino acids with a molecular weight of 53,361. The deduced amino acid sequence of the gene showed 52 and 29% identities to the ADP-dependent phosphofructokinase and glucokinase from Pyrococcus furiosus, respectively. The gene was overexpressed in Escherichia coli, and the produced enzyme was purified and characterized. To our surprise, the enzyme showed high ADP-dependent activities for both glucokinase and phosphofructokinase. A native molecular mass was estimated to be 55 kDa, and this indicates the enzyme is monomeric. The reaction rate for the phosphorylation Of D-glucose was almost 3 times that for D-fructose 6-phosphate. The K-m values for D-fructose 6-phosphate and D-glucose were calculated to be 0.010 and 1.6 mm, respectively. The K-m values for ADP were 0.032 and 0.63 mm when D-glucose and D-fructose 6-phosphate were used as a phosphoryl group acceptor, respectively. The gene encoding the enzyme is proposed to be an ancestral gene of an ADP-dependent phosphofructokinase and glucokinase. A gene duplication event might lead to the two enzymatic activities.	Univ Tokushima, Dept Biol Sci & Technol, Fac Engn, Tokushima 7708506, Japan; Asahi Chem Ind Co Ltd, Dept Diagnost Res & Dev, Shizuoka 4102321, Japan	Tokushima University	Kitahama, Y (corresponding author), Univ Tokushima, Dept Biol Sci & Technol, Fac Engn, Tokushima 7708506, Japan.							Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; ENOMOTO T, 1988, COMP BIOCHEM PHYS B, V90, P897, DOI 10.1016/0305-0491(88)90351-3; Hsieh PC, 1996, J BIOL CHEM, V271, P4909; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; Koga S, 2000, J BIOCHEM-TOKYO, V128, P1079, DOI 10.1093/oxfordjournals.jbchem.a022836; LI ZJ, 1995, PROTEIN EXPRES PURIF, V6, P319, DOI 10.1006/prep.1995.1042; Ronimus RS, 2001, BBA-GENE STRUCT EXPR, V1517, P384, DOI 10.1016/S0167-4781(00)00301-8; Sambrook J., 2002, MOL CLONING LAB MANU; Siebers B, 1998, J BACTERIOL, V180, P2137, DOI 10.1128/JB.180.8.2137-2143.1998; Tuininga JE, 1999, J BIOL CHEM, V274, P21023, DOI 10.1074/jbc.274.30.21023; Verhees CH, 2001, J BACTERIOL, V183, P7145, DOI 10.1128/JB.183.24.7145-7153.2001; YU JP, 1994, J BACTERIOL, V176, P325, DOI 10.1128/JB.176.2.325-332.1994	13	51	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12495	12498		10.1074/jbc.C200059200	http://dx.doi.org/10.1074/jbc.C200059200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11856730	hybrid			2022-12-25	WOS:000175036300003
J	Zingarelli, B; Hake, PW; Yang, ZQ; O'Connor, M; Denenberg, A; Wong, HR				Zingarelli, B; Hake, PW; Yang, ZQ; O'Connor, M; Denenberg, A; Wong, HR			Absence of inducible nitric oxide synthase modulates early reperfusion-induced NF-kappa B and AP-1 activation and enhances myocardial damage	FASEB JOURNAL			English	Article						apoptosis; nuclear factor kappa B; activator protein 1; heat shock protein 70; nitrotyrosine	INTERCELLULAR-ADHESION MOLECULE-1; PROGRAMMED CELL-DEATH; INFARCT SIZE; ISCHEMIA-REPERFUSION; ISCHEMIA/REPERFUSION INJURY; KINASE IKK; LATE-PHASE; IN-SITU; APOPTOSIS; HEART	The role of nitric oxide (NO) generated by the inducible NO synthase (iNOS) during myocardial ischemia and reperfusion is not understood. We investigated the role of iNOS during early reperfusion damage induced in genetically deficient iNOS (iNOS(-/-)) mice and wild-type littermates. In wild-type mice, ischemia (60 min) and reperfusion (60 min) induced an elevation in serum levels of creatine phosphokinase and myocardial injury characterized by the presence of scattered apoptotic myocytes and mild neutrophil infiltration. Northern blot analysis showed increased expression of iNOS, whose activity was markedly elevated after reperfusion. Immunohistochemistry showed staining for nitrotyrosine; Western blot analysis showed elevated expression of heat shock protein 70 (HSP70), a putative cardioprotective mediator. Plasma levels of nitrite and nitrate, tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), and IL-10 were also increased. These events were preceded by degradation of inhibitor kappaBalpha (IkappaBalpha), activation of IkappaB kinase complex (IKK) and c-Jun-NH2-terminal kinase (JNK), and subsequently activation of nuclear factor-kappaB (NF-kappaB) and activator protein 1 (AP-1) as early as 15 min after reperfusion. In contrast, iNOS(-/-) mice experienced 35% mortality after reperfusion. The extensive myocardial injury was associated with marked apoptosis and infiltration of neutrophils whereas expression of HSP70 was less pronounced. Nitrotyrosine formation and plasma levels of nitrite and nitrate were undetectable. TNF-alpha and IL-6 were increased and IL-10 was reduced in earlier stages of reperfusion. Activation of IKK and JNK and binding activity of NF-kappaB and AP-1 were significantly reduced. Thus, we conclude that iNOS plays a beneficial role in modulating the early defensive inflammatory response against reperfusion injury through regulation of signal transduction.	Childrens Hosp, Med Ctr, Div Crit Care, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Zingarelli, B (corresponding author), Childrens Hosp, Med Ctr, Div Crit Care Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	bzingarelli@chmcc.org	, Basilia/AAV-7582-2021		NHLBI NIH HHS [R01 HL-60730] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060730] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; BAIS R, 1982, CRC CR REV CL LAB SC, V16, P291, DOI 10.3109/10408368209107030; Chandrasekar B, 1997, FEBS LETT, V401, P30, DOI 10.1016/S0014-5793(96)01426-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; Colucci WS, 1996, NEW ENGL J MED, V335, P1224, DOI 10.1056/NEJM199610173351610; Connelly L, 2001, J IMMUNOL, V166, P3873, DOI 10.4049/jimmunol.166.6.3873; DarleyUsmar V, 1996, PHARM RES-DORDR, V13, P649, DOI 10.1023/A:1016079012214; Das DK, 1998, ANN NY ACAD SCI, V865, P297, DOI 10.1111/j.1749-6632.1998.tb11190.x; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DeMeester SL, 2001, FASEB J, V15, P270, DOI 10.1096/fj.00-0170hyp; Ferrari R, 1998, EUR HEART J, V19, pB2; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Grisham MB, 1998, FREE RADICAL BIO MED, V25, P404, DOI 10.1016/S0891-5849(98)00094-X; Guo Y, 1999, P NATL ACAD SCI USA, V96, P11507, DOI 10.1073/pnas.96.20.11507; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9; Imagawa J, 1999, BRIT J PHARMACOL, V126, P701, DOI 10.1038/sj.bjp.0702368; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; Jones SP, 1999, AM J PHYSIOL-HEART C, V276, pH1567, DOI 10.1152/ajpheart.1999.276.5.H1567; Kanno S, 2000, CIRCULATION, V101, P2742, DOI 10.1161/01.CIR.101.23.2742; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; LEFER DJ, 1993, CIRCULATION, V88, P2337, DOI 10.1161/01.CIR.88.5.2337; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Maulik N, 1999, FEBS LETT, V443, P331, DOI 10.1016/S0014-5793(98)01719-0; Mesri M, 1999, J BIOL CHEM, V274, P23111, DOI 10.1074/jbc.274.33.23111; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Mizuno T, 1998, J THORAC CARDIOV SUR, V115, P931, DOI 10.1016/S0022-5223(98)70376-9; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Mustapha S, 2000, AM J PHYSIOL-HEART C, V279, pH939, DOI 10.1152/ajpheart.2000.279.3.H939; Nossuli TO, 1997, CIRCULATION, V96, P2317; Nossuli TO, 2000, AM J PHYSIOL-HEART C, V278, pH1049, DOI 10.1152/ajpheart.2000.278.4.H1049; Onishi I, 1999, TRANSPLANT P, V31, P1077, DOI 10.1016/S0041-1345(98)01912-5; Pabla R, 1996, CIRC RES, V78, P65, DOI 10.1161/01.RES.78.1.65; PATEL VC, 1993, BIOCHEM BIOPH RES CO, V194, P234, DOI 10.1006/bbrc.1993.1809; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; Shimizu N, 1998, CARDIOVASC RES, V38, P116, DOI 10.1016/S0008-6363(97)00327-1; Song JS, 1999, J IMMUNOL, V163, P802; Szabo C, 1996, BRIT J PHARMACOL, V118, P1659, DOI 10.1111/j.1476-5381.1996.tb15589.x; Takano H, 1998, CIRCULATION, V98, P441, DOI 10.1161/01.CIR.98.5.441; Vadlamani L, 2000, Curr Cardiol Rep, V2, P120, DOI 10.1007/s11886-000-0008-3; Valen G, 2000, CARDIOVASC RES, V47, P49, DOI 10.1016/S0008-6363(00)00071-7; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Wildhirt SM, 1999, CARDIOVASC RES, V43, P698, DOI 10.1016/S0008-6363(99)00080-2; WOOLFSON RG, 1995, CIRCULATION, V91, P1545, DOI 10.1161/01.CIR.91.5.1545; Xi L, 1999, CIRCULATION, V99, P2157, DOI 10.1161/01.CIR.99.16.2157; Yang ZQ, 2000, CIRCULATION, V101, P1019, DOI 10.1161/01.CIR.101.9.1019; Zingarelli B, 1997, CARDIOVASC RES, V36, P205, DOI 10.1016/S0008-6363(97)00137-5; Zingarelli B, 1996, J IMMUNOL, V156, P350; Zingarelli B, 2001, GUT, V48, P610, DOI 10.1136/gut.48.5.610; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85; ZINGARELLI B, 2001, IN PRESS SHOCK; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	62	106	112	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0327	10.1096/fj.01-0533com	http://dx.doi.org/10.1096/fj.01-0533com			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874982				2022-12-25	WOS:000174755900025
J	Sanchez-Prieto, R; Sanchez-Arevalo, VJ; Servitja, JM; Gutkind, JS				Sanchez-Prieto, R; Sanchez-Arevalo, VJ; Servitja, JM; Gutkind, JS			Regulation of p73 by c-Abl through the p38 MAP kinase pathway	ONCOGENE			English	Article						p73; c-Abl; p38; p53; DNA damage	ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; DNA-DAMAGE; CELL-DEATH; APOPTOTIC RESPONSE; P53 GENE; STRESS; FAMILY; AGENTS	p73 is a novel member of the p53 family of tumor suppressor proteins which is involved in cellular differentiation, tumor suppression, and the response to genotoxic stress. The molecular mechanisms regulating p73 activity are still poorly understood. Recently, p73 was found to be a target of the enzymatic activity of c-Abl, a non-receptor tyrosine kinase that potently activated in response to DNA damage. Here, we present evidence that c-Abl induces the phosphorylation of p73 in threonine residues adjacent to prolines, and that the p38 MAP kinase pathway mediates this response. Furthermore, we found that activation of p38 is sufficient to enhance the stability of p73, and that the transcriptional activation of p73 by c-Abl requires the activity of p38. These findings indicate that members of the MAP kinases superfamily of signaling molecules can regulate p73, and support a role for the p38 MAP kinase in a novel biochemical pathway by which c-Abl regulates this p53-related molecule.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Clin Puerta Hierro, Dept Anat Patol, Unidad Patol Mol, Madrid 28035, Spain	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Sanchez-Prieto, Ricardo/AAY-4271-2021; Sanchez-Prieto, Ricardo/B-6877-2008; Prieto, Ricardo/AAZ-7221-2021; Gutkind, J. Silvio/A-1053-2009; Lobo, Victor Javier vjsal Sanchez-Arevalo/H-1069-2011; Lobo, Victor Javier Sanchez-Arevalo/N-8641-2019	Gutkind, J. Silvio/0000-0002-5150-4482; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lobo, Victor Javier vjsal Sanchez-Arevalo/0000-0002-4561-1505; Lobo, Victor Javier Sanchez-Arevalo/0000-0002-4561-1505; SERVITJA, JOAN-MARC/0000-0002-1241-8004	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agami R, 1999, NATURE, V399, P809; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gong JG, 1999, NATURE, V399, P806; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	32	93	94	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2002	21	6					974	979		10.1038/sj.onc.1205134	http://dx.doi.org/10.1038/sj.onc.1205134			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840343				2022-12-25	WOS:000173427100013
J	Backhed, F; Alsen, B; Roche, N; Angstrom, J; von Euler, A; Breimer, ME; Westerlund-Wikstrom, B; Teneberg, S; Richter-Dahlfors, A				Backhed, F; Alsen, B; Roche, N; Angstrom, J; von Euler, A; Breimer, ME; Westerlund-Wikstrom, B; Teneberg, S; Richter-Dahlfors, A			Identification of target tissue glycosphingolipid receptors for uropathogenic, F1C-fimbriated Escherichia coli and its role in mucosal inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY-TRACT INFECTION; EPITHELIAL-CELLS; F1C FIMBRIAE; BINDING; BACTERIA; SPECTROSCOPY; GLYCOLIPIDS; EXPRESSION; VIRULENCE; CERAMIDE	Bacterial adherence to mucosal cells is a key virulence trait of pathogenic bacteria. The type I fimbriae and the P-fimbriae of Escherichia coli have both been described to be important for the establishment of urinary tract infections. While P-fimbriae recognize kidney glycosphingolipids carrying the Galalpha4Gal determinant, type 1 fimbriae bind to the urothelial mannosylated glycoproteins uroplakin Ia and Ib. The F1C fimbriae are one additional type of fimbria correlated with uropathogenicity. Although it was identified 20 years ago its receptor has remained unidentified. Here we report that F1C-fimbriated bacteria selectively interact with two minor glycosphingolipids isolated from rat, canine, and human urinary tract. Binding-active compounds were isolated and characterized as galactosylceramide, and globotriaosylceramide, both with phytosphingosine and hydroxy fatty acids. Comparison with reference glycosphingolipids revealed that the receptor specificity is dependent on the ceramide composition. Galactosylceramide was present in the bladder, urethers, and kidney while globotriaosylceramide was present only in the kidney. Using a functional assay, we demonstrate that binding of F1C-fimbriated Escherichia coli to renal cells induces interleukin-8 production, thus suggesting a role for F1C-mediated attachment in mucosal defense against bacterial infections.	Univ Gothenburg, Inst Med Biochem, SE-40530 Gothenburg, Sweden; Karolinska Inst, Microbiol & Tumorbiol Ctr, SE-17177 Stockholm, Sweden; Sahlgrenska Univ Hosp, Dept Surg, SE-41345 Gothenburg, Sweden; Univ Helsinki, Dept Biosci, Div Gen Microbiol, FIN-00014 Helsinki, Finland	University of Gothenburg; Karolinska Institutet; Sahlgrenska University Hospital; University of Helsinki	Teneberg, S (corresponding author), Univ Gothenburg, Inst Med Biochem, POB 440, SE-40530 Gothenburg, Sweden.		Backhed, Fredrik/ABE-6613-2020	Backhed, Fredrik/0000-0002-4871-8818; Westerlund-Wikstrom, Benita/0000-0002-5307-3858; Richter-Dahlfors, Agneta/0000-0002-5479-7591				Angstrom J, 1998, GLYCOBIOLOGY, V8, P297, DOI 10.1093/glycob/8.4.297; ARONSON M, 1979, J INFECT DIS, V139, P329, DOI 10.1093/infdis/139.3.329; Backhed F, 2001, CELL MICROBIOL, V3, P153, DOI 10.1046/j.1462-5822.2001.00101.x; BREIMER ME, 1985, J BIOCHEM, V98, P1169, DOI 10.1093/oxfordjournals.jbchem.a135383; BREIMER ME, 1980, ADV MASS SPECTROM, V8, P1097; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; DABROWSKI J, 1980, CHEM PHYS LIPIDS, V26, P187, DOI 10.1016/0009-3084(80)90006-7; HAGBERG L, 1983, INFECT IMMUN, V40, P265, DOI 10.1128/IAI.40.1.265-272.1983; HAKOMORI S, 1983, HDB LIPID RES, V3, P1; HANSSON GC, 1985, ANAL BIOCHEM, V146, P158, DOI 10.1016/0003-2697(85)90410-5; Hedlund M, 1996, J EXP MED, V183, P1037, DOI 10.1084/jem.183.3.1037; HOLGERSSON J, 1991, GLYCOCONJUGATE J, V8, P424, DOI 10.1007/BF00731294; Hugosson S, 1998, J BIOCHEM-TOKYO, V124, P1138, DOI 10.1093/oxfordjournals.jbchem.a022232; JOHNSON JR, 1991, CLIN MICROBIOL REV, V4, P80, DOI 10.1128/CMR.4.1.80-128.1991; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Khan AS, 2000, INFECT IMMUN, V68, P3541, DOI 10.1128/IAI.68.6.3541-3547.2000; KOERNER TAW, 1983, BIOCHEMISTRY-US, V22, P2676, DOI 10.1021/bi00280a014; KORHONEN TK, 1985, INFECT IMMUN, V48, P486, DOI 10.1128/IAI.48.2.486-491.1985; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LEFFLER H, 1980, FEMS MICROBIOL LETT, V8, P127, DOI 10.1111/j.1574-6968.1980.tb05064.x; MARRE R, 1990, INFECT IMMUN, V58, P3434, DOI 10.1128/IAI.58.10.3434-3437.1990; MATTSBYBALTZER I, 1982, INFECT IMMUN, V35, P639, DOI 10.1128/IAI.35.2.639-646.1982; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; PARKKINEN J, 1986, INFECT IMMUN, V54, P37, DOI 10.1128/IAI.54.1.37-42.1986; PERE A, 1987, J INFECT DIS, V156, P567, DOI 10.1093/infdis/156.4.567; POPPE L, 1990, EUR J BIOCHEM, V189, P313, DOI 10.1111/j.1432-1033.1990.tb15492.x; RHEN M, 1985, J GEN MICROBIOL, V131, P571; ROBERTS JA, 1994, P NATL ACAD SCI USA, V91, P11889, DOI 10.1073/pnas.91.25.11889; SAMUELSSON BE, 1990, METHOD ENZYMOL, V193, P623, DOI 10.1016/0076-6879(90)93442-N; SIITONEN A, 1993, MICROB PATHOGENESIS, V15, P65, DOI 10.1006/mpat.1993.1057; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; STROMBERG N, 1988, FEBS LETT, V232, P193, DOI 10.1016/0014-5793(88)80415-0; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; VANDIE I, 1991, RES MICROBIOL, V142, P653, DOI 10.1016/0923-2508(91)90078-O; VIRKOLA R, 1988, INFECT IMMUN, V56, P2615, DOI 10.1128/IAI.56.10.2615-2622.1988; Waldi D., 1962, DUNNSCHICHT CHROMATO, P496; Wu XR, 1996, P NATL ACAD SCI USA, V93, P9630, DOI 10.1073/pnas.93.18.9630; YANG HJ, 1971, J BIOL CHEM, V246, P1192	41	65	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18198	18205		10.1074/jbc.M111640200	http://dx.doi.org/10.1074/jbc.M111640200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877427	hybrid			2022-12-25	WOS:000175685100102
J	LaCount, DJ; Barrett, B; Donelson, JE				LaCount, DJ; Barrett, B; Donelson, JE			Trypanosoma brucei FLA1 is required for flagellum attachment and cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAFLAGELLAR ROD; CELL-CYCLE; AFRICAN TRYPANOSOMES; GLYCOPROTEIN GP72; RNA INTERFERENCE; CRUZI; CYTOSKELETON; GENE; DELETION; ADHESION	The single flagellum of the protozoan parasite Trypanosoma brucei is attached along the length of the cell body by a complex structure that requires the FLA1 protein. We show here that inhibition of FLA1 expression by RNA interference in procyclic trypanosomes causes flagellar detachment and prevents cytokinesis. Despite being unable to divide, these cells undergo mitosis and develop a multinucleated phenotype. The Trypanosoma cruzi FLA1 homolog, GP72, is unable to complement either the flagellar detachment or cytokinesis defects in procyclic T. brucei that have been depleted of FLA1 by RNA interference. Instead, GP72 itself caused flagellar detachment when expressed in T. brucei. In contrast to T. brucei cells depleted of FLA1, procyclic T. brucei expressing GP72 continued to divide despite having detached flagella, demonstrating that flagellar attachment is not absolutely necessary for cytokinesis. We have also identified a FLA1-related gene (FLA2) whose sequence is similar but not identical to FLA1. Inhibition of FLA1 and FLA2 expression in bloodstream T. brucei caused flagellar detachment and blocked cytokinesis but did not inhibit mitosis. These experiments demonstrate that the FLA proteins are essential and suggest that in procyclic T. brucei, the FLA1 protein has separable functions in flagellar attachment and cytokinesis.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Donelson, JE (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Donelson, John E/F-5795-2010		NIAID NIH HHS [AI10512, AI40591] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; Bastin P, 1996, PARASITOL TODAY, V12, P302, DOI 10.1016/0169-4758(96)10031-4; Bastin P, 1998, NATURE, V391, P548, DOI 10.1038/35300; COOPER R, 1993, J CELL BIOL, V122, P149, DOI 10.1083/jcb.122.1.149; COOPER R, 1991, MOL BIOCHEM PARASIT, V49, P45, DOI 10.1016/0166-6851(91)90129-T; DEJESUS AR, 1993, J CELL SCI, V106, P1023; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; FERGUSON MAJ, 1983, BIOCHEM J, V213, P313, DOI 10.1042/bj2130313; Gull K, 1999, ANNU REV MICROBIOL, V53, P629, DOI 10.1146/annurev.micro.53.1.629; Haynes PA, 1996, J CELL SCI, V109, P2979; Hill KL, 1999, J CELL SCI, V112, P3091; HIRUMI H, 1980, PARASITOLOGY, V80, P371, DOI 10.1017/S0031182000000822; Kohl L, 1999, J EUKARYOT MICROBIOL, V46, P105, DOI 10.1111/j.1550-7408.1999.tb04592.x; Kohl L, 1998, MOL BIOCHEM PARASIT, V93, P1, DOI 10.1016/S0166-6851(98)00014-0; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; LaCount DJ, 2001, PROTIST, V152, P103, DOI 10.1078/1434-4610-00047; Maga JA, 1999, J CELL SCI, V112, P2753; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Nozaki T, 1996, MOL BIOCHEM PARASIT, V82, P245, DOI 10.1016/0166-6851(96)02741-7; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; SHERWIN T, 1989, PHILOS T R SOC B, V323, P573, DOI 10.1098/rstb.1989.0037; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODWARD R, 1990, J CELL SCI, V95, P49	25	151	151	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17580	17588		10.1074/jbc.M200873200	http://dx.doi.org/10.1074/jbc.M200873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877446	hybrid			2022-12-25	WOS:000175685100026
J	Johansson, AS; Mannervik, B				Johansson, AS; Mannervik, B			Active-site residues governing high steroid isomerase activity in human glutathione transferase A3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASES; 3-OXO-DELTA(5)-STEROID ISOMERASE; MALEYLACETOACETATE ISOMERASE; CATALYTIC MECHANISM; MU-CLASS; ISOMERIZATION; A1-1; ACID; IDENTIFICATION; PATHWAY	Glutathione transferase (GST) A3-3 is the most efficient human steroid double-bond isomerase known. The activity with Delta(5)-androstene-3,17-dione is highly dependent on the phenolic hydroxyl group of Tyr-9 and the thiolate of glutathione. Removal of these groups caused an 1.1 x 10(5)-fold decrease in k(cat); the Y9F mutant displayed a 150-fold lower isomerase activity in the presence of glutathione and a further 740-fold lower activity in the absence of glutathione. The Y9F mutation in GST A3-3 did not markedly decrease the activity with the alternative substrate 1-chloro-2,4-dinitrobenzene. Residues Phe-10, Leu-111, and Ala-216 selectively govern the activity with the steroid substrate. Mutating residue 111 into phenylalanine caused a 25-fold decrease in k(cat)/K-m for the steroid isomerization. The mutations A216S and F10S, separate or combined, affected the isomerase activity only marginally, but with the additional L111F mutation k(cat)/K-m was reduced to 0.8% of that of the wildtype value. In contrast, the activities with 1-chloro-2,4-dinitrobenzene and phenethylisothiocyanate were not largely affected by the combined mutations F10S/L111F/A216S. K-i values for Delta(5) -androstene-3,17-dione and Delta(4)-androstene-3,17-dione were increased by the triple mutation F10S/L111F/A216S. The pK(a) of the thiol group of active-site-bound glutathione, 6.1, increased to 6.5 in GST A3-3/Y9F. The pK(a) of the active-site Tyr-9 was 7.9 for the wild-type enzyme. The pH dependence of k(cat)/K-m of wild-type GST A3-3 for the isomerase reaction displays two kinetic pk(a) values, 6.2 and 8.1. The basic limb of the pH dependence of k(cat) and k(cat)/K-m disappears in the Y9F mutant. Therefore, the higher kinetic pK(a) reflects ionization of Tyr-9, and the lower one reflects ionization of glutathione. We propose a reaction mechanism for the double-bond isomerization involving abstraction of a proton from C4 in the steroid accompanied by protonation of C6, the thiolate of glutathione serving as a base and Tyr-9 assisting by polarizing the 3-oxo group of the substrate.	Uppsala Univ, Dept Biochem, Ctr Biomed, SE-75123 Uppsala, Sweden	Uppsala University	Mannervik, B (corresponding author), Uppsala Univ, Dept Biochem, Ctr Biomed, Box 576, SE-75123 Uppsala, Sweden.			Jemth, Ann-Sofie/0000-0002-7550-1833				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Atkins WM, 1997, PROTEIN SCI, V6, P873; BARDSLEY WG, 1995, COMPUT CHEM, V19, P75, DOI 10.1016/0097-8485(95)00007-F; BENSON AM, 1977, P NATL ACAD SCI USA, V74, P158, DOI 10.1073/pnas.74.1.158; Beuckmann CT, 2000, NEUROCHEM RES, V25, P733, DOI 10.1023/A:1007579507804; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; Blackburn AC, 1998, CYTOGENET CELL GENET, V83, P109, DOI 10.1159/000015145; Board PG, 1998, BIOCHEM J, V330, P827; BURGESS JR, 1989, BIOCHEM BIOPH RES CO, V158, P497, DOI 10.1016/S0006-291X(89)80076-2; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; Chen H, 1998, BIOCHEM J, V336, P223, DOI 10.1042/bj3360223; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P16; Dietze EC, 1996, BIOCHEMISTRY-US, V35, P11938, DOI 10.1021/bi961073r; Fernandez-Canon JM, 1998, J BIOL CHEM, V273, P329, DOI 10.1074/jbc.273.1.329; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; Gustafsson A, 2001, BIOCHEMISTRY-US, V40, P15835, DOI 10.1021/bi010429i; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Johansson AS, 2001, J BIOL CHEM, V276, P33061, DOI 10.1074/jbc.M104539200; JUNG G, 1972, EUR J BIOCHEM, V24, P438, DOI 10.1111/j.1432-1033.1972.tb19704.x; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Khojasteh-Bakht SC, 1999, ARCH BIOCHEM BIOPHYS, V370, P59, DOI 10.1006/abbi.1999.1361; Kim SW, 1997, BIOCHEMISTRY-US, V36, P14030, DOI 10.1021/bi971546+; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; KULIOPULOS A, 1989, BIOCHEMISTRY-US, V28, P149, DOI 10.1021/bi00427a022; MEYER DJ, 1995, BIOCHEM J, V306, P565, DOI 10.1042/bj3060565; Pettersson PL, 2001, J BIOL CHEM, V276, P11698, DOI 10.1074/jbc.M009146200; POLLACK RM, 1989, J AM CHEM SOC, V111, P6419, DOI 10.1021/ja00198a066; Sambrook J., 2001, MOL CLONING, V2; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; Thornburg LD, 2001, J AM CHEM SOC, V123, P9912, DOI 10.1021/ja016683f; Wu ZR, 1997, SCIENCE, V276, P415, DOI 10.1126/science.276.5311.415; Zhao TJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P216, DOI 10.1006/abbi.1999.1277	35	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16648	16654		10.1074/jbc.M201062200	http://dx.doi.org/10.1074/jbc.M201062200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872752	hybrid			2022-12-25	WOS:000175564500042
J	Laurila, MRL; Makeyev, EV; Bamford, DH				Laurila, MRL; Makeyev, EV; Bamford, DH			Bacteriophage phi 6 RNA-dependent RNA polymerase - Molecular details of initiating nucleic acid synthesis without primer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; DE-NOVO INITIATION; MINUS-STRAND RNA; PROTEIN 5B POLYMERASE; CRYSTAL-STRUCTURE; GENOMIC SEGMENTS; VIRAL-RNA; ESCHERICHIA-COLI; IDENTIFICATION; POLIOVIRUS	Like most RNA polymerases, the polymerase of double-strand RNA bacteriophage phi6 (phi6pol) is capable of primer-independent initiation. Based on the recently solved phi6pol initiation complex structure, a four-amino acid-long loop (amino acids 630-633) has been suggested to stabilize the first two incoming NTPs through stacking interactions with tyrosine, Tyr(630). A similar loop is also present in the hepatitis C virus polymerase, another enzyme capable of de novo initiation. Here, we use a series of phi6pol mutants to address the role of this element. As predicted, mutants at the Tyr(630) position are inefficient in initiation de novo. Unexpectedly, when the loop is disordered by changing Tyr(630)-Lys(631)-Trp(632) to GSG, phi6pol becomes a primer-dependent enzyme, either extending complementary oligonucleotide or, when the template 3' terminus can adopt a hairpin-like conformation, utilizing a "copy-back" initiation mechanism. In contrast to the wild-type phi6pol, the GSG mutant does not require high GTP concentration for its optimal activity. These findings suggest a general model for the initiation of de novo RNA synthesis.	Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Bamford, DH (corresponding author), Univ Helsinki, Dept Biosci, POB 56,Viikinkaari 5, FIN-00014 Helsinki, Finland.	dennis.bamford@helsinki.fi		Makeyev, Eugene/0000-0001-6034-6896				Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; BLUMENTHAL T, 1980, P NATL ACAD SCI-BIOL, V77, P2601, DOI 10.1073/pnas.77.5.2601; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; BREWER G, 1992, PROMEGA NOTES, V38, P1; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; GOTTLIEB P, 1992, J VIROL, V66, P2611, DOI 10.1128/JVI.66.5.2611-2616.1992; Guyatt KJ, 2001, J VIROL METHODS, V92, P37, DOI 10.1016/S0166-0934(00)00270-6; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HEY TD, 1986, J VIROL, V58, P790, DOI 10.1128/JVI.58.3.790-796.1986; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Hoogstraten D, 2000, VIROLOGY, V272, P218, DOI 10.1006/viro.2000.0374; Kao CC, 1996, J VIROL, V70, P6826, DOI 10.1128/JVI.70.10.6826-6830.1996; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; LOSICK R, 1976, RNA POLYM; LUBINSKI JM, 1987, J VIROL, V61, P2997, DOI 10.1128/JVI.61.10.2997-3003.1987; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Makeyev EV, 2000, EMBO J, V19, P6275, DOI 10.1093/emboj/19.22.6275; Makeyev EV, 2000, EMBO J, V19, P124, DOI 10.1093/emboj/19.1.124; Makeyev EV, 2001, RNA, V7, P774, DOI 10.1017/S1355838201002060; MINDICH L, 1994, VIROLOGY, V202, P258, DOI 10.1006/viro.1994.1341; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PAGRATIS N, 1990, VIROLOGY, V177, P273, DOI 10.1016/0042-6822(90)90480-F; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Pirttimaa MJT, 2000, RNA, V6, P880, DOI 10.1017/S1355838200992598; Qiao XY, 2000, VIROLOGY, V275, P218, DOI 10.1006/viro.2000.0501; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Steffens S, 1999, J GEN VIROL, V80, P2583, DOI 10.1099/0022-1317-80-10-2583; STERN S, 1988, METHOD ENZYMOL, V164, P481; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; Vazquez AL, 2001, ARCH VIROL, V146, P59, DOI 10.1007/s007050170191; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Yang HY, 2001, J VIROL, V75, P11088, DOI 10.1128/JVI.75.22.11088-11095.2001; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 1998, J VIROL, V72, P9365, DOI 10.1128/JVI.72.11.9365-9369.1998; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	44	55	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17117	17124		10.1074/jbc.M111220200	http://dx.doi.org/10.1074/jbc.M111220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877396	hybrid			2022-12-25	WOS:000175564500104
J	Yarian, C; Townsend, H; Czestkowski, W; Sochacka, E; Malkiewicz, AJ; Guenther, R; Miskiewicz, A; Agris, PF				Yarian, C; Townsend, H; Czestkowski, W; Sochacka, E; Malkiewicz, AJ; Guenther, R; Miskiewicz, A; Agris, PF			Accurate translation of the genetic code depends on tRNA modified nucleosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA BINDING; 30S RIBOSOMAL-SUBUNIT; ESCHERICHIA-COLI; ANTICODON STEM; CRYSTAL-STRUCTURE; SITES; LOOP; RECOGNITION; TETRACYCLINE; ANTIBIOTICS	Transfer RNA molecules translate the genetic code by recognizing cognate mRNA codons during protein synthesis. The anticodon wobble at position 34 and the nucleotide immediately 3' to the anticodon triplet at position 37 display a large diversity of modified nucleosides in the tRNAs of all organisms. We show that tRNA species translating 2-fold degenerate codons require a modified U-34 to enable recognition of their cognate codons ending in A or G but restrict reading of noncognate or near-cognate codons ending in U and C that specify a different amino acid. In particular, the nucleoside modifications 2-thiouridine at position 34 (s(2)U(34)), 5-methylaminomethyluridine at position 34 (mnm(5)U(34)), and 6-threonylcarbamoyladenosine at position 37 (t(6)A(37)) were essential for Watson-Crick (AAA) and wobble (AAG) cognate codon recognition by tRNA(UUU)(Lys), at the ribosomal aminoacyl and peptidyl sites but did not enable the recognition of the asparagine codons (AAU and AAC). We conclude that modified nucleosides evolved to modulate an anticodon domain structure necessary for many tRNA species to accurately translate the genetic code.	N Carolina State Univ, Dept Biochem, Raleigh, NC 27695 USA; Tech Univ Lodz, Inst Organ Chem, PL-90924 Lodz, Poland	University of North Carolina; North Carolina State University; Lodz University of Technology	Agris, PF (corresponding author), N Carolina State Univ, Dept Mol & Struct Biochem, 128 Polk Hall,Box 7622, Raleigh, NC 27695 USA.		Dziergowska, Agnieszka/H-5240-2017; Sochacka, Elzbieta/N-2520-2018	Dziergowska, Agnieszka/0000-0002-8888-380X; Sochacka, Elzbieta/0000-0003-3240-1143	NIGMS NIH HHS [GM23037] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023037] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529; Benas P, 2000, RNA, V6, P1347, DOI 10.1017/S1355838200000911; Beuning PJ, 1999, BIOPOLYMERS, V52, P1; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; DIAZ I, 1991, J MOL BIOL, V222, P1161, DOI 10.1016/0022-2836(91)90599-2; ERICSON G, 1995, J MOL BIOL, V250, P407, DOI 10.1006/jmbi.1995.0386; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Gumport R I, 1981, Gene Amplif Anal, V2, P313; HARRINGTON KM, 1993, BIOCHEMISTRY-US, V32, P7617, DOI 10.1021/bi00081a003; Joseph S, 1998, EMBO J, V17, P3478, DOI 10.1093/emboj/17.12.3478; KIRILLOV SV, 1980, NUCLEIC ACIDS RES, V8, P183, DOI 10.1093/nar/8.1.183; Li JN, 1997, J MOL BIOL, V271, P209, DOI 10.1006/jmbi.1997.1176; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; Lim VI, 2001, RNA, V7, P942, DOI 10.1017/S135583820100214X; LIM VI, 1994, J MOL BIOL, V240, P8, DOI 10.1006/jmbi.1994.1413; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Noah JW, 1999, J BIOL CHEM, V274, P16576, DOI 10.1074/jbc.274.23.16576; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Parfenov D. V., 1993, Molekulyarnaya Biologiya (Moscow), V27, P827; PARFENOV D V, 1985, Molekulyarnaya Biologiya (Moscow), V19, P1378; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Stuart JW, 2000, BIOCHEMISTRY-US, V39, P13396, DOI 10.1021/bi0013039; Sundaram M, 2000, BIOCHEMISTRY-US, V39, P12575, DOI 10.1021/bi0014655; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; Urbonavicius J, 2001, EMBO J, V20, P4863, DOI 10.1093/emboj/20.17.4863; vonAhsen U, 1997, RNA, V3, P49; Yarian C, 2000, BIOCHEMISTRY-US, V39, P13390, DOI 10.1021/bi001302g; YOKOYAMA S, 1985, P NATL ACAD SCI USA, V82, P4905, DOI 10.1073/pnas.82.15.4905; Yokoyama Shigeyuki, 1995, P207; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	32	185	192	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16391	16395		10.1074/jbc.M200253200	http://dx.doi.org/10.1074/jbc.M200253200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861649	hybrid			2022-12-25	WOS:000175564500008
J	Furukawa, M; Ohta, T; Xiong, Y				Furukawa, M; Ohta, T; Xiong, Y			Activation of UBC5 ubiquitin-conjugating enzyme by the RING finger of ROC1 and assembly of active ubiquitin ligases by all cullins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; CRYSTAL-STRUCTURE; CELL-DIVISION; BOX PROTEINS; U-BOX; IDENTIFICATION; COMPLEX; DOMAIN; SUBUNIT; APC11	Protein ubiquitination plays an important role in regulating the abundance and conformation of a broad range of eukaryotic proteins. This process involves a cascade of enzymes including ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3). E1 and E2 represent two families of structurally related proteins and are relatively well characterized. In contrast, the nature and mechanism of E3, proposed to contain activities in catalyzing isopeptide bond formation (ubiquitin ligation) and substrate targeting, remains inadeqnately understood. Two major families of E3 ubiquitin ligases, the HECT (for homologous to E6-AP C terminus) family and the RING family, have been identified that utilize distinct mechanisms in promoting isopeptide bond formation. Here, we showed that purified RING finger domain of ROC1, an essential subunit of SKP1-cullin/CDC53-F box protein ubiquitin ligases, was sufficient to activate UBCH5c to synthesize polyubiquitin chains. The sequence flanking the RING finger in ROC1 did not contribute to UBCH5c activation, but was required for binding with CUL1. We demonstrated that all cullins, through their binding with ROC proteins, constituted active ubiquitin ligases, suggesting the existence in vivo of a large number of cullin-RING ubiquitin ligases. These results are consistent with the notion that the RING finger domains allosterically activate E2. We suggest that RING-E2, rather than cullin-RING, constitutes the catalytic core of the ubiquitin ligase and that one major function of the cullin subunit is to assemble the RING-E2 catalytic core and substrates together.	Univ N Carolina, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Canc Res Ctr, CB 7295, Chapel Hill, NC 27599 USA.	yxiong@email.unc.edu		Ohta, Tomohiko/0000-0002-9700-7342				Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohta T, 1999, ONCOGENE, V18, P6758, DOI 10.1038/sj.onc.1203115; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; PTAK C, 1994, J BIOL CHEM, V269, P26539; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	48	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15758	15765		10.1074/jbc.M108565200	http://dx.doi.org/10.1074/jbc.M108565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861641	hybrid, Green Published			2022-12-25	WOS:000175510400073
J	Mizutani, T; Ito, T; Nishina, M; Yamamichi, N; Watanabe, A; Iba, H				Mizutani, T; Ito, T; Nishina, M; Yamamichi, N; Watanabe, A; Iba, H			Maintenance of integrated proviral gene expression requires Brm, a catalytic subunit of SWI/SNF complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOTYPED RETROVIRUS VECTOR; VIRALLY TRANSDUCED GENES; HISTONE DEACETYLASE; CELL-LINES; TRANSCRIPTION FACTOR; PROTEIN; ACETYLATION; METHYLATION; INDUCTION; MECHANISM	We show here that murine leukemia virus-based retrovirus vector transgene expression is rapidly silenced in human tumor cell lines lacking expression of Brm, a catalytic subunit of the SWI/SNF chromatin remodeling complex, even though these vectors can successfully enter, integrate, and initiate transcription. We detected this gene silencing as a reduction in the ratio of cells expressing the exogenous gene rather than a reduction in the average expression levels, indicating that down-regulation occurs in an all-or-none manner. Retroviral gene expression was protected from silencing and maintained in Brm-deficient host cells by exogenous expression of Brm but not BRG1, an alternative ATPase subunit in the SWI/SNF complex. Introduction of exogenous Brm to these cells suppressed recruitment of protein complexes containing YY1 and histone deacetylase (HDAC) I and 2 to the 5'-long terminal repeat region of the integrated provirus, leading to the enhancement of acetylation of specific lysine residues in histone H4 located in this region. Consistent with these observations, treatment of Brm-deficient cells with HDAC inhibitors but not DNA methylation inhibitors suppressed retroviral gene silencing. These results suggest that the Brm-containing SWI/SNF complex subfamily (trithorax-G) and a complex including YY1 and HDACs (Polycomb-G) counteract each other to maintain transcription of exogenously introduced genes.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	iba@ims.u-tokyo.ac.jp		Mizutani, Taketoshi/0000-0002-1329-6512				Arai T, 1999, VIROLOGY, V260, P109, DOI 10.1006/viro.1999.9773; Arai T, 1998, J VIROL, V72, P1115, DOI 10.1128/JVI.72.2.1115-1121.1998; Bestor TH, 2000, J CLIN INVEST, V105, P409, DOI 10.1172/JCI9459; Buchenau P, 1998, J CELL BIOL, V141, P469, DOI 10.1083/jcb.141.2.469; Butler R, 2000, FEBS LETT, V470, P198, DOI 10.1016/S0014-5793(00)01316-8; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; Chen WY, 2000, P NATL ACAD SCI USA, V97, P377, DOI 10.1073/pnas.97.1.377; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cherry SR, 2000, MOL CELL BIOL, V20, P7419, DOI 10.1128/MCB.20.20.7419-7426.2000; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Emery DW, 2000, P NATL ACAD SCI USA, V97, P9150, DOI 10.1073/pnas.160159597; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; Gebuhr TC, 2000, GENESIS, V26, P189, DOI 10.1002/(SICI)1526-968X(200003)26:3<189::AID-GENE4>3.0.CO;2-5; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Komatsu Y, 2001, CANCER RES, V61, P4459; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LeGouy E, 1998, DEV DYNAM, V212, P38, DOI 10.1002/(SICI)1097-0177(199805)212:1<38::AID-AJA4>3.0.CO;2-3; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; Pannell D, 2000, EMBO J, V19, P5884, DOI 10.1093/emboj/19.21.5884; Rivella S, 2000, J VIROL, V74, P4679, DOI 10.1128/JVI.74.10.4679-4687.2000; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wong AKC, 2000, CANCER RES, V60, P6171; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001	37	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15859	15864		10.1074/jbc.M112421200	http://dx.doi.org/10.1074/jbc.M112421200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11850427	hybrid			2022-12-25	WOS:000175510400087
J	Shen, MR; Yang, TP; Tang, MJ				Shen, MR; Yang, TP; Tang, MJ			A novel function of BCL-2 overexpression in regulatory volume decrease - Enhancing swelling-activated Ca2+ entry and Cl- channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CHLORIDE CHANNELS; CAPACITATIVE CALCIUM-ENTRY; CERVICAL-CANCER CELLS; KIDNEY-CELLS; MDCK CELLS; APOPTOSIS; KINASE; INVOLVEMENT; LYMPHOCYTES; EXPRESSION	The cellular function of the oncogene bcl-2, a key regulator of apoptosis, is still debated. The goal of this study was to explore the relationship between BCL-2 overexpression and cell volume regulation by using two independent models, Madin-Darby canine kidney (MDCK) cells stably transfected with BCL-2 and MDCK clones with inducible BCL-2 expression by the lac operator/repressor. BCL-2 overexpression enhanced the capability of regulatory volume decrease (RVD), a cellular defensive process against hypotonic stress. In various clones of MDCK cells, hypotonic stress induced an outwardly rectified Cl- current that was significantly upregulated by BCL-2 overexpression. Other fundamental characteristics of this channel were similar among different MDCK clones, such as sensitivity to Cl- channel inhibitor, anion permeability, and time-dependent inactivation at more positive potential. Most importantly, BCL-2 overexpression up-regulates the swelling-activated Ca2+ transient that is a critical signaling for normal RVD and the activation of swelling-activated Cl- channel in MDCK cells. BCL-2 overexpression also enhances the capacitative Ca2+ entry that can be differentiated from the swelling-activated Ca2+ transient by kinetic analysis and sensitivity to Gd3+. Moreover, neutralization of endogenous BCL-2 by antibody blocks the normal RVD response and the activation of swelling-activated Cl- channel in human cervical cancer HT-3 cells. These results provide a new insight into the novel function of BCL-2 overexpression in the regulation of cell volume and ion flux.	Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Obstet & Gynecol, Tainan 701, Taiwan; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	National Cheng Kung University; National Cheng Kung University; University of Oxford	Tang, MJ (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan.			Tang, Ming-Jer/0000-0002-0883-4363				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BANDERALI U, 1992, J MEMBRANE BIOL, V126, P219; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Chen Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1790, DOI 10.1152/ajpcell.1996.270.6.C1790; CHOU CY, 1995, CANCER RES, V55, P6077; Chou CY, 1998, J PHYSIOL-LONDON, V512, P435, DOI 10.1111/j.1469-7793.1998.435be.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haussinger D, 1996, BIOCHEM J, V313, P697; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; Lin HH, 1999, KIDNEY INT, V55, P168, DOI 10.1046/j.1523-1755.1999.00249.x; Lin HH, 1997, AM J PHYSIOL-RENAL, V273, pF300, DOI 10.1152/ajprenal.1997.273.2.F300; LIU HS, 1989, P NATL ACAD SCI USA, V86, P9951, DOI 10.1073/pnas.86.24.9951; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; Nilius B, 1996, GEN PHARMACOL-VASC S, V27, P1131, DOI 10.1016/S0306-3623(96)00061-4; OKADA Y, 1997, AM J PHYSIOL, V273, P755; PAULMICHL M, 1989, PFLUG ARCH EUR J PHY, V413, P456, DOI 10.1007/BF00594173; ROSS PE, 1995, J GEN PHYSIOL, V106, P415, DOI 10.1085/jgp.106.3.415; ROY G, 1987, J MEMBRANE BIOL, V100, P83, DOI 10.1007/BF02209143; Shen MR, 1998, CELL SIGNAL, V10, P113, DOI 10.1016/S0898-6568(97)00115-0; Shen MR, 2001, J PHYSIOL-LONDON, V537, P347, DOI 10.1111/j.1469-7793.2001.00347.x; Shen MR, 2000, J PHYSIOL-LONDON, V529, P385, DOI 10.1111/j.1469-7793.2000.00385.x; Shen MR, 1996, BBA-MOL BASIS DIS, V1315, P138, DOI 10.1016/0925-4439(95)00115-8; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Tang MJ, 1998, AM J PHYSIOL-CELL PH, V275, pC921, DOI 10.1152/ajpcell.1998.275.4.C921; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Urbach V, 1999, J MEMBRANE BIOL, V168, P29, DOI 10.1007/s002329900495; WEISS H, 1992, J MEMBRANE BIOL, V126, P109; Williams SS, 2000, CANCER RES, V60, P4358	30	26	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15592	15599		10.1074/jbc.M111043200	http://dx.doi.org/10.1074/jbc.M111043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861644	hybrid			2022-12-25	WOS:000175510400051
J	Zegerman, P; Canas, B; Pappin, D; Kouzarides, T				Zegerman, P; Canas, B; Pappin, D; Kouzarides, T			Histone H3 lysine 4 methylation disrupts binding of nucleosome remodeling and deacetylase (NuRD) repressor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROMODOMAIN; SIN3	Histone N-terminal tails are post-translationally modified in many ways. At lysine residues, histones can be either acetylated or methylated. Both modifications lead to the binding of specific proteins; bromodomain proteins, such as GCN5, bind acetyl lysines and the chromodomain protein, HP1, binds methyl lysine 9 of histone H3. Here we show that the previously characterized transcriptional repressor complex NuRD (nucleosome remodeling and deacetylase) binds to the histone H3 N-terminal tail and that methylation at lysine 4, but not lysine 9, prevents binding. Given that lysine 4 methylation is found at sites of active transcription, these results suggest that a function of lysine 4 methylation is to disrupt the association of histones with a repressor complex.	Wellcome Canc Res UK Inst, Cambridge CB2 1QR, England; Hammersmith Hosp, MRC, Chem Res Ctr, London W12 0NN, England	Imperial College London	Kouzarides, T (corresponding author), Wellcome Canc Res UK Inst, Tennis Court Rd, Cambridge CB2 1QR, England.		CANAS, BENITO/O-9256-2019	Kouzarides, Tony/0000-0002-8918-4162; Pappin, Darryl/0000-0002-8981-8401; Zegerman, Philip/0000-0002-5707-1083				Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MURRAY K, 1964, BIOCHEMISTRY-US, V3, P10, DOI 10.1021/bi00889a003; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Ridgway P, 2000, J CELL SCI, V113, P2647; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	27	197	202	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11621	11624		10.1074/jbc.C200045200	http://dx.doi.org/10.1074/jbc.C200045200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11850414	hybrid			2022-12-25	WOS:000174846400002
J	Chauhan, D; Auclair, D; Robinson, EK; Hideshima, T; Li, GL; Podar, K; Gupta, D; Richardson, P; Schlossman, RL; Krett, N; Chen, LB; Munshi, NC; Anderson, KC				Chauhan, D; Auclair, D; Robinson, EK; Hideshima, T; Li, GL; Podar, K; Gupta, D; Richardson, P; Schlossman, RL; Krett, N; Chen, LB; Munshi, NC; Anderson, KC			Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays	ONCOGENE			English	Article						multiple myeloma; dexamethasone; interleukin-6	NF-KAPPA-B; BRUTONS TYROSINE KINASE; MARROW STROMAL CELLS; GROWTH-FACTOR; INDUCED APOPTOSIS; EXPRESSION; INTERLEUKIN-6; RECEPTOR; TRANSCRIPTION; INDUCTION	Our previous studies have characterized Dexamethasone (Dex)-induced apoptotic signaling pathways in multiple myeloma (MM) cells; however, related transcriptional events are not fully defined. In the present study, gene expression profiles of Dex-treated MM cells were determined using oligonucleotide arrays. Dex triggers early transient induction of many genes involved in cell defense/repair-machinery. This is followed by induction of genes known to mediate cell death and repression of growth/survival-related genes. The molecular and genetic alterations associated with Dex resistance in MM cells are also unknown. We compared the gene expression profiles of Dex-sensitive and Dex-resistant MM cells and identified a number of genes which may confer Dex-resistance. Finally, gene profiling of freshly isolated MM patient cells validates our in vitro MM cell line data, confirming an in vivo relevance of these studies. Collectively, these findings provide insights into the basic mechanisms of Dex activity against MM, as well as mechanisms of Dex-resistance in MM cells. These studies may therefore allow improved therapeutic uses of Dex, based upon targeting genes that regulate MM cell growth and survival.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol Jerome Lipper Multiple, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Northwestern Univ, Med Sch, Robert H Lurie Canc Ctr, Chicago, IL USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Anderson, KC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol Jerome Lipper Multiple, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021; Podar, Klaus/ABD-1112-2020	Podar, Klaus/0000-0002-7414-3632	NCI NIH HHS [CA 78373] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANIAN R, 1992, BLOOD, V80, P887; Anderson KC, 1999, SEMIN HEMATOL, V36, P14; ANDERSON KC, 1989, BLOOD, V73, P1915; Anderson KC, 2001, SEMIN HEMATOL, V38, P286, DOI 10.1053/shem.2001.26010; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BARUT B, 1993, J CLIN INVEST, V92, P2346, DOI 10.1172/JCI116839; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; CHAUDHRY A, 1994, ANTICANCER RES, V14, P2085; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; CHAUHAN D, 1994, CANCER RES, V54, P2234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2001, APOPTOSIS, V6, P47, DOI 10.1023/A:1009620027205; CHAUHAN D, 1993, BLOOD, V81, P1540; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Desai SD, 2000, ANN NY ACAD SCI, V922, P306; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feinman R, 1999, BLOOD, V93, P3044; Fischer CP, 1996, ANN SURG, V223, P610, DOI 10.1097/00000658-199605000-00017; Fraticelli P, 2001, J CLIN INVEST, V107, P1173, DOI 10.1172/JCI11517; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; GOLDMANLEIKIN RE, 1989, J LAB CLIN MED, V113, P335; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HARDIN J, 1994, BLOOD, V84, P3063; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; JUGEMORINEAU N, 1995, BRIT J HAEMATOL, V90, P707, DOI 10.1111/j.1365-2141.1995.tb05605.x; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KLEIN B, 1989, BLOOD, V73, P517; Kohler HBK, 2001, VET DERMATOL, V12, P129, DOI 10.1046/j.1365-3164.2001.00237.x; Krett NL, 1997, CLIN CANCER RES, V3, P1781; Kudoh K, 2000, CANCER RES, V60, P4161; Levy Y, 1996, CLIN EXP IMMUNOL, V104, P167, DOI 10.1046/j.1365-2249.1996.d01-637.x; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MOALLI PA, 1993, CANCER RES, V53, P3877; MOALLI PA, 1992, BLOOD, V79, P213; Mori S, 1998, ANTICANCER RES, V18, P4403; Ogata A, 1997, J IMMUNOL, V159, P2212; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Rowland TL, 2001, INT IMMUNOPHARMACOL, V1, P49, DOI 10.1016/S0162-3109(00)00265-4; SALMON SE, 1984, CANCER TREAT REP, V68, P117; Smith MR, 1998, BRIT J HAEMATOL, V102, P1090, DOI 10.1046/j.1365-2141.1998.00850.x; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Tassone P, 2000, CELL DEATH DIFFER, V7, P327, DOI 10.1038/sj.cdd.4400635; UCHIYAMA H, 1993, BLOOD, V82, P3712; Urashima M, 1996, BLOOD, V87, P1928; Volin MV, 2001, AM J PATHOL, V159, P1521, DOI 10.1016/S0002-9440(10)62537-0; Wu C, 1999, J BIOL CHEM, V274, P29591, DOI 10.1074/jbc.274.42.29591; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Zimmermann J, 2000, ONCOGENE, V19, P2913, DOI 10.1038/sj.onc.1203606	67	128	131	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1346	1358		10.1038/sj.onc.1205205	http://dx.doi.org/10.1038/sj.onc.1205205			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857078				2022-12-25	WOS:000173861000005
J	Wilhelmsen, K; Burkhalter, S; van der Geer, P				Wilhelmsen, K; Burkhalter, S; van der Geer, P			C-Cbl binds the CSF-1 receptor at tyrosine 973, a novel phosphorylation site in the receptor's carboxy-terminus	ONCOGENE			English	Article						phosphotyrosine; protein-tyrosine kinase; v-fms; ubiquitination	COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; FMS PROTO-ONCOGENE; MEDIATED NEGATIVE REGULATION; FACTOR-I RECEPTOR; V-FMS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; KINASE INSERT; RING FINGER	The colony-stimulating factor-1 (CSF-1) receptor is a protein-tyrosine kinase that regulates the proliferation and differentiation of monocyte and macrophage precursors. Binding of CSF-1 to its receptor results in activation of the kinase domain and autophosphorylation on a number of tyrosine residues. Phosphorylated tyrosine residues function as binding sites for SH2 domain-containing signaling proteins. It is known that activated receptors are internalized and degraded, but the mechanics of this process remain largely unknown. Recently, evidence has started to emerge that the ubiquitin-protein ligase c-Cbl is involved in CSF-1 receptor degradation. In addition, there is evidence that the CSF-1 receptor carboxy-terminus is involved in down regulation of the receptor. Here we show that the c-Cbl tyrosine kinase-binding (TKB) domain binds in vitro and in vivo to the CSF-1 receptor. Binding is dependent on the receptor's protein-kinase activity. Deletion of the carboxy-terminus or mutation of Tyr 973 blocks binding. We further provide evidence that the CSF-1 receptor's carboxy-terminus is a substrate for autophosphorylation. Our observations are consistent with a model in which receptor autophosphorylation at Tyr 973 creates a binding site for c-Cbl. Association of c-Cbl with the receptor leads to ubiquitination, followed by receptor degradation.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	van der Geer, P (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.	geer@ucsd.edu			NCI NIH HHS [5T32 CA 09523] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWNING PJ, 1986, P NATL ACAD SCI USA, V83, P7800, DOI 10.1073/pnas.83.20.7800; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEISTERKAMP N, 1983, VIROLOGY, V126, P248, DOI 10.1016/0042-6822(83)90476-2; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KACINSKI BM, 1995, ANN MED, V27, P79, DOI 10.3109/07853899509031941; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Novak U, 1996, ONCOGENE, V13, P2607; Ota J, 2000, FEBS LETT, V466, P96, DOI 10.1016/S0014-5793(99)01767-6; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	53	62	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1079	1089		10.1038/sj.onc.1205166	http://dx.doi.org/10.1038/sj.onc.1205166			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850825				2022-12-25	WOS:000173580100011
J	Agazie, Y; Ischenko, I; Hayman, M				Agazie, Y; Ischenko, I; Hayman, M			Concomitant activation of the PI3K-Akt and the Ras-ERK signaling pathways is essential for transformation by the V-SEA tyrosine kinase oncogene	ONCOGENE			English	Article						V-SEA; oncogene; Ras-ERK; PI3K-Akt; transformation	AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTORS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MET RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; CELL-TRANSFORMATION; CATALYTIC SUBUNIT; DOCKING SITE; MAP KINASE	V-SEA is the transforming component of S13 Avian Erythroblastosis Retrovirus that causes erythroblastosis and anemia in chicken. Like all members in the family (MET, RON, SEA), its cytosolic domain possesses two tyrosine autophosphorylation sites in the tandemly arranged bidentate motif that serve as docking sites for SH2 domain-containing proteins. Here, we investigated phosphotyrosine-dependent activation of signaling pathways and their significance in V-SEA-induced transformation and/or proliferation. We demonstrated that V-SEA activates the PI3K-Akt signaling pathway primarily in Y557- and secondarily in Y564-dependent manner. V-SEA was also shown to induce the tyrosine phosphorylation of the Gab2 protein, leading to PI3K association and thus providing an alternative route for PI3K activation. On the other hand, activation of the Ras-ERK pathway is primarily via Y564 and secondarily via Y557. A dominant-negative form of Ras inhibited V-SEA-induced ERK phosphorylation in concentration dependent manner suggesting the importance of the Grb2-Ras signaling axis in V-SEA-induced ERK activation. The biological significance of activation of the PI3K-Akt and the Ras-ERK pathways in V-SEA-induced transformation was analysed in the V-SEARATI and V-SEA-3T3 cell lines by employing specific inhibitors, LV294002 and PD98059 compounds. Both the PD and LY compounds inhibited cell growth, but only the PD compound caused reversion of the transformed phenotype. In addition, both compounds inhibited focal colony formation by the transformants in soft agar. Thus, transformation by the V-SEA oncogene is a function of the concomitant activation of, at least, the PI3K-Akt and Ras-ERK signaling pathways that regulate cell growth and morphology.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, M (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	mhayman@ms.cc.sunysb.edu						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Borlado LR, 2000, FASEB J, V14, P895; BORNFELDT KE, 1991, DIABETOLOGIA, V34, P307, DOI 10.1007/BF00405001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; END P, 1993, J BIOL CHEM, V268, P10066; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRECO A, 1992, ONCOGENE, V7, P237; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KNIGHT J, 1990, VIROLOGY, V178, P232, DOI 10.1016/0042-6822(90)90398-B; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MORIMOTO AM, 1994, J VIROL, V68, P1837, DOI 10.1128/JVI.68.3.1837-1842.1994; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1984, PNAS, V84, P6379; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Wahl RC, 1999, J BIOL CHEM, V274, P26361, DOI 10.1074/jbc.274.37.26361; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	54	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					697	707		10.1038/sj.onc.1205115	http://dx.doi.org/10.1038/sj.onc.1205115			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850798				2022-12-25	WOS:000173427000001
J	Li, XP; Kan, HY; Lavrentiadou, S; Krieger, M; Zannis, V				Li, XP; Kan, HY; Lavrentiadou, S; Krieger, M; Zannis, V			Reconstituted discoidal ApoE-phospholipid particles are ligands for the scavenger receptor BI - The amino-terminal 1-165 domain of ApoE suffices for receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; HUMAN APOLIPOPROTEIN-E; TOCOPHEROL TRANSFER PROTEIN; E-DEFICIENT MICE; SR-BI; HDL RECEPTOR; III HYPERLIPOPROTEINEMIA; TRANSGENIC MICE; VITAMIN-E; IN-VIVO	The high density lipoprotein receptor, scavenger receptor class B type I (SR-BI), recognizes lipid-bound apolipoprotein A-I (apoA-I) and other apolipoproteins. Here, we have used large scale cultures of apoE-expressing cells to purify apoE and prepare apoE containing reconstituted discoidal 1-palmitoyl-2-oleoyl-L-phosphatidylcholine (POPC)-apoE particles. These particles have been used to examine their binding to wild-type and mutant forms of SR-BI expressed in transfected IdIA-7 cells. Specific binding to SR-BI was determined by subtracting from the total binding, nonspecific values measured using either control untransfected ldlA-7 cells or by inhibiting SR-BI-mediated binding with a high titer antireceptor-blocking antibody. POPC-apoE particles generated using apoE2, apoE3, apoE4, or the carboxyl-terminally truncated forms apoE165, apoE202, apoE229, and apoE259 all bound tightly to wild-type SR-BI with similar affinities (K-d = 35-45 mug/ml). Binding was nearly abolished in a cell line expressing the ldlA (Q402R/Q418R) double mutant form of SR-BI that is unable to bind native high density lipoprotein but binds low density lipoprotein normally. The findings establish that apoE is a ligand for SR-BI and that the receptor binding domain is located in the amino-terminal 1-165-region of the protein. SR-BI-apoE interactions may contribute to cholesterol homeostasis in tissues and cells expressing SR-BI that are accessible to apoE-containing lipoproteins.	Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Dept Biochem, Boston, MA 02118 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Boston University; Boston University; Massachusetts Institute of Technology (MIT)	Zannis, V (corresponding author), Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA.		Krieger, Marco/AAE-8611-2020	Zannis, Vassilis/0000-0002-1295-7155; Lavrentiadou, Sophia/0000-0002-4062-2336	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068216, R01HL052212, P01HL041484, R01HL048739] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52212, HL68216, HL48739, HL41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Aleshkov S, 1997, BIOCHEMISTRY-US, V36, P10571, DOI 10.1021/bi9626362; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Goti D, 2001, J NEUROCHEM, V76, P498, DOI 10.1046/j.1471-4159.2001.00100.x; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; Husemann J, 2001, AM J PATHOL, V158, P825, DOI 10.1016/S0002-9440(10)64030-8; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jishage K, 2001, J BIOL CHEM, V276, P1669, DOI 10.1074/jbc.C000676200; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Kypreos KE, 2001, BIOCHEMISTRY-US, V40, P6027, DOI 10.1021/bi002414a; Kypreos KE, 2001, J BIOL CHEM, V276, P19778, DOI 10.1074/jbc.M100418200; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LALAZAR A, 1989, J BIOL CHEM, V264, P8447; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; Mardones P, 2002, J NUTR, V132, P443, DOI 10.1093/jn/132.3.443; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MATZ CE, 1982, J BIOL CHEM, V257, P4535; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; SMIT M, 1990, J LIPID RES, V31, P45; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Terasawa Y, 2000, P NATL ACAD SCI USA, V97, P13830, DOI 10.1073/pnas.240462697; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Urban S, 2000, J BIOL CHEM, V275, P33409, DOI 10.1074/jbc.M004031200; van Dijk KW, 1999, ARTERIOSCL THROM VAS, V19, P2945, DOI 10.1161/01.ATV.19.12.2945; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; WARDELL MR, 1987, J CLIN INVEST, V80, P483, DOI 10.1172/JCI113096; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; Xu SZ, 1997, J LIPID RES, V38, P1289; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200; ZANNIS VI, 1998, NATO ASI SER, P179; Zhu YH, 1998, P NATL ACAD SCI USA, V95, P7585, DOI 10.1073/pnas.95.13.7585	64	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21149	21157		10.1074/jbc.M200658200	http://dx.doi.org/10.1074/jbc.M200658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11861652	hybrid			2022-12-25	WOS:000176286000007
J	Pohl, E; Brunner, N; Wilmanns, M; Hensel, R				Pohl, E; Brunner, N; Wilmanns, M; Hensel, R			The crystal structure of the allosteric non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase from the hyperthermophilic archaeum Thermoproteus tenax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ALDEHYDE DEHYDROGENASE; CATALYTIC MECHANISM; PROTEIN STABILITY; CRYSTALLOGRAPHY; DETERMINANTS; SPECIFICITY; MOLSCRIPT; REVEALS; PROGRAM; NAD	The NAD(+)-dependent non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from the hyperthermophilic archaeum Thermoproteus tenax represents an archaeal member of the diverse superfamily of aldehyde dehydrogenases (ALDHs). GAPN catalyzes the irreversible oxidation Of D-glyceraldehyde 3-phosphate to 3-phosphoglycerate. In this study, we present the crystal structure of GAPN in complex with its natural inhibitor NADP(+) determined by multiple anomalous diffraction methods. The structure was refined to a resolution of 2.4 Angstrom with an R-factor of 0.21. The overall fold of GAPN is similar to the structures of ALDHs described previously, consisting of three domains: a nucleotide-binding domain, a catalytic domain, and an oligomerization domain. Local differences in the active site are responsible for substrate specificity. The inhibitor NADP(+) binds at an equivalent site to the cosubstrate-binding site of other ALDHs and blocks the enzyme in its inactive state, possibly preventing the transition to the active conformation. Structural comparison between GAPN from the hyperthermophilic T. tenax and homologs of mesophilic organisms establishes several characteristics of thermostabilization. These include protection against heat-induced covalent modifications by reducing and stabilizing labile residues, a decrease in number and volume of empty cavities, an increase in beta-strand content, and a strengthening of subunit contacts by ionic and hydrophobic interactions.	Univ Essen Gesamthsch, Dept Microbiol, D-45117 Essen, Germany; Hamburg Outstn, European Mol Biol Lab, D-22603 Hamburg, Germany	University of Duisburg Essen; European Molecular Biology Laboratory (EMBL)	Pohl, E (corresponding author), Univ Essen Gesamthsch, Dept Microbiol, Univ Str 5, D-45117 Essen, Germany.	ehmke@embl-hamburg.de; r.hensel@uni-essen.de	Pohl, Ehmke/I-2408-2012; Hu, Ruogu/B-2203-2008	Pohl, Ehmke/0000-0002-9949-4471; Wilmanns, Matthias/0000-0002-4643-5435				Ahvazi B, 2000, BIOCHEM J, V349, P853, DOI 10.1042/bj3490853; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunner NA, 1998, J BIOL CHEM, V273, P6149, DOI 10.1074/jbc.273.11.6149; Brunner NA, 2001, EXTREMOPHILES, V5, P101, DOI 10.1007/s007920100181; Brunner NA, 2000, ACTA CRYSTALLOGR D, V56, P89, DOI 10.1107/S0907444999014134; Chakravarty S, 2000, FEBS LETT, V470, P65, DOI 10.1016/S0014-5793(00)01267-9; Cobessi D, 1999, J MOL BIOL, V290, P161, DOI 10.1006/jmbi.1999.2853; Cobessi D, 2000, J MOL BIOL, V300, P141, DOI 10.1006/jmbi.2000.3824; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Daniel RM, 1996, BIOCHEM J, V317, P1, DOI 10.1042/bj3170001; Elcock AH, 1998, J MOL BIOL, V284, P489, DOI 10.1006/jmbi.1998.2159; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Facchiano AM, 1998, PROTEIN ENG, V11, P753, DOI 10.1093/protein/11.9.753; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; HARPAZ Y, 1994, P NATL ACAD SCI USA, V91, P311, DOI 10.1073/pnas.91.1.311; Hennig M, 1997, BIOCHEMISTRY-US, V36, P6009, DOI 10.1021/bi962718q; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Johansson K, 1998, PROTEIN SCI, V7, P2106, DOI 10.1002/pro.5560071007; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar S, 2000, PROTEIN ENG, V13, P179, DOI 10.1093/protein/13.3.179; Ladenstein R, 1998, Adv Biochem Eng Biotechnol, V61, P37; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; Marchal S, 2000, BIOCHEMISTRY-US, V39, P3327, DOI 10.1021/bi9914208; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moore SA, 1998, STRUCTURE, V6, P1541, DOI 10.1016/S0969-2126(98)00152-X; Niederhut MS, 2001, PROTEIN SCI, V10, P697, DOI 10.1110/ps.45001; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; Sheikh S, 1997, J BIOL CHEM, V272, P18817, DOI 10.1074/jbc.272.30.18817; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P401; SILFHOUT RG, 1994, REV SCI INSTRUM, V66, P1818; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Sterner R, 2001, CRIT REV BIOCHEM MOL, V36, P39, DOI 10.1080/20014091074174; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thompson MJ, 1999, J MOL BIOL, V290, P595, DOI 10.1006/jmbi.1999.2889; Viguera AR, 1999, PROTEIN SCI, V8, P1733, DOI 10.1110/ps.8.9.1733; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Walden H, 2001, J MOL BIOL, V306, P745, DOI 10.1006/jmbi.2000.4433; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x	53	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19938	19945		10.1074/jbc.M112244200	http://dx.doi.org/10.1074/jbc.M112244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11842090	hybrid			2022-12-25	WOS:000175894800092
J	Collinson, EJ; Wheeler, GL; Garrido, EO; Avery, AM; Avery, SV; Grant, CM				Collinson, EJ; Wheeler, GL; Garrido, EO; Avery, AM; Avery, SV; Grant, CM			The yeast glutaredoxins are active as glutathione peroxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS-RESPONSE; SACCHAROMYCES-CEREVISIAE; REACTIVE OXYGEN; THIOLTRANSFERASE GLUTAREDOXIN; ESCHERICHIA-COLI; ERYTHROASCORBIC ACID; STATIONARY-PHASE; REDUCTASE; PROTEIN; PURIFICATION	The yeast Saccharomyces cerevisiae contains two glutaredoxins, encoded by GRX1 and GRX2, which are active as glutathione-dependent oxidoreductases. Our studies show that changes in the levels of glutaredoxins affect the resistance of yeast cells to oxidative stress induced by hydroperoxides. Elevating the gene dosage of GRX1 or GRX2 increases resistance to hydroperoxides including hydrogen peroxide, tert-butyl hydroperoxide and cumene hydroperoxide. The glutaredoxin-mediated resistance to hydroperoxides is dependent on the presence of an intact glutathione system, but does not require the activity of phospholipid hydroperoxide glutathione peroxidases (GPX1-3). Rather, the mechanism appears to be mediated via glutathione conjugation and removal from the cell because it is absent in strains lacking glutathione-S-transferases (GTT1, GTT2) or the GS-X pump (YCF1). We show that the yeast glutaredoxins can directly reduce hydroperoxides in a catalytic manner, using reducing power provided by NADPH, GSH, and glutathione reductase. With cumene hydroperoxide, high pressure liquid chromatography analysis confirmed the formation of the corresponding cumyl alcohol. We propose a model in which the glutathione peroxidase activity of glutaredoxins converts hydroperoxides to their corresponding alcohols; these can then be conjugated to GSH by glutathione-S-transferases and transported into the vacuole by Ycf1.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Nottingham, Sch Life & Environm Sci, Nottingham NG7 2RD, England	University of Manchester; University of Nottingham	Grant, CM (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, POB 88, Manchester M60 1QD, Lancs, England.	chris.grant@umist.ac.uk	Avery, Simon/U-5816-2019; Avery, Simon/AAS-5291-2021; Wheeler, Glen L/E-5034-2011	Avery, Simon/0000-0002-2102-2255; Grant, Chris/0000-0002-0616-6576	NIGMS NIH HHS [R01 GM57945] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057945] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BORA PS, 1989, P NATL ACAD SCI USA, V86, P4470, DOI 10.1073/pnas.86.12.4470; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Choi JH, 1998, J BIOL CHEM, V273, P29915, DOI 10.1074/jbc.273.45.29915; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; Demple B, 1998, SCIENCE, V279, P1655, DOI 10.1126/science.279.5357.1655; FRANKENBERG D, 1993, INT J RADIAT BIOL, V64, P511, DOI 10.1080/09553009314551721; Garrido EO, 2002, MOL MICROBIOL, V43, P993, DOI 10.1046/j.1365-2958.2002.02795.x; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1996, MOL MICROBIOL, V22, P739, DOI 10.1046/j.1365-2958.1996.d01-1727.x; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; Grant CM, 2000, BBA-GENE STRUCT EXPR, V1490, P33, DOI 10.1016/S0167-4781(99)00234-1; HALLIWELL B, 1991, AM J MED, V91, pS14, DOI 10.1016/0002-9343(91)90279-7; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1990, GLUTATHIONE METABOLI, P146; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; KIM HS, 1993, J FOOD SCI, V58, P845, DOI 10.1111/j.1365-2621.1993.tb09373.x; Lee JC, 2001, FEMS YEAST RES, V1, P57; Lefer DJ, 2000, AM J MED, V109, P315, DOI 10.1016/S0002-9343(00)00467-8; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; Mukhopadhyay R, 2000, J BIOL CHEM, V275, P21149, DOI 10.1074/jbc.M910401199; NICK JA, 1986, PLANT SCI, V46, P181, DOI 10.1016/0168-9452(86)90190-1; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; STEELS EL, 1994, MICROBIOL-SGM, V140, P569, DOI 10.1099/00221287-140-3-569; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TRAN LT, 1993, BIOCHIM BIOPHYS ACTA, V1164, P166, DOI 10.1016/0167-4838(93)90244-L; Vergauwen B, 2001, J BIOL CHEM, V276, P20890, DOI 10.1074/jbc.M102026200; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139; ZESHENG L, 1996, J BIOL CHEM, V271, P5609; Zhao TJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P216, DOI 10.1006/abbi.1999.1277	46	104	108	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16712	16717		10.1074/jbc.M111686200	http://dx.doi.org/10.1074/jbc.M111686200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875065	hybrid			2022-12-25	WOS:000175564500050
J	Kim, YM; Barak, LS; Caron, MG; Benovic, JL				Kim, YM; Barak, LS; Caron, MG; Benovic, JL			Regulation of arrestin-3 phosphorylation by casein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; BETA(2)-ADRENERGIC RECEPTOR; VISUAL ARRESTIN; ACTIVATION; BETA-ARRESTIN1; INTERNALIZATION; RESENSITIZATION; UBIQUITINATION	Arrestins play an important role in regulating the function of G protein-coupled receptors including receptor desensitization, internalization, down-regulation, and signaling via nonreceptor tyrosine kinases and mitogen-activated protein kinases. Previous studies have revealed that arrestins themselves are also subject to regulation. In the present study, we focused on identifying potential mechanisms involved in regulating the function of arrestin-3. Using metabolic labeling, phosphoamino acid analysis, and mutagenesis studies, we found that arrestin-3 is constitutively phosphorylated at Thr-382 and becomes dephosphorylated upon beta(2)-adrenergic receptor activation in COS-1 cells. Casein kinase II (CKII) appears to be the major kinase mediating arrestin-3 phosphorylation, since 1) Thr-382 is contained within a canonical consensus sequence for CKII phosphorylation and 2) wild type arrestin-3 but not a T382A mutant is phosphorylated by CKII in vitro. Functional analysis reveals that mutants mimicking the phosphorylated (T382E) and dephosphorylated (T382A or T382V) states of arrestin-3 promote beta(2)-adrenergic receptor internalization and bind clathrin, beta-adaptin, and Src to comparable levels as wild type arrestin-3. This suggests that the phosphorylation of arrestin-3 does not directly regulate interaction with endocytic (clathrin, beta-adaptin) or signaling (Src) components and is in contrast to arrestin-2, where phosphorylation appears to regulate interaction with clathrin and Src. However, additional analysis reveals that arrestin-3 phosphorylation may regulate formation of a large arrestin-3-containing protein complex. Differences between the regulatory roles of arrestin-2 and -3 phosphorylation may contribute to the different cellular functions of these proteins in G protein-coupled receptor signaling and regulation.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Duke Univ, Howard Hughes Med Inst, Dept Cell Biol, Durham, NC 27710 USA	Jefferson University; Duke University; Howard Hughes Medical Institute	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.		Kim, You-Me/I-5553-2013	Kim, You-Me/0000-0001-8780-704X				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Alloway PG, 1999, P NATL ACAD SCI USA, V96, P6072, DOI 10.1073/pnas.96.11.6072; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; CHEN CY, 1993, J BIOL CHEM, V268, P7825; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; MURAKAMI A, 1993, FEBS LETT, V334, P203, DOI 10.1016/0014-5793(93)81712-9; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	46	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16837	16846		10.1074/jbc.M201379200	http://dx.doi.org/10.1074/jbc.M201379200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877451	hybrid			2022-12-25	WOS:000175564500066
J	Thongboonkerd, V; Luengpailin, J; Cao, JK; Pierce, WM; Cai, J; Klein, JB; Doyle, RJ				Thongboonkerd, V; Luengpailin, J; Cao, JK; Pierce, WM; Cai, J; Klein, JB; Doyle, RJ			Fluoride exposure attenuates expression of streptococcus pyogenes virulence factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; CYSTEINE PROTEASE; 2-DIMENSIONAL ELECTROPHORESIS; WATER FLUORIDATION; SURFACE PROTEIN; RHEUMATIC-FEVER; HEART-DISEASE; INHIBITION; BINDING; MUTANS	Fluoridation causes an obvious reduction of dental caries by interference with cariogenic streptococci. However, the effect of fluoride on group A streptococci that causes rheumatic fever and acute poststreptococcal glomerulonephritis is not known. We have used proteomic analysis to create a reference proteome map for Streptococcus pyogenes and to determine fluoride-induced protein changes in the streptococci. Cellular and extracellular proteins were resolved by two-dimensional polyacrylamide gel electrophoresis and identified by matrix-assisted laser desorption ionization mass spectrometry. 183 protein spots were visualized, and 74 spots representing 60 unique proteins were identified. A 16-h exposure to sodium fluoride caused decreased expression of proteins required to respond to cellular stress, including anti-oxidants, glycolytic enzymes, transcriptional and translational regulators, and protein folding. Fluoride caused decreased cellular expression of two well-characterized S. pyogenes virulence factors. Fluoride decreased expression of glyceraldehyde-3-phosphate dehydrogenase, which acts to bind fibronectin and promote bacterial adherence. We also performed proteomic analysis of protein released by S. pyogenes into the culture supernatant and observed decreased expression of M proteins following fluoride exposure. These data provide evidence that fluoride causes decreased expression by S. pyogenes proteins used to respond to stress, virulence factors, and implicated in non-suppurative complications of S. pyogenes, including glomerulonephritis and rheumatic fever.	Univ Louisville, Kidney Dis Program, Cor Proteom Lab, Dept Med, Louisville, KY 40202 USA; Chiang Mai Univ, Fac Med, Dept Med, Chiang Mai 50200, Thailand; Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40202 USA; Vet Adm Med Ctr, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA	University of Louisville; Chiang Mai University; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Louisville; University of Louisville	Klein, JB (corresponding author), Univ Louisville, Kidney Dis Program, Cor Proteom Lab, Dept Med, 570 S Preston St, Louisville, KY 40202 USA.	jon.klein@louisville.edu	Klein, Jon/B-9833-2013; Thongboonkerd, Visith/C-6920-2009	Thongboonkerd, Visith/0000-0001-7865-0765	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066358] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL66358-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL BL, 1981, LANCET, V2, P910; Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; BENNASR A, 1995, BIOCHEM J, V305, P173, DOI 10.1042/bj3050173; BISNO AL, 1985, JAMA-J AM MED ASSOC, V254, P538, DOI 10.1001/jama.254.4.538; Boyle MDP, 2001, J MICROBIOL METH, V46, P87, DOI 10.1016/S0167-7012(01)00279-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURT BA, 1995, BRIT DENT J, V178, P49, DOI 10.1038/sj.bdj.4808645; Chaussee MS, 1996, J INFECT DIS, V173, P901, DOI 10.1093/infdis/173.4.901; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; CURRAN TM, 1994, FEMS MICROBIOL LETT, V119, P283; EASLEY MW, 1995, BRIT DENT J, V178, P72, DOI 10.1038/sj.bdj.4808658; EISENBERG AD, 1980, ARCH ORAL BIOL, V25, P133, DOI 10.1016/0003-9969(80)90089-8; Ekenback SB, 2001, EUR J ORAL SCI, V109, P182, DOI 10.1034/j.1600-0722.2001.00005.x; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Fontan PA, 2000, J INFECT DIS, V182, P1712, DOI 10.1086/317604; Hytonen J, 2001, MOL MICROBIOL, V39, P512, DOI 10.1046/j.1365-2958.2001.02269.x; Jayaraman GC, 1997, MOL MICROBIOL, V25, P329, DOI 10.1046/j.1365-2958.1997.4671835.x; Jensen ON, 1999, METH MOL B, V112, P513; JUNGBLUT P, 1995, J BIOTECHNOL, V41, P111, DOI 10.1016/0168-1656(95)00006-C; Kansal RG, 2000, INFECT IMMUN, V68, P6362, DOI 10.1128/IAI.68.11.6362-6369.2000; KAPUR V, 1993, P NATL ACAD SCI USA, V90, P7676, DOI 10.1073/pnas.90.16.7676; KAUFMANN M, 1992, CARIES RES, V26, P110, DOI 10.1159/000261494; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; Lei BF, 2000, INFECT IMMUN, V68, P6807, DOI 10.1128/IAI.68.12.6807-6818.2000; Lemos JAC, 1998, J MED MICROBIOL, V47, P711, DOI 10.1099/00222615-47-8-711; Luengpailin S, 2000, BBA-GEN SUBJECTS, V1474, P346, DOI 10.1016/S0304-4165(00)00024-6; Lukomski S, 2000, INFECT IMMUN, V68, P6542, DOI 10.1128/IAI.68.12.6542-6553.2000; Lyon WR, 1998, EMBO J, V17, P6263, DOI 10.1093/emboj/17.21.6263; Meier B, 1998, BIOCHEM J, V331, P403, DOI 10.1042/bj3310403; MESTERS JR, 1993, FEBS LETT, V321, P149, DOI 10.1016/0014-5793(93)80097-E; Nordstrand A, 1999, SCAND J INFECT DIS, V31, P523, DOI 10.1080/00365549950164382; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Pancholi V, 1997, J EXP MED, V186, P1633, DOI 10.1084/jem.186.10.1633; PANCHOLI V, 1993, P NATL ACAD SCI USA, V90, P8154, DOI 10.1073/pnas.90.17.8154; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; Perrin C, 2000, ELECTROPHORESIS, V21, P949, DOI 10.1002/(SICI)1522-2683(20000301)21:5&lt;949::AID-ELPS949&gt;3.0.CO;2-5; Quinn A, 1998, INFECT IMMUN, V66, P4418; Quinn A, 2001, INFECT IMMUN, V69, P4072, DOI 10.1128/IAI.69.6.4072-4078.2001; RIPA LW, 1993, J PUBLIC HEALTH DENT, V53, P17; Shanley TP, 1996, INFECT IMMUN, V64, P870, DOI 10.1128/IAI.64.3.870-877.1996; SUTTON SVW, 1987, INFECT IMMUN, V55, P2597, DOI 10.1128/IAI.55.11.2597-2603.1987; TALKINGTON DF, 1993, INFECT IMMUN, V61, P3369, DOI 10.1128/IAI.61.8.3369-3374.1993; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VYSE T, 1991, BRIT MED J, V302, P518, DOI 10.1136/bmj.302.6775.518; Wendrich TM, 1997, MOL MICROBIOL, V26, P65, DOI 10.1046/j.1365-2958.1997.5511919.x; Wilkins JC, 2001, APPL ENVIRON MICROB, V67, P3396, DOI 10.1128/AEM.67.8.3396-3405.2001; Yoshizawa N, 2000, INTERNAL MED, V39, P687, DOI 10.2169/internalmedicine.39.687	47	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16599	16605		10.1074/jbc.M200746200	http://dx.doi.org/10.1074/jbc.M200746200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867637	hybrid			2022-12-25	WOS:000175564500036
J	Ferkey, DM; Kimelman, D				Ferkey, DM; Kimelman, D			Glycogen synthase kinase-3 beta mutagenesis identifies a common binding domain for GBP and axin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; WNT SIGNALING PATHWAY; APC TUMOR-SUPPRESSOR; BETA-CATENIN; KINASE 3-BETA; NEGATIVE REGULATOR; XENOPUS-EMBRYOS; SUBSTRATE-SPECIFICITY; PROTEIN INTERACTIONS; EYE DEVELOPMENT	Glycogen synthase kinase-3beta (GSK-3) is a key downstream target of Wnt signaling and is regulated by its interactions with activating and inhibitory proteins. We and others have shown that GSK-3 activity toward nonprimed substrates is regulated in part through a competition between its activating (Axin) and inhibitory (GBP/ FRAT) binding partners. Here we use a reverse two-hybrid screen to identify mutations in GSK-3 that alter binding to GBP and Axin. We find that these mutations overlap and propose that GBP and Axin compete for binding to the same region of GSK-3. We use these mutations to examine the ability of GSK-3 to block eye development in Xenopus embryos and suggest that GSK-3 regulates eye development through a non-Wnt pathway.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Ctr Dev Biol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kimelman, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.	kimelman@u.washington.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007183] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027262] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27262, T32-HD07183] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Dominguez I, 2001, DEV BIOL, V235, P303, DOI 10.1006/dbio.2001.0317; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; FRASER E, 2001, J BIOL CHEM; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; Heisenberg CP, 2001, GENE DEV, V15, P1427, DOI 10.1101/gad.194301; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Inouye C, 1997, GENETICS, V147, P479; Itoh K, 1995, DEVELOPMENT, V121, P3979; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Kawahara K, 2000, J BIOL CHEM, V275, P8369, DOI 10.1074/jbc.275.12.8369; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Moon R. T., 1989, TECHNIQUE, V1, P76; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Ogino H, 2000, DEV GROWTH DIFFER, V42, P437; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Rasmussen JT, 2001, P NATL ACAD SCI USA, V98, P3861, DOI 10.1073/pnas.071586298; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; van de Water S, 2001, DEVELOPMENT, V128, P3877; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	54	51	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16147	16152		10.1074/jbc.M112363200	http://dx.doi.org/10.1074/jbc.M112363200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861647	hybrid			2022-12-25	WOS:000175510400123
J	Oka, T; Hakoshima, T; Itakura, M; Yamamori, S; Takahashi, M; Hashimoto, Y; Shiosaka, S; Kato, K				Oka, T; Hakoshima, T; Itakura, M; Yamamori, S; Takahashi, M; Hashimoto, Y; Shiosaka, S; Kato, K			Role of loop structures of neuropsin in the activity of serine protease and regulated secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; N-GLYCOSYLATION SITES; RAY CRYSTAL-STRUCTURE; SORTING SIGNAL; CHROMOGRANIN-A; LINKED OLIGOSACCHARIDES; SUBSTRATE-SPECIFICITY; GRANULE BIOGENESIS; MURINE HIPPOCAMPUS; AMINO-TERMINUS	Neuropsin involved in neural plasticity in adult mouse brain is a member of the S1 (clan SA) family of serine proteases and forms characteristic surface loops surrounding the substrate-binding site (Kishi, T., Kato, M., Shimizu, T., Kato, K., Matsumoto, K., Yoshida, S., Shiosaka, S., and Hakoshima, T. (1999) J. Biol. Chem. 274, 4220-4224). Little, however, is known about the roles of these loops. Thus, the present study investigated whether surface loop structures of neuropsin were essential for the generation of enzymatic activity and/or secretion of the enzyme via a regulated secretory pathway. The loops include those stabilized by six disulfide bonds or a loop C (Gly(69)-Glu(80)) and an N-glycosylated kallikrein loop (His(91)-Ile(103)) not containing a site linked by a disulfide bond. First, among the six disulfide bonds, only SS1 in loop E (Gly(142)-Leu(155)) and SS6 in loop G (Ser(185)-Gly(197)) were necessary for the catalytic efficiency of neuropsin. Second, disruptions of loop C and the N-linked oligosaccharide chain on the kallikrein loop affected the catalytic efficiency and P2 specificity, respectively. Alternatively, disruptions of loop C and the kallikrein loop enhanced the regulated secretion, whereas there was no one disruption that inhibited the secretion, indicating that there was no critical loop required for the regulated secretion among loops surrounding the substrate-binding site.	Nara Inst Sci & Technol, Div Struct Cell Biol, Nara 6300101, Japan; Nara Inst Sci & Technol, Div Struct Biol, Nara 6300101, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan	Nara Institute of Science & Technology; Nara Institute of Science & Technology	Kato, K (corresponding author), Nara Inst Sci & Technol, Div Struct Cell Biol, 8916-5 Takayama, Nara 6300101, Japan.	kato@bs.aist-nara.ac.jp	Shiosaka, Sadao/B-1142-2008					Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P5; BARTUNIK HD, 1989, J MOL BIOL, V210, P813, DOI 10.1016/0022-2836(89)90110-1; Bax B, 1997, STRUCTURE, V5, P1275, DOI 10.1016/S0969-2126(97)00280-3; BODE W, 1992, PROTEIN SCI, V1, P426; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; BURGESS TL, 1987, J CELL BIOL, V105, P659, DOI 10.1083/jcb.105.2.659; CHEN ZL, 1995, J NEUROSCI, V15, P5088; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; Davies B, 2001, J NEUROSCI, V21, P6993, DOI 10.1523/JNEUROSCI.21-18-06993.2001; Fernandez CJ, 1997, MOL BIOL CELL, V8, P2171, DOI 10.1091/mbc.8.11.2171; GABEL D, 1973, ACTA CHEM SCAND, V27, P1971, DOI 10.3891/acta.chem.scand.27-1971; Garwicz D, 1998, BLOOD, V92, P1415, DOI 10.1182/blood.V92.4.1415.416k28_1415_1422; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; HARAGUCHI M, 1995, BIOCHEM J, V312, P273, DOI 10.1042/bj3120273; Harlow E, 1988, ANTIBODIES LAB MANUA, P418; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; Jutras I, 2000, J BIOL CHEM, V275, P40337, DOI 10.1074/jbc.M004757200; Kadowaki T, 2000, J BIOL CHEM, V275, P25577, DOI 10.1074/jbc.M003521200; Kato K, 2001, J BIOL CHEM, V276, P14562, DOI 10.1074/jbc.M010725200; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; Kishi A, 1999, J BIOL CHEM, V274, P4220, DOI 10.1074/jbc.274.7.4220; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; Komai S, 2000, EUR J NEUROSCI, V12, P1479, DOI 10.1046/j.1460-9568.2000.00035.x; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; Martina JA, 1998, J BIOL CHEM, V273, P3725, DOI 10.1074/jbc.273.6.3725; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; Mizuguchi H, 1996, BIOCHEM BIOPH RES CO, V218, P402, DOI 10.1006/bbrc.1996.0070; Momota Y, 1998, EUR J NEUROSCI, V10, P760, DOI 10.1046/j.1460-9568.1998.00068.x; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; Mouchantaf R, 2001, J BIOL CHEM, V276, P26308, DOI 10.1074/jbc.M102514200; Nakagami Y, 2000, J NEUROSCI, V20, P2003; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Parmer RJ, 1997, J BIOL CHEM, V272, P1976, DOI 10.1074/jbc.272.3.1976; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; PETERS J, 1992, J BIOCHEM, V111, P643, DOI 10.1093/oxfordjournals.jbchem.a123812; Renatus M, 1997, EMBO J, V16, P4797, DOI 10.1093/emboj/16.16.4797; SAWYER N, 1991, DNA CELL BIOL, V10, P259, DOI 10.1089/dna.1991.10.259; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; Shimizu C, 1998, J BIOL CHEM, V273, P11189, DOI 10.1074/jbc.273.18.11189; Takahashi N, 1999, GLYCOCONJUGATE J, V16, P405, DOI 10.1023/A:1007082612019; WICK PF, 1993, J BIOL CHEM, V268, P10983; WILLETT WS, 1995, BIOCHEMISTRY-US, V34, P2172, DOI 10.1021/bi00007a010; YOO SH, 1993, FEBS LETT, V317, P113, DOI 10.1016/0014-5793(93)81503-R; Zhang CF, 1999, MOL ENDOCRINOL, V13, P527, DOI 10.1210/me.13.4.527; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	55	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14724	14730		10.1074/jbc.M110725200	http://dx.doi.org/10.1074/jbc.M110725200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11854276	hybrid			2022-12-25	WOS:000175203000049
J	Wilde, C; Barth, H; Sehr, P; Han, L; Schmidt, M; Just, I; Aktories, K				Wilde, C; Barth, H; Sehr, P; Han, L; Schmidt, M; Just, I; Aktories, K			Interaction of the Rho-ADP-ribosylating C3 exoenzyme with RalA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORDELLII LETHAL TOXIN; PHOSPHOLIPASE-D; CLOSTRIDIUM-BOTULINUM; RIBOSYLTRANSFERASE C-3; PUTATIVE EFFECTOR; PROTEIN SUBSTRATE; ESCHERICHIA-COLI; GENE-PRODUCT; RAS; PURIFICATION	RhoA, -B, and -C are ADP-ribosylated and biologically inactivated by Clostridium botulinum C3 exoenzyme and related C3-like transferases. We report that RalA GTPase, which is not ADP-ribosylated by C3, inhibits ADP-ribosylation of RhoA by C3 from C. botulinum (C3bot), Clostridium limosum (C3lim), and Bacillus cereus (C3cer) but not from Staphylococcus aureus (C3stau) in human platelet membranes and rat brain lysate. Inhibition by RalA occurs with the GDP- and guanosine 5'-3-O-(thio)triphosphate-bound forms of RalA and is overcome by increasing concentrations of C3. A direct interaction of RalA with C3 was verified by precipitation of the transferase with GST-RalA-Sepharose. The affinity constant (K-d) of the binding of RalA to C3lim was 12 nM as determined by fluorescence titration. RalA increased the NAD glycohydrolase activity of C3bot by about 5-fold. Although RalA had no effect on glucosylation of Rho GTPases by Clostridium difficile toxin B, C3bot and C3lim inhibited glucosylation of RalA by Clostridium sordellii lethal toxin. Furthermore, C3bot decreased activation of phospholipase D by Ral4, The data indicate that several C3 exoenzymes directly interact with RalA without ADP-ribosylating the GTPase. The interaction is of high affinity and interferes with essential functions of C3 and RalA.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Hannover Med Sch, Inst Toxikol, D-30625 Hannover, Germany; Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany	University of Freiburg; Hannover Medical School; University of Duisburg Essen	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Otto Krayer Haus,Albertstr 25, D-79104 Freiburg, Germany.	aktories@ruf.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022; Barth, Holger/E-7920-2013	Aktories, Klaus/0000-0002-5397-0436; Sehr, Peter/0000-0002-4348-5066				Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Aktories K, 2000, FR MOLEC B, V24, P311; Beltman J, 1999, J BIOL CHEM, V274, P3772, DOI 10.1074/jbc.274.6.3772; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bohmer J, 1996, BIOCHEMISTRY-US, V35, P282, DOI 10.1021/bi951784+; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; Busch C, 2000, CURR OPIN STRUC BIOL, V10, P528, DOI 10.1016/S0959-440X(00)00126-3; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; FRECH M, 1990, J BIOL CHEM, V265, P6353; Genth H, 1996, BIOCHEM BIOPH RES CO, V229, P370, DOI 10.1006/bbrc.1996.1812; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; Hofmann F, 1996, BIOCHEM BIOPH RES CO, V227, P77, DOI 10.1006/bbrc.1996.1470; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; JAKOBS KH, 1982, J BIOL CHEM, V257, P2829; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; JUST I, 1995, BIOCHEMISTRY-US, V34, P334, DOI 10.1021/bi00001a041; JUST I, 1992, J BIOL CHEM, V267, P10274; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; JUST I, 1997, BACTERIAL TOXINS TOO, P59; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Park SH, 1995, ONCOGENE, V11, P2349; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Schmidt M, 1999, J BIOL CHEM, V274, P14648, DOI 10.1074/jbc.274.21.14648; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VAN AL, 1997, GENE DEV, V11, P2295; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; Wilde C, 2001, J BIOL CHEM, V276, P9537, DOI 10.1074/jbc.M011035200; Wilde C, 2001, TOXICON, V39, P1647, DOI 10.1016/S0041-0101(01)00152-0	50	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14771	14776		10.1074/jbc.M201072200	http://dx.doi.org/10.1074/jbc.M201072200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847234	hybrid			2022-12-25	WOS:000175203000055
J	Kressler, D; Schreiber, SN; Knutti, D; Kralli, A				Kressler, D; Schreiber, SN; Knutti, D; Kralli, A			The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; HORMONE RECEPTORS; GAMMA COACTIVATOR-1; RESPONSE ELEMENTS; PROMOTER-CONTEXT; ACTIVATION; BINDING; IDENTIFICATION; DOMAINS	Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) is a tissue-specific coactivator that enhances the activity of many nuclear receptors and coordinates transcriptional programs important for energy metabolism. We describe here a novel PGC-1-related coactivator that is expressed in a similar tissue-specific manner as PGC-1, with the highest levels in heart and skeletal muscle. In contrast to PGC-1, the new coactivator shows high receptor specificity. It enhances potently the activity of estrogen receptor (ER) alpha, while having only small effects on other receptors. Because of its nuclear receptor selectivity, we have termed the new protein PERC (PGC-1 related Estrogen Receptor Coactivator). We show here that the coactivation function of PERC relies on a bipartite transcriptional activation domain and two LXXLL motifs that interact with the AF2 domain of ERalpha in an estrogen-dependent manner. PERC and PGC-1 are likely to have different functions in ER signaling. Whereas PERC acts selectively on ERalpha and not on the second estrogen receptor ERbeta, PGC-1 coactivates strongly both Ells. Moreover, PERC and PGC-1 show distinct preferences for enhancing ERalpha in different promoter contexts. Finally, PERC enhances the ERalpha-mediated response to the partial agonist tamoxifen, while PGG-1 modestly represses it. The two coactivators are likely to mediate distinct, tissue-specific responses to estrogens.	Univ Basel, Biozentrum, Div Biochem, CH-4056 Basel, Switzerland	University of Basel	Kralli, A (corresponding author), Univ Basel, Biozentrum, Div Biochem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	anastasia.kralli@unibas.ch	Kressler, Dieter/C-2218-2012	Kressler, Dieter/0000-0003-4855-3563				Andersson U, 2001, MOL CELL BIOL, V21, P3738, DOI 10.1128/MCB.21.11.3738-3749.2001; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Cooke PS, 2001, MOL CELL ENDOCRINOL, V178, P147, DOI 10.1016/S0303-7207(01)00414-2; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Driscoll MD, 1998, J BIOL CHEM, V273, P29321, DOI 10.1074/jbc.273.45.29321; Esterbauer H, 1999, GENOMICS, V62, P98, DOI 10.1006/geno.1999.5977; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Freedman LP, 1999, J CELL BIOCHEM, P103; Glass CK, 2000, GENE DEV, V14, P121; Grumbach MM, 1999, J CLIN ENDOCR METAB, V84, P4677, DOI 10.1210/jc.84.12.4677; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Jung DJ, 2002, J BIOL CHEM, V277, P1229, DOI 10.1074/jbc.M110417200; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Li DS, 1999, MOL CELL BIOL, V19, P7191; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Loven MA, 2001, J BIOL CHEM, V276, P45282, DOI 10.1074/jbc.M106211200; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McDonnell DP, 1999, TRENDS ENDOCRIN MET, V10, P301, DOI 10.1016/S1043-2760(99)00177-0; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Scheidegger KJ, 2000, J BIOL CHEM, V275, P38921, DOI 10.1074/jbc.M004691200; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1998, J BIOL CHEM, V273, P21554, DOI 10.1074/jbc.273.34.21554; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	58	180	188	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13918	13925		10.1074/jbc.M201134200	http://dx.doi.org/10.1074/jbc.M201134200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11854298	hybrid			2022-12-25	WOS:000175096000075
J	Smardon, AM; Tarsio, M; Kane, PM				Smardon, AM; Tarsio, M; Kane, PM			The RAVE complex is essential for stable assembly of the yeast V-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; UBIQUITIN-DEPENDENT DEGRADATION; CLATHRIN-COATED VESICLE; SACCHAROMYCES-CEREVISIAE; F-BOX; ADENOSINE-TRIPHOSPHATASE; SUBUNIT INTERACTIONS; ELECTRON-MICROSCOPY; GENE	Vacuolar proton-translocating ATPases are composed of a peripheral complex, V-1, attached to an integral membrane complex, V.. Association of the two complexes is essential for ATP-driven proton transport and is regulated post-translationally in response to glucose concentration. A new complex, RAVE, was recently isolated and implicated in glucose-dependent reassembly of V-ATPase complexes that had disassembled in response to glucose deprivation (Seol, J. H., Shevchenko, A., and Deshaies, R. J. (2001) Nat. Cell Biol. 3, 384-391). Here, we provide evidence supporting a role for RAVE in reassembly of the V-ATPase but also demonstrate an essential role in V-ATPase assembly under other conditions. The RAVE complex associates reversibly with V-1 complexes released from the membrane by glucose deprivation but binds constitutively to cytosolic V-1 sectors in a mutant lacking V-0 sectors. V-ATPase complexes from cells lacking RAVE subunits show serious structural and functional defects even in glucose-grown cells or in combination with a mutation that blocks disassembly of the V-ATPase. RAVE.V-1 interactions are specifically disrupted in cells lacking V-1 subunits E or G, suggesting a direct involvement for these subunits in interaction of the two complexes. Skp1p, a RAVE subunit involved in many different signal transduction pathways, binds stably to other RAVE subunits under conditions that alter RAVE.V-1 binding; thus, Skp1p recruitment to the RAVE complex does not appear to provide a signal for V-ATPase assembly.	SUNY Syracuse, Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Syracuse, Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	kanepm@upstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063742, R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM063742, GM50322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Curtis KK, 2002, J BIOL CHEM, V277, P8979, DOI 10.1074/jbc.M111708200; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; Forgac M, 1999, J BIOENERG BIOMEMBR, V31, P57, DOI 10.1023/A:1005496530380; FOURY F, 1990, J BIOL CHEM, V265, P18554; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mathias N, 1999, MOL CELL BIOL, V19, P1759; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Peng SB, 1999, J BIOL CHEM, V274, P2549, DOI 10.1074/jbc.274.4.2549; Radermacher M, 1999, FEBS LETT, V453, P383, DOI 10.1016/S0014-5793(99)00739-5; Radermacher M, 2001, J STRUCT BIOL, V135, P26, DOI 10.1006/jsbi.2001.4395; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Sherman F., 1982, METHODS YEAST GENETI; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Willems AR, 1999, PHILOS T ROY SOC B, V354, P1533, DOI 10.1098/rstb.1999.0497; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1994, J BIOL CHEM, V269, P23518	54	126	133	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13831	13839		10.1074/jbc.M200682200	http://dx.doi.org/10.1074/jbc.M200682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11844802	hybrid			2022-12-25	WOS:000175096000065
J	Li, H; Myeroff, L; Kasturi, L; Krumroy, L; Schwartz, S; Willson, JKV; Stanbridge, E; Casey, G; Markowitz, S				Li, H; Myeroff, L; Kasturi, L; Krumroy, L; Schwartz, S; Willson, JKV; Stanbridge, E; Casey, G; Markowitz, S			Chromosomal autonomy of hMLH1 methylation in colon cancer	ONCOGENE			English	Article						colon cancer; methylation; hMLH1	DNA METHYLATION; FUNCTIONAL EVIDENCE; SUPPRESSOR GENE; PROMOTER; INACTIVATION; EXPRESSION	Silencing of hMLH1 expression by aberrant hMLH1 promoter methylation accounts for the majority of sporadic colon cancers with microsatellite instability. We have previously shown hMLH1 silencing is biallelic and actively maintained. To study the mechanism of aberrant hMLH1 methylation, we assayed whether an hMLH1 methylated cell could transfer methylation and silencing to an exogenous hMLH1 promoter in somatic cell hybrids between hMLH1 methylated-silenced and hMLH1 unmethylated-expressing colon cancer cells. Conversely, we assayed whether these hybrids could reactivate expression of initially methylated and silenced hMLH1 alleles. Compellingly, within the hybrids each hMLH1 allele remained unchanged, retaining the expression status of its parental cell of origin. This chromosomal autonomy may not be simply determined by DNA methylation, as it is reasserted after experimentally forced demethylation of all hMLH1 alleles in the hybrids. Confirming findings included hMLH1 methylated cells being unable to methylate single transferred exogenous hMLH1 expressing chromosomes or transfected hMLH1 reporter constructs. hMLH1 silencing does not conform to either a dominant or recessive model, and is not determined by trans-acting factors differing between hMLH1 expressing or silenced genomes. We posit that hMLH1 methylation is dependent on and maintained by cis chromosomal marks, whose nature remains to be elucidated.	Case Western Reserve Univ, Dept Microbiol & Mol Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Univ Calif Irvine, Irvine, CA 92697 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; University Hospitals of Cleveland; Howard Hughes Medical Institute; Cleveland Clinic Foundation; Case Western Reserve University; University of California System; University of California Irvine	Markowitz, S (corresponding author), Case Western Reserve Univ, Dept Microbiol & Mol Biol, 2 Rm 200 11001 Cedar Rd, Cleveland, OH 44106 USA.	sxm10@po.cwru.edu			NCI NIH HHS [P30 CA43703, R01 CA67409, R01 CA72160] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067409, P30CA043703, R01CA072160] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arad U, 1998, BIOTECHNIQUES, V24, P760, DOI 10.2144/98245bm14; Baylin SB, 1998, ADV CANCER RES, V72, P141; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Deng GR, 1999, CANCER RES, V59, P2029; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; GEISER AG, 1989, CANCER RES, V49, P1572; Grady WM, 2001, CANCER RES, V61, P900; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hsieh CL, 2000, CURR OPIN GENET DEV, V10, P224, DOI 10.1016/S0959-437X(00)00064-2; Issa JP, 2000, ANN NY ACAD SCI, V910, P140; Ito E, 1999, BIOCHEM BIOPH RES CO, V256, P488, DOI 10.1006/bbrc.1999.0368; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Kane MF, 1997, CANCER RES, V57, P808; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Kuzmin I, 1999, ONCOGENE, V18, P5672, DOI 10.1038/sj.onc.1202959; LEE YW, 1995, MOL CELL BIOL, V15, P2547; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wiesner GL, 2001, J NATL CANCER I, V93, P635, DOI 10.1093/jnci/93.8.635; WILLSON JKV, 1987, CANCER RES, V47, P2704	26	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1443	1449		10.1038/sj.onc.1205247	http://dx.doi.org/10.1038/sj.onc.1205247			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857087				2022-12-25	WOS:000173861000014
J	Lee, G; Elwood, F; McNally, J; Weiszmann, J; Lindstrom, M; Amaral, K; Nakamura, M; Miao, S; Cao, P; Learned, RM; Chen, JL; Li, Y				Lee, G; Elwood, F; McNally, J; Weiszmann, J; Lindstrom, M; Amaral, K; Nakamura, M; Miao, S; Cao, P; Learned, RM; Chen, JL; Li, Y			T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; INHIBITS ADIPOCYTE DIFFERENTIATION; NUCLEAR HORMONE RECEPTORS; PPAR-GAMMA; CRYSTAL-STRUCTURE; BINDING; ACID; COACTIVATORS; ALPHA; ADIPOGENESIS	The nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARgamma (NR1C3)) plays a central role in adipogenesis and is the molecular target for the thiazolidinedione (TZD) class of antidiabetic drugs. In a search for novel non-TZD ligands for PPARgamma, T0070907 was identified as a potent and selective PPARgamma antagonist. With an apparent binding affinity (concentration at 50% inhibition of [H-3]rosiglitazone binding or IC50) of 1 nM, T0070907 covalently modifies PPARgamma on cysteine 313 in helix 3 of human PPARgamma2. T0070907 blocked PPARgamma function in both cell-based reporter gene and adipocyte differentiation assays. Consistent with its role as an antagonist of PPARgamma, T0070907 blocked agonist-induced recruitment of coactivator-derived peptides to PPARgamma in a homogeneous time-resolved fluorescence-based assay and promoted recruitment of the transcriptional corepressor NCoR to PPARgamma in both glutathione S-transferase pull-down assays and a PPARgamma/retinoid X receptor (RXR) alpha-dependent gel shift assay. Studies with mutant receptors suggest that T0070907 modulates the interaction of PPARgamma with these cofactor proteins by affecting the conformation of helix 12 of the PPARgamma ligand-binding domain. Interestingly, whereas the T0070907-induced NCoR recruitment to PPARgamma/RXRalpha heterodimer can be almost completely reversed by the simultaneous treatment with RXRalpha agonist LGD1069, T0070907 treatment has only modest effects on LGD1069-induced coactivator recruitment to the PPARgamma/RXRalpha heterodimer. These results suggest that the activity of PPARgamma antagonists can be modulated by the availability and concentration of RXR agonists. T0070907 is a novel tool for the study of PPARgamma/RXRalpha heterodimer function.	Tularik Inc, San Francisco, CA 94080 USA		Li, Y (corresponding author), Tularik Inc, 2 Corp Dr, San Francisco, CA 94080 USA.							Auwerx J, 1999, CELL, V97, P161; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; Brown PJ, 1997, CHEM BIOL, V4, P909, DOI 10.1016/S1074-5521(97)90299-4; Camp HS, 2001, ENDOCRINOLOGY, V142, P3207, DOI 10.1210/en.142.7.3207; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Elbrecht A, 1999, J BIOL CHEM, V274, P7913, DOI 10.1074/jbc.274.12.7913; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Papac DI, 1996, ANAL CHEM, V68, P3215, DOI 10.1021/ac960324z; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Wang YP, 2000, MOL ENDOCRINOL, V14, P1550, DOI 10.1210/me.14.10.1550; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	34	247	255	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19649	19657		10.1074/jbc.M200743200	http://dx.doi.org/10.1074/jbc.M200743200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11877444	hybrid			2022-12-25	WOS:000175894800055
J	Murakami, M; Yoshihara, K; Shimbara, S; Lambeau, G; Gelb, MH; Singer, AG; Sawada, M; Inagaki, N; Nagai, H; Ishihara, M; Ishikawa, Y; Ishii, T; Kudo, I				Murakami, M; Yoshihara, K; Shimbara, S; Lambeau, G; Gelb, MH; Singer, AG; Sawada, M; Inagaki, N; Nagai, H; Ishihara, M; Ishikawa, Y; Ishii, T; Kudo, I			Cellular arachidonate-releasing function and inflammation-associated expression of group IIF secretory phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT EXPRESSION; ACID RELEASE; MAST-CELLS; PANCREATIC PHOSPHOLIPASE-A2; PROSTAGLANDIN GENERATION; POTENTIAL ROLE; CLONING; BINDING; MOUSE; RAT	Here we report the cellular arachidonate (AA)-releasing function of group IIF secretory phospholipase A(2) (sPLA(2)-IIF), a sPLA(2) enzyme uniquely containing a longer C-terminal extension. sPLA(2)-IIF increased spontaneous and stimulus-dependent release of AA, which was supplied to downstream cyclooxygenases and 5-lipoxygenase for eicosanoid production. sPLA(2)-IIF also enhanced interleukin 1-stimulated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. AA release by sPLA(2)-IIF was facilitated by oxidative modification of cellular membranes. Cellular actions of sPLA(2)-IIF occurred independently of the heparan sulfate proteoglycan glypican, which acts as a functional adaptor for other group II subfamily sPLA(2)s. Confocal microscopy revealed the location of sPLA(2)-IIF on the plasma membrane. The unique C-terminal extension was crucial for its plasma membrane localization and optimal cellular functions. sPLA(2)-IIF expression was increased in various tissues from lipopolysaccharide-treated mice and in ears of mice with experimental atopic dermatitis. In human rheumatoid arthritic joints, sPLA2-IIF was detected in synovial lining cells, capillary endothelial cells, and plasma cells. These results suggest that sPLA(2)-IIF is a potent regulator of AA metabolism and participates in the inflammatory process under certain conditions.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Inst Pharmacol Mol & Cellulaire, CNRS, UPR 411, F-06560 Valbonne, France; Gifu Pharmaceut Univ, Dept Pharmacol, Higashi Ku, Gifu 5028585, Japan; Toho Univ, Sch Med, Dept Pathol, Ohta Ku, Tokyo 1438540, Japan	Showa University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Murakami, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.		Lambeau, Gerard/GRJ-5624-2022	gelb, michael/0000-0001-7000-5219; Lambeau, Gerard/0000-0002-9239-518X				Akiba S, 1997, J BIOCHEM-TOKYO, V122, P859; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Enomoto A, 2000, BIOCHEM BIOPH RES CO, V276, P667, DOI 10.1006/bbrc.2000.3468; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Jamal OS, 1998, ANN RHEUM DIS, V57, P550, DOI 10.1136/ard.57.9.550; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kuwata H, 2000, J IMMUNOL, V165, P4024, DOI 10.4049/jimmunol.165.7.4024; Laine VJO, 1999, J IMMUNOL, V162, P7402; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; Morioka Y, 2000, FEBS LETT, V487, P262, DOI 10.1016/S0014-5793(00)02350-4; Mounier C, 1996, EUR J BIOCHEM, V237, P778, DOI 10.1111/j.1432-1033.1996.0778p.x; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nagai H, 2000, BRIT J PHARMACOL, V129, P299, DOI 10.1038/sj.bjp.0703054; Nigam S, 2000, BBA-MOL CELL BIOL L, V1488, P167, DOI 10.1016/S1388-1981(00)00119-0; OKA S, 1991, J BIOL CHEM, V266, P9956; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Sawada H, 1999, EUR J BIOCHEM, V263, P826, DOI 10.1046/j.1432-1327.1999.00565.x; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; Tietge UJF, 2000, J BIOL CHEM, V275, P10077, DOI 10.1074/jbc.275.14.10077; TOJO H, 1988, J BIOL CHEM, V263, P5724; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, BIOCHEM BIOPH RES CO, V279, P223, DOI 10.1006/bbrc.2000.3908; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121; Zhang YP, 1999, J BIOL CHEM, V274, P27726, DOI 10.1074/jbc.274.39.27726; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	54	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19145	19155		10.1074/jbc.M112385200	http://dx.doi.org/10.1074/jbc.M112385200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877435	hybrid			2022-12-25	WOS:000175975800117
J	Humbert, O; Hermine, T; Hernandez, H; Bouget, T; Selves, J; Laurent, G; Salles, B; Lautier, D				Humbert, O; Hermine, T; Hernandez, H; Bouget, T; Selves, J; Laurent, G; Salles, B; Lautier, D			Implication of protein kinase C in the regulation of DNA mismatch repair protein expression and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSATELLITE INSTABILITY; CELL-LINES; GENE HMSH2; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; ACQUIRED-RESISTANCE; MUTATOR PHENOTYPE; P53 MUTATIONS; LEUKEMIA; MSH2; DEFECTS	The DNA mismatch repair (MMR) proteins are essential for the maintenance of genomic stability of human cells. Compared with hereditary or even sporadic carcinomas, MMR gene mutations are very uncommon in leukemia. However, genetic instability, attested by either loss of heterozygosity or microsatellite instability, has been extensively documented in chronic or acute malignant myeloid disorders. This observation suggests that in leukemia some internal or external signals may interfere with MMR protein expression and/or function. We investigated the effects of protein kinase C (PKC) stimulation by 12-O-tetradecanoylphorbol-13-acetate (TPA) on MMR protein expression and activity in human myeloid leukemia cell lines. First, we show here that unstimulated U937 cells displayed low level of PKC activity as well as MMR protein expression and activity compared with a panel of myeloid cell lines. Second, treatment of U937 cells with TPA significantly increased (3-5-fold) hMSH2 expression and, to a lesser extent, hMSH6 and hPMS2 expression, correlated to a restoration of MMR function. In addition, diacylglycerol, a physiological PKC agonist, induced a significant increase in hMSH-2 expression, whereas chelerythrine or calphostin C, two PKC inhibitors, significantly decreased TPA-induced hMSH2 expression. Reciprocally, treatment of HEL and KG1a cells that exhibited a high level of PKC expression, with chelerythrine significantly decreased hMSH2 and hMSH6 expression. Moreover, the alteration of MMR protein expression paralleled the difference in microsatellite instability and cell sensitivity to 6-thioguanine. Our results suggest that PKC could play a role in regulating MMR protein expression and function in some myeloid leukemia cells.	Inst Pharmacol & Biol Struct, CNRS, UMR 5089, F-31077 Toulouse, France; Inst Claudius Regaud, INSERM E9910, F-31052 Toulouse, France; Hop Purpan, Anat Pathol Lab, F-31059 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse	Lautier, D (corresponding author), Inst Pharmacol & Biol Struct, CNRS, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	lautier@icr.fnclcc.fr	Lautier, Dominique/G-3959-2017; salles, bernard/B-8531-2008					Aebi S, 1996, CANCER RES, V56, P3087; BAILLY JD, 1995, LEUKEMIA, V9, P799; BenYehuda D, 1996, BLOOD, V88, P4296; Boldogh I, 1998, CANCER RES, V58, P3950; BOYER JC, 1995, CANCER RES, V55, P6063; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Canitrot Y, 1997, BIOCHEM BIOPH RES CO, V234, P573, DOI 10.1006/bbrc.1997.6674; Chang DK, 2000, J BIOL CHEM, V275, P18424, DOI 10.1074/jbc.M001140200; CHEN JS, 1995, CANCER RES, V55, P174; Chen Y, 2001, CANCER RES, V61, P4112; Christmann M, 2000, J BIOL CHEM, V275, P36256, DOI 10.1074/jbc.M005377200; Clave E, 1996, INT J RADIAT ONCOL, V35, P709, DOI 10.1016/0360-3016(96)00137-X; delasAlas MM, 1997, J NATL CANCER I, V89, P1537, DOI 10.1093/jnci/89.20.1537; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GESCHER A, 1989, ANTI-CANCER DRUG DES, V4, P93; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; INDRACCOLO S, 1995, LEUKEMIA, V9, P1517; Indraccolo S, 1999, BLOOD, V94, P2424, DOI 10.1182/blood.V94.7.2424.419k09_2424_2432; Inoue K, 2000, LEUKEMIA RES, V24, P255, DOI 10.1016/S0145-2126(99)00182-4; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Karran P, 1996, CHEM BIOL, V3, P875, DOI 10.1016/S1074-5521(96)90175-1; KARRAN P, 1993, J BIOL CHEM, V268, P15878; Kodera T, 1999, GENE CHROMOSOME CANC, V26, P267, DOI 10.1002/(SICI)1098-2264(199911)26:3<267::AID-GCC13>3.0.CO;2-V; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lautier D, 1997, INT J CANCER, V71, P292; Leach FS, 1996, CANCER RES, V56, P235; Levati L, 1998, GENE CHROMOSOME CANC, V23, P159, DOI 10.1002/(SICI)1098-2264(199810)23:2<159::AID-GCC9>3.0.CO;2-1; Li QD, 1998, J BIOL CHEM, V273, P23419, DOI 10.1074/jbc.273.36.23419; LIU B, 1994, CANCER RES, V54, P4590; Lowsky R, 1997, BLOOD, V89, P2276, DOI 10.1182/blood.V89.7.2276; Macpherson P, 1998, MUTAT RES-DNA REPAIR, V408, P55, DOI 10.1016/S0921-8777(98)00017-2; Mansat V, 1997, CANCER RES, V57, P5300; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Marra G, 1996, ONCOGENE, V13, P2189; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; O'Driscoll M., 1998, NUCL ACID M, V12, P173; Oda S, 2000, EMBO J, V19, P1711, DOI 10.1093/emboj/19.7.1711; Pabst T, 1996, BLOOD, V88, P1026, DOI 10.1182/blood.V88.3.1026.bloodjournal8831026; Rimsza LM, 2000, LEUKEMIA, V14, P1044, DOI 10.1038/sj.leu.2401699; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; Shcherbakova PV, 2001, MOL CELL BIOL, V21, P940, DOI 10.1128/MCB.21.3.940-951.2001; Sill H, 1996, BRIT J CANCER, V74, P255, DOI 10.1038/bjc.1996.347; Srivenugopal KS, 2000, CANCER RES, V60, P282; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Tasaka T, 1997, BRIT J HAEMATOL, V98, P219, DOI 10.1046/j.1365-2141.1997.1672985.x; UMAR A, 1994, J BIOL CHEM, V269, P14367; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WILSON TM, 1995, CANCER RES, V55, P5146; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; Zhu YM, 1999, BLOOD, V94, P733, DOI 10.1182/blood.V94.2.733.414k03_733_740	65	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18061	18068		10.1074/jbc.M103451200	http://dx.doi.org/10.1074/jbc.M103451200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11880362	hybrid			2022-12-25	WOS:000175685100085
J	Yang, LT; Alexandropoulos, K; Sap, J				Yang, LT; Alexandropoulos, K; Sap, J			c-SRC mediates neurite outgrowth through recruitment of Crk to the scaffolding protein Sin/Efs without altering the kinetics of ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE-ALPHA; FOCAL ADHESION KINASE; NERVE GROWTH-FACTOR; PC12 CELL-DIFFERENTIATION; ADAPTER PROTEIN; PTP-ALPHA; V-SRC; SIGNALING PATHWAY; FAMILY KINASES; IN-VIVO	SRC family kinases have been consistently and recurrently implicated in neurite extension events, yet the mechanism underlying their neuritogenic role has remained elusive. We report that epidermal growth factor (EGF) can be converted from a non-neuritogenic into a neuritogenic factor through moderate activation of endogenous SRC by receptor-protein-tyrosine phosphatase a (a physiological SRC activator). We show that such a qualitative change in the response to EGF is not accompanied by changes in the extent or kinetics of ERK induction in response to this factor. Instead, the pathway involved relies on increased tyrosine phosphorylation of, and recruitment of Crk to, the SRC substrate Sin/Efs. The latter is a scaffolding protein structurally similar to the SRC substrate Cas, tyrosine phosphorylation of which is critical for migration in fibroblasts and epithelial cells. Expression of a dominant negative version of Sin interfered with receptor-protein-tyrosine phosphatase alpha/EGF- as well as fibroblast growth factor-induced neurite outgrowth. These observations uncouple neuritogenic signaling in PC12 cells from sustained activation of ERK kinases and for the first time identify an effector of SRC function in neurite extension.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	New York University; Columbia University	Sap, J (corresponding author), NYU, Sch Med, Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.		Yang, Liang-Tung/B-2661-2010		NCI NIH HHS [CA68365] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA068365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Helmke S, 1998, J CELL SCI, V111, P2465; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; Ishino M, 1995, ONCOGENE, V11, P2331; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kobayashi S, 1997, J BIOL CHEM, V272, P16262, DOI 10.1074/jbc.272.26.16262; Kobayashi S, 1998, J BIOCHEM-TOKYO, V123, P624; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Lammers R, 2000, J BIOL CHEM, V275, P3391, DOI 10.1074/jbc.275.5.3391; Law SF, 1996, MOL CELL BIOL, V16, P3327; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Petrone A, 2000, J CELL SCI, V113, P2345; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; Stoker A, 1998, BIOESSAYS, V20, P463, DOI 10.1002/(SICI)1521-1878(199806)20:6<463::AID-BIES4>3.0.CO;2-N; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1996, J BIOL CHEM, V271, P28026; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; Weinstein DE, 1999, DEV BRAIN RES, V116, P29, DOI 10.1016/S0165-3806(99)00072-3; Wu YY, 1996, J BIOL CHEM, V271, P13033, DOI 10.1074/jbc.271.22.13033; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; YANG LT, 1989, THESIS NEW YORK U NE; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; Zhong HY, 1999, BIOCHEM J, V344, P889, DOI 10.1042/0264-6021:3440889	57	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17406	17414		10.1074/jbc.M111902200	http://dx.doi.org/10.1074/jbc.M111902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11867627	hybrid			2022-12-25	WOS:000175685100006
J	Zhang, YJ; O'Neal, WK; Randell, SH; Blackburn, K; Moyer, MB; Boucher, RC; Ostrowski, LE				Zhang, YJ; O'Neal, WK; Randell, SH; Blackburn, K; Moyer, MB; Boucher, RC; Ostrowski, LE			Identification of dynein heavy chain 7 as an inner arm component of human cilia that is synthesized but not assembled in a case of primary ciliary dyskinesia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL LOCALIZATION; GENOMIC STRUCTURE; EPITHELIAL-CELLS; SITUS-INVERSUS; GENE; DIFFERENTIATION; EXPRESSION; MUTATIONS; FLAGELLA; MOVEMENT	Although the basic structure of the axoneme has been highly conserved throughout evolution, the varied functions of specialized axonemes require differences in structure and regulation. Cilia lining the respiratory tract propel mucus along airway surfaces, providing a critical function to the defense mechanisms of the pulmonary system, yet little is known of their molecular structure. We have identified and cloned a dynein heavy chain that is a component of the inner dynein arm. Bronchial epithelial cells were obtained from normal donors and from a patient with primary ciliary dyskinesia (PCD) whose cilia demonstrated an absence of inner dynein arms by electron microscopy. Cilia from normal and PCD cells were compared by gel electrophoresis, and mass spectrometry was used to identify DNAH7 as a protein absent in PCD cilia. The full-length DNAH7 cDNA was cloned and shares 68% similarity with an inner arm dynein heavy chain from Drosophila. DNAH7 was induced during ciliated cell differentiation, and immunohistochemistry demonstrated the presence of DNAH7 in normal cilia. In cilia from PCD cells, DNAH7 was undetectable, whereas intracellular DNAH7 was clearly present. These studies identify DNAH7 as an inner arm component of human cilia that is synthesized but not assembled in a case of PCD.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; GlaxoSmithKline, Proteom Technol Dept, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; GlaxoSmithKline	Ostrowski, LE (corresponding author), Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, CB 7248,6123A Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	ostro@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063103, P01HL034322] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63103, P0IHL34322] Funding Source: Medline; NIOSH CDC HHS [P5OHL60280] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIOSH CDC HHS		Andrews KL, 1996, MOL BIOL CELL, V7, P71, DOI 10.1091/mbc.7.1.71; Asai DJ, 2001, TRENDS CELL BIOL, V11, P196, DOI 10.1016/S0962-8924(01)01970-5; Bartoloni L, 2001, GENOMICS, V72, P21, DOI 10.1006/geno.2000.6462; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Chapelin C, 1997, FEBS LETT, V412, P325, DOI 10.1016/S0014-5793(97)00800-4; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Guichard C, 2001, AM J HUM GENET, V68, P1030, DOI 10.1086/319511; HAIMO LT, 1981, J CELL BIOL, V91, pS125, DOI 10.1083/jcb.91.3.125s; HASTIE AT, 1988, CELL MOTIL CYTOSKEL, V11, P157, DOI 10.1002/cm.970110303; HASTIE AT, 1986, CELL MOTIL CYTOSKEL, V6, P25, DOI 10.1002/cm.970060105; ISHIJIMA S, 1987, CELL MOTIL CYTOSKEL, V8, P375, DOI 10.1002/cm.970080410; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; Koc EC, 2000, J BIOL CHEM, V275, P32585, DOI 10.1074/jbc.M003596200; Maiti AK, 2000, EUR J HUM GENET, V8, P923, DOI 10.1038/sj.ejhg.5200555; Marszalek JR, 1999, P NATL ACAD SCI USA, V96, P5043, DOI 10.1073/pnas.96.9.5043; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Meeks M, 2000, PEDIATR PULM, V29, P307, DOI 10.1002/(SICI)1099-0496(200004)29:4<307::AID-PPUL11>3.0.CO;2-2; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; NAITOH Y, 1972, SCIENCE, V176, P523, DOI 10.1126/science.176.4034.523; Neesen J, 1997, GENE, V200, P193, DOI 10.1016/S0378-1119(97)00417-4; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Noone PG, 1999, AM J MED GENET, V82, P155, DOI 10.1002/(SICI)1096-8628(19990115)82:2<155::AID-AJMG11>3.0.CO;2-T; Olbrich H, 2002, NAT GENET, V30, P143, DOI 10.1038/ng817; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pennarun G, 1999, AM J HUM GENET, V65, P1508, DOI 10.1086/302683; Porter ME, 2000, J CELL BIOL, V151, pF37, DOI 10.1083/jcb.151.5.F37; Reed W, 2000, AM J RESP CELL MOL, V23, P734, DOI 10.1165/ajrcmb.23.6.4045; RENTHAL R, 1993, CELL MOTIL CYTOSKEL, V25, P19, DOI 10.1002/cm.970250104; SALATHE M, 1995, J CELL SCI, V108, P431; SATIR P, 1990, ANNU REV PHYSIOL, V52, P137, DOI 10.1146/annurev.ph.52.030190.001033; SCHIDLOW DV, 1994, ANN ALLERGY, V73, P457; Taulman PD, 2001, MOL BIOL CELL, V12, P589, DOI 10.1091/mbc.12.3.589; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; Zariwala M, 2001, AM J RESP CELL MOL, V25, P577, DOI 10.1165/ajrcmb.25.5.4619	35	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17906	17915		10.1074/jbc.M200348200	http://dx.doi.org/10.1074/jbc.M200348200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877439	hybrid, Green Published			2022-12-25	WOS:000175685100067
J	Abe, MK; Saelzler, MP; Espinosa, R; Kahle, KT; Hershenson, MB; Le Beau, MM; Rosner, MR				Abe, MK; Saelzler, MP; Espinosa, R; Kahle, KT; Hershenson, MB; Le Beau, MM; Rosner, MR			ERK-8, a new member of the mitogen-activated protein kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC SH2 DOMAIN; MAP KINASE; V-SRC; SIGNAL-TRANSDUCTION; C-SRC; IDENTIFICATION; SEQUENCE; PATHWAYS; ALIGNMENT; PP60C-SRC	The ERKs are a subfamily of the MAPKs that have been implicated in cell growth and differentiation. By using the rat ERK7 cDNA to screen a human multiple tissue cDNA library, we identified a new member of the ERK family, ERK8, that shares 69% amino acid sequence identity with ERK7. Northern analysis demonstrates that ERK8 is present in a number of tissues with maximal expression in the lung and kidney. Fluorescence in situ hybridization localized the ERK8 gene to chromosome 8, band q24.3. Expression of ERK8 in COS cells and bacteria indicates that, in contrast to constitutively active ERK7, ERK8 has minimal basal kinase activity and a unique substrate profile. ERK8, which contains two SH3-binding motifs in its C-terminal region, associates with the c-Src SH3 domain in vitro and co-immunoprecipitates with c-Src in vivo. Co-transfection with either v-Src or a constitutively active c-Src increases ERK8 activation indicating that ERK8 can be activated downstream of c-Src. ERK8 is also activated following serum stimulation, and the extent of this activation is reduced by pretreatment with the specific Src family inhibitor PP2. The ERK8 activation by serum or Src was not affected by the MEK inhibitor U0126 indicating that activation of ERK8 does not require MEK1, MEK2, or MEK5. Although most closely related to ERK7, the relatively low sequence identity, minimal basal activity, and different substrate profile identify ERK8 as a distinct member of the MAPK family that is activated by an Src-dependent signaling pathway.	Univ Chicago, Ben May Inst Canc Res, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Sect Hematol & Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Abe, MK (corresponding author), Univ Chicago, Ben May Inst Canc Res, Dept Pediat, 5841 S Maryland Ave,MC4064, Chicago, IL 60637 USA.				NCI NIH HHS [CA40046] Funding Source: Medline; NHLBI NIH HHS [HL63314, HL03867, HL54685, HL56399] Funding Source: Medline; NIGMS NIH HHS [GM61038] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054685, P50HL056399, R01HL063314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Abe MK, 1999, MOL CELL BIOL, V19, P1301; ABE MK, 1994, AM J RESP CELL MOL, V11, P577, DOI 10.1165/ajrcmb.11.5.7946386; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chao TSO, 1997, CANCER RES, V57, P3168; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Espinosa R 3rd, 1997, Methods Mol Biol, V68, P53; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Janulis M, 2001, MOL CELL BIOL, V21, P2235, DOI 10.1128/MCB.21.6.2235-2247.2001; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TURNER CE, 1994, J CELL SCI, V107, P1583; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	35	89	96	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16733	16743		10.1074/jbc.M112483200	http://dx.doi.org/10.1074/jbc.M112483200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875070	hybrid			2022-12-25	WOS:000175564500053
J	Evellin, S; Nolte, J; Tysack, K; vom Dorp, F; Thiel, M; Weernink, MAO; Jakobs, KH; Webb, EJ; Lomasney, JW; Schmidt, M				Evellin, S; Nolte, J; Tysack, K; vom Dorp, F; Thiel, M; Weernink, MAO; Jakobs, KH; Webb, EJ; Lomasney, JW; Schmidt, M			Stimulation of phospholipase C-epsilon by the M-3 muscarinic acetylcholine receptor mediated by cyclic AMP and the GTPase Rap2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS; ADENYLYL-CYCLASE; HEK-293 CELLS; RGS14; EFFECTOR; KINASE; TOXIN; SENSITIZATION; REGULATORS; C-DELTA-1	Stimulation of phospholipase C (PLC) by G(q)-coupled receptors such as the M-3 muscarinic acetylcholine receptor (mAChR) is caused by direct activation of PLC-beta enzymes by Galpha(q) proteins. We have recently shown that G(s)-coupled receptors can stimulate PLC-epsilon, apparently via formation of cyclic AMP and activation of the Ras-related GTPase Rap2B. Here we report that PLC stimulation by the M-3 mAChR expressed in HEK-293 cells also involves, in part, similar mechanisms. M-3 mAChR-mediated PLC stimulation and [Ca2+](i) increase were reduced by 2',5'-dideoxyadenosine (dd-Ado), a direct adenylyl cyclase inhibitor. On the other hand, overexpression of Galpha(s) or Epac1, a cyclic AMP-regulated guanine nucleotide exchange factor for Rap GTPases, enhanced M-3 mAChR-mediated PLC stimulation. Inactivation of Ras-related GTPases with clostridial toxins suppressed the M-3 mAChR responses. The inhibitory toxin effects were mimicked by expression of inactive Rap2B, but not of other inactive GTPases (Rac1, Ras, RalA Rap1A, and Rap2A). Activation of the M-3 mAChR induced GTP loading of Rap2B, an effect strongly enhanced by overexpression of Galpha(s) and inhibited by dd-Ado. Overexpression of PLC-epsilon and PLC-beta1, but not PLC-gamma1 or PLC-delta1, enhanced M, mAChR-mediated PLC stimulation and [Ca2+](i) increase. In contrast, expression of a catalytically inactive PLC-epsilon mutant reduced PLC stimulation by the M-3 mAChR and abrogated the potentiating effect of Galpha(s). In conclusion, our findings suggest that PLC stimulation by the M-3 mAChR is a composite action of PLC-beta1 stimulation by Galpha(q) and stimulation of PLC-epsilon apparently mediated by G(s)-dependent cyclic AMP formation and subsequent activation of Rap2B.	Univ Klinikum Essen, Inst Pharmakol, D-45122 Essen, Germany; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pharmacol, Chicago, IL 60611 USA	University of Duisburg Essen; Northwestern University; Northwestern University	Schmidt, M (corresponding author), Univ Klinikum Essen, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.							BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Chaves-Olarte E, 1999, J BIOL CHEM, V274, P11046, DOI 10.1074/jbc.274.16.11046; Cho H, 2000, MOL PHARMACOL, V58, P569, DOI 10.1124/mol.58.3.569; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Erlenbach I, 2001, J NEUROCHEM, V77, P1327, DOI 10.1046/j.1471-4159.2001.00344.x; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Hollinger S, 2001, J NEUROCHEM, V79, P941, DOI 10.1046/j.1471-4159.2001.00629.x; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Murthy SNP, 1999, P NATL ACAD SCI USA, V96, P11815, DOI 10.1073/pnas.96.21.11815; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; SCHMIDT M, 1995, J BIOL CHEM, V270, P19949, DOI 10.1074/jbc.270.34.19949; Schmidt M, 2000, J BIOL CHEM, V275, P32603, DOI 10.1074/jbc.M004784200; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40	36	57	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16805	16813		10.1074/jbc.M112024200	http://dx.doi.org/10.1074/jbc.M112024200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877431	hybrid			2022-12-25	WOS:000175564500062
J	Grams, J; Morris, JC; Drew, ME; Wang, ZF; Englund, PT; Hajduk, SL				Grams, J; Morris, JC; Drew, ME; Wang, ZF; Englund, PT; Hajduk, SL			A trypanosome mitochondrial RNA polymerase is required for transcription and replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETOPLAST DNA MINICIRCLES; ENCODE GUIDE RNAS; YEAST MITOCHONDRIAL; GENE-EXPRESSION; INTERFERENCE; BRUCEI; BACTERIOPHAGE-T3; ORGANIZATION; EVOLUTION; SEQUENCES	Understanding mitochondrial transcription is a requisite first step toward understanding the regulation of mitochondrial gene expression in kinetoplastids. Here we report the identification and functional characterization of a mitochondrial RNA polymerase (mtRNAP) from Trypanosoma brucei, the first trans-acting factor involved in kinetoplast mitochondrial transcription to be identified. Using sequences conserved among the catalytic domains of the single-subunit mtRNAPs, we were able to obtain a full-length sequence for a candidate mtRNAP from T. brucei. Sequence comparison indicates that it shares homology in its catalytic domain with other single-subunit mtRNAPs, including functionally conserved residues that are identical in all single-subunit RNAPs. We used RNA interference to functionally knock out the gene product to determine whether the candidate gene represents an mtRNAP. As predicted for a mitochondrial specific RNA polymerase, reduction of the gene product resulted in a specific decrease of mitochondrial versus nuclear transcripts. Additionally, similar to the mtRNAP of other organisms, the mtRNAP characterized here is involved in replication of the mitochondrial genome. Thus, based on sequence comparison and functional studies, we have cloned an mtRNAP from trypanosomes.	Univ Alabama Birmingham, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Dent, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Johns Hopkins Medicine	Hajduk, SL (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.	shajduk@uab.edu	Drew, Mark/E-2993-2011	Wang, Zefeng/0000-0002-6605-3637; Morris, James/0000-0003-2515-5714	NIAID NIH HHS [AI21401] Funding Source: Medline; NIGMS NIH HHS [5T32GM08361, GM27608] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021401, R21AI021401] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027608, R01GM027608, T32GM008361] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfonzo JD, 1997, NUCLEIC ACIDS RES, V25, P3751, DOI 10.1093/nar/25.19.3751; BASS B, 2001, NATURE, V411, P235; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; Cermakian N, 1997, J MOL EVOL, V45, P671, DOI 10.1007/PL00006271; Cermakian N, 1996, NUCLEIC ACIDS RES, V24, P648, DOI 10.1093/nar/24.4.648; Clement SL, 2001, GENE, V272, P209, DOI 10.1016/S0378-1119(01)00538-8; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; FEAGIN JE, 1985, NUCLEIC ACIDS RES, V13, P4577, DOI 10.1093/nar/13.12.4577; FEAGIN JE, 1988, MOL CELL BIOL, V8, P1259, DOI 10.1128/MCB.8.3.1259; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Grams J, 2000, EMBO J, V19, P5525, DOI 10.1093/emboj/19.20.5525; Gray MW, 1998, TRENDS MICROBIOL, V6, P1, DOI 10.1016/S0966-842X(97)01182-7; HAJDUK SL, 1998, MODIFICATION EDITING, P377; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; IGLOI GL, 1992, CRIT REV PLANT SCI, V10, P525, DOI 10.1080/07352689209382326; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P257, DOI 10.1016/0166-6851(86)90084-8; Klingbeil MM, 2001, PROTIST, V152, P255, DOI 10.1078/1434-4610-00066; Koslowsky DJ, 1997, MOL BIOCHEM PARASIT, V90, P81, DOI 10.1016/S0166-6851(97)00133-3; KOSTYUK DA, 1995, FEBS LETT, V369, P165, DOI 10.1016/0014-5793(95)00732-O; Lang BF, 1999, J EUKARYOT MICROBIOL, V46, P320, DOI 10.1111/j.1550-7408.1999.tb04611.x; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LEARN B, 1993, COLD SPRING HARB SYM, V58, P389, DOI 10.1101/SQB.1993.058.01.046; Lecrenier N, 2000, GENE, V246, P37, DOI 10.1016/S0378-1119(00)00107-4; Li CJ, 1997, J BIOL CHEM, V272, P20787, DOI 10.1074/jbc.272.33.20787; Li JN, 2001, MOL BIOCHEM PARASIT, V113, P261, DOI 10.1016/S0166-6851(01)00223-7; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MICHELOTTI EF, 1987, J BIOL CHEM, V262, P927; MICHELOTTI EF, 1992, MOL BIOCHEM PARASIT, V54, P31, DOI 10.1016/0166-6851(92)90092-X; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; NTAMBI JM, 1985, J BIOL CHEM, V260, P5574; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; READ LK, 1992, J BIOL CHEM, V267, P1123; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SIMPSON L, 1986, INT REV CYTOL, V99, P119; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; STEINERT M, 1980, PLASMID, V3, P7, DOI 10.1016/S0147-619X(80)90030-X; Stuart K, 1997, MICROBIOL MOL BIOL R, V61, P105, DOI 10.1128/.61.1.105-120.1997; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; Tuschl T, 2001, CHEMBIOCHEM, V2, P239, DOI 10.1002/1439-7633(20010401)2:4<239::AID-CBIC239>3.0.CO;2-R; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Woody AYM, 1996, BIOCHEMISTRY-US, V35, P144, DOI 10.1021/bi952037f; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	49	49	49	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16952	16959		10.1074/jbc.M200662200	http://dx.doi.org/10.1074/jbc.M200662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859084	hybrid			2022-12-25	WOS:000175564500082
J	Jeong, ST; Kim, HK; Kim, SJ; Chi, SW; Pan, JG; Oh, TK; Ryu, SE				Jeong, ST; Kim, HK; Kim, SJ; Chi, SW; Pan, JG; Oh, TK; Ryu, SE			Novel zinc-binding center and a temperature switch in the Bacillus stearothermophilus L1 lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOSTABLE LIPASE; CRYSTAL-STRUCTURE; OPEN CONFORMATION; ESCHERICHIA-COLI; THERMOALKALOPHILIC LIPASE; THERMOPHILIC LIPASE; PSEUDOMONAS-CEPACIA; GENE CLONING; PURIFICATION; THERMOCATENULATUS	The bacterial thermoalkalophilic lipases optimally hydrolyze saturated fatty acids at elevated temperatures. They also have significant sequence homology with staphylococcal lipases, and both the thermoalkalophilic and staphylococcal lipases are grouped as the lipase family 1.5. We report here the first crystal structure of the lipase family 1.5, the structure of a thermoalkalophilic lipase from Bacillus stearothermophilus L1 (L1 lipase) determined at 2.0-Angstrom resolution. The structure is in a closed conformation, and the active site is buried under a long lid helix. Unexpectedly, the structure exhibits a zinc-binding site in an extra domain that accounts for the larger molecular size of the family 1.5 enzymes in comparison to other microbial lipases. The zinc-coordinated extra domain makes tight interactions with the loop extended from the C terminus of the lid helix, suggesting that the activation of the family 1.5 lipases may be regulated by the strength of the interactions. The unusually long lid helix makes strong hydrophobic interactions with its neighbors. The structural information together with previous biochemical observations indicate that the temperature-mediated lid opening is triggered by the thermal dissociation of the hydrophobic interactions.	Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, Yusong Gu 305806, Daejon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Ryu, SE (corresponding author), Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, 52 Euh Eun Dong, Yusong Gu 305806, Daejon, South Korea.							Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAFLISCH A, 1995, J MOL BIOL, V252, P672, DOI 10.1006/jmbi.1995.0528; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cho AR, 2000, FEMS MICROBIOL LETT, V186, P235, DOI 10.1016/S0378-1097(00)00150-6; CHUNG GH, 1991, APPL MICROBIOL BIOT, V35, P237; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DEVEER AM, 1992, THESIS RIJKSUNIVERSI; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fujii T, 1996, NAT STRUCT BIOL, V3, P834, DOI 10.1038/nsb1096-834; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; Jeong ST, 2001, ACTA CRYSTALLOGR D, V57, P1300, DOI 10.1107/S0907444901010332; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim HK, 1998, BIOSCI BIOTECH BIOCH, V62, P66, DOI 10.1271/bbb.62.66; Kim KK, 1997, STRUCTURE, V5, P173, DOI 10.1016/S0969-2126(97)00177-9; Kim MH, 2000, BIOSCI BIOTECH BIOCH, V64, P280, DOI 10.1271/bbb.64.280; Kim MH, 2000, J MICROBIOL BIOTECHN, V10, P764; Kim SJ, 2001, NAT STRUCT BIOL, V8, P459, DOI 10.1038/87639; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang D, 1996, J MOL BIOL, V259, P704, DOI 10.1006/jmbi.1996.0352; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nardini M, 2000, J BIOL CHEM, V275, P31219, DOI 10.1074/jbc.M003903200; NOBEL MEM, 1993, FEBS LETT, V331, P123; Oh BC, 1999, FEMS MICROBIOL LETT, V179, P385, DOI 10.1016/S0378-1097(99)00439-5; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Rosenstein R, 2000, BIOCHIMIE, V82, P1005, DOI 10.1016/S0300-9084(00)01180-9; Rua ML, 1998, APPL MICROBIOL BIOT, V49, P405, DOI 10.1007/s002530051190; SCHMIDTDANNERT C, 1994, BBA-LIPID LIPID MET, V1214, P43, DOI 10.1016/0005-2760(94)90008-6; SchmidtDannert C, 1997, METHOD ENZYMOL, V284, P194; Schrag JD, 1997, STRUCTURE, V5, P187, DOI 10.1016/S0969-2126(97)00178-0; Simons JWFA, 1999, BIOCHEMISTRY-US, V38, P2, DOI 10.1021/bi981869l; Sinchaikul S, 2001, BIOCHEM BIOPH RES CO, V283, P868, DOI 10.1006/bbrc.2001.4854; SUGIHARA A, 1992, J BIOCHEM, V112, P598, DOI 10.1093/oxfordjournals.jbchem.a123946; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	39	83	85	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17041	17047		10.1074/jbc.M200640200	http://dx.doi.org/10.1074/jbc.M200640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859083	hybrid			2022-12-25	WOS:000175564500093
J	Kostic, TS; Tomic, M; Andric, SA; Stojilkovic, SS				Kostic, TS; Tomic, M; Andric, SA; Stojilkovic, SS			Calcium-independent and cAMP-dependent modulation of soluble guanylyl cyclase activity by G protein-coupled receptors in pituitary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; INTRACELLULAR CA2+ CONCENTRATION; CORTICOTROPIN-RELEASING FACTOR; PURIFIED RAT SOMATOTROPHS; GROWTH-HORMONE SECRETION; KINASE-C; PHOSPHORYLATION; EXPRESSION; GLAND; GONADOTROPHS	It is well established that G protein-coupled receptors stimulate nitric oxide-sensitive soluble guanylyl cyclase by increasing intracellular Ca2+ and activating Ca2+-dependent nitric-oxide synthases. In pituitary cells receptors that stimulated adenylyl cyclase, growth hormone-releasing hormone, corticotropin-releasing factor, and thyrotropin-releasing hormone also stimulated calcium signaling and increased cGMP levels, whereas receptors that inhibited adenylyl cyclase, endothelin-A, and dopamine-2 also inhibited spontaneous calcium transients and decreased cGMP levels. However, receptor-controlled up- and down-regulation of cyclic nucleotide accumulation was not blocked by abolition of Ca2+ signaling, suggesting that cAMP production affects cGMP accumulation. Agonist-induced cGMP accumulation was observed in cells incubated in the presence of various phosphodiesterase and soluble guanylyl cyclase inhibitors, confirming that G(s)-coupled receptors stimulated de novo cGMP production. Furthermore, cholera toxin (an activator of G(s)), forskolin (an activator of adenylyl cyclase), and 8-Br-cAMP (a permeable cAMP analog) mimicked the stimulatory action of G(s)-coupled receptors on cGMP production. Basal, agonist-, cholera toxin-, and forskolin-stimulated cGMP production, but not cAMP production, was significantly reduced in cells treated with H89, a protein kinase A inhibitor. These results indicate that coupling seven plasma membrane-domain receptors to an adenylyl cyclase signaling pathway provides an additional calcium-independent and cAMP-dependent mechanism for modulating soluble guanylyl cyclase activity in pituitary cells.	NICHHD, Sect Cellular Signaling, ERRB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stojilkovic, SS (corresponding author), NICHHD, Sect Cellular Signaling, ERRB, NIH, Bldg 49,Room 6A-36,49 convent Dr, Bethesda, MD 20892 USA.	stankos@helix.nih.gov	Kostic, Tatjana S/H-4038-2012; Tomic, Melanija/C-3371-2016	Andric, Silvana/0000-0002-2908-8136; Kostic, Tatjana/0000-0003-3440-8998	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABOUSAMRA AB, 1987, J BIOL CHEM, V262, P1129; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; Andric SA, 2001, J BIOL CHEM, V276, P844, DOI 10.1074/jbc.M004406200; ANTONI FA, 1989, BIOCHEM BIOPH RES CO, V158, P824, DOI 10.1016/0006-291X(89)92796-4; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bluet-Pajot MT, 1998, CELL MOL NEUROBIOL, V18, P101, DOI 10.1023/A:1022579327647; BREDT DS, 1992, J BIOL CHEM, V267, P10976; Bugajski J, 1998, J PHYSIOL PHARMACOL, V49, P607; BURRIS TP, 1991, EUR J PHARMACOL, V198, P223, DOI 10.1016/0014-2999(91)90627-3; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; CECCATELLI S, 1993, P NATL ACAD SCI USA, V90, P11292, DOI 10.1073/pnas.90.23.11292; Christopoulos A, 1998, LIFE SCI, V64, P1, DOI 10.1016/S0024-3205(98)00348-8; Conti M, 2000, MOL ENDOCRINOL, V14, P1317, DOI 10.1210/me.14.9.1317; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garrel G, 1998, ENDOCRINOLOGY, V139, P2163, DOI 10.1210/en.139.4.2163; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GUERINEAU N, 1991, ENDOCRINOLOGY, V129, P409, DOI 10.1210/endo-129-1-409; Hinkle PM, 1996, TRENDS ENDOCRIN MET, V7, P370, DOI 10.1016/S1043-2760(96)00188-9; IMAI T, 1992, BIOMED RES-TOKYO, V13, P371, DOI 10.2220/biomedres.13.371; KANYICSKA B, 1993, AM J PHYSIOL, V265, pE601, DOI 10.1152/ajpendo.1993.265.4.E601; KATO M, 1992, ENDOCRINOLOGY, V131, P2133, DOI 10.1210/en.131.5.2133; Koshimizu T, 2000, ENDOCRINOLOGY, V141, P4091, DOI 10.1210/en.141.11.4091; Kostic TS, 2001, MOL ENDOCRINOL, V15, P1010, DOI 10.1210/me.15.6.1010; KURYSHEV YA, 1995, ENDOCRINOLOGY, V136, P3925, DOI 10.1210/en.136.9.3925; Kwiecien R, 1997, J PHYSIOL-LONDON, V499, P613, DOI 10.1113/jphysiol.1997.sp021954; LOUIS JC, 1993, BIOCHIM BIOPHYS ACTA, V1177, P299, DOI 10.1016/0167-4889(93)90126-A; Lozach A, 1998, MOL CELL ENDOCRINOL, V143, P43, DOI 10.1016/S0303-7207(98)00135-X; Lucas KA, 2000, PHARMACOL REV, V52, P375; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P570, DOI 10.1210/endo-128-1-570; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P592, DOI 10.1210/endo-128-1-592; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; NAUMOV AP, 1994, PFLUG ARCH EUR J PHY, V427, P414, DOI 10.1007/BF00374255; OHTA K, 1993, J ENDOCRINOL, V138, P429, DOI 10.1677/joe.0.1380429; Olesen SP, 1998, BRIT J PHARMACOL, V123, P299, DOI 10.1038/sj.bjp.0701603; Parkinson SJ, 1999, BIOCHEMISTRY-US, V38, P6441, DOI 10.1021/bi990154v; Rybalkin SD, 2002, J BIOL CHEM, V277, P3310, DOI 10.1074/jbc.M106562200; SAMSON WK, 1992, BIOCHEM BIOPH RES CO, V187, P590, DOI 10.1016/0006-291X(92)91235-I; STOJILKOVIC SS, 1992, ENDOCRINOLOGY, V130, P465, DOI 10.1210/en.130.1.465; Stojilkovic SS, 2000, PRINCIPLES OF MOLECULAR REGULATION, P149; TAKANO K, 1996, AM J PHYSIOL, V270, pE1014; Tomic M, 1999, J NEUROSCI, V19, P7721; Tsumori W, 1999, J NEUROENDOCRINOL, V11, P451; Vankelecom H, 1997, J HISTOCHEM CYTOCHEM, V45, P847, DOI 10.1177/002215549704500609; VESELY DL, 1985, MOL CELL BIOCHEM, V66, P145; WOLFF D, 1992, BIOCHEM J, V128, P201; Xu X, 1997, CELL CALCIUM, V22, P217, DOI 10.1016/S0143-4160(97)90015-4; Xu XY, 2000, BIOCHEM PHARMACOL, V59, P509, DOI 10.1016/S0006-2952(99)00352-4; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; ZWILLER J, 1985, J BIOL CHEM, V260, P1350; ZWILLER J, 1981, BIOCHEM BIOPH RES CO, V101, P1381, DOI 10.1016/0006-291X(81)91600-4	54	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16412	16418		10.1074/jbc.M112439200	http://dx.doi.org/10.1074/jbc.M112439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867632	hybrid			2022-12-25	WOS:000175564500011
J	Lesieur, C; Cliff, MJ; Carter, R; James, RFL; Clarke, AR; Hirst, TR				Lesieur, C; Cliff, MJ; Carter, R; James, RFL; Clarke, AR; Hirst, TR			A kinetic model of intermediate formation during assembly of cholera toxin B-subunit pentamers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-LABILE ENTEROTOXIN; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GANGLIOSIDE GM1; MOLECULAR-BASIS; SECRETION; VACCINE	Cholera toxin is the most important virulence factor produced by Vibrio cholerae. The pentameric B-subunit of the toxin can bind to GM1-ganglioside receptors, leading to toxin entry into mammalian cells. Here, the in vitro disassembly and reassembly of CtxB(5) (the B subunit pentamer of cholera toxin) is investigated. When CtxB(5) was acidified at pH 1.0 and then neutralized, the B-subunits disassembled and could no longer migrate as SDS-stable pentamers on polyacrylamide gels or be captured by GM1. However, continued incubation at neutral pH resulted in the B-subunits regaining the capacity to be detected by GM1 enzyme-linked immunosorbent assay (t(1/2) similar to 8 min) and to migrate as SDS-stable pentamers (t(1/2) similar to 15 min). Time-dependent changes in Trp fluorescence intensity during B-subunit reassembly occurred with a half-time of similar to8 min, similar to that detected by GM1 enzyme-linked immunosorbent assay, suggesting that both methods monitor earlier events than B-pentamer formation alone. Based on the Trp fluorescence intensity measurements, a kinetic model of the pathway of CtxB(5) reassembly was generated that depended on trans to cis isomerization of Pro-93 to give an interface capable of subunit-subunit interaction. The model suggests formation of intermediates in the reaction, and these were successfully detected by glutaraldehyde cross-linking.	Univ Bristol, Sch Med Sci, Dept Pathol, Bristol BS8 1TD, Avon, England; Univ Leicester, Dept Surg, Leicester LE2 7LX, Leics, England; Univ Bristol, Sch Med Sci, Dept Microbiol, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol; University of Leicester; University of Bristol; University of Bristol	Hirst, TR (corresponding author), Univ Bristol, Sch Med Sci, Dept Pathol, Bristol BS8 1TD, Avon, England.	T.R.Hirst@bristol.ac.uk		Cliff, Matthew/0000-0002-7482-0234				Aman AT, 2001, P NATL ACAD SCI USA, V98, P8536, DOI 10.1073/pnas.161273098; AMIN T, 1994, PROTEIN EXPRES PURIF, V5, P198, DOI 10.1006/prep.1994.1031; Bergerot I, 1997, P NATL ACAD SCI USA, V94, P4610, DOI 10.1073/pnas.94.9.4610; de Haan L, 2000, J NAT TOXINS, V9, P281; DEWOLF MJS, 1994, BBA-MOL CELL RES, V1223, P285, DOI 10.1016/0167-4889(94)90239-9; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FINKELSTEIN RA, 1974, J IMMUNOL, V113, P145; FISHMAN PH, 1980, J BIOL CHEM, V255, P7657; FISHMAN PH, 1978, BIOCHEMISTRY-US, V17, P711, DOI 10.1021/bi00597a024; Galzitskaya OV, 2001, FEBS LETT, V489, P113, DOI 10.1016/S0014-5793(01)02092-0; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HIRST TR, 1984, J BACTERIOL, V157, P637, DOI 10.1128/JB.157.2.637-642.1984; Hirst TR, 1998, J APPL MICROBIOL, V84, p26S; HIRST TR, 1999, COMPREHENSIVE SOURCE, P104; HOLMGREN J, 1975, P NATL ACAD SCI USA, V72, P2520, DOI 10.1073/pnas.72.7.2520; Kaper JB, 1998, CURR OPIN MICROBIOL, V1, P103, DOI 10.1016/S1369-5274(98)80149-5; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Lesieur C, 1997, MOL MEMBR BIOL, V14, P45, DOI 10.3109/09687689709068435; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MEKALANOS JJ, 1985, CURR TOP MICROBIOL, V118, P97; NEILL RJ, 1983, SCIENCE, V221, P289, DOI 10.1126/science.6857285; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; Reimer U, 1998, J MOL BIOL, V279, P449, DOI 10.1006/jmbi.1998.1770; Richards CM, 2001, J VIROL, V75, P1664, DOI 10.1128/JVI.75.4.1664-1671.2001; RUDDOCK LW, 1995, J BIOL CHEM, V270, P29953; Ruddock LW, 1996, J BIOL CHEM, V271, P19118, DOI 10.1074/jbc.271.32.19118; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; SUN JB, 1994, P NATL ACAD SCI USA, V91, P10795, DOI 10.1073/pnas.91.23.10795; Sun JB, 1996, P NATL ACAD SCI USA, V93, P7196, DOI 10.1073/pnas.93.14.7196; Widmann M, 2000, J BIOL CHEM, V275, P18619, DOI 10.1074/jbc.C000156200; Williams NA, 1997, P NATL ACAD SCI USA, V94, P5290, DOI 10.1073/pnas.94.10.5290; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456; ZHANG RG, 1995, J MOL BIOL, V251, P550, DOI 10.1006/jmbi.1995.0455	35	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16697	16704		10.1074/jbc.M110561200	http://dx.doi.org/10.1074/jbc.M110561200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877421	hybrid			2022-12-25	WOS:000175564500048
J	Radons, J; Gabler, S; Wesehe, H; Korherr, C; Hofmeister, R; Falk, W				Radons, J; Gabler, S; Wesehe, H; Korherr, C; Hofmeister, R; Falk, W			Identification of essential regions in the cytoplasmic tail of interleukin-1 receptor accessory protein critical for interleukin-1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IL-1 RECEPTOR; MESSENGER-RNA; TRANSCRIPTION FACTOR; ADAPTER PROTEIN; KINASE PATHWAY; TAK1 MAPKKK; ACTIVATION; TRANSDUCTION; IRAK	Interleukin (IL)-1 plays an important role in inflammation and regulation of immune responses. The activated IL-1 receptor complex, which consists of the IL-1 receptor type I and the IL-1 receptor accessory protein (IL-1RAcP), generates multiple cellular responses including NF-kappaB activation, IL-2 secretion, and IL-2 promoter activation. Reconstitution experiments in EL4D6/76 cells lacking IL-1RAcP expression and IL-1 responsiveness were used to analyze structure-function relationships of the IL-1RAcP cytoplasmic tail. Mutating a potential tyrosine kinase phosphorylation motif and various conserved amino acid (aa) residues had no effect on IL-1 responsiveness. Truncation analyses revealed that box 3 of the TIR domain was required for NF-kappaB activation, IL-2 production, and c-Jun N-terminal kinase (JNK) activation, whereas IL-2 promoter activation was only partially inhibited. Surprisingly, deletion of aa 527-534 resulted in almost complete loss of all IL-1 responsiveness. Replacement of these aa with alanyl residues did not reconstitute NF-kappaB activation, IL-2 production, or JNK activation but partly restored IL-2 promoter activation. Immunoprecipitation data revealed a strong correlation between MyD88 binding with NF-kappaB activation and IL-2 production but not with IL-2 promoter activation. Taken together, our data indicate that box 3 of IL-1RAcP is critical for IL-1-dependent NF-kappaB activation and stabilization of IL-2 mRNA via JNK, whereas aa 527-534 largely contribute to IL-2 promoter activation.	Univ Regensburg, Klin & Poliklin Innere Med 1, D-93042 Regensburg, Germany; Tularik Inc, San Francisco, CA 94080 USA	University of Regensburg	Radons, J (corresponding author), Univ Regensburg, Klin & Poliklin Innere Med 1, D-93042 Regensburg, Germany.							Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Greene C, 1999, BBA-MOL CELL RES, V1451, P109, DOI 10.1016/S0167-4889(99)00079-8; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GREENFEDER SA, 1995, J BIOL CHEM, V270, P22460, DOI 10.1074/jbc.270.38.22460; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XX, 1999, MOL CELL BIOL, V19, P4643; LORD KA, 1990, ONCOGENE, V5, P1095; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; ONeill LAJ, 1997, BIOCHEM SOC T, V25, P295, DOI 10.1042/bst0250295; ONeill LAJ, 1995, INT J CLIN LAB RES, V25, P169, DOI 10.1007/BF02592694; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Ragheb JA, 1999, J IMMUNOL, V163, P120; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; Slack JL, 2000, J BIOL CHEM, V275, P4670, DOI 10.1074/jbc.275.7.4670; STRICKER K, 1993, EUR J IMMUNOL, V23, P1475, DOI 10.1002/eji.1830230712; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; VONHOEGEN I, 1989, EUR J IMMUNOL, V19, P329; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200	56	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16456	16463		10.1074/jbc.M201000200	http://dx.doi.org/10.1074/jbc.M201000200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880380	hybrid			2022-12-25	WOS:000175564500017
J	Rayner, TF; Gray, JV; Thorner, JW				Rayner, TF; Gray, JV; Thorner, JW			Direct and novel regulation of cAMP-dependent protein kinase by Mck1p, a yeast glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVEREXPRESSING GLYCOLYTIC-ENZYMES; SACCHAROMYCES-CEREVISIAE; PYRUVATE-KINASE; BINDING PROTEIN; GENE-PRODUCT; REVERSIBLE PHOSPHORYLATION; NEGATIVE REGULATOR; SIGNALING PATHWAY; ESCHERICHIA-COLI; SHUTTLE VECTORS	The MCK1 gene of Saccharomyces cerevisiae encodes a protein kinase homologous to metazoan glycogen synthase kinase-3. Previous studies implicated Mck1p in negative regulation of pyruvate kinase. In this study we find that purified Mck1p does not phosphorylate pyruvate kinase, suggesting that the link is indirect. We find that purified Tpk1p, a cAMP-dependent protein kinase catalytic subunit, phosphorylates purified pyruvate kinase in vitro, and that loss of the cAMP-dependent protein kinase regulatory subunit, Bcy1p, increases pyruvate kinase activity in vivo. We find that purified Mck1p inhibits purified Tpk1p in vitro, in the presence or absence of Bcy1p. Mck1p must be catalytically active to inhibit Tpk1p, but Mck1p does not phosphorylate this target. We find that abolition of Mck1p autophosphorylation on tyrosine prevents the kinase from efficiently phosphorylating exogenous substrates, but does not block its ability to inhibit Tpk1p in vitro. We find that this mutant form of Mck1p appears to retain the ability to negatively regulate cAMP-dependent protein kinase in vivo. We propose that Mck1p, in addition to phosphorylating some target proteins, also acts by a separate, novel mechanism: autophosphorylated Mck1p, binds to and directly inhibits, but does not phosphorylate, the catalytic subunits of cAMP-dependent protein kinase.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Univ Glasgow, Fac Biomed & Life Sci, Div Mol Genet, Glasgow G11 6NU, Lanark, Scotland	University of California System; University of California Berkeley; University of Glasgow	Rayner, TF (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA.	t.rayner@bio.gla.ac.uk	THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X; Rayner, Tim/0000-0002-6992-5592	NIGMS NIH HHS [GM21841] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021841, R37GM021841] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Andoh T, 2000, MOL CELL BIOL, V20, P6712, DOI 10.1128/MCB.20.18.6712-6720.2000; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BOWDISH KS, 1994, MOL CELL BIOL, V14, P7909, DOI 10.1128/MCB.14.12.7909; Brachmann CB, 1998, YEAST, V14, P115; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brazill DT, 1997, J BACTERIOL, V179, P4415, DOI 10.1128/jb.179.13.4415-4418.1997; CHENG HC, 1986, J BIOL CHEM, V261, P989; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Cowan KJ, 1999, MOL CELL BIOCHEM, V195, P173, DOI 10.1023/A:1006932221288; Cytrynska M, 2001, FEMS MICROBIOL LETT, V203, P223, DOI 10.1111/j.1574-6968.2001.tb10845.x; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; ENGSTROM L, 1987, ENZYMES, V8, P47; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIXSON CS, 1980, J BIOL CHEM, V255, P2137; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; JIANG WD, 1995, MOL GEN GENET, V246, P360, DOI 10.1007/BF00288609; Jiang WD, 1996, MOL GEN GENET, V251, P153; JOHNSON KE, 1987, J BIOL CHEM, V262, P8636; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM MY, 1993, J BIOL CHEM, V268, P21155; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NEIGEBORN L, 1991, GENE DEV, V5, P533, DOI 10.1101/gad.5.4.533; Pan XW, 1999, MOL CELL BIOL, V19, P4874; Piao HL, 1999, PLANT PHYSIOL, V119, P1527, DOI 10.1104/pp.119.4.1527; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Robertson LS, 1998, P NATL ACAD SCI USA, V95, P13783, DOI 10.1073/pnas.95.23.13783; ROSENZWEIG RF, 1992, GENET RES, V59, P35, DOI 10.1017/S0016672300030159; ROSENZWEIG RF, 1992, GENET RES, V59, P167, DOI 10.1017/S0016672300030445; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sherman F, 1986, LAB COURSE MANUAL ME; SHERO JH, 1991, GENE DEV, V5, P549, DOI 10.1101/gad.5.4.549; SIKORSKI RS, 1989, GENETICS, V122, P19; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WHITWAM RE, 1990, J EXP BIOL, V154, P321; WINGENDERDRISSEN R, 1983, FEBS LETT, V163, P28, DOI 10.1016/0014-5793(83)81155-7; WOODGETT J, 1995, PROTEIN KINASE FACTS, V1, P231; Zhan XL, 2000, MOL BIOL CELL, V11, P663, DOI 10.1091/mbc.11.2.663; ZOLLER MJ, 1988, J BIOL CHEM, V263, P9142	51	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16814	16822		10.1074/jbc.M112349200	http://dx.doi.org/10.1074/jbc.M112349200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877433	hybrid			2022-12-25	WOS:000175564500063
J	Serre, MC; Letzelter, C; Garel, JR; Duguet, M				Serre, MC; Letzelter, C; Garel, JR; Duguet, M			Cleavage properties of an archaeal site-specific recombinase, the SSV1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SULFOLOBUS-SHIBATAE; GENETIC ELEMENTS; TOPOISOMERASE-I; STRAND EXCHANGE; ACTIVE-SITE; FAMILY; DNA; VIRUS; SIMILARITIES	SSV1 is a virus infecting the extremely thermophilic archaeon Sulfolobus shibatae. The viral-encoded integrase is responsible for site-specific integration of SSV1 into its host genome. The recombinant enzyme was expressed in Escherichia coli, purified to homogeneity, and its biochemical properties investigated in vitro. We show that the SSV1 integrase belongs to the tyrosine recombinases family and that Tyr(314) is involved in the formation of a 3'-phosphotyrosine intermediate. The integrase cleaves both strands of a synthetic substrate in a temperature-dependent reaction, the cleavage efficiency increasing with temperature. A discontinuity was observed in the Arrhenius plot above 50 degreesC, suggesting that a conformational transition may occur in the integrase at this temperature. Analysis of cleavage time course suggested that noncovalent binding of the integrase to its substrate is rate-limiting in the cleavage reaction. The cleavage positions were localized on each side of the anticodon loop of the tRNA gene where SSV1 integration takes place. Finally, the SSV1 integrase is able to cut substrates harboring mismatches in the binding site. For the cleavage step, the chemical nature of the base in position -1 of cleavage seems to be more important than its pairing to the opposite strand.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Univ Paris 11, Inst Genet & Microbiol, Lab Enzymol Acides Nucl, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Serre, MC (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Bat 34,Ave Terrasse, F-91198 Gif Sur Yvette, France.		Serre, Marie-Claude/B-4159-2008	SERRE, Marie-Claude/0000-0002-7899-9833				ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brand L., 1967, METHODS ENZYMOL, P776, DOI [10.1016/S0076-6879(67)11091-4, DOI 10.1016/S0076-6879(67)11091-4]; CAMPBELL AM, 1992, J BACTERIOL, V174, P7495, DOI 10.1128/JB.174.23.7495-7499.1992; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; DUPONT L, 1995, J BACTERIOL, V177, P586, DOI 10.1128/jb.177.3.586-595.1995; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Grainge I, 1999, MOL MICROBIOL, V33, P449, DOI 10.1046/j.1365-2958.1999.01493.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hallet B, 1997, FEMS MICROBIOL REV, V21, P157, DOI 10.1016/S0168-6445(97)00055-7; HAUSER MA, 1992, J BIOL CHEM, V267, P6859; HENSEL R, 1987, EUR J BIOCHEM, V170, P325, DOI 10.1111/j.1432-1033.1987.tb13703.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING LAB MANU; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MUSKHELISHVILI G, 1994, SYST APPL MICROBIOL, V16, P605; MUSKHELISHVILI G, 1993, MOL GEN GENET, V237, P334, DOI 10.1007/BF00279436; Nash H, 1996, ESCHERICHIA COLI SAL, V2, P2363; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; PALM P, 1991, VIROLOGY, V185, P242, DOI 10.1016/0042-6822(91)90771-3; Pena CEA, 1996, J BACTERIOL, V178, P5533, DOI 10.1128/jb.178.18.5533-5536.1996; PIERSON LS, 1987, J MOL BIOL, V196, P487, DOI 10.1016/0022-2836(87)90026-X; Raynal A, 1998, MOL MICROBIOL, V28, P333, DOI 10.1046/j.1365-2958.1998.00799.x; REITER WD, 1989, NUCLEIC ACIDS RES, V17, P1907, DOI 10.1093/nar/17.5.1907; SCHLEPER C, 1992, P NATL ACAD SCI USA, V89, P7645, DOI 10.1073/pnas.89.16.7645; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007; YEATS S, 1982, EMBO J, V1, P1035, DOI 10.1002/j.1460-2075.1982.tb01292.x	32	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16758	16767		10.1074/jbc.M200707200	http://dx.doi.org/10.1074/jbc.M200707200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875075	hybrid			2022-12-25	WOS:000175564500056
J	Surinya, HH; Molina, L; Soos, MA; Brand, J; Kristensen, C; Siddle, K				Surinya, HH; Molina, L; Soos, MA; Brand, J; Kristensen, C; Siddle, K			Role of insulin receptor dimerization domains in ligand binding, cooperativity, and modulation by anti-receptor antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; FACTOR-I RECEPTORS; MONOCLONAL-ANTIBODIES; ALPHA-SUBUNIT; EXTRACELLULAR DOMAIN; STRUCTURAL BASIS; SPECIFICITY; IDENTIFICATION; DETERMINANTS; AFFINITY	To define the structures within the insulin receptor (IR) that are required for high affinity ligand binding, we have used IR fragments consisting of four amino-terminal domains (L1, cysteine-rich, L2, first fibronectin type III domain) fused to sequences encoded by exon 10 (including the carboxyl terminus of the alpha-subunit). The fragments contained one or both cysteine residues (amino acids 524 and 682) that form disulfides between alpha-subunits in native IR. A dimeric fragment designated IR593.CT (amino acids 1-593 and 704-719) bound I-125-insulin with high affinity comparable to detergent-solubilized wild. type IR and mIR.Fn0/Ex10 (amino acids 1-601 and 650-719) and greater than that of dimeric mIR.Fn0 (amino acids 1-601 and 704-719) and monomeric IR473.CT (amino acids 1-473 and 704-719). However, neither IR593.CT nor mIR.Fn0 exhibited negative cooperativity (a feature characteristic of the native insulin receptor and mIR.Fn0/Ex10), as shown by failure of unlabeled insulin to accelerate dissociation of bound I-125-insulin. Anti-receptor monoclonal antibodies that recognize epitopes in the first fibronectin type III domain (amino acids 471-593) and inhibit insulin binding to wild type IR inhibited insulin binding to mIR.Fn0/Ex10 but not IR593.CT or mIR.Fn0. We conclude the following: 1) precise positioning of the carboxyl-terminal sequence can be a critical determinant of binding affinity; 2) dimerization via the first fibronectin domain alone can contribute to high affinity ligand binding; and 3) the second dimerization domain encoded by exon 10 is required for ligand cooperativity and modulation by antibodies.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England; Novo Nordisk AS, Insulin Res, DK-2880 Bagsvaerd, Denmark	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Novo Nordisk	Siddle, K (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Hills Rd, Cambridge CB2 2QR, England.		Kristensen, Claus/O-8047-2015	Surinya, Kathy/0000-0003-0507-2962; Kristensen, Claus/0000-0002-2594-7722				ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; Bass J, 1996, J BIOL CHEM, V271, P19367, DOI 10.1074/jbc.271.32.19367; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; Brandt J, 2001, J BIOL CHEM, V276, P12378, DOI 10.1074/jbc.M009402200; Cosgrove L, 1995, PROTEIN EXPRES PURIF, V6, P789, DOI 10.1006/prep.1995.0010; DEMEYTS P, 1994, DIABETOLOGIA, V37, P135; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABRY M, 1992, J BIOL CHEM, V267, P8950; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; Hoyne PA, 2000, FEBS LETT, V479, P15, DOI 10.1016/S0014-5793(00)01872-X; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KJELDSEN T, 1994, J BIOL CHEM, V269, P32942; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; Kristensen C, 1999, J BIOL CHEM, V274, P37351, DOI 10.1074/jbc.274.52.37351; KUROSE T, 1994, J BIOL CHEM, V269, P29190; Marino-Buslje C, 1998, FEBS LETT, V441, P331, DOI 10.1016/S0014-5793(98)01509-9; Marino-Buslje C, 1999, BIOCHEM SOC T, V27, P715, DOI 10.1042/bst0270715; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Molina L, 2000, FEBS LETT, V467, P226, DOI 10.1016/S0014-5793(00)01161-3; Mulhern TD, 1998, TRENDS BIOCHEM SCI, V23, P465, DOI 10.1016/S0968-0004(98)01288-2; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; Mynarcik DC, 1997, J BIOL CHEM, V272, P18650, DOI 10.1074/jbc.272.30.18650; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHAFFER L, 1992, BIOCHEM BIOPH RES CO, V189, P650, DOI 10.1016/0006-291X(92)92250-2; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; Siddle K, 2001, BIOCHEM SOC T, V29, P513, DOI 10.1042/BST0290513; SIDDLE K, 1987, BIOCHEM SOC T, V15, P47, DOI 10.1042/bst0150047; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; Sparrow LG, 1997, J BIOL CHEM, V272, P29460, DOI 10.1074/jbc.272.47.29460; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Ward CW, 1999, GROWTH FACTORS, V16, P315, DOI 10.3109/08977199909069149; WHITTAKER J, 1994, MOL ENDOCRINOL, V8, P1521, DOI 10.1210/me.8.11.1521; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; YAMAGUCHI Y, 1993, ENDOCRINOLOGY, V132, P1132, DOI 10.1210/en.132.3.1132; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	40	29	52	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16718	16725		10.1074/bjc.M112014200	http://dx.doi.org/10.1074/bjc.M112014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875066				2022-12-25	WOS:000175564500051
J	Crider-Pirkle, S; Billingsley, P; Faust, C; Hardy, DM; Lee, V; Weitlauf, H				Crider-Pirkle, S; Billingsley, P; Faust, C; Hardy, DM; Lee, V; Weitlauf, H			Cubilin, a binding partner for galectin-3 in the murine utero-placental complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; FACTOR-VITAMIN B-12; YOLK-SAC; TERATOGENIC ANTIBODIES; METRIAL GLAND; EPITHELIAL-CELLS; MEDIATED ENDOCYTOSIS; GLYCOPROTEIN 280; PROTEIN; RECEPTOR	Galectin-3 is a lectin important in animal development and regulatory processes and is found selectively localized at the implantation site of the mouse embryo. To better understand the role of galectin-3 at the maternal-fetal interface, a binding partner was isolated and characterized. Homogenates of uteroplacental tissue were incubated with immobilized recombinant galectin-3, and specifically bound proteins were eluted using lactose. The principal protein, p400, had an M-r of 400,000 in SDS-PAGE. Physical properties of p400 and amino acid sequences of seven tryptic peptides were similar to cubilin from rats, humans, and dogs, identifying p400 as the murine ortholog of cubilin. This was further supported by the tissue distribution observed only in yolk sac, kidney, and ileum with monospecific antiserum for p400. Cubilin occurred in yolk sac epithelium throughout pregnancy, but galectin-3 was there only during the last week. Unexpectedly, cubilin was found only in perforin-containing granules of uterine natural killer (uNK) cells, although galectin-3 occurred throughout the cell cytoplasm. In situ hybridization revealed cubilin mRNA in yolk sac epithelium but not uNK cells, implying that yolk sac-derived cubilin is endocytosed by uNK cells via galectin-3. This is consistent with cubilin being an endogenous partner of galectin-3 at the maternal-fetal interface and suggests an important role for cubilin in uNK cell function.	Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Obstet & Gynecol, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Weitlauf, H (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, 3601 4th St, Lubbock, TX 79430 USA.	harry.weitlauf@ttuhsc.edu	Hardy, Daniel/AAP-5823-2020	Hardy, Daniel/0000-0002-7297-3093	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029801, R29HD035166] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-35166, HD-29801, HD-07271] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGRWAL N, 1993, J BIOL CHEM, V268, P14932; BAUTMAN V, 1998, AM J PHYSIOL, V275, pF246; Birn H, 1997, J BIOL CHEM, V272, P26497, DOI 10.1074/jbc.272.42.26497; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BRENT RL, 1990, TERATOLOGY, V41, P405, DOI 10.1002/tera.1420410406; BURKHARDT JK, 1990, J CELL BIOL, V111, P2327, DOI 10.1083/jcb.111.6.2327; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; Croy BA, 1996, NAT IMMUN, V15, P22; CROY BA, 1991, J REPROD IMMUNOL, V19, P149; CROY BA, 1991, CELL IMMUNOL, V133, P116, DOI 10.1016/0008-8749(91)90184-D; GAMBEL P, 1985, CELL IMMUNOL, V93, P303, DOI 10.1016/0008-8749(85)90136-4; Hammad SM, 2000, J BIOL CHEM, V275, P12003, DOI 10.1074/jbc.275.16.12003; Hammad SM, 1999, P NATL ACAD SCI USA, V96, P10158, DOI 10.1073/pnas.96.18.10158; Head JR, 1996, NAT IMMUN, V15, P7; Hickox JR, 2001, J BIOL CHEM, V276, P41502, DOI 10.1074/jbc.M106795200; JOLLIE WP, 1990, TERATOLOGY, V41, P361, DOI 10.1002/tera.1420410403; KAWASAKI A, 1990, INT IMMUNOL, V2, P677, DOI 10.1093/intimm/2.7.677; KNISLEY KA, 1993, J REPROD FERTIL, V97, P521; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; Kozyraki R, 2001, P NATL ACAD SCI USA, V98, P12491, DOI 10.1073/pnas.211291398; Kristiansen M, 1999, J BIOL CHEM, V274, P20540, DOI 10.1074/jbc.274.29.20540; Kusakabe K, 1999, J VET MED SCI, V61, P947, DOI 10.1292/jvms.61.947; Kusakabe K, 1999, J VET MED SCI, V61, P1093, DOI 10.1292/jvms.61.1093; Lee VH, 1998, BIOL REPROD, V58, P1277, DOI 10.1095/biolreprod58.5.1277; LePanse S, 1997, EUR J CELL BIOL, V72, P257; LEPANSE S, 1994, AM J PATHOL, V145, P1526; LePanse S, 1997, EXP NEPHROL, V5, P375; LLOYD JB, 1990, TERATOLOGY, V41, P383, DOI 10.1002/tera.1420410404; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; PARR EL, 1990, J IMMUNOL, V145, P2365; PARR EL, 1987, BIOL REPROD, V37, P1327, DOI 10.1095/biolreprod37.5.1327; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Phillips B, 1996, BIOL REPROD, V55, P548, DOI 10.1095/biolreprod55.3.548; SAHALI D, 1992, AM J PATHOL, V140, P33; SAHALI D, 1988, J EXP MED, V167, P213, DOI 10.1084/jem.167.1.213; SAHALI D, 1993, AM J PATHOL, V142, P1654; Seetharam B, 1997, J CLIN INVEST, V99, P2317, DOI 10.1172/JCI119411	37	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15904	15912		10.1074/jbc.M200331200	http://dx.doi.org/10.1074/jbc.M200331200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856751	hybrid			2022-12-25	WOS:000175510400093
J	Heron-Milhavet, L; LeRoith, D				Heron-Milhavet, L; LeRoith, D			Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; NUCLEAR EXCLUSION; SIGNALING PATHWAY; HUMAN FIBROBLASTS; UV-RADIATION; MDM2; RECEPTOR; CELLS; PHOSPHORYLATION; ERCC-1	In many tissues, the insulin-like growth factor I (IGF-I) receptor (IGF-IR) is known to functionally oppose apoptosis. Recently, we demonstrated a direct role for the IGF-IR in the rescue of DNA-damaged fibroblasts by activating a DNA repair pathway (Heron-Milhavet, L., Karas, M., Goldsmith, C. M., Baum, B. J., and LeRoith, D. (2001) J. Biol. Chem. 276, 18185-18192). p53 is a nuclear transcription factor that can block progression of the cell cycle, modulate DNA repair, and trigger apoptosis. In this work, we tested the effect of IGF-I on the regulation of the p53 signaling cascade. The DNA-damaging agent 4-nitroquinoline 1-oxide was applied to NIH-3T3 cells overexpressing normal IGF-IRs (NWTb3 cells). We showed that after 4-nitroquinoline 1-oxide-induced DNA damage, IGF-I induced exclusion of the p53 protein from the nucleus and led to its degradation in the cytoplasm, whereas p53 mRNA was unaffected. Degradation of the p53 protein was associated with an increase in MDM2, an upstream modulator of the half-life and activity of the p53 protein. p53 degradation was also associated with down-regulation of p21. We further showed that the effects of IGF-I on mdm2 transcription and on MDM2/p19 ARF association were mediated by the p38 MAPK pathway. In conclusion, we describe a novel role for IGF-I in the regulation of the MDM2/p53/p21 signaling pathway during DNA damage.	NIDDK, Sect Cellular & Mol Physiol, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Sect Cellular & Mol Physiol, Clin Endocrinol Branch, NIH, Bldg 10,Rm 8D12, Bethesda, MD 20892 USA.	Derek@helix.nih.gov	Heron-Milhavet, Lisa/O-4339-2017; Roszak, Joanna/F-4003-2010	Heron-Milhavet, Lisa/0000-0002-7099-0850; 				Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KATO H, 1993, J BIOL CHEM, V268, P2655; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; Lee-Kwon W, 1998, BIOCHEM J, V331, P591, DOI 10.1042/bj3310591; Lee-Kwon W, 1998, EXP CELL RES, V241, P458, DOI 10.1006/excr.1998.4087; Leri A, 1999, AM J PATHOL, V154, P567, DOI 10.1016/S0002-9440(10)65302-3; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Maki CG, 1996, CANCER RES, V56, P2649; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Perfetti R, 1997, ENDOCRINOLOGY, V138, P1829, DOI 10.1210/en.138.5.1829; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Takimoto R, 2001, P NATL ACAD SCI USA, V98, P781, DOI 10.1073/pnas.98.3.781; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906; Zhu QZ, 2000, MOL CARCINOGEN, V28, P215	34	95	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15600	15606		10.1074/jbc.M111142200	http://dx.doi.org/10.1074/jbc.M111142200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877395	hybrid			2022-12-25	WOS:000175510400052
J	Iverson, TM; Luna-Chavez, C; Croal, LR; Cecchini, G; Rees, DC				Iverson, TM; Luna-Chavez, C; Croal, LR; Cecchini, G; Rees, DC			Crystallographic studies of the Escherichia coli quinol-fumarate reductase with inhibitors bound to the quinol-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; SUCCINATE-UBIQUINONE OXIDOREDUCTASE; ANCHORING SUBUNIT QPS3; WOLINELLA-SUCCINOGENES; PROTON-TRANSFER; RESPIRATORY COMPLEX; ELECTRON-TRANSPORT; HEART-MITOCHONDRIA; CATALYTIC ACTIVITY; DEHYDROGENASE	The quinol-fumarate reductase (QFR) respiratory complex of Escherichia coli is a four-subunit integral-membrane complex that catalyzes the final step of anaerobic respiration when fumarate is the terminal electron acceptor. The membrane-soluble redox-active molecule menaquinol (MQH(2)) transfers electrons to QFR by binding directly to the membrane-spanning region. The crystal structure of QFR contains two quinone species, presumably MQH(2), bound to the transmembrane-spanning region. The binding sites for the two quinone molecules are termed Q(P) and Q(D), indicating their positions proximal Q(P)) or distal (Q(D)) to the site of fumarate reduction in the hydrophilic flavoprotein and iron-sulfur protein subunits. It has not been established whether both of these sites are mechanistically significant. Co-crystallization studies of the E. coli QFR with the known quinol-binding site inhibitors 2-heptyl-4-hydroxyquinoline-N-oxide and 2-[1-(p-chlorophenyl)ethyl] 4,6-dinitrophenol establish that both inhibitors block the binding of MQH(2) at the Q(P) site. In the structures with the inhibitor bound at Q(P), no density is observed at Q(D), which suggests that the occupancy of this site can vary and argues against a structurally obligatory role for quinol binding to Q(D). A comparison of the Q(P) site of the E. coli enzyme with quinone-binding sites in other respiratory enzymes shows that an acidic residue is structurally conserved. This acidic residue, Glu-C29, in the E. coli enzyme may act as a proton shuttle from the quinol during enzyme turnover.	CALTECH, Howard Hughes Med Inst, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Dept Vet Affairs Med Ctr, Mol Biol Div 151 S, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California San Francisco; California Institute of Technology	Rees, DC (corresponding author), CALTECH, Howard Hughes Med Inst, Div Chem & Chem Engn, MC 147-75CH, Pasadena, CA 91125 USA.	dcrees@caltech.edu			NIGMS NIH HHS [GM61606, GM45162] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM045162, R01GM061606, R01GM045162] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bartoschek S, 2001, J BIOL CHEM, V276, P35231, DOI 10.1074/jbc.C100365200; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; COLLINS MD, 1981, MICROBIOL REV, V45, P316, DOI 10.1128/MMBR.45.2.316-354.1981; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; GEISLER V, 1994, BBA-BIOENERGETICS, V1184, P219, DOI 10.1016/0005-2728(94)90226-7; Gottschalk G., 1986, BACTERIAL METABOLISM; GUEST JR, 1981, J GEN MICROBIOL, V122, P171; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; Hagerhall C, 1999, J BIOL CHEM, V274, P26157, DOI 10.1074/jbc.274.37.26157; Hirawake H, 1999, BBA-BIOENERGETICS, V1412, P295, DOI 10.1016/S0005-2728(99)00071-7; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Iverson TM, 2000, CURR OPIN STRUC BIOL, V10, P448, DOI 10.1016/S0959-440X(00)00113-5; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim YJ, 2000, J MICROBIOL BIOTECHN, V10, P48; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROGER A, 1992, ARCH MICROBIOL, V158, P311, DOI 10.1007/BF00245358; Lancaster CRD, 2000, P NATL ACAD SCI USA, V97, P13051, DOI 10.1073/pnas.220425797; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Luna-Chavez C, 2000, PROTEIN EXPRES PURIF, V19, P188, DOI 10.1006/prep.2000.1238; Maklashina E, 1998, J BACTERIOL, V180, P5989, DOI 10.1128/JB.180.22.5989-5996.1998; Maklashina E, 1999, ARCH BIOCHEM BIOPHYS, V369, P223, DOI 10.1006/abbi.1999.1359; Matsson M, 1998, ARCH MICROBIOL, V170, P27, DOI 10.1007/s002030050611; Matsson M, 2001, J BIOENERG BIOMEMBR, V33, P99, DOI 10.1023/A:1010744330092; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ohnishi T, 2000, STRUCTURE, V8, pR23, DOI 10.1016/S0969-2126(00)00098-8; OKAMURA MY, 1992, ANNU REV BIOCHEM, V61, P861; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P56; Oyedotun KS, 1999, J BIOL CHEM, V274, P23956, DOI 10.1074/jbc.274.34.23956; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Pershad HR, 1999, BBA-BIOENERGETICS, V1412, P262, DOI 10.1016/S0005-2728(99)00066-3; Rothery RA, 1998, BIOCHEM J, V332, P35, DOI 10.1042/bj3320035; Rothery RA, 1998, EUR J BIOCHEM, V254, P588, DOI 10.1046/j.1432-1327.1998.2540588.x; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; SALERNO JC, 1977, FEBS LETT, V82, P179, DOI 10.1016/0014-5793(77)80579-6; SARUTA F, 1996, BIOCHIM BIOPHYS ACTA, V1270, P1; Satoh A, 2002, J BIOL CHEM, V277, P2830, DOI 10.1074/jbc.M109090200; Shenoy SK, 1999, J BIOL CHEM, V274, P8717, DOI 10.1074/jbc.274.13.8717; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; SMIRNOVA IA, 1995, FEBS LETT, V359, P23, DOI 10.1016/0014-5793(94)01442-4; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; Winkler JR, 1999, PURE APPL CHEM, V71, P1753, DOI 10.1351/pac199971091753; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	60	85	92	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16124	16130		10.1074/jbc.M200815200	http://dx.doi.org/10.1074/jbc.M200815200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11850430	hybrid, Green Accepted			2022-12-25	WOS:000175510400120
J	Nentwich, HA; Mustafa, Z; Rugg, MS; Marsden, BD; Cordell, MR; Mahoney, DJ; Jenkins, SC; Dowling, B; Fries, E; Milner, CM; Loughlin, J; Day, AJ				Nentwich, HA; Mustafa, Z; Rugg, MS; Marsden, BD; Cordell, MR; Mahoney, DJ; Jenkins, SC; Dowling, B; Fries, E; Milner, CM; Loughlin, J; Day, AJ			A novel allelic variant of the human TSG-6 gene encoding an amino acid difference in the CUB module - Chromosomal localization, frequency analysis, modeling, and expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTER-ALPHA-INHIBITOR; HYALURONAN-BINDING PROTEIN; FACTOR-STIMULATED GENE-6; NECROSIS-FACTOR-ALPHA; LINK MODULE; EXTRACELLULAR-MATRIX; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; OSTEOARTHRITIS; ARTHRITIS	Tumor necrosis factor-stimulated gene-6 (TSG-6) encodes a 35-kDa protein, which is comprised of contiguous Link and CUB modules. TSG-6 protein has been detected in the articular joints of osteoarthritis (OA) patients, with little or no constitutive expression in normal adult tissues. It interacts with components of cartilage matrix (e.g. hyaluronan and aggrecan) and thus may be involved in extracellular remodeling during joint disease. In addition, TSG-6 has been found to have anti-inflammatory properties in models of acute and chronic inflammation. Here we have mapped the human TSG-6 gene to 2q23.3, a region of chromosome 2 linked with OA. A single nucleotide polymorphism was identified that involves a non-synonymous G --> A transition at nucleotide 431 of the TSG-6 coding sequence, resulting in an Arg to Gln alteration in the CUB module (at residue 144 in the preprotein). Molecular modeling of the CUB domain indicated that this amino acid change might lead to functional differences. Typing of 400 OA cases and 400 controls revealed that the A(431) variant identified here is the major TSG-6 allele in Caucasians (with over 75% being A(431) homozygotes) but that this polymorphism is not a marker for OA susceptibility in the patients we have studied. Expression of the Arg(144) and Gln(144) allotypes in Drosophila Schneider 2 cells, and functional characterization, showed that there were no significant differences in the ability of these full-length proteins to bind hyaluronan or form a stable complex with inter-alpha-inhibitor.	Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford, Inst Mol Med, Oxford OX3 IDS, England; Uppsala Univ, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	University of Oxford; University of Oxford; University of Oxford; Uppsala University	Day, AJ (corresponding author), Univ Oxford, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	tony.day@bioch.ox.ac.uk	Milner, Caroline M/P-5526-2015; Day, Anthony/O-1658-2015	Milner, Caroline M/0000-0001-7355-9655; Day, Anthony/0000-0002-1415-3134; Loughlin, John/0000-0003-2018-3361				Bardos T, 2001, AM J PATHOL, V159, P1711, DOI 10.1016/S0002-9440(10)63018-0; BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; Blake JA, 2001, NUCLEIC ACIDS RES, V29, P91, DOI 10.1093/nar/29.1.91; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; Chapman K, 1999, AM J HUM GENET, V65, P167, DOI 10.1086/302465; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; DRACOPOLI NC, 1995, CURRENT PROTOCOLS HU, V2, P1; Enghild JJ, 1999, BIOCHEMISTRY-US, V38, P11804, DOI 10.1021/bi9908540; FENG P, 1993, J BIOL CHEM, V268, P21453; FLANNELLY JK, 2001, T ORTHOP RES, V26, P228; Fujimoto T, 2002, AM J PATHOL, V160, P1495, DOI 10.1016/S0002-9440(10)62575-8; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; GOLDBERG RL, 1998, T ORTHOP RES, V23, P215; Jenkins SC, 2000, TISSUE ANTIGENS, V56, P38, DOI 10.1034/j.1399-0039.2000.560105.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; KLAMPFER L, 1995, J BIOL CHEM, V270, P3677, DOI 10.1074/jbc.270.8.3677; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE TH, 1993, J BIOL CHEM, V268, P6154; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Leppavuori J, 1999, AM J HUM GENET, V65, P1060, DOI 10.1086/302569; LIVINGSTONE C, 1989, NUCLEIC ACIDS RES, V17, P2366, DOI 10.1093/nar/17.6.2366; Loughlin J, 2000, RHEUMATOLOGY, V39, P377, DOI 10.1093/rheumatology/39.4.377; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Maier R, 1996, ARTHRITIS RHEUM, V39, P552, DOI 10.1002/art.1780390403; Margerie D, 1997, OSTEOARTHR CARTILAGE, V5, P129, DOI 10.1016/S1063-4584(97)80006-4; Mindrescu C, 2000, ARTHRITIS RHEUM, V43, P2668, DOI 10.1002/1529-0131(200012)43:12<2668::AID-ANR6>3.0.CO;2-E; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Mustafa Z, 2000, RHEUMATOLOGY, V39, P299, DOI 10.1093/rheumatology/39.3.299; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; Romao MJ, 1997, J MOL BIOL, V274, P650, DOI 10.1006/jmbi.1997.1423; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Solis D, 1998, FEBS LETT, V431, P273, DOI 10.1016/S0014-5793(98)00772-8; Varela PF, 1997, J MOL BIOL, V274, P635, DOI 10.1006/jmbi.1997.1424; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; Wright GD, 1996, ANN RHEUM DIS, V55, P317, DOI 10.1136/ard.55.5.317	52	51	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15354	15362		10.1074/jbc.M110765200	http://dx.doi.org/10.1074/jbc.M110765200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854277	hybrid			2022-12-25	WOS:000175510400019
J	Sato, O; Kuriki, C; Fukui, Y; Motojima, K				Sato, O; Kuriki, C; Fukui, Y; Motojima, K			Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor alpha and gamma ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; SCAVENGER RECEPTOR; INSULIN-RESISTANCE; SR-BI; CD36; EXPRESSION; IDENTIFICATION; DIFFERENTIATION; BINDING; RAT	Fatty acid translocase (FAT)/CD36 is a glycoprotein involved in multiple membrane functions including uptake of long-chain fatty acids and oxidized low density lipoprotein. In mice, expression of the gene is regulated by peroxisome proliferator-activated receptor (PPAR) alpha in the liver and by PPARgamma in the adipose tissues (Motojima, K., Passilly, P. P., Peters, J. M., Gonzalez, F. J., and Latruffe, N. (1998) J. Biol. Chem. 273, 16710-16714). However, the time course of PPARalpha ligand-induced expression of FAT/CD36 in the liver, and also in the cultured hepatoma cells, is significantly slower than those of other PPARalpha target genes. To study the molecular mechanism of the slow transcriptional activation of the gene by a PPAR ligand, we first cloned the 5' ends of the mRNA and then the mouse gene promoter region from a genomic bacterial artificial chromosome library. Sequencing analyses showed that transcription of the gene starts at two initiation sites 16 kb apart and splicing occurs alternatively, producing at least three mRNA species with different 5'-noneoding regions. The PPARalpha ligand-responsive promoter in the liver was identified as the new upstream promoter where we found several possible binding sites for lipid metabolism-related transcriptional factors but not for PPAR. Neither promoter responded to a PPARalpha ligand in the in vitro or in vivo reporter assays using cultured hepatoma cells and the liver of living mice. We also have cloned the human FAT/CD36 gene from a bacterial artificial chromosome library and identified a new independent promoter that is located 13 kb upstream of the previously reported promoter. Only the upstream promoter responded to PPARalpha and PPARgamma ligands in a cell type-specific manner. The absence of PPRE in the responding upstream promoter region, the delayed activation by the ligand, and the results of the reporter assays all suggested that transcriptional activation of the FAT/CD36 gene by PPAR ligands is indirectly dependent on PPAR.	Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan; Toho Univ, Sch Pharmaceut Sci, Dept Biochem, Chiba 2748510, Japan	Meiji Pharmaceutical University; Toho University	Motojima, K (corresponding author), Meiji Pharmaceut Univ, Dept Biochem, Noshio 2-522-1, Tokyo 2048588, Japan.	motojima@my-pharm.ac.jp						Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DEVILLIERS WJS, 1994, J EXP MED, V180, P705, DOI 10.1084/jem.180.2.705; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Fukui Y, 2000, DIABETES, V49, P759, DOI 10.2337/diabetes.49.5.759; Fukuwatari T, 1997, FEBS LETT, V414, P461, DOI 10.1016/S0014-5793(97)01055-7; GREENWALT DE, 1992, BLOOD, V80, P1105; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Iizuka Y, 2001, LANCET, V358, P243, DOI 10.1016/S0140-6736(01)05429-0; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; LAKE BG, 1989, TOXICOL APPL PHARM, V99, P148, DOI 10.1016/0041-008X(89)90120-8; Lazar MA, 2001, NAT MED, V7, P23, DOI 10.1038/83301; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; LI YS, 1993, MOL CELL BIOCHEM, V126, P61, DOI 10.1007/BF01772208; Miyaoka K, 2001, LANCET, V357, P686, DOI 10.1016/S0140-6736(00)04138-6; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; MOTOJIMA K, 1993, CELL STRUCT FUNCT, V18, P267, DOI 10.1247/csf.18.267; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Motojima K, 1997, BIOCHIMIE, V79, P101, DOI 10.1016/S0300-9084(97)81498-8; MOULTON KS, 1992, P NATL ACAD SCI USA, V89, P8102, DOI 10.1073/pnas.89.17.8102; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Osada S, 1996, ANN NY ACAD SCI, V804, P706, DOI 10.1111/j.1749-6632.1996.tb18674.x; Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; Tanaka T, 2001, J LIPID RES, V42, P751; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANG YL, 1994, J BIOL CHEM, V269, P6011; TAYLOR KT, 1993, GENE, V133, P205, DOI 10.1016/0378-1119(93)90639-K; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Yesner LM, 1996, ARTERIOSCL THROM VAS, V16, P1019, DOI 10.1161/01.ATV.16.8.1019	45	126	135	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15703	15711		10.1074/jbc.M110158200	http://dx.doi.org/10.1074/jbc.M110158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867619	hybrid			2022-12-25	WOS:000175510400066
J	Slater, SJ; Seiz, JL; Cook, AC; Buzas, CJ; Malinowski, SA; Kershner, JL; Stagliano, BA; Stubbs, CD				Slater, SJ; Seiz, JL; Cook, AC; Buzas, CJ; Malinowski, SA; Kershner, JL; Stagliano, BA; Stubbs, CD			Regulation of PKC alpha activity by C1-C2 domain interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHORBOL-ESTER-BINDING; MEMBRANE-TARGETING MODULES; CYSTEINE-RICH REGION; RAT-BRAIN; CONFORMATIONAL-CHANGES; ACTIVATION; CALCIUM; DIACYLGLYCEROL; PHOSPHATIDYLSERINE	In this study, the role of interdomain interactions involving the C1 and C2 domains in the mechanism of activation of PKC was investigated. Using an in vitro assay containing only purified recombinant proteins and the phorbol ester, 4beta-12-O-tetradecanoylphorbol-13-acetate (TPA), but lacking lipids, it was found that PKCalpha bound specifically, and with high affinity, to a alphaC1A-C1B fusion protein of the same isozyme. The alphaC1A-C1B domain also potently activated the isozyme in a phorbol ester- and diacylglycerol-dependent manner. The level of this activity was comparable with that resulting from membrane association induced under maximally activating conditions. Furthermore, it was found that alphaC1A-C1B bound to a peptide containing the C2 domain of PKCalpha. The alphaC1A-C1B domain also activated conventional PKCbetaI, -betaII, and -gamma isoforms, but not novel PKCdelta or -epsilon. PKCdelta and -epsilon were each activated by their own C1 domains, whereas PKCalpha, -betaI, -betaII, or -gamma activities were unaffected by the C1 domain of PKCdelta and only slightly activated by that of PKCepsilon. PKCzeta activity was unaffected by its own C1 domain and those of the other PKC isozymes. Based on these findings, it is proposed that the activating conformational change in PKCalpha results from the dissociation of intra-molecular interactions between the alphaC1A-C1B domain and the C2 domain. Furthermore, it is shown that PKCalpha forms dimers via intermolecular interactions between the C1 and C2 domains of two neighboring molecules. These mechanisms may also apply for the activation of the other conventional and novel PKC isozymes.	Thomas Jefferson Univ, Dept Pathol Cell Biol & Anat, Philadelphia, PA 19107 USA	Jefferson University	Stubbs, CD (corresponding author), Thomas Jefferson Univ, Dept Pathol Cell Biol & Anat, Rm 271 JAH, Philadelphia, PA 19107 USA.	Chris.Stubbs@mail.tju.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008022, R29AA008022, P50AA007186] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07215, AA08022, AA07465, AA07186] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P5002, DOI 10.1021/bi00390a018; BITTOVA L, 2000, J BIOL CHEM, V11, P11; Bogi K, 1999, FEBS LETT, V456, P27, DOI 10.1016/S0014-5793(99)00927-8; Bogi K, 1998, CANCER RES, V58, P1423; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Clarke H, 2000, ADV DRUG DELIVER REV, V41, P283, DOI 10.1016/S0169-409X(00)00047-8; DASILVA C, 1990, CANCER RES, V50, P2081; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Ho C, 2001, BIOCHEMISTRY-US, V40, P10334, DOI 10.1021/bi002839x; Ho CJ, 1999, BIOCHEM J, V344, P451, DOI 10.1042/0264-6021:3440451; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Huang SM, 1999, BIOCHEMISTRY-US, V38, P12020, DOI 10.1021/bi990594m; INOUE M, 1977, J BIOL CHEM, V252, P7610; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Janoshazi A, 1999, BIOCHEMISTRY-US, V38, P13316, DOI 10.1021/bi990427m; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P14679, DOI 10.1074/jbc.270.24.14679; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; LEE MH, 1986, J BIOL CHEM, V261, P4867; LEPEUCH CJ, 1983, P NATL ACAD SCI-BIOL, V80, P6858; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; LI WQ, 1994, J BIOL CHEM, V269, P2349; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; Marquez VE, 1999, PHARMACOL THERAPEUT, V82, P251, DOI 10.1016/S0163-7258(98)00048-5; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; Musashi M, 2000, INT J HEMATOL, V72, P12; NAKADATE T, 1987, CANCER RES, V47, P6537; Naruse K, 2000, CIRC RES, V86, P1104; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NEWTON AC, 1996, J BIOL CHEM, V48, P28495; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Parissenti AM, 1998, J BIOL CHEM, V273, P8940, DOI 10.1074/jbc.273.15.8940; Pepio AM, 1998, J BIOL CHEM, V273, P19040, DOI 10.1074/jbc.273.30.19040; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; Sando JJ, 1998, J BIOL CHEM, V273, P34022, DOI 10.1074/jbc.273.51.34022; SHIEH HL, 1995, MOL CARCINOGEN, V12, P166, DOI 10.1002/mc.2940120308; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; Slater SJ, 1998, J BIOL CHEM, V273, P23160, DOI 10.1074/jbc.273.36.23160; Slater SJ, 1997, J BIOL CHEM, V272, P6167, DOI 10.1074/jbc.272.10.6167; Slater SJ, 1996, J BIOL CHEM, V271, P4627; Slater SJ, 2001, BIOCHEMISTRY-US, V40, P4437, DOI 10.1021/bi001654n; Slater SJ, 1999, BIOCHEMISTRY-US, V38, P3804, DOI 10.1021/bi982778r; Slater SJ, 2000, BIOCHEMISTRY-US, V39, P271, DOI 10.1021/bi9916527; STABEL S, 1991, METHOD ENZYMOL, V200, P670; TADDEO FJ, 1998, THESIS T JEFFERSON U; Wang QMJ, 2001, J BIOL CHEM, V276, P19580, DOI 10.1074/jbc.M010089200; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	60	51	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15277	15285		10.1074/jbc.M112207200	http://dx.doi.org/10.1074/jbc.M112207200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11850425	hybrid			2022-12-25	WOS:000175510400010
J	Thrower, EC; Park, HY; So, SH; Yoo, SH; Ehrlich, BE				Thrower, EC; Park, HY; So, SH; Yoo, SH; Ehrlich, BE			Activation of the inositol 1,4,5-trisphosphate receptor by the calcium storage protein chromogranin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID CELL SECRETION; CHROMAFFIN GRANULES; (1,4,5)-TRISPHOSPHATE RECEPTOR; FREE CA-2+; CA2+; RELEASE; PEPTIDE; CHANNEL; CATECHOLAMINES; PANCREASTATIN	Secretory granules of neuroendocrine cells are inositol 1,4,5-trisphosphate (InsP(3))-sensitive Ca2+ stores in which the Ca2+ storage protein, chromogranin A (CGA), couples with InsP(3)-gated Ca2+ channels (InsP(3)R) located in the granule membrane. The functional aspect of this coupling has been investigated via release studies and planar lipid bilayer experiments in the presence and absence of CGA. CGA drastically increased the release activity of the InsP(3)R by increasing the channel open probability by 9-fold and the mean open time by 12-fold. Our results show that CGA-coupled InsP(3)Rs are more sensitive to activation than uncoupled receptors. This modulation of InsP(3)R channel activity by CGA appears to be an essential component in the control of intracellular Ca2+ concentration by secretory granules and may regulate the rate of vesicle fusion and exocytosis.	Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Secretory Granule Res, Taejon 305701, South Korea	Yale University; Yale University; Korea Advanced Institute of Science & Technology (KAIST)	Thrower, EC (corresponding author), Yale Univ, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	edwin.thrower@yale.edu	/AAX-8408-2021	/0000-0001-9657-9704	NIGMS NIH HHS [GM63496] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063496] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aardal S, 1996, SCAND J CLIN LAB INV, V56, P511, DOI 10.3109/00365519609088807; AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLASCHKO H, 1967, NATURE, V215, P58, DOI 10.1038/215058a0; BLONDEL O, 1995, TRENDS NEUROSCI, V18, P157, DOI 10.1016/0166-2236(95)93894-4; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; DANIELS AJ, 1978, NEUROSCIENCE, V3, P573, DOI 10.1016/0306-4522(78)90022-2; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; HELLE KB, 1993, NEUROCHEM INT, V22, P353, DOI 10.1016/0197-0186(93)90017-Y; Helle KB, 2000, ADV EXP MED BIOL, V482, P389; HELLE KB, 1966, MOL PHARMACOL, V2, P298; KOPELL WN, 1982, J BIOL CHEM, V257, P5707; LEWIS JJ, 1988, SURGERY, V104, P1031; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; ROSKAMS T, 1990, AM J PATHOL, V137, P1019; SIMON JP, 1989, BIOCHEM J, V262, P1; SMITH AD, 1967, BIOCHEM J, V103, P483, DOI 10.1042/bj1030483; Strub JM, 1997, J BIOL CHEM, V272, P11928, DOI 10.1074/jbc.272.18.11928; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; Thrower EC, 1998, BIOCHEM J, V330, P559; Thrower EC, 2000, J BIOL CHEM, V275, P36049, DOI 10.1074/jbc.M000970200; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1990, J BIOL CHEM, V265, P13446; Yoo SH, 2000, J BIOL CHEM, V275, P15067, DOI 10.1074/jbc.M909391199; Yoo SH, 2000, TRENDS NEUROSCI, V23, P424, DOI 10.1016/S0166-2236(00)01621-0	35	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15801	15806		10.1074/jbc.M110139200	http://dx.doi.org/10.1074/jbc.M110139200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11842082	hybrid			2022-12-25	WOS:000175510400079
J	Ding, FX; Schreiber, D; VerBerkmoes, NC; Becker, JM; Naider, F				Ding, FX; Schreiber, D; VerBerkmoes, NC; Becker, JM; Naider, F			The chain length dependence of helix formation of the second transmembrane domain of a G protein-coupled receptor of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR RECEPTOR; TRANSFORM INFRARED-SPECTROSCOPY; CIRCULAR-DICHROISM; MEMBRANE-PROTEINS; LIPID BILAYERS; ATR-FTIR; ELECTRON CRYSTALLOGRAPHY; 3-DIMENSIONAL STRUCTURE; AMINO-ACIDS; ORIENTATION	The chain length dependence of helix formation of transmembrane peptides in lipids was investigated using fragments corresponding to the second transmembrane domain of the alpha-factor receptor from Saccharomyces cerevisiae. Seven peptides with chain lengths of 10 (M2-10; FKYLLSNYSS), 14 (M2-14), 18 (M2-18),22 (M2-22),26 (M2-26),30 (M2-30) and 35 (M2-35; RSRKTPIFIINQVSLFLIILH-SALYFKYLLSNYSS) residues, respectively, were synthesized. CD spectra revealed that M2-10 was disor- dered, and all of the other peptides assumed partially a-helical secondary structures in 99% trifluoroethanol (TFE)/H2O. In 50% TFE/H2O, M2-30 assumed a beta-like structure. The other six peptides exhibited the same CD patterns as those found in 99% TFE/H2O. In 1,2-dimyristoyl-sn-glycero-3-phosphocholine/1,2-dimyristoyl-sn-glycero-3-phospho-rac-(1-glycerol) (4:1 ratio) vesicles, M2-22, M2-26, and M2-35 formed alpha-helical structures, whereas the other peptides formed beta-like structures. Fourier transform infrared spectroscopy in 1,2-dimyristoyl-sn-glycero-3-phosphocholine/1,2-dimyristoyl-sn-glycero-3-phospho- rac-(1-glycerol) (4:1) multilayers showed that M2-10, M2-14, M2-18, and M2-30 assumed beta-structures in this environment. Another homologous 30-residue pep- tide (M2-30B), missing residues SNYSS from the N terminus and extending to RSRKT on the C terminus, was helical in lipid bilayers, suggesting that residues at the termini of transmembrane domains influence their biophysical properties. Attenuated total reflection Fourier transform infrared spectroscopy revealed that M2-22, M2-26, M2-30B, and M2-35 were alpha-helical and oriented at angles of 12degrees, 13degrees, 36degrees, and 34degrees, respectively, with respect to the multilayer normal. This study showed that chain length must be taken into consideration when using peptides representing single transmembrane domains as surrogates for regions of an intact receptor. Furthermore, this work indicates that the tilt angle and conformation of transmembrane portions of G protein-coupled receptors may be estimated by detailed spectroscopic measurements of single transmembrane peptides.	CUNY Coll Staten Isl, Dept Chem, Staten Isl, NY 10314 USA; Univ Tennessee, Oak Ridge Natl Lab, Grad Sch Genome Sci & Technol, Oak Ridge, TN 37830 USA; Oak Ridge Natl Lab, Organ & Biol Mass Spect Grp, Oak Ridge, TN 37831 USA; Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA; Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA	City University of New York (CUNY) System; College of Staten Island (CUNY); United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville	Naider, F (corresponding author), CUNY Coll Staten Isl, Dept Chem, Staten Isl, NY 10301 USA.	naider@postbox.csi.cuny.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022087, R56GM022087, R56GM022086, R01GM022086] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22086, GM22087] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert AD, 2000, METHOD ENZYMOL, V315, P107; ARKIN IT, 1995, J MOL BIOL, V248, P824, DOI 10.1006/jmbi.1995.0263; Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; Arshava B, 1998, BIOPOLYMERS, V46, P343, DOI 10.1002/(SICI)1097-0282(199811)46:6<343::AID-BIP1>3.0.CO;2-L; Bianchi E, 1999, J AM CHEM SOC, V121, P7698, DOI 10.1021/ja9901617; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; BRENZIGER JE, 1995, J BIOL CHEM, V270, P29129; Carpenter KA, 1999, BIOCHEMISTRY-US, V38, P15295, DOI 10.1021/bi991081i; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; de Planque MRR, 2001, BIOCHEMISTRY-US, V40, P5000, DOI 10.1021/bi000804r; Deber CM, 1999, J PEPT RES, V54, P200, DOI 10.1034/j.1399-3011.1999.00118.x; Ding FX, 2001, BIOCHEMISTRY-US, V40, P8945, DOI 10.1021/bi010394m; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dube P, 2000, J BIOL CHEM, V275, P26492, DOI 10.1074/jbc.M002767200; EARNEST TN, 1990, BIOPHYS J, V58, P1539, DOI 10.1016/S0006-3495(90)82498-X; EISENBERG D, 1986, Proteins Structure Function and Genetics, V1, P16, DOI 10.1002/prot.340010105; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; Garavito R, 1998, CURR OPIN BIOTECH, V9, P344, DOI 10.1016/S0958-1669(98)80005-0; GREBOW PE, 1975, BIOPOLYMERS, V14, P871, DOI 10.1002/bip.1975.360140414; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Harrick N.J., 1967, INTERNAL REFLECTION; HOLLOWAY PW, 1990, BIOCHEMISTRY-US, V29, P9631, DOI 10.1021/bi00493a018; Hunt JF, 1997, BIOCHEMISTRY-US, V36, P15177, DOI 10.1021/bi970147b; Hunt JF, 1997, BIOCHEMISTRY-US, V36, P15156, DOI 10.1021/bi970146j; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KATAKAI R, 1977, J AM CHEM SOC, V99, P232, DOI 10.1021/ja00443a039; KATAKAI R, 1977, POLYMER, V18, P755, DOI 10.1016/0032-3861(77)90176-8; KATAKAI R, 1981, MACROMOLECULES, V14, P613, DOI 10.1021/ma50004a031; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; Kukol A, 1999, J MOL BIOL, V286, P951, DOI 10.1006/jmbi.1998.2512; Liu LP, 1998, J BIOL CHEM, V273, P23645, DOI 10.1074/jbc.273.37.23645; Lu LP, 1998, BIOPOLYMERS, V47, P41, DOI 10.1002/(SICI)1097-0282(1998)47:1<41::AID-BIP6>3.0.CO;2-X; MADISON V, 1972, BIOPOLYMERS, V11, P1041, DOI 10.1002/bip.1972.360110509; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; Martin NP, 1999, BIOCHEMISTRY-US, V38, P682, DOI 10.1021/bi982062w; Melnyk RA, 2001, BIOCHEMISTRY-US, V40, P11106, DOI 10.1021/bi010642e; Menikh A, 1997, BIOCHEMISTRY-US, V36, P15865, DOI 10.1021/bi970944+; Mitsuoka K, 1999, J MOL BIOL, V286, P861, DOI 10.1006/jmbi.1998.2529; NABET A, 1994, BIOCHEMISTRY-US, V33, P14792, DOI 10.1021/bi00253a018; Naider F., 1977, BIOORG CHEM, P177; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; PILLAI VNR, 1981, ACCOUNTS CHEM RES, V14, P122, DOI 10.1021/ar00064a005; PYSH ES, 1966, P NATL ACAD SCI USA, V56, P825, DOI 10.1073/pnas.56.3.825; REDDY AP, 1994, BIOPOLYMERS, V34, P679, DOI 10.1002/bip.360340510; Sharon M, 1999, BIOCHEMISTRY-US, V38, P15305, DOI 10.1021/bi991225t; SMITH SO, 1994, BIOCHEMISTRY-US, V33, P6334, DOI 10.1021/bi00186a037; TAMM LK, 1993, BIOCHEMISTRY-US, V32, P7720, DOI 10.1021/bi00081a017; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; TONIOLO C, 1979, INT J BIOL MACROMOL, V1, P188, DOI 10.1016/0141-8130(79)90048-5; Tsukihara T, 1999, J SYNCHROTRON RADIAT, V6, P918, DOI 10.1107/S0909049599006184; Valentine KG, 2001, BIOPOLYMERS, V59, P243, DOI 10.1002/1097-0282(20011005)59:4<243::AID-BIP1021>3.0.CO;2-H; Wigley WC, 1998, BIOCHEMISTRY-US, V37, P844, DOI 10.1021/bi972293n; WOODY RW, 1969, BIOPOLYMERS, V8, P669, DOI 10.1002/bip.1969.360080509; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Xie HB, 2000, BIOCHEMISTRY-US, V39, P15462, DOI 10.1021/bi001432p; ZHANG YP, 1992, BIOCHEMISTRY-US, V31, P11572, DOI 10.1021/bi00161a041; ZIEGLER SM, 1971, BIOCHEMISTRY-US, V10, P1330	61	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14483	14492		10.1074/jbc.M111382200	http://dx.doi.org/10.1074/jbc.M111382200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11854278	hybrid			2022-12-25	WOS:000175203000019
J	Jones, PA; Samuels, NM; Phillips, NJ; Munson, RS; Bozue, JA; Arseneau, JA; Nichols, WA; Zaleski, A; Gibson, BW; Apicella, MA				Jones, PA; Samuels, NM; Phillips, NJ; Munson, RS; Bozue, JA; Arseneau, JA; Nichols, WA; Zaleski, A; Gibson, BW; Apicella, MA			Haemophilus influenzae type b strain A2 has multiple sialyltransferases involved in lipooligosaccharide sialylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONTYPABLE HEMOPHILUS-INFLUENZAE; NEISSERIA-MENINGITIDIS; CAMPYLOBACTER-JEJUNI; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; SERUM RESISTANCE; SIALIC-ACID; LIPOPOLYSACCHARIDE BIOSYNTHESIS; STRUCTURAL CHARACTERIZATION; MOLECULAR ANALYSIS	The lipooligosaccharide (LOS) of Haemophilus influenzae contains sialylated glycoforms, and a sialyltransferase, Lic3A, has been previously identified. We report evidence for two additional sialyltransferases, SiaA, and LsgB, that affect N-acetyllactosamine containing glycoforms. Mutations in genes we have designated siaA and lsgB affected only the sialylated glycoforms containing N-acetylhexosamine. A mutation in siaA resulted in the loss of glycoforms terminating in sialyl-N-acetylhexosamine and the appearance of higher molecular weight glycoforms, containing the addition of phosphoethanolamine, N-acetylgalactosamine, and N-acetylneuraminic acid. Chromosomal complementation of the sigA mutant resulted in the expression of the original sialylated LOS phenotype. A mutation in lic3A resulted in the loss of sialylation only in glycoforms lacking N-acetylhexosamine and had no effect on sialylation of the terminal N-acetyllactosamine epitope. A double mutant in siaA and lic3A resulted in the complete loss of sialylation of the terminal N-acetyllactosamine epitope and expression of the higher molecular weight sialylated glycoforms seen in the siaA mutant. Mutation of lsgB resulted in persistence of sialylated glycoforms but a reduction in N-acetyllactosamine containing glycoforms. A triple mutant of siaA, lic3A, and lsgB contained no sialylated glycoforms. These results demonstrate that the sialylation of the LOS of H. influenzae is a complex process involving multiple sialyltransferases.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA; Ohio State Univ, Childrens Res Inst, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43205 USA; Buck Inst Age Res, Novato, CA 94945 USA	University of Iowa; University of California System; University of California San Francisco; Illinois State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Buck Institute for Research on Aging	Apicella, MA (corresponding author), Univ Iowa, Dept Microbiol, 51 Newton Rd, Iowa City, IA 52242 USA.		Bozue, Joel/AAE-4363-2022; Munson, Jr, Robert/E-3710-2011; Bozue, Joel/AAE-4357-2022	Bozue, Joel/0000-0001-6959-8176; Munson, Jr, Robert/0000-0002-3204-3019; Bozue, Joel/0000-0001-6959-8176	NIAID NIH HHS [AI24616, AI31254, AI65298] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024616, R01AI031254, R37AI024616, R56AI024616] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDILLAHI H, 1987, FEMS MICROBIOL LETT, V48, P367, DOI 10.1016/0378-1097(87)90077-2; ALEXEYEV MF, 1995, BIOTECHNIQUES, V18, P52; ASPINALL GO, 1994, INFECT IMMUN, V62, P2122, DOI 10.1128/IAI.62.5.2122-2125.1994; Borovkov AY, 1997, BIOTECHNIQUES, V22, P812, DOI 10.2144/97225bm04; Bozue JA, 1999, J BIOL CHEM, V274, P4106, DOI 10.1074/jbc.274.7.4106; CAMPAGNARI AA, 1987, INFECT IMMUN, V55, P882, DOI 10.1128/IAI.55.4.882-887.1987; EDWARDS U, 1994, MOL MICROBIOL, V14, P141, DOI 10.1111/j.1365-2958.1994.tb01274.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FLESHER AR, 1978, J INFECT DIS, V138, P719, DOI 10.1093/infdis/138.6.719; Gibson BW, 1997, J AM SOC MASS SPECTR, V8, P645, DOI 10.1016/S1044-0305(97)00042-1; Gilbert M, 1997, EUR J BIOCHEM, V249, P187, DOI 10.1111/j.1432-1033.1997.t01-1-00187.x; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; Gilbert M, 2000, J BIOL CHEM, V275, P3896, DOI 10.1074/jbc.275.6.3896; Guerry P, 2000, INFECT IMMUN, V68, P6656, DOI 10.1128/IAI.68.12.6656-6662.2000; HERRIOTT RM, 1970, J BACTERIOL, V101, P517, DOI 10.1128/JB.101.2.517-524.1970; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Hood DW, 1999, MOL MICROBIOL, V33, P679, DOI 10.1046/j.1365-2958.1999.01509.x; Hood DW, 2001, MOL MICROBIOL, V39, P341, DOI 10.1046/j.1365-2958.2001.02204.x; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; INZANA TJ, 1983, J INFECT DIS, V148, P492, DOI 10.1093/infdis/148.3.492; INZANA TJ, 1985, INFECT IMMUN, V48, P324, DOI 10.1128/IAI.48.2.324-330.1985; KIMURA A, 1987, INFECT IMMUN, V55, P1979, DOI 10.1128/IAI.55.9.1979-1986.1987; KIMURA A, 1986, INFECT IMMUN, V51, P69, DOI 10.1128/IAI.51.1.69-79.1986; LESSE AJ, 1990, J IMMUNOL METHODS, V126, P109, DOI 10.1016/0022-1759(90)90018-Q; MANDRELL RE, 1992, INFECT IMMUN, V60, P1322, DOI 10.1128/IAI.60.4.1322-1328.1992; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; MASKELL DJ, 1991, MOL MICROBIOL, V5, P1013, DOI 10.1111/j.1365-2958.1991.tb01874.x; Masoud H, 1997, BIOCHEMISTRY-US, V36, P2091, DOI 10.1021/bi961989y; MENARD R, 1993, J BACTERIOL, V175, P5899; MORAN AP, 1991, J BACTERIOL, V173, P618, DOI 10.1128/jb.173.2.618-626.1991; MURPHY TF, 1987, REV INFECT DIS, V9, P1; NAIRN CA, 1988, J GEN MICROBIOL, V134, P3295; PARR TR, 1984, CAN J MICROBIOL, V30, P1184, DOI 10.1139/m84-185; PARSONS NJ, 1993, MICROB PATHOGENESIS, V14, P329, DOI 10.1006/mpat.1993.1032; PARSONS NJ, 1988, MICROB PATHOGENESIS, V5, P303, DOI 10.1016/0882-4010(88)90103-9; PATRICK CC, 1987, INFECT IMMUN, V55, P2902, DOI 10.1128/IAI.55.12.2902-2911.1987; Phillips NJ, 1996, BIOCHEMISTRY-US, V35, P5937, DOI 10.1021/bi960059b; PHILLIPS NJ, 1993, BIOCHEMISTRY-US, V32, P2003, DOI 10.1021/bi00059a017; Phillips NJ, 2000, J BIOL CHEM, V275, P4747, DOI 10.1074/jbc.275.7.4747; PITTMAN MARGARET, 1931, JOUR EXP MED, V53, P471, DOI 10.1084/jem.53.4.471; Prendergast MM, 1998, INFECT IMMUN, V66, P3649, DOI 10.1128/IAI.66.8.3649-3655.1998; Preston A, 1996, CRIT REV MICROBIOL, V22, P139, DOI 10.3109/10408419609106458; Risberg A, 1999, EUR J BIOCHEM, V261, P171, DOI 10.1046/j.1432-1327.1999.00248.x; SCHNEIDER H, 1991, J EXP MED, V174, P1601, DOI 10.1084/jem.174.6.1601; SPINOLA SM, 1990, INFECT IMMUN, V58, P1558, DOI 10.1128/IAI.58.6.1558-1564.1990; Swords WE, 2000, MOL MICROBIOL, V37, P13, DOI 10.1046/j.1365-2958.2000.01952.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; TURK DC, 1982, HAEMOPHILUS INFLUENZ, P3; Vimr E, 2000, MOL MICROBIOL, V36, P1113, DOI 10.1046/j.1365-2958.2000.01925.x; WEISER JN, 1989, INFECT IMMUN, V57, P3045, DOI 10.1128/IAI.57.10.3045-3052.1989; WEISER JN, 1990, J BACTERIOL, V172, P3304, DOI 10.1128/jb.172.6.3304-3309.1990; WEISER JN, 1989, CELL, V59, P657, DOI 10.1016/0092-8674(89)90011-1; Whitby PW, 1998, FEMS MICROBIOL LETT, V158, P57, DOI 10.1016/S0378-1097(97)00500-4; YAMASAKI R, 1991, MOL IMMUNOL, V28, P1233, DOI 10.1016/0161-5890(91)90010-H; ZAMZE SE, 1987, J GEN MICROBIOL, V133, P1443; ZWAHLEN A, 1986, MICROB PATHOGENESIS, V1, P465, DOI 10.1016/0882-4010(86)90008-2	57	90	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14598	14611		10.1074/jbc.M110986200	http://dx.doi.org/10.1074/jbc.M110986200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11842084	hybrid			2022-12-25	WOS:000175203000033
J	Mashima, R; Tilley, L; Siomos, MA; Papalexis, V; Raftery, MJ; Stocker, R				Mashima, R; Tilley, L; Siomos, MA; Papalexis, V; Raftery, MJ; Stocker, R			Plasmodium falciparum histidine-rich protein-2 (PfHRP2) modulates the redox activity of ferri-protoporphyrin IX (FePPIX) - Peroxidase-like activity of the PfHRP2-FePPIX complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINCKEI-INFECTED ERYTHROCYTES; PROSTAGLANDIN-H SYNTHASE; ASCORBIC-ACID CONTENT; MALARIA PARASITE; LINOLEATE HYDROPEROXIDES; HORSERADISH-PEROXIDASE; HEMOGLOBIN DEGRADATION; OXIDATIVE STRESS; HEME-BINDING; PLASMA	Histidine-rich protein-2 from Plasmodium falciparum (PfHRP2) binds up to 50 molecules of ferri-protoporphyrin IX (FePPIX) (Choi, C. Y., Cerda, J. F., Chu, H. A., Babcock, G. T., and Marletta, M. A. (1999) Biochemistry 38, 16916-16924). We reasoned that the PfHRP2-FePPIX complex has antioxidant properties that could be beneficial to the parasite. Therefore, we examined whether binding to PfHRP2 modulated the redox properties of FePPIX. We observed that PfHRP2 completely inhibited the auto-oxidation of ascorbate mediated by free Fe-PIX We also investigated the peroxidase activity of PfHRP2-FePPIX using 13-hydroperoxy-9,11-octadienoate (18:2-OOH) as substrate. Reaction of PfHRP2-FePPIX with 18:2-OOH in the presence of added reducing agents gave 13-hydroxy-9,11-octadienoate (18:2-OH) as a major product and 13-keto-9,11-octadienoate (18:2=O) and 9,12,13-trihydroxy-10-octadecaenoate as minor products. Binding of FePPIX to PfHRP2 lowered the rate of decomposition of 18:2-OOH and increased the 18:2-OH to 18:2=O ratio. Similar to other authentic peroxidases, phenols, amines, and biological reductants like ascorbate promoted 18:2-OH production, and NaCN inhibited 18:2-OH production. Thioanisole also acted as a reductant and was converted to thioanisole sulfoxide, suggesting formation of compound I during the reaction. These data show that PfHRP2 modulates the redox activity of FePPIX and that the PfHRP2-FePPIX complex may have previously unrecognized antioxidant properties.	Heart Res Inst, Biochem Grp, Camperdown, NSW 2050, Australia; La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia; Univ New S Wales, Sch Pathol, Cytokine Res Unit, Kensington, NSW 2052, Australia	University of Sydney; Heart Research Institute; La Trobe University; University of New South Wales Sydney	Stocker, R (corresponding author), Univ New S Wales, Sch Med Sci, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.		Tilley, Leann/AAU-5281-2020; Stocker, Roland/AAV-4489-2021	Tilley, Leann/0000-0001-9910-0199				BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; CHAN HWS, 1977, LIPIDS, V12, P99, DOI 10.1007/BF02532979; Choi CYH, 1999, BIOCHEMISTRY-US, V38, P16916, DOI 10.1021/bi991665k; CHOU AC, 1981, J CLIN INVEST, V68, P672, DOI 10.1172/JCI110302; DEMONTELLANO PRO, 1987, BIOCHEMISTRY-US, V26, P5310, DOI 10.1021/bi00391a014; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DIX TA, 1985, J BIOL CHEM, V260, P5351; Dunford H. B, 1999, HEME PEROXIDASES, P1; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; Green MD, 1996, MOL BIOCHEM PARASIT, V83, P183, DOI 10.1016/S0166-6851(96)02769-7; HARRIS RZ, 1993, J BIOL CHEM, V268, P1637; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; HUNT NH, 1990, BLOOD CELLS, V16, P499; Landino LM, 1997, J BIOL CHEM, V272, P21565, DOI 10.1074/jbc.272.34.21565; Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363; Lynn A, 1999, FEBS LETT, V459, P267, DOI 10.1016/S0014-5793(99)01260-0; Marnett Lawrence J., 1995, P49; Mashima R, 2000, J LIPID RES, V41, P109; Mashima R, 1998, J LIPID RES, V39, P1133; PANTON LJ, 1989, MOL BIOCHEM PARASIT, V35, P149, DOI 10.1016/0166-6851(89)90117-5; Papalexis V, 2001, MOL BIOCHEM PARASIT, V115, P77, DOI 10.1016/S0166-6851(01)00271-7; PARRA ME, 1991, J CLIN MICROBIOL, V29, P1629, DOI 10.1128/JCM.29.8.1629-1634.1991; PLE P, 1989, J BIOL CHEM, V264, P13983; POULOS TL, 1980, J BIOL CHEM, V255, P8199; SAMOKYSZYN VM, 1987, J BIOL CHEM, V262, P14119; STOCKER R, 1986, BIOCHIM BIOPHYS ACTA, V876, P294, DOI 10.1016/0005-2760(86)90287-0; STOCKER R, 1986, BIOCHIM BIOPHYS ACTA, V881, P391, DOI 10.1016/0304-4165(86)90031-0; STOCKER R, 1987, LIPIDS, V22, P51, DOI 10.1007/BF02534875; STOCKER R, 1985, P NATL ACAD SCI USA, V82, P548, DOI 10.1073/pnas.82.2.548; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; TAPPEL AL, 1953, ARCH BIOCHEM BIOPHYS, V44, P378, DOI 10.1016/0003-9861(53)90056-3; WELLEMS TE, 1986, P NATL ACAD SCI USA, V83, P6065, DOI 10.1073/pnas.83.16.6065; Ziegler J, 1999, J AM CHEM SOC, V121, P2395, DOI 10.1021/ja983220+	35	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14514	14520		10.1074/jbc.M109386200	http://dx.doi.org/10.1074/jbc.M109386200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11859069	hybrid			2022-12-25	WOS:000175203000023
J	Shyr, CR; Hu, YC; Kim, E; Chang, CS				Shyr, CR; Hu, YC; Kim, E; Chang, CS			Modulation of estrogen receptor-mediated transactivation by orphan receptor TR4 in MCF-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; NUCLEAR RECEPTORS; CYCLE PROGRESSION; ANDROGEN RECEPTOR; ER-ALPHA; SUPERFAMILY; BETA; PROLIFERATION; CANCER; MICE	The human testicular orphan receptor 4 (TR4) is a member of the nuclear receptor superfamily that shows a broad tissue distribution with higher expression in the nervous system and male reproductive tract. TR4 functions as a transcriptional modulator that controls various target genes via binding to the DNA hormone response elements. Here we report that instead of direct binding to hormone response elements for gene regulation, TR4 can also go through direct protein-protein interaction to repress estrogen receptor (ER)-mediated transactivation. Electrophoretic mobility shift and glutathione S-transferase pull-down assays clearly demonstrate that the direct interaction between TR4 and ER will inhibit the homodimerization of ER and interrupt/prevent ER binding to the estrogen response element. The consequence of these events may then result in the suppression of ER target genes, such as cyclin D1 and pS2 and inhibition of ER-mediated cell proliferation in the MCF-7 cells stably transfected with TR4. Together, our results showing that TR4 can suppress ER function via protein-protein interaction not only represent a unique cross-talk signaling pathway in the nuclear receptor superfamily, it may also provide us with a new strategy to modulate ER function in the breast cancer cells.	Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.	chang@urmc.rochester.edu		Chang, Chawnshang/0000-0001-8510-3516; Hu, Yueh-Chiang/0000-0002-7992-0525	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47258] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; FONTANA JA, 1990, CANCER RES, V50, P1977; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; HENDERSON BE, 1988, CANCER RES, V48, P246; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lazennec G, 1999, MOL ENDOCRINOL, V13, P969, DOI 10.1210/me.13.6.969; Lee CH, 1998, J BIOL CHEM, V273, P25209, DOI 10.1074/jbc.273.39.25209; LEE HJ, 1995, J BIOL CHEM, V270, P30129; Lee SK, 1998, MOL ENDOCRINOL, V12, P1184, DOI 10.1210/me.12.8.1184; Lee YF, 1998, J BIOL CHEM, V273, P13437, DOI 10.1074/jbc.273.22.13437; Lee YF, 1999, J BIOL CHEM, V274, P16198, DOI 10.1074/jbc.274.23.16198; Lee YF, 1997, J BIOL CHEM, V272, P12215, DOI 10.1074/jbc.272.18.12215; Lee YF, 1999, P NATL ACAD SCI USA, V96, P14724, DOI 10.1073/pnas.96.26.14724; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mu XM, 2000, J BIOL CHEM, V275, P23877, DOI 10.1074/jbc.M910158199; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Resnick EM, 2000, J BIOL CHEM, V275, P7158, DOI 10.1074/jbc.275.10.7158; Schodin DJ, 1995, J BIOL CHEM, V270, P31163, DOI 10.1074/jbc.270.52.31163; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; SOULE HD, 1980, CANCER LETT, V10, P177, DOI 10.1016/0304-3835(80)90042-7; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Yan ZH, 1998, J BIOL CHEM, V273, P10948, DOI 10.1074/jbc.273.18.10948; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Young WJ, 1997, J BIOL CHEM, V272, P3109, DOI 10.1074/jbc.272.5.3109	38	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14622	14628		10.1074/jbc.M110051200	http://dx.doi.org/10.1074/jbc.M110051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11844790	hybrid			2022-12-25	WOS:000175203000035
J	Zou, W; Schwartz, H; Endres, S; Hartmann, G; Bar-Shavit, Z				Zou, W; Schwartz, H; Endres, S; Hartmann, G; Bar-Shavit, Z			CpG oligonucleotides: novel regulators of osteoclast differentiation	FASEB JOURNAL			English	Article						RANKL; TNF-alpha; M-CSF; bone; immunostimulatory oligodexynucleotide	COLONY-STIMULATING FACTOR; MARROW-DERIVED MACROPHAGES; NF-KAPPA-B; BACTERIAL-DNA; BONE-MARROW; OSTEOPROTEGERIN LIGAND; OP/OP MICE; IN-VITRO; ACTIVATION; OSTEOPETROSIS	The macrophage capability to recognize bacterial DNA is mimicked by oligodeoxynucleotides containing unmethylated CG dinucleotides (CpG' motifs) in specific sequence contexts (CpG ODN). CpG ODN stimulates NF-kappaB activation in murine macrophages. In light of the pivotal role played by NF-kappaB in osteoclast differentiation, we examined the ability of CpG ODN to modulate osteoclastogenesis. CpG ODN alone induced TRAP- positive cells in bone marrow macrophage (BMM) cultures, but not multinucleation or calcitonin receptor expression. CpG ODN inhibited RANKL- induced osteoclastogenesis when present from the beginning of BMM culture, but strongly increased RANKL- induced osteoclastogenesis in RANKL- pretreated BMMs. CpG ODN enhanced the expression of interleukin 1beta (IL-1beta) and tumor necrosis factor alpha (TNF-alpha). Antibodies to TNF-alpha and the TNF type 1 receptor, but not the addition of IL- 1 receptor antagonist, blocked CpG ODN- induced osteoclastogenesis in RANKL- pretreated cultures. On the other hand, CpG ODN reduced expression of the M- CSF receptor, which is critical during the initiation of osteoclast differentiation. These results suggest that CpG ODN, via the induction of TNF-alpha, support osteoclastogenesis in cells that are committed to the osteoclast differentiation pathway but, due to down- modulation of M- CSF receptor, inhibit early steps of osteoclast differentiation. Thus, CpG ODN represents a potential therapeutic tool for treating bone diseases.	Hebrew Univ Jerusalem, Fac Med, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel; Univ Munich, Dept Med, Div Clin Pharmacol, D-80336 Munich, Germany	Hebrew University of Jerusalem; University of Munich	Bar-Shavit, Z (corresponding author), Hebrew Univ Jerusalem, Fac Med, Hubert H Humphrey Ctr Expt Med & Canc Res, POB 12272, IL-91120 Jerusalem, Israel.	barsha@cc.huji.ac.il	Hartmann, Gunther/P-7492-2017	Hartmann, Gunther/0000-0003-1021-2018; Zou, Wei/0000-0001-8081-268X				Abboud SL, 1998, J CELL PHYSIOL, V176, P323, DOI 10.1002/(SICI)1097-4652(199808)176:2<323::AID-JCP10>3.0.CO;2-4; ABUAMER Y, 1994, J CELL BIOCHEM, V55, P435, DOI 10.1002/jcb.240550404; BARON R, 1986, AM J PATHOL, V122, P363; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; GOLDMAN R, 1979, J NATL CANCER I, V63, P1009; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Kahn A J, 1982, Prog Clin Biol Res, V110 Pt B, P239; Kawata T, 1999, ARCH ORAL BIOL, V44, P81, DOI 10.1016/S0003-9969(98)00082-X; KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2001, TRENDS MICROBIOL, V9, P249, DOI 10.1016/S0966-842X(01)02039-X; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Macfarlane DE, 1998, J IMMUNOL, V160, P1122; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371-2380.1996; Pisetsky DS, 1996, IMMUNITY, V5, P303, DOI 10.1016/S1074-7613(00)80256-3; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; Reddy SV, 1998, CRIT REV EUKAR GENE, V8, P1; RODAN GA, 1992, BONE, V13, pS3, DOI 10.1016/S8756-3282(09)80003-3; Sambrook J., 1989, MOL CLONING, pA1; Sester DP, 1999, J IMMUNOL, V163, P6541; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; Suda Tatsuo, 1996, P87; Takatsuka H, 1998, J SUBMICR CYTOL PATH, V30, P239; Umeda S, 1996, J SUBMICR CYTOL PATH, V28, P13; Weiner GJ, 2000, J LEUKOCYTE BIOL, V68, P455; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200; Zou W, 2001, J CELL BIOCHEM, V83, P70, DOI 10.1002/jcb.1202	38	48	52	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3					274	282	UNSP 0892-6638/02/0016-0283	10.1096/fj.01-0586com	http://dx.doi.org/10.1096/fj.01-0586com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874977				2022-12-25	WOS:000174755900020
J	Amicone, L; Terradillos, O; Calvo, L; Costabile, B; Cicchini, C; Della Rocca, C; Lozupone, F; Piacentini, M; Buendia, MA; Tripodi, M				Amicone, L; Terradillos, O; Calvo, L; Costabile, B; Cicchini, C; Della Rocca, C; Lozupone, F; Piacentini, M; Buendia, MA; Tripodi, M			Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: Importance of TGF-beta signalling in the control of liver homeostasis and transformation	ONCOGENE			English	Article						apoptosis; hepatocyte proliferation; liver mass homeostasis; oncogene cooperation	HEPATOCYTE GROWTH-FACTOR; FACTOR-SCATTER FACTOR; TRANSGENIC MICE; FACTOR-RECEPTOR; CELL-PROLIFERATION; IN-SITU; EXPRESSION; HEPATOCARCINOGENESIS; GENE; OVEREXPRESSION	The c-Met tyrosine kinase receptor and its ligand, Hepatocyte Growth Factor/ Scatter Factor, have been implicated in human cancer. We have previously described that the transgenic expression of a truncated form of human c-Met (cyto-Met) in the liver confers resistance to several apoptotic stimuli. Here we show the impact of cyto-Met expression on liver proliferation and transformation. Despite a sixfold increase of hepatocyte proliferation, adult transgenic livers displayed normal size and architecture. We present evidence showing that activation of TGF-beta1 signalling controls the liver mass in cyto-Met mice. The oncogenic potential of cyto-Met was further assessed in the context of c-Myc-induced hepatocarcinogenesis, using WHV/c-Myc transgenic mice. Co-expression of cyto-Met and c-Myc further enhanced hepatocyte proliferation and caused a dramatic acceleration of the Myc-induced tumorigenesis, leading to the emergence of hepatocarcinomas in 3-4-month-old animals. Importantly, the TGF-beta receptor type 11 expression was strongly downregulated in most tumours, indicating that impairment of TGF-beta1-mediated growth inhibition plays a major role in accelerated neoplastic development. The strong potential of cyto-Met for oncogenic cooperation without direct transforming activity designates cyto-Met mice as an ideal tool for studying the early steps of multistage hepatocarcinogenesis and for identification of prognostic markers of transformation.	Univ Roma La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Fondaz Ist Pasteur Cenci Bolognetti, I-00161 Rome, Italy; Inst Pasteur, Dept Retrovirus, Unite Recombinaison & Express Genet, F-75724 Paris 15, France; Univ Roma La Sapienza, Sez Anat Patol, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; IRCCS L Spallanzani, Ist Nazl Malattie Infett, Rome, Italy	Sapienza University Rome; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Sapienza University Rome; University of Rome Tor Vergata; IRCCS Lazzaro Spallanzani	Tripodi, M (corresponding author), Univ Roma La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Fondaz Ist Pasteur Cenci Bolognetti, I-00161 Rome, Italy.	tripodi@bce.med.uniroma1.it	Lozupone, Francesco/H-2998-2016; Piacentini, Mauro/I-2411-2016; Tripodi, Marco/ABO-1160-2022; Tripodi, Marco/F-1143-2011	Lozupone, Francesco/0000-0002-4959-9400; Piacentini, Mauro/0000-0003-2919-1296; Tripodi, Marco/0000-0001-6135-971X; Tripodi, Marco/0000-0001-6135-971X; Amicone, Laura/0000-0002-3487-5740; CICCHINI, Carla/0000-0003-4662-5674				AMICONE L, 1995, GENE, V162, P323, DOI 10.1016/0378-1119(95)00277-D; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BENEDETTI A, 1988, J HEPATOL, V6, P137, DOI 10.1016/S0168-8278(88)80024-2; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BLOCH B, 1993, J HISTOCHEM CYTOCHEM, V41, P1751, DOI 10.1177/41.12.8245422; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURSCH W, 1986, ARCH TOXICOL, V59, P221, DOI 10.1007/BF00290542; Clifford SC, 1998, BRIT J CANCER, V77, P1420, DOI 10.1038/bjc.1998.235; Columbano A, 1984, Toxicol Pathol, V12, P89; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Desiderio MA, 1998, EXP CELL RES, V242, P401, DOI 10.1006/excr.1998.4073; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; ETIEMBLE J, 1994, ONCOGENE, V9, P727; Factor VM, 1997, CANCER RES, V57, P2089; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; Grippo PJ, 2000, AM J PATHOL, V157, P805, DOI 10.1016/S0002-9440(10)64594-4; HUANG SN, 1995, HEPATOLOGY, V21, P620, DOI 10.1002/hep.1840210303; Jansen AP, 2001, CANCER RES, V61, P808; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; JIRTLE RL, 1991, J BIOL CHEM, V266, P22444; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; Liu P, 1997, HEPATOLOGY, V25, P874, DOI 10.1002/hep.510250415; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Santoni-Rugiu E, 1999, AM J PATHOL, V154, P1693, DOI 10.1016/S0002-9440(10)65425-9; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; SHULTEHERMANN R, 1995, APOPTOSIS HEPATOEARC, P141; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; von Schweinitz D, 2000, INT J CANCER, V85, P151, DOI 10.1002/(SICI)1097-0215(20000115)85:2<151::AID-IJC1>3.0.CO;2-6; WEBBER EM, 1994, AM J PATHOL, V145, P398; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; ZHEN Z, 1994, ONCOGENE, V9, P1691	43	19	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1335	1345		10.1038/sj.onc.1205199	http://dx.doi.org/10.1038/sj.onc.1205199			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857077				2022-12-25	WOS:000173861000004
J	Gao, YN; Lu, YJ; Xue, SA; Chen, HL; Wedderburn, N; Griffin, BE				Gao, YN; Lu, YJ; Xue, SA; Chen, HL; Wedderburn, N; Griffin, BE			Hypothesis: a novel route for immortalization of epithelial cells by Epstein-Barr virus	ONCOGENE			English	Article						'hit and run'; gene amplification; telomeres; chromosomal instability; double minute chromosomes (DMs)	DOUBLE-MINUTE CHROMOSOMES; HUMAN B-LYMPHOCYTES; NASOPHARYNGEAL CARCINOMA; RUN ONCOGENESIS; COMMON MARMOSET; GENE-EXPRESSION; KILOBASE PAIRS; SIMPLEX VIRUS; DNA-SEQUENCE; BAMHI-A	Transfection of primate tissue explants with a specific sub-fragment (p31) of EBV DNA results in epithelial (but no other) cells proliferating indefinitely (becoming 'immortalized') without evidence of a 'growth crisis'. Molecular evidence supports integration of viral information into the host chromosome, and an early genotypic alteration involving specific amplification of a subcomponent (IR1) of p31 DNA, followed by apparent loss of viral DNA from chromosomes, consistent with a 'hit and run' mechanism. However, analysis at the individual cell level during long-term culture, by FISH techniques, reveals chromosomal alferations, and viral sequences surviving within double minute (DM) bodies. Changing growth patterns occurring at different stages during propagation (>a year in culture) may be explained by sporadic reintegration of surviving viral DNA into the host chromosome. Notably, throughout culture, telomere lengths in chromosomal DNAs do not alter but rather retain the length observed in the primary cell populations. Introduction of a growth stimulating function of EBV, BARF1, into the immortalized, nonclonable epithelial cells under conditions which permit overexpression, allows clonal populations to be derived. Based on the data, mechanisms of immortalization, in the absence of a proven viral oncogene in p31 DNA, and possible genes involved, are considered.	Univ London Imperial Coll Sci Technol & Med, Dept Med, Viral Oncol Unit, London W2 1PG, England; Inst Canc Res, Sect Cell Biol & Expt Pathol, Sutton SM2 5NG, Surrey, England; Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	Imperial College London; University of London; Institute of Cancer Research - UK; University of Hong Kong	Griffin, BE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Med, Viral Oncol Unit, Norfolk Pl, London W2 1PG, England.	b.griffin@ic.ac.uk	Xue, Shao-An/A-2735-2011; Chen, Honglin/C-4224-2009	Chen, Honglin/0000-0001-5108-8338; Lu, Yong-Jie/0000-0001-6174-6621				Ambinder RF, 2000, AM J PATHOL, V156, P1, DOI 10.1016/S0002-9440(10)64697-4; Antunes SG, 1998, P NATL ACAD SCI USA, V95, P11745, DOI 10.1073/pnas.95.20.11745; ARRAND JR, 1981, NUCLEIC ACIDS RES, V9, P2999, DOI 10.1093/nar/9.13.2999; ARRAND JR, 1983, EMBO J, V2, P1673, DOI 10.1002/j.1460-2075.1983.tb01642.x; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAR AI, 1992, GENE CHROMOSOME CANC, V4, P314; BAUER G, 1992, INT J CANCER, V51, P754, DOI 10.1002/ijc.2910510515; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Brink AATP, 1998, J CLIN MICROBIOL, V36, P3164, DOI 10.1128/JCM.36.11.3164-3169.1998; BROERS JLV, 1986, J CELL SCI, V83, P37; CHEN HL, 1992, VIROLOGY, V191, P193, DOI 10.1016/0042-6822(92)90181-N; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Cox C, 1996, J GEN VIROL, V77, P1173, DOI 10.1099/0022-1317-77-6-1173; Delecluse HJ, 1997, J PATHOL, V182, P475; EIJWUNMI AB, 1987, THESIS U OXFORD UK; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; Farrell PJ, 1997, J GEN VIROL, V78, P1417, DOI 10.1099/0022-1317-78-6-1417; FRESHNEY RI, 1983, CULTURE ANIMAL CELLS; FRESHNEY RI, 1996, CULTURE IMMORTALIZED; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURUYA T, 1993, CANCER GENET CYTOGEN, V70, P132, DOI 10.1016/0165-4608(93)90183-M; GALLOWAY DA, 1983, NATURE, V302, P21, DOI 10.1038/302021a0; GALLOWAY DA, 1990, J MED VIROL, V31, P36, DOI 10.1002/jmv.1890310108; GELB L, 1984, J INVEST DERMATOL, V83, pS77, DOI 10.1111/1523-1747.ep12281388; GRIFFIN BE, 1984, NATURE, V309, P78, DOI 10.1038/309078a0; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; Harris A., 1996, EPITHELIAL CELL CULT; Hayes DP, 1999, J CLIN PATHOL-MOL PA, V52, P97, DOI 10.1136/mp.52.2.97; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; IWASAKA T, 1992, ACTA OBSTET GYN SCAN, V71, P219, DOI 10.3109/00016349209009922; JOX A, 1997, AM J PATHOL, V151, P1387; KARRAN L, 1990, INT J CANCER, V45, P763, DOI 10.1002/ijc.2910450432; KEMPKES B, 1995, J VIROL, V69, P231, DOI 10.1128/JVI.69.1.231-238.1995; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LIN CT, 1993, LAB INVEST, V68, P716; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; NIELSEN JL, 1993, CANCER GENET CYTOGEN, V65, P120, DOI 10.1016/0165-4608(93)90219-C; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; Rao PH, 1998, CANCER GENET CYTOGEN, V105, P160, DOI 10.1016/S0165-4608(98)00013-2; ROBERTSON E, 1995, J VIROL, V69, P983, DOI 10.1128/JVI.69.2.983-993.1995; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; Sambrook J., 1989, MOL CLONING LABORATO, V2, P916; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Shen YQ, 1997, P NATL ACAD SCI USA, V94, P3341, DOI 10.1073/pnas.94.7.3341; SKINNER GRB, 1976, BRIT J EXP PATHOL, V57, P361; SMITH KT, 1988, VIROLOGY, V164, P39, DOI 10.1016/0042-6822(88)90617-4; SMITH KT, 1993, ONCOGENE, V8, P151; Smith PR, 2000, J VIROL, V74, P3082, DOI 10.1128/JVI.74.7.3082-3092.2000; SMITH PR, 1993, J VIROL, V67, P3217, DOI 10.1128/JVI.67.6.3217-3225.1993; Srinivas SK, 1998, J INFECT DIS, V177, P1705, DOI 10.1086/517427; Steinberg Mark L., 1996, P95; Strockbine LD, 1998, J VIROL, V72, P4015, DOI 10.1128/JVI.72.5.4015-4021.1998; TRASK BJ, 1991, METHOD CELL BIOL, V35, P3; VANDERBLIEK AM, 1988, NUCLEIC ACIDS RES, V16, P4841, DOI 10.1093/nar/16.11.4841; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; Wei MX, 1997, ONCOGENE, V14, P3073, DOI 10.1038/sj.onc.1201128; WEI MX, 1994, CANCER RES, V54, P1843; WOLF J, 1995, VIROLOGY, V212, P179, DOI 10.1006/viro.1995.1466; Xue SA, 2000, J VIROL, V74, P2793, DOI 10.1128/JVI.74.6.2793-2803.2000; YAO K, 1990, INT J CANCER, V45, P83, DOI 10.1002/ijc.2910450116; ZHANG CX, 1988, J VIROL, V62, P1862, DOI 10.1128/JVI.62.6.1862-1869.1988; Zhang JX, 1998, J MED VIROL, V55, P227, DOI 10.1002/(SICI)1096-9071(199807)55:3<227::AID-JMV8>3.0.CO;2-3	68	21	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					825	835		10.1038/sj.onc.1205130	http://dx.doi.org/10.1038/sj.onc.1205130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850810				2022-12-25	WOS:000173427000013
J	Masaike, T; Muneyuki, E; Noji, H; Kinosita, K; Yoshida, M				Masaike, T; Muneyuki, E; Noji, H; Kinosita, K; Yoshida, M			F-1-ATPase changes its conformations upon phosphate release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN MOTOR DOMAIN; ESCHERICHIA-COLI F1-ATPASE; THERMOPHILIC BACILLUS PS3; 2 BETA-SUBUNITS; ALPHA(3)BETA(3)GAMMA COMPLEX; CATALYTIC SITES; CRYSTAL-STRUCTURE; MOLECULAR MOTOR; ATP HYDROLYSIS; CLOSED CONFORMATION	Motor proteins, myosin, and kinesin have gamma-phosphate sensors in the switch H loop that play key roles in conformational changes that support motility. Here we report that a rotary motor, F-1-ATPase, also changes its conformations upon phosphate release. The tryptophan mutation was introduced into Arg-333 in the beta subunit of F-1-ATPase from thermophilic Bacillus PS3 as a probe of conformational changes. This residue interacts with the switch II loop (residues 308-315) of the beta subunit in a nucleotide-bound conformation. The addition of ATP to the mutant F-1 subcomplex alpha(3)beta(R333W)(3)gamma caused transient increase and subsequent decay of the Trp fluorescence. The increase was caused by conformational changes on ATP binding. The rate of decay agreed well with that of phosphate release monitored by phosphate-binding protein assays. This is the first evidence that the beta subunit changes its conformation upon phosphate release, which may share a common mechanism of exerting motility with other motor proteins.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi 3320012, Japan; Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538505, Japan; Okazaki Natl Res Inst, Ctr Integrat Biosci, Aichi 4448585, Japan; Teikyo Univ, Biotechnol Ctr 3F, CREST, Genet Programming Team 13,Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan; Japan Sci & Technol Corp, ERATO, Kawaguchi 3320012, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST); University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Japan Science & Technology Agency (JST); Teikyo University; Japan Science & Technology Agency (JST)	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp		Masaike, Tomoko/0000-0003-3290-1893				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BOYER PD, 1981, ENERGY COUPLING PHOT, P407; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNNING J, 1994, PERSPEKT ANALYT PHIL, V1, P33; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Milgrom YM, 1998, BIOCHEM J, V330, P1037; Milgrom YM, 1997, J BIOL CHEM, V272, P32211, DOI 10.1074/jbc.272.51.32211; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; ODAKA M, 1994, J BIOCHEM-TOKYO, V115, P789, DOI 10.1093/oxfordjournals.jbchem.a124410; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ren H, 1999, J BIOL CHEM, V274, P31366, DOI 10.1074/jbc.274.44.31366; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; TOZAWA K, 1995, FEBS LETT, V376, P190, DOI 10.1016/0014-5793(95)01276-2; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; TURINA P, 1994, J BIOL CHEM, V269, P13465; TURINA P, 1994, BIOCHEMISTRY-US, V33, P14275, DOI 10.1021/bi00251a040; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Weber J, 1998, BIOCHEMISTRY-US, V37, P12042, DOI 10.1021/bi981089c; Yagi H, 1999, BIOPHYS J, V77, P2175, DOI 10.1016/S0006-3495(99)77057-8; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480	43	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21643	21649		10.1074/jbc.M110297200	http://dx.doi.org/10.1074/jbc.M110297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11880367	hybrid			2022-12-25	WOS:000176286000071
J	Segawa, H; Kaneko, I; Takahashi, A; Kuwahata, M; Ito, M; Ohkido, I; Tatsumi, S; Miyamoto, K				Segawa, H; Kaneko, I; Takahashi, A; Kuwahata, M; Ito, M; Ohkido, I; Tatsumi, S; Miyamoto, K			Growth-related renal type IINa/P-i cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHATE COTRANSPORTER; BORDER MEMBRANE-VESICLES; AMINO-ACID TRANSPORTER; RAT-KIDNEY; IDENTIFICATION; EXPRESSION; NAPI-2; REABSORPTION; ONTOGENY; OOCYTES	Growth is critically dependent on the retention of a variety of nutrients. The kidney contributes to this positive external balance. In the present study, we isolated a cDNA from the human and rat kidney that encodes a growth-related Na+-dependent inorganic phosphate (P-i) cotransporter (type IIc). Microinjection of type IIc cRNA into Xenopus oocytes demonstrated sodium-dependent P-i cotransport activity. Affinity for P-i was 0.07 mm in 100 mm Na+. The transport activity was dependent on extracellular pH. In electrophysiological studies, type IIc Na/P-i cotransport was electroneutral, whereas type IIa was highly electrogenic. In Northern blotting analysis, the type IIc transcript was only expressed in the kidney and highly in weaning animals. In immunohistochemical analysis, the type IIc protein was shown to be localized at the apical membrane of the proximal tubular cells in superficial and midcortical nephrons of weaning rat kidney. Hybrid depletion experiments suggested that type IIc could function as a Na/P-i cotransporter in weaning animals, but its role is reduced in adults. The finding of the present study suggest that the type IIc is a growth-related renal Na/P-i cotransporter, which has a high affinity for P-i and is electroneutral.	Univ Tokushima, Sch Med, Dept Nutr, Tokushima 7708503, Japan	Tokushima University	Miyamoto, K (corresponding author), Univ Tokushima, Sch Med, Dept Nutr, Kuramoto Cho 3, Tokushima 7708503, Japan.			Tatsumi, Sawako/0000-0002-4862-2955				Arar M, 1999, AM J PHYSIOL-RENAL, V276, pF72, DOI 10.1152/ajprenal.1999.276.1.F72; BARACNIETO M, 1991, AM J PHYSIOL, V261, pF153, DOI 10.1152/ajprenal.1991.261.1.F153; Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372; BUSCH A, 1994, P NATL ACAD SCI USA, V91, P8205, DOI 10.1073/pnas.91.17.8205; CAVERZASIO J, 1982, PFLUG ARCH EUR J PHY, V394, P217, DOI 10.1007/BF00589094; Chairoungdua A, 1999, J BIOL CHEM, V274, P28845, DOI 10.1074/jbc.274.41.28845; CHENG L, 1981, J BIOL CHEM, V256, P1556; Field J.A., 1999, BIOCHEM BIOPH RES CO, V258, P578; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; FORSTER I, 1991, J GEN PHYSIOL, V261, pF663; Hoag HM, 1999, J CLIN INVEST, V104, P679, DOI 10.1172/JCI7103; HOFFMANN N, 1976, PFLUG ARCH EUR J PHY, V362, P147, DOI 10.1007/BF00583641; Katai K, 1997, J BIOCHEM-TOKYO, V121, P50, DOI 10.1093/oxfordjournals.jbchem.a021569; LUCKEY TD, 1954, J NUTR, V54, P345; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MIYAMOTO KI, 1995, BIOCHEM J, V305, P81, DOI 10.1042/bj3050081; MUER H, 2000, PHYSIOL REV, V80, P1373; NEIBERGER RE, 1989, AM J PHYSIOL, V257, pF268, DOI 10.1152/ajprenal.1989.257.2.F268; OHARA B, 1990, CELL GROWTH DIFFER, V1, P119; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Silverstein D, 1996, KIDNEY INT, V49, P1023, DOI 10.1038/ki.1996.148; Silverstein DM, 1997, AM J PHYSIOL-REG I, V273, pR928, DOI 10.1152/ajpregu.1997.273.3.R928; Sorribas V, 1996, KIDNEY INT, V50, P855, DOI 10.1038/ki.1996.385; Spitzer A, 2001, PEDIATR NEPHROL, V16, P763, DOI 10.1007/s004670100629; Tatsumi S, 1998, J BIOL CHEM, V273, P28568, DOI 10.1074/jbc.273.44.28568; TAUFIQ A, 1997, AM J PHYSIOL, V272, pR134; Traebert M, 1999, J AM SOC NEPHROL, V10, P1407	28	219	247	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19665	19672		10.1074/jbc.M200943200	http://dx.doi.org/10.1074/jbc.M200943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11880379	hybrid			2022-12-25	WOS:000175894800057
J	Tydell, CC; Yount, N; Tran, D; Yuan, J; Selsted, ME				Tydell, CC; Yount, N; Tran, D; Yuan, J; Selsted, ME			Isolation, characterization, and antimicrobial properties of bovine oligosaccharide-binding protein - A microbicidal granule protein of eosinophils and neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDOGLYCAN RECOGNITION PROTEIN; PERMEABILITY-INCREASING PROTEIN; INNATE IMMUNE-SYSTEM; CUTICULAR PROTEIN; REACTIVE OXYGEN; CLEAVAGE SITES; BETA-DEFENSINS; BOMBYX-MORI; ACTIVATION; ENDOTOXIN	Peptidoglycan recognition proteins (PGRPs) constitute a recently characterized family of pattern-recognition molecules that are conserved from insects to humans and are implicated in mammalian innate immunity. Here we report the isolation, characterization, cDNA cloning, and antimicrobial activities of a bovine PGRP ortholog termed bovine oligosaccharide-binding protein (bOBP). Milligram quantities of bOBP were purified from peripheral leukocytes, thus allowing for the characterization of the disulfide array and for determining the in vitro antimicrobial activities of the native protein. Of the tissues analyzed, bOBP mRNA was detected only in bone marrow where the protein is synthesized as a 190 amino acid precursor. The mature 169 amino acid protein is stored in the cytoplasmic granules of neutrophils and eosinophils but is absent from lymphocytes, monocytes, and platelets. bOBP was microbicidal for Gram-positive and Gram-negative bacteria and yeast at low micromolar concentrations. The finding that bOBP was microbicidal for organisms in which peptidoglycan is absent (Cryptococcus neoformans) or buried (Salmonella typhimurium) indicates that previous conclusions about the specificity of peptidoglycan recognition proteins must be reevaluated and suggests that other envelope components may mediate the antimicrobial action of PGRP family members.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Selsted, ME (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.			Yount, Nannette/0000-0002-7079-5211	NIAID NIH HHS [AI22931] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022931, R01AI022931] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; AMREIN PC, 1980, BLOOD, V56, P442; BARANY G, 1992, INNOVATION PERSPECTI, P29; Beamer LJ, 1999, BIOCHEM PHARMACOL, V57, P225, DOI 10.1016/S0006-2952(98)00279-2; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P64, DOI 10.1016/S0952-7915(99)00052-7; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; Calafat J, 2000, APMIS, V108, P201, DOI 10.1034/j.1600-0463.2000.d01-45.x; Calafat J, 1998, BLOOD, V91, P4770, DOI 10.1182/blood.V91.12.4770.412k33_4770_4775; CHONCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; JACOBSON G, 1990, ELECTROPHORESIS, V11, P46, DOI 10.1002/elps.1150110111; Kaisho T, 2001, TRENDS IMMUNOL, V22, P78, DOI 10.1016/S1471-4906(00)01811-1; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Marcu O, 1998, INSECT BIOCHEM MOLEC, V28, P659, DOI 10.1016/S0965-1748(98)00048-4; Marcu O, 1999, J INSECT PHYSIOL, V45, P861, DOI 10.1016/S0022-1910(99)00070-0; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; VANABEL RJ, 1995, INT J PEPT PROT RES, V45, P401; VONDERMOHLEN MAM, 1995, J INFECT DIS, V172, P144, DOI 10.1093/infdis/172.1.144; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WEISS J, 1978, J BIOL CHEM, V253, P1664; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; YOUNT NY, 1995, J IMMUNOL, V155, P4476; Yount NY, 1999, J BIOL CHEM, V274, P26249, DOI 10.1074/jbc.274.37.26249	48	107	117	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19658	19664		10.1074/jbc.M200659200	http://dx.doi.org/10.1074/jbc.M200659200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11880375	hybrid			2022-12-25	WOS:000175894800056
J	Mukherjee, S; Gurevich, VV; Preninger, A; Hamm, HE; Bader, MF; Fazleabas, AT; Birnbaumer, L; Hunzicker-Dunn, M				Mukherjee, S; Gurevich, VV; Preninger, A; Hamm, HE; Bader, MF; Fazleabas, AT; Birnbaumer, L; Hunzicker-Dunn, M			Aspartic acid 564 in the third cytoplasmic loop of the luteinizing hormone/choriogonadotropin receptor is crucial for phosphorylation-independent interaction with arrestin2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN FOLLICULAR MEMBRANES; 3RD INTRACELLULAR LOOP; CHORIONIC-GONADOTROPIN RECEPTOR; PROTEIN-COUPLED RECEPTORS; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; AGONIST-INDUCED PHOSPHORYLATION; BETA-ADRENERGIC-RECEPTOR; RIBOSYLATION FACTOR ARF; ADP-RIBOSYLATION; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR	Arrestin2 binding to the active but unphosphorylated luteinizing hormone/choriogonadotropin receptor (LH/CG R) in ovarian follicles is triggered by activation of ADP-ribosylation factor 6 (ARF6) and leads to uncoupling of this receptor from cAMP signaling. We sought to determine how arrestin2 binds to LH/CG It, if binding is of high affinity, and if the receptor also binds arrestin3. Desensitization of intact LH/CG R was equally sensitive to ectopic constructs of arrestin2 that bind other G protein-coupled receptors (GPCRs) either in a phosphorylation-independent or -dependent manner. Intact LH/CG R was not desensitized by ectopic arrestin3 constructs. Surface plasmon resonance studies showed that arrestin2 bound a synthetic third intracellular (3i) LH/CG R loop peptide with picomolar affinity; arrestin3 bound with millimolar affinity. To determine whether Asp-564 in the 3i loop mimicked the phosphorylated residue of other GPCRs, human embryonic kidney (HEK) cells were transfected with wild-type (WT) and D564G LH/CG R, An agonist-stimulated ARF6-dependent arrestin2 undocking pathway to drive desensitization of WT receptor was recapitulated in HEK cell membranes, and ectopic arrestin2 promoted desensitization of WT LH/CG R. However, D564G LH/CG R in HEK cells was not desensitized, and synthetic 3i D564G peptide did not bind arrestin2. Synthetic 3i loop peptides containing D564E, D564V, or D564N also did not bind arrestin2. We conclude that the ARF6-mediated mechanism to release a pool of membrane-delimited arrestin to bind GPCRs may be a widespread mechanism to deliver arrestin to GPCRs for receptor desensitization. Unlike other GPCRs that additionally require receptor phosphorylation, LH/CG R activation is sufficient to expose a conformation in which Asp-564 in the 3i loop confers high affinity binding selectively to arrestin2.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Inst Neurosci, Chicago, IL 60611 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; CNRS, UPR 2356, F-67084 Strasbourg, France; Univ Illinois, Coll Med, Dept Obstet & Gynecol, Chicago, IL 60612 USA; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	Northwestern University; Northwestern University; Northwestern University; Vanderbilt University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.		Bader, Marie-France/O-2098-2016; Gurevich, Vsevolod/A-3236-2008; Hamm, Heidi E/G-2374-2014	Gurevich, Vsevolod/0000-0002-3950-5351; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038060] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY006062, R01EY010291, R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY 10291, EY 06062, R01 EY 11500] Funding Source: Medline; NICHD NIH HHS [R01 HD 38060] Funding Source: Medline; NIGMS NIH HHS [GM 63097] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; BENDER FE, 1982, STAT METHODS FOOD AG; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; EKSTROM RC, 1989, ENDOCRINOLOGY, V125, P2470, DOI 10.1210/endo-125-5-2470; EKSTROM RC, 1989, ENDOCRINOLOGY, V124, P956, DOI 10.1210/endo-124-2-956; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; HIPKIN RW, 1993, MOL ENDOCRINOL, V7, P823, DOI 10.1210/me.7.7.823; HIPKIN RW, 1995, MOL ENDOCRINOL, V9, P151, DOI 10.1210/me.9.2.151; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; Iacovelli L, 1996, MOL ENDOCRINOL, V10, P1138, DOI 10.1210/me.10.9.1138; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KNOSPE V, 1988, CURR EYE RES, V7, P1137, DOI 10.3109/02713688809001885; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kosugi S, 1998, MOL PHARMACOL, V53, P894; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; LAMM MLG, 1994, ENDOCRINOLOGY, V134, P1745, DOI 10.1210/en.134.4.1745; LAMM MLG, 1994, MOL ENDOCRINOL, V8, P1537, DOI 10.1210/me.8.11.1537; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Min L, 2002, J BIOL CHEM, V277, P702, DOI 10.1074/jbc.M106082200; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; Mukherjee S, 1999, P NATL ACAD SCI USA, V96, P493, DOI 10.1073/pnas.96.2.493; Mukherjee S, 2001, J BIOL CHEM, V276, P6524, DOI 10.1074/jbc.C000725200; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Munshi UM, 2001, EUR J BIOCHEM, V268, P1631, DOI 10.1046/j.1432-1033.2001.02032.x; Nakamura K, 2000, J BIOL CHEM, V275, P241, DOI 10.1074/jbc.275.1.241; Nakamura K, 1999, MOL ENDOCRINOL, V13, P1295, DOI 10.1210/me.13.8.1295; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; Rajagopalan-Gupta RM, 1999, ENDOCRINOLOGY, V140, P1612, DOI 10.1210/en.140.4.1612; RajagopalanGupta RM, 1997, MOL ENDOCRINOL, V11, P538, DOI 10.1210/me.11.5.538; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Salvador LM, 2001, J BIOL CHEM, V276, P33773, DOI 10.1074/jbc.M101498200; SANCHEZYAGUE J, 1992, J BIOL CHEM, V267, P7217; Santini F, 2000, J CELL SCI, V113, P2463; Schulz A, 2000, J BIOL CHEM, V275, P37860, DOI 10.1074/jbc.M006709200; Schulz A, 1999, MOL ENDOCRINOL, V13, P181, DOI 10.1210/me.13.2.181; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Troispoux C, 1999, MOL ENDOCRINOL, V13, P1599, DOI 10.1210/me.13.9.1599; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Wang Z, 1997, MOL ENDOCRINOL, V11, P183, DOI 10.1210/me.11.2.183; Wang Z, 1996, MOL ENDOCRINOL, V10, P748, DOI 10.1210/me.10.6.748; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900; ZHU X, 1993, J BIOL CHEM, V268, P1723	73	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17916	17927		10.1074/jbc.M110479200	http://dx.doi.org/10.1074/jbc.M110479200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11867621	hybrid			2022-12-25	WOS:000175685100068
J	Berggard, T; Miron, S; Onnerfjord, P; Thulin, E; Akerfeldt, KS; Enghild, JJ; Akke, M; Linse, S				Berggard, T; Miron, S; Onnerfjord, P; Thulin, E; Akerfeldt, KS; Enghild, JJ; Akke, M; Linse, S			Calbindin D-28k eExhibits properties characteristic of a Ca2+ sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; CONFORMATIONAL-CHANGES; CA2+-BINDING PROTEINS; PARTICULATE FRACTION; BUFFERING PROPERTIES; HIPPOCAMPAL-NEURONS; IN-VITRO; CALRETININ; D28K; PARVALBUMIN	Calbindin D-28k is a member of the calmodulin superfamily of Ca2+-binding proteins and contains six EF-hands. The protein is generally believed to function as a Ca2+ buffer, but the studies presented in this work indicate that it may also act as a Ca2+ sensor. The results show that Mg2+ binds to the same sites as Ca2+ with an association constant of similar to1.4.10(3) M-1 in 0.15 M KCl. The four high affinity sites in calbindin D-28k bind Ca2+ in a non-sequential, parallel manner. In the presence of physiological concentrations of Mg2+ the Ca2+ affinity is reduced by a factor of 2, and the cooperativity, which otherwise is modest, increases. Based on the binding constants determined in the presence of physiological salt concentrations, we estimate that at the Ca2+ concentration in a resting cell calbindin D-28k is saturated to 40-75% with Mg2+ but to less than 9% with Ca2+. In contrast, the protein is expected to be nearly fully saturated with Ca2+ at the Ca2+ level of an activated cell. A substantial conformational change is observed upon Ca2+ binding, but only minor structural changes take place upon Mg2+ binding. This suggests that calbindin D-28k undergoes Ca2+-induced structural changes upon Ca2+ activation of a cell. Thus, calbindin D-28k displays several properties that would be expected for a protein involved in Ca2+-induced signal transmission and hence may function not only as a Ca2+ buffer but also as a Ca2+ sensor. Digestion patterns resulting from limited proteolysis of the protein suggest that the loop of EF-hand 2, a variant site that does not bind Ca2+, becomes exposed upon Ca2+ binding.	Lund Univ, Dept Biophys Chem, SE-22100 Lund, Sweden; Haverford Coll, Dept Chem, Haverford, PA 19041 USA; Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus, Denmark; Lund Univ, BMC, Sect Connect Tissue Biol, SE-22184 Lund, Sweden	Lund University; Haverford College; Aarhus University; Lund University	Berggard, T (corresponding author), Lund Univ, Dept Biophys Chem, SE-22100 Lund, Sweden.		Onnerfjord, Patrik/R-3131-2019; Miron, Simona/M-9223-2018	Onnerfjord, Patrik/0000-0002-2345-2937; Akke, Mikael/0000-0002-2395-825X; Enghild, Jan Johannes/0000-0001-9292-9172; Linse, Sara/0000-0001-9629-7109				Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; Akerfeldt KS, 1996, BIOCHEMISTRY-US, V35, P3662, DOI 10.1021/bi9527956; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Andersson M, 1997, PROTEIN SCI, V6, P1139, DOI 10.1002/pro.5560060602; Berggard T, 2000, BIOCHEMISTRY-US, V39, P6864, DOI 10.1021/bi992394g; Berggard T, 2000, PROTEIN SCI, V9, P2094, DOI 10.1110/ps.9.11.2094; CHARD PS, 1995, P NATL ACAD SCI USA, V92, P5144, DOI 10.1073/pnas.92.11.5144; CHARD PS, 1993, J PHYSIOL-LONDON, V472, P341, DOI 10.1113/jphysiol.1993.sp019950; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; GROSS MD, 1993, J BIOL CHEM, V268, P20917; GROSS MD, 1987, J BIOL CHEM, V262, P6539; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; HUBBARD MJ, 1995, FEBS LETT, V374, P333, DOI 10.1016/0014-5793(95)01135-2; HUBBARD MJ, 1995, EUR J BIOCHEM, V230, P68, DOI 10.1111/j.1432-1033.1995.0068i.x; IACOPINO AM, 1990, P NATL ACAD SCI USA, V87, P4078, DOI 10.1073/pnas.87.11.4078; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Kawatsuki N, 1998, RRD POLYM SCI, V2, P277; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Klapstein GJ, 1998, NEUROSCIENCE, V85, P361, DOI 10.1016/S0306-4522(97)00632-5; KLOTZ IM, 1979, ARCH BIOCHEM BIOPHYS, V193, P314, DOI 10.1016/0003-9861(79)90036-5; KUZNICKI J, 1995, BIOCHEM J, V308, P607; LaBella V, 1996, BIOCHEM MOL BIOL INT, V38, P1199; LI ZH, 1995, J PHYSIOL-LONDON, V488, P601, DOI 10.1113/jphysiol.1995.sp020993; Linse S, 1997, PROTEIN SCI, V6, P2385; LINSE S, 1993, PROTEIN SCI, V2, P985, DOI 10.1002/pro.5560020612; LINSE S, 1987, BIOCHEMISTRY-US, V26, P6723, DOI 10.1021/bi00395a023; LINSE S, 1991, J BIOL CHEM, V266, P8050; LINSE S, 1990, BIOCHEMISTRY-US, V29, P5925, DOI 10.1021/bi00477a007; LUKAS W, 1994, NEUROSCIENCE, V61, P307, DOI 10.1016/0306-4522(94)90233-X; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; MORGAN DW, 1986, BIOCHEM BIOPH RES CO, V138, P547, DOI 10.1016/S0006-291X(86)80531-9; NORMAN AW, 1982, BIOCHEM BIOPH RES CO, V108, P220, DOI 10.1016/0006-291X(82)91854-X; OBERHOLTZER JC, 1988, P NATL ACAD SCI USA, V85, P3387, DOI 10.1073/pnas.85.10.3387; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Pauls TL, 1996, BBA-GENE STRUCT EXPR, V1306, P39, DOI 10.1016/0167-4781(95)00221-9; REISNER PD, 1992, FEBS LETT, V297, P127, DOI 10.1016/0014-5793(92)80342-E; Sayer RJ, 2000, CELL TISSUE RES, V302, P171, DOI 10.1007/s004410000285; Schwaller B, 1997, J BIOL CHEM, V272, P29663, DOI 10.1074/jbc.272.47.29663; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Thulin E, 1999, PROTEIN EXPRES PURIF, V15, P265, DOI 10.1006/prep.1999.1028; WINSKY L, 1995, J NEUROCHEM, V65, P381; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313	46	102	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16662	16672		10.1074/jbc.M200415200	http://dx.doi.org/10.1074/jbc.M200415200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872749	hybrid			2022-12-25	WOS:000175564500044
J	Deucher, A; Efimova, T; Eckert, RL				Deucher, A; Efimova, T; Eckert, RL			Calcium-dependent involucrin expression is inversely regulated by protein kinase C (PKC)alpha and PKC delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; SIGNAL-TRANSDUCTION PATHWAY; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; INDUCED-DIFFERENTIATION; MOUSE KERATINOCYTES; PROMOTER ACTIVITY; GENE-EXPRESSION; PHORBOL ESTER; TERMINAL DIFFERENTIATION	Calcium is an important physiologic regulator of keratinocyte function that may regulate keratinocyte differentiation via modulation of protein kinase C (PKC) activity. PKCalpha and PKCdelta are two PKC isoforms that are expressed at high levels in keratinocytes. In the present study, we examine the effect of PKCdelta and PKCalpha on calcium-dependent keratinocyte differentiation as measured by effects on involucrin (hINV) gene expression. Our studies indicate that calcium increases hINV promoter activity and endogenous hINV gene expression. This response requires PKCdelta, as evidenced by the observation that treatment with dominant-negative PKCdelta inhibits calcium-dependent hINV promoter activity, whereas wild type PKCdelta increases activity. PKCalpha, in contrast, inhibits calcium-dependent hINV promoter activation, a finding that is consistent with the ability of dominant-negative PKCalpha and the PKCalpha inhibitor, Go6976, to increase hINV gene expression. The calcium-dependent regulatory response is mediated by an AP1 transcription factor-binding site located within the hINV promoter distal regulatory region that is also required for PKCdelta-dependent regulation; moreover, both calcium and PKCdelta produce similar, but not identical, changes in AP1 factor expression. A key question is whether calcium directly influences PKC isoform function. Our studies show that calcium does not regulate PKCalpha or delta levels or cause a marked redistribution to membranes. However, tyrosine phosphorylation of PKCdelta is markedly increased following calcium treatment. These findings suggest that PKCalpha and PKCdelta are required for, and modulate, calcium-dependent keratinocyte differentiation in opposing directions.	Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.			Efimova, Tatiana/0000-0002-9869-1545				Ahn SK, 1999, J INVEST DERMATOL, V113, P189, DOI 10.1046/j.1523-1747.1999.00650.x; Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; BANKS EB, 1998, BIOCHEM J, V331, pS1; Bollag WB, 2001, MOL CELL ENDOCRINOL, V177, P173, DOI 10.1016/S0303-7207(01)00440-3; CHAKRAVARTHY BR, 1995, J BIOL CHEM, V270, P1362, DOI 10.1074/jbc.270.3.1362; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; Dashti SR, 2001, J BIOL CHEM, V276, P27214, DOI 10.1074/jbc.M100465200; Denning MF, 2000, EXP DERMATOL, V9, P192, DOI 10.1034/j.1600-0625.2000.009003192.x; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Deszo EL, 2001, J BIOL CHEM, V276, P10212, DOI 10.1074/jbc.M010589200; Dietrich C, 2001, BIOCHEM BIOPH RES CO, V282, P575, DOI 10.1006/bbrc.2001.4530; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; FYNAN TM, 1994, CELL GROWTH DIFFER, V5, P1293; Gniadecki R, 1998, ACTA DERM-VENEREOL, V78, P164; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Johansen C, 2000, J INVEST DERMATOL, V114, P1174, DOI 10.1046/j.1523-1747.2000.00003.x; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kashiwagi M, 2000, ONCOGENE, V19, P6334, DOI 10.1038/sj.onc.1204028; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; Lee YS, 1998, J INVEST DERMATOL, V111, P762, DOI 10.1046/j.1523-1747.1998.00365.x; Lee YS, 1997, MOL CARCINOGEN, V18, P44, DOI 10.1002/(SICI)1098-2744(199701)18:1<44::AID-MC6>3.0.CO;2-R; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI LW, 1995, CELL GROWTH DIFFER, V6, P1171; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; LI WQ, 1994, J BIOL CHEM, V269, P2349; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MATSUI MS, 1992, J INVEST DERMATOL, V99, P565, DOI 10.1111/1523-1747.ep12667411; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Mitev V, 1999, EXP DERMATOL, V8, P96, DOI 10.1111/j.1600-0625.1999.tb00355.x; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; Murakami A, 1996, J INVEST DERMATOL, V106, P790, DOI 10.1111/1523-1747.ep12346391; Neuzil J, 2001, FASEB J, V15, P403, DOI 10.1096/fj.00-0251com; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ng DC, 2000, J BIOL CHEM, V275, P24080, DOI 10.1074/jbc.M002508200; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Noe V, 2001, EUR J BIOCHEM, V268, P3163, DOI 10.1046/j.1432-1327.2001.02198.x; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; Osada K, 1997, J INVEST DERMATOL, V108, P482, DOI 10.1111/1523-1747.ep12289726; PUNNONEN K, 1993, J INVEST DERMATOL, V101, P719, DOI 10.1111/1523-1747.ep12371682; REYNOLDS NJ, 1994, J INVEST DERMATOL, V103, P364, DOI 10.1111/1523-1747.ep12394957; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; RUBIN AL, 1988, IN VITRO CELL DEV B, V24, P857; Rutberg SE, 1996, ONCOGENE, V13, P167; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shen S, 2001, DIABETES, V50, P255, DOI 10.2337/diabetes.50.2.255; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Stanwell C, 1996, J INVEST DERMATOL, V106, P482, DOI 10.1111/1523-1747.ep12343690; Takahashi H, 1998, J INVEST DERMATOL, V110, P218, DOI 10.1046/j.1523-1747.1998.00110.x; Tu CL, 1999, J INVEST DERMATOL, V113, P340, DOI 10.1046/j.1523-1747.1999.00698.x; Tu CL, 2001, J BIOL CHEM, V276, P41079, DOI 10.1074/jbc.M107122200; Ueda E, 1996, J BIOL CHEM, V271, P9790, DOI 10.1074/jbc.271.16.9790; Vicanova J, 1998, J INVEST DERMATOL, V111, P97, DOI 10.1046/j.1523-1747.1998.00251.x; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; Wang HQ, 2001, MOL PHARMACOL, V59, P860, DOI 10.1124/mol.59.4.860; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; WHITFIELD JF, 1995, J CELL BIOCHEM, P74; Xie ZJ, 1999, J BIOL CHEM, V274, P20421, DOI 10.1074/jbc.274.29.20421; YAAR M, 1993, EXP CELL RES, V206, P235, DOI 10.1006/excr.1993.1143; YAFFE MB, 1992, J BIOL CHEM, V267, P12233; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967	84	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17032	17040		10.1074/jbc.M109076200	http://dx.doi.org/10.1074/jbc.M109076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864971	hybrid			2022-12-25	WOS:000175564500092
J	Hinks, JA; Evans, MCW; de Miguel, Y; Sartori, AA; Jiricny, J; Pearl, LH				Hinks, JA; Evans, MCW; de Miguel, Y; Sartori, AA; Jiricny, J; Pearl, LH			An iron-sulfur cluster in the Family 4 uracil-DNA glycosylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL-DNA GLYCOSYLASE; ARCHAEON PYROBACULUM-AEROPHILUM; ENZYME ENDONUCLEASE-III; CRYSTAL-STRUCTURE; RECOGNITION; PROTEIN; MUTY; REPLICATION; SUPERFAMILY; ACONITASE	The 25-kDa Family 4 uracil-DNA glycosylase (UDG) from Pyrobaculum aerophilum has been expressed and purified in large quantities for structural analysis. In the process we observed it to be colored and subsequently found that it contained iron. Here we demonstrate that 1 aerophilum UDG has an iron-sulfur center with the EPR characteristics typical of a 4Fe4S high potential iron protein. Interestingly, it does not share any sequence similarity with the classic iron-sulfur proteins, although four cysteines (which are strongly conserved in the thermophilic members of Family 4 UDGs) may represent the metal coordinating residues. The conservation of these residues in other members of the family suggest that 4Fe4S clusters are a common feature. Although 4Fe4S clusters have been observed previously in Nth/MutY DNA repair enzymes, this is the first observation of such a feature in the UDG structural superfamily. Similar to the Nth/MutY enzymes, the Family 4 UDG centers probably play a structural rather than a catalytic role.	Inst Canc Res, Sect Struct Biol, Canc Res UK DNA Repair Enzyme Grp, London SW3 6JB, England; UCL, Dept Biol, London WC1E 6BT, England; Kings Coll London, Dept Chem, London WC2R 2LS, England; Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; University College London; University of London; King's College London; University of Zurich	Pearl, LH (corresponding author), Inst Canc Res, Sect Struct Biol, Canc Res UK DNA Repair Enzyme Grp, 237 Fulham Rd, London SW3 6JB, England.	l.pearl@icr.ac.uk	Sartori, Alessandro/AAK-7840-2021; de Miguel, Dr. Yolanda R./A-5526-2016	Sartori, Alessandro/0000-0003-2770-0333; Pearl, Laurence/0000-0002-6910-1809; de Miguel, Dr. Yolanda R./0000-0001-8650-5875				Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; FitzGibbon S, 1997, EXTREMOPHILES, V1, P36, DOI 10.1007/s007920050013; FOCHER F, 1992, CHROMOSOMA, V102, pS67, DOI 10.1007/BF02451788; FU WG, 1992, J BIOL CHEM, V267, P16135; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Golinelli MP, 1999, BIOCHEMISTRY-US, V38, P6997, DOI 10.1021/bi982300n; Jacobs KL, 1997, J BACTERIOL, V179, P3298, DOI 10.1128/jb.179.10.3298-3303.1997; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Koulis A, 1996, FEMS MICROBIOL LETT, V143, P267; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; Porello SL, 1998, BIOCHEMISTRY-US, V37, P6465, DOI 10.1021/bi972433t; Sandigursky M, 1999, CURR BIOL, V9, P531, DOI 10.1016/S0960-9822(99)80237-1; Sandigursky M, 2000, J BIOL CHEM, V275, P19146, DOI 10.1074/jbc.M001995200; Sartori AA, 2001, J BIOL CHEM, V276, P29979, DOI 10.1074/jbc.M102985200; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TYE BK, 1978, P NATL ACAD SCI USA, V75, P233, DOI 10.1073/pnas.75.1.233; VOLKL P, 1993, APPL ENVIRON MICROB, V59, P2918; Yang HJ, 2000, J BACTERIOL, V182, P1272, DOI 10.1128/JB.182.5.1272-1279.2000	27	59	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16936	16940		10.1074/jbc.M200668200	http://dx.doi.org/10.1074/jbc.M200668200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877410	hybrid, Green Accepted			2022-12-25	WOS:000175564500080
J	Ilias, A; Urban, Z; Seidl, TL; Le Saux, O; Sinko, E; Boyd, CD; Sarkadi, B; Varadi, A				Ilias, A; Urban, Z; Seidl, TL; Le Saux, O; Sinko, E; Boyd, CD; Sarkadi, B; Varadi, A			Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; CYSTIC-FIBROSIS GENE; INSECT CELLS; SULFONYLUREA RECEPTOR; CRYSTAL-STRUCTURE; DRUG-RESISTANCE; P-GLYCOPROTEIN; MUTATIONS; BINDING; NUCLEOTIDE	Mutations in the ABCC6 (MRP6) gene cause pseudoxanthoma elasticum (PXE), a rare heritable disorder resulting in the calcification of elastic fibers. In the present study a cDNA encoding a full-length normal variant of ABCC6 was amplified from a human kidney cDNA library, and the protein was expressed in Sf9 insect cells. In isolated membranes ATP binding as well as ATP-dependent active transport by ABCC6 was demonstrated. We found that glutathione conjugates, including leukotriene C-4 and N-ethylmaleimide S-glutathione (NEM-GS), were actively transported by human ABCC6. Organic anions (probenecid, benzbromarone, indomethacin), known to interfere with glutathione conjugate transport of human ABCC1 and ABCC2, inhibited the ABCC6-mediated NEM-GS transport in a specific manner, indicating that ABCC6 has a unique substrate specificity. We have also expressed three missense mutant forms of ABCC6, which have recently been shown to cause PXE. MgATP binding was normal in these proteins; ATP-dependent NEM-GS or leukotriene C-4 transport, however, was abolished. Our data indicate that human ABCC6 is a primary active transporter for organic anions. In the three ABCC6 mutant forms examined, the loss of transport activity suggests that these mutations result in a PXE phenotype through a direct influence on the transport activity of this ABC transporter.	Hungarian Acad Sci, Inst Enzymol, H-1113 Budapest, Hungary; Univ Hawaii, Pacific Biomed Res Ctr, Lab Matrix Pathobiol, Honolulu, HI 96822 USA; Hungarian Acad Sci, Res Grp, Inst Haematol & Immunol, Natl Med Ctr, H-1113 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; University of Hawaii System; Hungarian Academy of Sciences	Varadi, A (corresponding author), Hungarian Acad Sci, Inst Enzymol, Karolina Ut 29, H-1113 Budapest, Hungary.		Le Saux, Olivier/P-4668-2017; Varadi, Andras/A-2055-2012; Sarkadi, Balazs/I-5024-2013; Urban, Zsolt/B-1977-2008; Iliás, Attila/I-7072-2017; Urban, Zsolt/A-2018-2013	Le Saux, Olivier/0000-0002-5605-3617; Iliás, Attila/0000-0003-3196-0795; Urban, Zsolt/0000-0003-3890-1843	NCRR NIH HHS [P20 RR016453, RR03061] Funding Source: Medline; NEI NIH HHS [EY13019] Funding Source: Medline; NIAMS NIH HHS [AR46379] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016453] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR046379] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Belinsky MG, 1999, BRIT J CANCER, V80, P1342, DOI 10.1038/sj.bjc.6690527; Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; Cui YH, 1999, MOL PHARMACOL, V55, P929; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; Germain D P, 2000, Hum Mutat, V16, P449, DOI 10.1002/1098-1004(200011)16:5<449::AID-HUMU24>3.0.CO;2-O; Germain DP, 2000, BIOCHEM BIOPH RES CO, V274, P297, DOI 10.1006/bbrc.2000.3101; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; Hipfner DR, 1996, CANCER RES, V56, P3307; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1999, CANCER RES, V59, P175; Le Saux O, 2001, AM J HUM GENET, V69, P749, DOI 10.1086/323704; Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102; Madon J, 2000, MOL PHARMACOL, V57, P634, DOI 10.1124/mol.57.3.634; Muller M, 1996, J BIOL CHEM, V271, P1877; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Ringpfeil F, 2001, AM J HUM GENET, V68, P642, DOI 10.1086/318807; Ringpfeil F, 2000, P NATL ACAD SCI USA, V97, P6001, DOI 10.1073/pnas.100041297; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; SARKADI B, 1992, J BIOL CHEM, V267, P4854; STEMMER WPC, 1992, BIOTECHNIQUES, V13, P214; Struk B, 2000, J MOL MED, V78, P282, DOI 10.1007/s001090000114; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Szakacs G, 2000, BIOCHEM BIOPH RES CO, V276, P1314, DOI 10.1006/bbrc.2000.3576; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Uitto J, 2001, TRENDS MOL MED, V7, P13, DOI 10.1016/S1471-4914(00)01869-4; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang J, 2001, J HUM GENET, V46, P699, DOI 10.1007/s100380170003; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zeng H, 2000, CANCER RES, V60, P4779	48	190	197	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16860	16867		10.1074/jbc.M110918200	http://dx.doi.org/10.1074/jbc.M110918200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880368	hybrid			2022-12-25	WOS:000175564500069
J	Sesma, L; Montserrat, V; Lamas, JR; Marina, A; Vazquez, J; de Castro, JAL				Sesma, L; Montserrat, V; Lamas, JR; Marina, A; Vazquez, J; de Castro, JAL			The peptide repertoires of HLA-B27 subtypes differentially associated to spondyloarthropathy (B*2704 and B*2706) differ by specific changes at three anchor positions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL ANCHOR; HL-A 27; ANKYLOSING-SPONDYLITIS; NUCLEOTIDE-SEQUENCE; SUSCEPTIBILITY; BINDING; HLA-B-ASTERISK-2706; POLYMORPHISM; RECOGNITION; MECHANISM	HLA-B*2704 is strongly associated with ankylosing spondylitis. B*2706, which differs from B*2704 by two amino acid changes, is not associated with this disease. A systematic comparison of the B*2704- and B*2706-bound peptide repertoires was carried out to elucidate their overlap and differential features and to correlate them with disease susceptibility. Both subtypes shared about 90%, of their peptide repertoires, consisting of peptides with Arg(2) and C-terminal aliphatic or Phe residues. B*2706 polymorphism influenced specificity at three anchor positions: it favored basic residues at P3 and POmega-2 and impaired binding of Tyr and Arg at POmega. Thus, the main structural feature of peptides differentially bound to B*2704 was the presence of C-terminal Tyr or Arg, together with a strong preference for aliphatic/aromatic P3 residues. This is the only known feature of B*2704 and B*2706 that correlates to their differential association with spondyloarthropathy. The concomitant presence of basic P3 and POmega-2 residues was observed only among peptides differentially bound to B*2706, suggesting that it impairs binding to B*2704. Similarity between peptide overlap and the degree of cross-reaction with alloreactive T lymphocytes suggested that the majority of shared ligands maintain unaltered antigenic features in the context of both subtypes.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	de Castro, JAL (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Vazquez, Jesus/B-7697-2015; Ramírez, Anabel Marina/ABG-7125-2021; Lamas, José Ramón/C-8318-2012	Vazquez, Jesus/0000-0003-1461-5092; Ramírez, Anabel Marina/0000-0003-2927-6396; Lamas, José Ramón/0000-0003-1913-7261				Allen RL, 1999, J IMMUNOL, V162, P5045; Alvarez I, 2001, J BIOL CHEM, V276, P48740, DOI 10.1074/jbc.M108882200; Alvarez I, 2001, J BIOL CHEM, V276, P32729, DOI 10.1074/jbc.M104663200; APARICIO P, 1987, J EXP MED, V165, P428, DOI 10.1084/jem.165.2.428; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; Boyle LH, 2001, J IMMUNOL, V167, P2619, DOI 10.4049/jimmunol.167.5.2619; BREWERTON DA, 1973, LANCET, V2, P996, DOI 10.1016/S0140-6736(73)91091-X; BREWERTON DA, 1973, LANCET, V1, P904; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; DAMATO M, 1995, EUR J IMMUNOL, V25, P3199, DOI 10.1002/eji.1830251133; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; Fiorillo MT, 1997, EUR J IMMUNOL, V27, P368, DOI 10.1002/eji.1830270205; FIORILLO MT, 1995, IMMUNOGENETICS, V41, P38, DOI 10.1007/BF00188430; FRUCI D, 1994, HUM IMMUNOL, V41, P34, DOI 10.1016/0198-8859(94)90081-7; Galocha B, 1996, TISSUE ANTIGENS, V48, P509, DOI 10.1111/j.1399-0039.1996.tb02664.x; Garcia F, 1997, TISSUE ANTIGENS, V49, P215, DOI 10.1111/j.1399-0039.1997.tb02741.x; Garcia-Fernandez S, 2001, TISSUE ANTIGENS, V58, P259, DOI 10.1034/j.1399-0039.2001.580407.x; GonzalezRoces S, 1997, TISSUE ANTIGENS, V49, P116, DOI 10.1111/j.1399-0039.1997.tb02724.x; Huang F, 1997, ARTHRITIS RHEUM, V40, P694, DOI 10.1002/art.1780400414; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; Laitio P, 1997, EUR J IMMUNOL, V27, P1331, DOI 10.1002/eji.1830270606; Lamas JR, 1999, ARTHRITIS RHEUM-US, V42, P1975, DOI 10.1002/1529-0131(199909)42:9<1975::AID-ANR25>3.0.CO;2-V; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LOPEZLARREA C, 1995, TISSUE ANTIGENS, V45, P169, DOI 10.1111/j.1399-0039.1995.tb02436.x; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; Marina A, 1999, J MASS SPECTROM, V34, P17, DOI 10.1002/(SICI)1096-9888(199901)34:1<17::AID-JMS746>3.3.CO;2-Y; Mear JP, 1999, J IMMUNOL, V163, P6665; Nasution AR, 1997, J RHEUMATOL, V24, P1111; Paradela A, 2000, J IMMUNOL, V164, P329, DOI 10.4049/jimmunol.164.1.329; Paradela A, 1998, J IMMUNOL, V161, P5481; PARKER KC, 1994, BIOCHEMISTRY-US, V33, P7736, DOI 10.1021/bi00190a029; Ren EC, 1997, TISSUE ANTIGENS, V49, P67, DOI 10.1111/j.1399-0039.1997.tb02713.x; Rudwaleit M, 1996, IMMUNOGENETICS, V43, P160; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; Sudarsono D, 1999, J RHEUMATOL, V26, P1534; Tieng V, 1997, IMMUNOGENETICS, V47, P103, DOI 10.1007/s002510050334; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VEGA MA, 1986, J IMMUNOL, V137, P3557; VILCHES C, 1994, IMMUNOGENETICS, V39, P219, DOI 10.1007/BF00241265; Yague J, 1998, TISSUE ANTIGENS, V52, P416, DOI 10.1111/j.1399-0039.1998.tb03067.x; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	45	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16744	16749		10.1074/jbc.M200371200	http://dx.doi.org/10.1074/jbc.M200371200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875071	hybrid			2022-12-25	WOS:000175564500054
J	Trivedi, V; Gupta, A; Jala, VR; Saravanan, P; Rao, GSJ; Rao, NA; Savithri, HS; Subramanya, HS				Trivedi, V; Gupta, A; Jala, VR; Saravanan, P; Rao, GSJ; Rao, NA; Savithri, HS; Subramanya, HS			Crystal structure of binary and ternary complexes of serine hydroxymethyltransferase from Bacillus stearothermophilus - Insights into the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ANGSTROM RESOLUTION; REFINEMENT; BINDING; SUBSTRATE; ORIGIN	Serine hydroxymethyltransferase (SHMT), a member of the alpha-class of pyridoxal phosphate-dependent enzymes, catalyzes the reversible conversion of serine to glycine and tetrahydrofolate to 5,10-methylene tetrahydrofolate. We present here the crystal structures of the native enzyme and its complexes with serine, glycine, glycine, and 5-formyl tetrahydrofolate (FTHF) from Bacillus stearothermophilus. The first structure of the serine-bound form of SHMT allows identification of residues involved in serine binding and catalysis. The SHMT-serine complex does not show any significant conformational change compared with the native enzyme, contrary to that expected for a conversion from an "open" to "closed" form of the enzyme. However, the ternary complex with FTHF and glycine shows the reported conformational changes. In contrast to the Escherichia coli enzyme, this complex shows asymmetric binding of the FTHF to the two monomers within the dimer in a way similar to the murine SHMT. Comparison of the ternary complex with the native enzyme reveals the structural basis for the conformational change and asymmetric binding of FTHF. The four structures presented here correspond to the various reaction intermediates of the catalytic pathway and provide evidence for a direct displacement mechanism for the hydroxymethyl transfer rather than a retroaldol cleavage.	Cent Drug Res Inst, Mol & Struct Biol Div, Lucknow 226001, Uttar Pradesh, India; Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Indian Institute of Science (IISC) - Bangalore	Subramanya, HS (corresponding author), Cent Drug Res Inst, Mol & Struct Biol Div, Chatter Manzil Palace,Mahatma Gandhi Marg,PB 173, Lucknow 226001, Uttar Pradesh, India.	subshs@rediffmail.com	Jala, Venkatakrishna R/K-7255-2018	Jala, Venkatakrishna R/0000-0002-4206-7305				ANGELACCIO S, 1992, BIOCHEMISTRY-US, V31, P155, DOI 10.1021/bi00116a023; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; Arnone A, 1985, TRANSAMINASES, P138; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BHASKAR B, 1994, BBA-PROTEIN STRUCT M, V1209, P40, DOI 10.1016/0167-4838(94)90134-1; BLAKELEY RL, 1995, BIOCHEM J, V61, P315; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Contestabile R, 2000, BIOCHEMISTRY-US, V39, P7492, DOI 10.1021/bi000032z; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; EICHLER HG, 1981, BIOSCIENCE REP, V1, P101, DOI 10.1007/BF01117006; GORB CA, 1969, ANGEW CHEM INT EDIT, V8, P535; Huang T, 1998, BIOCHEMISTRY-US, V37, P13536, DOI 10.1021/bi980827u; Jagath JR, 1997, J BIOL CHEM, V272, P24355, DOI 10.1074/jbc.272.39.24355; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; JORDAN PM, 1970, BIOCHEM J, V247, P372; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARCH J, 1999, ADV ORGANIC CHEM REA, P294; Matthews RG, 1998, ADV ENZYME REGUL, V38, P377, DOI 10.1016/S0065-2571(97)00006-X; MATTHEWS RG, 1990, CHEM REV, V90, P1275, DOI 10.1021/cr00105a010; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rao JVK, 2000, EUR J BIOCHEM, V267, P5967, DOI 10.1046/j.1432-1327.2000.01667.x; RAO NA, 1991, NEW TRENDS BIOL CHEM, P333; Renwick SB, 1998, STRUCTURE, V6, P1105, DOI 10.1016/S0969-2126(98)00112-9; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Scarsdale JN, 2000, J MOL BIOL, V296, P155, DOI 10.1006/jmbi.1999.3453; Scarsdale JN, 1999, BIOCHEMISTRY-US, V38, P8347, DOI 10.1021/bi9904151; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; STOVER P, 1992, BIOCHEMISTRY-US, V31, P2155, DOI 10.1021/bi00122a037; STOVER P, 1991, J BIOL CHEM, V266, P1543; STOVER P, 1992, J BIOL CHEM, V267, P17679; Szebenyi DME, 2000, BIOCHEMISTRY-US, V39, P13313, DOI 10.1021/bi000635a; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THORNDIKE J, 1979, CANCER RES, V39, P3435	41	65	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17161	17169		10.1074/jbc.M111976200	http://dx.doi.org/10.1074/jbc.M111976200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877399	hybrid			2022-12-25	WOS:000175564500109
J	Jones, JA; Hannun, YA				Jones, JA; Hannun, YA			Tight binding inhibition of protein phosphatase-1 by phosphatidic acid - Specificity of inhibition by the phospholipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY-DOMAIN; LIPID 2ND-MESSENGER; CATALYTIC SUBUNIT; GROWTH-FACTOR; RAF-1 KINASE; CELLS; PHOSPHORYLATION; STIMULATION; ACTIVATION; TRANSITION	Phosphatidic acid (PA) has been identified as a bioactive lipid second messenger, yet despite extensive investigation, no cellular target has emerged as a mediator of its described biological effects. In this study, we identify the gamma isoform of the human protein phosphatase-1 catalytic subunit (PP1cgamma) as a high affinity in vitro target of PA. PA inhibited the enzyme dose-dependently with an IC50 of 15 nM. Mechanistically, PA inhibited the enzyme noncompetitively with the kinetics of a tight binding inhibitor and a K-i value of 0.97 +/- 0.24 nM. Together, these data describe one of the most potent in vitro effects of PA. To further elucidate the interaction between PA and PP1cgamma, structure/function analysis of the lipid was carried out using commercially available and synthetically generated analogs of PA. These studies disclosed that the lipid-protein interaction is dependent on the presence of the lipid phosphate as well as the presence of the fatty acid side chains, because lipids lacking either of these substituents resulted in complete loss of inhibition. However, the specific composition of the fatty acid side chains was not important for inhibition. Using 1-O-hexadecyl,2-oleoyl-PA, it was also shown that the carbonyl group of the sn-1 acyl linkage is not required for the lipid-protein interaction. Finally, using a lipid-protein overlay assay, it was demonstrated that PP1cgamma specifically and directly interacts with phosphatidic acid while not significantly binding other phospholipids. These results identify PA as a tight binding and specific inhibitor of PP1, and they raise the hypothesis that PP1cgamma may function as a mediator of PA action in cells. They also argue for the existence of a specific high affinity PA-binding domain on the enzyme.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Mol & Cellular Biol & Pathobiol Program, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.			Jones, Jeffrey/0000-0002-5133-0427	NCI NIH HHS [CA-87584] Funding Source: Medline; NIGMS NIH HHS [GM-43825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; AMES BN, 1960, J BIOL CHEM, V235, P769; BARTON PG, 1975, J BIOL CHEM, V250, P4470; Bligh E., 1959, CAN J BIOCH PHYSL, V37, P341, DOI [10.1139/y59-099, DOI 10.1139/Y59-099]; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; BURSTEN S, 1994, CIRC SHOCK, V44, P14; BURSTEN SL, 1994, AM J PHYSIOL, V266, pC1093, DOI 10.1152/ajpcell.1994.266.4.C1093; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; ElBawab S, 1997, EUR J BIOCHEM, V247, P1151, DOI 10.1111/j.1432-1033.1997.01151.x; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Ghosh S, 1997, BIOCHEM SOC T, V25, P561, DOI 10.1042/bst0250561; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; KASZKIN M, 1992, CANCER RES, V52, P5627; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; McPhail LC, 1999, BBA-MOL CELL BIOL L, V1439, P277, DOI 10.1016/S1388-1981(99)00100-6; MERIDA I, 1993, DNA CELL BIOL, V12, P473, DOI 10.1089/dna.1993.12.473; SIDDIQUI RA, 1995, CELL SIGNAL, V7, P247, DOI 10.1016/0898-6568(94)00083-N; Silvius J.R., 1982, LIPID PROTEIN INTERA; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Strum JC, 1997, ADV EXP MED BIOL, V407, P421; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Xu YQ, 2001, J BIOL CHEM, V276, P18407, DOI 10.1074/jbc.M101204200; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	35	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15530	15538		10.1074/jbc.M111555200	http://dx.doi.org/10.1074/jbc.M111555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856740	hybrid			2022-12-25	WOS:000175510400042
J	Kochl, R; Alken, M; Rutz, C; Krause, G; Oksche, A; Rosenthal, W; Schulein, R				Kochl, R; Alken, M; Rutz, C; Krause, G; Oksche, A; Rosenthal, W; Schulein, R			The signal peptide of the G protein-coupled human endothelin B receptor is necessary for translocation of the N-terminal tail across the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOPRESSIN V-2 RECEPTOR; INSERTION ORIENTATION; SEQUENCE; DOMAIN; CELLS; THYROTROPIN; TRANSPORT; YEAST	The initial step of the intracellular transport of G protein-coupled receptors, their insertion into the membrane of the endoplasmic reticulum, follows one of two different pathways. Whereas one group uses the first transmembrane domain of the mature receptor as an uncleaved signal anchor sequence for this process, a second group possesses additional cleavable signal peptides. The reason this second subset requires the additional signal peptide is not known. Here we have assessed the functional significance of the signal peptide of the endothelin B (ETB) receptor in transiently transfected COS.M6 cells. A green fluorescent protein-tagged ETB receptor mutant lacking the signal peptide was nonfunctional and retained in the endoplasmic reticulum, suggesting that it has a folding defect. To determine the defect in more detail, ETB receptor fragments containing the N-terminal tail, first transmembrane domain, and first cytoplasmic loop were constructed. We assessed N tail translocation across the endoplasmic reticulum membrane in the presence and absence of a signal peptide and show that the signal peptide is necessary for N tail translocation. We postulate that signal peptides are necessary for those G protein-coupled receptors for which post-translational translocation of the N terminus is impaired or blocked by the presence of stably folded domains.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Schulein, R (corresponding author), Forschungsinst Mol Pharmakol, Robert Rossle Str 10, D-13125 Berlin, Germany.		Oksche, Alexander/M-6678-2019	Oksche, Alexander/0000-0003-4592-1770; Kochl, Robert/0000-0003-3370-5501				AKAMIZU T, 1990, BIOCHEM BIOPH RES CO, V169, P947, DOI 10.1016/0006-291X(90)91985-2; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BAN T, 1992, ENDOCRINOLOGY, V131, P815, DOI 10.1210/en.131.2.815; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brodsky JL, 1998, INT REV CYTOL, V178, P277; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; EDVARDSEN O, 1997, 7TM J, V6, P1; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harley CA, 1998, J BIOL CHEM, V273, P24963, DOI 10.1074/jbc.273.38.24963; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HEDGE RS, 1997, CELL, V91, P575; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; Krause G, 2000, MOL PHARMACOL, V57, P232; Kristiansen K, 1996, PROTEINS, V26, P81, DOI 10.1002/(SICI)1097-0134(199609)26:1<81::AID-PROT8>3.0.CO;2-J; LOO TW, 1995, J BIOL CHEM, V270, P19345, DOI 10.1074/jbc.270.33.19345; Oksche A, 2000, MOL PHARMACOL, V57, P1104; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; SAITO Y, 1991, J BIOL CHEM, V266, P23433; Sambrook J., 2002, MOL CLONING LAB MANU; Satoh M, 1997, EUR J BIOCHEM, V249, P803, DOI 10.1111/j.1432-1033.1997.00803.x; Schoneberg T, 1999, MOL CELL ENDOCRINOL, V151, P181, DOI 10.1016/S0303-7207(99)00017-9; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulein R, 1996, J BIOL CHEM, V271, P28844, DOI 10.1074/jbc.271.46.28844; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; TERASAKI M, 1992, J CELL SCI, V101, P315; WADA K, 1990, BIOCHEM BIOPH RES CO, V167, P251, DOI 10.1016/0006-291X(90)91758-K; WADA K, 1995, PROTEIN EXPRES PURIF, V6, P228, DOI 10.1006/prep.1995.1029; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693	33	57	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16131	16138		10.1074/jbc.M111674200	http://dx.doi.org/10.1074/jbc.M111674200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854280	hybrid			2022-12-25	WOS:000175510400121
J	Scheller, C; Sopper, S; Chen, PF; Flory, E; Koutsilier, E; Racek, T; Ludwig, S; ten Meulen, V; Jassoy, C				Scheller, C; Sopper, S; Chen, PF; Flory, E; Koutsilier, E; Racek, T; Ludwig, S; ten Meulen, V; Jassoy, C			Caspase inhibition activates HIV in latently infected cells - Role of tumor necrosis factor receptor 1 and CD95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; ANTIRETROVIRAL THERAPY; INDUCED APOPTOSIS; DEATH DOMAIN; FAS; TNF; REPLICATION; LYMPHOCYTES	Stimulation of tumor necrosis factor receptor 1 (TNF-R1) triggers both caspase-dependent and caspase-independent signaling activities. The caspase-dependent signaling pathway induces apoptotic cell death in susceptible cells, whereas the caspase-independent signaling cascade leads to activation of nuclear factor kappaB and induces antiapoptotic signaling activities. Stimulation of nuclear factor kappaB via TNF-R1 is known to activate human immunodeficiency virus (HIV) replication in infected cells. Here we show that the broad range caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (ZVAD) activates HIV replication in the chronically infected T-cell line ACH-2. Virus activation was caused by a sensitization of TNF-R1 toward endogenously produced tumor necrosis factor alpha (TNF-alpha). Neutralizing anti-TNF-alpha antibodies completely abolished the virus-inducing activity of ZVAD. Treatment of cells with TNF-alpha in the presence of ZVAD caused increased expression of TNF-alpha and induced enhanced virus replication. Activation of CD95, another member of the TNF receptor family, similarly triggered HIV replication, which was further enhanced in the presence of ZVAD. Our data show that caspase inhibitors sensitize both CD95 and TNF-R1 to mediate activation of HIV in latently infected cells. Activation of HIV replication in latent virus reservoirs is currently discussed as a therapeutic strategy to achieve eradication of HIV in patients treated with antiretroviral therapy. Our results point to a novel role for caspase inhibitors as activators of virus replication in vivo.	Univ Wurzburg, Inst Virol & Immunobiol, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Paul Ehrlich Inst, D-63225 Langen, Germany	University of Wurzburg; University of Wurzburg; Paul Ehrlich Institute	Scheller, C (corresponding author), Univ Wurzburg, Inst Virol & Immunobiol, Versbacher Str 7, D-97078 Wurzburg, Germany.		Sopper, Sieghart/I-3155-2018	Sopper, Sieghart/0000-0003-2265-1974; Ludwig, Stephan/0000-0003-4490-3052				Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Caggiari L, 2000, CLIN EXP IMMUNOL, V120, P101, DOI 10.1046/j.1365-2249.2000.01187.x; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, NAT MED, V3, P333, DOI 10.1038/nm0397-333; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Dianzani F, 2000, ANTIVIR RES, V45, P95, DOI 10.1016/S0166-3542(99)00080-7; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; FOLKS T, 1985, P NATL ACAD SCI USA, V82, P4539, DOI 10.1073/pnas.82.13.4539; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; Fraser C, 2000, AIDS, V14, P659, DOI 10.1097/00002030-200004140-00005; Hoffmeyer A, 1999, J BIOL CHEM, V274, P4319, DOI 10.1074/jbc.274.7.4319; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Jang HD, 2001, BIOCHEM BIOPH RES CO, V281, P499, DOI 10.1006/bbrc.2001.4369; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lapointe R, 1996, BIOCHEM BIOPH RES CO, V229, P959, DOI 10.1006/bbrc.1996.1908; Leo E, 2001, J BIOL CHEM, V276, P8087, DOI 10.1074/jbc.M009450200; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Ruocco MR, 1996, J BIOL CHEM, V271, P22479, DOI 10.1074/jbc.271.37.22479; Schow SR, 1997, CELL IMMUNOL, V175, P199, DOI 10.1006/cimm.1996.1061; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141	28	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15459	15464		10.1074/jbc.M200763200	http://dx.doi.org/10.1074/jbc.M200763200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854296	hybrid			2022-12-25	WOS:000175510400033
J	Tsuboi, T; Terakawa, S; Scalettar, BA; Fantus, C; Roder, J; Jeromin, A				Tsuboi, T; Terakawa, S; Scalettar, BA; Fantus, C; Roder, J; Jeromin, A			Sweeping model of dynamin activity - Visualization of coupling between exocytosis and endocytosis under an evanescent wave microscope with green fluorescent proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULES; VESICLES	Vesicle recycling through exocytosis and endocytosis is mediated by a coordinated cascade of protein-protein interactions. Previously, exocytosis and endocytosis were studied separately so that the coupling between them was understood only indirectly. We focused on the coupling of these processes by observing the secretory vesicle marker synaptobrevin and the endocytotic vesicle marker dynamin I tagged with green and red fluorescent proteins under an evanescent wave microscope in pheochromocytoma cells. In control cells, many synaptobrevin-expressing vesicles were found as fluorescent spots near the plasma membrane. Upon electrical stimulation, many of these vesicles showed an exocytotic response as a transient increase in fluorescence intensity followed by their disappearance. In contrast, fluorescent dynamin appeared as clusters increasing slowly in number upon stimulation. The clusters of fluorescent dynamin moved around beneath the plasma membrane for a significant distance. Simultaneous observations of green fluorescent dynamin and red fluorescent synaptobrevin indicated that more than 70% of the exocytotic responses of synaptobrevin had no immediate dynamin counterpart at the same site. From these findings it was concluded that dynamin-mediated recycling is not directly coupled to exocytosis but rather completed by a scanning movement of dynamin for the sites of invaginating membrane destined to endocytosis.	Hamamatsu Univ Sch Med, Med Res Ctr, Lab Cell Imaging, Hamamatsu, Shizuoka 4313192, Japan; Lewis & Clark Coll, Dept Phys, Portland, OR 97219 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Hamamatsu University School of Medicine; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Terakawa, S (corresponding author), Hamamatsu Univ Sch Med, Med Res Ctr, Lab Cell Imaging, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	terakawa@hama-med.ac.jp	Roder, John/G-6468-2013; TSUBOI, Takashi/AAD-7976-2019	TSUBOI, Takashi/0000-0001-8290-2021	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM061539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bottomley MJ, 1999, CURR BIOL, V9, pR301, DOI 10.1016/S0960-9822(99)80184-5; Li ZY, 2001, NEURON, V31, P593, DOI 10.1016/S0896-6273(01)00398-1; MANIVANNAN S, 1994, J NEUROSCI, V14, P5917; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; Sankaranarayanan S, 2001, NAT NEUROSCI, V4, P129, DOI 10.1038/83949; Sankaranarayanan S, 2000, NAT CELL BIOL, V2, P197, DOI 10.1038/35008615; Schmoranzer J, 2000, J CELL BIOL, V149, P23, DOI 10.1083/jcb.149.1.23; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V235, P47, DOI 10.1006/bbrc.1997.6732; Toomre D, 2000, J CELL BIOL, V149, P33, DOI 10.1083/jcb.149.1.33; Tsuboi T, 2000, CURR BIOL, V10, P1307, DOI 10.1016/S0960-9822(00)00756-9; Tsuboi T, 2001, BIOCHEM BIOPH RES CO, V282, P621, DOI 10.1006/bbrc.2001.4603; Vasquez RJ, 1998, MOL BIOL CELL, V9, p196A	15	36	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15957	15961		10.1074/jbc.C200051200	http://dx.doi.org/10.1074/jbc.C200051200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856729	hybrid			2022-12-25	WOS:000175510400099
J	Kashlev, M; Komissarova, N				Kashlev, M; Komissarova, N			Transcription termination: Primary intermediates and secondary adducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; ELONGATION COMPLEX; NASCENT RNA; TERNARY COMPLEXES; CHAIN ELONGATION; CLEAVAGE FACTORS; IN-VIVO; DNA; MECHANISM	In living organisms, stable elongation complexes of RNA polymerase dissociate at specific template positions in a process of transcription termination. It has been suggested that the dissociation is not the immediate cause of termination but is preceded by catalytic inactivation of the elongation complex. In vitro reducing ionic strength can be used to stabilize very unstable and catalytically inactive complex at the point of termination; the previous biochemical characterization of this complex has led to important conclusions regarding termination mechanism. Here we analyze in detail the complexes formed between DNA template, nascent RNA, and Escherichia coli RNA polymerase during transcription through the tR2 terminator of bacteriophage A. At low ionic strength, the majority of elongation complexes fall apart upon reaching the terminator. Released RNA and DNA efficiently rebind RNA polymerase (RNAP) and form binary RNAP.RNA and RNAP.DNA complexes, which are indistinguishable from binary complexes obtained by direct mixing of the purified nucleic acids and the enzyme. A small fraction of elongation complexes that reach termination point escapes dissociation because RNA polymerase has backtracked from the terminator to an upstream DNA position. Thus, transcription elongation to a terminator site produces no termination intermediates that withstand dissociation in the time scale appropriate for biochemical studies.	NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Kashlev, M (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Bldg 539,Rm 222, Frederick, MD 21702 USA.	mkashlev@mail.ncifcrf.gov						ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; BERLIN V, 1983, J BIOL CHEM, V258, P1714; Borukhov S, 1996, METHOD ENZYMOL, V274, P315; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Darst SA, 2001, CURR OPIN STRUC BIOL, V11, P155; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; FULLER RS, 1978, NUCLEIC ACIDS RES, V5, P4613; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1998, P NATL ACAD SCI USA, V95, P14699, DOI 10.1073/pnas.95.25.14699; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Landick R, 1999, SCIENCE, V284, P598, DOI 10.1126/science.284.5414.598; Landick R, 2001, CELL, V105, P567, DOI 10.1016/S0092-8674(01)00381-6; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; Toulme F, 1999, EMBO J, V18, P5052, DOI 10.1093/emboj/18.18.5052; Toulme F, 2000, EMBO J, V19, P6853, DOI 10.1093/emboj/19.24.6853; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; Uptain SM, 1997, P NATL ACAD SCI USA, V94, P13548, DOI 10.1073/pnas.94.25.13548; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; Wilson KS, 1999, J MOL BIOL, V289, P1179, DOI 10.1006/jmbi.1999.2814; WILSON KS, 1994, J MOL BIOL, V244, P36, DOI 10.1006/jmbi.1994.1702; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611; Yin H, 1999, P NATL ACAD SCI USA, V96, P13124, DOI 10.1073/pnas.96.23.13124; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	41	27	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14501	14508		10.1074/jbc.M200215200	http://dx.doi.org/10.1074/jbc.M200215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11856750	hybrid			2022-12-25	WOS:000175203000021
J	Nawrocki, AR; Goldring, CE; Kostadinova, RM; Frey, FJ; Frey, BM				Nawrocki, AR; Goldring, CE; Kostadinova, RM; Frey, FJ; Frey, BM			In vivo footprinting of the human 11 beta-hydroxysteroid dehydrogenase type 2 promoter - Evidence for cell-specific regulation by Sp1 and Sp3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-CHAIN-REACTION; DEPENDENT PROTEIN-KINASE; LIGATION-MEDIATED PCR; NF-KAPPA-B; TRANSCRIPTIONAL REGULATION; CHROMOSOMAL LOCALIZATION; SALT SENSITIVITY; GENE-EXPRESSION; SYNTHASE GENE; IN-VIVO	11beta-Hydroxysteroid dehydrogenase type 2 is selectively expressed in aldosterone target tissues, where it confers aldosterone selectivity for the mineralocorticoid receptor by inactivating 11beta-hydroxyglucocorticoids with a high affinity for the mineralocorticoid receptor. The present investigation aimed to elucidate the mechanisms accounting for the rigorous control of the HSD11B2 gene in humans. Using dimethyl sulfate in vivo footprinting via ligation-mediated PCR, we identified potentially important regions for HSD11B2 regulation in human cell lines: two GC-rich regions in the first exon (I and II) and two upstream elements (III and IV). The footprints suggest a correlation between the extent of in vivo protein occupancy at three of these regions (I, II, and III) and the rate of HSD11B2 transcription in cells with high (SW620), intermediate (HCD, MCF-7, and HK-2), or low HSD11B2 mRNA levels (SUT). Moreover, gel shift assays with nuclear extracts from these cell lines revealed that decreased HSD11B2 expression is related to a decreased binding activity with oligonucleotides containing the putative regulatory elements. Antibody supershifts identified the majority of the components of the binding complexes as the transcription factors Sp1 and Sp3. Finally, transient transfections with various deletion mutant reporters define positive regulatory elements that might account for basal and selective expression of 11beta-hydroxysteroid dehydrogenase type 2.	Univ Hosp Bern, Dept Internal Med, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland; Univ Hosp Bern, Dept Clin Res, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Nawrocki, AR (corresponding author), Univ Hosp Bern, Dept Internal Med, Div Nephrol & Hypertens, Freiburgstr 15, CH-3010 Bern, Switzerland.	andrea.nawrocki@dkf2.unibe.ch						Aarskog NK, 2000, HUM GENET, V107, P494, DOI 10.1007/s004390000399; AGARWAL AK, 1995, GENOMICS, V29, P195, DOI 10.1006/geno.1995.1231; Agarwal AK, 2000, HYPERTENSION, V36, P187, DOI 10.1161/01.HYP.36.2.187; Agarwal AK, 1996, MOL CELL ENDOCRINOL, V121, P93, DOI 10.1016/0303-7207(96)03855-5; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Biller KJ, 2001, AM J PHYSIOL-RENAL, V280, pF172, DOI 10.1152/ajprenal.2001.280.1.F172; BORNSTEIN P, 1988, MOL CELL BIOL, V8, P4851, DOI 10.1128/MCB.8.11.4851; Bostonjoglo M, 1998, J AM SOC NEPHROL, V9, P1347; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; Escher G, 1997, J EXP MED, V186, P189, DOI 10.1084/jem.186.2.189; Escher G, 1998, ENDOCRINOLOGY, V139, P1533, DOI 10.1210/en.139.4.1533; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; Ge YB, 2001, J BIOL CHEM, V276, P43570, DOI 10.1074/jbc.M104930200; ISRAEL N, 1992, J IMMUNOL, V149, P3386; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kobayashi M, 1997, BIOCHEM BIOPH RES CO, V241, P169, DOI 10.1006/bbrc.1997.7781; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Liang FQ, 1999, ENDOCRINOLOGY, V140, P1695, DOI 10.1210/en.140.4.1695; Lovati E, 1999, J CLIN ENDOCR METAB, V84, P3745, DOI 10.1210/jc.84.10.3745; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Nawrocki A, 1999, ANAL BIOCHEM, V272, P280, DOI 10.1006/abio.1999.4195; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; Osborne BA, 2000, CURR OPIN IMMUNOL, V12, P301, DOI 10.1016/S0952-7915(00)00091-1; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Poch E, 2001, HYPERTENSION, V38, P1204, DOI 10.1161/hy1101.099479; PRIE D, 1995, KIDNEY INT, V47, P1310, DOI 10.1038/ki.1995.186; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Stewart PM, 1999, VITAM HORM, V57, P249; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; WARIISHI S, 1995, BIOCHEM BIOPH RES CO, V216, P729, DOI 10.1006/bbrc.1995.2682; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Zaehner T, 2000, KIDNEY INT, V58, P1413, DOI 10.1046/j.1523-1755.2000.00303.x; Zennaro MC, 1996, MOL ENDOCRINOL, V10, P1549, DOI 10.1210/me.10.12.1549; Zhang LQ, 1997, GENOMICS, V45, P519, DOI 10.1006/geno.1997.4982	57	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14647	14656		10.1074/jbc.M111549200	http://dx.doi.org/10.1074/jbc.M111549200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11850421	Green Submitted, hybrid			2022-12-25	WOS:000175203000039
J	Olson, FJ; Johansson, MEV; Klinga-Levan, K; Bouhours, D; Enerback, L; Hansson, GC; Karlsson, NG				Olson, FJ; Johansson, MEV; Klinga-Levan, K; Bouhours, D; Enerback, L; Hansson, GC; Karlsson, NG			Blood group A glycosyltransferase occurring as alleles with high sequence difference is transiently induced during a Nippostrongylus brasiliensis parasite infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED OLIGOSACCHARIDES; INSOLUBLE MUCIN COMPLEX; RAT LARGE-INTESTINE; GOBLET CELL MUCINS; GROUP-A; GLYCOSPHINGOLIPIDS; GLYCOSYLATION; CLONING; GENES; ORGANIZATION	Neutral mucin oligosaccharides from the small intestine of control rats and rats infected with the parasite Nippostrongylus brasiliensis were released and analyzed by gas chromatography-mass spectrometry. Infected animals expressed seven blood group A-like structures that were all absent in the control animals. The blood group A nature of these epitopes was confirmed by blood group A reactivity of the prepared mucins, of which Muc2 was one. Transferase assays and Northern blotting on small intestines from infected animals showed that an alpha-N-acetylgalactosaminyltransferase similar to the human blood group A glycosyltransferase had been induced. The expression was a transient event, with a maximum at day 6 of the 13-day-long infection. The rat blood group A glycosyltransferase was cloned, revealing two forms with an amino acid similarity of 95%. Both types had blood group A transferase activity and were probably allelic because none of 12 analyzed inbred strains carried both types. The second type was found in outbred rats and in one inbred strain. First generation offspring of inbred rats of each type were heterozygous, further supporting the allelic hypothesis. The transient induction and the large allelic variation could suggest that glycosyltransferases are part of a dynamic system altering mucins and other glycoconjugates as a protecting mechanism against microbial challenges.	Univ Gothenburg, Dept Biochem Med, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Dept Mol & Cell Biol, SE-40530 Gothenburg, Sweden; Univ Nantes, Fac Med, INSERM, UMR 539,Unite Rech Biol & Physiopathol, F-44035 Nantes 1, France; Univ Gothenburg, Sahlgrens Hosp, Dept Pathol, S-41345 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Sahlgrenska University Hospital; University of Gothenburg	Hansson, GC (corresponding author), Univ Gothenburg, Dept Biochem Med, POB 440,Medicinaregatan 9A, SE-40530 Gothenburg, Sweden.	gunnar.hansson@medkem.gu.se	Hansson, Gunnar C./AAF-7324-2019; Karlsson, Niclas/G-5235-2013; Johansson, Malin E. V./HCH-7451-2022; Hansson, Gunnar C/A-1236-2009	Hansson, Gunnar C./0000-0002-1900-1869; Karlsson, Niclas/0000-0002-3045-2628; Hansson, Gunnar C/0000-0002-1900-1869; Johansson, Malin E. V./0000-0002-4237-6677				ANGSTROM J, 1987, BIOCHIM BIOPHYS ACTA, V926, P79, DOI 10.1016/0304-4165(87)90184-X; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; BENNETT EP, 1995, BIOCHEM BIOPH RES CO, V206, P318, DOI 10.1006/bbrc.1995.1044; BOUHOURS D, 1995, BBA-LIPID LIPID MET, V1255, P131, DOI 10.1016/0005-2760(94)00229-R; BOUHOURS JF, 1987, J BIOL CHEM, V262, P16370; BREIMER ME, 1980, FEBS LETT, V114, P51, DOI 10.1016/0014-5793(80)80859-3; CARLSTEDT I, 1993, J BIOL CHEM, V268, P18771; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DAVID L, 1992, APMIS, V100, P162; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Hansson G C, 1988, Adv Exp Med Biol, V228, P465; HANSSON GC, 1994, BIOCHEM BIOPH RES CO, V198, P181, DOI 10.1006/bbrc.1994.1026; Hounsell EF, 1996, GLYCOCONJUGATE J, V13, P19, DOI 10.1007/BF01049675; ISHIKAWA N, 1994, IMMUNOLOGY, V81, P480; ISHIKAWA N, 1993, IMMUNOLOGY, V78, P303; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Karlsson NG, 1996, GLYCOCONJUGATE J, V13, P823, DOI 10.1007/BF00702346; Karlsson NG, 2000, BIOCHEM J, V350, P805, DOI 10.1042/0264-6021:3500805; KARLSSON NG, 1995, GLYCOCONJUGATE J, V12, P69, DOI 10.1007/BF00731871; Karlsson NG, 1997, J BIOL CHEM, V272, P27025, DOI 10.1074/jbc.272.43.27025; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; MILLER HRP, 1979, EXP PARASITOL, V47, P81, DOI 10.1016/0014-4894(79)90010-9; MILLER HRP, 1981, CURRENT TOPICS VET M, V12, P402; Moniaux N, 2001, FRONT BIOSCI-LANDMRK, V6, pD1192, DOI 10.2741/Moniaux; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Race RR., 1975, BLOOD GROUPS MAN; Sheehan JK, 1996, BIOCHEM J, V315, P1055, DOI 10.1042/bj3151055; SMITH EL, 1975, BIOCHEMISTRY-US, V14, P2120, DOI 10.1021/bi00681a012; WINGREN U, 1983, HISTOCHEMISTRY, V77, P145, DOI 10.1007/BF00506557; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YAMAMOTO F, 1995, GLYCOBIOLOGY, V5, P51, DOI 10.1093/glycob/5.1.51; Yamamoto M, 2001, J BIOL CHEM, V276, P13701, DOI 10.1074/jbc.M010805200	35	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15044	15052		10.1074/jbc.M112287200	http://dx.doi.org/10.1074/jbc.M112287200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11842091	hybrid			2022-12-25	WOS:000175203000088
J	Werz, O; Szellas, D; Steinhilber, D; Radmark, O				Werz, O; Szellas, D; Steinhilber, D; Radmark, O			Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-NEUTROPHILS; LEUKOTRIENE SYNTHESIS; FATTY-ACIDS; SUBSTRATE-SPECIFICITY; SIGNAL-TRANSDUCTION; DENDRITIC CELLS; HEAT-SHOCK; C2 DOMAIN	We demonstrated previously that 5-lipoxygenase (5-LO), a key enzyme in leukotriene biosynthesis, can be phosphorylated by p38 MAPK-regulated MAPKAP kinases (MKs). Here we show that mutation of Ser-271 to Ala in 5-LO abolished MK2 catalyzed phosphorylation and clearly reduced phosphorylation by kinases prepared from stimulated polymorphonuclear leukocytes and Mono Mac 6 cells. Compared with heat shock protein 27 (Hsp-27), 5-LO was a weak substrate for MK2. However, the addition of unsaturated fatty acids (i.e. arachidonate 1-50 muM) up-regulated phosphorylation of 5-LO, but not of Hsp-27, by active MK2 in vitro, resulting in a similar phosphorylation as for Hsp-27. 5-LO was phosphorylated also by other serine/threonine kinases recognizing the motif Arg-Xaa-Xaa-Ser (protein kinase A, Ca2+/calmodulin-dependent kinase 11), but these activities were not increased by fatty acids. HeLa cells expressing wild type 5-LO or S271A-5-LO, showed prominent 5-LO activity when incubated with Ca2+-ionophore plus arachidonate. However, when stimulated with only exogenous arachidonic acid, activity for the S271A mutant was significantly lower as compared with wild type 5-LO. It appears that phosphorylation at Ser-271 is more important for 5-LO activity induced by a stimulus that does not prominently increase intracellular Ca2+ and that arachidonic acid stimulates leukotriene biosynthesis also by promoting this MK2-catalyzed phosphorylation.	Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Frankfurt, Inst Pharmaceut Chem, D-60439 Frankfurt, Germany	Karolinska Institutet; Goethe University Frankfurt	Radmark, O (corresponding author), Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.		Steinhilber, Dieter/J-3221-2012					AHARONY D, 1986, J BIOL CHEM, V261, P1512; ANTOINE C, 1992, BIOCHIM BIOPHYS ACTA, V1128, P139, DOI 10.1016/0005-2760(92)90299-B; Balsinde J, 2000, J BIOL CHEM, V275, P4783, DOI 10.1074/jbc.275.7.4783; BLOBE GC, 1995, PROSTAG LEUKOTR ESS, V52, P129, DOI 10.1016/0952-3278(95)90011-X; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; Chang LC, 2000, J PHARM PHARMACOL, V52, P539, DOI 10.1211/0022357001774336; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Cheng TJ, 1998, J CELL BIOCHEM, V71, P169; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DOOLAN CM, 1994, BRIT J PHARMACOL, V111, P509, DOI 10.1111/j.1476-5381.1994.tb14766.x; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Eom YW, 2001, BIOCHEM BIOPH RES CO, V284, P126, DOI 10.1006/bbrc.2001.4937; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GRABER R, 1994, J LIPID MEDIAT CELL, V9, P91; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; LANDRY J, 1992, J BIOL CHEM, V267, P794; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Mogul R, 2000, BIOCHEMISTRY-US, V39, P4801, DOI 10.1021/bi992805t; NACCACHE PH, 1989, BRIT J PHARMACOL, V97, P461, DOI 10.1111/j.1476-5381.1989.tb11973.x; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Osterhout JL, 2000, J BIOL CHEM, V275, P8248, DOI 10.1074/jbc.275.11.8248; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Peters-Golden M, 2001, FEBS LETT, V487, P323, DOI 10.1016/S0014-5793(00)02374-7; PETERSGOLDEN M, 1991, AM J PHYSIOL, V261, pL462, DOI 10.1152/ajplung.1991.261.6.L462; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P8550, DOI 10.1073/pnas.86.21.8550; Provost P, 2001, J BIOL CHEM, V276, P16520, DOI 10.1074/jbc.M011205200; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sailer ER, 1998, EUR J BIOCHEM, V256, P364, DOI 10.1046/j.1432-1327.1998.2560364.x; Sala A, 1999, J BIOL CHEM, V274, P28264, DOI 10.1074/jbc.274.40.28264; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHATZMUNDING M, 1991, EUR J BIOCHEM, V197, P487, DOI 10.1111/j.1432-1033.1991.tb15936.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shin EA, 1999, FEBS LETT, V452, P355, DOI 10.1016/S0014-5793(99)00657-2; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; Spanbroek R, 2000, BLOOD, V96, P3857, DOI 10.1182/blood.V96.12.3857.h8003857_3857_3865; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Surette ME, 1999, MOL PHARMACOL, V56, P1055, DOI 10.1124/mol.56.5.1055; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 1996, EUR J BIOCHEM, V242, P90, DOI 10.1111/j.1432-1033.1996.0090r.x; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; Werz O, 2001, J LEUKOCYTE BIOL, V70, P830; Werz O, 1996, PHARMAZIE, V51, P893; WOLF BA, 1986, J BIOL CHEM, V261, P3501	57	100	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14793	14800		10.1074/jbc.M111945200	http://dx.doi.org/10.1074/jbc.M111945200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11844797	hybrid			2022-12-25	WOS:000175203000058
J	Sumbilla, C; Lewis, D; Hammerschmidt, T; Inesi, G				Sumbilla, C; Lewis, D; Hammerschmidt, T; Inesi, G			The slippage of the Ca2+ pump and its control by anions and curcumin in skeletal and cardiac sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INORGANIC-PHOSPHATE; ATP SYNTHESIS; PHOSPHORYLATION; CA2+-ATPASE; MYOCARDIUM; MEMBRANES; ENZYME	Ca2+ transport by sareoplasmic reticulum (SR) ATPase occurs with an optimal coupling ratio of 2 Ca2+ per ATP in pre-steady state. However, slippage of the pump and lower coupling ratios are observed in steady state. Slippage depends on the presence of high Ca2+ in the lumen of SR vesicles and high nucleotide in the medium. Thereby, Ca2+ and/or nucleotide-bound phosphoenzyme intermediates accumulate and undergo uncoupled cleavage, before vectorial translocation of bound Ca2+ in the forward direction of the cycle or before productive reversal to ATP synthesis. Transport efficiency and coupling ratios are improved by reduction of nucleotide concentration in the presence of ATP regenerating systems and/or complexation of luminal Ca2+ with phosphate or oxalate. Curcumin (1-5 muM) lowers the concentration of phosphate or oxalate required to reduce slippage of the Ca2+ pump. Thereby, under appropriate conditions, curcumin favors kinetic flow, completion of productive cycles, and improvement of coupling ratios. The findings obtained with isolated SR vesicles suggest that slippage is an important phenomenon under prevailing conditions of muscle fibers in situ. Ca2+ transport and its slippage can be improved by curcumin in cardiac as well as in skeletal SR, raising the possibility of pharmacological interventions to correct defective Ca2+ homeostasis. Higher curcumin concentrations (5-30 muM), however, inhibit overall ATPase activity and Ca2+ transport by interfering with phosphoenzyme formation with ATP or Pi.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Inesi, G (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	ginesi@umaryland.edu			NHLBI NIH HHS [HL27867] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEIL FU, 1977, EUR J BIOCHEM, V81, P151, DOI 10.1111/j.1432-1033.1977.tb11936.x; Dalton KA, 1999, BIOCHEM J, V342, P431, DOI 10.1042/0264-6021:3420431; de Meis L, 2001, J BIOL CHEM, V276, P25078, DOI 10.1074/jbc.M103318200; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; HASENFUSS G, 1994, CIRC RES, V75, P434, DOI 10.1161/01.RES.75.3.434; INESI G, 1968, ARCH BIOCHEM BIOPHYS, V126, P469, DOI 10.1016/0003-9861(68)90431-1; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1988, METHOD ENZYMOL, V157, P154; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Logan-Smith MJ, 2001, J BIOL CHEM, V276, P46905, DOI 10.1074/jbc.M108778200; MAKINOSE M, 1965, BIOCHEM Z, V343, P360; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MORGAN JP, 1990, CIRCULATION, V81, P21; Sumbilla C, 1999, AM J PHYSIOL-HEART C, V277, pH2381, DOI 10.1152/ajpheart.1999.277.6.H2381; VERJOVSKIALMEIDA S, 1979, J BIOL CHEM, V254, P18; VERJOVSKIALMEIDA S, 1978, BIOCHEMISTRY-US, V17, P5006, DOI 10.1021/bi00616a023; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	22	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13900	13906		10.1074/jbc.M111155200	http://dx.doi.org/10.1074/jbc.M111155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11844792	hybrid			2022-12-25	WOS:000175096000073
J	Brennan, ML; Wu, WJ; Fu, XM; Shen, ZZ; Song, W; Frost, H; Vadseth, C; Narine, L; Lenkiewicz, E; Borchers, MT; Lusis, AJ; Lee, JJ; Lee, NA; Abu-Soud, HM; Ischiropoulos, H; Hazen, SL				Brennan, ML; Wu, WJ; Fu, XM; Shen, ZZ; Song, W; Frost, H; Vadseth, C; Narine, L; Lenkiewicz, E; Borchers, MT; Lusis, AJ; Lee, JJ; Lee, NA; Abu-Soud, HM; Ischiropoulos, H; Hazen, SL			A tale of two controversies - Defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; HUMAN NEUTROPHILS; BROMINATING OXIDANTS; CATALYZED OXIDATION; LIPID-PEROXIDATION; TYROSINE NITRATION; HYDROGEN-PEROXIDE; PROTEIN OXIDATION; MOUSE MODELS; PEROXYNITRITE	Nitrotyrosine is widely used as a marker of post-translational modification by the nitric oxide ((NO)-N-circle, nitrogen monoxide)-derived oxidant peroxynitrite (ONOO-). However, since the discovery that myeloperoxidase (MPO) and eosinophil peroxidase (EPO) can generate nitrotyrosine via oxidation of nitrite (NO2-), several questions have arisen. First, the relative contribution of peroxidases to nitrotyrosine formation in vivo is unknown. Further, although evidence suggests that the one-electron oxidation product, nitrogen dioxide ((NO2)-N-circle), is the primary species formed, neither a direct demonstration that peroxidases form this gas nor studies designed to test for the possible concomitant formation of the two-electron oxidation product, ONOO-, have been reported. Using multiple distinct models of acute inflammation with EPO- and MPO-knockout mice, we now demonstrate that leukocyte peroxidases participate in nitrotyrosine formation in vivo. In some models, MPO and EPO played a dominant role, accounting for the majority of nitrotyrosine formed. However, in other leukocyte-rich acute inflammatory models, no contribution for either MPO or EPO to nitrotyrosine formation could be demonstrated. Head-space gas analysis of helium-swept reaction mixtures provides direct evidence that leukocyte peroxidases catalytically generate (NO2)-N-circle formation using H2O2 and NO2- as substrates. However, formation of an additional oxidant was suggested since both enzymes promote NO2--dependent hydroxylation of targets under acidic conditions, a chemical reactivity shared with ONOO- but not (NO2)-N-circle. Collectively, our results demonstrate that: 1) MPO and EPO contribute to tyrosine nitration in vivo; 2) the major reactive nitrogen species formed by leukocyte peroxidase-catalyzed oxidation of NO2- is the one-electron oxidation product, circleNO(2); 3) as a minor reaction, peroxidases may also catalyze the two-electron oxidation of NO2-, producing a ONOO--like product. We speculate that the latter reaction generates a labile Fe-ONOO complex, which may be released following protonation under acidic conditions such as might exist at sites of inflammation.	Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Univ Penn, Childrens Hosp Philadelphia, Stokes Res Inst, Philadelphia, PA 19104 USA; Mayo Clin Scottsdale, Dept Biochem, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Dept Mol Biol, Scottsdale, AZ 85259 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Genet, Los Angeles, CA 90095 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Hazen, SL (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	hazens@ccf.org	Hazen, Stanley L/ABD-5845-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054926, R01HL065228, R01HL061878, P01HL030568, R01HL060793, R01HL062526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54926, HL30568, HL61878, HL60793, HL65228, HL62526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P11866, DOI 10.1021/bi011206v; BAKKENIST ARJ, 1980, BIOCHIM BIOPHYS ACTA, V613, P337, DOI 10.1016/0005-2744(80)90088-1; Baldus S, 2001, J CLIN INVEST, V108, P1759; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; Denzler KL, 2000, J IMMUNOL, V165, P5509, DOI 10.4049/jimmunol.165.10.5509; Denzler KL, 2001, J IMMUNOL, V167, P1672, DOI 10.4049/jimmunol.167.3.1672; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; FLORIS R, 1993, EUR J BIOCHEM, V215, P767, DOI 10.1111/j.1432-1033.1993.tb18091.x; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; Fridovich I, 1985, CRC HDB METHODS OXYG, P213; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; Halliwell B, 1999, FREE RADICAL RES, V31, P651, DOI 10.1080/10715769900301221; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1999, CIRC RES, V85, P950; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HAZEN SL, 1997, J CLIN INVEST, V99, P1; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Herold S, 1999, FEBS LETT, V443, P80, DOI 10.1016/S0014-5793(98)01591-9; HORI H, 1994, J BIOL CHEM, V269, P8388; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; HUIE RE, 1994, TOXICOLOGY, V89, P193, DOI 10.1016/0300-483X(94)90098-1; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jiang Q, 1997, J BIOL CHEM, V272, P32767, DOI 10.1074/jbc.272.52.32767; Koppenol WH, 2001, REDOX REP, V6, P229, DOI 10.1179/135100001101536373; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Lymar SV, 1996, CHEM RES TOXICOL, V9, P845, DOI 10.1021/tx960046z; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; Malm-Erjefalt M, 2001, AM J RESP CELL MOL, V24, P352, DOI 10.1165/ajrcmb.24.3.4357; MARQUEZ LA, 1994, J BIOL CHEM, V269, P7950; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; Mitra SN, 2000, REDOX REP, V5, P215, DOI 10.1179/135100000101535771; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Patel RP, 1999, BBA-BIOENERGETICS, V1411, P385, DOI 10.1016/S0005-2728(99)00028-6; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; PRYOR WA, 1981, SCIENCE, V214, P435, DOI 10.1126/science.214.4519.435; Radi R, 1999, METHOD ENZYMOL, V301, P353; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; SAMPSON JB, 1998, METHOD ENZYMOL, V269, P210; SCHULTZ J, 1962, ARCH BIOCHEM BIOPHYS, V96, P465, DOI 10.1016/0003-9861(62)90321-1; THOMAS HV, 1968, SCIENCE, V159, P532, DOI 10.1126/science.159.3814.532; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; Whiteman M, 1999, BIOCHEM BIOPH RES CO, V258, P168, DOI 10.1006/bbrc.1999.0564; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; Wu WJ, 1999, BIOCHEMISTRY-US, V38, P3538, DOI 10.1021/bi982401l; Zhang RL, 2002, BLOOD, V99, P1802, DOI 10.1182/blood.V99.5.1802.h8001802_1802_1810	62	427	438	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17415	17427		10.1074/jbc.M112400200	http://dx.doi.org/10.1074/jbc.M112400200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877405	hybrid			2022-12-25	WOS:000175685100007
J	Itahana, K; Dimri, GP; Hara, E; Itahana, Y; Zou, Y; Desprez, PY; Campisi, J				Itahana, K; Dimri, GP; Hara, E; Itahana, Y; Zou, Y; Desprez, PY; Campisi, J			A role for p53 in maintaining and establishing the quiescence growth arrest in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; HUMAN PAPILLOMAVIRUS TYPE-16; SENESCENT HUMAN FIBROBLASTS; DEVELOPMENTAL NEURON DEATH; CELLULAR SENESCENCE; DNA-DAMAGE; REPLICATIVE SENESCENCE; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; SIMIAN VIRUS-40	The p53 tumor suppressor protein induces transient growth arrest or apoptosis in response to genotoxic stress and mediates the irreversible growth arrest of cellular senescence. We present evidence here that p53 also contributes to the reversible, growth factor-dependent arrest of quiescence (G(o)). Microinjection of expression vectors encoding either MDM2 or a pRb-binding mutant of SV40 T antigen, both of which abrogate p53 function, stimulated quiescent normal human fibroblasts to initiate DNA synthesis and were 40-70% as effective as wild-type T antigen. Electrophoretic mobility shift and p53 transactivation assays showed that p53 activity was higher in quiescent and senescent cells compared with proliferating cells. As proliferating cells entered Go after growth factor withdrawal, the p53 mRNA level increased, followed by transient accumulation of the protein. Shortly thereafter, the expression (mRNA and protein) of p21, a p53 target gene and effector of cell cycle arrest, increased. Finally, stable expression of the HPV16 E6 oncogene or dominant negative p53 peptide, GSE-22, both of which inhibit p53 function, delayed entry into quiescence following growth factor withdrawal. Our data indicate that p53 is activated during both quiescence and senescence. They further suggest that p53 activity contributes, albeit not exclusively, to the quiescent growth arrest.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Tufts Univ New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA; Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England; Calif Pacific Med Ctr, San Francisco, CA 94115 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Tufts Medical Center; Paterson Institute for Cancer Research; California Pacific Medical Center	Campisi, J (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,MS 84-171, Berkeley, CA 94720 USA.		Dimri, Goberdhan/AAO-4210-2021; Itahana, Koji/J-5505-2013	Itahana, Koji/0000-0002-7241-2894	NATIONAL CANCER INSTITUTE [R01CA082548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009909, R01AG009909] Funding Source: NIH RePORTER; NCI NIH HHS [CA82548] Funding Source: Medline; NIA NIH HHS [AG09909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1994, ONCOGENE, V9, P1885; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Buschmann T, 2000, CANCER RES, V60, P896; Campisi J, 2000, IN VIVO, V14, P183; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dimri GP, 1996, BIOL SIGNAL, V5, P154; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DIMRI GP, 1994, MOL GENETICS CANC, P67; Dulic V, 2000, MOL CELL BIOL, V20, P6741, DOI 10.1128/MCB.20.18.6741-6754.2000; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GORMAN SD, 1985, J CELL PHYSIOL, V125, P122, DOI 10.1002/jcp.1041250116; Hara E, 1996, DEV GENET, V18, P161; Hara E, 1996, MOL CELL BIOL, V16, P859; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prives C, 1999, J PATHOL, V187, P112; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wright Woodring E., 1996, V16, P153; Zhang XH, 2000, MOL BIOL CELL, V11, P2117, DOI 10.1091/mbc.11.6.2117	61	80	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18206	18214		10.1074/jbc.M201028200	http://dx.doi.org/10.1074/jbc.M201028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11880381	hybrid			2022-12-25	WOS:000175685100103
J	Barata, H; de Meis, L				Barata, H; de Meis, L			Uncoupled ATP hydrolysis and thermogenic activity of the sarcoplasmic reticulum Ca2+-ATPase - Coupling effects of dimethyl sulfoxide and low temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-PRODUCTION; CALCIUM-PUMP; CA2+; TRANSPORT; VESICLES; MUSCLE; EFFLUX; MEMBRANES; MECHANISM; RELEASE	The sarcoplasmic reticulum. Ca2+-ATPase transports Ca2+ using the energy derived from ATP hydrolysis. During catalysis, part of the energy is used to translocate Ca2+ across the membrane, and part is dissipated as heat. At 35 degreesC the heat released during the hydrolysis of each ATP molecule varies depending on the formation of a Ca2+ gradient across the membrane. With leaky vesicles (no gradient) the heat released varies between 9 and 12 kcal/mol of ATP cleaved, and with intact vesicles (gradient), the heat released increases to 20-24 kcal/mol of ATP. After Ca2+ accumulation, 82% of the Ca2+-ATPase activity is not coupled to Ca2+ transport, and the ratio between Ca2+ transported and ATP cleaved is 0.3. The addition of 20% dimethyl sulfoxide (v/v) to the medium or decreasing the temperature from 35 to 20 degreesC abolishes the difference of heat produced during ATP hydrolysis in the presence and absence of a gradient. This is accompanied by a simultaneous inhibition of the uncoupled ATPase activity and an increase of the Ca2+/ATP ratio from 0.3 to 1.3-1.4. It is concluded that the uncoupled Ca2+-ATPase is responsible for both the low Ca2+/ATP ratio measured during transport and the difference of heat produced during ATP hydrolysis in the presence and absence of a gradient.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	de Meis, L (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.	demeis@biqmed.ufrj.br						BARLOGIE B, 1971, FEBS LETT, V12, P267, DOI 10.1016/0014-5793(71)80194-1; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; CHIESI M, 1979, J BIOL CHEM, V254, P370; CHINET A, 1992, J PHYSIOL-LONDON, V455, P663, DOI 10.1113/jphysiol.1992.sp019321; De Meis L, 1998, AM J PHYSIOL-CELL PH, V274, pC1738, DOI 10.1152/ajpcell.1998.274.6.C1738; de Meis L, 2001, J BIOL CHEM, V276, P25078, DOI 10.1074/jbc.M103318200; de Meis L, 2001, BIOSCIENCE REP, V21, P113, DOI 10.1023/A:1013640006611; de Meis L, 2000, BIOCHEM BIOPH RES CO, V276, P35, DOI 10.1006/bbrc.2000.3418; deMeis L, 1996, BBA-BIOENERGETICS, V1275, P105, DOI 10.1016/0005-2728(96)00058-8; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; deMeis L, 1997, FEBS LETT, V406, P201, DOI 10.1016/S0014-5793(97)00244-5; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1981, TRANSPORT LIFE SCI, V2, P1; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; HASSELBACH W, 1964, PROGR BIOPHYS MOL BI, V14, P169; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; JANSKY L, 1995, PHYSIOL REV, V75, P237, DOI 10.1152/physrev.1995.75.2.237; Logan-Smith MJ, 2001, J BIOL CHEM, V276, P46905, DOI 10.1074/jbc.M108778200; MAKINOSE M, 1971, FEBS LETT, V12, P269, DOI 10.1016/0014-5793(71)80195-3; MCWHIRTER JM, 1987, BIOCHEM J, V245, P731, DOI 10.1042/bj2450731; MELTZER S, 1984, J BIOL CHEM, V259, P4244; Mitidieri F, 1999, J BIOL CHEM, V274, P28344, DOI 10.1074/jbc.274.40.28344; Reis M, 2001, J BIOL CHEM, V276, P42793, DOI 10.1074/jbc.M107625200; Silva JE, 2001, J CLIN INVEST, V108, P35, DOI 10.1172/JCI13397; Sumbilla C, 2002, J BIOL CHEM, V277, P13900, DOI 10.1074/jbc.M111155200; TANFORD C, 1984, CRC CR REV BIOCH MOL, V17, P123, DOI 10.3109/10409238409113603; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	32	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16868	16872		10.1074/jbc.M200648200	http://dx.doi.org/10.1074/jbc.M200648200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880374	hybrid			2022-12-25	WOS:000175564500070
J	Chuang, RY; Chretien, L; Dai, JL; Kelly, TJ				Chuang, RY; Chretien, L; Dai, JL; Kelly, TJ			Purification and characterization of the Schizosaccharomyces pombe origin recognition complex - Interaction with origin DNA and Cdc18 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; REPLICATION ORIGIN; S-PHASE; SACCHAROMYCES-CEREVISIAE; EUKARYOTIC CELLS; GENETIC-ANALYSIS; BUDDING YEAST; MCM PROTEINS; ARS ELEMENTS; BINDING	The origin recognition complex (ORC) plays a central role in the initiation of DNA replication in eukaryotic cells. It interacts with origins of DNA replication in chromosomal DNA and recruits additional replication proteins to form functional initiation complexes. These processes have not been well characterized at the biochemical level except in the case of Saccharomyces cerevisiae ORC. We report here the expression, purification, and initial characterization of Schizosaccharomyces pombe ORC (SpORC) containing six recombinant subunits. Purified SpORC binds efficiently to the ars1 origin of DNA replication via the essential N-terminal domain of the SpOrc4 subunit which contains nine AT-hook motifs. Competition binding experiments demonstrated that SpORC binds preferentially to DNA molecules rich in AT-tracts, but does not otherwise exhibit a high degree of sequence specificity. The complex is capable of binding to multiple sites within the ars1 origin of DNA replication with similar affinities, indicating that the sequence requirements for origin recognition in S. pombe are significantly less stringent than in S. cerevisiae. We have also demonstrated that SpORC interacts directly with Cdc18p, an essential fission yeast initiation protein, and recruits it to the ars1 origin in vitro. Recruitment of Cdc18p to chromosomal origins is a likely early step in the initiation of DNA replication in vivo. These data indicate that the purified recombinant SpORC retains at least two of its primary biological functions and that it will be useful for the eventual reconstitution of the initiation reaction with purified proteins.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Johns Hopkins University	Kelly, TJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.	tkelly@jhmi.edu						Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Brown GW, 1997, P NATL ACAD SCI USA, V94, P6142, DOI 10.1073/pnas.94.12.6142; CAMPBELL JL, 1991, MOL CELLULAR BIOL YE, V1, P41; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Clyne RK, 1995, EMBO J, V14, P6348, DOI 10.1002/j.1460-2075.1995.tb00326.x; Clyne RK, 1997, METHODS, V13, P221, DOI 10.1006/meth.1997.0522; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P45; Dijkwel PA, 1999, METHODS, V18, P418, DOI 10.1006/meth.1999.0800; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; DUBEY DD, 1994, EMBO J, V13, P3638, DOI 10.1002/j.1460-2075.1994.tb06671.x; Dubey DD, 1996, CURR BIOL, V6, P467, DOI 10.1016/S0960-9822(02)00514-6; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Feng L, 2000, MOL BIOL CELL, V11, P1673, DOI 10.1091/mbc.11.5.1673; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Gomez M, 1999, EMBO J, V18, P5683, DOI 10.1093/emboj/18.20.5683; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Kearsey SE, 2000, EMBO J, V19, P1681, DOI 10.1093/emboj/19.7.1681; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kim SM, 1998, MOL CELL BIOL, V18, P7294, DOI 10.1128/MCB.18.12.7294; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Kong DC, 2001, MOL CELL BIOL, V21, P8095, DOI 10.1128/MCB.21.23.8095-8103.2001; Kornberg A., 1992, DNA REPLICATION; Lee JK, 2001, P NATL ACAD SCI USA, V98, P13589, DOI 10.1073/pnas.251530398; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lygerou Z, 1999, J CELL SCI, V112, P3703; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MCKAY R, 1983, METHOD ENZYMOL, V92, P138; Mizushima T, 2000, GENE DEV, V14, P1631; Moon KY, 1999, P NATL ACAD SCI USA, V96, P12367, DOI 10.1073/pnas.96.22.12367; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; Newlon C. S., 1996, DNA REPLICATION EUKA, P873; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Vas A, 2001, MOL CELL BIOL, V21, P5767, DOI 10.1128/MCB.21.17.5767-5777.2001; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; Wang B, 1999, J BIOL CHEM, V274, P8291, DOI 10.1074/jbc.274.12.8291	44	38	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16920	16927		10.1074/jbc.M107710200	http://dx.doi.org/10.1074/jbc.M107710200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11850415	hybrid			2022-12-25	WOS:000175564500078
J	Harper, CC; South, ST; McCaffery, JM; Gould, SJ				Harper, CC; South, ST; McCaffery, JM; Gould, SJ			Peroxisomal membrane protein import does not require Pex17p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR DOCKING COMPLEX; PICHIA-PASTORIS; ZELLWEGER-SYNDROME; TARGETING SIGNAL; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL COMPLEMENTATION; BIOGENESIS DISORDERS; YARROWIA-LIPOLYTICA; GENE ENCODES; CDNA CLONING	Of the similar to20 proteins required for peroxisome biogenesis, only four have been implicated in the process of peroxisomal membrane protein (PMP) import: Pex3p, Pex16p, Pex17p, and Pex19p. To improve our understanding of the role that Pex17p plays in PMP import, we examined the behavior of PMPs in a Pichia pastoris pex17 mutant. Relative to wild-type cells, pex17 cells appeared to have a mild reduction in PMP stability and slightly aberrant PMP behavior in subcellular fractionation experiments. However, we also found that the behavior of PMPs in the pex17 mutant was indistinguishable from PMP behavior in a pex5 mutant, which has no defect in PMP import, and was far different from PMP behavior in a pex3 mutant, which has a bona fide defect in PMP import. Furthermore, we found that a pex14 mutant, which has no defect in PMP import, lacks detectable levels of Pex17p. Based on these and other results, we propose that Pex17p acts primarily in the matrix protein import pathway and does not play an important role in PMP import.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Integrated Imaging Ctr, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	agould@jhmi.edu			NIDDK NIH HHS [DK59479, DK45787] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787, R01DK059479] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Baes M, 1997, NAT GENET, V17, P49, DOI 10.1038/ng0997-49; BAKERBRACHMANN C, 1998, YEAST, V14, P115; Chang CC, 1999, J CELL SCI, V112, P1579; CRANE DI, 1994, J BIOL CHEM, V269, P21835; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gotte K, 1998, MOL CELL BIOL, V18, P616; GOULD SG, 2001, METABOLIC MOL BASES, V2, P3181; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; HEINEMANN P, 1992, FEBS LETT, V300, P179, DOI 10.1016/0014-5793(92)80191-I; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Hettema EH, 2000, BBA-MOL CELL BIOL L, V1486, P18, DOI 10.1016/S1388-1981(00)00045-7; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Johnson MA, 2001, YEAST, V18, P621, DOI 10.1002/yea.711; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; KALISH JE, 1995, MOL CELL BIOL, V15, P6406; Kalish JE, 1996, EMBO J, V15, P3275, DOI 10.1002/j.1460-2075.1996.tb00692.x; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; Snyder WB, 1999, MOL BIOL CELL, V10, P4005, DOI 10.1091/mbc.10.12.4005; South ST, 2000, J CELL BIOL, V149, P1345, DOI 10.1083/jcb.149.7.1345; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Tabak HF, 1999, TRENDS CELL BIOL, V9, P447, DOI 10.1016/S0962-8924(99)01650-5; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; Titorenko VI, 2000, J CELL BIOL, V150, P881, DOI 10.1083/jcb.150.4.881; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; vanRoermund CWT, 1995, BBA-GEN SUBJECTS, V1245, P348, DOI 10.1016/0304-4165(95)00099-2; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; Wanders RJA, 2001, BIOCHEM SOC T, V29, P250, DOI 10.1042/0300-5127:0290250; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973	44	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16498	16504		10.1074/jbc.M111728200	http://dx.doi.org/10.1074/jbc.M111728200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859077	hybrid			2022-12-25	WOS:000175564500023
J	Lassak, A; Del Valle, L; Peruzzi, F; Wang, JY; Enam, S; Croul, S; Khalili, K; Reiss, K				Lassak, A; Del Valle, L; Peruzzi, F; Wang, JY; Enam, S; Croul, S; Khalili, K; Reiss, K			Insulin receptor substrate 1 translocation to the nucleus by the human JC virus T-antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PLECKSTRIN HOMOLOGY DOMAIN; MOUSE EMBRYO FIBROBLASTS; IRS-1 SIGNALING SYSTEM; LARGE TUMOR-ANTIGEN; BIOLOGICAL PROPERTIES; SIMIAN VIRUS-40; CANCER CELLS; TRANSFORMATION; EXPRESSION	Insulin receptor substrate 1 (IRS-1) is the major signaling molecule for the insulin and insulin-like growth factor I receptors, which transduces both metabolic and growth-promoting signals, and has transforming properties when overexpressed in the cells. Here we show that IRS-1 is translocated to the nucleus in the presence of the early viral protein-T-antigen of the human polyomavirus JC. Nuclear IRS-1 was detected in T-antigen-positive cell lines and in T-antigen-positive biopsies from patients diagnosed with medulloblastoma. The IRS-1 domain responsible for a direct JC virus T-antigen binding was localized within the N-terminal portion of IRS-1 molecule, and the binding was independent from IRS-1 tyrosine phosphorylation and was strongly inhibited by IRS-1 serine phosphorylation. In addition, competition for the IRS-1-T-antigen binding by a dominant negative mutant of IRS-1 inhibited growth and survival of JC virus T-antigen-transformed cells in anchorage-independent culture conditions. Based on these findings, we propose a novel role for the IRS-1-T-antigen complex in controlling cellular equilibrium during viral infection. It may involve uncoupling of IRS-1 from its surface receptor and translocation of its function to the nucleus.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reiss, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St,Biol Life Sci Bldg,Rm 238, Philadelphia, PA 19122 USA.		Del Valle, Luis/J-4085-2015; Peruzzi, Francesca/M-9804-2014	Del Valle, Luis/0000-0003-3894-9206; Croul, Sidney/0000-0002-2224-5485	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS 36466] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; CSERMELY P, 1993, J BIOL CHEM, V268, P9747; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Del Valle L, 2001, CANCER RES, V61, P4287; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; FEI ZL, 1995, MOL CELL BIOL, V15, P4232; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Khalili K, 1999, LANCET, V353, P1152, DOI 10.1016/S0140-6736(99)00357-8; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; LANFORD RE, 1985, MOL CELL BIOL, V5, P1043, DOI 10.1128/MCB.5.5.1043; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Major E O, 1983, Prog Clin Biol Res, V105, P289; MAJOR EO, 1984, VIROLOGY, V136, P359, DOI 10.1016/0042-6822(84)90172-7; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; Nehrbass D, 1998, AM J PATHOL, V152, P341; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; PINKERT CA, 1987, VIROLOGY, V160, P169, DOI 10.1016/0042-6822(87)90057-2; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; White MF, 1998, RECENT PROG HORM RES, V53, P119; WHITE MF, 1997, DIABETOLOGIA, V40, P2	45	102	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17231	17238		10.1074/jbc.M110885200	http://dx.doi.org/10.1074/jbc.M110885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877394	hybrid			2022-12-25	WOS:000175564500117
J	Boucher, P; Liu, PS; Gotthardt, M; Hiesberger, T; Anderson, RGW; Herz, J				Boucher, P; Liu, PS; Gotthardt, M; Hiesberger, T; Anderson, RGW; Herz, J			Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low density lipoprotein receptor-related protein in caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETERGENT-RESISTANT COMPLEXES; MUSCLE-CELL-MIGRATION; APOLIPOPROTEIN-E; SIGNAL-TRANSDUCTION; UROKINASE RECEPTOR; ENDOCYTIC RECEPTOR; VLDL RECEPTOR; BINDING; LRP; THROMBOSPONDIN-1	The low density lipoprotein (LDL) receptor gene family represents a class of multifunctional, endocytic cell surface receptors. Recently, roles in cellular signaling have also emerged. For instance, the very low density lipoprotein receptor (VLDLR) and the apolipoprotein receptor-2 (apoER2) function in a developmental signaling pathway that regulates the lamination of cortical layers in the brain and involves the activation of tyrosine kinases. Furthermore, the cytoplasmic domain of the LDL receptor-related protein (LRP) was found to be a substrate for the non-receptor tyrosine kinase Src, but the physiological significance of this phosphorylation event remained unknown. Here we show that tyrosine phosphorylation of LRP occurs in caveolae and involves the platelet-derived growth factor (PDGF) receptor beta and phosphoinositide 3-kinase. Receptor-associated protein, an antagonist of ligand binding to LRP, and apoE-enriched beta-VLDL, a ligand for LRP, reduce PDGF-induced tyrosine phosphorylation of the LRP cytoplasmic domain. In the accompanying paper (Loukinova, E., Ranganathan, S., Kuznetsov, S., Gorlatova, N., Migliorini, M., Ulery, P. G., Mikhailenko, I., Lawrence, D. L., and Strickland, D. K. (2002) J. Biol. Chem. 277, 15499-15506) Loukinova et al. further demonstrate that one form of PDGF, PDGF-BB, binds specifically to LRP and that phosphorylation of LRP requires the activation of Src family kinases. Taken together, these findings provide a biochemical basis for a cellular signaling pathway that involves apoE and LRP.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Harry Hines Blvd, Dallas, TX 75390 USA.	Joachim.Herz@UTSouthwestern.edu	Gotthardt, Michael/ABE-8274-2021; Liu, Pingsheng/B-7124-2012	Gotthardt, Michael/0000-0003-1788-3172; Boucher, Philippe/0000-0002-3928-9812	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063732, P01HL020948, R37HL063762] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL063762, HL20948, HL63732] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BOHUSLAV J, 1993, EUR J IMMUNOL, V23, P825, DOI 10.1002/eji.1830230409; Bu GJ, 1998, J BIOL CHEM, V273, P13359, DOI 10.1074/jbc.273.21.13359; BULL HA, 1994, FEBS LETT, V351, P41, DOI 10.1016/0014-5793(94)00814-0; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Chen H, 1996, BIOCHEM J, V318, P959, DOI 10.1042/bj3180959; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Hasty AH, 1999, CIRCULATION, V99, P2571, DOI 10.1161/01.CIR.99.19.2571; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Ho YY, 2001, J BIOL CHEM, V276, P43455, DOI 10.1074/jbc.M105325200; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1999, BIOCHEM BIOPH RES CO, V261, P695, DOI 10.1006/bbrc.1999.1082; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; Swertfeger DK, 2001, FRONT BIOSCI-LANDMRK, V6, pD526, DOI 10.2741/Swertfeg; Swertfeger DK, 2001, J BIOL CHEM, V276, P25043, DOI 10.1074/jbc.M102357200; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Webb DJ, 2000, PROTEIN SCI, V9, P1986, DOI 10.1110/ps.9.10.1986; Webb DJ, 2000, J CELL SCI, V113, P123; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	41	171	177	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15507	15513		10.1074/jbc.M200428200	http://dx.doi.org/10.1074/jbc.M200428200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854295	hybrid			2022-12-25	WOS:000175510400039
J	Hara-Kuge, S; Ohkura, T; Ideo, H; Shimada, O; Atsumi, S; Yamashita, K				Hara-Kuge, S; Ohkura, T; Ideo, H; Shimada, O; Atsumi, S; Yamashita, K			Involvement of VIP36 in intracellular transport and secretion of glycoproteins in polarized Madin-Darby canine kidney (MDCK) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL SECRETION; MOLECULAR CHAPERONE; LEGUMINOUS LECTINS; EPITHELIAL-CELLS; N-GLYCOSYLATION; PROTEIN; PATHWAY; GLYCANS; COMPONENT; ERGIC-53	VIP36, an intracellular lectin that recognizes high mannose-type glycans (Hara-Ruge, S., Ohkura, T., Seko, A., and Yamashita, K. (1999) Glycobiology 9, 833-839), was shown to localize not only to the early secretory pathway but also to the plasma membrane of Madin-Darby canine kidney (MDCK) cells. In the plasma membrane, VIP36 exhibited an apical-predominant distribution, the apical/basolateral ratio being similar to2. Like VIP36, plasma membrane glycoproteins recognized by VIP36 were found in the apical and basolateral membranes in the ratio of similar to2 to 1. In addition, secretory glycoproteins recognized by VIP36 were secreted similar to2-fold more efficiently from the apical membrane than from the basolateral membrane. Thus, the apical/basolateral ratio of the transport of VIP36-recognized glycoproteins was correlated with that of VIP36 in MDCK cells. Upon overproduction of VIP36 in MDCK cells, the apical/basolateral ratios of both VIP36 and VIP36-recognized glycoproteins were changed from similar to2 to similar to4, and the secretion of VIP36-recognized glycoproteins was greatly stimulated. In contrast to the overproduction of VIP36, that of a mutant version of VIP36, which has no lectin activity, was of no effect on the distribution of glycoproteins to apical and basolateral membranes and inhibited the secretion of VIP36-recognized glycoproteins. Furthermore, the overproduction of VIP36 greatly stimulated the secretion of a major apical secretory glycoprotein of MDCK cells, clusterin, which was found to carry at least one high mannose-type glycan and to be recognized by VIP36. In contrast to the secretion of clusterin, that of a non-glycosylated apical-secretion protein, galectin-3, was not stimulated through the overproduction of VIP36. These results indicated that VIP36 was involved in the transport and sorting of glycoproteins carrying high mannose-type glycan(s).	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan; Yamanashi Med Univ, Dept Anat, Yamanashi 4093898, Japan	Japan Science & Technology Agency (JST); University of Yamanashi	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.							Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; ARAR C, 1995, J BIOL CHEM, V270, P3351; Dahm T, 2001, MOL BIOL CELL, V12, P1481, DOI 10.1091/mbc.12.5.1481; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; Fukushima K, 1997, J BIOL CHEM, V272, P10579; Fullekrug J, 1999, J CELL SCI, V112, P2813; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; Kobata A., 1993, GLYCOBIOLOGY PRACTIC, P103; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; Martinez-Maza R, 2001, J BIOL CHEM, V276, P2168, DOI 10.1074/jbc.M006774200; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; YAMASHITA K, 1980, BIOCHEM BIOPH RES CO, V96, P1335, DOI 10.1016/0006-291X(80)90097-2; YAMASHITA K, 1992, BIOCHEMISTRY-US, V31, P11647, DOI 10.1021/bi00161a052	27	73	75	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16332	16339		10.1074/jbc.M112188200	http://dx.doi.org/10.1074/jbc.M112188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11872745	hybrid			2022-12-25	WOS:000175510400144
J	Lapucci, A; Donnini, M; Papucci, L; Witort, E; Tempestini, A; Bevilacqua, A; Nicolin, A; Brewer, G; Schiavone, N; Capaccioli, S				Lapucci, A; Donnini, M; Papucci, L; Witort, E; Tempestini, A; Bevilacqua, A; Nicolin, A; Brewer, G; Schiavone, N; Capaccioli, S			AUF1 is a bcl-2 A+U-rich element-binding protein involved in bcl-2 mRNA destabilization during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; DOWN-REGULATION; 1ST STEP; SEQUENCE; IDENTIFICATION; HUR; STABILIZATION; PURIFICATION	We previously identified a conserved A + U-rich element (ARE) in the 3'-untranslated region of bcl-2 mRNA. We have also recently demonstrated that the bcl-2 ARE interacts with a number of ARE-binding proteins (AUBPs) whose pattern changes during apoptosis in association with bcl-2 mRNA half-life reduction. Here we show that the AUBP AUF1 binds in vitro to bcl-2 mRNA. The results obtained in a yeast RNA three-hybrid system have demonstrated that the 1-257-amino acid portion of p37 AUF1 (conserved in all isoforms), containing the two RNA recognition motifs, also binds to the bcl-2 ARE in vivo. UVC irradiation-induced apoptosis results in an increase of AUF1. Inhibition of apoptosis by a general caspase inhibitor reduces this increase by 2-3-fold. These results indicate involvement of AUF1 in the ARE/ AUBP-mediated modulation of bcl-2 mRNA decay during apoptosis.	Univ Florence, Sch Med, Dept Expt Pathol & Oncol, I-50134 Florence, Italy; Univ Milan, Sch Med, Dept Pharmacol, I-20129 Milan, Italy; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	University of Florence; University of Milan; Rutgers State University New Brunswick; Rutgers State University Medical Center	Schiavone, N (corresponding author), Univ Florence, Sch Med, Dept Expt Pathol & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.	nicola@unifi.it; sergio@unifi.it	Lapucci, Andrea/AAA-6645-2019; Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424; Schiavone, Nicola/0000-0002-1592-4244; LAPUCCI, Andrea/0000-0001-9613-7164; Papucci, Laura/0000-0002-8450-7428	NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; Blaxall BC, 2000, MOL CARCINOGEN, V28, P76; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Donnini M, 2001, BIOCHEM BIOPH RES CO, V287, P1063, DOI 10.1006/bbrc.2001.5700; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; GILLIS P, 1991, J BIOL CHEM, V266, P3172; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; Kingma BR, 2000, INTERLEND DOC SUPPLY, V28, P20, DOI 10.1108/02641610010314858; Kraemer B, 2000, METHOD ENZYMOL, V328, P297, DOI 10.1016/S0076-6879(00)28404-8; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Madireddi MT, 2000, ONCOGENE, V19, P1362, DOI 10.1038/sj.onc.1203424; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NAKAMAKI T, 1995, J CELL PHYSIOL, V165, P484, DOI 10.1002/jcp.1041650306; PENG SS, 1988, EMBO J, V17, P3461; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Putz U, 1996, NUCLEIC ACIDS RES, V24, P4838, DOI 10.1093/nar/24.23.4838; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sheflin LG, 2000, AM J PHYSIOL-ENDOC M, V278, pE50, DOI 10.1152/ajpendo.2000.278.1.E50; Suzuki A, 1996, ONCOGENE, V13, P31; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	45	78	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16139	16146		10.1074/jbc.M201377200	http://dx.doi.org/10.1074/jbc.M201377200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856759	hybrid			2022-12-25	WOS:000175510400122
J	Salicioni, AM; Mizelle, KS; Loukinova, E; Mikhailenko, I; Strickland, DK; Gonias, SL				Salicioni, AM; Mizelle, KS; Loukinova, E; Mikhailenko, I; Strickland, DK; Gonias, SL			The low density lipoprotein receptor-related protein mediates fibronectin catabolism and inhibits fibronectin accumulation on cell surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GROWTH FACTOR-BB; ALPHA-2-MACROGLOBULIN RECEPTOR; UROKINASE RECEPTOR; EXTRACELLULAR-MATRIX; PLASMA FIBRONECTIN; IN-VIVO; PLASMINOGEN ACTIVATORS; BIOLOGICAL-ACTIVITIES; BINDING-PROTEINS	Low density lipoprotein receptor-related protein (LRP) is a member of the low density lipoprotein receptor family, which functions as an endocytic receptor for diverse ligands. In this study, we demonstrate that murine embryonic fibroblasts (MEF-2 cells) and 13-5-1 Chinese hamster ovary cells, which are LRP-deficient, accumulate greatly increased levels of cell-surface fibronectin (Fn), compared with LRP-expressing MEF-1 and CHO-K1 cells. Increased Fn was also detected in conditioned medium from LRP-deficient MEF-2 cells; however, biosynthesis of Fn by MEF-1 and MEF-2 cells was not significantly different. When LRP-deficient cells were dissociated from monolayer culture, increased levels of Fn remained with the cells, as determined by cell-surface protein biotinylation, suggesting an intimate relationship with cell surface-binding sites. The LRP antagonist, receptor-associated protein (RAP), promoted Fn accumulation in association with MEF-1 cells, whereas expression of full-length LRP in MEF-2 cells substantially decreased Fn accumulation, confirming the role of LRP in this process. Purified LRP bound directly to immobilized Fn, and this interaction was inhibited by RAP. Furthermore, MEF-1 cells degraded I-125-Fn at an increased rate, compared with MEF-2 cells. I-125-Fn degradation by MEF-1 cells was inhibited by RAP. These results demonstrate that LRP functions as a catabolic receptor for Fn. The function of LRP in Fn degradation and the ability of LRP to regulate levels of other plasma membrane proteins represent possible mechanisms whereby LRP prevents Fn accumulation on cell surfaces.	Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Mol Genet, Charlottesville, VA 22908 USA; Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	University of Virginia; University of Virginia; University of Virginia; American Red Cross	Gonias, SL (corresponding author), Univ Virginia, Sch Med, Dept Pathol, Box 800214, Charlottesville, VA 22908 USA.	slg2t@virginia.edu	Salicioni, Ana Maria/ABD-8384-2021	Salicioni, Ana Maria/0000-0002-8951-3587	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060551, R01HL050784, P01HL054710] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50784, HL54710, HL60551] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Akamatsu H, 1996, CANCER RES, V56, P4541; Akimov SS, 2001, J CELL SCI, V114, P2989; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; Barmina OY, 1999, J BIOL CHEM, V274, P30087, DOI 10.1074/jbc.274.42.30087; Berry H, 1998, ANN NY ACAD SCI, V864, P198, DOI 10.1111/j.1749-6632.1998.tb10304.x; Bonnefoy A, 2000, THROMB RES, V98, P323, DOI 10.1016/S0049-3848(99)00242-X; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; Bu GJ, 2000, TRENDS CARDIOVAS MED, V10, P148, DOI 10.1016/S1050-1738(00)00045-1; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; FUKAI F, 1995, BIOCHEMISTRY-US, V34, P11453, DOI 10.1021/bi00036a018; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GOLD LI, 1989, BIOCHEM J, V262, P529, DOI 10.1042/bj2620529; Hamik A, 1999, J BIOL CHEM, V274, P4962, DOI 10.1074/jbc.274.8.4962; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hocking DC, 1998, J CELL BIOL, V141, P241, DOI 10.1083/jcb.141.1.241; HYNES RO, 1990, SPRINGER SERIES MOL, P200; Ilic D, 1998, J CELL BIOL, V143, P547; Kapila YL, 2002, J BIOL CHEM, V277, P8482, DOI 10.1074/jbc.M108932200; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; Koide A, 1998, J MOL BIOL, V284, P1141, DOI 10.1006/jmbi.1998.2238; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Mikhailenko I, 1999, J CELL SCI, V112, P3269; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOLLA A, 1988, BIOCHIM BIOPHYS ACTA, V955, P77; MOSHER DF, 1984, ANNU REV MED, V35, P561, DOI 10.1146/annurev.me.35.020184.003021; MOSHER DF, 1991, ANN NY ACAD SCI, V614, P167; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Plump AS, 1999, ARTERIOSCL THROM VAS, V19, P1105, DOI 10.1161/01.ATV.19.4.1105; Rostagno AA, 1999, BIOCHEM J, V338, P375, DOI 10.1042/0264-6021:3380375; Rotundo RF, 1999, AM J PHYSIOL-GASTR L, V277, pG1189, DOI 10.1152/ajpgi.1999.277.6.G1189; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SCHWARZBAUER JE, 1991, BIOESSAYS, V13, P527, DOI 10.1002/bies.950131006; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V154, P15, DOI 10.1111/j.1432-1033.1986.tb09353.x; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; WARSHAWSKY I, 1994, ANN NY ACAD SCI, V737, P70, DOI 10.1111/j.1749-6632.1994.tb44302.x; Watanabe K, 2000, BIOCHEMISTRY-US, V39, P7138, DOI 10.1021/bi992670r; Weaver AM, 1996, J BIOL CHEM, V271, P24894, DOI 10.1074/jbc.271.40.24894; Webb DJ, 2000, J CELL SCI, V113, P123; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; WILLNOW TE, 1994, J CELL SCI, V107, P719; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	66	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16160	16166		10.1074/jbc.M201401200	http://dx.doi.org/10.1074/jbc.M201401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867643	hybrid			2022-12-25	WOS:000175510400125
J	Hertzog, M; Yarmola, EG; Didry, D; Bubb, MR; Carlier, MF				Hertzog, M; Yarmola, EG; Didry, D; Bubb, MR; Carlier, MF			Control of actin dynamics by proteins made of beta-thymosin repeats - The actobindin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA ACTOBINDIN; ARP2/3 COMPLEX; F-ACTIN; BINDING PROTEIN; LATRUNCULIN-A; POLYMERIZATION; PROFILIN; FILAMENT; MODULATION; PURIFICATION	Actobindin is an actin-binding protein from amoeba, which consists of two beta-thymosin repeats and has been shown to inhibit actin polymerization by sequestering G-actin and by stabilizing actin dimers. Here we show that actobindin has the same biochemical properties as the Drosophila or Caenorhabditis elegans homologous protein that consists of three beta-thymosin repeats. These proteins define a new family of actin-binding proteins. They bind G-actin in a 1:1 complex with thermodynamic and kinetic parameters similar to beta-thymosins. Like beta-thymosins, they slow down nucleotide exchange on G-actin and make a ternary complex with G-actin and Latrunculin A. On the other hand, they behave as functional homologs of profilin because their complex with MgATP-G-actin, unlike beta-thymosin-actin, participates in filament barbed end growth, like profilin-actin complex. Therefore these proteins play an active role in actin-based motility processes. In addition, proteins of the actobindin family interact with the pointed end of actin filaments and inhibit pointed end growth, maybe via the interaction of the beta-thymosin repeats with two terminal subunits.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Univ Florida, Div Rheumatol, Gainesville, FL 32608 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; State University System of Florida; University of Florida	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.							Boquet I, 2000, CELL, V102, P797, DOI 10.1016/S0092-8674(00)00068-4; Boujemaa-Paterski R, 2001, BIOCHEMISTRY-US, V40, P11390, DOI 10.1021/bi010486b; BUBB MR, 1991, J BIOL CHEM, V266, P3820; BUBB MR, 1995, BIOCHEMISTRY-US, V34, P3921, DOI 10.1021/bi00012a008; BUBB MR, 1994, J BIOL CHEM, V269, P25592; BUBB MR, 1994, J BIOL CHEM, V269, P25587; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLIER MF, 1985, J BIOL CHEM, V260, P6565; CASELLA JF, 1986, J BIOL CHEM, V261, P915; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; De La Cruz EM, 2000, BIOPHYS J, V78, P2516, DOI 10.1016/S0006-3495(00)76797-X; DETMERS P, 1981, J BIOL CHEM, V256, P99; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; HUFF T, 1995, EUR J BIOCHEM, V230, P650; JEAN C, 1994, J MUSCLE RES CELL M, V15, P278; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAMBOOY PK, 1986, J BIOL CHEM, V261, P7150; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; Manuel M, 2000, J MOL EVOL, V51, P378, DOI 10.1007/s002390010100; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PAUNOLA E, 2001, FEBS LETT, P1; PERELROIZEN I, 1995, J BIOL CHEM, V270, P1501, DOI 10.1074/jbc.270.4.1501; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; SAFER D, 1991, J BIOL CHEM, V266, P4029; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; SAFER D, 1994, BIOESSAYS, V16, P473, DOI 10.1002/bies.950160706; Safer D, 1997, CELL MOTIL CYTOSKEL, V38, P163, DOI 10.1002/(SICI)1097-0169(1997)38:2<163::AID-CM5>3.0.CO;2-8; SANGER JM, 1995, CELL MOTIL CYTOSKEL, V31, P305; Simenel C, 2000, EUR J BIOCHEM, V267, P3530, DOI 10.1046/j.1432-1327.2000.01380.x; Stoeva S, 1997, J PEPT SCI, V3, P282; VANCOMPERNOLLE K, 1992, EMBO J, V11, P4739, DOI 10.1002/j.1460-2075.1992.tb05579.x; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; VANDEKERCKHOVE J, 1990, J BIOL CHEM, V265, P12801; WEBER A, 1994, BIOCHEMISTRY-US, V33, P4780, DOI 10.1021/bi00182a005; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; Yarmola EG, 2001, J BIOL CHEM, V276, P45555, DOI 10.1074/jbc.M105723200; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; YU FX, 1993, J BIOL CHEM, V268, P502	43	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14786	14792		10.1074/jbc.M112064200	http://dx.doi.org/10.1074/jbc.M112064200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11856744	Green Submitted, hybrid			2022-12-25	WOS:000175203000057
J	Kesavan, KP; Isaacson, CC; Ashendel, CL; Geahlen, RL; Harrison, ML				Kesavan, KP; Isaacson, CC; Ashendel, CL; Geahlen, RL; Harrison, ML			Characterization of the in vivo sites of serine phosphorylation on Lck identifying serine 59 as a site of mitotic phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; N-TERMINAL REGION; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; T-LYMPHOCYTES; SH2 DOMAIN; ACTIVATION; P56(LCK); SRC	The lymphocyte-specific protein-tyrosine kinase Lck plays a critical role in T cell activation. In response to T cell antigen receptor binding Lck undergoes phosphorylation on serine residues that include serines 59 and 194. Serine 59 is phosphorylated by ERK mitogen-activated protein kinase. Recently, we showed that in mitotic T cells Lck becomes hyper-phosphorylated on serine residues. In this report, using one-dimensional phosphopeptide mapping analysis, we identify serine 59 as a site of in vivo mitotic phosphorylation in Lck. The mitotic phosphorylation of serine 59 did not require either the catalytic activity or functional SH2 or SH3 domains of Lck. In addition, the presence of ZAP-70 also was dispensable for the phosphorylation of serine 59. Although previous studies demonstrated that serine 59 is a substrate for the ERK MAPK pathway, inhibitors of this pathway did not block the mitotic phosphorylation of serine 59. These results identify serine 59 as a site of mitotic phosphorylation in Lck and suggest that a pathway distinct from that induced by antigen receptor signaling is responsible for its phosphorylation. Thus, the phosphorylation of serine 59 is the result of two distinct signaling pathways, differentially activated in response to the physiological state of the T cell.	Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Harrison, ML (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, Life Sci Res Bldg, W Lafayette, IN 47907 USA.			Geahlen, Robert/0000-0001-8400-2924	NIGMS NIH HHS [GM48099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048099] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Ramadi BK, 1998, P NATL ACAD SCI USA, V95, P12498, DOI 10.1073/pnas.95.21.12498; AUGUST A, 1996, J BIOL CHEM, V271, P10045; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; DADD CA, 1993, BIOTECHNIQUES, V14, P266; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Galron D, 1997, CELL IMMUNOL, V178, P141, DOI 10.1006/cimm.1997.1120; GOLD MR, 1994, J IMMUNOL, V153, P2369; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; Huby RDJ, 1998, J BIOL CHEM, V273, P12024, DOI 10.1074/jbc.273.20.12024; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; JOUNG I, 1995, P NATL ACAD SCI USA, V92, P5778, DOI 10.1073/pnas.92.13.5778; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Lee JE, 1997, J IMMUNOL, V159, P61; LOU K, 1990, ONCOGENE, V5, P803; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MARTH JD, 1989, J IMMUNOL, V142, P2430; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; Moasser MM, 1999, CANCER RES, V59, P6145; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Norian LA, 2000, SEMIN IMMUNOL, V12, P43; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; Pathan NI, 1996, J BIOL CHEM, V271, P27517, DOI 10.1074/jbc.271.44.27517; Pathan NI, 1996, J BIOL CHEM, V271, P30315, DOI 10.1074/jbc.271.48.30315; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Schroder AJ, 2000, EUR J IMMUNOL, V30, P635, DOI 10.1002/1521-4141(200002)30:2<635::AID-IMMU635>3.0.CO;2-H; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; SOULA M, 1993, J BIOL CHEM, V268, P27420; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VORONOVA AF, 1986, J BIOL CHEM, V257, P10738; WATTS JD, 1993, J BIOL CHEM, V268, P23275; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; WINKLER DG, 1993, P NATL ACAD SCI USA, V90, P5176, DOI 10.1073/pnas.90.11.5176; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yasunaga M, 1996, J CELL BIOL, V132, P91, DOI 10.1083/jcb.132.1.91; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205	52	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14666	14673		10.1074/jbc.M111911200	http://dx.doi.org/10.1074/jbc.M111911200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847223	hybrid			2022-12-25	WOS:000175203000041
J	Kochs, G; Haener, M; Aebi, U; Haller, O				Kochs, G; Haener, M; Aebi, U; Haller, O			Self-assembly of human MxA GTPase into highly ordered dynamin-like oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CONFORMATIONAL CHANGE; ANTIVIRAL ACTIVITY; INFLUENZA-VIRUS; ALUMINUM FLUORIDE; TARGET STRUCTURES; BINDING PROTEINS; TRANSGENIC MICE; THOGOTO-VIRUS; DOMAINS; RESISTANCE	Human MxA protein is a member of the interferon-induced Mx protein family and an important component of the innate host defense against RNA viruses. The Mx family belongs to a superfamily of large GTPases that also includes the dynamins and the interferon-regulated guanylate-binding proteins. A common feature of these large GTPases is their ability to form high molecular weight oligomers. Here we determined the capacity of MxA to self-assemble into homo-oligomers in vitro. We show that recombinant MxA protein assembles into long filamentous structures with a diameter of about 20 nm at physiological salt concentration as demonstrated by sedimentation assays and electron microscopy. In the presence of guanosine nucleotides the filaments rearranged into rings and more compact helical arrays. Our data indicate that binding and hydrolysis of GTP induce conformational changes in MxA that may be essential for viral target recognition and antiviral activity.	Univ Freiburg, Inst Med Mikrobiol & Hyg, Abt Virol, D-79008 Freiburg, Germany; Univ Basel, Biozentrum, ME Muller Inst Microscopy, CH-4056 Basel, Switzerland	University of Freiburg; University of Basel	Kochs, G (corresponding author), Univ Freiburg, Inst Med Mikrobiol & Hyg, Abt Virol, D-79008 Freiburg, Germany.							Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Di Paolo C, 1999, J BIOL CHEM, V274, P32071, DOI 10.1074/jbc.274.45.32071; Flohr F, 1999, FEBS LETT, V463, P24, DOI 10.1016/S0014-5793(99)01598-7; FRESE M, 1995, J VIROL, V69, P3904, DOI 10.1128/JVI.69.6.3904-3909.1995; Gu XJ, 1996, EMBO J, V15, P695, DOI 10.1002/j.1460-2075.1996.tb00405.x; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; Hefti HP, 1999, J VIROL, V73, P6984, DOI 10.1128/JVI.73.8.6984-6991.1999; Hinshaw JE, 1999, CURR OPIN STRUC BIOL, V9, P260, DOI 10.1016/S0959-440X(99)80036-0; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Janzen C, 2000, J VIROL, V74, P8202, DOI 10.1128/JVI.74.17.8202-8206.2000; Kochs G, 1998, METHODS, V15, P255, DOI 10.1006/meth.1998.0629; Kochs G, 1999, J BIOL CHEM, V274, P4370, DOI 10.1074/jbc.274.7.4370; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; MELEN K, 1992, J BIOL CHEM, V267, P25898; MELEN K, 1994, J BIOL CHEM, V269, P2009; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; Niemann HH, 2001, EMBO J, V20, P5813, DOI 10.1093/emboj/20.21.5813; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Park JM, 1998, EMBO J, V17, P859, DOI 10.1093/emboj/17.4.859; PAVLOVIC J, 1995, J VIROL, V69, P4506, DOI 10.1128/JVI.69.7.4506-4510.1995; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Pitts KR, 1999, MOL BIOL CELL, V10, P4403, DOI 10.1091/mbc.10.12.4403; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; Sever S, 2000, TRAFFIC, V1, P385, DOI 10.1034/j.1600-0854.2000.010503.x; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; SIMON A, 1991, J VIROL, V65, P968, DOI 10.1128/JVI.65.2.968-971.1991; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STAEHELI P, 1985, MOL CELL BIOL, V5, P2150, DOI 10.1128/MCB.5.8.2150; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Wittinghofer A, 1997, CURR BIOL, V7, pR682, DOI 10.1016/S0960-9822(06)00355-1; Zhang ZM, 2000, J BIOL CHEM, V275, P8779, DOI 10.1074/jbc.275.12.8779	51	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14172	14176		10.1074/jbc.M200244200	http://dx.doi.org/10.1074/jbc.M200244200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11847228	hybrid			2022-12-25	WOS:000175096000106
J	Seimiya, H; Smith, S				Seimiya, H; Smith, S			The telomeric poly(ADP-ribose) polymerase, tankyrase 1, contains multiple binding sites for telomeric repeat binding factor 1 (TRF1) and a novel acceptor, 182-kDa tankyrase-binding protein (TAB182)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; ANKYRIN; ASSOCIATION; LOCALIZATION; COMPLEXES; LENGTH; DOMAIN; YEAST; GENE; P53	Tankyrase 1, a human telomeric poly(ADP-ribose) polymerase, was originally identified through its interaction with TRF1, a negative regulator of telomere length. Tankyrase I ADP-ribosylates TRF1 in vitro, and its overexpression induces telomere elongation in human cancer cells. In addition to its telomeric localization, tankyrase I resides at multiple subcellular sites, suggesting additional functions for this protein. Here we identify TAB182, a novel tankyrase 1-binding protein of 182 kDa. TAB182 displays a complex pattern of subcellular localization. TAB182 localizes to the nucleus in a heterochromatic staining pattern and to the cytoplasm, where it co-stains with the cortical actin network. TAB182 coimmunoprecipitates with tankyrase 1 from human cells and serves as an acceptor of poly(ADP-ribosyl)ation by tankyrase I in vitro. Like TRF1, TAB182 binds to the ankyrin domain (comprising 24 ankyrin repeats) of tankyrase 1. Surprisingly, dissection of this domain reveals multiple discrete and overlapping binding sites for TRF1 and TAB182. Thus, we demonstrate five well conserved ankyrin repeat clusters in tankyrase 1. Although each of the five ankyrin repeat clusters independently binds to TRF1, only three of the five bind toTAB182. These findings suggest that tankyrase I may act as a scaffold for large molecular mass complexes made up of multiple binding proteins. We discuss potential roles for tankyrase 1-mediated higher order complexes at telomeres and at other subcellular sites.	NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA	New York University	Smith, S (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, 540 1st Ave,2nd Floor, New York, NY 10016 USA.			Smith, Susan/0000-0002-8213-5915; Seimiya, Hiroyuki/0000-0003-3314-9736	NATIONAL CANCER INSTITUTE [R01CA095099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AME J, 2001, DNA DAMAGE STRESS SI, P1; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; DERNBURG AF, 1995, TELOMERES, P295; Evans SK, 2000, J CELL SCI, V113, P3357; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Kuimov AN, 2001, GENES IMMUN, V2, P52, DOI 10.1038/sj.gene.6363722; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Monz D, 2001, CLIN CANCER RES, V7, P113; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Rubtsov AM, 2000, FEBS LETT, V482, P1, DOI 10.1016/S0014-5793(00)01924-4; Scherthan H, 2001, NAT REV MOL CELL BIO, V2, P621, DOI 10.1038/35085086; Scherthan H, 2000, MOL BIOL CELL, V11, P4189, DOI 10.1091/mbc.11.12.4189; Schultz J, 1997, PROTEIN SCI, V6, P249; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Zhang B, 1996, J BIOL CHEM, V271, P28734, DOI 10.1074/jbc.271.46.28734; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	40	119	129	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14116	14126		10.1074/jbc.M112266200	http://dx.doi.org/10.1074/jbc.M112266200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11854288	hybrid			2022-12-25	WOS:000175096000100
J	Foddis, R; De Rienzo, A; Broccoli, D; Bocchetta, M; Stekala, E; Rizzo, P; Tosolini, A; Grobelny, JV; Jhanwar, SC; Pass, HI; Testa, JR; Carbone, M				Foddis, R; De Rienzo, A; Broccoli, D; Bocchetta, M; Stekala, E; Rizzo, P; Tosolini, A; Grobelny, JV; Jhanwar, SC; Pass, HI; Testa, JR; Carbone, M			SV40 infection induces telomerase activity in human mesothelial cells	ONCOGENE			English	Article						SV40; telomerase; asbestos; mesothelioma	LARGE-T-ANTIGEN; IMMORTALIZATION; ASSOCIATION; SIMIAN-VIRUS-40; TRANSFORMATION; EXPRESSION; PROTEIN; FIBROBLASTS; ELONGATION; ACTIVATION	Mesotheliomas are malignant tumors of the pleural and peritoneal membranes which are often associated with asbestos exposure and with Simian virus 40 (SV40) infection. Telomerase activity is repressed in somatic cells and tissues but is activated in immortal and malignant cells. We evaluated telomerase activity in seven primary malignant mesothelioma biopsies and matched lung specimens and 20 mesothelioma cell lines and eight corresponding primary tumor cultures. All the tumor biopsies, and nearly all primary cell mesothelioma cultures and cell lines were telomerase positive. The findings in cell lines paralleled those observed in primary cultures in cases where paired samples were available. Next, we found that SV40, a DNA tumor virus present in similar to50% of mesothelioma biopsies in the USA, induced telomerase activity in primary human mesothelial cells, but not in primary fibroblasts. Telomerase activity became detectable as early as 72 h following wild-type (strain 776) SV40 infection, and a clear DNA ladder was detectable I week after infection. The amount of telomerase activity increased during passage in cell culture and appeared to parallel increases in the cellular amounts of the SV40 large T-antigen. Thus, SV40 infection leads to telomerase activity before the infected mesothelial cells become transformed and immortalized. SV40 infection of human fibroblasts did not cause detectable telomerase activity. We also determined that the SV40 small t-antigen (tag) plays an important role in inducing telomerase activity because this activity was undetectable or minimal in mesothelial cells infected and/or transformed by SV40 tag mutants. Asbestos alone did not induce telomerase activity, and asbestos did not influence telomerase activity in mesothelial cells infected with SV40. Induction of telomerase activity by SV40 may be related to the very high rate of mesothelial cell immortalization that is characteristically associated with SV40 infection of mesothelial cells.	Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Dept Pathol, Canc Immunol Program, Maywood, IL 60153 USA; Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Wayne State Univ, Karmanos Canc Inst, Aerodigest Program, Detroit, MI 48201 USA	Loyola University Chicago; Fox Chase Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; Barbara Ann Karmanos Cancer Institute; Wayne State University	Carbone, M (corresponding author), Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Dept Pathol, Canc Immunol Program, Rm 205 2160 S 1st Ave, Maywood, IL 60153 USA.	mcarbon@orion.it.luc.edu		rizzo, paola/0000-0001-7174-9674; Pass, Harvey/0000-0003-3222-3471	NCI NIH HHS [CA-45745, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; CARBONE M, 1991, NATO ADV SCI I A-LIF, V209, P195; CARBONE M, 2002, IN PRESS SEMIN ONCOL; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KE Y, 1989, AM J PATHOL, V134, P979; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y; Klein G, 2000, P NATL ACAD SCI USA, V97, P9830, DOI 10.1073/pnas.190325697; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Rizzo P, 1998, Monaldi Arch Chest Dis, V53, P202; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; SAGER R, 1984, CANCER CELL, V2, P487; Schrump DS, 2001, SEMIN CANCER BIOL, V11, P73, DOI 10.1006/scbi.2000.0348; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; Testa JR, 1998, CANCER RES, V58, P4505; Testa JR, 2001, SEMIN CANCER BIOL, V11, P31, DOI 10.1006/scbi.2000.0344; Testa JR, 2001, CANC PRINCIPLES PRAC, P1937; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wright WE, 1996, DEV GENET, V18, P173; Yeager TR, 1999, CANCER RES, V59, P4175; YU J, 2002, VIROLOGY, V230, P132; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	46	83	91	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1434	1442		10.1038/sj.onc.1205203	http://dx.doi.org/10.1038/sj.onc.1205203			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857086				2022-12-25	WOS:000173861000013
J	Vortmeyer, A; Huang, SC; Pack, SD; Koch, CA; Lubensky, IA; Oldfield, EH; Zhuang, ZP				Vortmeyer, A; Huang, SC; Pack, SD; Koch, CA; Lubensky, IA; Oldfield, EH; Zhuang, ZP			Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion	ONCOGENE			English	Article						VHL disease; VHL gene; mutation; deletion	VONHIPPEL-LINDAU DISEASE; SUPPRESSOR GENE; CARCINOMA	The majority of patients with Von Hippel-Lindau (VHL) disease are affected by a VHL germline mutation involving one copy of the VHL gene. Loss of heterozygosity of the second VHL allele can be consistently demonstrated in tumor tissue from these patients, suggesting that allelic deletion is a very early or even initiating event for tumorigenesis. Approximately 20% of VHL disease patients, however, exhibit germline deletion of one entire copy or at least a substantial part of the VHL gene. To investigate the nature of the 'second genetic hit' in this patient population, we analysed two renal cell carcinomas and one CNS hemangioblastoma from three unrelated patients for genetic changes of the second copy of the VHL gene. All three tumors showed retention of one VHL allele by FISH. Single-strand conformation polymorphism and mutation analysis of microdissected tumor DNA revealed somatic point mutations of the wild-type VHL copies in each of the three tumors. The results indicate that the 'two hit model' is equally applicable to patients with VHL germline mutation and VHL germline deletion. In contrast to tumors from patients with VHL germline mutation, however, point mutations of the wild-type allele can be detected in tumors from patients with VHL germline deletion.	NINCDS, Surg Neurol Branch, Mol Pathogenesis Unit, Bethesda, MD 20892 USA; NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Zhuang, ZP (corresponding author), NINCDS, Surg Neurol Branch, Mol Pathogenesis Unit, Bldg 10,Room 5D37, Bethesda, MD 20892 USA.	zhuangp@ninds.nih.gov	Pack, Svetlana D./C-2020-2014; Koch, Christian A/A-4699-2008	Pack, Svetlana D./0000-0003-3256-6626; Koch, Christian A/0000-0003-3127-5739; Koch, Christian/0000-0003-0678-1242				CHOYKE PL, 1995, RADIOLOGY, V194, P629, DOI 10.1148/radiology.194.3.7862955; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; KNUDSON AG, 1985, CANCER RES, V45, P1437; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lubensky IA, 1996, AM J PATHOL, V149, P2089; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Pack SD, 1999, CANCER RES, V59, P5560; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; Zhuang Z, 1998, Cell Vis, V5, P43	11	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1167	1170		10.1038/sj.onc.1205121	http://dx.doi.org/10.1038/sj.onc.1205121			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850836				2022-12-25	WOS:000173729400004
J	Lamour, V; Hoermann, L; Jeltsch, JM; Oudet, P; Moras, D				Lamour, V; Hoermann, L; Jeltsch, JM; Oudet, P; Moras, D			An open conformation of the Thermus thermophilus gyrase B ATP-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; N-TERMINAL FRAGMENT; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; COUMARIN DRUGS; STRAND-PASSAGE; 2-GATE MECHANISM; GYRB MUTATIONS; OPERATED CLAMP; PROTEIN	DNA gyrase forms an A(2)B(2) tetramer involved in DNA replication, repair, recombination, and transcription in which the B subunit catalyzes ATP hydrolysis. The Thermus thermophilus and Escherichia coli gyrases are homologues and present the same catalytic activity. When compared with that of the E. coli 43K-5'-adenylyl-beta,gamma-imidodiphosphate complex, the crystal structure of Gyrase B 43K ATPase domain in complex with novobiocin, one of the most potent inhibitors of gyrase shows large conformational changes of the subdomains within the dimer. The stabilization of loop 98-118 closing the active site through dimeric contacts and interaction with domain 2 allows to observe novobiocin-protein interactions that could not be seen in the 24K-inhibitor complexes. Furthermore, this loop adopts a position which defines an "open" conformation of the active site in absence of ATP, in contrast with the "closed" conformation adopted upon ATP binding. All together, these results indicate how the subdomains may propagate conformational changes from the active site and provide crucial information for the design of more specific inhibitors.	ULP, INSERM, CNRS, Inst Mol Biol & Genet, F-67404 Illkirch Graffenstaden, France; Ecole Super Biotechnol Strasbourg, UMR7100, F-67400 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), ULP, INSERM, CNRS, Inst Mol Biol & Genet, BP163,1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr		Lamour, Valerie/0000-0001-7793-4029				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALTHAUS IW, 1988, J ANTIBIOT, V41, P373, DOI 10.7164/antibiotics.41.373; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; Brino L, 1999, BIOCHIMIE, V81, P973, DOI 10.1016/S0300-9084(99)00222-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Caron P R, 1994, Adv Pharmacol, V29B, P271; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CONTRERAS A, 1992, MOL MICROBIOL, V6, P1617; DRLICA K, 1989, PHARMACOL THERAPEUT, V44, P107, DOI 10.1016/0163-7258(89)90093-4; Fass D, 1999, NAT STRUCT BIOL, V6, P322; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; GILBERT EJ, 1994, MOL MICROBIOL, V12, P365, DOI 10.1111/j.1365-2958.1994.tb01026.x; HOLMES ML, 1991, J BACTERIOL, V173, P642, DOI 10.1128/jb.173.2.642-648.1991; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; HUFF AC, 1990, J BIOL CHEM, V265, P20496; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kampranis SC, 1999, P NATL ACAD SCI USA, V96, P8414, DOI 10.1073/pnas.96.15.8414; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE MP, 1994, J MOL BIOL, V235, P436, DOI 10.1006/jmbi.1994.1004; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; Li W, 1997, J BIOL CHEM, V272, P31190, DOI 10.1074/jbc.272.49.31190; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; Roca J, 1996, GENES CELLS, V1, P17, DOI 10.1046/j.1365-2443.1996.01001.x; SAMUELS DS, 1994, J BACTERIOL, V176, P3072, DOI 10.1128/JB.176.10.3072-3075.1994; Smith CV, 1998, BIOCHEMISTRY-US, V37, P9658, DOI 10.1021/bi9801309; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; TAMURA JK, 1990, J BIOL CHEM, V265, P21342; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Tsai FTF, 1997, PROTEINS, V28, P41; Vogeley L, 2001, J BIOL CHEM, V276, P17149, DOI 10.1074/jbc.M100017200; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Williams NL, 2001, J MOL BIOL, V306, P969, DOI 10.1006/jmbi.2001.4468; Williams NL, 1999, BIOCHEMISTRY-US, V38, P13502, DOI 10.1021/bi9912488	41	83	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18947	18953		10.1074/jbc.M111740200	http://dx.doi.org/10.1074/jbc.M111740200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11850422	hybrid			2022-12-25	WOS:000175975800091
J	Bottcher, B; Scheide, D; Hesterberg, M; Nagel-Steger, L; Friedrich, T				Bottcher, B; Scheide, D; Hesterberg, M; Nagel-Steger, L; Friedrich, T			A novel, enzymatically active conformation of the Escherichia coli NADH : ubiquinone oxidoreductase (complex I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING NADH; MITOCHONDRIAL NADH; NADHUBIQUINONE-OXIDOREDUCTASE; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; MEMBRANE; DEHYDROGENASE; SUBUNIT; GENERATION; PROTEINS	Electron microscopy has demonstrated the unusual L-shaped structure of the respiratory complex I consisting of two arms, which are arranged perpendicular to each other. We found that the Escherichia coli complex I has an additional stable conformation, with the two arms arranged side by side, resulting in a horseshoe-shaped structure. The structure of both conformations was determined by means of electron microscopy of gold thioglucose-stained single particles. They were distinguished from each other by titration of the complex with polyethylene glycol and by means of analytical ultracentrifugation. The transition between the two conformations is induced by the ionic strength of the buffer and is reversible. Only the horseshoe-shaped complex I exhibits enzyme activity in detergent solution, which is abolished by the addition of salt. Therefore, it is proposed that this structure is the native conformation of the complex in the membrane.	European Mol Biol Lab, Struct Biol & Biocomp Programme, D-69117 Heidelberg, Germany; Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany	European Molecular Biology Laboratory (EMBL); Heinrich Heine University Dusseldorf	Friedrich, T (corresponding author), Univ Freiburg, Inst Org Chem & Biochem, Albertstr 21, D-79104 Freiburg, Germany.	tfriedri@uni-freiburg.de	Bottcher, Bettina/E-9397-2010; Nagel-Steger, Luitgard/H-6415-2013	Bottcher, Bettina/0000-0002-7962-4849; Nagel-Steger, Luitgard/0000-0001-5232-2149				BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Buchanan SK, 1996, BIOCHEM J, V318, P343, DOI 10.1042/bj3180343; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Dupuis A, 2001, J BIOENERG BIOMEMBR, V33, P159, DOI 10.1023/A:1010770600418; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; FRIEDRICH T, 1989, EUR J BIOCHEM, V180, P173, DOI 10.1111/j.1432-1033.1989.tb14629.x; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0; Grivennikova VG, 2001, J BIOL CHEM, V276, P9038, DOI 10.1074/jbc.M009661200; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; HOPPER EA, 1999, THESIS U PENNSYLVANI; Ito M, 2001, FEBS LETT, V496, P117, DOI 10.1016/S0014-5793(01)02417-6; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LEONARD K, 1987, J MOL BIOL, V194, P277, DOI 10.1016/0022-2836(87)90375-5; Lustig A, 2000, BBA-BIOMEMBRANES, V1464, P199, DOI 10.1016/S0005-2736(99)00254-0; Musatov A, 2000, BIOCHEMISTRY-US, V39, P12996, DOI 10.1021/bi000884z; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; REYNOLDS JA, 1976, P NATL ACAD SCI USA, V73, P4467, DOI 10.1073/pnas.73.12.4467; Sazanov LA, 2000, J MOL BIOL, V302, P455, DOI 10.1006/jmbi.2000.4079; Schulte U, 1999, J MOL BIOL, V292, P569, DOI 10.1006/jmbi.1999.3096; Schulte U, 1995, METHOD ENZYMOL, V260, P3, DOI 10.1016/0076-6879(95)60126-0; Spehr V, 1999, BIOCHEMISTRY-US, V38, P16261, DOI 10.1021/bi9919605; Steuber J, 2000, MOL MICROBIOL, V35, P428, DOI 10.1046/j.1365-2958.2000.01712.x; Tersteegen A, 1999, EUR J BIOCHEM, V264, P930, DOI 10.1046/j.1432-1327.1999.00692.x; VANHEEL M, 1984, ULTRAMICROSCOPY, V13, P165, DOI 10.1016/0304-3991(84)90066-4; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Vinogradov AD, 1998, BBA-BIOENERGETICS, V1364, P169, DOI 10.1016/S0005-2728(98)00026-7; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; YAGI T, 1998, BIOCHIM BIOPHYS ACTA, V1364, P112	41	82	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17970	17977		10.1074/jbc.M112357200	http://dx.doi.org/10.1074/jbc.M112357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11880370	hybrid			2022-12-25	WOS:000175685100074
J	Fu, ZJ; Wang, M; Potter, D; Miziorko, HM; Kim, JJP				Fu, ZJ; Wang, M; Potter, D; Miziorko, HM; Kim, JJP			The structure of a binary complex between a mammalian mevalonate kinase and ATP - Insights into the reaction mechanism and human inherited disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIODIC FEVER SYNDROME; ACTIVE-SITE; CATALYTIC RESIDUES; CRYSTAL-STRUCTURES; HYPER-IGD; IDENTIFICATION; PROTEIN; BIOSYNTHESIS; MUTATIONS; HEXOKINASE	Mevalonate kinase catalyzes the ATP-dependent phosphorylation of mevalonic acid to form mevalonate 5-phosphate, a key intermediate in the pathways of isoprenoids and sterols. Deficiency in mevalonate kinase activity has been linked to mevalonic aciduria and hyperimmunoglobulinemia D/periodic fever syndrome (HIDS). The crystal structure of rat mevalonate kinase in complex with MgATP has been determined at 2.4-Angstrom resolution. Each monomer of this dimeric protein is composed of two domains with its active site located at the domain interface. The enzyme-bound ATP adopts an anti conformation, in contrast to the syn conformation reported for Methanococcus jannaschii homoserine kinase. The Mg2+ ion is coordinated to both beta- and gamma-phosphates of ATP and side chains of Glu(193) and Ser(146). Asp(204) is making a salt bridge with Lys(13) which in turn interacts with the gamma-phosphate. A model of mevalonic acid can be placed near the gamma-phosphoryl group of ATP; thus, the C5 hydroxyl is located within 4 Angstrom from Asp(204), Lys(13), and the gamma-phosphoryl of ATP. This arrangement of residues strongly suggests: 1) Asp(204) abstracts the proton from C5 hydroxyl of mevalonate; 2) the penta-coordinated gamma-phosphoryl group may be stabilized by Mg2+, Lys(13), and Glu(193); and 3) Lys(13) is likely to influence the pK(a) of the C5 hydroxyl of the substrate. V377I and I268T are the most common mutations found in patients with HIDS. Val(377) is located over 18 Angstrom away from the active site and a conservative replacement with Ile is unlikely to yield an inactive or unstable protein. Ile-268 is located at the dimer interface, and its Thr substitution may disrupt dimer formation.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053766] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53766] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aleshin AE, 2000, J MOL BIOL, V296, P1001, DOI 10.1006/jmbi.1999.3494; AMDUR BH, 1957, J AM CHEM SOC, V79, P2646, DOI 10.1021/ja01567a077; BERGER SA, 1992, BIOCHEMISTRY-US, V31, P9237, DOI 10.1021/bi00153a017; BEYTIA E, 1970, J BIOL CHEM, V245, P5450; BORK P, 1993, PROTEIN SCI, V2, P31; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cho YK, 2001, J BIOL CHEM, V276, P12573, DOI 10.1074/jbc.M011478200; CODIER H, 1999, CURR MICROBIOL, V38, P290; Cuisset L, 2001, EUR J HUM GENET, V9, P260, DOI 10.1038/sj.ejhg.5200614; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DORSEY JK, 1968, J BIOL CHEM, V243, P4667; Drenth JPH, 1999, NAT GENET, V22, P178, DOI 10.1038/9696; Hinson DD, 1997, J BIOL CHEM, V272, P26756, DOI 10.1074/jbc.272.42.26756; Hinson DD, 1999, AM J HUM GENET, V65, P327, DOI 10.1086/302489; Houten SM, 1999, HUM MOL GENET, V8, P1523, DOI 10.1093/hmg/8.8.1523; Houten SM, 2001, EUR J HUM GENET, V9, P253, DOI 10.1038/sj.ejhg.5200595; Huang KX, 1999, PROTEIN EXPRES PURIF, V17, P33, DOI 10.1006/prep.1999.1106; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krishna SS, 2001, BIOCHEMISTRY-US, V40, P10810, DOI 10.1021/bi010851z; Lange BM, 1999, P NATL ACAD SCI USA, V96, P13714, DOI 10.1073/pnas.96.24.13714; Luttgen H, 2000, P NATL ACAD SCI USA, V97, P1062, DOI 10.1073/pnas.97.3.1062; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potter D, 1997, J BIOL CHEM, V272, P5741, DOI 10.1074/jbc.272.9.5741; Potter D, 1997, J BIOL CHEM, V272, P25449, DOI 10.1074/jbc.272.41.25449; Rios SE, 2001, BBA-MOL CELL BIOL L, V1531, P165, DOI 10.1016/S1388-1981(01)00105-6; ROUSSEL A, 1994, TURBO FRODO MANUAL V; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; TCHEN TT, 1958, J BIOL CHEM, V233, P1100; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THAMSEN J, 1952, ACTA CHEM SCAND, V6, P270, DOI 10.3891/acta.chem.scand.06-0270; TSAY YH, 1991, MOL CELL BIOL, V11, P620, DOI 10.1128/MCB.11.2.620; Yang D, 2002, J BIOL CHEM, V277, P9462, DOI 10.1074/jbc.M110787200; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHOU T, 2000, STRUCTURE FOLD DES, V12, P1247	37	99	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18134	18142		10.1074/jbc.M200912200	http://dx.doi.org/10.1074/jbc.M200912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877411	hybrid			2022-12-25	WOS:000175685100095
J	Haggie, PM; Stanton, BA; Verkman, AS				Haggie, PM; Stanton, BA; Verkman, AS			Diffusional mobility of the cystic fibrosis transmembrane conductance regulator mutant, Delta F508-CFTR, in the endoplasmic reticulum measured by photobleaching of GFP-CFTR chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; CONFORMATIONAL MATURATION; DEGRADATION; PROTEASOME; MEMBRANE; TRAFFICKING; CHAPERONES; AGGRESOMES; RETENTION; TRANSPORT	Mutations in the cystic fibrosis transmembrane conductance regulator protein (CFTR) cause cystic fibrosis. The most common disease-causing mutation, DeltaF508, is retained in the endoplasmic reticulum (ER) and is unable to function as a plasma membrane chloride channel. To investigate whether the ER retention of DeltaF508-CFTR is caused by immobilization and/or aggregation, we have measured the diffusional mobility of green fluorescent protein (GFP) chimeras of wild type (wt)-CFTR and DeltaF508-CFTR by fluorescence recovery after photo-bleaching. GFP-labeled DeltaF508-CFTR was localized in the ER and wt-CFTR in the plasma membrane and intracellular membranes in transfected COS7 and Chinese hamster ovary K1 cells. Both chimeras localized to the ER after brefeldin A treatment. Spot photobleaching showed that CFTR diffusion (diffusion coefficient similar to10(-9) cm(2)/s) was not significantly slowed by the DeltaF508 mutation and that nearly all wt-CFTR and DeltaF508-CFTR diffused throughout the ER without restriction. Stabilization of molecular chaperone interactions by ATP depletion produced remarkable DeltaF508-CFTR immobilization (similar to50%) and slowed diffusion (6.5 x 10(-10) cm(2)/s) but had little effect on wt-CFTR. Fluorescence depletion experiments revealed that the immobilized DeltaF508-CFTR in ATP-depleted cells remained in an ER pattern. The mobility of wt-CFTR and DeltaF508-CFTR was reduced by maneuvers that alter CFTR processing or interactions with molecular chaperones, including tunicamycin, geldanamycin, and lactacystin. Photobleaching of the fluorescent ER lipid diOC(4)(3) showed that neither ER restructuring nor fragmentation during these maneuvers was responsible for the slowing and immobilization of CFTR. These results suggest that (a) the ER retention of DeltaF508-CFTR is not due to restricted ER mobility, (b) the majority of DeltaF508-CFTR is not aggregated or bound to slowly moving membrane proteins, and (e) DeltaF508-CFTR may interact to a greater extent with molecular chaperones than does wt-CFTR.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Dartmouth Coll Sch Med, Hanover, NH 03755 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Dartmouth College	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL60288, HL59198] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK45881, DK43840, DK34533] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045881, R01DK043840, R01DK034533] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bannykh SI, 2000, TRAFFIC, V1, P852, DOI 10.1034/j.1600-0854.2000.011105.x; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Dayel MJ, 1999, BIOPHYS J, V76, P2843, DOI 10.1016/S0006-3495(99)77438-2; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Levin MH, 2001, J BIOL CHEM, V276, P21331, DOI 10.1074/jbc.M101901200; Loffing-Cueni D, 2001, AM J PHYSIOL-CELL PH, V281, pC1889, DOI 10.1152/ajpcell.2001.281.6.C1889; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Olveczky BP, 1997, BIOPHYS J, V73, P2836, DOI 10.1016/S0006-3495(97)78312-7; Partikian A, 1998, J CELL BIOL, V140, P821, DOI 10.1083/jcb.140.4.821; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; PIND S, 1994, J BIOL CHEM, V269, P12784; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Umenishi F, 2000, BIOPHYS J, V78, P1024, DOI 10.1016/S0006-3495(00)76661-6; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wigley WC, 1999, J CELL BIOL, V145, P481; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180	36	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16419	16425		10.1074/jbc.M112361200	http://dx.doi.org/10.1074/jbc.M112361200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877404	hybrid			2022-12-25	WOS:000175564500012
J	Sobczak, K; Krzyzosiak, WJ				Sobczak, K; Krzyzosiak, WJ			Structural determinants of BRCA1 translational regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SECONDARY STRUCTURE; SPORADIC BREAST-CANCER; EUKARYOTIC MESSENGER-RNAS; OVARIAN-CANCER; PROMOTER REGION; SOMATIC MUTATIONS; ALU REPEATS; GENE; METHYLATION; EXPRESSION	The BRCA1 gene is involved in sporadic breast and ovarian cancer mainly through reduced expression. BRCA1 mRNAs containing different leader sequences show different patterns of expression. In a normal mammary gland mRNA with a shorter leader sequence, 5'-UTRa is expressed only, whereas in breast cancer tissue mRNA with a longer leader, 5'-UTRb is expressed also. We show that the translation efficiency of transcripts containing 5'-UTRb is 10 times lower than those containing 5'-UTRa. The structures of 5'-UTRa and 5'-UTRb were determined by chemical and enzymatic probing aided by a new method developed for monitoring the number of co-existing stable conformers. Specific factors responsible for reduced translation of mRNA containing 5'-UTRb were determined using a variety of transcripts with mutations in the leader sequence. These factors include a stable secondary structure formed by truncated Alu element and upstream AUG codons. The novel mechanism by which BRCA1 may be involved in sporadic breast and ovarian cancer is proposed. It is based on the expression patterns of BRCA1 mRNAs and differences in their translatability. According to this mechanism the deregulation of the BRCA1 transcription in cancer, resulting in a higher proportion of translationally inhibited transcripts containing 5'-UTRb, contributes to the decrease in the BRCA1 protein observed in sporadic breast and ovarian cancers.	Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, PL-61704 Poznan, Poland	Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Krzyzosiak, WJ (corresponding author), Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, Noskowskiego 12-14, PL-61704 Poznan, Poland.	wlodkrzy@man.poznan.pl		Sobczak, Krzysztof/0000-0001-8352-9812				Batzer MA, 1996, J MOL EVOL, V42, P3, DOI 10.1007/BF00163204; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; Brunel C, 2000, METHOD ENZYMOL, V318, P3; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou WL, 2001, BBA-GENE STRUCT EXPR, V1519, P209, DOI 10.1016/S0167-4781(01)00241-X; Ciesiolka J, 1998, J MOL BIOL, V275, P211, DOI 10.1006/jmbi.1997.1462; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; Deragon JM, 2000, ANN MED, V32, P264, DOI 10.3109/07853890009011771; Dobrovic A, 1997, CANCER RES, V57, P3347; Duga S, 1999, EUR J BIOCHEM, V259, P188, DOI 10.1046/j.1432-1327.1999.00029.x; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GORNICKI P, 1989, J BIOMOL STRUCT DYN, V6, P971, DOI 10.1080/07391102.1989.10506525; Hamdi H, 1999, J MOL BIOL, V289, P861, DOI 10.1006/jmbi.1999.2797; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jurka J, 1998, CURR OPIN STRUC BIOL, V8, P333, DOI 10.1016/S0959-440X(98)80067-5; Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kochetov AV, 1998, FEBS LETT, V440, P351, DOI 10.1016/S0014-5793(98)01482-3; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRZYZOSIAK WJ, 1988, BIOCHEMISTRY-US, V27, P5771, DOI 10.1021/bi00415a056; Krzyzosiak WJ, 1999, NATO ASI 3 HIGH TECH, V70, P303; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Michalowski D, 1996, BIOCHEMISTRY-US, V35, P10727, DOI 10.1021/bi9530393; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Napierala M, 1997, J BIOL CHEM, V272, P31079, DOI 10.1074/jbc.272.49.31079; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Ozcelik H, 1998, INT J CANCER, V77, P1; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; SINNETT D, 1991, J BIOL CHEM, V266, P8675; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; Suen TC, 2001, ONCOGENE, V20, P440, DOI 10.1038/sj.onc.1204078; Sugimura T, 2000, MUTAT RES-REV MUTAT, V462, P235, DOI 10.1016/S1383-5742(00)00005-3; Taylor J, 1998, INT J CANCER, V79, P334, DOI 10.1002/(SICI)1097-0215(19980821)79:4<334::AID-IJC5>3.0.CO;2-W; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vallejo Abbe N., 1995, P603; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Zheng WX, 2000, GYNECOL ONCOL, V76, P294, DOI 10.1006/gyno.1999.5664	60	86	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17349	17358		10.1074/jbc.M109162200	http://dx.doi.org/10.1074/jbc.M109162200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877386	hybrid			2022-12-25	WOS:000175564500131
J	Xie, Q; Zhang, Y; Zhai, CB; Bonanno, JA				Xie, Q; Zhang, Y; Zhai, CB; Bonanno, JA			Calcium influx factor from cytochrome P-450 metabolism and secretion-like coupling mechanisms for capacitative calcium entry in corneal endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CURRENT I-CRAC; INDUCED <CA2+>(I) OSCILLATIONS; OPERATED CATION CHANNELS; INHIBITORS OKADAIC ACID; GTP-BINDING PROTEIN; 2-AMINOETHOXYDIPHENYL BORATE; HUMAN PLATELETS; ACTIN CYTOSKELETON	Notwithstanding extensive efforts, the mechanism of capacitative calcium entry (CCE) remains unclear. Two seemingly opposed theories have been proposed: secretion-like coupling (Patterson, R. L., van Rossum, D. B., and Gill, D. L. (1999) Cell 98, 487-499) and the calcium influx factor (CIF) (Randriamampita, C., and Tsien, R. Y. (1993) Nature 364, 809-814). In the current study, a combinatorial approach was taken to investigate the mechanism of CCE in corneal endothelial cells. Induction of cytochrome P-450s by beta-naphthoflavone (BN) enhanced CCE measured by Sr2+ entry after store depletion. 5,6-Epoxyeicosatrienoic acid (5,6-EET), a proposed CIF generated by cytochrome P-450s (Rzigalinski, B. A., Willoughby, K. A., Hoffman, S. W., Falck, J. R., and Ellis, E. F. (1999) J. Biol. Chem. 274, 175-182), induced Ca2+ entry. Both BN-enhanced CCE and the 5,6-EET-induced Ca2+ entry were inhibited by the CCE blocker 2-aminoethoxydiphenyl borate, indicating a role for cytochrome P-450s in CCE. Treatment with calyculin A (CalyA), which causes condensation of cortical cytoskeleton, inhibited CCE. The actin polymerization inhibitor cytochalasin D partially reversed the inhibition of CCE by CalyA, suggesting a secretion-like coupling mechanism for CCE. However, CalyA could not inhibit CCE in BN-treated cells, and 5,6-EET caused a partial activation of CCE in CalyA-treated cells. These results further support the notion that cytochrome P-450 metabolites may be CIFs. The vesicular transport inhibitor brefeldin A inhibited CCE in both vehicle- and BN-treated cells. Surprisingly, Sr2+ entry in the absence of store depletion was enhanced in BN-treated cells, which was also inhibited by 2-aminoethoxydiphenyl borate. An integrative model suggests that both CIF from cytochrome P-450 metabolism and secretion-like coupling mechanisms play roles in CCE in corneal endothelial cells.	Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Bonanno, JA (corresponding author), Indiana Univ, Sch Optometry, 800 E Atwater Ave, Bloomington, IN 47405 USA.							Alderton JM, 2000, CELL CALCIUM, V28, P161, DOI 10.1054/ceca.2000.0144; ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; ALONSOTORRE SR, 1993, BIOCHEM J, V289, P761, DOI 10.1042/bj2890761; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; Ascher-Landsberg J, 1999, BIOCHEM BIOPH RES CO, V264, P979, DOI 10.1006/bbrc.1999.1602; Auld A, 2000, BBA-MOL CELL RES, V1497, P11, DOI 10.1016/S0167-4889(00)00045-8; Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Bruce JIE, 2000, BRIT J PHARMACOL, V131, P761, DOI 10.1038/sj.bjp.0703631; Capdevila JH, 2000, J LIPID RES, V41, P163; Chorna-Ornan I, 2001, J NEUROSCI, V21, P2622, DOI 10.1523/JNEUROSCI.21-08-02622.2001; Christian EP, 1996, BRIT J PHARMACOL, V119, P647, DOI 10.1111/j.1476-5381.1996.tb15722.x; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Fernando KC, 1997, BIOCHEM J, V328, P463; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; Gailly P, 1998, CELL CALCIUM, V24, P293, DOI 10.1016/S0143-4160(98)90053-7; GRAIER WF, 1993, BIOCHEM J, V291, P263, DOI 10.1042/bj2910263; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; Hoebel BG, 1997, BRIT J PHARMACOL, V121, P1579, DOI 10.1038/sj.bjp.0701304; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; Kiselyov K, 1999, TRENDS NEUROSCI, V22, P334, DOI 10.1016/S0166-2236(99)01426-5; Kiselyov K, 2001, BIOCHEM J, V360, P17, DOI 10.1042/0264-6021:3600017; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; KOCH BD, 1994, BIOCHEM J, V302, P187, DOI 10.1042/bj3020187; KREIENBUHL P, 1992, BLOOD, V80, P2911; Kukkonen JP, 2001, CELL CALCIUM, V30, P117, DOI 10.1054/ceca.2001.0219; Kunzelmann-Marche C, 2001, J BIOL CHEM, V276, P5134, DOI 10.1074/jbc.M007924200; KWAN CY, 1990, J BIOL CHEM, V265, P678; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MAURICE DM, 1951, BRIT J OPHTHALMOL, V35, P791, DOI 10.1136/bjo.35.12.791; Missiaen L, 2001, CELL CALCIUM, V29, P111, DOI 10.1054/ceca.2000.0163; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PINTO A, 1986, J PHARMACOL EXP THER, V236, P445; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney J W Jr, 2001, Mol Interv, V1, P84; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 2001, J CELL SCI, V114, P2223; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, TRENDS CARDIOVAS MED, V10, P327, DOI 10.1016/S1050-1738(01)00073-1; Rosado JA, 2001, AM J PHYSIOL-CELL PH, V280, pC1636, DOI 10.1152/ajpcell.2001.280.6.C1636; Rzigalinski BA, 1996, BBA-LIPID LIPID MET, V1299, P342, DOI 10.1016/0005-2760(95)00224-3; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; Sergeeva M, 2000, NEUROSCIENCE, V97, P765, DOI 10.1016/S0306-4522(00)00062-2; Simons PC, 1998, BIOCHEM BIOPH RES CO, V253, P561, DOI 10.1006/bbrc.1998.9823; Singh BB, 2000, J BIOL CHEM, V275, P36483, DOI 10.1074/jbc.C000529200; Srinivas SP, 1998, CURR EYE RES, V17, P994, DOI 10.1076/ceyr.17.10.994.5242; Sun XC, 2000, AM J PHYSIOL-CELL PH, V279, pC1648, DOI 10.1152/ajpcell.2000.279.5.C1648; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; TESFAI Y, 2001, BIOCH J, V358; Trepakova ES, 2000, J BIOL CHEM, V275, P26158, DOI 10.1074/jbc.M004666200; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; YANO Y, 1995, BIOCHEM J, V307, P439, DOI 10.1042/bj3070439; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	77	52	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16559	16566		10.1074/jbc.M109518200	http://dx.doi.org/10.1074/jbc.M109518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867616	hybrid			2022-12-25	WOS:000175564500031
J	Zhou, J; Panda, D; Landen, JW; Wilson, L; Joshi, HC				Zhou, J; Panda, D; Landen, JW; Wilson, L; Joshi, HC			Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENP-E; CHROMOSOME ALIGNMENT; MITOTIC CHECKPOINT; KINETIC STABILIZATION; STEADY-STATE; INDIVIDUAL MICROTUBULES; TRANSITION FREQUENCIES; EJECTION PROPERTIES; DEPENDENT CHANGES; INTERPHASE CELLS	We have previously identified the opium alkaloid noscapine as a microtubule interacting agent that binds stoichiometrically to tubulin and alters its conformation. Here we show that, unlike many other microtubule inhibitors, noscapine does not significantly promote or inhibit microtubule polymerization. Instead, it alters the steady-state dynamics of microtubule assembly, primarily by increasing the amount of time that the microtubules spend in an attenuated (pause) state. Further studies reveal that even at high concentrations, noscapine does not alter the tubulin polymer/monomer ratio in HeLa cells. C ells treated with noscapine arrest at mitosis with nearly normal bipolar spindles. Strikingly, although most of the chromosomes in these cells are aligned at the metaphase plate, the rest remain near the spindle poles, both of which exhibit loss of tension across kinetochore pairs. Furthermore, levels of the spindle checkpoint proteins Mad2, Bub1, and BubR1 decrease by 138-, 3.7-, and 3.9-fold, respectively, at the kinetochore region upon chromosome alignment. Our results thus suggest that an exquisite control of microtubule dynamics is required for kinetochore tension generation and chromosome alignment during mitosis. Our data also support the idea that Mad2 and Bub1/BubR1 respond to kinetochore-microtubule attachment and/or tension to different degrees.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	Emory University; Emory University; University of California System; University of California Santa Barbara	Joshi, HC (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, 1648 Pierce Dr, Atlanta, GA 30322 USA.							Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; AULT JG, 1991, J CELL SCI, V99, P701; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CASSIMERIS L, 1994, J CELL SCI, V107, P285; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; DHAMODHARAN R, 1995, MOL BIOL CELL, V6, P1215, DOI 10.1091/mbc.6.9.1215; Dustin P., 1984, MICROTUBULES; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; GILDERSLEEVE RF, 1992, J BIOL CHEM, V267, P7995; GLIKSMAN NR, 1993, MOL BIOL CELL, V4, P1035, DOI 10.1091/mbc.4.10.1035; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; Jordan MA, 1999, METHOD CELL BIOL, V61, P267; Joshi HC, 1998, CURR OPIN CELL BIOL, V10, P35, DOI 10.1016/S0955-0674(98)80084-7; JOSHI HC, 1989, J CELL BIOL, V109, P663, DOI 10.1083/jcb.109.2.663; King JM, 2000, J CELL BIOL, V151, P739, DOI 10.1083/jcb.151.4.739; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MARGOLIS RL, 1978, CELL, V13, P1, DOI 10.1016/0092-8674(78)90132-0; McEwen BF, 2001, MOL BIOL CELL, V12, P2776, DOI 10.1091/mbc.12.9.2776; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; PANDA D, 1995, BIOCHEMISTRY-US, V34, P9921, DOI 10.1021/bi00031a014; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; PEPPERKOK R, 1990, J CELL BIOL, V111, P3003, DOI 10.1083/jcb.111.6.3003; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Sambrook J., 2002, MOL CLONING LAB MANU; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shelby RD, 1996, J CELL BIOL, V135, P545, DOI 10.1083/jcb.135.3.545; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Waters JC, 1996, J CELL SCI, V109, P2823; WILSON L, 1995, CHEM BIOL, V2, P569, DOI 10.1016/1074-5521(95)90119-1; WISE D, 1991, CELL MOTIL CYTOSKEL, V18, P131, DOI 10.1002/cm.970180208; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Ye KQ, 1998, P NATL ACAD SCI USA, V95, P1601, DOI 10.1073/pnas.95.4.1601	47	174	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17200	17208		10.1074/jbc.M110369200	http://dx.doi.org/10.1074/jbc.M110369200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864974	hybrid			2022-12-25	WOS:000175564500113
J	Loukinova, E; Ranganathan, S; Kuznetsov, S; Gorlatova, N; Migliorini, MM; Loukinov, D; Ulery, PG; Mikhailenko, I; Lawrence, DA; Strickland, DK				Loukinova, E; Ranganathan, S; Kuznetsov, S; Gorlatova, N; Migliorini, MM; Loukinov, D; Ulery, PG; Mikhailenko, I; Lawrence, DA; Strickland, DK			Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP) - Evidence for integrated co-receptor function between LRP and the PDGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; VLDL RECEPTOR; MICE LACKING; BINDING; INTERNALIZATION; DEGRADATION; LIGAND; SHC; SRC; SIGNAL	The low density lipoprotein receptor-related protein (LRP) functions in the catabolism of numerous ligands including proteinases, proteinase inhibitor complexes, and lipoproteins. In the current study we provide evidence indicating an expanded role for LRP in modulating cellular signaling events. Our results show that platelet-derived growth factor (PDGF) BB induces a transient tyrosine phosphorylation of the LRP cytoplasmic domain in a process dependent on PDGF receptor activation and c-Src family kinase activity. Other growth factors, including basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor-1, were unable to mediate tyrosine phosphorylation of LRP. The basis for this selectivity may result from the ability of LRP to bind PDGFBB, because surface plasmon resonance experiments demonstrated that only PDGF, and not basic fibroblast growth factor, epidermal growth factor, or insulin-like growth factor-1, bound to purified LRP immobilized on a sensor chip. The use of LRP mini-receptor mutants as well as in vitro phosphorylation studies demonstrated that the tyrosine located within the second NPXY motif found in the LRP cytoplasmic domain is the primary site of tyrosine phosphorylation by Src and Src family kinases. Co-immunoprecipitation experiments revealed that PDGF-mediated tyrosine phosphorylation of LRPs cytoplasmic domain results in increased association of the adaptor protein She with LRP and that She recognizes the second NPXY motif within LRPs cytoplasmic domain. In the accompanying paper, Boucher et al. (Boucher, P., Liu, P. V., Gotthardt, M., Hiesberger, T., Anderson, R. G. W., and Herz, J. (2002) J. Biol. Chem. 275, 15507-15513) reveal that LRP is found in caveolae along with the PDGF receptor. Together, these studies suggest that LRP functions as a co-receptor that modulates signal transduction pathways initiated by the PDGF receptor.	Amer Red Cross, Dept Vasc Biol, Holland Lab, Rockville, MD 20855 USA; George Washington Univ, Inst Biomed Sci, Washington, DC 20037 USA; George Washington Univ, Dept Biochem & Mol Biol, Washington, DC 20037 USA	American Red Cross; George Washington University; George Washington University	Strickland, DK (corresponding author), Amer Red Cross, Dept Vasc Biol, Holland Lab, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	strickla@usa.redcross.org		Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784, P01HL054710] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50784, HL54710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KELLY JD, 1991, J BIOL CHEM, V266, P8987; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Kovalenko M, 1997, BIOCHEMISTRY-US, V36, P6260, DOI 10.1021/bi962553l; KOVALENKO M, 1994, CANCER RES, V54, P6106; LANDGREN E, 1995, ONCOGENE, V10, P2027; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	51	200	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15499	15506		10.1074/jbc.M200427200	http://dx.doi.org/10.1074/jbc.M200427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854294	hybrid			2022-12-25	WOS:000175510400038
J	Perry, AM; Ton-That, H; Mazmanian, SK; Schneewind, O				Perry, AM; Ton-That, H; Mazmanian, SK; Schneewind, O			Anchoring of surface proteins to the cell wall of Staphylococcus aureus - III. Lipid II is an in vivo peptidoglycan substrate for sortase-catalyzed surface protein anchoring	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; ESCHERICHIA-COLI; LPXTG MOTIF; BIOSYNTHESIS; PURIFICATION; PRECURSOR; BINDING; TRANSPEPTIDASE; PENICILLIN; PEPTIDE	Surface proteins of Staphylococcus aureus are anchored to the cell wall peptidoglycan by a mechanism requiring a C-terminal sorting signal with an LPXTG motif. Surface proteins are first synthesized in the bacterial cytoplasm and then transported across the cytoplasmic membrane. Cleavage of the N-terminal signal peptide of the cytoplasmic surface protein P1 precursor generates the extracellular P2 species, which is the substrate for the cell wall anchoring reaction. Sortase, a membrane-anchored transpeptidase, cleaves P2 between the threonine (T) and the glycine (G) of the LPXTG motif and catalyzes the formation of an amide bond between the carboxyl group of threonine and the amino group of cell wall cross-bridges. We have used metabolic labeling of staphylococcal cultures with [P-32]phosphoric acid to reveal a P3 intermediate. The P-32-label of immunoprecipitated surface protein is removed by treatment with lysostaphin, a glycyl-glycine endopeptidase that separates the cell wall anchor structure. Furthermore, the appearance of P3 is prevented in the absence of sortase or by the inhibition of cell wall synthesis. P-32-Labeled cell wall anchor species bind to nisin, an antibiotic that is known to form a complex with lipid II. Thus, it appears that the P3 intermediate represents surface protein linked to the lipid II peptidoglycan precursor. The data support a model whereby lipid II-linked polypeptides are incorporated into the growing peptidoglycan via the transpeptidation and transglycosylation reactions of cell wall synthesis, generating mature cell wall-linked surface protein.	Univ Chicago, Comm Microbiol, Chicago, IL 60637 USA	University of Chicago	Schneewind, O (corresponding author), Univ Chicago, Comm Microbiol, 920 E 58th St, Chicago, IL 60637 USA.	oschnee@delphi.bsd.uchicago.edu	Ton-That, Hung/AAB-6155-2020; Mazmanian, Sarkis/ABD-7729-2021	Mazmanian, Sarkis/0000-0003-2713-1513; Ton-That, Hung/0000-0003-1611-0469	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038897] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38897] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON JS, 1965, P NATL ACAD SCI USA, V53, P881, DOI 10.1073/pnas.53.4.881; BHUSHAN R, 1996, HDB THIN LAYER CHROM, V71, P427; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; CHATTERJEE AN, 1964, P NATL ACAD SCI USA, V51, P9, DOI 10.1073/pnas.51.1.9; Giesbrecht P, 1998, MICROBIOL MOL BIOL R, V62, P1371, DOI 10.1128/MMBR.62.4.1371-1414.1998; HANDWERGER S, 1992, J BACTERIOL, V174, P5982, DOI 10.1128/jb.174.18.5982-5984.1992; Heijenoort J.V, 1994, NEW COMPR BIOCH, V27, P39, DOI 10.1016/S0167-7306(08)60406-8; HIGASHI Y, 1967, P NATL ACAD SCI USA, V57, P1878, DOI 10.1073/pnas.57.6.1878; IZAKI K, 1966, P NATL ACAD SCI USA, V55, P656, DOI 10.1073/pnas.55.3.656; KUO SC, 1976, ARCH BIOCHEM BIOPHYS, V172, P574, DOI 10.1016/0003-9861(76)90110-7; LABISCHINSKI H, 1994, BACTERIAL CELL WALL, P23; LINNETT PE, 1973, ANTIMICROB AGENTS CH, V4, P231, DOI 10.1128/AAC.4.3.231; MATSUHAS.M, 1967, J BIOL CHEM, V242, P3191; MATSUHASHI M, 1965, P NATL ACAD SCI USA, V54, P587, DOI 10.1073/pnas.54.2.587; Matsuhashi M., 1994, BACTERIAL CELL WALL, P55; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Mazmanian SK, 2001, MOL MICROBIOL, V40, P1049, DOI 10.1046/j.1365-2958.2001.02411.x; MOVITZ J, 1974, EUR J BIOCHEM, V48, P131, DOI 10.1111/j.1432-1033.1974.tb03750.x; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; Navarre WW, 1999, J BIOL CHEM, V274, P15847, DOI 10.1074/jbc.274.22.15847; Navarre WW, 1996, J BACTERIOL, V178, P441, DOI 10.1128/jb.178.2.441-446.1996; Navarre WW, 1998, J BIOL CHEM, V273, P29135, DOI 10.1074/jbc.273.44.29135; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; PETIT JF, 1968, J BIOL CHEM, V243, P757; REISINGER P, 1980, ARCH MICROBIOL, V127, P187, DOI 10.1007/BF00427192; SANDERMANN H, 1972, J BIOL CHEM, V247, P5123; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SIEWERT G, 1967, P NATL ACAD SCI USA, V57, P767, DOI 10.1073/pnas.57.3.767; SJODAHL J, 1977, EUR J BIOCHEM, V73, P343, DOI 10.1111/j.1432-1033.1977.tb11324.x; Strominger J L, 1968, Harvey Lect, V64, P179; STROMINGER JL, 1967, FED PROC, V26, P9; TAKATSUKI A, 1971, J ANTIBIOT, V24, P215, DOI 10.7164/antibiotics.24.215; TAMURA G, 1976, AGR BIOL CHEM TOKYO, V40, P447, DOI 10.1080/00021369.1976.10862071; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; TIPPER DJ, 1968, J BIOL CHEM, V243, P3169; Ton-That H, 1998, J BIOL CHEM, V273, P29143, DOI 10.1074/jbc.273.44.29143; Ton-That H, 1999, J BIOL CHEM, V274, P24316, DOI 10.1074/jbc.274.34.24316; Ton-That H, 2000, J BIOL CHEM, V275, P9876, DOI 10.1074/jbc.275.13.9876; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; VANHEIJENOORT Y, 1987, J GEN MICROBIOL, V133, P667; WARD JB, 1977, FEBS LETT, V78, P151, DOI 10.1016/0014-5793(77)80294-9; Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200; YOKOGAWA K, 1974, ANTIMICROB AGENTS CH, V6, P156, DOI 10.1128/AAC.6.2.156	51	178	188	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16241	16248		10.1074/jbc.M109194200	http://dx.doi.org/10.1074/jbc.M109194200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856734	Green Accepted, hybrid			2022-12-25	WOS:000175510400134
J	Cziferszky, A; Mach, RL; Kubicek, CP				Cziferszky, A; Mach, RL; Kubicek, CP			Phosphorylation positively regulates DNA binding of the carbon catabolite repressor Cre1 of Hypocrea jecorina (Trichoderma reesei)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-NIDULANS; PROTEIN-KINASE; GLUCOSE REPRESSOR; MIG1 REPRESSOR; MEDIATED PHOSPHORYLATION; SCLEROTINIA-SCLEROTIORUM; FINGER PROTEINS; GENE-EXPRESSION	Cre1 of the ascomycete Hypocrea jecorina is a Cys(2)His(2) zinc finger DNA-binding protein functioning as regulator for carbon catabolite repression. It represents the functional equivalent of yeast Mig1, known to be negatively regulated by the Snf1-kinase at the nuclear import level. We demonstrate that Cre1 is also a phosphoprotein, and identify Ser(241) within an acidic protein region as phosphorylation target. In contrast to Mig1 phosphorylation is required for DNA binding of Cre1. A S241E mutation mimics phosphorylation, whereas a S241A mutant protein shows phosphorylation-independent DNA binding activity, suggesting that phosphorylation is required to release Cre1 from an inactive conformation involving unphosphorylated Ser241. Retransformation of a H. jecorina cre1-non functional mutant with Cre1-S241A leads to permanent carbon catabolite repression in cellobiohydrolase I expression. Contrary to Mig1, the amino acid sequence surrounding Ser241 (HSNDEDD) suggests that phosphorylation may occur by a casein kinase II-like protein. This is supported by a mutation of E244V leading to loss of phosphorylation, loss of DNA binding, and gain of carbon catabolite derepression. Our results imply that the regulation of carbon catabolite repression at the level of DNA binding strongly differs between Saccharomyces cerevisiae and H. jecorina.	Tech Univ Vienna, Inst Chem Engn, Sect Microbial Biochem & Gene Technol, A-1060 Vienna, Austria	Technische Universitat Wien	Mach, RL (corresponding author), Tech Univ Vienna, Inst Chem Engn, Sect Microbial Biochem & Gene Technol, Getreidemarkt 9-166, A-1060 Vienna, Austria.		Robert, Mach/AAU-8968-2020	Mach, Robert, L./0000-0003-2375-7244				Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; Benetti PH, 1997, MOL GEN GENET, V256, P355, DOI 10.1007/s004380050579; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; DRYSDALE MR, 1993, GENE, V130, P241, DOI 10.1016/0378-1119(93)90425-3; FERRER P, 1994, J MOL EVOL, V38, P263, DOI 10.1007/BF00176088; GRUBER F, 1990, CURR GENET, V18, P71, DOI 10.1007/BF00321118; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hazell BW, 2000, LETT APPL MICROBIOL, V30, P282, DOI 10.1046/j.1472-765X.2000.00715.x; Ilmen M, 1996, MOL GEN GENET, V251, P451, DOI 10.1007/s004380050189; Ilmen M, 1996, MOL GEN GENET, V253, P303, DOI 10.1007/s004380050326; Jekosch K, 2000, CURR GENET, V37, P388, DOI 10.1007/s002940000121; JOHNSTON M, 1994, MOL CELL BIOL, V14, P3834, DOI 10.1128/MCB.14.6.3834; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KLOCKE B, 1995, MOL CELL BIOCHEM, V142, P49, DOI 10.1007/BF00928913; KUBICEK CP, 1998, REGULATION PRODUCTIO, V2; Kuhls K, 1996, P NATL ACAD SCI USA, V93, P7755, DOI 10.1073/pnas.93.15.7755; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Lockington RA, 2001, MOL MICROBIOL, V40, P1311, DOI 10.1046/j.1365-2958.2001.02474.x; MACH RL, 1994, CURR GENET, V25, P567, DOI 10.1007/BF00351679; Mach RL, 1996, MOL MICROBIOL, V21, P1273, DOI 10.1046/j.1365-2958.1996.00094.x; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; Ostling J, 1998, EUR J BIOCHEM, V252, P162, DOI 10.1046/j.1432-1327.1998.2520162.x; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Redd MJ, 1997, J BIOL CHEM, V272, P11193; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; Sambrook J., 2002, MOL CLONING LAB MANU; Screen S, 1997, CURR GENET, V31, P511, DOI 10.1007/s002940050238; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; STANGL H, 1993, CURR GENET, V23, P115, DOI 10.1007/BF00352009; STRAUSS J, 1995, FEBS LETT, V376, P103, DOI 10.1016/0014-5793(95)01255-5; Strauss J, 1999, MOL MICROBIOL, V32, P169, DOI 10.1046/j.1365-2958.1999.01341.x; Takashima S, 1996, BIOSCI BIOTECH BIOCH, V60, P173, DOI 10.1271/bbb.60.173; Takashima S, 1998, BIOSCI BIOTECH BIOCH, V62, P2364, DOI 10.1271/bbb.62.2364; Tanaka N, 1998, BIOCHEM BIOPH RES CO, V245, P246, DOI 10.1006/bbrc.1998.8406; Tonukari NJ, 2000, PLANT CELL, V12, P237, DOI 10.1105/tpc.12.2.237; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; Tsutsui H, 1999, BIOCHEM BIOPH RES CO, V262, P198, DOI 10.1006/bbrc.1999.1130; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VALLIER LG, 1994, GENETICS, V137, P49; Vautard G, 1999, FEBS LETT, V453, P54, DOI 10.1016/S0014-5793(99)00691-2; Vautard-Mey G, 1999, EUR J BIOCHEM, V266, P252, DOI 10.1046/j.1432-1327.1999.00857.x; Vautard-Mey G, 2000, CURR GENET, V37, P328, DOI 10.1007/s002940050535; Zhou YY, 2001, MOL CELL BIOCHEM, V220, P1, DOI 10.1023/A:1011087910699	53	88	92	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14688	14694		10.1074/jbc.M200744200	http://dx.doi.org/10.1074/jbc.M200744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11850429	hybrid			2022-12-25	WOS:000175203000044
J	Malakhova, O; Malakhov, M; Hetherington, C; Zhang, DE				Malakhova, O; Malakhov, M; Hetherington, C; Zhang, DE			Lipopolysaccharide activates the expression of ISG15-specific protease UBP43 via interferon regulatory factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED RESPONSE ELEMENT; TRANSCRIPTION FACTOR IRF-2; INDUCED 15-KDA PROTEIN; DOUBLE-STRANDED-RNA; GENE-TRANSCRIPTION; INDUCIBLE GENES; INNATE IMMUNITY; VIRUS-INFECTION; FACTOR-II; UBIQUITIN	UBP43 is a protease that specifically removes a ubiquitin-like protein, ISG15, from its targets. Highest levels of UBP43 expression are detected in macrophages and in cell lines of monocytic lineage. Macrophages are important in host defense against bacterial and viral infections. The lipopolysaccharide (LPS) of the bacterial cell wall can mimic bacteria and activate monocytes/macrophages to provoke inflammatory responses. Here, we report that LPS strongly activates UBP43 expression in macrophages, which is paralleled by changes in UBP43 protein levels. Two interferon regulatory factor (IRF) binding sites in the UBP43 promoter are responsible for the induction of UBP43 expression by LPS, as well as for basal UBP43 promoter activity. We have identified two members of the IRF family (IRF-2 and IRF-3) that specifically bind to these sites. IRF-3 plays a primary role in the LPS-inducible activation of the UBP43 gene and IRF-2 confers a basal transcriptional activity to the UBP43 promoter. Furthermore, we demonstrate that LPS treatment increases the amount of ISG15-conjugates in macrophages. Coordinated induction of ISG15 and UBP43 suggests that ISG15 conjugation is a dynamic process and that a critical balance of ISG15-modification should be maintained during innate immune response.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Zhang, DE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-L51,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dzhang@scripps.edu			NCI NIH HHS [CA79849] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079849] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; DCunha J, 1996, J IMMUNOL, V157, P4100; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; Kimbrell DA, 2001, NAT REV GENET, V2, P256, DOI 10.1038/35066006; KNIGHT E, 1991, J IMMUNOL, V146, P2280; LANS MS, 1994, J BIOL CHEM, V269, P14170; Li J, 2001, J BIOL CHEM, V276, P18579, DOI 10.1074/jbc.M100846200; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; LOEB KR, 1994, MOL CELL BIOL, V14, P8408, DOI 10.1128/MCB.14.12.8408; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; MEMET S, 1991, J INTERFERON RES, V11, P131, DOI 10.1089/jir.1991.11.131; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; Navarro L, 1998, MOL CELL BIOL, V18, P3796, DOI 10.1128/MCB.18.7.3796; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; Schaefer BC, 1997, MOL CELL BIOL, V17, P873, DOI 10.1128/MCB.17.2.873; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TAMURA T, 1991, FEBS LETT, V282, P87, DOI 10.1016/0014-5793(91)80450-H; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wright SD, 1999, J EXP MED, V189, P605, DOI 10.1084/jem.189.4.605; Xi HK, 1999, ONCOGENE, V18, P5889, DOI 10.1038/sj.onc.1202969; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang XX, 1999, VIROLOGY, V262, P152, DOI 10.1006/viro.1999.9914	55	88	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14703	14711		10.1074/jbc.M111527200	http://dx.doi.org/10.1074/jbc.M111527200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11854279	hybrid			2022-12-25	WOS:000175203000046
J	Cristillo, AD; Highbarger, HC; Dewar, RL; Dimitrov, DS; Golding, H; Bierer, BE				Cristillo, AD; Highbarger, HC; Dewar, RL; Dimitrov, DS; Golding, H; Bierer, BE			Up-regulation of HIV coreceptor CXCR4 expression in human T lymphocytes is mediated in part by a cAMP-responsive element	FASEB JOURNAL			English	Article						CXCR4; HIV; cyclic AMP; CREB; chemokine receptors; AIDS	IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CXCR4; HEMATOPOIETIC PROGENITOR CELLS; DOWN-MODULATION; SURFACE EXPRESSION; CUTTING EDGE; CYCLIC-AMP; INFECTION; CLONING; SDF-1	The chemokine and HIV receptor CXCR4 has been shown to play a role in chemotaxis and HIV-1 entry into T cells. Dibutyryl cAMP (DcAMP), an analog of cAMP, has been shown to increase CXCR4 cell surface expression and HIV-1 infectivity, but the molecular mechanism(s) responsible is unknown. Here we show that DcAMP treatment of purified human T lymphocytes increased transcription of CXCR4 mRNA as well as cell surface and intracellular CXCR4 protein expression. DcAMP-mediated stimulation of human PBL increased T-trophic HIV-1 (X4) fusion and viral replication as measured by syncytia formation and p24 levels, respectively. To determine the region( s) of the CXCR4 promoter required for cAMP responsiveness, truncations and point mutations of the CXCR4 promoter (nucleotides -1098 to +59) fused to luciferase were constructed and transiently transfected into human PBL. Deletional analysis demonstrated that the -1098 to -93 region of the CXCR4 promoter construct could be eliminated; the residual (-93 to +59) promoter retained cAMP responsiveness. Site-directed mutagenesis of a putative cAMP-responsive element (CRE) in the 5' UTR (+41 to +49) significantly and specifically attenuated the ability of DcAMP to drive the minimal CXCR4 promoter. Electrophoretic mobility shift assays demonstrated the formation of a complex between the CREB transcription factor and the putative CXCR4 CRE site. Our findings demonstrate a CRE element within the CXCR4 promoter that regulates CXCR4 transcription in response to changes in cAMP signaling. The cAMP-dependent up-regulation of CXCR4 mRNA results in increased CXCR4 intracellular and cell surface protein expression as well as increased HIV infectivity.	NHLBI, Lab Lymphocyte Biol, NIH, Bethesda, MD 20892 USA; NIAID, SAIC AIDS Monitoring Lab, NIH, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, NIH, Bethesda, MD 20892 USA; US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; US Food & Drug Administration (FDA)	Bierer, BE (corresponding author), NHLBI, Lab Lymphocyte Biol, NIH, Bldg 10,Room 6C208,10 Ctr Dr, Bethesda, MD 20892 USA.	biererb@nih.gov		Bierer, Barbara/0000-0001-6448-8170				Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Ancuta P, 2001, J IMMUNOL, V166, P4244, DOI 10.4049/jimmunol.166.6.4244; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Cole SW, 1999, J IMMUNOL, V162, P1392; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Dolei A, 1998, AIDS, V12, P183, DOI 10.1097/00002030-199802000-00008; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Forster R, 1998, J IMMUNOL, V160, P1522; GOLDING H, 1992, AIDS RES HUM RETROV, V8, P1593, DOI 10.1089/aid.1992.8.1593; GOLDING H, 1995, J VIROL, V69, P6140, DOI 10.1128/JVI.69.10.6140-6148.1995; GOLDING H, 1994, J VIROL, V68, P1962, DOI 10.1128/JVI.68.3.1962-1969.1994; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gupta SK, 1999, J IMMUNOL, V163, P2368; Hioe CE, 2001, J VIROL, V75, P1077, DOI 10.1128/JVI.75.2.1077-1082.2001; Kawabata T, 1999, P NATL ACAD SCI USA, V96, P5663, DOI 10.1073/pnas.96.10.5663; Kim CH, 1998, BLOOD, V91, P100, DOI 10.1182/blood.V91.1.100.100_100_110; Kusunoki A, 1999, NUCLEOS NUCLEOT, V18, P1705, DOI 10.1080/07328319908044828; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mackay CR, 1997, CURR BIOL, V7, pR384, DOI 10.1016/S0960-9822(06)00181-3; Melchers F, 1999, CELL, V99, P351, DOI 10.1016/S0092-8674(00)81521-4; Moriuchi M, 1999, J IMMUNOL, V162, P5986; Moriuchi M, 1997, J IMMUNOL, V159, P4322; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Rabbi MF, 1998, VIROLOGY, V245, P257, DOI 10.1006/viro.1998.9158; Rabbi MF, 1997, VIROLOGY, V233, P235, DOI 10.1006/viro.1997.8602; Rohr O, 1999, J CELL BIOCHEM, V75, P404, DOI 10.1002/(SICI)1097-4644(19991201)75:3<404::AID-JCB6>3.0.CO;2-G; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 2000, CURR TOP MICROBIOL, V251, P167; Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600-065X.2000.17717.x; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Wang JB, 1998, J LEUKOCYTE BIOL, V64, P642, DOI 10.1002/jlb.64.5.642; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; Wegner SA, 1998, J BIOL CHEM, V273, P4754, DOI 10.1074/jbc.273.8.4754; Yang OO, 1999, J VIROL, V73, P4582, DOI 10.1128/JVI.73.6.4582-4589.1999; Zaitseva MB, 1998, J IMMUNOL, V161, P3103; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zoeteweij JP, 1998, J IMMUNOL, V161, P3219; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	56	38	39	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0354	10.1096/fj.01-0744com	http://dx.doi.org/10.1096/fj.01-0744com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874984				2022-12-25	WOS:000174755900027
J	Takimoto, E; Yao, A; Toko, H; Takano, H; Shimoyama, M; Sonoda, M; Wakimoto, K; Takahashi, T; Akazawa, H; Mizukami, M; Nagai, T; Nagai, R; Komuro, I				Takimoto, E; Yao, A; Toko, H; Takano, H; Shimoyama, M; Sonoda, M; Wakimoto, K; Takahashi, T; Akazawa, H; Mizukami, M; Nagai, T; Nagai, R; Komuro, I			Sodium calcium exchanger plays a key role in alteration of cardiac function in response to pressure overload	FASEB JOURNAL			English	Article						Na+-Ca2+ exchanger; sarcoplasmic reticulum; knockout mice; NCX	STAGE HEART-FAILURE; NA-CA EXCHANGER; NA+-CA2+ EXCHANGER; NA+/CA2+ EXCHANGER; SARCOPLASMIC-RETICULUM; VENTRICULAR MYOCYTES; MOLECULAR-CLONING; TRANSGENIC MICE; GENE-EXPRESSION; CONTRACTION	The Na+-Ca2+ exchanger (NCX) on the plasma membrane is thought to be the main calcium extrusion system from the cytosol to the extracellular space in many mammalian excitable cells, including cardiac myocytes. However, the pathophysiological role of NCX in the heart is still unclear because of the lack of known specific inhibitors of NCX. To determine the role of NCX in cardiac contraction and the development of cardiac hypertrophy, we imposed pressure overload on the heart of heterozygous NCX knockout (KO) mice by constricting transverse aorta, and examined cardiac function and morphology 3 wk after operation. Although there was no difference in cardiac function between sham-operated KO mice and sham-operated wild-type (WT) mice, KO mice showed higher left ventricular pressure and better systolic function than WT mice in response to pressure overload. Northern blot analysis revealed that mRNA levels of sarcoplasmic reticulum Ca2+-ATPase were reduced by pressure overload in left ventricles of WT but not of KO mice. However, hypertrophic changes with interstitial fibrosis were more prominent in KO mice than WT mice. These results suggest that reduction of NCX results in supernormalized cardiac function and causes marked cardiac hypertrophy in response to pressure overload.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba 2608670, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan; Tanabe Seiyaku Co Ltd, Discovery Lab, Yodogawa Ku, Osaka 5328505, Japan	Chiba University; University of Tokyo; Mitsubishi Tanabe Pharma Corporation	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	komuro-tky@umin.ac.jp	Takimoto, Eiki/AAC-5100-2021					Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; BARRY WH, 1993, CIRCULATION, V87, P1806, DOI 10.1161/01.CIR.87.6.1806; BENOTTI JR, 1980, CIRCULATION, V61, P1206, DOI 10.1161/01.CIR.61.6.1206; BERS DM, 1990, AM J PHYSIOL, V258, pC944, DOI 10.1152/ajpcell.1990.258.5.C944; BERS DM, 1993, CARDIOVASC RES, V27, P1772, DOI 10.1093/cvr/27.10.1772; BERS DM, 1989, CIRC RES, V65, P334, DOI 10.1161/01.RES.65.2.334; Bers DM, 2000, CIRC RES, V87, P275, DOI 10.1161/01.RES.87.4.275; Cernohorsky J, 1998, AM J PHYSIOL-HEART C, V275, pH264, DOI 10.1152/ajpheart.1998.275.1.H264; DEMARIA AN, 1991, CIRCULATION, V8, P1288; GAASCH WH, 1976, AM J CARDIOL, V38, P645, DOI 10.1016/S0002-9149(76)80015-X; Harada K, 1998, CIRC RES, V82, P779, DOI 10.1161/01.RES.82.7.779; Hasenfuss G, 1999, CIRCULATION, V99, P641, DOI 10.1161/01.CIR.99.5.641; Hasenfuss G, 1998, CARDIOVASC RES, V37, P279, DOI 10.1016/S0008-6363(97)00277-0; HATEM SN, 1994, CIRC RES, V74, P253, DOI 10.1161/01.RES.74.2.253; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; KENT RL, 1993, AM J PHYSIOL, V265, pH1024, DOI 10.1152/ajpheart.1993.265.3.H1024; KLITZNER TS, 1991, J AM COLL CARDIOL, V17, P218, DOI 10.1016/0735-1097(91)90730-W; Koban MU, 1998, CARDIOVASC RES, V37, P405, DOI 10.1016/S0008-6363(97)00276-9; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; KOMURO I, 1989, J CLIN INVEST, V83, P1102, DOI 10.1172/JCI113989; LI ZP, 1994, J BIOL CHEM, V269, P17434; LOMPRE AM, 1994, J MOL CELL CARDIOL, V26, P1109, DOI 10.1006/jmcc.1994.1130; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V273, pH2826, DOI 10.1152/ajpheart.1997.273.6.H2826; MORGAN JP, 1991, NEW ENGL J MED, V325, P625; NEGRETTI N, 1993, CARDIOVASC RES, V27, P1826, DOI 10.1093/cvr/27.10.1826; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; O'Rourke B, 1999, CIRC RES, V84, P562, DOI 10.1161/01.RES.84.5.562; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Pogwizd SM, 1999, CIRC RES, V85, P1009; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; Reed TD, 2000, J MOL CELL CARDIOL, V32, P453, DOI 10.1006/jmcc.1999.1095; Reinecke H, 1996, CARDIOVASC RES, V31, P48, DOI 10.1016/0008-6363(95)00176-X; Schillinger W, 2000, CIRC RES, V87, P581, DOI 10.1161/01.RES.87.7.581; SEGUCHI M, 1986, J MOL CELL CARDIOL, V18, P189, DOI 10.1016/S0022-2828(86)80471-0; Shimoyama M, 1999, CIRCULATION, V100, P2449, DOI 10.1161/01.CIR.100.24.2449; STUDER R, 1994, CIRC RES, V75, P443, DOI 10.1161/01.RES.75.3.443; Taffet GE, 1996, AM J PHYSIOL-HEART C, V270, pH2204; TAKAHASHI T, 1992, J CLIN INVEST, V90, P927, DOI 10.1172/JCI115969; Takeshima H, 1998, EMBO J, V17, P3309, DOI 10.1093/emboj/17.12.3309; Terracciano CMN, 1998, J PHYSIOL-LONDON, V512, P651, DOI 10.1111/j.1469-7793.1998.651bd.x; VETTER R, 1995, J MOL CELL CARDIOL, V27, P1689, DOI 10.1016/S0022-2828(95)90788-2; Wakimoto K, 2000, J BIOL CHEM, V275, P36991, DOI 10.1074/jbc.M004035200; Yao AS, 1998, CIRC RES, V82, P657, DOI 10.1161/01.RES.82.6.657	45	28	29	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0373	10.1096/fj.01-0735com	http://dx.doi.org/10.1096/fj.01-0735com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874986				2022-12-25	WOS:000174755900029
J	Sullivan, A; Yuille, M; Repellin, C; Reddy, A; Reelfs, O; Bell, A; Dunne, B; Gusterson, BA; Osin, P; Farrell, PJ; Yulug, I; Evans, A; Ozcelik, T; Gasco, M; Crook, T				Sullivan, A; Yuille, M; Repellin, C; Reddy, A; Reelfs, O; Bell, A; Dunne, B; Gusterson, BA; Osin, P; Farrell, PJ; Yulug, I; Evans, A; Ozcelik, T; Gasco, M; Crook, T			Concomitant inactivation of p53 and Chk2 in breast cancer	ONCOGENE			English	Article						p53; Chk2; breast cancer	MUTATIONS; BRCA1; GENE; FAMILIES; PHOSPHORYLATION; METHYLATION; CARCINOMAS; CHECKPOINT	The structure and expression of the human Rad53 homologue Chk2 was analysed in breast cancer. The previously described silent polymorphism at nucleotide 252 in codon 84 (GAA > GAG) was observed in 5/141 cases. Somatic Chk2 coding mutations were detected in 7/141 cases, these occurring in 4/18 BRCA1-associated breast cancers, 1/78 sporadic breast cancers and 2/25 typical medullary carcinomas. Each of the BRCA1-associated cancers with Chk2 mutations also contained mutations in p53, whereas the single sporadic cancer with Chk2 mutation was wild-type for p53. Expression of Chk2 was ubiquitously detected in normal ductal epithelium of the breast, but there was loss of expression in a significant proportion of breast carcinomas, and this occurred in cancers both with and without p53 mutation. A CpG island was identified 5' of the Chk2 transcriptional start site, but there was no evidence of cytosine methylation in any of the cancers with down-regulated Chk2 expression. Analysis of the germ-line of 45 individuals with hereditary or early onset breast cancer revealed wild-type Chk2 sequence in all cases. Thus, despite the rarity of somatic mutations in Chk2 in sporadic breast carcinomas, our results nevertheless reveal that concomitant loss of function in Chk2 (via down-regulation of expression) and p53 (via mutation) occurs in a proportion of sporadic cases. However, consistent with other studies, we show that germ-line mutations in Chk2 are unlikely to account for a significant proportion of non BRCA1-, non BRCA2-associated hereditary breast cancers.	Univ London Imperial Coll Sci & Technol, Fac Med, Ludwig Inst Canc Res, London W2 1PG, England; HGMC, Hinxton, England; Univ Glasgow, Western Infirm, Dept Pathol, Glasgow, Lanark, Scotland; UCL, Dept Hist, London WC1, England; Middlesex Hosp, Med Sch, London WC1, England; Bilkent Univ, Dept Mol Genet, Ankara, Turkey; Poole Gen Hosp, Dept Surg, Poole, Dorset, England; Azienda Osped S Croce & Carle, UO Oncol Med, I-12100 Cuneo, Italy	Imperial College London; Ludwig Institute for Cancer Research; University of Glasgow; University of London; University College London; University of London; University College London; Ihsan Dogramaci Bilkent University; Poole Hospital	Crook, T (corresponding author), Univ London Imperial Coll Sci & Technol, Fac Med, Ludwig Inst Canc Res, St Marys Campus Norfolk Pl, London W2 1PG, England.	t.crook@ic.ac.uk	gusterson, barry a/D-3752-2009; /AAD-1866-2020	Yulug, Isik/0000-0002-7577-2502; Farrell, Paul/0000-0002-6754-9351; Yuille, Martin/0000-0002-4992-5405				Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; Banelli B, 2000, ONCOGENE, V19, P4553, DOI 10.1038/sj.onc.1203807; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brooks LA, 2000, CANCER RES, V60, P6875; Chehab NH, 2000, GENE DEV, V14, P278; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Eisinger F, 1998, CANCER RES, V58, P1588; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Greenblatt MS, 2001, CANCER RES, V61, P4092; Haruki N, 2000, CANCER RES, V60, P4689; HERMAN JG, 1995, CANCER RES, V55, P4525; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Lakhani SR, 2000, CLIN CANCER RES, V6, P782; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Ozdag H, 2000, EUR J CANCER, V36, P2076, DOI 10.1016/S0959-8049(00)00277-X; Phillips KA, 1999, J NATL CANCER I, V91, P469, DOI 10.1093/jnci/91.5.469; Sodha N, 2000, Science, V289, P359; Vahteristo P, 2001, CANCER RES, V61, P5718; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200	27	66	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1316	1324		10.1038/sj.onc.1205207	http://dx.doi.org/10.1038/sj.onc.1205207			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857075	Green Published			2022-12-25	WOS:000173861000002
J	Brinker, A; Scheufler, C; von der Mulbe, F; Fleckenstein, B; Herrmann, C; Jung, G; Moarefi, I; Hartl, FU				Brinker, A; Scheufler, C; von der Mulbe, F; Fleckenstein, B; Herrmann, C; Jung, G; Moarefi, I; Hartl, FU			Ligand discrimination by TPR domains - Relevance and selectivity of EEVD-recognition in Hsp70 center dot Hop center dot Hsp90 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TETRATRICOPEPTIDE REPEAT; MOLECULAR CHAPERONE; COGNATE PROTEIN; SNAP HELIX; BINDING; HSP90; CO; MOTIF; HOP	Protein-protein interaction modules containing so-called tetratricopeptide repeats (TPRs) mediate the assembly of Hsp70/Hsp90 multi-chaperone complexes. The TPR1 and TPR2A domains of the Hsp70/Hsp90 adapter protein p60/Hop specifically bind to short peptides corresponding to the C-terminal tails of Hsp70 and Hsp90, respectively, both of which contain the highly conserved sequence motif EEVD-COOH. Here, we quantitatively assessed the contribution of TPR-mediated peptide recognition to Hsp70.Hop.Hsp90 complex formation. The interaction of TPR2A with the C-terminal pentapeptide of Hsp90 (AMEVD) is identified as the core contact for Hop binding to Hsp90. (In peptide sequences, italics are used to highlight residues specific for Hsp70 or Hsp90.) In contrast, formation of the Hsp70.Hop complex depends not only on recognition of the C-terminal Hsp70 heptapeptide (PTIEEVD) by TPR1 but also on additional contacts between Hsp70 and Hop. The sequence motifs for TPR1 and TPR2A binding were defined by alanine scanning of the C-terminal octapeptides of Hsp70 and Hsp90 and by screening of combinatorial peptide libraries. Asp0 and Val-1 of the EEVD motif are identified as general anchor residues, but the highly conserved glutamates of the EEVD sequence, which are critical in Hsp90 binding by TPR2A, do not contribute appreciably to the interaction of Hsp70 with TPR1. Rather, TPR1 prefers hydrophobic amino acids in these positions. Moreover, the TPR domains display a pronounced tendency to interact preferentially with hydrophobic aliphatic and aromatic side chains in positions -4 and -6 of their respective peptide ligands. Ile-4 in Hsp70 and Met-4 in Hsp90 are most important in determining the specific binding of TPR1 and TPR2A, respectively.	Max Planck Inst Biochem, Dept Cellular Biochem, D-85152 Martinsried, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; Max Planck Inst Mol Physiol, Dept Biol Struct, D-44227 Dortmund, Germany	Max Planck Society; Eberhard Karls University of Tubingen; Max Planck Society	Moarefi, I (corresponding author), SiREEN, Am Klopferspitz 19, D-82512 Martinsried, Germany.	moarefi@sireen.com; uhartl@biochem.mpg.de	Hartl, F. Ulrich/Y-8206-2019	Scheufler, Clemens/0000-0002-3693-3529				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Barral JM, 2002, SCIENCE, V295, P669, DOI 10.1126/science.1066648; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Brinker A, 2000, EUR J BIOCHEM, V267, P5085, DOI 10.1046/j.1432-1327.2000.01570.x; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Fleckenstein B, 1996, EUR J BIOCHEM, V240, P71, DOI 10.1111/j.1432-1033.1996.0071h.x; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Gebauer M, 1997, FEBS LETT, V417, P109, DOI 10.1016/S0014-5793(97)01267-2; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Grizot S, 2001, J BIOL CHEM, V276, P21627, DOI 10.1074/jbc.M100893200; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOHFELD J, 1995, CELL, V83, P589; Irmer H, 1997, J BIOL CHEM, V272, P2230; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; METZGER JW, 1994, ANAL BIOCHEM, V219, P261, DOI 10.1006/abio.1994.1266; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; STEVANOVIC S, 1993, ANAL BIOCHEM, V212, P212, DOI 10.1006/abio.1993.1314; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7; van der Spuy J, 2000, BIOCHEM J, V345, P645, DOI 10.1042/0264-6021:3450645; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; [No title captured]	50	185	188	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19265	19275		10.1074/jbc.M109002200	http://dx.doi.org/10.1074/jbc.M109002200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11877417	hybrid			2022-12-25	WOS:000175894800005
J	Biard, DSF; Miccoli, L; Despras, E; Frobert, Y; Creminon, C; Angulo, JF				Biard, DSF; Miccoli, L; Despras, E; Frobert, Y; Creminon, C; Angulo, JF			Ionizing radiation triggers chromatin-bound kin17 complex formation in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; REPLICATION PROTEIN-A; DNA-BINDING-PROTEIN; CURVED DNA; NUCLEAR-PROTEIN; CELLULAR-RESPONSE; ESCHERICHIA-COLI; MAMMALIAN-CELLS; CROSS-LINKING; MOUSE PROTEIN	The human DNA-binding (HSA)kin17 protein cross-reacts with antibodies raised against the stress-activated Escherichia coli RecA protein. We show here that HSAkin17 protein is directly associated with chromosomal DNA as judged by cross-linking experiments on living cells. We detected increased amounts of DNA-bound HSAkin17 protein 24 h after gamma irradiation, with 2.6-fold more (HSA)kin17 molecules after 6 Gy of irradiation (46,000-117,000 molecules). At this time we observed that highly proliferating RKO cells displayed the concentration and co-localization of (HSA)kin17 and replication protein A in nucleoplasmic foci. Our results suggest that 24 h post-irradiation HSAkin17 protein may localize at the sites of unrepaired DNA damages. RKO clones expressing an (HSA)KIN17 antisense transcript (RASK.5 and RASK.13 cells) revealed that reduced (HSA)kin17 protein levels are correlated with a decrease in clonogenic cell growth and cell proliferation, as well as an accumulation of cells in early and mid-S phase. Taken together our observations support the idea that HSAkin17 protein is a DNA maintenance protein involved in the cellular response to the presence of DNA damage and suggest that it helps to overcome the perturbation of DNA replication produced by unrepaired lesions.	CEA, DSV, DRR, Lab Genet Radiosensibil, F-92265 Fontenay Aux Roses, France; Ctr Etud Saclay, Direct Sci Vivant, Dept Rech Med,Serv Pharmacol & Immunol, CEA, F-91191 Gif Sur Yvette, France	CEA; CEA; UDICE-French Research Universities; Universite Paris Saclay	Biard, DSF (corresponding author), CEA, DSV, DRR, Lab Genet Radiosensibil, BP 6, F-92265 Fontenay Aux Roses, France.		miccoli, laurent/N-6638-2018; ANGULO, Jaime F./B-3024-2009	miccoli, laurent/0000-0002-5242-4388; ANGULO MORA, Jaime Francisco/0000-0003-1447-2263; BIARD, Denis Serge Francois/0000-0001-9697-4392				ANGULO JF, 1989, MUTAT RES, V217, P123, DOI 10.1016/0921-8777(89)90064-5; ANGULO JF, 1991, NUCLEIC ACIDS RES, V19, P5117, DOI 10.1093/nar/19.19.5117; Araneda S, 2001, BRAIN RES BULL, V56, P139, DOI 10.1016/S0361-9230(01)00620-7; Balajee AS, 2001, NUCLEIC ACIDS RES, V29, P1341, DOI 10.1093/nar/29.6.1341; Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Biard DSF, 1997, RADIAT RES, V147, P442, DOI 10.2307/3579501; Biard DSF, 1999, EXP CELL RES, V250, P499, DOI 10.1006/excr.1999.4515; Biard DSF, 1997, ARCH DERMATOL RES, V289, P448, DOI 10.1007/s004030050220; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; GRASSI J, 1989, J IMMUNOL METHODS, V123, P193, DOI 10.1016/0022-1759(89)90223-8; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; Kannouche P, 2000, CARCINOGENESIS, V21, P1701, DOI 10.1093/carcin/21.9.1701; Kannouche P, 1998, CARCINOGENESIS, V19, P781, DOI 10.1093/carcin/19.5.781; Kurumizaka H, 1996, J BIOL CHEM, V271, P33515, DOI 10.1074/jbc.271.52.33515; Li L, 2000, NUCLEIC ACIDS RES, V28, P1424, DOI 10.1093/nar/28.6.1424; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; MacPhail SH, 2001, RADIAT RES, V155, P672, DOI 10.1667/0033-7587(2001)155[0672:RFAAWC]2.0.CO;2; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MAZIN A, 1994, NUCLEIC ACIDS RES, V22, P4335, DOI 10.1093/nar/22.20.4335; MAZIN A, 1994, MOL GEN GENET, V244, P435, DOI 10.1007/BF00286696; Mermet N, 1998, NEUROSCI LETT, V243, P97, DOI 10.1016/S0304-3940(98)00094-9; NUNEZ MI, 1995, BRIT J CANCER, V71, P311, DOI 10.1038/bjc.1995.62; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rothkamm K, 2001, CANCER RES, V61, P3886; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Schweizer U, 1999, NUCLEIC ACIDS RES, V27, P3183, DOI 10.1093/nar/27.15.3183; Timchenko T, 1996, EMBO J, V15, P3986, DOI 10.1002/j.1460-2075.1996.tb00772.x; Wang M, 2000, BIOCHEMISTRY-US, V39, P6433, DOI 10.1021/bi000472q; Wang Y, 2000, GENE DEV, V14, P927; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	36	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19156	19165		10.1074/jbc.M200321200	http://dx.doi.org/10.1074/jbc.M200321200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11880372	hybrid			2022-12-25	WOS:000175975800118
J	Galvagni, F; Cantini, M; Oliviero, S				Galvagni, F; Cantini, M; Oliviero, S			The utrophin gene is transcriptionally up-regulated in regenerating muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-RELATED PROTEIN; SKELETAL-MUSCLE; MUSCULAR-DYSTROPHY; SATELLITE CELL; DIFFERENTIAL EXPRESSION; FUNCTIONAL-ANALYSIS; ACTIN-BINDING; MDX; PROMOTER; MICE	The utrophin gene codes for a large cytoskeletal protein closely related to dystrophin, the gene mutated in Duchenne's muscular dystrophy. Although utrophin could functionally substitute for dystrophin, in Duchenne's muscular dystrophy patients it did not compensate for the absence of dystrophin because in adult muscle utrophin was poorly expressed and limited to subsynaptic nuclei. However, increased levels of utrophin have been observed in regenerated muscles fibers suggesting that utrophin up-regulation in muscle is feasible. We observed that utrophin mRNA was transiently up-regulated at early time points after muscle Injury with a peak already 24 h after muscle damage and utrophin induction in activated satellite cells before fusion into young regenerated fibers. Injection of utrophin lacZ constructs into regenerating muscle demonstrated that the utrophin upstream promoter under the control of its intronic enhancer activated the transcription that leads to the expression of the reporter gene in the newly formed fibers, which was not limited to neuromuscular junctions. Utrophin enhancer activity was dependent on an AP-1 site, and in satellite cells of regenerating muscle the AP-1 factors Fra1, Fra2, and JunD were strongly induced. These results establish that utrophin was induced in adult muscle independently from neuromuscular junctions and suggest that growth factors and cytokines that mediate the muscle repair up-regulate utrophin transcription.	Univ Siena, Dept Biol Mol, I-53100 Siena, Italy; Univ Padua, Dipartimento Sci Biomed, Padua, Italy	University of Siena; University of Padua	Oliviero, S (corresponding author), Univ Siena, Dept Biol Mol, Via Fiorentina 1, I-53100 Siena, Italy.	oliviero@unisi.it	Galvagni, Federico/F-9186-2013; oliviero, salvatore/R-6657-2019	oliviero, salvatore/0000-0002-3405-765X	Telethon [GP0275Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Amann KJ, 1999, J BIOL CHEM, V274, P35375, DOI 10.1074/jbc.274.50.35375; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Burton EA, 1999, P NATL ACAD SCI USA, V96, P14025, DOI 10.1073/pnas.96.24.14025; CANTINI M, 1994, BIOCHEM BIOPH RES CO, V202, P1688, DOI 10.1006/bbrc.1994.2129; CANTINI M, 1995, J NEUROPATH EXP NEUR, V54, P121, DOI 10.1097/00005072-199501000-00014; CANTINI M, 1993, CELL BIOL INT, V17, P979, DOI 10.1006/cbir.1993.1025; CANTINI M, 1994, IN VITRO CELL DEV-AN, V30A, P131; Cooper RN, 1999, J CELL SCI, V112, P2895; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Dennis CL, 1996, NUCLEIC ACIDS RES, V24, P1646, DOI 10.1093/nar/24.9.1646; di Vignano AT, 2000, FEBS LETT, V471, P229, DOI 10.1016/S0014-5793(00)01400-9; Fabbro C, 1999, J BIOL CHEM, V274, P1759, DOI 10.1074/jbc.274.3.1759; Floss T, 1997, GENE DEV, V11, P2040, DOI 10.1101/gad.11.16.2040; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; Galvagni F, 1998, J BIOL CHEM, V273, P33708, DOI 10.1074/jbc.273.50.33708; Galvagni F, 1997, MOL CELL BIOL, V17, P1731, DOI 10.1128/MCB.17.3.1731; Galvagni F, 2000, J BIOL CHEM, V275, P3168, DOI 10.1074/jbc.275.5.3168; Galvagni F, 2001, J MOL BIOL, V306, P985, DOI 10.1006/jmbi.2000.4335; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Gramolini AO, 1999, J NEUROPATH EXP NEUR, V58, P235, DOI 10.1097/00005072-199903000-00003; Gramolini AO, 1999, NUCLEIC ACIDS RES, V27, P3603, DOI 10.1093/nar/27.17.3603; Gramolini AO, 1997, J BIOL CHEM, V272, P8117, DOI 10.1074/jbc.272.13.8117; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; KLAMUT HJ, 1990, MOL CELL BIOL, V10, P193, DOI 10.1128/MCB.10.1.193; KOELLE GB, 1949, P SOC EXP BIOL MED, V70, P617; LAW DJ, 1994, J CELL SCI, V107, P1477; Lescaudron L, 1999, NEUROMUSCULAR DISORD, V9, P72, DOI 10.1016/S0960-8966(98)00111-4; Lin S, 1998, J NEUROPATH EXP NEUR, V57, P780, DOI 10.1097/00005072-199808000-00007; Lin S, 2000, DEV BRAIN RES, V119, P289, DOI 10.1016/S0165-3806(99)00165-0; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MATSUMURA K, 1993, FEBS LETT, V334, P281, DOI 10.1016/0014-5793(93)80695-Q; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Megeney LA, 1999, P NATL ACAD SCI USA, V96, P220, DOI 10.1073/pnas.96.1.220; NUDEL U, 1988, NATURE, V331, P635, DOI 10.1038/331635a0; ORIMO S, 1991, MUSCLE NERVE, V14, P515, DOI 10.1002/mus.880140605; PEARCE M, 1993, HUM MOL GENET, V2, P1765, DOI 10.1093/hmg/2.11.1765; PONS F, 1993, NEUROMUSCULAR DISORD, V3, P507, DOI 10.1016/0960-8966(93)90106-T; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; SCHOFIELD J, 1993, DEV DYNAM, V198, P254, DOI 10.1002/aja.1001980403; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; VITADELLO M, 1994, HUM GENE THER, V5, P11, DOI 10.1089/hum.1994.5.1-11; WINDER SJ, 1995, J CELL SCI, V108, P63; Yamamoto K, 2000, HUM GENE THER, V11, P669, DOI 10.1089/10430340050015572	58	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19106	19113		10.1074/jbc.M109642200	http://dx.doi.org/10.1074/jbc.M109642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11875058	hybrid			2022-12-25	WOS:000175975800112
J	Hillion, J; Canals, M; Torvinen, M; Casado, V; Scott, R; Terasmaa, A; Hansson, A; Watson, S; Olah, ME; Mallol, J; Canela, EI; Zoli, M; Agnati, LF; Ibanez, CF; Lluis, C; Franco, R; Ferre, S; Fuxe, K				Hillion, J; Canals, M; Torvinen, M; Casado, V; Scott, R; Terasmaa, A; Hansson, A; Watson, S; Olah, ME; Mallol, J; Canela, EI; Zoli, M; Agnati, LF; Ibanez, CF; Lluis, C; Franco, R; Ferre, S; Fuxe, K			Coaggregation, cointernalization, and codesensitization of adenosine A(2A) receptors and dopamine D-2 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A(1); D-1; DESENSITIZATION; TRANSMISSION; IDENTIFICATION; MODULATION; DYSKINESIA; CAFFEINE; NUCLEUS; NEURONS	Antagonistic and reciprocal interactions are known to exist between adenosine and dopamine receptors in the striatum. In the present study, double immunofluorescence experiments with confocal laser microscopy showed a high degree of colocalization of adenosine A A receptors (A(2A)R) and dopamine D-2 receptors (D2R) in cell membranes of SH-SY5Y human neuroblastoma cells stably transfected with human D2R and in cultured striatal cells. A(2A)R/D2R heteromeric complexes were demonstrated in coimmunoprecipitation experiments in membrane preparations from D2R-transfected SH-SY5Y cells and from mouse fibroblast Ltk(-) cells stably transfected with human D2R (long form) and transiently cotransfected with the A(2A)R double-tagged with hemagglutinin. Long term exposure to A(2A)R and D2R agonists in D2R-cotransfected SH-SY5Y cells resulted in coaggregation, cointernalization and codesensitization of A(2A)R and D2R. These results give a molecular basis for adenosine-dopamine antagonism at the membrane level and have implications for treatment of Parkinson's disease and schizophrenia, in which D2R are involved.	Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Univ Michigan, Mental Hlth Inst, Ann Arbor, MI 48109 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ Modena, Dept Biomed Sci, I-41100 Modena, Italy; NIDA, Baltimore, MD 21224 USA	Karolinska Institutet; University of Barcelona; University of Michigan System; University of Michigan; Duke University; Universita di Modena e Reggio Emilia; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Hillion, J (corresponding author), NINCDS, Stroke Branch, NIH, Bethesda, MD 20892 USA.	hillionj@ninds.nih.gov	Franco, Rafael/C-3694-2015; Zoli, Michele/C-8899-2016; Scott, Rizaldy/AAC-5264-2020; Ferre, Sergi/K-6115-2014; Hansson, Anita C/K-8146-2013; soler, martha maricel m gomez/L-6025-2014; Mallol, Josefa/I-4194-2015; Scott, Rizaldy/Y-7584-2019; Casadó, Vicent/K-1660-2014; Canela, Enric I./M-8726-2013; Canals, Meritxell/A-6422-2013; Terasmaa, Anton/I-3312-2015	Franco, Rafael/0000-0003-2549-4919; Zoli, Michele/0000-0002-8034-2849; Ferre, Sergi/0000-0002-1747-1779; soler, martha maricel m gomez/0000-0002-4412-8108; Mallol, Josefa/0000-0002-2479-4162; Scott, Rizaldy/0000-0002-0288-8862; Casadó, Vicent/0000-0002-1764-3825; Canela, Enric I./0000-0003-4992-7440; Terasmaa, Anton/0000-0002-5139-1764; Canals, Meritxell/0000-0002-7942-5006; Fuxe, Kjell/0000-0001-8491-4288	NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000003, Z01DA000003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AGNATI LF, 1982, NEUROSCI LETT, V32, P253, DOI 10.1016/0304-3940(82)90302-0; Akhondzadeh S, 2000, J CLIN PHARM THER, V25, P131; Bjelke B, 1996, J CHEM NEUROANAT, V12, P37, DOI 10.1016/S0891-0618(96)00176-7; Chase TN, 2000, TRENDS NEUROSCI, V23, pS86, DOI 10.1016/S1471-1931(00)00018-5; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; Dasgupta S, 1996, EUR J PHARMACOL, V316, P325, DOI 10.1016/S0014-2999(96)00665-6; DUNCAN OD, 1977, MATH DEMOGRAPHY, P349; Fenu S, 2000, BEHAV BRAIN RES, V114, P97, DOI 10.1016/S0166-4328(00)00190-X; Ferre S, 1996, EUR J NEUROSCI, V8, P1545, DOI 10.1111/j.1460-9568.1996.tb01617.x; Ferre S, 1997, PSYCHOPHARMACOLOGY, V133, P107, DOI 10.1007/s002130050380; Ferre S, 2000, PROG BRAIN RES, V125, P353; Ferre S, 1998, J BIOL CHEM, V273, P4718, DOI 10.1074/jbc.273.8.4718; Ferre S, 1997, TRENDS NEUROSCI, V20, P482, DOI 10.1016/S0166-2236(97)01096-5; FERRE S, 1991, P NATL ACAD SCI USA, V88, P7238, DOI 10.1073/pnas.88.16.7238; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; FISHBURN CS, 1995, J BIOL CHEM, V270, P29819; Fuxe K, 1998, BRAIN RES REV, V26, P258, DOI 10.1016/S0165-0173(97)00049-0; GARRETT BE, 1994, EUR J PHARMACOL, V262, P65, DOI 10.1016/0014-2999(94)90029-9; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Kanda T, 1998, ANN NEUROL, V43, P507, DOI 10.1002/ana.410430415; Kull B, 1999, BIOCHEM PHARMACOL, V58, P1035, DOI 10.1016/S0006-2952(99)00184-7; Mundell SJ, 1998, BRIT J PHARMACOL, V125, P1594, DOI 10.1038/sj.bjp.0702234; Ng GYK, 1997, ENDOCRINOLOGY, V138, P4199, DOI 10.1210/en.138.10.4199; Nomoto M, 2000, J NEUROL, V247, P16, DOI 10.1007/PL00007779; Olah ME, 1997, J BIOL CHEM, V272, P337; PALMER TM, 1994, MOL PHARMACOL, V45, P1082; POPOLI P, 1994, EUR J PHARMACOL, V257, pR5, DOI 10.1016/0014-2999(94)90715-3; Richter A, 2000, EUR J PHARMACOL, V404, P299, DOI 10.1016/S0014-2999(00)00627-0; Salim H, 2000, J NEUROCHEM, V74, P432, DOI 10.1046/j.1471-4159.2000.0740432.x; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sarrio S, 2000, MOL CELL BIOL, V20, P5164, DOI 10.1128/MCB.20.14.5164-5174.2000; Saura CK, 1998, J BIOL CHEM, V273, P17610, DOI 10.1074/jbc.273.28.17610; SCHIFFMANN SN, 1991, J NEUROCHEM, V57, P1062, DOI 10.1111/j.1471-4159.1991.tb08257.x; Stromberg I, 2000, EUR J NEUROSCI, V12, P4033, DOI 10.1046/j.1460-9568.2000.00288.x; Zeng BY, 2000, EUR J NEUROSCI, V12, P1096, DOI 10.1046/j.1460-9568.2000.00988.x	35	403	414	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18091	18097		10.1074/jbc.M107731200	http://dx.doi.org/10.1074/jbc.M107731200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11872740	Green Published, hybrid			2022-12-25	WOS:000175685100089
J	Libri, D; Duconge, F; Levy, L; Vinauger, M				Libri, D; Duconge, F; Levy, L; Vinauger, M			A role for the Psi-U mismatch in the recognition of the 5 ' splice site of yeast introns by the U1 small nuclear ribonucleoprotein particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; 5'-SPLICE-SITE RECOGNITION; THERMODYNAMIC PARAMETERS; SECONDARY STRUCTURE; COMPLEX-FORMATION; SNRNP; PROTEIN; IDENTIFICATION; SELECTION	The U1 small nuclear ribonucleoprotein particle (snRNP)/5' splice site (5'SS) interaction in yeast is essential for the splicing process and depends on the formation of a short RNA duplex between the 5' arm of U1 snRNA and the 1st intronic nucleotides. This RNA/RNA interaction is characterized by the presence of a mismatch that occurs with almost all yeast introns and concerns nucleotides 4 on the pre-mRNA (a U) and 5 on U1 snRNA (a P). The latter nucleotide is well conserved from yeast to vertebrates, but its role in yeast and the significance of the associated mismatch in the U1 snRNA/5'SS interaction have never been fully explained. We report here that the presence of this mismatch is a determinant of stability that mainly affects the off rate of the interaction. To our knowledge this is the first report assigning a function to this noncanonical interaction. We also performed SELEX (systematic evolution of ligands by exponential enrichment) experiments by immunoprecipitating U1 snRNP and the associated RNA. The artificial phylogeny derived from these experiments allows the isolation of the selective pressure due to U1 snRNP binding on the 5'SS of yeast introns.	CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France; Serv Hosp Frederic Joliot, Commissariat Energie Atom, INSERM, Equipe Rech & Innovat Tech & Methodol 0103, F-91401 Orsay, France; Inst Pasteur, F-75015 Paris, France; CNRS, Inst Sci Vegetales, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Libri, D (corresponding author), CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France.		Duconge, Frederic/C-6729-2012	Duconge, Frederic/0000-0002-8595-0050				ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Breckenridge DG, 1999, P NATL ACAD SCI USA, V96, P852, DOI 10.1073/pnas.96.3.852; BURGE CB, 1998, RNA WORLD, V2, P525; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Collins CA, 1999, GENE DEV, V13, P1970, DOI 10.1101/gad.13.15.1970; Du H, 2001, RNA, V7, P133, DOI 10.1017/S1355838201001844; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Gottschalk A, 1998, RNA, V4, P374; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; Kao HY, 1996, MOL CELL BIOL, V16, P960; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRETZNER L, 1990, P NATL ACAD SCI USA, V87, P851, DOI 10.1073/pnas.87.2.851; Libri D, 2001, GENE DEV, V15, P36, DOI 10.1101/gad.852101; Libri D, 2000, RNA, V6, P352, DOI 10.1017/S1355838200991222; Long MY, 1997, CELL, V91, P739, DOI 10.1016/S0092-8674(00)80462-6; Lopez PJ, 1999, RNA, V5, P1135, DOI 10.1017/S135583829999091X; Massenet S, 1999, MOL CELL BIOL, V19, P2142; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; McConnell TS, 2001, EMBO J, V20, P3577, DOI 10.1093/emboj/20.13.3577; Moore M., 1993, RNA WORLD, P303; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; Nilsen TW, 2002, MOL CELL, V9, P8, DOI 10.1016/S1097-2765(02)00430-6; ODay CL, 1996, J BIOL CHEM, V271, P33261, DOI 10.1074/jbc.271.52.33261; Puig O, 1999, GENE DEV, V13, P569, DOI 10.1101/gad.13.5.569; Reyes J, 1996, RNA, V2, P213; SERAPHIN B, 1993, CELL, V73, P803, DOI 10.1016/0092-8674(93)90258-R; SERAPHIN B, 1989, GENE, V82, P145, DOI 10.1016/0378-1119(89)90039-5; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; Staley JP, 1999, MOL CELL, V3, P55, DOI 10.1016/S1097-2765(00)80174-4; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; Xia TB, 1998, BIOCHEMISTRY-US, V37, P14719, DOI 10.1021/bi9809425; Zhang D, 1999, GENE DEV, V13, P581, DOI 10.1101/gad.13.5.581; Zhang D, 2001, MOL CELL, V7, P319, DOI 10.1016/S1097-2765(01)00180-0; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701; Zuker M., 1999, V70, P11	46	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18173	18181		10.1074/jbc.M112460200	http://dx.doi.org/10.1074/jbc.M112460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877437	hybrid			2022-12-25	WOS:000175685100099
J	Karpinich, NO; Tafani, M; Rothman, RJ; Russo, MA; Farber, JL				Karpinich, NO; Tafani, M; Rothman, RJ; Russo, MA; Farber, JL			The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PROGRAMMED CELL-DEATH; PERMEABILITY TRANSITION; TOPOISOMERASE-II; INTRACELLULAR PH; BAX; PHOSPHORYLATION; INHIBITION; TRANSLOCATION; WITHDRAWAL	Treatment of L929 fibroblasts by the topoisomerase II inhibitor etoposide killed 50% of the cells within 72 h. The cell killing was preceded by the release of cytochrome c from the mitochondria. Simultaneous treatment of the cells with wortmannin, cycloheximide, furosemide, cyclosporin A, or decylubiquinone prevented the release of cytochrome c and significantly reduced the loss of viability. Etoposide caused the phosphorylation of p53 within 6 h, an effect prevented by wortmannin, an inhibitor of DNA-dependent protein kinase (DNA-PK). The activation of p53 by etoposide resulted in the up-regulation of the pro-apoptotic protein Bax, a result that was prevented by the protein synthesis inhibitor cycloheximide. The increase in the content of Bax was followed by the translocation of this protein from the cytosol to the mitochondria, an event that was inhibited by furosemide, a chloride channel inhibitor. Stably transfected L929 fibroblasts that overexpress Akt were resistant to etoposide and did not translocate Bax to the mitochondria or release cytochrome c. Bax levels in these transfected cells were comparable with the wild-type cells. The release of cytochrome c upon translocation of Bax has been attributed to induction of the mitochondrial permeability transition (MPT). Cyclosporin A and decylubiquinone, inhibitors of MPT, prevented the release of cytochrome c without affecting Bax translocation. These data define a sequence of biochemical events that mediates the apoptosis induced by etoposide. This cascade proceeds by coupling DNA damage to p53 phosphorylation through the action of DNA-PK. The activation of p53 increases Bax synthesis. The translocation of Bax to the mitochondria induces the MPT, the event that releases cytochrome c and culminates in the death of the cells.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy	Jefferson University; Sapienza University Rome	Farber, JL (corresponding author), Thomas Jefferson Univ, Dept Pathol, Rm 208,Jefferson alimni Hall, Philadelphia, PA 19107 USA.	john.farber@mail.tju.edu	Tafani, Marco/C-3275-2017; Tafani, Marco/U-7230-2019	Tafani, Marco/0000-0001-7128-810X; Tafani, Marco/0000-0001-7128-810X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007463] Funding Source: NIH RePORTER; NIAAA NIH HHS [T32 AA07463] Funding Source: Medline; NIDDK NIH HHS [DK 38305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Belaud-Rotureau MA, 2000, APOPTOSIS, V5, P551, DOI 10.1023/A:1009693630664; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Cooper GJ, 1997, J PHYSIOL-LONDON, V498, P49, DOI 10.1113/jphysiol.1997.sp021840; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deshmukh M, 1997, MOL PHARMACOL, V51, P897, DOI 10.1124/mol.51.6.897; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; McConnell K, 1996, CURR OPIN CELL BIOL, V8, P325, DOI 10.1016/S0955-0674(96)80005-6; MIYASHITA T, 1995, CELL, V80, P293; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Pawlowski J, 2000, P NATL ACAD SCI USA, V97, P529, DOI 10.1073/pnas.97.2.529; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Sarkaria JN, 1998, CANCER RES, V58, P4375; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, BIOCHEM SOC SYMP, P91; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Vander Heiden MG, 1999, MOL CELL, V3, P159; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	41	250	255	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16547	16552		10.1074/jbc.M110629200	http://dx.doi.org/10.1074/jbc.M110629200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864976	hybrid			2022-12-25	WOS:000175564500029
J	Kim, C; Crane, FL; Faulk, WP; Morre, DJ				Kim, C; Crane, FL; Faulk, WP; Morre, DJ			Purification and characterization of a doxorubicin-inhibited NADH-quinone (NADH-ferricyanide) reductase from rat liver plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFERRIC TRANSFERRIN REDUCTASE; COENZYME-Q REDUCTASE; HELA-CELL GROWTH; ELECTRON-TRANSPORT; OXIDASE ACTIVITY; 2-PHASE PARTITION; REDOX SYSTEMS; ADRIAMYCIN; STIMULATION; REQUIREMENT	Plasma membrane-associated redox systems play important roles in regulation of cell growth, internal pH, signal transduction, apoptosis, and defense against pathogens. Stimulation of cell growth and stimulation of the redox system of plasma membranes are correlated. When cell growth is inhibited by antitumor agents such as doxorubicin, capsaicin, and antitumor sulfonylureas, redox activities of the plasma membrane also are inhibited. A doxorubicin-inhibited NADH-quinone reductase was characterized and purified from plasma membranes of rat liver. First, an NADH-cytochrome b(5), reductase, which was doxorubicin-insensitive, was removed from the plasma membranes by the lysosomal protease, cathepsin D. After removal of the NADH-cytochrome b(5). reductase, the plasma membranes retained a doxorubicin-inhibited NADH-quinone reductase activity. The enzyme, with an apparent molecular mass of 57 kDa, was purified 200-fold over the cathepsin D-treated plasma membranes. The purified enzyme had also an NADH-coenzyme Q(o) reductase (NADH: external acceptor (quinone) reductase; EC 1.6.5..) activity. Partial amino acid sequence of the enzyme showed that it was unique with no sequence homology to any known protein. Antibody against the enzyme (peptide sequence) was produced and affinity-purified. The purified antibody immunoprecipitated both the NADH-ferricyanide reductase activity and NADH-coenzyme Qo reductase activity of plasma membranes and cross-reacted with human chronic myelogenous leukemia K562 cells and doxorubicin-resistant human chronic myelogenous leukemia K562R cells. Localization by fluorescence microscopy showed that the reaction was with the external surface of the plasma membranes. The doxorubicin-inhibited NADH-quinone reductase may provide a target for the anthracycline antitumor agents and a candidate ferricyanide reductase for plasma membrane electron transport.	Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Faulk Pharmaceut Res, Indianapolis, IN 46240 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kim, C (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, Hansen Life Sci Res Bldg, W Lafayette, IN 47907 USA.							Albertsson P A, 1982, Methods Biochem Anal, V28, P115, DOI 10.1002/9780470110485.ch2; BARABAS K, 1992, J BIOL CHEM, V267, P9437; BARABAS K, 1991, AM J REPROD IMMUNOL, V25, P120, DOI 10.1111/j.1600-0897.1991.tb01078.x; BARABAS K, 1993, BIOCHEM BIOPH RES CO, V197, P702, DOI 10.1006/bbrc.1993.2536; BERCZI A, 1995, ARCH BIOCHEM BIOPHYS, V320, P65, DOI 10.1006/abbi.1995.1343; BRIGHTMAN AO, 1988, PLANT PHYSIOL, V86, P1264, DOI 10.1104/pp.86.4.1264; BRUNO M, 1992, BIOCHEM J, V284, P625, DOI 10.1042/bj2840625; CASTILLOOLIVARE.A, 1996, BIOCHEM J, V314, P587; CHOURY D, 1981, J CLIN INVEST, V67, P149, DOI 10.1172/JCI110007; Chueh PJ, 2000, ANTIOXID REDOX SIGN, V2, P177, DOI 10.1089/ars.2000.2.2-177; CRANE FL, 1991, J BIOENERG BIOMEMBR, V23, P773, DOI 10.1007/BF00786001; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRANE FL, 1994, MOL ASPECTS MED, V15, P1; ELLEM KAO, 1983, BIOCHEM BIOPH RES CO, V112, P183, DOI 10.1016/0006-291X(83)91814-4; FAULK WP, 1991, BIOCHEM INT, V25, P815; GomezDiaz C, 1997, J BIOENERG BIOMEMBR, V29, P251, DOI 10.1023/A:1022410127104; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; ISRAEL M, 1978, CANCER RES, V38, P365; KIM C, 1995, PROTOPLASMA, V184, P111, DOI 10.1007/BF01276907; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALIBERTE JF, 1987, J BIOENERG BIOMEMBR, V19, P69; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; LOW H, 1986, BIOCHEM BIOPH RES CO, V139, P1117, DOI 10.1016/S0006-291X(86)80293-5; Luthje S, 1997, BBA-REV BIOMEMBRANES, V1331, P81, DOI 10.1016/S0304-4157(96)00016-0; Medina MA, 1997, BIOESSAYS, V19, P977, DOI 10.1002/bies.950191107; MISHRA RK, 1969, J MEMBRANE BIOL, V1, P214, DOI 10.1007/BF01869782; MORRE DJ, 1991, J BIOENERG BIOMEMBR, V23, P469, DOI 10.1007/BF00771015; MORRE DJ, 1989, BIOTECHNIQUES, V7, P946; MORRE DJ, 1995, BBA-BIOMEMBRANES, V1240, P11, DOI 10.1016/0005-2736(95)00164-7; Morre DJ, 2000, J APPL TOXICOL, V20, P157, DOI 10.1002/(SICI)1099-1263(200003/04)20:2<157::AID-JAT648>3.0.CO;2-9; MORRE DJ, 1995, P NATL ACAD SCI USA, V92, P1831, DOI 10.1073/pnas.92.6.1831; NAVARRO F, 1995, BIOCHEM BIOPH RES CO, V212, P138, DOI 10.1006/bbrc.1995.1947; NAVAS P, 1989, CANCER RES, V49, P2147; OAKEY BR, 1980, ANAL BIOCHEM, V105, P361; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SUN IL, 1990, BIOCHEM BIOPH RES CO, V172, P979, DOI 10.1016/0006-291X(90)91542-Z; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; SUN IL, 1987, BIOCHEM INT, V14, P119; SUN IL, 1984, J BIOENERG BIOMEMBR, V16, P209, DOI 10.1007/BF00751050; SUN IL, 1984, BIOCHEM INT, V9, P299; SUN IL, 1984, BIOCHEM BIOPH RES CO, V125, P649, DOI 10.1016/0006-291X(84)90588-6; SUN IL, 1985, BIOCHEM PHARMACOL, V34, P617, DOI 10.1016/0006-2952(85)90254-0; SUN IL, 1992, BIOCHIM BIOPHYS ACTA, V1105, P84, DOI 10.1016/0005-2736(92)90165-I; SUN IL, 1985, EXP CELL RES, V156, P528, DOI 10.1016/0014-4827(85)90559-2; SUN IL, 1987, J BIOL CHEM, V262, P15915; SZEKELY M, 1952, ACTA PHYSIOL HUNG, V3, P571; TAKESUE S, 1968, BIOCHEM BIOPH RES CO, V30, P723, DOI 10.1016/0006-291X(68)90573-1; TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561; VILLALBA JM, 1995, P NATL ACAD SCI USA, V92, P4887, DOI 10.1073/pnas.92.11.4887; WANG CS, 1978, J SUPRAMOL STR CELL, V9, P1, DOI 10.1002/jss.400090102; Wang S, 2001, BBA-MOL CELL RES, V1539, P192, DOI 10.1016/S0167-4889(01)00107-0; Wilkinson F, 1996, ARCH BIOCHEM BIOPHYS, V336, P275, DOI 10.1006/abbi.1996.0558	53	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16441	16447		10.1074/jbc.M112311200	http://dx.doi.org/10.1074/jbc.M112311200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875069	hybrid			2022-12-25	WOS:000175564500015
J	Lefrancois, S; May, T; Knight, C; Bourbeau, D; Morales, CR				Lefrancois, S; May, T; Knight, C; Bourbeau, D; Morales, CR			The lysosomal transport of prosaposin requires the conditional interaction of its highly conserved D domain with sphingomyelin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID ACTIVATOR PROTEINS; GAUCHER DISEASE VARIANT; SERTOLI CELLS; SAPOSIN-D; IN-VITRO; DEGRADATION; RAT; ENZYMES; OLIGOSACCHARIDES; IDENTIFICATION	Lysosomal prosaposin (65 kDa) is a nonenzymic protein that is transported to the lysosomes in a mannose 6-phosphate-independent manner. Selective deletion of the functional domains of prosaposin indicates that the D domain and the carboxyl-terminal region are necessary for its transport to the lysosomes. Inhibitors of sphingolipid biosynthesis, such as fumonisin B-1 (FB1) and tricyclodecan-9-yl xanthate potassium salt (D609), also interfere with the trafficking of prosaposin to lysosomes. In this study, we examine sphingomyelin as a direct candidate for the trafficking of prosaposin. Chinese hamster ovary and COS-7 cells overexpressing prosaposin or an albumin/prosaposin construct were incubated with these inhibitors, treated with sphingolipids, and then immunostained. Sphingomyelin restored the immunostaining in lysosomes in both FB1- and D609-treated cells and ceramide reestablished the immunostaining in FB1-treated cells only. D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), which inhibits glycosphingolipids, had no effect on the immunostaining pattern. To determine whether sphingomyelin has the same effect on the transport of endogenous prosaposin, testicular explants were treated with FB1 and D609. Sphingomyelin restored prosaposin immunogold labeling in the lysosomes of FB1- and D609-treated Sertoli cells, whereas ceramide restored the label in FB1 treatment only. Albumin linked to the D and COOH-terminal domains of prosaposin was used as a dominant negative competitor. The construct blocked the targeting of prosaposin and induced accumulation of membrane in the lysosomes, demonstrating that the construct uses the same transport pathway as endogenous prosaposin. In conclusion, our results showed that sphingomyelin, the D domain, and its adjacent COOH-terminal region play a crucial role in the transport of prosaposin to lysosomes. Although the precise nature of this lipid-protein interaction is not well established, it is proposed that sphingomyelin microdomains (lipid rafts) are part of a mechanism ensuring correct intercellular trafficking of prosaposin.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	McGill University	Morales, CR (corresponding author), McGill Univ, Dept Anat & Cell Biol, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.		Morales, Carlos R./H-1055-2011					CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; Ciaffoni F, 2001, J BIOL CHEM, V276, P31583, DOI 10.1074/jbc.M102736200; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GARTNER S, 1983, J BIOL CHEM, V258, P2378; HASILIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761, DOI 10.1016/0006-291X(81)91177-3; Hiraiwa M, 1997, ARCH BIOCHEM BIOPHYS, V341, P17, DOI 10.1006/abbi.1997.9958; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; IGDOURA SA, 1995, MOL REPROD DEV, V40, P91, DOI 10.1002/mrd.1080400112; Igdoura SA, 1996, CELL TISSUE RES, V283, P385, DOI 10.1007/s004410050549; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P1571, DOI 10.1515/bchm3.1987.368.2.1571; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; Lefrancois S, 1999, J LIPID RES, V40, P1593; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Morales CR, 2001, MOL REPROD DEV, V59, P54, DOI 10.1002/mrd.1007; Moran JF, 1996, PLANT PHYSIOL, V111, P327; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P403, DOI 10.1016/S0006-291X(88)80855-6; Mort JS, 1997, INT J BIOCHEM CELL B, V29, P715, DOI 10.1016/S1357-2725(96)00152-5; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; Sandhoff K, 1997, CLIN CHIM ACTA, V266, P51, DOI 10.1016/S0009-8981(97)00166-6; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; Scriver CS, 2000, METABOLIC MOL BASES, P3421; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; STEVENS RL, 1981, AM J HUM GENET, V33, P255; VARKI A, 1980, J BIOL CHEM, V255, P8398; Zhao Q, 2000, J BIOL CHEM, V275, P24829, DOI 10.1074/jbc.M003497200; Zhao Q, 1997, MOL REPROD DEV, V48, P1, DOI 10.1002/(SICI)1098-2795(199709)48:1&lt;1::AID-MRD1&gt;3.0.CO;2-N	37	24	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17188	17199		10.1074/jbc.M200343200	http://dx.doi.org/10.1074/jbc.M200343200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11856752	hybrid			2022-12-25	WOS:000175564500112
J	Pardo-Lopez, L; Zhang, M; Liu, J; Jiang, M; Possani, LD; Tseng, GN				Pardo-Lopez, L; Zhang, M; Liu, J; Jiang, M; Possani, LD; Tseng, GN			Mapping the binding site of a human ether-a-go-go-related gene-specific peptide toxin (ErgTx) to the channel's outer vestibule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; K+ CHANNEL; I-KR; CHARYBDOTOXIN BLOCK; SCORPION VENOMS; RECEPTOR-SITE; HERG-CHANNEL; MECHANISM; PORE; RECTIFICATION	The goals of this study are to investigate the mechanism and site of action whereby a human ether-a-go-go-related gene (HERG)-specific scorpion peptide toxin, ErgTx, suppresses HERG current. We apply cysteine-scanning mutagenesis to the S5-P and P-S6 linkers of HERG and examine the resulting changes in ErgTx potency. Data are compared with the characteristics of charybdotoxin (ChTx, or its analogs) binding to the Shaker channel. ErgTx binds to the outer vestibule of HERG but may not physically occlude the pore. In contrast to ChTx-Shaker interaction, elevating [K](o) (from 2 to 98 mm) does not affect ErgTx potency, and through-solution electrostatic forces only play a minor role in influencing ErgTx.HERG interaction. Cysteine mutations of three positions in S5-P linker (Trp-585, Gly-590, and Ile-593) and 1 position in P-S6 linker (Pro-632) induce profound changes in ErgTx binding (DeltaDeltaG > 2 kcal/ mol). We propose that the long S5-P linker of the HERG channel forms an amphipathic a-helix that, together with the P-S6 linker, forms a hydrophobic ErgTx binding site. This study paves the way for future mutant cycle analysis of interacting residues in the ErgTx.HERG complex, which, in conjunction with NMR determination of the ErgTx solution structure, will yield information about the topology of HERG's outer vestibule.	Virginia Commonwealth Univ, Dept Physiol, Richmond, VA 23298 USA; Univ Nacl Autonoma Mexico, Inst Biotechnol, Cuernavaca 62210, Morelos, Mexico	Virginia Commonwealth University; Universidad Nacional Autonoma de Mexico	Tseng, GN (corresponding author), Virginia Commonwealth Univ, Dept Physiol, 1101 E Marshall St, Richmond, VA 23298 USA.	gtseng@hsc.vcu.edu	Possani, Lourival D/J-2397-2013	Pardo Lopez, Liliana/0000-0002-8927-1733	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046451] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46451] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dun W, 1999, PFLUG ARCH EUR J PHY, V439, P141, DOI 10.1007/s004240051138; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; Fan JS, 1999, BIOPHYS J, V76, P3128, DOI 10.1016/S0006-3495(99)77464-3; Garcia ML, 2001, TOXICON, V39, P739, DOI 10.1016/S0041-0101(00)00214-2; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; Gurrola GB, 1999, FASEB J, V13, P953, DOI 10.1096/fasebj.13.8.953; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Imredy JP, 2000, J MOL BIOL, V296, P1283, DOI 10.1006/jmbi.2000.3522; Jiang M, 1999, AM J PHYSIOL-HEART C, V277, pH1283, DOI 10.1152/ajpheart.1999.277.4.H1283; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; Numaguchi H, 2000, CIRC RES, V87, P1012, DOI 10.1161/01.RES.87.11.1012; Pardo-Lopez L, 2002, FEBS LETT, V510, P45, DOI 10.1016/S0014-5793(01)03218-5; Possani LD, 1999, PERSPECT DRUG DISCOV, V16, P15; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Roden DM, 1999, CARDIOVASC RES, V44, P242, DOI 10.1016/S0008-6363(99)00224-2; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SCALONI A, 2000, FEBS LETT, V479, P155; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; Tseng GN, 2001, J MOL CELL CARDIOL, V33, P835, DOI 10.1006/jmcc.2000.1317; TSENGCRANK JCL, 1990, FEBS LETT, V268, P63, DOI 10.1016/0014-5793(90)80973-M; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Wang SM, 1997, FEBS LETT, V417, P43, DOI 10.1016/S0014-5793(97)01245-3	33	87	91	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16403	16411		10.1074/jbc.M200460200	http://dx.doi.org/10.1074/jbc.M200460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864985	hybrid			2022-12-25	WOS:000175564500010
J	Wick, MJ; Wick, KR; Chen, H; He, HL; Dong, LQ; Quon, MJ; Liu, F				Wick, MJ; Wick, KR; Chen, H; He, HL; Dong, LQ; Quon, MJ; Liu, F			Substitution of the autophosphorylation site Thr(516) with a negatively charged residue confers constitutive activity to mouse 3-phosphoinositide-dependent protein kinase-1 in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; PHOSPHORYLATION; INSULIN; TRANSLOCATION; MECHANISM; 3-KINASE; SERUM; LOCALIZATION; EXPRESSION; SIGNALS	3-Phosphoinositide-dependent protein kinase-1 (PDK-1) is a serine/threonine kinase that has been found to phosphorylate and activate several members of the AGC protein kinase family including protein kinase B (Akt), p70 S6 kinase, and protein kinase Czeta. However, the mechanism(s) by which PDK-1 is regulated remains unclear. Here we show that mouse PDK-1 (mPDK-1) undergoes autophosphorylation in vitro on both serine and threonine residues. In addition, we have identified Ser(399) and Thr(516) as the major mPDK-1 autophosphorylation sites in vitro. Furthermore, we have found that these two residues, as well as Ser(244) in the activation loop, are phosphorylated in cells and demonstrated that Ser(244) is a major in vivo phosphorylation site. Abolishment of phosphorylation at Ser(244), but not at Ser(399) or Thr(516), led to a significant decrease of mPDK-1 autophosphorylation and kinase activity in vitro, indicating that autophosphorylation at Ser(399) or Thr(516) is not essential for mPDK-1 autokinase activity. However, overexpression of mPDK-1(T516E), but not of mPDK-1(S244E) or mPDK-1(S399D), in Chinese hamster ovary and HEK293 cells was sufficient to induce Akt phosphorylation at Thr(308) to a level similar to that of insulin stimulation. Furthermore, this increase in phosphorylation was independent of the Pleckstrin homology domain of Akt. Taken together, our results suggest that mPDK-1 undergoes autophosphorylation at multiple sites and that this phosphorylation may be essential for PDK-1 to interact with and phosphorylate its downstream substrates in vivo.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	liuf@uthscsa.edu	Quon, Michael/B-1970-2008	QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [ZIAAT000002, Z01AT000002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000205] Funding Source: NIH RePORTER; NIA NIH HHS [2T32AG00205-11] Funding Source: Medline; NIDDK NIH HHS [DK56166] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chen H, 2001, BIOCHEMISTRY-US, V40, P11851, DOI 10.1021/bi010743c; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wick K. L. R., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P209; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200	31	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16632	16638		10.1074/jbc.M112402200	http://dx.doi.org/10.1074/jbc.M112402200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877406	hybrid			2022-12-25	WOS:000175564500040
J	Lai, CF; Cheng, SL				Lai, CF; Cheng, SL			Signal transductions induced by bone morphogenetic protein-2 and transforming growth factor-beta in normal human osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARROW STROMAL CELLS; TGF-BETA; C-FOS; GENE-EXPRESSION; MC3T3-E1 CELLS; FUNCTIONAL-CHARACTERIZATION; MYOGENIC DIFFERENTIATION; TRANSCRIPTIONAL CONTROL; CHEMOTACTIC RESPONSE; TARGETED DISRUPTION	Transforming growth factor beta (TGF-beta) activates Ras/MAPK signaling in many cell types. Because TGF-beta and BMP-2 exert similar effects, we examined if this signaling is stimulated by both factors and analyzed the relationship between this signaling and the Smads in osteoblasts. BMP-2 and TGF-beta stimulated Ras, MAPK, and AP-1 activities. The DNA binding activities of c-Fos, FosB/DeltaFosB, Fra-1, Fra-2, and JunB were up-regulated whereas JunD activity was decreased. c-Fos, FosB/DeltaFosB, and JunB were associated with Smad4. The stimulation of AP-1 by BMP-2 and TGF-beta was dependent on Smad signaling, and anti-Smad4 antibody interfered with AP-1 activity. Thus, BMP-2 and TGF-beta activate both Ras/MAPK/AP-1 and Smad signaling in osteoblasts with Smads modulating AP-1 activity. To determine the roles of MAPK in BMP-2 and TGF-beta function, we analyzed the effect of ERK and p38 inhibitors on the regulation of bone matrix protein expression and JunB and JunD levels by these two factors. ERK and p38 mediated TGF-beta suppression of osteocalcin and JunD as well as stimulation of JunB. p38 was essential in BMP-2 upregulation of type I collagen, fibronectin, osteopontin, osteocalcin, and alkaline phosphatase activity whereas ERK mediated BMP-2 stimulation of fibronectin and osteopontin. Thus, ERK and p38 differentially mediate TGF-beta and BMP-2 function in osteoblasts.	Washington Univ, Sch Med, Dept Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA	Washington University (WUSTL)	Cheng, SL (corresponding author), Barnes Jewish Hosp, Washington Univ, Sch Med, Div Bone & Mineral Dis, 216 S Kingshighway Blvd, St Louis, MO 63110 USA.	scheng@im.wustl.edu						Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Cheng SL, 2000, J CELL BIOCHEM, V77, P265, DOI 10.1002/(SICI)1097-4644(20000501)77:2<265::AID-JCB9>3.0.CO;2-6; Cheng SL, 1998, J BONE MINER RES, V13, P633, DOI 10.1359/jbmr.1998.13.4.633; Chung CY, 1999, BIOCHEM BIOPH RES CO, V265, P246, DOI 10.1006/bbrc.1999.1639; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Datto MB, 1999, MOL CELL BIOL, V19, P2495; DECESARE D, 1995, ONCOGENE, V11, P365; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; Fagenholz PJ, 2001, J CRANIOFAC SURG, V12, P183, DOI 10.1097/00001665-200103000-00016; Feng X, 2000, J BIOL CHEM, V275, P8331, DOI 10.1074/jbc.275.12.8331; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Hay E, 1999, J CELL BIOCHEM, V72, P81, DOI 10.1002/(SICI)1097-4644(19990101)72:1<81::AID-JCB9>3.0.CO;2-N; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; HUGHES FJ, 1992, BONE MINER, V19, P63, DOI 10.1016/0169-6009(92)90844-4; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731; Kim KJ, 1997, J BIOMED MATER RES, V35, P279, DOI 10.1002/(SICI)1097-4636(19970605)35:3<279::AID-JBM2>3.0.CO;2-E; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097-4644(19971201)67:3<386::AID-JCB10>3.3.CO;2-5; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lian J.B., 1999, PRIMER METABOLIC BON, P14; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIND M, 1995, APMIS, V103, P140, DOI 10.1111/j.1699-0463.1995.tb01089.x; Lind M, 1996, BONE, V18, P53, DOI 10.1016/8756-3282(95)00423-8; Locklin RM, 2001, J BONE MINER RES, V16, P2192, DOI 10.1359/jbmr.2001.16.12.2192; LOMRI A, 1990, J BONE MINER RES, V5, P1149; LONG MW, 1995, J CLIN INVEST, V95, P881, DOI 10.1172/JCI117738; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; LUCAS PA, 1989, BONE, V10, P459, DOI 10.1016/8756-3282(89)90079-3; MACHWATE M, 1995, MOL ENDOCRINOL, V9, P187, DOI 10.1210/me.9.2.187; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MCCABE LR, 1995, EXP CELL RES, V218, P255, DOI 10.1006/excr.1995.1154; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; MICHAEL K, 1995, J BIOL CHEM, V270, P16483; Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756-3282(99)00113-1; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; MUNDY GR, 1991, CIBA F SYMP, V157, P137; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Nielsen FC, 1996, DNA CELL BIOL, V15, P53, DOI 10.1089/dna.1996.15.53; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; NODA M, 1989, CONNECT TISSUE RES, V21, P401, DOI 10.3109/03008208909049997; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; OHTA S, 1992, FEBS LETT, V314, P356, DOI 10.1016/0014-5793(92)81505-G; Oyama M, 1998, HISTOL HISTOPATHOL, V13, P671, DOI 10.14670/HH-13.671; Palcy S, 2000, J BONE MINER RES, V15, P2352, DOI 10.1359/jbmr.2000.15.12.2352; PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P825; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; REDDI AH, 1993, J BONE MINER RES, V8, pS499; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; STRONG DD, 1994, CALCIFIED TISSUE INT, V55, P311, DOI 10.1007/BF00310411; STRONG DD, 1988, FASEB J, V2, pA842; SUBTAMANIAM M, 1995, J CELL BIOCHEM, V57, P52; Urist MR, 1997, J BONE MINER RES, V12, P343, DOI 10.1359/jbmr.1997.12.3.343; VAILLANCOURT RR, 1994, METHOD ENZYMOL, V238, P255; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	74	191	207	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15514	15522		10.1074/jbc.M200794200	http://dx.doi.org/10.1074/jbc.M200794200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854297	hybrid			2022-12-25	WOS:000175510400040
J	Versees, W; Decanniere, K; Van Holsbeke, E; Devroede, N; Steyaert, J				Versees, W; Decanniere, K; Van Holsbeke, E; Devroede, N; Steyaert, J			Enzyme-substrate interactions in the purine-specific nucleoside hydrolase from Trypanosoma vivax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; TRANSITION-STATE; CRITHIDIA-FASCICULATA; KINETIC MECHANISM; CATALYSIS; DESIGN; RING; CRYSTALLOGRAPHY; PURIFICATION; INHIBITORS	Nucleoside hydrolases are key enzymes in the purine salvage pathway of Trypanosomatidae and are considered as targets for drug design. We previously reported the first x-ray structure of an inosine-adenosine-guanosine preferring nucleoside hydrolase (IAG-NH) from Trypanosoma vivax (1). Here we report the 2.0-Angstrom crystal structure of the slow D10A mutant in complex with the inhibitor 3-deaza-adenosine and the 1.6-Angstrom crystal structure of the same enzyme in complex with a genuine substrate inosine. The enzyme-substrate complex shows the substrate bound to the enzyme in a different conformation from 3-deaza-adenosine and provides a snapshot along the reaction coordinate of the enzyme-catalyzed reaction. The chemical groups on the substrate important for binding and catalysis are mapped. The T-OH, T-OH, and 5'-OH contribute 4.6, 7.5, and 5.4 kcal/mol to k(cat)/K-m, respectively. Specific interactions with the exocyclic groups on the purine ring are not required for catalysis. Site-directed mutagenesis indicates that the purine specificity of the IAG-NHs is imposed by a parallel aromatic stacking interaction involving Trp(83) and Trp(260). The pH profiles of k(cat) and k(cat)/K-m indicate the existence of one or more proton donors, possibly involved in leaving group activation. However, mutagenesis of the active site residues around the nucleoside base and an alanine scan of a flexible loop near the active site fail to identify this general acid. The parallel aromatic stacking seems to provide the most likely alternative mechanism for leaving group activation.	Free Univ Brussels VIB, Dept Ultrastruct, Inst Mol Biol, ULTR,IMOL, B-1640 Rhode St Genese, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Steyaert, J (corresponding author), Free Univ Brussels VIB, Dept Ultrastruct, Inst Mol Biol, ULTR,IMOL, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	jsteyaer@vub.ac.be	Versées, Wim/H-5518-2015; steyaert, jan/GQP-7811-2022; Steyaert, Jan/H-4662-2011	Steyaert, Jan/0000-0002-3825-874X; Versees, Wim/0000-0002-4695-696X				ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; Aronov AM, 2000, BIOCHEMISTRY-US, V39, P4684, DOI 10.1021/bi992555g; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Bzowska A, 2000, PHARMACOL THERAPEUT, V88, P349, DOI 10.1016/S0163-7258(00)00097-8; Degano M, 1998, BIOCHEMISTRY-US, V37, P6277, DOI 10.1021/bi973012e; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; ESTUPINAN B, 1994, J BIOL CHEM, V269, P23068; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GARDINER PR, 1987, PARASITOL TODAY, V2, P255; Gopaul DN, 1996, BIOCHEMISTRY-US, V35, P5963, DOI 10.1021/bi952998u; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; Heroux A, 2000, STRUCTURE, V8, P1309, DOI 10.1016/S0969-2126(00)00546-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; ISHIDA T, 1993, FEBS LETT, V333, P214, DOI 10.1016/0014-5793(93)80656-F; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; LIU L, 1993, P NATL ACAD SCI USA, V90, P8604, DOI 10.1073/pnas.90.18.8604; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OGBUNUDE POJ, 1985, ANN TROP MED PARASIT, V79, P7, DOI 10.1080/00034983.1985.11811883; OLSON WK, 1982, J AM CHEM SOC, V104, P270, DOI 10.1021/ja00365a049; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARKIN DW, 1991, J BIOL CHEM, V266, P20658; Parkin DW, 1996, J BIOL CHEM, V271, P21713, DOI 10.1074/jbc.271.36.21713; Petsko GA, 2000, CURR OPIN CHEM BIOL, V4, P89, DOI 10.1016/S1367-5931(99)00057-5; ROUSSEL A, 1990, 15 IUCR C BORD FRANC, P66; ROY KB, 1983, NUCLEOS NUCLEOT, V2, P231, DOI 10.1080/07328318308078857; Schramm VL, 1998, ANNU REV BIOCHEM, V67, P693, DOI 10.1146/annurev.biochem.67.1.693; SEEGMILLER JE, 1967, SCIENCE, V155, P1682, DOI 10.1126/science.155.3770.1682; Shi WX, 2001, BIOCHEMISTRY-US, V40, P10800, DOI 10.1021/bi010465h; Shi WX, 1999, J BIOL CHEM, V274, P21114, DOI 10.1074/jbc.274.30.21114; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Versees W, 2001, J MOL BIOL, V307, P1363, DOI 10.1006/jmbi.2001.4548; Xu YM, 1998, BIOCHEMISTRY-US, V37, P4114, DOI 10.1021/bi972519m	40	52	52	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15938	15946		10.1074/jbc.M111735200	http://dx.doi.org/10.1074/jbc.M111735200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854281	hybrid, Green Published			2022-12-25	WOS:000175510400097
J	Flahaut, M; Rossier, BC; Firsov, D				Flahaut, M; Rossier, BC; Firsov, D			Respective roles of calcitonin receptor-like receptor (CRLR) and receptor activity-modifying proteins (RAMP) in cell surface expression of CRLR/RAMP heterodimeric receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; XENOPUS OOCYTES; GLYCOSYLATION; CLONING; DETERMINANT; NA,K-ATPASE; TRANSPORT; CHANNELS; BINDING; RAT	Receptor activity modifying proteins RAMP1, RAMP2, and RAMP3 are responsible for defining affinity to ligands of the calcitonin receptor-like receptor (CRLR). It has also been proposed that receptor activity-modifying proteins (RAMP) are molecular chaperones required for CRLR transport to the cell surface. Here, we have studied the respective roles of CRLR and RAMP in transporting CRLR/RAMP heterodimers to the plasma membrane by using a highly specific binding assay that allows quantitative detection of cell surface-expressed CRLR or RAMP in the Xenopus oocytes expression system. We show that: (i) heterodimer assembly is not a prerequisite for efficient cell surface expression of CRLR, (ii) N-glycosylated RAMP2 and RAMP3 are expressed at the cell surface and their transport to the plasma membrane requires N-glycans, (iii) RAMP1 is not N-glycosylated and is transported to the plasma membrane only upon formation of heterodimers with CRLR, and (iv) introduction of N-glycosylation sites in the RAMP1 sequence (D58N/G60S, Y71N, and K103N/P105S) allows cell surface expression of these mutants at levels similar to that of wild-type RAMP1 co-expressed with CRLR. Our data argue against a chaperone function for RAMP and identify the role of N-glycosylation in targeting these molecules to the cell surface.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Firsov, D (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.	dmitri.firsov@ipharm.unil.ch						Aldecoa A, 2000, FEBS LETT, V471, P156, DOI 10.1016/S0014-5793(00)01387-9; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Buhlmann N, 2000, FEBS LETT, V486, P320, DOI 10.1016/S0014-5793(00)02259-6; Chraibi A, 2001, J MEMBRANE BIOL, V183, P15, DOI 10.1007/s00232-001-0049-6; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; GEERING K, 1982, J BIOL CHEM, V257, P338; Geering K, 1997, CURR OPIN NEPHROL HY, V6, P434, DOI 10.1097/00041552-199709000-00005; Gromada J, 1998, FEBS LETT, V425, P277, DOI 10.1016/S0014-5793(98)00254-3; Gujer R, 2001, BIOCHEMISTRY-US, V40, P5392, DOI 10.1021/bi002497v; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; HORIUCHI T, 1991, J BIOL CHEM, V266, P4700; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; McGinnes LW, 1997, J VIROL, V71, P3083, DOI 10.1128/JVI.71.4.3083-3089.1997; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; Muff R, 1999, ENDOCRINOLOGY, V140, P2924, DOI 10.1210/en.140.6.2924; Oliver KR, 2001, EUR J NEUROSCI, V14, P618, DOI 10.1046/j.0953-816x.2001.01688.x; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; Ueda T, 2001, MOL BRAIN RES, V93, P36, DOI 10.1016/S0169-328X(01)00179-6; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	28	49	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14731	14737		10.1074/jbc.M112084200	http://dx.doi.org/10.1074/jbc.M112084200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11854283	hybrid			2022-12-25	WOS:000175203000050
J	Watanabe, K; Ozaki, T; Nakagawa, T; Miyazaki, K; Takahashi, M; Hosoda, M; Hayashi, S; Todo, S; Nakagawara, AK				Watanabe, K; Ozaki, T; Nakagawa, T; Miyazaki, K; Takahashi, M; Hosoda, M; Hayashi, S; Todo, S; Nakagawara, AK			Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; N-MYC; TRANSCRIPTIONAL ACTIVATION; P53-RELATED PROTEIN; EMBRYONIC LETHALITY; APOPTOTIC RESPONSE; P53-HOMOLOG P73; GENE-EXPRESSION; CANCER TISSUES; P53 MUTANTS	p73 shares high sequence homology with the tumor suppressor p53. Like p53, ectopic overexpression of p73 induces cell cycle arrest and/or apoptosis, and these biological activities are linked to its sequence-specific transactivation function. The COOH-terminal region of p73 is unique and has a function to modulate DNA-binding ability and transactivation activity. To identify and characterize cellular proteins that interact with the COOH-terminal region of p73alpha and regulate its activity, we employed a yeast-based two-hybrid screen with a human fetal brain cDNA library. We found MM1, a nuclear c-Myc-binding protein, was associated with p73alpha in both yeast two-hybrid and in vitro pull-down assays. In mammalian cells, MM1 co-immunoprecipitated with p73alpha, whereas p73)3 and tumor suppressor p53 did not interact with MM1. Overexpression of MM1 in p53-deficient osteosarcoma SAOS-2 cells enhanced the p73alpha-dependent transcription from the p53/p73-responsive Bax and PG13 promoters, whereas p73beta- and p53-mediated transcriptional activation was unaffected in the presence of MM1. MM1 also stimulated the p73alpha-mediated growth suppression in SAOS-2 cells. More importantly, we found that c-Myc was physically associated with p73a and significantly impaired the transcriptional activity of p73alpha on Bax and p21(waf1) promoters. Expression of MM1 strongly reduced the c-Myc-mediated inhibitory activity on p73alpha. These results suggest that MM1 may act as a molecular partner for p73 to prevent the c-Myc-mediated inhibitory effect on its activity.	Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Gen Surg, Sapporo, Hokkaido 0608638, Japan	Chiba Cancer Center; Hokkaido University	Nakagawara, AK (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-ccri.chuo.chiba.jp	Hosoda, Mitsuchika/A-7534-2012					Agami R, 1999, NATURE, V399, P809; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bai LG, 2001, MOL CELL BIOL, V21, P4670, DOI 10.1128/MCB.21.14.4670-4683.2001; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Chen CL, 2000, CLIN CANCER RES, V6, P3910; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Gong JG, 1999, NATURE, V399, P806; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Malynn BA, 2000, GENE DEV, V14, P1390; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; Ozaki T, 1999, CANCER RES, V59, P5902; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Satou A, 2001, J BIOL CHEM, V276, P46562, DOI 10.1074/jbc.M104937200; Scharnhorst V, 2000, J BIOL CHEM, V275, P10202, DOI 10.1074/jbc.275.14.10202; Shaw P, 1996, ONCOGENE, V12, P921; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Wang QJ, 1998, CANCER RES, V58, P5762; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Ye RQ, 2001, J BIOL CHEM, V276, P4828, DOI 10.1074/jbc.M004894200; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	62	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15113	15123		10.1074/jbc.M111281200	http://dx.doi.org/10.1074/jbc.M111281200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11844794	hybrid			2022-12-25	WOS:000175203000097
J	Shea-Herbert, B; Pongracz, K; Shay, JW; Gryaznov, SM				Shea-Herbert, B; Pongracz, K; Shay, JW; Gryaznov, SM			Oligonucleotide N3 '-> P5 ' phosphoramidates as efficient telomerase inhibitors	ONCOGENE			English	Article						telomerase inhibitors; oligonucleotide; phosphoramidates	RNA COMPONENT; CANCER-CELLS; PROLIFERATION; THERAPY; GLIOMA; TARGET	Human telomerase is a unique reverse transcriptase that is expressed in multiple cancers, but not in the vast majority of normal cells. The enzyme is responsible for telomere protection and maintenance, and supports the proliferative immortality of cancer cells. Thus, it has been proposed that the specific inhibition of telomerase activity in tumors might have significant and beneficial therapeutic effects. To this goal we have designed, synthesized, and evaluated several oligonucleotide N3'-->P5' phosphoramidates as telomerase inhibitors. These oligonucleotides are complementary to the template region of the RNA domain of telomerase (hTR). The prepared compounds were evaluated in HME50-5E breast epithelial cells, where their effects on telomerase activity were determined using a cell-based telomerase (TRAP) assay at 24 as well as 72 h after exposure to compounds. The oligo-N3' -->P5' phosphoramidate inhibited telomerase activity in cells in the presence of the cellular up-take enhancer (FuGENE6(TM)) in a dose- and sequence-dependent manner, with IC50 values of approximately 1 nM. Inhibition of telomerase activity by this compound without the lipid carrier was not efficient. However, the isosequential oligonucleotide N3 '--> P5' thio-phosphoramidate was able to inhibit telomerase activity with or without lipid carriers at nM, or low-muM concentrations, respectively. This inhibition of telomerase activity in HME50-5E cells by the oligonucleotide thio-phosphoramidates was also sequence specific. Long-term treatment of the cells with 0.5 muM of FuGENE6 formulated 13-mer thio-phosphoramidates, fully complementary to hTR, resulted in gradual telomere shortening, followed by cellular senescence and apoptosis, as would be predicted for a telomerase inhibitor. The mismatched control compound had no effect on cell proliferation. The results suggest that the oligonucleotide N3'-->P5' phosphoramidates, and particularly thio-phosphoramidates, might be further developed as selective anti-telomerase reagents.	Geron Corp, Menlo Pk, CA 94025 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Geron Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gryaznov, SM (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Pk, CA 94025 USA.		Shay, Jerry W/F-7878-2011					Bare LA, 1998, DRUG DEVELOP RES, V43, P109, DOI 10.1002/(SICI)1098-2299(199802)43:2<109::AID-DDR4>3.0.CO;2-O; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Elayadi AN, 2001, NUCLEIC ACIDS RES, V29, P1683, DOI 10.1093/nar/29.8.1683; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Gryaznov S, 2001, NUCLEOS NUCLEOT NUCL, V20, P401, DOI 10.1081/NCN-100002314; Gryaznov SM, 1999, BBA-GENE STRUCT EXPR, V1489, P131, DOI 10.1016/S0167-4781(99)00151-7; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hisatake J, 1999, CANCER RES, V59, P4023; Hurley LH, 2000, PHARMACOL THERAPEUT, V85, P141, DOI 10.1016/S0163-7258(99)00068-6; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Matthes E, 1999, NUCLEIC ACIDS RES, V27, P1152, DOI 10.1093/nar/27.4.1152; Naasani I, 1999, CANCER RES, V59, P4004; Naasani I, 1998, BIOCHEM BIOPH RES CO, V249, P391, DOI 10.1006/bbrc.1998.9075; Neidle S, 2000, PHARMACOL THERAPEUT, V85, P133, DOI 10.1016/S0163-7258(99)00065-0; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Pitts AE, 1998, P NATL ACAD SCI USA, V95, P11549, DOI 10.1073/pnas.95.20.11549; Pongracz K, 1999, TETRAHEDRON LETT, V40, P7661, DOI 10.1016/S0040-4039(99)01584-1; Sharma HW, 1996, ANTISENSE NUCLEIC A, V6, P3, DOI 10.1089/oli.1.1996.6.3; SHEAHERBERT B, 1999, P NATL ACAD SCI USA, V96, P14276; Wan MSK, 1998, ANTISENSE NUCLEIC A, V8, P309, DOI 10.1089/oli.1.1998.8.309; Yamaguchi F, 1999, ONCOL REP, V6, P773	23	104	123	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					638	642		10.1038/sj.onc.1205064	http://dx.doi.org/10.1038/sj.onc.1205064			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850790				2022-12-25	WOS:000173390500017
J	Ren, J; Li, YQ; Kufe, D				Ren, J; Li, YQ; Kufe, D			Protein kinase C beta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MEDIATED CELL-ADHESION; TRANSCRIPTION FACTOR LEF-1; TUMOR-SUPPRESSOR PROTEIN; E-CADHERIN; TYROSINE PHOSPHORYLATION; PROTEOLYTIC ACTIVATION; CYTOPLASMIC DOMAIN; GENETIC-DEFECTS; MAMMARY-GLAND	The DF3/MUC1 mucin-like glycoprotein is aberrantly overexpressed in most human carcinomas. The MUC1 cytoplasmic domain interacts directly with beta-catenin, a component of the adherens junction of mammalian epithelial cells. The present results demonstrate that MUC1 associates with protein kinase Cdelta (PKCdelta). A TDR sequence adjacent to the beta-catenin binding motif in the MUC1 cytoplasmic domain functions as a site for PKCdelta phosphorylation. We show that phosphorylation of MUC1 by PKCdelta increases binding of MUC1 and beta-catenin in vitro and in vivo. The functional significance of the MUC1-PKCdelta interaction is further supported by the demonstration that mutation of the PKCdelta phosphorylation site abrogates MUC1-mediated decreases in binding of beta-catenin to E-cadherin. We also show that the stimulatory effects of MUC1 on anchorage-independent growth are abrogated by mutation of the PKCdelta phosphorylation site. These findings support a novel role for PKCdelta in regulating the interaction between MUC1 and the beta-catenin signaling pathway.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA87421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA087421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baruch A, 1997, INT J CANCER, V71, P741; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOYER JC, 1995, CANCER RES, V55, P6063; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Kondo K, 1998, CANCER RES, V58, P2014; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	44	127	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17616	17622		10.1074/jbc.M200436200	http://dx.doi.org/10.1074/jbc.M200436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877440	hybrid			2022-12-25	WOS:000175685100030
J	Dorenbos, R; Stein, T; Kabel, J; Bruand, C; Bolhuis, A; Bron, S; Quax, WJ; van Dijl, JM				Dorenbos, R; Stein, T; Kabel, J; Bruand, C; Bolhuis, A; Bron, S; Quax, WJ; van Dijl, JM			Thiol-disulfide oxidoreductases are essential for the production of the lantibiotic sublancin 168	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS ATCC-6633; GRAM-POSITIVE BACTERIA; LACTOCOCCUS-LACTIS; NUCLEOTIDE-SEQUENCE; MASS-SPECTROMETRY; GENE-CLUSTER; PROTEIN; PEPTIDE; IMMUNITY; NISIN	Thiol-disulfide oxidoreductases are required for disulfide bond formation in proteins that are exported from the cytoplasm. Four enzymes of this type, termed BdbA, BdbB, BdbC, and BdbD, have been identified in the Gram-positive eubacterium Bacillus subtilis. BdbC and BdbD have been shown to be critical for the folding of a protein required for DNA uptake during natural competence. In contrast, no function has been assigned so far to the BdbA and BdbB proteins. The bdbA and bdbB genes are located in one operon that also contains the genes specifying the lantibiotic sublancin 168 and the ATP-binding cassette transporter SunT. Interestingly sublancin 168 contains two disulfide bonds. The present studies demonstrate that SunT and BdbB, but not BdbA, are required for the production of active sublancin 168. In addition, the BdbB paralogue BdbC is at least partly able to replace BdbB in sublancin 168 production. These observations show the unprecedented involvement of thiol-disulfide oxidoreductases in the synthesis of a peptide antibiotic. Notably BdbB cannot complement BdbC in competence development, showing that these two closely related thiol-disulfide oxidoreductases have different, but partly overlapping, substrate specificities.	Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands; Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany; INRA, F-78352 Jouy En Josas, France; Univ Groningen, Dept Genet, NL-9750 AA Haren, Netherlands	University of Groningen; Goethe University Frankfurt; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Groningen	Quax, WJ (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.		Quax, Wim/O-2875-2019; Bolhuis, Albert/E-9932-2010; Bruand, Claude/AAF-7695-2020; van Dijl, Jan Maarten/G-1205-2013; Quax, Wim/K-2802-2012	Quax, Wim/0000-0002-5162-9947; Bolhuis, Albert/0000-0001-9307-0515; Quax, Wim/0000-0002-5162-9947; Bruand, Claude/0000-0002-2367-0782				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BABASAKI K, 1985, J BIOCHEM, V98, P585, DOI 10.1093/oxfordjournals.jbchem.a135315; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; Bolhuis A, 1999, J BIOL CHEM, V274, P24531, DOI 10.1074/jbc.274.35.24531; CHAKICHERLA A, 1995, J BIOL CHEM, V270, P23533, DOI 10.1074/jbc.270.40.23533; CHUNG YJ, 1992, J BACTERIOL, V174, P1417, DOI 10.1128/jb.174.4.1417-1422.1992; Chung YS, 1998, MOL MICROBIOL, V29, P905, DOI 10.1046/j.1365-2958.1998.00989.x; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Franke CM, 1999, J BIOL CHEM, V274, P8484, DOI 10.1074/jbc.274.13.8484; FREMAUX C, 1995, MICROBIOL-SGM, V141, P1637, DOI 10.1099/13500872-141-7-1637; Guder A, 2000, BIOPOLYMERS, V55, P62, DOI 10.1002/1097-0282(2000)55:1<62::AID-BIP60>3.3.CO;2-P; HEMPHILL HE, 1980, CAN J MICROBIOL, V28, P1328; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ISHIHARA T, 1995, J BACTERIOL, V177, P745, DOI 10.1128/jb.177.3.745-749.1995; JACK RW, 1995, MICROBIOL REV, V59, P171, DOI 10.1128/MMBR.59.2.171-200.1995; Kiesau P, 1997, J BACTERIOL, V179, P1475, DOI 10.1128/jb.179.5.1475-1481.1997; Kim L, 1996, GENE, V181, P71, DOI 10.1016/S0378-1119(96)00466-0; KLEIN C, 1994, APPL ENVIRON MICROB, V60, P2793, DOI 10.1128/AEM.60.8.2793-2801.1994; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KUNST F, 1995, J BACTERIOL, V177, P2403, DOI 10.1128/jb.177.9.2403-2407.1995; Kussmann M, 1997, J MASS SPECTROM, V32, P593; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; Lazarevic V, 1999, MICROBIOL-UK, V145, P1055, DOI 10.1099/13500872-145-5-1055; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Marx R, 2001, J PROTEIN CHEM, V20, P501, DOI 10.1023/A:1012562631268; McAuliffe O, 2001, FEMS MICROBIOL REV, V25, P285, DOI 10.1016/S0168-6445(00)00065-6; McLaughlin RE, 1999, FEMS MICROBIOL LETT, V175, P171, DOI 10.1111/j.1574-6968.1999.tb13616.x; Meima R, 2002, J BIOL CHEM, V277, P6994, DOI 10.1074/jbc.M111380200; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Paik SH, 1998, J BIOL CHEM, V273, P23134, DOI 10.1074/jbc.273.36.23134; Peschel A, 1996, J BACTERIOL, V178, P531, DOI 10.1128/jb.178.2.531-536.1996; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; Sambrook J., 2002, MOL CLONING LAB MANU; Saris PEJ, 1996, ANTON LEEUW INT J G, V69, P151, DOI 10.1007/BF00399420; SIEGERS K, 1995, APPL ENVIRON MICROB, V61, P1082, DOI 10.1128/AEM.61.3.1082-1089.1995; Sonenshein A.L., 2001, BACILLUS SUBTILIS IT; Stein T, 2002, J BACTERIOL, V184, P1703, DOI 10.1128/JB.184.6.1703-1711.2002; STODDARD GW, 1992, APPL ENVIRON MICROB, V58, P1952, DOI 10.1128/AEM.58.6.1952-1961.1992; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VANDERMEER JR, 1994, J BIOL CHEM, V269, P3555; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Zheng GL, 2000, J BACTERIOL, V182, P3266, DOI 10.1128/JB.182.11.3266-3273.2000	47	94	105	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16682	16688		10.1074/jbc.M201158200	http://dx.doi.org/10.1074/jbc.M201158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872755	Green Published, hybrid			2022-12-25	WOS:000175564500046
J	Guerranti, R; Aguiyi, JC; Neri, S; Leoncini, R; Pagani, R; Marinello, E				Guerranti, R; Aguiyi, JC; Neri, S; Leoncini, R; Pagani, R; Marinello, E			Proteins from Mucuna pruriens and enzymes from Echis carinatus venom - Characterization and cross-reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAW-SCALED VIPER; PLATELET-AGGREGATION INHIBITOR; AMINO-ACID-SEQUENCE; PHOSPHOLIPASE A(2); PROTHROMBIN ACTIVATOR; ANIMAL LECTINS; PURIFICATION; BINDING; COMPLEX	Mucuna pruriens seeds have been widely used against snakebite in traditional medicine. The antivenin property of a water extract of seeds was assessed in vivo in mice. The serum of mice treated with extract was tested for its immunological properties. Two proteins of Echis carinatus venom with apparent molecular masses of 25 and 16 kDa were detected by Western blot analysis carried out using IgG of mice immunized with extract or its partially purified protein fractions. By enzymatic in-gel digestion and electrospray ionization-mass spectrometry/mass spectrometry analysis of immunoreactive venom proteins, phospholipase A(2), the most toxic enzyme of snake venom, was identified. These results demonstrate that the observed antivenin activity has an immune mechanism. Antibodies of mice treated with non-lethal doses of venom reacted against some proteins of M. pruriens extract. Proteins of E. carinatus venom and M. pruriens extract have at least one epitope in common as confirmed by immunodiffusion assay.	Univ Siena, Inst Biochem & Enzymol, I-53100 Siena, Italy; Univ Jos, Dept Pharmacol, Jos, Nigeria	University of Siena; University of Jos	Marinello, E (corresponding author), Univ Siena, Inst Biochem & Enzymol, Via A Moro 2, I-53100 Siena, Italy.		Leoncini, Roberto/D-4050-2012; Leoncini, Roberto/D-2247-2012	Leoncini, Roberto/0000-0001-5587-2074; 				Aguiyi JC, 1999, FITOTERAPIA, V70, P21, DOI 10.1016/S0367-326X(98)00004-5; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen YL, 1996, BIOCHEMISTRY-US, V35, P5264, DOI 10.1021/bi952520q; Chippaux JP, 1998, TOXICON, V36, P823, DOI 10.1016/S0041-0101(97)00160-8; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DRENTH J, 1980, J BIOL CHEM, V255, P2652; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; GAN ZR, 1988, J BIOL CHEM, V263, P19827; Guerranti R, 2001, J ETHNOPHARMACOL, V75, P175, DOI 10.1016/S0378-8741(00)00401-3; GUERRANTI R, 1999, J PREV MED HYG, V1, P25; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Kemparaju K, 1999, TOXICON, V37, P1659, DOI 10.1016/S0041-0101(99)00104-X; KEMPARAJU K, 1994, TOXICON, V32, P1187, DOI 10.1016/0041-0101(94)90348-4; Kerns RT, 1999, ARCH BIOCHEM BIOPHYS, V369, P107, DOI 10.1006/abbi.1999.1345; KIELISZEWSKI MJ, 1994, PLANT J, V5, P849, DOI 10.1046/j.1365-313X.1994.5060849.x; Kini RM, 1996, TOXICON, V34, P1287, DOI 10.1016/S0041-0101(96)00107-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Machuka J, 2000, FOOD CHEM, V68, P421, DOI 10.1016/S0308-8146(99)00211-3; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; Marcinkiewicz C, 2000, J BIOL CHEM, V275, P31930, DOI 10.1074/jbc.M003209200; MARTZ W, 1992, TOXICON, V30, P1131, DOI 10.1016/0041-0101(92)90429-9; MO HQ, 1994, GLYCOCONJUGATE J, V11, P424, DOI 10.1007/BF00731278; MORITA T, 1978, J BIOCHEM, V83, P559, DOI 10.1093/oxfordjournals.jbchem.a131944; Nagpal A, 1999, ACTA CRYSTALLOGR D, V55, P1240, DOI 10.1107/S0907444999004783; NISHIDA S, 1995, BIOCHEMISTRY-US, V34, P1771, DOI 10.1021/bi00005a034; OUCHTERLONY O, 1986, HDB EXPT IMMUNOLOGY, P321; PENG ML, 1994, BIOCHEM BIOPH RES CO, V205, P68, DOI 10.1006/bbrc.1994.2630; Polgar J, 1996, BIOCHEM J, V319, P961, DOI 10.1042/bj3190961; PRAS N, 1993, PHARM WORLD SCI, V15, P263, DOI 10.1007/BF01871128; RAJYALAKSHMI P, 1994, PLANT FOOD HUM NUTR, V46, P53, DOI 10.1007/BF01088461; REVILLEZA MJR, 1990, PLANT FOOD HUM NUTR, V40, P83, DOI 10.1007/BF02193782; SCHAEFFER RC, 1987, TOXICON, V25, P1343, DOI 10.1016/0041-0101(87)90012-2; Siddhuraju P, 1996, J AGR FOOD CHEM, V44, P2636, DOI 10.1021/jf950776x; Yamada D, 1996, J BIOL CHEM, V271, P5200, DOI 10.1074/jbc.271.9.5200; Yen TY, 2000, J MASS SPECTROM, V35, P990, DOI 10.1002/1096-9888(200008)35:8<990::AID-JMS27>3.0.CO;2-K	37	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17072	17078		10.1074/jbc.M201387200	http://dx.doi.org/10.1074/jbc.M201387200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867642	hybrid			2022-12-25	WOS:000175564500097
J	Hamada, S; Ito, H; Hiraga, S; Inagaki, K; Nozaki, K; Isono, N; Yoshimoto, Y; Takeda, Y; Matsui, H				Hamada, S; Ito, H; Hiraga, S; Inagaki, K; Nozaki, K; Isono, N; Yoshimoto, Y; Takeda, Y; Matsui, H			Differential characteristics and subcellular localization of two starch-branching enzyme Isoforms encoded by a single gene in Phaseolus vulgaris L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE-I; MAIZE ENDOSPERM; MULTIPLE FORMS; CHAIN-LENGTH; PURIFICATION; SUBSTRATE; AMYLOSE; PROTEIN; MECHANISM; GRANULES	Starch-branching enzymes (SBE) have a dominant role for amylopectin structure as they define chain length and frequency of branch points. We have previously shown that one of the SBE isoforms of kidney bean (Phaseolus vulgaris L.), designated PvSBE2, has a molecular mass (82 kDa) significantly smaller than those reported for isologous SBEs from pea (SBEI), maize (BEIIb), and rice (RBE3). Additionally, in contrast to the dual location of the pea SBEI in both the soluble and starch granule fractions, PvSBE2 was found only in the soluble fraction during seed development. Analysis of a pvsbe2 cDNA suggested that PvSBE2 is generated from a larger precursor with a putative plastid targeting sequence of 156 residues. Here we describe the occurrence of a larger 100-kDa form (LF-PvSBE2) of PvSBE2 found both in the soluble and starch granule fractions of the developing seeds. The determined N-terminal sequence, VKSSHDSD, of LF-PvSBE2 corresponded to a peptide sequence located 111 amino acids upstream from the N terminus of purified PvSBE2, suggesting that LF-PvSBE2 and PvSBE2 are products of the same gene. Analysis of the products by 5'-RACE (rapid amplification of cDNA ends) and reverse transcription PCR indicated that the two transcripts for pre-LF-PvSBE2 and pre-PvSBE2 are generated by alternative splicing. Recombinant LF-PvSBE2 (rLF-PvSBE2) was purified from Escherichia coli and the kinetic properties were compared with those of recombinant PvSBE2 (rPvSBE2). rLF-PvSBE2 had much higher affinity for amylopectin (K-m = 4.4 mg/ml) than rPvSBE2 (18.4 mg/ml), whereas the V-max of rLF-PvSBE2 (135 units/mg) for this substrate was much lower than that of rPvSBE2 (561 units/mg). These results suggest that the N-terminal extension of LF-PvSBE2 plays a critical role for localization in starch granules by altering its enzymatic properties.	Hokkaido Univ, Grad Sch Agr, Dept Appl Biosci, Sapporo, Hokkaido 0608589, Japan; Kagoshima Univ, Dept Biochem Sci & Technol, Kagoshima 8900065, Japan	Hokkaido University; Kagoshima University	Ito, H (corresponding author), Hokkaido Univ, Grad Sch Agr, Dept Appl Biosci, Sapporo, Hokkaido 0608589, Japan.	otih@chem.agr.hokudai.ac.jp		Isono, Naoto/0000-0002-2118-8677				Baga M, 1999, PLANT MOL BIOL, V40, P1019, DOI 10.1023/A:1006286807176; Baga M, 2000, PLANT PHYSIOL, V124, P253, DOI 10.1104/pp.124.1.253; BELSHAW NJ, 1990, FEBS LETT, V269, P350, DOI 10.1016/0014-5793(90)81191-P; BOROVSKY D, 1976, EUR J BIOCHEM, V62, P307, DOI 10.1111/j.1432-1033.1976.tb10162.x; BOROVSKY D, 1975, FEBS LETT, V54, P201, DOI 10.1016/0014-5793(75)80074-3; BOYER CD, 1978, CARBOHYD RES, V61, P321, DOI 10.1016/S0008-6215(00)84492-4; BOYER CD, 1978, BIOCHEM BIOPH RES CO, V80, P169, DOI 10.1016/0006-291X(78)91119-1; BURTON RA, 1995, PLANT J, V7, P3, DOI 10.1046/j.1365-313X.1995.07010003.x; CHATTERJEE B, 1992, J APPL BACTERIOL, V72, P208, DOI 10.1111/j.1365-2672.1992.tb01825.x; Commuri PD, 2001, PLANT J, V25, P475, DOI 10.1046/j.1365-313x.2001.00955.x; DENYER K, 1995, PLANTA, V196, P256, DOI 10.1007/BF00201382; DENYER K, 1993, PLANT J, V4, P191, DOI 10.1046/j.1365-313X.1993.04010191.x; Edwards A, 1996, PLANT PHYSIOL, V112, P89, DOI 10.1104/pp.112.1.89; FISHER DK, 1993, PLANT PHYSIOL, V102, P1045, DOI 10.1104/pp.102.3.1045; GUAN HP, 1993, PLANT PHYSIOL, V102, P1269, DOI 10.1104/pp.102.4.1269; Hamada S, 2001, BIOCHEM J, V359, P23, DOI 10.1042/0264-6021:3590023; Hanashiro I, 1996, CARBOHYD RES, V283, P151, DOI 10.1016/0008-6215(95)00408-4; Hong SJ, 2000, ARCH BIOCHEM BIOPHYS, V378, P349, DOI 10.1006/abbi.2000.1845; Hong SJ, 2001, ARCH BIOCHEM BIOPHYS, V386, P62, DOI 10.1006/abbi.2000.2179; Imparl-Radosevich JM, 1998, ARCH BIOCHEM BIOPHYS, V353, P64, DOI 10.1006/abbi.1998.0613; JESPERSEN HM, 1993, J PROTEIN CHEM, V12, P791, DOI 10.1007/BF01024938; Kuriki T, 1997, J BIOL CHEM, V272, P28999, DOI 10.1074/jbc.272.46.28999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN C, 1995, PLANT CELL, V7, P971, DOI 10.1105/tpc.7.7.971; MIZUNO K, 1993, J BIOL CHEM, V268, P19084; Morell MK, 1997, PLANT PHYSIOL, V113, P201, DOI 10.1104/pp.113.1.201; MuForster C, 1996, PLANT PHYSIOL, V111, P821, DOI 10.1104/pp.111.3.821; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nishi A, 2001, PLANT PHYSIOL, V127, P459, DOI [10.1104/pp.010127, 10.1104/pp.127.2.459]; Nozaki K, 2001, BIOSCI BIOTECH BIOCH, V65, P1141, DOI 10.1271/bbb.65.1141; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Simpson GG, 1996, PLANT MOL BIOL, V32, P1, DOI 10.1007/BF00039375; SIVAK MN, 1998, ADV FOOD NUTR RES, V41, P89; Slattery CJ, 2000, TRENDS PLANT SCI, V5, P291, DOI 10.1016/S1360-1385(00)01657-5; SMITH AM, 1988, PLANTA, V175, P270, DOI 10.1007/BF00392437; Smith AM, 1997, ANNU REV PLANT PHYS, V48, P65, DOI 10.1146/annurev.arplant.48.1.67; SMITH AM, 1990, PLANTA, V182, P599, DOI 10.1007/BF02341037; SVENSSON B, 1989, BIOCHEM J, V264, P309, DOI 10.1042/bj2640309; Takaoka M, 1997, J AGR FOOD CHEM, V45, P2929, DOI 10.1021/jf9702656; TAKEDA Y, 1993, CARBOHYD RES, V240, P253, DOI 10.1016/0008-6215(93)84188-C; TAKEDA Y, 1985, AGR BIOL CHEM TOKYO, V49, P1633, DOI 10.1080/00021369.1985.10866963	42	23	27	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16538	16546		10.1074/jbc.M110497200	http://dx.doi.org/10.1074/jbc.M110497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864975	hybrid			2022-12-25	WOS:000175564500028
J	Hideshima, T; Chauhan, D; Richardson, P; Mitsiades, C; Mitsiades, N; Hayashi, T; Munshi, N; Dang, L; Castro, A; Palombella, V; Adams, J; Anderson, KC				Hideshima, T; Chauhan, D; Richardson, P; Mitsiades, C; Mitsiades, N; Hayashi, T; Munshi, N; Dang, L; Castro, A; Palombella, V; Adams, J; Anderson, KC			NF-kappa B as a therapeutic target in multiple myeloma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MARROW STROMAL CELLS; DRUG-RESISTANCE; APOPTOSIS; ACTIVATION; INTERLEUKIN-6; THALIDOMIDE; INHIBITION; GROWTH; EXPRESSION	We have shown that thalidomide (Thal) and its immunomodulatory derivatives (IMiDs), proteasome inhibitor PS-341, and As2O3 act directly on multiple myeloma (MM) cells and in the bone marrow (BM) milieu to overcome drug resistance. Although Thal/IMiDs, PS-341, and As2O3 inhibit nuclear factor (NF)-kappaB activation, they also have multiple and varied other actions. In this study, we therefore specifically address the role of NF-kappaB blockade in mediating anti-AM activity. To characterize the effect of specific NF-kappaB blockade on AM cell growth and survival in vitro, we used an IkappaB kinase (IKK) inhibitor (PS-1145). Our studies demonstrate that PS-1145 and PS-341 block TNFalpha-induced NF-kappaB activation in a dose- and time-dependent fashion in AM cells through inhibition of IkappaBalpha phosphorylation and degradation of IkappaBalpha, respectively. Dexamethasone (Dex) which up-regulates IkappaBalpha protein, enhances blockade of NF-kappaB activation by PS-1145. Moreover, PS-1145 blocks the protective effect of IL-6 against Dex-induced apotosis. TNFa-induced intracellular adhesion molecule (ICAM)-1 expression on both RPM18226 and MMAS cells is also inhibited by PS-1145. Moreover, PS-1145 inhibits both IL-6 secretion from BMSCs triggered by AM cell adhesion and proliferation of AM cells adherent to BMSCs. However, in contrast to PS-341, PS-1145 only partially (20-50%) inhibits AM cell proliferation, suggesting that NF-kappaB blockade cannot account for all of the anti-AM activity of PS-341. Importantly, however, TNFalpha induces AM cell toxicity in the presence of PS-1145. These studies demonstrate that specific targeting of NF-kappaB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu. Furthermore, they provide the framework for clinical evaluation of novel AM therapies based upon targeting NF-kappaB.	Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021	Dang, Lenny/0000-0002-2073-6109	PHS HHS [P0-1 78378] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barlogie B, 2001, BLOOD, V98, P492, DOI 10.1182/blood.V98.2.492; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BORSET M, 1994, EUR J HAEMATOL, V53, P31; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; Davies FE, 2001, BLOOD, V98, P210, DOI 10.1182/blood.V98.1.210; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; GULTRIDGE DC, 1999, MOL CELL BIOL, V19, P5785; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Keifer JA, 2001, J BIOL CHEM, V276, P22382, DOI 10.1074/jbc.M100938200; Keller SA, 2000, BLOOD, V96, P2537; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Li P, 2000, J IMMUNOL, V164, P5990, DOI 10.4049/jimmunol.164.11.5990; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Ogata A, 1997, J IMMUNOL, V159, P2212; Otsuka G, 1999, CANCER RES, V59, P4446; Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671; Raje N, 1999, NEW ENGL J MED, V341, P1606, DOI 10.1056/NEJM199911183412110; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; UCHIYAMA H, 1993, BLOOD, V82, P3712; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200; Zandi E, 1999, MOL CELL BIOL, V19, P4547	45	773	845	2	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16639	16647		10.1074/jbc.M200360200	http://dx.doi.org/10.1074/jbc.M200360200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872748	hybrid			2022-12-25	WOS:000175564500041
J	Yamazaki, M; Miyazaki, H; Watanabe, H; Sasaki, T; Maehama, T; Frohman, MA; Kanaho, Y				Yamazaki, M; Miyazaki, H; Watanabe, H; Sasaki, T; Maehama, T; Frohman, MA; Kanaho, Y			Phosphatidylinositol 4-phosphate 5-kinase is essential for ROCK-mediated neurite remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-ASSOCIATED KINASE; GROWTH CONE COLLAPSE; STRESS-FIBER FORMATION; BINDING PROTEIN-RHO; ACTIN CYTOSKELETON; LIM-KINASE; LYSOPHOSPHATIDIC ACID; ADP-RIBOSYLATION; FOCAL ADHESIONS; MAMMALIAN-CELLS	Phosphatidylinositol 4-phosphate 5-kinase (PIP-5kin) regulates actin cytoskeletal reorganization through its product phosphatidylinositol 4,5-bisphosphate. In the present study we demonstrate that PIP-5kin is essential for neurite remodeling, which is regulated by actin cytoskeletal reorganization in neuroblastoma N1E-115 cells. Overexpression of wild-type mouse PIP-5kin-alpha inhibits the neurite formation that is normally stimulated by serum depletion, whereas a lipid kinase-defective mutant of PIP-5kin-alpha, D266A, triggers neurite extension even in the presence of serum and blocks lysophosphatidic acid-induced neurite retraction. These results phenocopy those previously reported for the small GTPase RhoA and its effector p160 Rho-associated coiled coil-forming protein kinase (ROCK). However, the ROCK-specific inhibitor Y-27632 failed to block the inhibition by PIP-5kin-alpha of neurite extension, whereas D266A did block the neurite retraction induced by overexpression of ROCK. These results, taken together, suggest that PIP-5kin-alpha functions as a downstream effector for RhoA/ROCK to couple lysophosphatidic acid signaling to neurite retraction presumably through its product phosphatidylinositol 4,5-bisphosphate.	Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Inst Technol, Dept Biol Informat, Midori Ku, Yokohama, Kanagawa 2268501, Japan; SUNY Stony Brook, Ctr Dev Genet, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA	Tokyo Metropolitan Institute of Medical Science; Tokyo Institute of Technology; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kanaho, Y (corresponding author), Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	ykanaho@rinshoken.or.jp	Maehama, Tomohiko/AAX-8926-2020; Watanabe, Hiroshi/GOP-0177-2022; Maehama, Tomohiko/HGB-4896-2022	Watanabe, Hiroshi/0000-0001-8887-5407; Maehama, Tomohiko/0000-0002-9685-2317; Sasaki, Takehiko/0000-0003-1837-3748	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054813] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54813] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizawa H, 2001, NAT NEUROSCI, V4, P367, DOI 10.1038/86011; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Aoki J, 2000, BIOCHEM BIOPH RES CO, V278, P604, DOI 10.1006/bbrc.2000.3842; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Bradke F, 2000, CURR OPIN NEUROBIOL, V10, P574, DOI 10.1016/S0959-4388(00)00124-0; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; Fritsche J, 1999, MOL CELL NEUROSCI, V14, P398, DOI 10.1006/mcne.1999.0777; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Jin Z, 1997, J NEUROSCI, V17, P6256; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; Jones DR, 2000, FEBS LETT, V476, P160, DOI 10.1016/S0014-5793(00)01702-6; JOSHI HC, 1985, J CELL BIOL, V101, P697, DOI 10.1083/jcb.101.3.697; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Keynes Roger J., 1995, Current Opinion in Neurobiology, V5, P75, DOI 10.1016/0959-4388(95)80090-5; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kranenburg O, 1997, J CELL SCI, V110, P2417; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Lin Chi-Hung, 1994, Current Opinion in Neurobiology, V4, P640, DOI 10.1016/0959-4388(94)90004-3; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Meberg PJ, 2000, J NEUROSCI, V20, P2459; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SPERO DA, 1985, DEV BRAIN RES, V23, P155, DOI 10.1016/0165-3806(85)90016-1; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	60	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17226	17230		10.1074/jbc.M109795200	http://dx.doi.org/10.1074/jbc.M109795200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877391	hybrid			2022-12-25	WOS:000175564500116
J	Golan, A; Yudkovsky, Y; Hershko, A				Golan, A; Yudkovsky, Y; Hershko, A			The cyclin-ubiquitin ligase activity of cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; XENOPUS EGG EXTRACTS; CELL-DIVISION; MITOSIS; PHOSPHORYLATION; PLX1; PURIFICATION; DESTRUCTION; APC; REGULATORS	The cyclosome/anaphase-promoting complex is a multisubunit ubiquitin ligase that targets for degradation mitotic cyclins and some other cell cycle regulators in exit from mitosis. It becomes enzymatically active at the end of mitosis. The activation of the cyclosome is initiated by its phosphorylation, a process necessary for its conversion to an active form by the ancillary protein Cdc20/Fizzy. Previous reports have implicated either cyclin-dependent kinase 1-cyclin B or polo-like kinase as the major protein kinase that directly phosphorylates and activates the cyclosome. These conflicting results could be due to the use of partially purified cyclosome preparations or of immunoprecipitated cyclosome, whose interactions with protein kinases or ancillary factors may be hampered by binding to immobilized antibody. To examine this problem, we have purified cyclo. some from HeLa cells by a combination of affinity chromatography and ion exchange procedures. With the use of purified preparations, we found that both cyclin-dependent kinase 1-cyclin B and polo-like kinase directly phosphorylated the cyclosome, but the pattern of the phosphorylation of the different cyclosome subunits by the two protein kinases was not similar. Each protein kinase could restore only partially the cyclin-ubiquitin ligase activity of dephosphorylated cyclosome. However, following phosphorylation by both protein kinases, an additive and nearly complete restoration of cyclin-ubiquitin ligase activity was observed. It is suggested that this joint activation may be due to the complementary phosphorylation of different cyclosome subunits by the two protein kinases.	Technion Israel Inst Technol, Biochem Unit, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Hershko, A (corresponding author), Technion Israel Inst Technol, Biochem Unit, IL-31096 Haifa, Israel.							Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Harlow E., 1988, ANTIBODIES LAB MANUA; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Landrieu I, 2001, J BIOL CHEM, V276, P1434, DOI 10.1074/jbc.M006420200; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Peters JM, 1999, EXP CELL RES, V248, P339, DOI 10.1006/excr.1999.4443; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V260, P193, DOI 10.1006/bbrc.1999.0884; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V257, P12, DOI 10.1006/bbrc.1999.0409; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Sudakin V, 1997, J BIOL CHEM, V272, P18051, DOI 10.1074/jbc.272.29.18051; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Yudkovsky Y, 2000, BIOCHEM BIOPH RES CO, V271, P299, DOI 10.1006/bbrc.2000.2622; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; ZHUO S, 1993, J BIOL CHEM, V268, P17754	29	144	151	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15552	15557		10.1074/jbc.M111476200	http://dx.doi.org/10.1074/jbc.M111476200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859075	hybrid			2022-12-25	WOS:000175510400045
J	Lee, CW; Ji, IH; Ryu, KS; Song, YS; Conn, PM; Ji, TH				Lee, CW; Ji, IH; Ryu, KS; Song, YS; Conn, PM; Ji, TH			Two defective heterozygous luteinizing hormone receptors can rescue hormone action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; HORMONE/CHORIONIC GONADOTROPIN RECEPTOR; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; LEYDIG-CELL HYPOPLASIA; LEUCINE-RICH REPEATS; HIGH-AFFINITY; EXTRACELLULAR DOMAIN; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; FUNCTIONAL EXPRESSION; TRANSMEMBRANE DOMAIN	Luteinizing hormone receptor is a G protein-coupled receptor and consists of two halves: the N-terminal extracellular half (exodomain) and C-terminal membrane-associated half (endodomain). Hormone binds to the exodomain, and the resulting hormone-exodomain complex modulates the endodomain to generate signals. There are mutations that impair either hormone binding or signal generation. We report that the coexpression of a binding defective mutant and a signal-defective mutant rescues signal generation to produce cAMP. This rescue requires both types of mutant receptors and is dependent on the human chorionic gonadotropin dose, the surface concentration of mutant receptors, and the amino acid position of mutations. Furthermore, random collisions among mutant receptors are not involved in the rescue. Our observations provide new in. sights into the mechanisms of the functional and structural relationship of the exo- and endodomain, signal transduction, and receptor genetics, in particular for defective heterozygotes.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Oregon Hlth Sci Univ, Oregon Reg Primate Res Ctr, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA	University of Kentucky; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University	Ji, TH (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.		Song, Yong Sang/E-7824-2012	SONG, YONGSANG/0000-0001-7115-4021	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; Hong SH, 1999, MOL ENDOCRINOL, V13, P1285, DOI 10.1210/me.13.8.1285; Hong SH, 1998, J BIOL CHEM, V273, P13835, DOI 10.1074/jbc.273.22.13835; Hong SH, 1997, J BIOL CHEM, V272, P4166, DOI 10.1074/jbc.272.7.4166; Hong SH, 1999, ENDOCRINOLOGY, V140, P2486, DOI 10.1210/en.140.6.2486; JI I, 1980, P NATL ACAD SCI-BIOL, V77, P7167, DOI 10.1073/pnas.77.12.7167; JI IH, 1991, J BIOL CHEM, V266, P14953; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; Ji IH, 1995, ENDOCRINE, V3, P907, DOI 10.1007/BF02738896; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; Laue LL, 1996, MOL ENDOCRINOL, V10, P987, DOI 10.1210/me.10.8.987; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; McGee EA, 2000, ENDOCR REV, V21, P200, DOI 10.1210/er.21.2.200; Misrahi M, 1997, J CLIN ENDOCR METAB, V82, P2159, DOI 10.1210/jcem.82.7.4039; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; Nakabayashi K, 2000, J BIOL CHEM, V275, P30264, DOI 10.1074/jbc.M005568200; Nishi S, 2002, J BIOL CHEM, V277, P3958, DOI 10.1074/jbc.M109617200; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; Song YS, 2001, J BIOL CHEM, V276, P3436, DOI 10.1074/jbc.M003773200; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Thomas D, 1996, MOL ENDOCRINOL, V10, P760, DOI 10.1210/me.10.6.760; TILLY JL, 1992, ENDOCRINOLOGY, V131, P799, DOI 10.1210/en.131.2.799; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; Wu SM, 1998, MOL ENDOCRINOL, V12, P1651, DOI 10.1210/me.12.11.1651; XIE YB, 1990, J BIOL CHEM, V265, P21411; Zeng HW, 2001, J BIOL CHEM, V276, P3451, DOI 10.1074/jbc.M007488200	41	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15795	15800		10.1074/jbc.M111818200	http://dx.doi.org/10.1074/jbc.M111818200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859079	hybrid			2022-12-25	WOS:000175510400078
J	Misaka, T; Miyashita, T; Kubo, Y				Misaka, T; Miyashita, T; Kubo, Y			Primary structure of a dynamin-related mouse mitochondrial GTPase and its distribution in brain, subcellular localization, and effect on mitochondrial morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT OPTIC ATROPHY; INTERMEMBRANE SPACE; DNA MAINTENANCE; OUTER-MEMBRANE; PROTEIN; YEAST; FISSION; FAMILY; DNM1P; IDENTIFICATION	A new member of the dynamin GTPase family (OPA1) was recently identified in humans and shown to be mutated in patients with dominant optic atrophy. To understand better the function of mammalian OPA1, we isolated a mouse ortholog (mOPA1) from brain and raised a specific antibody against its C terminus. The subcellular distribution of mOPA1 overexpressed in COS-7 cells largely overlapped that of endogenous cytochrome c, a well known mitochondrial marker, and dramatically affected mitochondrial morphology, altering it from tubular to vesicular. Mitochondrial targeting was mediated by the N-terminal region of mOPA1 as follows: deletion of the 124 N-terminal amino acids eliminated mitochondrial targeting, although fusion of the N-terminal 60 or 90 amino acids of mOPA1 with green fluorescent protein resulted in its mitochondrial targeting. mOPA1 was expressed widely in the mouse brain, especially in neurons of olfactory bulb, cerebral cortex, piriform cortex, hypothalamus, hippocampus, red nucleus, cochlear nucleus, motor trigeminal nucleus, facial nucleus, cerebellar nucleus, and Purkinje cells. Within dissociated cerebellar cells, mOPA1 protein was clearly observed in the dendrites and somas of neuronal cells, as well as in astrocytes and meningeal cells. In each case, it was distributed in the vesicular pattern seen in other cell types.	Tokyo Med & Dent Univ, Grad Sch, Dept Physiol, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Fac Med, Bunkyo Ku, Tokyo 1138519, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; Tokyo Metropolitan Inst Neurosci, Dept Mol Neurophysiol, Tokyo 1838526, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); University of Tokyo; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Kubo, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Physiol, Bunkyo Ku, D-566,1-5-45 Yushima, Tokyo 1138519, Japan.			Kubo, Yoshihiro/0000-0001-6707-0837; Misaka, Takumi/0000-0002-9547-5767				Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; BRANDA SS, 1995, J BIOL CHEM, V270, P27366, DOI 10.1074/jbc.270.45.27366; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HIRANO T, 1993, J NEUROPHYSIOL, V70, P1316, DOI 10.1152/jn.1993.70.4.1316; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; Kubokawa K, 1998, FEBS LETT, V431, P231, DOI 10.1016/S0014-5793(98)00762-5; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Pelloquin L, 1999, J CELL SCI, V112, P4151; Pelloquin L, 1998, BIOCHEM BIOPH RES CO, V251, P720, DOI 10.1006/bbrc.1998.9539; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WILSBACH K, 1993, EMBO J, V12, P3049, DOI 10.1002/j.1460-2075.1993.tb05974.x; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Yoon Y, 2001, CURR BIOL, V11, pR67, DOI 10.1016/S0960-9822(01)00011-2	33	120	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15834	15842		10.1074/jbc.M109260200	http://dx.doi.org/10.1074/jbc.M109260200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11847212	hybrid			2022-12-25	WOS:000175510400084
J	Post, GR; Swiderski, C; Waldrop, BA; Salty, L; Glembotski, CC; Wolthuis, RMF; Mochizuki, N				Post, GR; Swiderski, C; Waldrop, BA; Salty, L; Glembotski, CC; Wolthuis, RMF; Mochizuki, N			Guanine nucleotide exchange factor-like factor (Rlf) induces gene expression and potentiates alpha(1)-adrenergic receptor-induced transcriptional responses in neonatal rat ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ATRIAL-NATRIURETIC-FACTOR; MUSCLE CELL HYPERTROPHY; MYOSIN LIGHT CHAIN-2; DISSOCIATION STIMULATOR; CARDIAC-HYPERTROPHY; TRANSGENIC MICE; ADRENERGIC STIMULATION; MUSCARINIC RECEPTORS; DEPENDENT ACTIVATION	Expression of constitutively active Ras (V12Ras) in cultured neonatal rat ventricular myocytes or targeted cardiac expression of V12Ras in transgenic mice induces myocardial cell growth and expression of genes that are markers of cardiac hypertrophy including atrial natriuretic factor (ANF) and myosin light chain-2. However, the signaling pathways that modulate the effects of Ras on acquisition of the various features of cardiac hypertrophy are not known. We identified the Ral guanine nucleotide exchange factor-like factor (Rlf) in a yeast two-hybrid screen of human heart cDNA library using Ras as bait, suggesting that Ras signaling in the heart may involve Rlf. We demonstrate here that Rlf is expressed in human heart. Expression of wild type Rlf or Rlf-CAAX, a membrane-targeted mutant of Rlf, transactivated ANF and myosin light chain-2 promoters but did not activate canonical cAMP responsive elements or phorbol ester responsive elements, suggesting that Rlf expression does not lead to a generalized increase in transcription. Transfection of mutant ANF promoter-reporter gene constructs demonstrated that the proximal serum response element is both necessary and sufficient for Rlf-inducible ANF expression. Rlf-induced ANF promoter activation required Ral and Cdc42 but not RhoA, Rac1, ERK, or p38 kinase activation. In addition, Rlf potentiated alpha(1)-adrenergic receptor (alpha(1)-AR)-induced ANF expression. Prolonged activation of the alpha(1)-AR increases RalGTP levels in neonatal rat ventricular myocytes, further emphasizing a role for Ral guanine nucleotide exchange factors in alpha(1)-AR signaling. Overall, this study supports the concept that Rlf and Ral are important previously unrecognized signaling components that regulate transcriptional responses in myocardial cells.	Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; Univ Med Ctr Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, Osaka 5658565, Japan	University of Kentucky; California State University System; San Diego State University; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; National Cerebral & Cardiovascular Center - Japan	Post, GR (corresponding author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Rose St, Lexington, KY 40536 USA.	grpost@uky.edu		Wolthuis, Rob/0000-0002-3109-1588				Abdellatif M, 1997, J BIOL CHEM, V272, P525; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Brown JH, 1997, LIFE SCI, V60, P1077; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ehrhardt GRA, 2001, ONCOGENE, V20, P188, DOI 10.1038/sj.onc.1204053; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Fuller SJ, 1998, BIOCHEM J, V335, P241, DOI 10.1042/bj3350241; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; GOB T, 1999, MOL CELL BIOL, V19, P1731; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hines WA, 1999, MOL CELL BIOL, V19, P1841; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; IWAKI K, 1990, J BIOL CHEM, V265, P13809; Karlon WJ, 1998, ANAT RECORD, V252, P612, DOI 10.1002/(SICI)1097-0185(199812)252:4<612::AID-AR12>3.0.CO;2-1; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Lazou A, 1998, BIOCHEM J, V332, P459, DOI 10.1042/bj3320459; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; Mochizuki N, 1997, CIRCULATION, V96, P3112; Morissette MR, 2000, AM J PHYSIOL-HEART C, V278, pH1769, DOI 10.1152/ajpheart.2000.278.6.H1769; Murai H, 1997, J BIOL CHEM, V272, P10483; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Sawamoto K, 1999, ONCOGENE, V18, P1967, DOI 10.1038/sj.onc.1202522; Shao HP, 2000, J BIOL CHEM, V275, P26914; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang Yibin, 2001, Current Opinion in Pharmacology, V1, P134, DOI 10.1016/S1471-4892(01)00029-7; Wei L, 2001, FASEB J, V15, P785, DOI 10.1096/fj.00-026com; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	61	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15286	15292		10.1074/jbc.M111844200	http://dx.doi.org/10.1074/jbc.M111844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11847222	hybrid			2022-12-25	WOS:000175510400011
J	Rodriguez, JA; Valentine, JS; Eggers, DK; Roe, JA; Tiwari, A; Brown, RH; Hayward, LJ				Rodriguez, JA; Valentine, JS; Eggers, DK; Roe, JA; Tiwari, A; Brown, RH; Hayward, LJ			Familial amyotrophic lateral sclerosis-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; CU,ZN-SUPEROXIDE DISMUTASE; CONFORMATIONAL STABILITY; BINDING; DENATURATION; APOPROTEIN; RESOLUTION	We report the thermal stability of wild type (WT) and 14 different variants of human copper/zinc superoxide dismutase (SOD1) associated with familial amyotrophic lateral sclerosis (FALS). Multiple endothermic unfolding transitions were observed by differential scanning calorimetry for partially metallated SOD1 enzymes isolated from a baculovirus system. We correlated the metal ion contents of SOD1 variants with the occurrence of distinct melting transitions. Altered thermal stability upon reduction of copper with dithionite identified transitions resulting from the unfolding of copper-containing SOD1 species. We demonstrated that copper or zinc binding to a subset of "WT-like" FALS mutants (A4V, L38V, G41S, G72S, D76Y, D90A, G93A, and E133Delta) conferred a similar degree of incremental stabilization as did metal ion binding to WT SOD1. However, these mutants were all destabilized by similar to 1- 6 degreesC compared with the corresponding WT SOD1 species. Most of the "metal binding region" FALS mutants (H46R, G85R, D124V, D125H, and S134N) exhibited transitions that probably resulted from unfolding of metal-free species at similar to4-12 degreesC below the observed melting of the least stable WT species. We conclude that decreased conformational stability shared by all of these mutant SOD1s may contribute to SOD1 toxicity in FALS.	Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Loyola Marymount Univ, Dept Chem & Biochem, Los Angeles, CA 90045 USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles; Loyola Marymount University; Harvard University; Massachusetts General Hospital	Hayward, LJ (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol, 55 Lake Ave N, Worcester, MA 01655 USA.	Lawrence.Hayward@umassmed.edu	Valentine, Joan S/B-6665-2008; Tiwari, Ashutosh/A-7458-2008; Eggers, Daryl/U-4497-2019	Valentine, Joan S/0000-0002-7174-925X; Tiwari, Ashutosh/0000-0001-7373-349X; Eggers, Daryl/0000-0003-1915-5945; Hayward, Lawrence/0000-0003-0579-0358	NIGMS NIH HHS [GM28222] Funding Source: Medline; NINDS NIH HHS [P01NS31248, P01NS37912] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031248, R01NS037912] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Battistoni A, 1998, J BIOL CHEM, V273, P5655, DOI 10.1074/jbc.273.10.5655; Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; EDGE V, 1985, BIOCHEMISTRY-US, V24, P5899, DOI 10.1021/bi00342a032; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Goto JJ, 1998, J BIOL CHEM, V273, P30104, DOI 10.1074/jbc.273.46.30104; Goto JJ, 2000, J BIOL CHEM, V275, P1007, DOI 10.1074/jbc.275.2.1007; Hart PJ, 1998, PROTEIN SCI, V7, P545; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Hosler BA, 1996, NEUROMUSCULAR DISORD, V6, P361, DOI 10.1016/0960-8966(96)00353-7; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; LEPOCK JR, 1985, ARCH BIOCHEM BIOPHYS, V241, P243, DOI 10.1016/0003-9861(85)90380-7; Liu HB, 2000, BIOCHEMISTRY-US, V39, P8125, DOI 10.1021/bi000846f; MACH H, 1991, ARCH BIOCHEM BIOPHYS, V287, P41, DOI 10.1016/0003-9861(91)90385-V; MALINOWSKI DP, 1979, BIOCHEMISTRY-US, V18, P5055, DOI 10.1021/bi00590a005; Marklund SL, 1997, J NEUROCHEM, V69, P675; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEI G, 1992, BIOCHEMISTRY-US, V31, P7224, DOI 10.1021/bi00147a003; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; RICHARDSON JS, 1975, P NATL ACAD SCI USA, V72, P1349, DOI 10.1073/pnas.72.4.1349; ROE JA, 1988, BIOCHEMISTRY-US, V27, P950, DOI 10.1021/bi00403a017; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443	29	201	205	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15932	15937		10.1074/jbc.M112088200	http://dx.doi.org/10.1074/jbc.M112088200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854285	hybrid, Green Published			2022-12-25	WOS:000175510400096
J	Broschat, KO; Gorka, C; Page, JD; Martin-Berger, CL; Davies, MS; Huang, HC; Gulve, EA; Salsgiver, WJ; Kasten, TP				Broschat, KO; Gorka, C; Page, JD; Martin-Berger, CL; Davies, MS; Huang, HC; Gulve, EA; Salsgiver, WJ; Kasten, TP			Kinetic characterization of human glutamine-fructose-6-phosphate amidotransferase I - Potent feedback inhibition by glucosamine 6-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE SYNTHETASE-B; GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; ANGSTROM CRYSTAL-STRUCTURE; INSULIN-RESISTANCE; ESCHERICHIA-COLI; GLUCOSAMINE-6-PHOSPHATE SYNTHASE; SKELETAL-MUSCLE; FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; TRANSGENIC MICE; MESSENGER-RNA	Glutamine-fructose-6-phosphate amidotransferase (GFAT) catalyzes the first committed step in the pathway for biosynthesis of hexosamines in mammals. A member of the N-terminal nucleophile class of amidotransferases, GFAT transfers the amino group from the L-glutamine amide to D-fructose 6-phosphate, producing glutamic acid and glucosamine 6-phosphate. The kinetic constants reported previously for mammalian GFAT implicate a relatively low affinity for the acceptor substrate, fructose 6-phosphate (Fru-6-P, K-m 0.2-1 mM). Utilizing a new sensitive assay that measures the production of glucosamine 6-phosphate (GlcN-6-P), purified recombinant human GFAT1 (hGFAT1) exhibited a K-m for Fru-6-P of 7 muM, and was highly sensitive to product inhibition by GlcN-6-P. In a second assay method that measures the stimulation of glutaminase activity, a K-d of 2 muM was measured for Fru-6-P binding to hGFAT1. Further, we report that the product, GlcN-6-P, is a potent competitive inhibitor for the Fru-6-P site, with a K-i measured of 6 muM. Unlike other members of the amidotransferase family, where glutamate production is loosely coupled to amide transfer, we have demonstrated that hGFAT1 production of glutamate and GlcN-6-P are strictly coupled in the absence of inhibitors. Similar to other amidotransferases, competitive inhibitors that bind at the synthase site may inhibit the synthase activity without inhibiting the glutaminase activity at the hydrolase domain. GlcN-6-P, for example, inhibited the transfer reaction while fully activating the glutaminase activity at the hydrolase domain. Inhibition of hGFAT1 by the end product of the pathway, UDPGlcNAc, was competitive with a K-i of 4 muM. These data suggest that hGFAT1 is fully active at physiological levels of Fru-6-P and may be regulated by its product GlcN-6-P in addition to the pathway end product, UDP-GlcNAc.	Pharmacia Corp, Cardiovasc & Metab Dis, St Louis, MO 63167 USA; Pharmacia Corp, Discovery Biol, Skokie, IL 60077 USA; Pharmacia Corp, Biochem & Mol Biol, Chesterfield, MO 63198 USA; Pharmacia Corp, Discovery Chem, Chesterfield, MO 63198 USA	Pfizer; Pfizer; Pfizer; Pfizer	Broschat, KO (corresponding author), Pharmacia Corp, Cardiovasc & Metab Dis, T2M,800 N Lindbergh Blvd, St Louis, MO 63167 USA.							BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; BADET B, 1988, BIOCHEMISTRY-US, V27, P2282, DOI 10.1021/bi00407a006; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Bera AK, 2000, J BIOL CHEM, V275, P7975, DOI 10.1074/jbc.275.11.7975; Boehlein SK, 1998, BIOCHEMISTRY-US, V37, P13230, DOI 10.1021/bi981058h; Boehlein SK, 1997, BIOCHEMISTRY-US, V36, P10168, DOI 10.1021/bi970494l; BROSCHAT KO, 2002, IN PRESS ANAL BIOCH; CALLAHAN M, 1981, ANAL BIOCHEM, V115, P347, DOI 10.1016/0003-2697(81)90016-6; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; DeHaven JE, 2001, DIABETES, V50, P2419, DOI 10.2337/diabetes.50.11.2419; GHOSH S, 1960, J BIOL CHEM, V235, P1265; GOLINELLIPIMPANEAU B, 1989, J AM CHEM SOC, V111, P3029, DOI 10.1021/ja00190a042; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Huynh QK, 2000, ARCH BIOCHEM BIOPHYS, V379, P307, DOI 10.1006/abbi.2000.1895; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; KIKUCHI H, 1976, BIOCHIM BIOPHYS ACTA, V422, P231, DOI 10.1016/0005-2744(76)90022-X; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; Larsen TM, 2000, BIOCHEMISTRY-US, V39, P7330, DOI 10.1021/bi005109y; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; MARSHALL S, 1991, FASEB J, V5, P3031, DOI 10.1096/fasebj.5.15.1743436; Massiere F, 1998, CELL MOL LIFE SCI, V54, P205, DOI 10.1007/s000180050145; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Milewski S, 1999, J BIOL CHEM, V274, P4000, DOI 10.1074/jbc.274.7.4000; Milewski S, 1997, BIOORG CHEM, V25, P283, DOI 10.1006/bioo.1997.1077; Muchmore CRA, 1998, PROTEIN SCI, V7, P39, DOI 10.1002/pro.5560070104; Niimi M, 2001, J HUM GENET, V46, P566, DOI 10.1007/s100380170022; OBMOLOVA G, 1994, J MOL BIOL, V242, P703, DOI 10.1006/jmbi.1994.1619; Oki T, 1999, GENOMICS, V57, P227, DOI 10.1006/geno.1999.5785; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Richards NGJ, 1998, ADV ENZYMOL RAMB, V72, P145; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; Ross SA, 2000, BIOCHEM BIOPH RES CO, V273, P1033, DOI 10.1006/bbrc.2000.3082; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Tang JP, 2000, DIABETES, V49, P1492, DOI 10.2337/diabetes.49.9.1492; Teplyakov A, 1998, STRUCTURE, V6, P1047, DOI 10.1016/S0969-2126(98)00105-1; Teplyakov A, 1999, PROTEIN SCI, V8, P596; Thomson MJ, 1997, J BIOL CHEM, V272, P7759, DOI 10.1074/jbc.272.12.7759; TOURIAN A, 1983, NEUROCHEM RES, V8, P1589, DOI 10.1007/BF00964160; TRUJILLO JL, 1972, BIOCHIM BIOPHYS ACTA, V286, P330, DOI 10.1016/0304-4165(72)90268-1; TRUJILLO JL, 1973, BIOCHIM BIOPHYS ACTA, V304, P32, DOI 10.1016/0304-4165(73)90112-8; WINTERBU.PJ, 1971, BIOCHEM J, V121, P701, DOI 10.1042/bj1210701; WINTERBURN PJ, 1971, BIOCHEM J, V121, P711, DOI 10.1042/bj1210711; YkiJarvinen H, 1996, DIABETES, V45, P302, DOI 10.2337/diabetes.45.3.302; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; ZHOU JX, 1995, HUM GENET, V96, P99, DOI 10.1007/BF00214194	49	67	68	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14764	14770		10.1074/jbc.M201056200	http://dx.doi.org/10.1074/jbc.M201056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11842094	hybrid			2022-12-25	WOS:000175203000054
J	Frey, N; Olson, EN				Frey, N; Olson, EN			Calsarcin-3, a novel skeletal muscle-specific member of the calsarcin family, interacts with multiple Z-disc proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIRDLE MUSCULAR-DYSTROPHY; DILATED CARDIOMYOPATHY; SARCOMERIC PROTEIN; Z-BAND; T-CAP; MUTATIONS; PATHWAY; HEART; PDZ; SARCOGLYCAN	The Z-disc is a highly specialized multiprotein complex of striated muscles that serves as the interface of the sarcomere and the cytoskeleton. In addition to its role in muscle contraction, its juxtaposition to the plasma membrane suggests additional functions of the Z-disc in sensing and transmitting external and internal signals. Recently, we described two novel striated muscle-specific proteins, calsarcin-1 and calsarein-2, that bind a-actinin on the Z-disc and serve as intracellular binding proteins for calcineurin, a calcium/calmodulin-dependent phosphatase shown to be integral in cardiac hypertrophy as well as skeletal muscle differentiation and fiber-type specification. Here, we describe an additional member of the calsarcin family, calsarcin-3, which is expressed specifically in skeletal muscle and is enriched in fast-twitch muscle fibers. Like calsarcin-1 and calsarein-2, calsarcin-3 interacts with calcineurin, and the Z-disc proteins a-actinin, gamma-filamin, and telethonin. In addition, we show that calsarcins interact with the PDZ-LIM domain protein ZASP/Cypher/Oracle, which also localizes to the Z-disc. Calsarcins represent a novel family of sarcomeric proteins that serve as focal points for the interactions of an array of proteins involved in Z-disc structure and signal transduction in striated muscle.	Univ Texas, SW Med Ctr, Dept Biol Mol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Biol Mol, Dallas, TX 75390 USA.	eolson@hamon.swmed.edu	Frey, Norbert/A-9695-2010; Frey, Norbert/M-7749-2019	Frey, Norbert/0000-0001-7611-378X				Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; Faulkner G, 2000, J BIOL CHEM, V275, P41234, DOI 10.1074/jbc.M007493200; Faulkner G, 2001, IUBMB LIFE, V51, P275, DOI 10.1080/152165401317190761; Feit H, 1998, AM J HUM GENET, V63, P1732, DOI 10.1086/302166; Frey N, 2000, P NATL ACAD SCI USA, V97, P14632, DOI 10.1073/pnas.260501097; Furukawa T, 2001, J MOL BIOL, V313, P775, DOI 10.1006/jmbi.2001.5053; Goldfarb LG, 1998, NAT GENET, V19, P402, DOI 10.1038/1300; GOLDSTEIN MA, 1991, FASEB J, V5, P2167, DOI 10.1096/fasebj.5.8.2022313; Gregorio CC, 1998, J CELL BIOL, V143, P1013, DOI 10.1083/jcb.143.4.1013; Hauser MA, 2000, HUM MOL GENET, V9, P2141, DOI 10.1093/hmg/9.14.2141; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Liu YW, 2001, J CELL BIOL, V155, P27, DOI 10.1083/jcb.200103020; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Moreira ES, 2000, NAT GENET, V24, P163, DOI 10.1038/72822; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Pashmforoush M, 2001, NAT MED, V7, P591, DOI 10.1038/87920; Passier R, 2000, MECH DEVELOP, V92, P277, DOI 10.1016/S0925-4773(99)00330-5; Robia SL, 2001, BIOPHYS J, V80, P2140, DOI 10.1016/S0006-3495(01)76187-5; Sussman MA, 1999, AM J PATHOL, V155, P2101, DOI 10.1016/S0002-9440(10)65528-9; Takada F, 2001, P NATL ACAD SCI USA, V98, P1595, DOI 10.1073/pnas.041609698; Thompson TG, 2000, J CELL BIOL, V148, P115, DOI 10.1083/jcb.148.1.115; Valle G, 1997, FEBS LETT, V415, P163, DOI 10.1016/S0014-5793(97)01108-3; van der Ven PFM, 2000, J CELL BIOL, V151, P235, DOI 10.1083/jcb.151.2.235; Zatz M, 2000, CURR OPIN NEUROL, V13, P511, DOI 10.1097/00019052-200010000-00002; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092; Zou YZ, 2001, CIRCULATION, V104, P102, DOI 10.1161/hc2601.090987	33	136	153	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13998	14004		10.1074/jbc.M200712200	http://dx.doi.org/10.1074/jbc.M200712200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11842093	hybrid			2022-12-25	WOS:000175096000085
J	Itano, O; Ueda, M; Kikuchi, K; Hashimoto, O; Hayatsu, S; Kawaguchi, M; Seki, H; Aiura, K; Kitajima, M				Itano, O; Ueda, M; Kikuchi, K; Hashimoto, O; Hayatsu, S; Kawaguchi, M; Seki, H; Aiura, K; Kitajima, M			Correlation of postoperative recurrence in hepatocellular carcinoma with demethylation of repetitive sequences	ONCOGENE			English	Article						demethylation; repetitive sequence; hepatocellular carcinoma; postoperative recurrence; restriction landmark genomic scanning	GLOBAL DNA HYPOMETHYLATION; PROGNOSTIC FACTORS; METHYLATION; LIVER; EUKARYOTES; EXPRESSION; ONCOGENES	Restriction landmark genomic scanning (RLGS) was utilized to identify novel genomic alterations in hepatocellular carcinoma (HCC). Thirty-one HCC samples were examined by RLGS. Two high intensity spots were common to several RLGS profiles of different HCCs. Nucleotide sequencing and homology search analysis showed that these spots represented repetitive sequences, Human tandem repeat sequence (Genbank, L09552) and centromeric NotI cluster (Genbank, Y10752). These intensified signals were attributable to the occurrence of demethylated areas in the recognition sequence of the NotI site of the corresponding fragments. The intensity of these spots in the RLGS profile reflects their degree of demethylation, which was significantly correlated with postoperative recurrence, even in patients regarded as belonging to the good prognosis group by conventional prognostic factors. Multivariate analysis showed that the intensities of the two spots retained independent prognostic value. This is a new type of predictive factor for HCC based on epigenetic changes in hepatocarcinogenesis, and in the future it is expected to be of great value in making preoperative diagnosis and selecting postoperative therapy.	Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 1608582, Japan; Tokyo Denryoku Hosp, Dept Surg, Shinjuku Ku, Tokyo 1600016, Japan	Keio University	Ueda, M (corresponding author), Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.							Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; ARII S, 1992, CANCER, V69, P913, DOI 10.1002/1097-0142(19920215)69:4<913::AID-CNCR2820690413>3.0.CO;2-T; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender J, 1998, TRENDS BIOCHEM SCI, V23, P252, DOI 10.1016/S0968-0004(98)01225-0; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Cravo M, 1996, GUT, V39, P434, DOI 10.1136/gut.39.3.434; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HIMENO Y, 1988, LIVER, V8, P208; HSU HC, 1988, CANCER, V61, P2095, DOI 10.1002/1097-0142(19880515)61:10<2095::AID-CNCR2820611027>3.0.CO;2-H; Itano O, 2000, ONCOGENE, V19, P1676, DOI 10.1038/sj.onc.1203459; KIM YI, 1994, CANCER, V74, P893, DOI 10.1002/1097-0142(19940801)74:3<893::AID-CNCR2820740316>3.0.CO;2-B; Kubo S, 1998, JPN J CANCER RES, V89, P419, DOI 10.1111/j.1349-7006.1998.tb00580.x; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Lise M, 1998, CANCER, V82, P1028, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1028::AID-CNCR4>3.0.CO;2-A; *LIV CANC STUD GRO, 1997, CLASS PRIM LIV CANC, P1; MIWA W, 1995, ELECTROPHORESIS, V16, P227, DOI 10.1002/elps.1150160138; Nagai H, 1999, DNA Res, V6, P219, DOI 10.1093/dnares/6.4.219; Nagai H, 1999, GENE, V237, P15, DOI 10.1016/S0378-1119(99)00322-4; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; OHSUMI T, 1995, ELECTROPHORESIS, V16, P203, DOI 10.1002/elps.1150160135; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; Shen LL, 1998, HEPATO-GASTROENTEROL, V45, P1753; Shiraishi M, 1999, BIOL CHEM, V380, P81, DOI 10.1515/BC.1999.010; SIRABE K, 1991, HEPATOLOGY, V14, P913; Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.3.CO;2-K; TEUBNER B, 1994, EXP CELL RES, V2102, P192; Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4; ZHANG XK, 1987, BIOCHEM BIOPH RES CO, V142, P932, DOI 10.1016/0006-291X(87)91503-8; ZRIHANLICHT S, 1995, INT J CANCER, P245	30	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					789	797		10.1038/sj.onc.1205124	http://dx.doi.org/10.1038/sj.onc.1205124			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850807				2022-12-25	WOS:000173427000010
J	Agou, F; Ye, F; Goffinont, S; Courtois, G; Yamaoka, S; Israel, A; Veron, M				Agou, F; Ye, F; Goffinont, S; Courtois, G; Yamaoka, S; Israel, A; Veron, M			NEMO trimerizes through its coiled-coil C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSFER-RNA SYNTHETASE; KINASE COMPLEX; IKK-GAMMA; REGULATORY SUBUNIT; ACTIVATION; PROTEIN; ALPHA; EXPRESSION; PEPTIDE	NEMO/IkappaB kinase (IKK) gamma is the regulatory component of the IKK complex comprising the two protein kinases, IKKalpha and IKKbeta. To investigate the self-assembly properties of NEMO and to understand further the mechanism of activation of the IKK complex, we purified wildtype and mutant NEMO expressed in Escherichia coli. In the absence of its IKK partners, recombinant NEMO (rNEMO) is a metastable functional monomer correctly folded, according to its fluorescence and far-UV CD spectra, which is binding specifically to the IKK complex. A minor fraction of rNEMO was found tightly associated with DnaK (E. coli Hsp70). We also examined the interaction of NEMO with prokaryotic and eukaryotic Hsp70, and we showed that the Hsp70-NEMO complex forms a supramolecular structure probably corresponding to an assembly intermediate. In vivo crosslinking experiments indicate that native NEMO in association with IKK is in equilibrium between a dimeric and a trimeric form. Similarly to native NEMO, a NEMO mutant deleted from its IKK binding N-terminal domain (residues 242-388) forms a stable trimeric coiled-coil, suggesting that the association of NEMO with IKK or with Hsp70 prevents incorrect interdomain pairing reactions that could lead to aggregation or to an non-native oligomeric state of rNEMO. We propose a model in which the activation of the IKK complex occurs through the trimerization of NEMO upon binding to a not yet identified upstream activator.	Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, F-75724 Paris 15, France; Inst Pasteur, Unite Biol Mol Express Gen, CNRS, FRE 2364, F-75724 Paris, France; Tokyo Med & Dent Univ, Dept Microbiol, Bunkyo Ku, Tokyo, Japan	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Tokyo Medical & Dental University (TMDU)	Agou, F (corresponding author), Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, 25 Rue Docteur Roux, F-75724 Paris 15, France.		, AGOU/GXA-2760-2022	COURTOIS, Gilles/0000-0003-3117-9595				Agou F, 1996, BIOCHEMISTRY-US, V35, P15322, DOI 10.1021/bi9617926; AGOU F, 1995, BIOCHEMISTRY-US, V34, P569, DOI 10.1021/bi00002a023; Agou F, 1996, J BIOL CHEM, V271, P29295, DOI 10.1074/jbc.271.46.29295; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; DevilleBonne D, 1996, BIOCHEMISTRY-US, V35, P14643, DOI 10.1021/bi960945m; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; FONTAN E, 1994, P NATL ACAD SCI USA, V91, P8353, DOI 10.1073/pnas.91.18.8353; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HENNESSEY JP, 1982, ANAL BIOCHEM, V125, P177, DOI 10.1016/0003-2697(82)90400-6; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; Johnson M.L., 1994, MODERN ANAL ULTRACEN, P37; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li YG, 1998, MOL CELL BIOL, V18, P1601, DOI 10.1128/MCB.18.3.1601; Lustig A, 2000, BBA-BIOMEMBRANES, V1464, P199, DOI 10.1016/S0005-2736(99)00254-0; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REYNOLDS JA, 1976, P NATL ACAD SCI USA, V73, P4467, DOI 10.1073/pnas.73.12.4467; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schwamborn K, 2000, J BIOL CHEM, V275, P22780, DOI 10.1074/jbc.M001500200; Smahi A, 2000, NATURE, V405, P466; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; TELLER DC, 1976, NATURE, V260, P729, DOI 10.1038/260729a0; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	53	67	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17464	17475		10.1074/jbc.M201964200	http://dx.doi.org/10.1074/jbc.M201964200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877453	hybrid			2022-12-25	WOS:000175685100012
J	Carl, VS; Brown-Steinke, K; Nicklin, MJH; Smith, MF				Carl, VS; Brown-Steinke, K; Nicklin, MJH; Smith, MF			Toll-like receptor 2 and 4 (TLR2 and TLR4) agonists differentially regulate secretory interleukin-1 receptor antagonist gene expression in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SEQUENCE-BINDING PROTEIN; IL-1 RECEPTOR; HUMAN-MONOCYTES; SIGNAL-TRANSDUCTION; GP91(PHOX) EXPRESSION; PU.1; P38; INHIBITOR; PROMOTER	Treatment of macrophages with lipopolysaccharide (LPS) from Gram-negative bacteria or peptidoglyean (PGN) from Gram-positive bacteria activates multiple intracellular signaling pathways and a large, diverse group of nuclear transcription factors. The signaling receptors for PGN and LPS are now known to be the Toll-like receptors 2 and 4 (TLR2 and -4, respectively). While a large body of literature indicates that the members of the TLR family activate nearly identical cytoplasmic signaling programs, several recent reports have suggested that the functional outcomes of signaling via TLR2 or TLR4 are not equivalent. In the current studies, we compared the responses of the secretory IL-1 receptor antagonist (sIL-1Ra) gene to both LPS and PGN. Both LPS and PGN induced IL-1Ra gene expression; however, the combination of both stimuli synergistically increased sIL-1Ra mRNA expression and promoter activity, suggesting that the signals induced by PGN and LPS are not equivalent. While both LPS and PGN utilized the PU.1-binding sites in the proximal sIL-1Ra promoter region to generate a full response, additional distinct promoter elements were utilized by LPS or PGN. Activation of p38 stress-activated protein kinase was required for LPS- or PGN-induced IL-1Ra gene expression, but the p38-responsive promoter elements localized to distinct regions of the sIL-1Ra gene. Additionally, while the LPS-induced, p38-dependent response was dependent upon PU.1 binding, the PGN-induced, p38 response was not. Collectively, these data indicated that while some of the intracellular signaling events by TLR2 and TLR4 agonists are similar, there are clearly distinct differences in the responses elicited by these two bacterial products.	Univ Virginia Hlth Syst, Digest Hlth Ctr Excellence, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Sheffield, Royal Hallamshire Hosp, Div Genom Med, Sheffield S10 2JF, S Yorkshire, England	University of Virginia; University of Virginia; University of Sheffield	Smith, MF (corresponding author), Univ Virginia Hlth Syst, Digest Hlth Ctr Excellence, Bldg MR4,Rm 1031, Charlottesville, VA 22908 USA.			Nicklin, Martin/0000-0002-0127-1131	NIAID NIH HHS [AI34358] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034358, R29AI034358] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON J, 1992, EUR J IMMUNOL, V22, P2617, DOI 10.1002/eji.1830221022; AREND WP, 1991, J IMMUNOL, V147, P1530; AREND WP, 1989, J IMMUNOL, V143, P1851; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; Egan BS, 1999, J BIOL CHEM, V274, P9098, DOI 10.1074/jbc.274.13.9098; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Gabay C, 1999, CYTOKINE, V11, P561, DOI 10.1006/cyto.1998.0451; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lodie TA, 1997, J IMMUNOL, V158, P1848; Malyak M, 1998, J IMMUNOL, V161, P1997; Manthey CL, 1998, J LEUKOCYTE BIOL, V64, P409, DOI 10.1002/jlb.64.3.409; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Means TK, 1999, J IMMUNOL, V163, P6748; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Rao KMK, 2001, J LEUKOCYTE BIOL, V69, P3; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SMITH MF, 1994, J IMMUNOL, V153, P3584; SMITH MF, 1992, J IMMUNOL, V149, P2000; Smith MF, 1998, J BIOL CHEM, V273, P24272, DOI 10.1074/jbc.273.37.24272; Stutz AM, 1999, J IMMUNOL, V163, P4383; Wang SW, 1999, INFLAMM RES, V48, P533, DOI 10.1007/s000110050499; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200	48	48	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17448	17456		10.1074/jbc.M111847200	http://dx.doi.org/10.1074/jbc.M111847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877429	hybrid, Green Accepted			2022-12-25	WOS:000175685100010
J	Gilchrist, D; Mykytka, B; Rexach, M				Gilchrist, D; Mykytka, B; Rexach, M			Accelerating the rate of disassembly of karyopherin center dot cargo complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; IMPORTIN-ALPHA; YEAST NUCLEOPORIN; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; EXPORT RECEPTOR; TRANSPORT; NUP2P; SIGNAL; CSE1P	Transport of macromolecules across the nuclear pore complex (NPC) occurs in seconds and involves assembly of a karyopherin-cargo complex and docking to the NPC, translocation of the complex across the NPC via interaction with nucleoporins (Nups), and dissociation of the complex in the nucleoplasm. To identify rate-limiting steps in the Kap95p.Kap60p-mediated nuclear import pathway of Saccharomyces cerevisiae, we reconstituted key intermediate complexes and measured their rates of dissociation and affinities of interaction. We found that a nuclear localization signal-containing protein (NLS-cargo) dissociates slowly from Kap60p monomers and Kap60p.Kap95p heterodimers with half-lives (t(1/2)) of 7 and 73 min, respectively; that Kap60p and Kap60p.NLS-cargo complexes dissociate slowly from Kap95p (t(1/2) = 36 and 73 min, respectively); and that Kap95p.Kap60p-NLS-cargo complexes and Kap95p.Kap60p heterodimers dissociate rapidly from the nucleoporin Nup1p (t(1/2) less than or equal to 21 s) and other Nups. A search for factors that accelerate disassembly of the long-lived intermediates revealed that Nup1p and Nup2p accelerate 16- and 19-fold the rate of dissociation of NLS-cargo from Kap60p.Kap95p heterodimers; that Gsp1p-GTP accelerates greater than or equal to 447-fold the rate of dissociation of Kap60p.NLS-cargo from Kap95p; and that Nup2p and the Cse1p-Gsp1p-GTP complex independently accelerate greater than or equal to 22- and greater than or equal to 39-fold the rate of dissociation of NLS-cargo from Kap60p. We suggest that Nup1p, Nup2p, Cse1p, and Gsp1p accelerate disassembly of Kap95p.Kap60p-NLS-cargo complexes by triggering allosteric mechanisms within Kaps that cause rapid release of binding partners. In that way, Nup1p, Nup2p, Cse1p, and Gsp1p may function as karyopherin release factors (or KaRFs) in the nuclear basket structure of the S. cerevisiae NPC.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Rexach, M (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.			Gilchrist, Daniel/0000-0003-1668-2790				AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; Booth JW, 1999, J BIOL CHEM, V274, P32360, DOI 10.1074/jbc.274.45.32360; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Denning D, 2001, J CELL BIOL, V154, P937, DOI 10.1083/jcb.200101007; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Hood JK, 2000, J CELL SCI, V113, P1471; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; Keminer O, 1999, P NATL ACAD SCI USA, V96, P11842, DOI 10.1073/pnas.96.21.11842; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805	35	99	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18161	18172		10.1074/jbc.M112306200	http://dx.doi.org/10.1074/jbc.M112306200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11867631	hybrid			2022-12-25	WOS:000175685100098
J	Eide, EJ; Vielhaber, EL; Hinz, WA; Virshup, DM				Eide, EJ; Vielhaber, EL; Hinz, WA; Virshup, DM			The circadian regulatory proteins BMAL1 and cryptochromes are substrates of casein kinase I epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA CLOCK GENE; DOUBLE-TIME; NUCLEAR ENTRY; PHOSPHORYLATION; PERIOD; TRANSCRIPTION; MECHANISMS; MUTATION; CLONING; RNAS	The serine/threonine protein kinase casein kinase I epsilon (CKIepsilon) is a key regulator of metazoan circadian rhythm. Genetic and biochemical data suggest that CKIepsilon binds to and phosphorylates the PERIOD proteins. However, the PERIOD proteins interact with a variety of circadian regulators, suggesting the possibility that CKIepsilon may interact with and phosphorylate additional clock components as well. We find that CRY1 and BMAL1 are phosphoproteins in cultured cells. Mammalian PERIOD proteins act as a scaffold with distinct domains that simultaneously bind CKIepsilon and mCRY1 and mCRY2 (mCRY). mCRY is phosphorylated by CKIepsilon only when both proteins are bound to mammalian PERIOD proteins. BMAL1 is also a substrate for CKIepsilon in vitro, and CKIepsilon kinase activity positively regulates BMAL1-dependent transcription from circadian promoters in reporter assays. We conclude that CKIepsilon phosphorylates multiple circadian substrates and may exert its effects on circadian rhythm in part by a direct effect on BMAL1-dependent transcription.	Univ Utah, Sch Med, Huntsman Canc Inst, Ctr Children, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Virshup, DM (corresponding author), Univ Utah, Sch Med, Huntsman Canc Inst, Ctr Children, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	david.virshup@hci.utah.edu	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NCI NIH HHS [P30CA42014, P30 CA042014, R01CA71074] Funding Source: Medline; NIGMS NIH HHS [R01 GM060387-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071074, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allada R, 2001, ANNU REV NEUROSCI, V24, P1091, DOI 10.1146/annurev.neuro.24.1.1091; Camacho F, 2001, FEBS LETT, V489, P159, DOI 10.1016/S0014-5793(00)02434-0; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Eide EJ, 2001, CHRONOBIOL INT, V18, P389, DOI 10.1081/CBI-100103963; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Ishida Y, 2001, J NEUROSCI RES, V64, P612, DOI 10.1002/jnr.1114; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Keesler GA, 2000, NEUROREPORT, V11, P951, DOI 10.1097/00001756-200004070-00011; Kloss B, 2001, NEURON, V30, P699, DOI 10.1016/S0896-6273(01)00320-8; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Miyazaki K, 2001, MOL CELL BIOL, V21, P6651, DOI 10.1128/MCB.21.19.6651-6659.2001; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Rothenfluh A, 2000, CURR BIOL, V10, P1399, DOI 10.1016/S0960-9822(00)00786-7; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Sanada K, 2002, J BIOL CHEM, V277, P267, DOI 10.1074/jbc.M107850200; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Suri V, 2000, J NEUROSCI, V20, P7547; Takano A, 2000, FEBS LETT, V477, P106, DOI 10.1016/S0014-5793(00)01755-5; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Vielhaber EL, 2001, J BIOL CHEM, V276, P45921, DOI 10.1074/jbc.M107726200; Yagita K, 2000, GENE DEV, V14, P1353	33	237	245	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17248	17254		10.1074/jbc.M111466200	http://dx.doi.org/10.1074/jbc.M111466200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875063	Green Accepted, hybrid			2022-12-25	WOS:000175564500119
J	Ignjatovic, T; Tan, FL; Brovkovych, V; Skidgel, RA; Erdos, EG				Ignjatovic, T; Tan, FL; Brovkovych, V; Skidgel, RA; Erdos, EG			Novel mode of action of angiotensin I converting enzyme inhibitors - Direct activation of bradykinin B-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL-INFARCTION; NITRIC-OXIDE; ACE-INHIBITORS; HUMAN B1; KININS; EXPRESSION; CLONING; HEART; POTENTIATION; SUPEROXIDE	Angiotensin I converting enzyme (kininase II; ACE) inhibitors are important therapeutic agents widely used for treatment in cardiovascular and renal diseases. They inhibit angiotensin II release and bradykinin inactivation; these actions do not explain completely the clinical benefits. We found that enalaprilat and other ACE inhibitors in nanomolar concentrations activate human bradykinin B-1 receptors directly in the absence of ACE and the B-1 agonist des-Arg(10)-Lys(1)-bradykinin. These inhibitors activate at the Zn2+-binding consensus sequence HEXXH (195-199) in B-1 which is present also in ACE but not in the B-2 receptor. Activation elevates [Ca2+](i) and releases NO from endothelial or transfected cells expressing the B-1 receptor but is blocked by Ca-EDTA, a B-1 receptor antagonist, the synthetic undecapeptide sequence (192-202) of B-1, and the mutagenesis of His(195) to Ala(195). Except for the B-1 antagonist, these agents and manipulations did not block activation by a peptide ligand. Thus, Zn2+ is essential for B-1 receptor activation by ACE inhibitors at the zinc-binding consensus sequence. Ischemia or cytokines induce abundant B-1 receptor expression. B-1 receptor activation by ACE inhibitors, a novel mode of action reported here first, can contribute to their therapeutic effects by releasing NO in the heart and to some side effects.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Erdos, EG (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, MC 868,835 S wolcott Ave,Room E403, Chicago, IL 60612 USA.				NHLBI NIH HHS [HL58118, HL36473] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058118, R01HL036473, R37HL036473] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agata J, 2000, HYPERTENSION, V36, P364, DOI 10.1161/01.HYP.36.3.364; AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bouchard JF, 1998, BRIT J PHARMACOL, V123, P413, DOI 10.1038/sj.bjp.0701619; Brovkovych V, 2001, HYPERTENSION, V37, P34, DOI 10.1161/01.HYP.37.1.34; CASTANO MEM, 2002, CIRCULATION, V105, P627; CHAHINE R, 1993, BRIT J PHARMACOL, V108, P318, DOI 10.1111/j.1476-5381.1993.tb12802.x; Duka I, 2001, CIRC RES, V88, P275, DOI 10.1161/01.RES.88.3.275; Erdos EG, 1999, TRENDS ENDOCRIN MET, V10, P223, DOI 10.1016/S1043-2760(99)00156-3; Erdos EG, 1997, KININ SYSTEM, P111; Fathy DB, 2000, MOL PHARMACOL, V57, P171; Fathy DB, 1998, J BIOL CHEM, V273, P12210, DOI 10.1074/jbc.273.20.12210; Gaudron P, 2000, AM J CARDIOL, V86, P139, DOI 10.1016/S0002-9149(00)00849-3; GAVRAS H, 1974, NEW ENGL J MED, V291, P817, DOI 10.1056/NEJM197410172911603; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Lever AF, 1998, LANCET, V352, P179, DOI 10.1016/S0140-6736(98)03228-0; LINZ W, 1995, PHARMACOL REV, V47, P25; Lonn EM, 2001, CIRCULATION, V103, P919; Marceau F, 1998, PHARMACOL REV, V50, P357; Marcic B, 2000, J BIOL CHEM, V275, P16110, DOI 10.1074/jbc.M909490199; McLean PG, 2000, CARDIOVASC RES, V48, P194, DOI 10.1016/S0008-6363(00)00184-X; Menard J, 2001, ADV PROTEIN CHEM, V56, P13; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Minshall RD, 1997, CIRC RES, V81, P848; ONDETTI MA, 1971, BIOCHEMISTRY-US, V10, P4033, DOI 10.1021/bi00798a004; PFEFFER M, 2001, ANGIOTENSIN CONVERTI, P219; PFEFFER MA, 1993, AM HEART J, V126, P789, DOI 10.1016/0002-8703(93)90931-X; Phagoo SB, 1999, MOL PHARMACOL, V56, P325, DOI 10.1124/mol.56.2.325; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; Schetz JA, 1999, J PHARMACOL EXP THER, V289, P956; Siebeck M, 1996, IMMUNOPHARMACOLOGY, V33, P81, DOI 10.1016/0162-3109(96)00060-4; Skidgel R.A., 1993, RENIN ANGIOTENSIN SY, V1, DOI DOI 10.1-10.10; SMITH JAM, 1995, MOL PHARMACOL, V47, P525; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STEWART JM, 1971, BIOCHEM PHARMACOL, V20, P1557, DOI 10.1016/0006-2952(71)90284-X; Tschope C, 2000, BRIT J PHARMACOL, V129, P1537, DOI 10.1038/sj.bjp.0703239; Vergnani L, 2000, CIRCULATION, V101, P1261, DOI 10.1161/01.CIR.101.11.1261; WEI L, 1992, J BIOL CHEM, V267, P13398; Wittstein IS, 2001, J AM COLL CARDIOL, V38, P429, DOI 10.1016/S0735-1097(01)01404-8; YANG HYT, 1971, J PHARMACOL EXP THER, V177, P291; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zahler S, 1999, IMMUNOPHARMACOLOGY, V44, P27, DOI 10.1016/S0162-3109(99)00108-3	44	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16847	16852		10.1074/jbc.M200355200	http://dx.doi.org/10.1074/jbc.M200355200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880373	hybrid			2022-12-25	WOS:000175564500067
J	Joly, N; Danot, O; Schlegel, A; Boos, W; Richet, E				Joly, N; Danot, O; Schlegel, A; Boos, W; Richet, E			The Aes protein directly controls the activity of MalT, the central transcriptional activator of the Escherichia coli maltose regulon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; ATP-BINDING; MUTATIONS; SYSTEM; OPERON; ENZYME; TRANSPORT; REGULATOR; ESTERASE; GLUCOSE	MalT, the transcriptional activator of the maltose regulon from Escherichia coli, is the prototype of a new family of transcription factors. Its activity is controlled by multiple regulatory signals. ATP and maltotriose (the inducer) are two effectors of the activator that positively control its multimerization, a critical step in promoter binding. In addition, MalK, the ABC component of the maltodextrin transport system, and the two enzymes MalY and Aes down-regulate MalT activity in vivo. By using a biochemical approach, we demonstrate here that (i) Aes controls MalT activity through direct protein-protein interaction, (ii) Aes competes with maltotriose for MalT binding, (iii) ATP and ADP differentially affect the competition between Aes and the inducer, and (iv) part, if not all, of the Aes binding site is located in DT1, the N-terminal domain of the activator, which also contains the ATP binding site. All of these characteristics point toward an identical mode of action for MalY and Aes. However, we have identified an amino acid substitution in MalT that suppresses MalT inhibition by Aes without interfering with its inhibition by MalY, suggesting that the binding sites of the two inhibitory proteins do not coincide. The differential effects of ATP and ADP on the competition between the inducer and Aes (or MalY) suggest that the ATPase activity displayed by MalT plays a role in the negative control of its activity.	Inst Pasteur, Unite Genet Mol, CNRS, FRE 2364, F-75724 Paris 15, France; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Konstanz	Richet, E (corresponding author), Inst Pasteur, Unite Genet Mol, CNRS, FRE 2364, 25 Rue Dr Roux, F-75724 Paris 15, France.		Joly, Nicolas/H-6851-2018	Joly, Nicolas/0000-0003-2731-3827; Danot, Olivier/0000-0003-0002-7097				Bohm A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/jbc.M107905200; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; BREMER E, 1985, J BACTERIOL, V162, P1092, DOI 10.1128/JB.162.3.1092-1099.1985; CLAUSEN T, 1999, EMBO J; Danot O, 1996, J MOL BIOL, V262, P1, DOI 10.1006/jmbi.1996.0493; DANOT O, 1994, MOL MICROBIOL, V14, P335, DOI 10.1111/j.1365-2958.1994.tb01294.x; Danot O, 2001, P NATL ACAD SCI USA, V98, P435, DOI 10.1073/pnas.98.2.435; DARDONVILLE B, 1990, J BACTERIOL, V172, P1846, DOI 10.1128/jb.172.4.1846-1852.1990; De Schrijver A, 1999, MICROBIOL-UK, V145, P1287, DOI 10.1099/13500872-145-6-1287; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EHRMANN M, 1987, J BACTERIOL, V169, P3539, DOI 10.1128/jb.169.8.3539-3545.1987; HOFNUNG M, 1974, J BACTERIOL, V117, P40, DOI 10.1128/JB.117.1.40-47.1974; Kanaya S, 1998, BIOCHEM J, V332, P75, DOI 10.1042/bj3320075; KUHNAU S, 1991, J BACTERIOL, V173, P2180; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; Miller J.H., 1972, EXPT MOL GENETICS; Notley-McRobb L, 1999, ENVIRON MICROBIOL, V1, P45, DOI 10.1046/j.1462-2920.1999.00003.x; Panagiotidis CH, 1998, MOL MICROBIOL, V30, P535, DOI 10.1046/j.1365-2958.1998.01084.x; Peist R, 1997, J BACTERIOL, V179, P7679, DOI 10.1128/jb.179.24.7679-7686.1997; RAIBAUD O, 1985, J BACTERIOL, V161, P1201, DOI 10.1128/JB.161.3.1201-1208.1985; REIDL J, 1991, J BACTERIOL, V173, P4862, DOI 10.1128/jb.173.15.4862-4876.1991; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHLEGEL A, 2002, IN PRESS J BACTERIOL; Schreiber V, 1999, J BIOL CHEM, V274, P33220, DOI 10.1074/jbc.274.47.33220; Schreiber V, 2000, MOL MICROBIOL, V35, P765, DOI 10.1046/j.1365-2958.2000.01747.x; SEWITZ S, 1998, THESIS U KONSTANZ KO; Steegborn C, 2001, STRUCTURE, V9, P1051, DOI 10.1016/S0969-2126(01)00665-7; Valdez F, 1999, MICROBIOL-UK, V145, P2365, DOI 10.1099/00221287-145-9-2365; VIDALINGIGLIARDI D, 1993, J BIOL CHEM, V268, P24527; ZDYCH E, 1995, J BACTERIOL, V177, P5035, DOI 10.1128/jb.177.17.5035-5039.1995	33	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16606	16613		10.1074/jbc.M200991200	http://dx.doi.org/10.1074/jbc.M200991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867639	hybrid			2022-12-25	WOS:000175564500037
J	Nonato, MC; Widom, J; Clardy, J				Nonato, MC; Widom, J; Clardy, J			Crystal structure of the N-terminal segment of human eukaryotic translation initiation factor 2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; BINDING DOMAIN; BETA-SUBUNIT; FACTOR 5A; RNA; REFINEMENT; EXPRESSION; MECHANISM; SEQUENCES; ALIGNMENT	Eukaryotic translation initiation factor 2alpha (eIF2alpha) is a member of the eIF2 heterotrimeric complex that binds and delivers Met-tRNA(i)(Met) to the 40 S ribosomal subunit in a GTP-dependent manner. Phosphorylation/dephosphorylation of eIF2alpha at Ser-51 is the major regulator of protein synthesis in eukaryotic cells. Here, we report the first structural analysis on eIF2, the three-dimensional structure of a 22-kDa N-terminal portion of human eIF2alpha by x-ray diffraction at 1.9 Angstrom resolution. This structure contains two major domains. The N terminus is a beta-barrel with five antiparallel beta-strands in an oligonucleotide binding domain (OB domain) fold. The phosphorylation site (Ser-51) is on the loop connecting beta3 and beta4 in the OB domain. A helical domain follows the OB domain, and the first helix has extensive interactions, including a disulfide bridge, to fix its orientation with respect to the OB domain. The two domains meet along a negatively charged groove with highly conserved residues, indicating a likely site for protein-protein interaction.	Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University	Clardy, J (corresponding author), Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	jcc12@cornell.edu	Nonato, Maria Cristina C/C-5659-2012	Nonato, Maria Cristina C/0000-0002-4916-1505	NCI NIH HHS [CA59021] Funding Source: Medline; NCRR NIH HHS [RR-01646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059021] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ANTHONY DD, 1990, ARCH BIOCHEM BIOPHYS, V281, P157, DOI 10.1016/0003-9861(90)90426-Y; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bellizzi JJ, 1999, STRUCTURE, V7, pR263, DOI 10.1016/S0969-2126(00)80020-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DORRIS DR, 1995, EMBO J, V14, P2239, DOI 10.1002/j.1460-2075.1995.tb07218.x; Erickson FL, 1996, EMBO J, V15, P6311, DOI 10.1002/j.1460-2075.1996.tb01021.x; GASPAR NJ, 1994, J BIOL CHEM, V269, P3415; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim KK, 1998, P NATL ACAD SCI USA, V95, P10419, DOI 10.1073/pnas.95.18.10419; Kimball SR, 1998, J BIOL CHEM, V273, P12841, DOI 10.1074/jbc.273.21.12841; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laurino JP, 1999, MOL CELL BIOL, V19, P173; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nika J, 2001, J BIOL CHEM, V276, P1051, DOI 10.1074/jbc.M007398200; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; Peat TS, 1998, STRUCT FOLD DES, V6, P1207, DOI 10.1016/S0969-2126(98)00120-8; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; Sette M, 1997, EMBO J, V16, P1436, DOI 10.1093/emboj/16.6.1436; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thompson GM, 2000, BIOCHEM J, V347, P703, DOI 10.1042/0264-6021:3470703; TRACHSEL H, 1996, TRANSLATIONAL CONTRO, P113; WESTERMANN P, 1980, NUCLEIC ACIDS RES, V8, P3065, DOI 10.1093/nar/8.14.3065	47	52	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17057	17061		10.1074/jbc.M111804200	http://dx.doi.org/10.1074/jbc.M111804200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859078	hybrid			2022-12-25	WOS:000175564500095
J	Wilkinson, SM; Meyer, DJ; Taylor, MC; Bromley, EV; Miles, MA; Kelly, JM				Wilkinson, SM; Meyer, DJ; Taylor, MC; Bromley, EV; Miles, MA; Kelly, JM			The Trypanosoma cruzi enzyme TcGPXI is a glycosomal peroxidase and can be linked to trypanothione reduction by glutathione or tryparedoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; CRITHIDIA-FASCICULATA; MOLECULAR CHARACTERIZATION; PEROXIREDOXIN FAMILY; ANTIPARASITIC DRUGS; LEISHMANIA-DONOVANI; PARASITIC PROTOZOA; HYDROGEN-PEROXIDE; CANDIDA-BOIDINII; OXIDATIVE STRESS	Trypanosoma cruzi glutathione-dependent peroxidase I (TcGPXI) can reduce fatty acid, phospholipid, and short chain organic hydroperoxides utilizing a novel redox cycle in which enzyme activity is linked to the reduction of trypanothione, a parasite-specific thiol, by glutathione. Here we show that TcGPXI activity can also be linked to trypanothione reduction by an alternative pathway involving the thioredoxin-like protein tryparedoxin. The presence of this new pathway was first detected using dialyzed soluble fractions of parasite extract. Tryparedoxin was identified as the intermediate molecule following purification, sequence analysis, antibody studies, and reconstitution of the redox cycle in vitro. The system can be readily saturated by trypanothione, the rate-limiting step being the interaction of trypanothione with the tryparedoxin. Both tryparedoxin and TcGPXI operate by a ping-pong mechanism. Overexpression of TcGPXI in transfected parasites confers increased resistance to exogenous hydroperoxides. TcGPXI contains a carboxyl-terminal tripeptide (ARI) that could act as a targeting signal for the glycosome, a kinetoplastid-specific organelle. Using immunofluorescence, tagged fluorescent proteins, and biochemical fractionation, we have demonstrated that TcGPXI is localized to both the glycosome and the cytosol. The ability of TcGPXI to use alternative electron donors may reflect their availability at the corresponding subcellular sites.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Wilkinson, SM (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.			Taylor, Martin/0000-0003-4147-0693				BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BLATTNER J, 1992, J CELL BIOL, V119, P1129, DOI 10.1083/jcb.119.5.1129; BOVERIS A, 1980, BIOCHEM J, V188, P643, DOI 10.1042/bj1880643; BOVERIS A, 1977, EXPERIENTIA, V33, P1306, DOI 10.1007/BF01920148; CANNATA JJB, 1982, MOL BIOCHEM PARASIT, V6, P151, DOI 10.1016/0166-6851(82)90074-3; CARNIERI EGS, 1993, MOL BIOCHEM PARASIT, V61, P79, DOI 10.1016/0166-6851(93)90160-Y; DOCAMPO R, 1990, CHEM-BIOL INTERACT, V73, P1, DOI 10.1016/0009-2797(90)90106-W; Duffieux F, 2000, J BIOL CHEM, V275, P27559; EASTERBY JS, 1982, METHOD ENZYMOL, V90, P11; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; GIBSON WC, 1986, EMBO J, V5, P1299, DOI 10.1002/j.1460-2075.1986.tb04359.x; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; GOODMAN JM, 1990, J CELL SCI, V97, P193; HENDERSON GB, 1987, PARASITOL TODAY, V3, P312, DOI 10.1016/0169-4758(87)90190-6; HOLGREN A, 1989, J BIOL CHEM, V264, P13963; Horiguchi H, 2001, J BIOL CHEM, V276, P14279, DOI 10.1074/jbc.M011661200; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; Kelly J M, 1995, Methods Mol Biol, V47, P349; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KELLY JM, 1993, EUR J BIOCHEM, V218, P29, DOI 10.1111/j.1432-1033.1993.tb18348.x; KELLY JM, 1993, PROTOCOLS MOL PARASI; KENDALL G, 1990, EMBO J, V9, P2751, DOI 10.1002/j.1460-2075.1990.tb07462.x; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; Krauth-Siegel RL, 1999, PARASITOL TODAY, V15, P404, DOI 10.1016/S0169-4758(99)01516-1; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Lopez JA, 2000, FREE RADICAL BIO MED, V28, P767, DOI 10.1016/S0891-5849(00)00159-3; MartinezCalvillo S, 1997, GENE, V199, P71, DOI 10.1016/S0378-1119(97)00348-X; Mehlotra RK, 1996, CRIT REV MICROBIOL, V22, P295, DOI 10.3109/10408419609105484; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; MORENO SNJ, 1984, J BIOL CHEM, V259, P6298; Muller S, 2001, TRENDS PARASITOL, V17, P242, DOI 10.1016/S1471-4922(01)01908-0; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; OPPERDOES FR, 1994, BIOCHIMIC PARIS, V75, P231; Parsons M, 2001, MOL BIOCHEM PARASIT, V115, P19, DOI 10.1016/S0166-6851(01)00261-4; RUTTER GA, 1989, BIOCHEM J, V263, P445, DOI 10.1042/bj2630445; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Shih S, 1998, J BIOL CHEM, V273, P1534, DOI 10.1074/jbc.273.3.1534; Shih S, 1998, MOL BIOCHEM PARASIT, V92, P367, DOI 10.1016/S0166-6851(98)00007-3; SINGH AK, 1994, ARCH BIOCHEM BIOPHYS, V315, P331, DOI 10.1006/abbi.1994.1508; Singh I, 1996, ANN NY ACAD SCI, V804, P612, DOI 10.1111/j.1749-6632.1996.tb18648.x; SOMMER JM, 1994, ANNU REV MICROBIOL, V48, P105, DOI 10.1146/annurev.mi.48.100194.000541; Steinert P, 1999, FREE RADICAL BIO MED, V26, P844, DOI 10.1016/S0891-5849(98)00263-9; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Sztajer H, 2001, J BIOL CHEM, V276, P7397, DOI 10.1074/jbc.M008631200; Tetaud E, 1998, MOL BIOCHEM PARASIT, V96, P111, DOI 10.1016/S0166-6851(98)00120-0; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714; Viode C, 1999, BIOCHEM PHARMACOL, V57, P549, DOI 10.1016/S0006-2952(98)00324-4; WALSH C, 1991, TRENDS BIOCHEM SCI, V16, P305, DOI 10.1016/0968-0004(91)90124-E; Wilkinson SR, 2000, J BIOL CHEM, V275, P8220, DOI 10.1074/jbc.275.11.8220; Wilkinson SR, 2000, BIOCHEM J, V352, P755, DOI 10.1042/0264-6021:3520755; WILKINSON SR, 2002, MOL MECH PATHOGENESI; Yamashita H, 1999, J BIOL CHEM, V274, P29897, DOI 10.1074/jbc.274.42.29897	57	115	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17062	17071		10.1074/jbc.M111126200	http://dx.doi.org/10.1074/jbc.M111126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11842085	hybrid			2022-12-25	WOS:000175564500096
J	Xu, HP; Ito, T; Tawada, A; Maeda, H; Yamanokuchi, H; Isahara, K; Yoshida, K; Uchiyama, Y; Asari, A				Xu, HP; Ito, T; Tawada, A; Maeda, H; Yamanokuchi, H; Isahara, K; Yoshida, K; Uchiyama, Y; Asari, A			Effect of hyaluronan oligosaccharides on the expression of heat shock protein 72	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; STRESS-INDUCED APOPTOSIS; GENE-TRANSCRIPTION; FACTOR-I; PROTEIN; CELLS; ACID; OSTEOARTHRITIS; ACTIVATION; OLIGOMERIZATION	We have previously shown that intraarticular treatment with a hyaluronan (HA) preparation (840 kDa), HA84, up-regulates heat shock protein 72 (Hsp72) expression and suppresses degeneration of synovial cells in an arthritis model. In that study, the RA84 administered was degraded into HA oligosaccharides in the synovial tissue, suggesting that HA84 or degradation products of RA may up-regulate Hsp72 expression. Thus, in the present study, we examined the effects of HA of various molecular sizes on Hsp72 expression and cell death in stressed cells. Western blotting analysis showed that treatment of K562 cells with HA tetrasaccharides up-regulated Hsp72 expression after exposure to hyperthermia. On the other hand, treatment of the cells with HA of other sizes (di-, hexa-, deca-, dodecasaccharides), HA84, or tetrasaccharides of keratan sulfate did not elicit any change in expression of the Hsp72 protein. Treatment of the cells with tetrasaccharides of HA up-regulated not only expression of the Hsp72 protein but also Hsp72 mRNA expression and enhanced activation of HSF1, a transcription factor controlling Hsp72 expression, after exposure to hyperthermia. Because the level of Hsp72 protein was not affected by tetrasaccharides of RA when the K562 cells were kept at 37 degreesC without any stress, it is evident that tetrasaccharides of HA did not act as a stress factor. In addition, tetrasaccharides of HA suppressed cell death in the case of K562 cells exposed to hyperthermia and of PC12 cells under serum deprivation. These results suggest that a certain size of oligosaccharides, i.e. the tetrasaccharides of HA, up-regulates Hsp72 expression by enhancing the activation of HSF1 under stress conditions and suppresses cell death.	Seikagaku Corp, Tokyo 2070021, Japan; Osaka Univ, Sch Med, Dept Anat & Cell Biol, Suita, Osaka 5650871, Japan	Seikagaku Corporation; Osaka University	Asari, A (corresponding author), Seikagaku Corp, Tateno 3-1253, Tokyo 2070021, Japan.	asari@seikagaku.co.jp	Xu, Heping/A-4430-2008	Xu, Heping/0000-0003-4000-931X				AMICI C, 1995, CANCER RES, V55, P4452; Asari A, 1998, ARCH HISTOL CYTOL, V61, P125, DOI 10.1679/aohc.61.125; Asari A, 1996, OSTEOARTHR CARTILAGE, V4, P213, DOI 10.1016/S1063-4584(96)80018-5; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Deguine V, 1998, INT J BIOL MACROMOL, V22, P17, DOI 10.1016/S0141-8130(97)00084-6; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; INOUE Y, 1985, CARBOHYD RES, V141, P99, DOI 10.1016/S0008-6215(00)90759-6; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KIRINO T, 1991, J CEREBR BLOOD F MET, V11, P299, DOI 10.1038/jcbfm.1991.62; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; Kubota M, 2000, EUR J MASS SPECTROM, V6, P193, DOI 10.1255/ejms.338; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nagaya H, 1999, ANN RHEUM DIS, V58, P186, DOI 10.1136/ard.58.3.186; Neumann A, 1999, FEBS LETT, V453, P283, DOI 10.1016/S0014-5793(99)00731-0; Noble PW, 1998, WENN GR INT, V72, P219; Ohsawa Y, 1998, ARCH HISTOL CYTOL, V61, P395, DOI 10.1679/aohc.61.395; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Schrager HM, 1998, J CLIN INVEST, V101, P1708, DOI 10.1172/JCI2121; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; Takahashi K, 1999, OSTEOARTHR CARTILAGE, V7, P182, DOI 10.1053/joca.1998.0207; WEST DC, 1989, CIBA F SYMP, V143, P187; West DC, 1998, WENN GR INT, V72, P227; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094	31	91	98	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17308	17314		10.1074/jbc.M112371200	http://dx.doi.org/10.1074/jbc.M112371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864979	hybrid			2022-12-25	WOS:000175564500126
J	Baader, M; Gnerre, C; Stegeman, JJ; Meyer, UA				Baader, M; Gnerre, C; Stegeman, JJ; Meyer, UA			Transcriptional activation of cytochrome P450CYP2C45 by drugs is mediated by the chicken xenobiotic receptor (CXR) interacting with a phenobarbital response enhancer unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ANDROSTANE RECEPTOR; ORPHAN NUCLEAR RECEPTOR; PREGNANE-X RECEPTOR; GENE; IDENTIFICATION; INDUCTION; EXPRESSION; ELEMENT; CYP2H1; UPDATE	Cytochromes P450 (CYP)-2C enzymes fulfill an important role in xenobiotic metabolism and therefore have extensively been studied in rodents and humans. However, no CYP2C genes have been described in avian species to date. In this paper, we report the cloning, functional analysis, and regulation of chicken CYP2C45. The sequence shares up to 58% amino acid identity with CYP2Cs in other species. The overexpression of CYP2C45 in chicken hepatoma cells leghorn male hepatoma (LMH) led to increased scoparone metabolism. CYP2C45 regulation was studied in LMH cells at the mRNA level and in reporter gene assays using a construct containing 2.6 kb of its 5'-flanking region. Exposure of LMH cells to phenobarbital or metyrapone led to a 95- or 210-fold increase in CYP2C45 mRNA and a 140- or 290-fold increase in reporter gene expression, respectively. A phenobarbital response enhancer unit (PBRU) of 239 bp containing a DR-4 nuclear receptor binding site was identified within the 2.6-kb fragment. Site-specific mutation of the DR-4 revealed the requirement of this motif for CYP2C45 induction by drugs. The chicken xenobiotic receptor CXR interacted with the PBRU in electromobility shift and transactivation assays. Furthermore, the related nuclear receptors, mouse PXR and mouse CAR, transactivated this enhancer element, suggesting evolutionary conservation of nuclear receptor-DNA interactions in CYP2C induction.	Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, CH-4056 Basel, Switzerland; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	University of Basel; Woods Hole Oceanographic Institution	Meyer, UA (corresponding author), Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.	Urs-A.Meyer@unibas.ch		Stegeman, John/0000-0001-8204-5357	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007381] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42 ES07381] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Czerniak R, 2001, INT J TOXICOL, V20, P161, DOI 10.1080/109158101317097746; Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242; Handschin C, 2000, J BIOL CHEM, V275, P13362, DOI 10.1074/jbc.275.18.13362; Handschin C, 2001, MOL PHARMACOL, V60, P681; Handschin C, 2001, MOL ENDOCRINOL, V15, P1571, DOI 10.1210/me.15.9.1571; Handschin C, 2000, P NATL ACAD SCI USA, V97, P10769, DOI 10.1073/pnas.97.20.10769; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; IOANNIDES C, 1996, HUMAN CYP2C, P162; JAISWAL AK, 1990, NUCLEIC ACIDS RES, V18, P4237, DOI 10.1093/nar/18.14.4237; Kemper B, 1998, PROG NUCLEIC ACID RE, V61, P25, DOI 10.1016/S0079-6603(08)60824-7; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Klose TS, 1999, J BIOCHEM MOL TOXIC, V13, P289, DOI 10.1002/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO;2-N; LeCluyse EL, 2001, CHEM-BIOL INTERACT, V134, P283, DOI 10.1016/S0009-2797(01)00163-6; LEVY RH, 1995, EPILEPSIA, V36, pS8, DOI 10.1111/j.1528-1157.1995.tb06007.x; Masahiko N, 2000, EUR J PHARM SCI, V11, P259, DOI 10.1016/S0928-0987(00)00112-3; McGinnity DF, 2000, DRUG METAB DISPOS, V28, P1327; Meyer RP, 2001, BIOCHEM BIOPH RES CO, V285, P32, DOI 10.1006/bbrc.2001.5111; Michalets EL, 1998, PHARMACOTHERAPY, V18, P84; MOREL F, 1990, EUR J BIOCHEM, V191, P437, DOI 10.1111/j.1432-1033.1990.tb19140.x; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Okey AB, 1992, PHARMACOGENETICS DRU, P549; Ourlin JC, 2000, ARCH BIOCHEM BIOPHYS, V373, P375, DOI 10.1006/abbi.1999.1566; Pereira TM, 1998, DNA CELL BIOL, V17, P39, DOI 10.1089/dna.1998.17.39; Quattrochi LC, 2001, DRUG METAB DISPOS, V29, P615; RETTIE AE, 1992, CHEM RES TOXICOL, V5, P54, DOI 10.1021/tx00025a009; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Warrington JS, 2000, DRUG METAB DISPOS, V28, P392; YASUMORI T, 1993, PHARMACOGENETICS, V3, P291, DOI 10.1097/00008571-199312000-00003	34	29	30	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15647	15653		10.1074/jbc.M109882200	http://dx.doi.org/10.1074/jbc.M109882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867618	hybrid			2022-12-25	WOS:000175510400058
J	Budinger, GRS; Tso, M; McClintock, DS; Dean, DA; Sznajder, JI; Chandel, NS				Budinger, GRS; Tso, M; McClintock, DS; Dean, DA; Sznajder, JI; Chandel, NS			Hyperoxia-induced apoptosis does not require mitochondrial reactive oxygen species and is regulated by Bcl-2 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED LUNG INJURY; SUPEROXIDE-DISMUTASE; CELL-DEATH; ELECTRON-TRANSPORT; TRANSGENIC MICE; CYTOCHROME-C; GENE-EXPRESSION; FAMILY MEMBERS; DNA-DAMAGE; RAT LUNGS	Exposure of animals to hyperoxia results in lung injury that is characterized by apoptosis and necrosis of the alveolar epithelium and endothelium. The mechanism by which hyperoxia results in cell death, however, remains unclear. We sought to test the hypothesis that exposure to hyperoxia causes mitochondria-dependent apoptosis that requires the generation of reactive oxygen species from mitochondrial electron transport. Rat1a cells exposed to hyperoxia underwent apoptosis characterized by the release of cytochrome c, activation of caspase-9, and nuclear fragmentation that was prevented by the overexpression of Bcl-X-L. Murine embryonic fibroblasts from bax(-/-) bak(-/-) mice were resistant to hyperoxia-induced cell death. The administration of the antioxidants manganese (III) tetrakis (4-benzoic acid) porphyrin, ebselen, and N-acetylcysteine failed to prevent cell death following exposure to hyperoxia. Human fibrosarcoma cells (HT1080) lacking mitochondrial DNA (rho(0) cells) that failed to generate reactive oxygen species during exposure to hyperoxia were not protected against cell death following exposure to hyperoxia. We conclude that exposure to hyperoxia results in apoptosis that requires Bax or Bak and can be prevented by the overexpression of Bcl-X-L. The mitochondrial generation of reactive oxygen species is not required for cell death following exposure to hyperoxia.	Northwestern Univ, Div Pulm & Crit Care Med, Chicago, IL 60611 USA	Northwestern University	Budinger, GRS (corresponding author), Northwestern Univ, Div Pulm & Crit Care Med, 303 E Chicago Ave,Tarry 14-707, Chicago, IL 60611 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060472] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67835-01] Funding Source: Medline; NIGMS NIH HHS [GM60472] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Barazzone C, 2000, AM J RESP CELL MOL, V22, P517, DOI 10.1165/ajrcmb.22.5.f180; Barazzone C, 1998, AM J RESP CELL MOL, V19, P573, DOI 10.1165/ajrcmb.19.4.3173; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; DEL PL, 1997, SCIENCE, V278, P687; Folz RJ, 1999, J CLIN INVEST, V103, P1055, DOI 10.1172/JCI3816; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lu YB, 2001, J EXP MED, V193, P545, DOI 10.1084/jem.193.4.545; McClintock DS, 2002, MOL CELL BIOL, V22, P94, DOI 10.1128/MCB.22.1.94-104.2002; O'Reilly MA, 2001, AM J PHYSIOL-LUNG C, V281, pL291, DOI 10.1152/ajplung.2001.281.2.L291; O'Reilly MA, 2000, LAB INVEST, V80, P1845, DOI 10.1038/labinvest.3780195; OLIVERA WG, 1995, AM J RESP CRIT CARE, V152, P1229, DOI 10.1164/ajrccm.152.4.7551375; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Porras A, 1999, J VIROL, V73, P3102; SANDERS SP, 1993, J CLIN INVEST, V91, P46, DOI 10.1172/JCI116198; Senturker S, 2002, ARCH BIOCHEM BIOPHYS, V397, P262, DOI 10.1006/abbi.2001.2681; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TLSTY T, 1995, METHOD ENZYMOL, V254, P125; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WHITE CW, 1991, J CLIN INVEST, V87, P2162, DOI 10.1172/JCI115249; WISPE JR, 1992, J BIOL CHEM, V267, P23937; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323	40	84	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15654	15660		10.1074/jbc.M109317200	http://dx.doi.org/10.1074/jbc.M109317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877388	hybrid			2022-12-25	WOS:000175510400059
J	de Kreij, A; van den Burg, B; Venema, G; Vriend, G; Eijsink, VGH; Nielsen, JE				de Kreij, A; van den Burg, B; Venema, G; Vriend, G; Eijsink, VGH; Nielsen, JE			The effects of modifying the surface charge on the catalytic activity of a thermolysin-like protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS; NEUTRAL PROTEASE; 3-DIMENSIONAL STRUCTURE; SUBSTRATE-SPECIFICITY; TRANSITION-STATE; AMINO-ACID; SITE; STABILITY; SUBTILISIN; ENZYME	The impact of long range electrostatic interactions on catalysis in the thermolysin-like protease from Bacillus stearothermophilus was studied by analyzing the effects of inserting or removing charges on the protein surface. Various mutations were introduced at six different positions, and double-mutant cycle analysis was used to study the extent to which mutational effects were interdependent. The effects of single point mutations on the k(cat)/K-m were non-additive, even in cases where the point mutations were located 10, or more from the active site Zn2+ and separated from each other by up to 25 Angstrom. This shows that catalysis is affected by large electrostatic networks that involve major parts of the enzyme. The interdependence of mutations at positions as much as 25 Angstrom apart in space also indicates that other effects, such as active site dynamics, play an important role in determining active site electrostatics. Several mutations yielded a significant increase in the activity, the most active (quadruple) mutant being almost four times as active as the wild type. In some cases the shape of the pH-activity profile was changed significantly. Remarkably, large changes in the pH-optimum were not observed.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9751 NN Haren, Netherlands; Catholic Univ Nijmegen, Ctr Mol & Biomol Informat, NL-6525 ED Nijmegen, Netherlands; Agr Univ Norway, Dept Chem & Biotechnol, N-1432 As, Norway; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Groningen; Radboud University Nijmegen; Norwegian University of Life Sciences; European Molecular Biology Laboratory (EMBL)	Venema, G (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Genet, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Vriend, G./H-8112-2014; Vriend, Gert/D-6730-2011	Nielsen, Jens Erik/0000-0002-2831-7718				Albeck S, 2000, J MOL BIOL, V298, P503, DOI 10.1006/jmbi.2000.3656; Albeck S, 1999, BIOCHEMISTRY-US, V38, P11, DOI 10.1021/bi981772z; Banbula A, 1998, STRUCTURE, V6, P1185, DOI 10.1016/S0969-2126(98)00118-X; BEAUMONT A, 1998, HDB PROTEOLYTIC ENZY, P350; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; de Kreij A, 2001, EUR J BIOCHEM, V268, P4985, DOI 10.1046/j.0014-2956.2001.02434.x; EIJSINK VGH, 1995, NAT STRUCT BIOL, V2, P374, DOI 10.1038/nsb0595-374; EIJSINK VGH, 1990, PROTEIN ENG, V4, P99, DOI 10.1093/protein/4.1.99; FEDER J, 1968, BIOCHEMISTRY-US, V6, P2088; Fersht A, 1998, STRUCTURE MECH PROTE, P103; FERSHT AR, 1992, J MOL BIOL, V224, P771, DOI 10.1016/0022-2836(92)90561-W; FUJII M, 1983, J BACTERIOL, V154, P831, DOI 10.1128/JB.154.2.831-837.1983; Gaucher JF, 1999, BIOCHEMISTRY-US, V38, P12569, DOI 10.1021/bi991043z; GRAYCAR TP, 1992, ANN NY ACAD SCI, V673, P70; HANGAUER DG, 1984, BIOCHEMISTRY-US, V23, P5730, DOI 10.1021/bi00319a011; HARDY F, 1993, FEBS LETT, V317, P89, DOI 10.1016/0014-5793(93)81497-N; HAUSRATH AC, 1994, J BIOL CHEM, V269, P18839; Hernandez G, 2000, P NATL ACAD SCI USA, V97, P3166, DOI 10.1073/pnas.040569697; HOLMES MA, 1983, BIOCHEMISTRY-US, V22, P236, DOI 10.1021/bi00270a034; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P13909, DOI 10.1021/bi00213a021; Jin YH, 1998, BIOORG MED CHEM LETT, V8, P3515, DOI 10.1016/S0960-894X(98)00643-X; KESTER WR, 1977, BIOCHEMISTRY-US, V16, P2506, DOI 10.1021/bi00630a030; KIDOKORO S, 1995, FEBS LETT, V367, P73, DOI 10.1016/0014-5793(95)00537-J; Mansfeld J, 1997, J BIOL CHEM, V272, P11152, DOI 10.1074/jbc.272.17.11152; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Mei HC, 1998, PROTEIN ENG, V11, P109, DOI 10.1093/protein/11.2.109; MOCK WL, 1994, BIOCHEM J, V302, P57, DOI 10.1042/bj3020057; Mock WL, 1996, BIOCHEMISTRY-US, V35, P7369, DOI 10.1021/bi952827p; MOSIMANN S, 1995, PROTEINS, V23, P301, DOI 10.1002/prot.340230305; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Nielsen JE, 1999, PROTEIN ENG, V12, P657, DOI 10.1093/protein/12.8.657; Nielsen JE, 1999, EUR J BIOCHEM, V264, P816, DOI 10.1046/j.1432-1327.1999.00664.x; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; RUSSELL AJ, 1987, J MOL BIOL, V193, P803, DOI 10.1016/0022-2836(87)90360-3; STARK W, 1992, FEBS EUR J BIOCH, V984, P1; THAYER MM, 1991, J BIOL CHEM, V266, P2864; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; VANDENBURG B, 1989, J BIOCHEM BIOPH METH, V18, P209, DOI 10.1016/0165-022X(89)90005-5; Veltman OR, 1998, BIOCHEMISTRY-US, V37, P5305, DOI 10.1021/bi972374j; Veltman OR, 1997, FEBS LETT, V405, P241, DOI 10.1016/S0014-5793(97)00193-2; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; VRIEND G, 1993, J COMPUT AID MOL DES, V7, P367, DOI 10.1007/BF02337558; Vriend G, 1998, J BIOL CHEM, V273, P35074, DOI 10.1074/jbc.273.52.35074; WEAVER LH, 1977, J MOL BIOL, V114, P119, DOI 10.1016/0022-2836(77)90286-8; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Zhao HM, 1999, PROTEIN ENG, V12, P47, DOI 10.1093/protein/12.1.47	47	42	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15432	15438		10.1074/jbc.M200807200	http://dx.doi.org/10.1074/jbc.M200807200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859085	Green Published, hybrid			2022-12-25	WOS:000175510400029
J	Ng, KKS; Kolatkar, AR; Park-Snyder, S; Feinberg, H; Clark, DA; Drickamer, K; Weis, WI				Ng, KKS; Kolatkar, AR; Park-Snyder, S; Feinberg, H; Clark, DA; Drickamer, K; Weis, WI			Orientation of bound ligands in mannose-binding proteins - Implications for multivalent ligand recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; CRYSTAL-STRUCTURES; SITE ARCHITECTURE; SERUM-TYPE; COMPLEMENT; OLIGOSACCHARIDE; DIFFERENCE; HOMOLOGY; DOMAINS; SYSTEM	Mannose-binding proteins (AMPs) are C-type animal lectins that recognize high mannose oligosaccharides on pathogenic cell surfaces. MBPs bind to their carbohydrate ligands by forming a series of Ca2+ coordination and hydrogen bonds with two hydroxyl groups equivalent to the 3- and 4-OH of mannose. In this work, the determinants of the orientation of sugars bound to rat serum and liver MBPs (AMP-A and MBP-C) have been systematically investigated. The crystal structures of MBP-A soaked with monosaccharides and disaccharides and also the structure of the MBP-A trimer cross-linked by a high mannose asparaginyl oligosaccharide reveal that monosaccharides or alpha1-6-linked mannose bind to MBP-A in one orientation, whereas alpha1-2- or alpha1-3-linked mannose binds in an orientation rotated 180degrees around a local symmetry axis relating the 3- and 4-OH groups. In contrast, a similar set of ligands all bind to AMP-C in a single orientation. The mutation of MEP-A His(189) to its MBP-C equivalent, valine, causes Manalpha1-3Man to bind in a mixture of orientations. These data combined with modeling indicate that the residue at this position influences the orientation of bound ligands in AMP. We propose that the control of binding orientation can influence the recognition of multivalent ligands. A lateral association of trimers in the cross-linked crystals may reflect interactions within higher oligomers of MBP-A that are stabilized by multivalent ligands.	Stanford Univ, Sch Med, Dept Struct Chem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	Stanford University; Stanford University; University of Oxford	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Struct Chem, 299 Campus Dr W,Fairchild Bldg, Stanford, CA 94305 USA.		Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Ng, Kenneth K.S./0000-0001-7280-8445; Clark, Damon/0000-0001-8487-700X	NIGMS NIH HHS [GM50565] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR MANUAL VERSION; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; IKEDA K, 1987, J BIOL CHEM, V262, P7451; IMBERTY A, 1990, GLYCOCONJUGATE J, V7, P27, DOI 10.1007/BF01050401; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE RT, 1991, J BIOL CHEM, V266, P4810; Lee RT, 1997, GLYCOCONJUGATE J, V14, P357, DOI 10.1023/A:1018574729088; LOBST ST, 1994, J BIOL CHEM, V269, P15505; Mogues T, 1996, GLYCOBIOLOGY, V6, P543, DOI 10.1093/glycob/6.5.543; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petrescu AJ, 1999, GLYCOBIOLOGY, V9, P343, DOI 10.1093/glycob/9.4.343; Quesenberry MS, 1997, BIOCHEMISTRY-US, V36, P2724, DOI 10.1021/bi9622635; SHERIFF S, 1987, ACTA CRYSTALLOGR A, V43, P118, DOI 10.1107/S010876738709977X; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; SUPER M, 1990, CLIN EXP IMMUNOL, V79, P144; TENNER AJ, 1995, IMMUNITY, V3, P485, DOI 10.1016/1074-7613(95)90177-9; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Woods RJ, 1998, EUR J BIOCHEM, V258, P372, DOI 10.1046/j.1432-1327.1998.2580372.x	30	81	83	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16088	16095		10.1074/jbc.M200493200	http://dx.doi.org/10.1074/jbc.M200493200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11850428	hybrid			2022-12-25	WOS:000175510400116
J	Haier, J; Nicolson, GL				Haier, J; Nicolson, GL			PTEN regulates tumor cell adhesion of colon carcinoma cells under dynamic conditions of fluid flow	ONCOGENE			English	Article						PTEN; cell adhesion; colon carcinoma; shear stress; laminar flow; focal adhesion kinase	EXTRACELLULAR-MATRIX COMPONENTS; PROTEIN-TYROSINE PHOSPHATASES; FOCAL ADHESION; JUVENILE POLYPOSIS; SIGNAL-TRANSDUCTION; COWDEN-DISEASE; SUPPRESSOR; GENE; INTEGRIN; MUTATIONS	The regulation of integrin-mediated cell adhesion and its stabilization involves different phosphorylation and dephosphorylation events. Focal adhesion kinase (FAK) has been recently found to be a substrate of the dual-specific phosphatase PTEN in glioma cells, where it appears to be involved in regulation of cell spreading and migration as part of focal adhesions. We have investigated the role of PTEN in cell adhesion of HT-29 human colon carcinoma cells under static and hydrodynamic conditions of fluid flow. PTEN coprecipitated with FAK and paxillin dependent on the formation of adhesions to collagens. This corresponded with an adhesion-dependent increase in Tyr-phosphatase activity of PTEN. Using preparations of native FAK and PTEN from HT-29 cells in a specific Tyr-phosphatase assay FAK was identified as substrate for this dephosphorylation. If expression of PTEN was reduced using antisense oligonucleotides cell adhesion under dynamic conditions of laminar flow, but not under static conditions was significantly increased. In addition, cell spreading was increased in cells with reduced PTEN expression. We conclude that PTEN appears to be involved in the regulation of integrin-mediated adhesion through dephosphorylation of FAK. This phosphatase might play a role as a negative regulator for the formation of stable HT-29 cell adhesion to extracellular matrix.	Inst Mol Med, Huntington Beach, CA 92649 USA; Univ Hosp Muenster, Dept Surg, Mol Biol Lab, D-48149 Munster, Germany	University of Munster	Haier, J (corresponding author), Inst Mol Med, 15162 Triton Lane, Huntington Beach, CA 92649 USA.	haier@uni-muenster.de						Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Cairns P, 1997, CANCER RES, V57, P4997; Chang JG, 1999, EUR J CANCER, V35, P647, DOI 10.1016/S0959-8049(98)00411-0; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Chi SG, 1998, GASTROENTEROLOGY, V115, P1084, DOI 10.1016/S0016-5085(98)70078-2; Cool D E, 1993, Semin Cell Biol, V4, P443, DOI 10.1006/scel.1993.1052; Dahia PLM, 1997, CANCER RES, V57, P4710; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Haier J, 1999, INT J COLORECTAL DIS, V14, P119, DOI 10.1007/s003840050196; Haier J, 1999, CLIN EXP METASTAS, V17, P377, DOI 10.1023/A:1006658414040; Haier J, 1999, CLIN EXP METASTAS, V17, P713, DOI 10.1023/A:1006754829564; Haier J, 2000, J CANCER RES CLIN, V126, P699, DOI 10.1007/s004320000161; Haier J, 1999, BRIT J CANCER, V80, P1867, DOI 10.1038/sj.bjc.6690614; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maier D, 1999, CANCER RES, V59, P5479; Manes S, 1999, MOL CELL BIOL, V19, P3125; Marsh DJ, 1997, CANCER RES, V57, P5017; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Olschwang S, 1998, NAT GENET, V18, P12, DOI 10.1038/ng0198-12; Pesche S, 1998, ONCOGENE, V16, P2879, DOI 10.1038/sj.onc.1202081; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rasheed BKA, 1997, CANCER RES, V57, P4187; Resnick N, 1997, ADV EXP MED BIOL, V430, P155; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; Risinger JI, 1997, CANCER RES, V57, P4736; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TAKAGI J, 1995, CELL STRUCT FUNCT, V20, P403, DOI 10.1247/csf.20.403; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tsuchiya KD, 1998, GENE CHROMOSOME CANC, V21, P113, DOI 10.1002/(SICI)1098-2264(199802)21:2<113::AID-GCC6>3.0.CO;2-3; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yano Y, 1996, AM J PHYSIOL-CELL PH, V271, pC635, DOI 10.1152/ajpcell.1996.271.2.C635; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	62	38	50	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1450	1460		10.1038/sj.onc.1205213	http://dx.doi.org/10.1038/sj.onc.1205213			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857088				2022-12-25	WOS:000173861000015
J	Thyrell, L; Erickson, S; Zhivotovsky, B; Pokrovskaja, K; Sangfelt, O; Castro, J; Einhorn, S; Grander, D				Thyrell, L; Erickson, S; Zhivotovsky, B; Pokrovskaja, K; Sangfelt, O; Castro, J; Einhorn, S; Grander, D			Mechanisms of Interferon-alpha induced apoptosis in malignant cells	ONCOGENE			English	Article						interferon; apoptosis; caspase; mitochondria	CASPASE ACTIVATION; MULTIPLE-MYELOMA; PROTEIN-KINASE; UP-REGULATION; FAS LIGAND; IFN-GAMMA; B-CELLS; DEATH; INDUCTION; EXPRESSION	Interferon alpha (IFNalpha) has been used in the treatment of several types of cancer for almost 30 years, yet the mechanism(s) responsible for its anti-tumoral action remains unknown. A variety of cellular responses, including inhibition of cell growth and induction of apoptosis are induced by IFNs, and apoptotic induction by this cytokine has been proposed to be of importance for both its anti-tumoral in addition to its anti-viral responses. The aim of the present study was to delineate the pathways activated during IFNalpha-induced apoptosis in malignant cell lines. We found that apoptosis induced by IFNalpha was associated with activation of caspases-1, -2, -3, -8 and -9 and that this activation was a critical event. Caspase-3 activation was dependent on activity of caspases-8 and -9, moreover, activation of caspase-8 seems to be the upstream event in IFNalpha-induced caspase cascade. We also found loss of mitochondrial membrane potential as well as release of cytochrome c post IFN-treatment, clearly implicating the involvement of mitochondria in IFN-mediated apoptosis. Furthermore, IFNalpha-induced apoptosis was found to be independent on interactions between the Fas-receptor and its ligand. These studies form the basis for further investigations aiming to improve IFN therapy and the development of future strategies to overcome the IFN resistance observed in some malignancies.	Karolinska Hosp & Inst, Dept Pathol & Oncol, CCK, Res Lab Radiumhemmet, S-17176 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Dept Toxicol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Grander, D (corresponding author), Karolinska Hosp & Inst, Dept Pathol & Oncol, CCK, Res Lab Radiumhemmet, S-17176 Stockholm, Sweden.		Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482; Pokrovskaja Tamm, Katja/0000-0001-6359-1256				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bernassola F, 1999, CELL DEATH DIFFER, V6, P652, DOI 10.1038/sj.cdd.4400537; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Dai CH, 1998, BLOOD, V91, P1235, DOI 10.1182/blood.V91.4.1235; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; GRANDER D, 1993, EUR J CANCER, V14, P1940; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Kaser A, 1999, CYTOKINE, V11, P736, DOI 10.1006/cyto.1998.0484; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Luchetti F, 1998, HAEMATOLOGICA, V83, P974; MANABE A, 1993, LEUKEMIA, V7, P1990; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; Raza A, 2000, LEUKEMIA RES, V24, P63, DOI 10.1016/S0145-2126(99)00152-6; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RHIM JS, 1989, ANTICANCER RES, V9, P1345; Roth W, 1998, J NEUROIMMUNOL, V87, P121, DOI 10.1016/S0165-5728(98)00079-4; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sarkar SN, 1999, J BIOL CHEM, V274, P25535, DOI 10.1074/jbc.274.36.25535; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sedger LM, 1999, J IMMUNOL, V163, P920; SILINS SL, 1995, INT J CANCER, V60, P65, DOI 10.1002/ijc.2910600110; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Spets H, 1998, BLOOD, V92, P2914, DOI 10.1182/blood.V92.8.2914.420k14_2914_2923; Stridh H, 1999, BIOCHEM BIOPH RES CO, V266, P460, DOI 10.1006/bbrc.1999.1821; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; Witzig TE, 2000, CLIN CANCER RES, V6, P681; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	50	173	182	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1251	1262		10.1038/sj.onc.1205179	http://dx.doi.org/10.1038/sj.onc.1205179			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850845				2022-12-25	WOS:000173729400013
J	Kabsch, K; Alonso, A				Kabsch, K; Alonso, A			The human papillomavirus type 16 (HPV-16) E5 protein sensitizes human keratinocytes to apoptosis induced by osmotic stress	ONCOGENE			English	Article						fpapillomavirus; keratinocytes; apoptosis; osmotic shock	GROWTH-FACTOR RECEPTOR; EPITHELIAL-CELL LINE; ACTIVATION; GENE; CASPASES; FIBROBLASTS; ONCOPROTEIN; KINASE; HACAT; DEATH	We have studied the role of the HPV-16 E5 protein in apoptosis, using HaCaT cell lines stably transfected with either E5 (HaCaT/E5) or the empty vector (HaCaT/ pMSG) as control. When subjected to a hyperosmolar concentration of sorbitol, HaCaT/E5 cells respond with cytochrome e release, activation of caspase-3, -8, and -9, and PARP-cleavage, showing that the mitochondria and death-receptor mediated apoptotic pathways are involved in subsequent cell death. Similar effects are observed for the control cells only after extended sorbitol treatment. Thus, E5-expressing cells are more sensitive to osmotic stress, perhaps because of modifications of the cellular membranes caused by this strongly hydrophobic molecule.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Kabsch, K (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	k.kabsch@dkfz-heidelberg.de						Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1999, ONCOGENE, V18, P6714, DOI 10.1038/sj.onc.1203075; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; Crusius K, 2000, VIRUS GENES, V20, P65, DOI 10.1023/A:1008112207824; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; FAULKNERVALLE G, 1995, J GEN VIROL, V76, P1239; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; HACHISUKA H, 1990, CELL TISSUE RES, V260, P207, DOI 10.1007/BF00297507; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jost M, 2001, J INVEST DERMATOL, V116, P860, DOI 10.1046/j.1523-1747.2001.01356.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KELL B, 1994, J GEN VIROL, V75, P2451, DOI 10.1099/0022-1317-75-9-2451; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; LEPTAK C, 1992, J VIROL, V66, P1833; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PIM D, 1992, ONCOGENE, V7, P27; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; ULLMAN CG, 1994, BIOCHEM SOC T, V22, pS439, DOI 10.1042/bst022439s; Wang J, 2000, J CELL SCI, V113, P753	33	23	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					947	953		10.1038/sj.onc.1205147	http://dx.doi.org/10.1038/sj.onc.1205147			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840340				2022-12-25	WOS:000173427100010
J	Wu, SY; Hu, YY; Wang, JL; Chatterjee, M; Shi, YG; Kaufman, RJ				Wu, SY; Hu, YY; Wang, JL; Chatterjee, M; Shi, YG; Kaufman, RJ			Ultraviolet light inhibits translation through activation of the unfolded protein response kinase PERK in the lumen of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UV-IRRADIATION; INDUCED APOPTOSIS; ER STRESS; MAMMALIAN-CELLS; MESSENGER-RNA; IRE1; GENE; DIMERIZATION; EXPRESSION; PKR	Exposure to ultraviolet light can cause inflammation, premature skin aging, and cancer. UV irradiation alters the expression of multiple genes that encode functions to repair DNA damage, arrest cell growth, and induce apoptosis. In addition, UV irradiation inhibits protein synthesis, although the mechanism is not known. In this report, we show that UV irradiation induces phosphorylation of eukaryotic translation initiation factor 2 on the alpha-subunit (eIF2alpha) and inhibits protein synthesis in a dosage- and time-dependent manner. The UV-induced phosphorylation of eIF2alpha was prevented by the overexpression of a non-phosphorylatable mutant of eIF2alpha (S51A). PERK is an eIF2alpha protein kinase localized to the endoplasmic reticulum that is activated by the accumulation of unfolded proteins in the endoplasmic reticulum. Expression of trans-dominant-negative mutants of PERK also prevented eIF2alpha phosphorylation upon UV treatment and protected from the associated translation attenuation. The luminal domain of dominant-negative mutant PERK formed heterodimers with endogenous PERK to inhibit the PERK signaling pathway. In contrast, eIF2alpha phosphorylation was not inhibited by overexpression of a trans-dominant-negative mutant kinase, PKR, supporting the theory that UV-induced eIF2alpha phosphorylation is specifically mediated by PERK. These results support a novel mechanism by which UV irradiation regulates translation via an endoplasmic reticulum-stress signaling pathway.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA; Eli Lilly & Co, Lilly Res Labs, Div Endocrine, Indianapolis, IN 46285 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Eli Lilly	Wu, SY (corresponding author), Rm 4131,1331 E Ann St, Ann Arbor, MI 48109 USA.		Wu, Shiyong/I-3359-2013	Wu, Shiyong/0000-0002-4104-4160	NCI NIH HHS [R01 CA86926] Funding Source: Medline; NIAID NIH HHS [R01 AI42394] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bertolotti A, 2001, J CELL SCI, V114, P3207; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Chatterjee M, 2001, MOL CELL BIOCHEM, V219, P21, DOI 10.1023/A:1011083818452; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Fritz G, 1999, MOL CELL BIOL, V19, P1768; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Iordanov MS, 1998, J BIOL CHEM, V273, P15794, DOI 10.1074/jbc.273.25.15794; Iwawaki T, 2001, NAT CELL BIOL, V3, P158, DOI 10.1038/35055065; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; REDPATH NT, 1990, BIOCHEM J, V272, P175, DOI 10.1042/bj2720175; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Silverman RH, 1999, NATURE, V397, P208, DOI 10.1038/16586; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	35	96	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18077	18083		10.1074/jbc.M110164200	http://dx.doi.org/10.1074/jbc.M110164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877419	hybrid			2022-12-25	WOS:000175685100087
J	Feng, W; Yasumura, D; Matthes, MT; LaVail, MM; Vollrath, D				Feng, W; Yasumura, D; Matthes, MT; LaVail, MM; Vollrath, D			Mertk triggers uptake of photoreceptor outer segments during phagocytosis by cultured retinal pigment epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARREST-SPECIFIC GENE-6; MANNOSE RECEPTOR; RCS RAT; APOPTOTIC CELLS; ROYAL-COLLEGE; RPE CELLS; ROD; DYSTROPHY; BINDING; INTEGRIN	The RCS rat is a widely studied model of recessively inherited retinal degeneration. The genetic defect, known as rdy (retinal dystrophy), results in failure of the retinal pigment epithelium (RPE) to phagocytize shed photoreceptor outer segment membranes. We previously used positional cloning and in vivo genetic complementation to demonstrate that Mertk is the gene for rdy. We have now used a rat primary RPE cell culture system. to demonstrate that the RPE is the site of action of Mertk and to obtain functional evidence for a key role of Mertk in RPE phagocytosis. We found that Mertk protein is absent from RCS, but not wild-type, tissues and cultured RPE cells. Delivery of rat Mertk to cultured RCS RPE cells by means of a recombinant adenovirus restored the cells to complete phagocytic competency. Infected RCS RPE cells ingested exogenous outer segments to the same extent as wild-type RPE cells, but outer segment binding was unaffected. Mertk protein progressively co-localized with outer segment material during phagocytosis by primary RPE cells, and activated Mertk accumulated during the early stages of phagocytosis by RPE-J cells. We conclude that Mertk likely functions directly in the RPE phagocytic process as a signaling molecule triggering outer segment ingestion.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vollrath, D (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.				NEI NIH HHS [EY06842, EY01919, EY02162] Funding Source: Medline; NATIONAL EYE INSTITUTE [U01EY006842, R37EY001919, R01EY006842, R01EY001919, P30EY002162] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Alberts B., 1994, MOL BIOL CELL, P604; BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664; Bok D., 1979, RETINAL PIGMENT EPIT, P148; BOYLE D, 1991, INVEST OPHTH VIS SCI, V32, P1464; CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812; CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P821; CHANG CW, 1991, CURR EYE RES, V10, P1081, DOI 10.3109/02713689109020348; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645; da Cruz L, 1998, CURR EYE RES, V17, P668; DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73; FADOK VA, 1992, J IMMUNOL, V148, P2207; FENG W, 1996, INVESTIG OPHTHALMOL, V37, P378; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555; HALL MO, 1987, EXP EYE RES, V45, P907, DOI 10.1016/S0014-4835(87)80105-7; Hall MO, 2001, EXP EYE RES, V73, P509, DOI 10.1006/exer.2001.1062; HETH CA, 1994, INVEST OPHTH VIS SCI, V35, P409; HETH CA, 1992, INVEST OPHTH VIS SCI, V33, P2839; LAIRD DW, 1988, INVEST OPHTH VIS SCI, V29, P419; Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1; Lin H, 1998, INVEST OPHTH VIS SCI, V39, P1703; MAYERSON PL, 1986, J CELL BIOL, V103, P299, DOI 10.1083/jcb.103.1.299; Miceli MV, 1997, INVEST OPHTH VIS SCI, V38, P1588; MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483; NABI IR, 1993, J CELL SCI, V104, P37; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Ryeom SW, 1996, J CELL SCI, V109, P387; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; SHEPHERD VL, 1991, INVEST OPHTH VIS SCI, V32, P1779; SILVERSTEIN RL, 1998, EXP EYE RES, V67, P534; Strauss O, 1998, ACTA ANAT, V162, P101; Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198; Wilt SD, 1999, EXP EYE RES, V69, P405, DOI 10.1006/exer.1999.0714; YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392; YOUNG RW, 1978, INVEST OPHTH VIS SCI, V17, P105	39	178	185	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17016	17022		10.1074/jbc.M107876200	http://dx.doi.org/10.1074/jbc.M107876200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861639	hybrid			2022-12-25	WOS:000175564500090
J	Hayes, MM; Lane, BR; King, SR; Markovitz, DM; Coffey, MJ				Hayes, MM; Lane, BR; King, SR; Markovitz, DM; Coffey, MJ			Peroxisome proliferator-activated receptor gamma agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; MONOCYTE-DERIVED MACROPHAGES; ARACHIDONIC-ACID METABOLISM; ALPHA GENE-EXPRESSION; RETINOID-X RECEPTOR; SMOOTH-MUSCLE CELLS; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CYCLOPENTENONE PROSTAGLANDINS	Previous studies have demonstrated that cyclopentenone prostaglandins (cyPG) inhibit human immunodeficiency virus type 1 (HIV-1) replication in various cell types. We investigated the role of PG in the replication of HIV-1 in primary macrophages. The cyPG, PGA(1) and PGA(2), inhibited HIV-1 replication in acutely infected human monocyte-derived macrophages (MDM). Because PGA(1) and PGA(2) have previously been shown to be peroxisome proliferator-activated receptor gamma (PPARgamma) agonists, we examined the effect of synthetic PPARgamma agonists on HIV replication. The PPARgamma agonist ciglitazone inhibited HIV-1 replication in a dose-dependent manner in acutely infected human MDM. In addition, cyPG and ciglitazone reduced HIV replication in latently infected and viral entry-independent U1 cells, suggesting an effect at the level of HIV gene expression. Ciglitazone also suppressed HIV-1 mRNA levels as measured by reverse transcriptase PCR, in parallel with the decrease in reverse transcriptase activity. Co-transfection of PPARgamma wild type vectors and treatment with PPARgamma agonists inhibited HIV-1 promoter activity in U937 cells. Activation of PPARgamma also decreased HIV-1 mRNA stability following actinomycin D treatment. In summary, our experimental findings implicate PPARgamma as an important factor in the suppression of HIV-1 gene expression in MDM by cyPG. Thus natural and synthetic PPARgamma agonists may play a role in controlling HIV-1 infection in macrophages.	Univ Michigan, Med Ctr, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Div Rheumatol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Div Infect Dis, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Grad Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Coffey, MJ (corresponding author), Univ Michigan, Med Ctr, Div Pulm & Crit Care Med, 6301 MSRB III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NCRR NIH HHS [M01-RR00042] Funding Source: Medline; NHLBI NIH HHS [HL57885] Funding Source: Medline; NIAID NIH HHS [AI36685] Funding Source: Medline; NIGMS NIH HHS [T32GM07863] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asou H, 1999, INT J ONCOL, V15, P1027; Balter M, 1996, SCIENCE, V274, P1464, DOI 10.1126/science.274.5292.1464; Baron S, 2000, J IMMUNOL METHODS, V242, P115, DOI 10.1016/S0022-1759(00)00242-8; Barrios-Rodiles M, 1999, J IMMUNOL, V163, P963; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; Burke JR, 1999, BIOCHEM BIOPH RES CO, V260, P232, DOI 10.1006/bbrc.1999.0887; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Coffey MJ, 1996, J IMMUNOL, V157, P393; Coffey MJ, 1999, BLOOD, V94, P3897, DOI 10.1182/blood.V94.11.3897.423k12_3897_3905; D'Addario M, 2000, J MOL BIOL, V298, P765, DOI 10.1006/jmbi.2000.3717; De Marco A, 1998, EUR J BIOCHEM, V256, P334, DOI 10.1046/j.1432-1327.1998.2560334.x; DELEMARRE FGA, 1995, AIDS, V9, P441, DOI 10.1097/00002030-199509050-00005; DENIS M, 1994, CLIN EXP IMMUNOL, V98, P123; DOREDUFFY P, 1982, PROSTA LEUKOTR MED, V8, P73, DOI 10.1016/0262-1746(82)90129-9; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FERNANDEZCRUZ E, 1989, AIDS, V3, P91, DOI 10.1097/00002030-198902000-00007; FOLEY P, 1992, IMMUNOLOGY, V75, P391; FOLKS TM, 1988, J IMMUNOL, V140, P1117; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FROLDI M, 1992, J NEUROIMMUNOL, V38, P155, DOI 10.1016/0165-5728(92)90100-Y; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GRIFFIN DE, 1994, ANN NEUROL, V35, P592, DOI 10.1002/ana.410350513; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hardwick SJ, 1996, J PATHOL, V179, P294; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; HUGHESFULFORD M, 1992, ANTIMICROB AGENTS CH, V36, P2253, DOI 10.1128/AAC.36.10.2253; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kusumawati A, 1999, ANAL BIOCHEM, V269, P219, DOI 10.1006/abio.1999.4024; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lie YS, 1998, CURR OPIN BIOTECH, V9, P43, DOI 10.1016/S0958-1669(98)80082-7; LONGO N, 1993, J ACQ IMMUN DEF SYND, V6, P17; MASTINO A, 1993, CELL IMMUNOL, V152, P120, DOI 10.1006/cimm.1993.1272; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murakami K, 1999, BIOCHEM BIOPH RES CO, V260, P609, DOI 10.1006/bbrc.1999.0951; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OHNO K, 1986, BIOCHEM BIOPH RES CO, V139, P808, DOI 10.1016/S0006-291X(86)80062-6; Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857; Orlando C, 1998, CLIN CHEM LAB MED, V36, P255, DOI 10.1515/CCLM.1998.045; Pang JHS, 1996, BIOCHEM J, V319, P185, DOI 10.1042/bj3190185; Poli G, 1999, EUR J CLIN INVEST, V29, P723; POLI G, 1993, CLIN INFECT DIS, V17, pS224; RAMIS I, 1991, J CHROMATOGR, V557, P507, DOI 10.1016/S0021-9673(01)87159-4; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Rozera C, 1996, J CLIN INVEST, V97, P1795, DOI 10.1172/JCI118609; SANTORO MG, 1981, J GEN VIROL, V53, P75, DOI 10.1099/0022-1317-53-1-75; Santoro MG, 1997, TRENDS MICROBIOL, V5, P276, DOI 10.1016/S0966-842X(97)01066-4; Sasaki H, 1999, CANCER RES, V59, P3919; Shimokawa T, 2000, BIOCHEM BIOPH RES CO, V270, P94, DOI 10.1006/bbrc.2000.2388; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Sugawara A, 2001, ENDOCRINOLOGY, V142, P3125, DOI 10.1210/en.142.7.3125; Takeda K, 2000, CIRCULATION, V102, P1834; TANAKA A, 1986, PROSTAG LEUKOTR ESS, V25, P131, DOI 10.1016/0262-1746(86)90060-0; Thivierge M, 1998, BLOOD, V92, P40, DOI 10.1182/blood.V92.1.40.413k43_40_45; Thomas SC, 1998, FASEB J, V12, P1371, DOI 10.1096/fasebj.12.13.1371; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; Wang P, 2001, INT IMMUNOPHARMACOL, V1, P803, DOI 10.1016/S1567-5769(01)00015-7; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; YAMAMOTO N, 1987, BIOCHEM BIOPH RES CO, V146, P1987; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	72	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16913	16919		10.1074/jbc.M200875200	http://dx.doi.org/10.1074/jbc.M200875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11847231	hybrid			2022-12-25	WOS:000175564500077
J	Lu, ZCJ; Markham, GD				Lu, ZCJ; Markham, GD			Enzymatic properties of S-Adenosylmethionine synthetase from the archaeon Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; RADICAL MECHANISMS; CRYSTAL-STRUCTURE; ACTIVE-SITE; ADENOSYLTRANSFERASE; INTERMEDIATE; METHYLATION; CATALYSIS; PROTEINS; ANALOGS	S-Adenosylmethionine synthetase (ATP:L-methionine S-adenosyltransferase, MAT) catalyzes a unique enzymatic reaction that leads to formation of the primary biological alkylating agent. NUT from the hyperthermophilic archaeon Methanococcus jannaschii (MjMAT) is a prototype of the newly discovered archaeal class of NUT proteins that are nearly unrecognizable in sequence when compared with the class that encompasses both the eucaryal and bacterial enzymes. In this study the functional properties of purified recombinant MjMAT have been evaluated. The products of the reaction are AdoMet, PPi, and P-i; >90%, of the P-i originates from the gamma-phosphoryl group of ATP. The circular dichroism spectrum of the dimeric MjMAT indicates that the secondary structure is more helical than the Escherichia coli counterpart (EcMAT), suggesting a different protein topology. The steady state kinetic mechanism is sequential, with random addition of ATP and methionine; AdoMet is the first product released, followed by release of PPi and P-i. The substrate specificity differs remarkably from the previously characterized MATs; the nucleotide binding site has a very broad tolerance of alterations in the adenosine moiety. MjMAT has activity at 70 degreesC comparable with that of EcMAT at 37 degreesC, consistent with the higher temperature habitat of M. jannaschii. The activation energy for AdoMet formation is larger than that for the E. coli MAT-catalyzed reaction, in accord with the notion that enzymes from thermophilic organisms are often more rigid than their mesophilic counterparts. The broad substrate tolerance of this enzyme proffers routes to preparation of novel AdoMet analogs.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Markham, GD (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA06927] Funding Source: Medline; NIGMS NIH HHS [GM31186] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; Cleland W W, 1979, Methods Enzymol, V63, P103; Cooper A, 2001, BIOPHYS CHEM, V93, P215, DOI 10.1016/S0301-4622(01)00222-8; COULTER AW, 1974, MOL PHARMACOL, V10, P319; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1496, DOI 10.1021/bi00548a037; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; *GEN COMP GROUP, 1999, PEPT VERS 10; Gonzalez B, 2000, J MOL BIOL, V300, P363, DOI 10.1006/jmbi.2000.3858; Graham DE, 2000, J BIOL CHEM, V275, P4055, DOI 10.1074/jbc.275.6.4055; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; KAISER II, 1983, J BIOL CHEM, V258, P1747; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; Lonhienne T, 2000, BBA-PROTEIN STRUCT M, V1543, P1, DOI 10.1016/S0167-4838(00)00210-7; MA QF, 1990, BIOCHEMISTRY-US, V29, P1412, DOI 10.1021/bi00458a011; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; McQueney MS, 2000, BIOCHEMISTRY-US, V39, P4443, DOI 10.1021/bi992876s; MUDD SH, 1973, ENZYMES, V8, P21; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; Park J, 1996, BIOORGAN MED CHEM, V4, P2179, DOI 10.1016/S0968-0896(96)00228-3; Reczkowski RS, 1998, BIOCHEMISTRY-US, V37, P13499, DOI 10.1021/bi9811011; Reczkowski RS, 1999, BIOCHEMISTRY-US, V38, P9063, DOI 10.1021/bi990528k; Segel IH, 1975, ENZYME KINETICS BEHA; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; SOMERO GN, 1995, ANNU REV PHYSIOL, V57, P43, DOI 10.1146/annurev.ph.57.030195.000355; SUFRIN JR, 1982, BIOCHEM BIOPH RES CO, V106, P251, DOI 10.1016/0006-291X(82)91102-0; SZEDLACSEK SE, 1995, METHOD ENZYMOL, V249, P144; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Taylor JC, 2000, J BIOL CHEM, V275, P4060, DOI 10.1074/jbc.275.6.4060; TROWBRIDGE DB, 1972, J AM CHEM SOC, V94, P3816, DOI 10.1021/ja00766a026	34	36	39	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16624	16631		10.1074/jbc.M110456200	http://dx.doi.org/10.1074/jbc.M110456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872742	hybrid			2022-12-25	WOS:000175564500039
J	Chen, DY; Li, XY; Zhai, ZH; Shu, HB				Chen, DY; Li, XY; Zhai, ZH; Shu, HB			A novel zinc finger protein interacts with receptor-interacting protein (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-induced NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF RECEPTOR; DEATH DOMAIN; CD95 FAS/APO-1; CELL-DEATH; KINASE RIP; IKK-GAMMA; FADD; A20; SIGNAL; ALPHA	Receptor-interacting protein (RIP) is a serine/threonine protein kinase that is critically involved in tumor necrosis factor receptor-1 (TNF-R1)-induced NF-kappaB activation. In a yeast two-hybrid screening for potential RIP-interacting proteins, we identified ZIN (zinc finger protein inhibiting NF-kappaB), a novel protein that specifically interacts with RIP. ZIN contains four RING-like zinc finger domains at the middle and a proline-rich domain at the C terminus. Overexpression of ZIN inhibits RIP-, IKKbeta-, TNF-, and IL1-induced NF-kappaB activation in a dose-dependent manner in 293 cells. Domain mapping experiments indicate that the RING-like zinc finger domains of ZIN are required for its interaction with RIP and inhibition of RIP-mediated NF-kappaB activation. Overexpression of ZIN also potentiates RIP- and TNF-induced apoptosis. Moreover, immunofluorescent staining indicates that ZIN is a cytoplasmic protein and that it colocalizes with RIP. Our findings suggest that ZIN is an inhibitor of TNF- and IL1-induced NF-kappaB activation pathways.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University	Shu, HB (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Immunol, 1400 Jackson St,K516C, Denver, CO 80206 USA.	shuh@njc.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049992] Funding Source: NIH RePORTER; NIAID NIH HHS [1R01 AI49992-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Heyninck K, 1999, FEBS LETT, V442, P147, DOI 10.1016/S0014-5793(98)01645-7; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Jaattela M, 1996, J IMMUNOL, V156, P1166; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Klinkenberg M, 2001, FEBS LETT, V498, P93, DOI 10.1016/S0014-5793(01)02504-2; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	46	53	60	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15985	15991		10.1074/jbc.M108675200	http://dx.doi.org/10.1074/jbc.M108675200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854271	hybrid			2022-12-25	WOS:000175510400103
J	Makagiansar, IT; Nguyen, PD; Ikesue, A; Kuczera, KR; Dentler, W; Urbauer, JL; Galeva, N; Alterman, M; Siahaan, TJ				Makagiansar, IT; Nguyen, PD; Ikesue, A; Kuczera, KR; Dentler, W; Urbauer, JL; Galeva, N; Alterman, M; Siahaan, TJ			Disulfide bond formation promotes the cis- and trans-dimerization of the E-cadherin-derived first repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSISTED-LASER-DESORPTION/IONIZATION; CELL-CELL ADHESION; ESCHERICHIA-COLI; EXTRACELLULAR DOMAIN; EPITHELIAL CADHERIN; STRUCTURAL BASIS; CALCIUM-BINDING; ISOMERASE DSBA; N-CADHERIN; IN-VIVO	Cadherin is a cell adhesion molecule crucial for epithelial and endothelial cell monolayer integrity. The previously solved x-ray crystallographic structure of the E-CAD12 cis-dimer displayed an unpaired Cys(9), which protruded away from the Cys(9) on the other protomer. To investigate the possible biological function of Cys9 within the first repeat (the E-cadherin-derived N-terminal repeat), E-CAD1 was overexpressed and secreted into the periplasmic space of Escherichia coli cells. Recombinant E-CAD1 produced a mixed monomer and dimer in an equilibrium fashion. The dimer was linked by a disulfide through Cys(9) pairing. Analysis by high pressure liquid chromatography and electron microscopy suggested the existence of oligomeric complexes. Mutation at Trp(2) appears to indicate that these oligomeric complexes trans-dimerize. Interestingly, mutation of Cys(9) affected not only the cis-dimerization, but also the trans-oligomerization of E-CAD1. Accordingly, it is plausible that, under oxidative stress, the homophilic interactions of E-cadherin through E-CAD1 may be promoted and stabilized by this disulfide bond.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66047 USA; Univ Kansas, Biochem Res Lab, Lawrence, KS 66047 USA	University of Kansas; University of Kansas; University of Kansas	Siahaan, TJ (corresponding author), Univ Kansas, Dept Pharmaceut Chem, Simons Bldg,2095 Constant Ave, Lawrence, KS 66047 USA.				NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000226] Funding Source: NIH RePORTER; NIBIB NIH HHS [R01 EB000226, R01 EB000226-03, EB-00226] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Alattia JR, 1997, FEBS LETT, V417, P405, DOI 10.1016/S0014-5793(97)01333-1; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1988, PROTEINS THEORETICAL; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; Farmer TB, 1998, J MASS SPECTROM, V33, P697, DOI 10.1002/(SICI)1096-9888(199808)33:8<697::AID-JMS711>3.0.CO;2-H; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; Kitagawa M, 2000, BIOCHEM BIOPH RES CO, V271, P358, DOI 10.1006/bbrc.2000.2636; Koch AW, 1999, CURR OPIN STRUC BIOL, V9, P275, DOI 10.1016/S0959-440X(99)80038-4; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Mach H, 1995, Methods Mol Biol, V40, P91; Makagiansar IT, 2001, PHARMACEUT RES, V18, P446, DOI 10.1023/A:1011094025008; Masur K, 2001, MOL BIOL CELL, V12, P1973, DOI 10.1091/mbc.12.7.1973; Miyaguchi K, 2000, J STRUCT BIOL, V132, P169, DOI 10.1006/jsbi.2000.4244; Murase S, 2000, BIOCHEM BIOPH RES CO, V276, P1191, DOI 10.1006/bbrc.2000.3590; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; Overduin M, 1996, J BIOMOL NMR, V7, P173; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; REID RA, 1990, NUCLEIC ACIDS RES, V18, P5896, DOI 10.1093/nar/18.19.5896; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; TONG KI, 1994, FEBS LETT, V352, P318; Woods AS, 2001, J AM SOC MASS SPECTR, V12, P88, DOI 10.1016/S1044-0305(00)00197-5; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; Yan BX, 2000, J BIOL CHEM, V275, P39964, DOI 10.1074/jbc.M007041200; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019	43	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16002	16010		10.1074/jbc.M200916200	http://dx.doi.org/10.1074/jbc.M200916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856755	hybrid			2022-12-25	WOS:000175510400105
J	Sibinga, NES; Feinberg, MW; Yang, HY; Werner, F; Jain, MK				Sibinga, NES; Feinberg, MW; Yang, HY; Werner, F; Jain, MK			Macrophage-restrieted and interferon gamma-inducible expression of the allograft inflammatory factor-1 gene requires Pu.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PU.1; FACTOR-I; CD11B PROMOTER; PROTEIN; BINDS; IDENTIFICATION; REJECTION; ELEMENTS; RECEPTOR; HEARTS	Expression of allograft inflammatory factor-1 (Aif-1), a 17-kDa protein bearing an EF-hand Ca2+ binding motif, increases markedly in monocytes and macrophages participating in allo- and autoimmune reactions, including the perivascular inflammation in transplanted hearts, microglial infiltrates in experimental autoimmune neuritis, and the inflamed pancreas of prediabetic BB rats. To investigate the mechanism of this regulation, we isolated the mouse aif-1 gene and determined its genomic organization. The gene has six exons distributed over 1.6 kilobases, an interferon gamma-inducible DNase I-hypersensitive site near -900, and flanking sequences on either side predicted to associate with nuclear matrix. Reporter gene analyses identified sequences between -902 and -789, including consensus Ets and interferon regulatory factor elements, required for macrophage-specific and interferon gamma-inducible transcriptional activity. Pu.1 bound to the Ets site in electromobility shift assay and forced expression of Pu.1 activated the aif-1 promoter in 3T3 fibroblasts, in which it is normally inactive. However, the transcriptional activity of a con-catamer of the Ets site alone did not increase with interferon gamma treatment. Cooperation between Pu.1 and proteins binding to the interferon regulatory factor element appears to be necessary for both macrophage-specific and interferon gamma-inducible expression of the aif-1 gene.	Albert Einstein Coll Med, Div Cardiovasc, Dept Med, Bronx, NY 10461 USA; Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA	Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital	Sibinga, NES (corresponding author), Albert Einstein Coll Med, Div Cardiovasc, Dept Med, Forcheimer G46,1300 Morris Pk Ave, Bronx, NY 10461 USA.		Sibinga, Nicholas/GOJ-8544-2022	Feinberg, Mark/0000-0001-9523-3859; Sibinga, Nicholas/0000-0003-4838-910X	NHLBI NIH HHS [HL03274, HL03747] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Chen ZW, 1997, P NATL ACAD SCI USA, V94, P13879, DOI 10.1073/pnas.94.25.13879; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRETSINGER RH, 1993, J MOL EVOL, V36, P477, DOI 10.1007/BF02406723; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Meraro D, 1999, J IMMUNOL, V163, P6468; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Sambrook J., 2002, MOL CLONING LAB MANU; Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sibinga NES, 1999, J BIOL CHEM, V274, P12139, DOI 10.1074/jbc.274.17.12139; Simon MC, 1998, SEMIN IMMUNOL, V10, P111, DOI 10.1006/smim.1998.0112; Singh GB, 1997, NUCLEIC ACIDS RES, V25, P1419, DOI 10.1093/nar/25.7.1419; Tanaka S, 1998, J NEUROSCI, V18, P6358; UTANS U, 1994, P NATL ACAD SCI USA, V91, P6463, DOI 10.1073/pnas.91.14.6463; UTANS U, 1995, J CLIN INVEST, V95, P2954, DOI 10.1172/JCI118003; Utans U, 1996, TRANSPLANTATION, V61, P1387, DOI 10.1097/00007890-199605150-00018; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	28	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16202	16210		10.1074/jbc.M200935200	http://dx.doi.org/10.1074/jbc.M200935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861656	hybrid			2022-12-25	WOS:000175510400130
J	Velloso, LM; Svensson, K; Schneider, G; Pettersson, RF; Lindqvist, Y				Velloso, LM; Svensson, K; Schneider, G; Pettersson, RF; Lindqvist, Y			Crystal structure of the carbohydrate recognition domain of p58/ERGIC-53, a protein involved in glycoprotein export from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI INTERMEDIATE COMPARTMENT; COAGULATION-FACTORS V; MEMBRANE-PROTEIN; LECTIN ERGIC-53; QUALITY-CONTROL; CIS-GOLGI; MANNOSE; ER; VIP36; IDENTIFICATION	p58/ERGIC-53 is an animal calcium-dependent lectin that cycles between the endoplasmic reticulum (ER) and the Golgi complex and appears to act as a cargo receptor for a subset of soluble glycoproteins exported from the ER. We have determined the crystal structure of the carbohydrate recognition domain (CRD) of p58, the rat homologue of human ERGIC-53, to 1.46 Angstrom resolution. The fold and ligand binding site are most similar to those of leguminous lectins. The structure also resembles that of the CRD of the ER folding chaperone calnexin and the neurexins, a family of non-lectin proteins expressed on neurons. The CRD comprises one concave and one convex beta-sheet packed into a beta-sandwich. The ligand binding site resides in a negatively charged cleft formed by conserved residues. A large surface patch of conserved residues with a putative role in protein-protein interactions and oligomerization lies on the opposite side of the ligand binding site. Together with previous functional data, the structure defines a new and expanding class of calcium-dependent animal lectins and provides a starting point for the understanding of glycoprotein sorting between the ER and the Golgi.	Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Struct Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Stockholm Branch, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research	Lindqvist, Y (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Struct Biol, Tomtebodavagen 6, S-17177 Stockholm, Sweden.	ylva@alfa.mbb.ki.se	Lindqvist, Ylva/F-9009-2010	Lindqvist, Ylva/0000-0003-3162-8661; Schneider, Gunter/0000-0003-0622-5713				Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CASSET F, 1995, J BIOL CHEM, V270, P25619, DOI 10.1074/jbc.270.43.25619; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; Fullekrug J, 1999, J CELL SCI, V112, P2813; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; Hauri HP, 2000, J CELL SCI, V113, P587; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; Klumperman J, 1998, J CELL SCI, V111, P3411; Lahtinen U, 1999, EUR J BIOCHEM, V260, P392, DOI 10.1046/j.1432-1327.1999.00158.x; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Michel G, 2001, STRUCTURE, V9, P513, DOI 10.1016/S0969-2126(01)00612-8; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAISMITH JH, 1994, ACTA CRYSTALLOGR D, V50, P847, DOI 10.1107/S0907444994005287; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PIMPANEAU V, 1991, CARBOHYD RES, V213, P95, DOI 10.1016/S0008-6215(00)90601-3; RINI JM, 1993, J BIOL CHEM, V268, P10126; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Velloso LM, 2002, ACTA CRYSTALLOGR D, V58, P536, DOI 10.1107/S0907444902000203; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Yerushalmi N, 2001, GENE, V265, P55, DOI 10.1016/S0378-1119(01)00347-X	46	67	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15979	15984		10.1074/jbc.M112098200	http://dx.doi.org/10.1074/jbc.M112098200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11850423	hybrid			2022-12-25	WOS:000175510400102
J	Yoo, SH; You, SH; Kang, MK; Huh, YH; Lee, CS; Shim, CS				Yoo, SH; You, SH; Kang, MK; Huh, YH; Lee, CS; Shim, CS			Localization of the secretory granule marker protein chromogranin B in the nucleus - Potential role in transcription control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CONFORMATIONAL CHANGE; SECRETOGRANIN-I; MESSENGER-RNA; VESICLE BIOGENESIS; REGULATED PATHWAY; CDNA SEQUENCE; PH; AGGREGATION; BINDING	Chromogranins A (CGA) and B (CGB) are two major Ca2+ storage proteins of the secretory granules of neuroendocrine cells. Nevertheless, we found in the present study that CGB was also localized in the nucleus. In immunogold electron microscopy using bovine adrenal medullary chromaffin cells, it was found that the number of CGB-labeled gold particles localized per mum(2) Of the nucleus was equivalent to 20% that of CGB-labeled gold particles localized per mum(2) of the secretory granules. Considering that CGB is estimated to exist in the 0.1-0.2-mM range in the secretory granules of bovine chromaffin cells, 20% of these amounts to 20-40 muM. In addition, transfection of CGA and CGB into nonneuroendocrine COS-7 and NIH3T3 cells repeatedly indicated the nuclear localization of CGB in addition to its usual localization in the cytoplasm. Moreover, immunoblot and immunogold electron microscopy analyses of neuroendocrine PC12 cells also showed the existence of endogenous CGB in both the cytosol and the nucleus. Nuclear routing of CGB did not appear to depend entirely upon the nuclear localization signal as some of the nuclear localization signal mutant CGB were still targeted to the nucleus. In gene array assay, CGB was shown to either induce or suppress transcription of many genes including those of transcription factors. Of these we have analyzed eight genes, four induced (zinc finger protein, MEF2C, hCRP2, abLIM) and four suppressed (hcKrox, T3-receptor, troponin C, integrin) using the quantitative reverse transcription-PCR method and spectrophotometry to determine the transcription levels of each mRNA. CGB was shown to increase the transcription of zinc finger protein, MEF2C, hCRP2, and abLIM by 2.5-5-fold while suppressing that of hcKrox, T3-receptor, troponin C, and integrin by 60-75%. Given that MEF2C and hcKrox genes are transcription factors, these results pointed to the transcription control role of CGB in the nucleus.	Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Secretory Granule Res, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Yoo, SH (corresponding author), Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Secretory Granule Res, Yu Sung Gu, Taejon 305701, South Korea.							AHN TG, 1987, P NATL ACAD SCI USA, V84, P5043, DOI 10.1073/pnas.84.14.5043; BAUER JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P124, DOI 10.1016/0167-4781(91)90094-3; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; BOTTGER A, 1995, J CELL BIOL, V130, P1251, DOI 10.1083/jcb.130.6.1251; BROOKS PJ, 1993, MOL BRAIN RES, V19, P22, DOI 10.1016/0169-328X(93)90144-E; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; CASTRO MG, 1995, CELL TISSUE RES, V282, P367, DOI 10.1007/BF00318869; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; El Kharroubi A, 2001, J BIOL CHEM, V276, P8674, DOI 10.1074/jbc.M009392200; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GORR SU, 1989, AM J PHYSIOL, V257, P247; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HELLE KB, 1990, NEUROCHEM INT, V17, P165, DOI 10.1016/0197-0186(90)90139-K; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; KAETHER C, 1995, FEBS LETT, V369, P267, DOI 10.1016/0014-5793(95)00765-2; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MESKINI RE, 2001, ENDOCRINOLOGY, V142, P864; Murphy SM, 1998, J HISTOCHEM CYTOCHEM, V46, P1261, DOI 10.1177/002215549804601106; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; POHL TM, 1990, FEBS LETT, V262, P219, DOI 10.1016/0014-5793(90)80194-N; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; SIMON JP, 1989, BIOCHEM J, V262, P1; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; Widom RL, 1997, GENE, V198, P407, DOI 10.1016/S0378-1119(97)00360-0; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1994, J BIOL CHEM, V269, P12001; YOO SH, 1990, J BIOL CHEM, V265, P14414; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; Yoo SH, 1997, FEBS LETT, V406, P259, DOI 10.1016/S0014-5793(97)00276-7; Yoo SH, 2001, J BIOL CHEM, V276, P45806, DOI 10.1074/jbc.M107532200; YOO SH, 1991, J BIOL CHEM, V266, P7740	48	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16011	16021		10.1074/jbc.M105594200	http://dx.doi.org/10.1074/jbc.M105594200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854265	hybrid			2022-12-25	WOS:000175510400106
J	Bengtsson, E; Morgelin, M; Sasaki, T; Timpl, R; Heinegard, D; Aspberg, A				Bengtsson, E; Morgelin, M; Sasaki, T; Timpl, R; Heinegard, D; Aspberg, A			The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX PROTEIN; FIBROBLAST GROWTH-FACTOR; LAMININ-NIDOGEN COMPLEX; STRUCTURAL CHARACTERIZATION; DOMAIN-V; GLYCOSAMINOGLYCAN MODIFICATION; ELECTRON-MICROSCOPY; CALCIUM-BINDING; EXPRESSION	PRELP (proline arginine-rich end leucine-rich repeat protein) is a heparin-binding leucine-rich repeat protein in connective tissue extracellular matrix. In search of natural ligands and biological functions of this molecule, we found that PRELP binds the basement membrane heparan sulfate proteoglycan perlecan. Also, recombinant perlecan domains I and V carrying heparan sulfate bound PRELP, whereas other domains without glycosaminoglycan substitution did not. Heparin, but not chondroitin sulfate, inhibited the interactions. Glycosaminoglycan-free recombinant perlecan domain V and mutated domain I did not bind PRELP. The dissociation constants of the PRELP-perlecan interactions were in the range of 3-18 nm as determined by surface plasmon resonance. As expected, truncated PRELP, without the heparin-binding domain, did not bind perlecan. Confocal immunohistochemistry showed that PRELP outlines basement membranes with a location adjacent to perlecan. We also found that PRELP binds collagen type I and type 11 through its leucine-rich repeat domain. Electron microscopy visualized a complex with PRELP binding simultaneously to the triple helical region of procollagen I and the heparan sulfate chains of perlecan. Based on the location of PRELP and its interaction with perlecan heparan sulfate chains and collagen, we propose a function of PRELP as a molecule anchoring basement membranes to the underlying connective tissue.	Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, BMC, SE-21184 Lund, Sweden; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Lund University; Max Planck Society	Heinegard, D (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, BMC, C12, SE-21184 Lund, Sweden.		Bengtsson, Eva/AGH-2754-2022; Bengtsson, Eva/AAA-1968-2019	Bengtsson, Eva/0000-0001-7075-1772; Aspberg, Anders/0000-0002-6588-6944				Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Arikawa-Hirasawa E, 2001, NAT GENET, V27, P431, DOI 10.1038/86941; BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; Costell M, 1996, FEBS LETT, V396, P127, DOI 10.1016/0014-5793(96)01082-4; Costell M, 1997, EUR J BIOCHEM, V243, P115, DOI 10.1111/j.1432-1033.1997.t01-1-00115.x; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Friedrich MVK, 1999, J MOL BIOL, V294, P259, DOI 10.1006/jmbi.1999.3259; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Groffen AJA, 1996, EUR J BIOCHEM, V241, P827, DOI 10.1111/j.1432-1033.1996.00827.x; Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; HEINEGARD D, 1999, DYNAMICS BONE CARTIL, P59; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KELLER KM, 1986, BIOCHIM BIOPHYS ACTA, V882, P1, DOI 10.1016/0304-4165(86)90047-4; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KODA JE, 1985, J BIOL CHEM, V260, P8157; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Nicole S, 2000, NAT GENET, V26, P480, DOI 10.1038/82638; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PEJLER G, 1987, J BIOL CHEM, V262, P5036; Raats CJI, 1998, J BIOL CHEM, V273, P17832, DOI 10.1074/jbc.273.28.17832; Sasaki T, 1998, FEBS LETT, V435, P169, DOI 10.1016/S0014-5793(98)01063-1; SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; SCHULZE B, 1995, EUR J BIOCHEM, V231, P551, DOI 10.1111/j.1432-1033.1995.tb20731.x; Schulze B, 1996, MATRIX BIOL, V15, P349, DOI 10.1016/S0945-053X(96)90138-9; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Tapanadechopone P, 1999, BIOCHEM BIOPH RES CO, V265, P680, DOI 10.1006/bbrc.1999.1714; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079	51	113	117	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15061	15068		10.1074/jbc.M108285200	http://dx.doi.org/10.1074/jbc.M108285200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847210	hybrid			2022-12-25	WOS:000175203000090
J	Giri, TK; Linse, S; de Frutos, PG; Yamazaki, T; Villoutreix, BO; Dahlback, B				Giri, TK; Linse, S; de Frutos, PG; Yamazaki, T; Villoutreix, BO; Dahlback, B			Structural requirements of anticoagulant protein S for its binding to the complement regulator c4b-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY INTERACTION; FACTOR-VA; BETA-CHAIN; COFACTOR ACTIVITY; FACTOR-VIII; FUNCTIONAL-CHARACTERIZATION; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; FACTOR-X	The vitamin K-dependent anticoagulant protein S binds with high affinity to C4b-binding protein (C4BP), a regulator of complement. Despite the physiological importance of the complex, we have only a patchy view of the C4BP-binding site in protein S. Based on phage display experiments, protein S residues 447-460 were suggested to form part of the binding site. Several experimental approaches were now used to further elucidate the structural requirements for protein S binding to C4BP. Peptides comprising residues 447-460, 451460, or 453-460 of protein S were found to inhibit the protein S-C4BP interaction, whereas deletion of residues 459-460 from the peptide caused complete loss of inhibition. In recombinant protein S, each of residues 447-460 was mutated to Ala, and the protein S variants were tested for binding to C4BP. The Y456A mutation reduced binding to C4BP similar to10-fold, and a peptide corresponding to residues 447-460 of this mutant was less inhibitory than the parent peptide. A further decrease in binding was observed using a recombinant variant in which a site for N-linked glycosylation was moved from position 458 to 456 (Y456N/N458T). A monoclonal antibody (HPSf) selective for free protein S reacted poorly with the Y456A variant but reacted efficiently with the other variants. A second antibody, HPS 34, which partially inhibited the protein S-C4BP interaction, reacted poorly with several of the Ala mutants, suggesting that its epitope was located in the 451-460 region. Phage display analysis of the HPS 34 antibody further identified this region as its epitope. Taken together, our results suggest that residues 453-460 of protein S form part of a more complex binding site for C4BP. A recently developed three-dimensional model of the sex hormone-binding globulin-like region of protein S was used to analyze available experimental data.	Lund Univ, Univ Hosp, Dept Lab Med, Div Clin Chem,Wallenberg Lab, S-20502 Malmo, Sweden; Lund Univ, Div Biophys Chem, S-22100 Lund, Sweden; Univ Paris 05, INSERM, U428, F-75006 Paris, France	Lund University; Skane University Hospital; Lund University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dahlback, B (corresponding author), Lund Univ, Univ Hosp, Dept Lab Med, Div Clin Chem,Wallenberg Lab, S-20502 Malmo, Sweden.		Villoutreix, Bruno/I-4565-2015; de Frutos, Pablo García/B-8594-2011	Villoutreix, Bruno/0000-0002-6456-7730; de Frutos, Pablo García/0000-0003-1547-1190; Dahlback, Bjorn/0000-0003-1546-0328; Linse, Sara/0000-0001-9629-7109; Giri, Tusar/0000-0003-1682-2300				Aiach M, 1997, SEMIN HEMATOL, V34, P205; Borgel D, 1996, J LAB CLIN MED, V128, P218, DOI 10.1016/S0022-2143(96)90015-3; Brown MA, 2000, J BIOL CHEM, V275, P19795, DOI 10.1074/jbc.M002298200; CHANG CTG, 1994, THROMB HAEMOSTASIS, V71, P461; CHU MD, 1994, BBA-GENE STRUCT EXPR, V1217, P325, DOI 10.1016/0167-4781(94)90294-1; Cook BC, 2000, J BIOL CHEM, V275, P38774, DOI 10.1074/jbc.M004573200; CriadoGarcia O, 1997, HAEMOSTASIS, V27, P25; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1990, J BIOL CHEM, V265, P16082; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; DE FRUTOS PG, 1994, J IMMUNOL, V152, P2430; DE FRUTOS PG, 1994, BLOOD, V84, P815; Evenas P, 1999, EUR J BIOCHEM, V266, P935, DOI 10.1046/j.1432-1327.1999.00928.x; FERNANDEZ JA, 1993, J BIOL CHEM, V268, P16788; Fernandez JA, 1998, BLOOD CELL MOL DIS, V24, P101, DOI 10.1006/bcmd.1998.0175; Giri TK, 1999, THROMB HAEMOSTASIS, V82, P1627, DOI 10.1055/s-0037-1614890; Giri TK, 2000, BLOOD, V96, P523; Giri TK, 1998, THROMB HAEMOSTASIS, V79, P767, DOI 10.1055/s-0037-1615062; GREENGARD JS, 1995, BIOCHEM J, V305, P397, DOI 10.1042/bj3050397; Grishkovskaya I, 2000, EMBO J, V19, P504, DOI 10.1093/emboj/19.4.504; HACKENG TM, 1994, J BIOL CHEM, V269, P21051; Hardig Y, 1996, J BIOL CHEM, V271, P20861, DOI 10.1074/jbc.271.34.20861; He XH, 1997, BIOCHEMISTRY-US, V36, P3745, DOI 10.1021/bi962315q; HE XH, 1993, EUR J BIOCHEM, V217, P857, DOI 10.1111/j.1432-1033.1993.tb18314.x; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HILLARP A, 1988, J BIOL CHEM, V263, P12759; Hobba GD, 1998, J BIOL CHEM, V273, P19691, DOI 10.1074/jbc.273.31.19691; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; KOPPELMAN SJ, 1995, BLOOD, V86, P1062; LAW SKA, 1988, FOCUS COMPLEMENT, P22; Linse S, 1997, J BIOL CHEM, V272, P14658, DOI 10.1074/jbc.272.23.14658; Lu DS, 1997, THROMB HAEMOSTASIS, V77, P1156; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; NELSON RM, 1991, BIOCHEMISTRY-US, V30, P2384, DOI 10.1021/bi00223a013; O'Brien LM, 2000, BLOOD, V95, P1714, DOI 10.1182/blood.V95.5.1714.005k40_1714_1720; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; SCHWALBE R, 1990, J BIOL CHEM, V265, P16074; van de Poel RHL, 1999, J BIOL CHEM, V274, P15144, DOI 10.1074/jbc.274.21.15144; van Wijnen M, 1998, THROMB HAEMOSTASIS, V80, P930; van Wijnen M, 1998, BIOCHEM J, V330, P389; Villoutreix BO, 2001, PROTEINS, V43, P203, DOI 10.1002/1097-0134(20010501)43:2<203::AID-PROT1031>3.0.CO;2-W; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P322, DOI 10.1016/0003-9861(87)90037-3; WALKER FJ, 1989, J BIOL CHEM, V264, P17645; Webb JH, 2001, J BIOL CHEM, V276, P4330, DOI 10.1074/jbc.M006541200; WEINSTEIN RE, 1990, J CLIN INVEST, V86, P1928, DOI 10.1172/JCI114926; YASUDA F, 1995, J BIOCHEM-TOKYO, V117, P374, DOI 10.1093/jb/117.2.374; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	55	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15099	15106		10.1074/jbc.M103036200	http://dx.doi.org/10.1074/jbc.M103036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847209	hybrid			2022-12-25	WOS:000175203000095
J	Abbott, GW; Goldstein, SAN				Abbott, GW; Goldstein, SAN			Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism	FASEB JOURNAL			English	Article						MinK; MiRP1; MiRP2; KCNQ1; HERG; Kv3.4; periodic paralysis; cardiac arrhythmia	LONG-QT SYNDROME; GATED K+ CHANNEL; I-KS; CARDIAC-ARRHYTHMIA; LANGE-NIELSEN; MINK SUBUNITS; KVLQT1; FORM; GENE; KR	KCNE genes encode single transmembrane-domain subunits, the MinK-related peptides (MiRPs), which assemble with pore-forming alpha subunits to establish the attributes of potassium channels in vivo. To investigate whether MinK, MiRP1, and MiRP2 operate similarly with their known native alpha subunit partners (KCNQ1, HERG, and Kv3.4, respectively) two conserved residues associated with human disease and influential in channel function were evaluated. As MiRPs assemble with a variety of alpha subunits in experimental cells and may do so in vivo, each peptide was also assessed with the other two alpha subunits. Inherited mutation of aspartate to asparagine (D --> N) to yield D76N-MinK is linked to cardiac arrhythmia and deafness; the analogs D82N-MiRP1 and D90N-MiRP2 were studied. Mutation of arginine to histidine (R --> H) to yield R83H-MiRP2 is associated with periodic paralysis; the analogs K69H-MinK and K75H-MiRP1 were also studied. Macroscopic and single-channel currents showed that D 3 N mutations suppressed a subset of functions whereas R/K --> H changes altered the activity of MinK, MiRP1, and MiRP2 with all three alpha subunits. The findings indicate that the KCNE peptides interact similarly with different alpha subunits and suggest a hypothesis: that clinical manifestations of inherited KCNE point mutations result from disruption of multiple native currents via promiscuous interactions.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA	Yale University; Yale University	Goldstein, SAN (corresponding author), Sect Dev Biol & Biophys, 295 Congress Ave, New Haven, CT 06536 USA.	steve.goldstein@yale.edu	Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061; Abbott, Geoffrey/0000-0003-4552-496X				Abbott G W, 2001, Mol Interv, V1, P95; Abbott GW, 1998, Q REV BIOPHYS, V31, P357, DOI 10.1017/S0033583599003467; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CIRC RES, V88, P981, DOI 10.1161/hh1001.091869; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Ackerman MJ, 1998, MAYO CLIN PROC, V73, P250, DOI 10.4065/73.3.250; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 1999, HUM MOL GENET, V8, P1499, DOI 10.1093/hmg/8.8.1499; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Duggal P, 1998, CIRCULATION, V97, P142, DOI 10.1161/01.CIR.97.2.142; Franco D, 2001, CARDIOVASC RES, V52, P65, DOI 10.1016/S0008-6363(01)00349-2; Franqueza L, 1999, J BIOL CHEM, V274, P21063, DOI 10.1074/jbc.274.30.21063; Hille B., 1992, IONIC CHANNELS EXCIT; Kaczmarek LK, 1997, PHYSIOL REV, V77, P627, DOI 10.1152/physrev.1997.77.3.627; Kim LA, 2001, BIOPHYS J, V80, p437A; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Melman YF, 2001, J BIOL CHEM, V276, P6439, DOI 10.1074/jbc.M010713200; Nerbonne JM, 1998, J NEUROBIOL, V37, P37, DOI 10.1002/(SICI)1097-4695(199810)37:1<37::AID-NEU4>3.0.CO;2-9; Sanguinetti MC, 2000, J CARDIOVASC ELECTR, V11, P710, DOI 10.1111/j.1540-8167.2000.tb00035.x; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroer TA, 2000, TRAFFIC, V1, P3, DOI 10.1034/j.1600-0854.2000.010102.x; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tai KK, 1998, NATURE, V391, P605, DOI 10.1038/35416; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Tapper AR, 2000, J GEN PHYSIOL, V116, P379, DOI 10.1085/jgp.116.3.379; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Tristani-Firouzi M, 1998, J PHYSIOL-LONDON, V510, P37, DOI 10.1111/j.1469-7793.1998.037bz.x; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839; Zhu XR, 1999, RECEPTOR CHANNEL, V6, P387	36	73	79	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0390	10.1096/fj.01-0520hyp	http://dx.doi.org/10.1096/fj.01-0520hyp			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874988				2022-12-25	WOS:000174755900031
J	Yin, XL; Pang, JCS; Ng, HK				Yin, XL; Pang, JCS; Ng, HK			Identification of a region of homozygous deletion on 8p22-23.1 in medulloblastoma	ONCOGENE			English	Article						rnedulloblastoma; chromosome 8p; homozygous deletion; allelotyping	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENES; SHORT ARM; PROSTATE-CANCER; ALLELIC LOSS; CHROMOSOME 8P; CELL LINES; HETEROZYGOSITY; CARCINOMA; ABNORMALITIES	To identify critical tumor suppressor loci that are associated with the development of medulloblastoma, we performed a comprehensive genome-wide allelotype analysis in a series of 12 medulloblastomas. Non-random allelic imbalances were identified on chromosomes 7q (58.3%), 8p (66.7%), 16q (58.3%), 17p (58.3%) and 17q (66.7%). Comparative genomic hybridization analysis confirmed that allelic imbalances on 8p, 16q and 17p were due to loss of genetic materials. Finer deletion mapping in an expanded series of 23 medulloblastomas localized the common deletion region on 8p to an interval of 18.14 cM on 8p22-23.2. We then searched within the region of loss on 8p for loci that might contain homozygous deletion using comparative duplex PCR. An overlapping homozygous deletion region was identified in a 1.8 cM interval on 8p22-23.1, between markers D8S520 and D8S1130, in two medulloblastomas. This region of homozygous deletion also encompasses the 1.4 cM minimal deletion region detected on 8p in ductal carcinoma in situ of breast. In conclusion, we reported for the first time a detailed deletion mapping on 8p in medulloblastoma and have identified a region of homozygous deletion on 8p22-23.1 that is likely to contain a critical tumor suppressor gene involved in the development of medulloblastoma.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anatom & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Ng, HK (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anatom & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.	hkng@cuhk.edu.hk	Ng, Ho Keung/I-3952-2015; Pang, Jesse CS/H-3549-2013	Pang, Jesse CS/0000-0002-8716-4045				Arbieva ZH, 2000, GENOME RES, V10, P244, DOI 10.1101/gr.10.2.244; Avet-Loiseau H, 1999, BRIT J CANCER, V79, P1843, DOI 10.1038/sj.bjc.6690293; Baffa R, 2000, CLIN CANCER RES, V6, P1372; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; Blaeker H, 1996, GENE CHROMOSOME CANC, V15, P54, DOI 10.1002/(SICI)1098-2264(199601)15:1<54::AID-GCC8>3.3.CO;2-4; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Farrington SM, 1996, ONCOGENE, V12, P1803; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GIANGASPERO F, 2000, PATHOLOGY GENETICS T, P129; Gilhuis HJ, 2000, CLIN NEUROL NEUROSUR, V102, P203, DOI 10.1016/S0303-8467(00)00112-8; HEIDEMAN RL, 1997, PRINCIPLES PRACTICE, P651; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Ishii H, 2001, P NATL ACAD SCI USA, V98, P10374, DOI 10.1073/pnas.181222898; Ishwad CS, 1999, INT J CANCER, V80, P25, DOI 10.1002/(SICI)1097-0215(19990105)80:1<25::AID-IJC6>3.3.CO;2-7; Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.0.CO;2-1; KAGAN J, 1995, ONCOGENE, V11, P2121; Lassus H, 2001, LAB INVEST, V81, P517, DOI 10.1038/labinvest.3780260; Leung YF, 2001, BIOTECHNIQUES, V30, P334, DOI 10.2144/01302tt02; Levy A, 1999, GENE CHROMOSOME CANC, V24, P42, DOI 10.1002/(SICI)1098-2264(199901)24:1<42::AID-GCC6>3.0.CO;2-F; Ng IOL, 2000, CANCER RES, V60, P6581; Nicholson JC, 1999, BRIT J CANCER, V80, P1322, DOI 10.1038/sj.bjc.6690525; Nihei N, 1996, GENE CHROMOSOME CANC, V17, P260, DOI 10.1002/(SICI)1098-2264(199612)17:4<260::AID-GCC8>3.0.CO;2-1; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Prasad MA, 1998, GENE CHROMOSOME CANC, V23, P255, DOI 10.1002/(SICI)1098-2264(199811)23:3<255::AID-GCC8>3.3.CO;2-Q; Reardon DA, 1997, CANCER RES, V57, P4042; SAYLORS RL, 1991, CANCER RES, V51, P4721; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sun PC, 1999, GENOMICS, V62, P184, DOI 10.1006/geno.1999.6020; Sunwoo JB, 1999, ONCOGENE, V18, P2651, DOI 10.1038/sj.onc.1202838; Takle LA, 1996, ONCOGENE, V12, P1083; Tanaka K, 1996, ONCOGENE, V12, P405; Tong CYK, 2001, J NEUROSURG, V95, P9, DOI 10.3171/jns.2001.95.1.0009; Vecchione A, 2001, CLIN CANCER RES, V7, P1546; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; Wang JC, 1999, GENOMICS, V60, P1, DOI 10.1006/geno.1999.5905; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Wistuba II, 1999, CANCER RES, V59, P1973; Wright K, 1998, ONCOGENE, V17, P1185, DOI 10.1038/sj.onc.1202028; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Yin XL, 2000, J NEUROSURG, V93, P77, DOI 10.3171/jns.2000.93.1.0077; Yin XL, 2001, J NEUROSURG, V94, P799, DOI 10.3171/jns.2001.94.5.0799; Yuan BZ, 1998, CANCER RES, V58, P2196	43	24	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1461	1468		10.1038/sj.onc.1205204	http://dx.doi.org/10.1038/sj.onc.1205204			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857089				2022-12-25	WOS:000173861000016
J	Brennan, P; Mehl, AM; Jones, M; Rowe, M				Brennan, P; Mehl, AM; Jones, M; Rowe, M			Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells	ONCOGENE			English	Article						cyclin; survival; LY294002; PKB; latent membrane protein-1; EBNAZA	EPSTEIN-BARR-VIRUS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS; LATENT MEMBRANE-PROTEIN; KINASE-B ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; BURKITTS-LYMPHOMA; C-MYC; BAD PHOSPHORYLATION; DOWN-REGULATION; CYCLE ARREST	B-cell lymphoma, which is increasing world wide, includes such varied conditions as post-transplant lymphoproliferative disease (PTLD) and Burkitt's lymphoma. This study has characterized a role for the signalling molecule phosphatidylinositol 3-kinase, PI3K, in the regulation of growth and survival of immortalized B-lymphocytes. Burkitt's lymphoma cells die rapidly following inhibition of PI3K with LY294002, a chemical inhibitor. Furthermore, Epstein-Barr virus (EBV) immortalized B-cells, lymphoblastoid cell lines, which are a model of PTLD, do not die but are growth inhibited. This growth inhibition is due to an accumulation at G1 phase of the cell cycle and is paralleled by a loss of E2F transcriptional activity, which is essential for cell cycle entry. An active form of PI3K promotes E2F transcriptional activity in lymphoblastoid cell lines. Treatment of LCL with LY294002 causes a reduction of the expression of both cyclin D2 and cyclin D3, two key cyclins required for cell cycle progression but does not affect the expression of the EBV latent genes, EBNA2A or LMP-1. LY294002 also causes an increase in p27kip1, a cyclin dependent kinase inhibitor and results in the dephosphorylation of members of the pocket protein family. These data describe a mechanism by which PI3K plays a role in B-lymphocyte growth and suggests that a pathway from PI3K to D-type cyclin expression may provide diagnostic or treatment opportunities.	Cardiff Univ, Sect Infect & Immun, Cardiff CF14 4XX, S Glam, Wales	Cardiff University	Brennan, P (corresponding author), Cardiff Univ, Sect Infect & Immun, Tenovus Bldg, Cardiff CF14 4XX, S Glam, Wales.	brennanp@cf.ac.uk	Brennan, Paul/B-9210-2009; Brennan, Paul/ABB-9196-2021; Rowe, Martin/B-2880-2009	Brennan, Paul/0000-0001-8792-0499; Brennan, Paul/0000-0001-8792-0499; Rowe, Martin/0000-0003-4139-7326				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brennan P, 2001, SEMIN CANCER BIOL, V11, P415, DOI 10.1006/scbi.2001.0408; Butler MP, 1999, GENE CHROMOSOME CANC, V24, P322, DOI 10.1002/(SICI)1098-2264(199904)24:4<322::AID-GCC5>3.0.CO;2-9; Carey GB, 2001, J IMMUNOL, V166, P1618, DOI 10.4049/jimmunol.166.3.1618; Chung TDK, 2000, PROSTATE, V42, P1; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Crawley JB, 1996, J BIOL CHEM, V271, P16357, DOI 10.1074/jbc.271.27.16357; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Fais F, 1996, INT J CANCER, V68, P810, DOI 10.1002/(SICI)1097-0215(19961211)68:6<810::AID-IJC20>3.0.CO;2-2; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Gold MR, 2000, IMMUNOL REV, V176, P47; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; Griffiths PD, 1999, J MED VIROL, V59, P496, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt;496::AID-JMV12&gt;3.0.CO;2-U; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hinton HJ, 1999, J IMMUNOL, V162, P7002; *IARC W, 1997, EPST VIR KAP SARC HE, V70, P47; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Jones KD, 1999, BLOOD, V94, P2871; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MILNER AE, 1993, ONCOGENE, V8, P3385; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; Nalesnik MA, 1998, SPRINGER SEMIN IMMUN, V20, P325, DOI 10.1007/BF00838047; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALMERO I, 1993, ONCOGENE, V8, P1049; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROWE M, 1986, INT J CANCER, V37, P367, DOI 10.1002/ijc.2910370307; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Rowe M, 2001, Methods Mol Biol, V174, P229; Rowe M, 1998, SPRINGER SEMIN IMMUN, V20, P389, DOI 10.1007/BF00838051; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; SAMPLE J, 1990, J VIROL, V64, P1667, DOI 10.1128/JVI.64.4.1667-1674.1990; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Spender LC, 2001, J VIROL, V75, P3537, DOI 10.1128/JVI.75.8.3537-3546.2001; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Tosato G, 1998, SPRINGER SEMIN IMMUN, V20, P405, DOI 10.1007/BF00838052; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; YOUNG LS, 1987, J GEN VIROL, V68, P2853, DOI 10.1099/0022-1317-68-11-2853	58	51	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1263	1271		10.1038/sj.onc.1205182	http://dx.doi.org/10.1038/sj.onc.1205182			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850846				2022-12-25	WOS:000173729400014
J	Lalioti, VS; Vergarajauregui, S; Pulido, D; Sandoval, IV				Lalioti, VS; Vergarajauregui, S; Pulido, D; Sandoval, IV			The insulin-sensitive glucose transporter, GLUT4, interacts physically with Daxx - Two proteins with capacity to bind Ubc9 and conjugated to SUMO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CELL-DEATH; CENTROMERE PROTEIN; CENP-C; SIGNAL; PML; APOPTOSIS; MEMBRANE; SENTRIN; ND10; ACTIVATION	In this study we have used the yeast two-hybrid system to identify proteins that interact with the carboxyl-cytoplasmic domain (residues 464-509) of the insulin-sensitive glucose transporter GLUT4 (C-GLUT4). Using as bait C-GLUT4, we have isolated the carboxyl domain of Daxx (C-Daxx), the adaptor protein associated with the Fas and the type 11 TGF-beta (TbetaRII) receptors (1, 2). The two-hybrid interaction between C-GLUT4 and C-Daxx is validated by the ability of in vitro translated C-GLUT4 to interact with in vitro translated full-length Daxx and C-Daxx. C-Daxx does not interact with the C-cytoplasmic domain of GLUT1, the ubiquitous glucose transporter homologous to GLUT4. Replacement of alanine and serine for the dileucine pair (Leu(419)-Leu(490)) critical for targeting GLUT4 from the trans-Golgi network to the perinuclear intracellular store as well as for its surface internalization by endocytosis inhibits 2-fold the interaction of C-GLUT4 with Daxx. Daxx is pulled down with GLUT4 immunoprecipitated from lysates of 3T3-L1 fibroblasts stably transfected with GLUT4 and 3T3-L1 adipocytes expressing physiological levels of the two proteins. Similarly, GLUT4 is recovered with anti-Daxx immunoprecipitates. Using an established cell fractionation procedure we present evidence for the existence of two distinct intracellular Daxx pools in the nucleus and low density microsomes. Confocal immunofluorescence microscopy studies localize Daxx to promyelocytic leukemia nuclear bodies and punctate cytoplasmic structures, often organized in strings and underneath the plasma membrane. Daxx and GLUT4 are SUMOlated as shown by their reaction with an anti-SUM01 antibody and by the ability of this antibody to pull down Daxx and GLUT4.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Sandoval, IV (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Pulido, Diego/ABE-8310-2021; Vergarajauregui, Silvia/ABG-8402-2020	Vergarajauregui, Silvia/0000-0002-9247-6123; LALIOTI, VASILIKI/0000-0002-4273-6126				Bell P, 2000, J VIROL, V74, P5329, DOI 10.1128/JVI.74.11.5329-5336.2000; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; CZECH MP, 1993, J BIOL CHEM, V1, P127; Everett RD, 1999, J CELL SCI, V112, P3443; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; HARAGUCHI K, 1990, P NATL ACAD SCI USA, V87, P1208, DOI 10.1073/pnas.87.3.1208; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Michaelson JS, 2000, APOPTOSIS, V5, P217, DOI 10.1023/A:1009696227420; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Okura T, 1996, J IMMUNOL, V157, P4277; PERIMAN R, 2001, NAT CELL BIOL, V3, P708; Pluta AF, 1998, J CELL SCI, V111, P2029; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Ryu SW, 2000, BIOCHEM BIOPH RES CO, V279, P6, DOI 10.1006/bbrc.2000.3882; Sandoval IV, 2000, J BIOL CHEM, V275, P39874, DOI 10.1074/jbc.M006261200; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	36	61	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19783	19791		10.1074/jbc.M110294200	http://dx.doi.org/10.1074/jbc.M110294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11842083	hybrid			2022-12-25	WOS:000175894800071
J	Spencer, ML; Shao, H; Tucker, HM; Andres, DA				Spencer, ML; Shao, H; Tucker, HM; Andres, DA			Nerve Growth Factor-dependent activation of the small GTPase rin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE OUTGROWTH; MAP KINASE; SIGNAL-TRANSDUCTION; PC12 CELLS; NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA CELLS; EXCHANGE FACTORS; RHO GTPASES; RAS; PROTEIN	The Rit and Rin proteins comprise a distinct and evolutionarily conserved subfamily of Ras-related small GTPases. Although we have defined a role for Rit-mediated signal transduction in the regulation of cell proliferation and transformation, the function of Rin remains largely unknown. Because we demonstrate that Rin is developmentally regulated and expressed in adult neurons, we examined its role in neuronal signaling. In this study, we show that stimulation of PC6 cells with either epidermal growth factor or nerve growth factor (NGF) results in rapid activation of Rin. This activation correlates with the onset of Ras activation, and dominant-negative Ras completely inhibits Rin activation induced by NGF. Further examination of Ras-mediated Rin activation suggests that this process is dependent upon neuronally expressed regulatory factors. Expression of mutationally activated H-Ras fails to activate Rin in non-neuronal cells, but results in potent stimulation of Rin-GTP levels in a variety of neuronal cell lines. Furthermore, although constitutively activated Rin does not induce neurite outgrowth on its own, both NGF-induced and oncogenic Ras-induced neurite outgrowth were inhibited by the expression of dominant-negative Rin. Together, these studies indicate that Rin activation is a direct downstream effect of growth factor-dependent signaling in neuronal cells and suggest that Rin may function to transduce signals within the mature nervous system.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Andres, DA (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	dandres@pop.uky.edu						Andres DA, 1997, ARCH BIOCHEM BIOPHYS, V346, P113, DOI 10.1006/abbi.1997.0296; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHANDLER CE, 1983, J CELL PHYSIOL, V114, P321, DOI 10.1002/jcp.1041140311; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Curtis J, 1999, J NEUROSCI RES, V58, P88, DOI 10.1002/(SICI)1097-4547(19991001)58:1<88::AID-JNR9>3.3.CO;2-I; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Estus S, 1997, J NEUROSCI, V17, P7736; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; FUKUDA M, 1995, ONCOGENE, V11, P239; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; Orban PC, 1999, TRENDS NEUROSCI, V22, P38, DOI 10.1016/S0166-2236(98)01306-X; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Quilliam LA, 2001, METHOD ENZYMOL, V333, P187; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Shao HP, 2000, J BIOL CHEM, V275, P26914; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VAN AL, 1997, GENE DEV, V11, P2295; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	65	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17605	17615		10.1074/jbc.M111400200	http://dx.doi.org/10.1074/jbc.M111400200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877426	hybrid			2022-12-25	WOS:000175685100029
J	Camenisch, G; Pisabarro, MT; Sherman, D; Kowalski, J; Nagel, M; Hass, P; Xie, MH; Gurney, A; Bodary, S; Liang, XH; Clark, K; Beresini, M; Ferrara, N; Gerber, HP				Camenisch, G; Pisabarro, MT; Sherman, D; Kowalski, J; Nagel, M; Hass, P; Xie, MH; Gurney, A; Bodary, S; Liang, XH; Clark, K; Beresini, M; Ferrara, N; Gerber, HP			ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha(v)beta(3) and induces blood vessel formation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GAMMA-CHAIN; MOLECULAR-CLONING; TIE2 RECEPTOR; PROTEIN; ANGIOPOIETIN-1; EXPRESSION; IDENTIFICATION; LIGANDS; SPECIFICITY	The angiopoietin family of secreted factors is functionally defined by the C-terminal fibrinogen (FBN)-like domain, which mediates binding to the Tie2 receptor and thereby facilitates a cascade of events ultimately regulating blood vessel formation. By screening expressed sequence tag data bases for homologies to a consensus FBN-like motive, we have identified ANGPTL3, a liver-specific, secreted factor consisting of an N-terminal coiled-coil domain and the C-terminal FBN-like domain. Co-immunoprecipitation experiments, however, failed to detect binding of ANGPTL3 to the Tie2 receptor. A molecular model of the FBN-like domain of ANGPTL3 was generated and predicted potential binding to integrins. This hypothesis was experimentally confirmed by the finding that recombinant ANGPTL3 bound to alpha(v)beta(3) and induced integrin alpha(v)beta(3)-dependent haptotactic endothelial cell adhesion and migration and stimulated signal transduction pathways characteristic for integrin activation, including phosphorylation of Akt, mitogen-activated protein kinase, and focal adhesion kinase. When tested in the rat corneal assay, ANGPTL3 strongly induced angiogenesis with comparable magnitude as observed for vascular endothelial growth factor-A. Moreover, the C-terminal FBN-like domain alone was sufficient to induce endothelial cell adhesion and in vivo angiogenesis. Taken together, our data demonstrate that ANGPTL3 is the first member of the angiopoietin-like family of secreted factors binding to integrin alpha(v)beta(3) and suggest a possible role in the regulation of angiogenesis.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Res & Dev, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Gerber, HP (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	gerberhp@gene.com	Pisabarro, M. Teresa/D-4270-2012					Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; BREM RB, 1994, INVEST OPHTH VIS SCI, V35, P3466; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; CHUNTHARAPAI A, 1993, EXP CELL RES, V205, P345, DOI 10.1006/excr.1993.1096; Conklin D, 1999, GENOMICS, V62, P477, DOI 10.1006/geno.1999.6041; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Eliceiri BP, 1998, MOL MED, V4, P741, DOI 10.1007/BF03401768; Eliceiri BP, 2000, CANCER J, V6, pS245; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; Gadek TR, 2002, SCIENCE, V295, P1086, DOI 10.1126/science.295.5557.1086; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; HOSHIGA M, 1995, CIRC RES, V77, P1129, DOI 10.1161/01.RES.77.6.1129; Hynes RO, 1999, BRAZ J MED BIOL RES, V32, P501, DOI 10.1590/S0100-879X1999000500002; Hynes RO, 1997, THROMB HAEMOSTASIS, V78, P83; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kim I, 1999, FEBS LETT, V443, P353, DOI 10.1016/S0014-5793(99)00008-3; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Peek R, 1998, INVEST OPHTH VIS SCI, V39, P1782; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Suzuma K, 1998, INVEST OPHTH VIS SCI, V39, P1028; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; Walton HL, 2000, J CELL BIOCHEM, V78, P674, DOI 10.1002/1097-4644(20000915)78:4<674::AID-JCB16>3.0.CO;2-G; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485; Xin XH, 2001, AM J PATHOL, V158, P1111, DOI 10.1016/S0002-9440(10)64058-8; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; Yokoyama K, 2000, J BIOL CHEM, V275, P16891, DOI 10.1074/jbc.M000610200	39	180	220	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17281	17290		10.1074/jbc.M109768200	http://dx.doi.org/10.1074/jbc.M109768200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877390	hybrid			2022-12-25	WOS:000175564500123
J	Falsone, SF; Weichel, M; Crameri, R; Breitenbach, M; Kungl, AJ				Falsone, SF; Weichel, M; Crameri, R; Breitenbach, M; Kungl, AJ			Unfolding and double-stranded DNA binding of the cold shock protein homologue Cla h 8 from Cladosporium herbarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS CSPB; FUMIGATUS ALLERGEN-I/A; SOLUTION NMR STRUCTURE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; CDNA LIBRARIES; IGE-BINDING; TRANSCRIPTION; CLONING; DOMAIN	The cloning, purification, and biophysical characterization of the first eukaryotic cold shock protein homologue, Cla h 8, expressed as single functional polypeptide is reported here. It was discovered as a minor allergen of the mold Cladosporium herbarum by phage display using a library selectively enriched for IgE-binding proteins. Based on the sequence homology of Cla h 8 with bacterial cold shock proteins (CSPs), a homology-based computer model of the allergen was computed indicating an all-beta structure of Cla h 8. This major structural feature was confirmed by CD spectroscopy. Despite the structural similarities with bacterial CSPs, the DNA-binding and unfolding behavior of Cla h 8 exhibited unique and previously undescribed characteristics. High affinities of Cla h 8 for single-stranded DNA as well as for double-stranded DNA corresponding to the human Y-box were detected. The affinity for double-stranded DNA increased significantly with decreasing temperature, which was paralleled by an increase in the beta sheet content of the protein. Temperature-dependent fluorescence anisotropy and far-UV CD measurements revealed different unfolding transitions at 28 and at 35.7 degreesC, respectively, indicating a multistate transition, which is uncommon for CSPs. The enhanced affinity for DNA at low temperatures together with the low unfolding transition refer to the functional significance of Cla h 8 at reduced temperatures.	Graz Univ, Inst Phamraceut Chem & Pharmaceut Technol, Dept Prot Chem & Biophys, A-8010 Graz, Austria; Salzburg Univ, Inst Genet & Gen Biol, A-5020 Salzburg, Austria; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	University of Graz; Salzburg University; Swiss Institute of Allergy & Asthma Research	Kungl, AJ (corresponding author), Graz Univ, Inst Phamraceut Chem & Pharmaceut Technol, Dept Prot Chem & Biophys, A-8010 Graz, Austria.	andreas.kungl@kfunigraz.ac.at		Falsone, Salvatore Fabio/0000-0002-3724-5824; Kungl, Andreas/0000-0003-3362-797X				ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; Bae WH, 2000, P NATL ACAD SCI USA, V97, P7784, DOI 10.1073/pnas.97.14.7784; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; Crameri R, 2001, INT ARCH ALLERGY IMM, V124, P43, DOI 10.1159/000053664; Crameri R, 2001, COMB CHEM HIGH T SCR, V4, P145; Crameri R, 1997, GENE CLONING ANAL CU, P29; CRAMERI R, 2001, METHOD MOL BIOL, P461; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Falsone SF, 2001, BIOCHEM BIOPH RES CO, V285, P1180, DOI 10.1006/bbrc.2001.5318; Feng WQ, 1998, BIOCHEMISTRY-US, V37, P10881, DOI 10.1021/bi980269j; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GRAUMANN P, 1994, FEBS LETT, V338, P157, DOI 10.1016/0014-5793(94)80355-2; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Hillier BJ, 1998, FOLD DES, V3, P87, DOI 10.1016/S1359-0278(98)00014-5; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Jiang WN, 1997, J BIOL CHEM, V272, P196; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; Kristl S, 2000, FEBS LETT, V467, P87, DOI 10.1016/S0014-5793(00)01118-2; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; Lopez MM, 2000, BBA-PROTEIN STRUCT M, V1479, P196, DOI 10.1016/S0167-4838(00)00048-0; Lopez MM, 2001, J BIOL CHEM, V276, P15511, DOI 10.1074/jbc.M010474200; Lopez MM, 1999, J BIOL CHEM, V274, P33601, DOI 10.1074/jbc.274.47.33601; LUMRY R, 1966, BIOPOLYMERS, V4, P917, DOI 10.1002/bip.1966.360040808; MAIER E, 1994, J BIOTECHNOL, V12, P433; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; MOSER M, 1992, J IMMUNOL, V149, P454; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; Mueller U, 2000, J MOL BIOL, V297, P975, DOI 10.1006/jmbi.2000.3602; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NEWKIRK K, 1994, P NATL ACAD SCI USA, V91, P5114, DOI 10.1073/pnas.91.11.5114; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Phadtare S, 1999, CURR OPIN MICROBIOL, V2, P175, DOI 10.1016/S1369-5274(99)80031-9; Rodriguez HM, 2000, PROTEIN SCI, V9, P1993, DOI 10.1110/ps.9.10.1993; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; Schindler T, 1998, PROTEINS, V30, P401, DOI 10.1002/(SICI)1097-0134(19980301)30:4<401::AID-PROT7>3.3.CO;2-G; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Simon-Nobbe B, 2000, J ALLERGY CLIN IMMUN, V106, P887, DOI 10.1067/mai.2000.110799; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Wang N, 2000, MOL MICROBIOL, V38, P526, DOI 10.1046/j.1365-2958.2000.02146.x; Wassenberg D, 1999, J MOL BIOL, V289, P187, DOI 10.1006/jmbi.1999.2772; Yamanaka K, 2001, GENES CELLS, V6, P279, DOI 10.1046/j.1365-2443.2001.00424.x	53	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16512	16516		10.1074/jbc.M200833200	http://dx.doi.org/10.1074/jbc.M200833200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861653	hybrid			2022-12-25	WOS:000175564500025
J	Han, R; Tsui, SL; Smith, TJ				Han, R; Tsui, SL; Smith, TJ			Up-regulation of prostaglandin E-2 synthesis by interleukin-1 beta in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E-2 synthase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE H SYNTHASE-2; ACTIVATED PROTEIN-KINASE; CULTURED HUMAN-FIBROBLASTS; MESSENGER-RNA; LEUKOREGULIN INDUCTION; HYALURONATE SYNTHESIS; INTERFERON-GAMMA; G/H SYNTHASE; CYCLOOXYGENASE-2; CELLS	Prostaglandin E-2 (PGE(2)) production involves the activity of a multistep biosynthetic pathway. The terminal components of this cascade, two PGE(2) synthases (PGES), have very recently been identified as glutathione-dependent proteins. cPGES is cytoplasmic, apparently identical to the hsp90 chaperone, p23, and associates functionally with prostaglandin-endoperoxide H synthase-1 (PGHS-1), the constitutive cyclooxygenase. A second synthase, designated mPGES, is microsomal and can be regulated. Here we demonstrate that mPGES and PGHS-2 are expressed at very low levels in untreated human orbital fibroblasts. Interleukin (IL)-1beta treatment elicits high levels of PGHS-2 and mPGES expression. The induction of both enzymes occurs at the pretranslational level, is the consequence of enhanced gene promoter activities, and can be blocked by dexamethasone (10 nM). SC58125, a PGHS-2-selective inhibitor, could attenuate the induction of mPGES, suggesting a dependence of this enzyme on PGHS-2 activity. IL-1beta treatment activates p38 and ERK mitogen-activated protein kinases. Induction of both mPGES and PGHS-2 was susceptible to either chemical inhibition or molecular interruption of these pathways with dominant negative constructs. These results indicate that the induction of PGHS-2 and mPGES by IL-1beta underlies robust PGE(2) production in orbital fibroblasts.	Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Med, Div Mol Med, Torrance, CA 90502 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Smith, TJ (corresponding author), Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Med, Div Mol Med, C-2,1124 W Carson St, Torrance, CA 90502 USA.	tjsmith@ucla.edu	Smith, Terry/ABG-1360-2020	Smith, Terry/0000-0002-6279-9685	NEI NIH HHS [EY11708, EY08976] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008976, R01EY011708] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; BERENSON CS, 1995, J CLIN ENDOCR METAB, V80, P2668, DOI 10.1210/jc.80.9.2668; Cao HJ, 1999, AM J PHYSIOL-CELL PH, V277, pC1075, DOI 10.1152/ajpcell.1999.277.6.C1075; Cao HJ, 1998, J BIOL CHEM, V273, P29615, DOI 10.1074/jbc.273.45.29615; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Forsberg L, 2000, FEBS LETT, V471, P78, DOI 10.1016/S0014-5793(00)01367-3; Freeman BC, 2000, GENE DEV, V14, P422; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Hla T, 1996, PROSTAG OTH LIPID M, V51, P81, DOI 10.1016/0090-6980(95)00158-1; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HUFNAGEL TJ, 1984, OPHTHALMOLOGY, V91, P1411; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kehry M R, 1994, Semin Immunol, V6, P287, DOI 10.1006/smim.1994.1037; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; OBANION MK, 1991, J BIOL CHEM, V266, P23261; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Ridley SH, 1997, J IMMUNOL, V158, P3165; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Sciaky D, 2000, J IMMUNOL, V164, P3806, DOI 10.4049/jimmunol.164.7.3806; Sempowski GD, 1998, AM J PHYSIOL-CELL PH, V274, pC707, DOI 10.1152/ajpcell.1998.274.3.C707; Sempowski GD, 1996, J CELL PHYSIOL, V167, P290, DOI 10.1002/(SICI)1097-4652(199605)167:2<290::AID-JCP13>3.3.CO;2-A; Smith RS, 1997, AM J PATHOL, V151, P317; Smith TJ, 1999, ENDOCRINOLOGY, V140, P3518, DOI 10.1210/en.140.8.3518; SMITH TJ, 1989, J CLIN ENDOCR METAB, V69, P1019, DOI 10.1210/jcem-69-5-1019; SMITH TJ, 1992, AM J PHYSIOL, V263, pC24, DOI 10.1152/ajpcell.1992.263.1.C24; Smith TJ, 1998, RHEUM DIS CLIN N AM, V24, P501, DOI 10.1016/S0889-857X(05)70023-5; Smith TJ, 1999, EXP CLIN ENDOCR DIAB, V107, pS160, DOI 10.1055/s-0029-1212175; SMITH TJ, 1994, P NATL ACAD SCI USA, V91, P5094, DOI 10.1073/pnas.91.11.5094; SMITH TJ, 1993, AM J PHYSIOL, V265, pC138, DOI 10.1152/ajpcell.1993.265.1.C138; SMITH TJ, 1987, J CLIN INVEST, V79, P1493, DOI 10.1172/JCI112979; SMITH TJ, 1995, J CLIN ENDOCR METAB, V80, P2620, DOI 10.1210/jc.80.9.2620; SMITH TJ, 1988, METABOLISM, V37, P179, DOI 10.1016/S0026-0495(98)90015-4; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sorisky A, 1996, J CLIN ENDOCR METAB, V81, P3428, DOI 10.1210/jc.81.9.3428; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Thoren S, 2000, EUR J BIOCHEM, V267, P6428, DOI 10.1046/j.1432-1327.2000.01735.x; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; WANG HS, 1995, J CLIN ENDOCR METAB, V80, P3553, DOI 10.1210/jc.80.12.3553; Wang HS, 1996, J BIOL CHEM, V271, P22718, DOI 10.1074/jbc.271.37.22718; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; Young DA, 1998, P NATL ACAD SCI USA, V95, P8904, DOI 10.1073/pnas.95.15.8904	49	133	137	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16355	16364		10.1074/jbc.M111246200	http://dx.doi.org/10.1074/jbc.M111246200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11847219	hybrid			2022-12-25	WOS:000175564500003
J	Prado, F; Vicent, G; Cardalda, C; Beato, M				Prado, F; Vicent, G; Cardalda, C; Beato, M			Differential role of the proline-rich domain of nuclear factor 1-C splice variants in DNA binding and transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; REPLICATION; PROTEINS; YEAST; EXPRESSION; GENES; HETERODIMERS	We have addressed the functional significance of the existence of several natural splice variants of NF1-C* differing in their COOH-terminal proline-rich transactivation domain (PRD) by studying their specific DNA binding and transactivation in the yeast Saccharomyces cerevisiae. These parameters yielded the intrinsic transactivation potential (ITP), defined as the activation observed with equal amounts of DNA bound protein. Exchange of 83 amino acids at the COOH-terminal end of the PRD by 16 unrelated amino acids, as found in NF1-C2, and splicing out the central region of the PRD, as found in NF1-C7, enhanced DNA binding in vivo and in vitro. However, the ITP of the splice variants NF1-C2 and NF1-C7 was found to be similar to that of the intact NF1-C1. Additional mutations showed that the ITP of NF1-C requires the synergistic action of the PRD and a novel domain encoded in exons 5 and 6. Intriguingly the carboxyl-terminal domain-like motif encoded in exons 9/10 is not essential for transactivation of a reporter with a single NF1 site but is required for activation of a reporter with six NF1 sites in tandem. Our results imply that differential splicing is used to regulate transcription by generating variants with different DNA binding affinities but similar ITPs.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35033 Marburg, Germany	Philipps University Marburg	Beato, M (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Beato, Miguel/B-5564-2015; Prado, Felix/G-7700-2015; Vicent, Guillermo P./K-5432-2015	Beato, Miguel/0000-0002-2878-2222; Prado, Felix/0000-0001-9805-782X; Vicent, Guillermo P./0000-0002-0554-2226				Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; Baetz K, 1999, MOL CELL BIOL, V19, P6729; BOUSSET K, 1993, ONCOGENE, V8, P3211; Candau R, 1996, J STEROID BIOCHEM, V57, P19, DOI 10.1016/0960-0760(96)00262-2; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHAVEZ S, 1995, MOL CELL BIOL, V15, P6987; das Neves L, 1999, P NATL ACAD SCI USA, V96, P11946, DOI 10.1073/pnas.96.21.11946; Dekker J, 1996, MOL CELL BIOL, V16, P4073; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; DUSSERRE Y, 1992, MOL CELL BIOL, V12, P5228, DOI 10.1128/MCB.12.11.5228; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KIM TK, 1994, NUCLEIC ACIDS RES, V22, P251, DOI 10.1093/nar/22.2.251; KIM TK, 1993, J BIOL CHEM, V268, P20866; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Prado F, 2002, J BIOL CHEM, V277, P4911, DOI 10.1074/jbc.M110094200; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROULET E, 1995, MOL CELL BIOL, V15, P5552; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sherman F., 1986, METHODS YEAST GENETI; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WENDLER W, 1994, NUCLEIC ACIDS RES, V22, P2601, DOI 10.1093/nar/22.13.2601; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966	44	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16383	16390		10.1074/jbc.M200418200	http://dx.doi.org/10.1074/jbc.M200418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861650	hybrid			2022-12-25	WOS:000175564500007
J	Tarr, PE; Roncarati, R; Pelicci, G; Pelicci, PG; D'Adamio, L				Tarr, PE; Roncarati, R; Pelicci, G; Pelicci, PG; D'Adamio, L			Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; N-TERMINAL KINASE; ALZHEIMERS-DISEASE; AXONAL-TRANSPORT; OXIDATIVE STRESS; GAMMA-SECRETASE; APOPTOSIS; FE65; ACTIVATION; TAU	beta-Amyloid precursor protein (APP) is a widely expressed transmembrane protein of unknown function that is involved in the pathogenesis of Alzheimer's disease. The cytoplasmic tail of APP interacts with phosphotyrosine binding (PTB) domain containing proteins (Fe65, X11, mDab-1, and JIP-1) and may modulate gene expression and apoptosis. We now identify Shc A and She C, PTB-containing adapter proteins that signal to cellular differentiation and survival pathways, as novel APP-interacting proteins. The APP cytoplasmic tail contains a PTB-binding Motif (Y-682 ENPTY687) that, when phosphorylated on Tyr(682), precipitated the PTB domain of Shc A and Shc C, as well as endogenous full-length Shc A. APP and Shc C were physically associated in adult mouse brain homogenates. Increase in phosphorylation of APP by overexpression of the nerve growth factor receptor Trk A in 293T cells promoted the interaction of transfected APP and endogenous Shc A. Pervanadate treatment of N2a neuroblastoma cells resulted in tyrosine phosphorylation and association of endogenous APP and Shc A. Thus, APP and Shc proteins interact in vitro, in cells, and in the mouse brain. Tyrosine phosphorylation of APP may promote the interaction with Shc proteins.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; European Inst Oncol, Dept Expt Oncol, I-20149 Milan, Italy	Yeshiva University; Albert Einstein College of Medicine; IRCCS European Institute of Oncology (IEO)	D'Adamio, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave,Ullmann 1209, Bronx, NY 10461 USA.	Ldadamio@aecom.yu.edu	Pelicci, Pier Giuseppe/AAL-6572-2020; Pelicci, Giuliana/AAA-8921-2022	Pelicci, Giuliana/0000-0003-0986-8255; TARR, Philip/0000-0002-1488-5407; D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441; roncarati, roberta/0000-0002-2371-3316	NATIONAL CANCER INSTITUTE [T32CA009173] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 09173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chong YH, 2001, J BIOL CHEM, V276, P23511, DOI 10.1074/jbc.M009466200; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 2000, J CELL SCI, V113, P1857; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; Ferrer I, 2001, BRAIN PATHOL, V11, P144; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gartner U, 1999, NEUROSCIENCE, V91, P1, DOI 10.1016/S0306-4522(99)00059-7; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Guo Q, 1997, J NEUROSCI, V17, P4212; Heber S, 2000, J NEUROSCI, V20, P7951; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuda S, 2001, J NEUROSCI, V21, P6597; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Reynolds CH, 1997, J NEUROCHEM, V69, P191; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Russo C, 2001, NEUROBIOL DIS, V8, P173, DOI 10.1006/nbdi.2000.0357; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x	52	108	115	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16798	16804		10.1074/jbc.M110286200	http://dx.doi.org/10.1074/jbc.M110286200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877420	hybrid			2022-12-25	WOS:000175564500061
J	Westhoff, CM; Ferreri-Jacobia, M; Mak, DOD; Foskett, JK				Westhoff, CM; Ferreri-Jacobia, M; Mak, DOD; Foskett, JK			Identification of the erythrocyte Rh blood group glycoprotein as a mammalian ammonium transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; GROUP SYSTEM; KIDNEY; PROTEIN; NH4+; ANTIGEN	The Rh blood group proteins are well known as the erythrocyte targets of the potent antibody response that causes hemolytic disease of the newborn. These proteins have been described in molecular detail; however, little is known about their function. A transport function is suggested by their predicted structure and from phylogenetic analysis. To obtain evidence for a role in solute transport, we expressed Rh proteins in Xenopus oocytes and now demonstrate that the erythroid Rh-associated glycoprotein mediates uptake of ammonium across cell membranes. Rh-associated glycoprotein carrier-mediated uptake, characterized with the radioactive analog of ammonium [C-14]methylamine (MA), had an apparent EC50 of 1.6 mm and a maximum uptake rate (V-max) of 190 pmol/oocyte/min. Uptake was independent of the membrane potential and the Na+ gradient. RA transport was stimulated by raising extracellular pH or by lowering intracellular pH, suggesting that uptake was coupled to an outwardly directed H+ gradient. MA uptake was insensitive to additions of amiloride, amine-containing compounds tetramethyl. and tetraethylammonium chloride, glutamine, and urea. However, MA uptake was significantly antagonized by ammonium chloride with inhibition kinetics (IC50 = 1.14 mm) consistent with the hypothesis that the uptake of MA and ammonium involves a similar H+-coupled counter-transport mechanism.	Univ Penn, Dept Pathol & Lab Med, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Physiol, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Westhoff, CM (corresponding author), Univ Penn, Dept Pathol & Lab Med, Sch Med, 510 Stellar Chance, Philadelphia, PA 19104 USA.		Foskett, Kevin/R-2549-2019		NHLBI NIH HHS [T32 HL007775] Funding Source: Medline; NIDDK NIH HHS [DK 02751] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002751] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1987, J BIOL CHEM, V262, P17497; Avent ND, 2000, BLOOD, V95, P375, DOI 10.1182/blood.V95.2.375; BALLAS SK, 1984, BLOOD, V63, P1046; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P83, DOI 10.1007/BF00378645; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; Huang CH, 2000, SEMIN HEMATOL, V37, P150, DOI 10.1016/S0037-1963(00)90040-4; HUIZENGA JR, 1994, ANN CLIN BIOCHEM, V31, P529, DOI 10.1177/000456329403100602; KINNE R, 1986, J MEMBRANE BIOL, V94, P279, DOI 10.1007/BF01869723; KINSELLA JL, 1981, AM J PHYSIOL, V241, pC220, DOI 10.1152/ajpcell.1981.241.5.C220; Kitano T, 2000, IMMUNOGENETICS, V51, P856, DOI 10.1007/s002510000202; KLEINER D, 1981, BIOCHIM BIOPHYS ACTA, V639, P41, DOI 10.1016/0304-4173(81)90004-5; KNEPPER MA, 1989, PHYSIOL REV, V69, P179, DOI 10.1152/physrev.1989.69.1.179; Liu Z, 2000, J BIOL CHEM, V275, P25641, DOI 10.1074/jbc.M003353200; Liu Z, 2001, J BIOL CHEM, V276, P1424, DOI 10.1074/jbc.M007528200; Mak DOD, 2000, J GEN PHYSIOL, V115, P241, DOI 10.1085/jgp.115.3.241; MALLINSON G, 1990, TRANSFUSION, V30, P222, DOI 10.1046/j.1537-2995.1990.30390194341.x; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; Race RR., 1975, BLOOD GROUPS MAN; RIDGWELL K, 1994, J BIOL CHEM, V269, P6410; ROON RJ, 1975, J BACTERIOL, V122, P502, DOI 10.1128/JB.122.2.502-509.1975; SINGH SK, 1995, P NATL ACAD SCI USA, V92, P11573, DOI 10.1073/pnas.92.25.11573; Soupene E, 2001, MOL CELL BIOL, V21, P5733, DOI 10.1128/MCB.21.17.5733-5741.2001; STURGEON P, 1970, BLOOD-J HEMATOL, V36, P310, DOI 10.1182/blood.V36.3.310.310; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; Wall SM, 1996, MINER ELECTROL METAB, V22, P311	27	132	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12499	12502		10.1074/jbc.C200060200	http://dx.doi.org/10.1074/jbc.C200060200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11861637	hybrid			2022-12-25	WOS:000175036300004
J	Hu, T; Sage, H; Hsieh, TS				Hu, T; Sage, H; Hsieh, TS			ATPase domain of eukaryotic DNA topoisomerase II Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIS(2,6-DIOXOPIPERAZINE) DERIVATIVES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; 2-GATE MECHANISM; PROTEIN CLAMP; STEADY-STATE; DOUBLE HELIX; YEAST; TRANSPORT; ICRF-159	We have prepared full-length Drosophila and human topoisomerase 11 and truncation constructs containing the amino-terminal ATPase domain, and we have analyzed their biochemical properties. The ATPase activity of the truncation proteins, similar to that of the full-length proteins, is greatly stimulated by the presence of DNA. This activity of the truncation proteins is also sensitive to the inhibition by the drug bisdioxopiperazine, ICRF-193, albeit at a much lower level than the full-length protein. Therefore, bisdioxopiperazine can directly interact with the NH2-terminal ATPase domain, but the drug-enzyme interaction may involve other domains as well. The ATPase activity of the ATPase domain protein showed a quadratic dependence on enzyme concentration, suggesting that dimerization of the NH2-terminal domain is a rate-limiting step. Using both protein cross-linking and sedimentation equilibrium analysis, we showed that the ATPase domain exists as a monomer in the absence of cofactors but can readily dimerize in the presence of a nonhydrolyzable analog of ATP, 5-adenylyl-beta,gamma-imidodiphosphate. More interestingly, both ATP and ADP can also promote protein dimerization. This result thus suggests that the protein clamp, mediated through the dimerization of ATPase domain, remains closed after ATP hydrolysis and opens upon the dissociation of ADP.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hsieh, TS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	Hsieh@biochem.duke.edu	Hsieh, Tao-shih/G-9305-2012; Wu, Wan-lin/G-8937-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chang S, 1998, J BIOL CHEM, V273, P19822, DOI 10.1074/jbc.273.31.19822; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Gardiner LP, 1998, BIOCHEMISTRY-US, V37, P16997, DOI 10.1021/bi9818321; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HSIEH TS, 1980, CELL, V21, P115, DOI 10.1016/0092-8674(80)90119-1; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; Huang KC, 2001, J BIOL CHEM, V276, P44488, DOI 10.1074/jbc.M104383200; ISHIDA R, 1995, CANCER RES, V55, P2299; ISHIDA R, 1991, CANCER RES, V51, P4909; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Jensen S, 1996, MOL CELL BIOL, V16, P3866; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MP, 1994, J MOL BIOL, V235, P436, DOI 10.1006/jmbi.1994.1004; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MIZUUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P1847, DOI 10.1073/pnas.77.4.1847; Morris SK, 2000, J BIOL CHEM, V275, P2613, DOI 10.1074/jbc.275.4.2613; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; Olland S, 1999, J BIOL CHEM, V274, P21688, DOI 10.1074/jbc.274.31.21688; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Sehested M, 1998, CANCER RES, V58, P1460; TANABE K, 1991, CANCER RES, V51, P4903; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; Wessel I, 1999, CANCER RES, V59, P3442; WYCKOFF E, 1988, P NATL ACAD SCI USA, V85, P6272, DOI 10.1073/pnas.85.17.6272	40	48	50	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 22	2002	277	8					5944	5951		10.1074/jbc.M111394200	http://dx.doi.org/10.1074/jbc.M111394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524AF	11850431	hybrid			2022-12-25	WOS:000173989200033
J	Ortiz-Vega, S; Khokhlatchev, A; Nedwidek, M; Zhang, XF; Dammann, R; Pfeifer, GP; Avruch, J				Ortiz-Vega, S; Khokhlatchev, A; Nedwidek, M; Zhang, XF; Dammann, R; Pfeifer, GP; Avruch, J			The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1	ONCOGENE			English	Article						Ras; Nore1; RASSF1; tumor suppressor; apoptosis	PHOSPHOLIPASE-C; IDENTIFICATION; EFFECTOR; KINASE; ACTIVATION; EPSILON; FAMILY	Nore and RASSF1A are noncatalytic proteins that share 50% identity over their carboxyterminal 300 AA, a segment that encompasses a putative Ras-Rap association (RA) domain. RASSF1 is expressed as several splice variants, each of which contain an RA domain, however the 340 AA RASSF1A, but not the shorter RASSF1C variant, is a putative tumor suppressor. Nore binds to Ras and several Ras-like GTPases in a GTP dependent fashion however neither RASSF1 (A or C) or the C. elegans Nore/RASSF1 homolog, T24F1.3 exhibit any interaction with Ras or six other Ras-like GTPases in a yeast two-hybrid expression assay. A low recovery of RASSF1A (but not RASSF1C) in association with RasG12V is observed however on transient expression in COS cells. Nore and RASSF1A can each efficiently homodimerize and heterodimerize with each other through their nonhomologous aminoterminal segments. Recombinant RASSF1C exhibits a much weaker ability to homodimerize or heterodimerize; thus the binding of RASSF1C to Nore is very much less than the binding of RASSF1A to Nore. The association of RASSF1A with RasG12V in COS cells appears to reflect the hetero-dimerization of RASSF1A with Nore, inasmuch the recovery of RASSF1A with RasG12V is increased by concurrent expression of full length Nore, and abolished by expression of Nore deleted of its RA domain. The preferential ability of RASSF1A to heterodimerize with Nore and thereby associate with Ras-like GTPases may be relevant to its putative tumor suppressor function.	Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabetes Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; City of Hope; Beckman Research Institute of City of Hope	Avruch, J (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, 50 Blossom St, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007028] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32DK07028] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Barr MM, 1996, MOL CELL BIOL, V16, P5597; Baumann R, 1999, BLOOD, V94, P4314, DOI 10.1182/blood.V94.12.4314.424k16_4314_4320; Daniel TF, 2000, SYST BOT, V25, P15, DOI 10.2307/2666669; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Ehrhardt GRA, 2001, ONCOGENE, V20, P188, DOI 10.1038/sj.onc.1204053; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; Kalhammer G, 1997, FEBS LETT, V414, P599, DOI 10.1016/S0014-5793(97)01076-4; KEIKHOFT E, 1998, ONCOGENE, V17, P1457; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lerman MI, 2000, CANCER RES, V60, P6116; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	38	187	204	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1381	1390		10.1038/sj.onc.1205192	http://dx.doi.org/10.1038/sj.onc.1205192			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857081				2022-12-25	WOS:000173861000008
J	Djelloul, S; Tarunina, M; Barnouin, K; Mackay, A; Jat, PS				Djelloul, S; Tarunina, M; Barnouin, K; Mackay, A; Jat, PS			Differential protein expression, DNA binding and interaction with SV40 large tumour antigen implicate the p63-family of proteins in replicative senescence	ONCOGENE			English	Article						p63; p53; replicative senescence; DNA binding; SV40 T-antigen	LARGE-T-ANTIGEN; RAT EMBRYO FIBROBLASTS; P53 HOMOLOG; CELLULAR SENESCENCE; HUMAN-CELLS; LIFE-SPAN; P63; ANTIBODIES; DIVISION; DISTINCT	P53 activity plays a key role in mammalian cells when they undergo replicative senescence at their Hayflick limit. To determine whether p63 proteins, members of the family of p53-related genes, are also involved in this process, we examined their expression in serially passaged rat embryo fibroblasts. Upon senescence, two truncated DeltaNp63 proteins decreased in abundance whereas two TAp63 isoforms accumulated. 2-D get analysis showed that the DeltaNp63 proteins underwent post-translational modifications in both proliferating and senescent cells. Direct binding of DeltaNp63 proteins to a p53 consensus motif was greater in proliferating cells than senescent cells. In contrast p63alpha isoforms bound to DNA in a p53 dependent manner and this was higher in senescent cells than proliferating cells. An interaction of p63alpha proteins with SV40 large tumour antigen was also detected and ectopic expression of DeltaNp63alpha can extend the lifespan of rat embryo fibroblasts. Taken together the results indicate that p63 proteins may play a role in replicative senescence either by competition for p53 DNA binding sites or by direct interaction with p53 protein bound to DNA.	Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Royal Free & Univ Coll Sch Med, Dept Surg, LICR UCL Breast Canc Lab, London W1P 7LD, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London; University of London; University College London	Jat, PS (corresponding author), Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, Courtauld Bldg,91 Riding House St, London W1W 7BS, England.	parmjit@ludwig.ucl.ac.uk						Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Gonos ES, 1996, MOL CELL BIOL, V16, P5127; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayflick L, 1985, Clin Geriatr Med, V1, P15; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PEREIRASMITH OM, 1990, J CELL PHYSIOL, V144, P546, DOI 10.1002/jcp.1041440324; Powell AJ, 1999, ONCOGENE, V18, P7343, DOI 10.1038/sj.onc.1203154; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Roth J, 1999, J GEN VIROL, V80, P3251, DOI 10.1099/0022-1317-80-12-3251; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Stulik J, 1997, ELECTROPHORESIS, V18, P625, DOI 10.1002/elps.1150180347; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	33	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					981	989		10.1038/sj.onc.1205253	http://dx.doi.org/10.1038/sj.onc.1205253			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850815				2022-12-25	WOS:000173580100001
J	Honore, B; Baandrup, U; Nielsen, S; Vorum, H				Honore, B; Baandrup, U; Nielsen, S; Vorum, H			Endonuclein is a cell cycle regulated WD-repeat protein that is up-regulated in adenocarcinoma of the pancreas	ONCOGENE			English	Article						cell cycle regulated protein; nucleus, endoplasmic reticulum; signal transduction; chaperone activity	HUMAN CALUMENIN; CANCER; EXPRESSION; FAMILY; GENE; IDENTIFICATION; SECRETION; SURVIVAL; BINDING; MEMBERS	The transcript encoding endonuclein, the human homolog of yeast PWP1, was previously found up-regulated in pancreatic cancer tissue. By immunohistochemistry we detected a ubiquitous presence in several tissues examined: skin, liver, thyroid gland, heart muscle, neurons, kidney, bladder, pancreas, adrenal gland, ovary, uterus, testis and prostate gland. We especially noticed that normal pancreatic exocrine cells exhibited low protein levels while pancreatic adenocarcinoma cells revealed high levels. We found a heterogeneous subcellular distribution, especially with varying nuclear levels. In proliferating cells endonuclein protein expression and localization was cell cycle dependent, with increasing levels and nuclear focusing during the interphase toward mitosis. Ultrastructural analysis revealed ER and nuclear localization. Endonuclein contains five WD-repeats, indicating a putative role in crucial regulatory activities in the nucleus as well as in the ER.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Inst Anat, Dept Cell Biol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Pathol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University; Aarhus University	Honore, B (corresponding author), Aarhus Univ, Dept Med Biochem, Ole Worms Alle,Bldg 170, DK-8000 Aarhus C, Denmark.		Honoré, Bent/ABF-3650-2021	Honore, Bent/0000-0002-3459-7429				BOS JL, 1989, CANCER RES, V49, P4682; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELIS JE, 1994, CELL BIOL LAB HDB, V1, P288; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; Coppola D, 2000, Cancer Control, V7, P421; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; Gress TM, 1996, ONCOGENE, V13, P1819; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Honore B, 1999, FEBS LETT, V456, P274, DOI 10.1016/S0014-5793(99)00911-4; HONORE B, 1995, J BIOL CHEM, V270, P28780; HONORE B, 1994, GENE, V151, P291, DOI 10.1016/0378-1119(94)90673-4; Kang SA, 1996, BRIT J PHARMACOL, V117, P1780, DOI 10.1111/j.1476-5381.1996.tb15354.x; Kore M, 1992, J CLIN INVEST, V90, P1352; Kornmann M, 1998, ONCOLOGY-BASEL, V55, P363, DOI 10.1159/000011879; LIU QY, 1995, ONCOGENE, V10, P619; MURR MM, 1994, CA-CANCER J CLIN, V44, P304, DOI 10.3322/canjclin.44.5.304; MYERS MH, 1989, CA-CANCER J CLIN, V39, P21, DOI 10.3322/canjclin.39.1.21; Naka T, 1998, INT J ONCOL, V12, P1111; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1993, NAT GENET, V5, P3, DOI 10.1038/ng0993-3; SIMON B, 1994, GASTROENTEROLOGY, V106, P1645, DOI 10.1016/0016-5085(94)90422-7; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; Vorum H, 1998, BBA-PROTEIN STRUCT M, V1386, P121, DOI 10.1016/S0167-4838(98)00089-2	27	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1123	1129		10.1038/sj.onc.1205186	http://dx.doi.org/10.1038/sj.onc.1205186			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850830				2022-12-25	WOS:000173580100016
J	Ferreira, T; Mason, AB; Pypaert, M; Allen, KE; Slayman, CW				Ferreira, T; Mason, AB; Pypaert, M; Allen, KE; Slayman, CW			Quality control in the yeast secretory pathway - A misfolded Pma1 H+-ATPase reveals two checkpoints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; UNFOLDED-PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; CELL-SURFACE; SARCOPLASMIC-RETICULUM; EPITHELIAL-CELLS; URACIL PERMEASE; SHUTTLE VECTORS; ER	The yeast plasma-membrane H+-ATPase, encoded by PMA1, is delivered to the cell surface via the secretory pathway and has recently emerged as an excellent system for identifying quality control mechanisms along the pathway. In the present study, we have tracked the biogenesis of Pmal-G381A, a misfolded mutant form of the H+-ATPase. Although this mutant ATPase is arrested transiently in the peripheral endoplasmic reticulum, it does not become a substrate for endoplasmic reticulum-associated degradation nor does it appear to stimulate an unfolded protein response. Instead, Pma1-G381A accumulates in Kar2p-containing vesicular-tubular clusters that resemble those previously described in mammalian cells. Like their mammalian counterparts, the yeast vesicular-tubular clusters may correspond to specific exit ports from the endoplasmic reticulum, since Pmal-G381A eventually escapes from them (still in a misfolded, trypsin-sensitive form) to reach the plasma membrane. By comparison with wild-type ATPase, Pmal-G381A spends a short half-life at the plasma membrane before being removed and sent to the vacuole for degradation in a process that requires both End4p and Pep4p. Finally, in a separate set of experiments, Pma1-G381A was found to impose its phenotype on co-expressed wild-type ATPase, transiently retarding the wild-type protein in the ER and later stimulating its degradation in the vacuole. Both effects serve to lower the steady-state amount of wild-type ATPase in the plasma membrane and, thus, can explain the co-dominant genetic behavior of the G381A mutation. Taken together, the results of this study establish Pmal-G381A as a useful new probe for the yeast secretory system.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Ctr Cell & Mol Imaging, New Haven, CT 06510 USA	Yale University; Yale University	Mason, AB (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.	cw.slaymanlab@yale.edu	Mason, Anne B/A-6754-2008		NIGMS NIH HHS [GM15761] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015761, R37GM015761] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BARCO A, 1995, EMBO J, V14, P3349, DOI 10.1002/j.1460-2075.1995.tb07341.x; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BENITO B, 1991, BIOCHIM BIOPHYS ACTA, V1063, P265, DOI 10.1016/0005-2736(91)90381-H; BIEMANS R, 1991, DNA CELL BIOL, V10, P191, DOI 10.1089/dna.1991.10.191; BOWMAN BJ, 1985, J BIOL CHEM, V260, P8726; BOWMAN BJ, 1983, J BIOL CHEM, V258, P3002; BRADA D, 1988, J BACTERIOL, V170, P2775, DOI 10.1128/jb.170.6.2775-2783.1988; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; DeWitt ND, 1998, J BIOL CHEM, V273, P21744, DOI 10.1074/jbc.273.34.21744; dExaerde AD, 1996, YEAST, V12, P907; DEXAERDE AD, 1995, J BIOL CHEM, V270, P23828, DOI 10.1074/jbc.270.40.23828; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; FELDMAN RI, 1987, J BIOL CHEM, V262, P9332; Ferreira T, 2001, J BIOL CHEM, V276, P29613, DOI 10.1074/jbc.R100022200; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOFF CG, 1984, GENE, V27, P35, DOI 10.1016/0378-1119(84)90236-1; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HOLCOMB CL, 1988, J CELL BIOL, V106, P641, DOI 10.1083/jcb.106.3.641; Hong E, 1996, J CELL BIOL, V135, P623, DOI 10.1083/jcb.135.3.623; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kolling R, 1997, EMBO J, V16, P2251, DOI 10.1093/emboj/16.9.2251; Kolling R, 1996, EUR J BIOCHEM, V239, P356, DOI 10.1111/j.1432-1033.1996.0356u.x; KOPITO RR, 1999, PHYSIOL REV, V79, P167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lucero P, 1997, APPL ENVIRON MICROB, V63, P3831, DOI 10.1128/AEM.63.10.3831-3836.1997; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; Luo WJ, 2000, MOL BIOL CELL, V11, P579, DOI 10.1091/mbc.11.2.579; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MOLDANO AM, 1998, GENETICS, V150, P11; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morsomme P, 2000, BBA-REV BIOMEMBRANES, V1469, P133, DOI 10.1016/S0304-4157(00)00015-0; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NAO SQ, 1995, J BIOL CHEM, V270, P6815, DOI 10.1074/jbc.270.12.6815; NISHIKAWA S, 1994, MOL BIOL CELL, V5, P1129, DOI 10.1091/mbc.5.10.1129; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; POTENZA M, 1992, YEAST, V8, P549, DOI 10.1002/yea.320080706; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; RAO R, 1992, ANN NY ACAD SCI, V671, P195, DOI 10.1111/j.1749-6632.1992.tb43796.x; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; RICHTERRUOFF B, 1994, FEBS LETT, V354, P50, DOI 10.1016/0014-5793(94)01085-4; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rose MD., 1990, METHODS YEAST GENETI; Rossanese OW, 1999, J CELL BIOL, V145, P69, DOI 10.1083/jcb.145.1.69; ROSSI G, 1995, MOL BIOL CELL, V6, P1769, DOI 10.1091/mbc.6.12.1769; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Umebayashi K, 1999, EUR J CELL BIOL, V78, P726, DOI 10.1016/S0171-9335(99)80041-7; Umebayashi K, 1997, YEAST, V13, P1009; VERGERES G, 1993, J CELL SCI, V106, P249; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; VOLLAND C, 1992, J BIOL CHEM, V267, P23767; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; WANKER EE, 1995, J CELL BIOL, V130, P29, DOI 10.1083/jcb.130.1.29; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Wilson MH, 2000, BIOCHEMISTRY-US, V39, P693, DOI 10.1021/bi9920275; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	91	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					21027	21040		10.1074/jbc.M112281200	http://dx.doi.org/10.1074/jbc.M112281200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11877403	hybrid			2022-12-25	WOS:000176204500118
J	Farrell, CM; Mackey, AT; Klumpp, LM; Gilbert, SP				Farrell, CM; Mackey, AT; Klumpp, LM; Gilbert, SP			The role of ATP hydrolysis for kinesin processivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR PROTEINS; DICTYOSTELIUM MYOSIN; CRYSTAL-STRUCTURE; MOLECULAR MOTORS; DIMERIC KINESIN; SALT-BRIDGE; DOMAIN; MECHANISM; KINETICS; SITE	Conventional kinesin is a highly processive, plus-end-directed microtubule-based motor that drives membranous organelles toward the synapse in neurons. Although recent structural, biochemical, and mechanical measurements are beginning to converge into a common view of how kinesin converts the energy from ATP turnover into motion, it remains difficult to dissect experimentally the intermolecular domain cooperativity required for kinesin processivity. We report here our pre-steady-state kinetic analysis of a kinesin switch I mutant at Arg(210) (NXXSSRSH, residues 205-212 in Drosophila kinesin). The results show that the R210A substitution results in a dimeric kinesin that is defective for ATP hydrolysis and a motor that cannot detach from the microtubule although ATP binding and microtubule association occur. We propose a mechanistic model in which ATP binding at head 1 leads to the plus-end-directed motion of the neck linker to position head 2 forward at the next microtubule binding site. However, ATP hydrolysis is required at head 1 to lock head 2 onto the microtubule in a tight binding state before head 1 dissociation from the microtubule. This mechanism optimizes forward movement and processivity by ensuring that one motor domain is tightly bound to the microtubule before the second can detach.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gilbert, SP (corresponding author), Univ Pittsburgh, Dept Biol Sci, 518 Langley Hall, Pittsburgh, PA 15260 USA.				NIGMS NIH HHS [R01 GM054141, GM 54141] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054141, R01GM054141] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brendza KM, 1999, J BIOL CHEM, V274, P31506, DOI 10.1074/jbc.274.44.31506; Brendza KM, 2000, J BIOL CHEM, V275, P22187, DOI 10.1074/jbc.M001124200; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Crevel I, 1999, EMBO J, V18, P5863, DOI 10.1093/emboj/18.21.5863; Foster KA, 1998, J BIOL CHEM, V273, P35307, DOI 10.1074/jbc.273.52.35307; Foster KA, 2000, BIOCHEMISTRY-US, V39, P1784, DOI 10.1021/bi991500b; Furch M, 1999, J MOL BIOL, V290, P797, DOI 10.1006/jmbi.1999.2921; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1995, FEBS LETT, V368, P531, DOI 10.1016/0014-5793(95)00723-M; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Mandelkow E, 1998, TRENDS BIOCHEM SCI, V23, P429, DOI 10.1016/S0968-0004(98)01278-X; Minehardt TJ, 2001, BIOPHYS J, V80, P1151, DOI 10.1016/S0006-3495(01)76092-4; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; MOYER ML, 1998, THESIS PENNSYLVANIA; Muller J, 1999, BIOL CHEM, V380, P981, DOI 10.1515/BC.1999.122; Onishi H, 1998, P NATL ACAD SCI USA, V95, P6653, DOI 10.1073/pnas.95.12.6653; Pate E, 1997, BIOCHEMISTRY-US, V36, P12155, DOI 10.1021/bi970996z; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Sack S, 1999, EUR J BIOCHEM, V262, P1, DOI 10.1046/j.1432-1327.1999.00341.x; SADHU A, 1992, J BIOL CHEM, V267, P11352; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Schief WR, 2001, CURR OPIN CELL BIOL, V13, P19, DOI 10.1016/S0955-0674(00)00169-1; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Song YH, 2001, EMBO J, V20, P6213, DOI 10.1093/emboj/20.22.6213; Sosa H, 2001, NAT STRUCT BIOL, V8, P540, DOI 10.1038/88611; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Wriggers W, 1998, BIOPHYS J, V75, P646, DOI 10.1016/S0006-3495(98)77555-1; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; Yun MY, 2001, EMBO J, V20, P2611, DOI 10.1093/emboj/20.11.2611	50	46	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17079	17087		10.1074/jbc.M108793200	http://dx.doi.org/10.1074/jbc.M108793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864969	hybrid			2022-12-25	WOS:000175564500098
J	Hu, XT; Bryington, M; Fisher, AB; Liang, XM; Zhang, XH; Cui, DM; Datta, I; Zuckerman, KS				Hu, XT; Bryington, M; Fisher, AB; Liang, XM; Zhang, XH; Cui, DM; Datta, I; Zuckerman, KS			Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR-ALPHA; PROGENITOR CELLS; GENE-EXPRESSION; IN-VITRO; PROLIFERATION; PHOSPHORYLATION; ACTIVATION; INHIBITION; INTERLEUKIN-1	Tumor necrosis factor-alpha (TNF) is well known for its cytotoxic effect on malignant cells. Its role in cell cycle control is relatively less known. In this study, we found that TNF induced G(1) arrest of TF-1 and MV4-11 cells while simultaneously causing apoptosis. Treatment of the cells with TNF for 48 h caused cell cycle arrest, accompanied by dephosphorylation of pRb and reduction in D-type cyclin expression. The down-regulation of the D-type cyclins resulted in similar to50-80% decrease of the cyclin-dependent kinase activities. Cells treated with calpain-dependent inhibitor ALLN and apoptosis inhibitor zVAD-FMK suppressed degradation of IkappaBalpha and activation of caspase 3, respectively. However, treatment of cells with these two inhibitors was not able to prevent TNF-induced down-regulation of the D-type cyclins. In contrast, proteasome inhibitor MG-132 and lactacystin blocked both TNF-induced degradation of IkappaBalpha and down-regulation of D-type cyclins. These data suggest that down-regulation of D-type cyclins by TNF may be proteasome-proteolysis dependent. Additional support for this conclusion was obtained from experiments showing an increase of proteasome activity in TNF-treated cells and in vitro degradation of cyclin D3 by 26 S proteasome.	Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Dept Internal Med, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Hu, XT (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Hematol Malignancies Program, MDC44,MCC3142,12902 Magnolia Dr, Tampa, FL 33612 USA.	hu@moffitt.usf.edu						ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; ELIAS L, 1988, BIOCHEM BIOPH RES CO, V157, P963, DOI 10.1016/S0006-291X(88)80968-9; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hu XT, 1999, J IMMUNOL, V163, P3106; Hu XT, 2000, BIOCHEM BIOPH RES CO, V276, P930, DOI 10.1006/bbrc.2000.3556; Hu XT, 2001, CANCER RES, V61, P6290; JACOBSEN SEW, 1992, J EXP MED, V175, P1759, DOI 10.1084/jem.175.6.1759; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Orr-Weaver TL, 1998, NATURE, V392, P223, DOI 10.1038/32520; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUSTEN LS, 1994, J CLIN INVEST, V94, P165, DOI 10.1172/JCI117303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG Y, 1995, BLOOD, V86, P2930; ZUCALI JR, 1987, J CLIN INVEST, V80, P772, DOI 10.1172/JCI113133	34	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16528	16537		10.1074/jbc.M109929200	http://dx.doi.org/10.1074/jbc.M109929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864973	hybrid			2022-12-25	WOS:000175564500027
J	Shu, LL; Zhang, XW; Houghton, PJ				Shu, LL; Zhang, XW; Houghton, PJ			Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; P70 S6 KINASE; 4E-BP1 PHOSPHORYLATION; GROWTH; INHIBITION; BLOCKS; INACTIVATION; FIBROBLASTS; TRANSLATION; ACTIVATION	The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase known to control initiation of translation through two downstream pathways: eukaryotic initiation factor 4E-binding protein 1 (4E-BP1)/eukaryotic initiation factor 4E and ribosomal p70 S6 kinase (S6K1). We previously showed in C2C12 murine myoblasts that rapamycin arrests cells in G(1) phase and completely inhibits terminal myogenesis. To elucidate the pathways that regulate myogenesis'. we established stable C2C12 cell lines that express rapamycin-resistant mTOR mutants (mTORrr; S2035I) that have N-terminal deletions (Delta10 or Delta91) or are full-length kinase-dead mTORrr proteins. Additional clones expressing a constitutively active S6K1 were also studied. Our results show that Delta10mTORrr signals 4E-BP1 and permits rapamycin-treated myoblasts to differentiate, confirming the mTOR dependence of the inhibition of myogenesis by rapamycin. C2C12 cells expressing either Delta91 mTORrr or kinase-dead mTORrr(D2338A) could not phosphorylate 4E-BP1 in the presence of rapamycin and could not abrogate the inhibition of myogenesis. Taken together, our results indicate that both the kinase function of mTOR and the N terminus (residues 11-91, containing part of the first HEAT domain) are essential for myogenic differentiation. In contrast, constitutive activation of S6K1 does not abrogate rapamycin inhibition of either proliferation or myogenic differentiation.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Houghton, PJ (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.houghton@stjude.org	Houghton, Peter/E-3265-2011		NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA7776, CA23099, CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Arnold HH, 1996, INT J DEV BIOL, V40, P345; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DILLING MB, 1994, CANCER RES, V54, P903; Dudkin L, 2001, CLIN CANCER RES, V7, P1758; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hosoi H, 1999, CANCER RES, V59, P886; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Liu LN, 1998, CELL GROWTH DIFFER, V9, P699; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Shu L., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P12; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	42	55	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16726	16732		10.1074/jbc.M112285200	http://dx.doi.org/10.1074/jbc.M112285200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875068	hybrid			2022-12-25	WOS:000175564500052
J	Foley, HA; Ofori-Acquah, SF; Yoshimura, A; Critz, S; Baliga, BS; Pace, BS				Foley, HA; Ofori-Acquah, SF; Yoshimura, A; Critz, S; Baliga, BS; Pace, BS			Stat3 beta inhibits gamma-globin gene expression in erythroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSCRIPTIONAL ACTIVITY; ACTIVATION; PROTEIN; STAT1; BETA; PROMOTER; SURVIVAL; REQUIRES; ELEMENTS	We demonstrated previously gamma-globin gene inhibition in K562 cells and primary erythroid progenitors treated with interleukin-6. Although several cis-acting elements have been identified in the globin promoters, the precise mechanism for cytokine-mediated globin gene regulation remains to be elucidated. In this report we demonstrate inhibitors of Stat3 phosphorylation abrogate interleukin-6-mediated gamma gene silencing in erythroid cells. DNA-protein binding studies established Stat3 interaction in the 5'-untranslated gamma-globin promoter region. Furthermore, co-transfection experiments with Stat3beta demonstrate gamma promoter inhibition in a concentration-dependent manner, which was significantly reversed when the cognate Stat3-binding site in the 5'-untranslated region was mutated. These studies establish a novel mechanism for gamma gene silencing through the STAT signal transduction pathway.	Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA; Kyushu Univ, Dept Mol & Cellular Immunol, Fukuoka 812, Japan; Univ S Alabama, Dept Pediat, Mobile, AL 36606 USA	University of South Alabama; Kyushu University; University of South Alabama	Pace, BS (corresponding author), Univ S Alabama, Dept Cell Biol & Neurosci, 307 Univ Blvd,MSB 2406, Mobile, AL 36688 USA.	bpace@usouthal.edu	Yoshimura, Akihiko/K-5515-2013	Ofori-Acquah, Solomon/0000-0001-5000-3048; Pace, Betty/0000-0002-1275-4112	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038639] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38639] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMROLIA PJ, 1995, J BIOL CHEM, V270, P12892, DOI 10.1074/jbc.270.21.12892; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; Baliga BS, 2000, AM J HEMATOL, V65, P227, DOI 10.1002/1096-8652(200011)65:3<227::AID-AJH9>3.0.CO;2-V; Boosalis MS, 2001, BLOOD, V97, P3259, DOI 10.1182/blood.V97.10.3259; CAI SP, 1992, BLOOD, V79, P1342; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; Fernandez MN, 2001, BONE MARROW TRANSPL, V28, P355, DOI 10.1038/sj.bmt.1703143; Ferry AE, 1997, J BIOL CHEM, V272, P20030, DOI 10.1074/jbc.272.32.20030; Filipe A, 1999, EMBO J, V18, P687, DOI 10.1093/emboj/18.3.687; GEAHLEN RL, 1989, BIOCHEM BIOPH RES CO, V165, P241, DOI 10.1016/0006-291X(89)91060-7; Gotze KS, 2001, EXP HEMATOL, V29, P822, DOI 10.1016/S0301-472X(01)00652-X; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; Han B, 2001, INT J HEMATOL, V74, P42, DOI 10.1007/BF02982548; Helman D, 1998, FEBS LETT, V441, P287, DOI 10.1016/S0014-5793(98)01555-5; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; LEVITZKI A, 1990, BIOCHEM PHARMACOL, V40, P913, DOI 10.1016/0006-2952(90)90474-Y; Lewis BA, 2000, P NATL ACAD SCI USA, V97, P7172, DOI 10.1073/pnas.120181197; Li QL, 1997, P NATL ACAD SCI USA, V94, P2444, DOI 10.1073/pnas.94.6.2444; Li QL, 1998, J BIOL CHEM, V273, P17361, DOI 10.1074/jbc.273.28.17361; LUI B, 1998, P NATL ACAD SCI USA, V95, P10626; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; Pace BS, 2000, EXP HEMATOL, V28, P283, DOI 10.1016/S0301-472X(99)00153-8; Schaefer LK, 2000, CELL SIGNAL, V12, P143, DOI 10.1016/S0898-6568(99)00077-7; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Yang YM, 1997, AM J HEMATOL, V56, P252, DOI 10.1002/(SICI)1096-8652(199712)56:4<252::AID-AJH10>3.0.CO;2-B; Zhang XK, 2001, J BIOL CHEM, V276, P33576, DOI 10.1074/jbc.M104978200	39	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16211	16219		10.1074/jbc.M106556200	http://dx.doi.org/10.1074/jbc.M106556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856732	hybrid			2022-12-25	WOS:000175510400131
J	Kienlen-Campard, P; Miolet, S; Tasiaux, B; Octave, JN				Kienlen-Campard, P; Miolet, S; Tasiaux, B; Octave, JN			Intracellular amyloid-beta 1-42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; TRANSGENIC MICE; SECRETASE CLEAVAGE; TRANSFECTED CELLS; AXONAL-TRANSPORT; PLAQUE-FORMATION; GAMMA-SECRETASE; GENE-TRANSFER; ACCUMULATION	Alzheimer disease (AD), the most frequent cause of dementia, is characterized by an important neuronal loss. A typical histological hallmark of AD is the extracellular deposition of beta-amyloid peptide (Abeta), which is produced by the cleavage of the amyloid precursor protein (APP). Most of the gene mutations that segregate with the inherited forms of AD result in increasing the ratio of A42/Abeta40 production. Abeta42 also accumulates in neurons of AD patients. Altogether, these data strongly suggest that the neuronal production of Abeta42 is a critical event in AD, but the intraneuronal Abeta42 toxicity has never been demonstrated. Here, we report that the long term expression of human APP in rat cortical neurons induces apoptosis. Although APP processing leads to production of extracellular Abeta1-40 and soluble APP, these extracellular derivatives do not induce neuronal death. On the contrary, neurons undergo apoptosis as soon as they accumulate intracellular Abeta1-42 following the expression of full-length APP or a C-terminal deleted APP isoform. The inhibition of intraneuronal Abeta1-42 production by a functional gamma-secretase inhibitor increases neuronal survival. Therefore, the accumulation of intraneuronal Abeta1-42 is the key event in the neurodegenerative process that we observed.	Catholic Univ Louvain, FARL UCL 54 10, B-1200 Brussels, Belgium	Universite Catholique Louvain	Octave, JN (corresponding author), Catholic Univ Louvain, FARL UCL 54 10, Av Hippocrate 54, B-1200 Brussels, Belgium.	octave@nchm.ucl.ac.be		Kienlen-Campard, Pascal/0000-0003-1086-2942				BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Cotman CW, 1996, BRAIN PATHOL, V6, P493, DOI 10.1111/j.1750-3639.1996.tb00878.x; Czech C, 1997, MOL BRAIN RES, V47, P108, DOI 10.1016/S0169-328X(97)00039-9; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; EDWARDS SN, 1994, J CELL BIOL, V124, P537, DOI 10.1083/jcb.124.4.537; Essalmani R, 1996, BIOCHEM BIOPH RES CO, V218, P89, DOI 10.1006/bbrc.1996.0017; GEORGEHYSLOP PH, 2000, BIOL PSYCHIAT, V47, P183; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Gunawardena S, 2001, NEURON, V32, P389, DOI 10.1016/S0896-6273(01)00496-2; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; Lorenzo A, 2000, NAT NEUROSCI, V3, P460, DOI 10.1038/74833; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Macq AF, 1998, J BIOL CHEM, V273, P28931, DOI 10.1074/jbc.273.44.28931; Mochizuki A, 2000, LANCET, V355, P42, DOI 10.1016/S0140-6736(99)04937-5; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Neve RL, 2000, BRAIN RES, V886, P54, DOI 10.1016/S0006-8993(00)02869-9; Nishimura I, 1998, J NEUROSCI, V18, P2387, DOI 10.1523/jneurosci.18-07-02387.1998; Octave JN, 1995, REV NEUROSCIENCE, V6, P287; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Uetsuki T, 1999, J NEUROSCI, V19, P6955, DOI 10.1523/JNEUROSCI.19-16-06955.1999; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Xu J, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-01-j0001.2001; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yang AJ, 1999, J BIOL CHEM, V274, P20650, DOI 10.1074/jbc.274.29.20650; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786	47	155	160	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15666	15670		10.1074/jbc.M200887200	http://dx.doi.org/10.1074/jbc.M200887200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861655	hybrid			2022-12-25	WOS:000175510400061
J	Kim, YM; Yun, J; Lee, CK; Lee, H; Min, KR; Kim, Y				Kim, YM; Yun, J; Lee, CK; Lee, H; Min, KR; Kim, Y			Oxyresveratrol and hydroxystilbene compounds - Inhibitory effect on tyrosinase and mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPA OXIDASE ACTIVITY; TRANS-RESVERATROL; BOMBYX-MORI; KOJIC ACID; PIGMENTATION; PHENOLOXIDASE; PURIFICATION; HYDROQUINONE; TAUTOMERASE; CATECHOLASE	Tyrosinase is responsible for the molting process in insects, undesirable browning of fruits and vegetables, and coloring of skin, hair, and eyes in animals. To clarify the mechanism of the depigmenting property of hydroxystilbene compounds, inhibitory actions of oxyresveratrol and its analogs on tyrosinases from mushroom and murine melanoma B-16 have been elucidated in this study. Oxyresveratrol showed potent inhibitory effect with an IC50 value of 1.2 muM on mushroom tyrosinase activity, which was 32-fold stronger inhibition than kojic acid, a depigmenting agent used as the cosmetic material with skin-whitening effect and the medical agent for hyperpigmentation disorders. Hydroxystilbene compounds of resveratrol, 3,5-dihydroxy-4'-methoxystilbene, and rhapontigenin also showed more than 50% inhibition at 100 muM on mushroom tyrosinase activity, but other methylated or glycosylated hydroxystilbenes of 3,4-dimethoxy-5-hydroxystilbene, trimethylresveratrol, piceid, and rhaponticin did not inhibit significantly. None of the hydroxystilbene compounds except oxyresveratrol exhibited more than 50% inhibition at 100 muM on L-tyrosine oxidation by murine tyrosinase activity; oxyresveratrol showed an IC50 value of 52.7 muM on the enzyme activity. The kinetics and mechanism for inhibition of mushroom tyrosinase exhibited the reversibility of oxyresveratrol as a noncompetitive inhibitor with L-tyrosine as the substrate. The interaction between oxyresveratrol and tyrosinase exhibited a high affinity reflected in a K-i value of 3.2-4.2 x 10(-7) M. Oxyresveratrol did not affect the promoter activity of the tyrosinase gene in murine melanoma B-16 at 10 and 100 muM. Therefore, the depigmenting effect of oxyresveratrol works through reversible inhibition of tyrosinase activity rather than suppression of the expression and synthesis of the enzyme. The number and position of hydroxy substituents seem to play an important role in the inhibitory effects of hydroxystilbene compounds on tyrosinase activity.	Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea; Chungbuk Natl Univ, Res Ctr Bioresource & Hlth, Cheongju 361763, South Korea; Chonnam Natl Univ, Coll Nat Sci, Kwangju 500757, South Korea	Chungbuk National University; Chungbuk National University; Chonnam National University	Kim, Y (corresponding author), Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea.							April CS, 1998, GENE, V219, P45, DOI 10.1016/S0378-1119(98)00403-X; Asano T, 2001, J BIOL CHEM, V276, P11100, DOI 10.1074/jbc.M008426200; Battaini G, 2000, J BIOL INORG CHEM, V5, P262, DOI 10.1007/s007750050370; Bhat KPL, 2001, CANCER RES, V61, P7456; Burkitt MJ, 2000, ARCH BIOCHEM BIOPHYS, V381, P253, DOI 10.1006/abbi.2000.1973; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; CANANES J, 1994, J PHARM PHARMACOL, V46, P982; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; GALEAZZI MAM, 1984, ARCH LATINOAM NUTR, V34, P269; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Guevara IL, 2001, INT J DERMATOL, V40, P212, DOI 10.1046/j.1365-4362.2001.01167-2.x; Holmes-McNary M, 2000, CANCER RES, V60, P3477; HUGHES L, 1975, J INSECT PHYSIOL, V21, P1373, DOI 10.1016/0022-1910(75)90263-2; IOZUMI K, 1993, J INVEST DERMATOL, V100, P806, DOI 10.1111/1523-1747.ep12476630; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kang BS, 1998, MED SCI RES, V26, P235; KUBO I, 1995, J NAT PRODUCTS, V58, P739, DOI 10.1021/np50119a013; Kubo I, 2000, BIOORGAN MED CHEM, V8, P1749, DOI 10.1016/S0968-0896(00)00102-4; Kuriyama T, 1998, BBA-PROTEIN STRUCT M, V1388, P506, DOI 10.1016/S0167-4838(98)00214-3; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; Lim JTE, 1999, DERMATOL SURG, V25, P282, DOI 10.1046/j.1524-4725.1999.08236.x; Maeda K, 1996, J PHARMACOL EXP THER, V276, P765; Marmaras VJ, 1996, ARCH INSECT BIOCHEM, V31, P119, DOI 10.1002/(SICI)1520-6327(1996)31:2&lt;119::AID-ARCH1&gt;3.0.CO;2-V; Mills AA, 2001, GENE DEV, V15, P1461, DOI 10.1101/gad.909301; Moreno JJ, 2000, J PHARMACOL EXP THER, V294, P333; NAPPI AJ, 1993, PIGM CELL RES, V6, P117, DOI 10.1111/j.1600-0749.1993.tb00590.x; NGUYEN QH, 1995, INT J DERMATOL, V34, P75, DOI 10.1111/j.1365-4362.1995.tb03583.x; Oetting WS, 1999, HUM MUTAT, V13, P99, DOI 10.1002/(SICI)1098-1004(1999)13:2<99::AID-HUMU2>3.3.CO;2-3; Okan G, 1999, J EUR ACAD DERMATOL, V13, P218, DOI 10.1111/j.1468-3083.1999.tb00887.x; Olivares C, 2002, BIOCHEMISTRY-US, V41, P679, DOI 10.1021/bi011535n; Parkinson N, 2001, INSECT BIOCHEM MOLEC, V31, P57, DOI 10.1016/S0965-1748(00)00105-3; Perez-Bernal A, 2000, Am J Clin Dermatol, V1, P261; Perez-Gilabert M, 2000, J AGR FOOD CHEM, V48, P695, DOI 10.1021/jf990292r; Perez-Gilabert M, 2001, BIOCHEM BIOPH RES CO, V285, P257, DOI 10.1006/bbrc.2001.5189; PYE AE, 1974, NATURE, V251, P610, DOI 10.1038/251610a0; Riley PA, 2000, J THEOR BIOL, V203, P1, DOI 10.1006/jtbi.1999.1061; Riley PA, 1997, INT J BIOCHEM CELL B, V29, P1235, DOI 10.1016/S1357-2725(97)00013-7; RYU S Y, 1988, Archives of Pharmacal Research (Seoul), V11, P230, DOI 10.1007/BF02861314; Seo B, 1999, PLANTA MED, V65, P683, DOI 10.1055/s-1999-14092; Shin N. H., 1997, NAT PROD SCI, V3, P111; Shin NH, 1998, BIOCHEM BIOPH RES CO, V243, P801, DOI 10.1006/bbrc.1998.8169; Sturm RA, 1998, BIOESSAYS, V20, P712, DOI 10.1002/(SICI)1521-1878(199809)20:9<712::AID-BIES4>3.0.CO;2-I; SUGUMARAN M, 1992, ARCH INSECT BIOCHEM, V19, P271, DOI 10.1002/arch.940190406; Takahashi S, 1996, J ANTIBIOT, V49, P513, DOI 10.7164/antibiotics.49.513; TSUKAMOTO T, 1992, BIOCHEM BIOPH RES CO, V184, P86, DOI 10.1016/0006-291X(92)91161-I; Wang ZR, 2002, INT J MOL MED, V9, P77; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; YOSHIMOTO T, 1985, J BIOCHEM, V97, P1747, DOI 10.1093/oxfordjournals.jbchem.a135233; ZHAO XL, 1995, DEV COMP IMMUNOL, V19, P205, DOI 10.1016/0145-305X(95)00005-E; Zou JG, 1999, BIOCHEM MOL BIOL INT, V47, P1089	51	346	364	2	97	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16340	16344		10.1074/jbc.M200678200	http://dx.doi.org/10.1074/jbc.M200678200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864987	hybrid			2022-12-25	WOS:000175510400145
J	Lee, VY; McClintock, DS; Santore, MT; Budinger, GRS; Chandel, NS				Lee, VY; McClintock, DS; Santore, MT; Budinger, GRS; Chandel, NS			Hypoxia sensitizes cells to nitric oxide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; CYTOCHROME-C; BCL-2 FAMILY; PEROXYNITRITE; INHIBITION; SUPEROXIDE; OXYGEN; GLUTATHIONE; MECHANISMS; DEATH	Nitric oxide (NO) can induce apoptosis in a variety of cell types. A non-toxic concentration of nitric oxide under normal oxygen conditions triggered cell death under hypoxic conditions (1.5% O-2) in fibroblasts. Nitric oxide administered during hypoxia induced the release of cytochrome c, caspase-9 activation, and the loss of mitochondrial membrane potential followed by DNA fragmentation and lactate dehydrogenase release (markers of cell death). Bcl-X-L protected cells from nitric oxide-induced apoptosis during hypoxia by preventing the release of cytochrome c, caspase-9 activation, and by maintaining a mitochondrial membrane potential. Murine embryonic fibroblasts from bax(-/-) bak(-/-) mice exposed to nitric oxide during hypoxia did not die, indicating that pro-apoptotic Bcl-2 family members are required for NO-induced apoptosis during hypoxia. The nitric oxide-induced cell death during hypoxia was independent of cGMP and peroxynitrite. Cells devoid of mitochondrial DNA (rhodegrees-cells) lack a functional electron transport chain and were resistant to nitric oxide-induced cell death during hypoxia, suggesting that a functional electron transport chain is required for nitric oxide-induced apoptosis during hypoxia.	Northwestern Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA	Northwestern University	Chandel, NS (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Tarry Bldg 14-707,303 E Chicago Ave, Chicago, IL 60611 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL068456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060472] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68456-01] Funding Source: Medline; NIGMS NIH HHS [GM60472-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bal-Price A, 1999, ANN NY ACAD SCI, V893, P376, DOI 10.1111/j.1749-6632.1999.tb07859.x; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; Borutaite V, 2000, FEBS LETT, V467, P155, DOI 10.1016/S0014-5793(00)01140-6; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Estevez AG, 1998, J NEUROSCI, V18, P923; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Koivisto A, 1997, FEBS LETT, V417, P75, DOI 10.1016/S0014-5793(97)01258-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; Shen YH, 1998, FEBS LETT, V433, P125, DOI 10.1016/S0014-5793(98)00844-8; Sies H, 2000, FREE RADICAL BIO MED, V28, P1451, DOI 10.1016/S0891-5849(00)00253-7; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; Tamatani M, 1998, J NEUROCHEM, V71, P1588; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WANG JF, 1992, HEPATOLOGY, V15, P1112, DOI 10.1002/hep.1840150623; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	40	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16067	16074		10.1074/jbc.M111177200	http://dx.doi.org/10.1074/jbc.M111177200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861645	hybrid			2022-12-25	WOS:000175510400113
J	Oh, JI; Kaplan, S				Oh, JI; Kaplan, S			Oxygen adaptation - The role of the CcoQ subunit of the cbb(3) cytochrome c oxidase of Rhodobacter sphaeroides 2.4.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHESIS GENE-EXPRESSION; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; UBIQUINOL OXIDASE; PARACOCCUS-DENITRIFICANS; BRADYRHIZOBIUM-JAPONICUM; TERMINAL OXIDASE; RHODOBACTER-SPHAEROIDES-2.4.1; IV; MUTAGENESIS	The cbb(3) cytochrome c oxidase of Rhodobacter sphaeroides consists of four nonidentical subunits. Three subunits (CcoN, CcoO, and CcoP) comprise the catalytic "core" complex required for the reduction of O-2 and the oxidation of a c-type cytochrome. On the other hand, the functional role of subunit IV (CcoQ) of the cbb(3) oxidase was not obvious, although we previously suggested that it is involved in the signal transduction pathway controlling photosynthesis gene expression (Oh, J. I., and Kaplan, S. (1999) Biochemistry 38, 2688-2696). Here we go on to demonstrate that subunit IV protects the core complex, in the presence of O-2, from proteolytic degradation by a serine metalloprotease. In the absence of CcoQ, we suggest that the presence of O-2 leads to the loss of heme from the core complex, which destabilizes the cbb(3) oxidase into a "degradable" form, perhaps by altering its conformation. Under aerobic conditions the absence of CcoQ appears to affect the CcoP subunit most severely. It was further demonstrated, using a series of COOH-terminal deletion derivatives of CcoQ, that the minimum length of CcoQ required for stabilization of the core complex under aerobic conditions is the amino-terminal similar to48-50 amino acids.	Univ Texas, Hlth Sci Ctr, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Kaplan, S (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Med, Dept Microbiol & Mol Genet, 6431 Fannin, Houston, TX 77030 USA.				NIGMS NIH HHS [GM15590] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Bratton MR, 1999, BIOCHEMISTRY-US, V38, P16236, DOI 10.1021/bi9914107; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; DONOHUE TJ, 1988, BIOCHEMISTRY-US, V27, P1918, DOI 10.1021/bi00406a018; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P3120, DOI 10.1021/bi00176a047; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Jessee J., 1986, FOCUS, V8, P9; Jones C. W., 1985, METHOD MICROBIOL, V18, P285; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KOBACH ME, 1994, BIOTECHNIQUES, V16, P800; LENZ O, 1994, J BACTERIOL, V176, P4385, DOI 10.1128/jb.176.14.4385-4393.1994; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; Mouncey NJ, 1998, J BACTERIOL, V180, P2228, DOI 10.1128/JB.180.8.2228-2231.1998; Myllykallio H, 1999, P NATL ACAD SCI USA, V96, P4348, DOI 10.1073/pnas.96.8.4348; O'Gara JP, 1998, J BACTERIOL, V180, P4044; OGara JP, 1997, J BACTERIOL, V179, P1951, DOI 10.1128/jb.179.6.1951-1961.1997; Oh JI, 1999, BIOCHEMISTRY-US, V38, P2688, DOI 10.1021/bi9825100; Oh JI, 2001, MOL MICROBIOL, V39, P1116, DOI 10.1046/j.1365-2958.2001.02299.x; Oh JI, 2000, EMBO J, V19, P4237, DOI 10.1093/emboj/19.16.4237; Saiki K, 1996, J BIOL CHEM, V271, P15336, DOI 10.1074/jbc.271.26.15336; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Toledo-Cuevas M, 1998, BBA-BIOENERGETICS, V1365, P421, DOI 10.1016/S0005-2728(98)00095-4; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; van Niel CB, 1944, BACTERIOL REV, V8, P1; VILLANI G, 1995, BBA-BIOENERGETICS, V1232, P67, DOI 10.1016/0005-2728(95)00112-5; Witt H, 1997, J BIOL CHEM, V272, P5514, DOI 10.1074/jbc.272.9.5514; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zufferey R, 1998, J BIOL CHEM, V273, P6452, DOI 10.1074/jbc.273.11.6452; Zufferey R, 1996, J BIOL CHEM, V271, P9114, DOI 10.1074/jbc.271.15.9114	35	46	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16220	16228		10.1074/jbc.M200198200	http://dx.doi.org/10.1074/jbc.M200198200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864982	hybrid			2022-12-25	WOS:000175510400132
J	Tokumitsu, H; Inuzuka, H; Ishikawa, Y; Ikeda, M; Saji, I; Kobayashi, R				Tokumitsu, H; Inuzuka, H; Ishikawa, Y; Ikeda, M; Saji, I; Kobayashi, R			STO-609, a specific inhibitor of the Ca2+/calmodulin-dependent protein kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; REGULATORY MECHANISM; CALMODULIN; IV; ACTIVATION; PHOSPHORYLATION; CASCADE; IDENTIFICATION; EXPRESSION; CREB	STO-609, a selective inhibitor of Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK) was synthesized, and its inhibitory properties were investigated both in vitro and in vivo. STO-609 inhibits the activities of recombinant CaM-KKalpha and CaM-KKbeta isoforms, with K-i values of 80 and 15 ng/ml, respectively, and also inhibits their autophosphorylation activities. Comparison of the inhibitory potency of the compound against various protein kinases revealed that STO-609 is highly selective for CaM-KK without any significant effect on the downstream CaM kinases (CaM-KI and -IV), and the IC50 value of the compound against CaM-KII is similar to10 mug/ ml. STO-609 inhibits constitutively active CaM-KKa (glutathione S-transferase (GST)-CaM-KK-(84-434)) as well as the wild-type enzyme. Kinetic analysis indicates that the compound is a competitive inhibitor of ATP. In transfected HeLa cells, STO-609 suppresses the Ca2+- induced activation of CaM-KIV in a dose-dependent manner. In agreement with this observation, the inhibitor significantly reduces the endogenous activity of CaM-KK in SH-SY5Y neuroblastoma cells at a concentration of 1 mug/ml (similar to80% inhibitory rate). Taken together, these results indicate that STO-609 is a selective and cell-permeable inhibitor of CaM-KK and that it may be a useful tool for evaluating the physiological significance of the CaM-KK-mediated pathway in vivo as well as in vitro.	Kagawa Med Univ, Dept Chem, Miki, Kagawa 7610793, Japan; Sumitomo Pharmaceut Co Ltd, Div Res, Exploratory Res Grp, Takarazuka, Hyogo 665, Japan	Kagawa University	Tokumitsu, H (corresponding author), Kagawa Med Univ, Dept Chem, 1750-1 Miki Cho, Miki, Kagawa 7610793, Japan.	tokumit@kms.ac.jp	Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				Aletta JM, 1996, J BIOL CHEM, V271, P20930, DOI 10.1074/jbc.271.34.20930; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Joseph JD, 2000, J BIOL CHEM, V275, P38230, DOI 10.1074/jbc.M006422200; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; Kurokawa H, 2001, J MOL BIOL, V312, P59, DOI 10.1006/jmbi.2001.4822; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; Matsushita M, 1999, J BIOL CHEM, V274, P10086, DOI 10.1074/jbc.274.15.10086; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Nakaya K, 2001, B CHEM SOC JPN, V74, P173, DOI 10.1246/bcsj.74.173; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; Ribar TJ, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0004.2000; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tokumitsu H, 2000, J BIOL CHEM, V275, P20090, DOI 10.1074/jbc.M002193200; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; Tokumitsu H, 2001, BIOCHEMISTRY-US, V40, P13925, DOI 10.1021/bi010863k; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; Wu JY, 2000, ENDOCRINOLOGY, V141, P4777, DOI 10.1210/en.141.12.4777; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153	37	229	237	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15813	15818		10.1074/jbc.M201075200	http://dx.doi.org/10.1074/jbc.M201075200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867640	hybrid			2022-12-25	WOS:000175510400081
J	Kimoto, H; Kusaoke, H; Yamamoto, I; Fujii, Y; Onodera, T; Taketo, A				Kimoto, H; Kusaoke, H; Yamamoto, I; Fujii, Y; Onodera, T; Taketo, A			Biochemical and genetic properties of Paenibacillus glycosyl hydrolase having chitosanase activity and discoidin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CIRCULANS WL-12; AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; CELLULASE GENE; CLOSTRIDIUM-THERMOCELLUM; NUCLEOTIDE-SEQUENCE; CELLULOMONAS-FIMI; ESCHERICHIA-COLI; STRAIN N174; SP KSM-330	Cells of "Paenibacillus fukuinensis" D2 produced chitosanase into surrounding medium, in the presence of colloidal chitosan or glucosamine. The gene of this enzyme was cloned, sequenced, and subjected to site-directed mutation and deletion analyses. The nucleotide sequence indicated that the chitosanase was composed of 797 amino acids and its molecular weight was 85,610. Unlike conventional family 46 chitosanases, the enzyme has family 8 glycosyl hydrolase catalytic domain, at the amino-terminal side, and discoidin domain at the carboxyl-terminal region. Expression of the cloned gene in Escherichia coli revealed beta-1,4-glucanase function, besides chitosanase activity. Analyses by zymography and immunoblotting suggested that the active enzyme was, after removal of signal peptide, produced from inactive 81-kDa form by proteolysis at the carboxyl-terminal region. Replacements of Glu(115) and Asp(176), highly conserved residues in the family 8 glycosylase region, with Gln and Asn caused simultaneous loss of chitosanase and glucanase activities, suggesting that these residues formed part of the catalytic site. Truncation experiments demonstrated indispensability of an amino-terminal region spanning 425 residues adjacent to the signal peptide.	Fukui Med Univ, Fac Med, Dept Biochem 1, Fukui 9101193, Japan; Fukui Med Univ, Fac Med, Dept Chem, Fukui 9101193, Japan; Fukui Univ Technol, Dept Appl Phys & Chem, Fukui 910, Japan	University of Fukui; University of Fukui	Kimoto, H (corresponding author), Fukui Med Univ, Fac Med, Dept Biochem 1, 23-3 Shimoaizuki, Fukui 9101193, Japan.	hisashi@fmsrsa.fukui-med.ac.jp		Fujii, Yutaka/0000-0001-6357-3795				Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; ANDO A, 1992, J GEN APPL MICROBIOL, V38, P135, DOI 10.2323/jgam.38.135; BAGNARATARDIF C, 1992, GENE, V119, P17, DOI 10.1016/0378-1119(92)90062-T; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; BEGUIN P, 1985, J BACTERIOL, V162, P102; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUENO A, 1990, NUCLEIC ACIDS RES, V18, P4248, DOI 10.1093/nar/18.14.4248; CANTWELL BA, 1983, GENE, V23, P211, DOI 10.1016/0378-1119(83)90053-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DYGERT S, 1965, ANAL BIOCHEM, V13, P367, DOI 10.1016/0003-2697(65)90327-1; FUJINO T, 1993, J FERMENT BIOENG, V76, P243, DOI 10.1016/0922-338X(93)90188-E; Fukamizo T, 1997, BIOCHEM CELL BIOL, V75, P687, DOI 10.1139/bcb-75-6-687; GILKES NR, 1988, J BIOL CHEM, V263, P10401; GREENWOOD JM, 1989, FEBS LETT, V244, P127, DOI 10.1016/0014-5793(89)81177-9; GUISEPPI A, 1991, GENE, V106, P109, DOI 10.1016/0378-1119(91)90573-T; HEDGES A, 1974, J BACTERIOL, V120, P844, DOI 10.1128/JB.120.2.844-853.1974; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; IZUME M, 1992, BIOSCI BIOTECH BIOCH, V56, P448, DOI 10.1271/bbb.56.448; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; Kimoto H, 1997, J BIOCHEM, V122, P237; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGSFORD ML, 1987, FEBS LETT, V225, P163, DOI 10.1016/0014-5793(87)81150-X; Madden TL, 1996, METHOD ENZYMOL, V266, P131; Marcotte EM, 1996, NAT STRUCT BIOL, V3, P155, DOI 10.1038/nsb0296-155; MASSON JY, 1994, GENE, V140, P103, DOI 10.1016/0378-1119(94)90738-2; MASSON JY, 1995, MICROBIOL-SGM, V141, P2629, DOI 10.1099/13500872-141-10-2629; MILLER GL, 1960, ANAL BIOCHEM, V2, P127, DOI DOI 10.1016/0003-2697(60)90004-X; Mitsutomi M, 1998, BIOSCI BIOTECH BIOCH, V62, P2107, DOI 10.1271/bbb.62.2107; Monzingo AF, 1996, NAT STRUCT BIOL, V3, P133, DOI 10.1038/nsb0296-133; NAKAMURA K, 1986, J BIOTECHNOL, V4, P247, DOI 10.1016/0168-1656(86)90035-0; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OHTAKARA A, 1988, METHODS ENZYMOL, V161, P505; OZAKI K, 1991, J GEN MICROBIOL, V137, P2299, DOI 10.1099/00221287-137-10-2299; OZAKI K, 1994, BBA-PROTEIN STRUCT M, V1207, P159, DOI 10.1016/0167-4838(94)00060-3; Parro V, 1997, MICROBIOL-UK, V143, P1321, DOI 10.1099/00221287-143-4-1321; PedrazaReyes M, 1997, ARCH MICROBIOL, V168, P321, DOI 10.1007/s002030050505; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; SHEN H, 1995, BIOCHEM J, V311, P67, DOI 10.1042/bj3110067; STANDAL R, 1994, J BACTERIOL, V176, P665, DOI 10.1128/jb.176.3.665-672.1994; TEATHER RM, 1982, APPL ENVIRON MICROB, V43, P777, DOI 10.1128/AEM.43.4.777-780.1982; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; UCHIDA Y, 1988, METHOD ENZYMOL, V161, P501; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	52	54	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14695	14702		10.1074/jbc.M108660200	http://dx.doi.org/10.1074/jbc.M108660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11854270	hybrid			2022-12-25	WOS:000175203000045
J	Morikis, D; Roy, M; Sahu, A; Troganis, A; Jennings, PA; Tsokos, GC; Lambris, JD				Morikis, D; Roy, M; Sahu, A; Troganis, A; Jennings, PA; Tsokos, GC; Lambris, JD			The structural basis of compstatin activity examined by structure-function-based design of peptide analogs and NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT; ACTIVATION; BIOLOGY; C3; CONFORMATIONS; INHIBITION; IMMUNOLOGY	We have previously identified compstatin, a 13-residue cyclic peptide, that inhibits complement activation by binding to C3 and preventing C3 cleavage to C3a and C3b. The structure of compstatin consists of a disulfide bridge and a type I beta-turn located at opposite sides to each other. The disulfide bridge is part of a hydrophobic cluster, and the beta-turn is part of a polar surface. We present the design of compstatin analogs in which we have introduced a series of perturbations in key structural elements of their parent peptide, compstatin. We have examined the consistency of the structures of the designed analogs compared with compstatin using NMR, and we have used the resulting structural information to make structure-complement inhibitory activity correlations. We propose the following. 1) Even in the absence of the disulfide bridge, a linear analog has a propensity for structure formation consistent with a turn of a 3(10)-helix or a beta-turn. 2) The type I beta-turn is a necessary but not a sufficient condition for activity. 3) Our substitutions outside the type I beta-turn of compstatin have altered the turn population but not the turn structure. 4) Flexibility of the beta-turn is essential for activity. 5) The type I beta-turn introduces reversibility and sufficiently separates the two sides of the peptide, whereas the disulfide bridge prevents the termini from drifting apart, thus aiding in the formation of the hydrophobic cluster. 6) The hydrophobic cluster at the linked termini is involved in binding to C3 and activity but alone is not sufficient for activity. 7) beta-Turn residues Gln(5) (Asn(5))-Asp(6)-Trp(7)(Phe(7)) -Gly(8) are specific for the turn formation, but only Gln(5)(Asn(5)) -Asp(6)-Trp(7)-Gly(8) residues are specific for activity. 8) Trp(7) is likely to be involved in direct interaction with C3, possibly through the formation of a hydrogen bond. Finally we propose a binding model for the C3-compstatin complex.	Univ Calif Riverside, Dept Environm Chem & Engn, Riverside, CA 92521 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Natl Ctr Cell Sci, Pune 411007, Maharashtra, India; Univ Ioannina, Dept Biol Applicat & Technol, GR-45110 Ioannina, Greece; Walter Reed Army Inst Res, Silver Spring, MD 20910 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of California System; University of California Riverside; University of California System; University of California San Diego; Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); University of Ioannina; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of Pennsylvania	Lambris, JD (corresponding author), Univ Calif Riverside, Dept Environm Chem & Engn, Riverside, CA 92521 USA.	lambris@mail.med.upenn.edu	Morikis, Dimitrios/L-8527-2013; Lambris, John/Q-5633-2018; Sahu, Arvind/C-2178-2012; tsokos, george C/O-3360-2013	Morikis, Dimitrios/0000-0003-0083-4665; Lambris, John/0000-0002-9370-5776; tsokos, george C/0000-0001-9589-2360	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-62135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DYSON HJ, 1988, ANNU REV BIOPHYS BIO, V17, P305; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1995, FASEB J, V9, P37, DOI 10.1096/fasebj.9.1.7821757; Ernst R.R., 1990, PRINCIPLES NUCL MAGN; Fiane AE, 1999, XENOTRANSPLANTATION, V6, P52, DOI 10.1034/j.1399-3089.1999.00007.x; Furlong ST, 2000, IMMUNOPHARMACOLOGY, V48, P199, DOI 10.1016/S0162-3109(00)00205-8; Klepeis JL, 1999, J COMPUT CHEM, V20, P1354, DOI 10.1002/(SICI)1096-987X(199910)20:13<1354::AID-JCC3>3.0.CO;2-N; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lambris JD, 1999, IMMUNOL TODAY, V20, P207, DOI 10.1016/S0167-5699(98)01417-0; LAMBRIS JD, 2000, THERAPEUTIC INTERVEN; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MERUTKA G, 1993, BIOCHEMISTRY-US, V32, P13089, DOI 10.1021/bi00211a019; Morikis D, 1998, PROTEIN SCI, V7, P619, DOI 10.1002/pro.5560070311; Nilsson B, 1998, BLOOD, V92, P1661, DOI 10.1182/blood.V92.5.1661; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; Sahu A, 1996, J IMMUNOL, V157, P884; Sahu A, 2000, CONT IMMUN, V9, P75; Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x; Sahu A, 2000, J IMMUNOL, V165, P2491, DOI 10.4049/jimmunol.165.5.2491; Sahu A, 2000, IMMUNOPHARMACOLOGY, V49, P133, DOI 10.1016/S0162-3109(00)80299-4; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Soulika AM, 2000, CLIN IMMUNOL, V96, P212, DOI 10.1006/clim.2000.4903; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; Wuthrich K, 1986, NMR PROTEINS NUCL AC	29	45	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14942	14953		10.1074/jbc.M200021200	http://dx.doi.org/10.1074/jbc.M200021200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847226	hybrid			2022-12-25	WOS:000175203000076
J	Shi, L; Kishore, R; McMullen, MR; Nagy, LE				Shi, L; Kishore, R; McMullen, MR; Nagy, LE			Chronic ethanol increases lipopolysaccharide-stimulated Egr-1 expression in RAW 264.7 macrophages - Contribution to enhanced tumor necrosis factor alpha production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ALCOHOLIC LIVER-DISEASE; SIGNAL-REGULATED KINASE; EARLY GROWTH RESPONSE-1; NITRIC-OXIDE SYNTHASE; HUMAN MONOCYTIC CELLS; MESSENGER-RNA; PLASMA ENDOTOXIN; PC12 CELLS; PATHWAY	Increased production of tumor necrosis factor alpha (TNFalpha) is associated with the development of alcoholic liver disease. Culture of RAW264.7 macrophages with 25 mm ethanol for 48 h increased lipopolysaccharide (LPS)-stimulated accumulation of tumor necrosis factor alpha (TNFalpha) peptide and mRNA by 2-fold. We investigated whether chronic ethanol-induced increases in the DNA binding and/or promoter activity of the key transcription factors regulating LPS-stimulated TNFalpha promoter activity contribute to increased TNFalpha expression. Binding of Egr-1 to the TNFalpha promoter was increased by 2.5-fold after ethanol exposure, whereas NFkappaB binding was decreased to 30% of control. AP-1 binding was not affected. Changes in binding activity were paralleled by an increased contribution of the Egr-1 binding site and a decreased contribution of the NFkappaB site to LPS-stimulated TNFalpha promoter activity. Overexpression of dominant negative Egr-1 prevented the ethanol-induced increase in LPS-stimulated TNFalpha mRNA accumulation. Chronic ethanol exposure enhanced LPS-stimulated Egr-1 promoter-driven CAT expression and transcription of Egr-1. Induction of Egr-1 is dependent on ERK1/2 activation in other systems. Therefore, we investigated whether the ERK1/2 pathway mediated the chronic ethanol-induced increases in Egr-1 and TNFalpha. Increased Egr-1 promoter activity and TNFalpha mRNA accumulation after chronic ethanol were both prevented by overexpression of dominant negative ERK1/2. LPS-stimulated ERK1/2 phosphorylation was increased 2-fold in cells cultured with ethanol compared with controls. These results demonstrate that enhanced LPS-dependent activation of Egr-1 contributes to increased TNFalpha production after chronic ethanol exposure.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA	Case Western Reserve University	Nagy, LE (corresponding author), Case Western Reserve Univ, Dept Nutr, 2123 Abington Rd,Rm 201, Cleveland, OH 44106 USA.		Shi, Lei/AAV-1321-2020	Shi, Lei/0000-0002-4137-096X; Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA011975, R01AA011975] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-11975] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aggarwal B.B., 1995, HUMAN CYTOKINES THEI; Aldred A, 1999, AM J PHYSIOL-GASTR L, V276, pG98, DOI 10.1152/ajpgi.1999.276.1.G98; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; BODE C, 1987, J HEPATOL, V4, P8, DOI 10.1016/S0168-8278(87)80003-X; Chen CC, 1999, J BIOL CHEM, V274, P31559, DOI 10.1074/jbc.274.44.31559; Chen JP, 1998, BIOCHEM J, V334, P669, DOI 10.1042/bj3340669; COLEMAN DL, 1992, J IMMUNOL, V149, P3045; DeFranco AL, 1998, PROG CLIN BIOL RES, V397, P119; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Dieckgraefe BK, 1999, AM J PHYSIOL-GASTR L, V276, pG322, DOI 10.1152/ajpgi.1999.276.2.G322; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FUKUI H, 1991, J HEPATOL, V12, P162, DOI 10.1016/0168-8278(91)90933-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Greenberg SS, 1998, ALCOHOL, V16, P167, DOI 10.1016/S0741-8329(97)00187-0; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; HONCHEL R, 1992, ALCOHOL CLIN EXP RES, V16, P665, DOI 10.1111/j.1530-0277.1992.tb00656.x; HUANG RP, 1994, J CELL BIOCHEM, V56, P469, DOI 10.1002/jcb.240560407; KHORUTS A, 1991, HEPATOLOGY, V13, P267, DOI 10.1016/0270-9139(91)92439-F; Kishore R, 2002, AM J PHYSIOL-GASTR L, V282, pG6, DOI 10.1152/ajpgi.00328.2001; Kishore R, 2001, J BIOL CHEM, V276, P41930, DOI 10.1074/jbc.M107181200; MCCLAIN CJ, 1989, HEPATOLOGY, V9, P349, DOI 10.1002/hep.1840090302; Means TK, 2000, J LEUKOCYTE BIOL, V67, P885, DOI 10.1002/jlb.67.6.885; Motomura K, 2001, AM J PHYSIOL-ENDOC M, V281, pE420, DOI 10.1152/ajpendo.2001.281.3.E420; NANJI AA, 1993, AM J PATHOL, V142, P367; Papadakis KA, 2000, GASTROENTEROLOGY, V119, P1148, DOI 10.1053/gast.2000.18160; Papanikolaou NA, 2000, J BIOL CHEM, V275, P26683; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Reddy MA, 1996, BIOCHEM PHARMACOL, V51, P661, DOI 10.1016/S0006-2952(95)02239-2; ROIVAINEN R, 1995, P NATL ACAD SCI USA, V92, P1891, DOI 10.1073/pnas.92.6.1891; Rokos CL, 1997, J BIOL CHEM, V272, P13452, DOI 10.1074/jbc.272.20.13452; Sato K, 1999, MOL BRAIN RES, V74, P182, DOI 10.1016/S0169-328X(99)00279-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHI L, 2002, AM J PHYSIOL, V10, P1152; Silverman ES, 2001, AM J RESP CRIT CARE, V163, P778, DOI 10.1164/ajrccm.163.3.2003123; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Tilg H, 2000, NEW ENGL J MED, V343, P1467, DOI 10.1056/NEJM200011163432007; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Weng YI, 2000, EUR J PHARMACOL, V398, P323, DOI 10.1016/S0014-2999(00)00313-7; Wung BS, 1999, CIRC RES, V84, P804; Yan SF, 2000, J CLIN INVEST, V105, P553, DOI 10.1172/JCI9513; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9	46	308	319	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14777	14785		10.1074/jbc.M108967200	http://dx.doi.org/10.1074/jbc.M108967200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11856733	hybrid			2022-12-25	WOS:000175203000056
J	Mallee, JJ; Salvatore, CA; LeBourdelles, B; Oliver, KR; Longmore, J; Koblan, KS; Kane, SA				Mallee, JJ; Salvatore, CA; LeBourdelles, B; Oliver, KR; Longmore, J; Koblan, KS; Kane, SA			Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; TRIGEMINOVASCULAR SYSTEM; HUMANS; MIGRAINE; LIGAND; RAMPS	The heterodimeric CGRP receptor requires co-expression of calcitonin receptor-like receptor (CRLR) and an accessory protein called receptor activity-modifying protein (RAMP) 1 (McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., and Foord, S. M. (1998) Nature 393, 333-339). Several non-peptide CGRP receptor antagonists have been shown to exhibit marked species selectivity, with > 100-fold higher affinities for the human CGRP receptor than for receptors from other species (Doods, H., Hallermayer, G., Wu, D., Entzeroth, M., Rudolf, K., Engel, W., and Eberlein, W. (2000) Br. J. Pharmacol. 129, 420-423; Edvinsson, L., Sams, A., Jansen-Olesen, I., Tajti, J., Kane, S. A., Rutledge, R. Z., Koblan, K. S., Hill, R. G., and Longmore, J. (2001) Ear. J. Pharmacol. 415, 39-44). This observation provided an opportunity to map the determinants of receptor affinity exhibited by BIBN4096BS and the truncated analogs, Compounds 1 and 2. All three compounds exhibited higher affinity for the human receptor, human CRLR/human RAMP1, than for the rat receptor, rat CRLR/rat RAMP1. We have now demonstrated that this species selectivity was directed exclusively by RAMP1. By generating recombinant human/rat CRLR/RAMP1 receptors, we demonstrated that co-expression of human CRLR with rat RAMP1 produced rat receptor pharmacology, and vice versa. Moreover, with rat/human RAMP1 chimeras and site-directed mutants, we have identified a single amino acid at position 74 of RAMP1 that modulates the affinity of small molecule antagonists for CRLR/RAMP1. Replacement of lysine 74 in rat RAMP1 with tryptophan (the homologous amino acid in the human receptor) resulted in a greater than or equal to100-fold increase in antagonist affinities, similar to the K-i values for the human receptor. These observations suggest that important determinants of small molecule antagonist affinity for the CGRP receptor reside within the extracellular region of RAMP1 and provide evidence that this receptor accessory protein may participate in antagonist binding.	Merck Res Labs, Dept Mol Pharmacol, West Point, PA 19486 USA; Merck Res Labs, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England	Merck & Company; Merck & Company	Kane, SA (corresponding author), Merck Res Labs, Dept Mol Pharmacol, WP26A-2000, West Point, PA 19486 USA.	stefanie_kane@merck.com						Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; Doods H, 2000, BRIT J PHARMACOL, V129, P420, DOI 10.1038/sj.bjp.0703110; Edvinsson L, 2001, EUR J PHARMACOL, V415, P39, DOI 10.1016/S0014-2999(00)00934-1; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GOADSBY PJ, 1993, ANN NEUROL, V33, P48, DOI 10.1002/ana.410330109; GOADSBY PJ, 1990, ANN NEUROL, V28, P183, DOI 10.1002/ana.410280213; GOADSBY PJ, 2000, MOL B INT U, V10, P159; Hasbak P, 2001, BRIT J PHARMACOL, V133, P1405, DOI 10.1038/sj.bjp.0704210; Hilaire S, 2001, J BIOL CHEM, V276, P42182, DOI 10.1074/jbc.M107323200; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; JANSEN I, 1993, VASCULAR INNERVATION, P263; Lassen L.H., 1998, EUR J NEUROL, V5, pS63; LONGMORE J, 1994, EUR J PHARMACOL, V265, P53, DOI 10.1016/0014-2999(94)90222-4; Luebke AE, 1996, P NATL ACAD SCI USA, V93, P3455, DOI 10.1073/pnas.93.8.3455; May A, 1999, J CEREBR BLOOD F MET, V19, P115, DOI 10.1097/00004647-199902000-00001; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MULDERRY PK, 1985, NEUROSCIENCE, V14, P947, DOI 10.1016/0306-4522(85)90156-3; Oliver KR, 2001, EUR J NEUROSCI, V14, P618, DOI 10.1046/j.0953-816x.2001.01688.x; Semark Joanne E., 1992, Molecular Neuropharmacology, V2, P311; Tibaduiza EC, 2001, J BIOL CHEM, V276, P37787; VanRossum D, 1997, NEUROSCI BIOBEHAV R, V21, P649, DOI 10.1016/S0149-7634(96)00023-1	24	157	203	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14294	14298		10.1074/jbc.M109661200	http://dx.doi.org/10.1074/jbc.M109661200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11847213	hybrid			2022-12-25	WOS:000175096000122
J	Yamada, Y; Pannell, R; Forster, A; Rabbitts, TH				Yamada, Y; Pannell, R; Forster, A; Rabbitts, TH			The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target	ONCOGENE			English	Article						transcriptional regulation; tumour angiogenesis; chromosomal translocation; endothelium; cancer; neo-vascularization	T-CELL LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; CANCER; TRANSCRIPTION; ONCOGENES; RBTN2	The growth of solid tumours requires a blood supply provided by re-modeling of existing blood vessel endothelium (angiogenesis). Little is known about transcription regulators which are specific for the control of tumour angiogenesis. The proto-oncogene LM02 encodes a LIM domain transcription regulator which controls angiogenesis during mouse embryogenesis where it regulates remodelling of the capillary network into mature vessels. We now show that Lmo2 expression is augmented in tumour endothelium such as mouse thymomas and human lung tumours. The functional significance of this Lmo2 expression was assessed in teratocarcinomas induced in nude mice by subcutaneous implantation of Lmo2-lacZ targeted ES cells. CD31-positive, sprouting endothelium of ES-cell origin occurred in teratocarcinomas from heterozygous Lmo2-lacZ ES cells but none occurred from null Lmo2-lacZ ES cells. Therefore, in this model Lmo2 is an obligatory regulator of neo-vascularization of tumours. These data suggest that LM02 function may be a drug target in cancer and other conditions characterized by neo-vascularization.	Med Res Council Lab Mol Biol, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Medical Research Council UK (MRC)	Rabbitts, TH (corresponding author), Med Res Council Lab Mol Biol, Hills Rd, Cambridge CB2 2QH, England.	thr@mrc.lmb.cam.ac.uk	Mordwinkin, Nicholas M/A-4347-2010; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Taniere P, 2001, AM J PATHOL, V158, P33, DOI 10.1016/S0002-9440(10)63941-7; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320	23	45	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1309	1315		10.1038/sj.onc.1205285	http://dx.doi.org/10.1038/sj.onc.1205285			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857074	Bronze			2022-12-25	WOS:000173861000001
J	Nozell, S; Chen, XB				Nozell, S; Chen, XB			p21B, a variant of p21(Waf1/Cip1), is induced by the p53 family	ONCOGENE			English	Article						p53; p2l; p218; apoptosis	CELL-CYCLE ARREST; DNA-DAMAGE; BINDING PROTEIN; GENE; APOPTOSIS; P73; INHIBITOR; SIGNALS; IDENTIFICATION; TRANSCRIPT	Alternative splicing or expression from an alternate promoter can produce variants of a gene. To determine whether the p21(Waf1/Cip1) locus is regulated by these mechanisms, we searched for and found two transcripts, p21B and p21C, that are expressed from an alternate promoter in the first intron of the p21 gene. While p21C encodes the p21. cyclin-dependent kinase inhibitor, p21B encodes a novel protein and the transcript is ubiquitously expressed in 16 human tissues tested. Like p21, both p21B and p21C are induced by DNA damage, p53, and other p53 family members through a proximal p53 response element in the promoter of p21B and p21C. However, unlike p21, which induces cell cycle arrest, we found that overexpression of p21B induces apoptosis. These findings indicate that the p21 locus expresses at least two structurally distinct, but functionally related, variants of the p21 gene from discrete promoters.	Univ Alabama, Dept Cell Biol, UAB, Ctr Comprehens Canc,MCLM 656, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), Univ Alabama, Dept Cell Biol, UAB, Ctr Comprehens Canc,MCLM 656, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [R01CA076069, R01CA081237, R29CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [CA 81237, CA 76069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; DURO D, 1995, ONCOGENE, V11, P21; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARPER JW, 1993, CELL, V75, P805; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; MAO L, 1995, CANCER RES, V55, P2995; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; QUELLE DE, 1995, CELL, V83, P993; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; STONE S, 1995, CANCER RES, V55, P2988; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Tsubari M, 1997, CANCER RES, V57, P2966; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	46	54	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1285	1294		10.1038/sj.onc.1205191	http://dx.doi.org/10.1038/sj.onc.1205191			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850848				2022-12-25	WOS:000173729400016
J	Silberstein, GB; Dressler, GR; Van Horn, K				Silberstein, GB; Dressler, GR; Van Horn, K			Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth	ONCOGENE			English	Article						breast cancer; mammary; PAX2; progesterone; Wilms' tumor	TUMOR SUPPRESSOR GENE; WILMS-TUMOR; GLAND DEVELOPMENT; WT1; APOPTOSIS; RECEPTOR; KIDNEY; DIFFERENTIATION; REPRESSION; PRODUCT	In this study, we first describe expression of the paired domain transcription factor PAX2 in the normal and cancerous human breast, then demonstrate in a murine model a novel function for PAX2 in the regulation of progesterone stimulation of secondary ductal growth. In human mammary tissue, PAX2 expression was coincident with sub-populations of mammary ductal cells, some of which possessed an undifferentiated histiotype, and was also found in >50% of the human breast tumors surveyed (n=38). In the mouse, mammary parenchyma with a targeted deletion of PAX2 developed normal ductal systems when grafted into wild-type host mammary fat pads, but failed to undergo higher order side-branching and lobular development in response to progesterone. A previously unsuspected PAX2/WT1 (Wilms' tumor suppressor gene) regulatory axis in the mammary gland was also indicated. Using RT-PCR, a significant reduction in WT1 mRNA expression was detected in the PAX2 mutant glands compared to wildtype counterparts and double-antibody immunohistochemistry detected the co-localization of PAX2 and WT1 in the nuclei of normal and cancerous breast cells. These data indicate a role for PAX2 (and possibly WT1) in the regulation of the progesterone response of the mature mammary gland. The potential contribution of PAX2 to breast tumor pathogenesis is discussed.	Univ Calif Santa Cruz, Sinsheimer Labs, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of California System; University of California Santa Cruz; University of Michigan System; University of Michigan	Silberstein, GB (corresponding author), Univ Calif Santa Cruz, Sinsheimer Labs, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.				NIDDK NIH HHS [DK-48883, DK-54740] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054740, R01DK048883] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atwood CS, 2000, J ENDOCRINOL, V167, P39, DOI 10.1677/joe.0.1670039; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Brisken C, 2000, GENE DEV, V14, P650; Brunner E, 1999, DEV BIOL, V206, P178, DOI 10.1006/dbio.1998.9136; Dehbi M, 1996, ONCOGENE, V13, P447; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; DRESSLER GR, 2002, MOUSE DEV PATTERNING, P395; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DUBOIS M, 1984, DEV BIOL, V106, P70; GNARRA JR, 1995, CANCER RES, V55, P4092; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lange CA, 1999, MOL ENDOCRINOL, V13, P829, DOI 10.1210/me.13.6.829; Lipponen P, 1999, ENDOCR-RELAT CANCER, V6, P13, DOI 10.1677/erc.0.0060013; Loeb DM, 2001, CANCER RES, V61, P921; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Ostrom L, 2000, DEV BIOL, V219, P250, DOI 10.1006/dbio.2000.9618; Porteous S, 2000, HUM MOL GENET, V9, P1, DOI 10.1093/hmg/9.1.1; ROBINSON GW, 2000, METHODS MAMMARY GLAN, P307; Silberstein GB, 1996, CELL GROWTH DIFFER, V7, P945; Silberstein GB, 2001, MICROSC RES TECHNIQ, V52, P155, DOI 10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; SILBERSTEIN GB, 1982, DEV BIOL, V93, P272, DOI 10.1016/0012-1606(82)90259-7; SMITH GH, 1988, J CELL SCI, V89, P173; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1111/j.1432-0436.1998.00201.x; Stuart ET, 1996, CELL GROWTH DIFFER, V7, P405; TOKER C, 1967, J ULTRA MOL STRUCT R, V21, P9, DOI 10.1016/S0022-5320(67)80003-0; Torres MA, 1996, DEVELOPMENT, V122, P3381; Vicanek C, 1997, KIDNEY INT, V52, P614, DOI 10.1038/ki.1997.374; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; Zhang GJ, 1998, ONCOL REP, V5, P1211	34	61	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1009	1016		10.1038/sj.onc.1205172	http://dx.doi.org/10.1038/sj.onc.1205172			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850818				2022-12-25	WOS:000173580100004
J	Bar-Shira, A; Rashi-Elkeles, S; Zlochover, L; Moyal, L; Smorodinsky, NI; Seger, R; Shiloh, Y				Bar-Shira, A; Rashi-Elkeles, S; Zlochover, L; Moyal, L; Smorodinsky, NI; Seger, R; Shiloh, Y			ATM-dependent activation of the gene encoding MAP kinase phosphatase 5 by radiomimetic DNA damage	ONCOGENE			English	Article						ataxia-telangiectasia; ATM; MAP kinases; MAP kinase phosphatase; JNK; p38	PROTEIN-KINASE PHOSPHATASE; ATAXIA-TELANGIECTASIA CELLS; C-JUN; SIGNAL-TRANSDUCTION; GAMMA-RADIATION; SACCHAROMYCES-CEREVISIAE; PERSISTENT ACTIVATION; NEGATIVE REGULATOR; GENOTOXIC STRESS; JNK	Cellular responses to DNA damage are mediated by an extensive network of signaling pathways. The ATM protein kinase is a master regulator of the response to double-strand breaks (DSBs), the most cytotoxic DNA lesion caused by ionizing radiation. ATM is the protein missing or inactive in patients with the pleiotropic genetic disorder ataxia-telangiectasia (A-T). A major response to DNA damage is altered expression of numerous genes. While studying gene expression in control and A-T cells following treatment with the radiomimetic chemical neocarzinostatin (NCS), we identified an expressed sequence tag that represented a gene that was induced by DSBs in an ATM-dependent manner. The corresponding cDNA encoded a dual specificity phosphatase of the MAP kinase phosphatase family, MKP-5. MKP-5 dephosphorylates and inactivates the stress-activated MAP kinases JNK and p38. The phosphorylation-dephosphorylation cycle of JNK and p38 by NCS was attenuated in A-T cells. Thus, ATM modulates this cycle in response to DSBs. These results further highlight ATM as a link between the DNA damage response and major signaling pathways involved in proliferative and apoptotic processes.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, David & Inez Myers Lab Genet Res, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Hybridoma Unit, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Weizmann Institute of Science	Shiloh, Y (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, David & Inez Myers Lab Genet Res, IL-69978 Tel Aviv, Israel.	yossih@post.tau.ac.il			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS31763] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GOLDBERG IH, 1995, ENEDIYNE ANTIBIOTICS, P327; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Masuda K, 2000, CYTOGENET CELL GENET, V90, P71, DOI 10.1159/000015666; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; MELTZER B, 2001, J BIOL CHEM, V273, P33320; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Rincon M, 2000, FREE RADICAL BIO MED, V28, P1328, DOI 10.1016/S0891-5849(00)00219-7; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaus SE, 2001, P NATL ACAD SCI USA, V98, P11075, DOI 10.1073/pnas.191340698; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SHILOH Y, 1983, CARCINOGENESIS, V4, P1317, DOI 10.1093/carcin/4.10.1317; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Verheij M, 1998, RADIOTHER ONCOL, V47, P225, DOI 10.1016/S0167-8140(98)00007-3; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	46	26	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					849	855		10.1038/sj.onc.1205127	http://dx.doi.org/10.1038/sj.onc.1205127			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850813				2022-12-25	WOS:000173427000016
J	Ogasawara, H; Ishii, S; Yokomizo, T; Kakinuma, T; Komine, M; Tamaki, K; Shimizu, T; Izumi, T				Ogasawara, H; Ishii, S; Yokomizo, T; Kakinuma, T; Komine, M; Tamaki, K; Shimizu, T; Izumi, T			Characterization of mouse cysteinyl leukotriene receptors mCysLT(1) and mCysLT(2) - Differential pharmacological properties and tissue distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; MOLECULAR-CLONING; DOUBLE-BLIND; ANTAGONIST; POTENT; ASTHMA; CELLS; IDENTIFICATION; INFLAMMATION; MONTELUKAST	Cysteinyl leukotrienes (LTs) are important proinflammatory mediators. Their precise roles in mice need to be elucidated to interpret mouse models of inflammatory diseases. For this purpose, we cloned and characterized mouse receptors for cysteinyl LTs, mCysLT(1) and mCysLT(2). mCysLT(1) and mCysLT(2) were composed of 339 amino acids with 87.3% identity and 309 amino acids with 73.4% identity to human orthologues, respectively. A pharmacological difference was noted between mouse and human CysLT(2). Pranlukast, a specific inhibitor for human CysLT(1), antagonized mCysLT(2) responses as determined by Ca2+ elevation and receptor-induced promoter activation. The mRNA expressions of both mCysLTs were higher in C57BL/6 mice than in 129 mice. mCysLT(1) mRNA was expressed mainly in skin, lung, and small intestine. mCysLT(2) was seen more ubiquitously with high expressions in spleen, lung, and small intestine. By in situ hybridization we demonstrated for the first time that mCysLT(1) and mCysLT(2) were expressed in subcutaneous fibroblasts. The different pharmacological characteristics of CysLT(2) between human and mouse and the different distributions of CysLTs between mouse strains suggest that careful choice and interpretation are necessary for a study of CysLTs using animal models.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, CREST, Bunkyo Ku, Tokyo 1130033, Japan; Gunma Univ, Sch Med, Dept Biochem, Gunma 3718511, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Gunma University	Shimizu, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan.	tshimizu@m.u-tokyo.ac.jp	Ogasawara, Hideaki/B-9526-2008; Yokomizo, Takehiko/P-5673-2016	Ogasawara, Hideaki/0000-0003-4593-2891; Yokomizo, Takehiko/0000-0002-5219-1553; Komine, Mayumi/0000-0002-1086-1803				Abe M, 2000, J ALLERGY CLIN IMMUN, V106, pS78, DOI 10.1067/mai.2000.106058; CHAN CC, 1994, J PHARMACOL EXP THER, V269, P891; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; Drazen JM, 1998, AM J RESP CRIT CARE, V158, pS193, DOI 10.1164/ajrccm.158.supplement_2.13tac180; Goulet JL, 2000, J IMMUNOL, V164, P4899, DOI 10.4049/jimmunol.164.9.4899; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Hishinuma T, 2001, BRIT J DERMATOL, V144, P19, DOI 10.1046/j.1365-2133.2001.03947.x; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191, DOI 10.1139/y95-028; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; Kawasawa Y, 2000, BIOCHEM BIOPH RES CO, V276, P957, DOI 10.1006/bbrc.2000.3570; LAM BK, 1997, FRONT BIOSCI, V2, P380; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2001, P NATL ACAD SCI USA, V98, P2256, DOI 10.1073/pnas.041624398; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; OBATA T, 1992, JPN J PHARMACOL, V60, P227, DOI 10.1254/jjp.60.227; Penrose JF, 1999, P ASSOC AM PHYSICIAN, V111, P537, DOI 10.1046/j.1525-1381.1999.99212.x; PHAN SH, 1988, BIOCHEMISTRY-US, V27, P2846, DOI 10.1021/bi00408a028; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001; Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; YAMAZAWA T, 1992, FEBS LETT, V301, P181, DOI 10.1016/0014-5793(92)81243-F	34	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18763	18768		10.1074/jbc.M109447200	http://dx.doi.org/10.1074/jbc.M109447200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11854273	hybrid			2022-12-25	WOS:000175975800069
J	Geha, RM; Chen, K; Wouters, J; Ooms, F; Shih, JC				Geha, RM; Chen, K; Wouters, J; Ooms, F; Shih, JC			Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID OXIDASE; CRYSTAL-STRUCTURE; INHIBITOR SPECIFICITIES; SUBSTRATE-SPECIFICITY; DIRECTED MUTAGENESIS; POLYAMINE OXIDASE; BINDING SITE; METABOLISM; MUTANT; EXPRESSION	Monoamine oxidase (MAO) is a key enzyme responsible for the degradation of serotonin, norepinephrine, dopamine, and phenylethylamine. It is an outer membrane mitochondrial enzyme existing in two isoforms, A and B. We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity. Based on the polyamine oxidase three-dimensional crystal structure, it is suggested that Lys-305, Trp-397, and Tyr-407 in MAO A and Lys-296, Trp-388, and Tyr-398 in MAO B may be involved in the non-covalent binding to FAD. Tyr-407 and Tyr-444 in MAO A (Tyr-398 and Tyr-435 in MAO B) may form an aromatic sandwich that stabilizes the substrate binding. Asp-132 in MAO A (Asp-123 in MAO B) located at the entrance of the U-shaped substrate-binding site has no effect on MAO A nor MAO B catalytic activity. The similar impact of analogous mutants in MAO A and MAO B suggests that these amino acids have the same function in both isoenzymes. Three-dimensional modeling of MAO A and B using polyamine oxidase as template suggests that the overall tertiary structure and the active sites of MAO A and B may be similar.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA; Fac Univ Notre Dame Paix, B-5000 Namur, Belgium	University of Southern California; University of Southern California; University of Namur	Shih, JC (corresponding author), 1985 Zonal Ave, Los Angeles, CA 90089 USA.			Wouters, Johan/0000-0002-4920-6857	NIMH NIH HHS [R01 MH037020-16, R37 MH039085, R37 MH39085, R37 MH039085-23, R01 MH37020] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039085, R01MH037020] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACK AJW, 1988, P NATL ACAD SCI USA, V85, P4934; Binda C, 1999, STRUCTURE, V7, P265, DOI 10.1016/S0969-2126(99)80037-9; Binda C, 2002, NAT STRUCT BIOL, V9, P22, DOI 10.1038/nsb732; Cesura AM, 1996, EUR J BIOCHEM, V236, P996, DOI 10.1111/j.1432-1033.1996.00996.x; CHEN K, 1994, MOL PHARMACOL, V46, P1226; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; Dailey TA, 1998, J BIOL CHEM, V273, P13658, DOI 10.1074/jbc.273.22.13658; de Fays K, 1999, PROTEIN ENG, V12, P217, DOI 10.1093/protein/12.3.217; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Depiereux E, 1997, COMPUT APPL BIOSCI, V13, P249; FRITZ RR, 1985, FEBS LETT, V186, P224, DOI 10.1016/0014-5793(85)80713-4; Geha RM, 2000, J NEUROCHEM, V75, P1304, DOI 10.1046/j.1471-4159.2000.751304.x; Geha RM, 2001, J BIOL CHEM, V276, P9877, DOI 10.1074/jbc.M006972200; GOTTOWIK J, 1993, FEBS LETT, V317, P152, DOI 10.1016/0014-5793(93)81512-X; GOTTOWIK J, 1995, EUR J BIOCHEM, V230, P934, DOI 10.1111/j.1432-1033.1995.tb20639.x; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; GRIMSBY J, 1997, NAT GENET, V17, P1; JOHNSTON JP, 1968, BIOCHEM PHARMACOL, V17, P1285, DOI 10.1016/0006-2952(68)90066-X; KEARNEY EB, 1971, EUR J BIOCHEM, V24, P321, DOI 10.1111/j.1432-1033.1971.tb19689.x; Knoll J, 1972, Adv Biochem Psychopharmacol, V5, P393; KRISKEY TJ, 1998, BIOCHEMISTRY-US, V37, P12360; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; Miller JR, 1999, J BIOL CHEM, V274, P23515, DOI 10.1074/jbc.274.33.23515; MITOMA J, 1992, J BIOCHEM-TOKYO, V111, P20, DOI 10.1093/oxfordjournals.jbchem.a123712; Nandigama RK, 2001, BIOCHEMISTRY-US, V40, P14839, DOI 10.1021/bi011113d; Nandigama RK, 2000, J BIOL CHEM, V275, P20527, DOI 10.1074/jbc.M002132200; Pawelek PD, 2000, EMBO J, V19, P4204, DOI 10.1093/emboj/19.16.4204; PEGG AE, 1995, CANCER LETT, V95, P247, DOI 10.1016/0304-3835(95)03897-6; Rebrin I, 2001, J BIOL CHEM, V276, P29499, DOI 10.1074/jbc.M100431200; Roh JH, 2000, BIOCHEM BIOPH RES CO, V268, P293, DOI 10.1006/bbrc.2000.2113; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; Shih JC, 1999, AM J HUM GENET, V65, P593, DOI 10.1086/302562; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tiburcio AF, 1997, PHYSIOL PLANTARUM, V100, P664, DOI 10.1034/j.1399-3054.1997.1000330.x; TSUGENO Y, 1995, J BIOCHEM-TOKYO, V118, P974, DOI 10.1093/jb/118.5.974; WEYLER W, 1992, J NEURAL TRANSM-SUPP, V41, P3; Wouters J, 1998, PROTEINS, V32, P97; Wouters J, 1998, CURR MED CHEM, V5, P137; WOUTERS J, 1995, BIOCHEM BIOPH RES CO, V208, P773, DOI 10.1006/bbrc.1995.1404; WU HF, 1993, MOL PHARMACOL, V43, P888; WURTMAN RJ, 1963, BIOCHEM PHARMACOL, V12, P1439, DOI 10.1016/0006-2952(63)90215-6; YU PH, 1981, CAN J BIOCHEM CELL B, V59, P30, DOI 10.1139/o81-005; Zhou BP, 1998, J BIOL CHEM, V273, P14862, DOI 10.1074/jbc.273.24.14862	45	62	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17209	17216		10.1074/jbc.M110920200	http://dx.doi.org/10.1074/jbc.M110920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861643	hybrid, Green Accepted			2022-12-25	WOS:000175564500114
J	Ghilardi, N; Li, J; Hongo, JA; Yi, S; Gurney, A; de Sauvage, FJ				Ghilardi, N; Li, J; Hongo, JA; Yi, S; Gurney, A; de Sauvage, FJ			A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC ENTEROCOLITIS; HELICAL CYTOKINES; GENE; CLONING; CELLS; DIFFERENTIATION; TRANSCRIPTION; INTERLEUKIN-3; STIMULATION; REGULATOR	Here we report the cloning of a novel type I cytokine receptor, gp130-like monocyte receptor (GLM-R), with homology to the interleukin-6 receptor signal transducing chain, gp130, and granulocyte colony-stimulating factor receptor. Human and murine GLM-R cDNAs encode open reading frames of 732 and 716 amino acids, respectively, and the corresponding genes are located in close proximity to gp130 genes on human chromosome 5 and mouse chromosome 13. GLM-R is specifically expressed on CD14-positive cells and is up-regulated more than 50-fold upon activation of those cells. To address the question of whether GLM-R is a signaling receptor, we constructed a chimeric molecule, consisting of the extracellular domain of human growth hormone (hGH) receptor, and the intracellular domain of GLM-R. When transfected into factor-dependent 32D cells, this chimeric molecule could signal for proliferation and activate signal transducer and activator of transcription (STAT)-3 and STAT-5 upon stimulation with hGH. Thus, GLM-R is a novel signaling receptor chain potentially involved in the development and function of monocytes and macrophages.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Antibody Technol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	de Sauvage, FJ (corresponding author), Genentech Inc, Dept Mol Oncol, 1-DNA Way,Mailstop 40, San Francisco, CA 94080 USA.		de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584; Ghilardi, Nico/0000-0003-4945-3097				BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; Kawashima T, 2001, J IMMUNOL, V167, P3652, DOI 10.4049/jimmunol.167.7.3652; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; Riley JK, 1999, J BIOL CHEM, V274, P16513, DOI 10.1074/jbc.274.23.16513; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x	33	65	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16831	16836		10.1074/jbc.M201140200	http://dx.doi.org/10.1074/jbc.M201140200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877449	hybrid			2022-12-25	WOS:000175564500065
J	Haq, R; Halupa, A; Beattie, BK; Mason, JM; Zanke, BW; Barber, DL				Haq, R; Halupa, A; Beattie, BK; Mason, JM; Zanke, BW; Barber, DL			Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ERYTHROID-DIFFERENTIATION; DEPENDENT HCD57 CELLS; P38 MAP KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; DNA-BINDING; IFN-GAMMA; TARGETED DISRUPTION; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR	The STAT proteins are a family of latent transcription factors that are activated by a wide variety of cytokines. Upon receptor engagement, STATs become tyrosine phosphorylated, translocate to the nucleus, and induce expression of target genes. In addition to tyrosine phosphorylation, maximal activation of some STAT proteins requires serine phosphorylation within the transactivation domain. Here we focus on STAT phosphorylation after engagement of the erythropoietin receptor (EPOR). In Ba/F3-EPO-R cells, EPO induces tyrosine and serine phosphorylation of STAT1, STAT3, STAT5A, and STAT5B. Identical regions of the EPO-R couple to both tyrosine and serine phosphorylation of each cognate STAT protein. A proximal region of the EPO-R lacking cytoplasmic tyrosines couples to STAT1 and STAT3 phosphorylation as well as ERK and p38(HOG) activation, but not JNK/SAPK. STAT1 serine phosphorylation was perturbed by inhibition of ERK and p38 pathways, whereas only inhibition of ERK activation blocked STAT3 serine phosphorylation in response to EPO. STAT5A/B phosphorylation is downstream of EPO-R Tyr(343), however, STAT5A/B serine phosphorylation is unaffected by either ERK or p38 inhibition. Physiological responses induced by EPO may depend on regulation of serine phosphorylation of the STAT molecules by p38(HOG) and the ERK family of kinases as well as additional serine/threonine kinases.	Univ Toronto, Inst Med Sci, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Zanke, BW (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON M5G 2M9, Canada.			Barber, Dwayne/0000-0001-5528-8150				Aznar S, 2001, MOL BIOL CELL, V12, P3282, DOI 10.1091/mbc.12.10.3282; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BARBER DL, 1994, MOL CELL BIOL, V14, P2257, DOI 10.1128/MCB.14.4.2257; Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Boudot C, 1999, J BIOL CHEM, V274, P33966, DOI 10.1074/jbc.274.48.33966; Chida D, 1999, BLOOD, V93, P1567, DOI 10.1182/blood.V93.5.1567.405k29_1567_1578; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kieran MW, 1996, P NATL ACAD SCI USA, V93, P9126, DOI 10.1073/pnas.93.17.9126; Kirito K, 1998, BLOOD, V92, P462, DOI 10.1182/blood.V92.2.462.414k15_462_471; Kirito K, 1997, J BIOL CHEM, V272, P16507, DOI 10.1074/jbc.272.26.16507; Kirito K, 2002, BLOOD, V99, P102, DOI 10.1182/blood.V99.1.102; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOMATSU N, 1993, BLOOD, V82, P456; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lawson AE, 2000, BLOOD, V96, P2084, DOI 10.1182/blood.V96.6.2084.h8002084_2084_2092; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; Ohashi Takashi, 1997, Leukemia (Basingstoke), V11, P251; Pang QS, 2000, MOL CELL BIOL, V20, P4724, DOI 10.1128/MCB.20.13.4724-4735.2000; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; REN HY, 1994, J BIOL CHEM, V269, P19633; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stoecklin E, 1997, MOL CELL BIOL, V17, P6708, DOI 10.1128/MCB.17.11.6708; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156; Zauberman A, 1999, ONCOGENE, V18, P3886, DOI 10.1038/sj.onc.1202738; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	81	69	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17359	17366		10.1074/jbc.M201842200	http://dx.doi.org/10.1074/jbc.M201842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875080	hybrid			2022-12-25	WOS:000175564500132
J	Marinovic, AC; Zheng, B; Mitch, WE; Price, SR				Marinovic, AC; Zheng, B; Mitch, WE; Price, SR			Ubiquitin (UbC) expression in muscle cells is increased by glucocorticoids through a mechanism involving Sp1 and MEK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITY; END RULE PATHWAY; SKELETAL-MUSCLE; PROTEASOME PATHWAY; MESSENGER-RNA; TRANSCRIPTION FACTOR; GENE-EXPRESSION; PROMOTER; ACTIVATION	The muscle protein catabolism present in rats with insulin-dependent diabetes and other catabolic conditions is generally associated with increased glucocorticoid production and mRNAs encoding components of the ubiquitin-proteasome system. The mechanisms that increase ubiquitin (UbC) expression have not been identified. We studied the regulation of UbC expression in L6 muscle cells because dexamethasone stimulates the transcription of this gene and others encoding components of the ubiquitin-proteasome pathway. Results of in vivo genomic DNA footprinting experiments indicate that a protein(s) binds to Sp1 sites similar to50 bp upstream from the UbC transcription start site; dexamethasone changes the methylation pattern at these sites. Sp1 binds to DNA probes corresponding to the rat or human UbC promoter, and treating cells with dexamethasone increases this binding. Deletion and mutation analyses of the rat and human UbC promoters are consistent with an important role of Sp1 in UbC induction by glucocorticoids. Dexamethasone-induced ubiquitin expression is blocked by mithramycin, an inhibitor of Sp1 binding. UO126, a pharmacologic inhibitor of MEK1, also blocks UbC transcriptional activation by dexamethasone; L6 cells transfected to express constitutively active AMK1 exhibit increased UbC promoter activity. Thus, glucocorticoids increase UbC expression in muscle cells by a novel transcriptional mechanism involving Sp1 and MEK1.	Emory Univ, Div Renal, Atlanta, GA 30322 USA	Emory University	Price, SR (corresponding author), Emory Univ, Div Renal, Rm 338,WMB,1639 Pierce Dr, Atlanta, GA 30322 USA.				NIDDK NIH HHS [DK50740, DK37175, R37 DK037175] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037175, R01DK037175, R01DK050740] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alroy I, 1999, MOL CELL BIOL, V19, P1961; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; Bell LM, 2000, J BIOL CHEM, V275, P25262, DOI 10.1074/jbc.M002076200; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Du J, 2000, J BIOL CHEM, V275, P19661, DOI 10.1074/jbc.M907258199; FOJAS DB, 2001, EMBO J, V20, P5737; Gambari R, 2000, J PHARMACOL EXP THER, V294, P370; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HALLANGERAS M, 1991, SURGERY, V109, P468; Ibrahim NM, 2000, BIOTECHNIQUES, V29, P782, DOI 10.2144/00294st04; Jamieson CAM, 2000, P NATL ACAD SCI USA, V97, P7319, DOI 10.1073/pnas.97.13.7319; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; Lazarus DD, 1999, AM J PHYSIOL-ENDOC M, V277, pE332, DOI 10.1152/ajpendo.1999.277.2.E332; Lecker SH, 1999, J CLIN INVEST, V104, P1411, DOI 10.1172/JCI7300; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Liu A, 2001, J BIOL CHEM, V276, P45372, DOI 10.1074/jbc.M105399200; LLovera M, 1998, INT J MOL MED, V2, P69; Mansoor O, 1996, P NATL ACAD SCI USA, V93, P2714, DOI 10.1073/pnas.93.7.2714; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marinovic AC, 2000, BIOCHEM BIOPH RES CO, V274, P537, DOI 10.1006/bbrc.2000.3171; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Mitch WE, 1999, AM J PHYSIOL-CELL PH, V276, pC1132, DOI 10.1152/ajpcell.1999.276.5.C1132; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Nenoi M, 1996, GENE, V179, P297, DOI 10.1016/S0378-1119(96)00380-0; Parks CL, 1996, J BIOL CHEM, V271, P4417; Pickering WP, 2002, KIDNEY INT, V61, P1286, DOI 10.1046/j.1523-1755.2002.00276.x; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; PRICE SR, 1994, AM J PHYSIOL-CELL PH, V267, pC955, DOI 10.1152/ajpcell.1994.267.4.C955; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; SIF S, 1993, ONCOGENE, V8, P2501; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; Tiao G, 1997, AM J PHYSIOL-REG I, V272, pR849, DOI 10.1152/ajpregu.1997.272.3.R849; Tiao G, 1996, J CLIN INVEST, V97, P339, DOI 10.1172/JCI118421; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668; WING SS, 1995, BIOCHEM J, V307, P639, DOI 10.1042/bj3070639	48	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16673	16681		10.1074/jbc.M200501200	http://dx.doi.org/10.1074/jbc.M200501200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872750	hybrid			2022-12-25	WOS:000175564500045
J	Tan, JA; Hall, SH; Hamil, KG; Grossman, G; Petrusz, P; French, FS				Tan, JA; Hall, SH; Hamil, KG; Grossman, G; Petrusz, P; French, FS			Protein inhibitors of activated STAT resemble scaffold attachment factors and function as interacting nuclear receptor coregulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANDROGEN RECEPTOR; LIGAND-BINDING DOMAIN; THYROID-HORMONE RECEPTOR; ZINC FINGER REGION; DNA-BINDING; GLUCOCORTICOID RECEPTOR; MATRIX PROTEIN; HISTONE ACETYLTRANSFERASE; TRANSCRIPTION FACTORS; ESTROGEN-RECEPTOR	Protein inhibitor of activated STAT1 (PIAS1) functions as a nuclear receptor coregulator and is expressed in several cell types of human testis. However, the mechanism of PIAS1 coregulation is unknown. We report here that PIAS1 has characteristics of a scaffold attachment protein. PIAS1 localized in nuclei in a speckled pattern and bound A-T-rich double-stranded DNA, a function of scaffold attachment proteins in chromatin regions of active transcription. DNA binding was dependent on a 35-amino acid sequence conserved among members of the PIAS family and in scaffold attachment proteins. The PIAS family also bound the androgen receptor DNA binding domain, and binding required the second zinc finger of this domain. PIAS1 contained an intrinsic activation domain but had bi-directional effects on androgen receptor transactivation; lower expression levels inhibited and higher levels increased transactivation in CV1 cells. Other PIAS family members also had dose-dependent effects on transactivation, but they were in a direction opposite to those of PIAS1. When coexpressed with PIAS1, other PIAS family members counteracted PIAS1 coregulation of androgen receptor transactivation. The interaction of PIAS1 with other members of the PIAS family suggests a transcription coregulatory mechanism involving a multicomponent PUS nuclear scaffold.	Univ N Carolina, Sch Med, Labs Reprod Biol, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Labs Reprod Biol, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	French, FS (corresponding author), Univ N Carolina, Sch Med, Labs Reprod Biol, Dept Pediat, Chapel Hill, NC 27599 USA.	fsfrench@med.unc.edu	Hamil, Katherine G/D-5964-2015	Hamil, Katherine G/0000-0001-7430-8313	NICHD NIH HHS [HD-04466, U54 HD-35041] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004466, U54HD035041, R01HD004466] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aarnisalo P, 1999, ENDOCRINOLOGY, V140, P3097, DOI 10.1210/en.140.7.3097; Alen P, 1999, MOL CELL BIOL, V19, P6085; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bode J, 2000, CRIT REV EUKAR GENE, V10, P73; BROWN TR, 1995, J ANDROL, V16, P299; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cho SY, 2000, BIOCHEM J, V352, P645, DOI 10.1042/0264-6021:3520645; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Eggert M, 1997, J BIOL CHEM, V272, P28471, DOI 10.1074/jbc.272.45.28471; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; FERRELL JE, 2000, SCI STKE; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hari KL, 2001, GENE DEV, V15, P1334, DOI 10.1101/gad.877901; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P667, DOI 10.1073/pnas.012317299; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kuryshev YA, 2000, AM J PHYSIOL-CELL PH, V278, pC931, DOI 10.1152/ajpcell.2000.278.5.C931; Kuryshev YA, 2001, AM J PHYSIOL-CELL PH, V281, pC290, DOI 10.1152/ajpcell.2001.281.1.C290; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liao MM, 1999, BIOCHEMISTRY-US, V38, P9718, DOI 10.1021/bi990589i; Lichtarge O, 1997, J MOL BIOL, V274, P325, DOI 10.1006/jmbi.1997.1395; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MCPHAUL MJ, 1993, J CLIN ENDOCR METAB, V76, P17, DOI 10.1210/jc.76.1.17; MOHR SE, 1999, GENE, V299, P109; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; NUOVO GJ, 1997, PCR IN SITU HYBRIDIZ, P123; Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; ORDRONNEAU P, 1981, J HISTOCHEM CYTOCHEM, V29, P1397, DOI 10.1177/29.12.7033366; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; RABURN DJ, 1995, ENDOCRINOLOGY, V136, P5769, DOI 10.1210/en.136.12.5769; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Roy AK, 1999, VITAM HORM, V55, P309; SCHDEV S, 2001, GENE DEV, V15, P3088; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHLEGEL PN, 2001, 83 ANN M END SOC JUN, P401; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Valdez BC, 1998, BIOTECHNIQUES, V24, P1032, DOI 10.2144/98246cr03; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; WONG CI, 1993, J BIOL CHEM, V268, P19004; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	95	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16993	17001		10.1074/jbc.M109217200	http://dx.doi.org/10.1074/jbc.M109217200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877418	Green Published, hybrid			2022-12-25	WOS:000175564500087
J	Goto, M; Nakajima, Y; Hirotsu, K				Goto, M; Nakajima, Y; Hirotsu, K			Crystal structure of argininosuccinate synthetase from Thermus thermophilus HB8 - Structural basis for the catalytic action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NH3-DEPENDENT NAD(+) SYNTHETASE; MECHANISM; BIOSYNTHESIS; SUBSTRATE; MOLSCRIPT; UREA	Argininosuccinate synthetase catalyzes the ATP-de. pendent condensation of a citrulline with an aspartate to give argininosuccinate. The three-dimensional structures of the enzyme from Thermus thermophilus HB8 in its free form, complexed with intact ATP, and complexed with an ATP analogue (adenylyl imidodiphosphate) and substrate analogues (arginine and succinate) have been determined at 2.3-, 2.3-, and 1.95-Angstrom resolution, respectively. The structure is essentially the same as that of the Escherichia coli argininosuccinate synthetase. The small domain has the same fold as that of a new family of "N-type" ATP pyrophosphatases with the P-loop specific for the pyrophosphate of ATP. However, the enzyme shows the P-loop specific for the gamma-phosphate of ATP. The structure of the complex form is quite similar to that of the native one, indicating that no conformational change occurs upon the binding of ATP and the substrate analogues. ATP and the substrate analogues are bound to the active site with their reaction sites close to one another and located in a geometrical orientation favorable to the catalytic action. The reaction mechanism so far proposed seems to be consistent with the locations of ATP and the substrate analogues. The reaction may proceed without the large conformational change of the enzyme proposed for the catalytic process.	Osaka City Univ, Grad Sch Sci, Dept Chem, Osaka 5588585, Japan; RIKEN, Inst Phys & Chem Res, Harima Inst SPring 8, Hyogo 6795148, Japan	Osaka Metropolitan University; RIKEN	Hirotsu, K (corresponding author), Osaka City Univ, Grad Sch Sci, Dept Chem, Osaka 5588585, Japan.	hirotsu@sci.osaka-cu.ac.jp	Hu, Ruogu/B-2203-2008					BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BORK P, 1994, PROTEINS, V20, P347, DOI 10.1002/prot.340200407; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAPMAN TL, 1986, BIOCHEMISTRY-US, V25, P4739, DOI 10.1021/bi00365a003; Devedjiev Y, 2001, ACTA CRYSTALLOGR D, V57, P806, DOI 10.1107/S0907444901003523; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemke CT, 2001, STRUCTURE, V9, P1153, DOI 10.1016/S0969-2126(01)00683-9; LESLIE AGW, 1992, JOINT CCP 4 ESRF EES; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RAUSHEL FM, 1983, ARCH BIOCHEM BIOPHYS, V225, P979, DOI 10.1016/0003-9861(83)90114-5; Rizzi M, 1996, EMBO J, V15, P5125, DOI 10.1002/j.1460-2075.1996.tb00896.x; Rizzi M, 1998, STRUCTURE, V6, P1129, DOI 10.1016/S0969-2126(98)00114-2; ROCHOVAN.O, 1967, J BIOL CHEM, V242, P3839; ROCHOVANSKY O, 1961, J BIOL CHEM, V236, P2254; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yokoyama S, 2000, NAT STRUCT BIOL, V7, P943, DOI 10.1038/80712	24	11	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15890	15896		10.1074/jbc.M112430200	http://dx.doi.org/10.1074/jbc.M112430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11844799	hybrid, Green Submitted			2022-12-25	WOS:000175510400091
J	Jiang, YL; Drohat, AC; Ichikawa, Y; Stivers, JT				Jiang, YL; Drohat, AC; Ichikawa, Y; Stivers, JT			Probing the limits of electrostatic catalysis by uracil DNA glycosylase using transition state mimicry and mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL REPLICATION; BINDING-ENERGY; SUBSTRATE; ANALOGS; NMR; RECOGNITION; MECHANISM; INSIGHTS; PYRENE; PK(A)	The DNA repair enzyme uracil DNA glycosylase (UDG) hydrolyzes the glycosidic bond of deoxyuridine in DNA by a remarkable mechanism involving formation of a positively charged oxacarbenium ion-uracil anion intermediate. We have proposed that the positively charged intermediate is stabilized by being sandwiched between the combined negative charges of the anionic uracil leaving group and a conserved aspartate residue that are located on opposite faces of the sugar ring. Here we establish that a duplex DNA oligonucleotide containing a cationic 1-aza-deoxyribose (1) oxacarbenium ion mimic is a potent inhibitor of UDG that binds tightly to the enzyme-uracil anion (EU-) product complex (K-D of EU- = 110 pM). The tight binding of I to the EU- complex results from its extremely slow off rate (k(off) = 0.0008 s(-1)), which is 25,000-fold slower than substrate analogue DNA. Removal of Asp(64) and His(187), which are involved in stabilization of the cationic sugar and the anionic uracil leaving group, respectively, specifically weakens binding of I to the UDG-uracil complex by 154,000-fold, without significantly affecting substrate or product binding. These results suggest that electrostatic effects can effectively stabilize such an intermediate by at least -7 kcal/mol, without leading to anticatalytic stabilization of the substrate and products.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Optimer Pharmaceut Inc, San Diego, CA 92121 USA	Johns Hopkins University	Stivers, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.			Drohat, Alex/0000-0002-7458-8770	NIGMS NIH HHS [GM56834, R01 GM056834, GM52324] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056834] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bruice TC, 2000, BIOCHEMISTRY-US, V39, P6267, DOI 10.1021/bi0003689; Bulow A, 2000, J AM CHEM SOC, V122, P8567, DOI 10.1021/ja001762x; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Dong J, 2000, BIOCHEMISTRY-US, V39, P13241, DOI 10.1021/bi001437m; Drohat AC, 2000, BIOCHEMISTRY-US, V39, P11865, DOI 10.1021/bi000922e; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11876, DOI 10.1021/bi9910880; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11866, DOI 10.1021/bi9910878; Drohat AC, 2000, J AM CHEM SOC, V122, P1840, DOI 10.1021/ja993254x; Hansen SU, 1998, ACTA CHEM SCAND, V52, P1214, DOI 10.3891/acta.chem.scand.52-1214; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; Jiang YL, 2001, J BIOL CHEM, V276, P42347, DOI 10.1074/jbc.M106594200; Jiang YL, 2001, BIOCHEMISTRY-US, V40, P7710, DOI 10.1021/bi010622c; Makino K, 1998, TETRAHEDRON LETT, V39, P8245, DOI 10.1016/S0040-4039(98)01781-X; Prichard MN, 1996, J VIROL, V70, P3018, DOI 10.1128/JVI.70.5.3018-3025.1996; PYLES RB, 1994, J VIROL, V68, P4963, DOI 10.1128/JVI.68.8.4963-4972.1994; Ren RXF, 1996, J AM CHEM SOC, V118, P7671, DOI 10.1021/ja9612763; Sekino Y, 2000, J BIOL CHEM, V275, P36506, DOI 10.1074/jbc.C000585200; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P814, DOI 10.1021/bi9510789; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; Stivers JT, 2001, ARCH BIOCHEM BIOPHYS, V396, P1, DOI 10.1006/abbi.2001.2605; STUART DT, 1993, J VIROL, V67, P2503, DOI 10.1128/JVI.67.5.2503-2512.1993; Warshel A, 1998, J BIOL CHEM, V273, P27035, DOI 10.1074/jbc.273.42.27035; Werner RM, 2000, BIOCHEMISTRY-US, V39, P14054, DOI 10.1021/bi0018178; Werner RM, 2000, BIOCHEMISTRY-US, V39, P12585, DOI 10.1021/bi001532v; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; Xiao GY, 1999, PROTEINS, V35, P13	26	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15385	15392		10.1074/jbc.M200634200	http://dx.doi.org/10.1074/jbc.M200634200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859082	hybrid			2022-12-25	WOS:000175510400022
J	Kar, S; Sakaguchi, K; Shimohigashi, Y; Samaddar, S; Banerjee, R; Basu, G; Swaminathan, V; Kundu, TK; Roy, S				Kar, S; Sakaguchi, K; Shimohigashi, Y; Samaddar, S; Banerjee, R; Basu, G; Swaminathan, V; Kundu, TK; Roy, S			Effect of phosphorylation on the structure and fold of transactivation domain of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; TUMOR-SUPPRESSOR; ACETYLATION; PROTEIN; KINASE; HISTONES; PEPTIDE; BINDING; STATE	Several phosphorylations are known to occur in the N-terminal transactivation domain of human p53. To explore the structural effects of these phosphorylations, we have chemically synthesized the unphosphorylated p53-(1-39) and its three phosphorylated analogs, phosphorylated at Ser-15, Thr-18, and Ser-20. p53-(1-39) and its Ser-15 and Thr-18 phosphorylated analogs were tested for interaction with p300. The order of binding affinities was similar to that derived from biochemical experiments with the whole protein, indicating functional integrity of the domain. Differences in chemical shifts and coupling constants indicate significant structural changes upon phosphorylations. The single tryptophan in the unphosphorylated domain has an emission maximum and a Stern-Volmer constant that are characteristics of tryptophans situated in protein interiors. The diffusion constant is monomer-like, with an axial ratio of 1:7.5, indicating a significant degree of compaction. Upon phosphorylations, the emission maximum and diffusion constant change significantly toward values that indicate more open conformations. Binding of the hydrophobic probe bis-1-anilino-8-naphthalenesulfonate to the unphosphorylated and one of the phosphorylated domains is also significantly different, suggesting different conformations. We propose that phosphorylations switch the largely folded transactivation domain to more open conformations that interact with transcription factors such as p300/cAMP-responsive element-binding protein-binding protein, leading to enhancement of gene expression.	Bose Inst, Dept Biophys, Kolkata 700054, W Bengal, India; Kyushu Univ, Fac Sci, Dept Chem, Lab Struct Funct Biochem, Fukuoka 8128581, Japan; Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Transcript & Dis Lab, Bangalore 560064, Karnataka, India	Department of Science & Technology (India); Bose Institute; Kyushu University; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Roy, S (corresponding author), Bose Inst, Dept Biophys, P-1-12 CIT,Scheme VII M, Kolkata 700054, W Bengal, India.	sidroy@vsnl.com		Venkatesh, Swaminathan/0000-0001-9837-1501; Kundu, Tapas/0000-0001-7790-214X				Appella E, 2000, PATHOL BIOL, V48, P227; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Canet D., 1996, NUCL MAGNETIC RESONA; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2, P584; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Damia G, 2001, NEOPLASIA, V3, P10, DOI 10.1038/sj.neo.7900122; DAS BK, 1995, BIOCHEMISTRY-US, V34, P5242, DOI 10.1021/bi00015a038; Davie JR, 2000, CRIT REV EUKAR GENE, V10, P303; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; GAREL JR, 1976, EUR J BIOCHEM, V70, P179, DOI 10.1111/j.1432-1033.1976.tb10968.x; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Jabbur JR, 2000, ONCOGENE, V19, P6203, DOI 10.1038/sj.onc.1204017; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KIM YM, 1990, PROTEINS, V8, P377, DOI 10.1002/prot.340080411; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Melcher K, 2000, J MOL BIOL, V301, P1097, DOI 10.1006/jmbi.2000.4034; Nagadoi A, 1999, J MOL BIOL, V287, P593, DOI 10.1006/jmbi.1999.2620; Nakayama T, 2001, J BIOCHEM-TOKYO, V129, P491, DOI 10.1093/oxfordjournals.jbchem.a002882; Pal D, 2001, BIOCHEMISTRY-US, V40, P15512, DOI 10.1021/bi015677t; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Puri PL, 1999, MOLECULAR BASIS OF CELL CYCLE AND GROWTH CONTROL, P15; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Wuthrich K, 1986, NMR PROTEINS NUCL AC	40	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15579	15585		10.1074/jbc.M106915200	http://dx.doi.org/10.1074/jbc.M106915200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854266	hybrid			2022-12-25	WOS:000175510400049
J	Turkan, A; Gong, XM; Peng, T; Roche, TE				Turkan, A; Gong, XM; Peng, T; Roche, TE			Structural requirements within the lipoyl domain for the Ca2+-dependent binding and activation of pyruvate dehydrogenase phosphatase isoform 1 or its catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOYL ACETYLTRANSFERASE COMPONENT; PROTEIN-X; TRANSACETYLASE COMPONENT; BOVINE KIDNEY; REGULATORY PROPERTIES; MOLECULAR-CLONING; COMPLEX; PURIFICATION; EXPRESSION; KINASE	The inner lipoyl domain (L2) of the dihydrolipoyl acetyltransferase (E2) 60-mer forms a Ca2+-dependent complex with the pyruvate dehydrogenase phosphatase 1 (PDP1) or its catalytic subunit, PDP1c, in facilitating large enhancements of the activities of PDP1 (10-fold) or PDP1c (6-fold). L2 binding to PDP1 or PDP1c requires the lipoyl-lysine prosthetic group and specificity residues that distinguish L2 from the other lipoyl domains (L1 in E2 and L3 in the E3-binding component). The L2-surface structure contributing to binding was mapped by comparing the capacities of well folded mutant or lipoyl analog-substituted L2 domains to interfere with E2 activation by competitively binding to PDP1 or PDP1c. Our results reveal the critical importance of a regional set of residues near the lipoyl group and of the octanoyl but not the dithiolane ring structure of the lipoyl group. At the other end of the lipoyl domain, substitution of Glu(182) by alanine or glutamine removed L2 binding to PDP1 or PDP1c, and these substitutions for the neighboring Glu(179) also greatly hindered complex formation (E179A > E179Q). Among 11 substitutions in L2 at sites of major surface residue differences between the L1 and L2 domains, only the conversion of Val-Gln(181) located between the critical Glu(179) and Glu(182) to the aligned Ser-Leu sequence of the L1 domain greatly reduced L2 binding. Certain modified L2 altered E2 activation of PDP1 differently than PDP1c, supporting significant impact of the regulatory PDP1r subunit on PDP1 binding to L2. Our results indicate hydrophobic binding via the extended aliphatic structure of the lipoyl group and required adjacent L2 structure anchor PDP1 by acting in concert with an acidic cluster at the other end of the domain.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Roche, TE (corresponding author), Kansas State Univ, Dept Biochem, 104 Willard Hall, Manhattan, KS 66506 USA.				NIDDK NIH HHS [DK180320] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen GL, 1996, J BIOL CHEM, V271, P28064, DOI 10.1074/jbc.271.45.28064; Choi WS, 2000, PROTEIN EXPRES PURIF, V20, P128, DOI 10.1006/prep.2000.1294; DAMUNI Z, 1984, BIOCHEM BIOPH RES CO, V124, P95, DOI 10.1016/0006-291X(84)90921-5; DENTON RM, 1972, BIOCHEM J, V128, P161, DOI 10.1042/bj1280161; Gong X, 2000, FASEB J, V14, pA1528; Gong XM, 2000, J BIOL CHEM, V275, P13645, DOI 10.1074/jbc.275.18.13645; GOPALAKRISHNAN S, 1989, BIOCHEM BIOPH RES CO, V160, P715, DOI 10.1016/0006-291X(89)92492-3; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Harris RA, 1997, J BIOL CHEM, V272, P19746, DOI 10.1074/jbc.272.32.19746; Howard MJ, 1998, GASTROENTEROLOGY, V115, P139, DOI 10.1016/S0016-5085(98)70375-0; Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; JILKA JM, 1986, J BIOL CHEM, V261, P1858; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; Lawson JE, 1997, J BIOL CHEM, V272, P31625, DOI 10.1074/jbc.272.50.31625; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; LINN TC, 1969, P NATL ACAD SCI USA, V64, P227, DOI 10.1073/pnas.64.1.227; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; Liu SJ, 2001, ARCH BIOCHEM BIOPHYS, V386, P123, DOI 10.1006/abbi.2000.2222; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PETIT FH, 1972, BIOCHEM BIOPH RES CO, V49, P563; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; PRATT ML, 1982, EUR J BIOCHEM, V125, P349, DOI 10.1111/j.1432-1033.1982.tb06690.x; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P1245; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; REED LJ, 1996, ALPHA KETO ACID DEHY, P131; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; ROCHE TE, 1996, ALPHA KETO ACID DEHY, P33; ROWLES JC, 1996, J BIOL CHEM, V37, P22376; Sanderson SJ, 1996, BIOCHEM J, V319, P109, DOI 10.1042/bj3190109; TEAGUE WM, 1982, BIOCHEMISTRY-US, V21, P5585, DOI 10.1021/bi00265a031; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; THOMAS AP, 1986, BIOCHEM J, V238, P83, DOI 10.1042/bj2380083; THOMAS AP, 1986, BIOCHEM J, V238, P93, DOI 10.1042/bj2380093; Turkan A, 2000, FASEB J, V14, pA1528; Yan JG, 1996, P NATL ACAD SCI USA, V93, P4953, DOI 10.1073/pnas.93.10.4953; Yang DQ, 1998, J BIOL CHEM, V273, P14130, DOI 10.1074/jbc.273.23.14130; Yang DQ, 1997, J BIOL CHEM, V272, P6361, DOI 10.1074/jbc.272.10.6361	43	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14976	14985		10.1074/jbc.M108434200	http://dx.doi.org/10.1074/jbc.M108434200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11842080	hybrid			2022-12-25	WOS:000175203000079
J	Bewley, CA; Louis, JM; Ghirlando, R; Clore, GM				Bewley, CA; Louis, JM; Ghirlando, R; Clore, GM			Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIV GP41; ENVELOPE GLYCOPROTEINS; ACTIVE CONFORMATION; SYNTHETIC PEPTIDE; ATOMIC-STRUCTURE; VIRUS-INFECTION; TYPE-1 GP41; ENTRY; ECTODOMAIN; PROTEIN	The pre-hairpin intermediate of gp41 from the human immunodeficiency virus (HIV) is the target for two classes of fusion inhibitors that bind to the C-terminal region or the trimeric coiled-coil of N-terminal helices, thereby preventing formation of the fusogenic trimer of hairpins. Using rational design, two 36-residue peptides, N36(Mut(e,g)) and N36(Mut(a,d)), were derived from the parent N36 peptide comprising the N-terminal helix of the gp41 ectodomain (residues 546-581 of HIV-1 envelope), characterized by analytical ultracentrifugation and CD, and assessed for their ability to inhibit HIV fusion using a quantitative vaccinia virus-based fusion assay. N36(Mut(e,g)) contains nine amino acid substitutions designed to disrupt interactions with the C-terminal region of gp41 while preserving contacts governing the formation of the trimeric coiled-coil. N36(Mut(a,d)) contains nine substitutions designed to block formation of the trimeric coiled-coil but retains residues that interact with the C-terminal region of gp41. N36(Mut(a,d)) is monomeric, is largely random coil, does not interact with the C34 peptide derived from the C-terminal region of gp41 (residues 628-661), and does not inhibit fusion. The trimeric coiled-coil structure is therefore a prerequisite for interaction with the C-terminal region of gp41. N36(Mut(e,g)) forms a monodisperse, helical trimer in solution, does not interact with C34, and yet inhibits fusion about 50-fold more effectively than the parent N36 peptide (IC50 -similar to308 nM versus similar to16 muM). These results indicate that N36(Mut(e,g)) acts by disrupting the homotrimeric coiled-coil of N-terminal helices in the pre-hairpin intermediate to form heterotrimers. Thus N36(Mut(e,g)) represents a novel third class of gp41-targeted HIV fusion inhibitor. A quantitative model describing the interaction of N36(Mut(e,g)) with the pre-hairpin intermediate is presented.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 8, Bethesda, MD 20892 USA.		Clore, G Marius/L-2546-2018; Ghirlando, Rodolfo/A-8880-2009; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Louis, John M/0000-0002-0052-1899; Bewley, Carole/0000-0003-2203-0852	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032103, Z01DK029023, ZIADK032103, ZIADK029023] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 1999, PROTEIN SCI, V8, P1904, DOI 10.1110/ps.8.9.1904; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHANCE EM, 1979, R8775 AT EN RES EST; Clore G. M., 1983, COMPUTING BIOL SCI, P313; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Peisajovich SG, 2001, J MOL BIOL, V311, P249, DOI 10.1006/jmbi.2001.4875; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; POZNIAK A, 2001, J HIV RES, V6, P92; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Wingfield PT, 1997, PROTEIN SCI, V6, P1653, DOI 10.1002/pro.5560060806	30	121	135	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14238	14245		10.1074/jbc.M201453200	http://dx.doi.org/10.1074/jbc.M201453200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11859089	Green Submitted, hybrid			2022-12-25	WOS:000175096000115
J	Fukuda, M; Kuroda, TS; Mikoshiba, K				Fukuda, M; Kuroda, TS; Mikoshiba, K			Slac2-a/melanophilin, the missing link between Rab27 and myosin Va - Implications of a tripartite protein complex for melanosome transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLP HOMOLOGY DOMAIN; DOUBLE C2 PROTEIN; SYNAPTOTAGMIN FAMILY; FUNCTIONAL DIVERSITY; CYSTEINE CLUSTER; BINDING DOMAIN; ASHEN MICE; CELLS; TRANSMEMBRANE; MELANOCYTES	Myosin Va is a member of the unconventional class V myosin family, and a mutation in the myosin Va gene causes pigment granule transport defects in human Griscelli syndrome and dilute mice. How myosin Va recognizes its cargo (i.e. melanosomes), however, has remained undetermined over the past decade. In this study, we discovered Slac2-a/melanophilin to be the "missing link" between myosin Va and GTP-Rab27A present in the melanosome. Deletion analysis and site-directed mutagenesis showed that the N-terminal Slp (synaptotagmin-like protein) homology domain of Slac2-a specifically binds Rab27A/B isoforms and that the C-terminal half directly binds the globular tail of myosin Va. The tripartite protein complex (Rab27A(.)Slac2-a(.)myosin Va) in melanoma cells was further confirmed by immunoprecipitation. The discovery that myosin Va indirectly recognizes its cargo through Slac2-a, a novel Rab27A/B effector, should shed light on molecular recognition of its specific cargo by class V myosin.	RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan	RIKEN; University of Tokyo	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Mikoshiba, Katsuhiko/N-7943-2015; Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853; Kuroda, Taruho/0000-0001-6693-4496				Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Berkowitz JKM, 2001, J BIOL CHEM, V276, P18855, DOI 10.1074/jbc.M011167200; Cheney RE, 2001, SCIENCE, V293, P1263, DOI 10.1126/science.1064602; Duncan RR, 2000, BIOCHIMIE, V82, P421, DOI 10.1016/S0300-9084(00)00214-5; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2001, BIOCHEM J, V360, P441, DOI 10.1042/0264-6021:3600441; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, J BIOL CHEM, V276, P24441, DOI 10.1074/jbc.C100119200; Fukuda M, 2001, FEBS LETT, V503, P217, DOI 10.1016/S0014-5793(01)02738-7; Fukuda M, 2001, J BIOL CHEM, V276, P27670, DOI 10.1074/jbc.M100851200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Miyata M, 2000, NEURON, V28, P233, DOI 10.1016/S0896-6273(00)00099-4; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOORE KJ, 1988, P NATL ACAD SCI USA, V85, P8131, DOI 10.1073/pnas.85.21.8131; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Takagishi Y, 1996, NEUROSCI LETT, V215, P169, DOI 10.1016/S0304-3940(96)12967-0; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2001, J CELL SCI, V114, P1091; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	42	275	284	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12432	12436		10.1074/jbc.C200005200	http://dx.doi.org/10.1074/jbc.C200005200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11856727	hybrid			2022-12-25	WOS:000174846400109
J	Missiaen, L; Vanoevelen, J; Parys, JB; Raeymaekers, L; De Smedt, H; Callewaert, G; Erneux, C; Wuytack, F				Missiaen, L; Vanoevelen, J; Parys, JB; Raeymaekers, L; De Smedt, H; Callewaert, G; Erneux, C; Wuytack, F			Ca2+ uptake and release properties of a thapsigargin-insensitive nonmitochondrial Ca2+ store in A7r5 and 16HBE14o-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; CALCIUM-RELEASE; GOLGI-APPARATUS; FUNCTIONAL-PROPERTIES; PROPERTIES DISTINCT; CELLS; CA-2+-ATPASE; INHIBITOR; RECEPTOR	In a previous study we overexpressed the thapsigargin (tg)-insensitive Pmr1 Ca2+ pump of the Golgi apparatus of Caenorhabditis elegans in COS-1 cells and studied the properties of the Ca2+ store into which it was integrated. Here we assessed the properties of an endogenous tg-insensitive nonmitochondrial Ca2+ store in A7r5 and 16HBE14o- cells, which express a mammalian homologue of Pmr1. The tg-insensitive Ca2+ store was considerably less leaky for Ca2+ than the sarco(endo)plasmic-reticulum Ca2+-ATPase (SERCA)-containing Ca2+ store. Moreover like for the worm Pmr1 Ca2+ pump expressed in COS-1 cells, Ca2+ accumulation into the endogenous tg-insensitive store showed a 2 orders of magnitude lower sensitivity to cyclopiazonic acid than the SERCA-mediated transport. 2,5-Di-(tert-butyl)-1,4-benzohydroquinone was only a very weak inhibitor of the tg-insensitive Ca2+ uptake in A7r5 and 16HBE14o-cells and in COS-1 cells overexpressing the worm Pmr1. Inositol 1,4,5-trisphosphate released 11% of the Ca2+ accumulated in permeabilized A7r5 cells pretreated with tg with an EC50 that was 5 times higher than for the SERCA-containing Ca2+ store but failed to release Ca2+ in 16HBE14o- cells. In the presence of tg, 15% of intact A7r5 cells responded to 10 muM arginine-vasopressin with a small rise in cytosolic Ca2+ concentration after a long latency. In conclusion, A7r5 and 16HBE14o- cells express a Pmr1-containing Ca2+ store with properties that differ substantially from the SERCA-containing Ca2+ store.	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Free Univ Brussels, IRIBHN, Interdisciplinary Res Inst, B-1070 Brussels, Belgium	KU Leuven; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Missiaen, L (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg O-N,Herestr 49, B-3000 Louvain, Belgium.		Vanoevelen, Jo M/F-2686-2013	Vanoevelen, Jo M/0000-0003-1830-8858; Parys, Jan/0000-0002-3591-4967				ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Galione A, 2000, BIOL CELL, V92, P197, DOI 10.1016/S0248-4900(00)01070-4; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; Missiaen L, 1996, BIOCHEM J, V317, P849, DOI 10.1042/bj3170849; Missiaen L, 2001, J BIOL CHEM, V276, P39161, DOI 10.1074/jbc.M104044200; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rojas P, 2000, CELL BIOL INT, V24, P229, DOI 10.1006/cbir.2000.0496; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Sorin A, 1997, J BIOL CHEM, V272, P9895; Surroca A, 2000, J MEMBRANE BIOL, V177, P243, DOI 10.1007/s002320010008; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; Van Baelen K, 2001, J BIOL CHEM, V276, P10683, DOI 10.1074/jbc.M010553200; YOSHIMOTO A, 1990, CELL BIOCHEM FUNCT, V8, P191, DOI 10.1002/cbf.290080402; Yusufi ANK, 2001, BIOCHEM J, V353, P531, DOI 10.1042/0264-6021:3530531; ZHA XH, 1995, AM J PHYSIOL-CELL PH, V268, pC1133, DOI 10.1152/ajpcell.1995.268.5.C1133	22	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6898	6902		10.1074/jbc.M110939200	http://dx.doi.org/10.1074/jbc.M110939200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11861657	hybrid			2022-12-25	WOS:000174104300021
J	Rong, R; He, Q; Liu, Y; Sheikh, MS; Huang, Y				Rong, R; He, Q; Liu, Y; Sheikh, MS; Huang, Y			TC21 mediates transformation and cell survival via activation of phosphatidylinositol 3-kinase/Akt and NF-kappa B signaling pathway	ONCOGENE			English	Article						TC21; PI3-K; Akt; transformation; cell survival; NF-kappa B	PHOSPHOINOSITIDE 3-KINASE; KINASE CASCADE; RAS; PROTEIN; AKT; EXPRESSION; INDUCTION; TARGET; FAMILY; DEATH	The signaling pathways of TC21-mediated transformation and cell survival are not well-established. In this study, we have investigated the role of PI3-K/Akt signaling pathway in oncogenic-TC21-mediated transformation and cell survival. We found that oncogenic-TC21 stimulated the PI3-K activity. This was associated with the activation of Akt, a key, component of PI3-K signaling pathway. We also found that TC21 interacted and formed complex with PI3-K. Mutations in the GTP-binding region of TC21, which enhanced GTP-binding potential of this protein, also stimulated its association with PI3-K, suggesting that PI3-K may preferentially interact with the GTP-bound form. Suppression of PI3-K and Akt by specific inhibitors LY294002 and Wortmannin reversed TC21-induced transformation. Likewise, inhibition of PI3-K activity by the PI3-K phosphotase PTEN reduced TC21-mediated focus formation in NIH3T3 cells. Investigation of TC21's effect on cell survival revealed that mutant-TC21 expressing cells were more resistant to etoposide- and cisplatin-induced cell death, and this was associated with the activation of anti-apoptotic protein NF-kappaB, a downstream target of Akt. Treatment of PI3-K inhibitor LY294002 significantly suppressed TC21-mediated NF-kappaB activation. In conclusion, we have identified PI3-K as an effector of TC21 and demonstrated that the PI3-K/Akt signaling pathway plays important roles in TC21-mediated transformation and cell survival.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@mail.upstate.edu	Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109				Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; AUGER KR, 1992, J BIOL CHEM, V267, P5408; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Clark GJ, 1996, ONCOGENE, V12, P169; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Graham WJ, 1996, HEALTH POLICY PLANN, V11, P16, DOI 10.1093/heapol/11.1.16; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUANG Y, 1995, ONCOGENE, V11, P1255; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; HUTTER D, 2000, BIOCH J 1, V15, P352; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marais R, 1996, CANCER SURV, V27, P101; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Ozes ON, 1999, NATURE, V401, P82; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; Woodgett JR, 1996, CANCER SURV, V27, P127; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	59	41	43	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1062	1070		10.1038/sj.onc.1205154	http://dx.doi.org/10.1038/sj.onc.1205154			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850823				2022-12-25	WOS:000173580100009
J	Henry, H; Thomas, A; Shen, Y; White, E				Henry, H; Thomas, A; Shen, Y; White, E			Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death	ONCOGENE			English	Article						p53; apoptosis; Bcl-2 family; caspase	CYTOCHROME-C RELEASE; TUMOR-SUPPRESSOR P53; PORE-FORMING DOMAIN; ADENOVIRUS E1B 19K; BCL-2 FAMILY; P53-DEPENDENT APOPTOSIS; 19-KILODALTON PROTEIN; CONFORMATIONAL CHANGE; DELTA-ENDOTOXIN; BAX GENE	The p53 tumor suppressor protein inhibits tumor formation, in part by inducing apoptosis, which is inhibited by anti-apoptotic Bcl-2 family members Bcl-2 and adenovirus E1B 19K. We have identified p53-apoptotic signaling events which are targeted for inhibition by E1B 19K. Apoptotic signaling by p53 induced a Bid-independent conformational change in Bax, a Bax-Bak interaction, release of cytochrome c and Smac/DIABLO from mitochondria, caspase-9 and 3 activation, cleavage of known caspase substrates, and apoptosis. When p53-dependent apoptosis was blocked by E1B 19K expression, E1B 19K bound Bak, and the Bax-Bak interaction was inhibited. Cytochrome c and Smac/DIABLO release from mitochondria was also inhibited in E1B 19K expressing cells and cells remained viable. After a prolonged p53 death stimulus, the inhibition of the mitochondrial death checkpoint by E1B 19K failed, and cytochrome c and Smac/DIABLO were released from mitochondria, and became degraded. Despite this eventual failure to inhibit the mitochondrial checkpoint, caspase-9 and -3 were not activated, and cells remained viable even upon treatment with an exogenous death stimulus. Thus, p53 induces apoptosis in part through Bax and Bak, and even an incomplete inhibition of this mitochondrial checkpoint may be sufficient to confer resistance to cell death.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Canc Inst New Jersey, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	White, E (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, Howard Hughes Med Inst, 679 Hoes Lane, Piscataway, NJ 08854 USA.		White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA53370, CA60088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053370, R01CA060088, R01CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; BOYD JM, 1995, ONCOGENE, V11, P1921; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Gao CF, 2001, EXP CELL RES, V265, P145; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; SUNDARARAJAN R, 2001, IN PRESS J BIOL CHEM, V276; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tan YJ, 1999, BIOCHEM BIOPH RES CO, V255, P334, DOI 10.1006/bbrc.1999.0222; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	54	53	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					748	760		10.1038/sj.onc.1205125	http://dx.doi.org/10.1038/sj.onc.1205125			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850803				2022-12-25	WOS:000173427000006
J	Saavedra, AP; Tsygankova, OM; Prendergast, GV; Dworet, JH; Cheng, G; Meinkoth, JL				Saavedra, AP; Tsygankova, OM; Prendergast, GV; Dworet, JH; Cheng, G; Meinkoth, JL			Role of cAMP, PKA and Rap1A in thyroid follicular cell survival	ONCOGENE			English	Article						thyroid; apoptosis; PKA; cAMP; Rap1	DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; MEDIATED APOPTOSIS; SIGNALING PATHWAYS; PHOSPHORYLATION; ACTIVATION; INHIBITION; GROWTH; RAS; MONOPHOSPHATE	Cyclic AMP (cAMP) rescues cells from apoptosis stimulated by diverse insults. We examined the role of cAMP as a survival factor, and the signaling pathways through which cAMP affords protection. Rat thyroid cells were selected for these studies given the predominant role of cAMP in thyrotropin (TSH)-stimulated proliferation and as an oncogene in thyroid cells. Wistar rat thyroid (WRT) cells perished via apoptosis following sodium nitroprusside (SNP) treatment. Elevations in cAMP following treatment with forskolin, 8BrcAMP or IBMX rescued cells from SNP-induced cell death. Notably, TSH prevented apoptosis, implicating an important role for this hormone as a survival factor. Cyclic AMP activates multiple signaling pathways including those mediated through PKA, PI3K, p70S6k and the Ras-related small G protein, Rap1. Intriguingly, multiple pathways modulate thyroid cell survival. Interference with cAMP-stimulated p70S6k, but not PI3K, activity abrogated cell survival. Treatment with PKA inhibitors was sufficient to stimulate apoptosis in hormone-deprived cells and markedly enhanced cell death in response to SNP. Cells expressing an activated Rap1A mutant exhibited an enhanced sensitivity to SNP-induced apoptosis, while those expressing dominant negative Rap1A were resistant to SNP-initiated cell death. Together, these findings establish an important role for PKA and Rap1 in the control of thyroid cell survival.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.	meinkoth@pharm.med.upenn.edu	Meinkoth, Judy L/G-2900-2010		NIDDK NIH HHS [R01 DK02494, K 02 DK 55757] Funding Source: Medline; NINDS NIH HHS [5-F31-NS09883] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS009883] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Arscott PL, 1997, ENDOCRINOLOGY, V138, P5019, DOI 10.1210/en.138.11.5019; Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; BRANDI ML, 1987, MOL CELL ENDOCRINOL, V54, P91, DOI 10.1016/0303-7207(87)90142-0; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; BUBIS J, 1988, J BIOL CHEM, V263, P9668; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Cheng GJ, 2001, ONCOGENE, V20, P7334, DOI 10.1038/sj.onc.1204928; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DANIEL V, 1973, P NATL ACAD SCI USA, V70, P76, DOI 10.1073/pnas.70.1.76; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dremier S, 2000, BIOCHEM BIOPH RES CO, V267, P7, DOI 10.1006/bbrc.1999.1919; DREMIER S, 1994, BIOCHEM BIOPH RES CO, V200, P52, DOI 10.1006/bbrc.1994.1412; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Jun CD, 1998, CELL IMMUNOL, V183, P13, DOI 10.1006/cimm.1997.1232; Kawakami A, 1996, ENDOCRINOLOGY, V137, P3163, DOI 10.1210/en.137.8.3163; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Li X, 1999, ENDOCRINOLOGY, V140, P5962, DOI 10.1210/en.140.12.5962; LINTIG FCV, 2000, ONCOGENE, V19, P4029; MAENHAUT C, 1991, BIOCHIMIE, V73, P29, DOI 10.1016/0300-9084(91)90070-H; MALY FE, 1994, J BIOL CHEM, V269, P18743; Medina DL, 2000, EUR J ENDOCRINOL, V143, P161, DOI 10.1530/eje.0.1430161; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Motohashi S, 1996, LIFE SCI, V59, pPL227, DOI 10.1016/0024-3205(96)00437-7; Myklebust JH, 1999, J CELL PHYSIOL, V180, P71; Niwa M, 1999, EUR J PHARMACOL, V371, P59, DOI 10.1016/S0014-2999(99)00145-4; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; Ottonello L, 1998, EXP HEMATOL, V26, P895; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; Polte T, 1998, BIOCHEM BIOPH RES CO, V251, P460, DOI 10.1006/bbrc.1998.9486; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Somers JP, 1999, MOL ENDOCRINOL, V13, P1364, DOI 10.1210/me.13.8.1364; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Villone G, 1997, CELL GROWTH DIFFER, V8, P1181; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WALKER C, 1983, J IMMUNOL, V130, P1770; Walton M, 1999, J NEUROCHEM, V73, P1836; Webster CRL, 1998, HEPATOLOGY, V27, P1324, DOI 10.1002/hep.510270519; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yao R, 1996, ONCOGENE, V13, P343; Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200	62	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					778	788		10.1038/sj.onc.1205123	http://dx.doi.org/10.1038/sj.onc.1205123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850806				2022-12-25	WOS:000173427000009
J	Zhang, RG; Kim, Y; Skarina, T; Beasley, S; Laskowski, R; Arrowsmith, C; Edwards, A; Joachimiak, A; Savchenko, A				Zhang, RG; Kim, Y; Skarina, T; Beasley, S; Laskowski, R; Arrowsmith, C; Edwards, A; Joachimiak, A; Savchenko, A			Crystal structure of Thermotoga maritima 0065, a member of the IclR transcriptional factor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUNCTIONAL-CHARACTERIZATION; HELIX PROTEIN; DNA COMPLEX; REPRESSOR; OPERON; GENES; PURIFICATION; EXPRESSION; REVEALS	Members of the IclR family of transcription regulators modulate signal-dependent expression of genes involved in carbon metabolism in bacteria and archaea. The Thermotoga maritima TM0065 gene codes for a protein (TM-IclR) that is homologous to the IclR family. We have determined the crystal structure of TM-IclR at 2.2 Angstrom resolution using MAD phasing and synchrotron radiation. The protein is composed of two domains: the N-terminal DNA-binding domain contains the winged helix-turn-helix motif, and the C-terminal presumed regulatory domain is involved in binding signal molecule. In a proposed signal-binding site, a bound Zn2+ ion was found. In the crystal, TM-IclR forms a dimer through interactions between DNA-binding domains. In the dimer, the DNA-binding domains are 2-fold related, but the dimer is asymmetric with respect to the orientation of signal-binding domains. Crystal packing analysis showed that TM-IclR dimers form a tetramer through interactions exclusively by signal-binding domains. A model is proposed for binding of IclR-like factors to DNA, and it suggests that signal-dependent transcription regulation is accomplished by affecting an oligomerization state of IclR and therefore its affinity for DNA target.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA; Univ Hlth Network, Clin Genom Ctr Proteom, Toronto, ON M5G 1L7, Canada; Univ London Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England	University of Toronto; United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of London; Birkbeck University London	Joachimiak, A (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	andrzejj@anl.gov	Beasley, Steven/B-8106-2019	Laskowski, Roman/0000-0001-5528-0087; Arrowsmith, Cheryl/0000-0002-4971-3250; Edwards, Aled/0000-0002-4782-6016; Beasley, Steven/0000-0002-8702-5651; Kim, Youngchang/0000-0002-1610-4889	NIGMS NIH HHS [P50 GM062414, P50 GM062414-02, GM62414] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; CORTAY JC, 1991, EMBO J, V10, P675, DOI 10.1002/j.1460-2075.1991.tb07996.x; Donald LJ, 1996, PROTEIN SCI, V5, P1613, DOI 10.1002/pro.5560050815; Donald LJ, 2001, PROTEIN SCI, V10, P1370, DOI 10.1110/ps.780101; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gui LZ, 1996, J BACTERIOL, V178, P4704, DOI 10.1128/jb.178.15.4704-4709.1996; HINDLE Z, 1994, MOL MICROBIOL, V12, P737, DOI 10.1111/j.1365-2958.1994.tb01061.x; Ibanez E, 2000, J BACTERIOL, V182, P4617, DOI 10.1128/JB.182.16.4617-4624.2000; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kok RG, 1998, J BACTERIOL, V180, P5058, DOI 10.1128/JB.180.19.5058-5069.1998; Korolev S, 2002, NAT STRUCT BIOL, V9, P27, DOI 10.1038/nsb737; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; MALOY SR, 1982, J BACTERIOL, V149, P173, DOI 10.1128/JB.149.1.173-180.1982; *MOL SIM INC, 2000, QUANTA; NASSER W, 1994, J MOL BIOL, V236, P427, DOI 10.1006/jmbi.1994.1155; NASSER W, 1992, MOL MICROBIOL, V6, P257, DOI 10.1111/j.1365-2958.1992.tb02007.x; Nomura K, 1998, P NATL ACAD SCI USA, V95, P14034, DOI 10.1073/pnas.95.24.14034; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan B, 1996, J BACTERIOL, V178, P3982, DOI 10.1128/jb.178.13.3982-3984.1996; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; Pohl E, 1999, J MOL BIOL, V292, P653, DOI 10.1006/jmbi.1999.3073; SUNNARBORG A, 1990, J BACTERIOL, V172, P2642, DOI 10.1128/jb.172.5.2642-2649.1990; van Wezel GP, 2000, J BACTERIOL, V182, P5653, DOI 10.1128/JB.182.20.5653-5662.2000; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514	30	59	63	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19183	19190		10.1074/jbc.M112171200	http://dx.doi.org/10.1074/jbc.M112171200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877432	Green Accepted, hybrid			2022-12-25	WOS:000175975800121
J	Kannius-Janson, M; Johansson, EM; Bjursell, G; Nilsson, J				Kannius-Janson, M; Johansson, EM; Bjursell, G; Nilsson, J			Nuclear factor 1-C2 contributes to the tissue-specific activation of a milk protein gene in the differentiating mammary gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER LIPASE GENE; TRANSCRIPTION FACTOR NF1; RECEPTOR-BINDING SITES; TUMOR VIRUS PROMOTER; FACTOR-I FAMILY; GLUCOCORTICOID RECEPTOR; EXOCRINE PANCREAS; DNA-REPLICATION; CELL-LINES; EXPRESSION	Members of the nuclear factor 1 (NF1) transcription factor family have been postulated to be involved in the regulation of milk genes. In this work we have been able to identify the splice variant NF1-C2 as an important member of a tissue-specific activating complex that regulates the milk gene encoding carboxyl ester lipase (CEL). Mutation of the NF1-binding site in the CEL gene promoter results in a drastic reduction of the gene expression to about 15% in mammary epithelial cells. Furthermore, we demonstrate that the NF1-C2 protein interacts with a higher affinity to the NF1-binding site in the CEL gene promoter than other NF1 family members do and that NF1-C2 in the mouse mammary gland is a phosphorylated protein. During development of the mouse mammary gland, binding of NF1-C2 to the CEL gene promoter is induced at midpregnancy, in correlation with the induction of CEL gene expression. The fact that the NF1-C2 involving complex remains throughout the lactation period and decreases during the weaning period, when the CEL gene is down-regulated, supports its importance in the regulation of CEL gene expression. To our knowledge, this is the first report identifying a specific, endogenously expressed NF1 isoform to be involved in the tissue-specific activation of a gene.	Dept CMB Mol Biol, S-40530 Gothenburg, Sweden		Kannius-Janson, M (corresponding author), Dept CMB Mol Biol, Box 462, S-40530 Gothenburg, Sweden.		Kannius Janson, Marie/M-3052-2015; Nilsson, Jeanette/M-3051-2015					Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Behrens M, 2000, EUR J NEUROSCI, V12, P1372, DOI 10.1046/j.1460-9568.2000.00032.x; Bisgrove DA, 2000, J BIOL CHEM, V275, P30668, DOI 10.1074/jbc.M003828200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; Chaudhry AZ, 1999, J BIOL CHEM, V274, P7072, DOI 10.1074/jbc.274.11.7072; Chaudhry AZ, 1998, J BIOL CHEM, V273, P18538, DOI 10.1074/jbc.273.29.18538; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; Cooke DW, 1999, BIOCHEM BIOPH RES CO, V260, P600, DOI 10.1006/bbrc.1999.0959; de Jong RN, 1999, GENE, V236, P1, DOI 10.1016/S0378-1119(99)00249-8; DOPPLER W, 1995, J BIOL CHEM, V270, P17962, DOI 10.1074/jbc.270.30.17962; DUSSERRE Y, 1992, MOL CELL BIOL, V12, P5228, DOI 10.1128/MCB.12.11.5228; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; Gao B, 1998, J BIOL CHEM, V273, P31784, DOI 10.1074/jbc.273.48.31784; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; HUANG Y, 1991, J BIOL CHEM, V266, P6720; INOUE T, 1990, J BIOL CHEM, V265, P19065; Kane R, 2000, ADV EXP MED BIOL, V480, P117; Kannius-Janson M, 1998, BIOCHEM J, V336, P577, DOI 10.1042/bj3360577; Kannius-Janson M, 2000, BIOCHEM J, V351, P367, DOI 10.1042/0264-6021:3510367; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; Kulkarni S, 1996, CELL GROWTH DIFFER, V7, P501; LI S, 1995, MOL CELL BIOL, V15, P2063; Lidberg U, 1998, J BIOL CHEM, V273, P31417, DOI 10.1074/jbc.273.47.31417; Liu YC, 1997, J BIOL CHEM, V272, P10739; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; Mukhopadhyay SS, 2001, MOL CELL BIOL, V21, P6859, DOI 10.1128/MCB.21.20.6859-6869.2001; NEBL G, 1994, J BIOL CHEM, V269, P7371; NEBL G, 1995, CELL MOL BIOL RES, V41, P85; Osada S, 1999, BIOCHEM J, V342, P189, DOI 10.1042/0264-6021:3420189; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; ROY RJ, 1994, EUR J BIOCHEM, V219, P799, DOI 10.1111/j.1432-1033.1994.tb18560.x; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Singh MV, 1998, BBA-GENE STRUCT EXPR, V1398, P148, DOI 10.1016/S0167-4781(98)00037-2; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WELTE T, 1993, J STEROID BIOCHEM, V47, P75, DOI 10.1016/0960-0760(93)90059-6; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	44	23	23	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17589	17596		10.1074/jbc.M105979200	http://dx.doi.org/10.1074/jbc.M105979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877413	hybrid			2022-12-25	WOS:000175685100027
J	Li, L; Shaw, PE				Li, L; Shaw, PE			Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; PROTEIN-COUPLED RECEPTORS; CANCER-CELLS; EGF RECEPTOR; CONSTITUTIVE ACTIVATION; ANGIOTENSIN-II; MAMMARY-TUMORS; NIH-3T3 CELLS; SRC	The intracellular signals driving the proliferation of breast carcinoma (BC) cells have been widely studied. Both the mitotic and metastatic potential of BC cells have been linked to the frequent overexpression of ErbB family members. Other signaling molecules, including the estrogen receptor, the tyrosine kinases c-Src and Syk, and STAT proteins, especially STAT3, have also been implicated in BC tumor growth. Here we have examined ErbB and STAT protein expression and activation in six BC-derived cell lines. ErbB expression and tyrosine phosphorylation varied considerably among the six cell lines. However, STAT protein expression and activation were more consistent. Two levels of STAT3 activation were distinguished in DNA-binding assays: an epidermal growth factor-inducible, high level that requires both ErbB1 and Janus kinase (JAK) activity and an elevated serum-dependent level that is maintained by autocrine/paracrine signaling and requires JAK activity but is independent of ErbB1 kinase activity. BC cell growth could be inhibited by dominant-negative versions of STAT3 and the JAR inhibitor AG490 but not by PD153035 or PD168393, inhibitors of ErbB1 kinase activity. This indicates that BC cell proliferation may be a consequence of STAT3 activation by autocrine/paracrine signals.	Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham	Shaw, PE (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.			SHAW, Peter/0000-0002-2598-4283				Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; IMAI Y, 1982, CANCER RES, V42, P4394; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kodama H, 1998, CIRC RES, V82, P244; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leonard WJ, 2000, J ALLERGY CLIN IMMUN, V105, P877, DOI 10.1067/mai.2000.106899; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Ni Z, 2000, CANCER RES, V60, P1225; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sano M, 2000, BIOCHEM BIOPH RES CO, V269, P798, DOI 10.1006/bbrc.2000.2364; Sartor CI, 1997, CANCER RES, V57, P978; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Yamauchi T, 2000, J BIOL CHEM, V275, P33937, DOI 10.1074/jbc.M000743200; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	43	94	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17397	17405		10.1074/jbc.M109962200	http://dx.doi.org/10.1074/jbc.M109962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11859072	hybrid			2022-12-25	WOS:000175685100005
J	Sun-Wada, GH; Imai-Senga, Y; Yamamoto, A; Murata, Y; Hirata, T; Wada, Y; Futai, M				Sun-Wada, GH; Imai-Senga, Y; Yamamoto, A; Murata, Y; Hirata, T; Wada, Y; Futai, M			A proton pump ATPase with testis-specific E1-subunit isoform required for acrosome acidification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; RENAL TUBULAR-ACIDOSIS; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; PROTEOLIPID SUBUNIT; 116-KDA SUBUNIT; V-ATPASE; GENE; EXPRESSION; PROTEIN	The vacuolar-type H+-ATPases (V-ATPases) are a family of multimeric proton pumps involved in a wide variety of physiological processes. We have identified two novel mouse genes, Atp6e1 and Atp6e2, encoding testis-specific (E1) and ubiquitous (E2) V-ATPase subunit E isoforms, respectively. The E1 transcript appears about 3 weeks after birth, corresponding to the start of meiosis, and is expressed specifically in round spermatids in seminiferous tubules. Immunohistochemistry with isoform-specific antibodies revealed that the V-ATPase with E1 and a2 isoforms is located specifically in developing acrosomes of spermatids and acrosomes in mature sperm. In contrast, the E2 isoform was expressed in all tissues examined and present in the perinuclear compartments of spermatocytes. The E1 isoform exhibits 70% identity with the E2, and both isoforms functionally complemented a null mutation of the yeast counterpart VMA4, indicating that they are bona fide V-ATPase subunits. The chimeric enzymes showed slightly lower K-m(ATP) than yeast V-ATPase. Consistent with the temperature-sensitive growth of Deltavma4-expressing E1 isoform, vacuolar membrane vesicles exhibited temperature-sensitive coupling between ATP hydrolysis and proton transport. These results suggest that E1 isoform is essential for energy coupling involved in acidification of acrosome.	Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Japan Sci & Technol Corp,CREST, Osaka 5670047, Japan; Kansai Med Univ, Dept Physiol, Osaka 5708506, Japan	Japan Science & Technology Agency (JST); Osaka University; Kansai Medical University	Futai, M (corresponding author), Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Japan Sci & Technol Corp,CREST, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp						Bardin C.W., 1988, P933; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Futai M, 2000, J EXP BIOL, V203, P107; GLASSNER M, 1991, DEV BIOL, V146, P438, DOI 10.1016/0012-1606(91)90245-X; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; Hayami K, 2001, GENE, V273, P199, DOI 10.1016/S0378-1119(01)00590-X; HERMO L, 1980, AM J ANAT, V157, P357, DOI 10.1002/aja.1001570405; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2000, J BIOL CHEM, V275, P386, DOI 10.1074/jbc.275.1.386; HO MN, 1993, J BIOL CHEM, V268, P18286; Inoue H, 1999, BBA-BIOENERGETICS, V1413, P130, DOI 10.1016/S0005-2728(99)00096-1; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kawa G, 2000, INT J ANDROL, V23, P278, DOI 10.1046/j.1365-2605.2000.00244.x; Kawamura Y, 2000, J BIOL CHEM, V275, P6515, DOI 10.1074/jbc.275.9.6515; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Mattsson JP, 2000, EUR J BIOCHEM, V267, P4115, DOI 10.1046/j.1432-1327.2000.01445.x; Murata Y, 1997, PEDIATR RES, V42, P436, DOI 10.1203/00006450-199710000-00003; Nakanishi T, 2001, DEV BIOL, V237, P222, DOI 10.1006/dbio.2001.0353; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; NEZU J, 1992, J BIOCHEM, V112, P212, DOI 10.1093/oxfordjournals.jbchem.a123879; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Oka T, 2001, J BIOL CHEM, V276, P33079, DOI 10.1074/jbc.M101652200; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Peng SB, 1999, J BIOL CHEM, V274, P2549, DOI 10.1074/jbc.274.4.2549; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SINOWATZ F, 1981, CELL TISSUE RES, V219, P511, DOI 10.1007/BF00209990; Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Sun-Wada GH, 2000, DEV BIOL, V228, P315, DOI 10.1006/dbio.2000.9963; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Wada Y, 1997, J CELL SCI, V110, P1299; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470	44	97	100	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18098	18105		10.1074/jbc.M111567200	http://dx.doi.org/10.1074/jbc.M111567200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11872743	hybrid			2022-12-25	WOS:000175685100090
J	Swatton, JE; Taylor, CW				Swatton, JE; Taylor, CW			Fast biphasic regulation of type 3 inositol trisphosphate receptors by cytosolic calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; FUNCTIONAL-PROPERTIES; ADENOPHOSTIN-A; CA2+ RELEASE; PARTIAL INACTIVATION; RAPID ACTIVATION; INSP(3) RECEPTOR; CELLS; INHIBITION	In cytosol-like medium (CLM) with a free [Ca2+] of 200 nM, a supramaximal concentration of inositol 1,4,5-trisphosphate (IP3) (30 muM) evoked Ca-45(2+) release from type 3 IP3 receptors only after a latency of 48+/-6 ms; this latency could not be reduced by increasing the IP3 concentration. In CLM containing a low free [Ca2+] (similar to4 nM), 300 muM IP3 evoked Ca-45(2+) release after a latency of 66+/-11 ms; this was reduced to 14+/-3 ms when the [Ca2+] was 1 mM. Preincubation with CLM containing 100 mum Ca2+ caused a rapid (half-time=33+/-9ms), complete, and fully reversible inhibition that could not be overcome by a high concentration of IP3 (300 muM). Hepatic (type 2) IP3 receptors were not inhibited by Ca2+ once they had bound IP3, but 100 muM Ca2+ rapidly inhibited type 3 IP3 receptors whether it was delivered before addition of IP3 or at any stage during a response to IP3. Ca2+ increases the affinity of IP3 for hepatic receptors by slowing IP3 dissociation, but Ca2+ had no effect on IP3 binding to type 3 receptors. The rate of inhibition of type 3 IP3 receptors by Ca2+ was faster than the rate of IP3 dissociation, and occurred at similar rates whether receptors had bound a high (adenophostin) or low affinity (3-deoxy-3-fluoro-IP3) agonist. Dissociation of agonist is not therefore required for Ca2+ to inhibit type 3 IP3 receptors. We conclude that type 2 and 3 IP3 receptors are each biphasically regulated by Ca2+, but by different mechanisms. For both, IP3 binding causes a stimulatory Ca2+-binding site to be exposed allowing Ca2+ to bind and open the channel. IP3 binding protects type 2 receptors from Ca2+ inhibition, but type 3 receptors are inhibited by Ca2+ whether or not they have IP3 bound. Increases in cytosolic [Ca2+] will immediately inhibit type 3 receptors, but inhibit type 2 receptors only after IP3 has dissociated.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	Taylor, CW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	cwt1000@cam.ac.uk	Taylor, Colin/G-2447-2010	Taylor, Colin/0000-0001-7771-1044				Adkins CE, 1999, CURR BIOL, V9, P1115, DOI 10.1016/S0960-9822(99)80481-3; Adkins CE, 2000, BIOCHEM J, V352, P929, DOI 10.1042/0264-6021:3520929; BAUMANN O, 1989, J COMP PHYSIOL A, V165, P627, DOI 10.1007/BF00610994; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Boehning D, 2001, J BIOL CHEM, V276, P13509, DOI 10.1074/jbc.C100094200; Cardy TJA, 1997, BIOCHEM J, V328, P785, DOI 10.1042/bj3280785; Cardy TJA, 1998, BIOCHEM J, V334, P447, DOI 10.1042/bj3340447; Carter TD, 1997, J PHYSIOL-LONDON, V504, P17, DOI 10.1111/j.1469-7793.1997.00017.x; Correa V, 2001, MOL PHARMACOL, V59, P1206, DOI 10.1124/mol.59.5.1206; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; El-Daher SS, 2000, BLOOD, V95, P3412, DOI 10.1182/blood.V95.11.3412.011k03_3412_3422; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hirata K, 1999, INVEST OPHTH VIS SCI, V40, P2046; HIROTA J, 1995, J BIOL CHEM, V270, P19046, DOI 10.1074/jbc.270.32.19046; Mak DOD, 2000, J GEN PHYSIOL, V115, P241, DOI 10.1085/jgp.115.3.241; Mak DOD, 1998, P NATL ACAD SCI USA, V95, P15821, DOI 10.1073/pnas.95.26.15821; Mak DOD, 2001, J GEN PHYSIOL, V117, P435, DOI 10.1085/jgp.117.5.435; Marchant JS, 1997, CURR BIOL, V7, P510, DOI 10.1016/S0960-9822(06)00222-3; Marchant JS, 1998, BIOCHEMISTRY-US, V37, P11524, DOI 10.1021/bi980808k; Marchant JS, 1997, BIOCHEMISTRY-US, V36, P12780, DOI 10.1021/bi971397v; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MARSHALL ICB, 1994, BIOCHEM J, V301, P591, DOI 10.1042/bj3010591; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; Missiaen L, 1999, J BIOL CHEM, V274, P13748, DOI 10.1074/jbc.274.20.13748; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; Nerou EP, 2001, BIOCHEM J, V355, P59, DOI 10.1042/bj3550059; Ogden D, 1997, J GEN PHYSIOL, V109, P741, DOI 10.1085/jgp.109.6.741; Parker I, 1996, BIOPHYS J, V70, P222, DOI 10.1016/S0006-3495(96)79565-6; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; PIETRI F, 1990, J BIOL CHEM, V265, P17478; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; Swatton JE, 1999, BIOCHEM J, V344, P55, DOI 10.1042/0264-6021:3440055; Swatton JE, 2001, BIOCHEM J, V359, P435, DOI 10.1042/0264-6021:3590435; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; Taylor C.W., 1999, SIGNAL TRANSDUCTION, P361; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591; Yule DI, 2001, J GEN PHYSIOL, V117, P431, DOI 10.1085/jgp.117.5.431	49	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17571	17579		10.1074/jbc.M200524200	http://dx.doi.org/10.1074/jbc.M200524200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11875073	hybrid			2022-12-25	WOS:000175685100025
J	Done, SC; Leibiger, IB; Efendiev, R; Katz, AI; Leibiger, B; Berggren, PO; Pedemonte, CH; Bertorello, AM				Done, SC; Leibiger, IB; Efendiev, R; Katz, AI; Leibiger, B; Berggren, PO; Pedemonte, CH; Bertorello, AM			Tyrosine 537 within the Na+,K+-ATPase alpha-subunit is essential for AP-2 binding and clathrin-dependent endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; PHOSPHORYLATION; CELLS; RECRUITMENT; DOPAMINE; TRANSCRIPTION; NA,K-ATPASE; PROTEINS; SIGNAL; PUMP	In renal epithelial cells endocytosis of Na+,K+-ATPase molecules is initiated by phosphorylation of its alpha(1)-subunit, leading to activation of phosphoinositide 3-kinase and adaptor protein-2 (AP-2)/clathrin recruitment. The present study was performed to establish the identity of the AP-2 recognition domain(s) within the Na+,K+-ATPase alpha(1)-subunit. We identified a conserved sequence ((YLEL)-L-537) within the alpha(1)-subunit that represents an AP-2 binding site. Binding of AP-2 to the Na+,K+-ATPase alpha(1)-subunit in response to dopamine (DA) was increased in OK cells stably expressing the wild type rodent alpha-subunit (OK-WT), but not in cells expressing the Y537A mutant (OK-Y537A). DA treatment was associated with increased alpha(1)-subunit abundance in clathrin vesicles from OK-WT but not from OK-Y537A cells. In addition, this mutation also impaired the ability of DA to inhibit Na+,K+-ATPase activity. Because phorbol esters increase Na+,K+-ATPase activity in OK cells, and this effect was not affected by the Y537A mutation, the present results suggest that the identified motif is specifically required for DA-induced AP-2 binding and Na+,K+-ATPase endocytosis.	Karolinska Hosp, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden; Univ Houston, Coll Pharm, Houston, TX 77204 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Karolinska Institutet; Karolinska University Hospital; University of Houston System; University of Houston; University of Chicago	Bertorello, AM (corresponding author), Karolinska Hosp, Dept Mol Med, Rolf Luft Ctr Diabet Res, L3, S-17176 Stockholm, Sweden.	Alejandro.Bertoello@molmed.ki.se		Berggren, Per-Olof/0000-0001-8991-413X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053460] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53460] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; Carranza ML, 1998, J PHYSIOL-LONDON, V511, P235, DOI 10.1111/j.1469-7793.1998.235bi.x; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; Chibalin AV, 1997, AM J PHYSIOL-CELL PH, V273, pC1458, DOI 10.1152/ajpcell.1997.273.5.C1458; Chibalin AV, 1998, MOL BIOL CELL, V9, P1209, DOI 10.1091/mbc.9.5.1209; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; Efendiev R, 1999, FEBS LETT, V456, P45, DOI 10.1016/S0014-5793(99)00925-4; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; HAMMOND TG, 1994, AM J PHYSIOL-RENAL, V267, pF516, DOI 10.1152/ajprenal.1994.267.4.F516; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; Ogimoto G, 2000, P NATL ACAD SCI USA, V97, P3242, DOI 10.1073/pnas.060025597; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Pedemonte CH, 1997, J MEMBRANE BIOL, V155, P219, DOI 10.1007/s002329900174; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SERI I, 1990, AM J PHYSIOL, V258, pF52, DOI 10.1152/ajprenal.1990.258.1.F52; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Sweeney G, 2001, AM J PHYSIOL-CELL PH, V281, pC1797, DOI 10.1152/ajpcell.2001.281.6.C1797; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297	26	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17108	17111		10.1074/jbc.M201326200	http://dx.doi.org/10.1074/jbc.M201326200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859087	hybrid			2022-12-25	WOS:000175564500102
J	Kaneda, Y; Whittier, RF; Yamanaka, H; Carredano, E; Gotoh, M; Sota, H; Hasegawa, Y; Shinohara, Y				Kaneda, Y; Whittier, RF; Yamanaka, H; Carredano, E; Gotoh, M; Sota, H; Hasegawa, Y; Shinohara, Y			The high specificities of Phaseolus vulgaris erythro- and leukoagglutinating lectins for bisecting GlcNAc or beta 1-6-linked branch structures, respectively, are attributable to loop B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING PEPTIDES; LEGUME LECTINS; PHYTOHEMAGGLUTININ-L; AFFINITY-CHROMATOGRAPHY; OLIGOSACCHARIDES; GLYCANS; SITE; GLYCOSYLATION; GLYCOPROTEIN; PROTEIN	Despite very similar tertiary structures based upon a common framework, legume lectins exhibit an amazing variety of sugar binding specificities. While most of these lectins recognize rather discrete sugar linkages, Phaseolus vulgaris erythroagglutinating and leukoagglutinating lectins (E-4- and L-4-PHA) are unique in recognizing larger structures. E-4- and L-4-PHA are known to recognize complex type N-glycans containing bisecting GlcNAc or a beta1,6-linked branch, respectively. However, the detailed mechanisms of molecular recognition are poorly understood. In order to dissect the contributions of different portions of each lectin, we carried out region-swapping mutagenesis between E-4 and L-4-PHA. We prepared six chimeric lectins by exchanging different combinations of loop B and the central portion of loop C, two of four loops thought to be important for the recognition of monosaccharides (Sharma, V., and Surolia, A. (1997) J. Mol. Biol. 267, 433-445). The chimeric lectins' sugar binding activities were evaluated quantitatively by surface plasmon resonance. These comparisons indicate that the high specificities of E-4- and L-4- PHA toward bisecting GlcNAc and beta1,6-linked branch structures are almost solely attributable to loop B. The contribution of the central portion of loop C to the recognition of those structural motifs was found to be negligible. Instead, it modulates affinity toward LacNAc residues present at the nonreducing terminus. Moreover, some of the chimeric lectins prepared in this study showed even higher specificities/affinities than native E-4- and L-4-PHA toward complex sugar chains containing either a bisecting GlcNAc residue or a beta1,6-linked branch.	Amersham Biosci, Tokyo Res & Dev, Shinjuku Ku, Tokyo 1690073, Japan; Amersham Biosci, Uppsala Res & Dev, SE-75125 Uppsala, Sweden		Shinohara, Y (corresponding author), Amersham Biosci, Tokyo Res & Dev, Shinjuku Ku, 3-25-1 Hyakunincho, Tokyo 1690073, Japan.	yasuro.shinohara@jp.amershambiosciences.com						Asada M, 1997, CANCER RES, V57, P1073; BIERHUIZEN MFA, 1988, EUR J BIOCHEM, V175, P387, DOI 10.1111/j.1432-1033.1988.tb14208.x; BIERHUIZEN MFA, 1988, GLYCOCONJUGATE J, V5, P85, DOI 10.1007/BF01048334; BompardGilles C, 1996, STRUCTURE, V4, P1441, DOI 10.1016/S0969-2126(96)00151-7; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DaoThi MH, 1996, PROTEINS, V24, P134, DOI 10.1002/(SICI)1097-0134(199601)24:1<134::AID-PROT9>3.0.CO;2-K; EGORIN MJ, 1979, J BIOL CHEM, V254, P894; Etzler ME, 1998, TRENDS GLYCOSCI GLYC, V10, P247, DOI 10.4052/tigg.10.247; FERNANDES B, 1991, CANCER RES, V51, P718; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; GREEN ED, 1987, J BIOL CHEM, V262, P12018; Hakomori S, 1996, CANCER RES, V56, P5309; Hamelryck TW, 1996, J BIOL CHEM, V271, P32796, DOI 10.1074/jbc.271.51.32796; Hamelryck TW, 1996, J BIOL CHEM, V271, P20479, DOI 10.1074/jbc.271.34.20479; HAMMARSTROM S, 1982, P NATL ACAD SCI-BIOL, V79, P1611, DOI 10.1073/pnas.79.5.1611; HOFFMAN LM, 1982, NUCLEIC ACIDS RES, V10, P7819, DOI 10.1093/nar/10.23.7819; HOFFMAN LM, 1987, BIO-TECHNOL, V5, P157, DOI 10.1038/nbt0287-157; HOFFMAN LM, 1985, EMBO J, V4, P883, DOI 10.1002/j.1460-2075.1985.tb03714.x; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; KOBATA A, 1992, J CHROMATOGR, V597, P111, DOI 10.1016/0021-9673(92)80101-Y; KOBATA A, 1989, METHOD ENZYMOL, V179, P46; KONAMI Y, 1992, J CHROMATOGR, V597, P213, DOI 10.1016/0021-9673(92)80113-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEAVITT RD, 1977, J BIOL CHEM, V252, P2961; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; MASTRYUKOV VS, 1993, THEOCHEM, V99, P199; MIRKOV TE, 1993, GLYCOBIOLOGY, V3, P581, DOI 10.1093/glycob/3.6.581; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; Shinohara Y, 1996, ANAL CHEM, V68, P2573, DOI 10.1021/ac960004f; Shinohara Y, 1997, GLYCOBIOLOGY, V7, P1201, DOI 10.1093/glycob/7.8.1201; VANEIJSDEN RR, 1992, PLANT MOL BIOL, V20, P1049, DOI 10.1007/BF00028892; Yamamoto H, 2000, CANCER RES, V60, P134; Yamamoto K, 2000, J BIOCHEM-TOKYO, V127, P137, DOI 10.1093/oxfordjournals.jbchem.a022575; YAMAMOTO K, 1992, J BIOCHEM-TOKYO, V111, P436, DOI 10.1093/oxfordjournals.jbchem.a123775; YOUNG NM, 1992, J MOL BIOL, V228, P924, DOI 10.1016/0022-2836(92)90875-K	40	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16928	16935		10.1074/jbc.M112382200	http://dx.doi.org/10.1074/jbc.M112382200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864980	hybrid			2022-12-25	WOS:000175564500079
J	Kosugi, S; Ohashi, Y				Kosugi, S; Ohashi, Y			E2Ls, E2F-like Repressors of Arabidopsis that bind to E2F sites in a monomeric form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; NUCLEAR-LOCALIZATION; HISTONE DEACETYLASE; S-PHASE; SUBCELLULAR-LOCALIZATION; FAMILY MEMBERS; PLANT E2F; GENE	E2F transcription factors are major regulators of cell proliferation, and each factor contributes differently to cell cycle control. Arabidopsis contains six E2F homologs, of which three are proteins that exhibit an overall similarity to animal E2Fs and interact with DPa and DPb to stimulate DNA binding. Here we describe the other three E2F-like proteins from Arabidopsis, E2L1-3, which have two copies of a domain with a limited similarity only to the DNA binding domain of E2F. Unlike known E2Fs, the three E2L proteins failed to interact with DPa and DPb and could efficiently bind E2F sites in a monomeric form through the dual-type domain. Transfection assays revealed that E2Ls repress the transcription of reporter genes under the control of E2F-regulated promoters, indicating that E2Ls function to antagonize transactivation mediated by E2F-DP. When fused to green fluorescence protein, E2L1 and E2L3 were predominantly localized to the nucleus whereas E2L2 was detected in both the nucleus and cytoplasm. Because the transcripts of E2Ls were abundant in meristematic rather than fully differentiated tissues, E2Ls may balance the activities of E2F-DP and play a role in restraining cell proliferation.	Natl Inst Agrobiol Sci, Dept Mol Genet, Tsukuba, Ibaraki 3058602, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Chiyoda Ku, Tokyo 1010062, Japan	National Institute of Agrobiological Sciences - Japan; Japan Science & Technology Agency (JST)	Ohashi, Y (corresponding author), Natl Inst Agrobiol Sci, Dept Mol Genet, Tsukuba, Ibaraki 3058602, Japan.							Albani D, 2000, J BIOL CHEM, V275, P19258, DOI 10.1074/jbc.M909390199; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Chaboute ME, 2000, PLANT CELL, V12, P1987, DOI 10.1105/tpc.12.10.1987; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Choo Y, 2000, CURR OPIN STRUC BIOL, V10, P411, DOI 10.1016/S0959-440X(00)00107-X; de Jager SM, 2001, PLANT MOL BIOL, V47, P555, DOI 10.1023/A:1011848528377; delaLuna S, 1996, J CELL SCI, V109, P2443; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Egelkrout EM, 2001, PLANT CELL, V13, P1437, DOI 10.1105/tpc.13.6.1437; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Frolov MV, 2001, GENE DEV, V15, P2146, DOI 10.1101/gad.903901; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jin HL, 1999, PLANT MOL BIOL, V41, P577, DOI 10.1023/A:1006319732410; Kim JS, 1998, P NATL ACAD SCI USA, V95, P2812, DOI 10.1073/pnas.95.6.2812; KOSUGI S, 1991, NUCLEIC ACIDS RES, V19, P1571, DOI 10.1093/nar/19.7.1571; Kosugi S, 2000, NUCLEIC ACIDS RES, V28, P960, DOI 10.1093/nar/28.4.960; Kosugi S, 1997, PLANT CELL, V9, P1607, DOI 10.1105/tpc.9.9.1607; Kosugi S, 2002, PLANT J, V29, P45, DOI 10.1046/j.1365-313x.2002.01196.x; Kosugi S, 2002, PLANT PHYSIOL, V128, P833, DOI 10.1104/pp.010642; Lavia P, 1999, BIOESSAYS, V21, P221; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magae J, 1996, J CELL SCI, V109, P1717; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Magyar Z, 2000, FEBS LETT, V486, P79, DOI 10.1016/S0014-5793(00)02238-9; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Muller H, 1997, MOL CELL BIOL, V17, P5508; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; Ramirez-Parra E, 1999, NUCLEIC ACIDS RES, V27, P3527, DOI 10.1093/nar/27.17.3527; Ramirez-Parra E, 2000, FEBS LETT, V486, P73, DOI 10.1016/S0014-5793(00)02239-0; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; Sawado T, 1998, BIOCHEM BIOPH RES CO, V251, P409, DOI 10.1006/bbrc.1998.9407; Sekine M, 1999, FEBS LETT, V460, P117, DOI 10.1016/S0014-5793(99)01296-X; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	50	67	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16553	16558		10.1074/jbc.M200913200	http://dx.doi.org/10.1074/jbc.M200913200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867638	hybrid			2022-12-25	WOS:000175564500030
J	Stadheim, TA; Suh, N; Ganju, N; Sporn, MB; Eastman, A				Stadheim, TA; Suh, N; Ganju, N; Sporn, MB; Eastman, A			The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; DNA-DAMAGING AGENTS; KAPPA-B ACTIVATION; CYTOCHROME-C; SIGNALING PATHWAYS; JNK ACTIVATION; FACTOR-ALPHA; DEATH; INDUCTION	Tumor necrosis factor (TNF) is a potent activator of the nuclearfactor-kappaB (NF-kappaB) pathway that leads to upregulation of anti-apoptotic proteins. Hence, TNF induces apoptosis in the presence of inhibitors of protein or RNA synthesis. We report that a novel triterpenoid, 2-cyano-3,12-dioxooleana-1,9,-dien-28-oic acid (CDDO) inhibits NF-kappaB-mediated gene expression at a step after translocation of activated NF-kappaB to the nucleus. This effect appears specific for the NF-kappaB pathway as CDDO does not inhibit gene expression induced by the phorbol ester 12-0-tetradecanoylphorbol-13-acetate (TPA). CDDO in combination with TNF caused a dramatic increase in apoptosis in ML-1 leukemia cells that was associated with activation of caspase-8, cleavage of Bid, translocation of Bax, cytochrome c release, and caspase-3 activation. Experiments with caspase inhibitors demonstrated that caspase-8 was an initiator of this pathway. TNF also induced a transient activation of c-Jun N-terminal kinase (JNK), which upon addition of CDDO was converted to a sustained activation. The activation of JNK was also dependent on caspase-8. Sustained activation of JNK is frequently pro-apoptotic, yet inhibition of JNK did not prevent Bax translocation or cytochrome c release, demonstrating its lack of involvement in CDDO/TNF-induced apoptosis. Apoptosis was acutely induced by CDDO/TNF in every leukemia cell line tested including those that overexpress Bcl-X-L, suggesting that the mitochondrial pathway is not required for apoptosis by this combination. These results suggest that the apoptotic potency of the CDDO/TNF combination occurs through selective inhibition of NF-kappaB-dependent anti-apoptotic proteins, bypassing potential mitochondrial resistance mechanisms, and thus may provide a basis for the development of novel approaches to the treatment of leukemia.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	Eastman, A (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.				NATIONAL CANCER INSTITUTE [R01CA050224, F32CA086476, R55CA050224] Funding Source: NIH RePORTER; NCI NIH HHS [CA50224, F32 CA86476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Barchowsky A, 1995, AM J PHYSIOL-LUNG C, V269, pL829, DOI 10.1152/ajplung.1995.269.6.L829; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Ibrado AM, 1997, CANCER RES, V57, P1109; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito Y, 2001, MOL PHARMACOL, V59, P1094, DOI 10.1124/mol.59.5.1094; Ito Y, 2000, CELL GROWTH DIFFER, V11, P261; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Krieser RJ, 1999, CELL DEATH DIFFER, V6, P412, DOI 10.1038/sj.cdd.4400515; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mudipalli A, 2001, LEUKEMIA, V15, P808, DOI 10.1038/sj.leu.2402083; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6; Stadheim TA, 2000, BIOCHEM PHARMACOL, V59, P407, DOI 10.1016/S0006-2952(99)00330-5; Stadheim TA, 2001, CANCER RES, V61, P1533; Suh NJ, 1999, CANCER RES, V59, P336; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang YP, 2000, MOL ENDOCRINOL, V14, P1550, DOI 10.1210/me.14.10.1550; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R	40	87	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16448	16455		10.1074/jbc.M108974200	http://dx.doi.org/10.1074/jbc.M108974200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880365	hybrid			2022-12-25	WOS:000175564500016
J	Sigoillot, FD; Evans, DR; Guy, HI				Sigoillot, FD; Evans, DR; Guy, HI			Growth-dependent regulation of mammalian pyrimidine biosynthesis by the protein kinase A and NLAPK signaling cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; MULTIFUNCTIONAL PROTEIN; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; HAMSTER-CELLS; NUCLEOTIDE BIOSYNTHESIS; MAP KINASE; CAD; ENZYMES; ACID	The carbamoyl phosphate synthetase domain of the multifunctional protein CAD catalyzes the initial, rate-limiting step in mammalian de novo pyrimidine biosynthesis. In addition to allosteric regulation by the inhibitor UTP and the activator PRPP, the carbamoyl phosphate synthetase activity is controlled by mitogen-activated protein kinase (MAPK)- and protein kinase A (PKA)-mediated phosphorylation. MAPK phosphorylation, both in vivo and in vitro, increases sensitivity to PRPP and decreases sensitivity to the inhibitor UTP, whereas PKA phosphorylation reduces the response to both allosteric effectors. To elucidate the factors responsible for growth state-dependent regulation of pyrimidine biosynthesis, the activity of the de novo pyrimidine pathway, the MAPK and PKA activities, the phosphorylation state, and the allosteric regulation of CAD were measured as a function of growth state. As cells entered the exponential growth phase, there was an 8-fold increase in pyrimidine biosynthesis that was accompanied by a 40-fold increase in MAPK activity and a 4-fold increase in CAD threonine phosphorylation. PRPP activation increased to 21-fold, and UTP became a modest activator. These changes were reversed when the cultures approach confluence and growth ceases. Moreover, CAD phosphoserine, a measure of PKA phosphorylation, increased 2-fold in confluent cells. These results are consistent with the activation of CAD by MAPK during periods of rapid growth and its down-regulation in confluent cells associated with decreased MAPK phosphorylation and a concomitant increase in PKA phosphorylation. A scheme is proposed that could account for growth-dependent regulation of pyrimidine biosynthesis based on the sequential action of MAPK and PKA on the carbamoyl phosphate synthetase activity of CAD.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Guy, HI (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	hguy@cmb.biosci.wayne.edu		Sigoillot, Frederic/0000-0002-8695-4838	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060371] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM/CA60371, R01 GM060371] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI T, 1981, SCIENCE, V212, P463, DOI 10.1126/science.7209543; Banerjei LC, 1997, SOMAT CELL MOLEC GEN, V23, P37, DOI 10.1007/BF02679954; CALVA E, 1959, CANCER RES, V19, P679; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CHEN JJ, 1978, MICROENVIRONMENTS ME, P211; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; Fairbanks LD, 1999, J CHROMATOGR B, V732, P487, DOI 10.1016/S0378-4347(99)00303-5; Graves LM, 1996, TRENDS ENDOCRIN MET, V7, P43, DOI 10.1016/1043-2760(95)00204-9; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GUY HI, 1994, J BIOL CHEM, V269, P23808; GUY HI, 1994, ADV EXP MED BIOL, V370, P729; HAGER SE, 1967, J BIOL CHEM, V242, P5674; HAGER SE, 1967, J BIOL CHEM, V242, P5667; HUISMAN WH, 1979, J BIOL CHEM, V254, P2595; Irvine HS, 1997, EUR J BIOCHEM, V247, P1063, DOI 10.1111/j.1432-1033.1997.01063.x; ITO K, 1973, J BIOL CHEM, V248, P389; JACKSON RC, 1980, CANCER RES, V40, P1286; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; KIM HS, 1992, J BIOL CHEM, V267, P7177; KIM S, 1965, ARCH BIOCHEM BIOPHYS, V109, P421, DOI 10.1016/0003-9861(65)90385-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE EM, 1965, P NATL ACAD SCI USA, V53, P350, DOI 10.1073/pnas.53.2.350; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIAO WSL, 1986, J BIOL CHEM, V261, P5577; LIU X, 1994, J BIOL CHEM, V269, P27747; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NORDMANN Y, 1964, NATURE, V201, P616, DOI 10.1038/201616a0; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; Purcarea C, 1997, J BACTERIOL, V179, P4143, DOI 10.1128/jb.179.13.4143-4157.1997; ROUX JM, 1973, J BIOL CHEM, V248, P1196; Sahay N, 1998, J BIOL CHEM, V273, P31195, DOI 10.1074/jbc.273.47.31195; SHAMBAUGH GE, 1974, DEV BIOL, V37, P171, DOI 10.1016/0012-1606(74)90177-8; SHAW SM, 1992, EUR J BIOCHEM, V207, P957, DOI 10.1111/j.1432-1033.1992.tb17130.x; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SMITH ML, 1979, J CELL PHYSIOL, V101, P293, DOI 10.1002/jcp.1041010210; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TATIBANA M, 1969, J BIOL CHEM, V244, P5403; TATIBANA M, 1972, BIOCHEM BIOPH RES CO, V46, P491, DOI 10.1016/S0006-291X(72)80165-7; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WARD GA, 1973, J CELL PHYSL, V73, P213	49	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15745	15751		10.1074/jbc.M201112200	http://dx.doi.org/10.1074/jbc.M201112200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11872754	hybrid			2022-12-25	WOS:000175510400071
J	Torrungruang, K; Alvarez, M; Shah, R; Onyia, JE; Rhodes, SJ; Bidwell, JP				Torrungruang, K; Alvarez, M; Shah, R; Onyia, JE; Rhodes, SJ; Bidwell, JP			DNA binding and gene activation properties of the Nmp4 nuclear matrix transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; TRANSACTIVATION FUNCTION; PROMOTER ELEMENT; RECOGNITION; DOMAINS; EXPRESSION; OSTEOBLAST; SEQUENCES; SPECIFICITY; MOTIFS	Splice variants of the Nmp4 gene include nuclear matrix transcription factors that regulate the type I collagen alpha1(I) polypeptide chain (COL1A1) promoter and several matrix metalloproteinase (MMP) genes. To date, these are the only Cys(2)His(2) zinc finger proteins known to bind within the minor groove of homopolymeric (dA.dT) DNA. Nmp4 isoforms contain from 5 to 8 Cys(2)His(2) zinc fingers, an SH3-binding domain that overlaps with a putative AT-hook and a polyglutamine-alanine repeat (poly(QA)). To determine the mechanistic significance of Cys(2)His(2) zinc finger association with this unusual consensus DNA binding element, we identified the Nmp4 DNA-binding and transcriptional activation domains. Zinc fingers 2, 3, and 6 mediated association with the homopolymeric (dA.dT) COL1A1/MMP DNA consensus element. The N terminus of the Nmp4 protein exhibited a strong trans-activation capacity when fused to the GAL4 DNA-binding domain, but this activity was masked within the context of the full-length Nmp4-GAL4 DNA-binding domain chimera. However, upon binding to the COL1A1/MMP homopolymeric (dA.dT) element, the native Nmp4 protein up-regulated transcription, and the poly(QA) domain acquired a significant role in trans-activation. We propose that allosteric effects induced upon zinc finger association with the homopolymeric (dA.dT) minor groove confer context-specific functionality to this unusual family of Cys(2)His(2) transcription factors.	Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Dent, Dept Periodont, Indianapolis, IN 46202 USA; Lilly Res Labs, Gene Regulat Bone & Inflammat Res Div, Indianapolis, IN 46285 USA; Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly; Indiana University System; Indiana University-Purdue University Indianapolis	Bidwell, JP (corresponding author), Indiana Univ, Sch Med, Dept Anat & Cell Biol, Med Sci Bldg 5035,635 Barnhill Dr, Indianapolis, IN 46202 USA.	jbidwell@iupui.edu	torrungruang, kitti/ABH-5125-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053796, R01DK053796] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53796-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Daya A, 1997, NUCLEIC ACIDS RES, V25, P4962, DOI 10.1093/nar/25.24.4962; Alvarez M, 1998, J CELL BIOCHEM, V69, P336, DOI 10.1002/(SICI)1097-4644(19980601)69:3<336::AID-JCB11>3.0.CO;2-A; Alvarez M, 1997, ENDOCRINOLOGY, V138, P482, DOI 10.1210/en.138.1.482; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Beilin J, 2000, J MOL ENDOCRINOL, V25, P85, DOI 10.1677/jme.0.0250085; Bewley CA, 1998, ANNU REV BIOPH BIOM, V27, P105, DOI 10.1146/annurev.biophys.27.1.105; Bode J, 2000, CRIT REV EUKAR GENE, V10, P73; Bushmeyer SM, 1998, J CELL BIOCHEM, V68, P484, DOI 10.1002/(SICI)1097-4644(19980315)68:4<484::AID-JCB8>3.3.CO;2-F; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; Feister HA, 2000, J CELL BIOCHEM, V79, P506, DOI 10.1002/1097-4644(20001201)79:3<506::AID-JCB150>3.3.CO;2-1; Furuya K, 2000, EXP CELL RES, V261, P329, DOI 10.1006/excr.2000.5051; Gogos JA, 1996, P NATL ACAD SCI USA, V93, P2159, DOI 10.1073/pnas.93.5.2159; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; He XY, 2000, J BIOL CHEM, V275, P11799, DOI 10.1074/jbc.275.16.11799; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; Iuchi S, 2001, CELL MOL LIFE SCI, V58, P625, DOI 10.1007/PL00000885; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KIM SK, 1993, FEBS LETT, V315, P61, DOI 10.1016/0014-5793(93)81133-K; Koch KA, 1999, J BIOL CHEM, V274, P23752, DOI 10.1074/jbc.274.34.23752; Lascaris RF, 2000, NUCLEIC ACIDS RES, V28, P1390, DOI 10.1093/nar/28.6.1390; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Lukens AK, 2000, NUCLEIC ACIDS RES, V28, P3853, DOI 10.1093/nar/28.20.3853; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; Luo X, 1996, MOL CELL BIOL, V16, P1367; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; McBryant SJ, 1996, NUCLEIC ACIDS RES, V24, P2567, DOI 10.1093/nar/24.13.2567; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649-1658.2000; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Shaw PE, 2000, METH MOL B, V148, P221; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; Suter B, 2000, NUCLEIC ACIDS RES, V28, P4083, DOI 10.1093/nar/28.21.4083; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Thunyakitpisal P, 2001, J BONE MINER RES, V16, P10, DOI 10.1359/jbmr.2001.16.1.10; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432	53	25	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16153	16159		10.1074/jbc.M107496200	http://dx.doi.org/10.1074/jbc.M107496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867614	hybrid			2022-12-25	WOS:000175510400124
J	Wang, YQ; Dohlman, HG				Wang, YQ; Dohlman, HG			Pheromone-dependent ubiquitination of the mitogen-activated protein kinase kinase Ste7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOA4 DEUBIQUITINATING ENZYME; FREE POLYUBIQUITIN CHAINS; SACCHAROMYCES-CEREVISIAE; RESPONSE PATHWAY; SIGNAL-TRANSDUCTION; MAP KINASE; TRANSCRIPTION FACTOR; MATING PHEROMONE; FACTOR RECEPTOR; 26S PROTEASOME	Many cell signaling pathways are regulated by phosphorylation, ubiquitination, and degradation of constituent proteins. As with phosphorylation, protein ubiquitination can be reversed, through the action of ubiquitin-specific processing proteases (UBPs). Here we have analyzed 15 UBP disruption mutants in the yeast Saccharomyces cerevisiae and identified one (ubp3Delta) that acts specifically in the pheromone response pathway. Upon pheromone stimulation, ubp3Delta mutants accumulate unconjugated polyubiquitin chains as well as polyubiquitinated forms of the mitogen-activated protein kinase kinase Ste7. The ubp3Delta mutants exhibit a potentiated response to pheromone, as measured by in vivo MAP kinase activity, transcriptional induction, and cell cycle arrest. Signaling is likewise enhanced upon direct activation of Ste4 (G protein beta subunit) and Ste11 (Ste7 kinase) but not the downstream transcription factor Ste12. These findings reveal a mechanism by which pheromone-triggered ubiquitination of Ste7 can modulate the pheromone response in vivo.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Dohlman, HG (corresponding author), Univ N Carolina, Dept Biochem & Biophys, 405 Mary Ellen Jones Bldg,Campus Box 7260, Chapel Hill, NC 27599 USA.			Dohlman, Henrik/0000-0003-2443-0729	NIGMS NIH HHS [GM59167, R01 GM055316, R01 GM059167, GM55316] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059167, R01GM055316, R29GM055316] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Amerik AY, 1997, EMBO J, V16, P4826; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKER RT, 1992, J BIOL CHEM, V267, P23364; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chung CY, 1998, GENE DEV, V12, P3564, DOI 10.1101/gad.12.22.3564; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; Farley FW, 1999, GENETICS, V151, P1425; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; HADARI T, 1992, J BIOL CHEM, V267, P719; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoffman GA, 2002, METHOD ENZYMOL, V344, P617; Huang YZ, 1996, DEVELOPMENT, V122, P3207; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Lindsey DF, 1998, J BIOL CHEM, V273, P29178, DOI 10.1074/jbc.273.44.29178; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; NAKAMURA T, 1992, ONCOGENE, V7, P733; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Penela P, 1998, J BIOL CHEM, V273, P35238, DOI 10.1074/jbc.273.52.35238; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; RINE J, 1987, GENETICS, V116, P9; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Springael JY, 1999, J CELL SCI, V112, P1375; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275	60	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15766	15772		10.1074/jbc.M111733200	http://dx.doi.org/10.1074/jbc.M111733200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864977	hybrid			2022-12-25	WOS:000175510400074
J	Wolf, AA; Fujinaga, Y; Lencer, WI				Wolf, AA; Fujinaga, Y; Lencer, WI			Uncoupling of the cholera toxin-G(M1) ganglioside receptor complex from endocytosis, retrograde Golgi trafficking, and downstream signal transduction by depletion of membrane cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; DETERGENT-RESISTANT MEMBRANES; TOXIN B-SUBUNIT; CELL-SURFACE; EPITHELIAL-CELLS; PHOSPHATIDYLCHOLINE BILAYERS; BIOLOGICAL-MEMBRANES; POLARIZED EPITHELIA; HIPPOCAMPAL-NEURONS; LABILE TOXIN	To induce toxicity, cholera toxin (CT) must first bind ganglioside G(M1) at the plasma membrane, enter the cell by endocytosis, and then traffic retrograde into the endoplasmic reticulum. We recently proposed that G(M1) provides the sorting motif necessary for retrograde trafficking into the biosynthetic/secretory pathway of host cells, and that such trafficking depends on association with lipid rafts and lipid raft function. To test this idea, we examined whether CT action in human intestinal T84 cells depends on membrane cholesterol. Chelation of cholesterol with 2-hydroxypropyl beta-cyclodextrin or methyl beta-cyclodextrin reversibly inhibited CT-induced chloride secretion and prolonged the time required for CT to enter the cell and induce toxicity. These effects were specific to CT, as identical conditions did not alter the potency or toxicity of anthrax edema toxin that enters the cell by another mechanism. We found that endocytosis and trafficking of CT into the Golgi apparatus depended on membrane cholesterol. Cholesterol depletion also changed the density and specific protein content of CT-associated lipid raft fractions but did not entirely displace the CT-G(M1) complex from these lipid raft microdomains. Taken together these data imply that cholesterol may function to couple the CT-G(M1) complex with raft domains and with other membrane components of the lipid raft required for CT entry into the cell.	Childrens Hosp, Dept Pediat, Gastrointestinal Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Digest Dis Ctr, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Lencer, WI (corresponding author), Childrens Hosp, Dept Pediat, Gastrointestinal Cell Biol, 300 Longwood Ave, Boston, MA 02115 USA.			Lencer, Wayne/0000-0001-7346-2730	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048106, R37DK048106, P30DK034854, F32DK009863] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34854, DK48106, F32 DK09863] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrami L, 1999, J CELL BIOL, V147, P175, DOI 10.1083/jcb.147.1.175; Badizadegan K, 2000, AM J PHYSIOL-GASTR L, V278, pG895, DOI 10.1152/ajpgi.2000.278.6.G895; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Beauregard KE, 1999, INFECT IMMUN, V67, P3026, DOI 10.1128/IAI.67.6.3026-3030.1999; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Christian AE, 1997, J LIPID RES, V38, P2264; Falguieres T, 2001, MOL BIOL CELL, V12, P2453, DOI 10.1091/mbc.12.8.2453; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Francis SA, 1999, EUR J CELL BIOL, V78, P473, DOI 10.1016/S0171-9335(99)80074-0; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Grimmer S, 2000, MOL BIOL CELL, V11, P4205, DOI 10.1091/mbc.11.12.4205; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; LENCER WI, 1992, J CELL BIOL, V117, P1197, DOI 10.1083/jcb.117.6.1197; LENCER WI, 1995, P NATL ACAD SCI USA, V92, P10094, DOI 10.1073/pnas.92.22.10094; LENCER WI, 1995, J CELL BIOL, V131, P951, DOI 10.1083/jcb.131.4.951; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Lencer WI, 2001, AM J PHYSIOL-GASTR L, V280, pG781, DOI 10.1152/ajpgi.2001.280.5.G781; Lencer WI, 1997, J BIOL CHEM, V272, P15562, DOI 10.1074/jbc.272.24.15562; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nusrat A, 2000, J CELL SCI, V113, P1771; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Peyron P, 2000, J IMMUNOL, V165, P5186, DOI 10.4049/jimmunol.165.9.5186; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; RESTA R, 1993, GENE, V133, P171, DOI 10.1016/0378-1119(93)90635-G; ROCK P, 1990, BIOCHEMISTRY-US, V29, P8484, DOI 10.1021/bi00488a040; ROCK P, 1991, BIOCHEMISTRY-US, V30, P19, DOI 10.1021/bi00215a003; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rodighiero C, 1999, J BIOL CHEM, V274, P3962, DOI 10.1074/jbc.274.7.3962; Rodighiero C, 2001, J BIOL CHEM, V276, P36939, DOI 10.1074/jbc.M104245200; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Shogomori H, 2001, J BIOL CHEM, V276, P9182, DOI 10.1074/jbc.M009414200; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Sooksawate T, 2001, NEUROPHARMACOLOGY, V40, P178, DOI 10.1016/S0028-3908(00)00159-3; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917	59	87	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16249	16256		10.1074/jbc.M109834200	http://dx.doi.org/10.1074/jbc.M109834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859071	hybrid			2022-12-25	WOS:000175510400135
J	Antonyak, MA; Boehm, JE; Cerione, RA				Antonyak, MA; Boehm, JE; Cerione, RA			Phosphoinositide 3-kinase activity is required for retinoic acid-induced expression and activation of the tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; TYROSINE PHOSPHORYLATION; GENE PROMOTER; DIFFERENTIATION; CELLS; IDENTIFICATION; APOPTOSIS; RECEPTOR; KINASE; INHIBITION	Tissue transglutaminase (TGase) is a dual function enzyme that couples an ability to bind GTP with transamidation activity. Retinoic acid (RA) consistently induces TGase expression and activation, and it was recently shown that increased TGase expression protected cells from apoptosis. To better understand how RA regulates TGase, we considered whether RA employed pro-survival signaling pathways to mediate TGase expression and activation. It was found that RA stimulation of NIH3T3 cells activated ERK and phosphoinositide 3-kinase (PI3K); however, only PI3K activation was necessary for RA-induced TGase expression. The overexpression of a constitutively active form of PI3K did not induce TGase expression, indicating that PI3K signaling was necessary but not sufficient for TGase expression. The exposure of cells expressing exogenous TGase to the PI3K inhibitor, LY294002, reduced the ability of TGase to be photoaffinity-labeled with [alpha-P-32]GTP, providing evidence that PI3K regulates the GTP binding activity of TGase as well as its expression. Moreover, cell viability assays showed that incubation of RA-treated cells with LY294002 together with the TGase inhibitor, monodansylcadaverine (MDC), converted RA from a differentiation factor to an apoptotic stimulus. These findings demonstrate that PI3K activity is required for the RA-stimulated expression and GTP binding activity of TGase, thereby linking the up-regulation of TGase with a well established cell survival factor.	Cornell Univ, VMC, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Cerione, RA (corresponding author), Cornell Univ, VMC, Dept Mol Med, Ithaca, NY 14853 USA.				NIGMS NIH HHS [R01 GM61762, F32 GM208052] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; BERGERING BM, 1995, NATURE, V376, P599; Bertagnolo V, 1999, CANCER RES, V59, P542; BERTRAM JS, 1983, CANCER SURV, V2, P243; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MANGELSDORF DJ, 1994, RETINOIDS BIOL CHEM; Nagy L, 1996, J BIOL CHEM, V271, P4355; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; PFAHL M, 1994, VITAM HORM, V49, P327; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; PIACENTINI M, 1988, J BIOL CHEM, V263, P3790; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SPORN MB, 1983, CANCER RES, V43, P3034; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Yen A, 1998, CANCER RES, V58, P3163; Zhu WY, 1999, CANCER RES, V59, P85	32	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14712	14716		10.1074/jbc.M112259200	http://dx.doi.org/10.1074/jbc.M112259200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11854287	hybrid			2022-12-25	WOS:000175203000047
J	Stromblad, S; Fotedar, A; Brickner, H; Theesfeld, C; de Diaz, EA; Friedlander, M; Cheresh, DA				Stromblad, S; Fotedar, A; Brickner, H; Theesfeld, C; de Diaz, EA; Friedlander, M; Cheresh, DA			Loss of p53 compensates for alpha(v)-integrin function in retinal neovascularization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; AGENT TNP-470; ANGIOGENESIS; INTEGRINS; APOPTOSIS; P21(WAF1/CIP1); ALPHA(V)BETA(3); ALPHA-V-BETA-3; VITRONECTIN; REQUIREMENT	alpha(v)-Integrin antagonists block neovascularization in various species, whereas 20% of alpha(v)-integrin null mice are born with many normal looking blood vessels. Given that blockade of alpha(v)-integrins during angiogenesis induces p53 activity, we utilized p53 null mice to elucidate whether loss of p53 can compensate for av-integrin function in neovascularization of the retina. Murine retinal vascularization was inhibited by systemic administration of an alpha(v)-integrin antagonist. In contrast, mice lacking p53 were refractory to this treatment, indicating that neovascularization in normal mice depends on alpha(v)-integrin-mediated suppression of p53. Blockade of alpha(v)-integrins during neovascularization resulted in an induction of p21(CIP1) in wild type and, surprisingly, in p53 null retinas, indicating that alpha(v)-integrin ligation regulates p21(CIP1) levels in a p53-independent manner. In conclusion, we demonstrate for the first time an in vivo intracellular mechanism for compensation of integrin function and that p53 and alpha(v)-integrins act in concert during retinal neovascularization.	Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Sodertorns Hogskola, Dept Microbiol Pathol & Immunol, S-14104 Huddinge, Sweden	Scripps Research Institute; Scripps Research Institute; Sodertorn University	Stromblad, S (corresponding author), Huddinge Univ Hosp F46, Karolinska Inst, SE-14186 Huddinge, Sweden.			Stromblad, Staffan/0000-0002-1236-6339	NATIONAL CANCER INSTITUTE [R01CA074435, R01CA045726] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011254] Funding Source: NIH RePORTER; NCI NIH HHS [CA 502289, CA 45726, CA74435] Funding Source: Medline; NEI NIH HHS [EY11254] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; ELDIERY WS, 1994, CANCER RES, V54, P1169; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fotedar R, 1999, ONCOGENE, V18, P3652, DOI 10.1038/sj.onc.1202693; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Seewaldt VL, 2001, J CELL BIOL, V155, P471, DOI 10.1083/jcb.200011001; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Yeh JRJ, 2000, P NATL ACAD SCI USA, V97, P12782, DOI 10.1073/pnas.97.23.12782; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427	23	24	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13371	13374		10.1074/jbc.C200044200	http://dx.doi.org/10.1074/jbc.C200044200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11856728	hybrid			2022-12-25	WOS:000175096000004
J	Huang, ZY; Baldwin, RL; Hedrick, NM; Gutmann, DH				Huang, ZY; Baldwin, RL; Hedrick, NM; Gutmann, DH			Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo	ONCOGENE			English	Article						glioma; astrocytoma; p53; retinoblastoma; tumor suppressor	HUMAN-MALIGNANT GLIOMAS; P53-DEPENDENT APOPTOSIS; MUTANT MICE; CELL-GROWTH; GENE; AMPLIFICATION; RB; GLIOBLASTOMAS; INACTIVATION; SUPPRESSION	The development of malignant gliomas (astrocytomas) involves the accumulation of multiple genetic changes, including mutations in the p53 and retinoblastoma (Rb) cell cycle regulatory pathways. One Rb pathway alteration seen in high-grade astrocytomas is amplification of cyclin dependent kinase-4 (CDK4). To define the function of CDK4 amplification/overexpression in astrocytoma pathogenesis, we generated three transgenic mouse lines that overexpress human CDK4 (hCDK4) in astrocytes using the human glial fibrillary acidic protein (GFAP) promoter. CFAP-hCDK4 mice do not develop brain tumors, but exhibit a small increase in astrocyte number. Cultured astrocytes from these mice do not demonstrate a cell-autonomous growth advantage in vitro and lack properties of transformed cells. To determine whether cdk4 overexpression provides a cooperative growth advantage in vitro, CDK4-overexpressing C6 glioma cell lines were generated and found to exhibit increased cell growth. In addition, GFAP-hCDK4; p53 + / - as well as p53 + / -; Rb + / - mice exhibited increased numbers of astrocytes compared to GFAP-hCDK4, p53 + / -, or Rb + / - mice in vivo. No cooperative effect was observed with CFAP-hCDK4; Rb+/- mice. These results support the hypothesis that cdk4 overexpression alone is not sufficient for astrocytoma formation, but can provide a cooperative growth advantage in concert with genetic alterations in the p53 pathway.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111 660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041097] Funding Source: NIH RePORTER; NINDS NIH HHS [NS41097] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bajenaru ML, 2001, GLIA, V33, P314, DOI 10.1002/1098-1136(20010315)33:4<314::AID-GLIA1030>3.0.CO;2-Q; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Bogler O, 1999, CELL GROWTH DIFFER, V10, P73; BOGLER O, 1995, CANCER RES, V55, P2746; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; Ding H, 2001, CANCER RES, V61, P3826; DING H, 2000, NEURO-ONCOLOGY, V2, P259; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA, V3rd; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Gutmann DH, 1999, ONCOGENE, V18, P4450, DOI 10.1038/sj.onc.1202829; Gutmann DH, 2000, NEUROPATH APPL NEURO, V26, P361, DOI 10.1046/j.1365-2990.2000.00258.x; Hegi ME, 2000, CANCER RES, V60, P3019; HEWETT SJ, 1993, BRAIN RES, V625, P337, DOI 10.1016/0006-8993(93)91078-7; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; Ichimura K, 2000, CANCER RES, V60, P417; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Kleihues P., 2000, WORLD HLTH ORG CLASS; Lau N, 2000, J NEUROPATH EXP NEUR, V59, P759, DOI 10.1093/jnen/59.9.759; LI FP, 1969, J NATL CANCER I, V43, P1365; Listernick R, 1999, AM J MED GENET, V89, P38, DOI 10.1002/(SICI)1096-8628(19990326)89:1<38::AID-AJMG8>3.0.CO;2-M; Marino S, 2000, GENE DEV, V14, P994; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; ROSE K, 1993, VITRO BIOL METHODS, P46; Schlegel J, 1999, PATHOBIOLOGY, V67, P202, DOI 10.1159/000028073; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Timiryasova TM, 1999, INT J ONCOL, V14, P845; Ueki K, 1996, CANCER RES, V56, P150; Wakabayashi T, 1999, BIOTECHNIQUES, V26, P302, DOI 10.2144/99262st04; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAHANDA AM, 1995, MOL CELL BIOL, V15, P4249; YIN DL, 1995, NEUROSURGERY, V37, P758, DOI 10.1227/00006123-199510000-00021; ZHOU L, 1997, DEV BIOL, V187, P36	41	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1325	1334		10.1038/sj.onc.1205206	http://dx.doi.org/10.1038/sj.onc.1205206			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857076				2022-12-25	WOS:000173861000003
J	Schafer, MA; Tastan, AO; Patzke, S; Blaha, G; Spahn, CMT; Wilson, DN; Nierhaus, KH				Schafer, MA; Tastan, AO; Patzke, S; Blaha, G; Spahn, CMT; Wilson, DN; Nierhaus, KH			Codon-anticodon interaction at the P site is a prerequisite for tRNA interaction with the small ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; TRANSFER-RNA BINDING; ANGSTROM RESOLUTION; A-SITE; CRYSTAL-STRUCTURE; DECODING REGION; 70S RIBOSOME; PROTEIN L2; TRANSLOCATION; LOOP	The arrival of high resolution crystal structures for the ribosomal subunits opens a new phase of molecular analysis and asks for corresponding analyses of ribosomal function. Here we apply the phosphorothioate technique to dissect tRNA interactions with the ribosome. We demonstrate that a tRNA bound to the P site of non-programmed 70 S ribosomes contacts predominantly the 50 S, as opposed to the 30 S subunit, indicating that codon-anticodon interaction at the P site is a prerequisite for 30 S binding. Protection patterns of tRNAs bound to isolated subunits and programmed 70 S ribosomes were compared. The results suggest the presence of a movable domain in the large ribosomal subunit that carries tRNA and reveal that only similar to15% of a tRNA, namely residues 30 +/- 1 to 43 +/- 1, contact the 30 S subunit of programmed 70 S ribosomes, whereas the remaining 85% make contact with the 50 S subunit. Identical protection patterns of two distinct elongator tRNAs at the P site were identified as tRNA species-independent phosphate backbone contacts. The sites of protection correlate nicely with the predicted ribosomal-tRNA contacts deduced from a 5.5-Angstrom crystal structure of a programmed 70 S ribosome, thus refining which ribosomal components are critical for tRNA fixation at the P site.	AG Ribosomen, Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Max Planck Society	Nierhaus, KH (corresponding author), AG Ribosomen, Max Planck Inst Mol Genet, Ihnestr 73, D-14195 Berlin, Germany.		Bishop, Ozlem Tastan/J-3084-2016; Wilson, Daniel/AAE-8504-2019; Patzke, Sebastian/G-9909-2019	Bishop, Ozlem Tastan/0000-0001-6861-7849; Wilson, Daniel/0000-0003-3816-3828; Patzke, Sebastian/0000-0001-6821-197X				Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BOMMER U, 1996, SUBCELLULAR FRACTION, P271; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; Carter AP, 2001, SCIENCE, V291, P498, DOI 10.1126/science.1057766; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Dabrowski M, 1998, J BIOL CHEM, V273, P32793, DOI 10.1074/jbc.273.49.32793; DABROWSKI M, 1995, EMBO J, V14, P4872, DOI 10.1002/j.1460-2075.1995.tb00168.x; Diedrich G, 2000, EMBO J, V19, P5241, DOI 10.1093/emboj/19.19.5241; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; ECKSTEIN F, 1989, TRENDS BIOCHEM SCI, V14, P97, DOI 10.1016/0968-0004(89)90130-8; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; GNIRKE A, 1986, J BIOL CHEM, V261, P4506; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; Joseph S, 1998, EMBO J, V17, P3478, DOI 10.1093/emboj/17.12.3478; Joseph S, 1996, EMBO J, V15, P910, DOI 10.1002/j.1460-2075.1996.tb00425.x; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; Nierhaus KH, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P319; NIERHAUS KH, 1996, RIBOSOMAL RNA GROUP, P69; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; QUIGLEY GJ, 1978, P NATL ACAD SCI USA, V75, P64, DOI 10.1073/pnas.75.1.64; RHEINBERGER HJ, 1987, J BIOMOL STRUCT DYN, V5, P435, DOI 10.1080/07391102.1987.10506403; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Schnitzer W, 1997, P NATL ACAD SCI USA, V94, P12823, DOI 10.1073/pnas.94.24.12823; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; VanLoock MS, 2000, J MOL BIOL, V304, P507, DOI 10.1006/jmbi.2000.4213; Willumeit R, 2001, J MOL BIOL, V305, P167, DOI 10.1006/jmbi.2000.4289; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	36	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19095	19105		10.1074/jbc.M108902200	http://dx.doi.org/10.1074/jbc.M108902200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11867615	hybrid			2022-12-25	WOS:000175975800111
J	Mulholland, DJ; Cheng, H; Reid, K; Rennie, PS; Nelson, CC				Mulholland, DJ; Cheng, H; Reid, K; Rennie, PS; Nelson, CC			The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; GLUCOCORTICOID RECEPTOR; GENE-EXPRESSION; LIVING CELLS; TRAFFICKING; IDENTIFICATION; VISUALIZATION; DOMAINS	We provide evidence that the androgen receptor (AR) can promote nuclear translocation of beta-catenin in LNCaP and PC3 prostate cancer cells. Using AR-expressing cells (LNCaP) and non-AR-expressing cells (PC3) we showed by time course cell fractionation that the AR can shuttle beta-catenin into the nucleus when exposed to exogenous androgen. Cells exposed to the synthetic androgen, R1881, show distinct, punctate, nuclear co-localization of the AR and beta-catenin. We further showed that the AR does not interact with adenomatous polyposis coli or glycogen synthase kinase-3beta and, therefore, conclude that androgen-mediated transport of beta-catenin occurs through a distinct pathway. The minimal necessary components of the AR and beta-catenin required for binding nuclear accumulation of beta-catenin nuclear import appears to be the DNA/ligand binding regions and the Armadillo repeats of B-catenin. We also employed a novel DNA binding assay to illustrate that beta-catenin has the capacity to bind to the probasin promoter in an AR-dependent manner. The physiological relevance of AR-mediated transport of beta-catenin and binding to an AR promoter appeared to be a substantial increase in AR transcriptional reporter activity. AR-mediated import represents a novel mode of nuclear accumulation of beta-catenin.	Vancouver Gen Hosp, Prostate Res Ctr, Vancouver, BC V6H 3Z6, Canada	University of British Columbia	Mulholland, DJ (corresponding author), Vancouver Gen Hosp, Prostate Res Ctr, 2660 Oak St,Jack Bell Res, Vancouver, BC V6H 3Z6, Canada.	djm@interchange.ubc.ca		Reid, Kim/0000-0001-5484-7205				Barker N, 2000, BIOESSAYS, V22, P961; Bieche I, 2001, CARCINOGENESIS, V22, P1521, DOI 10.1093/carcin/22.9.1521; Bunn CF, 2001, MOL ENDOCRINOL, V15, P512, DOI 10.1210/mend.15.4.0619; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Helmbrecht K, 2001, ENDOCRINOLOGY, V142, P5261, DOI 10.1210/en.142.12.5261; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Janne OA, 2000, BIOCHEM SOC T, V28, P401, DOI 10.1042/0300-5127:0280401; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; MacLean HE, 1997, J STEROID BIOCHEM, V62, P233, DOI 10.1016/S0960-0760(97)00049-6; NELSON C, 2001, IN PRESS BIOTECHNIQU; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; RAKESH KT, 2000, MOL ENDOCRINOL, V14, P1162; Reid KJ, 2001, J BIOL CHEM, V276, P2943, DOI 10.1074/jbc.M009170200; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Snoek R, 1998, PROSTATE, V36, P256; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Truica CI, 2000, CANCER RES, V60, P4709; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WONG W, 2000, CANCER RES, V60, P6841; YEH S, 1999, KEIO J MED, V2, P87; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	43	145	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17933	17943		10.1074/jbc.M200135200	http://dx.doi.org/10.1074/jbc.M200135200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11856748	hybrid			2022-12-25	WOS:000175685100070
J	Johnson, EN; Druey, KM				Johnson, EN; Druey, KM			Functional characterization of the G protein regulator RGS13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; SIGNALING RGS; EXPRESSION; GAIP; LOCALIZATION; RECEPTOR; DOMAIN; BINDS; PALMITOYLATION; CLONING	The signaling cascades evoked by G protein-coupled receptors are a predominant mechanism of cellular communication. The regulators of G protein signaling (RGS) comprise a family of proteins that attenuate G protein-mediated signal transduction. Here we report the characterization of RGS13, the smallest member of the RGS family, which has been cloned from human lung. RGS13 has been found most abundantly in human tonsil, followed by thymus, lung, lymph node, and spleen. RGS13 is a GTPase-activating protein for Galpha(i) and Galpha(o) but not Galpha(s). RGS13 binds Galpha(q) in the presence of aluminum magnesium fluoride, suggesting that it bears GTPase-activating protein activity toward Galpha(q). RGS13 blocks MAPK activity induced by Ga-i- or Galpha(q)-coupled receptors. RGS13 also attenuates GTPase-deficient Galpha(q) (Galpha(q)QL) mediated cAMP response element activation but not transcription evoked by constitutively active Galpha(12) or Galpha(13). Surprisingly, RGS13 inhibits cAMP generation elicited by stimulation of the beta(2)-adrenergic receptor. These data suggest that RGS13 may regulate Galpha(i)-, Galpha(q)-, and Galpha(s)-coupled signaling cascades.	NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Druey, KM (corresponding author), 12441 Parklawn Dr,Rm 200E, Rockville, MD 20852 USA.	kdruey@niaid.nih.gov						Beadling C, 1999, J IMMUNOL, V162, P2677; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gold SJ, 1997, J NEUROSCI, V17, P8024; Grafstein-Dunn E, 2001, MOL BRAIN RES, V88, P113, DOI 10.1016/S0169-328X(01)00038-9; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; JOHNSON EN, 2002, IN RESS J ALLERGY CL; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; MANNING DR, 1999, G PROTEINS TECHNIQUE, P23; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Norlin EM, 2001, MOL CELL NEUROSCI, V17, P872, DOI 10.1006/mcne.2001.0976; Parks IK, 2001, J BIOL CHEM, V276, P915, DOI 10.1074/jbc.M005947200; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Snow BE, 1998, GENE, V206, P247, DOI 10.1016/S0378-1119(97)00593-3; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Yowe D, 2001, BIOCHEM J, V359, P109, DOI 10.1042/0264-6021:3590109; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	37	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16768	16774		10.1074/jbc.M200751200	http://dx.doi.org/10.1074/jbc.M200751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875076	hybrid			2022-12-25	WOS:000175564500057
J	Ma, TH; Hara, M; Sougrat, R; Verbavatz, JM; Verkman, AS				Ma, TH; Hara, M; Sougrat, R; Verbavatz, JM; Verkman, AS			Impaired stratum corneum hydration in mice lacking epidermal water channel aquaporin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PROBE ANALYSIS; KIDNEY COLLECTING DUCT; LUNG FLUID TRANSPORT; HUMAN-SKIN; PERMEABILITY; EXPRESSION; GLYCEROL; SECRETION; MEMBRANE; BARRIER	The water and solute transporting properties of the epidermis have been proposed to be important determinants of skin moisture content and barrier properties. The water/small solute-transporting protein aquaporin-3 (AQP3) was found by immunofluorescence and immunogold electron microscopy to be expressed at the plasma membrane of epidermal keratinocytes in mouse skin. We studied the role of AQP3 in stratum corneum (SC) hydration by comparative measurements in wildtype and AQP3 null mice generated in a hairless SKH1 genetic background. The hairless AQP3 null mice had normal perinatal survival, growth, and serum chemistries but were polyuric because of defective urinary concentrating ability. AQP3 deletion resulted in a >4-fold reduced osmotic water permeability and >2-fold reduced glycerol permeability in epidermis. Epidermal, dermal, and SC thickness and morphology were not grossly affected by AQP3 deletion. Surface conductance measurements showed remarkably reduced SC water content in AQP3 null mice in the hairless genetic background (165 +/- 10 versus 269 +/- 12 microsiemens (muS), p < 0.001), as well as in a CD1 genetic background (209 +/- 21 versus 469 +/- 11 mu S). Reduced SC hydration was seen from 3 days after birth. SC hydration in hairless wild-type and AQP3 null mice was reduced to comparable levels (90-100 mu S) after a 24-h exposure to a dry atmosphere, but the difference was increased when surface evaporation was prevented by occlusion or exposure to a humidified atmosphere (179 +/- 13 versus 441 +/- 34 mu S). Conductance measurements after serial tape stripping suggested reduced water content throughout the SC in AQP3 null mice. Water sorption-desorption experiments indicated reduced water holding capacity in the SC of AQP3 null mice. The impaired skin hydration in AQP3 null mice provides the first functional evidence for the involvement of AQP3 in skin physiology. Modulation of AQP3 expression or function may thus alter epidermal moisture content and water loss in skin diseases.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Kanebo Ltd, Basic Res Lab, Odawara, Kanagawa 2500002, Japan; CEA, Serv Biol Cellulaire, F-91191 Gif Sur Yvette, France	University of California System; University of California San Francisco; University of California System; University of California San Francisco; CEA; UDICE-French Research Universities; Universite Paris Saclay	Ma, TH (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower,Box 0521, San Francisco, CA 94143 USA.	tonghui@itsa.ucsf.edu		Verbavatz, Jean-Marc/0000-0002-4654-1174; Sougrat, Rachid/0000-0001-6476-1886	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043840, R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; BLANK IH, 1965, J INVEST DERMATOL, V45, P249, DOI 10.1038/jid.1965.125; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; ELIAS PM, 1983, J INVEST DERMATOL, V80, pS44, DOI 10.1038/jid.1983.12; Farinas J, 1997, J GEN PHYSIOL, V110, P283, DOI 10.1085/jgp.110.3.283; FRIGERI A, 1995, J CELL SCI, V108, P2993; HARA M, 1993, ACTA DERM-VENEREOL, V73, P283; HORII I, 1989, BRIT J DERMATOL, V121, P587, DOI 10.1111/j.1365-2133.1989.tb08190.x; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; LANDMANN L, 1988, ANAT EMBRYOL, V178, P1, DOI 10.1007/BF00305008; Li J, 2001, J BIOL CHEM, V276, P31233, DOI 10.1074/jbc.M104368200; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; MA TH, 1994, J BIOL CHEM, V269, P21845; Ma TH, 2001, AM J PHYSIOL-CELL PH, V280, pC126; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Matsuzaki T, 1999, J HISTOCHEM CYTOCHEM, V47, P1275, DOI 10.1177/002215549904701007; OBATA M, 1989, J INVEST DERMATOL, V92, P854, DOI 10.1111/1523-1747.ep12696875; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; Song YL, 2001, J BIOL CHEM, V276, P41288, DOI 10.1074/jbc.M107257200; Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573; SOUGRAT R, 2002, IN PRESS J INVESTIG; SPRUIT D, 1970, DERMATOLOGICA, V141, P54, DOI 10.1159/000252436; Sugiyama Y, 2001, BBA-GENE STRUCT EXPR, V1522, P82, DOI 10.1016/S0167-4781(01)00320-7; TAGAMI H, 1994, ACTA DERM-VENEREOL, P29; TAGAMI H, 1985, ARCH DERMATOL, V121, P642, DOI 10.1001/archderm.121.5.642; TAGAMI H, 1980, J INVEST DERMATOL, V75, P500, DOI 10.1111/1523-1747.ep12524316; TAKENOUCHI M, 1986, J INVEST DERMATOL, V87, P574, DOI 10.1111/1523-1747.ep12455817; Tanaka M, 1997, AM J PHYSIOL-LUNG C, V273, pL1090, DOI 10.1152/ajplung.1997.273.5.L1090; THUNE P, 1989, ACTA DERM-VENEREOL, P133; WARNER RR, 1988, J INVEST DERMATOL, V90, P218, DOI 10.1111/1523-1747.ep12462252; WARNER RR, 1988, J INVEST DERMATOL, V90, P78, DOI 10.1111/1523-1747.ep12462576; Warner RR, 1999, J INVEST DERMATOL, V113, P960, DOI 10.1046/j.1523-1747.1999.00774.x; WARNER RR, 1995, J INVEST DERMATOL, V104, P530, DOI 10.1111/1523-1747.ep12606037; WATANABE M, 1991, ARCH DERMATOL, V127, P1689, DOI 10.1001/archderm.127.11.1689; Yang BX, 2001, J BIOL CHEM, V276, P624, DOI 10.1074/jbc.M008664200; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	39	187	199	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17147	17153		10.1074/jbc.M200925200	http://dx.doi.org/10.1074/jbc.M200925200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880378	hybrid			2022-12-25	WOS:000175564500107
J	Mofid, MR; Finking, R; Marahiel, MA				Mofid, MR; Finking, R; Marahiel, MA			Recognition of hybrid peptidyl carrier proteins/Acyl carrier proteins in nonribosomal peptide synthetase modules by the 4 '-phophopantetheinyl transferases AcpS and Sfp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAMICIDIN-S SYNTHETASE; BACILLUS-SUBTILIS; PHOSPHOPANTETHEINYL TRANSFERASE; BIOCHEMICAL-CHARACTERIZATION; ESCHERICHIA-COLI; BIOSYNTHESIS; SYNTHASE; DOMAIN; IDENTIFICATION; EPIMERIZATION	The acyl carrier proteins (ACPs) of fatty acid synthase and polyketide synthase as well as peptidyl carrier proteins (PCPs) of nonribosomal peptide synthetases are modified by 4'-phosphopantetheinyl transferases from inactive apo-enzymes to their active holo forms by transferring the 4'-phosphopantetheinyl moiety of coenzyme A to a conserved serine residue of the carrier protein. 4'-Phosphopantetheinyl transferases have been classified into two types; the AcpS type accepts ACPs of fatty acid synthase and some ACPs of type If polyketide synthase as substrates, whereas the Sfp type exhibits an extraordinarily broad substrate specificity. Based on the previously published co-crystal structure of Bacillus subtilis AcpS and ACP that provided detailed information about the interacting residues of the two proteins, we designed a novel hybrid PCP by replacing the Bacillus brevis TycC3-PCP helix 2 with the corresponding helix of B. subtilis ACP that contains the interacting residues. This was performed for the PCP domain as a single protein as well as for the TycA-PCP domain within the nonribosomal peptide synthetase module TycA from B. brevis. Both resulting proteins, designated hybrid PCP (hPCP) and hybrid TycA (hTycA), were modified in vivo during heterologous expression in Escherichia coli (hPCP, 51%; hTycA, 75%) and in vitro with AcpS as well as Sfp to 100%,. The designated hTycA module contains two other domains: an adenylation domain (activating phenylalanine to Phe-AMP and afterward transferring the Phe to the PCP domain) and an epimerization domain (converting the PCP-bound L-Phe to DPhe). We show here that the modified PCP domain of hTycA communicates with the adenylation domain and that the co-factor of holo-hPCP is loaded with Phe. However, communication between the hybrid PCP and the epimerization domain seems to be disabled. Nevertheless, hTycA is recognized by the next proline-activating elongation module TycB1 in vitro, and the dipeptide is formed and released as diketopiperazine.	Univ Marburg, Fachbereich Chem Biochem, D-35032 Marburg, Germany	Philipps University Marburg	Marahiel, MA (corresponding author), Univ Marburg, Fachbereich Chem Biochem, Hans Meerwein Str, D-35032 Marburg, Germany.			mofid, mohammad reza/0000-0002-0347-8152				Debabov DV, 1996, J BACTERIOL, V178, P3869, DOI 10.1128/jb.178.13.3869-3876.1996; DECRECYLAGARD V, 1995, CR ACAD SCI III-VIE, V318, P927; Flaman AS, 2001, J BIOL CHEM, V276, P35934, DOI 10.1074/jbc.M101849200; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; Linne U, 2001, BIOCHEMISTRY-US, V40, P15824, DOI 10.1021/bi011595t; Luo LS, 2001, BIOCHEMISTRY-US, V40, P5329, DOI 10.1021/bi015518+; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; McAllister KA, 2000, J BIOL CHEM, V275, P30864, DOI 10.1074/jbc.M004475200; Mofid MR, 1999, ACTA CRYSTALLOGR D, V55, P1098, DOI 10.1107/S0907444999003674; Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997; Mootz HD, 2000, P NATL ACAD SCI USA, V97, P5848, DOI 10.1073/pnas.100075897; Mootz HD, 2001, J BIOL CHEM, V276, P37289, DOI 10.1074/jbc.M103556200; NAKANO MM, 1992, MOL GEN GENET, V232, P313, DOI 10.1007/BF00280011; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Reuter K, 1999, EMBO J, V18, P6823, DOI 10.1093/emboj/18.23.6823; RITSEMA T, 1994, J BACTERIOL, V176, P7740, DOI 10.1128/JB.176.24.7740-7743.1994; Sambrook J., 2002, MOL CLONING LAB MANU; Schwarzer D, 2001, NATURWISSENSCHAFTEN, V88, P93, DOI 10.1007/s001140100211; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; Stachelhaus T, 1996, CHEM BIOL, V3, P913, DOI 10.1016/S1074-5521(96)90180-5; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; Stachelhaus T, 2000, BIOCHEMISTRY-US, V39, P5775, DOI 10.1021/bi9929002; STACHELHAUS T, 2002, NONRIBOSOMAL ASSEMBL, P415; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; TURGAY K, 1992, MOL MICROBIOL, V6, P2743, DOI 10.1111/j.1365-2958.1992.tb01451.x; Walsh CT, 1997, CURR OPIN CHEM BIOL, V1, P309, DOI 10.1016/S1367-5931(97)80067-1; Weber W, 2000, SUPPORT CARE CANCER, V8, P1; Xu GY, 2001, STRUCTURE, V9, P277, DOI 10.1016/S0969-2126(01)00586-X; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200	33	70	75	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17023	17031		10.1074/jbc.M200120200	http://dx.doi.org/10.1074/jbc.M200120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867633	hybrid			2022-12-25	WOS:000175564500091
J	Taschenberger, G; Mougey, A; Shen, S; Lester, LB; LaFranchi, S; Shyng, SL				Taschenberger, G; Mougey, A; Shen, S; Lester, LB; LaFranchi, S; Shyng, SL			Identification of a familial hyperinsulinism-causing mutation in the sulfonylurea receptor 1 that prevents normal trafficking and function of K-ATP channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; PANCREATIC BETA-CELLS; SUBUNIT STOICHIOMETRY; HYPOGLYCEMIA; INFANCY; SUR1; COMPLEX; BINDING; KIR6.2; MGADP	Mutations in the pancreatic ATP-sensitive potassium (K-ATP) channel subunits sulfonylurea receptor 1 (SUR1) and the inwardly rectifying potassium channel Kir6.2 cause persistent hyperinsulinemic hypoglycemia of infancy. We have identified a SUR1 mutation, L1544P, in a patient with the disease. Channels formed by co-transfection of Kir6.2 and the mutant SUR1 in COS cells have reduced response to MgADP (similar to10% that of the wild-type channels) and reduced surface expression (similar to19% that of the wild-type channels). However, the steady-state level of the SUR1 protein is unaffected. Treating cells with lysosomal or proteasomal inhibitors did not improve surface expression of the mutant channels, suggesting that increased degradation of mutant channels by either pathway is unlikely to account for the reduced surface expression. Removal of the RKR endoplasmic reticulum retention/retrieval trafficking motif in either SUR1 or Kir6.2 increased the surface expression of the mutant channel by similar to35 and similar to20%, respectively. The simultaneous removal of the RKR motif in both channel subunits restored surface expression of the mutant channel to the wild-type channel levels. Thus, the L1544P mutation may interfere with normal trafficking of K-ATP channels by causing improper shielding of the RKR endoplasmic reticulum retention/retrieval trafficking signals in the two channel subunits.	Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Shyng, SL (corresponding author), Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057699] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57699, R01 DK057699] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2001, J BIOL CHEM, V276, P41270, DOI 10.1074/jbc.M106555200; Dunne MJ, 1999, TRENDS ENDOCRIN MET, V10, P146, DOI 10.1016/S1043-2760(98)00135-0; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; Enkvetchakul D, 2000, BIOPHYS J, V78, P2334, DOI 10.1016/S0006-3495(00)76779-8; Glaser B, 2000, SEMIN PERINATOL, V24, P150, DOI 10.1053/sp.2000.6365; Huopio H, 2000, J CLIN INVEST, V106, P897, DOI 10.1172/JCI9804; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; LANDAU H, 1991, PEDIATRIC SURGERY LI, P187; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Matsuo M, 2000, J BIOL CHEM, V275, P41184, DOI 10.1074/jbc.M006503200; Miki T, 1999, J MOL ENDOCRINOL, V22, P113, DOI 10.1677/jme.0.0220113; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; PERMUTT MA, 1996, DIABETES REV, V4, P347; Sharma N, 2000, KIDNEY INT, V57, P803, DOI 10.1046/j.1523-1755.2000.00918.x; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	35	101	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17139	17146		10.1074/jbc.M200363200	http://dx.doi.org/10.1074/jbc.M200363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867634	hybrid			2022-12-25	WOS:000175564500106
J	Li, ZY; Zou, CB; Yao, Y; Hoyt, MA; McDonough, S; Mackey, ZB; Coffino, P; Wang, CC				Li, ZY; Zou, CB; Yao, Y; Hoyt, MA; McDonough, S; Mackey, ZB; Coffino, P; Wang, CC			An easily dissociated 26 S proteasome catalyzes an essential ubiquitin-mediated protein degradation pathway in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GENOMIC ANALYSIS; DOUBLE-STRANDED-RNA; REGULATORY PARTICLE; 20S PROTEASOME; ATPASE; YEAST; IDENTIFICATION; INHIBITION; SUBUNITS; GENES	The 26 S proteasome, a complex between the 20 S proteasome and 19 S regulatory units, catalyzes ATP-dependent degradation of unfolded and ubiquitinated proteins in eukaryotes. We have identified previously 20 S and activated 20 S proteasomes in Trypanosoma brucei, but not 26 S proteasome. However, the presence of 26 S proteasome in T. brucei was suggested by the hydrolysis of casein by cell lysate, a process that requires ATP but is inhibited by lactacystin, and the lactacystin-sensitive turnover of ubiquitinated proteins in the intact cells. T. brucei cDNAs encoding the six proteasome ATPase homologues (Rpt) were cloned and expressed. Five of the six T. brucei Rpt cDNAs, except for Rpt2, were capable of functionally complementing the corresponding rpt deletion mutants of Saccharomyces cerevisiae. Immunoblots showed the presence in T. brucei lysate of the Rpt proteins, which co-fractionated with the yeast 19 S proteasome complex by gel filtration and localized in the 19 S fraction of a glycerol gradient. All the Rpt and putative 19 S non-ATPase (Rpn) proteins were co-immunoprecipitated from T. brucei lysate by individual anti-Rpt antibodies. Treatment of T. brucei cells with a chemical cross-linker resulted in co-immunoprecipitation of 20 S proteasome with all the Rpt and Rpn proteins that sedimented in a glycerol gradient to the position of 26 S proteasome. These data demonstrate the presence of 26 S proteasome in T. brucei cells, which apparently dissociate into 19 S and 20 S complexes upon cell lysis. RNA interference to block selectively the expression of proteasome 20 S core and Rpt subunits resulted in significant accumulation of ubiquitinated proteins accompanied by cessation of cell growth. Expression of yeast RPT2 gene in T. brucei Rpt2-deficient cells could not rescue the lethal phenotype, thus confirming the incompatibility between the two Rpt2s. The T. brucei 11 S regulator (PA26)-deficient RNA interference cells grew normally, suggesting the dispensability of activated 20 S proteasome in T. brucei.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu	Zou, Chunbin/L-7488-2019	Zou, Chunbin/0000-0003-1355-4726; Coffino, Philip/0000-0003-0344-5083; Li, Ziyin/0000-0002-3960-9716; Mackey, Zachary/0000-0002-4533-0973	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021786] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-21786, R01 AI021786] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Fu HY, 1999, PLANT J, V18, P529, DOI 10.1046/j.1365-313X.1999.00479.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; Hendil KB, 1998, BIOCHEM J, V332, P749, DOI 10.1042/bj3320749; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; Hua SB, 1996, MOL BIOCHEM PARASIT, V78, P33, DOI 10.1016/S0166-6851(96)02599-6; Huang L, 2001, J BIOL CHEM, V276, P28327, DOI 10.1074/jbc.M008342200; Huang L, 1999, MOL BIOCHEM PARASIT, V102, P211, DOI 10.1016/S0166-6851(99)00096-1; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LOWRIE DJ, 1993, AM J TROP MED HYG, V49, P545, DOI 10.4269/ajtmh.1993.49.545; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Mutomba MC, 1997, MOL BIOCHEM PARASIT, V90, P491, DOI 10.1016/S0166-6851(97)00197-7; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Singer SM, 1998, MOL BIOCHEM PARASIT, V92, P59, DOI 10.1016/S0166-6851(97)00225-9; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; Sommer JM, 1996, MOL BIOCHEM PARASIT, V76, P83, DOI 10.1016/0166-6851(95)02543-X; To WY, 1997, FEBS LETT, V404, P253, DOI 10.1016/S0014-5793(97)00116-6; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WONG S, 1992, MOL BIOCHEM PARASIT, V55, P187, DOI 10.1016/0166-6851(92)90139-B; Yao Y, 1999, J BIOL CHEM, V274, P33921, DOI 10.1074/jbc.274.48.33921; Yao Y, 1999, BIOCHEM J, V344, P349, DOI 10.1042/0264-6021:3440349; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008	52	56	57	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15486	15498		10.1074/jbc.M109029200	http://dx.doi.org/10.1074/jbc.M109029200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854272	hybrid			2022-12-25	WOS:000175510400037
J	Macpherson, P; Kostrominova, T; Tang, HB; Goldman, D				Macpherson, P; Kostrominova, T; Tang, HB; Goldman, D			Protein kinase c and calcium/calmodulin-activated protein kinase II (CaMIK II) suppress nicotinic acetylcholine receptor gene expression in mammalian muscle - A specific role for CaMK II in activity-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT MESSENGER-RNA; E-BOX ELEMENTS; ELECTRICAL-ACTIVITY; ALPHA-SUBUNIT; SKELETAL-MUSCLE; MYOGENIC FACTORS; GAMMA-SUBUNIT; BETA-SUBUNIT; RAT; PHOSPHORYLATION	Nicotinic acetylcholine receptor (nAChR) gene expression is regulated by both muscle activity and increased intracellular calcium. This regulation is an important developmental event that rids receptors from the extrajunctional region of the developing muscle fiber. In avian muscle, it has been proposed that muscle activity suppresses nAChR gene expression via calcium-activated protein kinase C (PKC)-dependent phosphorylation of the myogenic transcription factor, myogenin. Here, we examined the role that PKC and other kinases play in mediating calcium- and activity-dependent suppression of nAChR genes in rat primary myotubes. We found that although activated PKC could regulate nAChR promoter activity and transiently suppressed both nAChR and myogenin gene expression, it did not appear to be required for calcium- or activity-dependent control of nAChR gene expression in mammalian muscle. Neither depletion of PKC from myotubes nor specific pharmacological inhibition of PKC blocked the suppression of nAChR gene expression produced by calcium or muscle depolarization. In contrast, we provide evidence that calcium/calmodulin-activated protein kinase II participates in mediating the effects of muscle depolarization on nAChR and myogenin gene expression.	Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Goldman, D (corresponding author), Univ Michigan, Mental Hlth Res Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	neuroman@umich.edu	Kostrominova, Tatiana/AAS-2371-2020		NIA NIH HHS [P01 AG10821] Funding Source: Medline; NINDS NIH HHS [R01 NS25153] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010821] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams L, 1998, J NEUROBIOL, V35, P245, DOI 10.1002/(SICI)1097-4695(19980605)35:3<245::AID-NEU2>3.0.CO;2-Z; ADAMS L, 1995, J CELL BIOL, V131, P1341, DOI 10.1083/jcb.131.5.1341; Altiok N, 2001, FEBS LETT, V487, P333, DOI 10.1016/S0014-5793(00)02311-5; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHAHINE KG, 1993, J BIOL CHEM, V268, P2893; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHENG TC, 1995, P NATL ACAD SCI USA, V92, P561, DOI 10.1073/pnas.92.2.561; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DUCLERT A, 1991, NEUROREPORT, V2, P25, DOI 10.1097/00001756-199101000-00006; DURR I, 1994, EUR J BIOCHEM, V224, P353, DOI 10.1111/j.1432-1033.1994.00353.x; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; Fields RD, 1997, J NEUROSCI, V17, P7252; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GU X, 1995, SCIENCE, V234, P80; GUNDERSEN K, 1995, MOL CELL BIOL, V15, P7127; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; HUANG CF, 1994, NEURON, V13, P167, DOI 10.1016/0896-6273(94)90467-7; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KLARSFELD A, 1985, P NATL ACAD SCI USA, V82, P4558, DOI 10.1073/pnas.82.13.4558; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; Kostrominova TY, 2000, AM J PHYSIOL-REG I, V279, pR179, DOI 10.1152/ajpregu.2000.279.1.R179; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MENDELZON D, 1994, BIOCHEMISTRY-US, V33, P2568, DOI 10.1021/bi00175a028; MERLIE JP, 1984, J CELL BIOL, V99, P332, DOI 10.1083/jcb.99.1.332; NEVILLE C, 1991, NEUROREPORT, V2, P655, DOI 10.1097/00001756-199111000-00005; NEVILLE CM, 1992, CELL MOL NEUROBIOL, V12, P511, DOI 10.1007/BF00711232; NIEDEL JE, 1986, PHOSPHOINOSITIDES RE, V7, P47; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Tang HB, 2001, J BIOL CHEM, V276, P26057, DOI 10.1074/jbc.M101670200; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; WALKE W, 1994, J BIOL CHEM, V269, P19447; Walke W, 1996, J NEUROSCI, V16, P3641; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232	42	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15638	15646		10.1074/jbc.M109864200	http://dx.doi.org/10.1074/jbc.M109864200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877392	hybrid			2022-12-25	WOS:000175510400057
J	Austin, J; First, EA				Austin, J; First, EA			Catalysis of tyrosyl-adenylate formation by the human tyrosyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SITE-DIRECTED MUTAGENESIS; MULTIPLE SEQUENCE ALIGNMENT; NATURAL PRODUCT SB-219383; CRYSTAL-STRUCTURE; MOBILE LOOP; SP I; INHIBITORS; ANALOGS; POTENT	Although the active site residues in the Bacillus stearothermophilus and human tyrosyl-tRNA synthetases are largely conserved, several differences exist between the two enzymes. In particular, three amino acids that stabilize the transition state for the activation of tyrosine in B. stearothermophilus tyrosyl-tRNA synthetase (Cys-35, His-48, and Lys-233) are not present in the human enzyme. This raises the question of whether the activation energy for the tyrosine activation step is higher for the human tyrosyl-tRNA synthetase than for the B. stearothermophilus enzyme. In this paper, we demonstrate that intrinsic fluorescence changes can be used to monitor the pre-steady state kinetics of human tyrosyl-tRNA synthetase. In contrast to the B. stearothermophilus enzyme, catalysis of the tyrosine activation step is potassium-dependent in the human tyrosyl-tRNA synthetase. Specifically, potassium increases the forward rate constant for tyrosine activation 260-fold in the human tyrosyl-tRNA synthetase. Comparison of the forward rate constants for catalysis of tyrosine activation by the human and B. stearothermophilus enzymes indicates that despite differences in their active sites and the potassium requirement of the human enzyme, the activation energies for tyrosine activation are identical for the two enzymes. The results of these investigations suggest that differences exist between the active sites of the bacterial and human tyrosyl-tRNA synthetases that could be exploited to design antimicrobials that target the bacterial enzyme.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	First, EA (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053693] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53693] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BEIKIRCH H, 1972, EUR J BIOCHEM, V26, P182, DOI 10.1111/j.1432-1033.1972.tb01755.x; Berge JM, 2000, BIOORG MED CHEM LETT, V10, P1811, DOI 10.1016/S0960-894X(00)00348-6; Berge JM, 2000, J ANTIBIOT, V53, P1282, DOI 10.7164/antibiotics.53.1282; Brown MJB, 2000, BIOCHEMISTRY-US, V39, P6003, DOI 10.1021/bi000148v; Brown P, 2001, BIOORG MED CHEM LETT, V11, P711, DOI 10.1016/S0960-894X(01)00039-7; Bush K, 1997, CURR OPIN CHEM BIOL, V1, P169, DOI 10.1016/S1367-5931(97)80006-3; Casas C, 2001, J NEUROCHEM, V77, P904, DOI 10.1046/j.1471-4159.2001.00314.x; Engel P. C., 1996, ENZYMOLOGY LABFAX; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P5, DOI 10.1021/bi00672a002; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P13, DOI 10.1021/bi00672a003; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13651, DOI 10.1021/bi00212a033; FIRST EA, 1995, BIOCHEMISTRY-US, V34, P5030, DOI 10.1021/bi00015a014; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13658, DOI 10.1021/bi00212a034; FIRST EA, 1998, COMPREHENSIVE BIOL C, V1, P573; FISHER PA, 1976, BIOCHEMISTRY-US, V15, P4065, DOI 10.1021/bi00663a023; HO CK, 1986, BIOCHEMISTRY-US, V25, P1891, DOI 10.1021/bi00356a009; Houge-Frydrych CSV, 2000, J ANTIBIOT, V53, P351, DOI 10.7164/antibiotics.53.351; Jarvest RL, 1999, BIOORG MED CHEM LETT, V9, P2859, DOI 10.1016/S0960-894X(99)00488-6; Jarvest RL, 2001, BIOORG MED CHEM LETT, V11, P2499, DOI 10.1016/S0960-894X(01)00475-9; Jarvest RL, 2001, BIOORG MED CHEM LETT, V11, P715, DOI 10.1016/S0960-894X(01)00040-3; KIM JS, 1993, PROTEIN SCI, V2, P348; Kirillov S, 1997, RNA, V3, P905; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; KOCH GLE, 1974, NATURE, V249, P316, DOI 10.1038/249316a0; KOCH GLE, 1974, BIOCHEMISTRY-US, V13, P2307, DOI 10.1021/bi00708a011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDES C, 1995, BIOCHIMIE, V77, P194, DOI 10.1016/0300-9084(96)88125-9; Lodish H., 1995, MOL CELL BIOL; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; Macarron R, 2000, ANAL BIOCHEM, V284, P183, DOI 10.1006/abio.2000.4665; Martinis Susan A., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P4591, DOI 10.1093/emboj/18.17.4591; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; Qiu XY, 2001, PROTEIN SCI, V10, P2008, DOI 10.1110/ps.18001; QUIVY JP, 1988, J BIOL CHEM, V263, P15277; Raczniak G, 2001, TOXICOLOGY, V160, P181, DOI 10.1016/S0300-483X(00)00454-6; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schimmel P, 1998, FASEB J, V12, P1599, DOI 10.1096/fasebj.12.15.1599; Stefanska AL, 2000, J ANTIBIOT, V53, P345, DOI 10.7164/antibiotics.53.345; Stefanska AL, 2000, J ANTIBIOT, V53, P357, DOI 10.7164/antibiotics.53.357; Stefanska AL, 2000, J ANTIBIOT, V53, P1346, DOI 10.7164/antibiotics.53.1346; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; WARNER CK, 1976, CAN J BIOCHEM CELL B, V54, P650, DOI 10.1139/o76-094; WELLS TNC, 1991, BIOCHEMISTRY-US, V30, P5151, DOI 10.1021/bi00235a006; WELLS TNC, 1986, BIOCHEMISTRY-US, V25, P1881, DOI 10.1021/bi00356a007; WELLS TNC, 1985, NATURE, V316, P656, DOI 10.1038/316656a0; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; WILKINSON AJ, 1984, NATURE, V307, P187, DOI 10.1038/307187a0	51	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14812	14820		10.1074/jbc.M103396200	http://dx.doi.org/10.1074/jbc.M103396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11856731	hybrid			2022-12-25	WOS:000175203000060
J	Xiao, YQ; Malcolm, K; Worthen, GS; Gardai, S; Schiemann, WP; Fadok, VA; Bratton, DL; Henson, PM				Xiao, YQ; Malcolm, K; Worthen, GS; Gardai, S; Schiemann, WP; Fadok, VA; Bratton, DL; Henson, PM			Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; MONOCYTE-CHEMOATTRACTANT PROTEIN-1; DEPENDENT GENE-EXPRESSION; INGESTED APOPTOTIC CELLS; TUMOR-NECROSIS-FACTOR; TGF-BETA; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; HUMAN NEUTROPHILS	Phagocytosis of apoptotic cells by macrophages results in the production of transforming growth factor-beta (TGF-beta), which plays an important role in induction of an anti-inflammatory phenotype and resolution of inflammation. In this study, we show that TGF-beta prevents pro-inflammatory cytokine production through inhibition of p38 mitogen-activated protein kinase (MAPK) and NF-kappaB. Blockade of extracellular signal-regulated kinase (ERK) signaling by the MEK-1/2 inhibitor PD 98059 reversed the inhibitory effects of TGF-beta, suggesting that cross-talk between MAPKs is essential for this response. Further investigation indicated that TGF-beta activated ERK, which in turn up-regulated MAPK phosphatase-1, thereby inactivating p38 MAPK. On the other hand, TGF-beta maintained or slightly increased production of the CC chemokine MCP-1, which is regulated predominantly by AP-1. Although SB 203580, an inhibitor of p38 MAPK, and dominant-negative p38 MAPK both increased AP-1 transcription, lack of effect of TGF-beta on lipopolysaccharide-stimulated SAPK/JNK phosphorylation along with a demonstrated inhibition of TGF-beta-induced AP-1 activation by dominant-negative Smad3 suggest that TGF-beta-stimulated AP-1 activation was not caused by inhibition of p38 MAPK but rather through the activation of Smads. Our data provide evidence that TGF-beta selectively inhibits inflammatory cytokine production through cross-talk between MAPKs.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA	National Jewish Health	Henson, PM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.							Aggeli IKS, 2001, AM J PHYSIOL-REG I, V281, pR1689, DOI 10.1152/ajpregu.2001.281.5.R1689; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Carter KB, 2000, J BIOL CHEM, V275, P27858; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Finzer P, 2000, ONCOGENE, V19, P3235, DOI 10.1038/sj.onc.1203643; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Frey RS, 1997, CANCER RES, V57, P628; Friedland JS, 2001, J LEUKOCYTE BIOL, V70, P447; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hobbie S, 1997, J IMMUNOL, V159, P5550; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638; Imai K, 2000, INFECT IMMUN, V68, P2418, DOI 10.1128/IAI.68.5.2418-2423.2000; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee SK, 2001, KIDNEY INT, V60, P55, DOI 10.1046/j.1523-1755.2001.00770.x; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; McDonald PP, 1999, J IMMUNOL, V163, P6164; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Nakayama K, 2001, J IMMUNOL, V167, P1145, DOI 10.4049/jimmunol.167.3.1145; Nick JA, 1996, J IMMUNOL, V156, P4867; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; PAZDRAK K, 1995, J IMMUNOL, V155, P4454; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Simeone DM, 2001, AM J PHYSIOL-CELL PH, V281, pC311, DOI 10.1152/ajpcell.2001.281.1.C311; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Valledor AF, 1999, J IMMUNOL, V163, P2452; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Xiao YQ, 1999, BBA-MOL CELL RES, V1450, P155, DOI 10.1016/S0167-4889(99)00042-7; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	55	198	208	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14884	14893		10.1074/jbc.M111718200	http://dx.doi.org/10.1074/jbc.M111718200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11842088	hybrid			2022-12-25	WOS:000175203000069
J	Stiewe, T; Theseling, CC; Putzer, BM				Stiewe, T; Theseling, CC; Putzer, BM			Transactivation-deficient triangle TA-p73 inhibits p53 by direct competition for DNA binding - Implications for tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P73 GENE; NEUROBLASTOMA; P63; OVEREXPRESSION; EXPRESSION; HOMOLOG; DIFFERENTIATION; ACTIVATION; DELTA-NP73; PROMOTERS	The p53 family member p73 displays significant structural and functional homology to p53. However, instead of mutational inactivation, overexpression of wild-type p73 has been reported in various tumor types compared with normal tissues, arguing against a classical tumor suppressor function. Recently, N-terminally truncated, transactivation-deficient p73 isoforms (DeltaTA-p73) have been identified as a second class of p73 proteins. Because overexpression of p73 in tumors includes DeltaTA-p73, we further characterized these novel p73 isoforms. We show that DeltaTA-p73 retains DNA-binding competence but lacks transactivation functions, resulting in an inability to induce growth arrest and apoptosis. Importantly, DeltaTA-p73 acts as a dominant-negative inhibitor of p53 and full-length p73 (TA-p73). We demonstrate that inhibition of p53 involves competition for DNA binding, whereas TA-p73 can be inhibited by direct protein-protein interaction. Further, we show that up-regulation of endogenous p73 just like ectopic overexpression of DeltaTA-p73 confers resistance to p53-mediated apoptosis induced by the chemotherapeutic agent H-7. Because inhibition of p53 is a common theme in human cancer, our data strongly support a role of DeltaTA-p73 expression for tumor formation.	Univ Essen Gesamthsch, Inst Mol Biol, Ctr Canc Res & Canc Therapy, Sch Med, D-45122 Essen, Germany	University of Duisburg Essen	Putzer, BM (corresponding author), Univ Essen Gesamthsch, Inst Mol Biol, Ctr Canc Res & Canc Therapy, Sch Med, Hufelandstr 55, D-45122 Essen, Germany.	brigitte.puetzer@uni-essen.de		Stiewe, Thorsten/0000-0003-0134-7826				Casciano I, 1999, CELL DEATH DIFFER, V6, P391, DOI 10.1038/sj.cdd.4400522; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishimoto O, 2002, CANCER RES, V62, P636; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Novak U, 2001, ANN ONCOL, V12, P981, DOI 10.1023/A:1011153206003; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Putzer BM, 2000, GENE THER, V7, P1317, DOI 10.1038/sj.gt.3301235; Ronca F, 1999, J BIOL CHEM, V274, P18128, DOI 10.1074/jbc.274.25.18128; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stiewe T, 2001, APOPTOSIS, V6, P447, DOI 10.1023/A:1012433522902; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Sunahara M, 1998, INT J ONCOL, V13, P319; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika AI, 1999, CANCER RES, V59, P3257	41	160	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14177	14185		10.1074/jbc.M200480200	http://dx.doi.org/10.1074/jbc.M200480200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11844800	hybrid			2022-12-25	WOS:000175096000107
J	Forman, BM				Forman, BM			The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; INSULIN-RESISTANCE; DIABETES-MELLITUS; TARGET GENE; EXPRESSION; MICE; DIFFERENTIATION; LIPODYSTROPHY; TROGLITAZONE; EFFICACY	Insulin resistance and non-insulin-dependent diabetes mellitus are major causes of morbidity and mortality in industrialized nations. Despite the alarming rise in the prevalence of this disorder, the initial molecular events that promote insulin resistance remain unclear. The data presented here demonstrate that LG100754, an antidiabetic RXR ligand, defines a novel type of nuclear receptor agonist. Surprisingly, LG100754 has minimal intrinsic transcriptional activity, instead it enhances the potency of proliferator-activated receptor (PPAR) gamma-retinoid X receptor heterodimers for PPARgamma ligands. The ability of LG100754 to both increase PPARgamma sensitivity and relieve insulin resistance implies that a deficiency in endogenous PPARgamma ligands may represent an early step in the development of insulin resistance.	City Hope Natl Med Ctr, Beckman Res Inst, Gonda Diabet & Genet Res Ctr, Div Mol Med, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Forman, BM (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Gonda Diabet & Genet Res Ctr, Div Mol Med, 1500 E Duarte Rd, Duarte, CA 91010 USA.							Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Cesario RM, 2001, MOL ENDOCRINOL, V15, P1360, DOI 10.1210/me.15.8.1360; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; Forman Barry Marc, 2001, Trends in Molecular Medicine, V7, P331, DOI 10.1016/S1471-4914(01)02074-3; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kishida K, 2001, J BIOL CHEM, V276, P48572, DOI 10.1074/jbc.M108213200; Kolehmainen M, 2001, OBES RES, V9, P706, DOI 10.1038/oby.2001.95; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; Olefsky JM, 2000, TRENDS ENDOCRIN MET, V11, P362, DOI 10.1016/S1043-2760(00)00306-4; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Reginato MJ, 1999, TRENDS ENDOCRIN MET, V10, P9, DOI 10.1016/S1043-2760(98)00110-6; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Savage DB, 2001, DIABETES, V50, P2199, DOI 10.2337/diabetes.50.10.2199; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; Way JM, 2001, J BIOL CHEM, V276, P25651, DOI 10.1074/jbc.C100189200; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Young PW, 1998, J PHARMACOL EXP THER, V284, P751; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455	40	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12503	12506		10.1074/jbc.C200004200	http://dx.doi.org/10.1074/jbc.C200004200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11877384	hybrid			2022-12-25	WOS:000175036300005
J	Stansel, RM; Subramanian, D; Griffith, JD				Stansel, RM; Subramanian, D; Griffith, JD			p53 binds telomeric single strand overhangs and t-loop junctions in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; PROTEIN; END; KU; YEAST; TRF2	The interaction of p53 with a human model telomere in vitro was examined by electron microscopy. p53 demonstrated a sequence-independent affinity for telomeric DNA in vitro, localizing to the 3' single strand overhang and the t-loop junction both in the presence and absence of associated TRF2. Binding was not observed above background along the duplex telomeric repeats. However, the efficiency of TRF2-catalyzed t-loop formation on the model DNA was increased 2-fold in the presence of p53 although a variety of single strand or Holliday junction-binding proteins did not facilitate t-loop formation. These results suggest that p53 has an active role in telomere maintenance and structure through association with the t-loop junction.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	jdg@med.unc.edu			NCI NIH HHS [CA70343] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; BIANCHI A, 1999, THESIS ROCKEFELLER U; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Murti KG, 1999, P NATL ACAD SCI USA, V96, P14436, DOI 10.1073/pnas.96.25.14436; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Stansel RM, 2001, EMBO J, V20, P5532; STEINMEYER K, 1988, ONCOGENE, V3, P501; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497	28	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11625	11628		10.1074/jbc.C100764200	http://dx.doi.org/10.1074/jbc.C100764200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11859067	Green Published, hybrid			2022-12-25	WOS:000174846400003
J	Shimada, H; Liu, TL; Ochiai, T; Shimizu, T; Haupt, Y; Hamada, H; Abe, T; Oka, M; Takiguchi, M; Hiwasa, T				Shimada, H; Liu, TL; Ochiai, T; Shimizu, T; Haupt, Y; Hamada, H; Abe, T; Oka, M; Takiguchi, M; Hiwasa, T			Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells	ONCOGENE			English	Article						p33(ING1); p53; gene therapy; esophageal cancer; Mdm2	CYSTEINE PROTEINASE-INHIBITORS; CANDIDATE TUMOR-SUPPRESSOR; CYCLIN-DEPENDENT KINASES; NIH3T3 MOUSE FIBROBLASTS; P53 GENE; RETINOBLASTOMA PROTEIN; POTENTIAL MEDIATOR; GROWTH CONTROL; MESSENGER-RNA; CANCER-CELLS	To investigate the effect of p33(ING1) on wild-type p53 gene therapy, T.Tn human esophageal carcinoma cells were stably transfected with p33(ING1) cDNA. Infection with Adp53 (recombinant adenovirus containing wild-type p53) into p33-transfected cells reduced cell viability, while infection with empty vector had little effect. This reduced viability was shown to be due to apoptotic cell death by the TUNEL (terminal deoxynucleotidyl transferase-mediated nick end-labeling) assay. Following infection with Ad-p53, levels of p53 were similar in p33-expressing cells and in the parental tine. However, levels of p21 and Mdm2 were elevated in p33-transfected cells. Nonetheless, this enhanced expression of Mdm2 appeared to be ineffective in downregulating p53. Transient transfection with mutant Mdm2 prior to Ad-p53 infection provided a significant protection as compared with cells transfected with wild-type Mdm2. These results imply a synergistic effect between p33 and p53 in the induction of apoptosis of human esophageal carcinoma cells. A role for Mdm2 in this synergism is suggested.	Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Acad Dept Surg, Chuo Ku, Chiba 2608670, Japan; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; Sapporo Med Univ, Dept Mol Med, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Yamaguchi Univ, Sch Med, Dept Surg 2, Yamaguchi 7558505, Japan	Chiba University; Chiba University; Hebrew University of Jerusalem; Sapporo Medical University; Yamaguchi University	Hiwasa, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	hiwasa@med.m.chiba-u.ac.jp		Haupt, Ygal/0000-0001-5925-0096				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; ASCHELE C, 1992, CANCER RES, V52, P1855; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; Bargou RC, 1996, J EXP MED, V183, P1205, DOI 10.1084/jem.183.3.1205; BENNETT WP, 1992, CANCER RES, V52, P6092; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chang YC, 2000, ONCOGENE, V19, P4713, DOI 10.1038/sj.onc.1203833; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LS, 2001, CANCER RES, V61, P4345; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Cheung KJ, 2001, CANCER RES, V61, P4974; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GORCZYCA W, 1992, INT J ONCOL, V1, P639; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Gunduz M, 2000, CANCER RES, V60, P3143; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Helbing CC, 1997, CANCER RES, V57, P1255; Hiwasa T, 1996, INT J ONCOL, V8, P125; Hiwasa T, 1996, J BIOL CHEM, V271, P9181, DOI 10.1074/jbc.271.16.9181; HIWASA T, 1987, CANCER RES, V47, P953; Hiwasa T, 1996, CANCER LETT, V99, P87, DOI 10.1016/0304-3835(95)04041-2; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HOUGHTON JA, 1986, BIOCHEM PHARMACOL, V35, P1351, DOI 10.1016/0006-2952(86)90281-9; Hsing A, 2000, J BIOL CHEM, V275, P26024, DOI 10.1074/jbc.M002455200; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kobayashi S, 1999, AM J SURG, V177, P497, DOI 10.1016/S0002-9610(99)00085-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; MIYASHITA T, 1995, CELL, V80, P293; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NABEYA Y, 1995, INT J CANCER, V64, P37, DOI 10.1002/ijc.2910640109; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohmori M, 1999, AM J HEMATOL, V62, P118; OKA M, 1995, J INTERF CYTOK RES, V15, P1005, DOI 10.1089/jir.1995.15.1005; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Oki E, 1999, CANCER LETT, V147, P157, DOI 10.1016/S0304-3835(99)00288-8; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimada H, 2001, SURG TODAY, V31, P597, DOI 10.1007/s005950170093; Shinoura N, 1999, CANCER RES, V59, P5521; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Takahashi K., 1990, JPN J ORAL MAXILLOFA, V36, P307; Tokunaga E, 2000, CANCER LETT, V152, P15, DOI 10.1016/S0304-3835(99)00434-6; Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	71	40	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1208	1216		10.1038/sj.onc.1205176	http://dx.doi.org/10.1038/sj.onc.1205176			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850840				2022-12-25	WOS:000173729400008
J	Takata, M; Tachiiri, S; Fujimori, A; Thompson, LH; Miki, Y; Hiraoka, M; Takeda, S; Yamazaoe, M				Takata, M; Tachiiri, S; Fujimori, A; Thompson, LH; Miki, Y; Hiraoka, M; Takeda, S; Yamazaoe, M			Conserved domains in the chicken homologue of BRCA2	ONCOGENE			English	Article						BRCA2; homologous recombination; Rad51; BRC repeat	DNA RECOMBINATION; RADIATION HYPERSENSITIVITY; GENE; RAD51; REPAIR; MICE; EXPRESSION; REPEATS; IDENTIFICATION; CHECKPOINT	Germline mutation of the BRCA2 gene causes a high risk of developing breast and ovarian cancer. Although the BRCA2 protein has been implicated in homologous recombination (HR) of DNA and in transcription, it is still unclear how mutation leads to tumorigenesis. We have identified a nonmammalian homologue of BRCA2 from chicken, which encodes a protein with 3397 amino acids (aa) and shows only 40% identity to human BRCA2. However, comparison of the mammalian and chicken sequences revealed remarkably high homology in several segments. These include a N-terminal region (similar to100 aa), which was previously shown to possess intrinsic transcriptional activity, and a C-terminal region (aa residue similar to2480-similar to3180 in human BRCA2), which has not been clearly assigned any function. In contrast, although the eight BRC repeats of mammalian BRCA2 are believed to play an important role in HR by interacting with Rad51, the BRC3, BRC5, and BRC6 repeats exhibit virtually no similarity to their mammalian counterparts. Among 311 missense mutations listed as unclassified variants in the NIH Breast Cancer Information Core database, only 83 of these sites are identical in chicken BRCA2. Thus, chicken BRCA2 may provide a means to identify domains and residues associated with cancer predisposition.	Kawasaki Med Sch, Dept Immunol & Mol Genet, Kurashiki, Okayama 7010192, Japan; Kyoto Univ, Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Sch Med, Dept Therapeut Radiol & Oncol, Sakyo Ku, Kyoto 6068507, Japan; Lawrence Livermore Natl Lab, BBR Program, Livermore, CA 94551 USA; Japanese Fdn Canc Res, Toshima Ku, Tokyo 1708640, Japan	Kawasaki Medical School; Kyoto University; Kyoto University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Japanese Foundation for Cancer Research	Takata, M (corresponding author), Kawasaki Med Sch, Dept Immunol & Mol Genet, 577 Matsushima, Kurashiki, Okayama 7010192, Japan.	mtakata@med.kawasaki-m.ac.jp		Takata, Minoru/0000-0002-4926-3675; Takeda, Shunichi/0000-0002-7924-7991				Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen CH, 1998, HUM MUTAT, V11, P328; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Friedman LS, 1998, CANCER RES, V58, P1338; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Futamura M, 2000, CANCER RES, V60, P1531; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; McAllister KA, 1997, CANCER RES, V57, P3121; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Morimatsu M, 1998, CANCER RES, V58, P3441; Morrison C, 2000, INT J BIOCHEM CELL B, V32, P817, DOI 10.1016/S1357-2725(00)00033-9; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Orelli BJ, 2001, ONCOGENE, V20, P4433, DOI 10.1038/sj.onc.1204485; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 2001, PHILOS T ROY SOC B, V356, P111, DOI 10.1098/rstb.2000.0755; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Wagner TMU, 1999, HUM MOL GENET, V8, P413, DOI 10.1093/hmg/8.3.413; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	37	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1130	1134		10.1038/sj.onc.1205168	http://dx.doi.org/10.1038/sj.onc.1205168			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850831				2022-12-25	WOS:000173580100017
J	Valenzuela, MT; Guerrero, R; Nunez, MI; de Almodovar, JMR; Sarker, M; de Murcia, G; Oliver, FJ				Valenzuela, MT; Guerrero, R; Nunez, MI; de Almodovar, JMR; Sarker, M; de Murcia, G; Oliver, FJ			PARP-1 modifies the effectiveness of p53-mediated DNA damage response	ONCOGENE			English	Article						PARP-1; p53-mediated DNA damage response; ionising radiation; alkylating agent	POLY(ADP-RIBOSE) POLYMERASE GENE; IONIZING-RADIATION; EXCISION-REPAIR; MICE RESISTANT; CELL-LINES; P53; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; MDM2	The tumour supressor protein p53 plays a key role in the cell's decision to arrest the cell cycle or undergo apoptosis following a genotoxic insult. p53 is stabilized and activated after DNA damage, however the cascade of events signalling from DNA lesions to p53 stabilization and activation is still controversial. Poly (ADP-ribosylation) of different nuclear acceptors by PARP-1 is an early event when a single strand DNA lesion is produced. We present here evidences that interplay between PARP-1 and p53 is dependent on the type of damage induced to DNA. Primary mouse embryonic fibroblasts derived from parp-1-/- mice exhibited decreased p53 accumulation and activation following gamma-irradiation compared to parp-1 proficient cells. On the other hand. treatment with the single alklating agent 2'-methyl-2'-nitrose-urea (MNU), resulted in the rapid and sustained accumulation and activation of p53 in parp-1-deficient cells, while very little accumulation was observed in parp-1 +/+ cells. After IR, the turnover of the p53 inhibitory protein MDM-2 is perturbed and the level of phosphorylation of p53 at serine-15 is blunted in parp-1-/- cells. PARP-1 is determinant in the cytotoxic response to alkylating agents but only partially contributes to radiation-induced cell killing, as determined by colony forming assay. Altogether, these results suggest that PARP-1 participates in the p53 response following irradiation, resides upstream of p53 and indirectly modulates the level of phosphorylation of key substrates in this pathway while treatment with MNU results in an enhanced p53-mediated response in parp-1-null cells.	Hosp Univ San Cecilio, Unidad Mixta Invest Med, Granada 18012, Spain; Univ Granada, Fac Med, Dept Radiol, Granada 18012, Spain; CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Univ Louis Pasteur Strasbourg 1, Ecole Super Biotechnol, CNRS, UPR 9003, F-67400 Illkirch Graffenstaden, France	Hospital Universitario San Cecilio; University of Granada; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Oliver, FJ (corresponding author), Hosp Univ San Cecilio, Unidad Mixta Invest Med, Avda Dr Oloriz 16, Granada 18012, Spain.		Oliver, Javier/S-1725-2018; Núñez, María Isabel/L-9924-2014	Oliver, Javier/0000-0001-8468-1998; Núñez, María Isabel/0000-0001-8159-7969; Ruiz De Almodovar Rivera, Jose Mariano/0000-0002-7053-1072				Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beneke R, 2000, MOL CELL BIOL, V20, P6695, DOI 10.1128/MCB.20.18.6695-6703.2000; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CURTIS SB, 1986, RADIAT RES, V106, P252, DOI 10.2307/3576798; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEALMODOVAR JMR, 1994, BRIT J CANCER, V69, P457, DOI 10.1038/bjc.1994.83; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Fernet M, 2000, INT J RADIAT BIOL, V76, P1621, DOI 10.1080/09553000050201118; Freedman DA, 1999, CANCER RES, V59, P1; HALL EJ, 1994, RADIOBIOLOGY RADIOLO, P29; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Menissier De Murcia Josiane, 1997, Proceedings of the National Academy of Sciences of the United States of America, V94, P7303; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Oliver FJ, 1999, AM J HUM GENET, V64, P1282, DOI 10.1086/302389; OLSON DC, 1993, ONCOGENE, V8, P2353; Schlicker A, 1999, INT J RADIAT BIOL, V75, P91, DOI 10.1080/095530099140843; STEEL GG, 1997, BASIC CLIN RADIOBIOL, P52; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wang YX, 1998, PANCREAS, V17, P289, DOI 10.1097/00006676-199810000-00011; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	37	101	104	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1108	1116		10.1038/sj.onc.1205169	http://dx.doi.org/10.1038/sj.onc.1205169			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850828				2022-12-25	WOS:000173580100014
J	Arai, Y; Kondo, T; Tanabe, K; Zhao, QL; Li, FJ; Ogawa, R; Li, M; Kasuya, M				Arai, Y; Kondo, T; Tanabe, K; Zhao, QL; Li, FJ; Ogawa, R; Li, M; Kasuya, M			Enhancement of hyperthermia-induced apoptosis by local anesthetics on human histiocytic lymphoma U937 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RANDOMIZED-TRIAL; LEUKEMIA-CELLS; MELANOMA; ATP; MITOCHONDRIA; POTENTIATION; RADIOTHERAPY; IRRADIATION; LIDOCAINE; MECHANISM	The combined effects of hyperthermia. at 44 degreesC and local anesthetics on apoptosis in human histiocytic lymphoma U937 cells were investigated. When the cells were exposed to hyperthermia for 10 min marginal DNA fragmentation and nuclear fragmentation were observed. In the presence of amide-type local anesthetics further enhancement was found depending on concentration. The order of the concentration required for maximum induction was the reverse order of the lipophilicity (prilocaine > lidocaine > bupivacaine). Western blotting revealed that in hyperthermia there was initial release of Ca2+ from the intracellular store site as indicated by increased expression of the type 1 inositol-1,4,5-trisphosphate receptor. However, the combination with lidocaine did not induce any further enhancement. Lidocaine enhanced the decrease in ATP content and the increase in intracellular Ca2+ concentration in individual cells induced by hyperthermia. In addition, superoxide formation, decrease in the mitochondrial membrane potential, and activation of intracellular caspase-3 were found in the cells treated with hyperthermia and lidocaine. All of these were suppressed in part in the presence of the intracellular Ca2+ ion chelator BAPTA-AM (bis-(O-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl). The present results indicate that local anesthetics at optimal concentrations enhance hyperthermia-induced apoptosis via Ca2+- and mitochondria-dependent pathways. Initial release of Ca2+ from intracellular store sites caused by hyperthermia and followed by the subsequent increase in the intracellular Ca2+ concentration and the additional activation of the mitochondrial caspase-dependent pathway (partly regulated by intracellular Ca2+ concentration) plays a crucial role in the enhancement of apoptosis induced by the combination of hyperthermia and lidocaine.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Radiol Sci, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Publ Hlth, Toyama 9300194, Japan	University of Toyama; University of Toyama	Kondo, T (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Radiol Sci, 2630 Sugitani, Toyama 9300194, Japan.	kondot@ms.toyama-mpu.ac.jp						Arita K, 2000, BIOCHEM PHARMACOL, V60, P905, DOI 10.1016/S0006-2952(00)00406-8; Bruno T, 1998, ONCOL RES, V10, P143; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; CLARK AW, 1983, CANCER RES, V43, P1716; COSS RA, 1989, INT J HYPERTHER, V5, P383, DOI 10.3109/02656738909140465; Eguchi Y, 1997, CANCER RES, V57, P1835; Eguchi Y, 1999, CANCER RES, V59, P2174; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GROUSELLE M, 1990, BIOCHEM J, V271, P269, DOI 10.1042/bj2710269; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HABARA Y, 1991, CELL CALCIUM, V12, P533, DOI 10.1016/0143-4160(91)90073-N; Hopcia KL, 1996, RADIAT RES, V145, P315, DOI 10.2307/3578987; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Kameda K, 2001, INT J RADIAT ONCOL, V49, P1369, DOI 10.1016/S0360-3016(01)01437-7; Karniel M, 2000, MOL GENET METAB, V69, P40, DOI 10.1006/mgme.1999.2954; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kimura C, 1998, EXP CELL RES, V239, P411, DOI 10.1006/excr.1997.3912; KINGSTON CA, 1993, ANTICANCER RES, V13, P2335; KONDO T, 1993, CELL CALCIUM, V14, P621, DOI 10.1016/0143-4160(93)90087-M; Li M, 2000, J BIOL CHEM, V275, P39702, DOI 10.1074/jbc.M007369200; MIZUNO S, 1982, CANCER RES, V42, P4726; OVERGAARD J, 1989, INT J RADIAT ONCOL, V16, P535, DOI 10.1016/0360-3016(89)90470-7; Overgaard J, 1996, INT J HYPERTHER, V12, P3, DOI 10.3109/02656739609023685; ROBINS HI, 1984, CANCER, V54, P2831, DOI 10.1002/1097-0142(19841215)54:12<2831::AID-CNCR2820541202>3.0.CO;2-8; ROBINS HI, 1983, CANCER RES, V43, P3187; SCURR C, 1990, SCI FDN ANESTHESIA, P636; Seegenschmiedt M. H., 1995, Strahlentherapie und Onkologie, V171, P560; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Senisterra GA, 2000, INT J HYPERTHER, V16, P1, DOI 10.1080/026567300285385; Sneed PK, 1998, INT J RADIAT ONCOL, V40, P287, DOI 10.1016/S0360-3016(97)00731-1; UEDA I, 1977, ANESTHESIOLOGY, V46, P327, DOI 10.1097/00000542-197705000-00004; van der Zee J, 2000, LANCET, V355, P1119, DOI 10.1016/S0140-6736(00)02059-6; VANHEERDE WL, 1995, THROMB HAEMOSTASIS, V73, P172; Vernon CC, 1996, INT J RADIAT ONCOL, V35, P731; Wessalowski R, 1998, CANCER, V82, P793, DOI 10.1002/(SICI)1097-0142(19980215)82:4<793::AID-CNCR24>3.3.CO;2-Q; YATVIN MB, 1979, SCIENCE, V205, P195, DOI 10.1126/science.451588; YAU TM, 1979, RADIAT RES, V80, P523, DOI 10.2307/3574994; Zapata JM, 1998, J BIOL CHEM, V273, P6916, DOI 10.1074/jbc.273.12.6916	39	68	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18986	18993		10.1074/jbc.M108084200	http://dx.doi.org/10.1074/jbc.M108084200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11861640	hybrid			2022-12-25	WOS:000175975800097
J	Weber, J; Wilke-Mounts, S; Senior, AE				Weber, J; Wilke-Mounts, S; Senior, AE			Quantitative determination of binding affinity of delta-subunit in Escherichia coli F-1-ATPase - Effects of mutation, Mg2+, and pH on K-d	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVITY CONFERRING PROTEIN; PROTON-TRANSLOCATING ATPASE; CROSS-LINKING; CATALYTIC SITES; ALPHA-SUBUNIT; EPSILON-SUBUNIT; B-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; MITOCHONDRIAL F1-ATPASE; ELECTRON-MICROSCOPY	To study the stator function in ATP synthase, a fluorimetric assay has been devised for quantitative determination of binding affinity of delta-subunit to Escherichia coli F-1-ATPase. The signal used is that of the natural tryptophan at residue delta28, which is enhanced by 50% upon binding of delta-subunit to alpha(3)beta(3)gammaepsilon complex. K-d for delta binding is 1.4 nM, which is energetically equivalent (50.2 kJ/mol) to that required to resist the rotor strain. Only one site for 8 binding was detected. The deltaW28L mutation increased K-d to 4.6 nM, equivalent to a loss of 2.9 kJ/mol binding energy. While this was insufficient to cause detectable functional impairment, it did facilitate preparation of delta-depleted F-1. The alphaG29D mutation reduced K-d to 26 nM, equivalent to a loss of 7.2 kJ/mol binding energy. This mutation did cause serious functional impairment, referable to interruption of binding of delta to F-1. Results with the two mutants illuminate how finely balanced is the stator resistance function. delta' fragment, consisting of residues delta1-134, bound with the same K-d as intact delta, showing that, at least in absence of F-o subunits, the C-terminal domain of 5 contributes zero binding energy. Mg2+ ions had a strong effect on increasing delta binding affinity, supporting the possibility of bridging metal ion involvement in stator function. High pH environment greatly reduced 5 binding affinity, suggesting the involvement of protonatable side-chains in the binding site.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ABRAMS A, 1976, BIOCHEM BIOPH RES CO, V69, P804, DOI 10.1016/0006-291X(76)90946-3; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Altendorf K, 2000, J EXP BIOL, V203, P19; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Capaldi RA, 2000, J EXP BIOL, V203, P29; Deckers-Hebestreit G, 2000, BBA-BIOENERGETICS, V1458, P364, DOI 10.1016/S0005-2728(00)00087-6; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1980, J BIOL CHEM, V255, P6891; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; DUPUIS A, 1985, BIOCHEMISTRY-US, V24, P734, DOI 10.1021/bi00324a030; DUPUIS A, 1985, BIOCHEMISTRY-US, V24, P728, DOI 10.1021/bi00324a029; DUPUIS A, 1987, BIOCHEMISTRY-US, V26, P410, DOI 10.1021/bi00376a011; DUPUIS A, 1983, FEBS LETT, V156, P99, DOI 10.1016/0014-5793(83)80256-7; Fillingame RH, 2000, J EXP BIOL, V203, P9; Golden TR, 1998, BIOCHEMISTRY-US, V37, P13871, DOI 10.1021/bi981120a; Hasler K, 1999, BIOCHEMISTRY-US, V38, P13759, DOI 10.1021/bi991236m; HAZARD AL, 1994, J BIOL CHEM, V269, P418; HUNDAL T, 1983, FEBS LETT, V162, P5, DOI 10.1016/0014-5793(83)81038-2; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; Junge W, 2001, FEBS LETT, V504, P152, DOI 10.1016/S0014-5793(01)02745-4; Kaim G, 1998, EMBO J, V17, P688, DOI 10.1093/emboj/17.3.688; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Ketchum CJ, 1998, BIOCHEM J, V330, P707; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUMAMOTO CA, 1986, J BIOL CHEM, V261, P37; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; MABUCHI K, 1981, BIOCHEM BIOPH RES CO, V102, P172, DOI 10.1016/0006-291X(81)91504-7; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; McLachlin DT, 2000, BIOCHEMISTRY-US, V39, P3486, DOI 10.1021/bi992586b; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; RAO R, 1988, J BIOL CHEM, V263, P5569; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SENIOR AE, 2002, IN PRESS BIOCH BIOPH; SMITH JB, 1975, J SUPRAMOL STRUCT, V2, P248; SMITH RA, 1985, BIOCHEMISTRY-US, V24, P4490, DOI 10.1021/bi00337a034; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; Vik SB, 2000, BBA-BIOENERGETICS, V1458, P457, DOI 10.1016/S0005-2728(00)00094-3; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Weber J, 2000, FEBS LETT, V483, P1, DOI 10.1016/S0014-5793(00)02071-8; WEBER J, 1992, J BIOL CHEM, V267, P1712; Weber J, 2000, BIOCHEMISTRY-US, V39, P5287, DOI 10.1021/bi992730t; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1998, BIOCHEMISTRY-US, V37, P12042, DOI 10.1021/bi981089c; WILKEMOUNTS S, 1994, ARCH BIOCHEM BIOPHYS, V309, P363, DOI 10.1006/abbi.1994.1125; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; WILKENS S, 1997, NAT STRUCT BIOL, V4, P197; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; ZIEGLER M, 1994, J BIOL CHEM, V269, P4233	62	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18390	18396		10.1074/jbc.M201047200	http://dx.doi.org/10.1074/jbc.M201047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11864990	hybrid			2022-12-25	WOS:000175975800019
J	Bowler, RP; Nicks, M; Olsen, DA; Thogersen, IB; Valnickova, Z; Hojrup, P; Franzusoff, A; Enghild, JJ; Crapo, JD				Bowler, RP; Nicks, M; Olsen, DA; Thogersen, IB; Valnickova, Z; Hojrup, P; Franzusoff, A; Enghild, JJ; Crapo, JD			Furin proteolytically processes the heparin-binding region of extracellular superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EC-SOD GENE; TRANSGENE OVEREXPRESSION; EMBRYONIC-DEVELOPMENT; MYOCARDIAL-FUNCTION; CARBOXYPEPTIDASE-E; CEREBRAL-ISCHEMIA; CELL-LINES; MUTATION; AFFINITY; SERUM	Extracellular superoxide dismutase (EC-SOD) is an antioxidant enzyme that attenuates brain and lung injury from oxidative stress. A polybasic region in the carboxyl terminus distinguishes EC-SOD from other superoxide dismutases and determines EC-SOD's tissue half-life and affinity for heparin. There are two types of EC-SOD that differ based on the presence or absence of this heparin-binding region. It has recently been shown that proteolytic removal of the heparin-binding region is an intracellular event (Enghild, J. J., Thogersen, I. B., Oury, T. D., Valnickova, Z., Hojrup, P., and Crapo, J. D. (1999) J. Biol. Chem. 274, 14818-14822). By using mammalian cell lines, we have now determined that removal of the heparin-binding region occurs after passage through the Golgi network but before being secreted into the extracellular space. Specific protease inhibitors and overexpression of intracellular proteases implicate furin as a processing protease. In vitro experiments using furin and purified EC-SOD suggest that furin proteolytically cleaves EC-SOD in the middle of the polybasic region and then requires an additional carboxypeptidase to remove the remaining lysines and arginines. A mutation in Arg(213) renders EC-SOD resistant to furin processing. These results indicate that furin-dependent processing of EC-SOD is important for determining the tissue distribution and half-life of EC-SOD.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Cell & Struct Biol, Denver, CO 80220 USA; Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus, Denmark; Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Aarhus University; University of Southern Denmark	Bowler, RP (corresponding author), Natl Jewish Med & Res Ctr, K736A,1400 Jackson St, Denver, CO 80206 USA.		Højrup, Peter/ABG-8477-2020; Bowler, Russell P/J-8283-2015	Bowler, Russell P/0000-0003-4651-363X; Enghild, Jan Johannes/0000-0001-9292-9172; Hojrup, Peter/0000-0002-7838-6180	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031992, P01HL042444] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42444, HL-31992, HL-04407] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI T, 1992, ARCH BIOCHEM BIOPHYS, V297, P155, DOI 10.1016/0003-9861(92)90654-F; Adachi T, 1996, BIOCHEM J, V313, P235, DOI 10.1042/bj3130235; ADACHI T, 1992, CLIN CHIM ACTA, V212, P89, DOI 10.1016/0009-8981(92)90176-Q; Adachi T, 1996, J BIOCHEM, V120, P184; Adachi T, 1998, BIOL PHARM BULL, V21, P1090; Bowler RP, 2001, AM J RESP CRIT CARE, V164, P290, DOI 10.1164/ajrccm.164.2.2011054; Chen EP, 1998, J THORAC CARDIOV SUR, V115, P450, DOI 10.1016/S0022-5223(98)70289-2; Chen EP, 1996, CIRCULATION, V94, P412; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; DREWS R, 1995, P NATL ACAD SCI USA, V92, P10462, DOI 10.1073/pnas.92.23.10462; Enghild JJ, 1999, J BIOL CHEM, V274, P14818, DOI 10.1074/jbc.274.21.14818; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Folz RJ, 1999, J CLIN INVEST, V103, P1055, DOI 10.1172/JCI3816; FOLZ RJ, 1994, HUM MOL GENET, V3, P2251, DOI 10.1093/hmg/3.12.2251; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; Fukai T, 1999, CIRC RES, V85, P23; HENDY GN, 1995, J BIOL CHEM, V270, P9517, DOI 10.1074/jbc.270.16.9517; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; KALRA J, 1992, MOL CELL BIOCHEM, V110, P165, DOI 10.1007/BF02454194; KARLSSON K, 1993, BIOCHEM J, V290, P623, DOI 10.1042/bj2900623; KARLSSON K, 1994, LAB INVEST, V70, P705; KARLSSON K, 1993, FREE RADICAL BIO MED, V14, P185, DOI 10.1016/0891-5849(93)90009-J; Lookene A, 2000, BIOCHEMISTRY-US, V39, P230, DOI 10.1021/bi991512x; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; Marklund SL, 1997, J INTERN MED, V242, P5, DOI 10.1046/j.1365-2796.1997.00160.x; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; Nabarra B, 1997, MECH AGEING DEV, V96, P59, DOI 10.1016/S0047-6374(97)01892-7; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nakayama T, 2000, CELL MOL LIFE SCI, V57, P943, DOI 10.1007/PL00000736; Nozik-Grayck E, 2000, AM J PHYSIOL-LUNG C, V279, pL977, DOI 10.1152/ajplung.2000.279.5.L977; OURY TD, 1994, LAB INVEST, V70, P889; Oury TD, 1996, BIOCHEM J, V317, P51, DOI 10.1042/bj3170051; Oury TD, 1999, BRAIN RES, V850, P96, DOI 10.1016/S0006-8993(99)02103-4; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; SALVESEN G, 1991, BIOMED BIOCHIM ACTA, V50, P665; SALVESEN G, 1989, PROTEOLYTIC ENZYMES, P259; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; Sheng H, 2000, EXP NEUROL, V163, P392, DOI 10.1006/exnr.2000.7363; Sheng HX, 1999, NEUROSCI LETT, V267, P13, DOI 10.1016/S0304-3940(99)00316-X; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; Varlamov O, 1999, J BIOL CHEM, V274, P14040, DOI 10.1074/jbc.274.20.14040; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Yamada H, 2000, NEPHRON, V84, P218, DOI 10.1159/000045580; Yamada H, 1997, JPN J HUM GENET, V42, P353, DOI 10.1007/BF02766958	47	54	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16505	16511		10.1074/jbc.M105409200	http://dx.doi.org/10.1074/jbc.M105409200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861638	hybrid			2022-12-25	WOS:000175564500024
J	Lu, RQ; Moore, PA; Pitha, PM				Lu, RQ; Moore, PA; Pitha, PM			Stimulation of IRF-7 gene expression by tumor necrosis factor alpha - Requirement for NF kappa B transcription factor and gene accessibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR; POSITIVE FEEDBACK; SWI/SNF COMPLEX; ACTIVATION; SEQUENCE; DISTINCT; REGION; 11P15; IDENTIFICATION; RECRUITMENT	Interferon regulatory factor 7 (IRF-7) plays an important role in innate immunity, where, together with IRF-3, it controls the expression of interferon A/B genes as well as chemokine RANTES (regulated on activation normal T cell expressed and secreted). Previously, we characterized human IRF-7 promoter and showed that an interferon-stimulated response element site in the first intron binds interferon-stimulated gene factor 3 (ISGF3) and confers the response to interferon. Here we report the stimulation of IRF-7 expression by 12-O-tetradecanoylphorbol-13-acetate (TPA) and tumor necrosis factor alpha (TNFalpha) in human peripheral blood monocytes. Using promoter analysis in combination with electrophoretic mobility shift assays, we have demonstrated that an NFkappaB site located next to the TATA box, binds p50 and p65 heterodimer and is required for the induction of the IRF-7 gene by TPA and TNFalpha. In addition, we report stimulation of IRF-7 gene expression by topoisomerase II (TOPII) inhibitors. We show by chromatin immunoprecipitation assay that treatment with the TOPII inhibitor etoposide induces association of acetylated histone 3 with the promoter of IRF-7 gene, indicating that TOPII-mediated changes in chromatin structure could be responsible for the induction. This suggests that the IRF-7 gene is localized in the condensed area of the chromosome where it is inaccessible to transcription factors that would promote its constitutive expression.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; GlaxoSmithKline; Human Genome Sciences Inc	Pitha, PM (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Bunting & Blaustein Canc Res Bldg,Rm 351,1650 Orl, Baltimore, MD 21231 USA.	parowe@jhmi.edu			NIAID NIH HHS [AI19737-19] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI019737, R01AI019737] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Au WC, 2001, J BIOL CHEM, V276, P41629, DOI 10.1074/jbc.M105121200; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Boland MP, 2000, J BIOL CHEM, V275, P25231, DOI 10.1074/jbc.275.33.25231; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Collins I, 2001, MOL CELL BIOL, V21, P8437, DOI 10.1128/MCB.21.24.8437-8451.2001; Feinberg AP, 1999, CANCER RES, V59, p1743S; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; Hu RJ, 1997, GENOMICS, V46, P9, DOI 10.1006/geno.1997.4981; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karnik P, 1998, ONCOGENE, V17, P237, DOI 10.1038/sj.onc.1201959; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lowther WJ, 1999, DNA CELL BIOL, V18, P685, DOI 10.1089/104454999314962; Lu RQ, 2000, P NATL ACAD SCI USA, V97, P3993, DOI 10.1073/pnas.97.8.3993; Lu RQ, 2001, J BIOL CHEM, V276, P45491, DOI 10.1074/jbc.C100421200; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Onyango P, 2000, GENOME RES, V10, P1697, DOI 10.1101/gr.161800; Paris MJ, 2000, GENOMICS, V69, P196, DOI 10.1006/geno.2000.6339; PETERSON G, 1995, J NUTR, V125, pS784, DOI 10.1093/jn/125.suppl_3.784S; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schwienbacher C, 1998, P NATL ACAD SCI USA, V95, P3873, DOI 10.1073/pnas.95.7.3873; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tsai SC, 2000, NAT GENET, V26, P349, DOI 10.1038/81671; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yeow WS, 2001, J VIROL, V75, P3021, DOI 10.1128/JVI.75.6.3021-3027.2001; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang LW, 2000, J VIROL, V74, P1061, DOI 10.1128/JVI.74.3.1061-1068.2000	45	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16592	16598		10.1074/jbc.M111440200	http://dx.doi.org/10.1074/jbc.M111440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877397	hybrid			2022-12-25	WOS:000175564500035
J	Paine, ML; Lei, YP; Dickerson, K; Snead, ML				Paine, ML; Lei, YP; Dickerson, K; Snead, ML			Altered amelogenin self-assembly based on mutations observed in human X-linked amelogenesis imperfecta (AIH1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INTERACTIONS; PORCINE AMELOGENIN; SECRETORY-STAGE; ENAMEL; NANOSPHERES	A hallmark of biological systems is a reliance on protein assemblies to perform complex functions. We have focused attention on mammalian enamel formation because it relies on a self-assembling protein complex to direct mineral habit. The principle protein of enamel is amelogenin, a 180-amino acid hydrophobic protein that self-assembles to form nanospheres. We have used independent technical methods, consisting of the yeast two-hybrid (Y2H) assay and surface plasmon resonance (SPR), to demonstrate the importance of amelogenin self-assembly domains. In addition, we have analyzed mutations in amelogenin observed in patients with amelogenesis imperfecta who demonstrate defects in enamel formation. Assessments of self-assembly of these mutant amelogenins by either SPR or Y2H assay yield concordant data. These data support the conclusion that the amelogenin amino-terminal self-assembly domain is essential to the creation of an enamel extracellular organic matrix capable of directing mineral formation. It also suggests that a pathway through which point mutations in the amelogenin protein can adversely impact on the formation of the enamel organ is by disturbing self-assembly of the organic matrix. These data support the utilization of the Y2H assay to search for protein interactions among extracellular matrix proteins that contribute to biomineralization and provide functional information on protein-protein and protein-mineral interactions.	Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Biacore Inc, San Diego, CA 92121 USA	University of Southern California	Paine, ML (corresponding author), Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, 2250 Alcazar St,CSA Room 142, Los Angeles, CA 90033 USA.	paine@hsc.usc.edu			NIDCR NIH HHS [DE13404, DE13405] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013405, R01DE013404] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AOBA T, 1987, CALCIFIED TISSUE INT, V41, P86, DOI 10.1007/BF02555250; Bartlett JD, 1999, CRIT REV ORAL BIOL M, V10, P425, DOI 10.1177/10454411990100040101; FINCHAM AG, 1995, J STRUCT BIOL, V115, P50, DOI 10.1006/jsbi.1995.1029; FINCHAM AG, 1994, CALCIFIED TISSUE INT, V55, P398, DOI 10.1007/BF00299322; GOTO Y, 1993, J BIOCHEM-TOKYO, V113, P55, DOI 10.1093/oxfordjournals.jbchem.a124003; Kirkham J, 2000, J DENT RES, V79, P1943, DOI 10.1177/00220345000790120401; Korneeva NL, 2001, J BIOL CHEM, V276, P2872, DOI 10.1074/jbc.M006345200; LENCH NJ, 1995, HUM MUTAT, V5, P251, DOI 10.1002/humu.1380050310; Moradian-Oldak J, 2000, J STRUCT BIOL, V131, P27, DOI 10.1006/jsbi.2000.4237; Nielsen VH, 2000, MAMM GENOME, V11, P1087, DOI 10.1007/s003350010212; Paine ML, 1998, J DENT RES, V77, P496, DOI 10.1177/00220345980770030901; Paine ML, 1997, J BONE MINER RES, V12, P221, DOI 10.1359/jbmr.1997.12.2.221; Paine ML, 2000, J STRUCT BIOL, V132, P191, DOI 10.1006/jsbi.2000.4324; Ravassipour DB, 2000, J DENT RES, V79, P1476, DOI 10.1177/00220345000790070801; Sarikaya M, 1999, P NATL ACAD SCI USA, V96, P14183, DOI 10.1073/pnas.96.25.14183; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; TERMINE JD, 1980, BIOPOLYMERS, V19, P741, DOI 10.1002/bip.1980.360190403; Wen HB, 2001, MATRIX BIOL, V20, P387, DOI 10.1016/S0945-053X(01)00144-5; White SN, 2000, J AM CERAM SOC, V83, P238, DOI 10.1111/j.1151-2916.2000.tb01181.x	19	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17112	17116		10.1074/jbc.M110473200	http://dx.doi.org/10.1074/jbc.M110473200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877393	hybrid			2022-12-25	WOS:000175564500103
J	Hayward, LJ; Rodriguez, JA; Kim, JW; Tiwari, A; Goto, JJ; Cabelli, DE; Valentine, JS; Brown, RH				Hayward, LJ; Rodriguez, JA; Kim, JW; Tiwari, A; Goto, JJ; Cabelli, DE; Valentine, JS; Brown, RH			Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALS-LINKED SOD1; WILD-TYPE; CU,ZN-SUPEROXIDE DISMUTASE; ZINC; COPPER; MUTATIONS; DISEASE; BINDING; MICE; GENE	Over 90 different mutations in the gene encoding copper/zinc superoxide dismutase (SOD1) cause similar to2% of amyotrophic lateral sclerosis (ALS) cases by an unknown mechanism. We engineered 14 different human ALS-related SOD1 mutants and obtained high yields of biologically metallated proteins from an Sf21 insect cell expression system. Both the wild type and mutant "as isolated" SOD1 variants were deficient in copper and were heterogeneous by native gel electrophoresis. By contrast, although three mutant SOD1s with substitutions near the metal binding sites (H46R, G85R, and D124V) were severely deficient in both copper and zinc ions, zinc deficiency was not a consistent feature shared by the as isolated mutants. Eight mutants (A4V, L38V, G41S, G72S, D76Y, D90A, G93A, and E133Delta) exhibited normal SOD activity over pH 5.5-10.5, per equivalent of copper, consistent with the presumption that bound copper was in the proper metal-binding site and was fully active. The H48Q variant contained a high copper content yet was 100-fold less active than the wild type enzyme and exhibited a blue shift in the visible absorbance peak of bound Cu(II), indicating rearrangement of the Cu(II) coordination geometry. Further characterization of these as-isolated SOD1 proteins may provide new insights regarding mutant SOD1 enzyme toxicity in ALS.	Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles; Harvard University; Massachusetts General Hospital; United States Department of Energy (DOE); Brookhaven National Laboratory	Hayward, LJ (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol, 55 Lake Ave N, Worcester, MA 01655 USA.	Lawrence.Hayward@umassmed.edu	Tiwari, Ashutosh/A-7458-2008; Valentine, Joan S/B-6665-2008	Tiwari, Ashutosh/0000-0001-7373-349X; Valentine, Joan S/0000-0002-7174-925X; Hayward, Lawrence/0000-0003-0579-0358	NIGMS NIH HHS [GM28222] Funding Source: Medline; NINDS NIH HHS [P01NS37912, P01NS31248] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037912, P01NS031248] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANCI L, 1991, EUR J BIOCHEM, V196, P123, DOI 10.1111/j.1432-1033.1991.tb15794.x; Beckman JS, 2001, TRENDS NEUROSCI, V24, pS15, DOI 10.1016/S0166-2236(00)01981-0; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BROWN RH, 1995, CELL, V80, P687, DOI 10.1016/0092-8674(95)90346-1; Brown RH, 1995, CURR OPIN NEUROBIOL, V5, P841, DOI 10.1016/0959-4388(95)80114-6; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Cabelli DE, 2000, BIOMIMETIC OXIDATIONS CATALYZED BY TRANSITION METAL COMPLEXES, P461, DOI 10.1142/9781848160699_0010; Cafe C, 2000, J MOL NEUROSCI, V15, P71, DOI 10.1385/JMN:15:2:71; CARRI MT, 1994, FEBS LETT, V356, P314, DOI 10.1016/0014-5793(94)01295-4; Cleveland DW, 2000, NAT MED, V6, P1320, DOI 10.1038/82122; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Crow JP, 1997, J NEUROCHEM, V69, P1936; Cudkowicz ME, 1997, ANN NEUROL, V41, P210, DOI 10.1002/ana.410410212; DalCanto MC, 1997, ACTA NEUROPATHOL, V93, P537; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; Ellerby LM, 1996, J AM CHEM SOC, V118, P6556, DOI 10.1021/ja953845x; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FUJII J, 1995, J NEUROCHEM, V64, P1456; Gaudette M, 2000, AMYOTROPH LATERAL SC, V1, P83, DOI 10.1080/14660820050515377; Goto JJ, 1998, J BIOL CHEM, V273, P30104, DOI 10.1074/jbc.273.46.30104; Goto JJ, 2000, J BIOL CHEM, V275, P1007, DOI 10.1074/jbc.275.2.1007; GRADEN JA, 1994, J AM CHEM SOC, V116, P9743, DOI 10.1021/ja00100a047; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hart PJ, 1999, BIOCHEMISTRY-US, V38, P2167, DOI 10.1021/bi982284u; Hart PJ, 1998, PROTEIN SCI, V7, P545; Hosler BA, 1996, NEUROMUSCULAR DISORD, V6, P361, DOI 10.1016/0960-8966(96)00353-7; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jaarsma D, 2000, NEUROBIOL DIS, V7, P623, DOI 10.1006/nbdi.2000.0299; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; KLUG D, 1972, J BIOL CHEM, V247, P4839; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V346, P263, DOI 10.1006/abbi.1997.0298; Liochev SI, 2000, J BIOL CHEM, V275, P38482, DOI 10.1074/jbc.M007891200; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; Lyons TJ, 2000, J BIOL INORG CHEM, V5, P189, DOI 10.1007/s007750050363; Marklund SL, 1997, J NEUROCHEM, V69, P675; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PANTOLIANO MW, 1982, J INORG BIOCHEM, V17, P325, DOI 10.1016/S0162-0134(00)80093-8; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUBRAMANIAM JR, 2000, SOC NEUR ABSTR, V26; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WILLIAMSON TL, 2000, SCIENCE, V288, pA399; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; WONG PC, 1995, CURR OPIN NEUROL, V8, P294, DOI 10.1097/00019052-199508000-00008; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	55	292	297	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15923	15931		10.1074/jbc.M112087200	http://dx.doi.org/10.1074/jbc.M112087200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854284	hybrid			2022-12-25	WOS:000175510400095
J	Nasdala, I; Wolburg-Buchholz, K; Wolburg, H; Kuhn, A; Ebnet, K; Brachtendorf, G; Samulowitz, U; Kuster, B; Engelhardt, B; Vestweber, D; Butz, S				Nasdala, I; Wolburg-Buchholz, K; Wolburg, H; Kuhn, A; Ebnet, K; Brachtendorf, G; Samulowitz, U; Kuster, B; Engelhardt, B; Vestweber, D; Butz, S			A transmembrane tight junction protein selectively expressed on endothelial cells and platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE JAM; BLOOD-BRAIN-BARRIER; IMMUNOGLOBULIN SUPERFAMILY; IN-VIVO; POLYACRYLAMIDE GELS; MEMBRANE-PROTEIN; OCCLUDIN; IDENTIFICATION; RECRUITMENT; RECEPTOR	Searching for cell surface proteins expressed at interendothelial cell contacts, we have raised monoclonal antibodies against intact mouse endothelial cells. We obtained two monoclonal antibodies, 1G8 and 4C10, that stain endothelial cell contacts and recognize a protein of 55 kDa. Purification and identification by mass spectrometry of this protein revealed that it contains two extracellular Ig domains, reminiscent of the JAM family, but a much longer 120-amino acid cytoplasmic domain. The antigen is exclusively expressed on endothelial cells of various organs as was analyzed by immunohistochemistry. Immunogold labeling of ultrathin sections of brain as well as skeletal muscle revealed that the antigen strictly colocalizes in capillaries with the tight junction markers occludin, claudin-5, and ZO-1. Upon transfection into MDCK cells, the antigen was restricted to the most apical tip of the lateral cell surface, where it colocalized with ZO-1 but not with beta-catenin. In contrast to JAM-1, however, the 1G8 antigen does not associate with the PDZ domain proteins ZO-1, AF-6, or ASIP/PAR-3, despite the presence of a PDZ-binding motif. The 1G8 antigen was not detected on peripheral blood mouse leukocytes, whereas similar to JAM-1 it was strongly expressed on platelets and megakaryocytes. The 1G8 antigen supports homophilic interactions on transfected Chinese hamster ovary cells. Based on the similarity to the JAM molecules, it is plausible that the 1G8 antigen might be involved in interendothelial cell adhesion.	Univ Munster, ZMBE, Inst Cell Biol, D-48149 Munster, Germany; Max Planck Inst, D-69117 Heidelberg, Germany; Cellzome AG, D-72076 Tubingen, Germany; Univ Tubingen, Inst Pathol, D-7400 Tubingen, Germany	University of Munster; Max Planck Society; GlaxoSmithKline; Cellzome GmbH; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Vestweber, D (corresponding author), Univ Munster, ZMBE, Inst Cell Biol, Von Esmarch Str 56, D-48149 Munster, Germany.		Engelhardt, Britta/K-7267-2014; Ebnet, Klaus T/C-8314-2009; Kuster, Bernhard/Q-6031-2016	Engelhardt, Britta/0000-0003-3059-9846; Ebnet, Klaus T/0000-0002-0417-7888; Kuster, Bernhard/0000-0002-9094-1677; Vestweber, Dietmar/0000-0002-3517-732X				ANDERSON JM, 1995, AM J PHYSIOL, V269, P467; Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Aurrand-Lions MA, 2000, CURR TOP MICROBIOL, V251, P91; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; Dejana E, 2000, INT J DEV BIOL, V44, P743; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Frenette PS, 2000, J EXP MED, V191, P1413, DOI 10.1084/jem.191.8.1413; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; GEKLE M, 1994, PFLUG ARCH EUR J PHY, V428, P157, DOI 10.1007/BF00374853; Gotsch U, 1997, J CELL SCI, V110, P583; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hirata K, 2001, J BIOL CHEM, V276, P16223, DOI 10.1074/jbc.M100630200; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Jensen ON, 1997, ANAL CHEM, V69, P4741, DOI 10.1021/ac970896z; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Liebner S, 2000, ACTA NEUROPATHOL, V100, P323, DOI 10.1007/s004010000180; Liu Y, 2000, J CELL SCI, V113, P2363; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Morgan SM, 1999, BLOOD, V93, P165, DOI 10.1182/blood.V93.1.165.401k25_165_175; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; NAIK UP, 1995, BIOCHEM J, V310, P155, DOI 10.1042/bj3100155; Ozaki H, 2000, BIOCHEM BIOPH RES CO, V276, P873, DOI 10.1006/bbrc.2000.3574; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; SCHULZE C, 1993, J CELL SCI, V104, P773; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sobocka MB, 2000, BLOOD, V95, P2600; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Vestweber D, 2000, J PATHOL, V190, P281; Williams LA, 1999, MOL IMMUNOL, V36, P1175, DOI 10.1016/S0161-5890(99)00122-4; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WUNSCH S, 1995, J CELL PHYSIOL, V164, P164, DOI 10.1002/jcp.1041640121	46	161	164	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16294	16303		10.1074/jbc.M111999200	http://dx.doi.org/10.1074/jbc.M111999200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11847224	hybrid			2022-12-25	WOS:000175510400140
J	Pascolo, E; Wenz, C; Lingner, J; Hauel, N; Priepke, H; Kauffmann, I; Garin-Chesa, P; Rettig, WJ; Damm, K; Schnapp, A				Pascolo, E; Wenz, C; Lingner, J; Hauel, N; Priepke, H; Kauffmann, I; Garin-Chesa, P; Rettig, WJ; Damm, K; Schnapp, A			Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; HUMAN TUMOR-CELLS; NONNUCLEOSIDE INHIBITORS; CATALYTIC SUBUNIT; RNA COMPONENT; HUMAN CANCER; RECONSTITUTION; PROCESSIVITY; DNA	Telomerase, a ribonucleoprotein acting as a reverse transcriptase, has been identified as a target for cancer drug discovery. The synthetic, non-nucleosidic compound, BIBR1532, is a potent and selective telomerase inhibitor capable of inducing senescence in human cancer cells (1). In the present study, the mode of drug action was characterized. BIBR1532 inhibits the native and recombinant human telomerase, comprising the human telomerase reverse transcriptase and human telomerase RNA components, with similar potency primarily by interfering with the processivity of the enzyme. Enzyme-kinetic experiments show that BIBR1532 is a mixed-type non-competitive inhibitor and suggest a drug binding site distinct from the sites for deoxyribonucleotides and the DNA primer, respectively. Thus, BIBR1532 defines a novel class of telomerase inhibitor with mechanistic similarities to non-nucleosidic inhibitors of HIV1 reverse transcriptase.	Boehringer Ingelheim Pharma KG, Dept Med Chem, D-88397 Biberach, Germany; Boehringer Ingelheim Pharma KG, Dept Oncol Res, D-88397 Biberach, Germany; Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Boehringer Ingelheim Austria GmbH, A-1120 Vienna, Austria	Boehringer Ingelheim; Boehringer Ingelheim; Swiss Institute Experimental Cancer Research; Boehringer Ingelheim	Schnapp, A (corresponding author), Boehringer Ingelheim Pharma KG, Dept Oncol Res, Birkendorfer Str 65, D-88397 Biberach, Germany.			Lingner, Joachim/0000-0002-2853-5803				Bachand F, 1999, J BIOL CHEM, V274, P38027, DOI 10.1074/jbc.274.53.38027; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Bisoffi M, 1998, EUR J CANCER, V34, P1242, DOI 10.1016/S0959-8049(98)00049-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bosoy D, 2001, J BIOL CHEM, V276, P46305, DOI 10.1074/jbc.M108168200; Bryan TM, 2000, J BIOL CHEM, V275, P24199, DOI 10.1074/jbc.M003246200; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; Fletcher TM, 1996, BIOCHEMISTRY-US, V35, P15611, DOI 10.1021/bi961228v; Ford LP, 2000, MOL CELL BIOL, V20, P9084, DOI 10.1128/MCB.20.23.9084-9091.2000; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Gu ZX, 1995, J BIOL CHEM, V270, P31046, DOI 10.1074/jbc.270.52.31046; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miller MC, 2000, EMBO J, V19, P4412, DOI 10.1093/emboj/19.16.4412; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Peng Y, 2001, MOL CELL, V7, P1201, DOI 10.1016/S1097-2765(01)00268-4; Quan YD, 1998, NUCLEIC ACIDS RES, V26, P5692, DOI 10.1093/nar/26.24.5692; Schnapp G, 1998, NUCLEIC ACIDS RES, V26, P3311, DOI 10.1093/nar/26.13.3311; Segel IH., 1993, ENZYME KINETICS BEHA; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Strahl C, 1996, MOL CELL BIOL, V16, P53; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; Tendian SW, 2000, MOL PHARMACOL, V57, P695, DOI 10.1124/mol.57.4.695; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	40	210	226	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15566	15572		10.1074/jbc.M201266200	http://dx.doi.org/10.1074/jbc.M201266200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854300	hybrid			2022-12-25	WOS:000175510400047
J	Susa, M; Sen, R; Shimamoto, N				Susa, M; Sen, R; Shimamoto, N			Generality of the branched pathway in transcription initiation by Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-R PROMOTER; ABORTIVE TRANSCRIPTION; CONSERVED REGION-3; TERNARY COMPLEXES; CHAIN ELONGATION; T7 DNA; SIGMA(70); ENZYME; MECHANISM; STAGE	Transcription initiation has been assumed to be a multi-step sequential process, although additional steps could exist. Initiation from the T7A1 promoter, in particular, apparently behaves in vitro in a manner that can be fully explained by the sequential pathway. However, initiation from the lambdaP(R)AL promoter has been shown to follow a branched pathway from which a part of the enzyme-promoter complex is arrested at the promoter raising the question as to which mechanism is general. We found that a moribund complex, characteristic of the arrested branch, is formed at the T7A1 promoter, especially in low salt condition indicating that the initiation mechanism for this promoter is also branched. The results of DNA footprinting suggested that holoenzyme in the moribund complex is dislocated on DNA from the position of productive complex. However, only a small fraction of the binary complex becomes arrested at this promoter, and the interconversion between subspecies of binary complex is apparently more reversible than at the APAL promoter, which explains why the reaction pathway appears to be sequential. These findings suggest a generality of the branched pathway mechanism, which would resolve contradictory observations that have been reported for various promoters.	Natl Inst Genet, Struct Biol Ctr, Mishima, Shizuoka 4118540, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Genet, Mishima, Shizuoka 4118540, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan	Shimamoto, N (corresponding author), Natl Inst Genet, Struct Biol Ctr, 1111 Yata, Mishima, Shizuoka 4118540, Japan.		Susa, Motoki/D-5416-2012; Shimamoto, Nobuo/AAJ-4999-2020	Shimamoto, Nobuo/0000-0001-7579-0084				ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FUJIOKA M, 1991, BIOCHEMISTRY-US, V30, P1801, DOI 10.1021/bi00221a011; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Hernandez VJ, 1996, J BIOL CHEM, V271, P18775, DOI 10.1074/jbc.271.31.18775; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; Kubori T, 1997, NUCLEIC ACIDS RES, V25, P2640, DOI 10.1093/nar/25.13.2640; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; METZGER W, 1993, J MOL BIOL, V232, P35, DOI 10.1006/jmbi.1993.1368; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Nagai H, 1997, GENES CELLS, V2, P725, DOI 10.1046/j.1365-2443.1997.1600357.x; NIERMAN WC, 1979, J BIOL CHEM, V254, P7921; OEN H, 1979, BIOCHEMISTRY-US, V18, P4148, DOI 10.1021/bi00586a015; Owens JT, 1998, BIOCHEMISTRY-US, V37, P7670, DOI 10.1021/bi980188n; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; Sen R, 2001, GENES CELLS, V6, P389, DOI 10.1046/j.1365-2443.2001.00436.x; Sen R, 2000, J BIOL CHEM, V275, P10899, DOI 10.1074/jbc.275.15.10899; Sen R, 1998, J BIOL CHEM, V273, P9872, DOI 10.1074/jbc.273.16.9872; SHIMAMOTO N, 1981, BIOCHEMISTRY-US, V20, P4745, DOI 10.1021/bi00519a034; SMAGOWICZ WJ, 1978, NUCLEIC ACIDS RES, V5, P1919, DOI 10.1093/nar/5.6.1919; STAHL SJ, 1977, J MOL BIOL, V112, P577, DOI 10.1016/S0022-2836(77)80165-4; Tagami H, 1998, EMBO J, V17, P1759, DOI 10.1093/emboj/17.6.1759; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; ZHOU YN, 1992, J BACTERIOL, V174, P5005, DOI 10.1128/JB.174.15.5005-5012.1992	28	27	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15407	15412		10.1074/jbc.M112481200	http://dx.doi.org/10.1074/jbc.M112481200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854291	hybrid			2022-12-25	WOS:000175510400025
J	Tsuruta, F; Masuyama, N; Gotoh, Y				Tsuruta, F; Masuyama, N; Gotoh, Y			The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; NF-KAPPA-B; CYTOCHROME-C RELEASE; PROTEIN-KINASE B; SURVIVAL SIGNALS; CELL-DEATH; NITRIC-OXIDE; APOPTOSIS; AKT; CYTOSOL	Bax, a proapoptotic member of the Bcl-2 family, localizes largely in the cytoplasm but redistributes to mitochondria in response to apoptotic stimuli, where it induces cytochrome c release. In this study, we show that the phosphatidylinositol 3-OH kinase (PI3K)-Akt pathway plays an important role in the regulation of Bax subcellular localization. We found that LY294002, a PI3K inhibitor, blocked the effects of serum to prevent Bax translocation to mitochondria and that expression of an active form of PI3K suppressed staurosporine-induced Bax translocation, suggesting that PI3K activity is essential for retaining Bax in the cytoplasm. In contrast, both U0126, a MEK inhibitor, and active MEK had little effect on Bax localization. In respect to downstream effectors of PI3K, we found that expression of active Akt, but not serum and glucocorticoid-induced protein kinase (SGK), suppressed staurosporine-induced translocation of Bax, whereas dominant negative Akt moderately promoted Bax translocation. Expression of Akt did not alter the levels of Bax, Bcl-2, Bcl-X-L, or phosphorylated JNK under the conditions used, suggesting that there were alternative mechanisms for Akt in the suppression of Bax translocation. Collectively, these results suggest that the PI3K-Akt pathway inhibits Bax translocation from cytoplasm to mitochondria and have revealed a novel mechanism by which the PI3K-Akt pathway promotes survival.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Gotoh, Y (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ygotoh@iam.u-tokyo.ac.jp						Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; delPeso L, 1997, SCIENCE, V278, P687; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Gao CF, 2001, EXP CELL RES, V265, P145; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kanuka H, 1999, P NATL ACAD SCI USA, V96, P145, DOI 10.1073/pnas.96.1.145; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Leverrier Y, 1999, CELL DEATH DIFFER, V6, P290, DOI 10.1038/sj.cdd.4400492; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nomura M, 1999, CANCER RES, V59, P5542; Ozes ON, 1999, NATURE, V401, P82; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tsui-Pierchala BA, 2000, J NEUROSCI, V20, P7228; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	51	312	323	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14040	14047		10.1074/jbc.M108975200	http://dx.doi.org/10.1074/jbc.M108975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11842081	hybrid			2022-12-25	WOS:000175096000090
J	Xia, H; Qi, HL; Li, YF; Pei, J; Barton, J; Blackstad, M; Xu, T; Tao, WF				Xia, H; Qi, HL; Li, YF; Pei, J; Barton, J; Blackstad, M; Xu, T; Tao, WF			LATS1 tumor suppressor regulates G2/M transition and apoptosis	ONCOGENE			English	Article						LATS1; tumor suppressor; G2/M transition; apoptosis	HUMAN BREAST-CANCER; CELL-CYCLE ARREST; PROTEIN-KINASE; MITOTIC APPARATUS; GENE; P53; MITOSIS; ENCODES; HOMOLOG; MICE	The LATS1 gene is a mammalian member of the novel lats tumor suppressor family. Both lats mosaic flies and LATS1 deficient mice spontaneously develop tumors. Our previous studies have shown that inactivation of Drosophila lats leads to up-regulation of cyclin A in the fly, and the human LATS1 protein associates with CDC2 in early mitosis in HeLa cells, suggesting that the lats gene family may negatively regulate cell proliferation by modulating CDC2/Cyclin A activity. We demonstrate here that transduction of the human breast cancer cell MCF-7 with recombinant LATS1 adenovirus (Ad-LATS1), but not with EGFP adenovirus (Ad-EGFP), inhibits in vitro cell proliferation. Ectopic expression of LATS1 in MCF-7 cells specifically downregulates Cyclin A and Cyclin B protein levels and dramatically reduces CDC2 kinase activity, leading to a G2/M blockade. Furthermore, Ad-LATS] suppresses anchorage-independent growth of MCF-7 cells in soft agar and tumor formation in athymic nude mice. We also demonstrate that ectopic expression of LATS1 in MCF-7 cells and human lung cancer cell H460 upregulates the level of BAX proteins and induces apoptosis. Finally, we show that LATS1 kinase activity is required for its ability to inhibit cell growth and induce apoptosis. The results indicate that the LATS1 tumor suppressor may play an important role in the control of human tumor development and that LATS1 suppresses tumorigenesis by negatively regulating cell proliferation and modulating cell survival.	Univ Minnesota, Ctr Canc, Div Hematol Oncol & Transplantat, Stem Cell Inst, Minneapolis, MN 55455 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06536 USA	University of Minnesota System; University of Minnesota Twin Cities; Yale University	Tao, WF (corresponding author), Univ Minnesota, Ctr Canc, Div Hematol Oncol & Transplantat, Stem Cell Inst, Minneapolis, MN 55455 USA.							Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gaumann A, 2001, CANCER-AM CANCER SOC, V92, P1237, DOI 10.1002/1097-0142(20010901)92:5<1237::AID-CNCR1443>3.0.CO;2-E; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; LEE JH, 1990, CANCER RES, V50, P2724; Mazurenko N, 1999, ONCOL REP, V6, P859; MIYASHITA T, 1995, CELL, V80, P293; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morinaga N, 2000, INT J ONCOL, V17, P1125; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Theile M, 1996, ONCOGENE, V13, P677; Turenchalk GS, 1999, BBA-REV CANCER, V1424, pM9, DOI 10.1016/S0304-419X(99)00021-9; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	35	129	133	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1233	1241		10.1038/sj.onc.1205174	http://dx.doi.org/10.1038/sj.onc.1205174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850843				2022-12-25	WOS:000173729400011
J	Thornborrow, EC; Patel, S; Mastropietro, AE; Schwartzfarb, EM; Manfredi, JJ				Thornborrow, EC; Patel, S; Mastropietro, AE; Schwartzfarb, EM; Manfredi, JJ			A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes	ONCOGENE			English	Article						bax; p53; transcription; DNA-binding	TUMOR-SUPPRESSOR P53; CYTOCHROME-C; CELL-DEATH; IN-VIVO; BINDING-SITE; APOPTOSIS; SEQUENCE; PROMOTER; PROTEIN; OVEREXPRESSION	Both the human and the mouse bax promoters contain p53 binding sites which are sufficient to confer p53-dependent transcriptional activation in a heterologous setting. Nevertheless in the context of the bax promoter, these sites do not mediate a p53-dependent response, suggesting that bax may not be a direct transcriptional target of p53. Here, data are presented identifying a conserved p53 response element in the first intron of both the human and the murine bax genes. This element both in isolation and in the context of the first intron conferred p53-dependent transcriptional activation upon a minimal promoter. Electrophoretic mobility shift assays demonstrated that this sequence also is capable of mediating sequence specific binding to p53. p53 effectively activated transcription through both human and murine bax gene reporter constructs, whereas deletion of the intronic response element abrogated the p53-responsiveness of both reporters. Interestingly, tumor-derived mutants of p53 which are defective in inducing an apoptotic response retain the ability to activate transcription via the bax intronic p53 site. Since these mutants are transcriptionally inactive on the p53 site in the bax promoter, the ability of these mutants to up-regulating endogenous bax mRNA levels supports a role for the intronic element in p53-dependent up-regulation of bax expression. Taken together, these results show the requirement for a novel intronic element in the p53-dependent transcriptional activation of bax, and demonstrate that bax is indeed a direct and evolutionarily conserved transcriptional target of p53.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Manfredi, JJ (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R29CA069161] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69161] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim CN, 1997, CANCER RES, V57, P3115; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	29	97	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					990	999		10.1038/sj.onc.1205069	http://dx.doi.org/10.1038/sj.onc.1205069			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850816				2022-12-25	WOS:000173580100002
J	Seth, P; Krop, I; Porter, D; Polyak, K				Seth, P; Krop, I; Porter, D; Polyak, K			Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression)	ONCOGENE			English	Article						estrogen; tamoxifen; SAGE (Serial Analysis of Gene Expression); breast cancer	SURGICAL ADJUVANT BREAST; FACTOR-RESPONSIVE GENE; MESSENGER-RNAS; CANCER; GROWTH; SM-20; POLYMORPHISM; DISPLAY	The breast cancer promoting effects of estrogen and the chemopreventive effects of tamoxifen are thought to be mediated by the estrogen receptor, a ligand-dependent transcription factor. Therefore, comprehensive analysis of gene expression profiles following estrogen or tamoxifen treatment may help us better understand the role estrogen plays in tumorigenesis. We utilized SAGE (Serial Analysis of Gene Expression) technology to identify genes regulated by estrogen and tamoxifen in the ZR75-1 estrogen dependent breast cancer cell line. In this manner we have identified several genes that were regulated by estrogen or tamoxifen. Here we report the identification and initial characterization of EIT-6 (Estrogen Induced Tag-6), a novel nuclear protein and a new member of the evolutionarily conserved SM-20 family of growth regulatory immediate-early genes. EIT-6 appears to be a direct transcriptional target of the estrogen receptor and constitutive expression of EIT-6 promotes colony growth in human breast cancer cells. These data indicate that EIT-6 may play a role in estrogen induced cell growth.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Polyak, K (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St D740C, Boston, MA 02115 USA.	Kornelia_Polyak@dfci.harvard.edu						Bauer MF, 1999, J MOL BIOL, V289, P69, DOI 10.1006/jmbi.1999.2751; Berry LD, 1997, J CELL BIOL, V137, P1337, DOI 10.1083/jcb.137.6.1337; Charpentier AH, 2000, CANCER RES, V60, P5977; deCupis A, 1997, TRENDS PHARMACOL SCI, V18, P245, DOI 10.1016/S0165-6147(97)90632-5; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Foca C, 2000, MOL HUM REPROD, V6, P712, DOI 10.1093/molehr/6.8.712; Freedman LP, 1999, TRENDS ENDOCRIN MET, V10, P403, DOI 10.1016/S1043-2760(99)00208-8; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Inadera H, 2000, BIOCHEM BIOPH RES CO, V275, P108, DOI 10.1006/bbrc.2000.3276; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Katzenellenbogen BS, 1997, BREAST CANCER RES TR, V44, P23, DOI 10.1023/A:1005835428423; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Lal A, 1999, CANCER RES, V59, P5403; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Madden SL, 1996, CANCER RES, V56, P5384; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANNING DL, 1990, CANCER RES, V50, P4098; MANNING DL, 1995, ACTA ONCOL, V34, P641, DOI 10.3109/02841869509094041; MANNING DL, 1988, MOL CELL ENDOCRINOL, V59, P205, DOI 10.1016/0303-7207(88)90105-0; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Moschella MC, 1999, GENE EXPRESSION, V8, P59; Nakashiro K, 1998, CANCER RES, V58, P549; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Porter DA, 2001, CANCER RES, V61, P5697; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Seth P, 2000, CANCER RES, V60, P6859; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; TRENT C, 1983, GENETICS, V104, P619; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WAX SD, 1994, J BIOL CHEM, V269, P13041; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zheng W, 2001, CANCER EPIDEM BIOMAR, V10, P89	41	92	97	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					836	843		10.1038/sj.onc.1205113	http://dx.doi.org/10.1038/sj.onc.1205113			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850811				2022-12-25	WOS:000173427000014
J	Chen, XQ; Edwards, JAS; Logsdon, CD; Ernst, SA; Williams, JA				Chen, XQ; Edwards, JAS; Logsdon, CD; Ernst, SA; Williams, JA			Dominant negative Rab3D inhibits amylase release from mouse pancreatic acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; GTP-BINDING PROTEINS; CA2+-DEPENDENT EXOCYTOSIS; NEUROENDOCRINE CELLS; PC12 CELLS; EXPRESSION; SECRETION; RAT; CHOLECYSTOKININ; MUTANTS	Rab3 proteins are believed to play an important role in regulated exocytosis and previous work has demonstrated the presence of Rab3D on pancreatic zymogen granules. To further understand the function of Rab3D in acinar cell exocytosis, adenoviral constructs were prepared encoding hemagglutinin-tagged wild type Rab3D and three mutant forms, N135I and T36N (both deficient in guanine nucleotide binding) and Q81L (deficient in GTP hydrolysis), which also expressed enhanced green fluorescent protein driven by a separate promoter. When isolated mouse pancreatic acini were cultured with 5 x 10(6) pfu/ml adenovirus, nearly 100% of acini were infected as visualized by expression of green fluorescent protein. Cultured acini showed a biphasic dose-response to cholecystokinin (CCK); basal amylase secretion was 1.8 +/- 0.30%/30 min, peak release was 7.3 +/- 0.2%/30 min at 30 pm CCK and reduced secretion was observed at higher CCK concentrations. Control beta-galactosidase virus infection had no effect on either basal or CCK-induced secretion in the titer range from 0.5 to 10 x 10(6) pfu/ml. While the expression of Rab3D and Rab3D Q81L had no effect on amylase secretion, Rab3D N135I and T36N functioned as dominant negative mutants and inhibited CCK-induced amylase release by 40-50% at all points on the CCK dose-response curve from 3 to 300 pm. Inhibition was stronger during the first 5 min (71 +/- 5%) than over 30 min (36% +/- 5%). Similar inhibition was found using other agonists including bombesin, carbachol, A23187, and cAMP. Localization of adenoviral expressed Rab protein showed wild type Rab3D localized to zymogen granules. The two dominant negative mutants did not localize to granules and were primarily in the basolateral region of the cell. Since both dominant negative Rab3D mutants had no effect on intracellular calcium increase induced by CCK, it is unlikely that they acted at receptors or transmembrane signaling. These results suggest that Rab3D plays an important role in regulating the terminal steps of acinar exocytosis and that this effect is greatest on the early phase of amylase release.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Chen, XQ (corresponding author), Univ Michigan, Dept Physiol, 7734 Med Sci Bldg 2, Ann Arbor, MI 48109 USA.	xuequnc@umich.edu		Williams, John/0000-0002-6063-7615				Baldini G, 1998, J CELL BIOL, V140, P305, DOI 10.1083/jcb.140.2.305; Bean AJ, 1997, NEURON, V19, P751, DOI 10.1016/S0896-6273(00)80957-5; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; Collins RN, 1997, J BIOL CHEM, V272, P18281, DOI 10.1074/jbc.272.29.18281; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Han B, 2000, AM J PHYSIOL-CELL PH, V278, pC344, DOI 10.1152/ajpcell.2000.278.2.C344; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Iezzi M, 1999, MOL ENDOCRINOL, V13, P202, DOI 10.1210/me.13.2.202; JAMIESON JD, 1967, J CELL BIOL, V34, P597, DOI 10.1083/jcb.34.2.597; JAMIESON JD, 1971, J CELL BIOL, V50, P135, DOI 10.1083/jcb.50.1.135; Ji BA, 2000, J BIOL CHEM, V275, P19115, DOI 10.1074/jbc.M001685200; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; JONES S, 1995, J CELL BIOL, V130, P1051, DOI 10.1083/jcb.130.5.1051; LI GP, 1994, J BIOL CHEM, V269, P14631; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; Luo HR, 2001, NEURON, V31, P439, DOI 10.1016/S0896-6273(01)00384-1; Martelli AM, 2000, TRAFFIC, V1, P976, DOI 10.1034/j.1600-0854.2000.011207.x; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Nicke B, 1999, AM J PHYSIOL-GASTR L, V276, pG499, DOI 10.1152/ajpgi.1999.276.2.G499; Ohnishi H, 1996, AM J PHYSIOL-GASTR L, V271, pG531, DOI 10.1152/ajpgi.1996.271.3.G531; Ohnishi H, 1997, J CLIN INVEST, V100, P3044, DOI 10.1172/JCI119859; Padfield PJ, 1998, BIOCHEM J, V330, P329; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Roa M, 1997, J IMMUNOL, V159, P2815; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanaka M, 2001, MOL BIOL CELL, V12, P1421, DOI 10.1091/mbc.12.5.1421; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Valentijn JA, 1996, EUR J CELL BIOL, V71, P129; Valentijn JA, 1996, EUR J CELL BIOL, V70, P33; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; YULE DI, 1992, J BIOL CHEM, V267, P13830; YULE DI, 1994, PHYSL GASTROINTESTIN	48	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18002	18009		10.1074/jbc.M201248200	http://dx.doi.org/10.1074/jbc.M201248200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11875077	hybrid			2022-12-25	WOS:000175685100078
J	Silkov, A; Wolstein, O; Shachar, I; Dikstein, R				Silkov, A; Wolstein, O; Shachar, I; Dikstein, R			Enhanced apoptosis of B and T lymphocytes in TAF(II)105 dominant-negative transgenic mice is linked to nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION IN-VIVO; THYROID-HORMONE RECEPTORS; CELL-CYCLE PROGRESSION; HISTONE-LIKE TAFS; MAMMALIAN-CELLS; ACTIVATION; COMPLEX; YEAST; BINDING; SAGA	The general transcription factor TFIID is composed of the TATA-binding protein (TBP) and 12-14 TBP-associated factors (TAF(II)s). Some TAF(II)s act as bridges between transcription activators and the general transcription machinery through direct interaction with activation domains. Although TAF-mediated transcription activation has been established, there is little genetic evidence connecting it to binding of an activator. TAF(II)105 is a substoichiometric subunit of transcription factor IID highly expressed in B lymphocytes. In this study, we examined the physiological role of TAF(II)105 and its mechanism of action in vivo by expressing two forms of dominant-negative mutant TAF(II)105 in mice. We show that TAF(II)105 has a pro-survival role in B and T lymphocytes, where the native protein is expressed. In addition, TAF(II)105 is important for T cell maturation and for production of certain antibody isotypes. These phenotypic alterations were absent in mice expressing a dominant-negative mutant that lacks one of the domains mediating p65/RelA binding in vitro. These findings provide support to the notion that interaction between the activator and TAF is important for their function in vivo.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Dikstein, R (corresponding author), Weizmann Inst Sci, Dept Biol Chem, 2 Hertzel St, IL-76100 Rehovot, Israel.							Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bertolotti A, 1999, ONCOGENE, V18, P8000, DOI 10.1038/sj.onc.1203207; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; de Martin R, 1999, MUTAT RES-REV MUTAT, V437, P231, DOI 10.1016/S1383-5742(99)00089-7; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; Foo SY, 1999, TRENDS GENET, V15, P229; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Furukawa T, 2000, J BIOL CHEM, V275, P29847, DOI 10.1074/jbc.M002989200; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Horwitz BH, 1999, J IMMUNOL, V162, P1941; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lavigne AC, 1999, MOL CELL BIOL, V19, P5486; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Metzger D, 1999, EMBO J, V18, P4823, DOI 10.1093/emboj/18.17.4823; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Pham AD, 1999, MECH DEVELOP, V84, P3, DOI 10.1016/S0925-4773(99)00051-9; Reese JC, 2000, J BIOL CHEM, V275, P17391, DOI 10.1074/jbc.M001635200; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; Sambrook J., 2002, MOL CLONING LAB MANU; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TEWARI M, 1995, J IMMUNOL, V154, P1699; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1996, GENE DEV, V11, P3020; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WILLIAMS GT, 1994, BIOCHEM CELL BIOL, V72, P447, DOI 10.1139/o94-059; Wolstein O, 2000, J BIOL CHEM, V275, P16459, DOI 10.1074/jbc.275.22.16459; WYLLIE AH, 1987, INT REV CYTOL S, V17, P755; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483	50	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17821	17829		10.1074/jbc.M200696200	http://dx.doi.org/10.1074/jbc.M200696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11856754	hybrid			2022-12-25	WOS:000175685100056
J	Wang, HY; Gauthier, BR; Hagenfeldt-Johansson, KA; Iezzi, M; Wollheim, CB				Wang, HY; Gauthier, BR; Hagenfeldt-Johansson, KA; Iezzi, M; Wollheim, CB			Foxa2 (HNF3 beta) controls multiple genes implicated in metabolism-secretion coupling of glucose-induced insulin release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR 3-BETA; PANCREATIC BETA-CELLS; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; SULFONYLUREA RECEPTOR GENE; UNCOUPLING PROTEIN-2; FAMILIAL HYPERINSULINISM; TRANSCRIPTION FACTORS; MOLECULAR-BASIS; HEPATOCYTE; EXPRESSION	The transcription factor Foxa2 is implicated in blood glucose homeostasis. Conditional expression of Foxa2 or its dominant-negative mutant DN-Foxa2 in INS-1 cells reveals that Foxa2 regulates the expression of genes important for glucose sensing in pancreatic beta-cells. Overexpression of Foxa2 results in blunted glucose-stimulated insulin secretion, whereas induction of DN-Foxa2 causes a left shift of glucose-induced insulin release. The mRNA levels of GLUT2 and glucokinase are drastically decreased after induction of Foxa2. In contrast, loss of Foxa2 function leads to up-regulation of hexokinase (HK) I and II and glucokinase (HK-IV) mRNA expression. The glucokinase and the low K-m hexokinase activities as well as glycolysis are increased proportionally. In addition, induction of DN-Foxa2 a so reduces the expression of beta-cell K-ATP channel subunits Sur1 and Kir6.2 by 70%. Furthermore, in contrast to previous reports, induction of Foxa2 causes pronounced decreases in the HNF4alpha and HNF1alpha mRNA levels. Foxa2 fails to regulate the expression of Pdx1 transcripts. The expression of insulin and islet amyloid polypeptide is markedly suppressed after induction of Foxa2, while the glucagon mRNA levels are significantly increased. Conversely, Foxa2 is required for glucagon expression in these INS-1-derived cells. These results suggest that Foxa2 is a vital transcription factor evolved to control the expression of genes essential for maintaining beta-cell glucose sensing and glucose homeostasis.	Ctr Med Univ Geneva, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Wang, HY (corresponding author), Ctr Med Univ Geneva, Dept Med Interne, Div Biochim Clin & Diabetol Expt, CH-1211 Geneva 4, Switzerland.	Haiyan.Wang@medicine.unige.ch	Gauthier, Benoit R/C-3138-2017	Gauthier, Benoit R/0000-0001-8146-7486				Abderrahmani A, 2000, DIABETES, V49, P306, DOI 10.2337/diabetes.49.2.306; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; BECKER TC, 1994, J BIOL CHEM, V269, P21234; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Clocquet AR, 2000, DIABETES, V49, P1856, DOI 10.2337/diabetes.49.11.1856; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Gauthier BR, 2002, MOL ENDOCRINOL, V16, P170, DOI 10.1210/me.16.1.170; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Hinokio Y, 2000, DIABETES, V49, P302, DOI 10.2337/diabetes.49.2.302; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; Meissner T, 1999, HUM MUTAT, V13, P351, DOI 10.1002/(SICI)1098-1004(1999)13:5<351::AID-HUMU3>3.0.CO;2-R; Miki T, 1997, P NATL ACAD SCI USA, V94, P11969, DOI 10.1073/pnas.94.22.11969; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; PHILIPPE J, 1995, MOL ENDOCRINOL, V9, P368, DOI 10.1210/me.9.3.368; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Shih DQ, 1999, P NATL ACAD SCI USA, V96, P10152, DOI 10.1073/pnas.96.18.10152; Stanley CA, 2000, DIABETES, V49, P667, DOI 10.2337/diabetes.49.4.667; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; Tan YJ, 2002, HEPATOLOGY, V35, P30, DOI 10.1053/jhep.2002.30317; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; VALLET V, 1995, MOL CELL BIOL, V15, P5453; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	49	80	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17564	17570		10.1074/jbc.M111037200	http://dx.doi.org/10.1074/jbc.M111037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11875061	hybrid, Green Published			2022-12-25	WOS:000175685100024
J	Expert-Bezancon, A; Le Caer, JP; Marie, J				Expert-Bezancon, A; Le Caer, JP; Marie, J			Heterogeneous nuclear ribonucleoprotein (hnRNP) K is a component of an intronic splicing enhancer complex that activates the splicing of the alternative Exon 6A from Chicken beta-tropomyosin Pre-mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; FACTOR RECEPTOR 2; IN-VIVO; SECONDARY STRUCTURE; SILENCER ELEMENT/; EXCLUSIVE EXONS; A/B PROTEINS; BRANCH POINT; SITES; GENE	Splicing of the chicken beta-tropomyosin exon 6A is stimulated, both in vivo and in vitro, by an intronic pyrimidine-rich element (S4) located 37 nucleotides downstream of exon 6A. Several pyrimidine-rich sequences are able to substitute for the natural S4 enhancer with various stimulatory effects. We show that the different enhancer sequences recruit U1 small nuclear ribonucleoprotein (SnRNP) to the exon 6A 5' splice site, with an efficiency that correlates with the splicing activation. By using RNA affinity and two-dimensional gel electrophoresis, we characterized several proteins that bind to the different enhancer sequences. Heterogeneous nuclear ribonucleoprotein (hnRNP) K and hnRNP I (polypyrimidine track-binding protein, PTB) exhibit a higher level of interaction with the strong enhancer sequences (S4) than with the weakest enhancers. Functional analysis shows that hnRNP K is a component of the enhancer complex that promotes exon 6A splicing through the wild-type S4 sequence. The addition of recombinant hnRNP K to nuclear extracts preincubated with poly(rC) RNA competitor completely restores splicing efficiency to the original level. hnRNP I (PTB) was also found associated with the strong enhancer sequences. Its function in the splicing of exon 6A is discussed.	CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France; Ecole Super Phys & Chim Ind Ville Paris, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Marie, J (corresponding author), CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France.	marie@cgm.cnrs-gif.fr						Adams MD, 1997, GENE DEV, V11, P129, DOI 10.1101/gad.11.1.129; Ashiya M, 1997, RNA, V3, P996; BALVAY L, 1992, NUCLEIC ACIDS RES, V20, P3987, DOI 10.1093/nar/20.15.3987; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; BLACK DL, 1995, RNA, V1, P763; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Carlo T, 2000, MOL CELL BIOL, V20, P3988, DOI 10.1128/MCB.20.11.3988-3995.2000; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Chabot B, 1997, MOL CELL BIOL, V17, P1776, DOI 10.1128/MCB.17.4.1776; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Chou MY, 1999, MOL CELL BIOL, V19, P69; Cote J, 2001, J BIOL CHEM, V276, P8535, DOI 10.1074/jbc.M008924200; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Eperon IC, 2000, MOL CELL BIOL, V20, P8303, DOI 10.1128/MCB.20.22.8303-8318.2000; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; FU XD, 1995, RNA, V1, P663; GALLEGO ME, 1992, MOL CELL BIOL, V12, P5415, DOI 10.1128/MCB.12.12.5415; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Gooding C, 1998, RNA, V4, P85; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; Hahm B, 1998, FEBS LETT, V425, P401, DOI 10.1016/S0014-5793(98)00269-5; Hertel KJ, 1998, MOL CELL, V1, P449, DOI 10.1016/S1097-2765(00)80045-3; Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Le Guiner C, 2001, J BIOL CHEM, V276, P43677, DOI 10.1074/jbc.M107381200; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; LIBRI D, 1992, MOL CELL BIOL, V12, P3204, DOI 10.1128/MCB.12.7.3204; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McCullough AJ, 2000, MOL CELL BIOL, V20, P9225, DOI 10.1128/MCB.20.24.9225-9235.2000; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Perez I, 1997, RNA, V3, P764; Pret AM, 1999, DNA CELL BIOL, V18, P671, DOI 10.1089/104454999314953; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Southby J, 1999, MOL CELL BIOL, V19, P2699; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; Tange TO, 2001, EMBO J, V20, P5748; Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wollerton MC, 2001, RNA, V7, P819, DOI 10.1017/S1355838201010214	64	67	70	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16614	16623		10.1074/jbc.M201083200	http://dx.doi.org/10.1074/jbc.M201083200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867641	hybrid			2022-12-25	WOS:000175564500038
J	Gong, F; Yanofsky, C				Gong, F; Yanofsky, C			Analysis of tryptophanase operon expression in vitro - Accumulation of TnaC-peptidyl-tRNA in a release factor 2-depleted S-30 extract prevents Rho factor action, simulating induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTION TERMINATION; ESCHERICHIA-COLI; LEADER PEPTIDE; NUCLEOTIDE-SEQUENCE; ANTITERMINATION; BOXA; TRANSLATION; PROTEIN; REGION; NUSA	Expression of the tryptophanase (tna) operon in Escherichia coli is regulated by catabolite repression and tryptophan-induced transcription antitermination. The key feature of this antitermination mechanism has been shown to be the retention of uncleaved TnaC-peptidyl-tRNA in the translating ribosome. This ribosome remains stalled at the tna stop codon and blocks the access of Rho factor to the tna transcript, thereby preventing transcription termination. In normal S-30 preparations, synthesis of a TnaC peptide containing arginine instead of tryptophan at position 12 (Arg(12)-TnaC) was shown to be insensitive to added tryptophan, i.e. Arg(12)-TnaC-peptidyl-tRNA was cleaved, and there was normal Rho-dependent transcription termination. When the S-30 extract used was depleted of release factor 2, Arg(12)-TnaC-tRNA(Pro) was accumulated in the absence or presence of added tryptophan. Under these conditions the accumulation of Arg(12)-TnaC-tRNA(Pro) prevented Rho-dependent transcription termination, mimicking normal induction. Using a minimal in vitro transcription system consisting of a tna template, RNA polymerase, and Rho, it was shown that RNA sequences immediately adjacent to the tnaC stop codon, the presumed boxA and rut sites, contributed most significantly to Rho-dependent termination. The tna boxA-like sequence appeared to serve as a segment of the Rho "entry" site, despite its likeness to the boxA element.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Yanofsky, C (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	yanofsky@cmgm.stanford.edu						BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; BOTSFORD JL, 1971, J BACTERIOL, V105, P303, DOI 10.1128/JB.105.1.303-312.1971; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; DEELEY MC, 1981, J BACTERIOL, V147, P787, DOI 10.1128/JB.147.3.787-796.1981; EDWARDS RM, 1982, BIOCHEM J, V204, P617, DOI 10.1042/bj2040617; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FRIEDMAN DI, 1983, CELL, V34, P143, DOI 10.1016/0092-8674(83)90144-7; Gaba A, 2001, EMBO J, V20, P6453, DOI 10.1093/emboj/20.22.6453; Geballe AP, 2000, COLD SPRING HARBOR M, V39, P595; GISH K, 1995, J BACTERIOL, V177, P7245, DOI 10.1128/jb.177.24.7245-7254.1995; GOLLNICK P, 1990, J BACTERIOL, V172, P3100, DOI 10.1128/jb.172.6.3100-3107.1990; Gong F, 2001, J BIOL CHEM, V276, P1974, DOI 10.1074/jbc.M008892200; Gong F, 2001, P NATL ACAD SCI USA, V98, P8997, DOI 10.1073/pnas.171299298; Graham JE, 1998, J BIOL CHEM, V273, P20764, DOI 10.1074/jbc.273.33.20764; Gusarov I, 2001, CELL, V107, P437, DOI 10.1016/S0092-8674(01)00582-7; Hopkins FG, 1903, J PHYSIOL-LONDON, V29, P451; KAMATH AV, 1992, J BIOL CHEM, V267, P19978; KAZARINOFF MN, 1977, J BIOL CHEM, V252, P7598; Konan KV, 2000, J BACTERIOL, V182, P3981, DOI 10.1128/JB.182.14.3981-3988.2000; LANDICK R, 1985, P NATL ACAD SCI USA, V82, P4663, DOI 10.1073/pnas.82.14.4663; LAU LF, 1985, J BIOL CHEM, V260, P574; LI SC, 1984, CELL, V38, P851, DOI 10.1016/0092-8674(84)90280-0; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; Mogridge J, 1998, J BIOL CHEM, V273, P4143, DOI 10.1074/jbc.273.7.4143; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; NODWELL JR, 1993, CELL, V72, P261, DOI 10.1016/0092-8674(93)90665-D; OLSON ER, 1984, J MOL BIOL, V180, P1053, DOI 10.1016/0022-2836(84)90270-5; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; ROBERTS JW, 1993, CELL, V72, P653, DOI 10.1016/0092-8674(93)90394-6; ROBLEDO R, 1991, J MOL BIOL, V220, P613, DOI 10.1016/0022-2836(91)90104-E; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; STEWART V, 1986, J BACTERIOL, V166, P217, DOI 10.1128/jb.166.1.217-223.1986; STEWART V, 1986, J BACTERIOL, V167, P383, DOI 10.1128/jb.167.1.383-386.1986; STEWART V, 1985, J BACTERIOL, V164, P731, DOI 10.1128/JB.164.2.731-740.1985; WARD DF, 1983, J MOL BIOL, V168, P73, DOI 10.1016/S0022-2836(83)80323-4; Weisberg RA, 1999, J BACTERIOL, V181, P359, DOI 10.1128/JB.181.2.359-367.1999; WINKLER ME, 1981, BIOCHEMISTRY-US, V20, P3738, DOI 10.1021/bi00516a011; YANOFSKY C, 1995, J BACTERIOL, V177, P4451, DOI 10.1128/jb.177.15.4451-4456.1995; ZALATAN F, 1992, J BIOL CHEM, V267, P19082; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411; Zuker M, 2000, CURR OPIN STRUC BIOL, V10, P303, DOI 10.1016/S0959-440X(00)00088-9	43	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17095	17100		10.1074/jbc.M201213200	http://dx.doi.org/10.1074/jbc.M201213200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880383	hybrid			2022-12-25	WOS:000175564500100
J	Rosconi, MP; London, E				Rosconi, MP; London, E			Topography of helices 5-7 in membrane-inserted diphtheria toxin T domain - Identification and insertion boundaries of two hydrophobic sequences that do not form a stable transmembrane hairpin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; PENETRATION DEPTH; PARALLAX ANALYSIS; CRYSTAL-STRUCTURE; REFINED STRUCTURE; MODEL MEMBRANES; PLASMA-MEMBRANE; B-FRAGMENT; FLUORESCENCE; TOPOLOGY	The T domain of diphtheria toxin undergoes a low pH-induced conformational change that allows it to penetrate cell membranes. T domain hydrophobic helices 8 and 9 can adopt two conformations, one close to the membrane surface (P state) and a second in which they apparently form a transmembrane hairpin (TM state). We have now studied T domain helices 5-7, a second cluster of hydrophobic helices, using Cys-scanning mutagenesis. After fluorescently labeling a series of Cys residues, penetration into a non-polar environment, accessibility to externally added antibodies, and relative depth in the bilayer were monitored. It was found that helices 5-7 insert shallowly in the P state and deeply in the TM state. Thus, the conformational changes in helices 5-7 are both similar and somehow linked to those in helices 8 and 9. The boundaries of deeply inserting sequences were also identified. One deeply inserted segment was found to span residues 270 to 290, which overlaps helix 5, and a second spanned residues 300 to 320, which includes most of helix 6 and all of helix 7. This indicates that helices 6 and 7 form a continuous hydrophobic segment despite their separation by a Pro-containing kink. Additionally, it is found that in the TM state some residues in the hydrophilic loop between helices 5 and 6 become more highly exposed than they are in the P state. Their exposure to external solution in the TM state indicates that helices 5-7 do not form a stable transmembrane hairpin. However, helix 5 and/or helices 6 plus 7 could form transmembrane structures that are in equilibrium with non-transmembrane states, or be kinetically prevented from forming a transmembrane structure. How helices 5-7 might influence the mechanism by which the T domain aids translocation of the diphtheria toxin A chain across membranes is discussed.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	London, E (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031986] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31986] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1993, BIOCHEMISTRY-US, V32, P10826, DOI 10.1021/bi00091a038; Bell CE, 1997, BIOCHEMISTRY-US, V36, P481, DOI 10.1021/bi962214s; BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; BENNETT MJ, 1994, PROTEIN SCI, V3, P1444, DOI 10.1002/pro.5560030911; CABIAUX V, 1994, MOL MICROBIOL, V11, P43, DOI 10.1111/j.1365-2958.1994.tb00288.x; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; D'Silva PR, 2000, J BIOL CHEM, V275, P11771, DOI 10.1074/jbc.275.16.11771; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; JOHNSON ID, 1991, ANAL BIOCHEM, V198, P228, DOI 10.1016/0003-2697(91)90418-S; Kachel K, 1998, J BIOL CHEM, V273, P22950, DOI 10.1074/jbc.273.36.22950; Kaiser RD, 1998, BBA-BIOMEMBRANES, V1375, P13, DOI 10.1016/S0005-2736(98)00127-8; KAROLIN J, 1994, J AM CHEM SOC, V116, P7801, DOI 10.1021/ja00096a042; MADSHUS IH, 1994, J BIOL CHEM, V269, P4648; Malenbaum SE, 1998, BIOCHEMISTRY-US, V37, P17915, DOI 10.1021/bi981230h; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Oh KJ, 1999, BIOCHEMISTRY-US, V38, P10336, DOI 10.1021/bi990520a; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; Quertenmont P, 1996, MOL MICROBIOL, V21, P1283, DOI 10.1046/j.1365-2958.1996.851446.x; Ren JH, 1999, BIOCHEMISTRY-US, V38, P976, DOI 10.1021/bi981576s; Ren JH, 1999, SCIENCE, V284, P955, DOI 10.1126/science.284.5416.955; Senzel L, 1998, J GEN PHYSIOL, V112, P317, DOI 10.1085/jgp.112.3.317; Senzel L, 2000, J GEN PHYSIOL, V115, P421, DOI 10.1085/jgp.115.4.421; Sharpe JC, 1999, J MEMBRANE BIOL, V171, P209, DOI 10.1007/s002329900572; SILVERMAN JA, 1994, J BIOL CHEM, V269, P22524; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Wang Y, 1997, BIOCHEMISTRY-US, V36, P16300, DOI 10.1021/bi971281z; Wang Y, 1997, J BIOL CHEM, V272, P25091, DOI 10.1074/jbc.272.40.25091; Zakharov SD, 1999, BIOCHEMISTRY-US, V38, P11325, DOI 10.1021/bi9903087; ZHAN HJ, 1994, BIOCHEMISTRY-US, V33, P11254, DOI 10.1021/bi00203a022; ZHAN HJ, 1995, BIOCHEMISTRY-US, V34, P4856, DOI 10.1021/bi00014a043	35	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16517	16527		10.1074/jbc.M200442200	http://dx.doi.org/10.1074/jbc.M200442200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859081	hybrid			2022-12-25	WOS:000175564500026
J	Saito, T; Miyoshi, E; Sasai, K; Nakano, N; Eguchi, H; Honke, K; Taniguchi, N				Saito, T; Miyoshi, E; Sasai, K; Nakano, N; Eguchi, H; Honke, K; Taniguchi, N			A secreted type of beta 1,6-N-acetylglucosaminyltransferase V (GnT-V) induces tumor angiogenesis without mediation of glycosylation - A novel function of GnT-V distinct from the original glycosyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; ENDOTHELIAL GROWTH-FACTOR; HAMSTER-KIDNEY CELLS; BREAST-CANCER CELLS; LINKED OLIGOSACCHARIDES; EXPRESSION; METASTASIS; CARCINOMA; PLACENTA; PURIFICATION	Angiogenesis is the first regulatory step of tumor progression. Herein, we report on some findings that show that beta1,6-N-acetylglucosaminyltransferase V (GnT-V) functions as an inducer of angiogenesis that has a novel and completely different function from the original function of glycosyltransferase. A secreted type of GnT-V protein itself promoted angiogenesis in vitro and in vivo at physiological concentrations. The highly basic domain of GnT-V induced the release of fibroblast growth factor-2 from heparan sulfate proteoglycan on the cell surface and/or extracellular matrix, leading to angiogenesis. These findings provide some novel information on the relationship between GnT-V and tumor metastasis. The inhibition of GnT-V secretion or its expression represents a novel potential strategy for the inhibition of tumor angiogenesis.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Osaka University	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Saito, Takashi/G-2563-2015; Eguchi, Hiromi/GWC-5633-2022; Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Saito, Takashi/0000-0002-9659-9251; Taniguchi, Naoyuki/0000-0001-5889-5968; 				Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562; Barillari G, 1998, AM J PATHOL, V152, P1161; Bernardini G, 2000, BLOOD, V96, P4039, DOI 10.1182/blood.V96.13.4039.h8004039_4039_4045; BIARD A, 1988, P NATL ACAD SCI USA, V85, P2324; CHEN L, 1995, GLYCOCONJUGATE J, V12, P813, DOI 10.1007/BF00731243; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; Granovsky M, 2000, NAT MED, V6, P306; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; Ikeda Y, 2000, J BIOCHEM, V128, P609, DOI 10.1093/oxfordjournals.jbchem.a022793; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu PP, 1996, BIOORGAN MED CHEM, V4, P2011, DOI 10.1016/S0968-0896(96)00180-0; MACAFFERY G, 1993, COMP BIOCH PHYSL B, V104, P91; MAREZ A, 1987, BIOCHIMIE, V69, P125, DOI 10.1016/0300-9084(87)90244-6; Murata K, 2000, CLIN CANCER RES, V6, P1772; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Petretti T, 2000, GUT, V46, P359, DOI 10.1136/gut.46.3.359; PIERCE M, 1986, J BIOL CHEM, V261, P772; RISAU W, 1988, EMBO J, V7, P959, DOI 10.1002/j.1460-2075.1988.tb02901.x; ROTHENTHAL RA, 1990, GROWTH FACTORS, V4, P53; Sasai K, 2002, GLYCOBIOLOGY, V12, P119, DOI 10.1093/glycob/12.2.119; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; SUZUKI K, 1993, AM J PHYSIOL, V265, pH1173, DOI 10.1152/ajpheart.1993.265.4.H1173; TISCHER E, 1991, J BIOL CHEM, V266, P11947; UGARTE MA, 1991, INT J BIOCHEM, V23, P719, DOI 10.1016/0020-711X(91)90043-M; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; Yao M, 1998, J CANCER RES CLIN, V124, P27, DOI 10.1007/s004320050129; Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038/sj.onc.1203685; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zhu TY, 1997, J CANCER RES CLIN, V123, P296, DOI 10.1007/s004320050061	41	75	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17002	17008		10.1074/jbc.M200521200	http://dx.doi.org/10.1074/jbc.M200521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872751	hybrid			2022-12-25	WOS:000175564500088
J	Haracska, L; Prakash, S; Prakash, L				Haracska, L; Prakash, S; Prakash, L			Yeast Rev1 protein is a G template-specific DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-THYMINE DIMER; SACCHAROMYCES-CEREVISIAE; ABASIC SITES; ESCHERICHIA-COLI; REPLICATION PAST; ETA; BYPASS; FIDELITY; ZETA; PHOTOPRODUCT	Rev1 protein of Saccharomyces cerevisiae functions with DNA polymerase in mutagenic trans-lesion synthesis. Because of the reported preferential incorporation of a C residue opposite an abasic site, Rev1 has been referred to as a deoxycytidyltransferase. Here, we use steady-state kinetics to examine nucleotide incorporation by Rev1 opposite undamaged and damaged template residues. We show that Rev1 specifically inserts a C residue opposite template G, and it is similar to25-, 40-, and 400-fold less efficient at inserting a C residue opposite an abasic site, an O-6-methylguanine, and an 8-oxoguanine lesion, respectively. Rev1 misincorporates G, A, and T residues opposite template G with a frequency of similar to10(-3) to 10(-4). Consistent with this finding, Rev1 replicates DNA containing a string of Gs in a template-specific manner, but it has a low processivity incorporating 1.6 nucleotides per DNA binding event on the average. From these observations, we infer that Rev1 is a G template-specific DNA polymerase.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mechan St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NIGMS NIH HHS [GM19261] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Creighton S, 1995, METHOD ENZYMOL, V262, P232; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; GIBBS PEM, 1995, NUCLEIC ACIDS RES, V23, P1919, DOI 10.1093/nar/23.11.1919; GIBBS PEM, 1993, J BACTERIOL, V175, P2607, DOI 10.1128/JB.175.9.2607-2612.1993; Goodman MF, 2000, CURR OPIN GENET DEV, V10, P162, DOI 10.1016/S0959-437X(00)00057-5; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Haracska L, 2000, MOL CELL BIOL, V20, P8001, DOI 10.1128/MCB.20.21.8001-8007.2000; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1998, GENE DEV, V12, P3137, DOI 10.1101/gad.12.19.3137; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P924, DOI 10.1021/bi00403a013; Minko IG, 2001, J BIOL CHEM, V276, P2517, DOI 10.1074/jbc.M007867200; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; Tissier A, 2000, GENE DEV, V14, P1642; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; Yu SL, 2001, MOL CELL BIOL, V21, P185, DOI 10.1128/MCB.21.1.185-188.2001	28	130	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15546	15551		10.1074/jbc.M112146200	http://dx.doi.org/10.1074/jbc.M112146200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11850424	hybrid			2022-12-25	WOS:000175510400044
J	Holland, PM; Milne, A; Garka, K; Johnson, RS; Willis, C; Sims, JE; Rauch, CT; Bird, TA; Virca, GD				Holland, PM; Milne, A; Garka, K; Johnson, RS; Willis, C; Sims, JE; Rauch, CT; Bird, TA; Virca, GD			Purification, cloning, and characterization of Nek8, a novel NIMA-related kinase, and its candidate substrate Bicd2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; TUMOR-NECROSIS-FACTOR; CELL-CYCLE REGULATORS; BETA-CASEIN KINASE; PROTEIN-KINASE; ASPERGILLUS-NIDULANS; MITOTIC REGULATOR; BICAUDAL-D; CHROMATIN CONDENSATION; HUMAN HOMOLOG	We describe the isolation, cloning, and characterization of human Nek8, a new mammalian NIMA-related kinase, and its candidate substrate Bicd2. Nek8 was isolated as a beta-casein kinase activity in rabbit lung and has an N-terminal catalytic domain homologous to the Nek family of protein kinases. Nek8 also contains a central domain with homology to RCC1, a guanine nucleotide exchange factor for the GTPase Ran, and a C-terminal coiled-coil domain. Like Nek2, Nek8 prefers beta-casein over other exogenous substrates, has shared biochemical requirements for kinase activity, and is capable of autophosphorylation and oligomerization. Nek8 activity is not cell cycle regulated, but like Nek3, levels are consistently higher in G(0)-arrested cells. During the purification of Nek8 a second protein co-chromatographed with Nek8 activity. This protein, Bicd2, is a human homolog of the Drosophila protein Bicaudal D, a coiled-coil protein. Bicd2 is phosphorylated by Nek8 in vitro, and the endogenous proteins associate in vivo. Bicd2 localizes to cytoskeletal structures, and its subcellular localization is dependent on microtubule morphology. Treatment of cells with nocodazole leads to dramatic reorganization of Bicd2, and correlates with Nek8 phosphorylation. This may be indicative of a role for Nek8 and Bicd2 associated with cell cycle independent microtubule dynamics.	Immunex Res & Dev Corp, Seattle, WA 98101 USA		Holland, PM (corresponding author), Immunex Res & Dev Corp, 51 Univ St, Seattle, WA 98101 USA.	hollandp@immunex.com		Sims, John/0000-0002-5667-9185				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Azuma Y, 1999, J MOL BIOL, V289, P1119, DOI 10.1006/jmbi.1999.2820; Baens M, 1997, GENOMICS, V45, P601, DOI 10.1006/geno.1997.4971; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Chen A, 1999, GENE, V234, P127, DOI 10.1016/S0378-1119(99)00165-1; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1997, METHOD ENZYMOL, V283, P270; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; GUESDON F, 1993, J BIOL CHEM, V268, P4236; Guesdon F, 1997, CYTOKINE, V9, P471, DOI 10.1006/cyto.1996.0190; GUESDON F, 1994, BIOCHEM J, V304, P761, DOI 10.1042/bj3040761; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hayashi K, 1999, BIOCHEM BIOPH RES CO, V264, P449, DOI 10.1006/bbrc.1999.1536; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hoogenraad CC, 2001, EMBO J, V20, P4041, DOI 10.1093/emboj/20.15.4041; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Kandli M, 2000, GENOMICS, V68, P187, DOI 10.1006/geno.2000.6293; KOCH EA, 1983, CELL TISSUE RES, V228, P21; Krien MJE, 1998, J CELL SCI, V111, P967; Lehman AL, 1998, P NATL ACAD SCI USA, V95, P9436, DOI 10.1073/pnas.95.16.9436; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; LU KP, 1993, J BIOL CHEM, V268, P8769; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; NOGUCHI PD, 1991, CURRENT PROTOCOLS IM; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; PU RT, 1995, J BIOL CHEM, V270, P18110, DOI 10.1074/jbc.270.30.18110; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; Tanaka K, 1999, J BIOL CHEM, V274, P13491, DOI 10.1074/jbc.274.19.13491; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	48	44	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16229	16240		10.1074/jbc.M108662200	http://dx.doi.org/10.1074/jbc.M108662200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864968	hybrid			2022-12-25	WOS:000175510400133
J	Hyman, LE; Kwon, E; Ghosh, S; McGee, J; Chachulska, AMB; Jackson, T; Baricos, WH				Hyman, LE; Kwon, E; Ghosh, S; McGee, J; Chachulska, AMB; Jackson, T; Baricos, WH			Binding to Elongin C inhibits degradation of interacting proteins in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; RNA-POLYMERASE-II; CYCLIN-DEPENDENT KINASE; SACCHAROMYCES-CEREVISIAE; UBIQUITIN SYSTEM; 3'-END FORMATION; BUDDING YEAST; SNF4 PROTEIN; HIF-ALPHA; COMPLEX	Elongin C is a highly conserved, low molecular weight protein found in a variety of multiprotein complexes in human, rat, fly, worm, and yeast cells. Among the best characterized of these complexes is a mammalian E3 ligase that targets proteins for ubiquitination and subsequent degradation by the 26 S proteasome. Despite its crucial role as a component of such E3 ligases and other complexes, the specific function of Elongin C is unknown. In yeast, Elongin C is a non-essential gene and there is no obvious phenotype as associated with its absence. We previously reported that in Saccharomyces cerevisiae Elongin C (Elc1) interacts specifically and strongly with a class of proteins loosely defined as stress response proteins. In the present study, we examined the role of yeast Elc1 in the turnover of two of these binding partners, Snf4 and Pcl6. Deletion of Elc1 resulted in decreased steady-state levels of Snf4 and Pcl6 as indicated by Western blot analysis. Northern blot analysis of mRNA prepared from elc1 null and wild type strains revealed no difference in mRNA levels for Snf4 and Pc16 establishing that the effects of Elc1 are not transcriptionally mediated. Reintroduction of either yeast or human Elongin C into Elc1 null strains abrogated this effect. Taken together, these data document that the levels of Snf4 and Pcl6 are dependent on the presence of Elc1 and that binding to Elc1 inhibits the degradation of these proteins. The results suggest a new function for yeast Elongin C that is distinct from a direct role in targeting proteins for ubiquitination and subsequent proteolysis.	Tulane Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA	Tulane University	Hyman, LE (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Biochem, 1430 Tulane Ave, New Orleans, LA 70112 USA.			Hyman, Linda/0000-0002-2511-2928	NCI NIH HHS [CA84095, CA65436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA084095, T32CA065436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGATEP R, 1998, TRANSFORMATION SACCH; Aso T, 1997, BIOCHEM BIOPH RES CO, V241, P334, DOI 10.1006/bbrc.1997.7819; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Botuyan MV, 1999, P NATL ACAD SCI USA, V96, P9033, DOI 10.1073/pnas.96.16.9033; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; Conrad NK, 2000, GENETICS, V154, P557; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; GUTHRIE C, 1991, GUIDE YEAST GENETICS, P12; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1983, CELL, V34, P11, DOI 10.1016/0092-8674(83)90131-9; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HYMAN LE, 1993, MOL CELL BIOL, V13, P5159, DOI 10.1128/MCB.13.9.5159; HYMAN LE, 1991, MOL CELL BIOL, V11, P2004, DOI 10.1128/MCB.11.4.2004; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jackson T, 2000, BBA-GENE STRUCT EXPR, V1491, P161, DOI 10.1016/S0167-4781(00)00052-X; Kaelin WG, 1998, J INTERN MED, V243, P535; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Krek W, 2000, NAT CELL BIOL, V2, pE121, DOI 10.1038/35017129; Lee M, 2000, MOL MICROBIOL, V38, P411, DOI 10.1046/j.1365-2958.2000.02140.x; Magrath C, 1999, GENETICS, V152, P129; Mathias N, 1999, MOL CELL BIOL, V19, P1759; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; Miller CA, 1998, NUCLEIC ACIDS RES, V26, P3577, DOI 10.1093/nar/26.15.3577; Moffat J, 2000, Prog Cell Cycle Res, V4, P97; NEIGEBORN L, 1984, GENETICS, V108, P845; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; SHERMAN F, 1986, LABORATORY COURSE MA, P163; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Smothers DB, 2000, MOL CELL BIOL, V20, P7845, DOI 10.1128/MCB.20.21.7845-7852.2000; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5	49	5	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15586	15591		10.1074/jbc.M200800200	http://dx.doi.org/10.1074/jbc.M200800200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864988	hybrid			2022-12-25	WOS:000175510400050
J	Stangler, T; Mayr, LM; Willbold, D				Stangler, T; Mayr, LM; Willbold, D			Solution structure of human GABA(A) receptor-associated protein GABARAP - Implications for biological function and its regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-15 RESONANCE ASSIGNMENTS; PROGRAM; C-13; GATE-16; BINDING; SYSTEM; H-1	Control of neurotransmitter receptor expression and delivery to the postsynaptic membrane is of critical importance for neural signal transduction at synapses. The gamma-aminobutyric acid, type A (GABA(A)) receptor-associated protein GABARAP was reported to have an important role for movement and sorting of GABA(A) receptor molecules to the postsynaptic membrane. GABARAP not only binds to GABA(A) receptor gamma2-subunit but also to tubulin, gephyrin, and ULK1. We present for the first time the high resolution structure of human GABARAP determined by nuclear magnetic resonance in aqueous solution. One part of the molecule, despite being well ordered and rigid on a MHz time scale, exists in at least two different conformations that interchange with each other on a time scale slower than 25 Hz. An important feature of the solution structure is the observation that amino- and carboxyl-terminal ends of the protein directly interact with each other, which is not seen in recently reported crystal structures. The possible biological relevance of these observations for the regulation of GABARAP interactions and functions is discussed.	Univ Dusseldorf, Inst Biol Phys, D-40225 Dusseldorf, Germany; Inst Mol Biotechnol, D-07745 Jena, Germany; Novartis Pharma AG, CH-4002 Basel, Switzerland; Forschungszentrum Julich, D-52425 Julich, Germany	Heinrich Heine University Dusseldorf; Novartis; Helmholtz Association; Research Center Julich	Willbold, D (corresponding author), Univ Dusseldorf, Inst Biol Phys, D-40225 Dusseldorf, Germany.	dieter.willbold@uni-duesseldorf.de	Willbold, Dieter/A-6280-2013	Willbold, Dieter/0000-0002-0065-7366				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Coyle JE, 2002, NEURON, V33, P63, DOI 10.1016/S0896-6273(01)00558-X; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Harris R, 2001, J BIOMOL NMR, V21, P185, DOI 10.1023/A:1012473609468; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; Knight D, 2002, J BIOL CHEM, V277, P5556, DOI 10.1074/jbc.M109753200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; Okazaki N, 2000, MOL BRAIN RES, V85, P1, DOI 10.1016/S0169-328X(00)00218-7; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Stangler T, 2001, J BIOMOL NMR, V21, P183, DOI 10.1023/A:1012416810974; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	22	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13363	13366		10.1074/jbc.C200050200	http://dx.doi.org/10.1074/jbc.C200050200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11875056	hybrid			2022-12-25	WOS:000175096000002
J	Basso, AD; Solit, DB; Munster, PN; Rosen, N				Basso, AD; Solit, DB; Munster, PN; Rosen, N			Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2	ONCOGENE			English	Article						Akt; HER2; cyclin D; ansamycins	HER2/NEU-OVEREXPRESSING METASTATIC BREAST; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOCORTICOID RECEPTOR; MONOCLONAL-ANTIBODY; PHASE-II; GELDANAMYCIN; HSP90	Ansamycin antibiotics, such as 17-allylaminogeldanamycin (17-AAG), bind to Hsp90 and regulate its function, resulting in the proteasomal degradation of a subset of signaling proteins that require Hsp90 for conformational maturation. HER2 is a very sensitive target of these drugs. Ansamycins cause RB-dependent G1 arrest that is associated with loss of D-cyclins via a PI3 kinase, Akt dependent pathway. Downregulation of D-cyclin was due, in part, to loss of Akt expression in response to drug. Moreover, in HER2 overexpressing breast cancer cells, 17-AAG caused rapid inhibition of Akt activity prior to any change in Akt protein. Ansamycins; caused rapid degradation of HER2 and a concomitant loss in HER3 associated PI3 kinase activity. This led to a loss of Akt activity, dephosphorylation of Akt substrates, and loss of D-cyclin expression. Introduction into cells of a constitutively membrane bound form of PI3 kinase prevented the effects of the drug on Akt activity and D-cyclins. Thus, in breast cancer cells with high HER2, Akt activation by HER2/HER3 heterodimers; is required for D-cyclin expression. In murine xenograft models, non-toxic doses of 17-AAG markedly reduced the expression of HER2 and phosphorylation of Akt and inhibited tumor growth. Thus, pharmacological inhibition of Akt activation is achievable with ansamycins and may be useful for the treatment of HER2 driven tumors.	Mem Sloan Kettering Canc Ctr, Program Cell Biol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Pharmacol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Rosen, N (corresponding author), Mem Sloan Kettering Canc Ctr, Program Cell Biol, 1275 York Ave, New York, NY 10021 USA.		Rosen, Neal/ABF-2677-2020; Solit, David B./AAC-5309-2019		NCI NIH HHS [P50 CA068425-05, CA0951, P50 CA 68425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA068425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gilewski T, 2000, CANCER CHEMOTH PHARM, V46, pS23, DOI 10.1007/PL00014044; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Munster PN, 2001, CLIN CANCER RES, V7, P2228; Page C, 2000, ANTICANCER RES, V20, P407; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TAL M, 1988, CANCER RES, V48, P1517; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Webb CP, 2000, CANCER RES, V60, P342; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200	39	236	243	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1159	1166		10.1038/sj.onc.1205184	http://dx.doi.org/10.1038/sj.onc.1205184			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850835	Green Accepted			2022-12-25	WOS:000173729400003
J	Gottlieb, TM; Leal, JFM; Seger, R; Taya, Y; Oren, M				Gottlieb, TM; Leal, JFM; Seger, R; Taya, Y; Oren, M			Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis	ONCOGENE			English	Article						p53; Akt; Mdm2; apoptosis; caspase	TUMOR-SUPPRESSOR PROTEIN; HEMATOPOIETIC-CELLS; CASPASE ACTIVATION; CLEAVAGE; SURVIVAL; AKT/PKB; DOMAIN; KINASE; DEATH	The p53 tumor suppressor protein and the Akt/PKB kinase play important roles in the transduction of proapoptotic and anti-apoptotic signals, respectively. We provide evidence that conflicting signals transduced by Akt and p53 are integrated via negative feedback between the two pathways. On the one hand, the combination of ionizing radiation and survival factor deprivation, which leads to rapid apoptosis of IL-3 dependent DA-1 cells, entails a caspase- and p53-dependent destruction of Akt. This destruction of Akt is not a secondary consequence of apoptosis, since it is not seen when the same cells are triggered to undergo apoptosis under different conditions. On the other hand upon serum stimulation, when Akt becomes active and enhances cell survival, phosphorylation occurs at an Akt consensus site (serine 166) within the Mdm2 protein, a key regulator of p53 function. Taken together, our findings suggest that depending on the balance of signals, p53-dependent downregulation of Akt may promote an irreversible commitment to apoptotic cell death, whereas effective recruitment of Akt by appropriate survival signals may lead to activation of Mdm2, inactivation of p53, and eventually inhibition of p53-dependent apoptosis.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Natl Canc Ctr, Div Radiobiol, Tokyo 1040045, Japan	Weizmann Institute of Science; Weizmann Institute of Science; National Cancer Center - Japan	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Leal, Juan F Martinez/N-6328-2013	Leal, Juan F Martinez/0000-0002-7538-0875; Oren, Moshe/0000-0003-4311-7172	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; GOTTLIEB TM, 1996, BIOCHIM BIOPHYS ACTA, V1267, P77; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Mathieu AL, 2001, J BIOL CHEM, V276, P10935, DOI 10.1074/jbc.M007147200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Someya Y, 2000, J BIOL CHEM, V275, P210, DOI 10.1074/jbc.275.1.210; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141	33	371	385	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1299	1303		10.1038/sj.onc.1205181	http://dx.doi.org/10.1038/sj.onc.1205181			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850850				2022-12-25	WOS:000173729400018
J	Miyazaki, YJ; Hamada, J; Tada, M; Furuuchi, K; Takahashi, Y; Kondo, S; Katoh, H; Moriuchi, T				Miyazaki, YJ; Hamada, J; Tada, M; Furuuchi, K; Takahashi, Y; Kondo, S; Katoh, H; Moriuchi, T			HOXD3 enhances motility and invasiveness through the TGF-beta-dependent and -independent pathways in A549 cells	ONCOGENE			English	Article						homeobox gene; HOXD3; microarray; lung cancer cells; TGF-beta; invasion	GROWTH-FACTOR-BETA; GENE-EXPRESSION; HOMEOBOX GENES; MYELOID-LEUKEMIA; CARCINOMA-CELLS; TUMOR BEHAVIOR; LATENT; FACTOR-BETA-1; ACTIVATION; TGF-BETA-1	Homeobox genes regulate sets of genes that determine cellular fates in embryonic morphogenesis and maintenance of adult tissue architecture by regulating cellular motility and cell-cell interactions. Our previous studies showed that a specific member, HOXD3, when overexpressed, upregulates integrin beta3 expression in human erythroleukemia HEL cells and lung cancer A549 cells, and enhances their motility and invasiveness. We performed a microarray study of over 7075 genes to determine the mechanisms underlying the HOXD3-enhanced motility and invasiveness in A549 cells. RT - PCR-based tracking gene analyses highlighted a set of TGF-beta-upregulated genes, which included matrix metalloproteinase-2, syndecan-1, CD44, and TGF-beta-induced 68 kDa protein. Exogenous TGF-beta also caused this pattern of upregulation in A549 cells and enhanced their migratory and invasive activity, confirming the involvement of TGF-beta signaling. However, HOXD3 reduced the expression of TGF-beta-independent genes coding for desmosomal components such as desmoglein, desmoplakin and plakoglobin which are known to suppress tumor invasion and metastasis. These results suggest that HOXD3 enhances the invasive and metastatic potential of cancer cells through the TGF-beta-dependent and -independent pathways.	Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Med, Div Canc Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University	Hamada, J (corresponding author), Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	jhamada@med.hokudai.ac.jp	Kondo, Satoshi/B-1114-2008; Hamada, Jun-ichi/D-7452-2012					ALBINI A, 1987, CANCER RES, V47, P3239; Apiou F, 1996, CYTOGENET CELL GENET, V73, P114, DOI 10.1159/000134320; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; CILLO C, 1994, INVAS METAST, V14, P38; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; CONN IG, 1990, BRIT J UROL, V65, P176, DOI 10.1111/j.1464-410X.1990.tb14694.x; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Hamada J, 2001, INT J CANCER, V93, P516, DOI 10.1002/ijc.1357; HARADA T, 1992, INT J ORAL MAX SURG, V21, P346, DOI 10.1016/S0901-5027(05)80759-3; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; Hiraki A, 1996, BRIT J CANCER, V73, P1491, DOI 10.1038/bjc.1996.282; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Khalil N, 1999, MICROBES INFECT, V1, P1255, DOI 10.1016/S1286-4579(99)00259-2; Kimelman D, 2000, CURR OPIN GENET DEV, V10, P350, DOI 10.1016/S0959-437X(00)00095-2; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LUCAS C, 1991, METHOD ENZYMOL, V198, P303; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; Massague J, 2000, GENE DEV, V14, P627; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MOORADIAN DL, 1992, J NATL CANCER I, V84, P523, DOI 10.1093/jnci/84.7.523; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Nagayasu H, 1998, BRIT J CANCER, V77, P1371, DOI 10.1038/bjc.1998.229; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nakashio T, 1997, INT J CANCER, V70, P612, DOI 10.1002/(SICI)1097-0215(19970304)70:5<612::AID-IJC20>3.3.CO;2-Y; NEGOESCU A, 1995, EXP CELL RES, V217, P404, DOI 10.1006/excr.1995.1103; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; Penta K, 1999, J BIOL CHEM, V274, P11101, DOI 10.1074/jbc.274.16.11101; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; Shinohara M, 1998, J PATHOL, V184, P369, DOI 10.1002/(SICI)1096-9896(199804)184:4<369::AID-PATH1236>3.0.CO;2-L; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; TANIGUCHI Y, 1995, BLOOD, V85, P2786, DOI 10.1182/blood.V85.10.2786.bloodjournal85102786; TIBERIO C, 1994, INT J CANCER, V58, P608, DOI 10.1002/ijc.2910580426; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Yehualaeshet T, 1999, AM J PATHOL, V155, P841, DOI 10.1016/S0002-9440(10)65183-8; Yu Q, 2000, GENE DEV, V14, P163	46	42	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					798	808		10.1038/sj.onc.1205126	http://dx.doi.org/10.1038/sj.onc.1205126			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850808				2022-12-25	WOS:000173427000011
J	Yang, HB; Kim, O; Wu, J; Qiu, Y				Yang, HB; Kim, O; Wu, J; Qiu, Y			Interaction between tyrosine kinase Etk and a RUN domain- and FYVE domain-containing protein RUFY1 - A possible role of Etk in regulation of vesicle trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; ENDOSOMAL LOCALIZATION; PH-DOMAIN; FINGER; ACTIVATION; ETK/BMX; EFFECTOR; RECEPTOR	Etk/BMX tyrosine kinase is involved in regulation of various cellular processes including proliferation, differentiation, motility, and apoptosis. Through a yeast two-hybrid screening for the effectors of Etk, a new gene family designated as RUFY was identified. The RUFY gene family (RUFY1 and RUFY2) contains an N-terminal RUN domain and a C-terminal FYVE domain with two coiled-coil domains in-between. They appear to be homologues of a recently identified mouse Rabip4 (Cormant, M., Mari, M., Galmiche, A., Hofman, P., and Le Marchand-Brustel, Y. (2001) Proc. Natl. Acad Sci. U. S. A. 98, 1637-1642). RUFY proteins are localized predominantly to endosomes as evidenced by their co-localization with early endosome antigen marker (EEA1). Etk interacts with RUFY1 through its SH3 and SH2 domains. RUFY1 is tyrosine-phosphorylated and appears to be a substrate of Etk. The RUFY1 mutant lacking the phosphorylation sites failed to go to the endosomes. Furthermore, overexpression of Etk in COS-1 and B82L cells resulted in increased plasma membrane localization of the epidermal growth factor receptor and delayed its induced endocytosis in COS-1 cells. The effects of Etk were blocked by the FYVE domain of RUFY1. Interestingly, the FYVE domain of RUFY1 is targeted to the plasma membrane through an interaction between its proline-rich motif and the SH3 domain of Etk or possibly some other membrane-associated SH3 domain-containing protein(s), whereas the lipid binding activity of the FYVE domain is not required. Our data suggest that Etk may be involved in regulation of endocytosis through its interaction with an endosomal protein RUFY1.	Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Qiu, Y (corresponding author), Univ Maryland, Dept Pharmacol & Expt Tech, 655 W Baltimore St, Baltimore, MD 21201 USA.	yqiu@som.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER; NCI NIH HHS [CA85380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Cormont M, 2001, P NATL ACAD SCI USA, V98, P1637, DOI 10.1073/pnas.031586998; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Gaullier JM, 1999, CHEM PHYS LIPIDS, V98, P87, DOI 10.1016/S0009-3084(99)00021-3; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hayakawa A, 2000, J BIOL CHEM, V275, P29636, DOI 10.1074/jbc.M002696200; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Mari M, 2001, J BIOL CHEM, V276, P42501, DOI 10.1074/jbc.M104885200; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Saharinen P, 1997, BLOOD, V90, P4341; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seet LF, 2001, J BIOL CHEM, V276, P42445, DOI 10.1074/jbc.M105917200; Shin ME, 2001, J BIOL CHEM, V276, P41388, DOI 10.1074/jbc.M105665200; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Vihinen Mauno, 1997, Frontiers in Bioscience (online), V2, pD27; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687	24	45	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30219	30226		10.1074/jbc.M111933200	http://dx.doi.org/10.1074/jbc.M111933200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	11877430	hybrid			2022-12-25	WOS:000177509300107
J	Jeon, S; Kim, S; Park, JB; Suh, PG; Kim, YS; Bae, CD; Park, J				Jeon, S; Kim, S; Park, JB; Suh, PG; Kim, YS; Bae, CD; Park, J			RhoA and Rho kinase-dependent phosphorylation of moesin at Thr-558 in hippocampal neuronal cells by glutamate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROCONVULSIVE SHOCK INCREASES; ELEMENT-BINDING PROTEIN; EPIDERMAL GROWTH-FACTOR; RAT HIPPOCAMPUS; ERM PROTEINS; TYROSINE PHOSPHORYLATION; EZRIN/RADIXIN/MOESIN PROTEINS; CONE MORPHOLOGY; IN-VIVO; ACTIVATION	When we were studying phosphorylated proteins in the rat brain after electroconvulsive shock (ECS), we observed the rapid phosphorylation of a 75-kDa protein, which cross-reacted with the anti-phospho-p70 S6 kinase antibody. The phosphorylated protein was purified and identified as moesin, a member of the ezrin/radixin/moesin (ERM) family and a general cross-linker between cortical actin filaments and plasma membranes. The purified moesin from rat brain was phosphorylated at serine and threonine residues. Moesin was rapidly phosphorylated at the threonine 558 residue after ECS in the rat hippocampus, peaked at 1 min, and returned to the basal level by 2 min after ECS. To investigate the mechanism of moesin phosphorylation in neuronal cells, we stimulated a rat hippocampal progenitor cell, H19-7/IGF-IR, with glutamate, and observed the increased phosphorylation of moesin at Thr-558. Glutamate transiently activated RhoA, and constitutively active RhoA increased the basal level phosphorylation of moesin. The inhibition of RhoA and its effector, Rho kinase, abolished increased Thr-558 phosphorylation by glutamate in H19-7/IGF-IR cells, suggesting that the phosphorylation of moesin at Thr-558 in H19-7/IGF-IR cells by glutamate is mediated by RhoA and Rho kinase activation.	Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, Suwon 440746, South Korea; Pohang Inst Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul 110744, South Korea	Sungkyunkwan University (SKKU); Pohang University of Science & Technology (POSTECH); Seoul National University (SNU)	Park, JB (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, Suwon 440746, South Korea.	jbpark@med.skku.ac.kr	Suh, Pann-Ghill/F-3610-2010					AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; Baron C, 1996, J NEUROCHEM, V66, P1005; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 1997, J CELL SCI, V110, P3011; del Pozo MA, 1998, CELL ADHES COMMUN, V6, P125, DOI 10.3109/15419069809004468; FOCHTMANN LJ, 1994, PSYCHOPHARMACOL BULL, V30, P321; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; GonzalezAgosti C, 1996, CELL MOTIL CYTOSKEL, V34, P122, DOI 10.1002/(SICI)1097-0169(1996)34:2<122::AID-CM4>3.0.CO;2-D; Jeon SH, 1997, NEUROPHARMACOLOGY, V36, P411; Jeon SH, 2001, BIOCHEM BIOPH RES CO, V282, P1026, DOI 10.1006/bbrc.2001.4686; KANG UG, 1994, J NEUROCHEM, V63, P1979; Kang UG, 2000, NEUROPHARMACOLOGY, V39, P703, DOI 10.1016/S0028-3908(99)00184-7; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; KRIEG J, 1992, J BIOL CHEM, V267, P19258; LEE YH, 1993, BIOCHEM BIOPH RES CO, V194, P665, DOI 10.1006/bbrc.1993.1873; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; Oh SW, 1999, NEUROSCI LETT, V271, P101, DOI 10.1016/S0304-3940(99)00535-2; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Paglini G, 1998, J CELL BIOL, V143, P443, DOI 10.1083/jcb.143.2.443; Pende M, 1997, J NEUROSCI, V17, P1291; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; ROWLEY HL, 1995, NEUROSCIENCE, V68, P415, DOI 10.1016/0306-4522(95)00159-G; SCHWARTZALBIEZ R, 1995, EUR J CELL BIOL, V67, P189; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; VAN AL, 1997, GENE DEV, V11, P2295; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999	38	51	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16576	16584		10.1074/jbc.M110380200	http://dx.doi.org/10.1074/jbc.M110380200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867620	hybrid			2022-12-25	WOS:000175564500033
J	Kustanovich, I; Shalev, DE; Mikhlin, M; Gaidukov, L; Mor, A				Kustanovich, I; Shalev, DE; Mikhlin, M; Gaidukov, L; Mor, A			Structural requirements for potent versus selective cytotoxicity for antimicrobial dermaseptin S4 derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; SURFACE-PLASMON RESONANCE; NUCLEAR-MAGNETIC-RESONANCE; PEPTIDE ANTIBIOTICS; PHOSPHOLIPID-MEMBRANES; AQUEOUS-SOLUTIONS; NMR-SPECTROSCOPY; DRUG-RESISTANCE; INNATE IMMUNITY; CHEMICAL-SHIFT	To better understand the structural requirements for selective cytotoxicity of antimicrobial peptides, seven dermaseptin S4 analogs were produced and investigated with respect to molecular organization in solution, binding properties to model phospholipid membranes, and cytotoxic properties. Native dermaseptin S4 displayed high aggregation in solution and high binding affinity. These properties correlated with high cytotoxicity. Yet, potency was progressively limited when facing cells whose plasma membrane was surrounded by increasingly complex barriers. Increasing the positive charge of the native peptide led to partial depolymerization that correlated with higher binding affinity and with virtually non-discriminative high cytotoxicity against all cell types. The C-terminal hydrophobic domain was found responsible for binding to membranes but not for their disruption. Truncations of the C terminus combined with increased positive charge of the N-terminal domain resulted in short peptides having similar binding affinity as the parent compound but displaying selective activity against microbes with reduced toxicity toward human red blood cells. Nuclear magnetic resonance-derived three-dimensional structures of three active derivatives enabled the delineation of a common amphipathic structure with a clear separation of two lobes of positive and negative electrostatic potential surfaces. Whereas the spatial positive electrostatic potential extended considerably beyond the peptide dimensions and was required for potency, selectivity was affected primarily by hydrophobicity. The usefulness of this approach for the design of potent and/or selective cytolytic peptides is discussed herein.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Kustanovich, I (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Safra Campus, IL-91904 Jerusalem, Israel.	irinak@macbeth.Is.huji.ac.il	Shalev, Deborah E/AAY-2873-2021					Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x; Avrahami D, 2001, BIOCHEMISTRY-US, V40, P12591, DOI 10.1021/bi0105330; BAX A, 1989, ANNU REV BIOCHEM, V58, P223; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; Blondelle SE, 2000, BIOPOLYMERS, V55, P74, DOI 10.1002/1097-0282(2000)55:1&lt;74::AID-BIP70&gt;3.0.CO;2-S; Boisbouvier J, 1998, EUR J BIOCHEM, V257, P263, DOI 10.1046/j.1432-1327.1998.2570263.x; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BROWN LR, 1980, BIOCHIM BIOPHYS ACTA, V622, P231, DOI 10.1016/0005-2795(80)90034-3; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; Chen J, 2000, BIOPOLYMERS, V55, P88, DOI 10.1002/1097-0282(2000)55:1<88::AID-BIP80>3.3.CO;2-B; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Cooper MA, 1998, BBA-BIOMEMBRANES, V1373, P101, DOI 10.1016/S0005-2736(98)00091-1; Davies J, 1996, NATURE, V383, P219, DOI 10.1038/383219a0; DENOBEL JG, 1991, YEAST, V7, P313, DOI 10.1002/yea.320070402; Feder R, 2000, J BIOL CHEM, V275, P4230, DOI 10.1074/jbc.275.6.4230; Feder R, 2001, PEPTIDES, V22, P1683, DOI 10.1016/S0196-9781(01)00504-6; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Ghosh J.K.., 1997, J BIOL CHEM, V267, P6502; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; Gura T, 2001, SCIENCE, V291, P2068, DOI 10.1126/science.291.5511.2068; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HERNANDEZ C, 1992, EUR J CELL BIOL, V59, P414; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hirota N, 1998, J MOL BIOL, V275, P365, DOI 10.1006/jmbi.1997.1468; HONIG B, 1993, J PHYS CHEM-US, V97, P1101, DOI 10.1021/j100108a002; Huang HW, 2000, BIOCHEMISTRY-US, V39, P8347, DOI 10.1021/bi000946l; JIMENEZ MA, 1987, FEBS LETT, V221, P320, DOI 10.1016/0014-5793(87)80948-1; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Jouenne T, 1998, J ANTIMICROB CHEMOTH, V42, P87, DOI 10.1093/jac/42.1.87; Krugliak M, 2000, ANTIMICROB AGENTS CH, V44, P2442, DOI 10.1128/AAC.44.9.2442-2451.2000; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lamb HM, 1998, DRUGS, V56, P1047, DOI 10.2165/00003495-199856060-00011; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Levy O, 2000, BLOOD, V96, P2664; MALOY LW, 1995, BIOPOLYMERS, V37, P105; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; MERUTKA G, 1995, J BIOMOL NMR, V5, P14, DOI 10.1007/BF00227466; MILIK M, 1993, PROTEINS, V15, P10, DOI 10.1002/prot.340150104; MOR A, 1994, BIOCHEMISTRY-US, V33, P6642, DOI 10.1021/bi00187a034; MOR A, 1994, J BIOL CHEM, V269, P1934; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; Mor A., 2001, KIRKOTHMER ENCY CHEM; Navon-Venezia S, 2002, ANTIMICROB AGENTS CH, V46, P689, DOI 10.1128/AAC.46.3.689-694.2002; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; NILGES M, 1991, NATO ADV SCI I A-LIF, V225, P451; Oren Z, 1998, BIOPOLYMERS, V47, P451; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; Sharon M, 1999, BIOCHEMISTRY-US, V38, P15305, DOI 10.1021/bi991225t; SOBALLE PW, 1995, INT J CANCER, V60, P280; Sokolov Y, 1999, BBA-BIOMEMBRANES, V1420, P23, DOI 10.1016/S0005-2736(99)00086-3; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; STRAHILEVITZ J, 1994, BIOCHEMISTRY-US, V33, P10951, DOI 10.1021/bi00202a014; Tanford C., 1980, HYDROPHOBIC EFFECT F, V2; Tossi A, 2000, BIOPOLYMERS, V55, P4; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; Uematsu N, 2000, BIOPHYS J, V79, P2075, DOI 10.1016/S0006-3495(00)76455-1; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; Wang W, 1998, J BIOL CHEM, V273, P27438, DOI 10.1074/jbc.273.42.27438; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; *WHO, 1995, WHO TECH REP SER, V850; WHOTE SH, 1998, BIOCHIM BIOPHYS ACTA, V1376, P339; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4	72	137	143	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16941	16951		10.1074/jbc.M111071200	http://dx.doi.org/10.1074/jbc.M111071200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11847217	hybrid			2022-12-25	WOS:000175564500081
J	Doi, J; Takemori, H; Lin, XZ; Horike, N; Katoh, Y; Okamoto, M				Doi, J; Takemori, H; Lin, XZ; Horike, N; Katoh, Y; Okamoto, M			Salt-inducible kinase represses cAMP-dependent protein kinase-mediated activation of human cholesterol side chain cleavage cytochrome P450 promoter through the CREB basic leucine zipper domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; BOVINE ADRENOCORTICAL-CELLS; TRANSCRIPTION FACTOR; CYCLIC-AMP; GENE-TRANSCRIPTION; EXPRESSION; CYP11A1; PHOSPHORYLATION; CLONING; REGION	Salt-inducible kinase (SIK), one of the serine/threonine protein kinases, was transiently expressed in Y1 cells during the early phase of the ACTH/cAMP-dependent protein kinase (PKA)-mediated signal transduction. The overexpression of SIK(N), the SIK's N-terminal kinase domain, repressed the expression of the side chain cleavage cytochrome P450 (CYP11A) gene. To elucidate the mechanism of the repression by SIK, several CYP11A promoter constructs were tested for the promoter activities in the presence of PKA and/or SIK(N). A cAMP-response element (CRE)-like sequence present in the promoter was shown to be responsible not only for the PKA-mediated promoter activation but also for the SIK(N)-mediated repression. When the Gal4 DNA binding domain-linked full-length CRE-binding protein (CREB) construct was cotransfected with Gal4 reporter gene, SIK(N) repressed the PKA-induced reporter gene expression. However, SIK(N) could not repress the PKA. induced reporter activity conferred by Gal4 DNA binding domain-linked basic leucine zipper (bZIP)-less CREB or bZIP-disrupted CREB. On the other hand, SIK(N) could repress the kinase-inducible domain-disrupted CREB-dependent reporter gene expression in the presence of PKA. The in vitro kinase reaction studies showed that SIK(N) could not phosphorylate CREB, and PKA failed to phosphorylate SIK(N). Taken together, these results suggest that SIK(N), cooperating with PKA, may act on the CREB's bZIP domain and repress the CREB-mediated transcriptional activation of the CYP11A gene.	Osaka Univ, Med Sch H 1, Dept Mol Physiol Chem, Suita, Osaka 5650871, Japan; Kinran Coll, Dept Life Sci, Osaka 5650873, Japan	Osaka University	Okamoto, M (corresponding author), Osaka Univ, Med Sch H 1, Dept Mol Physiol Chem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mokamoto@mr-mbio.med.osaka-u.ac.jp						AHLGREN R, 1990, J BIOL CHEM, V265, P3313; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; Ariyoshi N, 1998, J BIOL CHEM, V273, P7610, DOI 10.1074/jbc.273.13.7610; Bassett MH, 2000, ENDOCR RES, V26, P941, DOI 10.3109/07435800009048620; Bird IM, 1998, J CLIN ENDOCR METAB, V83, P1592, DOI 10.1210/jc.83.5.1592; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chen CC, 2000, LIFE SCI, V67, P2045, DOI 10.1016/S0024-3205(00)00790-6; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; Chung BC, 1997, STEROIDS, V62, P37, DOI 10.1016/S0039-128X(96)00156-0; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; Fass DM, 2001, J BIOL CHEM, V276, P2992, DOI 10.1074/jbc.M008274200; Felinski EA, 1999, J BIOL CHEM, V274, P11672, DOI 10.1074/jbc.274.17.11672; Felinski EA, 2001, MOL CELL BIOL, V21, P1001, DOI 10.1128/MCB.21.4.1001-1010.2001; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Gavaravarapu S, 2000, BIOCHEM BIOPH RES CO, V269, P758, DOI 10.1006/bbrc.2000.2358; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Groussin L, 2000, J CLIN ENDOCR METAB, V85, P345, DOI 10.1210/jc.85.1.345; GUO IC, 1994, J BIOL CHEM, V269, P6362; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hirai S, 1996, ONCOGENE, V12, P641; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hong SH, 2001, J BIOL CHEM, V276, P28098, DOI 10.1074/jbc.M010912200; Hu MC, 2001, MOL ENDOCRINOL, V15, P812, DOI 10.1210/me.15.5.812; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; JOHN ME, 1986, MOL CELL ENDOCRINOL, V45, P197, DOI 10.1016/0303-7207(86)90148-6; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200; KRAMER RE, 1984, J BIOL CHEM, V259, P707; KRAMER RE, 1983, STEROIDS, V41, P207, DOI 10.1016/0039-128X(83)90008-9; Lefebvre DL, 2001, BIOCHEM J, V355, P297, DOI 10.1042/0264-6021:3550297; Lin XZ, 2001, MOL ENDOCRINOL, V15, P1264, DOI 10.1210/me.15.8.1264; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OLSON MF, 1993, MOL ENDOCRINOL, V7, P477, DOI 10.1210/me.7.4.477; Parker D, 1996, MOL CELL BIOL, V16, P694; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Reddy UR, 1999, ONCOGENE, V18, P4474, DOI 10.1038/sj.onc.1202813; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; RICE DA, 1990, J BIOL CHEM, V265, P11713; Schumacher MA, 2000, J BIOL CHEM, V275, P35242, DOI 10.1074/jbc.M007293200; Shaywitz AJ, 2000, MOL CELL BIOL, V20, P9409, DOI 10.1128/MCB.20.24.9409-9422.2000; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Stocco DM, 2000, BBA-MOL CELL BIOL L, V1486, P184, DOI 10.1016/S1388-1981(00)00056-1; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKAYAMA K, 1994, J BIOCHEM-TOKYO, V116, P193, DOI 10.1093/oxfordjournals.jbchem.a124493; Takemori H, 2001, EUR J BIOCHEM, V268, P205, DOI 10.1046/j.1432-1327.2001.01847.x; Wang ZN, 1999, FEBS LETT, V453, P135, DOI 10.1016/S0014-5793(99)00708-5; WATANABE N, 1994, EUR J BIOCHEM, V222, P825, DOI 10.1111/j.1432-1033.1994.tb18929.x; WHITE PC, 1987, NEW ENGL J MED, V316, P1519, DOI 10.1056/NEJM198706113162406; Wu XL, 2001, J BIOL CHEM, V276, P1735, DOI 10.1074/jbc.M006727200	64	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15629	15637		10.1074/jbc.M109365200	http://dx.doi.org/10.1074/jbc.M109365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864972	hybrid			2022-12-25	WOS:000175510400056
J	Nelson, SW; Honzatko, RB; Fromm, HJ				Nelson, SW; Honzatko, RB; Fromm, HJ			Hybrid tetramers of porcine liver fructose-1,6-bisphosphatase reveal multiple pathways of allosteric inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE; SITE-DIRECTED MUTAGENESIS; L-LACTATE DEHYDROGENASE; FRUCTOSE 2,6-BISPHOSPHATE; ASPARTATE TRANSCARBAMOYLASE; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; AMP INHIBITION; LIGAND-BINDING; DYNAMIC LOOP	Fructose-1,6-bisphosphatase is a square planar tetramer of identical subunits, which exhibits cooperative allosteric inhibition of catalysis by AMP. Protocols for in vitro subunit exchange provide three of five possible hybrid tetramers of fructose-1,6-bisphosphatase in high purity. The two hybrid types with different subunits in the top and bottom halves of the tetramer co-purify. Hybrid tetramers, formed from subunits unable to bind AMP and subunits with wild-type properties, differ from the wild-type enzyme only in regard to their properties of AMP inhibition. Hybrid tetramers exhibit cooperative, potent, and complete (100%) AMP inhibition if at least one functional AMP binding site exists in the top and bottom halves of the tetramer. Furthermore, titrations of hybrid tetramers with AMP, monitored by a tryptophan reporter group, reveal cooperativity and fluorescence changes consistent with an R- to T-state transition, provided that again at least one functional AMP site exists in the top and bottom halves of the tetramer. In contrast, hybrid tetramers, which have functional AMP binding sites in only one half (top/bottom), exhibit an R- to T-state transition and complete AMP inhibition, but without cooperativity. Evidently, two pathways of allosteric inhibition of fructose-1,6-bisphosphatase are possible, only one of which is cooperative.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.				NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carcamo JG, 2000, EUR J BIOCHEM, V267, P2242, DOI 10.1046/j.1432-1327.2000.01227.x; Chiadmi M, 1999, EMBO J, V18, P6809, DOI 10.1093/emboj/18.23.6809; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; CORNISHBOWDEN AJ, 1971, J BIOL CHEM, V246, P3092; Fushinobu S, 1998, J BIOL CHEM, V273, P2971, DOI 10.1074/jbc.273.5.2971; Fushinobu S, 1996, J BIOL CHEM, V271, P25611, DOI 10.1074/jbc.271.41.25611; GIBBONS I, 1976, BIOCHEMISTRY-US, V15, P1324, DOI 10.1021/bi00651a024; GIBBONS I, 1976, BIOCHEMISTRY-US, V15, P52, DOI 10.1021/bi00646a009; Iversen LF, 1997, PROTEIN SCI, V6, P971, DOI 10.1002/pro.5560060503; KE H, 1990, J MOL BIOL, V212, P513, DOI 10.1016/0022-2836(90)90329-K; KE HM, 1991, P NATL ACAD SCI USA, V88, P2989, DOI 10.1073/pnas.88.8.2989; Kelley N, 1996, BIOCHEM BIOPH RES CO, V219, P848, DOI 10.1006/bbrc.1996.0321; Kelley-Loughnane N, 2001, PROTEINS, V44, P255, DOI 10.1002/prot.1090; Kurbanov FT, 1998, J BIOL CHEM, V273, P17511, DOI 10.1074/jbc.273.28.17511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE RS, 1986, J BIOL CHEM, V261, P3079; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LIU F, 1988, J BIOL CHEM, V263, P9122; LU G, 1997, J BIOL CHEM, V297, P5076; Lu GQ, 1996, PROTEIN SCI, V5, P2333, DOI 10.1002/pro.5560051120; LUI F, 1990, J BIOL CHEM, V265, P7401; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; Nelson SW, 2001, J BIOL CHEM, V276, P6119, DOI 10.1074/jbc.M009485200; Nelson SW, 2001, FEBS LETT, V492, P254, DOI 10.1016/S0014-5793(01)02262-1; Nelson SW, 2000, BIOCHEMISTRY-US, V39, P11100, DOI 10.1021/bi000609c; Nelson SW, 2000, J BIOL CHEM, V275, P29986, DOI 10.1074/jbc.M000473200; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; Roitel O, 1999, BIOCHEMISTRY-US, V38, P16084, DOI 10.1021/bi9912802; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; Shyur LF, 1997, J BIOL CHEM, V272, P26295, DOI 10.1074/jbc.272.42.26295; Shyur LF, 1996, J BIOL CHEM, V271, P3005, DOI 10.1074/jbc.271.6.3005; Shyur LF, 1996, BIOCHEMISTRY-US, V35, P7492, DOI 10.1021/bi960367+; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Van Schaftingen E., 1987, ADV ENZYMOL RELAT AR, V59, P45; Wen J, 2001, PHOTOCHEM PHOTOBIOL, V74, P679, DOI 10.1562/0031-8655(2001)074<0679:EOTIPF>2.0.CO;2; XUE YF, 1994, P NATL ACAD SCI USA, V91, P12482, DOI 10.1073/pnas.91.26.12482; YANG YR, 1980, P NATL ACAD SCI-BIOL, V77, P5187, DOI 10.1073/pnas.77.9.5187; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	47	21	21	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15539	15545		10.1074/jbc.M112304200	http://dx.doi.org/10.1074/jbc.M112304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854289	Green Published, hybrid			2022-12-25	WOS:000175510400043
J	Obukhov, AG; Nowycky, MC				Obukhov, AG; Nowycky, MC			TRPC4 can be activated by G-protein-coupled receptors and provides sufficient Ca2+ to trigger exocytosis in neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; PDZ-DOMAIN PROTEIN; TRANSIENT RECEPTOR; CALCIUM CURRENT; ANGIOTENSIN-II; PC12 CELLS; CHANNEL; ENTRY; DEPLETION; RELEASE	Transient receptor potential (TRP) channels form a large family of plasma membrane cation channels. Mammalian members of the "short" TRP family (TRP channel (TRPC) 1-7 are Ca2+-permeant, non-selective cation channels that are widely expressed in various cell types, including neurons. TRPC activity is linked through unknown mechanisms to G-protein-coupled receptors or receptor tyrosine kinases that activate phospholipase C. To investigate the properties and function of TRPC4 in neuronally derived cells, we transiently expressed mouse TRPC4 and histamine H-1 receptor in mouse adrenal chromaffin cells and PC12 cells. Histamine, but not thapsigargin, stimulated Mn2+ influx in transfected cells. In the whole-cell patch clamp mode, histamine triggered a transient current in TRPC4-expressing cells. No current was evoked by perfusion with inositol 1,4,5-trisphosphate. When exocytosis was monitored with the capacitance detection technique, the magnitude of the membrane capacitance increase (DeltaC(m)) on application of histamine in H-1 receptor/TRPC4-expressing chromaffin cells was comparable with that triggered by a train of depolarizing pulses. Our results indicate that TRPC4 channels behave as receptor, but not store-operated, channels in neuronally derived cells. TRPC4 channels can provide sufficient Ca2+ influx to trigger a robust secretory response in voltage-clamped neurosecretory cells. Similar mechanisms may modulate exocytosis in other neuronal systems.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Nowycky, MC (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave, Newark, NJ 07103 USA.	mnowycky@compuserve.com	Obukhov, Alexander G/C-7246-2008	Obukhov, Alexander G/0000-0002-3862-6004	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040167] Funding Source: NIH RePORTER; NINDS NIH HHS [NS40167] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; CHEEK TR, 1993, J CELL SCI, V105, P913; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; Currie KPM, 2000, J NEUROPHYSIOL, V83, P1435, DOI 10.1152/jn.2000.83.3.1435; Elhamdani A, 2000, J NEUROSCI, V20, P2495; Fomina AF, 1999, J NEUROSCI, V19, P3711; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Gillis Kevin D., 1995, P155; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kiselyov K, 1999, TRENDS NEUROSCI, V22, P334, DOI 10.1016/S0166-2236(99)01426-5; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Mori Y, 1998, NEUROREPORT, V9, P507; Moser T, 1997, P NATL ACAD SCI USA, V94, P6735, DOI 10.1073/pnas.94.13.6735; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; SEWARD EP, 1995, J NEUROSCI, V15, P3390; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; Singh BB, 2001, FASEB J, V15, P1652, DOI 10.1096/fj.00-0749fje; Smith C, 1999, J NEUROSCI, V19, P589; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Teschemacher AG, 2000, J NEUROSCI, V20, P4776; Tesfai Y, 2001, BIOCHEM J, V358, P717, DOI 10.1042/0264-6021:3580717; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Tischler AS, 1997, FUND APPL TOXICOL, V35, P216, DOI 10.1006/faat.1996.2277; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Zerbes M, 1998, CELL CALCIUM, V23, P379, DOI 10.1016/S0143-4160(98)90094-X; Zerbes M, 2001, CELL CALCIUM, V29, P49, DOI 10.1054/ceca.2000.0160; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	45	66	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16172	16178		10.1074/jbc.M111664200	http://dx.doi.org/10.1074/jbc.M111664200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856742	hybrid			2022-12-25	WOS:000175510400127
J	Pisarev, AV; Skabkin, MA; Thomas, AA; Merrick, WC; Ovchinnikov, LP; Shatsky, IN				Pisarev, AV; Skabkin, MA; Thomas, AA; Merrick, WC; Ovchinnikov, LP; Shatsky, IN			Positive and negative effects of the major mammalian messenger ribonucleoprotein p50 on binding of 40 S ribosomal subunits to the initiation codon of beta-globin mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-ASSOCIATED PROTEIN; TRANSLATION INITIATION; ENCEPHALOMYOCARDITIS VIRUS; EXTENSION INHIBITION; TRANSCRIPTION FACTOR; CYTOPLASMIC MRNP; XENOPUS-OOCYTES; SOMATIC-CELLS; CORE PROTEIN; IN-VITRO	p50, the major core protein bound to mammalian mRNAs, has been reported to stimulate translation at low p50/mRNA ratios and inhibit translation at high p50/mRNA ratios. This study aims to address the molecular mechanisms underlying these phenomena using the in vitro assembly of 48 S preinitiation complexes from fully purified translational components in the presence or absence of p50 as analyzed by the toeprint assay. With limited concentrations of eIF2, eIF3, and eIF4F, p50 (but not pyrimidine tract-binding protein, which was taken for comparison) strongly stimulates formation of the 48 S preinitiation complexes with beta-globin mRNA. This stimulation is observed when just a few molecules of p50 are bound per molecule of the mRNA. When the amount of p50 in solution is increased over some threshold p50/mRNA ratio, a remarkable repression is observed that can still be relieved by adding more eIF2 and eIF4F. At even higher concentrations of p50, the inhibitory effect becomes irreversible. The threshold ratio depends upon the extent of secondary structure of the 5'-untranslated region linked to the P-globin coding region. Chemical probing has confirmed that the binding of p50 to mRNA involves only the sugar-phosphate backbone of the mRNA leaving nucleotide bases free for interaction with other messenger ribonucleoprotein (mRNP) components. These data are best compatible with the functional role of p50 as a "manager" of mRNA-protein interactions in mammalian mRNPs.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia; Univ Utrecht, Dept Dev Biol, NL-3584 CH Utrecht, Netherlands; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Lomonosov Moscow State University; Russian Academy of Sciences; Utrecht University; Case Western Reserve University	Shatsky, IN (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia.	Shatsky@libro.genebee.msu.su	Ovchinnikov, Lev/L-2397-2015; Shatsky, Ivan N/A-5331-2012					ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; Belsham GJ, 2000, TRENDS MICROBIOL, V8, P330, DOI 10.1016/S0966-842X(00)01788-1; BOROVJAGIN A, 1994, FEBS LETT, V351, P299, DOI 10.1016/0014-5793(94)00848-5; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HELLEN CUT, 1994, J VIROL, V68, P941, DOI 10.1128/JVI.68.2.941-950.1994; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HUTTENHOFER A, 1994, EMBO J, V13, P3892, DOI 10.1002/j.1460-2075.1994.tb06700.x; JAIN SK, 1979, FEBS LETT, V97, P84, DOI 10.1016/0014-5793(79)80058-7; KASPERAITIS MAM, 1995, FEBS LETT, V365, P47, DOI 10.1016/0014-5793(95)00427-B; Kolupaeva VG, 1996, RNA, V2, P1199; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; MINICH WB, 1993, EUR J BIOCHEM, V212, P633, DOI 10.1111/j.1432-1033.1993.tb17701.x; MINICH WB, 1990, MOL BIOL REP, V14, P65, DOI 10.1007/BF00360418; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Skabkin MA, 2001, J BIOL CHEM, V276, P44841, DOI 10.1074/jbc.M107581200; Sonenberg N, 1998, NAT STRUCT BIOL, V5, P172, DOI 10.1038/nsb0398-172; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; TZAREVA NV, 1994, FEBS LETT, V337, P189, DOI 10.1016/0014-5793(94)80271-8; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	38	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15445	15451		10.1074/jbc.M111954200	http://dx.doi.org/10.1074/jbc.M111954200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854282	hybrid			2022-12-25	WOS:000175510400031
J	Stone, JR; Collins, T				Stone, JR; Collins, T			Rapid phosphorylation of heterogeneous nuclear ribonucleoprotein C1/C2 in response to Physiologic levels of hydrogen peroxide in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; OXYR TRANSCRIPTION FACTOR; LAMINAR SHEAR-STRESS; GROWTH-FACTOR; NADPH OXIDASE; C-PROTEINS; HNRNP C; TYROSINE PHOSPHORYLATION; H2O2 GENERATION	Hydrogen peroxide (H2O2) has been implicated as a signaling agent in numerous signal transduction pathways in mammalian cells. However, to date, no sensor for low concentrations (<10 mu M) of H2O2 has been identified. Using a functional proteomic approach, nuclear extracts from human umbilical vein endothelial cells were analyzed by two-dimensional PAGE with or without prior treatment with a low concentration of H2O2. A protein doublet with a molecular mass of 39-41 kDa and a pI of similar to 5.0 was observed to be consistently altered by the treatment. Using proteolytic peptide mass fingerprinting, the protein was identified as heterogeneous nuclear ribonucleoprotein C1/C2, a nuclear restricted, pre-mRNA-binding protein. Upon two-dimensional PAGE, each heterogeneous nuclear ribonucleoprotein-C splice form was present as multiple spots because of differing levels of phosphorylation. Upon treatment with H2O2, there was an increase in phosphorylation at 10-20 min, which partially reversed by 30 min. Subsequently, at 60 min after treatment, a population of unphosphorylated protein was transiently present. The effects were observed with as little as 1 mu M H2O2 and were maximal with 5-8 mu M H2O2. The H2O2-stimulated phosphorylation was inhibited by catalase, but not by the transcriptional inhibitor actinomycin D.	Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Collins, T (corresponding author), Childrens Hosp, Dept Pathol, 300 Longwood Ave, Boston, MA 02115 USA.	tcollins@rics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035716, T32HL007627] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07627, R37 HL35716] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barchowsky A, 1995, AM J PHYSIOL-LUNG C, V269, pL829, DOI 10.1152/ajplung.1995.269.6.L829; BARNETT SF, 1989, MOL CELL BIOL, V9, P492, DOI 10.1128/MCB.9.2.492; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brown MR, 1999, CIRC RES, V85, P524, DOI 10.1161/01.RES.85.6.524; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Burdon RH, 1996, FREE RADICAL RES, V24, P81, DOI 10.3109/10715769609088004; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chae HJ, 2000, IMMUNOPHARM IMMUNOT, V22, P317, DOI 10.3109/08923970009016423; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fung PA, 1997, P NATL ACAD SCI USA, V94, P1064, DOI 10.1073/pnas.94.4.1064; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Greene EL, 2000, AM J PHYSIOL-RENAL, V278, pF650, DOI 10.1152/ajprenal.2000.278.4.F650; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Heinloth A, 2000, J AM SOC NEPHROL, V11, P1819, DOI 10.1681/ASN.V11101819; Herbert JM, 1996, FEBS LETT, V395, P43, DOI 10.1016/0014-5793(96)00998-2; HOLCOMB ER, 1984, J BIOL CHEM, V259, P31; Junn E, 2000, J IMMUNOL, V165, P2190, DOI 10.4049/jimmunol.165.4.2190; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; Mayrand SH, 1996, MOL CELL BIOL, V16, P1241; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Ohguro N, 1999, BRIT J OPHTHALMOL, V83, P1064, DOI 10.1136/bjo.83.9.1064; OHNO Y, 1985, J BIOL CHEM, V260, P8438; Ostrovidov S, 1998, IN VITRO CELL DEV-AN, V34, P259; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; Sella O, 1999, MOL CELL BIOL, V19, P5429; Slomiany BA, 2000, BIOTECHNIQUES, V28, P938, DOI 10.2144/00285st08; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thannickal VJ, 2000, FASEB J, V14, P1741, DOI 10.1096/fj.99-0878com; Torres M, 1999, ARCH BIOCHEM BIOPHYS, V366, P231, DOI 10.1006/abbi.1999.1225; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Williamson DJ, 2000, MOL CELL BIOL, V20, P4094, DOI 10.1128/MCB.20.11.4094-4105.2000; Yasuda M, 1998, LIFE SCI, V64, P249, DOI 10.1016/S0024-3205(98)00560-8; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	59	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15621	15628		10.1074/jbc.M112153200	http://dx.doi.org/10.1074/jbc.M112153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877401	hybrid			2022-12-25	WOS:000175510400055
J	Villalobos, C; Nunes, L; Montero, M; Garcia, AG; Alonso, MT; Chamero, P; Alvarez, J; Garcia-Sancho, J				Villalobos, C; Nunes, L; Montero, M; Garcia, AG; Alonso, MT; Chamero, P; Alvarez, J; Garcia-Sancho, J			Redistribution of Ca2+ among cytosol and organella during stimulation of bovine chromaffin cells	FASEB JOURNAL			English	Article						calcium; mitochondria; aequorin; nucleus	ENDOPLASMIC-RETICULUM; SYMPATHETIC NEURONS; CALCIUM; MITOCHONDRIA; RELEASE; PARTICIPATION; MICRODOMAINS; CLEARANCE; AEQUORIN; KINETICS	Recent results indicate that Ca2+ transport by organella contributes to shaping Ca2+ signals and exocytosis in adrenal chromaffin cells. Therefore, accurate measurements of [Ca2+] inside cytoplasmic organella are essential for a comprehensive analysis of the Ca2+ redistribution that follows cell stimulation. Here we have studied changes in Ca2+ inside the endoplasmic reticulum, mitochondria, and nucleus by imaging aequorins targeted to these compartments in cells stimulated by brief depolarizing pulses with high K+ solutions. We find that Ca2+ entry through voltage-gated Ca2+ channels generates subplasmalemmal high [Ca2+](c) domains adequate for triggering exocytosis. A smaller increase of [Ca2+](c) is produced in the cell core, which is adequate for recruitment of the reserve pool of secretory vesicles to the plasma membrane. Most of the Ca2+ load is taken up by a mitochondrial pool, M1, closer to the plasma membrane; the increase of [Ca2+](M) stimulates respiration in these mitochondria, providing local support for the exocytotic process. Relaxation of the [Ca2+](c) transient is due to Ca2+ extrusion through the plasma membrane. At this stage, mitochondria release Ca2+ to the cytosol through the Na+/Ca2+ exchanger, thus maintaining [Ca2+](c) discretely increased, especially at core regions of the cell, for periods that outlast the duration of the stimulus.	Fac Med, Dept Bioquim & Fisiol, Consejo Super Invest Cient, E-47005 Valladolid, Spain; Univ Valladolid, IBGM, E-47005 Valladolid, Spain; Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, Inst Teofilo Hernando, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Autonomous University of Madrid	Garcia-Sancho, J (corresponding author), Fac Med, IBGM, Dept Bioquim & Fisiol, E-47005 Valladolid, Spain.	jgsancho@ibgm.uva.es	Alvarez, Javier/K-8210-2014; Villalobos, Carlos/M-9839-2017; Alonso Alonso, Maria Teresa/K-5003-2014; Montero, Mayte/K-8212-2014; GARCIA, ANTONIO G/E-9961-2018; Garcia-Sancho, Javier/K-2975-2014	Alvarez, Javier/0000-0003-0636-5521; Villalobos, Carlos/0000-0002-0429-3846; Montero, Mayte/0000-0001-7702-6653; GARCIA, ANTONIO G/0000-0002-6517-3565; Nunez, Lucia/0000-0002-9638-5747; Garcia-Sancho, Javier/0000-0003-4573-7930; Chamero, Pablo/0000-0002-4305-1073				Alonso MT, 1998, CELL CALCIUM, V24, P87, DOI 10.1016/S0143-4160(98)90076-8; Alonso MT, 1999, J CELL BIOL, V144, P241, DOI 10.1083/jcb.144.2.241; Alvarez J, 1999, NEWS PHYSIOL SCI, V14, P161; Alvarez Javier, 2001, P147; ARTALEJO CR, 1987, J BIOL CHEM, V262, P915; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Colegrove SL, 2000, J GEN PHYSIOL, V115, P351, DOI 10.1085/jgp.115.3.351; COLL KE, 1982, J BIOL CHEM, V257, P8696; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; FRAWLEY LS, 1994, ENDOCRINOLOGY, V135, P468, DOI 10.1210/en.135.1.468; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HOLMAN ME, 1994, J PHYSIOL-LONDON, V478, P115, DOI 10.1113/jphysiol.1994.sp020235; Horikawa Y, 1998, BIOPHYS J, V74, P1579, DOI 10.1016/S0006-3495(98)77869-5; Mogami H, 1999, J PHYSIOL-LONDON, V518, P463, DOI 10.1111/j.1469-7793.1999.0463p.x; Montero M, 1997, FASEB J, V11, P881, DOI 10.1096/fasebj.11.11.9285486; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Montero M, 2001, MOL BIOL CELL, V12, P63, DOI 10.1091/mbc.12.1.63; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Naraghi M, 1998, BIOPHYS J, V75, P1635, DOI 10.1016/S0006-3495(98)77606-4; Neher E, 1998, CELL CALCIUM, V24, P345, DOI 10.1016/S0143-4160(98)90058-6; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Nunez L, 1995, AM J PHYSIOL-CELL PH, V269, pC1540, DOI 10.1152/ajpcell.1995.269.6.C1540; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Park YB, 1996, J PHYSIOL-LONDON, V492, P329, DOI 10.1113/jphysiol.1996.sp021312; Petersen OH, 1996, TRENDS NEUROSCI, V19, P411; Pivovarova NB, 1999, J NEUROSCI, V19, P6372; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; UCEDA G, 1995, EUR J PHARM-MOLEC PH, V289, P73, DOI 10.1016/0922-4106(95)90170-1; Xu T, 1997, BIOPHYS J, V73, P532, DOI 10.1016/S0006-3495(97)78091-3; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813	44	103	105	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0343	10.1096/fj.01-0630com	http://dx.doi.org/10.1096/fj.01-0630com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874983				2022-12-25	WOS:000174755900026
J	Zheng, XL; Sadler, JE				Zheng, XL; Sadler, JE			Mucin-like domain of enteropeptidase directs apical targeting in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; SORTING SIGNALS; TRANSMEMBRANE DOMAIN; ENTEROKINASE; CHOLESTEROL; GLYCANS; PROTEIN; GLYCOSYLATION; ASSOCIATION	Enteropeptidase, a type II transmembrane protein of the enterocyte brush border, is sorted directly to the apical membrane of Madin-Darby canine kidney II cells. Apical targeting appears to be mediated by an N-terminal segment that contains a 27-amino acid residue O-glycosylated mucin-like domain consisting of two short mucin-like repeats, A and B. Targeting signals within these repeats were characterized by using green fluorescent protein (GFP) as a reporter. Constructs with a cleavable signal peptide and both repeats A and B were secreted apically. Similar constructs lacking mucin repeats were secreted randomly. Either repeat A or B was sufficient to direct apical targeting of GFP. O-linked oligosaccharides alone were not sufficient for targeting because fusion to a different O-glycosylated motif did not alter the random secretion of GFP, and several constructs with mutations in either repeat A or B were O-glycosylated and secreted randomly. In addition, repeat B appears to contain an apical. targeting signal that functions in the absence of glycosylation. Density gradient centrifugation indicated that, unlike several other apically targeted membrane and soluble proteins, apical sorting of mucin-GFP chimeric proteins does not appear to utilize lipid rafts.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.	esadler@im.wustl.edu	Zheng, X. Long/ABD-7362-2021; Sadler, Evan/D-8556-2011	Zheng, X. Long/0000-0003-1680-5295; 	NIDDK NIH HHS [DK 50053] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050053] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Blazquez M, 2000, BIOCHEM J, V349, P843, DOI 10.1042/bj3490843; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; Graichen R, 1996, J BIOL CHEM, V271, P15854, DOI 10.1074/jbc.271.27.15854; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HERMONTAYLOR J, 1977, GUT, V18, P259, DOI 10.1136/gut.18.4.259; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; Lisanti M, 1989, Soc Gen Physiol Ser, V44, P167; Lu DS, 1997, J BIOL CHEM, V272, P31293, DOI 10.1074/jbc.272.50.31293; Martin-Belmonte F, 2000, J BIOL CHEM, V275, P41074, DOI 10.1074/jbc.M005429200; Milewski MI, 2001, J CELL SCI, V114, P719; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Panzer P, 1998, J BIOL CHEM, V273, P13861, DOI 10.1074/jbc.273.22.13861; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Slimane TA, 2000, EXP CELL RES, V258, P184; Spodsberg N, 2001, J BIOL CHEM, V276, P23506, DOI 10.1074/jbc.C100219200; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; VOGEL LK, 1992, FEBS LETT, V308, P14, DOI 10.1016/0014-5793(92)81039-O; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yuan X, 1998, AM J PHYSIOL-GASTR L, V274, pG342, DOI 10.1152/ajpgi.1998.274.2.G342; Zheng XL, 1999, J BIOL CHEM, V274, P1596, DOI 10.1074/jbc.274.3.1596	33	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6858	6863		10.1074/jbc.M109857200	http://dx.doi.org/10.1074/jbc.M109857200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11878264	hybrid			2022-12-25	WOS:000174104300016
J	Hsu, JH; Shi, YJ; Hu, LP; Fisher, M; Franke, TF; Lichtenstein, A				Hsu, JH; Shi, YJ; Hu, LP; Fisher, M; Franke, TF; Lichtenstein, A			Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses	ONCOGENE			English	Article						multiple myeloma; AKT; interleukin-6	PHOSPHATIDYLINOSITOL 3-KINASE; CELL-GROWTH; MONOCLONAL-ANTIBODY; INDUCED APOPTOSIS; PLASMA-CELLS; INTERLEUKIN-6; ACTIVATION; EXPRESSION; ONCOGENE; PROTOONCOGENE	IL-6 is an established growth factor for multiple myeloma tumor cells, stimulating proliferative and survival responses. Recent work indicates that IL-6 can activate the AKT kinase in myeloma cells. Thus, to test a potential role for AKT in IL-6-induced cellular responses, we transfected myeloma cell lines with an active 'E40K' or dominant negative 'PH' AKT construct using an adenoviral vector. Transfection of the E40K into myeloma cells resulted in enhanced tumor cell growth and expression of the PH dominant negative AKT resulted in both inhibition of the IL-6-dependent proliferative response and a decrease in S phase distribution. While transfection of E40K protected myeloma cells front dexamethasone-induced apoptosis, the dominant negative PH had no effect on the ability of IL-6 to protect these cells front dexamethasone. These results clearly demonstrate that AKT activation is critical for the IL-6 proliferative response. In addition, although the level of AKT activation can regulate sensitivity to dexamethasone-induced apoptosis, additional cytokine-induced AKT-independent pathways can mediate IL-6 protection against dexamethasone.	Univ Calif Los Angeles, Med Ctr, Dept Med & Pathol, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Columbia University	Lichtenstein, A (corresponding author), VA West LA Hosp, W111H 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	alichten@ucla.edu						ANDERSON KC, 1989, BLOOD, V73, P1915; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; HSU JH, 2001, IN PRESS BLOOD; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jin Z., 1994, OCEANOLOGY CHINA SEA, P179, DOI DOI 10.1007/978-94-011-0862-1_19; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 1991, BLOOD, V78, P1198; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Lee IS, 1997, FEBS LETT, V401, P133, DOI 10.1016/S0014-5793(96)01456-1; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Ogata A, 1997, J IMMUNOL, V159, P2212; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Prince HM, 1998, EXP HEMATOL, V26, P27; REIBNEGGER G, 1991, CANCER RES, V51, P6250; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Sekulic A, 2000, CANCER RES, V60, P3504; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; SOONYANG Z, 1997, P NATL ACAD SCI USA, V94, P11345; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Teoh G, 1998, BLOOD, V92, P4591, DOI 10.1182/blood.V92.12.4591.424k08_4591_4601; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tu YP, 2000, CANCER RES, V60, P6763; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251	44	76	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1391	1400		10.1038/sj/onc/1205194	http://dx.doi.org/10.1038/sj/onc/1205194			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857082				2022-12-25	WOS:000173861000009
J	Mitchell, JW; Church, FC				Mitchell, JW; Church, FC			Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote intramolecular interactions during glycosaminoglycan binding and thrombin inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE; BLOOD-COAGULATION; REACTIVE-SITE; PROTEINASE-INHIBITORS; PROTEASE RECEPTORS; ANTITHROMBIN-III; SERPINS; INFLAMMATION; HEMOSTASIS; ACTIVATION	We used site-directed mutagenesis to investigate the role of Glu(69), Asp(70), Asp(71), Asp(72), Tyr-sulfate(73), and Asp(75) in the second acidic region (AR2) of the serpin heparin cofactor 11 (HCII) during formation of the thrombin(.)HCII complex with and without glycosaminoglycans. E69Q/D70N/D71N recombinant (r)HCII, D72N/Y73F/D75N rHCII, and E69Q/D70N/D71N/D72N/Y73F/D75N rHCII were prepared to localize acidic residues important for thrombin inhibition. Interestingly, D72N/Y73F/D75N rHCII had significantly enhanced thrombin inhibition without glycosaminoglycan (4-fold greater) and with heparin (6-fold greater), showing maximal activity at 2 mug/ml heparin compared with wild-type recombinant HCII (wt-rHCII) with maximal activity at 20 mug/ml heparin. The other rHCII mutants had lesser-enhanced activities, but they all eluted from heparin-Sepharose at significantly higher ionic strengths compared with wt-rHCII. Neutralizing and reversing the charge of Asp(72), Tyr-sulfate(73), and Asp(75) were done to characterize their individual contribution to HCII activity. Only Y73K rHCII and D75K rHCII have significantly increased heparin cofactor activity compared with wt-rHCII; however, all of the individual rHCII mutants required substantially less glycosaminoglycan at maximal inhibition than did wt-rHCII. Inhibition of either alpha-thrombin/hirugen or gamma(T)-thrombin (both with an altered anion-binding exosite-1) by the AR2 rHCII mutants was similar to wt-rHCII. D72N/Y73F/D75N rHCII and D75K rHCII were significantly more active than wt-rHCII in a plasma-based thrombin inhibition assay with glycosaminoglycans. These results indicate that improved thrombin inhibition in the AR2 HCII mutants is mediated by enhanced interactions between the acidic domain and anion-binding exosite-1 of thrombin and that AR2 may be a "molecular rheostat" to promote thrombin inhibition in the presence of glycosaminoglycans.	Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Ctr Thrombosis & Hemostasis,Div Hematol Oncol Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Ctr Thrombosis & Hemostasis, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Ctr Thrombosis & Hemostasis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Church, FC (corresponding author), Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Ctr Thrombosis & Hemostasis,Div Hematol Oncol Med, Campus Box 7035,932 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	fchurch@email.unc.edu			NHLBI NIH HHS [HL32656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIN TP, 2001, INT SOC THROMB HAEM; Bauman SJ, 1999, J BIOL CHEM, V274, P34556, DOI 10.1074/jbc.274.49.34556; BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; BRINKMEYER S, 2001, INT SOC THROMB HAEM, pP2082; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CHURCH FC, 1994, TRENDS CARDIOVAS MED, V4, P140, DOI 10.1016/1050-1738(94)90066-3; CHURCH FC, 1997, ADV EXP MED BIOL, V425, P358; Ciaccia AV, 1997, J BIOL CHEM, V272, P14074, DOI 10.1074/jbc.272.22.14074; Ciaccia AV, 1997, J BIOL CHEM, V272, P888, DOI 10.1074/jbc.272.2.888; Ciaccia AV, 1995, PROTEIN EXPRES PURIF, V6, P806, DOI 10.1006/prep.1995.0012; Cirino G, 2000, TRENDS PHARMACOL SCI, V21, P170, DOI 10.1016/S0165-6147(00)01469-3; Cocks TM, 2000, TRENDS PHARMACOL SCI, V21, P103, DOI 10.1016/S0165-6147(99)01440-6; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; GETTINS PGW, 1996, SERPIUS STRUCTURE FU; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; GRIFFITH MJ, 1983, BLOOD, V61, P111; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; Hoffman M, 2001, THROMB HAEMOSTASIS, V85, P958, DOI 10.1055/s-0037-1615947; Holland CA, 2000, FEBS LETT, V484, P87, DOI 10.1016/S0014-5793(00)02131-1; HORTIN G, 1986, J BIOL CHEM, V261, P5827; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Liaw PCY, 1999, J BIOL CHEM, V274, P27597, DOI 10.1074/jbc.274.39.27597; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; MCGUIRE EA, 1987, J BIOL CHEM, V262, P169; Myles T, 1998, J BIOL CHEM, V273, P31203, DOI 10.1074/jbc.273.47.31203; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1993, BLOOD COAGUL FIBRIN, V4, P479, DOI 10.1097/00001721-199306000-00013; PRATT CW, 1991, SEMIN HEMATOL, V28, P3; Preissner KT, 2000, J PATHOL, V190, P360; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1990, J BIOL CHEM, V265, P22386; RAGG H, 1986, NUCLEIC ACIDS RES, V14, P1073, DOI 10.1093/nar/14.2.1073; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; Shirk RA, 2000, J BIOL CHEM, V275, P18085, DOI 10.1074/jbc.M001659200; Shirk RA, 1996, ARTERIOSCL THROM VAS, V16, P1138, DOI 10.1161/01.ATV.16.9.1138; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; TOLLEFSEN DM, 1985, BLOOD, V66, P769; TOLLEFSEN DM, 1989, ANN NY ACAD SCI, V556, P116; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WHINNA HC, 1993, J BIOL CHEM, V268, P3920	49	23	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19823	19830		10.1074/jbc.M200630200	http://dx.doi.org/10.1074/jbc.M200630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11856753	hybrid			2022-12-25	WOS:000175894800077
J	Fernandez, J; Yaman, I; Sarnow, P; Snider, MD; Hatzoglou, M				Fernandez, J; Yaman, I; Sarnow, P; Snider, MD; Hatzoglou, M			Regulation of internal ribosomal entry site-mediated translation by phosphorylation of the translation initiation factor eIF2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; MESSENGER-RNA; C-MYC; IDENTIFICATION; RECRUITMENT; CELLS	Initiation of translation from most cellular mRNAs occurs via scanning; the 40 S ribosomal subunit binds to the m(7)G-cap and then moves along the mRNA until an initiation codon is encountered. Some cellular mRNAs contain internal ribosome entry sequences (IRESs) within their 5'-untranslated regions, which allow initiation independently of the 5'-cap. This study investigated the ability of cellular stress to regulate the activity of IRESs in cellular mRNAs. Three stresses were studied that cause the phosphonylation of the translation initiation factor, eIF2alpha, by activating specific kinases: W amino acid starvation, which activates GCN2; (ii) endoplasmic reticulum (ER) stress, which activates PKR-like ER kinase, PERK kinase; and (iii) double-stranded RNA, which activates double-stranded RNA-dependent protein kinase (PKR) by mimicking viral infection. Amino acid starvation and ER stress caused transient phosphorylation of eIF2a during the first hour of treatment, whereas double-stranded RNA caused a sustained phosphorylation of eIF2alpha after 2 h. The effects of these treatments on IRES-mediated initiation were investigated using bicistronic mRNA expression vectors. No effect was seen for the IRESs from the mRNAs for the chaperone BiP and the protein kinase Pim-1. In contrast, translation mediated by the IRESs from the cationic amino acid transporter, cat-1, and of the cricket paralysis virus intergenic region, were stimulated 3- to 10-fold by all three treatments. eIF2alpha phosphorylation was required for the response because inactivation of phosphorylation prevented the stimulation. It is concluded that cellular stress can stimulate translation from some cellular IRESs via a mechanism that requires the phosphorylation of eIF2a. Moreover, there are distinct regulatory patterns for different cellular mRNAs that contain IRESs within their 5'-untranslated regions.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA	Case Western Reserve University; Case Western Reserve University; Stanford University	Hatzoglou, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, 109 Euclid Ave, Cleveland, OH 44106 USA.	mxh8@po.cwru.edu	yaman, ibrahim/A-7192-2016	yaman, ibrahim/0000-0002-3987-1984; Sarnow, Peter/0000-0002-2043-2770	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053307, T32DK007319, R01DK060596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055979] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32 DK07319, DK60596-01, R01 DK53307-01] Funding Source: Medline; NIGMS NIH HHS [GM 55979] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; CHOI SY, 1992, J BIOL CHEM, V267, P286; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; FERNANDEZ JM, 2002, J BIOL CHEM, V7, P7; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Hyatt SL, 1997, J BIOL CHEM, V272, P19951, DOI 10.1074/jbc.272.32.19951; Jackson RJ, 1995, RNA, V1, P985; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kieft JS, 2001, RNA, V7, P194, DOI 10.1017/S1355838201001790; Kimball Sr, 2000, COLD SPRING HARBOR M, V39, P561; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Martinez-Salas E, 2001, J GEN VIROL, V82, P973, DOI 10.1099/0022-1317-82-5-973; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Thompson SR, 2001, P NATL ACAD SCI USA, V98, P12972, DOI 10.1073/pnas.241286698; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Wilson JE, 2000, MOL CELL BIOL, V20, P4990, DOI 10.1128/MCB.20.14.4990-4999.2000; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x	37	162	167	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19198	19205		10.1074/jbc.M201052200	http://dx.doi.org/10.1074/jbc.M201052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877448	hybrid			2022-12-25	WOS:000175975800123
J	Lee, JH; Koo, TH; Hwang, BY; Lee, JJ				Lee, JH; Koo, TH; Hwang, BY; Lee, JJ			Kaurane diterpene, kamebakaurin, inhibits NF-kappa B by directly targeting the DNA-binding activity of p50 and blocks the expression of antiapoptotic NF-kappa B target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SESQUITERPENE LACTONES; PROTEASOME PATHWAY; INDUCED APOPTOSIS; NITRIC-OXIDE; ACTIVATION; PROTEINS; SUBUNIT; KINASE; CELLS	Kaurane diterpenes have been identified from numerous medicinal plants, which have been used for treatment of inflammation and cancer, however, their molecular mechanism of action remains unclear. We have previously shown that kamebakaurin and other three kaurane diterpenes selectively inhibit activation of transcription factor NF-kappaB, a central mediator of apoptosis and immune responses. We here demonstrate that kamebakaurin is a potent inhibitor of NF-kappaB activation by directly targeting DNA-binding activity of p50. Kamebakaurin prevented the activation of NF-kappaB by different stimuli in various cell types. Kamebakaurin did not prevent either stimuli-induced degradation of IkappaB-alpha or nuclear translocation of NF-kappaB, however, it significantly interfered DNA binding activity of activated NF-kappaB in cell and in vitro and preferentially prevented p50-mediated DNA-binding activity of NF-kappaB rather than that of RelA as measured using in vitro translated p50 and RelA proteins. Moreover, a p50 mutant with a Cys-62 --> Ser mutation was not inhibited with kamebakaurin, indicating that the effect of kamebakaurin was probably due to its interaction with cysteine 62 in p50. The covalent modification of p50 by kamebakaurin was further demonstrated by mass spectrometry analysis that showed an increase in the molecular mass of kamebakaurin-treated p50, and this modification was not reverted by addition of dithiothreitol. These results suggested that kamebakaurin exhibited its inhibitory activity by a direct covalent modification of cysteine 62 in the p50. Also, treatment of cells with kamebakaurin prevented the tumor necrosis factor-alpha (TNF-alpha)-induced expression of antiapoptotic NF-kappaB target genes encoding c-IAP1 (hiap-2) and c-IAP2 (hiap-1), members of the inhibitor of apoptosis family, and Bfl-1/A1, a prosurvival Bcl-2 homologue, and augmented the TNF-alpha-induced caspase 8 activity, thereby resulting in sensitizing MCF-7 cells to TNF-alpha-induced apoptosis. Taken together, kamebakaurin is a valuable candidate for the intervention of NF-kappaB-dependent pathological conditions such as inflammation and cancer.	Korea Res Inst Biosci & Biotechnol, Anticanc Res Lab, Yuseong 305600, Daejeon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Lee, JJ (corresponding author), Korea Res Inst Biosci & Biotechnol, Anticanc Res Lab, POB 115, Yuseong 305600, Daejeon, South Korea.	jjlee@mail.kribb.re.kr						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Castrillo A, 2001, J BIOL CHEM, V276, P15854, DOI 10.1074/jbc.M100010200; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; FUJITA E, 1976, CHEM PHARM BULL, V24, P2118; FUJITA T, 1988, PLANTA MED, P414, DOI 10.1055/s-2006-962485; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Hwang BY, 2001, PLANTA MED, V67, P406, DOI 10.1055/s-2001-15808; Klatt P, 2000, BIOCHEM J, V349, P567, DOI 10.1042/0264-6021:3490567; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074-5521(01)00049-7; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Rungeler P, 1999, BIOORGAN MED CHEM, V7, P2343, DOI 10.1016/S0968-0896(99)00195-9; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; TAKEDA Y, 1987, J CHEM SOC PERK T 1, P2403, DOI 10.1039/p19870002403; Tang W, 1992, CHINESE DRUGS PLANT, P817; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	44	136	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18411	18420		10.1074/jbc.M201368200	http://dx.doi.org/10.1074/jbc.M201368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877450	hybrid			2022-12-25	WOS:000175975800022
J	Brouard, S; Berberat, PO; Tobiasch, E; Seldon, MP; Bach, FH; Soares, MP				Brouard, S; Berberat, PO; Tobiasch, E; Seldon, MP; Bach, FH; Soares, MP			Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; SUPEROXIDE-DISMUTASE; SIGNALING COMPLEX; INHIBITOR; DEATH; EXPRESSION; INDUCTION; BCL-2; GENE; PHOSPHORYLATION	We have shown that carbon monoxide (CO) generated by heme oxygenase-1 (HO-1) protects endothelial cells (EC) from tumor necrosis alpha (TNF-alpha)-mediated apoptosis. This effect relies on the activation of p38 MAPK. We now demonstrate that HO-1/CO requires the activation of the transcription factor NF-kappaB to exert this anti-apoptotic effect. Our data suggest that EC have basal levels of NF-kappaB activity that sustain the expression of NF-kappaB-dependent anti-apoptotic genes required to support the anti-apoptotic effect of HO-1/CO. Over-expression of the inhibitor of NF-kappaB alpha (IkappaBalpha) suppresses the anti-apoptotic action of HO-1/CO. Reconstitution of NF-kappaB activity, by co-expression of IkappaBalpha with different members of the NF-kappaB family, ie. p65/RelA or p65/RelA plus c-Rel, restores the anti-apoptotic effect of HO-1/CO. Expression of the NF-kappaB family members p65/RelA or p65/RelA with p50 or c-Rel up-regulates the expression of the anti-apoptotic genes A1, A20, c-LAP2, and manganese superoxide dismutase (MnSOD). Inhibition of NF-kappaB activity by overexpression of IkappaBalpha suppresses the expression of some of these anti-apoptotic genes, i.e. c-LAP2. Under inhibition of NF-kappaB, co-expression of some of these anti-apoptotic genes, ie. c-LAP2 and A1, restores the anti-apoptotic action of HO-1/CO, whereas expression of A20 or MnSOD cannot. The ability of c-IAP2 and/or A1 to restore the anti-apoptotic action of HO-1/CO is abolished when p38 MAPK activation is blocked by over-expression of a p38 MAPK dominant negative mutant. In conclusion, we demonstrate that HO-1/CO cooperates with NF-kappaB-dependent anti-apoptotic genes, i.e. c-LAP2 and A1, to protect EC from TNF-alpha-mediated apoptosis. This effect is dependent on the ability of HO-1/CO to activate the p38 MAPK signal transduction pathway.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr,Dept Surg, Boston, MA 02115 USA; Inst Gulbenkian Ciencias, P-2781901 Oeiras, Portugal	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Instituto Gulbenkian de Ciencia	Soares, MP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Immunobiol Res Ctr, 99 Brookline Ave, Boston, MA 02215 USA.		brouard, sophie c/Q-1285-2016; Soares, Miguel P/G-4188-2011	Soares, Miguel/0000-0002-9314-4833	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058688, R01HL067040] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58688, HL67040] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Anrather J, 1997, J CLIN INVEST, V99, P763, DOI 10.1172/JCI119222; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; GAN HX, 1995, J IMMUNOL, V155, P1304; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Soares MP, 1998, J IMMUNOL, V161, P4572; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Soares MP, 2000, EMERGING THERAPEUTIC, V4, P11; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; THORNBERRY NA, 1998, SCIENCE, V281; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	50	265	288	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17950	17961		10.1074/jbc.M108317200	http://dx.doi.org/10.1074/jbc.M108317200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11880364	hybrid			2022-12-25	WOS:000175685100072
J	Kashiwagi, K; Shirai, Y; Kuriyama, M; Sakai, N; Saito, N				Kashiwagi, K; Shirai, Y; Kuriyama, M; Sakai, N; Saito, N			Importance of C1B domain for lipid messenger-induced targeting of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; CYSTEINE-RICH DOMAINS; NERVE GROWTH-FACTOR; ARACHIDONIC-ACID; CELL-DEATH; SYNAPTIC TRANSMISSION; INDUCED TRANSLOCATION; SIGNAL TRANSDUCTION; PHOSPHOLIPASE A(2); LIVING CELLS	The molecular mechanisms by which arachidonic acid (AA) and ceramide elicit translocation of protein kinase C (PKC) were investigated. Ceramide translocated epsilonPKC from the cytoplasm to the Golgi complex, but with a mechanism distinct from that utilized by AA. Using fluorescence recovery after photobleaching, we showed that, upon treatment with AA, epsilonPKC was tightly associated with the Golgi complex; ceramide elicited an accumulation of epsilonPKC which was exchangeable with the cytoplasm. Stimulation with ceramide after AA converted the AA-induced Golgi complex staining to one elicited by ceramide alone; AA had no effect on the ceramide-stimulated localization. Using point mutants and deletions of epsilonPKC, we determined that the epsilonC1B domain was responsible for the ceramide- and AA-induced translocation. Switch chimeras, containing the C1B from epsilonPKC in the context of deltaPKC (delta(epsilonC1B)) and vice versa (epsilon(deltaC1B)), were generated and tested for their translocation in response to ceramide and AA. delta(epsilonCIB) translocated upon treatment with both ceramide and AA, epsilon(deltaC1B) responded only to ceramide. Thus, through the C1B domain, AA and ceramide induce different patterns of epsilonPKC translocation and the C1B domain defines the subtype specific sensitivity of PKCs to lipid second messengers.	Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Kobe, Hyogo 6578501, Japan	Kobe University	Saito, N (corresponding author), 1-1 Rokkodai Cho,Nada Ku, Kobe, Hyogo 6578501, Japan.		Shirai, Yasuhito/O-3255-2018					AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Bogi K, 1999, FEBS LETT, V456, P27, DOI 10.1016/S0014-5793(99)00927-8; Brann AB, 1999, J NEUROSCI, V19, P8199; DRAPEAU C, 1990, NEUROSCI LETT, V115, P286, DOI 10.1016/0304-3940(90)90470-T; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; Huang XP, 1997, J CELL SCI, V110, P1625; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; KASAHARA K, 1995, J BIOCHEM-TOKYO, V117, P648, DOI 10.1093/oxfordjournals.jbchem.a124758; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Macdonald NJ, 1999, J NEUROSCI RES, V57, P219, DOI 10.1002/(SICI)1097-4547(19990715)57:2<219::AID-JNR7>3.0.CO;2-C; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Nojima H, 2000, BRAIN RES, V852, P233, DOI 10.1016/S0006-8993(99)02206-4; Nomura T, 2001, LIFE SCI, V68, P2885, DOI 10.1016/S0024-3205(01)01072-4; O'Flaherty JT, 2001, J BIOL CHEM, V276, P24743, DOI 10.1074/jbc.M101093200; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; SAITO N, 1993, BRAIN RES, V607, P241, DOI 10.1016/0006-8993(93)91512-Q; Sawai H, 1997, J BIOL CHEM, V272, P2452; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHIEH HL, 1995, MOL CARCINOGEN, V12, P166, DOI 10.1002/mc.2940120308; Shieh HL, 1996, CANCER DETECT PREV, V20, P576; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Shirai Y, 2000, J CELL SCI, V113, P1335; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; Yang SN, 2000, NEUROSCIENCE, V96, P253, DOI 10.1016/S0306-4522(99)00582-5; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; YELIN MM, 1997, MOL BIOL CELL, V8, P1889	50	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18037	18045		10.1074/jbc.M111761200	http://dx.doi.org/10.1074/jbc.M111761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877428	hybrid			2022-12-25	WOS:000175685100082
J	Naumann, TA; Reznikoff, WS				Naumann, TA; Reznikoff, WS			Tn5 transposase active site mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; HIV-1 INTEGRASE; RESIDUES; BINDING	Tn5 transposase (Tnp) is a 53.3-kDa protein that is encoded by and facilitates movement of transposon Tn5. Tnp monomers contain a single active site that is responsible for catalyzing a series of four DNA breaking/joining reactions at one transposon end. Based on primary sequence homology and protein structural information, we designed and constructed a series of plasmids that encode for Tnps containing active site mutations. Following Tnp expression and purification, the active site mutants were tested for their ability to form protein-DNA complexes and perform each of the four catalytic steps in the transposition pathway in vitro. The results demonstrate that Asp-97, Asp-188, and Glu-326, visible in the active site of Tn5 crystal structures, are absolutely required for all catalytic steps. Mutations within a series of amino acid residues that are conserved in the IS4 family of transposases and retroviral integrases also impair Trip catalytic activity. Mutations at either Tyr-319 or Arg-322 reduce both hairpin resolution and strand transfer activity within protein-DNA complexes. Mutations at Lys-333 reduce the ability of Tnps to form protein-DNA complexes, whereas mutations at the less strongly conserved Lys-330 have less of an effect on both synaptic complex formation and catalytic activity.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Reznikoff, WS (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	Reznikoff@biochem.wisc.edu			NIGMS NIH HHS [GM08349, GM50692] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allingham JS, 2001, EMBO J, V20, P2931, DOI 10.1093/emboj/20.11.2931; Allingham JS, 1999, J MOL BIOL, V289, P1195, DOI 10.1006/jmbi.1999.2837; Bhasin A, 1999, J BIOL CHEM, V274, P37021, DOI 10.1074/jbc.274.52.37021; Bhasin A, 2000, J MOL BIOL, V302, P49, DOI 10.1006/jmbi.2000.4048; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bujacz G, 1997, J BIOL CHEM, V272, P18161, DOI 10.1074/jbc.272.29.18161; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; Davies DR, 1999, J BIOL CHEM, V274, P11904, DOI 10.1074/jbc.274.17.11904; DELONG A, 1991, P NATL ACAD SCI USA, V88, P6072, DOI 10.1073/pnas.88.14.6072; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Kennedy AK, 1998, CELL, V95, P125, DOI 10.1016/S0092-8674(00)81788-2; Kennedy AK, 1996, J MOL BIOL, V256, P533, DOI 10.1006/jmbi.1996.0106; KREBS MP, 1988, GENE, V63, P277, DOI 10.1016/0378-1119(88)90531-8; MARTIN A, 1995, NUCLEIC ACIDS RES, V23, P1642, DOI 10.1093/nar/23.9.1642; Naumann TA, 2000, P NATL ACAD SCI USA, V97, P8944, DOI 10.1073/pnas.160107997; Reznikoff WS, 1999, BIOCHEM BIOPH RES CO, V266, P729, DOI 10.1006/bbrc.1999.1891; REZSOHAZY R, 1993, MOL MICROBIOL, V9, P1283, DOI 10.1111/j.1365-2958.1993.tb01258.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Steiniger-White M, 2000, J BIOL CHEM, V275, P23127, DOI 10.1074/jbc.M003411200; Tavakoli NP, 1997, J MOL BIOL, V274, P491, DOI 10.1006/jmbi.1997.1410; Twining SS, 2001, J BIOL CHEM, V276, P23135, DOI 10.1074/jbc.M010748200; WEINREICH MD, 1994, GENE DEV, V8, P2363, DOI 10.1101/gad.8.19.2363; Zhou M, 1998, J MOL BIOL, V276, P913, DOI 10.1006/jmbi.1997.1579; Zhou M, 1997, J MOL BIOL, V271, P362, DOI 10.1006/jmbi.1997.1188	30	31	36	4	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17623	17629		10.1074/jbc.M200742200	http://dx.doi.org/10.1074/jbc.M200742200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877443	hybrid			2022-12-25	WOS:000175685100031
J	Beloin, C; McKenna, S; Dorman, CJ				Beloin, C; McKenna, S; Dorman, CJ			Molecular dissection of VirB, a key regulator of the virulence cascade of Shigella flexneri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; DNA-BINDING DOMAINS; ESCHERICHIA-COLI; COILED-COILS; IN-VIVO; H-NS; TRANSCRIPTIONAL ACTIVATION; EPITHELIAL-CELLS; GENE-EXPRESSION; INVASION GENES	The VirB protein is a key regulator of virulence gene expression in the facultative enteroinvasive pathogen Shigella flexneri. While genetic evidence has shown that it is required for activation of transcription of virulence genes located on a 230-kb plasmid in this bacterium, hitherto, evidence that VirB is a DNA-binding protein has been lacking. Although VirB shows extensive homology to proteins involved in plasmid partitioning, it does not resemble any known conventional transcription factor. Here we show for the first time that VirB binds to the promoter regions of the virulence genes in vivo. We also show that VirB forms dimeric and higher oligomeric structures both in vivo and in vitro and that this property is independent of DNA binding. The oligomerization activity of VirB is distributed over two, domains: a leucine zipper-like motif and a carboxyl-terminal domain likely to form triple coiled structures. VirB possesses a helix-turn-helix motif, which is required for DNA binding. The amino-terminal domain of the protein is also required for DNA binding and virulence gene activation. The possibility that VirB requires a co-factor for specific interaction with target promoters in vivo is discussed.	Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland	Trinity College Dublin	Dorman, CJ (corresponding author), Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland.	cjdorman@tcd.ie	Dorman, Charles J/N-9867-2015; Dorman, Charles/P-3481-2019; BELOIN, Christophe/F-9284-2012	Dorman, Charles J/0000-0002-6018-9170; Dorman, Charles/0000-0002-6018-9170; BELOIN, Christophe/0000-0002-0344-3443				ABELES AL, 1985, J MOL BIOL, V185, P261, DOI 10.1016/0022-2836(85)90402-4; ADLER B, 1989, MOL MICROBIOL, V3, P627, DOI 10.1111/j.1365-2958.1989.tb00210.x; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Bignell C, 2001, J BIOTECHNOL, V91, P1, DOI 10.1016/S0168-1656(01)00293-0; Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Boss A, 1999, J BACTERIOL, V181, P1755, DOI 10.1128/JB.181.6.1755-1766.1999; Bouet JY, 2000, J BIOL CHEM, V275, P8213, DOI 10.1074/jbc.275.11.8213; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; Day WA, 2001, INFECT IMMUN, V69, P15, DOI 10.1128/IAI.69.1.15-23.2001; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; Dorman CJ, 1998, MOL MICROBIOL, V29, P677, DOI 10.1046/j.1365-2958.1998.00902.x; Dorman CJ, 2001, INT J MED MICROBIOL, V291, P89, DOI 10.1078/1438-4221-00105; Falconi M, 1998, EMBO J, V17, P7033, DOI 10.1093/emboj/17.23.7033; Fezoui Y, 2000, NAT STRUCT BIOL, V7, P1095, DOI 10.1038/81937; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P1011, DOI 10.1038/nsb1296-1011; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Haren L, 1998, J MOL BIOL, V283, P29, DOI 10.1006/jmbi.1998.2053; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; Hays LB, 2000, BIOTECHNIQUES, V29, P288, DOI 10.2144/00292st04; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; HROMOCKYJ AE, 1989, INFECT IMMUN, V57, P2963, DOI 10.1128/IAI.57.10.2963-2970.1989; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lin DCH, 1998, CELL, V92, P675, DOI 10.1016/S0092-8674(00)81135-6; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MAURELLI AT, 1984, INFECT IMMUN, V43, P195, DOI 10.1128/IAI.43.1.195-201.1984; MAURELLI AT, 1985, INFECT IMMUN, V49, P164, DOI 10.1128/IAI.49.1.164-171.1985; MENARD R, 1994, EMBO J, V13, P5293, DOI 10.1002/j.1460-2075.1994.tb06863.x; Miller J.H., 1972, EXPT MOL GENETICS; Nakayama SI, 1998, J BACTERIOL, V180, P3522, DOI 10.1128/JB.180.14.3522-3528.1998; Ochs M, 1996, MOL GEN GENET, V250, P455; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Porter ME, 2002, J BACTERIOL, V184, P531, DOI 10.1128/JB.184.2.531-539.2002; Porter ME, 1997, J BACTERIOL, V179, P6537, DOI 10.1128/jb.179.21.6537-6550.1997; PORTER ME, 1994, J BACTERIOL, V176, P4187, DOI 10.1128/JB.176.13.4187-4191.1994; PORTER ME, 1998, THESIS TRINITY COLL; POUWELS PH, 1985, CLONING VECTORS, P451; Radnedge L, 1996, EMBO J, V15, P1155, DOI 10.1002/j.1460-2075.1996.tb00454.x; Rodionov O, 1999, SCIENCE, V283, P546, DOI 10.1126/science.283.5401.546; Sansonetti PI, 1999, ASM NEWS, V65, P611; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Surtees JA, 1999, J BACTERIOL, V181, P5898, DOI 10.1128/JB.181.19.5898-5908.1999; Surtees JA, 2001, J BIOL CHEM, V276, P12385, DOI 10.1074/jbc.M009370200; TOBE T, 1995, J BACTERIOL, V177, P1094, DOI 10.1128/jb.177.4.1094-1097.1995; TOBE T, 1991, MOL MICROBIOL, V5, P887, DOI 10.1111/j.1365-2958.1991.tb00762.x; TOBE T, 1993, J BACTERIOL, V175, P6142, DOI 10.1128/JB.175.19.6142-6149.1993; VELETROP JS, 1995, GENE, V153, P63; WASSEF JS, 1989, INFECT IMMUN, V57, P858, DOI 10.1128/IAI.57.3.858-863.1989; WATANABE H, 1990, J BACTERIOL, V172, P619, DOI 10.1128/jb.172.2.619-629.1990; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2; Zeng XG, 1997, GENE, V185, P245, DOI 10.1016/S0378-1119(96)00652-X	55	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15333	15344		10.1074/jbc.M111429200	http://dx.doi.org/10.1074/jbc.M111429200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11850420	Green Published, hybrid			2022-12-25	WOS:000175510400017
J	Leach, JK; Black, SM; Schmidt-Ullrich, RK; Mikkelson, RB				Leach, JK; Black, SM; Schmidt-Ullrich, RK; Mikkelson, RB			Activation of constitutive nitric-oxide sythase activity is an early signaling event induced by ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MANGANESE-SUPEROXIDE-DISMUTASE; DOMINANT-NEGATIVE MUTANTS; SMOOTH-MUSCLE CELLS; CYCLIC-GMP; OXIDATIVE STRESS; GENE-EXPRESSION; TUMOR-CELLS; IN-VITRO; PEROXYNITRITE	Ionizing radiation at clinical dose levels activates both pro- and anti-proliferative signal transduction pathways, the balance of which determines cell fate. The initiating and amplifying mechanisms involved in the activation are poorly understood. We demonstrate that one mechanism involves stimulation of constitutive nitric-oxide synthase (NOS) activity. NOS activity of Chinese hamster ovary cells was measured by the arginine --> citrulline conversion assay. Irradiation stimulated a transient activation of NOS with maximal activity at 5 min of post-irradiation. Western blot analysis and genetic manipulation by overexpression of wild type or dominant negative NOS mutant identify the radiation-induced isoform. as NOS-1. Further evidence that NOS-1 is activated by radiation was the demonstration of radiation-induced cGMP formation in cells transiently transfected with the NO-dependent soluble guanylate cyclase. Protein Tyr nitration, a footprint of peroxynitrite formation, followed radiation exposure and was inhibited by expression of a dominant negative NOS-1 mutant. Radiation-induced ERK1/2 kinase activity, a cytoprotective response to radiation, was also blocked by inhibiting NOS activity. These experiments establish NO-dependent signal transduction pathways as being radioresponsive. Given the lipophilic and relatively stable properties of NO, these results also suggest a possible mechanism by which ionization events in one cell may activate signaling processes in adjacent cells.	Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Northwestern Univ, Div Neonatol, Chicago, IL 60611 USA	Virginia Commonwealth University; Northwestern University	Mikkelson, RB (corresponding author), Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA.				NATIONAL CANCER INSTITUTE [P01CA072955, R01CA065896] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007150] Funding Source: NIH RePORTER; NCI NIH HHS [CA65896, CA72955] Funding Source: Medline; NHLBI NIH HHS [HL60190] Funding Source: Medline; NICHD NIH HHS [HD398110] Funding Source: Medline; NIDDK NIH HHS [5T32DK07150] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balazy M, 1998, J BIOL CHEM, V273, P32009, DOI 10.1074/jbc.273.48.32009; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Becker EM, 1999, NITRIC OXIDE-BIOL CH, V3, P55, DOI 10.1006/niox.1999.0207; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bonner JA, 1998, INT J RADIAT ONCOL, V42, P921, DOI 10.1016/S0360-3016(98)00325-3; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; Cordelier P, 1999, FASEB J, V13, P2037, DOI 10.1096/fasebj.13.14.2037; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Deora AA, 2000, BIOCHEMISTRY-US, V39, P9901, DOI 10.1021/bi992954b; Ducrocq C, 1999, CELL MOL LIFE SCI, V55, P1068, DOI 10.1007/s000180050357; Goda N, 1996, AM J PHYSIOL-HEART C, V271, pH1893, DOI 10.1152/ajpheart.1996.271.5.H1893; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Gu MF, 2000, J BIOL CHEM, V275, P11389, DOI 10.1074/jbc.275.15.11389; Gudi T, 1996, J BIOL CHEM, V271, P4597; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Ibuki Y, 1997, FREE RADICAL BIO MED, V22, P1029, DOI 10.1016/S0891-5849(96)00500-X; JANSSEN MYW, 1998, AM J PHYSIOL, V275, pL1100; Janssens MY, 1998, CANCER RES, V58, P5646; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Kuo WN, 1999, MOL CELL BIOCHEM, V201, P11, DOI 10.1023/A:1007024126947; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Leach JK, 2001, CANCER RES, V61, P3894; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580; Morales A, 1998, INT J RADIAT ONCOL, V42, P191, DOI 10.1016/S0360-3016(98)00185-0; Narayanan PK, 1997, CANCER RES, V57, P3963; Niu XF, 1996, CIRC RES, V79, P992, DOI 10.1161/01.RES.79.5.992; Phung YT, 1999, IUBMB LIFE, V48, P333, DOI 10.1080/152165499307062; Possel H, 1997, FEBS LETT, V416, P175, DOI 10.1016/S0014-5793(97)01197-6; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STEPHENSON MA, 1994, CANCER RES, V54, P12; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; TODD DG, 1994, CANCER RES, V54, P5224; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WARD JF, 1994, RADIAT RES, V138, pS85, DOI 10.2307/3578769; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YUEN PST, 1994, J BIOL CHEM, V269, P791; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	54	113	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15400	15406		10.1074/jbc.M110309200	http://dx.doi.org/10.1074/jbc.M110309200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856735	hybrid			2022-12-25	WOS:000175510400024
J	Leite, MF; Hirata, K; Pusl, T; Burgstahler, AD; Okazaki, K; Ortega, JM; Goes, AM; Prado, MAM; Spray, DC; Nathanson, MH				Leite, MF; Hirata, K; Pusl, T; Burgstahler, AD; Okazaki, K; Ortega, JM; Goes, AM; Prado, MAM; Spray, DC; Nathanson, MH			Molecular basis for pacemaker cells in epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INTERCELLULAR CALCIUM WAVES; PANCREATIC ACINAR-CELLS; GAP JUNCTION CHANNELS; RAT HEPATOCYTES; CA2+ WAVES; CONFOCAL MICROSCOPY; NONEXCITABLE CELLS; RYANODINE RECEPTOR; EXOCRINE PANCREAS	Intercellular signaling is highly coordinated in excitable tissues such as heart, but the organization of intercellular signaling in epithelia is less clear. We examined Ca2+ signaling in hepatoma cells expressing the hepatocyte gap junction protein connexin32 (cx32) or the cardiac gap junction protein cx43, plus a fluorescently tagged V-1a vasopressin receptor (V1aR). Release of inositol 1,4,5-trisphosphate (InsP(3)) in wild type cells increased Ca2+ in the injected cell but not in neighboring cells, while the Ca2+ signal spread to neighbors when gap junctions were expressed. Photorelease of caged Ca2+ rather than InsP. resulted in a small increase in Ca2+ that did not spread to neighbors with or without gap junctions. However, photorelease of Ca2+ in cells stimulated with low concentrations of vasopressin resulted in a much larger increase in Ca2+, which spread to neighbors via gap junctions. Cells expressing tagged V1aR similarly had increased sensitivity to vasopressin, and could signal to neighbors via gap junctions. Higher concentrations of vasopressin elicited Ca2+ signals in all cells. In cx32 or cx43 but not in wild type cells, this signaling was synchronized and began in cells expressing the tagged V1aR. Thus, intercellular Ca2+ signals in epithelia are organized by three factors: 1) InsP(3) must be generated in each cell to support a Ca2+ signal in that cell; 2) gap junctions are necessary to synchronize Ca2+ signals among cells; and 3) cells with relatively increased expression of hormone receptor will initiate Ca2+ signals and thus serve as pacemakers for their neighbors. Together, these factors may allow epithelia to act in an integrated, organ-level fashion rather than as a collection of isolated cells.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Dept Cell Biol, New Haven, CT 06520 USA; Univ Fed Minas Gerais, Dept Physiol & Biophys, BR-31270901 Belo Horizonte, MG, Brazil; Univ Occupat & Environm Hlth, Dept Surg, Kitakyushu, Fukuoka 8078555, Japan; Univ Fed Minas Gerais, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil; Univ Fed Minas Gerais, Dept Pharmacol, Belo Horizonte, MG, Brazil; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Yale University; Yale University; Universidade Federal de Minas Gerais; University of Occupational & Environmental Health - Japan; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Yeshiva University; Albert Einstein College of Medicine	Nathanson, MH (corresponding author), Yale Univ, Sch Med, Dept Med, 333 Cedar St,Rm 1080 LMP, New Haven, CT 06520 USA.	michael.nathan-son@yale.edu	Prado, Marco Antonio Maximo/K-7638-2013; Ortega, J Miguel/E-8272-2011; de Fatima Leite, Maria/AAK-2555-2021	Prado, Marco Antonio Maximo/0000-0002-3028-5778; Ortega, J Miguel/0000-0002-8047-9191; Spray, David/0000-0001-8368-5073	FIC NIH HHS [TW01452] Funding Source: Medline; NCRR NIH HHS [RR04224] Funding Source: Medline; NIDDK NIH HHS [DK45710, DK57751, DK41918, DK34989] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, P01DK057751, R01DK045710, P01DK041918, R29DK045710] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Blatter LA, 1997, P NATL ACAD SCI USA, V94, P4176, DOI 10.1073/pnas.94.8.4176; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; Brown EB, 1999, BIOPHYS J, V76, P489, DOI 10.1016/S0006-3495(99)77217-6; Chanson M, 1998, J CELL BIOL, V141, P1267, DOI 10.1083/jcb.141.5.1267; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Clair C, 2001, J CELL SCI, V114, P1999; COMBETTES L, 1994, BIOCHEM J, V304, P585, DOI 10.1042/bj3040585; Dufour JF, 1999, HEPATOLOGY, V30, P1018, DOI 10.1002/hep.510300421; EGHBALI B, 1990, P NATL ACAD SCI USA, V87, P1328, DOI 10.1073/pnas.87.4.1328; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Eugenin EA, 1998, AM J PHYSIOL-GASTR L, V274, pG1109, DOI 10.1152/ajpgi.1998.274.6.G1109; FALLON MB, 1995, AM J PHYSIOL-CELL PH, V268, pC1186, DOI 10.1152/ajpcell.1995.268.5.C1186; FINCH EA, 1994, SCIENCE, V265, P813, DOI 10.1126/science.265.5173.813-a; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; Fishman GI, 1995, CELL ADHES COMMUN, V3, P353, DOI 10.3109/15419069509081019; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hirata K, 1999, INVEST OPHTH VIS SCI, V40, P2046; Hirata K, 1998, P NATL ACAD SCI USA, V95, P8381, DOI 10.1073/pnas.95.14.8381; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; ISHAC EJN, 1992, J CELL PHYSIOL, V152, P79, DOI 10.1002/jcp.1041520111; Kaneko T, 2000, CIRC RES, V86, P1093, DOI 10.1161/01.RES.86.10.1093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamont C, 1998, J PHYSIOL-LONDON, V512, P669, DOI 10.1111/j.1469-7793.1998.669bd.x; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Leite MF, 1999, BIOCHEM J, V337, P305, DOI 10.1042/0264-6021:3370305; Leite MF, 2002, GASTROENTEROLOGY, V122, P415, DOI 10.1053/gast.2002.30982; Mackenzie L, 2001, J PHYSIOL-LONDON, V530, P417, DOI 10.1111/j.1469-7793.2001.0417k.x; Marchant J, 1999, EMBO J, V18, P5285, DOI 10.1093/emboj/18.19.5285; Marchant JS, 2001, EMBO J, V20, P65, DOI 10.1093/emboj/20.1.65; MEDA P, 1990, J CLIN INVEST, V86, P759, DOI 10.1172/JCI114772; MEDA P, 1987, P NATL ACAD SCI USA, V84, P4901, DOI 10.1073/pnas.84.14.4901; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; Motoyama K, 1999, AM J PHYSIOL-REG I, V276, pR575, DOI 10.1152/ajpregu.1999.276.2.R575; Nathanson MH, 1999, GASTROENTEROLOGY, V116, P1176, DOI 10.1016/S0016-5085(99)70021-1; NATHANSON MH, 1995, AM J PHYSIOL-GASTR L, V269, pG167, DOI 10.1152/ajpgi.1995.269.1.G167; NATHANSON MH, 1992, MOL BIOL CELL, V3, P113, DOI 10.1091/mbc.3.1.113; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; Paemeleire K, 2000, MOL BIOL CELL, V11, P1815, DOI 10.1091/mbc.11.5.1815; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SAEZ JC, 1989, AM J PHYSIOL, V257, pC1, DOI 10.1152/ajpcell.1989.257.1.C1; SANDERSON MJ, 1990, CELL REGUL, V1, P585, DOI 10.1091/mbc.1.8.585; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; Serriere V, 2001, FASEB J, V15, P1484, DOI 10.1096/fj.00-0659fje; Stumpel F, 1998, HEPATOLOGY, V28, P1616, DOI 10.1002/hep.510280622; Swillens S, 1999, P NATL ACAD SCI USA, V96, P13750, DOI 10.1073/pnas.96.24.13750; Thomas D, 2000, CURR BIOL, V10, P8, DOI 10.1016/S0960-9822(99)00258-4; Tordjmann T, 1998, EMBO J, V17, P4695, DOI 10.1093/emboj/17.16.4695; Tordjmann T, 1997, EMBO J, V16, P5398, DOI 10.1093/emboj/16.17.5398; Tordjmann T, 1996, GASTROENTEROLOGY, V111, P1343, DOI 10.1053/gast.1996.v111.pm8898649; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538; Yule DI, 1996, AM J PHYSIOL-CELL PH, V271, pC1285, DOI 10.1152/ajpcell.1996.271.4.C1285; Yule DI, 1997, J BIOL CHEM, V272, P9093; Zimmermann B, 1999, EMBO J, V18, P3222, DOI 10.1093/emboj/18.12.3222	64	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16313	16323		10.1074/jbc.M109207200	http://dx.doi.org/10.1074/jbc.M109207200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11850419	hybrid			2022-12-25	WOS:000175510400142
J	Tassotto, ML; Mathews, CK				Tassotto, ML; Mathews, CK			Assessing the metabolic function of the MutT 8-oxodeoxyguanosine triphosphatase in Escherichia coli by nucleotide pool analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; MUTAGENIC SUBSTRATE; DNA-SYNTHESIS; REPLICATION FIDELITY; STEADY-STATE; PROTEIN; CELLS; 8-HYDROXYGUANINE; BACTERIOPHAGE-T4; 5'-TRIPHOSPHATE	In Escherichia coli the mutT gene is one of several that acts to minimize mutagenesis by reactive oxygen species. The bacterial MutT protein and its mammalian homolog have been shown to catalyze in vitro the hydrolysis of the oxidized deoxyguanosine nucleotide, 8-oxo-dGTP, to its corresponding monophosphate. Thus, the protein is thought to "sanitize" the nucleotide pool by ridding the cell of a nucleotide whose incorporation into DNA would be intensely mutagenic. However, because others have shown mutT mutations to be mutagenic under some conditions of anaerobic growth, and have shown 8-oxo-dGTP to be a poor DNA polymerase substrate, there is reason to question this model. We have devised an assay for 8-oxo-dGTP in bacterial extracts. Using this assay, which involves reversed-phase high-performance liquid chromatography and electrochemical detection, we have been unable to detect 8-oxo. dGTP in extracts of three different mutT mutants of E. coli, even after growth of the bacteria in the presence of hydrogen peroxide. Our estimated upper limit for 8-oxo-dGTP content of these bacteria is about 200 molecules/ cell, corresponding to a concentration of about 0.34 muM. When 8-oxo-dGTP was added at 0.34 muM to an in vitro DNA replication system primed with a DNA template that permits scoring of replication errors and with the four normal dNTPs at their estimated intracellular concentrations, there was no detectable effect upon the frequency of replication errors. These findings lead us to question the conclusion that 8-oxo-dGTP is the most significant physiological substrate for the MutT protein.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.				NIGMS NIH HHS [GM 55134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055134] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; Bialkowski K, 1998, NUCLEIC ACIDS RES, V26, P3194, DOI 10.1093/nar/26.13.3194; CHENG KC, 1992, J BIOL CHEM, V267, P166; DIPIERRO D, 1995, ANAL BIOCHEM, V231, P407, DOI 10.1006/abio.1995.0071; Einolf HJ, 2001, J BIOL CHEM, V276, P3764, DOI 10.1074/jbc.M006696200; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; FOWLER RG, 1994, J BACTERIOL, V176, P7727, DOI 10.1128/JB.176.24.7727-7729.1994; Fujikawa K, 1999, J BIOL CHEM, V274, P18201, DOI 10.1074/jbc.274.26.18201; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; Hayakawa H, 1999, BIOCHEMISTRY-US, V38, P3610, DOI 10.1021/bi982361l; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Martomo SA, 2002, MUTAT RES-FUND MOL M, V499, P197, DOI 10.1016/S0027-5107(01)00283-4; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MINNICK DT, 1994, NUCLEIC ACIDS RES, V22, P5658, DOI 10.1093/nar/22.25.5658; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SARGENT RG, 1987, J BIOL CHEM, V262, P5546; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; ZHANG XL, 1995, J BIOL CHEM, V270, P8401, DOI 10.1074/jbc.270.15.8401	25	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15807	15812		10.1074/jbc.M200965200	http://dx.doi.org/10.1074/jbc.M200965200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856756	hybrid			2022-12-25	WOS:000175510400080
J	Wang, X; Yang, Y; Guo, XJ; Sampson, ER; Hsu, CL; Tsai, MY; Yeh, SY; Wu, G; Guo, YL; Chang, CS				Wang, X; Yang, Y; Guo, XJ; Sampson, ER; Hsu, CL; Tsai, MY; Yeh, SY; Wu, G; Guo, YL; Chang, CS			Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; TYROSINE KINASE; SIGNALING PATHWAY; ESTROGEN-RECEPTOR; GROWTH-FACTOR; ACTIVATION; PROTEIN; IDENTIFICATION; COACTIVATOR; EXPRESSION	The proline-rich tyrosine kinase 2 (Pyk2) was first identified as a key kinase linked to the MAP kinase and JNK signaling pathways that play important roles in cell growth and adhesion. The linkage between Pyk2 and the androgen receptor (AR), an important transcription factor in prostate cancer progression, however, remains unclear. Here we report that using the full-length androgen receptor-associated protein, ARA55, coregulator as bait, we were able to isolate an ARA55-interacting protein, Pyk2, and demonstrated that Pyk2 could repress AR transactivation via inactivation of ARA55. This inactivation may result from the direct phosphorylation of ARA55 by Pyk2 at tyrosine 43, impairing the coactivator activity of ARA55 and/or sequestering ARA55 to reduce its interaction with AR. Our finding that Pyk2 can indirectly modulate AR function via interaction and/or phosphorylation of ARA55 not only expands the role of Pyk2 in AR-mediated prostate cancer growth but also strengthens the role of ARA55 as an AR coregulator.	Univ Rochester, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Peking Univ, Hosp 1, Beijing 100034, Peoples R China	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Peking University	Chang, CS (corresponding author), Univ Rochester, Dept Urol, George Whipple Lab Canc Res, 601 Elmwood Ave, Rochester, NY 14642 USA.			Chang, Chawnshang/0000-0001-8510-3516	NCI NIH HHS [CA71570] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; MIZOKAMI A, 1994, MOL ENDOCRINOL, V8, P77, DOI 10.1210/me.8.1.77; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sampson ER, 2001, J BIOL REG HOMEOS AG, V15, P123; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Stanzione R, 2001, LAB INVEST, V81, P51, DOI 10.1038/labinvest.3780211; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Wang X, 2001, J BIOL CHEM, V276, P40417, DOI 10.1074/jbc.M104765200; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	32	38	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15426	15431		10.1074/jbc.M111218200	http://dx.doi.org/10.1074/jbc.M111218200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856738	hybrid			2022-12-25	WOS:000175510400028
J	Zhang, YM; Marrakchi, H; Rock, CO				Zhang, YM; Marrakchi, H; Rock, CO			The FabR (YijC) transcription factor regulates unsaturated fatty acid biosynthesis in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME; THERMAL REGULATION; FACTOR FADR; DEPENDENT REGULATION; SYNTHASE-I; BINDING; GENE; METABOLISM; EXPRESSION; BACTERIA	Unsaturated fatty acid biosynthesis is a vital facet of Escherichia coli physiology and requires the expression of two genes, fabA and fabB, in the type II fatty acid synthase system. This study links the FabR (YijC) transcription factor to the regulation of unsaturated fatty acid content through the regulation of fabB gene expression. The yijC (fabR) gene was deleted by replacement with a selectable cassette, and the resulting strains (fabR::kan) possessed significantly elevated levels of unsaturated fatty acids, particularly cis-vaccenate, in their membrane phospholipids. The altered fatty acid composition was observed in the fabR::kan fabF1 double mutant pinpointing fabB as the condensing enzyme responsible for the increased cis-vaccenate production. The fabR::kan strains had 4- to 8-fold higher levels of fabB and a 2- to 3-fold increase in fabA transcripts as judged by Northern blotting, Affymetrix array analysis, and real-time PCR. FabR did not regulate the enzymes of fatty acid beta-oxidation. The elevated level of fabB mRNA was reflected by higher condensing enzyme activity in fabR::kan fabF1 double mutants. Thus, FabR functions as a repressor that potently controls the expression of the fabB gene, which in turn, modulates the physical properties of the membrane by altering the level of unsaturated fatty acid production.	St Jude Childrens Res Hosp, Prot Sci Div, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Biosci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Prot Sci Div, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	charles.rock@stjude.org	Marrakchi, Hedia/AAF-2657-2020		NCI NIH HHS [CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Black PN, 2000, J NUTR, V130, p305S, DOI 10.1093/jn/130.2.305S; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCH K, 1971, ENZYMES, P441; BOOTH BR, 1980, BIOCHEM BIOPH RES CO, V94, P1029, DOI 10.1016/0006-291X(80)90522-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN T, 1994, CURRENT PROTOCOLS MO; Campbell JW, 2001, J BACTERIOL, V183, P5982, DOI 10.1128/JB.183.20.5982-5990.2001; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; CLARK DP, 1983, BIOCHEMISTRY-US, V22, P5897, DOI 10.1021/bi00294a032; Cronan JE, 1998, MOL MICROBIOL, V29, P937, DOI 10.1046/j.1365-2958.1998.00917.x; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; Cronan JE, 1997, J BACTERIOL, V179, P1819, DOI 10.1128/jb.179.5.1819-1823.1997; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; DEMENDOZA D, 1983, TRENDS BIOCHEM SCI, V8, P49, DOI 10.1016/0968-0004(83)90388-2; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; DiRusso CC, 1999, PROG LIPID RES, V38, P129, DOI 10.1016/S0163-7827(98)00022-8; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DIRUSSO CC, 1985, J BACTERIOL, V161, P583, DOI 10.1128/JB.161.2.583-588.1985; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; Gui LZ, 1996, J BACTERIOL, V178, P4704, DOI 10.1128/jb.178.15.4704-4709.1996; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; McCue LA, 2001, NUCLEIC ACIDS RES, V29, P774, DOI 10.1093/nar/29.3.774; MOHAN S, 1994, J BIOL CHEM, V269, P32896; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; NUNN WD, 1983, J BACTERIOL, V154, P554, DOI 10.1128/JB.154.2.554-560.1983; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; RAMAN N, 1995, J BIOL CHEM, V270, P1092, DOI 10.1074/jbc.270.3.1092; Rock C O, 1981, Methods Enzymol, V72, P397; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; van Aalten DMF, 2000, EMBO J, V19, P5167, DOI 10.1093/emboj/19.19.5167; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; Xu YB, 2001, J BIOL CHEM, V276, P17373, DOI 10.1074/jbc.M100195200; YANG SY, 1988, J BACTERIOL, V170, P2543, DOI 10.1128/jb.170.6.2543-2548.1988	41	86	117	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15558	15565		10.1074/jbc.M201399200	http://dx.doi.org/10.1074/jbc.M201399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859088	hybrid			2022-12-25	WOS:000175510400046
J	Krajewski, WA				Krajewski, WA			Histone acetylation status and DNA sequence modulate ATP-dependent nucleosome repositioning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN; TRANSCRIPTION; DROSOPHILA; ORGANIZATION; HYPERACETYLATION; RECRUITMENT; COMPLEX; ENERGY; GENE	A cell-free system derived from Drosophila embryos was used to investigate positioning of nucleosomes on specific DNA sequences. This system can be used to reconstitute differently acetylated nucleosome arrays possessing ATP-dependent dynamic properties that are not observed with chromatin assembled from pure components. Nucleosome positioning on different DNA sequences was studied by restriction endonuclease assay. The sequence of DNA and the acetylation status of histories had profound effects on the distribution of nucleosomes, suggesting their cooperative effect on nucleosome repositioning.	Russian Acad Sci, Inst Dev Biol, Biochem Lab, Moscow 117808, Russia	Russian Academy of Sciences; Koltzov Institute of Developmental Biology of the Russian Academy of Sciences	Krajewski, WA (corresponding author), Russian Acad Sci, Inst Dev Biol, Biochem Lab, Vavilova St 26, Moscow 117808, Russia.	wkrajewski@hotmail.com	Krajewski, Wladyslaw/J-5414-2018	Krajewski, Wladyslaw/0000-0002-9669-5614				Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Anselmi C, 2000, BIOPHYS J, V79, P601, DOI 10.1016/S0006-3495(00)76319-3; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Esposito F, 1988, Oxf Surv Eukaryot Genes, V5, P1; Filesi I, 2000, BIOPHYS CHEM, V83, P223, DOI 10.1016/S0301-4622(99)00143-X; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Gu WG, 2000, EMBO J, V19, P5202, DOI 10.1093/emboj/19.19.5202; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; Ito T, 2000, GENE DEV, V14, P1899; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Krajewski WA, 1999, METH MOL B, V119, P207; Krajewski WA, 2000, MOL GEN GENET, V263, P38, DOI 10.1007/PL00008674; Krajewski WA, 1996, MOL GEN GENET, V252, P249; Krajewski WA, 1999, FEBS LETT, V452, P215, DOI 10.1016/S0014-5793(99)00637-7; KRAJEWSKI WA, 1992, MOL GEN GENET, V235, P381, DOI 10.1007/BF00279384; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Lee DH, 2000, DATA KNOWL ENG, V34, P77, DOI 10.1016/S0169-023X(00)00009-4; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; LUTTER LC, 1989, P NATL ACAD SCI USA, V86, P8712, DOI 10.1073/pnas.86.22.8712; MUYLDERMANS S, 1994, J MOL BIOL, V235, P855, DOI 10.1006/jmbi.1994.1044; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; Paro R, 2000, NATURE, V406, P579, DOI 10.1038/35020675; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; Ramakrishnan V, 1997, ANNU REV BIOPH BIOM, V26, P83, DOI 10.1146/annurev.biophys.26.1.83; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Travers AA, 1996, J MOL BIOL, V257, P486, DOI 10.1006/jmbi.1996.0178; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; Whitehouse I, 2000, BIOCHEM SOC T, V28, P376, DOI 10.1042/0300-5127:0280376; ZHURKIN VB, 1985, J BIOMOL STRUCT DYN, V2, P785, DOI 10.1080/07391102.1985.10506324	36	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14509	14513		10.1074/jbc.M107510200	http://dx.doi.org/10.1074/jbc.M107510200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11859068	hybrid			2022-12-25	WOS:000175203000022
J	Steffen, SE; Katz, FS; Bryant, FR				Steffen, SE; Katz, FS; Bryant, FR			Complete inhibition of Streptococcus pneumoniae RecA protein-catalyzed ATP hydrolysis by single-stranded DNA-binding protein (SSB protein) - Implications for the mechanism of SSB protein-stimulated DNA strand exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NTP HYDROLYSIS; PURIFICATION; COMPETENCE; TRANSFORMATION; GENOME; SSDNA	The ATP-dependent three-strand exchange activity of the Streptococcus pneumoniae RecA protein (RecA(Sp)), like that of the Escherichia coli RecA protein (RecA(Ec)), is strongly stimulated by the single-stranded DNA-binding protein (SSB) from either E. coli (SSB(Ec)) or S. pneumoniae (SSB(Sp)). The RecA(Sp) protein differs from the RecA(Ec) protein, however, in that its ssDNA-dependent ATP hydrolysis activity is completely inhibited by SSB(Ec) or SSB(Sp) protein, apparently because these proteins displace RecA(Sp) protein from ssDNA. These results indicate that in contrast to the mechanism that has been established for the RecA(Ec) protein, SSB protein does not stimulate the RecA(Sp) protein-promoted strand exchange reaction by facilitating the formation of a presynaptic complex between the RecA(Sp) protein and the ssDNA substrate. In addition to acting presynaptically, however, it has been proposed that SSB(Ec) protein also stimulates the RecA(Ec) protein strand exchange reaction postsynaptically, by binding to the displaced single strand that is generated when the ssDNA substrate invades the homologous linear dsDNA. In the RecA(Sp) protein-promoted reaction, the stimulatory effect of SSB protein may be due entirely to this postsynaptic mechanism. The competing displacement of RecA(Sp) protein from the ssDNA substrate by SSB protein, however, appears to limit the efficiency of the strand exchange reaction (especially at high SSB protein concentrations or when SSB protein is added to the ssDNA before RecA(Sp) protein) relative to that observed under the same conditions with the RecA(Ec) protein.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bryant, FR (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA.		Katz, Francine/AAE-8953-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036516] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36516] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Campbell EA, 1998, MOL MICROBIOL, V27, P929, DOI 10.1046/j.1365-2958.1998.00737.x; Claverys JP, 2000, MOL MICROBIOL, V35, P251, DOI 10.1046/j.1365-2958.2000.01718.x; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; Katz FS, 2001, BIOCHEMISTRY-US, V40, P11082, DOI 10.1021/bi011030x; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; LACKS S, 1962, J MOL BIOL, V5, P119, DOI 10.1016/S0022-2836(62)80067-9; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MARTIN B, 1992, NUCLEIC ACIDS RES, V20, P6412, DOI 10.1093/nar/20.23.6412; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; MORRISON DA, 1979, NATURE, V282, P215, DOI 10.1038/282215a0; Mortier-Barriere I, 1998, MOL MICROBIOL, V27, P159, DOI 10.1046/j.1365-2958.1998.00668.x; Nayak S, 1999, J BIOL CHEM, V274, P25979, DOI 10.1074/jbc.274.37.25979; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Steffen SE, 2000, ARCH BIOCHEM BIOPHYS, V382, P303, DOI 10.1006/abbi.2000.2029; Steffen SE, 2001, ARCH BIOCHEM BIOPHYS, V388, P165, DOI 10.1006/abbi.2001.2286; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; ULLSPERGER CJ, 1995, BIOCHEMISTRY-US, V34, P10859, DOI 10.1021/bi00034a019; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126	24	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14493	14500		10.1074/jbc.M112444200	http://dx.doi.org/10.1074/jbc.M112444200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11854290	hybrid			2022-12-25	WOS:000175203000020
J	Yang, JY; Widmann, C				Yang, JY; Widmann, C			The RasGAP N-terminal fragment generated by caspase cleavage protects cells in a Ras/PI3K/Akt-dependent manner that does not rely on NF kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; MEK KINASE; APOPTOSIS; ALPHA; SUBSTRATE; RECEPTOR; PROLIFERATION; INDUCTION; FAMILY; GAP	RasGAP, a regulator of Ras GTPase family members, is cleaved at low levels of caspase activity into an N-terminal fragment (fragment N) that generates potent anti-apoptotic signals. At higher levels of caspase activity, fragment N is further cleaved into two fragments that strongly potentiate apoptosis. RasGAP could thus function as a sensor of caspase activity to determine whether a cell should survive or not. Here we show that fragment N protects cells by activating the Ras-PI3K-Akt pathway. Surprisingly, even though nuclear factor kappaB (NFkappaB) can be activated by Akt, it plays no role in the anti-apoptotic functions of fragment N. This indicates that Akt effectors are differentially regulated when fragment N is generated.	Univ Lausanne, Inst Biol Cellulaire & Morphol, CH-1005 Lausanne, Switzerland; CHU Vaudois, Dept Med Interne, CH-1011 Lausanne, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Widmann, C (corresponding author), Univ Lausanne, Inst Biol Cellulaire & Morphol, Bugnon 9, CH-1005 Lausanne, Switzerland.	Christian.Widmann@ibcm.unil.ch	Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Foo SY, 1999, TRENDS GENET, V15, P229; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; PARK S, 1992, J BIOL CHEM, V267, P11612; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; Prigent M, 2000, J BIOL CHEM, V275, P36441, DOI 10.1074/jbc.M004751200; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; WIDMANN C, 1995, BIOCHEM J, V310, P203, DOI 10.1042/bj3100203; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001	36	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14641	14646		10.1074/jbc.M111540200	http://dx.doi.org/10.1074/jbc.M111540200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847220	hybrid			2022-12-25	WOS:000175203000038
J	Schempp, CM; Kirkin, V; Simon-Haarhaus, B; Kersten, A; Kiss, J; Termeer, CC; Gilb, B; Kaufmann, T; Borner, C; Sleeman, JP; Simon, JC				Schempp, CM; Kirkin, V; Simon-Haarhaus, B; Kersten, A; Kiss, J; Termeer, CC; Gilb, B; Kaufmann, T; Borner, C; Sleeman, JP; Simon, JC			Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis	ONCOGENE			English	Article						programmed cell death; Hypericum perforatum; mitochondrial membrane permeabilization; caspases; cytochrome c	CYTOCHROME-C; LIGAND TRAIL; MITOCHONDRIA; ACTIVATION; BCL-2; RELEASE; INVOLVEMENT; METABOLITE; DEATH; CD44	Hyperforin is a plant derived antibiotic from St. John's wort. Here we describe a novel activity of hyperforin, namely its ability to inhibit the growth of tumour cells by induction of apoptosis. Hyperforin inhibited the growth of various human and rat tumour cell lines in vivo, with IC50 values between 3-15 muM. Treatment of tumour cells with hyperforin resulted in a dose-dependent generation of apoptotic oligonucleosomes, typical DNA-laddering and apoptosis-specific morphological changes. In MT-450 mammary carcinoma cells hyperforin increased the activity of caspase-9 and caspase-3, and hyperforin-mediated apoptosis was blocked by the broad-range caspase inhibitor zVAD.fmk. When added to MT-450 cells, hyperforin, but not paclitaxel, induced a rapid loss of the mitochondrial transmembrane potential Deltapsi(m), and subsequent morphological changes such as homogenization and vacuolization of mitochondria. Monitoring of Deltapsi(m) revealed that the hyperforin-mediated mitochondrial permeability transition can not be prevented by zVAD.fmk. This indicates that mitochondrial permeabilization is a cause rather than a consequence of caspase activation. Moreover, hyperforin was capable of releasing cytochrome c from isolated mitochondria. These findings suggest that hyperforin activates a mitochondria-mediated apoptosis pathway. In vivo, hyperforin inhibited the growth of autologous MT-450 breast carcinoma in immunocompetent Wistar rats to a similar extent as the cytotoxic drug paclitaxel, without any signs of acute toxicity. Owing to the combination of significant antitumour activity, low toxicity in vivo and natural abundance of the compound, hyperforin holds the promise of being an interesting novel antineoplastic agent that deserves further laboratory and in vivo exploration.	Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Univ Freiburg, Inst Pathol, D-79104 Freiburg, Germany; HWI Analyt, D-78106 Rheinzabern, Germany; Univ Freiburg, Inst Mol Med, D-79106 Freiburg, Germany	University of Freiburg; Helmholtz Association; Karlsruhe Institute of Technology; University of Freiburg; University of Freiburg	Schempp, CM (corresponding author), Univ Freiburg, Dept Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	schempp@haut.ukl.uni-freiburg.de	Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687; Kirkin, Vladimir/0000-0002-8049-3663; Kaufmann, Thomas/0000-0001-9906-874X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BYSTROV NS, 1975, TETRAHEDRON LETT, P2791; Castedo M, 1996, J IMMUNOL, V157, P512; Debatin KM, 1999, ADV EXP MED BIOL, V457, P237; DECOSTERD LA, 1989, HELV CHIM ACTA, V72, P464, DOI 10.1002/hlca.19890720307; Erdelmeier CAJ, 1998, PHARMACOPSYCHIATRY, V31, P2, DOI 10.1055/s-2007-979339; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUREVICH AI, 1971, ANTIBIOT MED BIOTEK, V16, P510; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; KIM U, 1986, J SURG ONCOL, V33, P151, DOI 10.1002/jso.2930330303; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAISENBACHER P, 1992, PLANTA MED, V58, P351, DOI 10.1055/s-2006-961483; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Muller WE, 1998, PHARMACOPSYCHIATRY, V31, P16, DOI 10.1055/s-2007-979341; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Revillard JP, 1998, IMMUNOL TODAY, V19, P291, DOI 10.1016/S0167-5699(98)01279-1; ROTH L, 1990, ECOMED, P97; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Schempp CM, 1999, LANCET, V353, P2129, DOI 10.1016/S0140-6736(99)00214-7; Schempp CM, 2000, BRIT J DERMATOL, V142, P979, DOI 10.1046/j.1365-2133.2000.03482.x; Schempp CM, 2001, FEBS LETT, V493, P26, DOI 10.1016/S0014-5793(01)02268-2; Sleeman JP, 1996, CANCER RES, V56, P3134; Sleeman JP, 1999, ONCOGENE, V18, P4485, DOI 10.1038/sj.onc.1202808; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Termeer C, 2001, J LEUKOCYTE BIOL, V70, P715; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	44	194	213	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1242	1250		10.1038/sj.onc.1205190	http://dx.doi.org/10.1038/sj.onc.1205190			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850844				2022-12-25	WOS:000173729400012
J	Recio, JA; Merlino, G				Recio, JA; Merlino, G			Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1	ONCOGENE			English	Article						melanoma; HGF/SF; p38; ATF-2; c-Met	FACTOR SCATTER FACTOR; ELEMENT-BINDING PROTEIN; FOCAL ADHESION KINASE; TYROSINE KINASE; C-MET; LEUCINE ZIPPER; SOMATIC MUTATIONS; RESPONSE ELEMENT; GENE-EXPRESSION; RECEPTOR	Members of the mitogen-activated protein kinase (MAPK) superfamily, including p38 kinase and SAPK/JNK, play a central role in mediating cellular response to environmental stress. growth factors and cytokines. Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional cytokine capable of eliciting mitogenic, motogenic and morphogenetic activities in responsive cells, and has been implicated in tumor development and metastasis. Binding of HGF/SF to its tyrosine kinase receptor c-Met stimulates multiple signal transduction pathways, leading to the activation of numerous transcription factors. We here report that HGF/SF can induce cyclin D1 expression in mouse melanoma cells. and that this up-regulation is mediated in part by the activating transcription factor-2 (ATF-2). HGF/SF-mediated phosphorylation of ATF-2 was reduced in the presence of either the p38 kinase-specific inhibitor SB203580, a dominant negative p38 mutant, the SAPK/JNK inhibitor JNK-interacting protein-1 (JIP-1), or the phosphatidylinositol 3-kinase (PI3K)-specific inhibitor LY294002. Activation of p38 kinase by HGF/SF was partially blocked by the PI3K-specific inhibitor as well. The upstream kinases for p38, MKK3/6, did not become activated following HGF/SF exposure, and ATF-2 activation was undiminished by transient transfection of a dominant negative MKK6 mutant. However, transcriptional up-regulation of cyclin D1 by HGF/SF was partially inhibited by the p38 kinase-specific inhibitor, and cyclin D1 protein induction was partially blocked by a dominant negative ATF-2 mutant. Notably, the p38 kinase-specific inhibitor was able to block melanoma cell proliferation but not motility. We conclude that the ATF-2 transcription factor becomes activated by HGF/SF through p38 MAPK and SAPK/JNK. Moreover, the p38-ATF-2 pathway can help mediate proliferation signals in tumor cells through transcriptional activation of key cell cycle regulators.	NCI, Mol Biol Lab, Mol Genet Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Merlino, G (corresponding author), NCI, Mol Biol Lab, Mol Genet Sect, NIH, Bldg 37,Room 5002,MSC 4264, Bethesda, MD 20892 USA.	gmerlino@helix.nih.gov		Recio, Juan Angel/0000-0002-7320-3832				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; Awasthi V, 2000, AM J PHYSIOL-LUNG C, V279, pL942, DOI 10.1152/ajplung.2000.279.5.L942; Bales ES, 1999, J INVEST DERMATOL, V113, P1039, DOI 10.1046/j.1523-1747.1999.00812.x; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Beviglia L, 1999, INT J CANCER, V83, P640, DOI 10.1002/(SICI)1097-0215(19991126)83:5<640::AID-IJC13>3.0.CO;2-D; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Chen RF, 2000, RARE METALS, V19, P231; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chuang SM, 2000, CARCINOGENESIS, V21, P1491, DOI 10.1093/carcin/21.8.1491; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coupland SE, 2000, J PATHOL, V191, P120; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; FERRACINI R, 1995, ONCOGENE, V10, P739; Ferracini R, 1996, ONCOGENE, V12, P1697; FILMUS J, 1994, ONCOGENE, V9, P3627; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nakanishi K, 1999, CLIN EXP METASTAS, V17, P507, DOI 10.1023/A:1006685218766; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Otsuka T, 1998, CANCER RES, V58, P5157; Park WS, 1999, CANCER RES, V59, P307; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; ROSEN EM, 1997, J BIOL CHEM, V270, P27780; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Saha Debabrata, 1999, Neoplasia (New York), V1, P508; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Shambaugh GE, 1996, J NEUROPATH EXP NEUR, V55, P1009, DOI 10.1097/00005072-199609000-00008; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Spector M, 2000, EXP CELL RES, V258, P109, DOI 10.1006/excr.2000.4907; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tolnay E, 1998, J CANCER RES CLIN, V124, P291, DOI 10.1007/s004320050171; Tsai EY, 1996, MOL CELL BIOL, V16, P459; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weimar IS, 1998, LEUKEMIA, V12, P1195, DOI 10.1038/sj.leu.2401080; YAMASHITA J, 1994, CANCER RES, V54, P1630; Yao Y, 1996, AM J PATHOL, V149, P1707; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225	70	132	144	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1000	1008		10.1038/sj.onc.1205150	http://dx.doi.org/10.1038/sj.onc.1205150			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850817				2022-12-25	WOS:000173580100003
J	Zhong, MH; Lu, ZM; Foster, DA				Zhong, MH; Lu, ZM; Foster, DA			Downregulating PKC delta provides a PI3K/Akt-independent survival signal that overcomes apoptotic signals generated by c-Src overexpression	ONCOGENE			English	Article						apoptosis; c-Src; PKC delta; tumor promoter; TPA	PROTEIN-KINASE-C; V-SRC; EMBRYO FIBROBLASTS; CELL-SURVIVAL; ACTIVATION; RAS; CANCER; DEGRADATION; SUPPRESSION; CODON-531	3Y1 rat fibroblasts overexpressing the tyrosine kinase c-Src (3Y1(c-Src) cells) become transformed by downregulation of protein kinase C delta (PKC delta). However, when 3Y1(c-Src) cells were subjected to serum withdrawal, they underwent apoptosis via a cytochrome c/caspase 9 pathway. In contrast, neither parental nor v-Src-transformed 3Y1 cells underwent apoptosis when subjected to serum withdrawal. If PKC delta was downregulated, the apoptotic phenotypes induced by serum withdrawal in the 3Y1(c-Src) cells were suppressed. The apparent survival signal generated by PKC delta downregulation was independent of the phosphatidylinositol-3-kinase (PI3K)/Akt survival pathway. Collectively, these data indicate that (1) c-Src overexpression renders cells sensitive to apoptotic stress, and (2) that downregulation of PKC delta provides a novel PI3K/Akt-independent survival signal capable of suppressing apoptotic signals.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.				NCI NIH HHS [CA 46677] Funding Source: Medline; NCRR NIH HHS [RR 03037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CRESSMAN CM, 1995, FEBS LETT, V367, P223, DOI 10.1016/0014-5793(95)00543-I; Daigo Y, 1999, CANCER RES, V59, P4222; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DOTTO GP, 1985, NATURE, V318, P472; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Wang NM, 2000, CANCER LETT, V150, P201, DOI 10.1016/S0304-3835(99)00398-5; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	39	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1071	1078		10.1038/sj/onc/1205165	http://dx.doi.org/10.1038/sj/onc/1205165			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850824				2022-12-25	WOS:000173580100010
J	Kukushkin, AN; Abramova, MV; Svetlikova, SB; Darieva, ZA; Pospelova, TV; Pospelov, VA				Kukushkin, AN; Abramova, MV; Svetlikova, SB; Darieva, ZA; Pospelova, TV; Pospelov, VA			Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter	ONCOGENE			English	Article						c-fos repression; Elk-1; histone deacetylase; chromatin; E1A and ras oncogenes	SIGNAL-TRANSDUCTION PATHWAYS; SERUM RESPONSE ELEMENT; P38 MAP KINASE; HISTONE ACETYLATION; PROTEIN-KINASE; JUN PROMOTER; DNA-BINDING; IN-VIVO; INHIBITION; EXPRESSION	REF cells transformed by oncogenes E1A and cHa-ras reveal high and constitutive DNA-binding activity of AP-1 factor lacking in c-Fos protein. Consistently, the transcription of c-fos gene has been found to be downregulated. To elucidate the mechanisms of c-fos downregulation in E1A+cHa-ras transformants, we studied the levels of activity of ERK, JNK/SAPK and p38 kinases and phosphorylation state of Elk-1 transcription factor involved in regulation of c-fos gene. Using two approaches, Western blot analysis with phospho-specific antibodies to MAP kinases and in vitro kinase assay with specific substrates, we show here that ectopic expression of E1A and ras oncogenes leads to a sustained activation of ERK and p38 kinases, whereas JNK/SAPK kinase activity is similar to that in non-transformed REF52 cells. Due to sustained activity of the MAP kinase cascades, Elk-1 transcription factor is being phosphorylated even in serum-starved E1A+cHa-ras cells; moreover, serum does not additionally increase phosphorylation of Elk-1, which is predominant TCF protein bound to SRE region of c-fos gene promoter in these cells. Although the amount of ternary complexes SRE/SRF/TCF estimated by EMSA was similar both in serum-starved and serum-stimulated transformed cells, serum addition still caused a modest activation of c-fos gene transcription at the level of 20% to normal REF cells. In attempt to determine how serum caused the stimulatory effect, we found that PD98059, an inhibitor of MEK/ERK kinase cascade, completely suppressed serum-induced c-fos transcription both in REF and E1A+cHa-ras cells, implicating the ERK as primary kinase for c-fos transcription in these cells. In contrast, SB203580, an inhibitor of p38 kinase, augmented noticeably serum-stimulated transcription of c-fos gene in REF cells, implying the involvement of p38 kinase in negative regulation of c-fos. Furthermore, sodium butyrate, an inhibitor of histone deacetylase activity, was capable of activating c-fos transcription both in serum-stimulated and even in serum-starved E1A+cHa-ras cells. Conversely, serum-starved REF cells fail to respond to sodium butyrate treatment by c-fos activation confirming necessity of prior Elk-1 phosphorylation. Taken together, these data suggest that downregulation of c-fos in E1A+cHa-ras cells seems to occur due to a maintenance of a refractory state that arises in normal REF cells after serum-stimulation. The refractory state of c-fos in E1A+cHa-ras cells is likely a consequence of Ras-induced sustained activation of MAPK (ERK) cascade and persistent phosphorylation of TCF (Elk-1) bound to SRE. Combination of these events eventually does contribute to formation of an inactive chromatin structure at c-fos promoter mediated through recruitment of histone deacetylase activity.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Pospelov, VA (corresponding author), Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia.	vap@link.cytspb.rssi.ru	Igotti, Maria V/U-4868-2017; Kukushkin, Alexander/W-7241-2018	Igotti, Maria/0000-0001-9596-5195				ABRAMOVA MV, 2002, MOL BIOL MOSCOW, V36; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; Ding XZ, 2001, BIOCHEM BIOPH RES CO, V282, P447, DOI 10.1006/bbrc.2001.4595; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Herrera RE, 1997, CHROMOSOMA, V106, P284, DOI 10.1007/s004120050249; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Kessler R, 1999, ONCOGENE, V18, P1733, DOI 10.1038/sj.onc.1202484; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; LAVARONE A, 1999, MOL CELL BIOL, V19, P916; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Malashicheva AB, 2000, ONCOGENE, V19, P3858, DOI 10.1038/sj.onc.1203736; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nakajima T, 1998, J BIOL CHEM, V273, P20036, DOI 10.1074/jbc.273.32.20036; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pospelova TV, 1999, GENE EXPRESSION, V8, P19; Pospelova TV, 1996, MOL BIOL+, V30, P394; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rosenberger SF, 1999, ONCOGENE, V18, P3626, DOI 10.1038/sj.onc.1202695; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; ROZEK D, 1995, J CELL BIOCHEM, V57, P479, DOI 10.1002/jcb.240570313; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	61	27	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					719	730		10.1038/sj.onc.1205118	http://dx.doi.org/10.1038/sj.onc.1205118			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850800				2022-12-25	WOS:000173427000003
J	Tulin, EE; Onoda, N; Hasegawa, M; Nomura, H; Kitamura, T				Tulin, EE; Onoda, N; Hasegawa, M; Nomura, H; Kitamura, T			Inhibition of human endothelial cell proliferation by ShIF, a vacuolar H+-ATPase-like protein	ONCOGENE			English	Article						ShIF; V-ATPase; endothelial cell proliferation; HUVEC	POLYPEPTIDE; SYNTHASE	ShIF is a bone marrow stroma cell-derived factor originally identified to support proliferation of bone marrow cells in vitro. This protein shares high sequence homology to the yeast vacuolar H+-ATPase subunit, Vph1p, and the 116 kDa proton pump of the rat and bovine synaptic vesicle, Vpp1. We examined the function of ShIF in the proliferation of human umbilical vein endothelial cells (HUVEC). ShIF inhibited HUVEC proliferation in a dose-dependent manner. Recombinant ShIF added at 10 and 20 ng/ml inhibited HUVEC proliferation by 21.6 and 44.3%, respectively and increasing the concentration of ShIF to 100 ng/ml inhibited proliferation by as much as 55.5%. When HUVEC cells were cultured at various concentrations of ShIF in the presence of anti-ShIF antibody, the inhibitory effects of ShIF to HUVEC proliferation were abrogated by 89-91% indicating that the activity of ShIF to HUVEC was specific. HUVEC cultured in the presence of ShIF and bafilomycin, a specific inhibitor of ATPase, resulted to a 90% growth inhibition. Thus, ShIF may act as an antagonist to the ATPase complex by disrupting the production of cellular ATP thereby decreasing the ability of HUVEC to proliferate.	Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan; Mol Med Inc, Chugai Res Inst, Niihari, Ibaraki 3004101, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy,Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo	Tulin, EE (corresponding author), Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Kitamura, Toshio/AAA-2071-2021					BODIN P, 1995, EXPERIENTIA, V51, P256, DOI 10.1007/BF01931108; Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; KANE PM, 1992, J EXP BIOL, V172, P93; KANE PM, 1989, J BIOL CHEM, V264, P19236; Kawamura Y, 2001, EUR J BIOCHEM, V268, P2801, DOI 10.1046/j.1432-1327.2001.02139.x; LEE CK, 1990, MOL IMMUNOL, V27, P1137; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROZENGURT E, 1977, J BIOL CHEM, V252, P4584; Tulin EE, 2001, J BIOL CHEM, V276, P27519, DOI 10.1074/jbc.M101781200; Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397; Zheng JB, 1999, BIOCHEM BIOPH RES CO, V261, P499, DOI 10.1006/bbrc.1999.1063	18	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					844	848		10.1038/sj.onc.1205114	http://dx.doi.org/10.1038/sj.onc.1205114			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850812				2022-12-25	WOS:000173427000015
J	Voss, TS; Mini, T; Jenoe, P; Beck, HP				Voss, TS; Mini, T; Jenoe, P; Beck, HP			Plasmodium falciparum possesses a cell cycle-regulated short type replication protein A large subunit encoded by an unusual transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SIMIAN VIRUS-40 DNA; STAGE-SPECIFIC EXPRESSION; POLYMERASE-ALPHA; BINDING-PROTEIN; MALARIA PARASITE; FACTOR-A; MOLECULAR CHARACTERIZATION; CRITHIDIA-FASCICULATA; FUNCTIONAL DOMAINS	DNA replication in Plasmodium parasites takes place at multiple distinct points during their complex life cycle in the mosquito and vertebrate hosts. Although several parasite proteins involved in DNA replication have been described, the various mechanisms engaged in DNA metabolism of this major pathogen remain largely unexplored. As a step toward understanding this complex network, we describe the identification of Plasmodium falciparum replication protein A large subunit (pfRPA1) through affinity purification and mass spectral analysis of a purified 55-kDa factor. Gel retardation experiments revealed that pfRPA is the major single-stranded DNA binding activity in parasite protein extracts. The activity was expressed in a cell cycle-dependent manner with peak activities in late trophozoites and schizonts, thus correlating with the beginning of chromosomal DNA replication. Accordingly, the pfrpa1 message was detected in parasites 20-24 h post-invasion which is in agreement with the expression of other P. falciparum DNA replication genes. Our results show that pfRPA1 is encoded by an unusual 6.5-kb transcript containing a single open reading frame of which only the C-terminal 42% of the deduced protein sequence shows homologies to other reported RPA1s. Like the orthologues of other protozoan parasites, pfRPA1 lacks the N-terminal protein interaction domain and is thus remarkably smaller than the RPA1s of higher eukaryotes.	Swiss Trop Inst, Dept Med Parasitol & Infect Biol, CH-4051 Basel, Switzerland; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Basel; Swiss Tropical & Public Health Institute; University of Basel	Beck, HP (corresponding author), Swiss Trop Inst, Dept Med Parasitol & Infect Biol, Socinstr 59, CH-4051 Basel, Switzerland.			Beck, Hans-Peter/0000-0001-8326-4834				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BROWN GW, 1994, MOL BIOCHEM PARASIT, V63, P135, DOI 10.1016/0166-6851(94)90016-7; BROWN GW, 1992, P NATL ACAD SCI USA, V89, P10227, DOI 10.1073/pnas.89.21.10227; Brush GS, 1995, METHOD ENZYMOL, V262, P522; Carlton J, 2000, PARASITOL TODAY, V16, P409, DOI 10.1016/S0169-4758(00)01781-6; CHAVALITSHEWINKOON P, 1993, MOL BIOCHEM PARASIT, V61, P243, DOI 10.1016/0166-6851(93)90070-E; CHEESMAN S, 1994, NUCLEIC ACIDS RES, V22, P2547, DOI 10.1093/nar/22.13.2547; Cheesman S, 1998, MOL BIOCHEM PARASIT, V92, P39, DOI 10.1016/S0166-6851(97)00223-5; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; FOX BA, 1993, MOL BIOCHEM PARASIT, V61, P37, DOI 10.1016/0166-6851(93)90156-R; FOX BA, 1991, MOL BIOCHEM PARASIT, V49, P289, DOI 10.1016/0166-6851(91)90072-E; GarciaMaya MM, 1997, FEBS LETT, V413, P181, DOI 10.1016/S0014-5793(97)00897-1; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; GEORGAKI A, 1993, NUCLEIC ACIDS RES, V21, P3659, DOI 10.1093/nar/21.16.3659; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P10558, DOI 10.1021/bi9607517; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; Horrocks P, 1996, MOL BIOCHEM PARASIT, V79, P177, DOI 10.1016/0166-6851(96)02657-6; INSELBURG J, 1984, MOL BIOCHEM PARASIT, V10, P79, DOI 10.1016/0166-6851(84)90020-3; Ishiai M, 1996, J BIOL CHEM, V271, P20868, DOI 10.1074/jbc.271.34.20868; JAIKARIA NS, 1993, MOL BIOCHEM PARASIT, V57, P269, DOI 10.1016/0166-6851(93)90203-A; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KILBEY BJ, 1993, NUCLEIC ACIDS RES, V21, P239, DOI 10.1093/nar/21.2.239; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LI WB, 1989, NUCLEIC ACIDS RES, V17, P9621, DOI 10.1093/nar/17.23.9621; LI WB, 1991, MOL BIOCHEM PARASIT, V46, P229, DOI 10.1016/0166-6851(91)90047-A; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; Martin D, 2000, MOL BIOCHEM PARASIT, V110, P93, DOI 10.1016/S0166-6851(00)00260-7; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; MCCUTCHAN TF, 1984, SCIENCE, V225, P808, DOI 10.1126/science.6382604; MELENDY T, 1993, J BIOL CHEM, V268, P3389; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; POLLACK Y, 1982, NUCLEIC ACIDS RES, V10, P539, DOI 10.1093/nar/10.2.539; RIDLEY RG, 1991, NUCLEIC ACIDS RES, V19, P6731, DOI 10.1093/nar/19.24.6731; Scaife J.G., 1988, Genetic Engineering, V7, P57; SEROUSSI E, 1993, J BIOL CHEM, V268, P7147; Stahl DC, 1996, J AM SOC MASS SPECTR, V7, P532, DOI 10.1016/1044-0305(96)00057-8; TOSH K, 1995, GENE, V163, P151, DOI 10.1016/0378-1119(95)00376-H; Tosh K, 1999, EXP PARASITOL, V91, P126, DOI 10.1006/expr.1998.4362; TRAGER W, 1978, NATURE, V273, P621, DOI 10.1038/273621a0; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Voss TS, 2000, MOL BIOCHEM PARASIT, V107, P103, DOI 10.1016/S0166-6851(00)00176-6; WEBER JL, 1987, GENE, V52, P103, DOI 10.1016/0378-1119(87)90399-4; White JH, 1996, PARASITOL TODAY, V12, P151, DOI 10.1016/0169-4758(96)10005-3; WHITE JH, 1993, NUCLEIC ACIDS RES, V21, P3643, DOI 10.1093/nar/21.16.3643; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Zhu G, 1999, FEMS MICROBIOL LETT, V176, P367, DOI 10.1111/j.1574-6968.1999.tb13685.x	70	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17493	17501		10.1074/jbc.M200100200	http://dx.doi.org/10.1074/jbc.M200100200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11880371	hybrid			2022-12-25	WOS:000175685100015
J	Friedrich, EB; Sinha, S; Li, L; Dedhar, S; Force, T; Rosenzweig, A; Gerszten, RE				Friedrich, EB; Sinha, S; Li, L; Dedhar, S; Force, T; Rosenzweig, A; Gerszten, RE			Role of integrin-linked kinase in leukocyte recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLOW CONDITIONS; CELL-ADHESION; PHOSPHOINOSITIDE 3-KINASE-GAMMA; VASCULAR ENDOTHELIUM; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; BETA-GAMMA; IN-VITRO; ACTIVATION	Chemokines modulate leukocyte integrin avidity to coordinate adhesion and subsequent transendothelial migration, although the sequential signaling pathways involved remain poorly characterized. Here we show that integrin-linked kinase (ILK), a 59-kDa serine-threonine protein kinase that interacts principally with beta(1), integrins, is highly expressed in human mononuclear cells and is activated by exposure of leukocytes to the chemokine monocyte chemoattractant protein-1. Biochemical inhibitor studies show that chemokine-triggered activation of ILK is downstream of phosphoinositide 3-kinase. In functional assays under physiologically relevant flow conditions, overexpression of wild-type ILK in human monocytic cells diminishes beta(1), integrin/vascular cell adhesion molecule-1-dependent firm adhesion to human endothelial cells. These data implicate ILK in the dynamic signaling events involved in the regulation of leukocyte integrin avidity for endothelial substrates.	Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Program Cardiovasc Gene Therapy, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Harvard Med Sch, Boston, MA USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6H 3Z6, Canada; Vancouver Gen Hosp & Hlth Serv Ctr, Jack Bell Canc Ctr, Vancouver, BC V6H 3Z6, Canada; Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of British Columbia; University of British Columbia; Tufts Medical Center; Tufts University	Gerszten, RE (corresponding author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, E 8307,149 13tg St, Charlestown, MA 02129 USA.			Dedhar, Shoukat/0000-0003-4355-1657; Force, Thomas/0000-0002-0450-8659	NHLBI NIH HHS [HL59521, HL61688, HL67768, HL65584, HL54202] Funding Source: Medline; NIAID NIH HHS [AI40970] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054202, K02HL067768, R01HL061688, R29HL054202, R01HL059521, R01HL065584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040970] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Aoukaty A, 1999, J IMMUNOL, V162, P3249; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Gerszten RE, 1996, CIRC RES, V79, P1205, DOI 10.1161/01.RES.79.6.1205; Gerszten RE, 2001, J BIOL CHEM, V276, P26846, DOI 10.1074/jbc.M011235200; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stockwell BR, 1998, CHEM BIOL, V5, P385, DOI 10.1016/S1074-5521(98)90072-2; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; TURNER L, 1995, J IMMUNOL, V155, P2437; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Youn BS, 2001, BLOOD, V98, P925, DOI 10.1182/blood.V98.4.925; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	32	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16371	16375		10.1074/jbc.M201240200	http://dx.doi.org/10.1074/jbc.M201240200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11856758	hybrid			2022-12-25	WOS:000175564500005
J	Kvaratskhelia, M; Budihas, SR; Le Grice, SFJ				Kvaratskhelia, M; Budihas, SR; Le Grice, SFJ			Pre-existing distortions in nucleic acid structure aid polypurine tract selection by HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEQUENCE FEATURES IMPORTANT; MURINE LEUKEMIA-VIRUS; STRAND DNA-SYNTHESIS; HOLLIDAY JUNCTION; CRYSTAL-STRUCTURE; RNA; COMPLEX; INITIATION; POLYMERASE	Precise cleavage at the polypurine tract (PPT)/U3 junction by human immunodeficiency virus type 1 (HIV-1) reverse transcriptase RNase H is critical for generating a correct viral DNA end for subsequent integration. Using potassium permanganate (KMnO4) modification, we have identified a significant distortion in the nucleic acid structure at the HIV-1 PPT/U3 junction in the absence of trans-acting factors. Unusually high reactivity of template thymine +1 is detected when the PPT primer is extended by DNA or RNA at its 3' terminus. Chemical footprinting suggests that the extent of base unstacking in the wild-type species is comparable when the +1 A:T base pair is replaced by a C:T mismatch. However, reactivity of this template base is diminished after alterations to upstream (rA)(4):(dT)(4) or (rG)(6):(dC)(6) tracts. Importantly, there is a correlation between the structural deformation at base pair +1 and precise cleavage at the PPT/U3 junction by HIV-1 reverse transcriptase/RNase H. KMnO4 modification also revealed unusually high reactivity for one of two (dT)(4): (rA)(4) duplexes upstream of the PPT/U3 junction, suggesting a significant structural distortion within the PPT itself in the absence of the retroviral polymerase. Structural abnormalities in this region are not only essential for resistance of the PPT to hydrolysis but also significantly impact the conformation of the PPT/U3 junction. Our data collectively suggest that the entire PPT sequence contributes to the structural distortion at the PPT/U3 junction, potentially providing a mechanism for its selective processing.	NCI Frederick, Reverse Transcriptase Biochem Sect, Resistance Mech Lab, HIV Drug Resistance Program,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Le Grice, SFJ (corresponding author), NCI Frederick, Reverse Transcriptase Biochem Sect, Resistance Mech Lab, HIV Drug Resistance Program,NIH, 535 Sultan St, Frederick, MD 21702 USA.	slegrice@ncifcrf.gov						ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Bacharach E, 2000, J VIROL, V74, P4755, DOI 10.1128/JVI.74.10.4755-4764.2000; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; Declais AC, 2000, J MOL BIOL, V296, P421, DOI 10.1006/jmbi.1999.3479; Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8; Farah JA, 1997, J MOL BIOL, V272, P699, DOI 10.1006/jmbi.1997.1259; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; Friant S, 1996, BIOCHIMIE, V78, P674, DOI 10.1016/S0300-9084(96)80013-7; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; Gralla JD, 1996, METHOD ENZYMOL, V273, P99; Han GW, 2001, ACTA CRYSTALLOGR D, V57, P213, DOI 10.1107/S0907444900017595; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; Ilyinskii PO, 1998, EMBO J, V17, P3766, DOI 10.1093/emboj/17.13.3766; Kahl BF, 2000, J MOL BIOL, V299, P75, DOI 10.1006/jmbi.2000.3743; Katz RA, 2001, J BIOL CHEM, V276, P34213, DOI 10.1074/jbc.M104632200; Kvaratskhelia M, 2000, J BIOL CHEM, V275, P25540, DOI 10.1074/jbc.M003420200; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; Monsalve M, 1996, EMBO J, V15, P383, DOI 10.1002/j.1460-2075.1996.tb00368.x; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; Qureshi M, 1997, BIOCHEMISTRY-US, V36, P12303, DOI 10.1021/bi9701179; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; Rausch JW, 2000, J BIOL CHEM, V275, P13879, DOI 10.1074/jbc.275.18.13879; Reddy YVR, 2000, J MOL BIOL, V298, P597, DOI 10.1006/jmbi.2000.3673; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Smith CM, 1998, J VIROL, V72, P6805, DOI 10.1128/JVI.72.8.6805-6812.1998; Telesnitsky A., 1997, P121; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889	37	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16689	16696		10.1074/jbc.M109914200	http://dx.doi.org/10.1074/jbc.M109914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875059	hybrid			2022-12-25	WOS:000175564500047
J	Manivet, P; Schneider, B; Smith, JC; Choi, DS; Maroteaux, L; Kellermann, O; Launay, JM				Manivet, P; Schneider, B; Smith, JC; Choi, DS; Maroteaux, L; Kellermann, O; Launay, JM			The serotonin binding site of human and murine 5-HT2B-receptors - Molecular modeling and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; 5-HYDROXYTRYPTAMINE(2A) RECEPTORS; 3-DIMENSIONAL MODELS; 5-HT2B RECEPTORS; AGONIST BINDING; LIGAND-BINDING; ACTIVATION; RESIDUES; RHODOPSIN; BACTERIORHODOPSIN	Bacteriorhodopsin and rhodopsin crystal structures were used as templates to build structural models of the mouse and human serotonin (5-HT)-2B receptors (5-HT(2B)Rs). Serotonin was docked to the receptors, and the amino acids predicted to participate to its binding were subjected to mutagenesis. 5-HT binding affinity and 5-HT-induced inositol triphosphate production were measured in LMTK- cells transfected with either wildtype or mutated receptor genes. According to these measurements, the bacteriorhodopsin-based models of the 5-HT(2B)Rs appear more confident than the rhodopsin-based ones. Residues belonging to the transmembrane domains 3 and 6, i.e. Asp(3.32), Ser(3.36), Phe(6.52), and Asn(6.55), make direct contacts with 5-HT. In addition, Trp(3.28), Phe(3.35), Phe(6.52) and Phe(7.38) form an aromatic box surrounding 5-HT. The specificity of human and mouse 5-HT(2B)Rs may be reflected by different rear-rangements of the aromatic network upon 5-HT binding. Two amino acids close to Pro(5.50) in the human transmembrane domain 5 sequence were permuted to introduce a "mouse-like" sequence. This change was enough to confer the human 5-HT2BR properties similar to those of the mouse. Taken together, the computed models and the site-directed mutagenesis experiments give a structural explanation to (i) the different 5-HT pK(D) values measured with the human and mouse 5-HT(2B)Rs (7.9 and 5.8, respectively) and (ii) the specificity of 5-HT binding to 5-HT(2B)Rs as compared with other serotonergic G-protein coupled receptors.	Hop Lariboisiere, Serv Biochim, Ctr Rech Claude Bernard Pathol Expt & Commun Cell, IFR 6, F-75475 Paris 10, France; Ecole Polytech, Lab Dept Chim Mecan React, F-91112 Palaiseau, France; Inst Andre Lwoff, CNRS, UPR 1983, F-94801 Villejuif, France; Univ Heidelberg, Leturstuhl Biocomp, IWR, D-69120 Heidelberg, Germany; Univ Strasbourg, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Launay, JM (corresponding author), Hop Lariboisiere, Serv Biochim, Ctr Rech Claude Bernard Pathol Expt & Commun Cell, IFR 6, 2 Rue Ambroise PAre, F-75475 Paris 10, France.		Choi, Doo-Sup/G-9474-2012; smith, jeremy c/B-7287-2012; Schneider, Benoit/AAF-3850-2019; Maroteaux, Luc/H-4585-2019; Manivet, Philippe/AAA-1884-2021	Choi, Doo-Sup/0000-0002-6796-9938; smith, jeremy c/0000-0002-2978-3227; Maroteaux, Luc/0000-0002-9499-8603; Schneider, Benoit/0000-0002-1377-2670				Almaula N, 1996, J BIOL CHEM, V271, P14672, DOI 10.1074/jbc.271.25.14672; Almaula N, 1996, MOL PHARMACOL, V50, P34; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brouland JP, 2001, ENDOCR PATHOL, V12, P77, DOI 10.1385/EP:12:1:77; Chattopadhyay A, 1996, BIOPHYS J, V71, P1952, DOI 10.1016/S0006-3495(96)79393-1; Choi DS, 1995, BEHAV BRAIN RES, V73, P253; CHOI DS, 1994, FEBS LETT, V352, P393, DOI 10.1016/0014-5793(94)00968-6; CHOUDHARY MS, 1995, MOL PHARMACOL, V47, P450; Deane CM, 2001, J BIOL CHEM, V276, P37962; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; EDVARDSEN O, 1992, MOL BRAIN RES, V14, P166, DOI 10.1016/0169-328X(92)90171-7; FOGUET M, 1992, EMBO J, V11, P3481, DOI 10.1002/j.1460-2075.1992.tb05427.x; GHINEA G, 1995, PROTEIN-STRUCT FUNCT, V23, P415; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HOYER D, 1994, PHARMACOL REV, V46, P157; Hulme EC, 1999, EUR J PHARMACOL, V375, P247, DOI 10.1016/S0014-2999(99)00297-6; Kristiansen K, 1996, EUR J PHARMACOL, V306, P195, DOI 10.1016/0014-2999(96)00180-X; LORIC S, 1995, MOL PHARMACOL, V47, P458; LORIC S, 1992, FEBS LETT, V312, P203, DOI 10.1016/0014-5793(92)80936-B; Lu ZL, 2001, J BIOL CHEM, V276, P34098, DOI 10.1074/jbc.M104217200; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Nebigil CG, 2001, CIRCULATION, V103, P2973, DOI 10.1161/01.CIR.103.24.2973; OLIVEIRA L, 1993, J COMPUT AID MOL DES, V7, P649, DOI 10.1007/BF00125323; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Roth BL, 1997, MOL PHARMACOL, V52, P259, DOI 10.1124/mol.52.2.259; Roth BL, 1998, PHARMACOL THERAPEUT, V79, P231, DOI 10.1016/S0163-7258(98)00019-9; Schmuck K, 1996, EUR J NEUROSCI, V8, P959, DOI 10.1111/j.1460-9568.1996.tb01583.x; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; Shapiro DA, 2000, MOL PHARMACOL, V58, P877, DOI 10.1124/mol.58.5.877; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Thompson JD, 1999, NUCLEIC ACIDS RES, V27, P2682, DOI 10.1093/nar/27.13.2682; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; Wainscott DB, 1996, J PHARMACOL EXP THER, V276, P720; WANG CD, 1993, MOL PHARMACOL, V43, P931; WESTKAEMPER RB, 1993, MED CHEM RES, V3, P317; ZHANG DQ, 1994, FEBS LETT, V337, P207, DOI 10.1016/0014-5793(94)80274-2	41	61	62	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17170	17178		10.1074/jbc.M200195200	http://dx.doi.org/10.1074/jbc.M200195200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859080	hybrid			2022-12-25	WOS:000175564500110
J	Oberkofler, H; Esterbauer, H; Linnemayr, V; Strosberg, AD; Krempler, F; Patsch, W				Oberkofler, H; Esterbauer, H; Linnemayr, V; Strosberg, AD; Krempler, F; Patsch, W			Peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 recruitment regulates PPAR subtype specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; NUCLEAR RECEPTOR; BROWN-FAT; RETINOIC ACID; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; UCP1 GENE; EXPRESSION; ALPHA; ADIPOCYTES	The peroxisome proliferator-activated receptors (PPAR) alpha and gamma play key roles in the transcriptional control of contrasting metabolic pathways such as adipogenesis and fatty acid beta-oxidation. Both ligand-activated nuclear receptors bind to common target gene response elements and interact with distinct domains of the transcriptional coactivator PGC-1 to attain their full transcriptional potency. Thus, PPAR subtype specificity may be determined by ligand availability and transcription factor or coactivator expression levels. To identify other, perhaps more precise mechanisms contributing to PPAR subtype specificity, we studied PGC-1 recruitment by PPARs using a previously described hormone response element in the human UCP1 promoter and a human brown adipocyte cell line as our model system. As in rodents, PGC-1 is involved in the transcriptional regulation of the UCP1 gene in humans and mediates the effects of PPARalpha and PPARgamma agonists and retinoic acid. Interestingly, a previously postulated PGC-1 repressor selectively affects the PPARalpha-mediated activation of UCP1 gene expression. Furthermore, inhibition of p38 MAPK signaling, known to regulate the PGC-1-/repressor interaction, decreases the stimulatory effect of PPARalpha agonist treatment without reducing the response to thiazolidinedione or retinoic acid. These data support a model whereby PPAR subtype specificity is regulated by recruitment of PGC-1.	Landeskliniken Salzburg, Dept Lab Med, A-5020 Salzburg, Austria; Krankenhaus Hallein, Dept Internal Med, A-5400 Hallein, Austria; Inst Cochin Genet Mol, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Patsch, W (corresponding author), Landeskliniken Salzburg, Dept Lab Med, A-5020 Salzburg, Austria.			Esterbauer, Harald/0000-0001-7343-7455				ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; Barbera MJ, 2001, J BIOL CHEM, V276, P1486, DOI 10.1074/jbc.M006246200; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Cao WH, 2001, J BIOL CHEM, V276, P27077, DOI 10.1074/jbc.M101049200; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Digby JE, 1998, DIABETES, V47, P138, DOI 10.2337/diabetes.47.1.138; Ek J, 2001, DIABETOLOGIA, V44, P2220, DOI 10.1007/s001250100032; Esterbauer H, 1999, GENOMICS, V62, P98, DOI 10.1006/geno.1999.5977; Esterbauer H, 2002, DIABETES, V51, P1281, DOI 10.2337/diabetes.51.4.1281; Esterbauer H, 2001, NAT GENET, V28, P178, DOI 10.1038/88911; Gonzalez-Barroso MD, 2000, J BIOL CHEM, V275, P31722, DOI 10.1074/jbc.M001678200; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; Larose M, 1996, J BIOL CHEM, V271, P31533, DOI 10.1074/jbc.271.49.31533; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; SAFONOVA I, 1994, MOL CELL ENDOCRINOL, V104, P201, DOI 10.1016/0303-7207(94)90123-6; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SILVA JE, 1988, MOL ENDOCRINOL, V2, P706, DOI 10.1210/mend-2-8-706; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Valmaseda A, 1999, MOL CELL ENDOCRINOL, V154, P101, DOI 10.1016/S0303-7207(99)00081-7; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Zilberfarb V, 1997, J CELL SCI, V110, P801	42	66	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16750	16757		10.1074/jbc.M200475200	http://dx.doi.org/10.1074/jbc.M200475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875072	hybrid			2022-12-25	WOS:000175564500055
J	Short, MK; Krykbaev, RA; Jeffrey, PD; Margolies, MN				Short, MK; Krykbaev, RA; Jeffrey, PD; Margolies, MN			Complementary combining site contact residue mutations of the anti-digoxin Fab 26-10 permit high affinity wild-type binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-AZOPHENYLARSONATE FAB-36-71; DIRECTED MUTAGENESIS; ANTIDIGOXIN ANTIBODY-26-10; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODY; VARIABLE REGION; HAPTEN BINDING; SPECIFICITY; LYSOZYME; INCREASE	Antibody 26-10, obtained in a secondary immune response, binds digoxin with high affinity (K-a = 1.3 x 10(10) M-1) because of extensive shape complementarity. We demonstrated previously that mutations of the hapten contact residue HTrp-100 to Arg (where H refers to the heavy chain) resulted in increased specificity for digoxin analogs substituted at the cardenolide 16 position. However, mutagenesis of H:CDRI did not result in such a specificity change despite the proximity of the H:CDR1 hapten contact residue Asn-35 to the cardenolide 16 position. Here we constructed a bacteriophage-displayed library containing randomized mutations at H chain residues 30-35 in a 26-10 mutant containing Arg-100 (26-10-RRALD). Phage were selected by panning against digoxin, gitoxin (16-OH), and 16-acetylgitoxin coupled to bovine serum albumin. Clones that retained wild-type Asn at position 35 showed preferred binding to gitoxin, like the 26-10-RRALD parent. In contrast, clones containing Val-35 selected mainly on digoxin-bovine serum albumin demonstrated a shift back to wild-type specificity. Several clones containing Val-35 bound digoxin with increased affinity, approaching that of the wild type in a few instances, in contrast to the mutation Val-35 in the wild-type 26-10 background, which reduces affinity for digoxin 90-fold. It has therefore proven possible to reorder the 26-10 binding site by mutations including two major contact residues on opposite sides of the site and yet to retain high affinity for binding for digoxin. Thus, even among antibodies that have undergone affinity maturation in vivo, different structural solutions to high affinity binding may be revealed.	Massachusetts Gen Hosp, Dept Surg, Antibody Engn Lab, Boston, MA 02114 USA; Mem Sloan Kettering Canc Ctr, Dept Cellular Biochem & Biophys, New York, NY 10021 USA	Harvard University; Massachusetts General Hospital; Memorial Sloan Kettering Cancer Center	Margolies, MN (corresponding author), Massachusetts Gen Hosp, Dept Surg, Antibody Engn Lab, 15 Parkman St,WACC 465, Boston, MA 02114 USA.			Jeffrey, Philip/0000-0002-4351-5341	NHLBI NIH HHS [HLCA24432, HL47415] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047415] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; GLOCKSHUBER R, 1991, BIOCHEMISTRY-US, V30, P3049, DOI 10.1021/bi00226a010; HAWKINS RE, 1993, J MOL BIOL, V234, P958, DOI 10.1006/jmbi.1993.1650; JEFFREY PD, 1993, P NATL ACAD SCI USA, V90, P10310, DOI 10.1073/pnas.90.21.10310; Kabat EA, 1991, SEQUENCES PROTEINS I; Krykbaev RA, 2001, J BIOL CHEM, V276, P8149, DOI 10.1074/jbc.M008108200; LAVOIE TB, 1992, J IMMUNOL, V148, P503; MANSER T, 1987, J EXP MED, V166, P1456, DOI 10.1084/jem.166.5.1456; MUDGETTHUNTER M, 1985, MOL IMMUNOL, V22, P477, DOI 10.1016/0161-5890(85)90132-4; MUDGETTHUNTER M, 1982, J IMMUNOL, V129, P1165; NEAR RI, 1991, J IMMUNOL, V146, P627; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PARHAMISEREN B, 1993, J IMMUNOL, V150, P1829; SCHILDBACH JF, 1994, PROTEIN SCI, V3, P737; SCHILDBACH JF, 1993, J BIOL CHEM, V268, P21739; SCHILDBACH JF, 1991, J BIOL CHEM, V266, P4640; SHARON J, 1989, J IMMUNOL, V142, P596; SHARON J, 1990, P NATL ACAD SCI USA, V87, P4814, DOI 10.1073/pnas.87.12.4814; Short MK, 2001, PROTEIN ENG, V14, P287, DOI 10.1093/protein/14.4.287; SHORT MK, 1995, J BIOL CHEM, V270, P28541, DOI 10.1074/jbc.270.48.28541; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3739, DOI 10.1021/bi00229a022; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3749, DOI 10.1021/bi00229a023; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; Yang PL, 1999, J MOL BIOL, V294, P1191, DOI 10.1006/jmbi.1999.3197	25	8	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16365	16370		10.1074/jbc.M110444200	http://dx.doi.org/10.1074/jbc.M110444200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11854275	hybrid			2022-12-25	WOS:000175564500004
J	Yan, KS; Kuti, M; Yan, S; Mujtaba, S; Farooq, A; Goldfarb, MP; Zhou, MM				Yan, KS; Kuti, M; Yan, S; Mujtaba, S; Farooq, A; Goldfarb, MP; Zhou, MM			FRS2 PTB domain conformation regulates interactions with divergent neurotrophic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; FIBROBLAST-GROWTH-FACTOR; AMYLOID PRECURSOR PROTEIN; INSULIN-RECEPTOR; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; STRUCTURAL BASIS; TYROSINE KINASE; SH3 DOMAINS; IN-VIVO	Membrane-anchored adaptor proteins FRS2alpha/beta (also known as SNT-1/2) mediate signaling of fibroblast growth factor receptors (FGFRs) and neurotrophin receptors (TRKs) through their N-terminal phosphotyrosine binding (PTB) domains. The FRS2 PTB domain recognizes tyrosine-phosphorylated TRKs at an NPXpY (where pY is phosphotyrosine) motif, whereas its constitutive association with FGFR involves a receptor juxtamembrane region lacking Tyr and Asn residues. Here we show by isothermal titration calorimetry that the FRS2alpha PTB domain binding to peptides derived from TRKs or FGFR is thermodynamically different. TRK binding is largely enthalpy-driven, whereas the FGFR interaction is governed by a favorable entropic contribution to the free energy of binding. Furthermore, our NMR spectral analysis suggests that disruption of an unstructured region C-terminal to the PTB domain alters local conformation and dynamics of the residues at the ligand-binding site, and that structural disruption of the beta8-strand directly weakens the PTB domain association with the FGFR ligand. Together, our new findings support a molecular mechanism by which conformational dynamics of the FRS2alpha PTB domain dictates its association with either fibroblast growth factor or neurotrophin receptors in neuronal development.	NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University	Zhou, MM (corresponding author), NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, 1425 Madison Ave,Box 1677, New York, NY 10029 USA.		Farooq, Amjad/B-5084-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059432] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059432-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Burgar HR, 2002, J BIOL CHEM, V277, P4018, DOI 10.1074/jbc.M107785200; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Farooq A, 1999, J BIOL CHEM, V274, P6114, DOI 10.1074/jbc.274.10.6114; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Howell BW, 1999, MOL CELL BIOL, V19, P5179; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; Jelesarov I, 1999, J MOL RECOGNIT, V12, P3, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<3::AID-JMR441>3.0.CO;2-6; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li SC, 1998, NAT STRUCT BIOL, V5, P1075, DOI 10.1038/4185; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; Mayer BJ, 2001, J CELL SCI, V114, P1253; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 2000, GENE DEV, V14, P1027; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Wang JK, 1996, ONCOGENE, V13, P721; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Xu H, 2001, J BIOL CHEM, V276, P13049, DOI 10.1074/jbc.M009925200; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; Zwahlen C, 2000, EMBO J, V19, P1505, DOI 10.1093/emboj/19.7.1505	43	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17088	17094		10.1074/jbc.M107963200	http://dx.doi.org/10.1074/jbc.M107963200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877385	hybrid			2022-12-25	WOS:000175564500099
J	Little, R; Colombo, V; Leech, A; Dixon, R				Little, R; Colombo, V; Leech, A; Dixon, R			Direct interaction of the NifL regulatory protein with the GlnK signal transducer enables the Azotobacter vinelandii NifL-NifA regulatory system to respond to conditions replete for nitrogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE-SYNTHETASE ADENYLYLATION; ESCHERICHIA-COLI; P-II; TRANSCRIPTIONAL ACTIVATION; IN-VITRO; KLEBSIELLA-PNEUMONIAE; INTERNAL GLUTAMINE; ENTERIC BACTERIA; GENE-EXPRESSION; FIXATION GENES	The Azotobacter vinelandii NifL-NifA regulatory system integrates metabolic signals for redox, energy, and nitrogen status to fine tune regulation of the synthesis of molybdenum nitrogenase. The NifL protein utilizes discrete mechanisms to perceive these signals leading to the formation of a protein-protein complex, which inhibits NifA activity. Whereas redox signaling is mediated via a flavin-containing PAS domain in the N-terminal region of NifL, the nitrogen status is sensed via interaction with PII-like signal transduction proteins and small molecular weight effectors. The nonuridylylated form of the PII-like protein encoded by A vinelandii glnK (Av GlnK) stimulates NifL to inhibit transcriptional activation by NifA in vitro. Here we demonstrate that the nonmodified form of Av GlnK directly interacts with A vinelandii NifL and that this interaction is dependent on Mg2+, ATP, and 2-oxoglutarate. Differences were observed in the regulation of the Av GlnK-NifL interaction by 2-oxoglutarate compared with the role of this effector in modulating the interaction of enteric PII-like proteins with their receptors. We also report that the interaction between Av GlnK and NifL is abolished by site-directed substitution of a single amino acid in the T-loop region of Av GlnK and that uridylylation of the conserved tyrosine residue in the T-loop inhibits the interaction. No association was detected between Av GlnK and the N-terminal region of NifL and our results demonstrate that Av GlnK directly interacts with the C-terminal histidine protein kinase-like domain.	John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of East Anglia	Dixon, R (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England.			Dixon, Ray/0000-0002-6348-639X; Colombo Rodriguez, Maria Victoria/0000-0003-4540-882X	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000016] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Arcondeguy T, 2000, J BIOL CHEM, V275, P38452, DOI 10.1074/jbc.M001935200; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; ATKINSON MR, 1994, J BIOL CHEM, V269, P28288; Atkinson MR, 1999, MOL MICROBIOL, V32, P301, DOI 10.1046/j.1365-2958.1999.01349.x; AUSTIN S, 1994, J BACTERIOL, V176, P3460, DOI 10.1128/JB.176.12.3460-3465.1994; Barrett J, 2001, MOL MICROBIOL, V39, P480, DOI 10.1046/j.1365-2958.2001.02243.x; BLANCO G, 1993, MOL MICROBIOL, V9, P869, DOI 10.1111/j.1365-2958.1993.tb01745.x; Carr PD, 1996, ACTA CRYSTALLOGR D, V52, P93, DOI 10.1107/S0907444995007293; CHEAH E, 1994, STRUCTURE, V2, P981, DOI 10.1016/S0969-2126(94)00100-6; Colnaghi R, 2001, MICROBIOL-SGM, V147, P1267, DOI 10.1099/00221287-147-5-1267; CONTRERAS A, 1991, J BACTERIOL, V173, P7741, DOI 10.1128/jb.173.24.7741-7749.1991; Dixon R, 1998, ARCH MICROBIOL, V169, P371, DOI 10.1007/s002030050585; EYDMANN T, 1995, J BACTERIOL, V177, P1186, DOI 10.1128/jb.177.5.1186-1195.1995; Forchhammer K, 1997, EUR J BIOCHEM, V244, P869, DOI 10.1111/j.1432-1033.1997.00869.x; He LH, 1998, J BACTERIOL, V180, P6661, DOI 10.1128/JB.180.24.6661-6667.1998; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; Ikeda TP, 1996, J MOL BIOL, V259, P589, DOI 10.1006/jmbi.1996.0342; Jack R, 1999, J BACTERIOL, V181, P1156, DOI 10.1128/JB.181.4.1156-1162.1999; Jaggi R, 1997, EMBO J, V16, P5562, DOI 10.1093/emboj/16.18.5562; Jaggi R, 1996, FEBS LETT, V391, P223, DOI 10.1016/0014-5793(96)00737-5; Jiang P, 2000, BIOCHEMISTRY-US, V39, P13433, DOI 10.1021/bi000794u; Jiang P, 1997, J BACTERIOL, V179, P4342, DOI 10.1128/jb.179.13.4342-4353.1997; Jiang P, 1997, J BACTERIOL, V179, P4354, DOI 10.1128/jb.179.13.4354-4360.1997; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12802, DOI 10.1021/bi980666u; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12795, DOI 10.1021/bi9802420; Jiang P, 1999, J BACTERIOL, V181, P1906, DOI 10.1128/JB.181.6.1906-1911.1999; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12782, DOI 10.1021/bi980667m; KAMBEROV ES, 1994, CELL MOL BIOL RES, V40, P175; KAMBEROV ES, 1995, J BIOL CHEM, V270, P17797, DOI 10.1074/jbc.270.30.17797; Little R, 2000, EMBO J, V19, P6041, DOI 10.1093/emboj/19.22.6041; Macheroux P, 1998, BIOCHEM J, V332, P413, DOI 10.1042/bj3320413; Martinez-Argudo I, 2002, J BACTERIOL, V184, P200, DOI 10.1128/JB.184.1.200-206.2002; Meletzus D, 1998, J BACTERIOL, V180, P3260, DOI 10.1128/JB.180.12.3260-3264.1998; Money T, 1999, J BACTERIOL, V181, P4461, DOI 10.1128/JB.181.15.4461-4468.1999; Money T, 2001, J BACTERIOL, V183, P1359, DOI 10.1128/JB.183.4.1359-1368.2001; Ninfa AJ, 2000, CURR TOP CELL REGUL, V36, P31; Ninfa AJ, 2000, TRENDS MICROBIOL, V8, P172, DOI 10.1016/S0966-842X(00)01709-1; Pioszak AA, 2000, BIOCHEMISTRY-US, V39, P13450, DOI 10.1021/bi000795m; Reyes-Ramirez F, 2001, J BACTERIOL, V183, P3076, DOI 10.1128/JB.183.10.3076-3082.2001; Rudnick P, 2002, J BACTERIOL, V184, P812, DOI 10.1128/JB.184.3.812-820.2002; RUDNICK P, 1998, BIOL NITROGEN FIXATI, P123; Schmitz RA, 2000, CURR MICROBIOL, V41, P357, DOI 10.1007/s002840010149; SENIOR PJ, 1975, J BACTERIOL, V123, P407, DOI 10.1128/JB.123.2.407-418.1975; Soderback E, 1998, MOL MICROBIOL, V28, P179, DOI 10.1046/j.1365-2958.1998.00788.x; WOODLEY P, 1994, MOL MICROBIOL, V13, P619, DOI 10.1111/j.1365-2958.1994.tb00456.x; Xu YB, 1998, J MOL BIOL, V282, P149, DOI 10.1006/jmbi.1998.1979; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	47	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15472	15481		10.1074/jbc.M112262200	http://dx.doi.org/10.1074/jbc.M112262200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856746	hybrid			2022-12-25	WOS:000175510400035
J	Nyman, T; Page, R; Schutt, CE; Karlsson, R; Lindberg, U				Nyman, T; Page, R; Schutt, CE; Karlsson, R; Lindberg, U			A cross-linked profilin-actin heterodimer interferes with elongation at the fast-growing end of F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-MUSCLE CELLS; ACANTHAMOEBA PROFILIN; NUCLEOTIDE-BINDING; BETA-ACTIN; ANGSTROM RESOLUTION; DIFFRACTION DATA; BARBED-END; FILAMENT; POLYMERIZATION; EXCHANGE	Profilin and beta/gamma-actin from calf thymus were covalently linked using the zero-length cross-linker 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide in combination with N-hydroxysuccinimide, yielding a single product with an apparent molecular mass of 60 kDa. Sequence analysis and x-ray crystallographic investigations showed that the cross-linked residues were glutamic acid 82 of profilin and lysine 113 of actin. The cross-linked complex was shown to bind with high affinity to deoxyribonuclease I and poly(L-proline). It also bound and exchanged ATP with kinetics close to that of unmodified profilin-actin and inhibited the intrinsic ATPase activity of actin. This inhibition occurred even in conditions where actin normally forms filaments. By these criteria the cross-linked profilin-actin complex retains the characteristics of unmodified profilin-actin. However, the cross-linked complex did not form filaments nor copolymerized with unmodified actin, but did interfere with elongation of actin filaments in a concentration-dependent manner. These results support a polymerization mechanism where the profilin-actin heterodimer binds to the (+)-end of actin filaments, followed by dissociation of profilin, and ATP hydrolysis and P-i release from the actin subunit as it assumes its stable conformation in the helical filament.	Stockholm Univ, Dept Cell Biol, S-10691 Stockholm, Sweden; Stockholm Univ, Wenner Gren Inst, S-10691 Stockholm, Sweden; Princeton Univ, Dept Chem, Henry H Hoyt Lab, Princeton, NJ 08544 USA	Stockholm University; Stockholm University; Princeton University	Lindberg, U (corresponding author), Stockholm Univ, Dept Cell Biol, S-10691 Stockholm, Sweden.	uno@cellbio.su.se			NIGMS NIH HHS [GM44083] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORKEGREN C, 1993, FEBS LETT, V333, P123, DOI 10.1016/0014-5793(93)80388-B; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; BRENNER SL, 1980, J BIOL CHEM, V255, P841; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CARRAWAY KL, 1970, BIOCHIM BIOPHYS ACTA, V200, P564, DOI 10.1016/0005-2795(70)90112-1; CEDERGRENZEPPEZAUER ES, 1994, J MOL BIOL, V240, P459, DOI 10.1006/jmbi.1994.1461; CHEN X, 1995, J BIOL CHEM, V270, P11415, DOI 10.1074/jbc.270.19.11415; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; Gutsche-Perelroizen I, 1999, J BIOL CHEM, V274, P6234, DOI 10.1074/jbc.274.10.6234; Hajkova L, 2000, EXP CELL RES, V256, P112, DOI 10.1006/excr.1999.4786; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAISER DA, 1986, J CELL BIOL, V102, P221, DOI 10.1083/jcb.102.1.221; Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963; Kinosian HJ, 2000, BIOCHEMISTRY-US, V39, P13176, DOI 10.1021/bi001520+; KINOSIAN HJ, 1993, J BIOL CHEM, V268, P8683; Korenbaum E, 1998, BIOCHEMISTRY-US, V37, P9274, DOI 10.1021/bi9803675; LARSSON H, 1988, BIOCHIM BIOPHYS ACTA, V953, P95, DOI 10.1016/0167-4838(88)90013-1; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; Mahoney NM, 1997, NAT STRUCT BIOL, V4, P953, DOI 10.1038/nsb1197-953; MARKEY F, 1982, BIOCHIM BIOPHYS ACTA, V704, P43, DOI 10.1016/0167-4838(82)90130-3; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page R, 1998, J MOL BIOL, V280, P463, DOI 10.1006/jmbi.1998.1879; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PERELROIZEN I, 1995, J BIOL CHEM, V270, P1501, DOI 10.1074/jbc.270.4.1501; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; ROZYCKI M, 1991, METHOD ENZYMOL, V196, P100; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; Schuler H, 2000, EUR J BIOCHEM, V267, P476, DOI 10.1046/j.1432-1327.2000.01023.x; Schuler H, 1999, EUR J BIOCHEM, V265, P210, DOI 10.1046/j.1432-1327.1999.00716.x; SCHULER H, 2000, THESIS STOCKHOLM U S; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Selden LA, 1999, BIOCHEMISTRY-US, V38, P2769, DOI 10.1021/bi981543c; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; SPUDICH JA, 1974, J BIOL CHEM, V249, P6013; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; SUGINO Y, 1964, J BIOL CHEM, V239, P2360; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; TOBACMAN LS, 1982, J BIOL CHEM, V257, P4166; VALENTINRANC C, 1989, J BIOL CHEM, V264, P20871; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; WEST JJ, 1967, J BIOL CHEM, V242, P1140	52	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15828	15833		10.1074/jbc.M112195200	http://dx.doi.org/10.1074/jbc.M112195200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11844798	hybrid			2022-12-25	WOS:000175510400083
J	Wang, XJ; Michael, D; de Murcia, G; Oren, M				Wang, XJ; Michael, D; de Murcia, G; Oren, M			p53 activation by nitric oxide involves down-regulation of Mdm2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATM-DEPENDENT PHOSPHORYLATION; HYPOXIA-RESPONSIVE ELEMENT; DNA-DAMAGE CHECKPOINT; POLY(ADP-RIBOSE) BINDS; CELL-CYCLE; EXPRESSION; ACCUMULATION; STABILITY; PROTEIN; LOCALIZATION	Nitric oxide (NO) is an important bioactive molecule involved in a variety of physiological and pathological processes. At the same time, NO is also an inducer of stress signaling, owing to its ability to damage proteins and DNA. NO was reported to be a potent activator of the p53 tumor suppressor protein. However, the mechanisms underlying p53 activation by NO remain to be elucidated. We report here that NO induces the accumulation of transcriptionally active p53 in a variety of cell types and that NO signaling to p53 does not require ataxia telangiectasia-mutated (ATM), poly(ADP-ribose) polymerase 1, or the ARF tumor suppressor protein. In mouse embryonic fibroblasts, NO elicits a down-regulation of Mdm2 protein levels that precedes the rise in p53. NO-induced down-regulation of Mdm2 protein but not its mRNA also occurs in several p53-deficient cell types and is thus p53-independent. The drop in endogenous Mdm2 levels following NO treatment is accompanied by a corresponding reduction in the rate of p53 ubiquitination. Thus, the down-regulation of Mdm2 by NO is likely to contribute to the activation of p53.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Ecole Super Biotechnol Strasbourg, CNRS, Unite 9003, F-67400 Illkirch Graffenstaden, France	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS)	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il		Michael, Dan/0000-0003-2942-4301; Oren, Moshe/0000-0003-4311-7172	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon R, 1999, CANCER RES, V59, P6046; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Gaston B, 1999, BBA-BIOENERGETICS, V1411, P323, DOI 10.1016/S0005-2728(99)00023-7; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hupp TR, 1999, CELL MOL LIFE SCI, V55, P88, DOI 10.1007/s000180050272; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Ma Yongxian, 2000, Molecular Cell Biology Research Communications, V3, P122, DOI 10.1006/mcbr.2000.0201; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Matsumoto H, 1999, NITRIC OXIDE-BIOL CH, V3, P180, DOI 10.1006/niox.1999.0221; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MESSMER UK, 1994, FEBS LETT, V355, P23; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Prives C, 1999, J PATHOL, V187, P112; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XJ, 1998, ONCOGENE, V17, P2819, DOI 10.1038/sj.onc.1202216; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Wesierska-Gadek J, 1999, CANCER RES, V59, P28; Wesierska-Gadek J, 2001, CELL MOL BIOL LETT, V6, P117; WHITACRE CM, 1995, CANCER RES, V55, P3697; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3	54	94	100	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15697	15702		10.1074/jbc.M112068200	http://dx.doi.org/10.1074/jbc.M112068200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867628	hybrid			2022-12-25	WOS:000175510400065
J	Willets, JM; Challiss, RAJ; Nahorski, SR				Willets, JM; Challiss, RAJ; Nahorski, SR			Endogenous G protein-coupled receptor kinase 6 regulates M-3 muscarinic acetylcholine receptor phosphorylation and desensitization in human SH-SY5Y neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SELECTIVE REGULATION; AGONIST; INTERNALIZATION; IDENTIFICATION; SITES; G-ALPHA(Q/11); INVOLVEMENT; ALPHA	We have previously shown that overexpression of G protein-coupled receptor kinase 6 (GRK6) enhanced the phosphorylation and desensitization of the endogenously expressed M, muscarinic acetylcholine (mACh) receptor in human SH-SY5Y neuroblastoma cells. In this study we have examined the potential role of endogenous GRK6 in the regulation of M-3 mACh receptor by blocking its action through the introduction of a kinase-dead, dominant-negative GRK6 ((K215R)GPK6). (K215R)GRK6 expression inhibited methacholine-stimulated M-3 mACh receptor phosphorylation by 50% compared with plasmid transfected control cells. Guanosine-5'-O-(3-[S-35]thio)triphosphate binding and immunoprecipitation studies, conducted after agonist pretreatment (3 min), indicated that M-3 mACh receptor-Galpha(q/11), uncoupling was attenuated by 50% in cells expressing (K215R)GRK6 when compared with control cells. In contrast, expression of the related dominant-negative kinase (K215R)GRK5 had no effect on M-3 mACh receptor phosphorylation or uncoupling. Time course studies also showed that agonist-stimulated [H-3]inositol phosphate accumulations were more sustained in cells expressing (K215R)GRK6 compared with control and (K215R)GRK5-expressing cells, whereas (K215R)GRK6 expression had no effect on the phospholipase C response to direct stimulation of G proteins with AlF4-. The ability of (K215R)GRK6 to inhibit agonist-mediated M-3 mACh receptor phosphorylation and G protein uncoupling suggests that endogenous GRK6 mediates, at least in part, M-3 mACh receptor desensitization in the SH-SY5Y cell line.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Willets, JM (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Maurice Shock Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.	jmw23@le.ac.uk	Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848				Aiyar N, 2000, EUR J PHARMACOL, V403, P1, DOI 10.1016/S0014-2999(00)00419-2; Akam EC, 2001, BRIT J PHARMACOL, V132, P950, DOI 10.1038/sj.bjp.0703892; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; Bundey RA, 2001, BRIT J PHARMACOL, V134, P257, DOI 10.1038/sj.bjp.0704229; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; CHALLISS RAJ, 1993, NEUROPROTOCOLS, V3, P135; CLARK RB, 1989, MOL PHARMACOL, V36, P343; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; Kellerbauer A, 2001, N-S ARCH PHARMACOL, V363, pR21; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Maestes DC, 1999, J BIOL CHEM, V274, P29791, DOI 10.1074/jbc.274.42.29791; Mundell SJ, 1998, BRIT J PHARMACOL, V125, P347, DOI 10.1038/sj.bjp.0702081; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; Tsuga H, 1998, J PHARMACOL EXP THER, V284, P1218; Willars GB, 1999, AM J PHYSIOL-CELL PH, V277, pC859, DOI 10.1152/ajpcell.1999.277.5.C859; Willets J, 2001, EUR J PHARMACOL, V431, P133, DOI 10.1016/S0014-2999(01)01360-7; Willets JM, 2001, MOL PHARMACOL, V60, P321, DOI 10.1124/mol.60.2.321; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Zhou HP, 2001, J PHARMACOL EXP THER, V298, P1243	35	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15523	15529		10.1074/jbc.M111217200	http://dx.doi.org/10.1074/jbc.M111217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856737	hybrid			2022-12-25	WOS:000175510400041
J	Im, HJ; Pittelkow, MR; Kumar, R				Im, HJ; Pittelkow, MR; Kumar, R			Divergent regulation of the growth-promoting gene IEX-1 by the p53 tumor suppressor and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY-RESPONSE GENE; NF-KAPPA-B; CELL-LINE; TRANSCRIPTIONAL ACTIVATION; TARGET GENE; EXPRESSION; KERATINOCYTES; APOPTOSIS; P22/PRG1; PROTEIN	IEX-1, a recently discovered early response gene, regulates cell growth and apoptosis. IEX-1 gene expression is regulated by a variety of factors such as x-irradiation, ultraviolet radiation, steroids, growth factors, and inflammatory stimuli. By systematic examination of the IEX-1 promoter, we show that IEX-1 gene expression is controlled by multiple conserved gene regulatory elements and that IEX-1 is a downstream target of the p53 tumor suppressor and Sp1. In addition, p300, Sox, nuclear factor-kappaB, and AP4 appear to be modulators of IEX-1 gene expression to a lesser degree. We found that there is at least one Sp1 element that functions as an activator and contributes to high basal transcriptional levels of the IEX-1 gene. We demonstrate the presence of a p53 response element that represses IEX-1 promoter activity in HaCaT keratinocytes, indicating that Sp1 and p53 have opposite effects on IEX-1 gene expression. We conclude that IEX-1 expression in cells is regulated by the p53 tumor suppressor and Sp1, thus providing a direct mechanism for control of cell proliferation.	Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Dermatol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Kumar, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med, 911A Guggenheim,200 1st St SW, Rochester, MN 55905 USA.			Kumar, Rajiv/0000-0003-3497-3057	NATIONAL CANCER INSTITUTE [P30CA015083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR027032, R01AR053220, R01AR027032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025409, R01DK058546, R01DK059505] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002647] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA015083, N01 CA015083, CA015083] Funding Source: Medline; NIAMS NIH HHS [R01 AR053220, R01 AR027032, AR27032, R01 AR053220-04, R56 AR027032] Funding Source: Medline; NIDDK NIH HHS [DK59505, DK58546, R01 DK059505, R01 DK058546, DK25409, R01 DK025409] Funding Source: Medline; BLRD VA [I01 BX002647] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); BLRD VA		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bravo R, 1990, Semin Cancer Biol, V1, P37; CHARLES CH, 1993, ONCOGENE, V8, P796; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Im HJ, 2001, MOL PHARMACOL, V59, P1486, DOI 10.1124/mol.59.6.1486; Ko JL, 1998, J BIOL CHEM, V273, P27678, DOI 10.1074/jbc.273.42.27678; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Pietzsch A, 1997, BIOCHEM BIOPH RES CO, V235, P4, DOI 10.1006/bbrc.1997.6715; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; POUMAY Y, 1995, J INVEST DERMATOL, V104, P271, DOI 10.1111/1523-1747.ep12612810; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; van Kranen H J, 1999, J Epidemiol, V9, pS58	35	47	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14612	14621		10.1074/jbc.M109414200	http://dx.doi.org/10.1074/jbc.M109414200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11844788	hybrid, Green Accepted			2022-12-25	WOS:000175203000034
J	Mancini, A; Koch, A; Wilms, R; Tamura, T				Mancini, A; Koch, A; Wilms, R; Tamura, T			c-Cbl associates directly with the C-terminal tail of the receptor for the macrophage colony-stimulating factor, c-Fms, and down-modulates this receptor but not the viral oncogene v-Fms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN CSF-1 RECEPTOR; TYROSINE KINASE; POINT MUTATION; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE; BINDING-SITE; FACTOR-I; ACTIVATION; DOMAIN	The receptor for the macrophage colony-stimulating factor (CSF-1, also termed M-CSF), the tyrosine kinase c-Fms, was originally determined to be the oncogene product of the McDonough strain of feline sarcoma virus, v-Fms. The structural difference between c-Fms and v-Fms amounts to only five point mutations in the extracellular domain, two mutations in the cytoplasmic domain, and the replacement of 50 amino acids by 14 unrelated amino acids at the C-terminal tail. Here, we have identified c-Cbl as the direct binding partner for c-Fms. c-Cbl binds to phosphotyrosine residue 977 at the C-terminal end of feline c-Fms, which is absent in v-Fms. The replacement of the C-terminal end of v-Fms by the corresponding part of c-Fms (vc-Fms) restored the binding potential. As a result, vc-Fms reduced the transforming potency of v-Fms. The overexpression of Cbl did not influence the v-Fms-transformed phenotype, although c-Cbl forms a complex with v-Fms indirectly. In contrast, the expression of Cbl drastically reduced the vc-Fms-transformed phenotype and the activation of Erk and enhanced Fms ubiquitination via phosphotyrosine residue 977. Furthermore, the replacement of tyrosine 977 into phenylalanine in feline c-Fms and vc-Fms reduced the Cbl-dependent ubiquitination. These data suggest that an indirect association of c-Cbl via multimeric complex induced a different signaling pathway from the pathway induced by c-Cbl direct interaction.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany	Hannover Medical School	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.							Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; BAKER AH, 1995, LEUKEMIA, V9, P155; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Cerboni C, 1998, EUR J IMMUNOL, V28, P1005, DOI 10.1002/(SICI)1521-4141(199803)28:03<1005::AID-IMMU1005>3.0.CO;2-O; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Grishin A, 2000, ONCOGENE, V19, P97, DOI 10.1038/sj.onc.1203254; Husson H, 1997, ONCOGENE, V14, P2331, DOI 10.1038/sj.onc.1201074; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Joos H, 1996, J BIOL CHEM, V271, P24476, DOI 10.1074/jbc.271.40.24476; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; McGlynn H, 1998, LEUKEMIA RES, V22, P365, DOI 10.1016/S0145-2126(98)00006-X; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; MORI S, 1993, J BIOL CHEM, V268, P577; Novak U, 1996, ONCOGENE, V13, P2607; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ota J, 2000, FEBS LETT, V466, P96, DOI 10.1016/S0014-5793(99)01767-6; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; Saci A, 1999, J BIOL CHEM, V274, P1898, DOI 10.1074/jbc.274.4.1898; Sattler M, 1996, ONCOGENE, V12, P839; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Wang Y, 1999, J CELL BIOCHEM, V72, P119; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5	38	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14635	14640		10.1074/jbc.M109214200	http://dx.doi.org/10.1074/jbc.M109214200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847211	hybrid			2022-12-25	WOS:000175203000037
J	Vabulas, RM; Ahmad-Nejad, P; Ghose, S; Kirschning, CJ; Issels, RD; Wagner, H				Vabulas, RM; Ahmad-Nejad, P; Ghose, S; Kirschning, CJ; Issels, RD; Wagner, H			HSP70 as endogenous stimulus of the toll/interleukin-1 receptor signal pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TOLL-LIKE RECEPTOR-4; DENDRITIC CELLS; HOST-DEFENSE; MATURATION; INNATE; IMMUNITY; SYSTEM; DEATH; MECHANISM	Human heat-shock protein (HSP)70 activates innate immune cells and hence requires no additional adjuvants to render bound peptides immunogenic. Here we tested the assumption that endogenous HSP70 activates the Toll/IL-1 receptor signal pathway similar to HSP60 and pathogen-derived molecular patterns. We show that HSP70 induces interleukin-12 (IL-12) and endothelial cell-leukocyte adhesion molecule-1 (ELAM-1) promoters in macrophages and that this is controlled by MyD88 and TRAF6. Furthermore, HSP70 causes MyD88 relocalization and MyD88-deficient dendritic cells do not respond to HSP70 with proinflammatory cytokine production. Using the system of genetic complementation with Toll-like receptors (TLR) we found that TLR2 and TLR4 confer responsiveness to HSP70 in 293T fibroblasts. The expanding list of endogenous ligands able to activate the ancient Toll/IL-1 receptor signal pathway is in line with the "danger hypothesis" proposing that the innate immune system senses danger signals even if they originate from self.	Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany; Inst Immunol, LT-2021 Vilnius, Lithuania; Univ Munich, Klinikum Grosshadern, Med Clin 3, D-81377 Munich, Germany; Natl Res Ctr Environm & Hlth, KKG Hyperthermie, Inst Mol Immunol, D-81377 Munich, Germany	Technical University of Munich; University of Munich; University of Munich	Wagner, H (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Trogerstr 9, D-81675 Munich, Germany.		Vabulas, R. Martin/D-3506-2011	Issels, Rolf/0000-0002-3494-6561				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Chen W, 1999, J IMMUNOL, V162, P3212; Ebnet K, 1999, HISTOCHEM CELL BIOL, V112, P1, DOI 10.1007/s004180050387; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hunter CA, 2000, CURR OPIN IMMUNOL, V12, P413, DOI 10.1016/S0952-7915(00)00110-2; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Kuppner MC, 2001, EUR J IMMUNOL, V31, P1602, DOI 10.1002/1521-4141(200105)31:5<1602::AID-IMMU1602>3.0.CO;2-W; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Moroi Y, 2000, P NATL ACAD SCI USA, V97, P3485, DOI 10.1073/pnas.070550797; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Somersan S, 2001, J IMMUNOL, V167, P4844, DOI 10.4049/jimmunol.167.9.4844; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354	30	742	791	3	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15107	15112		10.1074/jbc.M111204200	http://dx.doi.org/10.1074/jbc.M111204200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11842086	hybrid			2022-12-25	WOS:000175203000096
J	Takesono, A; Nowak, MW; Cismowski, M; Duzic, E; Lanier, SM				Takesono, A; Nowak, MW; Cismowski, M; Duzic, E; Lanier, SM			Activator of G-protein signaling 1 blocks GIRK channel activation by a G-protein-coupled receptor - Apparent disruption of receptor signaling complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+-CHANNEL; BINDING; CELLS	The Ras-related protein, activator of G-protein signal. ing 1 (AGS1) or Dexras1, interacts with G(i)/G(o)alpha and activates heterotrimeric G-protein signaling systems independent of a G-protein-coupled receptor (GPCR). As an initial approach to further define the cellular role of AGS1 in GPCR signaling, we determined the influence of AGS1 on the regulation of G(betagamma)-regulated inwardly rectifying K+ channel (GIRK) current (I-ACh) by M-2-muscarinic receptor (M-2-MR) in Xenopus oocytes. AGS1 expression inhibited receptor-mediated current activation by >80%. Mutation of a key residue (G31V) within the G, domain involved in nucleotide binding for Ras-related proteins eliminated the action of AGS1. The inhibition of I-ACh was not overcome by increasing concentrations of the muscarinic agonist acetylcholine but was progressively lost upon injection of increasing amounts of M-2-MR cRNA. These data suggest that AGS1 may antagonize GPCR signaling by altering the pool of heterotrimeric G-proteins available for receptor coupling and/or disruption of a preformed signaling complex. Such regulation would be of particular importance for those receptors that exist precoupled to heterotrimeric G-protein and for receptors operating within signaling complexes.	Louisiana State Univ, Ctr Hlth Sci, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA	Louisiana State University System; Medical University of South Carolina	Lanier, SM (corresponding author), Louisiana State Univ, Ctr Hlth Sci, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70118 USA.	slanie@lsuhsc.edu	Cismowski, Mary/E-2897-2011	Nowak, Mark/0000-0001-5097-2682; Lanier, Stephen/0000-0002-2740-7607	NIAAA NIH HHS [K01 AA00287] Funding Source: Medline; NIMH NIH HHS [MH 59331] Funding Source: Medline; NINDS NIH HHS [R01-NS24821] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K01AA000287] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Graham TE, 2001, ENDOCRINOLOGY, V142, P2631, DOI 10.1210/en.142.6.2631; Graham TE, 2002, J BIOL CHEM, V277, P10876, DOI 10.1074/jbc.M110397200; Herlitze X, 1999, J PHYSIOL-LONDON, V517, P341, DOI 10.1111/j.1469-7793.1999.0341t.x; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Kemppainen RJ, 1998, J BIOL CHEM, V273, P3129, DOI 10.1074/jbc.273.6.3129; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; Kroslak T, 2001, J BIOL CHEM, V276, P39772, DOI 10.1074/jbc.M106991200; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Vorobiov D, 2000, J BIOL CHEM, V275, P4166, DOI 10.1074/jbc.275.6.4166; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	19	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13827	13830		10.1074/jbc.M201064200	http://dx.doi.org/10.1074/jbc.M201064200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11842095	hybrid			2022-12-25	WOS:000175096000064
J	Reuther, GW; Lambert, QT; Rebhun, JF; Caligiuri, MA; Quilliam, LA; Der, CJ				Reuther, GW; Lambert, QT; Rebhun, JF; Caligiuri, MA; Quilliam, LA; Der, CJ			RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELL LINE; EXCHANGE FACTOR; PROTEIN; TRANSFORMATION; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; SPECIFICITY; INHIBITION; MUTATIONS	Although a number of genetic defects are commonly associated with acute myeloid leukemia (AML), a large percentage of AML cases are cytogenetically normal. This suggests a functional screen for transforming genes is required to identify genetic mutations that are missed by cytogenetic analyses. We utilized a retrovirus-based cDNA expression system to identify transforming genes expressed in cytogenetically normal AML patients. We identified a new member of the Ras guanyl nucleotide-releasing protein (RasGRP) family of Ras guanine nucleotide exchange factors, designating it RasGRP4. Subsequently, cDNA sequences encoding rodent and human RasGRP4 protei. Ins were deposited in GenBank(TM). RasGRP4 contains the same protein domain structure as other members of the RasGRP family, including a Ras exchange motif, a CDC25 homology domain, a C1/diacyglycerol-binding domain, and putative calcium-binding EF hands. We show that expression of RasGRP4 induces anchorage-independent growth of Rat1 fibroblasts. RasGRP4 is a Ras-specific activator and, interestingly, is highly expressed in peripheral blood leukocytes and myeloid cell lines. Unlike other RasGRP proteins, RasGRP4 is not expressed in the brain or in lymphoid cells. We demonstrated that 32D myeloid cells expressing RasGRP4 have elevated levels of activated Ras compared with control cells, and phorbol 12-myristate 13-acetate (PMA) treatment greatly enhanced Ras activation. PMA induced membrane localization of RasGRP4 and 32D cells expressing RasGRP4 were capable of cytokine-independent proliferation in the presence of PMA. We conclude that RasGRP4 is a member of the RasGRP family of Ras guanine nucleotide exchange factors that may play a role in myeloid cell signaling growth regulation pathways that are responsive to diacylglycerol levels.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Columbus, OH 43210 USA	University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Reuther, GW (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.		Rebhun, John F/H-7235-2019; Quilliam, Lawrence/Q-4987-2019; Reuther, Gary/AFR-2892-2022; Quilliam, Lawrence/B-6447-2015	Rebhun, John F/0000-0002-0764-5210; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA 42978] Funding Source: Medline; PHS HHS [T32 H 07774] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOS JL, 1987, BLOOD, V69, P1237; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; COX AD, 1995, METHOD ENZYMOL, V255, P195; DER CJ, 1988, ONCOGENE, V3, P105; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Dupuy AJ, 2001, J BIOL CHEM, V276, P11804, DOI 10.1074/jbc.M008970200; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Gilliland DG, 2001, CURR OPIN HEMATOL, V8, P189, DOI 10.1097/00062752-200107000-00001; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Kedra D, 1997, HUM GENET, V100, P611, DOI 10.1007/s004390050562; KINOSHITA T, 1995, ONCOGENE, V10, P2207; LANEUVILLE P, 1994, CANCER RES, V54, P1360; LEE JC, 1982, J IMMUNOL, V128, P2393; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lorenzo PS, 2001, CANCER RES, V61, P943; MAVILIO F, 1989, ONCOGENE, V4, P301; METCALF D, 1985, BLOOD, V65, P357; Miller Kenneth B., 1995, P993; MITELMAN F, 2002, MITELMAN DATABASE CH; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Mrozek K, 1997, SEMIN ONCOL, V24, P17; NEEDLEMAN SW, 1986, BLOOD, V67, P753; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200	42	69	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30508	30514		10.1074/jbc.M111330200	http://dx.doi.org/10.1074/jbc.M111330200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	11880369	hybrid, Green Published			2022-12-25	WOS:000177579800016
J	Baud, S; Margeat, E; Lumbroso, S; Paris, F; Sultan, C; Royer, C; Poujol, N				Baud, S; Margeat, E; Lumbroso, S; Paris, F; Sultan, C; Royer, C; Poujol, N			Equilibrium binding assays reveal the elevated stoichiometry and salt dependence of the interaction between full-length human sex-determining region on the Y chromosome (SRY) and DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-DETERMINING FACTOR; ESTROGEN-RECEPTOR-ALPHA; FLUORESCENCE ANISOTROPY; GONADAL-DYSGENESIS; DETERMINING GENE; BOX; PROTEIN; REVERSAL; DOMAIN; RECOGNITION	In an effort to better define the molecular mechanism of the functional specificity of human sex-determining region on the Y chromosome (SRY), we have carried out equilibrium binding assays to study the interaction of the full-length bacterial-expressed protein with a DNA response element derived from the CD3epsilon gene enhancer. These assays are based on the observation of the fluorescence anisotropy of a fluorescein moiety covalently bound to the target oligonucleotide. The low anisotropy value due to the fast tumbling of the free oligonucleotide in solution increases substantially upon binding the protein to the labeled target DNA. Our results indicate that the full-length human wild-type SRY (SRYWT) forms a complex of high stoichiometry with its target DNA. Moreover, we have demonstrated a strong salt dependence of both the affinity and specificity of the interaction. We have also addressed the DNA bending properties of full-length human SRYWT in solution by fluorescence resonance energy transfer and revealed that maximal bending is achieved with a protein to DNA ratio significantly higher than the classical 1:1. Oligomerization thus appears, at least in vitro, to be tightly coupled to SRY-DNA interactions. Alteration of protein-protein interactions observed for the mutant protein SRYY129N,identified in a patient presenting with 46,XY sex reversal, suggests that oligomerization may play an important role in vivo as well.	Univ Montpellier 1, Ctr Biochim Struct, UMR INSERM 554, CNRS 5048, F-34090 Montpellier, France; CHU Montpellier, Lab Hormonol, INSERM, U439, F-34295 Montpellier, France; CHU Montpellier, Hop A de Villeneuve, Unite Endocrinol Pediat, F-34295 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Poujol, N (corresponding author), Ctr Med Biol, Lab Anal Med, 16 Rue 8 Mai 1945, F-34200 Sete, France.		Lumbroso, Serge/AFS-0438-2022; Margeat, Emmanuel/AAY-9167-2021; Paris, Francoise/AAC-6553-2019; Royer, Catherine A/E-5266-2016	Margeat, Emmanuel/0000-0001-6063-6420; Royer, Catherine A/0000-0002-2670-3391				BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Boyer M, 2000, NUCLEIC ACIDS RES, V28, P2494, DOI 10.1093/nar/28.13.2494; Brown S, 1998, AM J HUM GENET, V62, P189, DOI 10.1086/301684; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Deckert J, 1999, NUCLEIC ACIDS RES, V27, P3518, DOI 10.1093/nar/27.17.3518; Desclozeaux M, 1998, BBA-GENE STRUCT EXPR, V1397, P247, DOI 10.1016/S0167-4781(98)00041-4; Domenice S, 1998, HUM GENET, V102, P213, DOI 10.1007/s004390050680; Engel J, 2000, MATRIX BIOL, V19, P283, DOI 10.1016/S0945-053X(00)00075-5; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1994, P NATL ACAD SCI USA, V91, P3368, DOI 10.1073/pnas.91.8.3368; Grillo AO, 1999, J MOL BIOL, V287, P539, DOI 10.1006/jmbi.1999.2625; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; HARLEY VR, 1994, MOL REPROD DEV, V39, P184, DOI 10.1002/mrd.1080390211; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; LnenicekAllen M, 1996, NUCLEIC ACIDS RES, V24, P1047, DOI 10.1093/nar/24.6.1047; Margeat E, 2001, J MOL BIOL, V306, P433, DOI 10.1006/jmbi.2000.4418; MCELREAVEY K, 1993, P NATL ACAD SCI USA, V90, P3368, DOI 10.1073/pnas.90.8.3368; McElreavey K, 1996, P NATL ACAD SCI USA, V93, P8590, DOI 10.1073/pnas.93.16.8590; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; Ozers MS, 1997, J BIOL CHEM, V272, P30405, DOI 10.1074/jbc.272.48.30405; PETERS R, 1995, BIOCHEMISTRY-US, V34, P4569, DOI 10.1021/bi00014a009; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; Schaffler A, 2000, J CLIN ENDOCR METAB, V85, P2287, DOI 10.1210/jc.85.6.2287; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; Trimmer EE, 1998, BIOCHEMISTRY-US, V37, P352, DOI 10.1021/bi971675q; Ukiyama E, 2001, MOL ENDOCRINOL, V15, P363, DOI 10.1210/me.15.3.363; Veitia RA, 2001, MOL CELL ENDOCRINOL, V179, P3, DOI 10.1016/S0303-7207(01)00460-9; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	32	8	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18404	18410		10.1074/jbc.M112366200	http://dx.doi.org/10.1074/jbc.M112366200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877434	hybrid			2022-12-25	WOS:000175975800021
J	Sun, LJ; Halaihel, N; Zhang, WP; Rogers, T; Levi, M				Sun, LJ; Halaihel, N; Zhang, WP; Rogers, T; Levi, M			Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND TRANSCRIPTION FACTOR; FATTY-ACID BIOSYNTHESIS; LEUCINE ZIPPER PROTEIN; GROWTH-FACTOR-BETA; MESANGIAL CELLS; TRANSGENIC MICE; CHOLESTEROL-SYNTHESIS; AUTOCRINE ACTIVATION; GENE-EXPRESSION; CULTURED-CELLS	Diabetic renal disease is associated with lipid deposits in the kidney. The purpose of our study was to determine whether there is altered regulation of the sterol regulatory element-binding proteins (SREBPs) in the diabetic kidney and whether SREBPs mediate the abnormal renal lipid metabolism and diabetic renal disease. In streptozotocin-induced diabetes in the rat, there were marked increases in SREBP-1 and fatty acid synthase (FAS) expression, resulting in increased triglyceride (TG) accumulation. Treatment of diabetic rats with insulin prevented the increased renal expression of SREBP-1 and the accumulation of TG. The role of hyperglycemia in the up-regulation of SREBP-1 was confirmed in renal cells cultured in a high glucose media. High glucose induced increased expression of SREBP-1a and -1c mRNA, SREBP-1 protein, and FAS, resulting in increased TG content. To determine a direct role for SREBP in mediating the increase in renal lipids and glomerulosclerosis, we studied SREBP-1a transgenic mice with increased renal expression of SREBP-1. The increase in SREBP-1 was associated with increased expression of FAS and acetyl CoA carboxylase, resulting in increased TG content, increased expression of transforming growth factor beta1 and vascular endothelial growth factor, mesangial expansion, glomerulosclerosis, and proteinuria. Our study therefore indicates that renal SREBP-1 expression is increased in diabetes and that SREBP-1 plays an important role in the increased lipid synthesis, TG accumulation, mesangial expansion, glomerulosclerosis, and proteinuria by increasing the expression of transforming growth factor beta and vascular endothelial growth factor.	Univ Texas, SW Med Ctr, Vet Affairs Med Ctr, Dept Med, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr, Vet Affairs Med Ctr, Dept Pathol, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Levi, M (corresponding author), Univ Texas, SW Med Ctr, Vet Affairs Med Ctr, Dept Med, 4500 S Lancaster Rd,MC 151, Dallas, TX 75216 USA.	Moshe.Levi@UTSouthwestern.edu	Halaihel, Nabil/J-2973-2016	Levi, Moshe/0000-0002-6225-946X				[Anonymous], 1999, USRDS 1999 ANN DAT R; Basile DP, 1999, CURR OPIN NEPHROL HY, V8, P21, DOI 10.1097/00041552-199901000-00005; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993; Di Paolo S, 1999, CLIN EXP IMMUNOL, V117, P355; Duymelinck C, 1997, KIDNEY INT, V51, P1818, DOI 10.1038/ki.1997.249; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GUIJARRO C, 1995, AM J KIDNEY DIS, V26, P152, DOI 10.1016/0272-6386(95)90169-8; Han DC, 1999, J AM SOC NEPHROL, V10, P1891; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Keane WF, 2000, KIDNEY INT, V57, pS27, DOI 10.1046/j.1523-1755.2000.07503.x; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kimmelstiel P, 1936, AM J PATHOL, V12, P83; Kirschenbaum MA, 1996, MINER ELECTROL METAB, V22, P47; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HS, 1996, KIDNEY INT, V50, P1582, DOI 10.1038/ki.1996.474; Lee YS, 1999, COMPUT IND ENG, V36, P67, DOI 10.1016/S0360-8352(99)00002-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Nishida Y, 1999, KIDNEY INT, V56, pS51, DOI 10.1046/j.1523-1755.1999.07113.x; OBARA K, 1993, CLIN NEPHROL, V39, P59; Oda H, 1997, KIDNEY INT, V52, pS36; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; ROVIN BH, 1993, KIDNEY INT, V43, P218, DOI 10.1038/ki.1993.35; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SCHLEIFFER T, 1994, HAEMOSTASIS, V24, P49; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Smulders YM, 1997, EUR J CLIN INVEST, V27, P997, DOI 10.1046/j.1365-2362.1997.2330779.x; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004	45	255	277	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18919	18927		10.1074/jbc.M110650200	http://dx.doi.org/10.1074/jbc.M110650200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11875060	hybrid			2022-12-25	WOS:000175975800088
J	Pichler, A; Schroeder, R				Pichler, A; Schroeder, R			Folding problems of the 5 ' splice site containing the P1 stem of the group I thymidylate synthase intron - Substrate binding inhibition in vitro and mis-splicing in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYMENA-THERMOPHILA RIBOZYME; RIBOSOMAL-RNA EXONS; PHAGE-T4 TD INTRON; ACTIVE-SITE; TERTIARY INTERACTIONS; CATALYTIC CORE; SEQUENCE; HELIX; COMPLEMENTARY; RECOGNITION	We developed an in vitro cleaving assay for the thymidylate synthase (td) group I intron and observed that the off-rate of the substrate is faster than cleavage. From the sequence stems P1 and P2 can vary from 4 to 8 and from 6 to 10 base pairs, respectively, with folding of a long P1 stem being in competition with folding of a long P2 stem. Shorter substrates, which cannot compete with the formation of an extended P2, result in faster cleavage, suggesting that binding of the substrate indeed interferes with folding of stem P2. In vivo splicing analyses of mutants containing alterations in stems P1 and P2 indicate that the wild-type exon sequence of P1 is suboptimal for splicing. Furthermore, folding of P1 in vivo is in competition with an alternative cryptic P1 stem resulting in mis-splicing. Translation promotes splicing at the correct 5' splice site, whereas in the absence of translation, mis-splicing is favored. The combination of the in vitro and in vivo assays clearly displays the folding problems for correct splice site selection in this group I intron.	Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Schroeder, R (corresponding author), Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, Dr Bohrgasse 9-4, A-1030 Vienna, Austria.	renee@gem.univie.ac.at						BELFORT M, 1987, COLD SPRING HARB SYM, V52, P181, DOI 10.1101/SQB.1987.052.01.023; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; Brion P, 1999, RNA, V5, P947, DOI 10.1017/S1355838299990477; Cao Y, 2000, RNA, V6, P1248, DOI 10.1017/S1355838200000893; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHANDRY PS, 1987, GENE DEV, V1, P1028, DOI 10.1101/gad.1.9.1028; Clodi E, 1999, EMBO J, V18, P3776, DOI 10.1093/emboj/18.13.3776; Costa M, 1997, EMBO J, V16, P3289, DOI 10.1093/emboj/16.11.3289; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034; Ho Y, 1997, P NATL ACAD SCI USA, V94, P8994, DOI 10.1073/pnas.94.17.8994; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; Narlikar GJ, 1999, BIOCHEMISTRY-US, V38, P14192, DOI 10.1021/bi9914309; Narlikar GJ, 1997, BIOCHEMISTRY-US, V36, P2465, DOI 10.1021/bi9610820; Nikolcheva T, 1999, J MOL BIOL, V292, P557, DOI 10.1006/jmbi.1999.3083; Pan J, 1998, J MOL BIOL, V280, P597, DOI 10.1006/jmbi.1998.1901; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; Russell R, 1999, RNA, V5, P158, DOI 10.1017/S1355838299981839; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SCHROEDER R, 1991, BIOCHEMISTRY-US, V30, P3295, DOI 10.1021/bi00227a018; Semrad K, 1998, GENE DEV, V12, P1327, DOI 10.1101/gad.12.9.1327; Serra MJ, 1995, METHOD ENZYMOL, V259, P242; Strauss-Soukup JK, 2000, J MOL BIOL, V302, P339, DOI 10.1006/jmbi.2000.4056; Strobel SA, 1998, NAT STRUCT BIOL, V5, P60, DOI 10.1038/nsb0198-60; STROBEL SA, 1993, BIOCHEMISTRY-US, V32, P13593, DOI 10.1021/bi00212a027; Szewczak AA, 1999, P NATL ACAD SCI USA, V96, P11183, DOI 10.1073/pnas.96.20.11183; Treiber DK, 2001, CURR OPIN STRUC BIOL, V11, P309, DOI 10.1016/S0959-440X(00)00206-2; VONAHSEN U, 1992, J MOL BIOL, V226, P935, DOI 10.1016/0022-2836(92)91043-O; Waldsich C, 1998, RNA, V4, P1653, DOI 10.1017/S1355838298981444; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; WOODSON SA, 1993, MOL CELL BIOL, V13, P1137, DOI 10.1128/MCB.13.2.1137; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	38	21	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17987	17993		10.1074/jbc.M111798200	http://dx.doi.org/10.1074/jbc.M111798200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11867626	hybrid			2022-12-25	WOS:000175685100076
J	Zhang, T; Seow, KT; Ong, CT; Cao, XM				Zhang, T; Seow, KT; Ong, CT; Cao, XM			Interdomain interaction of Stat3 regulates its Src homology 2 domain-mediated receptor binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; CYTOKINE RECEPTORS; CYTOPLASMIC DOMAIN; ACTIVATION; TRANSCRIPTION; INTERLEUKIN-6; ASSOCIATION	Activation of Stat proteins by cytokines is initiated by their Src homology 2 (SH2) domain-mediated association with the cytokine receptors. Previously, we identified an essential role of the coiled-coil domain of Stat3 in binding of the receptor peptides derived from the interleukin-6 receptor subunit, gp130. In this study, we further investigated the molecular basis of this regulation. We found that the C-terminal domain of Stat3 negatively regulates its receptor binding activity only in the absence of the first alpha-helix of the coiled-coil domain, which leads to a hypothesis of intramolecular interaction. Physical interactions between the coiled-coil domain and the C-terminal domain, as well as the SH2 domain, were indeed detected. Furthermore, a sub-region of the C-terminal domain (amino acids 720-740), which is also involved in the interaction with the coiled-coil domain, was demonstrated to be critical for the regulation of the receptor binding. Correspondingly, phosphorylation on Ser-727 within this region inhibits this interaction. In agreement with the peptide binding results, both the coiled-coil domain and the C-terminal sub-region are necessary for the functional recruitment of Stat3 to the cellular gp130 in response to interleukin-6, suggesting that the interdomain interaction is a prerequisite for the SH2-mediated receptor binding in interleukin-6 signaling.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Cao, XM (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Haan S, 2000, BIOCHEM J, V345, P417, DOI 10.1042/0264-6021:3450417; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kammerer RA, 1997, MATRIX BIOL, V15, P555, DOI 10.1016/S0945-053X(97)90031-7; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Murphy TL, 2000, MOL CELL BIOL, V20, P7121, DOI 10.1128/MCB.20.19.7121-7131.2000; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stancato LF, 1996, J BIOL CHEM, V271, P4134; VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WONG SH, 1993, J BIOL CHEM, V268, P22853; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yang E, 1999, MOL CELL BIOL, V19, P5106; Zhang T, 2000, MOL CELL BIOL, V20, P7132, DOI 10.1128/MCB.20.19.7132-7139.2000; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	46	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17556	17563		10.1074/jbc.M105525200	http://dx.doi.org/10.1074/jbc.M105525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11872739	hybrid			2022-12-25	WOS:000175685100023
J	Belorgey, D; Crowther, DC; Mahadeva, R; Lomas, DA				Belorgey, D; Crowther, DC; Mahadeva, R; Lomas, DA			Mutant neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; SERINE-PROTEASE INHIBITOR; LONG-TERM POTENTIATION; CONFORMATIONAL DISEASE; REACTIVE LOOP; NEURODEGENERATIVE DISEASE; NEURONAL DEGENERATION; NEUTROPHIL ELASTASE; CRYSTAL-STRUCTURE; LATE-PHASE	Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is an autosomal dominant dementia that is characterized by intraneuronal inclusions of mutant neuroserpin. We report here the expression, purification, and characterization of wild-type neuroserpin and neuroserpin containing the S49P mutation that causes FENIB. Wild-type neuroserpin formed SDS-stable complexes with tPA with an association rate constant and K-i of 1.2 x 10(4) M-1 s(-1) and 5.8 nM, respectively. In contrast, S49P neuroserpin formed unstable complexes with an association rate constant and K-i of 0.3 x 10(4) M-1 s(-1) and 533.3 nM, respectively. Am assessment by circular dichroism showed that S49P neuroserpin had a lower melting temperature than wild-type protein (49.9 and 56.6 degreesC, respectively) and more readily formed loop-sheet polymers under physiological conditions. Neither the wildtype nor S49P neuroserpin accepted the P7-P2 alpha(1)-antitrypsin or P14-P3 antithrombin-reactive loop peptides that have been shown to block polymer formation in other members of the serpin superfamily. Taken together, these data demonstrate that S49P neuroserpin is a poor proteinase inhibitor and readily forms loop-sheet polymers. These findings provide strong support for the role of neuroserpin polymerization in the formation of the intraneuronal inclusions that are characteristic of FENIB.	Univ Cambridge, Dept Med, Neurol Unit, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Med, Resp Med Unit, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge	Belorgey, D (corresponding author), Univ Cambridge, Dept Med, Neurol Unit, Cambridge Inst Med Res, Wellcome Trust Med Res Council Bldg,Hills Rd, Cambridge CB2 2XY, England.	db301@cam.ac.uk						Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Belorgey D, 1998, BIOCHEMISTRY-US, V37, P16416, DOI 10.1021/bi981536o; Berger P, 1999, MOL CELL NEUROSCI, V14, P455, DOI 10.1006/mcne.1999.0804; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BJORK I, 1992, J BIOL CHEM, V267, P1976; Bradshaw CB, 2001, ARCH NEUROL-CHICAGO, V58, P1429, DOI 10.1001/archneur.58.9.1429; Briand C, 2001, FEBS LETT, V505, P18, DOI 10.1016/S0014-5793(01)02764-8; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Dafforn TR, 2001, J BIOL CHEM, V276, P49310, DOI 10.1074/jbc.M108896200; Davis RL, 1999, AM J PATHOL, V155, P1901, DOI 10.1016/S0002-9440(10)65510-1; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Elliott PR, 1996, NAT STRUCT BIOL, V3, P910, DOI 10.1038/nsb1196-910; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; FALLER B, 1993, BIOCHEMISTRY-US, V32, P9230, DOI 10.1021/bi00086a031; Fitton HL, 1997, BIOL CHEM, V378, P1059; Frey U, 1996, J NEUROSCI, V16, P2057; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; Hill RM, 2000, BIOCHEM J, V345, P595, DOI 10.1042/0264-6021:3450595; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; Krueger SR, 1997, J NEUROSCI, V17, P8984; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Mahadeva R, 2002, J BIOL CHEM, V277, P6771, DOI 10.1074/jbc.C100722200; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Osterwalder T, 1998, J BIOL CHEM, V273, P2312, DOI 10.1074/jbc.273.4.2312; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Renatus M, 1997, EMBO J, V16, P4797, DOI 10.1093/emboj/16.16.4797; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schrimpf SP, 1997, GENOMICS, V40, P55, DOI 10.1006/geno.1996.4514; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; STOECKLI ET, 1989, EUR J BIOCHEM, V180, P249, DOI 10.1111/j.1432-1033.1989.tb14640.x; Takao M, 2000, J NEUROPATH EXP NEUR, V59, P1070, DOI 10.1093/jnen/59.12.1070; Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5; Tsirka SE, 1997, J NEUROSCI, V17, P543; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Yazaki M, 2001, AM J PATHOL, V158, P227, DOI 10.1016/S0002-9440(10)63961-2; Yepes M, 2000, BLOOD, V96, P569; Zhou A, 2001, J BIOL CHEM, V276, P9115, DOI 10.1074/jbc.M010631200; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	54	81	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17367	17373		10.1074/jbc.M200680200	http://dx.doi.org/10.1074/jbc.M200680200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880376	hybrid			2022-12-25	WOS:000175564500133
J	Chen, F; Kamradt, M; Mulcahy, M; Byun, Y; Xu, HL; McKay, MJ; Cryns, VL				Chen, F; Kamradt, M; Mulcahy, M; Byun, Y; Xu, HL; McKay, MJ; Cryns, VL			Caspase proteolysis of the cohesin component RAD21 promotes apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; DEPENDENT PROTEIN-KINASE; STRAND-BREAK REPAIR; SCHIZOSACCHAROMYCES-POMBE; POLY(ADP-RIBOSE) POLYMERASE; CHROMOSOME SEGREGATION; DNA FRAGMENTATION; FAMILY PROTEASES; ENDONUCLEASE-G; HUMAN SURVIVIN	Caspases are a conserved family of proteases that play a critical role in the execution of apoptosis by cleaving key cellular proteins at Asp residues and modifying their function. Using an expression cloning strategy we recently developed, we isolated human RAD21/SCC1/MCD1 as a novel caspase substrate. RAD21 is a component of the cohesin complex that holds sister chromatids together during mitosis and repairs double-strand DNA breaks. Interestingly, RAD21 is cleaved by a caspase-like Esp1/separase at the onset of anaphase to trigger sister chromatid separation. Here, we demonstrate that human RAD21 is preferentially cleaved at Asp 279 by caspases-3 and -7 in vitro to generate two major proteolytic products of similar to65 and 48 kDa. Moreover, we show that RAD21 is specifically proteolyzed by caspases into a similarly sized 65-kDa carboxyl-terminal product in cells undergoing apoptosis in response to diverse stimuli. We also demonstrate that caspase proteolysis of RAD21 precedes apoptotic chromatin condensation and has important functional consequences, viz. the partial removal of RAD21 from chromatin and the production of a proapoptotic carboxyl-terminal cleavage product that amplifies the cell death signal. Taken together, these findings point to an entirely novel function of RAD21 in the execution of apoptosis.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Peter MacCallum Canc Inst, Melbourne, Vic 8006, Australia	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Peter Maccallum Cancer Center	Cryns, VL (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Tarry 15-755,303 E Chicago Ave, Chicago, IL 60611 USA.		McKay, Michael/ABA-9029-2021		NCI NIH HHS [CA79447, 5T32-CA70085] Funding Source: Medline; NINDS NIH HHS [NS31957] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA079447, T32CA070085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031957] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Hoque MT, 2001, J BIOL CHEM, V276, P5059, DOI 10.1074/jbc.M007809200; Hotti A, 2000, ONCOGENE, V19, P2354, DOI 10.1038/sj.onc.1203567; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; McKay MJ, 1996, GENOMICS, V36, P305, DOI 10.1006/geno.1996.0466; Morishima N, 1999, GENES CELLS, V4, P401, DOI 10.1046/j.1365-2443.1999.00270.x; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tamm I, 1998, CANCER RES, V58, P5315; Tatebayashi K, 1998, GENETICS, V148, P49; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Warren WD, 2000, CURR BIOL, V10, P1463, DOI 10.1016/S0960-9822(00)00806-X; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774	61	47	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16775	16781		10.1074/jbc.M201322200	http://dx.doi.org/10.1074/jbc.M201322200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875078	hybrid			2022-12-25	WOS:000175564500058
J	Kotamraju, S; Chitambar, CR; Kalivendi, SV; Joseph, J; Kalyanaraman, B				Kotamraju, S; Chitambar, CR; Kalivendi, SV; Joseph, J; Kalyanaraman, B			Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells - Role of oxidant-induced iron signaling in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; REGULATORY PROTEIN-1; REACTIVE OXYGEN; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; LIPID PEROXIDATION; HYDROGEN-PEROXIDE; RADICAL FORMATION; CARDIAC TOXICITY; FERRITIN	In the past, investigators have successfully used iron chelators to mitigate the cardiotoxicity of doxorubicin (DOX), a widely used anticancer drug that induces reactive oxygen species (ROS), oxidative damage, and apoptosis. Although intracellular iron plays a critical role in initiating DOX-induced apoptosis, the molecular mechanism(s) that link iron, ROS, and apoptosis are still unknown. In this study, we demonstrate that apoptosis results from the exposure of bovine aortic endothelial cells to DOX and that the apoptotic cell death is accompanied by a significant increase in cellular iron (Fe-55) uptake and activation of iron regulatory protein-1. Furthermore, DOX-induced iron uptake was shown to be mediated by the transferrin receptor (TfR)-dependent mechanism. Treatment with the anti-TfR antibody (IgA class) dramatically inhibited DOX-induced apoptosis, iron uptake, and intracellular oxidant formation as measured by fluorescence using dichlorodihydrofluorescein. Treatment with cell-permeable iron chelators and ROS scavengers inhibited DOX-induced cellular Fe-55 uptake, ROS formation, and apoptosis. Based on these findings, we conclude that DOX-induced iron signaling is regulated by the cell surface TfR expression, intracellular oxidant levels, and iron regulatory proteins. The implications of TfR-dependent iron transport in oxidant-induced apoptosis in endothelial cells are discussed.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Radical Res Ctr, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Div Neoplast Dis, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	balarama@mcw.edu			NATIONAL CANCER INSTITUTE [R01CA077822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NCI NIH HHS [CA77822] Funding Source: Medline; NCRR NIH HHS [RR01008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; BACHUR NR, 1977, MOL PHARMACOL, V13, P901; BALLA G, 1992, J BIOL CHEM, V267, P18148; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Bergeron RJ, 1999, BLOOD, V93, P370, DOI 10.1182/blood.V93.1.370.401k29_370_375; BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249; BRISTOW MR, 1978, CANCER TREAT REP, V62, P873; Burkitt MJ, 2001, BIOCHEM BIOPH RES CO, V282, P329, DOI 10.1006/bbrc.2001.4578; CHITAMBAR CR, 1986, J CLIN INVEST, V78, P1538, DOI 10.1172/JCI112746; CURRAN CF, 1991, CANCER TREAT REV, V18, P241, DOI 10.1016/0305-7372(91)90015-R; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347; Duffy SJ, 2001, CIRCULATION, V103, P2799; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Gehring NH, 1999, J BIOL CHEM, V274, P6219, DOI 10.1074/jbc.274.10.6219; GOODMAN J, 1977, BIOCHEM BIOPH RES CO, V77, P797, DOI 10.1016/S0006-291X(77)80048-X; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griendling KK, 1999, CIRC RES, V85, P562, DOI 10.1161/01.RES.85.6.562; HANDA K, 1976, GANN, V67, P523; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HASINOFF BB, 1993, AGENTS ACTIONS, V39, P72, DOI 10.1007/BF01975717; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Hausladen A, 1996, METHOD ENZYMOL, V269, P37; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HERMAN EH, 1985, CANCER RES, V45, P276; Imrich A, 1999, J LEUKOCYTE BIOL, V65, P499, DOI 10.1002/jlb.65.4.499; JANZEN EG, 1990, ADV FREE RADICAL CHE, P253; Kalivendi SV, 2001, J BIOL CHEM, V276, P47266, DOI 10.1074/jbc.M106829200; KALYANARAMAN B, 1980, BIOCHIM BIOPHYS ACTA, V630, P119, DOI 10.1016/0304-4165(80)90142-7; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; Konorev EA, 1999, ARCH BIOCHEM BIOPHYS, V368, P421, DOI 10.1006/abbi.1999.1337; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lee JB, 1998, J AM CHEM SOC, V120, P7493, DOI 10.1021/ja980507y; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Li WG, 2001, J BIOL CHEM, V276, P29251, DOI 10.1074/jbc.M102124200; Minotti G, 1998, FASEB J, V12, P541, DOI 10.1096/fasebj.12.7.541; Minotti G, 2001, CANCER RES, V61, P8422; Minotti G, 1999, FASEB J, V13, P199, DOI 10.1096/fasebj.13.2.199; MINOW RA, 1975, CANCER CHEMOTH REP 3, V6, P195; Monnier VM, 2001, J CLIN INVEST, V107, P799, DOI 10.1172/JCI12635; MUINDI JRF, 1984, FEBS LETT, V172, P226, DOI 10.1016/0014-5793(84)81130-8; MYERS CE, 1982, BIOCHEMISTRY-US, V21, P1707, DOI 10.1021/bi00537a001; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; Pennathur S, 2001, J CLIN INVEST, V107, P853, DOI 10.1172/JCI11194; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; Quinlan GJ, 2001, CLIN SCI, V100, P169, DOI 10.1042/CS20000155; Rehman A, 1999, FEBS LETT, V448, P120, DOI 10.1016/S0014-5793(99)00339-7; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Sarvazyan N, 1996, AM J PHYSIOL-HEART C, V271, pH2079, DOI 10.1152/ajpheart.1996.271.5.H2079; Sawyer DB, 1999, CIRC RES, V84, P257, DOI 10.1161/01.RES.84.3.257; Schueck ND, 2001, MITOCHONDRION, V1, P51, DOI 10.1016/S1567-7249(01)00004-6; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; SPEYER JL, 1988, NEW ENGL J MED, V319, P745, DOI 10.1056/NEJM198809223191203; SVINGEN BA, 1981, ARCH BIOCHEM BIOPHYS, V209, P119, DOI 10.1016/0003-9861(81)90263-0; TAETLE R, 1986, CANCER RES, V46, P1759; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; TESTA U, 1993, CRIT REV ONCOGENESIS, V4, P241; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; THOMAS CE, 1986, ARCH BIOCHEM BIOPHYS, V248, P684, DOI 10.1016/0003-9861(86)90523-0; van Reyk DM, 2001, FREE RADICAL BIO MED, V30, P82, DOI 10.1016/S0891-5849(00)00449-4; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; WORWOOD M, 1989, J INTERN MED, V226, P381, DOI 10.1111/j.1365-2796.1989.tb01412.x; YOUNG RC, 1981, NEW ENGL J MED, V305, P139, DOI 10.1056/NEJM198107163050305	72	165	171	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17179	17187		10.1074/jbc.M111604200	http://dx.doi.org/10.1074/jbc.M111604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11856741	hybrid			2022-12-25	WOS:000175564500111
J	Lin, TK; Hughes, G; Muratovska, A; Blaikie, FH; Brookes, PS; Darley-Usmar, V; Smith, RAJ; Murphy, MP				Lin, TK; Hughes, G; Muratovska, A; Blaikie, FH; Brookes, PS; Darley-Usmar, V; Smith, RAJ; Murphy, MP			Specific modification of mitochondrial protein thiols in response to oxidative stress - A proteomics approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RAT-LIVER MITOCHONDRIA; PERMEABILITY TRANSITION; S-NITROSYLATION; COMPLEX-I; SULFHYDRYL-GROUPS; CELL RESPIRATION; PEROXYNITRITE; GLUTATHIONE; STATE	Mitochondria play a central role in redox-linked processes in the cell through mechanisms that are thought to involve modification of specific protein thiols, but this has proved difficult to assess. In particular, specific labeling and quantitation of mitochondrial protein cysteine residues have not been achieved due to the lack of reagents available that can be applied to the intact organelle or cell. To overcome these problems we have used a combination of mitochondrial proteomics and targeted labeling of mitochondrial thiols using a novel compound, (4-iodobutyl)triphenylphosphonium (IBTP). This lipophilic cation is accumulated by mitochondria and yields stable thioether adducts in a thiol-specific reaction. The selective uptake into mitochondria, due to the large membrane potential across the inner membrane, and the high pH of the matrix results in specific labeling of mitochondrial protein thiols by IBTP. Individual mitochondrial proteins that changed thiol redox state following oxidative stress could then be identified by their decreased reaction with IBTP and isolated by two-dimensional electrophoresis. We demonstrate the selectivity of IBTP labeling and use it to show that glutathione oxidation and exposure to an S-nitrosothiol or to peroxynitrite cause extensive redox changes to mitochondrial thiol proteins. In conjunction with blue native gel electrophoresis, we used IBTP labeling to demonstrate that thiols are exposed on the matrix faces of respiratory Complexes I, II, and IV. This novel approach enables measurement of the thiol redox state of individual mitochondrial proteins during oxidative stress and cell death. In addition the methodology has the potential to identify novel redox-dependent modulation of mitochondrial proteins.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Otago, Dept Biochem, Dunedin, New Zealand; Univ Otago, Dept Chem, Dunedin, New Zealand; Chang Gung Mem Hosp, Dept Neurol, Kaohsiung 833, Taiwan; Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago; University of Otago; Chang Gung Memorial Hospital; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, MRC Wellcome Trust Bldg,Hills Rd, Cambridge CB2 2XY, England.		Murphy, Michael P/C-2120-2009	Murphy, Michael P/0000-0003-1115-9618; Brookes, Paul/0000-0002-8639-8413; Filipovska, Aleksandra/0000-0002-6998-8403; Darley-Usmar, Victor/0000-0001-8921-7086	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058031] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58031] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akerboom T P, 1981, Methods Enzymol, V77, P373; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Appleby RD, 1999, EUR J BIOCHEM, V262, P108, DOI 10.1046/j.1432-1327.1999.00350.x; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Beltran B, 2000, BRIT J PHARMACOL, V129, P953, DOI 10.1038/sj.bjp.0703147; BROWN GC, 1985, BIOCHEM J, V225, P399, DOI 10.1042/bj2250399; BRUNE B, 1995, REV PHYSL BIOCH PHAR, V127, P1; BURNS RJ, 1995, ARCH BIOCHEM BIOPHYS, V322, P60, DOI 10.1006/abbi.1995.1436; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; DARLEYUSMAR VM, 1985, J BIOCHEM, V97, P1767, DOI 10.1093/oxfordjournals.jbchem.a135235; Demple B, 1998, SCIENCE, V279, P1655, DOI 10.1126/science.279.5357.1655; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P334, DOI 10.1016/0003-9861(84)90206-6; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; Gavrikova EV, 1999, FEBS LETT, V455, P36, DOI 10.1016/S0014-5793(99)00850-9; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Gitler C, 1997, ANAL BIOCHEM, V252, P48, DOI 10.1006/abio.1997.2294; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; LEQUOC D, 1989, ARCH BIOCHEM BIOPHYS, V273, P466, DOI 10.1016/0003-9861(89)90506-7; LEQUOC K, 1981, BIOCHEMISTRY-US, V20, P1705, DOI 10.1021/bi00510a001; LIBERMAN EA, 1969, NATURE, V222, P1076, DOI 10.1038/2221076a0; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Muratovska A, 2001, NUCLEIC ACIDS RES, V29, P1852, DOI 10.1093/nar/29.9.1852; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; RADI R, 1991, J BIOL CHEM, V266, P4244; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; RIGOBELLO MP, 1995, ARCH BIOCHEM BIOPHYS, V319, P225, DOI 10.1006/abbi.1995.1286; Scarlett JL, 1996, BIOCHEM PHARMACOL, V52, P1047, DOI 10.1016/0006-2952(96)99426-5; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S	45	170	176	3	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17048	17056		10.1074/jbc.M110797200	http://dx.doi.org/10.1074/jbc.M110797200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861642	hybrid			2022-12-25	WOS:000175564500094
J	Han, Q; Fang, JM; Li, JY				Han, Q; Fang, JM; Li, JY			3-hydroxy-kynurenine transaminase identity with alanine glyoxylate transaminase - A probable detoxification protein in Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR BRANCH PATHWAY; NEURONAL CELL-DEATH; XANTHURENIC ACID; KYNURENINE AMINOTRANSFERASE; ENDOGENOUS NEUROTOXIN; HUNTINGTONS-DISEASE; FRONTAL-CORTEX; RAT-BRAIN; 3-HYDROXYKYNURENINE; MOSQUITO	This study describes the functional characterization of a specific mosquito transaminase responsible for catalyzing the transamination. of 3-hydroxykynurenine (3-HK) to xanthurenic acid (XA). The enzyme was purified from Aedes aegypti larvae by ammonium sulfate fractionation, heat treatment, and various chromatographic techniques, plus non-denaturing electrophoresis. The purified transaminase has a relative molecular mass of 42,500 by SDS-PAGE. N-terminal and internal sequencing of the purified protein and its tryptic fragments resolved a partial N-terminal sequence of 19 amino acid residues and 3 partial internal peptide sequences with 7, 10, and 7 amino acid residues. Using degenerate primers based on the partial internal sequences for PCR amplification and cDNA library screening, a full-length cDNA clone with a 1,167-bp open reading frame was isolated. Its deduced amino acid sequence consists of 389 amino acid residues with a predicted molecular mass of 43,239 and shares 45-46% sequence identity with mammalian alanine glyoxylate transaminases. Northern analysis shows the active transcription of the enzyme in larvae and developing eggs. Substrate specificity analysis of this mosquito transaminase demonstrates that the enzyme is active with 3-HK, kynurenine, or alanine substrates. The enzyme has greater affinity and catalytic efficiency for 3-HK than for kynurenine and alanine. The biochemical characteristics of the enzyme in conjunction with the profiles of 3-HK transaminase, activity and XA accumulation during mosquito development clearly point out its physiological function in the 3-HK to XA pathway. Our data suggest that the mosquito transaminase was evolved in a manner precisely reflecting the physiological requirement of detoxifying 3-HK produced in the tryptophan oxidation pathway in the mosquito.	Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign	Li, JY (corresponding author), Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA.	jli2@uiuc.edu	Han, Qian/AAS-2134-2020; Han, Qian/J-8696-2014	Han, Qian/0000-0001-6245-5252	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044399] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44399] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antoine FR, 1999, J AGR FOOD CHEM, V47, P5100, DOI 10.1021/jf990032+; Aquilina JA, 2000, BIOCHEMISTRY-US, V39, P16176, DOI 10.1021/bi001230t; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; Chiarugia A, 1999, FEBS LETT, V453, P197, DOI 10.1016/S0014-5793(99)00724-3; Chiou SJ, 1998, BIOCHEM BIOPH RES CO, V246, P457, DOI 10.1006/bbrc.1998.8644; CHRISTENSEN BM, 1984, J INVERTEBR PATHOL, V44, P267, DOI 10.1016/0022-2011(84)90024-7; ELASRAR AM, 1993, INVEST OPHTH VIS SCI, V33, P3463; FANG J, 2002, IN PRESS INSECT BIOC; Garcia GE, 1998, J BIOL CHEM, V273, P12003, DOI 10.1074/jbc.273.20.12003; Goldstein AJ, 2000, J CONSULT CLIN PSYCH, V68, P947, DOI 10.1037/0022-006X.68.6.947; GUILARTE TR, 1993, J NEUROL SCI, V116, P227, DOI 10.1016/0022-510X(93)90330-2; Han Q, 2001, BIOCHEM J, V360, P617, DOI 10.1042/0264-6021:3600617; HIRAKU Y, 1995, CARCINOGENESIS, V16, P349, DOI 10.1093/carcin/16.2.349; Hood BD, 1999, J BIOL CHEM, V274, P32547, DOI 10.1074/jbc.274.46.32547; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JY, 1997, INSECT BIOCHEM MOLEC, V27, P859, DOI 10.1016/S0965-1748(97)00068-4; Li JY, 1999, INSECT BIOCHEM MOLEC, V29, P329, DOI 10.1016/S0965-1748(99)00007-7; MOSCA M, 1994, FEBS LETT, V353, P21, DOI 10.1016/0014-5793(94)01003-X; Nakagami Y, 1996, NEUROSCI LETT, V216, P211; Okuda S, 1998, J NEUROCHEM, V70, P299; Okuda S, 1996, P NATL ACAD SCI USA, V93, P12553, DOI 10.1073/pnas.93.22.12553; OKUNO E, 1991, J NEUROCHEM, V57, P533, DOI 10.1111/j.1471-4159.1991.tb03783.x; OKUNO E, 1990, BRAIN RES, V534, P37, DOI 10.1016/0006-8993(90)90109-O; PEARSON SJ, 1991, J CHROMATOGR-BIOMED, V565, P436, DOI 10.1016/0378-4347(91)80406-3; PEARSON SJ, 1992, NEUROSCI LETT, V144, P199, DOI 10.1016/0304-3940(92)90749-W; Plant N, 1997, EUR J DRUG METAB PH, V22, P335, DOI 10.1007/BF03190967; SARDAR AM, 1995, J NEUROCHEM, V64, P932; SARDAR AM, 1995, NEUROSCI LETT, V187, P9, DOI 10.1016/0304-3940(95)11324-P; STONE TW, 1993, PHARMACOL REV, V45, P309; Toma S, 1997, FEBS LETT, V408, P5, DOI 10.1016/S0014-5793(97)00374-8; Urenjak J, 2000, NEUROREPORT, V11, P1341, DOI 10.1097/00001756-200004270-00038; Wei HF, 2000, J NEUROCHEM, V75, P81, DOI 10.1046/j.1471-4159.2000.0750081.x	32	28	29	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15781	15787		10.1074/jbc.M201202200	http://dx.doi.org/10.1074/jbc.M201202200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11880382	hybrid			2022-12-25	WOS:000175510400076
J	Salminen, A; Parfenyev, AN; Salli, K; Efimova, IS; Magretova, NN; Goldman, A; Baykov, AA; Lahti, R				Salminen, A; Parfenyev, AN; Salli, K; Efimova, IS; Magretova, NN; Goldman, A; Baykov, AA; Lahti, R			Modulation of dimer stability in yeast pyrophosphatase by mutations at the subunit interface and ligand binding to the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INORGANIC PYROPHOSPHATASE; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; STREPTOCOCCUS-GORDONII; DIRECTED MUTAGENESIS; SUBSTITUTIONS; CONSERVATION; CEREVISIAE; PHOSPHATE; MANGANESE	Yeast (Saccharomyces cerevisiae) pyrophosphatase (Y-PPase) is a tight homodimer with two active sites separated in space from the subunit interface. The present study addresses the effects of mutation of four amino acid residues at the subunit interface on dimer stability and catalytic activity. The W52S variant of Y-PPase is monomeric up to an enzyme concentration of 300 muM, whereas R51S, H87T, and W279S variants produce monomer only in dilute solutions at pH greater than or equal to 8.5, as revealed by sedimentation, gel electrophoresis, and activity measurements. Monomeric Y-PPase is considerably more sensitive to the SH reagents N-ethylmaleimide and p-hydroxymercurobenzosulfonate than the dimeric protein. Additionally, replacement of a single cysteine residue (Cys(83)), which is not part of the subunit interface or active site, with Ser resulted in insensitivity of the monomer to SH reagents and stabilization against spontaneous inactivation during storage. Active site ligands (Mg2+ cofactor, P-i product, and the PPi analog imidodiphosphate) stabilized the W279S dimer versus monomer predominantly by decreasing the rate of dimer to monomer conversion. The monomeric protein exhibited a markedly increased (5-9-fold) Michaelis constant, whereas k(cat) remained virtually unchanged, compared with dimer. These results indicate that dimerization of Y-PPase improves its substrate binding performance and, conversely, that active site adjustment through cofactor, product, or substrate binding strengthens intersubunit interactions. Both effects appear to be mediated by a conformational change involving the C-terminal segment that generally shields the Cys(83) residue in the dimer.	Univ Turku, Dept Biochem, FIN-20500 Turku, Finland; Moscow MV Lomonosov State Univ, An Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Moscow MV Lomonosov State Univ, Sch Chem, Moscow 119899, Russia; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	Finland National Institute for Health & Welfare; University of Turku; Lomonosov Moscow State University; Lomonosov Moscow State University; University of Helsinki	Lahti, R (corresponding author), Univ Turku, Dept Biochem, FIN-20500 Turku, Finland.		Baykov, Alexander/AAH-5301-2021; Baykov, Alexander A/C-7981-2012	Baykov, Alexander/0000-0002-2495-8200				Ahn S, 2001, J MOL BIOL, V313, P797, DOI 10.1006/jmbi.2001.5070; Aoki M, 1998, BIOCHEM J, V331, P143, DOI 10.1042/bj3310143; Baykov A A, 1999, Prog Mol Subcell Biol, V23, P127; BAYKOV AA, 1992, EUR J BIOCHEM, V206, P463, DOI 10.1111/j.1432-1033.1992.tb16947.x; BAYKOV AA, 1982, BIOORG KHIM+, V8, P195; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; Baykov AA, 1995, J BIOL CHEM, V270, P30804, DOI 10.1074/jbc.270.51.30804; Belogurov GA, 2000, BIOCHEMISTRY-US, V39, P13931, DOI 10.1021/bi000895s; CHEN J, 1990, J BACTERIOL, V172, P5686, DOI 10.1128/jb.172.10.5686-5689.1990; CHERVENKA CH, 1972, METHODS ANAL ULTRACE, P23; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; Fabrichniy IP, 1997, BIOCHEMISTRY-US, V36, P7746, DOI 10.1021/bi9629844; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HAMES BD, 1990, ELECTROPHORESIS PROT, P32; Harutyunyan EH, 1996, EUR J BIOCHEM, V239, P220, DOI 10.1111/j.1432-1033.1996.0220u.x; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; Heikinheimo P, 1996, EUR J BIOCHEM, V239, P138, DOI 10.1111/j.1432-1033.1996.0138u.x; Heikinheimo P, 2001, P NATL ACAD SCI USA, V98, P3121, DOI 10.1073/pnas.061612498; KOLAKOWSKI LF, 1988, NUCLEIC ACIDS RES, V16, P10441, DOI 10.1093/nar/16.22.10441; KUNITZ M, 1952, J GEN PHYSIOL, V35, P423, DOI 10.1085/jgp.35.3.423; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; Merckel MC, 2001, STRUCTURE, V9, P289, DOI 10.1016/S0969-2126(01)00587-1; OVERINGTON J, 1992, PROTEIN SCI, V1, P216; Parfenyev AN, 2001, J BIOL CHEM, V276, P24511, DOI 10.1074/jbc.M101829200; PLAKSINA EA, 1981, BIOORG KHIM+, V7, P357; Salminen A, 1999, J BIOL CHEM, V274, P33898, DOI 10.1074/jbc.274.48.33898; Shintani T, 1998, FEBS LETT, V439, P263, DOI 10.1016/S0014-5793(98)01381-7; Sivula T, 1999, FEBS LETT, V454, P75, DOI 10.1016/S0014-5793(99)00779-6; SMIRNOVA IN, 1986, FEBS LETT, V206, P121, DOI 10.1016/0014-5793(86)81352-7; Tsai CJ, 1999, P NATL ACAD SCI USA, V96, P9970, DOI 10.1073/pnas.96.18.9970; Velichko IS, 1998, BIOCHEMISTRY-US, V37, P734, DOI 10.1021/bi9714823; Young TW, 1998, MICROBIOL-SGM, V144, P2563, DOI 10.1099/00221287-144-9-2563	32	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15465	15471		10.1074/jbc.M200101200	http://dx.doi.org/10.1074/jbc.M200101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854292	hybrid			2022-12-25	WOS:000175510400034
J	Silveira, MS; Costa, MR; Bozza, M; Linden, R				Silveira, MS; Costa, MR; Bozza, M; Linden, R			Pituitary adenylyl cyclase-activating polypeptide prevents induced cell death in retinal tissue through activation of cyclic AMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT RETINA; ULTRASTRUCTURAL-LOCALIZATION; VASODILATORY PEPTIDE; PACAP RECEPTOR; APOPTOSIS; EXPRESSION; MAXADILAN; NEUROTOXICITY; INHIBITION; OUTGROWTH	Multiple neuroactive substances are secreted by neurons and/or glial cells and modulate the sensitivity to cell death. In the developing retina, it has been shown that increased intracellular levels of cAMP protect cells from degeneration. We tested the hypothesis that the neuroactive peptide pituitary adenylyl cyclase-activating polypeptide (PACAP) has neuroprotective effects upon the developing rat retina. PACAP38 prevented anisomycin-induced cell death in the neuroblastic layer (NBL) of retinal explants, and complete inhibition of induced cell death was obtained with 1 nM. A similar protective effect was observed with PACAP27 and with the specific PAC1 receptor agonist maxadilan but not with glucagon. Photoreceptor cell death induced by thapsigargin was also prevented by PACAP38. The neuroprotective effect of PACAP38 upon the NBL could be reverted by the competitive PACAP receptor antagonist PACAP6-38 and by the specific PAC1 receptor antagonist Maxd.4. Molecular and immunohistochemical analysis demonstrated PAC1 receptors, and treatment with PACAP38 induced phospho-cAMP-response element-binding protein immunoreactivity in the anisomycin-sensitive undifferentiated postmitotic cells within the NBL. PACAP38 produced an increase in cAMP but not inositol triphosphate, and treatment with the cAMP-dependent protein kinase inhibitor R-p-cAMPS blocked the protective effect of PACAP38. The results indicate that activation of PAC1 receptors by PACAP38 modulates cell death in the developing retina through the intracellular cAMP/cAMP-dependent protein kinase pathway.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Lab Neurogenese, BR-21949900 Rio de Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21949900 Rio de Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Silveira, MS (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Lab Neurogenese, Bloco G,Cidade Univ, BR-21949900 Rio de Janeiro, Brazil.	silveira@biof.ufrj.br	Silveira, Mariana/M-4865-2013; Linden, Rafael/F-2275-2011	Silveira, Mariana/0000-0002-0496-1517; Linden, Rafael/0000-0003-3287-336X; Bozza, Marcelo/0000-0003-3683-7550				Alexiades MR, 1997, DEVELOPMENT, V124, P1119; AryPires R, 1997, INT J DEV NEUROSCI, V15, P239; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Braas KM, 1999, J BIOL CHEM, V274, P27702, DOI 10.1074/jbc.274.39.27702; Casaccia-Bonnefil P, 1999, ADV EXP MED BIOL, V468, P275; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; Chiarini LB, 2000, CELL DEATH DIFFER, V7, P272, DOI 10.1038/sj.cdd.4400639; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; CRAFT JL, 1982, CURR EYE RES, V2, P295, DOI 10.3109/02713688209000773; Cui Q, 2000, NEUROREPORT, V11, P3921, DOI 10.1097/00001756-200011270-00062; D'Agata V, 1998, MOL BRAIN RES, V54, P161, DOI 10.1016/S0169-328X(97)00335-5; DEARAUJO EG, 1993, EUR J NEUROSCI, V5, P1181; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; Gonzalez BJ, 1997, NEUROSCIENCE, V78, P419, DOI 10.1016/S0306-4522(96)00617-3; Guimaraes CA, 2001, J NEUROCHEM, V76, P1233, DOI 10.1046/j.1471-4159.2001.00126.x; Hefti F, 1997, ANNU REV PHARMACOL, V37, P239, DOI 10.1146/annurev.pharmtox.37.1.239; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; Izumi S, 2000, ANN NY ACAD SCI, V921, P317; Journot L, 1998, ANN NY ACAD SCI, V865, P100, DOI 10.1111/j.1749-6632.1998.tb11168.x; KATER SB, 1995, TRENDS NEUROSCI, V18, P71, DOI 10.1016/0166-2236(95)93877-Z; LERNER EA, 1991, J BIOL CHEM, V266, P11234; Linden R, 1999, PROG RETIN EYE RES, V18, P133, DOI 10.1016/S1350-9462(98)00020-2; Linden R, 2000, BRAIN RES REV, V32, P146, DOI 10.1016/S0165-0173(99)00073-9; LOCKSHIN RA, 1990, J GERONTOL, V45, pB135, DOI 10.1093/geronj/45.5.B135; Lu NR, 1997, P NATL ACAD SCI USA, V94, P3357, DOI 10.1073/pnas.94.7.3357; Lu NR, 1998, J NEUROSCI RES, V53, P651, DOI 10.1002/(SICI)1097-4547(19980915)53:6<651::AID-JNR3>3.0.CO;2-4; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966; Moro O, 1999, J BIOL CHEM, V274, P23103, DOI 10.1074/jbc.274.33.23103; Namura S, 1998, J NEUROSCI, V18, P3659; Olianas MC, 1997, J NEUROCHEM, V69, P1213; ONALI P, 1994, BRAIN RES, V641, P132, DOI 10.1016/0006-8993(94)91825-2; Rehen SK, 1996, DEVELOPMENT, V122, P1439; Rehen SK, 1999, EUR J NEUROSCI, V11, P4349, DOI 10.1046/j.1460-9568.1999.00868.x; REIS RAM, 1995, NEUROCHEM INT, V26, P375, DOI 10.1016/0197-0186(94)00143-I; Rocha M, 1999, BRAIN RES, V827, P79, DOI 10.1016/S0006-8993(99)01307-4; Seki T, 1998, ANN NY ACAD SCI, V865, P408, DOI 10.1111/j.1749-6632.1998.tb11205.x; Seki T, 1997, NEUROSCI LETT, V238, P127, DOI 10.1016/S0304-3940(97)00869-0; Seki T, 2000, PEPTIDES, V21, P109, DOI 10.1016/S0196-9781(99)00180-1; Shoge K, 1999, BRAIN RES, V839, P66, DOI 10.1016/S0006-8993(99)01690-X; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Suh JH, 2001, NAT NEUROSCI, V4, P123, DOI 10.1038/83936; Tabuchi A, 2001, NEUROSCI RES, V39, P85, DOI 10.1016/S0168-0102(00)00200-5; Varella MH, 1999, J NEUROCHEM, V73, P485, DOI 10.1046/j.1471-4159.1999.0730485.x; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 1999, P NATL ACAD SCI USA, V96, P9415, DOI 10.1073/pnas.96.16.9415	49	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16075	16080		10.1074/jbc.M110106200	http://dx.doi.org/10.1074/jbc.M110106200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11847214	hybrid			2022-12-25	WOS:000175510400114
J	Collard, CD; Park, KA; Montalto, MC; Alapati, S; Buras, JA; Stahl, GL; Colgan, SP				Collard, CD; Park, KA; Montalto, MC; Alapati, S; Buras, JA; Stahl, GL; Colgan, SP			Neutrophil-derived glutamate regulates vascular endothelial barrier function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; ACTIVATED PROTEIN-KINASE; CEREBELLAR GRANULE CELLS; INTACT HUMAN PLATELETS; VASP IN-VITRO; NITRIC-OXIDE; 5'-ADENOSINE MONOPHOSPHATE; INDUCED APOPTOSIS; RECEPTORS; PHOSPHORYLATION	Endothelial barrier function is altered by the release of soluble polymorphonuclear leukocyte (PMN)-derived mediators during inflammatory states. However, endogenous pathways to describe such changes are only recently appreciated. Using an in vitro endothelial paracellular permeability model, cell-free supernatants from formylmethionylleucylphenylalanine-stimulated PMNs were observed to significantly alter endothelial permeability. Biophysical and biochemical analysis of PMN supernatants identified PMN-derived glutamate in modulating endothelial permeability. Furthermore, novel expression of metabotropic glutamate receptor 1 (mGluR1), mGluR4, and mGluR5 by human brain and dermal microvascular endothelial cells was demonstrated by reverse transcription-PCR, in situ hybridization, immunofluorescence, and Western blot analysis. Treatment of human brain endothelia with glutamate or selective, mGluR group I or III agonists resulted in a time-dependent loss of phosphorylated vasodilator-stimulated phosphoprotein (VASP) and significantly increased endothelial permeability. Glutamate-induced decreases in brain endothelial barrier function and phosphorylated VASP were significantly attenuated by pretreatment of human brain endothelia with selective mGluR antagonists. These observations were extended to an in vivo hypoxic mouse model in which pretreatment with mGluR antagonists significantly decreased fluorescein isothiocyanate-dextran flux across the blood-brain barrier. We conclude that activated human PMNs release glutamate and that endothelial expression of group I or III mGluRs function to decrease human brain endothelial VASP phosphorylation and barrier function. These results identify a novel pathway by which PMN-derived glutamate may regulate human endothelial barrier function.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Beth Israel Deaconess Hosp, Dept Emergency Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Colgan, SP (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Thorn 704,20 Shattuck St, Boston, MA 02115 USA.		Colgan, Sean P./B-4573-2009	Stahl, Gregory/0000-0002-4805-8119	NHLBI NIH HHS [HL-03854, F32-HL103870, HL60569/DE13499, HL-52866] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060569] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; ALBELDA SM, 1988, J APPL PHYSIOL, V64, P308, DOI 10.1152/jappl.1988.64.1.308; AMSTERDAM EA, 1995, AM J PHYSIOL-HEART C, V268, pH448, DOI 10.1152/ajpheart.1995.268.1.H448; Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; Blumcke I, 1996, BRAIN RES, V736, P217; Boeck CR, 2000, NEUROREPORT, V11, P709, DOI 10.1097/00001756-200003200-00011; BUTT E, 1994, J BIOL CHEM, V269, P14509; CASNOCHA SA, 1989, J APPL PHYSIOL, V67, P1997, DOI 10.1152/jappl.1989.67.5.1997; CHANG JY, 1981, BIOCHEM J, V199, P547, DOI 10.1042/bj1990547; Collard CD, 1999, AM J PHYSIOL-CELL PH, V276, pC450, DOI 10.1152/ajpcell.1999.276.2.C450; COMERFORD KM, 2002, FASEB J         0212; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Copani A, 2000, BRAIN RES, V867, P165, DOI 10.1016/S0006-8993(00)02293-9; Cotran RS, 1998, PATHOL BIOL, V46, P164; Curi Tania C. Pithon, 1997, American Journal of Physiology, V273, pC1124; CURI TC, 1997, BIOCH SOC T S, V25, P249; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115; Gasparini F, 1999, J PHARMACOL EXP THER, V289, P1678; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Gill SS, 1999, BRAIN RES BULL, V48, P143, DOI 10.1016/S0361-9230(98)00154-3; Gill SS, 2001, TOXICOL PATHOL, V29, P208, DOI 10.1080/019262301317052486; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grima G, 1997, EUR J NEUROSCI, V9, P2248, DOI 10.1111/j.1460-9568.1997.tb01643.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Hediger MA, 1999, AM J PHYSIOL-RENAL, V277, pF477, DOI 10.1152/ajprenal.1999.277.4.F477; HENSON PM, 1975, J CLIN INVEST, V56, P1053, DOI 10.1172/JCI108152; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KALLMANN BA, 2002, FASEB J         0212; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Krizbai IA, 1998, J NEUROSCI RES, V54, P814; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; MADARA JL, 1993, J CLIN INVEST, V91, P2320, DOI 10.1172/JCI116462; Mayhan WG, 1996, STROKE, V27, P965, DOI 10.1161/01.STR.27.5.965; Mitra D, 1997, BLOOD, V89, P1224, DOI 10.1182/blood.V89.4.1224; MIZUNOYAGYU Y, 1987, BIOCHEM PHARMACOL, V36, P3809; Morley P, 1998, J CEREBR BLOOD F MET, V18, P396, DOI 10.1097/00004647-199804000-00008; Nakahara K, 1997, J NEUROCHEM, V69, P1467; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; Schinkmann KA, 2000, J NEUROCHEM, V74, P1931, DOI 10.1046/j.1471-4159.2000.0741931.x; Scott A.I., 1964, INTERPRETATION ULTRA, P15; Sporbert A, 1999, MOL BRAIN RES, V67, P258, DOI 10.1016/S0169-328X(99)00067-4; Stevens T, 2000, AM J PHYSIOL-LUNG C, V279, pL419, DOI 10.1152/ajplung.2000.279.3.L419; Stevens T, 1999, AM J PHYSIOL-LUNG C, V277, pL119, DOI 10.1152/ajplung.1999.277.1.L119; Taylor CT, 1999, J BIOL CHEM, V274, P19447, DOI 10.1074/jbc.274.27.19447; TIZZANO JP, 1995, NEUROPHARMACOLOGY, V34, P1063, DOI 10.1016/0028-3908(95)00083-I; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YANO S, 1994, J BIOL CHEM, V269, P5428; Zund G, 1997, AM J PHYSIOL-CELL PH, V273, pC1571, DOI 10.1152/ajpcell.1997.273.5.C1571	54	128	135	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14801	14811		10.1074/jbc.M110557200	http://dx.doi.org/10.1074/jbc.M110557200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847215	hybrid			2022-12-25	WOS:000175203000059
J	Afrikanova, I; Yeh, E; Bartos, D; Watowich, SS; Longmore, GD				Afrikanova, I; Yeh, E; Bartos, D; Watowich, SS; Longmore, GD			Oncogene cooperativity in Friend erythroleukemia: erythropoietin receptor activation by the env gene of SFFV leads to transcriptional upregulation of PU.1, independent of SFFV proviral insertion	ONCOGENE			English	Article						erythroleukemia; oncogene cooperativity; PU. 1 transcription; Friend virus	FOCUS-FORMING VIRUS; LONG TERMINAL REPEAT; TRANSGENIC MICE DEVELOP; CONSTITUTIVE ACTIVATION; PUTATIVE ONCOGENE; SPLEEN; SPI-1; EXPRESSION; KINASE; GROWTH	Cancer is a multi-step, multi-genetic event. Whether oncogenic mutations cooperate with one another to transform cells and how is not well understood. The Friend murine retroviral erythroleukemia model involves mitogenic activation of the erythropoietin receptor (EpoR) by the virus env gene (F-gp55), aberrant over-expression of the transcription factor PU.1, and inactivating mutations in p53. In this report we demonstrate that concurrent expression of F-gp55 and PU.1 in erythroid target cells, in vivo, cooperate to accelerate erythroleukemia induction. Early in the disease, prior to the detection of clonal leukemic cells, activation of the EpoR by F-gp55, but not erythropoietin, resulted in transcriptional upregulation of PU.1 through a trans regulatory mechanism. This could occur in the absence of an integrated provirus within the PU.1 gene locus. The regulation of PU.1 transcription in established erythroleukemia cell lines differed depending upon the level of PU.1 protein present. Our results suggest that the action of F-gp55 contributes to both early and late stages of Friend erythroleukemia and that persistence of F-gp55 expression may be required not only to initiate erythroleukemia but to also maintain erythroleukemia following Friend virus infection.	Washington Univ, Sch Med, Dept Med, Div Hematol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	Washington University (WUSTL); Washington University (WUSTL); University of Texas System; UTMD Anderson Cancer Center	Longmore, GD (corresponding author), Washington Univ, Sch Med, Dept Med, Div Hematol, Campus Box 8125,660 S Euclid Ave, St Louis, MO 63110 USA.	longmorg@medicine.wustl.edu		Watowich, Stephanie/0000-0003-1969-659X	NCI NIH HHS [R01 CA 75315, R01 CA077447-02, R01 CA077447-03, R01 CA 77447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077447, R01CA075315] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; Beckman DL, 1999, BLOOD, V94, P2667, DOI 10.1182/blood.V94.8.2667.420k27_2667_2675; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; Chen HM, 1996, J BIOL CHEM, V271, P15743, DOI 10.1074/jbc.271.26.15743; CHEN HM, 1995, ONCOGENE, V11, P1549; CHOI SY, 1995, J VIROL, V69, P7054, DOI 10.1128/JVI.69.11.7054-7060.1995; Elnitski L, 1999, BLOOD CELL MOL DIS, V25, P299, DOI 10.1006/bcmd.1999.0257; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Ghosh SK, 1999, J VIROL, V73, P4931, DOI 10.1128/JVI.73.6.4931-4940.1999; Hoatlin Maureen E., 1995, Trends in Microbiology, V3, P51, DOI 10.1016/S0966-842X(00)88875-7; HOWARD JC, 1993, ONCOGENE, V8, P2721; HROMAS R, 1993, BLOOD, V82, P2998; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; LI JP, 1987, J VIROL, V61, P2782, DOI 10.1128/JVI.61.9.2782-2792.1987; LI JP, 1995, J VIROL, V69, P1714, DOI 10.1128/JVI.69.3.1714-1719.1995; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Muszynski KW, 1998, J VIROL, V72, P919, DOI 10.1128/JVI.72.2.919-925.1998; Muszynski KW, 2000, J VIROL, V74, P8444, DOI 10.1128/JVI.74.18.8444-8451.2000; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; Pereira R, 2000, ONCOGENE, V19, P5106, DOI 10.1038/sj.onc.1203886; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; ROSEN CA, 1985, SCIENCE, V227, P320, DOI 10.1126/science.2981432; Ruscetti SK, 1999, INT J BIOCHEM CELL B, V31, P1089, DOI 10.1016/S1357-2725(99)00074-6; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; Tarr K, 1997, J BIOL CHEM, V272, P9099; TRAN QC, 1997, EMBO J, V16, P5639; Vannucchi AM, 2000, BLOOD, V95, P2559; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P307; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	45	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1272	1284		10.1038/sj.onc.1205183	http://dx.doi.org/10.1038/sj.onc.1205183			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850847	Green Accepted, Bronze			2022-12-25	WOS:000173729400015
J	Miyakoda, M; Suzuki, K; Kodama, S; Watanabe, M				Miyakoda, M; Suzuki, K; Kodama, S; Watanabe, M			Activation of ATM and phosphorylation of p53 by heat shock	ONCOGENE			English	Article						ATM; p53; heat shock; serine 15; phosphorylation	TUMOR-SUPPRESSOR PROTEIN; DAMAGE-INDUCED PHOSPHORYLATION; CELL-CYCLE CHECKPOINT; DOUBLE-STRAND BREAKS; N-TERMINAL SITES; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; DEPENDENT PHOSPHORYLATION; IONIZING-RADIATION; POTENTIAL MEDIATOR	p53 protein is phosphorylated in response to various stresses. Here we examined phosphorylation of p53 protein in normal human diploid cells after heat shock at 43degreesC for 2 h. We found that heat shock stimulates phosphorylation of p53 at Ser15 but not at Ser20, while X-irradiation at 4 Gy and 10 J/m(2) of UV induces phosphorylation of p53 at Ser15 and less significantly at Ser20. Increased phosphorylation of Ser15 was also observed in heat shocked GM638, the SV40-transformed human fibroblast cell line. Although X-ray irradiation induced phosphorylation of Ser6, 9, 20, and 37 in GM638 cells, heat shock did not affect the phosphorylation level of these serines. We observed little or no phosphorylation of p53 at Ser15 in two primary ataxia telangiectasia fibroblast cells, that are defective in ATM. Using an in vitro kinase assay, we confirmed that immunoprecipitated ATM from both heat-shocked and X-irradiated normal human diploid cells can phosphorylate p53 at Ser15 to a similar extent. These results indicate that heat shock induces phosphorylation of p53, especially at Ser15, and its phosphorylation is mediated by ATM kinase.	Nagasaki Univ, Sch Pharmaceut Sci, Lab Radiat & Life Sci, Nagasaki 8528521, Japan	Nagasaki University	Watanabe, M (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Lab Radiat & Life Sci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	nabe@net.nagasaki-u.ac.jp						Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ikeda M, 1999, BIOL REPROD, V61, P393, DOI 10.1095/biolreprod61.2.393; JORRITSMA JBM, 1984, RADIAT RES, V98, P198, DOI 10.2307/3576063; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lavin MF, 2000, NAT CELL BIOL, V2, pE215, DOI 10.1038/35046628; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MILNE DM, 1992, ONCOGENE, V7, P1361; Miyakoda M, 1999, BIOCHEM BIOPH RES CO, V266, P377, DOI 10.1006/bbrc.1999.1829; MIYASHITA T, 1995, CELL, V80, P293; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; WATANABE M, 1992, INT J RADIAT BIOL, V62, P711, DOI 10.1080/09553009214552661; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	54	41	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1090	1096		10.1038/sj.onc.1205196	http://dx.doi.org/10.1038/sj.onc.1205196			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850826				2022-12-25	WOS:000173580100012
J	Zamo, A; Chiarle, R; Piva, R; Howes, J; Fan, Y; Chilosi, M; Levy, DE; Inghirami, G				Zamo, A; Chiarle, R; Piva, R; Howes, J; Fan, Y; Chilosi, M; Levy, DE; Inghirami, G			Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death	ONCOGENE			English	Article						ALCL; t(2;5); NPM-ALK signaling; Stat3; Bcl-x(L), apoptosis	NON-HODGKINS-LYMPHOMA; RECEPTOR TYROSINE KINASE; SIGNAL TRANSDUCER; GENE; TRANSCRIPTION; APOPTOSIS; INHIBITOR; FUSION; NPM; EXPRESSION	The anaplastic lymphoma kinase (ALK) gene is characteristically translocated in Anaplastic Large Cell Lymphomas (ALCL) and the juxtaposion of the ALK gene to multiple partners results in its constitutive protein tyrosine kinase activity. We show here that expression of activated ALK induces the constitutive phosphorylation of Stat3 in transfected cells as well as in primary human ALCLs. Furthermore, immunohistochemical studies demonstrate that among distinct human B and T cell lymphomas, activation of Stat3 nuclear translocation is uniquely associated with ALK expression. NPM-ALK also binds and activates Jak3; however, Jak3 is not required for Stat3 activation or for cell transformation in vitro. Moreover, src family kinases are not necessary for NPM-ALK-mediated Stat3 activation or transformation, suggesting that Stat3 may be phosphorylated directly by ALK. To evaluate relevant targets of ALK-activated Stat3, we investigated the regulation of the anti-apoptotic protein Bcl-x(L) and its role in cell survival in NPM-ALK positive cells. NPM-ALK expression caused enhanced Bcl-x(L) transcription, largely mediated by Stat3. Increased expression of Bcl-x(L) provided sufficient anti-apoptotic signals to protect cells from treatment with specific inhibitors of the Jaks/Stat pathway or the Brc-Abl kinase. These studies support a pathogenic mechanism whereby stimulation of anti-apoptotic signals through activation of Stat3 contributes to the successful outgrowth of ALK positive tumor cells.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Univ Verona, Dept Pathol, Rome, Italy; Univ Turin, Dept Pathol, Turin, Italy	New York University; New York University; University of Verona; University of Turin	Inghirami, G (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.		Levy, David/GPS-4945-2022; Piva, Roberto/H-7315-2013; Levy, David/AAG-6202-2019; Zamò, Alberto/ABF-4436-2020; Piva, Roberto/B-9580-2018	Levy, David/0000-0002-7320-7788; Piva, Roberto/0000-0002-2273-3470; CHIARLE, Roberto/0000-0003-1564-8531; Zamo, Alberto/0000-0001-6203-7966	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 28900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Chiarle R, 1999, J IMMUNOL, V163, P194; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Donato NJ, 2001, BLOOD, V97, P2846, DOI 10.1182/blood.V97.9.2846; Drexler HG, 2000, LEUKEMIA, V14, P1533, DOI 10.1038/sj.leu.2401878; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Grignani F, 1998, CANCER RES, V58, P14; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARRIS NL, 1994, BLOOD, V84, P1361; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Slupianek A, 2001, CANCER RES, V61, P2194; Takeda K, 1998, J IMMUNOL, V161, P4652; Trinei M, 2000, CANCER RES, V60, P793; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548	34	292	303	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1038	1047		10.1038/sj.onc.1205152	http://dx.doi.org/10.1038/sj.onc.1205152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850821	Bronze			2022-12-25	WOS:000173580100007
J	Crish, JF; Bone, F; Banks, EB; Eckert, RL				Crish, JF; Bone, F; Banks, EB; Eckert, RL			The human involucrin gene contains spatially distinct regulatory elements that regulate expression during early versus late epidermal differentiation	ONCOGENE			English	Article						transgenic mice; activator protein-1; AP1; jun; fos; Sp1; gene regulation; epidermal keratinocyte; keratinocyte differentiation; tissue specific	PROTEIN-KINASE-C; CORNIFIED CELL-ENVELOPE; CROSS-LINKED ENVELOPE; HUMAN KERATIN-1 GENE; PROMOTER ACTIVITY; TRANSGENIC MICE; TERMINAL DIFFERENTIATION; AP-1 ELEMENT; TRANSCRIPTION; FOS	Human involucrin (hINV) is a keratinocyte protein that is expressed in the suprabasal compartment of the epidermis and other stratifying surface epithelia. Involucrin gene expression is initiated early in the differentiation process and is maintained until terminal cell death. The distal regulatory region (DRR) is a segment of the hINV promoter (nucleotides -2473/ -1953) that accurately recapitulates the normal pattern of suprabasal (spinous and granular layer) expression in transgenic mouse epithelia. To identify sequences that mediate expression at specific stages of differentiation, we divided the DRR into two segments, a 376 nucleotide upstream region (DRR-2473/-2100) and a 147 nucleotide downstream region (DRR-2100/-1953), and evaluated the ability of these sequences to drive expression in transgenic mice. The DRR-2473/-2100 segment drives expression at a level comparable to that observed for the DRR, but expression is restricted to the upper granular layers (i.e., no spinous layer expression). In contrast, the DRR-2100/-1953 segment does not drive expression. However, reassembling the DRR restores the complete range of expression. These results suggest that two distinct, spatially-separate elements are required to specify the complete differenation-dependent program of involucrin gene expression. To identify specific transcription factor binding sites involved in this regulation, we mutated an activator protein-1 binding site, AP1-5, located within DRR-2473/-2100 segment. This site binds AP1 transcription factors present in mouse epidermal extracts, and its mutation eliminates appropriate hINV expression. This result suggests that AP1 factors participate as components of a multicomponent transcription factor complex that is required for regulation.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Room E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39750] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; Bernerd Francoise, 1993, Gene Expression, V3, P187; BICKENBACH JR, 1995, J INVEST DERMATOL, V104, P405, DOI 10.1111/1523-1747.ep12665896; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; FEI YJ, 1995, BIOTECHNIQUES, V18, P984; FISHER C, 1991, DEVELOPMENT, V111, P253; Green H, 1980, Harvey Lect, V74, P101; HOHL D, 1993, DIFFERENTIATION, V54, P25, DOI 10.1111/j.1432-0436.1993.tb00656.x; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HUFF CA, 1993, J BIOL CHEM, V268, P377; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; LU B, 1994, J BIOL CHEM, V269, P7443; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; MURTHY S, 1993, J STRUCT BIOL, V111, P68, DOI 10.1006/jsbi.1993.1037; Ng DC, 2000, J BIOL CHEM, V275, P24080, DOI 10.1074/jbc.M002508200; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; Rutberg SE, 1996, ONCOGENE, V13, P167; Steinert P M, 1995, Cell Death Differ, V2, P33; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; Takahashi H, 1998, J INVEST DERMATOL, V110, P218, DOI 10.1046/j.1523-1747.1998.00110.x; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yamada K, 1997, HUM MOL GENET, V6, P2223, DOI 10.1093/hmg/6.13.2223	49	37	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					738	747		10.1038/sj.onc.1205038	http://dx.doi.org/10.1038/sj.onc.1205038			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850802				2022-12-25	WOS:000173427000005
J	Westwood, G; Dibling, BC; Cuthbert-Heavens, D; Burchill, SA				Westwood, G; Dibling, BC; Cuthbert-Heavens, D; Burchill, SA			Basic fibroblast growth factor (bFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway	ONCOGENE			English	Article						bFGF; cell death; caspase; Ewing's sarcoma	CYTOCHROME-C RELEASE; EWING TUMOR-CELLS; INDUCED APOPTOSIS; P53; MITOCHONDRIAL; PROTEIN; SARCOMA; MODULATION; BCL-2; BAX	The mechanism of bFGF-induced cell death in tumours of the Ewing's sarcoma family (ESFT) has been investigated. bFGF-induces phosphorylation of FGFr 1 and activation of Ras/ERK in ESFT cells that die when exposed to bFGF. Induction of cell death was associated with activation of both initiator (caspases-2, -8 and -10) and effector (caspases-3, -6 and -7) caspases. Moreover, the general caspase inhibitor Z-VAD-FMK protected cells from bFGF-induced cell death. After treatment with bFGF, a loss of mitochondrial transmembrane potential was accompanied by down-regulation of Bcl-2. However, the observed cell death was not associated with release of cytochrome c from the mitochondria. Furthermore, expression of wild-type p53 was not required for bFGF-induced cell death. These observations suggest that bFGF-induced cell death may be mediated through a cell death receptor mechanism, supported by up-regulation of the p75 neurotrophin receptor. bFGF-induced cell death was associated with up-regulation of p21 and p53, down-regulation of PCNA and cyclin A and a decrease in active pRb1, changes consistent with accumulation of cells in G1. These data demonstrate that bFGF-induced cell death is effected through a caspase-dependent and p53-independent mechanism, that may be mediated through a cell death receptor pathway.	Univ Leeds, St James Hosp, Imperial Canc Res Fund, Canc Med Res Unit,Candlelighters Childrens Canc R, Leeds LS9 7TF, W Yorkshire, England; Univ Leeds, St James Hosp, Imperial Canc Res Fund, Canc Med Res Unit,Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds	Burchill, SA (corresponding author), Univ Leeds, St James Hosp, Imperial Canc Res Fund, Canc Med Res Unit,Candlelighters Childrens Canc R, Beckett St, Leeds LS9 7TF, W Yorkshire, England.			Heavens, Darren/0000-0001-5418-7868				Achenbach TV, 2000, J BIOL CHEM, V275, P32089, DOI 10.1074/jbc.M005267200; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BARTEK J, 1990, ONCOGENE, V5, P893; BIEDLER JL, 1973, CANCER RES, V33, P2643; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dobrowsky RT, 2000, J NEUROSCI RES, V61, P237, DOI 10.1002/1097-4547(20000801)61:3<237::AID-JNR1>3.0.CO;2-M; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; ITOH N, 1993, J BIOL CHEM, V268, P10932; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Kontny HU, 1998, CANCER RES, V58, P5842; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 2000, ONCOGENE, V19, P4096, DOI 10.1038/sj.onc.1203780; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088; Kumar A, 2001, ONCOGENE, V20, P1010, DOI 10.1038/sj.onc.1204154; Kusaka K, 1998, CURR EYE RES, V17, P524, DOI 10.1076/ceyr.17.5.524.5196; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; OConnor PM, 1997, CANCER RES, V57, P4285; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; OWENSCHAUB LB, 1995, CANCER LETT, V94, P1, DOI 10.1016/0304-3835(95)03834-J; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Radig K, 1998, PATHOL RES PRACT, V194, P157, DOI 10.1016/S0344-0338(98)80016-2; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Schuelke M, 2000, NAT BIOTECHNOL, V18, P233, DOI 10.1038/72708; SCHWEIGERER L, 1987, J CLIN INVEST, V80, P1516, DOI 10.1172/JCI113236; Smits VAJ, 2000, J BIOL CHEM, V275, P19375, DOI 10.1074/jbc.M001764200; Sturla LM, 2000, CANCER RES, V60, P6160; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wang HS, 1997, CANCER RES, V57, P1750; Wang Q, 1998, EXP CELL RES, V238, P177, DOI 10.1006/excr.1997.3820; Wang X, 2001, J BIOL CHEM, V276, P33812, DOI 10.1074/jbc.M010548200; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	49	25	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					809	824		10.1038/sj.onc.1205128	http://dx.doi.org/10.1038/sj.onc.1205128			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850809				2022-12-25	WOS:000173427000012
J	Mbebi, C; See, V; Mercken, L; Pradier, L; Muller, U; Loeffler, JP				Mbebi, C; See, V; Mercken, L; Pradier, L; Muller, U; Loeffler, JP			Amyloid precursor protein family-induced neuronal death is mediated by impairment of the neuroprotective calcium/calmodulin protein kinase IV-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ELEMENT-BINDING PROTEIN; CYCLASE-ACTIVATING POLYPEPTIDE; CEREBELLAR GRANULE NEURONS; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; CULTURED NEURONS; CREB PHOSPHORYLATION	The aberrant metabolism of beta-amyloid precursor protein (APP) and the progressive deposition of its derived fragment beta-amyloid peptide are early and constant pathological hallmarks of Alzheimer's disease. Because APP is able to function as a cell surface receptor, we investigated here whether a disruption of the normal function of APP may contribute to the pathogenic mechanisms in Alzheimer's disease. To this aim, we generated a specific chicken polyclonal antibody directed against the extracellular domain of APP, which is common with the beta-amyloid precursor-like protein type 2. Exposure of cultured cortical neurons to this antibody (APP-Ab) induced cell death preceded by neurite degeneration, oxidative stress, and nuclear condensation. Interestingly, caspase-3-like protease was not activated in this neurotoxic action suggesting a different mode of cell death than classical apoptosis. Further analysis of the molecular mechanisms revealed a calpain- and calcineurin-dependent proteolysis of the neuroprotective calcium/ calmodulin-dependent protein kinase IV and its nuclear target protein cAMP responsive element binding protein. These effects were abolished by the G protein inhibitor pertussis toxin, strongly suggesting that APP binding operates via a GTPase-dependent pathway to cause neuronal death.	Univ Strasbourg, Fac Med, EA Mol Signaling & Neurodegenerat 3433, F-67000 Strasbourg, France; Aventis Pharma, Dept Neurodegenerat Dis Grp, F-94400 Vitry Sur Seine, France; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Sanofi-Aventis; Sanofi France; Max Planck Society	Loeffler, JP (corresponding author), Univ Strasbourg, Fac Med, EA Mol Signaling & Neurodegenerat 3433, 11 Rue Humann, F-67000 Strasbourg, France.	loeffler@neurochem.u-strasbg.fr	LOEFFLER, Jean-Philippe/AAS-4401-2020					Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Brouillet E, 1999, J NEUROSCI, V19, P1717; Bursztajn S, 1998, J NEUROSCI, V18, P9790; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; CHENG SV, 1988, P NATL ACAD SCI USA, V85, P6032, DOI 10.1073/pnas.85.16.6032; D'Mello SR, 2000, J NEUROSCI RES, V59, P24, DOI 10.1002/(SICI)1097-4547(20000101)59:1<24::AID-JNR4>3.3.CO;2-#; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Giambarella U, 1997, EMBO J, V16, P4897, DOI 10.1093/emboj/16.16.4897; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Gringhuis SI, 1997, J BIOL CHEM, V272, P31809, DOI 10.1074/jbc.272.50.31809; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Heber S, 2000, J NEUROSCI, V20, P7951; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Ishihara I, 2000, NEUROSCI LETT, V279, P97, DOI 10.1016/S0304-3940(99)00960-X; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Ivins KJ, 1998, NEUROBIOL DIS, V5, P365, DOI 10.1006/nbdi.1998.0228; Jung SS, 1996, J NEUROSCI RES, V46, P336, DOI 10.1002/(SICI)1097-4547(19961101)46:3<336::AID-JNR7>3.3.CO;2-L; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Masumura M, 2000, MOL BRAIN RES, V80, P219, DOI 10.1016/S0169-328X(00)00163-7; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; Nishimura I, 1998, J NEUROSCI, V18, P2387, DOI 10.1523/jneurosci.18-07-02387.1998; Okamoto T, 1996, EMBO J, V15, P3769, DOI 10.1002/j.1460-2075.1996.tb00750.x; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Oppenheim RW, 2001, J NEUROSCI, V21, P4752, DOI 10.1523/JNEUROSCI.21-13-04752.2001; PAPPOLLA MA, 1992, AM J PATHOL, V140, P621; Patel M, 1998, J NEUROCHEM, V71, P1068, DOI 10.1046/j.1471-4159.1998.71031068.x; Pike CJ, 1997, J NEUROCHEM, V69, P1601; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Przywara DA, 1998, J NEUROCHEM, V71, P1889; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Ray SK, 2000, BRAIN RES, V852, P326, DOI 10.1016/S0006-8993(99)02148-4; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Rohn TT, 2000, J NEUROCHEM, V74, P2331, DOI 10.1046/j.1471-4159.2000.0742331.x; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Sandbrink R, 1994, Neurobiol Dis, V1, P13, DOI 10.1006/nbdi.1994.0003; SCHWARZ MA, 1994, J BIOL CHEM, V269, P15238; See V, 2001, J BIOL CHEM, V276, P35049, DOI 10.1074/jbc.M104988200; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; Sudo H, 2000, MOL CELL NEUROSCI, V16, P708, DOI 10.1006/mcne.2000.0910; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uetsuki T, 1999, J NEUROSCI, V19, P6955, DOI 10.1523/JNEUROSCI.19-16-06955.1999; Vaudry D, 1998, NEUROSCIENCE, V84, P801, DOI 10.1016/S0306-4522(97)00545-9; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; WAITE J, 1992, NEUROBIOL AGING, V13, P595, DOI 10.1016/0197-4580(92)90062-3; Walton M, 1999, J NEUROCHEM, V73, P1836; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Webster MT, 1999, NEUROSCI LETT, V276, P107, DOI 10.1016/S0304-3940(99)00800-9; White AR, 1999, J NEUROSCI, V19, P9170; White AR, 1998, J NEUROSCI, V18, P6207; Xie HQ, 1998, J NEUROSCI RES, V53, P153, DOI 10.1002/(SICI)1097-4547(19980715)53:2<153::AID-JNR4>3.3.CO;2-5; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; YAN GZ, 1994, MOL CELL ENDOCRINOL, V101, pR25, DOI 10.1016/0303-7207(94)90255-0; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	90	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20979	20990		10.1074/jbc.M107948200	http://dx.doi.org/10.1074/jbc.M107948200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11877414	hybrid			2022-12-25	WOS:000176204500113
J	Ustinov, VA; Plow, EF				Ustinov, VA; Plow, EF			Delineation of the key amino acids involved in neutrophil inhibitory factor binding to the I-domain supports a mosaic model for the capacity of integrin alpha(M)beta(2) to recognize multiple ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADHESION SITE; A-DOMAIN; COMPLEMENT RECEPTOR; MONOCLONAL-ANTIBODY; LEUKOCYTE ADHESION; CD11B/CD18 INTEGRIN; CRYSTAL-STRUCTURE; MAC-1 CD11B/CD18; BETA-2 INTEGRINS; ADHERENCE	To gain insight into the mechanism by which the alpha(M)I-domain of integrin alpha(M)beta(2) interacts with multiple and unrelated ligands, the identity of the neutrophil inhibitory factor (NIF) recognition site was sought. A systematic strategy in which individual amino acid residues within three previously implicated segments were changed to those in the alpha(L)I-domain, which is structurally very similar but does not bind NIF, was implemented. The capacity of the resulting mutants, expressed as glutathione S-transferase fusion proteins, to recognize NIF was assessed. These analyses ultimately identified Asp(149), Arg(151), Gly(207), Tyr(252), and Glu(258) as critical for NIF binding. Cation binding, a function of the metal ion-dependent adhesion site (MIDAS) motif, was assessed by terbium luminescence to evaluate conformational perturbations induced by the mutations. All five mutants bound terbium with unaltered affinities. When the five residues were inserted into the alpha(L)I-domain, the chimera bound NIF with high affinity. Another ligand of alpha(M)beta(2) C3bi, which is known to use the same segments of the alpha(M)I-domain in engaging the receptor, failed to bind to the chimeric alpha(L)I-domain. Thus, the alpha(M)I-domain appears to present a mosaic of exposed amino acids within surface loops on its MIDAS face, and different ligands interact with different residues to attain high affinity binding.	Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Cardiol NB50, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Plow, EF (corresponding author), Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	plowe@ccf.org	Ustinov, Valentin/J-6301-2018		NHLBI NIH HHS [HL 66197] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066197] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; Arnaout MA, 2000, KIDNEY INT, V58, P2599, DOI 10.1046/j.1523-1755.2000.00446.x; BARNARD JW, 1995, J IMMUNOL, V155, P4876; BAUER C, 1995, SHOCK, V4, P187, DOI 10.1097/00024382-199509000-00006; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; BJORNHOLM B, 1993, BIOCHEMISTRY-US, V32, P2954; BOHNSACK JF, 1992, J IMMUNOL, V149, P1340; Bouvard D, 2001, CIRC RES, V89, P211, DOI 10.1161/hh1501.094874; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; CARLOS TM, 1994, BLOOD, V84, P2068; CIERNIEWSKI CS, 1994, BIOCHEMISTRY-US, V33, P12238, DOI 10.1021/bi00206a029; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; Dickeson SK, 1998, BIOCHEMISTRY-US, V37, P11280, DOI 10.1021/bi9727848; DIRENZO L, 1991, EUR J IMMUNOL, V21, P1755, DOI 10.1002/eji.1830210726; ELEMER GS, 1994, J IMMUNOL, V152, P5836; Forsyth CB, 1998, J IMMUNOL, V161, P6198; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Leitinger B, 2000, NAT STRUCT BIOL, V7, P614, DOI 10.1038/77895; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Lo SK, 1999, MOL PHARMACOL, V56, P926, DOI 10.1124/mol.56.5.926; LUK CK, 1971, BIOPOLYMERS, V10, P1317, DOI 10.1002/bip.360100806; Madden K, 1997, INFLAMM RES, V46, P216, DOI 10.1007/s000110050176; MALHOTRA V, 1986, EUR J IMMUNOL, V16, P1117, DOI 10.1002/eji.1830160915; McDonald JA, 2000, J BIOL CHEM, V275, P21783, DOI 10.1074/jbc.R000007200; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; Orchekowski RP, 2000, J LEUKOCYTE BIOL, V68, P641; ORTLEPP S, 1995, EUR J IMMUNOL, V25, P637, DOI 10.1002/eji.1830250302; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; ROSS GD, 1982, J EXP MED, V155, P96, DOI 10.1084/jem.155.1.96; Ruoslahti E, 1997, J CLIN INVEST, V99, P1149, DOI 10.1172/JCI119269; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; SCHMALSTIEG FC, 1988, PEDIATR INFECT DIS J, V7, P867; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; Springer T A, 1990, Scand J Immunol, V32, P211, DOI 10.1111/j.1365-3083.1990.tb02912.x; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VAUGHAN DE, 1990, CIRC RES, V67, P1281, DOI 10.1161/01.RES.67.5.1281; VONASMUTH EJU, 1991, J IMMUNOL, V147, P3869; Woska JR, 2001, J LEUKOCYTE BIOL, V70, P329; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; XIE JL, 1995, J IMMUNOL, V155, P3619; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Yakubenko VP, 2001, J BIOL CHEM, V276, P13995, DOI 10.1074/jbc.M010174200; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h; Zhang L, 1996, J BIOL CHEM, V271, P29953, DOI 10.1074/jbc.271.47.29953; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	71	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18769	18776		10.1074/jbc.M110242200	http://dx.doi.org/10.1074/jbc.M110242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11880366	hybrid			2022-12-25	WOS:000175975800070
J	Vlcek, S; Korbei, B; Foisner, R				Vlcek, S; Korbei, B; Foisner, R			Distinct functions of the unique C terminus of LAP2 alpha in cell proliferation and nuclear assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMINA-ASSOCIATED POLYPEPTIDE-2; DREIFUSS MUSCULAR-DYSTROPHY; A-TYPE LAMINS; MEMBRANE PROTEIN; DNA-REPLICATION; LEM-DOMAIN; TRANSCRIPTIONAL REPRESSION; STRUCTURE DYNAMICS; ENVELOPE FORMATION; TARGETING DOMAIN	The non-membrane-bound lamina-associated polypeptide 2 isoform, LAP2alpha, forms nucleoskeletal structures with A-type lamins and interacts with chromosomes in a cell cycle-dependent manner. LAP2alpha contains a LEM (LAP2, emerin, and MAN1) domain in the constant N terminus that binds to chromosomal barrier-to-autointegration factor, and a C-terminal unique region that is essential for chromosome binding. Here we show that C-terminal LAP2alpha fragment efficiently bound to mitotic chromosomes and inhibited assembly of endogenous LAP2alpha, nuclear membranes, and lamins A/C in in vitro nuclear assembly assays. Full-length recombinant LAP2alpha, which bound to chromosomes, and N-terminal fragment, which did not bind, had no effect on assembly. This suggested an essential role for the LAP2alpha C terminus in chromosome association and for the N-terminal LEM domain in subsequent assembly stages. In vivo analysis upon transient expression of GFP-tagged LAP2alpha fragments confirmed that, unlike the N-terminal fragment, the C-terminal fragment was able to bind to chromosomes during mitosis, if expressed weakly. At higher expression levels, C-terminal LAP2alpha fragment and full-length protein led to cell cycle arrest in interphase and apoptosis, as shown by fluorescence-activated cell sorter analysis, time lapse microscopy, and BrdUrd incorporation assays. These data indicated distinct functions of LAP2alpha in cell cycle progression during interphase and in nuclear reassembly during mitosis.	Univ Vienna, Vienna Bioctr, Dept Biochem & Mol Cell Biol, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Foisner, R (corresponding author), Univ Vienna, Vienna Bioctr, Dept Biochem & Mol Cell Biol, Dr Bohrgasse 9, A-1030 Vienna, Austria.		Foisner, Roland/AAD-1833-2019	Foisner, Roland/0000-0003-4734-4647; Korbei, Barbara/0000-0002-0439-0435				Berger R, 1996, GENOME RES, V6, P361, DOI 10.1101/gr.6.5.361; Bonne G, 2000, ANN NEUROL, V48, P170, DOI 10.1002/1531-8249(200008)48:2<170::AID-ANA6>3.0.CO;2-J; BRIDGER JM, 1993, J CELL SCI, V104, P297; Broers JLV, 1999, J CELL SCI, V112, P3463; Buendia B, 1999, J CELL SCI, V112, P1743; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; Burke B, 2001, J CELL BIOL, V153, pF5, DOI 10.1083/jcb.153.3.F5; Cai ML, 2001, EMBO J, V20, P4399, DOI 10.1093/emboj/20.16.4399; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Clements L, 2000, BIOCHEM BIOPH RES CO, V267, P709, DOI 10.1006/bbrc.1999.2023; Cohen M, 2001, TRENDS BIOCHEM SCI, V26, P41, DOI 10.1016/S0968-0004(00)01727-8; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; de la Luna S, 1999, EMBO J, V18, P212, DOI 10.1093/emboj/18.1.212; Dechat T, 2000, J CELL SCI, V113, P3473; Dechat T, 2000, J STRUCT BIOL, V129, P335, DOI 10.1006/jsbi.2000.4212; Dechat T, 1998, EMBO J, V17, P4887, DOI 10.1093/emboj/17.16.4887; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Ellis DJ, 1997, J CELL SCI, V110, P2507; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; Furukawa K, 1997, BIOCHEM BIOPH RES CO, V238, P240, DOI 10.1006/bbrc.1997.7235; Furukawa K, 1999, J CELL SCI, V112, P2485; Furukawa K, 1998, J BIOL CHEM, V273, P4213, DOI 10.1074/jbc.273.7.4213; Gant TM, 1999, J CELL BIOL, V144, P1083, DOI 10.1083/jcb.144.6.1083; Gotzmann J, 1999, CRIT REV EUKAR GENE, V9, P257, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.100; Gotzmann J, 2000, J CELL SCI, V113, P3769; Gruenbaum Y, 2000, J STRUCT BIOL, V129, P313, DOI 10.1006/jsbi.2000.4216; Haraguchi T, 2000, J CELL SCI, V113, P779; HARRIS CA, 1994, P NATL ACAD SCI USA, V91, P6283, DOI 10.1073/pnas.91.14.6283; HOZAK P, 1995, J CELL SCI, V108, P635; Hutchison CJ, 2001, J CELL SCI, V114, P9; Jagatheesan G, 1999, J CELL SCI, V112, P4651; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Laguri C, 2001, STRUCTURE, V9, P503, DOI 10.1016/S0969-2126(01)00611-6; Lang C, 1999, J CELL SCI, V112, P749; Lavia P, 1999, BIOESSAYS, V21, P221; LenzBohme B, 1997, J CELL BIOL, V137, P1001, DOI 10.1083/jcb.137.5.1001; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; Moir RD, 2000, J CELL BIOL, V149, P1179, DOI 10.1083/jcb.149.6.1179; Moir RD, 2000, J CELL BIOL, V151, P1155, DOI 10.1083/jcb.151.6.1155; Morris GE, 1999, HUM MOL GENET, V8, P1847, DOI 10.1093/hmg/8.10.1847; Nagano A, 2000, CURR OPIN NEUROL, V13, P533, DOI 10.1097/00019052-200010000-00005; Neri LM, 1999, J CELL PHYSIOL, V178, P284, DOI 10.1002/(SICI)1097-4652(199903)178:3<284::AID-JCP2>3.0.CO;2-P; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; Nili E, 2001, J CELL SCI, V114, P3297; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Sakaki M, 2001, J BIOCHEM-TOKYO, V129, P321, DOI 10.1093/oxfordjournals.jbchem.a002860; Schirmer EC, 2001, J CELL BIOL, V153, P479, DOI 10.1083/jcb.153.3.479; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; Spann TP, 1997, J CELL BIOL, V136, P1201, DOI 10.1083/jcb.136.6.1201; Steen RL, 2001, J CELL BIOL, V153, P621, DOI 10.1083/jcb.153.3.621; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Vlcek S, 1999, EMBO J, V18, P6370, DOI 10.1093/emboj/18.22.6370; Wilson KL, 2000, TRENDS CELL BIOL, V10, P125, DOI 10.1016/S0962-8924(99)01708-0; Wilson KL, 2001, CELL, V104, P647, DOI 10.1016/S0092-8674(02)01452-6; Wolff N, 2001, FEBS LETT, V501, P171, DOI 10.1016/S0014-5793(01)02649-7; Yang L, 1997, J CELL BIOL, V139, P1077, DOI 10.1083/jcb.139.5.1077	61	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18898	18907		10.1074/jbc.M200048200	http://dx.doi.org/10.1074/jbc.M200048200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11864981	hybrid			2022-12-25	WOS:000175975800085
J	Moriarity, JL; Hurt, KJ; Resnick, AC; Storm, PB; Laroy, W; Schnaar, RL; Snyder, SH				Moriarity, JL; Hurt, KJ; Resnick, AC; Storm, PB; Laroy, W; Schnaar, RL; Snyder, SH			UDP-glucuronate decarboxylase, a key enzyme in proteoglycan synthesis - Cloning, characterization, and localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; HEPARAN-SULFATE PROTEOGLYCANS; CAENORHABDITIS-ELEGANS; EPITHELIAL INVAGINATION; ENDOPLASMIC-RETICULUM; TOUT-VELU; DROSOPHILA; BIOSYNTHESIS; GLYCOSYLATION; PURIFICATION	UDP-glucuronate decarboxylase (UGD) catalyzes the formation of UDP-xylose from UDP-glucuronate. UDP-xylose is then used to initiate glycosaminoglycan biosynthesis on the core protein of proteoglycans. In a yeast two-hybrid screen with the protein kinase Akt (protein kinase B), we detected interactions with a novel sequence, which we cloned and expressed. The expressed protein displayed UGD activity but did not display the activities of homologous nucleotide sugar epimerases or dehydratases. We did not detect phosphorylation of UGD by Akt nor did we detect any influence of Akt on UGD activity. Effects of UGD on Akt kinase activity were also absent. Northern blot and Western blot analyses revealed the presence of UGD in multiple tissues and brain regions. Subcellular studies and histochemistry localized UGD protein to the perinuclear Golgi where xylosylation of proteoglycan core proteins is known to occur.	Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Neurol Surg, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Snyder, SH (corresponding author), Johns Hopkins Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Hurt, K. Joseph/J-8266-2019; Schnaar, Ronald L/S-8967-2016	Hurt, K. Joseph/0000-0001-6906-350X; Schnaar, Ronald L/0000-0002-7701-5484	NIDA NIH HHS [DA-00074] Funding Source: Medline; NIMH NIH HHS [MH18501, MH20062] Funding Source: Medline; NINDS NIH HHS [NS37096] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, T32MH020062, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037096, R37NS037096] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANKEL H, 1965, BIOCHEMISTRY-US, V4, P2468, DOI 10.1021/bi00887a028; ANKEL H, 1966, BIOCHEMISTRY-US, V5, P182, DOI 10.1021/bi00865a024; Bar-Peled M, 2001, P NATL ACAD SCI USA, V98, P12003, DOI 10.1073/pnas.211229198; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Jackson SM, 1997, DEVELOPMENT, V124, P4113; JOHN KV, 1977, J BIOL CHEM, V252, P6707; JOHN KV, 1977, J BIOL CHEM, V252, P8013; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Ma YF, 2001, ANTIMICROB AGENTS CH, V45, P1407, DOI 10.1128/AAC.45.5.1407-1416.2001; MANDELES S, 1966, ANAL BIOCHEM, V17, P540, DOI 10.1016/0003-2697(66)90189-8; NG WG, 1967, NATURE, V214, P283, DOI 10.1038/214283a0; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; Prydz K, 2000, J CELL SCI, V113, P193; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; SHEARS SB, 1997, SIGNALLING INOSITIDE; SILBERT JE, 1967, BIOCHIM BIOPHYS ACTA, V141, P193, DOI 10.1016/0304-4165(67)90263-2; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6294, DOI 10.1021/bi970025j; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; VARA JA, 1988, J BIOL CHEM, V263, P14992; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; ZARKOWSKY H, 1969, J BIOL CHEM, V244, P4750	41	59	61	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16968	16975		10.1074/jbc.M109316200	http://dx.doi.org/10.1074/jbc.M109316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877387	hybrid			2022-12-25	WOS:000175564500084
J	Karkkainen, M; Oka, T; Olkkonen, VM; Metso, J; Hattori, H; Jauhiainen, M; Ehnholm, C				Karkkainen, M; Oka, T; Olkkonen, VM; Metso, J; Hattori, H; Jauhiainen, M; Ehnholm, C			Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; CHOLESTEROL; DISEASE; FRAMINGHAM; CONVERSION; EXCHANGE; MICE	Plasma phospholipid transfer protein (PLTP) plays an important role in lipoprotein metabolism. Two forms of PLTP exist in human plasma, one catalytically active (high activity form, HA-PLTP) and the other inactive (low activity form, LA-PLTP) (Oka, T., Kujiraoka, T., Ito, M., Egashira, T., Takahashi, S., Nanjee, N. M., Miller, N. E., Metso, J., Olkkonen, V. M., Ehnhohn, C., Jauhiainen, M., and Hattori, H. (2000) J. Lipid Res. 41, 1651-1657). The two forms are associated with macromolecular complexes of different size. The apparent size of LA-PLTP is 520 kDa and that of HA-PLTP is 160 kDa. Of the circulating PLTP mass only a minor portion is in the HA-PLTP form in normolipidemic subjects. In the present study we have isolated and partially characterized the LA and HA forms of PLTP. Both LA- and HA-PLTP bind to heparin-Sepharose and can be separated by elution with 0-0.5 M NaCl gradient, with HA-PLTP displaying higher affinity for the matrix. LA-PLTP was further purified using hydrophobic butyl-Sepharose and anti-PLTP immunoaffinity chromatography steps. HA-PLTP was subjected to a second heparin-Sepharose step and hydroxylapatite chromatography. Analysis of the two forms of PLTP by SDS-PAGE, Western blotting, immunoprecipitation, and gel filtration demonstrates that LA-PLTP is complexed with apoA-I whereas HA-PLTP is not. Instead, HA-PLTP copurified with apoE. Based on these findings we suggest a model in which nascent PLTP enters the circulation as a high specific activity form not associated with apoA-I. During or after the transfer of lipolytic surface remnants to HDL, PLTP is transferred to apoA-I-containing HDL particles and thereby becomes part of the low activity complex.	Natl Publ Hlth Inst, Dept Mol Med, Biomedicum, FIN-00251 Helsinki, Finland; BML Inc, Ctr Res & Dev, Div Res, Kawagoe, Saitama 3501101, Japan	Finland National Institute for Health & Welfare; BML, Inc.	Ehnholm, C (corresponding author), Natl Publ Hlth Inst, Dept Mol Med, Biomedicum, POB 104,Haartmaninkatu 8, FIN-00251 Helsinki, Finland.			Olkkonen, Vesa/0000-0001-5553-7997				Barlage S, 2001, J LIPID RES, V42, P281; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; DAY JR, 1994, J BIOL CHEM, V269, P9388; Desrumaux C, 1999, ARTERIOSCL THROM VAS, V19, P266, DOI 10.1161/01.ATV.19.2.266; Ehnholm S, 1998, J LIPID RES, V39, P1248; FIELDING CJ, 1995, J LIPID RES, V36, P211; HALL WH, 1993, JAMA-J AM MED ASSOC, V269, P505; Huuskonen J, 1998, J LIPID RES, V39, P2021; Huuskonen J, 1999, J LIPID RES, V40, P1123; Huuskonen J, 2000, CURR OPIN LIPIDOL, V11, P285, DOI 10.1097/00041433-200006000-00009; Huuskonen J, 2000, ATHEROSCLEROSIS, V151, P451, DOI 10.1016/S0021-9150(99)00429-3; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Jiang XC, 1998, J BIOL CHEM, V273, P15714, DOI 10.1074/jbc.273.25.15714; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KANNEL WB, 1983, AM J CARDIOL, V52, pB9, DOI 10.1016/0002-9149(83)90649-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Oka T, 2000, CLIN CHEM, V46, P1357; Oka T, 2000, J LIPID RES, V41, P1651; Pussinen PJ, 1998, J LIPID RES, V39, P152; TALL AR, 1983, J BIOL CHEM, V258, P2174; TALL AR, 1985, J LIPID RES, V26, P842; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TU AY, 1993, J BIOL CHEM, V268, P23098; van Haperen R, 2000, ARTERIOSCL THROM VAS, V20, P1082, DOI 10.1161/01.ATV.20.4.1082	30	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15413	15418		10.1074/jbc.M112247200	http://dx.doi.org/10.1074/jbc.M112247200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854286	hybrid			2022-12-25	WOS:000175510400026
J	Lyle, JM; Clewell, A; Richmond, K; Richards, OC; Hope, DA; Schultz, SC; Kirkegaard, K				Lyle, JM; Clewell, A; Richmond, K; Richards, OC; Hope, DA; Schultz, SC; Kirkegaard, K			Similar structural basis for membrane localization and protein priming by an RNA-dependent RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; ACTING REPLICATION ELEMENT; SITE-DIRECTED MUTAGENESIS; POLIOVIRUS RNA; ENZYMATIC-ACTIVITY; 3D POLYMERASE; IN-VITRO; 3AB; IDENTIFICATION; VPG	Protein primers are used to initiate genomic synthesis of several RNA and DNA viruses, although the structural details of the primer-polymerase interactions are not yet known. Poliovirus polymerase binds with high affinity to the membrane-bound viral protein 3AB but uridylylates only the smaller peptide 3B in vitro. Mutational analysis of the polymerase identified four surface residues on the three-dimensional structure of poliovirus polymerase whose wild-type identity is required for 3AB binding. These mutants also decreased 3B uridylylation, arguing that the binding sites for the membrane tether and the protein primer overlap. Mutation of flanking residues between the 3AB binding site and the polymerase active site specifically decreased 3B uridylylation, likely affecting steps subsequent to binding. The physical overlap of sites for protein priming and membrane association should facilitate replication initiation in the membrane-associated complex.	Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	Stanford University; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Kirkegaard, K (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Sch Med, 299 Campus Dr, Stanford, CA 94305 USA.	karlak@stanford.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042119] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-42119] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARCO A, 1995, GENE, V156, P19, DOI 10.1016/0378-1119(94)00872-P; BAROUDY BM, 1982, CELL, V28, P315, DOI 10.1016/0092-8674(82)90349-X; Barton DJ, 1996, VIROLOGY, V217, P459, DOI 10.1006/viro.1996.0140; Beckman MTL, 1998, J BIOL CHEM, V273, P6724, DOI 10.1074/jbc.273.12.6724; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BURNS CC, 1992, VIROLOGY, V189, P568, DOI 10.1016/0042-6822(92)90580-I; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Chen JB, 2000, J VIROL, V74, P4310, DOI 10.1128/JVI.74.9.4310-4318.2000; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; DATTA U, 1994, J VIROL, V68, P4468, DOI 10.1128/JVI.68.7.4468-4477.1994; DELANGE AM, 1986, J VIROL, V59, P249, DOI 10.1128/JVI.59.2.249-259.1986; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; Dufour E, 2000, J MOL BIOL, V304, P289, DOI 10.1006/jmbi.2000.4216; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; Goodfellow I, 2000, J VIROL, V74, P4590, DOI 10.1128/JVI.74.10.4590-4600.2000; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Hobson SD, 2001, EMBO J, V20, P1153, DOI 10.1093/emboj/20.5.1153; HOBSON SD, 2000, THESIS U COLORADO; Hope DA, 1997, J VIROL, V71, P9490, DOI 10.1128/JVI.71.12.9490-9498.1997; JABLONSKI SA, 1991, J VIROL, V65, P4565, DOI 10.1128/JVI.65.9.4565-4572.1991; JABLONSKI SA, 1993, J VIROL, V67, P373, DOI 10.1128/JVI.67.1.373-381.1993; Jager Joachim, 1999, Current Opinion in Structural Biology, V9, P21, DOI 10.1016/S0959-440X(99)80004-9; Ke SH, 1997, NUCLEIC ACIDS RES, V25, P3371, DOI 10.1093/nar/25.16.3371; Kim MJ, 2000, J VIROL, V74, P10312, DOI 10.1128/JVI.74.22.10312-10322.2000; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMA J, 1994, J BIOL CHEM, V269, P66; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; PATA JD, 1995, RNA, V1, P466; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; PAUL AV, 1994, J BIOL CHEM, V269, P29173; PLOTCH SJ, 1995, J VIROL, V69, P7169, DOI 10.1128/JVI.69.11.7169-7179.1995; Richards OC, 1998, J BIOL CHEM, V273, P12832, DOI 10.1074/jbc.273.21.12832; Rieder E, 2000, J VIROL, V74, P10371, DOI 10.1128/JVI.74.22.10371-10380.2000; Rodriguez-Wells V, 2001, NUCLEIC ACIDS RES, V29, P2715, DOI 10.1093/nar/29.13.2715; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; Teterina NL, 2001, J VIROL, V75, P3841, DOI 10.1128/JVI.75.8.3841-3850.2001; Towner JS, 1998, J VIROL, V72, P7191, DOI 10.1128/JVI.72.9.7191-7200.1998; Towner JS, 1996, J BIOL CHEM, V271, P26810, DOI 10.1074/jbc.271.43.26810; Wittschieben J, 1998, NUCLEIC ACIDS RES, V26, P490, DOI 10.1093/nar/26.2.490; Xiang WK, 1998, J VIROL, V72, P6732, DOI 10.1128/JVI.72.8.6732-6741.1998; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhu CX, 1998, J BIOL CHEM, V273, P8783, DOI 10.1074/jbc.273.15.8783	50	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16324	16331		10.1074/jbc.M112429200	http://dx.doi.org/10.1074/jbc.M112429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877407	hybrid			2022-12-25	WOS:000175510400143
J	Ma, D; Nelson, LS; LeCoz, K; Poole, C; Carlow, CKS				Ma, D; Nelson, LS; LeCoz, K; Poole, C; Carlow, CKS			A novel cyclophilin from parasitic and free-living nematodes with a unique substrate- and drug-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; MOLECULAR-WEIGHT CYCLOPHILIN; A-INSENSITIVE CYCLOPHILIN; X-RAY STRUCTURE; CYCLOSPORINE-A; BRUGIA-MALAYI; CAENORHABDITIS-ELEGANS; TOXOPLASMA-GONDII; BIOCHEMICAL-CHARACTERIZATION; SCHISTOSOMA-MANSONI	A highly diversified member of the cyclophilin family of peptidyl-prolyl cis-trans isomerases has been isolated from the human parasite Onchocerea volvulus (OvCYP-16). This 25-kDa cyclophilin shares 43-46% similarity to other filarial cyclophilins but does not belong to any of the groups previously defined in invertebrates or vertebrates. A homolog was also isolated from Caenorhabditis elegans (CeCYP-16). Both recombinant O. volvulus and C. elegans cyclophilins were found to possess an enzyme activity with similar substrate preference and insensitivity to cyclosporin A. They represent novel cyclophilins with important differences in the composition of the drug-binding site in particular, namely, a Glu(124) (C. elegans) or Asp(123) (O. volvulus) residue present in a critical position. Site-directed mutagenesis studies and kinetic characterization demonstrated that the single residue dictates the degree of binding to substrate and cyclosporin A. CeCYP-16::GFP-expressing lines were generated with expression in the anterior and posterior distal portions of the intestine, in all larval stages and adults. An exception was found in the dauer stage, where fluorescence was observed in both the cell bodies and processes of the ventral chord motor neurons but was absent from the intestine. These studies highlight the extensive diversification of cyclophilins in an important human parasite and a closely related model organism.	New England Biolabs Inc, Beverly, MA 01915 USA		Carlow, CKS (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.							BELL A, 1994, BIOCHEM PHARMACOL, V48, P495, DOI 10.1016/0006-2952(94)90279-8; BRENNER S, 1974, GENETICS, V77, P71; BUEDING E, 1981, AGENTS ACTIONS, V11, P380, DOI 10.1007/BF01982474; CHAPPELL LH, 1993, J CELL BIOCHEM     S, V17, P114; Ellis PJ, 2000, BIOCHEMISTRY-US, V39, P592, DOI 10.1021/bi991730q; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GRANDEA AG, 1989, MOL BIOCHEM PARASIT, V35, P31, DOI 10.1016/0166-6851(89)90139-4; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HIGH KP, 1994, J BIOL CHEM, V269, P9105; Hong XQ, 1998, MOL BIOCHEM PARASIT, V91, P353, DOI 10.1016/S0166-6851(97)00219-3; Hong XQ, 1998, EXP PARASITOL, V88, P246, DOI 10.1006/expr.1998.4226; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; Lizotte-Waniewski M, 2000, INFECT IMMUN, V68, P3491, DOI 10.1128/IAI.68.6.3491-3501.2000; Ma D, 1998, MOL BIOCHEM PARASIT, V92, P361, DOI 10.1016/S0166-6851(98)00006-1; Ma D, 1996, MOL BIOCHEM PARASIT, V79, P235, DOI 10.1016/0166-6851(96)02654-0; MACK DG, 1984, ANTIMICROB AGENTS CH, V26, P26, DOI 10.1128/AAC.26.1.26; MCCABE RE, 1986, TRANSPLANTATION, V41, P611, DOI 10.1097/00007890-198605000-00012; Mikol V, 1998, PROTEIN SCI, V7, P1310, DOI 10.1002/pro.5560070606; MUNRO GH, 1990, PARASITOLOGY, V100, P19, DOI 10.1017/S0031182000060078; MUNRO GH, 1990, PARASITOLOGY, V100, P29, DOI 10.1017/S003118200006008X; Page AP, 1996, BIOCHEM J, V317, P179, DOI 10.1042/bj3170179; Page AP, 1999, MOL BIOCHEM PARASIT, V99, P301, DOI 10.1016/S0166-6851(99)00044-4; PAGE AP, 1995, BIOCHEMISTRY-US, V34, P11545, DOI 10.1021/bi00036a030; Page AP, 1998, MOL BIOCHEM PARASIT, V95, P215, DOI 10.1016/S0166-6851(98)00096-6; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; Sambrook J., 2002, MOL CLONING LAB MANU; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; TAKACS AM, 1988, P NATL ACAD SCI USA, V85, P7932, DOI 10.1073/pnas.85.21.7932; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Taylor P, 1998, FEBS LETT, V425, P361, DOI 10.1016/S0014-5793(98)00264-6; THOMMENSCOTT K, 1981, AGENTS ACTIONS, V11, P770, DOI 10.1007/BF01978803; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALSH CT, 1992, J BIOL CHEM, V267, P13115; Wood WB, 1988, NEMATODE CAENORHABDI; ZAHNER H, 1987, J HELMINTHOL, V61, P282, DOI 10.1017/S0022149X0001018X	42	13	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14925	14932		10.1074/jbc.M112293200	http://dx.doi.org/10.1074/jbc.M112293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847225	hybrid			2022-12-25	WOS:000175203000074
J	Dilling, MB; Germain, GS; Dudkin, L; Jayaraman, AL; Zhang, XW; Harwood, FC; Houghton, PJ				Dilling, MB; Germain, GS; Dudkin, L; Jayaraman, AL; Zhang, XW; Harwood, FC; Houghton, PJ			4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITE; P70 S6 KINASE; RNA 5 CAP; C-MYC; TRANSLATION INITIATION; PHAS-I; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; MALIGNANT-TRANSFORMATION; RHABDOMYOSARCOMA CELLS; MAMMALIAN PROTEIN	To determine whether inhibition of either the ribosomal p70 S6 kinase or eukaryotic initiation factor (eIF) 4E pathways downstream of the mammalian target of rapamycin, mTOR, contributes to rapamycin-induced growth arrest, clones of Rh30 rhabdomyosarcoma cells were selected for rapamycin resistance. Expression of c-Myc and anchorage-independent growth were enhanced in resistant cells. Resistance was unstable in each of three clones characterized. In resistant cells, as compared with parental cells, similar to10-fold less 4E-binding protein (4E-BP) was bound to eIF4E, and total cellular 4E-BP was markedly reduced. Levels of eIF4E were unchanged. Steady-state levels of 4E-BP transcript remained unaltered, but the rate of 4E-BP synthesis was reduced in resistant cells. In cells that reverted to rapamycin sensitivity, levels of total 4E-BP returned to those of parental cells. Compared with parental cells, resistant clones had either similar or lower levels and activity of ribosomal p70 S6 kinase, but c-Myc levels were elevated in both resistant and revertant clones. Several colon carcinoma cell lines with intrinsic rapamycin resistance were found to have low 4E-BP:eIF4E ratios. In stable clones of HCT8 carcinoma engineered to overexpress 4E-BP, rapamycin sensitivity increased markedly (>1000-fold) as 4E-BP expression increased. These results suggest that the 4E-BP:eIF4E ratio is an important determinant of rapamycin resistance and controls certain aspects of the malignant phenotype.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Houghton, PJ (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.houghton@stjude.org	Houghton, Peter/E-3265-2011		NATIONAL CANCER INSTITUTE [P30CA021765, P01CA023099, R25CA023944, R01CA077776] Funding Source: NIH RePORTER; NCI NIH HHS [CA77776, R25 CA023944, CA23099, CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 1999, CANCER RES, V59, P2615; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; Beamish H, 1996, ONCOGENE, V13, P963; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CAFFERKEY R, 1994, GENE, V141, P133, DOI 10.1016/0378-1119(94)90141-4; Carter PS, 1999, ONCOGENE, V18, P4326, DOI 10.1038/sj.onc.1202890; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DILLING MB, 1994, CANCER RES, V54, P903; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; DUMONT FJ, 1995, CELL IMMUNOL, V163, P70, DOI 10.1006/cimm.1995.1100; Freeman K, 1996, GENE, V172, P143, DOI 10.1016/0378-1119(96)00168-0; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hosoi H, 1999, CANCER RES, V59, P886; HOUGHTON PJ, 1989, P NATL ACAD SCI USA, V86, P1377, DOI 10.1073/pnas.86.4.1377; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; KOSER PL, 1993, GENE, V129, P159, DOI 10.1016/0378-1119(93)90264-4; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Marx SO, 1999, MOL CELL BIOL, V19, P6041; McKendrick L, 1999, INT J BIOCHEM CELL B, V31, P31, DOI 10.1016/S1357-2725(98)00129-0; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Seufferlein T, 1996, CANCER RES, V56, P3895; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Sonenberg Nahum, 1993, Gene Expression, V3, P317; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Sugiyama H, 1996, J IMMUNOL, V157, P656; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426	52	91	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13907	13917		10.1074/jbc.M110782200	http://dx.doi.org/10.1074/jbc.M110782200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11847216	hybrid			2022-12-25	WOS:000175096000074
J	Sun, L; Adebanjo, OA; Koval, A; Anandatheerthavarada, HK; Iqbal, J; Wu, XY; Moonga, BS; Wu, XB; Biswas, G; Bevis, PJR; Kumegawa, M; Epstein, S; Huang, CLH; Avadhani, NG; Abe, E; Zaidi, M				Sun, L; Adebanjo, OA; Koval, A; Anandatheerthavarada, HK; Iqbal, J; Wu, XY; Moonga, BS; Wu, XB; Biswas, G; Bevis, PJR; Kumegawa, M; Epstein, S; Huang, CLH; Avadhani, NG; Abe, E; Zaidi, M			A novel mechanism for coupling cellular intermediary metabolism to cytosolic Ca2+ signaling via CD38/ADP-ribosyl cyclase, a putative intracellular NAD(+) sensor	FASEB JOURNAL			English	Article						endoplasmic reticulum; ryanodine receptor; myristoylation; osteoblasts	CYCLIC ADP-RIBOSE; TRANSMEMBRANE GLYCOPROTEIN CD38; ENDOPLASMIC-RETICULUM; INSULIN-SECRETION; OUTER SURFACE; HYDROLYSIS; PROTEIN; INTERNALIZATION; INACTIVATION; MITOCHONDRIA	CD38 is an ectocyclase that converts NAD(+) to the Ca2+ -releasing second messenger cyclic ADP- ribose (cADPr). Here we report that in addition to CD38 ecto- catalysis, intracellularly expressed CD38 may catalyze NAD(+) --> cADPr conversion to cause cytosolic Ca2+ release. High levels of CD38 were found in the plasma membranes, endoplasmic reticulum, and nuclear membranes of osteoblastic MC3T3- E1 cells. More important, intracellular CD38 was colocalized with target ryanodine receptors. The cyclase also converted a NAD(+) surrogate, NGD(+), to its fluorescent product, cGDPr (K-m similar to5.13 muM). NAD(+) also triggered a cytosolic Ca2+ signal. Similar results were obtained with NIH3T3 cells, which overexpressed a CD38- EGFP fusion protein. The Delta(-49) - CD38- EGFP mutant with a deleted amino- terminal tail and transmembrane domain appeared mainly in the mitochondria with an expected loss of its membrane localization, but the NAD(+) -induced cytosolic Ca2+ signal was preserved. Likewise, Ca2+ release persisted in cells transfected with the Myr-Delta(-49) -CD38- EGFP or Delta(-49) -CD38- EGFP- Fan mutants, both directed to the plasma membrane but in an opposite topology to the full- length CD38- EGFP. Finally, ryanodine inhibited Ca2+ signaling, indicating the downstream activation of ryanodine receptors by cADPr. We conclude that intracellularly expressed CD38 might link cellular NAD(+) production to cytosolic Ca2+ signaling.	Mt Sinai Bone Program, Dept Med, New York, NY 10029 USA; Mt Sinai Bone Program, Dept Geriatr, New York, NY 10029 USA; Bronx Vet Affairs Geriatr Res Educ & Clin Ctr, New York, NY 10029 USA; Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA; Physiol Lab, Cambridge CB2 3EG, England; Meikai Univ, Kawagoe, Saitama, Japan	Geriatric Research Education & Clinical Center; University of Pennsylvania; University of Cambridge; Meikai University	Zaidi, M (corresponding author), Mt Sinai Sch Med, Div Endocrinol, POB 1055,Annenberg 5,1 Gustave Levy Pl, New York, NY 10029 USA.	mone.zaidi@mssm.edu	Huang, Christopher LH/A-6248-2008		NCI NIH HHS [CA 22762] Funding Source: Medline; NIA NIH HHS [R01 AG14917-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022762, R37CA022762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; ADDAYA S, 1999, J CELL BIOL, V139, P589; Adebanjo OA, 1999, NAT CELL BIOL, V1, P409, DOI 10.1038/15640; Adebanjo OA, 2000, AM J PHYSIOL-RENAL, V278, pF784, DOI 10.1152/ajprenal.2000.278.5.F784; Adebanjo OA, 1996, AM J PHYSIOL-RENAL, V270, pF469, DOI 10.1152/ajprenal.1996.270.3.F469; Anandatheerthavarada HK, 1999, J BIOL CHEM, V274, P6617, DOI 10.1074/jbc.274.10.6617; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Berthelier V, 1998, BIOCHEM J, V330, P1383, DOI 10.1042/bj3301383; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Bruzzone S, 1998, FEBS LETT, V433, P275, DOI 10.1016/S0014-5793(98)00929-6; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; De Flora A, 2000, CHEM IMMUNOL, V75, P79; De Flora Antonio, 1998, Cell Biochemistry and Biophysics, V28, P45; Deaglio S, 1998, J IMMUNOL, V160, P395; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; Ferrero E, 2000, CHEM IMMUNOL, V75, P1; Franco L, 1998, FASEB J, V12, P1507; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; LEE CL, 2000, HUMAN CD38 RELATED M, P39; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; Liang M, 1999, ARCH BIOCHEM BIOPHYS, V371, P317, DOI 10.1006/abbi.1999.1463; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Morita K, 1997, J BIOL CHEM, V272, P21002, DOI 10.1074/jbc.272.34.21002; Munshi CB, 1997, METHOD ENZYMOL, V280, P318; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; Sun L, 1999, J CELL BIOL, V146, P1161, DOI 10.1083/jcb.146.5.1161; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Yamada M, 1997, BRAIN RES, V756, P52, DOI 10.1016/S0006-8993(97)00117-0; ZAIDI M, 1995, J CLIN INVEST, V96, P1582, DOI 10.1172/JCI118197; Ziegler M, 1997, BIOCHEM J, V326, P401, DOI 10.1042/bj3260401; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	43	54	60	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0302	10.1096/fj.01-0705com	http://dx.doi.org/10.1096/fj.01-0705com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874980				2022-12-25	WOS:000174755900023
J	Seo, YR; Fishel, ML; Amundson, S; Kelley, MR; Smith, ML				Seo, YR; Fishel, ML; Amundson, S; Kelley, MR; Smith, ML			Implication of p53 in base excision DNA repair: in vivo evidence	ONCOGENE			English	Article						p53; DNA-repair; polymerase-beta	DAMAGE; PROTEIN; CELLS; SENSITIVITY; FIBROBLASTS; EXPRESSION; MUTATIONS; AGENTS; GADD45; REF-1	The tumor suppressor p53 plays an important role in response to DNA damage, including DNA repair. One DNA repair pathway, nucleotide excision repair (NER), has been well-documenteav6d to be regulated by p53. It seemed probable that p53 may affect other DNA repair pathways. We employed matched isogenic pairs of cell lines, wild-type or p53-deficient, to investigate this question using methyl methanesulfonate (MMS), a base-damaging agent. Alkylation damage induced by MMS is repaired exclusively by the base excision repair (BER) pathway. Cells carrying mutant or no p53 genes exhibited slow BER of MMS-induced DNA damage, and exhibited MMS-sensitivity. One contributing factor is the abundance of DNA polymerase beta (beta-pol), an enzyme required for BER, which was almost absent in p53 mutant and p53-null cells. Our findings demonstrate an in vivo requirement for p53 in regulating the base excision repair response, a novel finding of great potential importance in understanding the DNA repair branch of the p53 pathway.	Indiana Univ, Ctr Canc, Dept Microbiol, Walther Oncol Ctr,Sch Med, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN USA; Indiana Univ, Ctr Canc, Dept Biochem, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Wells Ctr Pediat Oncol, Indianapolis, IN 46202 USA; NCI, Bethesda, MD 20892 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Smith, ML (corresponding author), Indiana Univ, Ctr Canc, Dept Microbiol, Walther Oncol Ctr,Sch Med, 1044 W Walnut,R-155, Indianapolis, IN 46202 USA.		Fishel, Melissa L./AAH-6608-2020	Fishel, Melissa L./0000-0002-9436-6382; Kelley, Mark/0000-0002-6120-9532				Brown JM, 1999, CANCER RES, V59, P1391; COLLINS AR, 1995, MUTAT RES-DNA REPAIR, V336, P69, DOI 10.1016/0921-8777(94)00043-6; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; FAN SJ, 1995, CANCER RES, V55, P1649; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Fortini P, 2000, NUCLEIC ACIDS RES, V28, P3040, DOI 10.1093/nar/28.16.3040; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hawkins DS, 1996, CANCER RES, V56, P892; Hollander MC, 2001, CANCER RES, V61, P2487; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Morris EJ, 1999, BIOTECHNIQUES, V26, P282, DOI 10.2144/99262st02; Offer H, 2001, CANCER RES, V61, P88; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Okorokov AL, 1999, MOL CELL BIOL, V19, P7501; SEO YR, 2001, IN PRESS BREAST CANC; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	29	89	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					731	737		10.1038/sj.onc.1205129	http://dx.doi.org/10.1038/sj.onc.1205129			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850801				2022-12-25	WOS:000173427000004
J	Locke, D; Chen, H; Liu, Y; Liu, CD; Kahn, ML				Locke, D; Chen, H; Liu, Y; Liu, CD; Kahn, ML			Lipid rafts orchestrate signaling by the platelet receptor glycoprotein VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; DURISSUS-TERRIFICUS VENOM; SRC FAMILY KINASES; T-CELL ACTIVATION; MEMBRANE DOMAINS; GAMMA-CHAIN; TYROSINE PHOSPHORYLATION; COLLAGEN RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; AGGREGATING PROTEIN	The platelet collagen receptor glycoprotein VI (GPVI) couples to the immune receptor adaptor Fc receptor gamma-chain (FcRgamma) and signals using many of the same intracellular signaling molecules as immune receptors. Studies of immune receptor signaling have revealed a critical role for specialized areas of the cell membrane known as lipid rafts, which are enriched in essential signaling molecules. However, the role of lipid rafts in signaling in nonimmune cells such as platelets remains poorly defined. This study shows that GPVI-FcRgamma does not constitutively associate with rafts, but is recruited to lipid rafts following receptor stimulation in both GPVI-expressing RBL-2H3 cells and human platelets. FcRgamma is required for GPVI association with lipid rafts, as mutant GPVI receptors that do not couple to FcRgamma were unable to associate with lipid rafts after receptor clustering. Following GPVI stimulation in platelets, virtually all phosphorylated FcRgamma was found in lipid rafts, but inhibition of FcRgamma phosphorylation did not block receptor association with lipid rafts. This work demonstrates that lipid rafts orchestrate GPVI receptor signaling in platelets in a manner analogous to immune cell receptors and supports a model of GPVI signaling in which FcRgamma phosphorylation is controlled by ligand-dependent association with lipid rafts.	Univ Penn, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Kahn, ML (corresponding author), Univ Penn, Dept Med, Div Cardiol, BRB 2-3,Rm 952,421 Curie Blvd, Philadelphia, PA 19104 USA.							Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; Broudy VC, 1998, BLOOD, V91, P898, DOI 10.1182/blood.V91.3.898.898_898_906; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Chen H, 2002, J BIOL CHEM, V277, P3011, DOI 10.1074/jbc.M109714200; Cicmil M, 2000, J BIOL CHEM, V275, P27339; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; Dorahy DJ, 1998, BIOCHEM J, V333, P373, DOI 10.1042/bj3330373; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Field KA, 1999, J BIOL CHEM, V274, P1753, DOI 10.1074/jbc.274.3.1753; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Holowka D, 2001, SEMIN IMMUNOL, V13, P99, DOI 10.1006/smim.2000.0301; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; JUDD BA, 2002, IN PRESS; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; Leduc M, 1998, BIOCHEM J, V333, P389, DOI 10.1042/bj3330389; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; MARLAS G, 1983, BIOCHIMIE, V65, P619; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Pierini L, 1996, J CELL BIOL, V134, P1427, DOI 10.1083/jcb.134.6.1427; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Watson S. P., 1996, PLATELETS PRACTICAL; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200	41	83	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18801	18809		10.1074/jbc.M111520200	http://dx.doi.org/10.1074/jbc.M111520200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11844795	hybrid			2022-12-25	WOS:000175975800074
J	Engblom, AC; Carlson, BX; Olsen, RW; Schousboe, A; Kristiansen, U				Engblom, AC; Carlson, BX; Olsen, RW; Schousboe, A; Kristiansen, U			Point mutation in the first transmembrane region of the beta 2 subunit of the gamma-aminobutyric acid type a receptor alters desensitization kinetics of gamma-aminobutyric acid- and anesthetic-induced channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA(A) RECEPTORS; RECOMBINANT HUMAN; LINING RESIDUES; AMINO-ACID; DEACTIVATION; BENZODIAZEPINE; ACTIVATION; RESPONSES; RHO-1; IDENTIFICATION	A conserved glycine residue in the first transmembrane (TM1) domain of the beta2 subunit has been identified to be involved with desensitization induced by gamma-aminobutyric acid (GABA) and anesthetics. Recombinant GABA(A) receptors expressed in Sf9 cells were recorded using semi-fast agonist application. Upon direct activation by GABA or anesthetics, the main effect of the TM1 point mutation on the beta2 subunit (G219F) was to slow the time constant (tau) of desensitization. At GABA concentrations eliciting maximum currents, the corresponding median tau values were 0.87 s (25-75% interval (0.76; 1.04 s)), 0.93 s (0.76; 1.23 s), and 1.36 s (1.17; 1.57 s) for alpha1beta2gamma2, alpha1(G223F)beta2gamma2, and alpha1beta2(G219F)gamma2, respectively. The tau value for the beta2-mutant receptor was significantly longer than alpha1beta2gamma2 (p<0.01) and alpha 1(G223F)beta 2 gamma 2 (p<0.05). For pentobarbital-induced currents (500 muM), the corresponding median tau values were 1.36 s (0.81; 1.41 s), 1.47 s (1.31; 2.38 s), and 2.82 s (2.21; 5.56 s) for alpha1beta2gamma2, alpha1(G223F)beta2gamma2, and alpha1beta2(G219F)gamma2, respectively. The tau value for the beta2-mutant receptor was significantly longer than that for alpha1beta2gamma2 (p<0.01). The present findings suggest that this TM1 glycine residue is critical for the rate at which desensitization occurs and that both GABA and intravenous anesthetics implement an analogous pathway for generating desensitization.	Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Royal Danish School of Pharmacy; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kristiansen, U (corresponding author), Royal Danish Sch Pharm, Dept Pharmacol, Univ Pk 2, DK-2100 Copenhagen, Denmark.	uk@dfh.dk		Schousboe, Arne/0000-0001-9600-402X; Kristiansen, Uffe/0000-0001-9050-7806	NINDS NIH HHS [NS28772] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028772] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; Akk G, 2000, BRIT J PHARMACOL, V130, P249, DOI 10.1038/sj.bjp.0703335; Amin J, 1999, MOL PHARMACOL, V55, P411; Bai DL, 1999, J NEUROSCI, V19, P10635, DOI 10.1523/JNEUROSCI.19-24-10635.1999; Belelli D, 1997, P NATL ACAD SCI USA, V94, P11031, DOI 10.1073/pnas.94.20.11031; Belelli D, 1999, TRENDS PHARMACOL SCI, V20, P496, DOI 10.1016/S0165-6147(99)01405-4; Bianchi MT, 2001, J NEUROSCI, V21, P1127; Carlson BX, 2000, MOL PHARMACOL, V57, P474, DOI 10.1124/mol.57.3.474; Chang YC, 1999, BIOPHYS J, V77, P2542, DOI 10.1016/S0006-3495(99)77089-X; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; Dalziel JE, 2000, MOL PHARMACOL, V57, P875; Elster L, 2001, NEUROCHEM INT, V38, P581, DOI 10.1016/S0197-0186(00)00122-4; Findlay GS, 2001, NEUROSCI LETT, V305, P76, DOI 10.1016/S0304-3940(01)01879-1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Kristiansen U, 1996, NEUROPHARMACOLOGY, V35, P1181, DOI 10.1016/S0028-3908(96)00070-6; KUSAMA T, 1993, BRIT J PHARMACOL, V109, P200, DOI 10.1111/j.1476-5381.1993.tb13554.x; Lavoie AM, 1997, BIOPHYS J, V73, P2518, DOI 10.1016/S0006-3495(97)78280-8; LI W, 2000, J NEUROSCI, V20, P898; Lobitz N, 2001, MOL PHARMACOL, V59, P844, DOI 10.1124/mol.59.4.844; Lu L, 1998, J MEMBRANE BIOL, V164, P115, DOI 10.1007/s002329900398; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Martinez-Torres A, 2000, P NATL ACAD SCI USA, V97, P3562, DOI 10.1073/pnas.050582397; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Moody EJ, 1997, J NEUROCHEM, V69, P1310; Renard S, 1999, J BIOL CHEM, V274, P13370, DOI 10.1074/jbc.274.19.13370; SANNA E, 1995, J PHARMACOL EXP THER, V274, P353; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; Thompson SA, 1999, BRIT J PHARMACOL, V127, P1349, DOI 10.1038/sj.bjp.0702687; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zhu WJ, 1997, J NEUROSCI, V17, P4022	31	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17438	17447		10.1074/jbc.M111215200	http://dx.doi.org/10.1074/jbc.M111215200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877425	hybrid			2022-12-25	WOS:000175685100009
J	Smith, E; Coetzee, GA; Frenkel, B				Smith, E; Coetzee, GA; Frenkel, B			Glucocorticoids inhibit cell cycle progression in differentiating osteoblasts via glycogen synthase kinase-3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; TRANSCRIPTION FACTOR; C-MYC; SUBCELLULAR-LOCALIZATION; SUBSTRATE-SPECIFICITY; INDUCED OSTEOPOROSIS; SIGNAL-TRANSDUCTION; KINASE 3-BETA; IN-VIVO; LITHIUM	Differentiating osteoblasts in culture undergo a commitment stage, during which cobblestone-like cells grow to high density past confluency. In contrast to earlier proliferative stages, the cell cycle during this commitment stage is inhibited by glucocorticoids (GC). Chronic GC treatment also impedes mineral deposition if steroid administration commences early enough during commitment. This study defines a role for glycogen synthase kinase-3beta (GSK3beta) and its target, c-Myc, in the GC-sensitive osteoblast persistent cell cycle. c-Myc levels decreased as cells reached confluence, but then increased during growth to high density. GC administration at this stage resulted in down-regulation of c-Myc. This was accompanied by GC-mediated attenuation of GSK3beta Ser(9) inhibitory phosphorylation and increased GSK3beta kinase activity. Down-regulation of c-Myc was attributable to enhanced Thr(58) phosphorylation, leading to accelerated degradation. In contrast, GC did not inhibit the c-Myc synthesis rate or the level of beta-catenin, a transcriptional coactivator of c-myc. The attenuated cell cycle and the reduced c-Myc level were returned to control levels by specific inhibition of GSK3beta using lithium chloride. These results suggest that tonal GSK3beta repression at the cobblestone stage of osteoblast differentiation permits osteoblast growth to high density. GC interfere with this growth-permissive axis by GSK3beta activation, resulting in c-Myc down-regulation and impediment of the G(1)/S cell cycle transition.	Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Orthoped Surg, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Urol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California	Frenkel, B (corresponding author), Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, 2250 Alcazar St,CSC IGM240, Los Angeles, CA 90033 USA.		coetzee, Gerhard/AAT-6203-2020; Coetzee, Gerhard/AAG-8439-2019	Coetzee, Gerhard/0000-0001-8820-8364	NATIONAL CANCER INSTITUTE [T32CA009659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047052] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09659] Funding Source: Medline; NIAMS NIH HHS [R01-AR47052] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aizawa T, 1999, J BONE JOINT SURG BR, V81B, P921, DOI 10.1302/0301-620X.81B5.9492; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BROULIK PD, 1984, CLIN CHIM ACTA, V140, P151, DOI 10.1016/0009-8981(84)90339-5; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; GOLD MR, 1995, INT REV CYTOL, V157, P181, DOI 10.1016/S0074-7696(08)62159-2; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Haden ST, 1997, J CLIN ENDOCR METAB, V82, P2844, DOI 10.1210/jc.82.9.2844; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Hobmayer B, 2000, NATURE, V407, P186, DOI 10.1038/35025063; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Liang JD, 1999, CALCIFIED TISSUE INT, V65, P369, DOI 10.1007/s002239900715; Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756-3282(96)00138-X; Lukert Barbara P., 1996, P533; MADIEHE AM, 1995, BIOCHEM BIOPH RES CO, V209, P768, DOI 10.1006/bbrc.1995.1565; Mak TWL, 1998, J CLIN ENDOCR METAB, V83, P3857, DOI 10.1210/jc.83.11.3857; Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061; MILLER AD, 1984, CELL, V36, P51; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PULVERER BJ, 1994, ONCOGENE, V9, P59; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	49	73	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18191	18197		10.1074/jbc.M109708200	http://dx.doi.org/10.1074/jbc.M109708200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877389	hybrid			2022-12-25	WOS:000175685100101
J	Zuhorn, IS; Kalicharan, R; Hoekstra, D				Zuhorn, IS; Kalicharan, R; Hoekstra, D			Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC LIPOSOMES; GENE DELIVERY; DNA COMPLEXES; CAVEOLAE; EFFICIENT; ENTRY; INTERNALIZATION; INHIBITION; DEPLETION; REVEALS	Synthetic amphiphiles are widely used as a carrier system. However, to match transfection efficiencies as obtained for viral vectors, further insight is required into the properties of lipoplexes that dictate transfection efficiency, including the mechanism of delivery. Although endocytosis is often referred to as the pathway of lipoplex entry and transfection, its precise nature has been poorly defined. Here, we demonstrate that lipoplex-mediated transfection is inhibited by more than 80%, when plasma membrane cholesterol is depleted with methyl-beta-cyclodextrin. Cholesterol replenishment restores the transfection capacity. Investigation of the cellular distribution of lipoplexes after cholesterol depletion revealed an exclusive inhibition of internalization, whereas cell-association remained unaffected. These data strongly support the notion that complex internalization, rather than the direct translocation of plasmid across the plasma membrane, is a prerequisite for accomplishing effective lipoplex-mediated transfection. We demonstrate that internalized lipoplexes colocalize with transferrin in early endocytic compartments and that lipoplex internalization is inhibited in potassium-depleted cells and in cells overexpressing dominant negative Eps15 mutants. In conjunction with the notion that eaveolae-mediated internalization can be excluded, we conclude that efficient lipoplex-mediated transfection requires complex internalization via the cholesterol-dependent clathrin-mediated pathway of endocytosis.	Univ Groningen, Dept Membrane Cell Biol, NL-9713 AV Groningen, Netherlands; Univ Groningen, Lab Cell Biol & Electron Microscopy, NL-9713 EZ Groningen, Netherlands	University of Groningen; University of Groningen	Hoekstra, D (corresponding author), Univ Groningen, Dept Membrane Cell Biol, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	d.hoekstra@med.rug.nl		Zuhorn, Inge/0000-0002-7695-915X				Audouy S, 2000, J GENE MED, V2, P465, DOI 10.1002/1521-2254(200011/12)2:6<465::AID-JGM141>3.0.CO;2-Z; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; Boleti H, 1999, J CELL SCI, V112, P1487; Castanho MARB, 1999, BBA-BIOMEMBRANES, V1419, P1, DOI 10.1016/S0005-2736(99)00049-8; CROWTHER RA, 1976, J MOL BIOL, V103, P785, DOI 10.1016/0022-2836(76)90209-6; Erbacher P, 1996, EXP CELL RES, V225, P186, DOI 10.1006/excr.1996.0169; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Francis SA, 1999, EUR J CELL BIOL, V78, P473, DOI 10.1016/S0171-9335(99)80074-0; Friend DS, 1996, BBA-BIOMEMBRANES, V1278, P41, DOI 10.1016/0005-2736(95)00219-7; Fujimoto T, 2000, J CELL SCI, V113, P3509; FUJITA H, 1981, HISTOCHEMISTRY, V73, P57, DOI 10.1007/BF00493133; Godbey WT, 1999, P NATL ACAD SCI USA, V96, P5177, DOI 10.1073/pnas.96.9.5177; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Koval M, 1998, EXP CELL RES, V242, P265, DOI 10.1006/excr.1998.4110; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; MATLIN KS, 1982, J MOL BIOL, V156, P609, DOI 10.1016/0022-2836(82)90269-8; Meekel AAP, 2000, EUR J ORG CHEM, V2000, P665; MONTESANO R, 1981, J CELL SCI, V51, P95; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Oberle V, 2000, BIOPHYS J, V79, P1447, DOI 10.1016/S0006-3495(00)76396-X; Ohvo H, 1996, BIOCHEMISTRY-US, V35, P8018, DOI 10.1021/bi9528816; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; Pires P, 1999, BBA-BIOMEMBRANES, V1418, P71, DOI 10.1016/S0005-2736(99)00023-1; Pouton CW, 1998, J CONTROL RELEASE, V53, P289, DOI 10.1016/S0168-3659(98)00015-7; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Shi FX, 2001, NUCLEIC ACIDS RES, V29, P2079, DOI 10.1093/nar/29.10.2079; Shin JS, 2001, SCIENCE, V293, P1447, DOI 10.1126/science.1061079; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; STEGMANN T, 1997, BIOCHIM BIOPHYS ACTA, V3, P71; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; VanDerWoude I, 1997, P NATL ACAD SCI USA, V94, P1160, DOI 10.1073/pnas.94.4.1160; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; WROBEL I, 1995, BBA-BIOMEMBRANES, V1235, P296, DOI 10.1016/0005-2736(95)80017-A; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; ZUHORN IS, 2002, BIOCHIM BIOPHYS ACTA, P1	46	276	283	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18021	18028		10.1074/jbc.M111257200	http://dx.doi.org/10.1074/jbc.M111257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11875062	hybrid			2022-12-25	WOS:000175685100080
J	Akhtar, S; Shamotienko, O; Papakosta, M; Ali, F; Dolly, JO				Akhtar, S; Shamotienko, O; Papakosta, M; Ali, F; Dolly, JO			Characteristics of brain Kv1 channels tailored to mimic native counterparts by tandem linkage of alpha subunits - Implications for K+ channelopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNELS; RAT-BRAIN; VOLTAGE-DEPENDENCE; SENSORY NEURONS; BETA-SUBUNITS; ION CHANNELS; DENDROTOXIN; EXPRESSION; SUBTYPES; IDENTIFICATION	Most neuronal Kv1 channels contain Kvl.1, Kv1.2 alpha, and Kvbeta2.1 subunits, yet the influences of their stoichiometries on properties of the (alpha)(4)(beta)(4) variants remain undefined. cDNAs were engineered to contain 0, 1, 2, or 4 copies of Kvl.1 with the requisite number of Kv1.2 and co-expressed in mammalian cells with Kvbeta2.1 to achieve "native-like" hetero-oligomers. The monomeric (Kv1.1 or 1.2), dimeric (Kv1.1-1.2 or 1.2-1.2), and tetrameric (Kv1.1-(1.2)(3)) constructs produced proteins Of M-r similar to62,000, 120,000, and 240,000, which assembled into (alpha)(4)(beta)(4) complexes. Each alpha cRNA yielded a distinct K+ current in oocytes, with voltage dependence of activation being shifted negatively as the Kv1.1 content in tetramers was increased. Channels containing 1, 2, or 4 copies of Kv1.1 were blocked by dendrotoxin k (DTX)(k) with similarly high potencies, whereas Kv(1.2)(4) proved nonsusceptible. Accordingly, Kv1.2/beta2.1 expressed in baby hamster kidney cells failed to bind DTXk; in contrast, oligomers containing only one Kv1.1 subunit in a tetramer exhibited high affinity, with additional copies causing modest increases. Thus, one Kv1.1 subunit largely confers high affinity for DTXk, whereas channel electrophysiological properties are tailored by the content of Kv1.1 relative to Kv1.2. This notable advance could explain the diversity of symptoms of human episodic ataxia 1, which is often accompanied by myokymia, due to mutated Kv1.1 being assembled in different combinations with wild-type and Kv1.2.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ctr Neurobiochem, London SW7 2AY, England	Imperial College London	Dolly, JO (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ctr Neurobiochem, Exhibit Rd,S Kensington, London SW7 2AY, England.	o.dolly@ic.ac.uk	Dolly, Oliver/G-1532-2012; Dolly, Oliver/ABH-6677-2020	Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320				Adelman JP, 1995, NEURON, V15, P1449, DOI 10.1016/0896-6273(95)90022-5; Akhtar S, 1999, BIOCHEMISTRY-US, V38, P16984, DOI 10.1021/bi992114x; AWAN KA, 1991, NEUROSCIENCE, V40, P29, DOI 10.1016/0306-4522(91)90172-K; BROWNE DL, 1995, HUM MOL GENET, V4, P1671, DOI 10.1093/hmg/4.9.1671; COCHRAN SM, 1997, BRIT J PHARMACOL, V122, P256; Coleman SK, 1999, J NEUROCHEM, V73, P849, DOI 10.1046/j.1471-4159.1999.0730849.x; D'Adamo MC, 1998, EMBO J, V17, P1200, DOI 10.1093/emboj/17.5.1200; Dolly JO, 1996, J BIOENERG BIOMEMBR, V28, P231, DOI 10.1007/BF02110698; DOLLY JO, 1984, J PHYSIOL-PARIS, V79, P280; Gamkrelidze G, 1998, J NEUROSCI, V18, P1449; Gasparini S, 1998, J BIOL CHEM, V273, P25393, DOI 10.1074/jbc.273.39.25393; Gold MS, 1996, J NEUROPHYSIOL, V75, P2629, DOI 10.1152/jn.1996.75.6.2629; HALL A, 1994, BRIT J PHARMACOL, V113, P959, DOI 10.1111/j.1476-5381.1994.tb17086.x; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; Hollerer-Beitz G, 1999, PFLUG ARCH EUR J PHY, V438, P141, DOI 10.1007/s004240050891; Hopkins WF, 1998, J PHARMACOL EXP THER, V285, P1051; HURST RS, 1991, MOL PHARMACOL, V40, P572; Imredy JP, 2000, J MOL BIOL, V296, P1283, DOI 10.1006/jmbi.2000.3522; KEIGHLEY WW, 1994, J PHYSIOL-LONDON, V480P, pP68; Koschak A, 1998, J BIOL CHEM, V273, P2639, DOI 10.1074/jbc.273.5.2639; Lehmann-Horn F, 1999, PHYSIOL REV, V79, P1317, DOI 10.1152/physrev.1999.79.4.1317; Main MJ, 1998, FEBS LETT, V441, P6, DOI 10.1016/S0014-5793(98)01507-5; McIntosh P, 1997, PFLUG ARCH EUR J PHY, V435, P43, DOI 10.1007/s004240050482; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; Rasband M, 1998, J NEUROSCI, V18, P36; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Schweitz H, 1999, PERSPECT DRUG DISCOV, V16, P83; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; Shamotienko O, 1999, BIOCHEMISTRY-US, V38, P16766, DOI 10.1021/bi991039n; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; STANSFELD CE, 1986, NEUROSCI LETT, V64, P299, DOI 10.1016/0304-3940(86)90345-9; STOCKER M, 1991, P ROY SOC B-BIOL SCI, V245, P101, DOI 10.1098/rspb.1991.0094; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TYTGAT J, 1995, J BIOL CHEM, V270, P24776, DOI 10.1074/jbc.270.42.24776; Varshney A, 2000, NEUROREPORT, V11, P2913, DOI 10.1097/00001756-200009110-00017; Wang FC, 1999, EUR J BIOCHEM, V263, P230, DOI 10.1046/j.1432-1327.1999.00493.x; Wang FC, 1999, EUR J BIOCHEM, V263, P222, DOI 10.1046/j.1432-1327.1999.00494.x; Wang H, 1995, NEURON, V15, P1337, DOI 10.1016/0896-6273(95)90012-8; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	42	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16376	16382		10.1074/jbc.M109698200	http://dx.doi.org/10.1074/jbc.M109698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859070	hybrid			2022-12-25	WOS:000175564500006
J	Hsu, YY; Wang, YH				Hsu, YY; Wang, YH			Human fragile site FRA16B DNA excludes nucleosomes in the presence of distamycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROOVE BINDING LIGANDS; MENTAL-RETARDATION; CORE PARTICLES; CGG REPEAT; X SYNDROME; SEQUENCE; INSTABILITY; CHROMATIN; ALTER; RECONSTITUTION	Human fragile sites are weak staining gaps in chromosomes generated by specific culture conditions. The short CGG repeating DNA derived from folate-sensitive fragile sites has been shown to exclude single nucleosomes. To test whether this nucleosome exclusion model provides a general molecular mechanism for the formation of fragile sites, a different class of fragile site, the 33-base pair AT-rich repeating DNAs derived from the rare distamycin-inducible site, FRA16B, was examined for its ability to assemble single nucleosomes and nucleosome arrays using in vitro nucleosome reconstitution methods. The FRA16B DNA fragments strongly exclude nucleosome assembly only in the presence of distamycin, and increasing the number of 33-bp repeats increases the effect of distamycin in the destabilization of the nucleosome formation, suggesting a common mechanism for the formation of fragile sites.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Wang, YH (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.				NCI NIH HHS [CA85826, R01 CA085826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABUDAYA A, 1995, NUCLEIC ACIDS RES, V23, P3385, DOI 10.1093/nar/23.17.3385; Brown PM, 1996, J MOL BIOL, V262, P671, DOI 10.1006/jmbi.1996.0544; Bulger M., 1994, METH MOL G, V5, P241; Chen FM, 1998, BIOCHEMISTRY-US, V37, P11143, DOI 10.1021/bi980950l; CHURCHILL MEA, 1990, BIOCHEMISTRY-US, V29, P6043, DOI 10.1021/bi00477a023; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; DEKABAN A, 1965, J NUCL MED, V6, P740; FOX KR, 1984, NUCLEIC ACIDS RES, V12, P9271, DOI 10.1093/nar/12.24.9271; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; Godde JS, 1996, J BIOL CHEM, V271, P24325, DOI 10.1074/jbc.271.40.24325; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; Kirkpatrick DT, 1999, MOL CELL BIOL, V19, P7661; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P3296, DOI 10.1021/bi00359a032; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; LOW CML, 1986, NUCLEIC ACIDS RES, V14, P6785, DOI 10.1093/nar/14.17.6785; Loyola A, 2001, GENE DEV, V15, P2837; Mann DB, 1997, P NATL ACAD SCI USA, V94, P2215, DOI 10.1073/pnas.94.6.2215; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; POPESCU NC, 1994, CRIT REV ONCOGENESIS, V5, P121, DOI 10.1615/CritRevOncog.v5.i2-3.20; PORTUGAL J, 1987, NUCLEIC ACIDS RES, V15, P885, DOI 10.1093/nar/15.3.885; PORTUGAL J, 1987, FEBS LETT, V225, P195, DOI 10.1016/0014-5793(87)81156-0; PORTUGAL J, 1986, NUCLEIC ACIDS RES, V14, P8735, DOI 10.1093/nar/14.22.8735; SUTHERLAND GR, 1991, GENET ANAL-BIOMOL E, V8, P161, DOI 10.1016/1050-3862(91)90056-W; SUTHERLAND GR, 1984, AM J HUM GENET, V36, P110; VANDYKE MW, 1982, P NATL ACAD SCI-BIOL, V79, P5470; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; Wang YH, 1996, P NATL ACAD SCI USA, V93, P8863, DOI 10.1073/pnas.93.17.8863; Wang YH, 1996, J BIOL CHEM, V271, P22937, DOI 10.1074/jbc.271.38.22937; Wang YH, 1996, J MOL BIOL, V263, P511, DOI 10.1006/jmbi.1996.0593; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17315	17319		10.1074/jbc.M200901200	http://dx.doi.org/10.1074/jbc.M200901200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880377	hybrid			2022-12-25	WOS:000175564500127
J	Lin, TH; Lai, HL; Kao, YY; Sun, CN; Hwang, MJ; Chern, YJ				Lin, TH; Lai, HL; Kao, YY; Sun, CN; Hwang, MJ; Chern, YJ			Protein kinase C inhibits type VI adenylyl cyclase by phosphorylating the regulatory N domain and two catalytic C1 and C2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; RECEPTOR; BINDING; DESENSITIZATION; IDENTIFICATION; ACTIVATION; REGION; SITES	We previously showed that phosphorylation of Ser(10) of the N terminus domain of the type VI adenylyl cyclase (ACVI) partly mediated protein kinase C (PKC)-induced inhibition of ACVI. We now report that phosphorylation of the other two cytosolic domains (C1 and C2), which form the catalytic core complex of ACVI, also contributes to PKC-mediated inhibition. In vitro phosphorylation by PKC of the recombinant C1a and C2 domains, and of the synthetic peptides representing potential PKC phosphorylation sites, suggests that Ser(568) and Ser(674) of the C1 domain and Thr(931) of the C2 domain might act as substrates for PKC. We next created several full-length ACVI mutants in which one or more of the four likely PKC phosphorylation sites (Ser(10), Ser(568), Ser(674), and Thr(931)) were mutated to alanine. Simultaneous mutation of at least two of the three likely residues located in the N and C1 domains (Ser(10), Ser(568), and Ser(674)) was required to render ACVI variants completely insensitive to PKC treatment. In contrast, a single mutation of Thr(931) was sufficient to create a functional ACVI mutant that exhibited no detectable PKC-mediated inhibition, demonstrating the essentiality of Thr(931), to PKC-mediated regulation. Based on these results, we propose that the three cytosolic domains of ACVI might form a regulatory complex. Phosphorylation of this regulatory complex at different sites might induce a fine-tuning of the catalytic core complex and subsequently lead to alternation in the catalytic activity of ACVI.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Chung Shan Med Univ, Dept Life Sci, Taichung 402, Taiwan; Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan	Academia Sinica - Taiwan; Chung Shan Medical University; National Yang Ming Chiao Tung University	Chern, YJ (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.		chern, yijuang/S-7013-2018; Hwang, Ming-jing/E-9210-2012	chern, yijuang/0000-0002-5842-5429; Hwang, Ming-jing/0000-0002-9657-5663; Lin, Ting-Hui/0000-0001-9669-362X				Bol GF, 1997, BIOCHEM BIOPH RES CO, V237, P251, DOI 10.1006/bbrc.1997.7123; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; CHERN YJ, 1993, MOL PHARMACOL, V44, P950; CHERN YJ, 1995, MOL PHARMACOL, V48, P1; Chern YJ, 2000, CELL SIGNAL, V12, P195, DOI 10.1016/S0898-6568(99)00084-4; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; GLANTZ SA, 1997, PRIMER BIOSTATISTICS, P99; GRAFF JM, 1989, J BIOL CHEM, V264, P2818; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; Gu C, 2001, CURR BIOL, V11, P185, DOI 10.1016/S0960-9822(01)00044-6; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; Lai HL, 1999, MOL PHARMACOL, V56, P644, DOI 10.1124/mol.56.3.644; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; Liu FC, 1998, FEBS LETT, V436, P92, DOI 10.1016/S0014-5793(98)01098-9; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Miyakawa Y, 2000, J BIOL CHEM, V275, P32214, DOI 10.1074/jbc.M005080200; Parent CA, 2002, J BIOL CHEM, V277, P1354, DOI 10.1074/jbc.M106430200; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Tan CM, 2001, BIOCHEMISTRY-US, V40, P1702, DOI 10.1021/bi0015818; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Weitmann S, 1999, BIOCHEMISTRY-US, V38, P3409, DOI 10.1021/bi982229l; Wu GC, 2001, J BIOL CHEM, V276, P35450, DOI 10.1074/jbc.M009704200; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; Yan SZ, 2001, J BIOL CHEM, V276, P8500, DOI 10.1074/jbc.M010361200; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941	35	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15721	15728		10.1074/jbc.M111537200	http://dx.doi.org/10.1074/jbc.M111537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877398	hybrid			2022-12-25	WOS:000175510400068
J	Pandya, K; Townes, TM				Pandya, K; Townes, TM			Basic residues within the Kruppel zinc finger DNA binding domains are the critical nuclear localization determinants of EKLF/KLF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; FACTOR EKLF; GLOBIN TRANSGENE; LAC REPRESSOR; 3 FINGERS; PROTEINS; SIGNALS; GENE; EXPRESSION; TRANSACTIVATION	EKLF/KLF-1 is an erythroid-restricted transcription factor essential for expression of the adult beta-globin gene. EKLF/KLF-1 is a 358-amino acid nuclear protein with an amino-terminal proline-rich domain and a carboxyl-terminal DNA binding domain. The nuclear localization signal (NLS) of EKLF/KLF-1 has not been empirically determined. We generated a series of epitope-tagged deletion and point mutants and assessed their subcellular localization. Our results delimit the NLS to the 83-amino acid (amino acids 276-358) DNA binding domain that consists of three Kruppel zinc fingers. All three zinc fingers are necessary for efficient nuclear localization; deletion of any individual finger results in cytoplasmic accumulation. Fusion of the three zinc fingers to green fluorescent protein (GFP) targeted GFP to the nucleus, demonstrating that the zinc finger domain is sufficient for nuclear localization. EKLF/KLF-1 containing histidine to alanine mutations that disrupt the structure of all three fingers retains appropriate nuclear localization, indicating that neither the tertiary structure of the zinc fingers nor specific DNA binding are necessary for nuclear localization. We demonstrate that basic residues within the fingers are the critical determinants for nuclear localization; mutations of these basic residues to alanine resulted in cytoplasmic mislocalization. The basic residues of all mammalian Kruppel zinc fingers are highly conserved; therefore we propose that these basic residues are a common NLS shared by all Kruppel family members.	Univ Alabama, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Townes, TM (corresponding author), Univ Alabama, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.							Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Brown RC, 2002, MOL CELL BIOL, V22, P161, DOI 10.1128/MCB.22.1.161-170.2002; Bruening W, 1996, FEBS LETT, V393, P41, DOI 10.1016/0014-5793(96)00853-8; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; GREENWOOD JA, 1995, EXP CELL RES, V220, P332, DOI 10.1006/excr.1995.1323; Guy LG, 2000, J BIOL CHEM, V275, P3675, DOI 10.1074/jbc.275.5.3675; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kuwahara J, 1999, NUCL ACIDS S SER, V42, P293; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; MATHENY C, 1994, J BIOL CHEM, V269, P8176; NEDVED ML, 1994, NUCLEIC ACIDS RES, V22, P4705, DOI 10.1093/nar/22.22.4705; NISHI K, 1994, J BIOL CHEM, V269, P6320; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Pandya K, 2001, J BIOL CHEM, V276, P8239, DOI 10.1074/jbc.M008457200; Perkins A, 1999, INT J BIOCHEM CELL B, V31, P1175, DOI 10.1016/S1357-2725(99)00083-7; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 2000, BLOOD, V95, P1827, DOI 10.1182/blood.V95.5.1827.004k10_1827_1833; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Phillips RS, 2002, J BIOL CHEM, V277, P11606, DOI 10.1074/jbc.M111457200; REVZIN A, 1977, BIOCHEMISTRY-US, V16, P4769, DOI 10.1021/bi00641a002; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shimojo M, 2001, J BIOL CHEM, V276, P13121, DOI 10.1074/jbc.M011193200; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Yang ML, 1999, J BIOL CHEM, V274, P27399, DOI 10.1074/jbc.274.39.27399; Yu Z, 1998, J ENDOCRINOL, V159, P53, DOI 10.1677/joe.0.1590053	32	64	66	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16304	16312		10.1074/jbc.M200866200	http://dx.doi.org/10.1074/jbc.M200866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11844803	hybrid			2022-12-25	WOS:000175510400141
J	Salim, K; Fenton, T; Bacha, J; Urien-Rodriguez, H; Bonnert, T; Skynner, HA; Watts, E				Salim, K; Fenton, T; Bacha, J; Urien-Rodriguez, H; Bonnert, T; Skynner, HA; Watts, E			Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GABA(B) RECEPTOR; SEROTONIN 5-HT1B; MESSENGER-RNA; CELLS; BRAIN; HETERODIMERIZATION; IDENTIFICATION; DIMERIZATION; COEXPRESSION; CORTEX	Recent studies have shown that G-protein-coupled receptors (GPCRs) can assemble as high molecular weight homo- and hetero-oligomeric complexes. This can result in altered receptor-ligand binding, signaling, or intracellular trafficking. We have co-transfected HEK-293 cells with differentially epitope-tagged GPCRs from different subfamilies and determined whether oligomeric complexes were formed by co-immunoprecipitation and immunoblot analysis. This gave the surprising result that the 5HT(1A) receptor was capable of forming hetero-oligomers with all GPCRs tested including the 5HT(1B), 5HT(1D), EDG(1), EDG(3), GPR(26), and GABA(B2) receptors. The testing of other GPCR combinations showed similar results with hetero-oligomer formation occurring for the 5HT(1D) with the 5HT(1B) and EDG(1) receptor. Control studies showed that these complexes were present in co-transfected cells before the time of lysis and that the hetero-oligomers were comprised of GPCRs at discrete stoichiometries. These findings suggest that GPCRs have a natural tendency to form oligomers when co-transfected into cells. Future studies should therefore investigate the presence and physiological role of GPCR hetero-oligomers in cells in which they are endogenously expressed.	Merck Sharp & Dohme Ltd, Dept Biochem & Mol Biol, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England	Merck & Company	Salim, K (corresponding author), Merck Sharp & Dohme Ltd, Dept Biochem & Mol Biol, Neurosci Res Ctr, Terlings Pk, Harlow CM20 2QR, Essex, England.			Fenton, Tim/0000-0002-4737-8233; guest, paul/0000-0002-5030-7137				Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Bonaventure P, 1998, NEUROSCIENCE, V82, P469; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Davis LG, 1994, BASIC METHODS MOL BI; Durkin MM, 1999, MOL BRAIN RES, V71, P185, DOI 10.1016/S0169-328X(99)00182-5; FINK K, 1995, N-S ARCH PHARMACOL, V352, P451; Fukushima Y, 1997, FEBS LETT, V409, P283, DOI 10.1016/S0014-5793(97)00531-0; GUEST PC, 1991, ENDOCRINOLOGY, V129, P734, DOI 10.1210/endo-129-2-734; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DK, 2000, BIOCHIM BIOPHYS ACTA, V149, P311; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Singer II, 2001, J VIROL, V75, P3779, DOI 10.1128/JVI.75.8.3779-3790.2001; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Xie XD, 1999, FEBS LETT, V456, P63, DOI 10.1016/S0014-5793(99)00918-7; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7	29	89	112	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15482	15485		10.1074/jbc.M201539200	http://dx.doi.org/10.1074/jbc.M201539200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854302	hybrid, Green Accepted			2022-12-25	WOS:000175510400036
J	Inoue, T; Stuart, J; Leno, R; Maki, CG				Inoue, T; Stuart, J; Leno, R; Maki, CG			Nuclear import and export signals in control of the p53-related protein p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; KINASE C-ABL; P53 PROTEIN; DNA-DAMAGE; APOPTOTIC RESPONSE; SPONTANEOUS TUMORS; MDM2; LOCALIZATION; P63; DEGRADATION	The p53-family of proteins, including p53, p63, and p73, shares a high degree of structural similarity and can carry out some redundant functions. However, mechanisms that regulate the localization and activity of these proteins have not been fully clarified. In this study, a nuclear localization signal (NLS) was identified in p73, which is required for p73 nuclear import and which could promote the nuclear import of a heterologous, cytoplasmic protein. Mutants lacking the NLS localized to the cytoplasm and displayed diminished transcriptional activity. A nuclear export signal (NES) was also recognized in p73s C terminus, the deletion of which caused p73 to display a more nuclear localization pattern. This NES was sensitive to leptomycin B and could function as an independent export signal when fused to a heterologous protein. Interestingly, p73 mutant proteins lacking the NLS or the NES were more stable than wild-type p73, suggesting that nuclear import and nuclear export are required for efficient p73 degradation. Our results indicate that p73 localization is controlled by both nuclear import and export and suggest that the overall distribution of p73 is likely to result from the balance between these two processes. Proper control of nuclear import and export is likely to be an important regulatory determinant of p73.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Maki, CG (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,4th Floor, Boston, MA 02115 USA.				NCI NIH HHS [1R01CA80918-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gong JG, 1999, NATURE, V399, P806; Gu JJ, 2001, CANCER RES, V61, P6703; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Inoue T, 2001, J BIOL CHEM, V276, P45255, DOI 10.1074/jbc.M107477200; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Liang SH, 1999, ONCOGENE, V18, P2163, DOI 10.1038/sj.onc.1202350; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	31	46	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15053	15060		10.1074/jbc.M200248200	http://dx.doi.org/10.1074/jbc.M200248200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847229	hybrid			2022-12-25	WOS:000175203000089
J	Smoyer, WE; Ransom, RF				Smoyer, WE; Ransom, RF			Hsp27 regulates podocyte cytoskeletal changes in an in vitro model of podocyte process retraction	FASEB JOURNAL			English	Article						actin; stress fibers; nephrotic syndrome; puromycin aminonucleoside	HEAT-SHOCK PROTEIN; PUROMYCIN AMINONUCLEOSIDE NEPHROSIS; GLOMERULAR EPITHELIAL-CELLS; ACTIN POLYMERIZATION; CELLULAR THERMORESISTANCE; CONFERS RESISTANCE; OXIDATIVE STRESS; PHOSPHORYLATION; EXPRESSION; ORGANIZATION	Nephrotic syndrome (NS) is characterized by structural changes in the actin- rich foot processes of glomerular podocytes. We previously identified high concentrations of the small heat shock protein hsp27 within podocytes as well as increased glomerular accumulation and phosphorylation of hsp27 in puromycin aminonucleoside (PAN) -induced experimental NS. Here we analyzed murine podocytes stably transfected with hsp27 sense, antisense, and vector control constructs using a newly developed in vitro PAN model system. Cell morphology and the microfilament structure of untreated sense and antisense transfectants were altered compared with controls. Vector cell survival, polymerized actin content, cell area, and hsp27 content increased after 1.25 mug/ ml PAN treatment and decreased after 5.0 mug/ ml treatment. In contrast, sense cells were unaffected by 1.25 mug/ ml PAN treatment whereas antisense cells showed decreases or no changes in all parameters. Treatment of sense cells with 5.0 mug/ ml PAN resulted in increased cell survival and cell area whereas antisense cells underwent significant decreases in all parameters. Hsp27 provided dramatic protection against PAN- induced microfilament disruption in sense > vector > antisense cells. We conclude that hsp27 is able to regulate both the morphological and actin cytoskeletal response of podocytes in an in vitro model of podocyte injury.	Univ Michigan, Med Ctr, Pediat Nephrol Div, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Ransom, RF (corresponding author), Univ Michigan, Med Ctr, Pediat Nephrol Div, 8220D MSRB 3,Box 0646,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	rransom@umich.edu			NIDDK NIH HHS [K08 DK02455-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002455] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PM, 1984, ANAT REC, V210, P1, DOI 10.1002/ar.1092100102; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; CAULFIELD JP, 1976, LAB INVEST, V34, P43; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FARQUHAR MG, 1957, J EXP MED, V106, P649, DOI 10.1084/jem.106.5.649; FISHMAN JA, 1985, AM J PATHOL, V118, P398; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; GLASSOCK RJ, 1988, NEPHROTIC SYNDROME, P163; Hara M, 1998, AM J NEPHROL, V18, P35, DOI 10.1159/000013302; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HUOT J, 1991, CANCER RES, V51, P5245; Huot J, 1996, CANCER RES, V56, P273; Inokuchi S, 1996, KIDNEY INT, V50, P1278, DOI 10.1038/ki.1996.439; ITO K, 1986, ACTA PATHOL JAPON, V36, P253; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; LACHAPELLE M, 1991, VIRCHOWS ARCH B, V60, P105, DOI 10.1007/BF02899534; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Nakamura T, 2000, AM J NEPHROL, V20, P175, DOI 10.1159/000013580; Reiser J, 2000, KIDNEY INT, V57, P2035, DOI 10.1046/j.1523-1755.2000.00070.x; RYAN GB, 1975, KIDNEY INT, V8, P219, DOI 10.1038/ki.1975.105; Schneider GB, 1998, J CELL PHYSIOL, V177, P575, DOI 10.1002/(SICI)1097-4652(199812)177:4<575::AID-JCP8>3.0.CO;2-1; Shelden E, 1999, CELL MOTIL CYTOSKEL, V42, P12, DOI 10.1002/(SICI)1097-0169(1999)42:1<12::AID-CM2>3.0.CO;2-W; SINGHAL PC, 1992, J AM SOC NEPHROL, V3, P80; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smoyer WE, 1998, J MOL MED, V76, P172, DOI 10.1007/s001090050206; Smoyer WE, 1996, J CLIN INVEST, V97, P2697, DOI 10.1172/JCI118723; STOKOE D, 1992, FEBS LETT, V313, P317; VASMANT D, 1984, ANAT REC, V210, P17, DOI 10.1002/ar.1092100104; VERNIER RL, 1959, J EXP MED, V109, P115, DOI 10.1084/jem.109.1.115; WHITESIDE CI, 1993, AM J PATHOL, V142, P1641; Wu W, 1996, TOXICOL APPL PHARM, V141, P330	43	55	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0315	10.1096/fj.01-0681com	http://dx.doi.org/10.1096/fj.01-0681com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874981				2022-12-25	WOS:000174755900024
J	Ala-Aho, R; Grenman, R; Seth, P; Kahari, VM				Ala-Aho, R; Grenman, R; Seth, P; Kahari, VM			Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells	ONCOGENE			English	Article						p53; collagenase; matrix metalloproteinase; squamous cell carcinoma	WILD-TYPE; MATRIX METALLOPROTEINASES; MESSENGER-RNA; HUMAN HEAD; GROWTH; CANCER; KERATINOCYTES; ACTIVATION; APOPTOSIS; PROMOTER	Squamous cell carcinomas (SCCs) of the head and neck are characterized by high tendency to invade locally and metastasize to lymph nodes. SCC cells express several matrix metalloproteinases (MMPs) and they often harbor mutations in p53 tumor suppressor gene. Collagenase-3 (MMP-13) is specifically expressed by tumor cells of SCCs and it apparently plays an important role in their invasion and metastasis. We used adenoviral gene delivery to examine the effect of wild-type p53 on MMP-13 expression in four head and neck SCC cell lines with mutated p53. Adenoviral delivery of p53 resulted in potent inhibition in production of proMMP-13 (by 71 to 92%) and collagenase-1 (MMP-1) (by 27 to 93%) by all cell lines in 24 h, whereas production of gelatinase-A (MMP-2) and gelatinase-B (MMP-9) was not altered. Adenoviral expression of p53 also suppressed invasion of SCC cells through Matrigel by 35%. Expression of cyclin-dependent kinase inhibitor p21(Waf1/Cip1) was induced 24 h after p53 gene delivery in all SCC cell lines, except one, which lacked detectable p21(Waf1/Cip1) expression. Number of viable cells was not altered and no apoptotic cells were seen 24 h after p53 delivery. These results show, that wild-type p53 potently inhibits expression of MMP-13 and MMP-1 by SCC cells independently of its pro-apoptotic effect. Together there results indicate, that p53 exerts a bi-phasic tumor suppressor effect on SCC cells: inhibition of cell invasion followed by induction of programmed cell death.	Univ Turku, Dept Med Biochem, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, FIN-20520 Turku, Finland; Des Moines Univ, Univ Res, Des Moines, IA 50312 USA; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; University of Turku; University of Turku	Kahari, VM (corresponding author), Univ Turku, Dept Med Biochem, Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Kahari, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368				Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Ala-Aho R, 2002, INT J CANCER, V97, P283, DOI 10.1002/ijc.1619; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bostrom PJ, 2000, INT J CANCER, V88, P417, DOI 10.1002/1097-0215(20001101)88:3<417::AID-IJC14>3.3.CO;2-7; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clayman GL, 1999, CLIN CANCER RES, V5, P1715; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; Eicheler W, 2002, J HISTOCHEM CYTOCHEM, V50, P197, DOI 10.1177/002215540205000207; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Etoh T, 2000, GUT, V47, P50, DOI 10.1136/gut.47.1.50; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Heppner KJ, 1996, AM J PATHOL, V149, P273; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Johansson N, 2000, J CELL SCI, V113, P227; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; LANSFORD CD, 1999, HUMAN CELL CULTURE, V2, P185; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Nikkola J, 2001, MELANOMA RES, V11, P157, DOI 10.1097/00008390-200104000-00011; OGRADY RL, 1984, ANAL BIOCHEM, V140, P490, DOI 10.1016/0003-2697(84)90199-4; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PYKE C, 1992, CANCER RES, V52, P1336; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Servomaa K, 1996, CELL PROLIFERAT, V29, P219, DOI 10.1046/j.1365-2184.1996.01009.x; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	58	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1187	1195		10.1038/sj.onc.1205198	http://dx.doi.org/10.1038/sj.onc.1205198			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850838				2022-12-25	WOS:000173729400006
J	Bluteau, O; Beaudoin, JC; Pasturaud, P; Belghiti, J; Franco, D; Bioulac-Sage, P; Laurent-Puig, P; Zucman-Rossi, J				Bluteau, O; Beaudoin, JC; Pasturaud, P; Belghiti, J; Franco, D; Bioulac-Sage, P; Laurent-Puig, P; Zucman-Rossi, J			Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping	ONCOGENE			English	Article						hepatocellular carcinoma; loss of heterozygosity; chromosome 4; mutation; alcohol intake	PRIMARY LIVER-CANCER; MUTATIONS; PROTEIN; GENE; HETEROZYGOSITY; DISEASE; 4Q	One of the most frequent deletions in hepatocellular carcinoma (HCC) is that involving the long arm of chromosome 4 (30 to 70% of the cases). These chromosomal deletions are closely related to hepatitis B virus (HBV) infection. A tumor suppressor gene (TSG) located on 4q has been proposed in liver carcinogenesis, but has not been identified as yet. Despite previous LOH studies focused on 4q in HCC, a clear minimal common region of deletion (MCRD) could not be delimited. To further investigate the role of chromosome 4q LOH in the pathogenesis of HCC, 85 microsatellite markers spanning chromosome 4q were systematically analysed in a series of 154 well-characterized primary liver tumors. In 59 tumors (38%), LOHs were observed for at least two adjacent markers. Analysis of 31 tumors demonstrating a partial or interstitial 4q deletion allowed to define three MCRDs of 15, 9 and 8 Mb at the 4q22, 4q34 and 4q35 regions, respectively. Seven putative candidate genes located in 4q22, DAPP1, BMPR1B, PKD2, HERC3, SMARCAD1, CEB1 and ENH were screened for mutations but no somatic alterations were identified. Search for relationships between the specific regions of deletion and clinical parameters showed a significant association between loss of the 4q34-35 region with alcohol intake (P=0.005) and with high grade of differentiation (P=0.02). These results are in contrast with the close association between HBV infection and the whole 4q LOH and reveal heterogeneity of 4q LOH in relation to different risk factors. In the light of these new findings, which link different 4q LOH regions to different etiologic factors, the molecular mechanisms underlying 4q deletions in HCC and the targeted gene(s) remain to be identified.	Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Hop Beaujon, F-92110 Clichy, France; Hop Antoine Beclere, F-92140 Clamart, France; Hop Pellegrin, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; CHU Bordeaux	Zucman-Rossi, J (corresponding author), Ctr Etud Polymorphisme Humain, INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.	Zucman@cephb.fr	Laurent-Puig, Pierre/K-3641-2019; zucman-rossi, Jessica/B-5098-2009; Bluteau, Olivier/T-9907-2017; laurent-puig, pierre/B-2226-2013; bluteau, olivier/A-8844-2008	Laurent-Puig, Pierre/0000-0001-8475-5459; zucman-rossi, Jessica/0000-0002-5687-0334; Bluteau, Olivier/0000-0002-6943-8858; laurent-puig, pierre/0000-0001-8475-5459; 				Adra CN, 2000, GENOMICS, V69, P162, DOI 10.1006/geno.2000.6281; Bando K, 1999, GENE CHROMOSOME CANC, V25, P284, DOI 10.1002/(SICI)1098-2264(199907)25:3<284::AID-GCC11>3.0.CO;2-I; Bluteau O, 1999, GASTROEN CLIN BIOL, V23, P1225; Boige V, 1997, CANCER RES, V57, P1986; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Cruz C, 2001, FEBS LETT, V488, P74, DOI 10.1016/S0014-5793(00)02371-1; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Deuffic S, 1998, LANCET, V351, P214, DOI 10.1016/S0140-6736(05)78179-4; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Marchio AS, 2000, ONCOGENE, V19, P3733, DOI 10.1038/sj.onc.1203713; Mitsui K, 1999, BIOCHEM BIOPH RES CO, V266, P115, DOI 10.1006/bbrc.1999.1777; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Piao Z, 1998, INT J CANCER, V79, P356, DOI 10.1002/(SICI)1097-0215(19980821)79:4<356::AID-IJC8>3.0.CO;2-U; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Wong N, 2000, CLIN CANCER RES, V6, P4000; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; ZHANG X, 1994, CANCER RES, V54, P4177	27	49	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1225	1232		10.1038/sj.onc.1205197	http://dx.doi.org/10.1038/sj.onc.1205197			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850842				2022-12-25	WOS:000173729400010
J	Le Bras, M; Delattre, V; Bensaad, K; Blandino, G; Soussi, T				Le Bras, M; Delattre, V; Bensaad, K; Blandino, G; Soussi, T			Monoclonal antibodies raised against Xenopus p53 interact with human p73	ONCOGENE			English	Article						p53; p73; antibodies; xenopus laevis	PROTEIN; MUTATIONS; DOMAIN	The p53 tumor suppressor gene belongs to a multigene family that includes two paralogues, p63 and p73. The structure of the p63 and p73 genes is quite similar, but both have common activities with p53, such as DNA binding and transactivation. Both p53 and p73 bind to mdm2, but only p53 is degraded through the activity of mdm2. p63 neither binds to nor is degraded by mdm2 despite important conservation in the key interacting residues. Using a panel of monoclonal antibodies raised against human and Xenopus p53, we have been able to find several antibodies that cross-react strongly with human p73. These antibodies react both with exogenous p73 expressed in mammalian cells and with endogenous p73. Interestingly, all these antibodies react with the same epitope localized in the amino-terminus of p53, but have no cross-reaction with p63. This epitope corresponds to the exact mdm2 binding site to p53. These antibodies inhibit the interaction between either p53 or p73 and mdm2, and may be useful tools for the study of these proteins. Furthermore, our studies suggest that there exist specific spatial requirements for the interaction between p53 or p73 and mdm2.	Inst Curie, Lab Genotoxicol Tumeurs, F-75005 Paris 05, France; Univ Paris 06, F-75005 Paris, France; Mol Oncogenesis Lab, I-00158 Rome, Italy	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite	Soussi, T (corresponding author), Inst Curie, Lab Genotoxicol Tumeurs, 26 Rue Ulm, F-75005 Paris 05, France.		Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241; soussi, thierry/0000-0001-8184-3293; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591				Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Portefaix JM, 2000, J IMMUNOL METHODS, V244, P17, DOI 10.1016/S0022-1759(00)00246-5; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Tominaga O, 2001, BRIT J CANCER, V84, P57, DOI 10.1054/bjoc.2000.1542; VOJTESEK B, 1995, ONCOGENE, V10, P389; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127	15	4	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1304	1308		10.1038/sj.onc.1205189	http://dx.doi.org/10.1038/sj.onc.1205189			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850851				2022-12-25	WOS:000173729400019
J	Lebedeva, IV; Su, ZZ; Chang, Y; Kitada, S; Reed, JC; Fisher, PB				Lebedeva, IV; Su, ZZ; Chang, Y; Kitada, S; Reed, JC; Fisher, PB			The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells	ONCOGENE			English	Article						melanoma differentiation associated gene-7; tumor suppressor cell cycle; cancer specific cytokine; gene therapy; BCL-family	DIFFERENTIATION-ASSOCIATED GENE; TERMINAL DIFFERENTIATION; NUDE-MICE; IN-VITRO; EXPRESSION; PROGRESSION; DNA; INHIBITOR; CLONING; ARREST	Human melanoma cells growth arrest irreversibly, lose tumorigenic potential and terminally differentiate after treatment with a combination of fibroblast interferon (IFN-beta) and the protein kinase C activator mezerein (MEZ). Applying subtraction hybridization to this model differentiation system permitted cloning of melanoma differentiation associated gene-7, mda-7. Expression of mda-7 inversely correlates with melanoma development and progression, with elevated expression in normal melanocytes and nevi and increasingly reduced expression in radial growth phase, vertical growth phase and metastatic melanoma. When expressed by means of a replication incompetent adenovirus (Ad.mda-7) growth of melanoma, but not normal early passage or immortal human melanocytes, is dramatically suppressed and cells undergo programmed cell death (apoptosis). Infection of metastatic melanoma cells with Ad.mda-7 results in an increase in cells in the G(2)/M phase of the cell cycle and changes in the ratio of pro-apoptotic (BAX, BAK) to anti-apoptotic (BCL-2, BCL-XL) proteins. Ad.mda-7 infection results in a temporal increase in mda-7 mRNA and intracellular MDA-7 protein in most of the melanocyte/melanoma cell lines and secretion of MDA-7 protein is readily detected following Ad.mda-7 infection of both melanocytes and melanoma cells. The present studies document a differential response of melanocytes versus melanoma cells to ectopic expression of mda-7 and support future applications of mda-7 for the gene-based therapy of metastatic melanoma.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Burnham Inst, La Jolla, CA 92037 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Sanford Burnham Prebys Medical Discovery Institute; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, 630 W 168th St,BB-1501, New York, NY 10032 USA.	pbfl@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA035675, R21CA087170] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA87170] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ARMSTRONG BK, 1994, CANCER SURV, V20, P219; Chaiken IM, 1996, TRENDS BIOTECHNOL, V14, P369, DOI 10.1016/0167-7799(96)10050-0; CIRIELLI C, 1995, INT J CANCER, V63, P673, DOI 10.1002/ijc.2910630512; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Ekmekcioglu S, 2001, INT J CANCER, V94, P54, DOI 10.1002/ijc.1437; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; Fechner H, 2000, GENE THER, V7, P1954, DOI 10.1038/sj.gt.3301321; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARPER JW, 1993, CELL, V75, P805; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; Hidaka C, 1999, J CLIN INVEST, V103, P579, DOI 10.1172/JCI5309; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; JIAN Y, 1993, GAIT POSTURE, V1, P1; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1995, ONCOGENE, V11, P1179; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; KERBEL RS, 1984, J NATL CANCER I, V72, P93, DOI 10.1093/jnci/72.1.93; Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200; Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2; Li DQ, 1999, CLIN CANCER RES, V5, P4175; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; Madireddi MT, 2000, J CELL PHYSIOL, V185, P36, DOI 10.1002/1097-4652(200010)185:1<36::AID-JCP3>3.0.CO;2-V; Madireddi MT, 2000, ONCOGENE, V19, P1362, DOI 10.1038/sj.onc.1203424; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MELBER K, 1989, CANCER RES, V49, P3650; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Pearson AS, 1999, CLIN CANCER RES, V5, P4208; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 1995, ANTICANCER RES, V15, P1841; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VOLKERT FC, 1983, VIROLOGY, V125, P175, DOI 10.1016/0042-6822(83)90072-7; WAXMAN S, 1996, DIFFERENTIATION THER; Wilson MR, 1998, CELL DEATH DIFFER, V5, P646, DOI 10.1038/sj.cdd.4400394; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Yang FC, 2001, SEMIN CANCER BIOL, V11, P261, DOI 10.1006/scbi.2000.0376; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	57	191	227	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					708	718		10.1038/sj.onc.1205116	http://dx.doi.org/10.1038/sj.onc.1205116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850799				2022-12-25	WOS:000173427000002
J	Bauer, H; Kanzok, SM; Schirmer, RH				Bauer, H; Kanzok, SM; Schirmer, RH			Thioredoxin-2 but not thioredoxin-1 is a substrate of thioredoxin peroxidase-1 from Drosophila melanogaster - Isolation and characterization of a second thioredoxin in D-melanogaster and evidence for distinct biological functions of Trx-1 and Trx-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-REDUCTASE; PLASMODIUM-FALCIPARUM; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; ACTIVE-SITE; PEROXIREDOXIN; MECHANISM; MALARIA; SYSTEM; ERYTHROCYTES	As Drosophila melanogaster does not contain glutathione reductase, the thioredoxin system has a key function for glutathione disulfide reduction in insects (Kanzok, S. M., Fechner, A., Bauer, H., Ulschmid, J. K., Muller, H. M., Botella-Munoz, J., Schneuwly, S., Schirmer, R. H., and Becker, K. (2001) Science 291, 643-646). In view of these unique conditions, the protein systems participating in peroxide metabolism and in redox signaling are of special interest. The genes for a second thioredoxin (DmTrx-2) and a thioredoxin peroxidase (DmTPx-1) were cloned and expressed, and the proteins were characterized. In its disulfide form, the 13-kDa protein thioredoxin-2 is a substrate of thioredoxin reductase-1 (K-m=5.2 muM, k(cat)=14.5 s(-1)) and in its dithiol form, an electron donor for TPx-1 (K-m=9 muM, k(cat)=5.4 s(-1)). DmTrx-2 is capable of reducing glutathione disulfide with a second order rate constant of 170 M-1 s(-1) at pH 7.4 and 25degreesC. Western blot analysis indicated that this thioredoxin represents up to 1% of the extractable protein of D. melanogaster Schneider cells or whole fruit flies. Recombinant thioredoxin peroxidase-1 (subunit molecular mass=23 kDa) was found to be a decameric protein that can efficiently use Trx-2 but not Trx-1 as a reducing substrate. The new electron pathway found in D. melanogaster is also representative for insects that serve as vectors of disease. As a first step we have cloned and functionally expressed the gene that is the orthologue of DmTrx-2 in the malaria mosquito Anopheles gambiae.	Univ Heidelberg, Biochem Ctr, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bauer, H (corresponding author), Univ Heidelberg, Biochem Ctr, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.							Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Davioud-Charvet E, 2001, J MED CHEM, V44, P4268, DOI 10.1021/jm010268g; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; Fritsche G, 2001, J INFECT DIS, V183, P1388, DOI 10.1086/319860; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Gromer S, 2002, METHOD ENZYMOL, V347, P382; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUNT NH, 1990, BLOOD CELLS, V16, P499; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Missirlis F, 2002, J BIOL CHEM, V277, P11521, DOI 10.1074/jbc.M111692200; Missirlis F, 2001, CURR BIOL, V11, P1272, DOI 10.1016/S0960-9822(01)00393-1; Nishinaka Y, 2001, REDOX REP, V6, P289, DOI 10.1179/135100001101536427; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; PellicenaPalle A, 1997, MECH DEVELOP, V62, P61, DOI 10.1016/S0925-4773(96)00650-8; Radyuk SN, 2001, FREE RADICAL BIO MED, V31, P1090, DOI 10.1016/S0891-5849(01)00692-X; Rodriguez J, 2000, EUR J BIOCHEM, V267, P487, DOI 10.1046/j.1432-1327.2000.01022.x; Ross SJ, 2000, MOL BIOL CELL, V11, P2631, DOI 10.1091/mbc.11.8.2631; SALZ HK, 1994, GENETICS, V136, P1075; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Savvides SN, 2002, J BIOL CHEM, V277, P2779, DOI 10.1074/jbc.M108190200; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; SOHAL RS, 1990, MECH AGEING DEV, V56, P223, DOI 10.1016/0047-6374(90)90084-S; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang PF, 1999, BIOCHEMISTRY-US, V38, P3187, DOI 10.1021/bi982674g; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	38	67	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17457	17463		10.1074/jbc.M200636200	http://dx.doi.org/10.1074/jbc.M200636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877442	hybrid			2022-12-25	WOS:000175685100011
J	Birolo, L; Dal Piaz, F; Pucci, P; Marino, G				Birolo, L; Dal Piaz, F; Pucci, P; Marino, G			Structural characterization of the M* partly folded intermediate of wild type and P138A aspartate aminotransferase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMIDE HYDROGEN-EXCHANGE; VIRUS NS3 PROTEASE; MASS-SPECTROMETRY; CONFORMATIONAL-CHANGES; LIMITED PROTEOLYSIS; SEMINAL RNASE; BINDING; COMPLEX; FLUORESCENCE; PROTEINS	A combination of spectroscopic techniques, hydrogen/deuterium exchange, and limited proteolysis experiments coupled to mass spectrometry analysis was used to depict the topology of the monomeric M* partly folded intermediate of aspartate aminotransferase from Escherichia coli in wild type (WT) as well as in a mutant form in which the highly conserved cis-proline at position 138 was replaced by a trans-alanine (P138A). Fluorescence analysis indicates that, although M* is an off-pathway intermediate in the folding of WT aspartate aminotransferase from E. coli, it seems to coincide with an on-pathway folding intermediate for the P138A mutant. Spectroscopic data, hydrogen/deuterium exchange, and limited proteolysis experiments demonstrated the occurrence of conformational differences between the two M* intermediates, with P138A-M* being conceivably more compact than WT-M*. Limited proteolysis data suggested that these conformational differences might be related to a different relative orientation of the small and large domains of the protein induced by the presence of the cis-proline residue at position 138. These differences between the two M* species indicated that in WT-M* Pro138 is in the cis conformation at this stage of the folding process. Moreover, hydrogen/deuterium exchange results showed the occurrence of few differences in the native N-2 forms of WT and P138A, the spectroscopic features and crystallographic structures of which are almost superimposable.	Univ Naples Federico II, Dipartimento Chim Organ & Biochim, I-80126 Naples, Italy	University of Naples Federico II	Birolo, L (corresponding author), Univ Naples Federico II, Dipartimento Chim Organ & Biochim, Complesso Univ Monte Sant Angelo,Via Cinthia, I-80126 Naples, Italy.		Dal Piaz, Fabrizio/D-1843-2010	Dal Piaz, Fabrizio/0000-0002-8643-5018; PUCCI, Pietro/0000-0002-5885-1495; BIROLO, Leila/0000-0002-0915-7501				Atkinson RA, 2000, BIOCHEMISTRY-US, V39, P5255, DOI 10.1021/bi991891u; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Bianchi E, 1999, BIOCHEMISTRY-US, V38, P13844, DOI 10.1021/bi991220w; Birolo L, 1999, BIOCHEMISTRY-US, V38, P905, DOI 10.1021/bi981467d; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; De Lorenzo C, 1998, PROTEIN SCI, V7, P2653; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Engen JR, 1999, BIOCHEMISTRY-US, V38, P8926, DOI 10.1021/bi982611y; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Halgand F, 1999, BIOCHEMISTRY-US, V38, P6025, DOI 10.1021/bi982412e; HEROLD M, 1992, FEBS LETT, V308, P26, DOI 10.1016/0014-5793(92)81042-K; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; JOHNSON RS, 1994, PROTEIN SCI, V3, P2411, DOI 10.1002/pro.5560031224; KATTA V, 1991, RAPID COMMUN MASS SP, V5, P214, DOI 10.1002/rcm.1290050415; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; Li RH, 1999, PROTEIN SCI, V8, P1571, DOI 10.1110/ps.8.8.1571; Mattingly JR, 1998, J BIOL CHEM, V273, P23191, DOI 10.1074/jbc.273.36.23191; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; Orru S, 1999, PROTEIN SCI, V8, P1445, DOI 10.1110/ps.8.7.1445; OVCHINNIKOV YA, 1973, FEBS LETT, V29, P31, DOI 10.1016/0014-5793(73)80008-0; Piccoli R, 2000, J BIOL CHEM, V275, P8000, DOI 10.1074/jbc.275.11.8000; Scaloni A, 1998, J MOL BIOL, V277, P945, DOI 10.1006/jmbi.1998.1629; Scaloni A, 1999, BIOCHEMISTRY-US, V38, P64, DOI 10.1021/bi981300k; Scognamiglio R, 2001, PROTEIN SCI, V10, P482, DOI 10.1110/ps.35701; Smith DL, 1997, J MASS SPECTROM, V32, P135, DOI 10.1002/(SICI)1096-9888(199702)32:2<135::AID-JMS486>3.0.CO;2-M; Torella C, 1998, J BIOL CHEM, V273, P3915, DOI 10.1074/jbc.273.7.3915; Urbani A, 1999, BIOCHEMISTRY-US, V38, P5206, DOI 10.1021/bi982773u; WOODWARD C, 1982, MOL CELL BIOCHEM, V48, P135, DOI 10.1007/BF00421225; YANO T, 1991, J BIOL CHEM, V266, P6079; Zappacosta F, 1996, PROTEIN SCI, V5, P802, DOI 10.1002/pro.5560050502; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522; Zhang ZQ, 1996, PROTEIN SCI, V5, P1282	38	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17428	17437		10.1074/jbc.M200650200	http://dx.doi.org/10.1074/jbc.M200650200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11875074	hybrid			2022-12-25	WOS:000175685100008
J	Balklava, Z; Verderio, E; Collighan, R; Gross, S; Adams, J; Griffin, M				Balklava, Z; Verderio, E; Collighan, R; Gross, S; Adams, J; Griffin, M			Analysis of tissue transglutaminase function in the migration of swiss 3T3 fibroblasts - The active-state conformation of the enzyme does not affect cell motility but is important for its secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS PEPTIDE-BONDS; GROWTH-FACTOR-I; CROSS-LINKING; GTP-BINDING; FIBRONECTIN; ADHESION; MATRIX; EXPRESSION; RELEASE; SURFACE	Increasing evidence suggests that tissue transglutaminase (tTGase; type II) is externalized from cells, where it may play a key role in cell attachment and spreading and in the stabilization of the extracellular matrix (ECM) through protein cross-linking. However, the relationship between these different functions and the enzyme's mechanism of secretion is not fully understood. We have investigated the role of tTGase in cell migration using two stably transfected fibroblast cell lines in which expression of tTGase in its active and inactive (C277S mutant) states is inducible through the tetracycline-regulated system. Cells overexpressing both forms of tTGase showed increased cell attachment and decreased cell migration on fibronectin. Both forms of the enzyme could be detected on the cell surface, but only the clone overexpressing catalytically active tTGase deposited the enzyme into the ECM and cell growth medium. Cells overexpressing the inactive form of tTGase did not deposit the enzyme into the ECM or secrete it into the cell culture medium. Similar results were obtained when cells were transfected with tTGase mutated at Tyr(274) (Y274A), the proposed site for the cis-, trans peptide bond, suggesting that tTGase activity and/or its tertiary conformation dependent on this bond may be essential for its externalization mechanism. These results indicate that tTGase regulates cell motility as a novel cell-surface adhesion protein rather than as a matrix-cross-linking enzyme. They also provide further important insights into the mechanism of externalization of the enzyme into the extracellular matrix.	Nottingham Trent Univ, Dept Life Sci, Nottingham NG11 8NS, England; Smith & Nephew Grp Res Ctr, York YO10 5DF, N Yorkshire, England	Nottingham Trent University; Smith & Nephew	Griffin, M (corresponding author), Nottingham Trent Univ, Dept Life Sci, Clifton Lane, Nottingham NG11 8NS, England.	martin.griffin@ntu.ac.uk	Verderio, Elisabetta/H-2789-2016; Balklava, Zita/AAU-6146-2021	Verderio, Elisabetta/0000-0001-9153-8997; gross, stephane/0000-0002-0867-8866; Griffin, Martin/0000-0003-3824-306X; Balklava, Zita/0000-0001-9039-9710				ACHYUTHAN KE, 1995, J IMMUNOL METHODS, V180, P69, DOI 10.1016/0022-1759(94)00300-L; AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Ball DJ, 2001, PHOTOCHEM PHOTOBIOL, V73, P47, DOI 10.1562/0031-8655(2001)073<0047:DEOTOC>2.0.CO;2; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BOWNESS JM, 1988, BIOCHIM BIOPHYS ACTA, V967, P234; BOWNESS JM, 1987, CONNECT TISSUE RES, V16, P57, DOI 10.3109/03008208709001994; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; CAI D, 1991, BIOCHEM BIOPH RES CO, V175, P1119, DOI 10.1016/0006-291X(91)91681-2; CARIELLO L, 1994, BIOCHEM BIOPH RES CO, V205, P565, DOI 10.1006/bbrc.1994.2702; Di Venere A, 2000, J BIOL CHEM, V275, P3915, DOI 10.1074/jbc.275.6.3915; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FREUND KF, 1994, BIOCHEMISTRY-US, V33, P10109, DOI 10.1021/bi00199a039; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; Gaudry CA, 1999, EXP CELL RES, V252, P104, DOI 10.1006/excr.1999.4633; GENTILE V, 1991, J BIOL CHEM, V266, P478; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIFFIN M, 1984, MOL CELL BIOCHEM, V58, P37, DOI 10.1007/BF00240603; Haroon ZA, 1999, FASEB J, V13, P1787, DOI 10.1096/fasebj.13.13.1787; Isobe T, 1999, EUR J CELL BIOL, V78, P876, DOI 10.1016/S0171-9335(99)80089-2; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; Johnson TS, 1997, J CLIN INVEST, V99, P2950, DOI 10.1172/JCI119490; JOHNSON TS, 1994, ONCOGENE, V9, P2935; Johnson TS, 1999, J AM SOC NEPHROL, V10, P2146; Jones RA, 1997, J CELL SCI, V110, P2461; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1202, P1, DOI 10.1016/0167-4838(93)90055-V; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; Miyakawa K, 1999, J BIOL CHEM, V274, P29352, DOI 10.1074/jbc.274.41.29352; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; TARANTINI F, 1995, J BIOL CHEM, V270, P29039, DOI 10.1074/jbc.270.49.29039; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; Verderio E, 1999, J HISTOCHEM CYTOCHEM, V47, P1417, DOI 10.1177/002215549904701108; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; Weiss MS, 1998, FEBS LETT, V423, P291, DOI 10.1016/S0014-5793(98)00098-2	45	117	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16567	16575		10.1074/jbc.M109836200	http://dx.doi.org/10.1074/jbc.M109836200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867617	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000175564500032
J	Bhunia, AK; Schwarzmann, G; Chatterjee, S				Bhunia, AK; Schwarzmann, G; Chatterjee, S			GD3 recruits reactive oxygen species to induce cell proliferation and apoptosis in human aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; GENE-EXPRESSION; GANGLIOSIDE; LACTOSYLCERAMIDE; GROWTH; ADHESION; BCL-2; GLYCOSPHINGOLIPIDS	Sialic acid containing glycosphingolipids (gangliosides) are expressed on the surface of all mammalian cells and have been implicated in regulating various biological phenomena; however, the detailed signaling mechanisms involved in this process are not known. We report here a novel aspect of disialoganglioside, GD3-mediated regulation of cell proliferation and cell death via the recruitment of reactive oxygen species (ROS). A low concentration (2.5-10 muM) of GD3, incubated with human aortic smooth muscle cells for a short period of time (10-30 min), stimulates superoxide generation via the activation of both NADPH oxidase and NADH oxidase activity. This leads to downstream signaling leading to cell poliferation and apoptosis. However, [H-3]GD3 incubated with the cells under such conditions was found in a trypsin-sensitive fraction that was separable from endogenous GD3. The exact mechanism causing ROS generation and downstream signaling remains to be elucidated. The uptake of GD3 was accompanied by a 2.5-fold stimulation in the activity of mitogen-activated protein (MAP) kinase and 5-fold stimulation in cell proliferation. Preincubation of cells with membrane-permeable antioxidants, pyrrolidine dithiocarbamate, and N-acetylcysteine abrogated the superoxide generation and cell proliferation. In contrast, at higher concentrations (50-200 muM) GD3 inhibited the generation of superoxides but markedly stimulated the generation of nitric oxide (NO) (10-fold compared with control). This in turn stimulated mitochondrial cytochrome c release and intrachromosomal DNA fragmentation, which lead to apoptosis. In sum, at a low concentration, GD3 recruits superoxides to activate p44 MAPK and stimulates cell proliferation. In contrast, at high concentrations GD3 recruits nitric oxide to scavenge superoxide radicals that triggered signaling events that led to apoptosis. These observations might have relevance in regard to the potential role of GD3 in aortic smooth muscle cell proliferation and apoptosis that may contribute to plaque rupture in atherosclerosis.	Johns Hopkins Univ, Sch Med, Dept Pediat,Lipid Res Atherosclerosis Unit, Sphingoglycolipid Signaling & Vasc Biol Lab, Baltimore, MD 21044 USA; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	Johns Hopkins University; University of Bonn	Chatterjee, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat,Lipid Res Atherosclerosis Unit, Sphingoglycolipid Signaling & Vasc Biol Lab, 550 N Broadway,Suite 312, Baltimore, MD 21044 USA.	chatter@jhmi.edu						ALBINO AP, 1992, ONCOGENE, V7, P2315; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; Bhunia AK, 1996, J BIOL CHEM, V271, P10660, DOI 10.1074/jbc.271.18.10660; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; Chatterjee S, 2000, METHOD ENZYMOL, V311, P73; Chatterjee SB, 1997, GLYCOBIOLOGY, V7, P57, DOI 10.1093/glycob/7.1.57; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Furukawa K., 1990, HUMAN MELANOMA BASIC, P15; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 1999, HEPATOLOGY, V30, p411A; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maria R.D., 1997, SCIENCE, V277, P1652; MCCORD JM, 1993, CLIN BIOCHEM, V26, P351, DOI 10.1016/0009-9120(93)90111-I; MUKHIN DN, 1995, ARTERIOSCL THROM VAS, V15, P1607, DOI 10.1161/01.ATV.15.10.1607; NAKAKUMA H, 1984, J BIOCHEM-TOKYO, V96, P1471, DOI 10.1093/oxfordjournals.jbchem.a134976; Nakano J, 1996, J INVEST DERMATOL, V107, P543, DOI 10.1111/1523-1747.ep12582802; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SCHWARZMANN G, 1983, BIOCHEMISTRY-US, V22, P5041, DOI 10.1021/bi00290a025; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SONDERFELD S, 1985, EUR J BIOCHEM, V149, P247, DOI 10.1111/j.1432-1033.1985.tb08919.x; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TILLACK TW, 1993, BIOCHIM BIOPHYS ACTA, V793, P15; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zimmerman JW, 1998, J BIOL CHEM, V273, P22014, DOI 10.1074/jbc.273.34.22014	35	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16396	16402		10.1074/jbc.M200877200	http://dx.doi.org/10.1074/jbc.M200877200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861654	hybrid			2022-12-25	WOS:000175564500009
J	DeLong, CJ; Hicks, AM; Cui, Z				DeLong, CJ; Hicks, AM; Cui, Z			Disruption of choline methyl group donation for phosphatidylethanolamine methylation in hepatocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; N-METHYLTRANSFERASE; BETAINE ALDEHYDE; DNA METHYLATION; HEPATOCELLULAR CARCINOMAS; METHIONINE METABOLISM; GENE-EXPRESSION; HEPATOMA-CELLS; N-METHYLTRANSFERASE-2; HOMOCYSTEINE	Despite being widely hypothesized, the actual contribution of choline as a methyl source for phosphatidylethanolamine (PE) methylation has never been demonstrated, mainly due to the inability of conventional methods to distinguish the products from that of the CDP-choline pathway. Using a novel combination of stable-isotope labeling and tandem mass spectrometry, we demonstrated for the first time that choline contributed to phosphatidylcholine (PC) synthesis both as an intact choline moiety via the CDP-choline pathway and as a methyl donor via PE methylation pathway. When hepatocytes were labeled with d(9)-choline containing three deuterium atoms on each of the three methyl groups, d(3)-PC and d(6)-PC were detected, indicating that newly synthesized PC contained one or more individually mobilized methyl groups from d(9)-choline. The synthesis of d(3)-PC and d(6)-PC was sensitive to the general methylation inhibitor 3-deazaadenosine and were specific products of PE methylation using choline as a one-carbon donor. While the contribution to the CDP-choline pathway remained intact in hepatocarcinoma cells, contribution of choline to PE methylation was completely disrupted. In addition to a previously identified lack of PE methyltransferase, hepatocarcinoma cells were found to lack the abilities to oxidize choline to betaine and to donate the methyl group from betaine to homocysteine, whereas the usage of exogenous methionine as a methyl group donor was normal. The failure to use choline as a methyl source in hepatocarcinoma cells may contribute to methionine dependence, a widely observed aberration of one-carbon metabolism in malignancy.	Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Cui, Z (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA.	zhengcui@wfubmc.edu		DeLong, Cynthia/0000-0002-6823-8619	NCI NIH HHS [R01CA7960, CA-09422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avila MA, 2000, J HEPATOL, V33, P907, DOI 10.1016/S0168-8278(00)80122-1; BALAGHI M, 1993, BIOCHEM BIOPH RES CO, V193, P1184, DOI 10.1006/bbrc.1993.1750; Barak AJ, 1996, ALCOHOL, V13, P395, DOI 10.1016/0741-8329(96)00030-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANDAR N, 1988, CARCINOGENESIS, V9, P259, DOI 10.1093/carcin/9.2.259; Chern MK, 1999, BIOCHEM CELL BIOL, V77, P179, DOI 10.1139/bcb-77-3-179; Chern MK, 2000, BIOCHEM PHARMACOL, V60, P1629, DOI 10.1016/S0006-2952(00)00469-X; CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7; COPELAND DH, 1946, AM J PATHOL, V22, P1059; CUI Z, 1994, J BIOL CHEM, V269, P24531; Cui Z, 1996, J BIOL CHEM, V271, P2839, DOI 10.1074/jbc.271.5.2839; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; Cui Z, 1995, BIOCHEM J, V312, P939, DOI 10.1042/bj3120939; CUI Z, 1993, J BIOL CHEM, V268, P16655; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; DeLong CJ, 2001, J LIPID RES, V42, P1959; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; DIZIK M, 1991, CARCINOGENESIS, V12, P1307, DOI 10.1093/carcin/12.7.1307; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; Heil SG, 2000, MOL GENET METAB, V71, P511, DOI 10.1006/mgme.2000.3078; Houweling M, 1997, BBA-LIPID LIPID MET, V1346, P1, DOI 10.1016/S0005-2760(97)00011-8; ISHIDATE K, 1989, PHOSPHATIDYLCHOLINE, P9; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KRAMAR R, 1984, H-S Z PHYSIOL CHEM, V365, P1207, DOI 10.1515/bchm2.1984.365.2.1207; LIEBER CS, 1965, J CLIN INVEST, V44, P1009, DOI 10.1172/JCI105200; LOCKER J, 1986, CARCINOGENESIS, V7, P1309, DOI 10.1093/carcin/7.8.1309; MATTHEWS RG, 1987, ADV ENZYME REGUL, V26, P157, DOI 10.1016/0065-2571(87)90012-4; Park EI, 1999, J BIOL CHEM, V274, P7816, DOI 10.1074/jbc.274.12.7816; PRITCHARD PH, 1982, J BIOL CHEM, V257, P6362; Rampersaud GC, 2000, AM J CLIN NUTR, V72, P998; Sunden SLF, 1997, ARCH BIOCHEM BIOPHYS, V345, P171, DOI 10.1006/abbi.1997.0246; Tessitore L, 1999, CARCINOGENESIS, V20, P561, DOI 10.1093/carcin/20.4.561; Tessitore L, 1999, BIOCHEM J, V337, P23, DOI 10.1042/0264-6021:3370023; Tessitore L, 1997, BIOCHEM J, V322, P151, DOI 10.1042/bj3220151; Tessitore L, 2000, INT J CANCER, V86, P362, DOI 10.1002/(SICI)1097-0215(20000501)86:3&lt;362::AID-IJC10&gt;3.0.CO;2-A; Tsujiuchi T, 1999, JPN J CANCER RES, V90, P909, DOI 10.1111/j.1349-7006.1999.tb00834.x; Vance DE, 1996, ANTICANCER RES, V16, P1413; VANCE DE, 1989, PHOSPHATIDYLCHOLINE; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; WONG ER, 1972, BIOCHIM BIOPHYS ACTA, V260, P259, DOI 10.1016/0005-2760(72)90037-9; Zeisel SH, 1996, ADV EXP MED BIOL, V399, P131; ZHANG J, 1992, BIOCHIM BIOPHYS ACTA, V1117, P333, DOI 10.1016/0304-4165(92)90033-Q	43	26	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17217	17225		10.1074/jbc.M108911200	http://dx.doi.org/10.1074/jbc.M108911200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864970	hybrid			2022-12-25	WOS:000175564500115
J	Taniura, S; Kamitani, H; Watanabe, T; Eling, TE				Taniura, S; Kamitani, H; Watanabe, T; Eling, TE			Deacetylase inhibitors in normal human astrocyte cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; SIGNAL-TRANSDUCTION PATHWAY; HUMAN COLORECTAL-CARCINOMA; HISTONE DEACETYLASE; GROWTH-FACTOR; SP1 SITES; TRANSCRIPTIONAL REPRESSION; SODIUM-BUTYRATE; G/H SYNTHASE-2; GENE PROMOTER	While cyclooxygenase (COX)-2 is a highly inducible gene, COX-1 is widely known as a noninducible gene and is constitutively expressed in a variety of cell lines and human tissues. Recently, several reports have indicated that COX-1 is also regulated at the transcriptional level by various stimuli. We present evidence that histone deacetylase (HDAC) inhibitors induce COX-1 transcription and translation in normal human astrocyte (NHA) cells and glioma cell lines. HDAC inhibitors increased acetylated histone H4 protein expression in NHA cells. The levels of COX-1 mRNA and protein were maximal at 24 and 48 h, respectively, after treatment with the specific HDAC inhibitor, trichostatin A (TSA). In addition, TSA-treated NHA cells produced prostaglandin E-2 as determined by enzyme-linked immunosorbent assay after incubation with 10 muM exogenous arachidonic acid, indicating that the induced COX-1 is functionally active. In addition to NHA cells, this up-regulation of COX-1 after treatment with HDAC inhibitors was observed in 5 different glioma cell lines. The nucleotide sequence of the inducible COX-1 cDNA was confirmed identical to human COX-1 that was previously reported. HDAC inhibitors stimulated COX-1 promoter activity as measured by luciferase reporter assays, suggesting that the induction of COX-1 is regulated at the transcriptional level. Furthermore, mutation analysis of the COX-1 promoter suggests that TSA-responsive element exists in the proximal Sp1-binding site at +25 to +31. In conclusion, COX-1 is an inducible gene in glial-derived cells including immortalized cells, and appears to be transcriptionally regulated by a unique mechanism associated with histone acetylation.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; Tottori Univ, Fac Med, Inst Neurol Sci, Div Neurosurg, Yonago, Tottori 6838504, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Tottori University	Eling, TE (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050143, Z01ES050144, ZIAES050144] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Bethea JR, 1997, J IMMUNOL, V158, P5815; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Cohn SM, 1997, J CLIN INVEST, V99, P1367, DOI 10.1172/JCI119296; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Han JW, 2000, CANCER RES, V60, P6068; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Husmann M, 1996, EUR J IMMUNOL, V26, P3008, DOI 10.1002/eji.1830261228; JONES DA, 1993, J BIOL CHEM, V268, P9049; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Kamitani H, 2001, CARCINOGENESIS, V22, P187, DOI 10.1093/carcin/22.1.187; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kaplan MD, 1997, J BIOL CHEM, V272, P18534, DOI 10.1074/jbc.272.30.18534; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; KAWASAKI M, 1993, MOL BRAIN RES, V19, P39, DOI 10.1016/0169-328X(93)90146-G; Koyama Y, 1999, J NEUROCHEM, V73, P1004, DOI 10.1046/j.1471-4159.1999.0731004.x; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; OBanion MK, 1996, J NEUROCHEM, V66, P2532; Pairet M, 1996, FUND CLIN PHARMACOL, V10, P1, DOI 10.1111/j.1472-8206.1996.tb00144.x; Pistritto G, 1998, NEUROSCI LETT, V246, P45, DOI 10.1016/S0304-3940(98)00226-2; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; Rioux N, 2000, CARCINOGENESIS, V21, P1745, DOI 10.1093/carcin/21.9.1745; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Salminen A, 1998, MOL BRAIN RES, V61, P203, DOI 10.1016/S0169-328X(98)00210-1; Satoh K, 2000, NEUROSCI LETT, V283, P221, DOI 10.1016/S0304-3940(00)00926-5; Schneider N, 2001, J NEUROCHEM, V77, P416, DOI 10.1046/j.1471-4159.2001.00264.x; Shankaranarayanan P, 2001, J BIOL CHEM, V276, P42753, DOI 10.1074/jbc.M102626200; Shaw-White JR, 1999, J BIOL CHEM, V274, P2658, DOI 10.1074/jbc.274.5.2658; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Taplick J, 1998, FEBS LETT, V436, P349, DOI 10.1016/S0014-5793(98)01164-8; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943; Xu XM, 1996, AM J PHYSIOL-CELL PH, V270, pC259, DOI 10.1152/ajpcell.1996.270.1.C259; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; Yermakova AV, 1999, J NEUROPATH EXP NEUR, V58, P1135, DOI 10.1097/00005072-199911000-00003; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	47	64	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16823	16830		10.1074/jbc.M200527200	http://dx.doi.org/10.1074/jbc.M200527200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877441	hybrid			2022-12-25	WOS:000175564500064
J	Turek, JW; Halmos, T; Sullivan, NL; Antonakis, K; Le Breton, GC				Turek, JW; Halmos, T; Sullivan, NL; Antonakis, K; Le Breton, GC			Mapping of a ligand-binding site for the human thromboxane A(2) receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN; AGONIST; BIOSYNTHESIS; DOMAIN; ROLES	The human thromboxane A(2) (TP) receptor, a member of the G protein-coupled receptor superfamily, consists of seven transmembrane segments. Attempts to elucidate the specific segment(s) that define the receptor ligand-binding pocket have produced less than definitive and sometimes conflicting results. On this basis, the present work identified an amino acid sequence of the TP receptor that is directly involved in ligand binding. Mapping of this domain was confirmed by two separate approaches: photoaffinity labeling and site-specific antibodies. The newly synthesized, biotinylated photoaffinity probe, SQBAzide, was first shown to specifically label TP receptor protein. Sequential digestion of this protein with CNBr/trypsin revealed photolabeling of a 2.9-kDa peptide. Using anti-peptide antibodies directed against different regions of the receptor protein, it was established that this peptide represents the predicted cleavage product for CNBr/trypsin and corresponds to amino acids Arg(174)-Met(202) of the receptor protein. Furthermore, antibody screening revealed that inhibition of the amino acid region Cys(183)-Asp(193) was critical for radioligand binding and platelet aggregation, whereas inhibition of Gly(172)-Cys(183) was not. Collectively these findings provide evidence that ligands interact with amino acids contained within the C-terminal portion of the third extracellular domain (ED3) of the receptor protein. This information should be of significant value in the study of TP receptor structure and signaling.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Ecole Natl Super Chim Paris, CNRS, UMR 133, F-75231 Paris, France	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Chimie ParisTech	Le Breton, GC (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,M-C 868, Chicago, IL 60612 USA.	gcl@uic.edu		Turek, Joseph/0000-0002-4006-7555	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024530] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24530] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alla SA, 1996, J BIOL CHEM, V271, P1748, DOI 10.1074/jbc.271.3.1748; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; BORG C, 1993, BIOCHEM PHARMACOL, V45, P2071, DOI 10.1016/0006-2952(93)90018-R; Chiang N, 1996, ARCH BIOCHEM BIOPHYS, V334, P9, DOI 10.1006/abbi.1996.0423; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P235; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P159, DOI [10.1136/bmj.308.6922.159, DOI 10.1136/BMJ.308.6922.159]; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; Dorn GW, 1997, J BIOL CHEM, V272, P12399, DOI 10.1074/jbc.272.19.12399; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FITZGERALD GA, 1987, FASEB J, V46, P154; FUNK CD, 1993, MOL PHARMACOL, V44, P934; Gros E., 1967, METHOD ENZYMOL, V11, P238; HAGER KM, 1994, B BIORAD LAB, V1685; Halmos T, 1999, BIOORG MED CHEM LETT, V9, P2963, DOI 10.1016/S0960-894X(99)00511-9; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; KATTELMAN EJ, 1986, THROMB RES, V41, P471, DOI 10.1016/0049-3848(86)91692-0; Komiotis D, 1996, BIOCHEM PHARMACOL, V52, P763, DOI 10.1016/0006-2952(96)00359-0; MATSUI H, 1989, BIOCHEMISTRY-US, V28, P4125, DOI 10.1021/bi00435a075; MONCADA S, 1978, PHARMACOL REV, V30, P293; NARUMIYA S, 1993, J LIPID MEDIATOR, V6, P155; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; OGLETREE ML, 1987, FED PROC, V46, P133; PATRONO C, 1990, STROKE, V21, P130; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; Ruan KH, 2001, BIOCHEMISTRY-US, V40, P275, DOI 10.1021/bi001867c; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TUREK JW, 1998, B BIORAD LAB, V2344; WONG SKF, 1988, J BIOL CHEM, V263, P7925; YAMAMOTO Y, 1993, J MED CHEM, V36, P820, DOI 10.1021/jm00059a005	30	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16791	16797		10.1074/jbc.M105872200	http://dx.doi.org/10.1074/jbc.M105872200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877412	hybrid			2022-12-25	WOS:000175564500060
J	Broadwater, JA; Whittle, E; Shanklin, J				Broadwater, JA; Whittle, E; Shanklin, J			Desaturation and Hydroxylation - Residues 148 and 324 of Arabidopsis FAD2, in addition to substrate chain length, exert a major influence in partitioning of catalytic specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLEATE DESATURASE; FATTY-ACIDS; GENE; ENZYME; THALIANA; YEAST; CRYPTOREGIOCHEMISTRY; TRANSFORMATION; MONOOXYGENASE; EXPRESSION	Exchanging the identity of amino acids at four key locations within the Arabidopsis thaliana oleate desaturase (FAD2) and the Lesquerella fendleri hydroxylase/desaturase (LFAH) was shown to influence partitioning between desaturation and hydroxylation (Broun, P., Shanklin, J., Whittle, E., and Somerville, C. (1998) Science 282, 1315-1317). We report that four analogous substitutions in the FAD2 sequence by their equivalents from the castor oleate hydroxylase result in hydroxy fatty acid accumulation in A. thaliana to the same levels as for the wild-type castor hydroxylase. We also describe the relative contribution of these substitutions, both individually and in combination, by analyzing the products resulting from their expression in A. thaliana and/or Saccharomyces cerevisiae. Yeast expression showed that M324V, a change reachable by a single point mutation, altered the product distribution similar to49-fold, and that residue 148 is also a predominant determinant of reaction outcome. Comparison of residues at position 148 of FAD2, LFAH, and the Ricinus oleate hydroxylase prompted us to rationally engineer LFAH-N149I, a variant with similar to1.9-fold increase in hydroxylation specificity compared with that of wild-type LFAH. Control experiments showed that the wild-type Arabidopsis thaliana FAD2 desaturase has inherent, low level, hydroxylation activity. Further, fatty acid desaturases from different kingdoms and with different regio-specificities exhibit similar intrinsic hydroxylase activity, underscoring fundamental mechanistic similarities between desaturation and hydroxylation. For LFAH mutants the hydroxylation:desaturation ratio is 5-9-fold higher for 18-carbon versus 16-carbon substrates, supporting our hypothesis that substrate positioning in the active site plays a key role in the partitioning of catalytic specificity.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Shanklin, J (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463,50 Bell Ave, Upton, NY 11973 USA.			Shanklin, John/0000-0002-6774-8043				Aguilar PS, 1998, J BACTERIOL, V180, P2194, DOI 10.1128/JB.180.8.2194-2200.1998; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; AWAYA J, 1975, BIOCHIM BIOPHYS ACTA, V409, P267, DOI 10.1016/0005-2760(75)90022-3; Behrouzian B, 2001, EUR J BIOCHEM, V268, P3545, DOI 10.1046/j.1432-1327.2001.02258.x; BOSSIE MA, 1989, J BACTERIOL, V171, P64089; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; Broun P, 1997, PLANT PHYSIOL, V113, P933, DOI 10.1104/pp.113.3.933; Broun P, 1998, SCIENCE, V282, P1315, DOI 10.1126/science.282.5392.1315; Brown AP, 1998, J AM OIL CHEM SOC, V75, P77, DOI 10.1007/s11746-998-0014-y; Buist PH, 1996, J AM CHEM SOC, V118, P6295, DOI 10.1021/ja953262n; Buist PH, 1998, J AM CHEM SOC, V120, P871, DOI 10.1021/ja971362i; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; CONACHER H B S, 1970, Lipids, V5, P137, DOI 10.1007/BF02531108; Covello PS, 1996, PLANT PHYSIOL, V111, P223, DOI 10.1104/pp.111.1.223; Dallerac R, 2000, P NATL ACAD SCI USA, V97, P9449, DOI 10.1073/pnas.150243997; DATLA RSS, 1992, GENE, V122, P383, DOI 10.1016/0378-1119(92)90232-E; Dyer JM, 2001, FEBS LETT, V494, P44, DOI 10.1016/S0014-5793(01)02315-8; Fauconnot L, 2001, BIOORG MED CHEM LETT, V11, P2879, DOI 10.1016/S0960-894X(01)00579-0; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; Gherman BF, 2001, J AM CHEM SOC, V123, P3836, DOI 10.1021/ja0055108; GIRKE T, 1998, ADV PLANT LIPID RES, P103; Jin Y, 2001, J BIOL INORG CHEM, V6, P717, DOI 10.1007/s007750100250; KANEKO H, 1976, LIPIDS, V11, P837, DOI 10.1007/BF02532989; Kim C, 1997, J AM CHEM SOC, V119, P3635, DOI 10.1021/ja963578a; Kinumi T, 2000, J MASS SPECTROM, V35, P417, DOI 10.1002/(SICI)1096-9888(200003)35:3<417::AID-JMS952>3.0.CO;2-#; Kridl J. C., 1991, Seed Science Research, V1, P209, DOI 10.1017/S0960258500000921; MORRIS LJ, 1967, BIOCHEM BIOPH RES CO, V29, P311, DOI 10.1016/0006-291X(67)90454-8; OKULEY J, 1994, PLANT CELL, V6, P147, DOI 10.1105/tpc.6.1.147; Pikus JD, 1997, BIOCHEMISTRY-US, V36, P9283, DOI 10.1021/bi971049t; RESNICK MA, 1966, J BACTERIOL, V92, P597, DOI 10.1128/JB.92.3.597-600.1966; SAVILE CK, 2001, J CHEM SOC P1, V9, P1116; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Shanklin J, 1997, P NATL ACAD SCI USA, V94, P2981, DOI 10.1073/pnas.94.7.2981; Smith C. R., 1970, PROGR CHEM FATS OTHE, V11, P139, DOI [10.1002/food.19910350121, DOI 10.1002/FOOD.19910350121]; SMITH CR, 1961, J ORG CHEM, V26, P2903, DOI 10.1021/jo01066a067; Smith M, 2000, BIOCHEM SOC T, V28, P947, DOI 10.1042/BST0280947; SPERLING P, 1993, J BIOL CHEM, V268, P26935; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Whittle E, 2001, J BIOL CHEM, V276, P21500, DOI 10.1074/jbc.M102129200	41	128	147	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15613	15620		10.1074/jbc.M200231200	http://dx.doi.org/10.1074/jbc.M200231200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864983	hybrid			2022-12-25	WOS:000175510400054
J	Charvet, C; Auberger, P; Tartare-Deckert, S; Bernard, A; Deckert, M				Charvet, C; Auberger, P; Tartare-Deckert, S; Bernard, A; Deckert, M			Vav1 couples T cell receptor to serum response factor-dependent transcription via a MEK-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX FACTORS; NF-KAPPA-B; C-FOS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; UP-REGULATION; ACTIVATION; FAMILY; KINASE; SRF	The Vav family of guanine nucleotide exchange factors for Rho family GTPases plays a critical role in lymphocyte proliferation, gene transcription, and cytoskeleton reorganization following immunoreceptor stimulation. However, its role in immediate early gene activation is unclear. In this study, we have investigated the mechanisms by which Vav1 can regulate c-fos serum response element transcriptional activity. We show that T cell antigen receptor (TCR) stimulation induces the phosphorylation of serum response factor (SRF) on serine 103 and increases the binding of SRF complexes on serum response element in a MEK- and p38-dependent pathway. The physiological relevance of our findings is supported by the inhibition of the interleukin-2 gene transcriptional activity by a dominant negative SRF mutant. Overexpression of Vav1, which partially mimics TCR stimulation, promotes SRF-dependent transcription, and dominant negative Vav1 mutants block SRF activation by TCR. SRF activation by Vav1 occurs through a signaling cascade consisting of Rac1/Cdc42 and the serine/threonine kinases Pak1 and MEK, but independently of the phosphatidylinositol 3-kinase pathway. Interestingly, Vav2 also enhances SRF through Rho GTPases, suggesting that Vav proteins are general regulators of SRF activation in lymphocytes. This report establishes Vav proteins as a direct link between antigen receptors and SRF-dependent early gene expression.	Hop Archet, INSERM, U343, IFR50, F-06202 Nice 3, France; Fac Med, INSERM, U526, F-06107 Nice 2, France; Fac Med, INSERM, U385, IFR50, F-06107 Nice 2, France	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Deckert, M (corresponding author), Hop Archet, INSERM, U343, IFR50, F-06202 Nice 3, France.	deckert@unice.ft	AUBERGER, Patrick/G-1491-2013; TARTARE-DECKERT, Sophie/P-6057-2015; Deckert, Marcel/M-4998-2016; Deckert, Marcel/T-3566-2019	AUBERGER, Patrick/0000-0002-2481-8275; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Deckert, Marcel/0000-0003-2094-559X				Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Altman A, 1999, ADV IMMUNOL, V72, P1, DOI 10.1016/S0065-2776(08)60017-6; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; CHATTA GS, 1994, J IMMUNOL, V153, P5393; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DeFranco AL, 2001, NAT IMMUNOL, V2, P482, DOI 10.1038/88669; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Glimcher LH, 1999, CELL, V96, P13, DOI 10.1016/S0092-8674(00)80955-1; Goodman RH, 2000, GENE DEV, V14, P1553; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin J, 2001, J CELL SCI, V114, P243; MagnaghiJaulin L, 1996, FEBS LETT, V391, P247, DOI 10.1016/0014-5793(96)00745-4; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Movilla N, 1999, MOL CELL BIOL, V19, P7870; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Parry RV, 1997, EUR J IMMUNOL, V27, P2495, DOI 10.1002/eji.1830271006; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Salojin KV, 1999, J IMMUNOL, V163, P844; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tartare-Deckert S, 2001, J BIOL CHEM, V276, P20849, DOI 10.1074/jbc.M010588200; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Villalba M, 2000, EUR J IMMUNOL, V30, P1587, DOI 10.1002/1521-4141(200006)30:6<1587::AID-IMMU1587>3.0.CO;2-T; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Woodside DG, 1998, J IMMUNOL, V161, P649; WU J, 1995, MOL CELL BIOL, V15, P4337; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647	59	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15376	15384		10.1074/jbc.M111627200	http://dx.doi.org/10.1074/jbc.M111627200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859076	hybrid			2022-12-25	WOS:000175510400021
J	Golts, N; Snyder, H; Frasier, M; Theisler, C; Choi, P; Wolozin, B				Golts, N; Snyder, H; Frasier, M; Theisler, C; Choi, P; Wolozin, B			Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER A-BETA; PARKINSONS-DISEASE; IN-VITRO; PRION-PROTEIN; LEWY BODIES; NEURODEGENERATIVE DISEASES; NACP/ALPHA-SYNUCLEIN; BASAL GANGLIA; WILD-TYPE; FERRITIN	Multiple studies implicate metals in the pathophysiology of neurodegenerative diseases. Disturbances in brain iron metabolism are linked with synucleinopathies. For example, in Parkinson's disease, iron levels are increased and magnesium levels are reduced in the brains of patients. To understand how changes in iron and magnesium might affect the pathophysiology of Parkinson's disease, we investigated binding of iron to alpha-synuclein, which accumulates in Lewy bodies. Using fluorescence of the four tyrosines in alpha-synuclein as indicators of metal-related conformational changes in alpha-synuclein, we show that iron and magnesium both interact with alpha-synuclein. alpha-Synuclein exhibits fluorescence peaks at 310 and 375 nm. Iron lowers both fluorescence peaks, while magnesium increases the fluorescence peak only at 375 nm, which suggests that magnesium affects the conformation of alpha-synuclein differently than iron. Consistent with this hypothesis, we also observe that magnesium inhibits alpha-synuclein aggregation, measured by immunoblot, cellulose acetate filtration, or thioflavine-T fluorescence. In each of these studies, iron increases alpha-synuclein aggregation, while magnesium at concentrations >0.75 mM inhibits the aggregation of alpha-synuclein induced either spontaneously or by incubation with iron. These data suggest that the conformation of alpha-synuclein can be modulated by metals, with iron promoting aggregation and magnesium inhibiting aggregation.	Loyola Univ, Med Ctr, Dept Pharmacol, Maywood, IL 60153 USA	Loyola University Chicago	Wolozin, B (corresponding author), Loyola Univ, Med Ctr, Dept Pharmacol, Bldg 102,Rm 3634,2160 S 1st Ave, Maywood, IL 60153 USA.	bwolozi@lumc.edu			NINDS NIH HHS [NS41786-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041786] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Barbiroli B, 1999, MOVEMENT DISORD, V14, P430, DOI 10.1002/1531-8257(199905)14:3<430::AID-MDS1007>3.0.CO;2-S; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Castellani RJ, 2000, ACTA NEUROPATHOL, V100, P111, DOI 10.1007/s004010050001; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; Durlach J, 1998, MAGNESIUM RES, V11, P25; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Galvin JE, 2000, AM J PATHOL, V157, P361, DOI 10.1016/S0002-9440(10)64548-8; Garzon-Rodriguez W, 1999, BIOORG MED CHEM LETT, V9, P2243, DOI 10.1016/S0960-894X(99)00357-1; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Gorell JM, 1999, NEUROTOXICOLOGY, V20, P239; Griffiths PD, 1999, BRAIN, V122, P667, DOI 10.1093/brain/122.4.667; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; HIRSCH EC, 1989, ACTA NEUROL SCAND, V80, P19, DOI 10.1111/j.1600-0404.1989.tb01778.x; Hoehn MM, 1998, NEUROLOGY, V50, P318, DOI 10.1212/WNL.50.2.318; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; MANN VM, 1994, ANN NEUROL, V36, P876, DOI 10.1002/ana.410360612; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Nielsen MS, 2001, J BIOL CHEM, V276, P22680, DOI 10.1074/jbc.M101181200; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Paik SR, 2000, ARCH BIOCHEM BIOPHYS, V378, P269, DOI 10.1006/abbi.2000.1822; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ponka P, 1998, SEMIN HEMATOL, V35, P35; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; SZABO AG, 1978, FEBS LETT, V94, P249, DOI 10.1016/0014-5793(78)80948-X; Thomson AM, 1999, INT J BIOCHEM CELL B, V31, P1139, DOI 10.1016/S1357-2725(99)00080-1; UITTI RJ, 1989, CAN J NEUROL SCI, V16, P310, DOI 10.1017/S0317167100029140; Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Wolozin B, 2002, NEUROSCIENTIST, V8, P22, DOI 10.1177/107385840200800107; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	44	150	154	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16116	16123		10.1074/jbc.M107866200	http://dx.doi.org/10.1074/jbc.M107866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11850416	hybrid			2022-12-25	WOS:000175510400119
J	Ballweber, P; Markl, J; Burmester, T				Ballweber, P; Markl, J; Burmester, T			Complete hemocyanin subunit sequences of the hunting spider Cupiennius salei - Recent hemocyanin remodeling in entelegyne spiders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARANTULA EURYPELMA-CALIFORNICUM; ARTHROPOD HEMOCYANINS; QUATERNARY STRUCTURE; CRYSTAL-STRUCTURE; EVOLUTION; SITE	Hemocyanins are large copper-containing respiratory proteins found in many arthropod species. Scorpions and orthognath spiders possess a highly conserved 4 x 6-mer hemocyanin that consists of at least seven distinct subunit types (termed a to g). However, many "modern" entelegyne spiders such as Cupiennius salei differ from the standard arachnid scheme and have 2 x 6-mer hemocyanins. Here we report the complete primary structure of the 2 x 6-mer hemocyanin of C. salei as deduced from cDNA sequencing, gel electrophoresis, and matrix-assisted laser desorption spectroscopy. Six distinct subunit types (1 through 6) and three additional allelic sequences were identified. Each 1 x 6-mer half-molecule most likely is composed of subunits 1-6, with subunit 1 linking the two hexamers via a disulfide bridge located in a C-terminal extension. The C. salei hemocyanin subunits all belong to the arachnid g-type, whereas the other six types (a-f) have been lost in evolution. The reconstruction of a complex hemocyanin from a single g-type subunit, which commenced about 190 million years ago and was completed about 90 million years ago, might be explained by physiological and behavioral changes that occurred during the evolution of the entelegyne spiders.	Univ Mainz, Inst Zool, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Markl, J (corresponding author), Univ Mainz, Inst Zool, Mullerweg 6, D-55099 Mainz, Germany.		Burmester, Thorsten/I-7225-2013	Burmester, Thorsten/0000-0002-5772-7863				[Anonymous], PHYLIP PHYLOGENY INF; Burmester T, 2001, MOL BIOL EVOL, V18, P184, DOI 10.1093/oxfordjournals.molbev.a003792; Burmester T, 1998, J MOL EVOL, V47, P93, DOI 10.1007/PL00006366; Burmester T, 1996, J MOL EVOL, V42, P713, DOI 10.1007/BF02338804; Burmester T, 2002, J COMP PHYSIOL B, V172, P95, DOI 10.1007/s00360-001-0247-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CODDINGTON JA, 1991, ANNU REV ECOL SYST, V22, P565, DOI 10.1146/annurev.es.22.110191.003025; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Dayhoff M., 1978, ATLAS PROTEIN SEQ ST, V5; DECKER H, 1980, H-S Z PHYSIOL CHEM, V361, P1707, DOI 10.1515/bchm2.1980.361.2.1707; Dunlop J.A., 1998, Systematics Association Special Volume Series, V55, P221; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Harris JR, 1999, MICRON, V30, P597, DOI 10.1016/S0968-4328(99)00036-0; HAZES B, 1993, PROTEIN SCI, V2, P597; KEMPTER B, 1985, BIOL CHEM H-S, V366, P77, DOI 10.1515/bchm3.1985.366.1.77; KEMPTER B, 1983, NATURWISSENSCHAFTEN, V70, P255, DOI 10.1007/BF00405449; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kusche K, 2001, MOL BIOL EVOL, V18, P1566, DOI 10.1093/oxfordjournals.molbev.a003943; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMY J, 1979, H-S Z PHYSIOL CHEM, V360, P889, DOI 10.1515/bchm2.1979.360.2.889; Lieb B, 2001, P NATL ACAD SCI USA, V98, P4546, DOI 10.1073/pnas.071049998; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; MARKL J, 1984, H-S Z PHYSIOL CHEM, V365, P619, DOI 10.1515/bchm2.1984.365.1.619; MARKL J, 1981, H-S Z PHYSIOL CHEM, V362, P1631, DOI 10.1515/bchm2.1981.362.2.1631; MARKL J, 1979, J COMP PHYSIOL, V130, P283, DOI 10.1007/BF00689845; MARKL J, 1980, J COMP PHYSIOL, V140, P199, DOI 10.1007/BF00690404; Markl J., 1992, Advances in Comparative and Environmental Physiology, V13, P325; MARKL J, 1986, BIOL BULL, V171, P90, DOI 10.2307/1541909; MARKL J, 1981, H-S Z PHYSIOL CHEM, V362, P1255, DOI 10.1515/bchm2.1981.362.2.1255; Markl J., 1981, P125; MARKL J, 1976, H-S Z PHYSIOL CHEM, V357, P1713, DOI 10.1515/bchm2.1976.357.2.1713; MARKL J, 1981, H-S Z PHYSIOL CHEM, V362, P429, DOI 10.1515/bchm2.1981.362.1.429; MARKL J, 1990, INVERTEBRATE DIOXYGEN CARRIERS, P497; Selden PA, 1993, FOSS REC, V2, P297; Topham R, 1999, ARCH BIOCHEM BIOPHYS, V369, P261, DOI 10.1006/abbi.1999.1367; van Holde KE, 2001, J BIOL CHEM, V276, P15563, DOI 10.1074/jbc.R100010200; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; Voit R, 2000, J BIOL CHEM, V275, P39339, DOI 10.1074/jbc.M005442200	38	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14451	14457		10.1074/jbc.M111368200	http://dx.doi.org/10.1074/jbc.M111368200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11842087	hybrid			2022-12-25	WOS:000175203000015
J	van Montfort, BA; Schuurman-Wolters, GK; Wind, J; Broos, J; Robillard, GT; Poolman, B				van Montfort, BA; Schuurman-Wolters, GK; Wind, J; Broos, J; Robillard, GT; Poolman, B			Mapping of the dimer interface of the Escherichia coli mannitol permease by cysteine cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; SITE-SPECIFIC MUTAGENESIS; PROJECTION STRUCTURE; TRANSPORT PROTEIN; ENZYME-IIMTL; TRANSMEMBRANE DOMAIN; ANGSTROM RESOLUTION; PHOSPHOENOLPYRUVATE; MEMBRANE; PHOSPHORYLATION	A cysteine cross-linking approach was used to identify residues at the dimer interface of the Escherichia colt mannitol permease. This transport protein comprises two cytoplasmic domains and one membrane-embedded C domain per monomer, of which the latter provides the dimer contacts. A series of single-cysteine His-tagged C domains present in the native membrane were subjected to Cu(II)-(1,10-phenanthroline)(3)-catalyzed disulfide formation or cysteine cross-linking with dimaleimides of different length. The engineered cysteines were at the borders of the predicted membrane-spanning a-helices. Two residues were found to be located in close proximity of each other and capable of forming a disulfide, while four other locations formed cross-links with the longer dimaleimides. Solubilization of the membranes did only influence the cross-linking behavior at one position (Cys(73)). Mannitol binding only effected the cross-linking of a cysteine at the border of the third transmembrane helix (Cys(134)), indicating that substrate binding does not lead to large rearrangements in the helix packing or to dissociation of the dimer. Upon mannitol binding, the Cys(134) becomes more exposed but the residue is no longer capable of forming a stable disulfide in the dimeric IIC domain. In combination with the recently obtained projection structure of the IIC domain in two-dimensional crystals, a first proposal is made for a-helix packing in the mannitol permease.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biochem, NL-9747 AG Groningen, Netherlands	University of Groningen	Poolman, B (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biochem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Poolman, Bert/D-1882-2012					BOER H, 1994, J BIOL CHEM, V269, P17863; Boer H, 1996, BIOCHEMISTRY-US, V35, P12901, DOI 10.1021/bi9611016; Broos J, 1998, J BIOL CHEM, V273, P3865, DOI 10.1074/jbc.273.7.3865; Broos J, 1999, BIOCHEMISTRY-US, V38, P9798, DOI 10.1021/bi991157a; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Chang YY, 1997, BIOCHEMISTRY-US, V36, P11564, DOI 10.1021/bi9709102; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; Heymann JAW, 2001, EMBO J, V20, P4408, DOI 10.1093/emboj/20.16.4408; Koning RI, 1999, J MOL BIOL, V287, P845, DOI 10.1006/jmbi.1999.2650; Kwaw I, 2000, BIOCHEMISTRY-US, V39, P3134, DOI 10.1021/bi992509g; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10659, DOI 10.1021/bi00499a012; Meijberg W, 1998, J BIOL CHEM, V273, P20785, DOI 10.1074/jbc.273.33.20785; Mindell JA, 2001, NATURE, V409, P219, DOI 10.1038/35051631; Nagy JK, 2000, BIOCHEMISTRY-US, V39, P4154, DOI 10.1021/bi991781n; PAS HH, 1987, BIOCHEMISTRY-US, V26, P6689, DOI 10.1021/bi00395a019; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; ROBILLARD GT, 1993, BIOCHEMISTRY-US, V32, P9553, DOI 10.1021/bi00088a006; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P211, DOI 10.1021/bi00297a006; ROOSSIEN FF, 1986, FEBS LETT, V196, P284, DOI 10.1016/0014-5793(86)80264-2; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P5682, DOI 10.1021/bi00319a003; SaraceniRichards CA, 1997, J BACTERIOL, V179, P5171, DOI 10.1128/jb.179.16.5171-5177.1997; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P4046, DOI 10.1021/bi00362a009; STODDARD BL, 1992, BIOCHEMISTRY-US, V31, P11978, DOI 10.1021/bi00163a004; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77; van Montfort BA, 2001, J BIOL CHEM, V276, P12756, DOI 10.1074/jbc.M010728200; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; Veenhoff LM, 2001, EMBO J, V20, P3056, DOI 10.1093/emboj/20.12.3056; VILLAFRANCA JE, 1987, BIOCHEMISTRY-US, V26, P2182, DOI 10.1021/bi00382a017; WENG QP, 1992, J BIOL CHEM, V267, P19529; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Wu JH, 1997, J MOL BIOL, V270, P285, DOI 10.1006/jmbi.1997.1099	35	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14717	14723		10.1074/jbc.M201533200	http://dx.doi.org/10.1074/jbc.M201533200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11854301	Green Published, hybrid			2022-12-25	WOS:000175203000048
J	Ahmed, N; Niu, J; Dorahy, DJ; Gu, XH; Andrews, S; Meldrum, CJ; Scott, RJ; Baker, MS; Macreadie, IG; Agrez, MV				Ahmed, N; Niu, J; Dorahy, DJ; Gu, XH; Andrews, S; Meldrum, CJ; Scott, RJ; Baker, MS; Macreadie, IG; Agrez, MV			Direct integrin alpha v beta 6-ERK binding: implications for tumour growth	ONCOGENE			English	Article						alpha v beta 6 integrin; colon cancer; ERK2; tumour growth	ACTIVATED PROTEIN-KINASE; SIGNALING PATHWAY; EXPRESSION; CELLS; TRANSDUCTION; SUBUNIT; ALPHA-NU-BETA-6; FIBRONECTIN; SPECIFICITY; ERK	Blockade of the mitogen-activated protein (MAP) kinase pathway suppresses growth of colon cancer in vivo. Here we demonstrate a direct link between the extracellular signal-regulated kinase ERK2 and the growth-promoting cell adhesion molecule, integrin alphavbeta6, in colon cancer cells. Down-regulation of beta6 integrin subunit expression inhibits tumour growth in vivo and MAP kinase activity in response to serum stimulation. In alphavbeta6-expressing cells ERK2 is bound only to the beta6 subunit. The increase in cytosolic MAP kinase activity upon epidermal growth factor stimulation is all accounted for by beta6-bound ERK. Deletion of the ERK2 binding site on the beta6 cytoplasmic domain inhibits tumour growth and leads to an association between ERK and the beta5 subunit. The physical interaction between integrin alphavbeta6 and ERK2 defines a novel paradigm of integrin-mediated signalling and provides a therapeutic target for cancer treatment.	Univ Newcastle, Fac Med & Hlth Sci, Discipline Surg Sci, Newcastle, NSW 2308, Australia; John Hunter Hosp, Hunter Med Res Inst, Newcastle Bowel Canc Res Collaborat, Newcastle, NSW, Australia; Royal Womens Hosp, Gynaecol Canc Res Ctr, Melbourne, Vic, Australia; Univ Melbourne, Melbourne, Vic, Australia; CSIRO Hlth Sci & Nutr, Parkville, Vic, Australia	University of Newcastle; Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle; University of Melbourne; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Agrez, MV (corresponding author), Univ Newcastle, Fac Med & Hlth Sci, Discipline Surg Sci, Newcastle, NSW 2308, Australia.	Michael.Agrez@newcastle.edu.au	Macreadie, Ian/L-4437-2019; Macreadie, Ian/Q-7430-2019; Macreadie, Ian G/F-5997-2010; Scott, Rodney J/B-2827-2013	Macreadie, Ian/0000-0001-5335-7220; Macreadie, Ian G/0000-0001-5335-7220; Scott, Rodney J/0000-0001-7724-3404; Baker, Mark/0000-0001-5858-4035; Meldrum, Cliff/0000-0002-5685-1918				Agrez M, 1999, INT J CANCER, V81, P90, DOI 10.1002/(SICI)1097-0215(19990331)81:1<90::AID-IJC16>3.0.CO;2-K; AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; Agrez MV, 1996, BRIT J CANCER, V73, P887, DOI 10.1038/bjc.1996.158; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Arihiro K, 2000, Breast Cancer, V7, P19, DOI 10.1007/BF02967183; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREUSS JM, 1995, J CELL SCI, V108, P2241; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONE RI, 1994, CELL ADHES COMMUN, V2, P101, DOI 10.3109/15419069409004430; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Duesbery NS, 1999, NAT MED, V5, P736, DOI 10.1038/10457; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hamidi S, 2000, BRIT J CANCER, V82, P1433, DOI 10.1054/bjoc.1999.1130; HEWITT RE, 1991, INT J CANCER, V49, P666, DOI 10.1002/ijc.2910490507; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Johansson N, 2000, J CELL SCI, V113, P227; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Licato LL, 1997, GASTROENTEROLOGY, V113, P1589, DOI 10.1053/gast.1997.v113.pm9352861; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Niu J, 2001, INT J CANCER, V92, P40, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1157>3.0.CO;2-B; Partik G, 1999, J CANCER RES CLIN, V125, P379, DOI 10.1007/s004320050290; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; Thomas GJ, 1997, ORAL ONCOL, V33, P381, DOI 10.1016/S0964-1955(97)00021-3; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	37	81	90	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1370	1380		10.1038/sj.onc.1205286	http://dx.doi.org/10.1038/sj.onc.1205286			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857080				2022-12-25	WOS:000173861000007
J	Baldeyron, C; Jacquemin, E; Smith, J; Jacquemont, C; De Oliveira, I; Gad, S; Feunteun, J; Stoppa-Lyonnet, D; Papadopoulo, D				Baldeyron, C; Jacquemin, E; Smith, J; Jacquemont, C; De Oliveira, I; Gad, S; Feunteun, J; Stoppa-Lyonnet, D; Papadopoulo, D			A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining	ONCOGENE			English	Article						BRCA1; DNA repair; double strand break; end-joining fidelity; heterozygous state	HISTONE H2AX; DNA; REPAIR; CANCER; CELLS; COMPLEX; IDENTIFICATION; REARRANGEMENTS; RECOMBINATION; ASSOCIATION	Heterozygosity for mutations in the BRCA1 gene in humans confers high risk for developing breast cancer, but a biochemical basis for this phenotype has not yet been determined. Evidence has accumulated implicating BRCA1, in the maintenance of genomic integrity and the protection of cells against DNA double strand breaks (DSB). Here we present evidence that human cells heterozygous for BRCA1 mutations exhibit impaired DNA end-joining, which is the major DSB repair pathway in mammalian somatic cells. Using an in vivo host cell end-joining assay, we observed that the fidelity of DNA end-joining is strongly reduced in three BRCA1(+/-) cell lines in comparison to two control cell lines. Moreover, cell-free BRCA1(+/-) extracts are unable to promote accurate DNA end-joining in an in vitro reaction. The steady-state level of the wild type BRCA1 protein was significantly lower than the 50% expected in BRCA1(+/-) cells and thus may underlie the observed end-joining defect. Together, these data strongly suggest that BRCA1 is necessary for faithful rejoining of broken DNA ends and that a single mutated BRCA1 allele is sufficient to impair this process. This defect will compromise genomic stability in BRCA1 germ-line mutation carriers, triggering the genetic changes necessary for the initiation of neoplastic transformation.	CNRS, UMR 218, Inst Curie, Sect Rech, F-75248 Paris 05, France; Sect Med, Inst Curie, Serv Genet Oncol, F-75248 Paris 05, France; Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Papadopoulo, D (corresponding author), CNRS, UMR 218, Inst Curie, Sect Rech, F-75248 Paris 05, France.	papadopoulo@curie.fr	Feunteun, Jean/AAZ-1267-2020; Baldeyron, Céline/F-6990-2019	Baldeyron, Céline/0000-0003-2311-1523; Feunteun, Jean/0000-0003-1212-9189; GAD (LAPITEAU), Sophie/0000-0002-3158-6791				Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; GOVEN LC, 1998, SCIENCE, V281, P1009; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Le Page F, 2000, CANCER RES, V60, P5548; Lee MS, 2000, ENDOCRINOLOGY, V141, P883, DOI 10.1210/en.141.3.883; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Pluth JM, 2001, CANCER RES, V61, P2649; Puget N, 1999, CANCER RES, V59, P455; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothfuss A, 2000, CANCER RES, V60, P390; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Smith J, 1998, J MOL BIOL, V281, P815, DOI 10.1006/jmbi.1998.1971; Smith J, 2001, NUCLEIC ACIDS RES, V29, P4783, DOI 10.1093/nar/29.23.4783; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; Wang HC, 2001, CANCER RES, V61, P270; Wang Y, 2000, GENE DEV, V14, P927; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	37	92	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1401	1410		10.1038/sj.onc.1205200	http://dx.doi.org/10.1038/sj.onc.1205200			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857083				2022-12-25	WOS:000173861000010
J	Croxton, R; Ma, YH; Song, LX; Haura, EB; Cress, WD				Croxton, R; Ma, YH; Song, LX; Haura, EB; Cress, WD			Direct repression of the Mcl-1 promoter by E2F1	ONCOGENE			English	Article						apoptosis; cell cycle; E2F; Mcl-1; microarray	S-PHASE ENTRY; BCL-2 FAMILY-MEMBER; DNA-SYNTHESIS; RETINOBLASTOMA PROTEIN; SIGNALING PATHWAY; BINDING PROTEIN; STABILIZES P53; CYTOCHROME-C; CELL-DEATH; APOPTOSIS	E2F1 induces apoptosis via both p53-dependent and p53-independent mechanisms. The direct targets in the p53-independent pathway remain enigmatic; however, the induction of this pathway does not require the transactivation domain of E2F1. Using cells that are defective in p53 activation, we show that E2F1 potently represses the expression of Mcl-1 - an anti-apoptotic Bcl-2 family member whose depletion results in apoptosis. We also show that this transcriptional repression is direct and dependent upon E2F1's DNA-binding domain, but does not require the transactivation domain of E2F1. Consistent with this DNA binding requirement of E2F1 to repress Mcl-1, we show that E2F1 binds to the Mcl-1 promoter both in vitro and in vivo, and have identified the DNA element (- 143/ -117) within this promoter that is required for E2F1 binding and repression. Additionally, cell lines constitutively expressing Mcl-1 are resistant to E2F1-mediated apoptosis - suggesting that Mcl-1 downregulation is a necessary event in the p53-independent apoptotic process. Thus, we identify a p53 family-independent mechanism of E2F1-induced apoptosis in which E2F1 directly represses Mcl-1 expression.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Res Inst, Tampa, FL 33612 USA; Univ S Florida, Clin Invest Program, H Lee Moffitt Comprehens Canc Ctr, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Inst Biomol Sci, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cress, WD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R29CA078214] Funding Source: NIH RePORTER; NCI NIH HHS [CA78214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dong YB, 1999, CANCER, V86, P2021, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2021::AID-CNCR20>3.0.CO;2-1; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsu SY, 2000, PHYSIOL REV, V80, P593, DOI 10.1152/physrev.2000.80.2.593; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Liu TJ, 1999, CANCER GENE THER, V6, P163, DOI 10.1038/sj.cgt.7700007; Lomo J, 1996, CANCER RES, V56, P40; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Takahashi Y, 2000, GENE DEV, V14, P804; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yang HL, 2000, CLIN CANCER RES, V6, P1579; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhao RB, 2000, GENE DEV, V14, P981; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829	72	123	126	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1359	1369		10.1038/sj.onc.1205157	http://dx.doi.org/10.1038/sj.onc.1205157			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857079				2022-12-25	WOS:000173861000006
J	Aouacheria, A; Ory, S; Schmitt, JR; Rigal, D; Jurdic, P; Gillet, G				Aouacheria, A; Ory, S; Schmitt, JR; Rigal, D; Jurdic, P; Gillet, G			p60(v-src) and serum control cell shape and apoptosis via distinct pathways in quail neuroretina cells	ONCOGENE			English	Article						v-src; cytoskeleton; apoptosis; MAP kinases; G-proteins; retina	FOCAL ADHESION KINASE; PP60C-SRC PROTEIN-KINASE; SRC TYROSINE KINASE; V-SRC; SUBSTRATUM ADHESIONS; SIGNALING PATHWAYS; TRANSFORMATION; RAS; ACTIVATION; RHO	We made use of QNR cells transformed by a thermosensitive (tsNY68) strain of the Rous sarcoma virus (RSV) to compare the effect of p60(v-src) and serum in cultured nerve cells. In this system, both p60(v-src) heat inactivation and serum removal resulted in growth arrest in G1. In both cases, growth arrest was reversible since cell proliferation was rapidly re-induced following respectively p60v-src renaturation or serum re-addition. However, cells did not fully recover their ability to grow in soft agar, suggesting that, in contrast to the cell cycle machinery, the transforming capacities of these cells have been irreversibly altered. We found that p60(v-src) kinase activity prevented detachment from the substratum and cell death following serum removal. Thermal inactivation of p60(v-src) at restrictive temperature (41.5degreesC), but not serum removal, resulted in dramatic morphological changes, which occured 4 h after temperature shift up to 41.5degreesC. Later on, typical features of apoptotic cells could be observed. Cell death was greatly reduced by the caspase-3 inhibitor ZVAD.FMK, but not by the caspase-1 inhibitor Ac-YVAD.CHO. Together, these results suggested that p60(v-src) and serum factors act on distinct pathways, at least in part. In an attempt to identify the signalling pathways involved in the cell response to p60(v-src) down regulation, we found that Erk and Rac were rapidly inactivated following temperature shift up to 41.5degreesC. Thus, the combined effects of p60(v-src) and serum factors on the cytoskeleton dynamics and the apoptosis machinery are essential for full neoplastic transformation of neuroretina cells.	Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France; Ecole Normale Super Lyon, UMR 5665, Biol Cellulaire & Mol Lab, CNRS, F-69364 Lyon 07, France; Etab Transfus Sanguine, F-69007 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Gillet, G (corresponding author), NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA.	g.gillet@ibcp.fr	Ory, Stéphane/G-9714-2019; gillet, germain/A-9095-2013; Ory, Stéphane/E-9947-2010	Ory, Stéphane/0000-0003-4359-1157; Ory, Stéphane/0000-0003-4359-1157; GILLET, Germain/0000-0002-1514-327X				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; Armstrong RC, 1997, J NEUROSCI, V17, P553; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Castellani L, 1996, J CELL SCI, V109, P1335; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; Dehm S, 2001, FEBS LETT, V487, P367, DOI 10.1016/S0014-5793(00)02354-1; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVAZZI I, 1989, J CELL SCI, V94, P85; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; Gillet G, 1996, TRENDS MICROBIOL, V4, P312, DOI 10.1016/0966-842X(96)10047-0; GILLET G, 1993, ONCOGENE, V8, P565; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Meijne AML, 1997, EXP CELL RES, V234, P477, DOI 10.1006/excr.1997.3637; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; NERMUT MV, 1991, EXP CELL RES, V193, P382, DOI 10.1016/0014-4827(91)90111-7; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Ory S, 2000, J CELL SCI, V113, P1177; PATCH LA, 1995, J CELL SCI, V108, P1371; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; PESSAC B, 1983, NATURE, V302, P616, DOI 10.1038/302616a0; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Routes JM, 2000, J IMMUNOL, V165, P4522, DOI 10.4049/jimmunol.165.8.4522; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUDOL M, 1993, MOL BASIS HUMAN CANC, P203; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; WU LW, 1995, ONCOGENE, V11, P1459; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	66	9	9	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1171	1186		10.1038/sj.onc.1205170	http://dx.doi.org/10.1038/sj.onc.1205170			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850837				2022-12-25	WOS:000173729400005
J	Baillat, G; Gaillard, S; Castets, F; Monneron, A				Baillat, G; Gaillard, S; Castets, F; Monneron, A			Interactions of phocein with nucleoside-diphosphate kinase, Eps15, and dynamin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; NERVE-TERMINALS; ENDOCYTIC PATHWAY; DENDRITIC SPINES; STRIATIN; MEMBRANE; GTPASE; FAMILY; RAT; COMPONENTS	Phocein, an intracellular protein interacting with striatin, bears a few homologies with the sigma-subunits of clathrin adaptor proteins (Baillat, G., Moqrich, A., Castets, F., Baude, A., Bailly, Y., Benmerah, A., and Monneron, A. (2001) Mol. Biol. Cell 12, 663-673). Using phocein as a bait in a yeast two-hybrid screen, we identified two novel interacting proteins, nucleoside-diphosphate kinase (NDPK) and Eps15. Immunoprecipitation and pull-down experiments involving native and/or recombinant phocein and, respectively, NDPK and Eps15, biochemically validated their interactions. NDPK and Eps15 were recently shown to be functional neighbors of dynamin. Dynamin I is shown here to directly interact with NDPK through its C-terminal proline-rich domain, whereas recombinant phocein associates with native dynamin I. Immunocytochemical studies of rat embryonic hippocampal neurons demonstrated partial co-localization of phocein and dynamin I. Phocein thus appears to be a component of the complexes involved in some steps of the vesicular traffic machinery.	Fac Med Nord, INSERM, U464, F-13916 Marseille 20, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Castets, F (corresponding author), Fac Med Nord, INSERM, U464, Bd Pierre Dramard, F-13916 Marseille 20, France.			Gaillard, Stephane/0000-0001-9326-5363				Baillat G, 2001, MOL BIOL CELL, V12, P663, DOI 10.1091/mbc.12.3.663; Bartoli M, 1999, J NEUROBIOL, V40, P234, DOI 10.1002/(SICI)1097-4695(199908)40:2<234::AID-NEU9>3.3.CO;2-K; Bartoli M, 1998, J BIOL CHEM, V273, P22248, DOI 10.1074/jbc.273.35.22248; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Cao H, 2000, J CELL SCI, V113, P1993; Castets F, 2000, J BIOL CHEM, V275, P19970, DOI 10.1074/jbc.M909782199; Castets F, 1996, J CELL BIOL, V134, P1051, DOI 10.1083/jcb.134.4.1051; Dagher MC, 1997, BIOTECHNIQUES, V22, P916, DOI 10.2144/97225st05; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Estes PS, 1996, J NEUROSCI, V16, P5443; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goslin K., 1998, CULTURING NERVE CELL, P339; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Iannolo G, 1997, CANCER RES, V57, P240; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMMEL AR, 1987, METHOD ENZYMOL, V152, P307; Klinker JF, 1999, EUR J BIOCHEM, V261, P72, DOI 10.1046/j.1432-1327.1999.00209.x; Krishnan KS, 2001, NEURON, V30, P197, DOI 10.1016/S0896-6273(01)00273-2; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; Moreno CS, 2001, J BIOL CHEM, V276, P24253, DOI 10.1074/jbc.M102398200; NODA Y, 1993, NEUROSCIENCE, V55, P113, DOI 10.1016/0306-4522(93)90459-S; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POWELL KA, 1995, NEUROSCIENCE, V64, P821, DOI 10.1016/0306-4522(94)00337-5; Salcini AE, 2001, NAT CELL BIOL, V3, P755, DOI 10.1038/35087075; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	41	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18961	18966		10.1074/jbc.M108818200	http://dx.doi.org/10.1074/jbc.M108818200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11872741	hybrid			2022-12-25	WOS:000175975800093
J	Srisailam, S; Wang, HM; Kumar, TKS; Rajalingam, D; Sivaraja, V; Sheu, HS; Chang, YC; Yu, C				Srisailam, S; Wang, HM; Kumar, TKS; Rajalingam, D; Sivaraja, V; Sheu, HS; Chang, YC; Yu, C			Amyloid-like fibril formation in an all beta-barrel protein involves the formation of partially structured intermediate(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; ALZHEIMERS-DISEASE; PRION PROTEIN; SH3 DOMAIN; AGGREGATION; FIBRILLOGENESIS; TRANSTHYRETIN; PATHWAY; MODEL; STATE	In the present study, we demonstrate the thermal induced amyloid formation in a beta-barrel protein, such as the acidic fibroblast growth factor from Notopthalmus viridescens (nFGF-1). Fibril formation in nFGF-1 is observed to occur maximally at 65 degreesC. Electron microscope analysis of the thermal induced fibrils of nFGF-1 shows that they are filamentous with an average diameter of about 20 nm. X-ray diffraction analysis reveals that the thermal induced fibrils of nFGF-1 have a typical "cross-beta" structure with the beta-strands perpendicular to the fibril axis. By using a variety of biophysical techniques including multidimensional NMR, we demonstrate that fibril formation involves the formation of a partially structured intermediate(s) in the thermal unfolding pathway of the protein (nFGF-1). Results of the anilino-8-napthalene sulfonate binding experiments indicate that fibril formation occurs due to the coalescence of the protein (in the intermediate state(s)) through the solvent-exposed non-polar surface(s). In this study, we also demonstrate that organic osmolytes, such as proline, can efficiently prevent the thermal induced amyloid formation in nFGF-1. Proline is found to stabilize the native conformation of the protein. The addition, proline is observed to increase the cooperativity of the unfolding (native <-> denatured) reaction and consequently decrease the population of the "sticky" thermal equilibrium intermediate(s) responsible for the fibril formation.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan; Synchrotron Radiat Res Ctr, Hsinchu 30043, Taiwan; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30043, Taiwan	National Tsing Hua University; National Synchrotron Radiation Research Center; National Tsing Hua University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Sci Based Ind Pk, Hsinchu 30043, Taiwan.	cyu@mx.nthu.edu.tw	Kumar, Dr Suresh/HHZ-2615-2022; Kumar, Suresh Thallapuranam/R-5606-2016; KUMAR, P. SURESH/AAT-8951-2020	Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; KUMAR, P. SURESH/0000-0003-3222-2604				Arunkumar AI, 2000, J BIOMOL NMR, V17, P279, DOI 10.1023/A:1008339701691; Blackley HKL, 1999, EXP NEUROL, V158, P437, DOI 10.1006/exnr.1999.7114; CAIT E, 2000, J AM CHEM SOC, V122, P12707; Callahan NA, 2001, J BIOL CHEM, V276, P28022, DOI 10.1074/jbc.M103629200; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Chi YH, 2000, J BIOL CHEM, V275, P39444, DOI 10.1074/jbc.M007205200; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, J BIOL CHEM, V276, P46714, DOI 10.1074/jbc.M107040200; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; HARIS PI, 1995, BIOPOLYMERS, V37, P251, DOI 10.1002/bip.360370404; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Inouye H, 2000, J STRUCT BIOL, V130, P123, DOI 10.1006/jsbi.2000.4258; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; Kelly JW, 2000, NAT STRUCT BIOL, V7, P824, DOI 10.1038/82815; Lashuel HA, 1999, BIOCHEMISTRY-US, V38, P13560, DOI 10.1021/bi991021c; MacPhee CE, 2000, J MOL BIOL, V297, P1203, DOI 10.1006/jmbi.2000.3600; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; Pertinhez TA, 2001, FEBS LETT, V495, P184, DOI 10.1016/S0014-5793(01)02384-5; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Samuel D, 2001, J BIOL CHEM, V276, P4134, DOI 10.1074/jbc.M005921200; Samuel D, 2000, PROTEIN SCI, V9, P344; Samuel D, 2000, J BIOL CHEM, V275, P34968, DOI 10.1074/jbc.M005147200; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SERPELL LC, 1995, J MOL BIOL, V254, P113, DOI 10.1006/jmbi.1995.0604; Souillac PO, 2002, J BIOL CHEM, V277, P12666, DOI 10.1074/jbc.M109229200; SRINIVAS V, 1995, LANGMUIR, V11, P2830, DOI 10.1021/la00007a077; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970; Zurdo J, 2001, J MOL BIOL, V311, P325, DOI 10.1006/jmbi.2001.4858; Zurdo J, 2001, J AM CHEM SOC, V123, P8141, DOI 10.1021/ja016229b	45	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19027	19036		10.1074/jbc.M110762200	http://dx.doi.org/10.1074/jbc.M110762200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877422	hybrid			2022-12-25	WOS:000175975800102
J	Tristani-Firouzi, M; Chen, J; Sanguinetti, MC				Tristani-Firouzi, M; Chen, J; Sanguinetti, MC			Interactions between S4-S5 linker and S6 transmembrane domain modulate gating of HERG K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; VOLTAGE SENSOR; ACTIVATION; INACTIVATION; REGION; CONDUCTION; MOVEMENT; CURRENTS; PARTS; PORE	Outward movement of the voltage sensor is coupled to activation in voltage-gated ion channels; however, the precise mechanism and structural basis of this gating event are poorly understood. Potential insight into the coupling mechanism was provided by our previous finding that mutation to Lys of a single residue (Asp(540)) located in the S4-S5 linker endowed HERG (human ether-a-go-go-related gene) K+ channels with the unusual ability to open in response to membrane depolarization and hyperpolarization in a voltage-dependent manner. We hypothesized that the unusual hyperpolarization-induced gating occurred through an interaction between Lys(540) and the C-terminal end of the S6 domain, the region proposed to form the activation gate. Therefore, we mutated six residues located in this region of S6 (Ile(662)-Tyr(667)) to Ala in D540K HERG channels. Mutation of Arg(665), but not the other five residues, prevented hyperpolarization-dependent reopening of D540K HERG channels. Mutation of Arg(665) to Gln or Asp also prevented reopening. In addition, D540R and D540K/R665K BERG reopened in response to hyperpolarization. Together these findings suggest that a single residue (Arg(665)) in the S6 domain interacts with Lys(540) by electrostatic repulsion to couple voltage sensing to hyperpolarization-dependent opening of D540K EIERG K+ channels. Moreover, our findings suggest that the C-terminal ends of S4 and S6 are in close proximity at hyperpolarized membrane potentials.	Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Tristani-Firouzi, M (corresponding author), Univ Utah, Sch Med, Suite 1500 PCMC,100 N Med Dr, Salt Lake City, UT 84113 USA.	mfirouzi@hmbg.utah.edu	Sanguinetti, Michael/AAN-2615-2020		NHLBI NIH HHS [HL03816, HL65299] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065299] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; Caprini M, 2001, J BIOL CHEM, V276, P21070, DOI 10.1074/jbc.M100487200; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Chiavegatto S, 2001, P NATL ACAD SCI USA, V98, P1277, DOI 10.1073/pnas.031487198; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Gillian AL, 2001, BIOPHYS J, V80, p212A; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Mitcheson JS, 2000, J GEN PHYSIOL, V115, P229, DOI 10.1085/jgp.115.3.229; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; PEROZO E, 1992, BIOPHYS J, V62, P160, DOI 10.1016/S0006-3495(92)81802-7; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shieh CC, 1997, J GEN PHYSIOL, V109, P767, DOI 10.1085/jgp.109.6.767; STEFANI E, 1994, BIOPHYS J, V66, P996, DOI 10.1016/S0006-3495(94)80881-1; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Tang CY, 2000, J GEN PHYSIOL, V115, P319, DOI 10.1085/jgp.115.3.319; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448	26	142	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18994	19000		10.1074/jbc.M200410200	http://dx.doi.org/10.1074/jbc.M200410200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11864984	hybrid			2022-12-25	WOS:000175975800098
J	Kanduri, C; Fitzpatrick, G; Mukhopadhyay, R; Kanduri, M; Lobanenkov, V; Higgins, M; Ohlsson, R				Kanduri, C; Fitzpatrick, G; Mukhopadhyay, R; Kanduri, M; Lobanenkov, V; Higgins, M; Ohlsson, R			A differentially methylated imprinting control region within the Kcnq1 locus harbors a methylation-sensitive chromatin insulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BECKWITH-WIEDEMANN-SYNDROME; ENHANCER-BLOCKING ACTIVITY; GENE; CTCF; EXPRESSION; DISRUPTION; TRANSCRIPT; ELEMENTS; KVLQT1; H19	The mechanisms underlying the phenomenon of genomic imprinting remain poorly understood. In one instance, a differentially methylated imprinting control region (ICR) at the H19 locus has been shown to involve a methylation-sensitive chromatin insulator function that apparently partitions the neighboring Igf2 and H19 genes in different expression domains in a parent of origin-dependent manner. It is not known, however, if this mechanism is unique to the Igf2/H19 locus or if insulator function is a common feature in the regulation of imprinted genes. To address this question, we have studied an ICR in the Kcnq1 locus that regulates long range repression on the paternally derived p57Kip2 and Kcnq1 alleles in an imprinting domain that includes Igf2 and H19. We show that this ICR appears to possess a unidirectional chromatin insulator function in somatic cells of both mesodermal and endodermal origins. Moreover, we document that CpG methylation regulates this insulator function suggesting that a methylation-sensitive chromatin insulator is a common theme in the phenomenon of genomic imprinting.	Uppsala Univ, Evolut Biol Ctr, Dept Genet & Dev, S-75236 Uppsala, Sweden; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; NIAID, Immunopathol Lab, NIH, Bethesda, MD 20892 USA	Uppsala University; Roswell Park Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kanduri, C (corresponding author), Uppsala Univ, Evolut Biol Ctr, Dept Genet & Dev, Norbyvagen 18A, S-75236 Uppsala, Sweden.		Lobanenkov, Victor V./AGQ-8903-2022; Lobanenkov, Victor/ABD-5710-2021; kanduri, meena/AAG-1813-2019; KANDURI, MEENA/AAI-6169-2021	KANDURI, MEENA/0000-0003-2781-4779; Kanduri, Chandrasekhar/0000-0001-6271-9078; Lobanenkov, Victor/0000-0001-6665-3635	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000860, ZIAAI000860, Z01AI000859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Cleary MA, 2001, NAT GENET, V29, P78, DOI 10.1038/ng715; Engel JR, 2000, J MED GENET, V37, P921, DOI 10.1136/jmg.37.12.921; Gould TD, 1998, HUM MOL GENET, V7, P483, DOI 10.1093/hmg/7.3.483; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Holmgren C, 2001, CURR BIOL, V11, P1128, DOI 10.1016/S0960-9822(01)00314-1; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; John RM, 2001, HUM MOL GENET, V10, P1601, DOI 10.1093/hmg/10.15.1601; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Onyango P, 2000, GENOME RES, V10, P1697, DOI 10.1101/gr.161800; Paulsen M, 1998, HUM MOL GENET, V7, P1149, DOI 10.1093/hmg/7.7.1149; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Zhong XP, 1999, J IMMUNOL, V163, P295	17	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18106	18110		10.1074/jbc.M200031200	http://dx.doi.org/10.1074/jbc.M200031200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877438	hybrid			2022-12-25	WOS:000175685100091
J	Ihara, S; Miyoshi, E; Ko, JH; Murata, K; Nakahara, S; Honke, K; Dickson, RB; Lin, CY; Taniguchi, N				Ihara, S; Miyoshi, E; Ko, JH; Murata, K; Nakahara, S; Honke, K; Dickson, RB; Lin, CY; Taniguchi, N			Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; PLASMINOGEN-ACTIVATOR; SERINE-PROTEASE; TRANSCRIPTIONAL REGULATION; LINKED OLIGOSACCHARIDES; CARBOHYDRATE ANTIGENS; CARCINOMA-CELLS; METASTASIS; INHIBITOR; EXPRESSION	Oligosaccharide moieties of glycoproteins are structurally altered during development, carcinogenesis, and malignant transformations. It is well known that beta1-6 GlcNAc branching, a product of UDP-GlcNAc alpha-mannoside beta1-6-N-acetylglucosaminyltransferase (GnT-V), is associated with malignant transformation as the results of such alterations. However, the mechanism by which beta1-6 GlcNAc branching is linked to metastasis remains unclear, because the identification of specific glycoprotein(s) that are glycosylated by GnT-V and its biological function have not been examined. We herein report that matriptase, which activates both urokinase-type plasminogen activator and hepatocyte growth factor, is a target protein for GnT-V. The overexpression of GnT-V in gastric cancer cells leads to severe peritoneal dissemination in athymic mice, which can be attributed to the increased expression of matriptase. This increase was due to the acquired resistance of matriptase to degradation, since it is glycosylated by GnT-V and a corresponding increase in the active form. These results indicate that this process is a key element in malignant transformation, its the direct result of oligosaccharide modification.	Osaka Univ, Sch Med, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; KRIBB, Proteome Res Lab, Taejon 305333, South Korea; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg Oncol, Osaka 5378511, Japan; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	Osaka University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Osaka Medical Center for Cancer & Cardiovascular Diseases; Georgetown University	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Grad Sch Med, Dept Biochem, B1,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Ihara, Shinji/AAH-6730-2019; Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; Chen L, 1998, ONCOGENE, V17, P2087, DOI 10.1038/sj.onc.1202124; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; FERNANDES B, 1991, CANCER RES, V51, P718; Fukuda M, 1996, CANCER RES, V56, P2237; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Granovsky M, 2000, NAT MED, V6, P306; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Ito Y, 2001, INT J CANCER, V91, P631, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1118>3.3.CO;2-6; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MIWA K, 1985, GENE, V39, P281; Miyata S, 2000, J BIOL CHEM, V275, P4592, DOI 10.1074/jbc.275.7.4592; MIYOSHI E, 1993, CANCER RES, V53, P3899; Murata K, 2000, CLIN CANCER RES, V6, P1772; NAITO K, 1993, AGENTS ACTIONS, V39, P182, DOI 10.1007/BF01998972; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; PIERCE M, 1986, J BIOL CHEM, V261, P772; QUAX PHA, 1991, J CELL BIOL, V115, P191, DOI 10.1083/jcb.115.1.191; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; Seberger PJ, 1999, GLYCOBIOLOGY, V9, P235, DOI 10.1093/glycob/9.3.235; Seelentag WKF, 1998, CANCER RES, V58, P5559; SHI YE, 1993, CANCER RES, V53, P1409; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; WANG CI, 1995, J BIOL CHEM, V270, P12250, DOI 10.1074/jbc.270.20.12250; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	40	165	179	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16960	16967		10.1074/jbc.M200673200	http://dx.doi.org/10.1074/jbc.M200673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864986	hybrid			2022-12-25	WOS:000175564500083
J	Hellstern, S; Sasaki, T; Fauser, C; Lustig, A; Timpl, R; Engel, J				Hellstern, S; Sasaki, T; Fauser, C; Lustig, A; Timpl, R; Engel, J			Functional studies on recombinant domains of Mac-2-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAC-2 BINDING-PROTEIN; CYSTEINE-RICH DOMAIN; RING-LIKE STRUCTURES; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; CALCIUM-BINDING; BTB/POZ DOMAIN; ANTIGEN; SUPERFAMILY; ONCOPROTEIN	Mac-2-binding protein (M2BP) is a secreted glycoprotein suggested to have a role in host defense. It forms linear and ring-shaped oligomers, with each ring segment being composed of two monomers. We have produced recombinant human M2BP fragments comprising domains 1 and 2 (M2BP-1,2) and domains 3 and 4 (M2BP-3,4) in 293 human kidney cells to characterize structural and functional properties of M2BP. Both fragments were obtained in a native and glycosylated form, as analyzed by CD spectroscopy, trypsin susceptibility, and enzymatic deglycosylation. These results strongly suggest that both fragments are autonomous folding units. All three potential N-glycosylation sites in M2BP-1,2 and all four in M2BP-3,4 were found to be occupied. M2BP-1,2 expressed in tunicamycin-treated cells contained no glycosyl residues, indicating that O-glycosylation is not occurring. Ultracentrifugation revealed that M2BP-1,2 is homogeneously dimeric in the nanomolar range reflecting the properties of intact M2BP. Domain 2 (BTB/POZ domain) is thus identified as the dimerization domain of M2BP, because it has been formerly shown that recombinant domain 1 is monomeric. M2BP-3,4 showed a concentration-dependent self-association, and aggregates of different size and shape were shown by electron microscopy. In contrast to this irregular aggregation of M2BP-3,4, it has been formerly shown that a fragment comprising domains 2-4 still has the ability to form ring-like structures, although the rings are protein-filled, and thus domain 2 appears to be indispensable for ring formation. Solid phase assays showed that M2BP-3,4 contains binding sites for galectin-3, nidogen, and collagens V and VI, whereas M2BP-1,2 is inactive in binding. Both fragments showed no cell adhesive activity in contrast to native M2BP, suggesting that a concerted binding action and/or multivalent interactions of rings are necessary for cell attachment.	Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Basel; Max Planck Society	Engel, J (corresponding author), Univ Basel, Biozentrum, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.							Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; IACOBELLI S, 1988, BREAST CANCER RES TR, V11, P19, DOI 10.1007/BF01807554; INOHARA H, 1994, BIOCHEM BIOPH RES CO, V201, P1366, DOI 10.1006/bbrc.1994.1854; Inohara H, 1996, CANCER RES, V56, P4530; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KOTHS K, 1993, J BIOL CHEM, V268, P14245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Li XM, 1999, CANCER RES, V59, P5275; LONGO G, 1993, BRIT J HAEMATOL, V85, P207, DOI 10.1111/j.1365-2141.1993.tb08674.x; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Muller SA, 1999, J MOL BIOL, V291, P801, DOI 10.1006/jmbi.1999.2996; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; POWELL TJ, 1995, J IMMUNOTHER, V17, P209, DOI 10.1097/00002371-199505000-00003; Ralston G., 1993, INTRO ANAL ULTRACENT; ROSENBERG I, 1991, J BIOL CHEM, V266, P18731; Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; Trahey M, 1999, P NATL ACAD SCI USA, V96, P3006, DOI 10.1073/pnas.96.6.3006; ULLRICH A, 1994, J BIOL CHEM, V269, P18401	25	43	44	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15690	15696		10.1074/jbc.M200386200	http://dx.doi.org/10.1074/jbc.M200386200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867635	hybrid			2022-12-25	WOS:000175510400064
J	Valenzuela-Fernandez, A; Planchenault, T; Baleux, F; Staropoli, I; Le-Barillec, K; Leduc, D; Delaunay, T; Lazarini, F; Virelizier, JL; Chignard, M; Pidard, D; Arenzana-Seisdedos, F				Valenzuela-Fernandez, A; Planchenault, T; Baleux, F; Staropoli, I; Le-Barillec, K; Leduc, D; Delaunay, T; Lazarini, F; Virelizier, JL; Chignard, M; Pidard, D; Arenzana-Seisdedos, F			Leukocyte elastase negatively regulates stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; IMMUNODEFICIENCY-VIRUS CORECEPTOR; HEMATOPOIETIC PROGENITOR CELLS; ENCODING NEUTROPHIL ELASTASE; CATHEPSIN-G; BONE-MARROW; LYMPHOCYTE CHEMOATTRACTANT; INTERLEUKIN-8 IL-8; THROMBIN-RECEPTOR; T-LYMPHOCYTES	Activation of CXCR4 by the CXC chemokine stromal cell-derived factor-1 (SDF-1) requires interaction of the amino-terminal domains of both molecules. We report that proteinases released from either mononucleated blood cells or polymorphonuclear neutrophils degranulated by inflammatory stimuli generate an SDF-1 fragment that is deleted from amino-terminal residues Lys(1)-Pro(2)-Val(3), as characterized by mass spectrometry analysis. The proteolyzed chemokine fails to induce agonistic functions and is unable to prevent the fusogenic capacity of CXCR4-tropic human immunodeficiency viruses. Furthermore, we observed that exposure of CXCR4-expressing cells to leukocyte proteinases results in the proteolysis of the extracellular amino. terminal domain of the receptor, as assessed by flow cytometry analysis and electrophoretic separation of immunoprecipitated CXCR4. Blockade of SDF-1 and CXCR4 proteolysis by the specific leukocyte elastase inhibitor, N-methoxysuccinyl-alanine-alanine-proline-valine-chloromethyl ketone, identified elastase as the major enzyme among leukocyte-secreted proteinases that accounts for inactivation of both SDF-1 and CXCR4. Indeed, purified leukocyte elastase generated in either SDF-1 or CXCR4 a pattern of cleavage indistinguishable from that observed with leukocyte-secreted proteinases. Our findings suggest that elastase-mediated proteolysis of SDF-1/CXCR4 is part of a mechanism regulating their biological functions in both homeostatic and pathologic processes.	Inst Pasteur, Dept Mol Med, Unite Immunol Virale, F-75724 Paris 15, France; Inst Pasteur, Unite Chim Organ, F-75724 Paris 15, France; Inst Pasteur, Unite Def Innee & Inflammat, INSERM, U485, F-75724 Paris 15, France; INRA, Pathol Vegetale Stn, F-33883 Villenave Dornon, France; Inst Pasteur, Unite Neurovirol & Regenerat Syst Nerveux, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; INRAE; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Arenzana-Seisdedos, F (corresponding author), Inst Pasteur, Dept Mol Med, Unite Immunol Virale, 28 Rue Dr Roux, F-75724 Paris 15, France.	farenzan@pasteur.fr	Arenzana-Seisdedos, Fernando/E-5835-2016; Chignard, Michel/B-4351-2008; Valenzuela-Fernández, Agustín/P-1638-2019; Valenzuela-Fernández, Agustín/B-6219-2014	Chignard, Michel/0000-0003-3810-6575; Valenzuela-Fernández, Agustín/0000-0002-2585-8703; Valenzuela-Fernández, Agustín/0000-0002-2585-8703; Pidard, Dominique/0000-0002-5732-3279; Lazarini, Francoise/0000-0001-5572-6982				Abi-Younes S, 2000, CIRC RES, V86, P131, DOI 10.1161/01.RES.86.2.131; Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; Buckley CD, 2000, J IMMUNOL, V165, P3423, DOI 10.4049/jimmunol.165.6.3423; Burger JA, 2001, J CLIN INVEST, V107, P305, DOI 10.1172/JCI11092; CAMPBELL EJ, 1989, J IMMUNOL, V143, P2961; COLDITZ IG, 1987, LEUKOCYTE EMIGRATION, P14; Coulomb-L'Hermine A, 2000, AIDS RES HUM RETROV, V16, P1097, DOI 10.1089/08892220050075372; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; Deichmann M, 1997, BLOOD, V89, P3522, DOI 10.1182/blood.V89.10.3522.3522_3522_3528; Delgado MB, 2001, EUR J IMMUNOL, V31, P699, DOI 10.1002/1521-4141(200103)31:3<699::AID-IMMU699>3.0.CO;2-6; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Detheux M, 2000, J EXP MED, V192, P1501, DOI 10.1084/jem.192.10.1501; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Falanga A, 1999, BLOOD, V93, P2506, DOI 10.1182/blood.V93.8.2506.408k31_2506_2514; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Gonzalo JA, 2000, J IMMUNOL, V165, P499, DOI 10.4049/jimmunol.165.1.499; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hargreaves DC, 2001, J EXP MED, V194, P45, DOI 10.1084/jem.194.1.45; HEBERT CA, 1990, J IMMUNOL, V145, P3033; Hecquet C, 2000, MOL PHARMACOL, V58, P828, DOI 10.1124/mol.58.4.828; Hoglund M, 1997, EUR J HAEMATOL, V58, P195; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Iikura M, 2001, J LEUKOCYTE BIOL, V70, P113; Imai K, 1999, BRIT J HAEMATOL, V106, P905, DOI 10.1046/j.1365-2141.1999.01644.x; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; Juremalm M, 2000, EUR J IMMUNOL, V30, P3614, DOI 10.1002/1521-4141(200012)30:12<3614::AID-IMMU3614>3.0.CO;2-B; Kawabata T, 1999, P NATL ACAD SCI USA, V96, P5663, DOI 10.1073/pnas.96.10.5663; KOSTMANN R, 1956, Acta Paediatr Suppl, V45, P1; Le-Barillec K, 2000, J LEUKOCYTE BIOL, V68, P209; Lee WL, 2001, AM J RESP CRIT CARE, V164, P896, DOI 10.1164/ajrccm.164.5.2103040; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935; Nanki T, 2000, J IMMUNOL, V165, P6590, DOI 10.4049/jimmunol.165.11.6590; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Opdenakker G, 1998, IMMUNOL TODAY, V19, P182, DOI 10.1016/S0167-5699(97)01243-7; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; PADRINES M, 1994, FEBS LETT, V352, P231, DOI 10.1016/0014-5793(94)00952-X; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Price B, 2000, J BIOL CHEM, V275, P28308; Proost P, 1998, J IMMUNOL, V160, P4034; Reeves PJ, 1996, P NATL ACAD SCI USA, V93, P11487, DOI 10.1073/pnas.93.21.11487; Reinhold D, 1998, J NEUROIMMUNOL, V87, P203, DOI 10.1016/S0165-5728(98)00100-3; RENESTO P, 1993, BLOOD, V82, P139, DOI 10.1182/blood.V82.1.139.bloodjournal821139; Renesto P, 1997, BLOOD, V89, P1944, DOI 10.1182/blood.V89.6.1944; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Samis John A., 1998, Blood, V92, P1287; SCHWARTZ O, 1994, VIROLOGY, V198, P360, DOI 10.1006/viro.1994.1042; SEEMULLER U, 1977, H-S Z PHYSIOL CHEM, V358, P1105, DOI 10.1515/bchm2.1977.358.2.1105; SHI YF, 1993, J IMMUNOL METHODS, V164, P149, DOI 10.1016/0022-1759(93)90307-S; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; STEIN RL, 1986, BIOCHEMISTRY-US, V25, P5414, DOI 10.1021/bi00367a011; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO;2-G; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625; TRAVIS J, 1988, AM J MED, V84, P37; Valenzuela-Fernandez A, 2001, J BIOL CHEM, V276, P26550, DOI 10.1074/jbc.M100411200; VANDAMME J, 1989, EUR J BIOCHEM, V181, P337; Vender RL, 1996, J INVEST MED, V44, P531; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Watanabe T, 1999, BLOOD, V93, P1157, DOI 10.1182/blood.V93.4.1157.404k13_1157_1163; Welte K, 1997, SEMIN HEMATOL, V34, P267; WRIGHT DG, 1988, METHOD ENZYMOL, V162, P538; Wuyts A, 1999, EUR J BIOCHEM, V260, P421, DOI 10.1046/j.1432-1327.1999.00166.x; YOSHIMURA T, 1989, MOL IMMUNOL, V26, P87; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	93	177	191	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15677	15689		10.1074/jbc.M111388200	http://dx.doi.org/10.1074/jbc.M111388200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867624	Green Published, hybrid			2022-12-25	WOS:000175510400063
J	Wong, MH; Huelsken, J; Birchmeier, W; Gordon, JI				Wong, MH; Huelsken, J; Birchmeier, W; Gordon, JI			Selection of multipotent stem cells during morphogenesis of small intestinal crypts of Lieberkuhn is perturbed by stimulation of Lef-1/beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; FORCED EXPRESSION; EPITHELIAL-CELLS; GENE-EXPRESSION; COLON-CARCINOMA; XENOPUS EMBRYOS; MICE	Studies of chimeric mice have disclosed that the stem cell hierarchy in the small intestinal epithelium is established during formation of its proliferative units (crypts of Lieberkuhn). This process involves a selection among several multipotential progenitors so that ultimately only one survives to supply descendants to the fully formed crypt. In this report, we examine the hypothesis that the level of beta-catenin (beta-cat)-mediated signaling is an important factor regulating this stem cell selection. In the canonical Wnt signaling pathway, beta-catenin can partner with Lef-1/Tcf high mobility group (HMG) box transcription factors to control gene expression. Both Lef-1 and Tcf-4 mRNAs are produced in the fetal mouse small intestine. Tcf-4 expression is sustained, whereas Lef-1 levels fall as crypt formation is completed during the first two postnatal weeks. A Tcf-4 gene knockout is known to block intestinal epithelial proliferation in late fetal life. Therefore, to test the hypothesis, we enhanced beta-catenin signaling in a chimeric mouse model in which the stem cell selection could be monitored. A fusion protein containing the HMG box domain of Lef-1 linked to the trans-activation domain of beta-catenin (Lef-1/beta-cat) was constructed to promote direct stimulation of signaling without being retained in the cytoplasm through interactions with E-cadherin and Apc/Axin. Lef-1/beta-cat was expressed in 129/Sv embryonic stem cell-derived small intestinal epithelial progenitors present in developing B6-ROSA26<->129/Sv chimeras. Lef-1/beta-cat stimulated expression of a known beta-catenin target (E-cadherin), suppressed expression of Apc and Axin, and induced apoptosis in 129/Sv but not in neighboring B6-ROSA26 epithelial cells. This apoptotic response was not associated with any detectable changes in cell division within the Lef-1/beta-cat-expressing epithelium. By the time crypt development was completed, all 129/Sv epithelial cells were lost. These results indicate that developmental changes in beta-catenin-mediated signaling can play an important role in establishing a stem cell hierarchy during crypt morphogenesis.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Washington University (WUSTL); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Euclid,Campus Box 8103, St Louis, MO 63110 USA.		Huelsken, Joerg/AAC-9581-2021	Huelsken, Joerg/0000-0003-3105-9606	NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Ballif BA, 1996, P NATL ACAD SCI USA, V93, P5544, DOI 10.1073/pnas.93.11.5544; Barker N, 2000, ADV CANCER RES, V77, P1; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bejsovec A, 2000, CURR BIOL, V10, pR919, DOI 10.1016/S0960-9822(00)00852-6; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CALVERT R, 1990, ANAT REC, V227, P199, DOI 10.1002/ar.1092270208; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; CLEVERS H, 1989, EMBO J, V8, P2527, DOI 10.1002/j.1460-2075.1989.tb08390.x; Easwaran V, 1999, J BIOL CHEM, V274, P16641, DOI 10.1074/jbc.274.23.16641; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; Haertel-Wiesmann M, 2000, J BIOL CHEM, V275, P32046, DOI 10.1074/jbc.M000074200; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hasegawa S, 2002, P NATL ACAD SCI USA, V99, P297, DOI 10.1073/pnas.012264999; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Howes R, 2000, CURR BIOL, V10, pR222, DOI 10.1016/S0960-9822(00)00377-8; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Karlsson L, 2000, DEVELOPMENT, V127, P3457; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lickert H, 2001, MECH DEVELOP, V105, P181, DOI 10.1016/S0925-4773(01)00390-2; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; Nagy A., 1993, Gene targeting: a practical approach., P147; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Stappenbeck TS, 2000, DEVELOPMENT, V127, P2629; Strigini M, 2000, CURR BIOL, V10, P293, DOI 10.1016/S0960-9822(00)00378-X; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Wong MH, 2000, P NATL ACAD SCI USA, V97, P12601, DOI 10.1073/pnas.230237997; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Xu LF, 2000, GENE DEV, V14, P585; Yanagawa SI, 1997, J BIOL CHEM, V272, P25243, DOI 10.1074/jbc.272.40.25243; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200	60	65	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15843	15850		10.1074/jbc.M200184200	http://dx.doi.org/10.1074/jbc.M200184200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854293	hybrid			2022-12-25	WOS:000175510400085
J	Arsham, AM; Plas, DR; Thompson, CB; Simon, MC				Arsham, AM; Plas, DR; Thompson, CB; Simon, MC			Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR-I; FACTOR 1-ALPHA HIF-1-ALPHA; ACTIVATED PROTEIN-KINASE; FACTOR EXPRESSION; TUMOR ANGIOGENESIS; NITRIC-OXIDE; FACTOR-ALPHA; HIF-ALPHA; CELLS	The serine/threonine kinase Akt/PKB and the oxygen-responsive transcription factor HIF-1 share the ability to induce such processes as angiogenesis, glucose uptake, and glycolysis. Akt activity and HIF-1 are both essential for development and implicated in tumor growth. Upon activation by products of phosphatidylinositol 3-kinase (PI3K), Akt phosphorylates downstream targets that stimulate growth and inhibit apoptosis. Previous reports suggest that Akt may achieve its effects on angiogenesis and glucose metabolism by stimulating HIF-1 activity. We report here that, whereas serum stimulation can induce a slight accumulation of HIF-1alpha protein in a PI3K/Akt pathway-dependent fashion, hypoxia induces much higher levels of HIF-1alpha protein and HIF-1 DNA binding activity independently of PI3K and mTOR activity. In addition, we find the effects of constitutively active Akt on HIF-1 activity are cell-type specific. High levels of Akt signaling can modestly increase HIF-1alpha protein, but this increase does not affect HIF-1 target gene expression. Therefore, the PI3K/ Akt pathway is not necessary for hypoxic induction of HIF-1 subunits or activity, and constitutively active Akt is not itself sufficient to induce HIF-1 activity.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Chicago; Howard Hughes Medical Institute; University of Pennsylvania	Simon, MC (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, 450 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	celeste2@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021	Arsham, Andrew/0000-0002-5274-8710				Adi S, 2001, ENDOCRINOLOGY, V142, P498, DOI 10.1210/en.142.1.498; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baek SH, 2001, J CELL PHYSIOL, V188, P223, DOI 10.1002/jcp.1117; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Blancher C, 2001, CANCER RES, V61, P7349; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRUICK RK, 2001, SCIENCE, V11, P11; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Chilov D, 1999, J CELL SCI, V112, P1203; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jones A, 2001, CLIN CANCER RES, V7, P1263; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Maltepe E, 2000, BIOCHEM BIOPH RES CO, V273, P231, DOI 10.1006/bbrc.2000.2928; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MILLER AG, 1981, J BIOL CHEM, V256, P2433; MILLER AG, 1983, J BIOL CHEM, V258, P3523; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; PONTEN J, 1978, MED BIOL, V56, P184; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sandau KB, 2000, BIOCHEM BIOPH RES CO, V278, P263, DOI 10.1006/bbrc.2000.3789; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Sodhi A, 2000, CANCER RES, V60, P4873; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363; Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9; Zundel W, 2000, GENE DEV, V14, P391	59	156	162	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15162	15170		10.1074/jbc.M111162200	http://dx.doi.org/10.1074/jbc.M111162200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11859074	hybrid			2022-12-25	WOS:000175203000102
J	Li, XD; Saint-Cyr-Proulx, E; Aktories, K; Lamarche-Vane, N				Li, XD; Saint-Cyr-Proulx, E; Aktories, K; Lamarche-Vane, N			Rac1 and Cdc42 but not RhoA or Rho kinase activities are required for neurite outgrowth induced by the netrin-1 receptor DCC (Deleted in Colorectal Cancer) in N1E-115 neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIONEER AXON MIGRATIONS; ACTIN STRESS FIBERS; GROWTH CONES; NERVE GROWTH; GUIDES CELL; PROTEIN; BINDING; GTPASES; GUIDANCE; FAMILY	Netrins are chemotropic guidance cues that attract or repel growing axons during development. DCC (deleted in colorectal cancer), a transmembrane protein that is a receptor for netrin-1, is implicated in mediating both responses. However, the mechanism by which this is achieved remains unclear. Here we report that Rho GTPases are required for embryonic spinal commissural axon outgrowth induced by netrin-1. Using N1E-115 neuroblastoma cells, we found that both Rac1 and Cdc42 activities are required for DCC-induced neurite outgrowth. In contrast, down-regulation of RhoA and its effector Rho kinase stimulates the ability of DCC to induce neurite outgrowth. In Swiss 3T3 fibroblasts, DCC was found to trigger actin reorganization through activation of Rac1 but not Cdc42 or RhoA. We detected that stimulation of DCC receptors with netrin-1 resulted in a 4-fold increase in Rac1 activation. These results implicate the small GTPases Rac1, Cdc42, and RhoA as essential components that participate in signaling the response of axons to netrin-1 during neural development.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	McGill University; University of Freiburg	Lamarche-Vane, N (corresponding author), McGill Univ, Dept Anat & Cell Biol, Strathcona Anat Bldg,3640 Univ St, Montreal, PQ H3A 2B2, Canada.	nlamarch@med.mcgill.ca	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; Awasaki T, 2000, NEURON, V26, P119, DOI 10.1016/S0896-6273(00)81143-5; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bateman J, 2000, NEURON, V26, P93, DOI 10.1016/S0896-6273(00)81141-1; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Busca R, 1998, MOL BIOL CELL, V9, P1367, DOI 10.1091/mbc.9.6.1367; Chisholm A, 1999, CURR OPIN NEUROBIOL, V9, P603, DOI 10.1016/S0959-4388(99)00021-5; Culotti JG, 1998, CURR OPIN CELL BIOL, V10, P609, DOI 10.1016/S0955-0674(98)80036-7; de la Torre JR, 1997, NEURON, V19, P1211, DOI 10.1016/S0896-6273(00)80413-4; Dickson BJ, 2001, EMBO REP, V2, P182, DOI 10.1093/embo-reports/kve051; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1996, BIOCHIM BIOPHYS ACTA, V1288, P17; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kennedy Timothy E., 1995, Current Opinion in Neurobiology, V5, P83, DOI 10.1016/0959-4388(95)80091-3; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Manitt C, 2001, J NEUROSCI, V21, P3911, DOI 10.1523/JNEUROSCI.21-11-03911.2001; Meyerhardt JA, 1999, CELL GROWTH DIFFER, V10, P35; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; REALE MA, 1994, CANCER RES, V54, P4493; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Stein E, 2001, SCIENCE, V291, P1976, DOI 10.1126/science.1059391; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Suter DM, 1998, CURR OPIN NEUROBIOL, V8, P106, DOI 10.1016/S0959-4388(98)80014-7; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zheng JQ, 2000, NATURE, V403, P89, DOI 10.1038/47501	53	144	147	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15207	15214		10.1074/jbc.M109913200	http://dx.doi.org/10.1074/jbc.M109913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11844789	hybrid			2022-12-25	WOS:000175203000107
J	Spiegelman, V; Tang, WG; Katoh, M; Slaga, TJ; Fuchs, SY				Spiegelman, V; Tang, WG; Katoh, M; Slaga, TJ; Fuchs, SY			Inhibition of HOS expression and activities by Wnt pathway	ONCOGENE			English	Article						beta TrCP; HOS; ubiquitin ligase; F-box protein; beta-catenin; NF-kappa B	I-KAPPA-B; F-BOX PROTEIN; BETA-CATENIN; UBIQUITIN LIGASE; ALPHA UBIQUITINATION; SIGNALING PATHWAYS; COMPLEX; TRCP; ACTIVATION; SCF	betaTrCP and HOS are closely related F-box proteins, which play key roles in ubiquitination and degradation of beta-catenin and IkappaB through associating with those phosphorylated substrates and recruiting SCF E3 ubiquitin ligase. Here we report that activation of Wnt/beta-catenin signal transduction pathway elevates betaTrCP levels but inhibits expression of HOS in 293T cells. Similar disparity is likely to exist in human colorectal tumors. In the NIH3T3 cells, which express HOS, but not betaTrCP, Wnt/beta-catenin signaling leads to inhibition of HOS promoter activity and NF-kappaB-driven transcription as well as to stabilization of P-catenin. These results indicate that expression and activities of HOS are negatively regulated by Wnt/beta-catenin pathway.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; AMC Canc Res Ctr, Lakewood, CO 80214 USA; Natl Canc Ctr, Res Inst, Div Genet, Tokyo 1040045, Japan	University of Pennsylvania; AMC Cancer Research Center; National Cancer Center - Japan	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 3800 Spruce St,Room 161E,VET, Philadelphia, PA 19104 USA.			Spiegelman, Vladimir S/0000-0003-4847-155X	NCI NIH HHS [CA 92900, CA 76262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koike J, 2000, BIOCHEM BIOPH RES CO, V269, P103, DOI 10.1006/bbrc.2000.2241; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Saitoh T, 2001, INT J ONCOL, V18, P959; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; SPIEGELMAN VS, 2001, J BIOL CHEM, V24, P24; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	30	62	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					856	860		10.1038/sj.onc.1205132	http://dx.doi.org/10.1038/sj.onc.1205132			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850814				2022-12-25	WOS:000173427000017
J	Takagaki, K; Iwafune, M; Kakizaki, I; Ishido, K; Kato, Y; Endo, M				Takagaki, K; Iwafune, M; Kakizaki, I; Ishido, K; Kato, Y; Endo, M			Cleavage of the xylosyl serine linkage between a core peptide and a glycosaminoglycan chain by cellulases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDO-BETA-XYLOSIDASE; SWARM RAT CHONDROSARCOMA; SPRAY MASS-SPECTROMETRY; HUMAN SKIN FIBROBLASTS; CARTILAGE PROTEOGLYCANS; ASPERGILLUS-NIGER; ANTITHROMBIN-III; BINDING SEQUENCE; SULFATE; HEPARIN	We previously found that endo-beta-xylosidase from Patinopecten is an endo-type glycosidase that cleaves the xylosyl serine linkage between a glycosaminoglycan chain and its core protein (Takagaki, K., Kon, A., Kawasaki, H., Nakamura, T., Tamura, S., and Endo, M. (1990) J. Biol. Chem. 265, 854-860). Screening for endo-beta-xylosidase activity in several cellulases detected this activity in the enzymes from Aspergillus niger, Penicillium funiculosum, Trichoderma reesei, Trichoderma viride, and Irpex lacteus. The cellulase derived from A. niger was purified, and its molecular weight was determined to be 26,000 by SDS-PAGE. Examination of the specificity of the cellulase revealed that 1) the enzyme acts on the linkage region (xylosyl serine) between a core peptide and a glycosaminoglycan chain; 2) enzymatic activity is greater with shorter glycosaminoglycan chains; 3) the enzyme readily hydrolyzes the linkage in glycosaminoglycan peptides, but intact proteoglycan is cleaved only slowly; and 4) the activity is unaffected by the glycosaminoglyean component (chondroitin sulfate, dermatan sulfate, and heparan sulfate). Judging from these enzymatic characteristics, this cellulase is different from the endo-beta-xylosidase of Patinopecten. We believe that this cellulase will become a useful tool in the further development of glycotechnology, because, like the endo-beta-xylosidase of Patinopecten, it enables the release of intact glycosaminoglyeans from glycosaminoglycan peptides.	Hirosaki Univ, Sch Med, Dept Biochem, Hirosaki, Aomori 0368562, Japan; Hirosaki Univ, Fac Educ, Food Sci Lab, Hirosaki, Aomori 0368560, Japan	Hirosaki University; Hirosaki University	Endo, M (corresponding author), Hirosaki Univ, Sch Med, Dept Biochem, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.		Kakizaki, Ikuko/AAO-5489-2020	Kakizaki, Ikuko/0000-0002-6702-5830				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Byrne KA, 1999, GENE, V239, P317, DOI 10.1016/S0378-1119(99)00396-0; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CHERNOGLAZOV VM, 1989, ANAL BIOCHEM, V179, P186, DOI 10.1016/0003-2697(89)90222-4; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FUKUDA M, 1969, J BIOCHEM-TOKYO, V65, P191; FUKUDA M, 1969, J BIOCHEM-TOKYO, V66, P157, DOI 10.1093/oxfordjournals.jbchem.a129131; Girard C, 1999, INSECT BIOCHEM MOLEC, V29, P1129, DOI 10.1016/S0965-1748(99)00104-6; GROOTENHUIS PDJ, 1991, J AM CHEM SOC, V113, P2743, DOI 10.1021/ja00007a058; HASCALL VC, 1986, FUNCTIONS PROTEOGLYC, P1; HEINEGAR.D, 1972, BIOCHIM BIOPHYS ACTA, V285, P193, DOI 10.1016/0005-2795(72)90191-2; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HUNTER GK, 1988, ARCH BIOCHEM BIOPHYS, V260, P161, DOI 10.1016/0003-9861(88)90437-7; HURST PL, 1977, BIOCHEM J, V165, P33, DOI 10.1042/bj1650033; Ishido K, 2002, J BIOL CHEM, V277, P11889, DOI 10.1074/jbc.M112183200; Kimura I, 1999, J BIOSCI BIOENG, V87, P538, DOI 10.1016/S1389-1723(99)80107-8; KON A, 1991, J BIOCHEM-TOKYO, V110, P132, DOI 10.1093/oxfordjournals.jbchem.a123531; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; Lo N, 2000, CURR BIOL, V10, P801, DOI 10.1016/S0960-9822(00)00561-3; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MATSUE H, 1987, BIOCHIM BIOPHYS ACTA, V923, P470, DOI 10.1016/0304-4165(87)90056-0; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; OKADA G, 1985, AGR BIOL CHEM TOKYO, V49, P1257, DOI 10.1080/00021369.1985.10866894; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; ROBINSON D, 1967, BIOCHIM BIOPHYS ACTA, V132, P212, DOI 10.1016/0005-2744(67)90215-X; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROUX L, 1988, J BIOL CHEM, V263, P8879; SAITO H, 1968, J BIOL CHEM, V243, P1536; SHIBATA S, 1995, J BIOL CHEM, V270, P13794, DOI 10.1074/jbc.270.23.13794; Smant G, 1998, P NATL ACAD SCI USA, V95, P4906, DOI 10.1073/pnas.95.9.4906; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; TAKAGAKI K, 1985, FEBS LETT, V181, P271, DOI 10.1016/0014-5793(85)80274-X; Takagaki K, 1998, GLYCOBIOLOGY, V8, P719, DOI 10.1093/glycob/8.7.719; TAKAGAKI K, 1994, BIOCHEMISTRY-US, V33, P6503, DOI 10.1021/bi00187a017; TAKAGAKI K, 1992, GLYCOCONJUGATE J, V9, P174, DOI 10.1007/BF00731162; TAKAGAKI K, 1990, J BIOL CHEM, V265, P854; TAKAGAKI K, 1988, BIOCHIM BIOPHYS ACTA, V966, P94, DOI 10.1016/0304-4165(88)90132-8; TAKAGAKI K, 1989, J BIOCHEM BIOPH METH, V19, P207, DOI 10.1016/0165-022X(89)90027-4; TAKAGAKI K, 1994, J BIOCHEM BIOPH METH, V28, P313, DOI 10.1016/0165-022X(94)90007-8; TAKAGAKI K, 1990, J BIOCHEM BIOPH METH, V21, P209, DOI 10.1016/0165-022X(90)90014-4; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; Tokuda G, 1999, BBA-GENE STRUCT EXPR, V1447, P146, DOI 10.1016/S0167-4781(99)00169-4; Watanabe H, 1998, NATURE, V394, P330, DOI 10.1038/28527; WEBER K, 1969, J BIOL CHEM, V244, P4406	46	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18397	18403		10.1074/jbc.M111985200	http://dx.doi.org/10.1074/jbc.M111985200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877400	hybrid			2022-12-25	WOS:000175975800020
J	Dash, C; Vathipadiekal, V; George, SP; Rao, M				Dash, C; Vathipadiekal, V; George, SP; Rao, M			Slow-tight binding inhibition of xylanase by an aspartic protease inhibitor - Kinetic parameters and conformational changes that determine the affinity and selectivity of the bifunctional nature of the inhibitor's	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTREMOPHILIC BACILLUS SP; ACTIVE-SITE; BIOTECHNOLOGICAL ASPECTS; IRREVERSIBLE INHIBITORS; THERMOSTABLE XYLANASE; THERMOMONOSPORA SP; CRYSTAL-STRUCTURE; IDENTIFICATION; FLUORESCENCE; GLYCOSIDASES	The first report of slow-tight inhibition of xylanase by a bifunctional inhibitor alkalo-thermophilic Bacillus inhibitor (ATBI), from an extremophilic Bacillus sp. is described. ATBI inhibits aspartic protease (Dash, C., and Rao, M. (2001) J. Biol. Chem., 276, 2487-2493) and xylanase (Xyl I) from a Thermomonospora sp. The steady-state kinetics revealed time-dependent competitive inhibition of Xyl I by ATBI, consistent with two-step inhibition mechanism. The inhibition followed a rapid equilibrium step to form a reversible enzyme-inhibitor complex (EI), which isomerizes to the second enzyme-inhibitor complex (EI*), which dissociated at a very slow rate. The rate constants determined for the isomerization of El to EI*, and the dissociation of EI* were 13 +/- 1 x 10(-6) s(-1) and 5 +/- 0.5 x 10(-8) s(-1), respectively. The K-i value for the formation of EI complex was 2.5 +/- 0.5 mum, whereas the overall inhibition constant K-i* was 7 +/- 1 nm. The conformational changes induced in Xyl I by ATBI were monitored by fluorescence spectroscopy and the rate constants derived were in agreement with the kinetic data. Thus, the conformational alterations were correlated to the isomerization of El to EI*. ATBI binds to the active site of the enzyme and disturbs the native interaction between the histidine and lysine, as demonstrated by the abolished isoindole fluorescence of o-phthalaldehyde (OPTA)-labeled Xyl I. Our results revealed that the inactivation of Xyl I is due to the disruption of the hydrogen-bonding network between the essential histidine and other residues involved in catalysis and a model depicting the probable interaction between ATBI or OPTA with Xyl I has been proposed.	Natl Chem Lab, Div Biochem Sci, Pune 411008, Maharashtra, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL)	Rao, M (corresponding author), Natl Chem Lab, Div Biochem Sci, Pune 411008, Maharashtra, India.			Dash, Chandravanu/0000-0003-4466-8355; /0000-0002-8181-6890				BEITH JG, 1995, METHOD ENZYMOL, V248, P59; BIELY P, 1985, TRENDS BIOTECHNOL, V3, P286, DOI 10.1016/0167-7799(85)90004-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheung H.C., 1991, TOPICS FLUORESCENCE, P127; Cleland W W, 1979, Methods Enzymol, V63, P103; Dash C, 2001, ANTIMICROB AGENTS CH, V45, P2008, DOI 10.1128/AAC.45.7.2008-2017.2001; Dash C, 2001, J BIOL CHEM, V276, P2487, DOI 10.1074/jbc.M005662200; Dash C, 2001, BIOCHEMISTRY-US, V40, P11525, DOI 10.1021/bi010594y; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DEY D, 1992, CAN J MICROBIOL, V38, P436, DOI 10.1139/m92-073; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ELBEIN AD, 1984, ARCH BIOCHEM BIOPHYS, V235, P579, DOI 10.1016/0003-9861(84)90232-7; George SP, 2001, BIOCHEM BIOPH RES CO, V282, P48, DOI 10.1006/bbrc.2001.4543; George SP, 2001, EUR J BIOCHEM, V268, P2881, DOI 10.1046/j.1432-1327.2001.02174.x; George SP, 2001, BIORESOURCE TECHNOL, V77, P171, DOI 10.1016/S0960-8524(00)00150-4; HALAZY S, 1990, BIOORG CHEM, V18, P330, DOI 10.1016/0045-2068(90)90007-R; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; Houtzager V, 1996, BIOCHEMISTRY-US, V35, P10974, DOI 10.1021/bi960053m; Kati WM, 1998, BIOCHEM BIOPH RES CO, V244, P408, DOI 10.1006/bbrc.1998.8282; Kulkarni N, 1999, FEMS MICROBIOL REV, V23, P411, DOI 10.1111/j.1574-6976.1999.tb00407.x; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P180; LEGER G, 1968, HOPPESEYLER Z PHYSL, V349, P767; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; Leroy E, 1999, ORG LETT, V1, P775, DOI 10.1021/ol990754m; LY HD, 1999, ANNU REV BIOCHEM, V316, P695; MARSHALL PJ, 1980, J CHEM SOC P1, P366; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; Natesh R, 1999, J MOL BIOL, V288, P999, DOI 10.1006/jmbi.1999.2727; PALCZEWSKI K, 1983, EUR J BIOCHEM, V137, P429, DOI 10.1111/j.1432-1033.1983.tb07846.x; PAWAGI AB, 1990, BIOCHEMISTRY-US, V29, P950, DOI 10.1021/bi00456a015; PEGG MS, 1994, BIOCHEM MOL BIOL INT, V32, P851; Ploux O, 1999, EUR J BIOCHEM, V259, P63, DOI 10.1046/j.1432-1327.1999.00006.x; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; ROYER JC, 1989, ENZYME MICROB TECH, V11, P405, DOI 10.1016/0141-0229(89)90134-8; Sculley MJ, 1996, BBA-PROTEIN STRUCT M, V1298, P78, DOI 10.1016/S0167-4838(96)00118-5; SIMONS SS, 1979, BIOCHEMISTRY-US, V18, P4915, DOI 10.1021/bi00589a020; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Stutz AE, 1999, IMMUNOSUGARS GLYCOSI, P95; SZEDLACSEK SE, 1995, METHOD ENZYMOL, V249, P144; TARVAINEN K, 1991, CLIN EXP ALLERGY, V21, P609, DOI 10.1111/j.1365-2222.1991.tb00854.x; TRUSCHEIT E, 1981, ANGEW CHEM INT EDIT, V20, P744, DOI 10.1002/anie.198107441; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; Williams J W, 1979, Methods Enzymol, V63, P437; WITHERS SG, 1995, PROTEIN SCI, V4, P361; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415; Yiallouros I, 1998, BIOCHEM J, V331, P375, DOI 10.1042/bj3310375	50	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17978	17986		10.1074/jbc.M111250200	http://dx.doi.org/10.1074/jbc.M111250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11844793	hybrid			2022-12-25	WOS:000175685100075
J	Fernandis, AZ; Cherla, RP; Chernock, RD; Ganju, RK				Fernandis, AZ; Cherla, RP; Chernock, RD; Ganju, RK			CXCR4/CCR5 down-modulation and chemotaxis are regulated by the proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CXC CHEMOKINE RECEPTOR-4; SIGNALING PATHWAYS; ALPHA-CHEMOKINE; HIV-1 INFECTION; CCR5 SIGNALS; T-CELLS; INHIBITION; DEGRADATION; PROTEIN	Chemokines and their receptors play a critical role in host immune surveillance and are important mediators of human immunodeficiency virus (HIV) pathogenesis and inflammatory response. The chemokine receptors CCR5 and CXCR4, which act as co-receptors along with CD4 for HIV docking and entry, are down-modulated by their respective ligands, MIP-1beta3/SDF-1alpha or by the HIV envelope protein, gp120. We have studied the role of the proteasome pathway in the down-regulation of these receptors. Using the yeast and mammalian two-hybrid systems, we observed that the CCR5 receptor is constitutively associated with the subunit of proteasome. Immunoprecipitation studies in CCR5 L1.2 cells revealed that this association was increased with MIP-1beta stimulation. The proteasome inhibitors, lactacystin and epoxomicin, attenuated MIP-1beta induced CCR5 down-modulation as detected by fluorescence-activated cell sorter analysis and confocal microscopy. The proteasome inhibitors also inhibited the SDF-1alpha and gp120 protein-induced down-modulation of the CXCR4 receptor in Jurkat cells. However, the inhibitors had no significant effect on the gp120-induced internalization of the CD4 receptor. These inhibitors also blocked cognate ligand-mediated chemotaxis but had no effect on SDF1alpha-induced p44/42 MAP kinase or MIP-1beta-induced p38 kinase activities, thus indicating differential effects of the inhibitors on signaling mediated by these receptors. These results indicate that the CCR5 and CXCR4 receptor down-modulation mechanism and chemotaxis mediated by these receptors are dependent upon proteasome activity.	Harvard Univ, Sch Med, Inst Med, Beth Israel Deaconess Med Ctr,Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ganju, RK (corresponding author), Harvard Univ, Sch Med, Inst Med, Beth Israel Deaconess Med Ctr,Div Expt Med, 4 Blackfan Cr,Rm 343, Boston, MA 02115 USA.		Fernandis, Aaron/C-3718-2012	Chernock, Rebecca/0000-0001-6253-0478	NATIONAL CANCER INSTITUTE [R29CA076950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049140] Funding Source: NIH RePORTER; NCI NIH HHS [CA76950] Funding Source: Medline; NIAID NIH HHS [AI49140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Androlewicz MJ, 2001, CURR OPIN HEMATOL, V8, P12, DOI 10.1097/00062752-200101000-00003; Ansel KM, 2001, CURR OPIN IMMUNOL, V13, P172, DOI 10.1016/S0952-7915(00)00201-6; Baron V, 2000, J BIOL CHEM, V275, P39318, DOI 10.1074/jbc.M003618200; Brandt SM, 2002, J BIOL CHEM, V277, P17291, DOI 10.1074/jbc.M108232200; Broder CC, 1997, J LEUKOCYTE BIOL, V62, P20, DOI 10.1002/jlb.62.1.20; Broxmeyer HE, 2001, INT J HEMATOL, V74, P9, DOI 10.1007/BF02982544; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; Christopherson K, 2001, STEM CELLS, V19, P388, DOI 10.1634/stemcells.19-5-388; De Groot C J, 2001, Prog Brain Res, V132, P533; DRISCOLL J, 1994, HISTOL HISTOPATHOL, V9, P197; Fujita K, 1997, J GEN VIROL, V78, P619, DOI 10.1099/0022-1317-78-3-619; Ganju RK, 2000, J BIOL CHEM, V275, P17263, DOI 10.1074/jbc.M000689200; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Ikebe T, 1998, INT J CANCER, V77, P578; Jiang Y, 1999, J HUMAN VIROL, V2, P123; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kinter A, 2000, IMMUNOL REV, V177, P88, DOI 10.1034/j.1600-065X.2000.17708.x; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2000, INT J HEMATOL, V72, P412; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; Shioda T, 2001, J VIROL, V75, P3462, DOI 10.1128/JVI.75.7.3462-3468.2001; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Simmons G, 2000, IMMUNOL REV, V177, P112, DOI 10.1034/j.1600-065X.2000.17719.x; Stantchev TS, 2001, CYTOKINE GROWTH F R, V12, P219, DOI 10.1016/S1359-6101(00)00033-2; Su SB, 1999, J IMMUNOL, V162, P7128; Townson JR, 2000, J BIOL CHEM, V275, P39254, DOI 10.1074/jbc.M006768200; Valenzuela-Fernandez A, 2001, J BIOL CHEM, V276, P26550, DOI 10.1074/jbc.M100411200; Van Drenth C, 2000, J IMMUNOL, V165, P6356, DOI 10.4049/jimmunol.165.11.6356; Van Gassen G, 1999, NEUROBIOL DIS, V6, P376, DOI 10.1006/nbdi.1999.0265; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Venkatesan S, 2002, J BIOL CHEM, V277, P2287, DOI 10.1074/jbc.M108321200; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; Wang JH, 2001, J BIOL CHEM, V276, P49236, DOI 10.1074/jbc.M108523200; Wang JM, 1998, J IMMUNOL, V161, P4309; Wojcik C, 1999, CELL MOL LIFE SCI, V56, P908, DOI 10.1007/s000180050483; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200	50	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18111	18117		10.1074/jbc.M200750200	http://dx.doi.org/10.1074/jbc.M200750200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877445	hybrid			2022-12-25	WOS:000175685100092
J	Wible, BA; Wang, LM; Kuryshev, YA; Basu, A; Haldar, S; Brown, AM				Wible, BA; Wang, LM; Kuryshev, YA; Basu, A; Haldar, S; Brown, AM			Increased K+ efflux and apoptosis induced by the potassium channel modulatory protein KChAP/PIAS3 beta in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; GENE ACTIVATION; YEAST SEPTINS; P53; INHIBITOR; CONJUGATION; SIGNAL; SUMO-1; PHOSPHORYLATION; TRANSACTIVATION	K+ channel-associated protein/protein inhibitor of activated STAT (KChAP/PIAS3beta) is a potassium (K+) channel modulatory protein that boosts protein expression of a subset of K+ channels and increases currents without affecting gating. Since increased K+ efflux is an early event in apoptosis, we speculated that KChAP might induce apoptosis through its up-regulation of K+ channel expression. KChAP belongs to the protein inhibitor of activated STAT family, members of which also interact with a variety of transcription factors including the proapoptotic protein, p53. Here we report that KChAP induces apoptosis in the prostate cancer cell line, LNCaP, which expresses both K+ currents and wild-type p53. Infection with a recombinant adenovirus encoding KChAP (Ad/KChAP) increases K+ efflux and reduces cell size as expected for an apoptotic volume decrease. The apoptosis inducer, staurosporine, increases endogenous KChAP levels, and LNCaP cells, 2 days after Ad/KChAP infection, show increased sensitivity to staurosporine. KChAP increases p53 levels and stimulates phosphorylation of p53 residue serine 15. Consistent with activation of p53 as a transcription factor, p21 levels are increased in infected cells. Wild-type p53 is not essential for induction of apoptosis by KChAP, however, since KChAP also induces apoptosis in DU145 cells, a prostate cancer cell line with mutant p53. Consistent with its proapoptotic properties, KChAP prevents growth of DU145 and LNCaP tumor xenografts in nude mice, indicating that infection with Ad/KChAP might represent a novel method of cancer treatment.	Case Western Reserve Univ, Rammelkamp Ctr Educ & Res, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44109 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Wible, BA (corresponding author), Case Western Reserve Univ, Rammelkamp Ctr Educ & Res, Metrohlth Campus,2500 Metrohlth Dr, Cleveland, OH 44109 USA.				NHLBI NIH HHS [HL60759, HL-61642, HL-36930, HL-55404] Funding Source: Medline; NIDDK NIH HHS [3DK54178] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060759, R01HL036930, R01HL055404, R01HL061642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK054178] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hughes FM, 1999, ADV ENZYME REGUL, V39, P157, DOI 10.1016/S0065-2571(98)00010-7; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISAACS WB, 1991, CANCER RES, V51, P4716; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Krick S, 2001, AM J PHYSIOL-LUNG C, V281, pL887, DOI 10.1152/ajplung.2001.281.4.L887; Krick S, 2001, AM J PHYSIOL-CELL PH, V280, pC970, DOI 10.1152/ajpcell.2001.280.4.C970; Kuryshev YA, 2000, AM J PHYSIOL-CELL PH, V278, pC931, DOI 10.1152/ajpcell.2000.278.5.C931; Kuryshev YA, 2001, AM J PHYSIOL-CELL PH, V281, pC290, DOI 10.1152/ajpcell.2001.281.1.C290; Laniado ME, 2001, PROSTATE, V46, P262, DOI 10.1002/1097-0045(20010301)46:4<262::AID-PROS1032>3.0.CO;2-F; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Nelson V, 2001, APOPTOSIS, V6, P221, DOI 10.1023/A:1011392811628; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SKYRMA RN, 1997, PROSTATE, V33, P112; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Terstappen GC, 1999, ANAL BIOCHEM, V272, P149, DOI 10.1006/abio.1999.4179; Trimarchi JR, 2002, AM J PHYSIOL-CELL PH, V282, pC588, DOI 10.1152/ajpcell.00365.2001; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3; Yu SP, 1999, J NEUROCHEM, V73, P933, DOI 10.1046/j.1471-4159.1999.0730933.x	42	59	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17852	17862		10.1074/jbc.M201689200	http://dx.doi.org/10.1074/jbc.M201689200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877452	hybrid			2022-12-25	WOS:000175685100060
J	Bruck, I; Yuzhakov, A; Yurieva, O; Jeruzalmi, D; Skangalis, M; Kuriyan, J; O'Donnell, M				Bruck, I; Yuzhakov, A; Yurieva, O; Jeruzalmi, D; Skangalis, M; Kuriyan, J; O'Donnell, M			Analysis of a multicomponent thermostable DNA polymerase III replicase from an extreme thermophile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAGGING-STRAND REPLICATION; ONE HOLOENZYME PARTICLE; ESCHERICHIA-COLI; CLAMP LOADER; ACCESSORY PROTEINS; SLIDING CLAMPS; GAMMA-COMPLEX; DELTA-SUBUNIT; CRYSTAL-STRUCTURE; BINDING PROTEIN	This report takes a proteomic/genomic approach to characterize the DNA polymerase III replication apparatus of the extreme thermophile, Aquifex aeolicus. Genes (dnaX, holA, and holB) encoding the subunits required for clamp loading activity (tau, delta, and delta') were identified. The dnaX gene produces only the full-length product, tau, and therefore differs from Escherichia coli dnaX that produces two proteins (gamma and tau). Nonetheless, the A. aeolicus proteins form a taudeltadelta' complex. The dnaN gene encoding the beta clamp was identified, and the taudeltadelta' complex is active in loading beta onto DNA. A. aeolicus contains one dnaE homologue, encoding the alpha subunit of DNA polymerase III. Like E. coli, A aeolicus alpha and tau interact, although the interaction is not as tight as the alpha-tau contact in E. coli. In addition, the A. aeolicus homologue to dnaQ, encoding the epsilon proofreading 3'-5'-exonuclease, interacts with alpha but does not form a stable alpha.epsilon complex, suggesting a need for a brace or bridging protein to tightly couple the polymerase and exonuclease in this system. Despite these differences to the E. coli system, the A. aeolicus proteins function to yield a robust replicase that retains significant activity at 90 degreesC. Similarities and differences between the A. aeolicus and E. coli pol III systems are discussed, as is application of thermostable pol III to biotechnology.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute	O'Donnell, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.			O'Donnell, Michael/0000-0001-9002-4214	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 45547, R01 GM 38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; BARNES MH, 1979, NUCLEIC ACIDS RES, V6, P1203, DOI 10.1093/nar/6.3.1203; Bertram JG, 2000, J BIOL CHEM, V275, P28413, DOI 10.1074/jbc.M910441199; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; Bruck I, 2000, J BIOL CHEM, V275, P28971, DOI 10.1074/jbc.M003565200; Bruck I, 2001, GENOME BIOL, V2; Davey MJ, 2000, CURR OPIN CHEM BIOL, V4, P581, DOI 10.1016/S1367-5931(00)00134-4; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gao DX, 2001, J BIOL CHEM, V276, P4433, DOI 10.1074/jbc.M009828200; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; Larsen B, 2000, P NATL ACAD SCI USA, V97, P1683, DOI 10.1073/pnas.97.4.1683; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MAKI H, 1985, J BIOL CHEM, V260, P2987; McHenry CS, 1997, J MOL BIOL, V272, P178, DOI 10.1006/jmbi.1997.1238; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; ROWEN L, 1978, J BIOL CHEM, V253, P758; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SLATER SC, 1994, J BACTERIOL, V176, P815, DOI 10.1128/jb.176.3.815-821.1994; Stewart J, 2001, J BIOL CHEM, V276, P19182, DOI 10.1074/jbc.M100592200; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; XIAO H, 1993, J BIOL CHEM, V268, P11779; Yurieva O, 1997, J BIOL CHEM, V272, P27131, DOI 10.1074/jbc.272.43.27131; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	60	20	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17334	17348		10.1074/jbc.M110198200	http://dx.doi.org/10.1074/jbc.M110198200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859073	hybrid			2022-12-25	WOS:000175564500130
J	Honda, A; Yamagata, K; Sugiura, S; Watanabe, K; Baba, T				Honda, A; Yamagata, K; Sugiura, S; Watanabe, K; Baba, T			A mouse serine protease TESP5 is selectively included into lipid rafts of sperm membrane presumably as a glycosylphosphatidylinositol-anchored protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZONA-PELLUCIDA; ACROSOME REACTION; MAMMALIAN SPERM; FERTILIZATION; PENETRATION; GENE; AMINOBENZAMIDINE; ORGANIZATION; ACTIVATION; MATURATION	We have previously indicated that at least in mouse, sperm serine protease(s) other than acrosin probably act on the limited proteolysis of egg zona pellucida to create a penetration pathway for motile sperm, although the participation of acrosin cannot be ruled out completely. A 42-kDa gelatin-hydrolyzing serine protease present in mouse sperm is a candidate enzyme involved in the sperm penetration of the zona pellucida. In this study, we have PCR-amplified an EST clone encoding a testicular serine protease, termed TESP5, and then screened a mouse genomic DNA library using the DNA fragment as a probe. The DNA sequence of the isolated genomic clones indicated that the TESP5 gene is identical to the genes coding for testicular testisin and eosinophilic esp-1. Immunochemical analysis using affinity-purified anti-TESP5 antibody revealed that 42- and 41-kDa forms of TESP5 with the isoelectric points of 5.0 to 5.5 are localized in the head, cytoplasmic droplet, and midpiece of cauda epididymal sperm probably as a membranous protein. Moreover, these two forms of TESP5 were selectively included into Triton X-100-insoluble microdomains, lipid rafts, of the sperm membranes These results show the identity between TESP5/testisin/esp-1 and the 42-kDa sperm serine protease. When HEK293 cells were transformed by an expression plasmid carrying the entire protein-coding region of TESP5, the recombinant protein produced was released from the cell membrane by treatment with Bacillus cereus phosphatidylinositol-specific phospholipase C, indicating that TESP5 is glycosylphosphatidylinositol-anchored on the cell surface. Enzymatic properties of recombinant TESP5 was similar to but distinguished from those of rat acrosin and pancreatic trypsin by the substrate specificity and inhibitory effects of serine protease inhibitors.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba	Baba, T (corresponding author), Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan.							BABA T, 1989, J BIOL CHEM, V264, P11920; BABA T, 1994, J BIOL CHEM, V269, P31845; BABA T, 1994, J BIOL CHEM, V269, P10133; Bedford JM, 1998, BIOL REPROD, V59, P1275, DOI 10.1095/biolreprod59.6.1275; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; FRASER LR, 1982, J REPROD FERTIL, V65, P185, DOI 10.1530/jrf.0.0650185; FULLER SA, 1991, CURRENT PROTOCOLS MO; GUTHER MLS, 1994, ANAL BIOCHEM, V219, P249, DOI 10.1006/abio.1994.1264; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hooper JD, 1999, CANCER RES, V59, P3199; Inoue M, 1999, BIOCHEM BIOPH RES CO, V266, P564, DOI 10.1006/bbrc.1999.1870; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Johnson LR, 1997, DEV BIOL, V192, P340, DOI 10.1006/dbio.1997.8767; Kashiwabara S, 2000, DEV BIOL, V228, P106, DOI 10.1006/dbio.2000.9894; KLEMM U, 1991, HUM GENET, V87, P635; Kohno N, 1998, BIOCHEM BIOPH RES CO, V245, P658, DOI 10.1006/bbrc.1998.8501; MIYAMOTO H, 1973, BIOL REPROD, V9, P533, DOI 10.1093/biolreprod/9.5.533; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohmura K, 1999, J BIOL CHEM, V274, P29426, DOI 10.1074/jbc.274.41.29426; Ohta K, 1999, BIOCHEM BIOPH RES CO, V258, P616, DOI 10.1006/bbrc.1999.0686; PERONA JJ, 1995, PROTEIN SCI, V4, P337; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Scarman AL, 2001, EUR J BIOCHEM, V268, P1250, DOI 10.1046/j.1432-1327.2001.01986.x; Seaton GJ, 2000, BIOL REPROD, V62, P1667, DOI 10.1095/biolreprod62.6.1667; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stambaugh R., 1969, Biology of Reproduction, V1, P223, DOI 10.1095/biolreprod1.3.223; TANII I, 1994, CELL TISSUE RES, V277, P61, DOI 10.1007/BF00303081; TOSHIMORI K, 1995, MOL REPROD DEV, V42, P72, DOI 10.1002/mrd.1080420110; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Wong GW, 2001, J BIOL CHEM, V276, P20648, DOI 10.1074/jbc.M010422200; Yamagata K, 1998, ZYGOTE, V6, P311, DOI 10.1017/S0967199498000264; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470; Yamagata K, 1999, DEV GENET, V25, P115, DOI 10.1002/(SICI)1520-6408(1999)25:2&lt;115::AID-DVG5&gt;3.0.CO;2-1; Yanagimachi R., 1994, P189; ZANEVELD LJD, 1971, P INT RES C PROTEINA, P236	41	109	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16976	16984		10.1074/jbc.M112470200	http://dx.doi.org/10.1074/jbc.M112470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861648	hybrid			2022-12-25	WOS:000175564500085
J	Noya, F; Chien, WM; Wu, XY; Banerjee, NS; Kappes, JC; Broker, TR; Chow, LT				Noya, F; Chien, WM; Wu, XY; Banerjee, NS; Kappes, JC; Broker, TR; Chow, LT			The promoter of the human proliferating cell nuclear antigen gene is not sufficient for cell cycle-dependent regulation in organotypic cultures of keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA TUMOR-SUPPRESSOR; ADENOVIRUS E1A ONCOPROTEIN; KINASE-II PHOSPHORYLATION; EPITHELIAL RAFT CULTURES; WILD-TYPE P53; DIFFERENTIATED KERATINOCYTES; TRANSCRIPTION FACTOR; DNA-SYNTHESIS; E7 PROTEIN	The proliferating cell nuclear antigen (PCNA) is essential for DNA replication of mammalian cells and their small DNA tumor viruses. The mechanism of the cell cycle-dependent regulation of the human PCNA promoter is not clear despite extensive investigations. In this report, we employed organotypic cultures of primary human keratinocytes, which closely resemble native skin comprising both proliferating and postmitotic, differentiated cells, to examine the cell cycle-dependent regulation of the human PCNA gene (hPCNA) in the absence or presence of the human papillomavirus type 18 (HPV-18) E7 protein. HPV-18 E7 promotes S phase re-entry in post-mitotic differentiated keratinocytes by abrogating the transcription repression of E2F transcription factors by the retinoblastoma susceptibility protein, pRb. We demonstrated that E7 reactivated the transcription of the endogenous hPCNA in differentiated keratinocytes. In contrast, with or without E7, the expression of a transduced hPCNA promoter-driven reporter did not correlate with that of the endogenous hPCNA gene in either proliferating or differentiated cells. Moreover, in Chinese hamster ovary and L-cells, HPV E7 and the adenovirus E1A protein repressed the transduced hPCNA promoter, but both activated an extended promoter construct spanning the first intron. Mutations of two E2F sites in the intron reduced the basal activity and abolished the response to E7 or E1A. Promoter repression or activation required the CR2 domain of E7 and, to a lesser extent, CR1. as well. However, in organotypic cultures, this extended promoter construct failed to recapitulate the cell cycle-dependent regulation of the endogenous hPCNA gene. Only when a full-length Myc-tagged hPCNA spanning the 5' promoter and all exons and introns was used was the native pattern of expression largely restored, indicative of the complexity of its regulation.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Hematol Oncol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Chow, LT (corresponding author), Univ Alabama, Dept Biochem & Mol Genet, 510 McCallum Basic Hlth Sci Bldt,1918 Univ Blvd, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BANKS L, 1990, ONCOGENE, V5, P1383; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHANG CD, 1991, J BIOL CHEM, V266, P8663; Charollais Renee-Helene, 1992, Gene Expression, V2, P285; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CHESTERS PM, 1990, J GEN VIROL, V71, P449, DOI 10.1099/0022-1317-71-2-449; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; Chien WM, 2000, CELL GROWTH DIFFER, V11, P425; Chien WM, 2002, J VIROL, V76, P2964, DOI 10.1128/JVI.76.6.2964-2972.2002; Chow Louise T., 1997, P267; Chow LT, 1997, CLIN DERMATOL, V15, P217, DOI 10.1016/S0738-081X(97)00069-2; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DAVIES RC, 1992, J GEN VIROL, V73, P2135, DOI 10.1099/0022-1317-73-8-2135; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEMETER LM, 1994, HUM PATHOL, V25, P343, DOI 10.1016/0046-8177(94)90141-4; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FIRZLAFF J M, 1989, New Biologist, V1, P44; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; Ghazizadeh S, 1997, J VIROL, V71, P9163, DOI 10.1128/JVI.71.12.9163-9169.1997; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Huang DY, 1996, J BIOL CHEM, V271, P1218, DOI 10.1074/jbc.271.2.1218; Izumi M, 2000, BBA-GENE STRUCT EXPR, V1492, P341, DOI 10.1016/S0167-4781(00)00117-2; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; Jian YC, 1999, CELL GROWTH DIFFER, V10, P101; Jian YC, 1998, ONCOGENE, V17, P2027, DOI 10.1038/sj.onc.1202142; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kannabiran C, 1999, ONCOGENE, V18, P7825, DOI 10.1038/sj.onc.1203294; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KUO SR, 1994, J BIOL CHEM, V269, P24058; LABRIE C, 1993, MOL CELL BIOL, V13, P1697, DOI 10.1128/MCB.13.3.1697; LABRIE C, 1995, NUCLEIC ACIDS RES, V23, P3732, DOI 10.1093/nar/23.18.3732; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lee BH, 1998, J VIROL, V72, P1138, DOI 10.1128/JVI.72.2.1138-1145.1998; Lee Hu-Hui, 1995, Gene Expression, V4, P95; Lee KY, 1998, J VIROL, V72, P4911, DOI 10.1128/JVI.72.6.4911-4917.1998; Li QL, 1999, TRENDS GENET, V15, P403, DOI 10.1016/S0168-9525(99)01780-1; LIANG CP, 1992, ELECTROPHORESIS, V13, P346, DOI 10.1002/elps.1150130172; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MORRIS GF, 1994, MOL CELL BIOL, V14, P543, DOI 10.1128/MCB.14.1.543; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Noya F, 2001, J VIROL, V75, P6121, DOI 10.1128/JVI.75.13.6121-6134.2001; OTTAVIO L, 1990, MOL CELL BIOL, V10, P303, DOI 10.1128/MCB.10.1.303; OTTAVIO L, 1990, BIOCHEM BIOPH RES CO, V169, P509, DOI 10.1016/0006-291X(90)90360-Y; Parker JN, 1997, CELL GROWTH DIFFER, V8, P751; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; SELL C, 1992, J CELL PHYSIOL, V152, P177, DOI 10.1002/jcp.1041520122; SHIPMANAPPASAMY P, 1990, J BIOL CHEM, V265, P19180; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; STAGGERS WR, 1995, GENE, V153, P297, DOI 10.1016/0378-1119(94)00731-7; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; Tommasi S, 1999, J BIOL CHEM, V274, P27829, DOI 10.1074/jbc.274.39.27829; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WOODWORTH CD, 1992, ONCOGENE, V7, P619; Wu XY, 2000, MOL THER, V2, P47, DOI 10.1006/mthe.2000.0095; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; Zhao W, 1997, J VIROL, V71, P8832, DOI 10.1128/JVI.71.11.8832-8840.1997; Zhao W, 1999, J VIROL, V73, P5026, DOI 10.1128/JVI.73.6.5026-5033.1999; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	88	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17271	17280		10.1074/jbc.M112441200	http://dx.doi.org/10.1074/jbc.M112441200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877408	hybrid			2022-12-25	WOS:000175564500122
J	Shuto, T; Imasato, A; Jono, H; Sakai, A; Xu, HD; Watanabe, T; Rixter, DD; Kai, H; Andalibi, A; Linthicum, F; Guan, YL; Han, JH; Cato, ACB; Lim, DJ; Akira, S; Li, JD				Shuto, T; Imasato, A; Jono, H; Sakai, A; Xu, HD; Watanabe, T; Rixter, DD; Kai, H; Andalibi, A; Linthicum, F; Guan, YL; Han, JH; Cato, ACB; Lim, DJ; Akira, S; Li, JD			Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; GENE-REGULATION; ACTIVATION; INNATE; TRANSCRIPTION; INDUCTION; PROTEINS; PATHWAY; POTENT	The recognition of invading microbes followed by the induction of effective innate immune response is crucial for host survival. Human surface epithelial cells are situated at host-environment boundaries and thus act as the first line of host defense against invading microbes. They recognize the microbial ligands via Toll-like receptors (TLRs) expressed on the surface of epithelial cells. TLR2 has gained importance as a major receptor for a variety of microbial ligands. In contrast to its high expression in lymphoid tissues, TLR2 is expressed at low level in epithelial cells. Thus, it remains unclear whether the low amount of TLR2 expressed in epithelial cells is sufficient for mediating bacteria-induced host defense and immune response and whether TLR2 expression can be upregulated by bacteria during infection. Here, we show that TLR2, although expressed at very low level in unstimulated human epithelial cells, is greatly up-regulated by nontypeable Hemophilus influenzae (NTHi), an important human bacterial pathogen causing otitis media and chronic obstructive pulmonary diseases. Activation of an IKKbeta-IkappaBalpha-dependent NF-kappaB pathway is required for TLR2 induction, whereas inhibition of the MKK3/6-p38alpha/beta pathway leads to enhancement of NTHi-induced TLR2 up-regulation. Surprisingly, glucocorticoids, well known potent anti-inflammatory agents, synergistically enhance NTRi-induced TLR2 up-regulation likely via a negative cross-talk with the p38 MAP kinase pathway. These studies may bring new insights into the role of bacteria and glucocorticoids in regulating host defense and immune response and lead to novel therapeutic strategies for modulating innate immune and inflammatory responses for otitis media and chronic obstructive pulmonary diseases.	Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90057 USA; Kumamoto Univ, Dept Mol Med, Kumamoto 8620973, Japan; Univ So Calif, House Ear Inst, Dept Histopathol, Los Angeles, CA 90057 USA; Scripps Res Inst, Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Forschungszentrum Karlsruhe, Inst Genet & Toxicol, D-76021 Karlsruhe, Germany; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Japan Sci & Technol Corp,CREST, Suita, Osaka 5650871, Japan	House Research Institute; University of Southern California; University of Southern California; Kumamoto University; House Research Institute; University of Southern California; Scripps Research Institute; Helmholtz Association; Karlsruhe Institute of Technology; Japan Science & Technology Agency (JST); Osaka University	Li, JD (corresponding author), Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, 2100 W 3rd St, Los Angeles, CA 90057 USA.	jdli@hei.org	Han, J/G-4671-2010; Cato, Andrew C. B./H-2071-2013; Akira, Shizuo/C-3134-2009	Cato, Andrew C. B./0000-0001-8508-3834; Li, Jian-Dong/0000-0002-5593-050X	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004562] Funding Source: NIH RePORTER; NIDCD NIH HHS [R0-1 DC04562] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adams J L, 1999, Curr Opin Drug Discov Devel, V2, P96; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Beauparlant P, 1996, J VIROL, V70, P5777, DOI 10.1128/JVI.70.9.5777-5785.1996; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Krutzik SR, 2001, CURR OPIN IMMUNOL, V13, P104, DOI 10.1016/S0952-7915(00)00189-8; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Means TK, 2000, LIFE SCI, V68, P241, DOI 10.1016/S0024-3205(00)00939-5; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1	24	128	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17263	17270		10.1074/jbc.M112190200	http://dx.doi.org/10.1074/jbc.M112190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867630	hybrid			2022-12-25	WOS:000175564500121
J	Vidal, A; Millard, SS; Miller, JP; Koff, A				Vidal, A; Millard, SS; Miller, JP; Koff, A			Rho activity can alter the translation of p27 mRNA and is important for Ras(V12)-induced transformation in a manner dependent on p27 status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; CELL-CYCLE PROGRESSION; GTP-BINDING PROTEINS; GROWTH-FACTOR; MICE LACKING; RETINOBLASTOMA-PROTEIN; RAS TRANSFORMATION; SIGNALING PATHWAY; TUMOR SUPPRESSION; MESSENGER-RNA	The amount of P27(Kip1) establishes a threshold to which G(1) cyclin-cyclin-dependent kinase complexes must surpass prior to cells progressing into S-phase. The amount of p27 is greatest in G(o) cells, intermediate in G(1) cells, and lowest in S-phase cells. However, there is little known regarding the pathways and mechanisms controlling p27 accumulation in G(o) cells. We report that inhibition of Rho, by either lovastatin or C3 exoenzyme, can increase the translational efficiency of p27 mRNA. Similar pharmacologic inhibition of the phosphatidylinositol 3-kinase, the S6 kinase, and the Mek1 kinase pathways all fail to increase translational efficiency in MDA468 cells. This Rho-responsive element lies within a 300-nucleotide region at the 3'-end of the mRNA. By supporting the significance of this signaling pathway to Rho function, we showed that the suppression of Ras(V12) transformation by RhoA(N19) is blocked in p27-/- cells. In contrast this activity is not blocked in Rb-/- or p16-/- cells. The resistance of p27-/- cells to RhoA(N19) is not associated with a failure of RhoA(N19) to accumulate to amounts sufficient to block Rho activity as measured by the organization of actin stress fibers. Together these results indicate a link between Rho and p27.	Mem Sloan Kettering Canc Ctr, Programs Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Grad Program Mol Biol & Cell Biol & Genet, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Koff, A (corresponding author), Mem Sloan Kettering Canc Ctr, Programs Mol Biol, RRL917D,Box 207,1275 York Ave, New York, NY 10021 USA.		Vidal, Anxo/B-5010-2015; Millard, Sean/A-8522-2013	Vidal, Anxo/0000-0002-0866-4202; Millard, Sean/0000-0001-8573-4625; Koff, Andrew/0000-0003-3271-3067	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM052597, R01GM052597] Funding Source: NIH RePORTER; NCI NIH HHS [CA08748] Funding Source: Medline; NIGMS NIH HHS [GM52597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hirano M, 2001, EXP CELL RES, V271, P356, DOI 10.1006/excr.2001.5384; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kranenburg O, 1997, J CELL SCI, V110, P2417; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245	57	81	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16433	16440		10.1074/jbc.M112090200	http://dx.doi.org/10.1074/jbc.M112090200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875067	hybrid			2022-12-25	WOS:000175564500014
J	Akakura, R; Winans, SC				Akakura, R; Winans, SC			Mutations in the occQ operator that decrease OccR-induced DNA bending do not cause constitutive promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR; SALMONELLA-TYPHIMURIUM; PSEUDOMONAS-PUTIDA; AGROBACTERIUM-TUMEFACIENS; REGIONS IMPORTANT; BINDING-SITES; NAHR PROTEIN; LYSR FAMILY; NOD BOX; REGULATOR	OccR is a LysR-type transcriptional regulator of Agrobacterium tumefaciens that positively regulates the octopine catabolism operon of the Ti plasmid. Positive control of the occ genes occurs in response to octopine, a metabolite released from plant tumors. Octopine causes DNA-bound OccR to undergo a conformational change from an inactive to an active state; this change is marked by a decrease in footprint length from 55 to 45 nucleotides as well as a relaxation of a high angle DNA bend. In this study, we first used gel filtration chromatography to show that OccR is dimeric in solution, and we used gel shift assays to show that OccR is tetrameric when bound to DNA. We then created a series of site-directed mutations in the OccR-binding site. Some mutations were designed to lock OccR-DNA complexes into a conformation resembling the inactive conformation, whereas other mutations were designed to lock complexes into the active conformation. These mutations altered the conformation of OccR-DNA complexes and their responses to octopine in ways that we had predicted. As expected, operator mutations that locked complexes into a conformation having a long footprint and a high angle DNA bend blocked activation by octopine in vivo. Surprisingly, however, mutations that lock OccR into a short footprint and low angle DNA bend failed to cause the protein to function constitutively. Furthermore, some of the latter mutations interfered with activation by octopine. We conclude that locking OccR into a conformation having a short footprint is not sufficient to cause constitutive activation, and octopine must cause at least one additional conformational change in the protein.	Cornell Univ, Dept Microbiol, Ithaca, NY 14853 USA	Cornell University	Winans, SC (corresponding author), Cornell Univ, Dept Microbiol, 360A Wing Hall, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM41892] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akakura R, 2002, J BIOL CHEM, V277, P5866, DOI 10.1074/jbc.M110555200; Busby S, 1997, MOL MICROBIOL, V23, P853, DOI 10.1046/j.1365-2958.1997.2771641.x; CHANG M, 1991, J BACTERIOL, V173, P1590, DOI 10.1128/jb.173.5.1590-1597.1991; CHEN CY, 1991, J BACTERIOL, V173, P1139, DOI 10.1128/jb.173.3.1139-1144.1991; Cho KY, 1996, J BACTERIOL, V178, P1872, DOI 10.1128/jb.178.7.1872-1880.1996; CHO KY, 1993, J BACTERIOL, V175, P7715, DOI 10.1128/JB.175.23.7715-7719.1993; COCO WM, 1994, J BACTERIOL, V176, P5530, DOI 10.1128/JB.176.17.5530-5533.1994; Dessaux Y., 1992, MOL SIGNALS PLANT MI, P109; DWEN P, 1995, THESIS CORNELL U ITH; FISHER RF, 1993, J MOL BIOL, V233, P336, DOI 10.1006/jmbi.1993.1515; Fuqua C, 1996, MOL MICROBIOL, V20, P1199, DOI 10.1111/j.1365-2958.1996.tb02640.x; GAO J, 1991, EMBO J, V10, P4137, DOI 10.1002/j.1460-2075.1991.tb04991.x; GOETHALS K, 1992, P NATL ACAD SCI USA, V89, P1646, DOI 10.1073/pnas.89.5.1646; HABEEB LF, 1991, MOL PLANT MICROBE IN, V4, P279; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HRYNIEWICZ MM, 1994, J BACTERIOL, V176, P3673, DOI 10.1128/JB.176.12.3673-3682.1994; HRYNIEWICZ MM, 1995, J BACTERIOL, V177, P2343, DOI 10.1128/jb.177.9.2343-2353.1995; KULLIK I, 1995, J BACTERIOL, V177, P1285, DOI 10.1128/jb.177.5.1285-1291.1995; Liu ST, 1998, ANAL BIOCHEM, V255, P158, DOI 10.1006/abio.1997.2457; Lochowska A, 2001, J BIOL CHEM, V276, P2098, DOI 10.1074/jbc.M007192200; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; MILLER BE, 1987, J BIOL CHEM, V262, P6006; PARSEK MR, 1992, J BACTERIOL, V174, P7798, DOI 10.1128/JB.174.23.7798-7806.1992; PARSEK MR, 1995, MOL MICROBIOL, V15, P819, DOI 10.1111/j.1365-2958.1995.tb02352.x; Perez-Rueda E, 2000, NUCLEIC ACIDS RES, V28, P1838, DOI 10.1093/nar/28.8.1838; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SCHELL MA, 1990, J BIOL CHEM, V265, P3844; SCHELL MA, 1989, J BACTERIOL, V171, P837, DOI 10.1128/jb.171.2.837-846.1989; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TIEDEMANN AA, 1998, NUCLEIC ACIDS RES, V8, P3587; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; WANG L, 1995, J MOL BIOL, V253, P691, DOI 10.1006/jmbi.1995.0583; WANG L, 1995, J MOL BIOL, V253, P32, DOI 10.1006/jmbi.1995.0533; WANG L, 1992, CELL, V69, P659, DOI 10.1016/0092-8674(92)90229-6; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhu J, 2001, P NATL ACAD SCI USA, V98, P1507, DOI 10.1073/pnas.98.4.1507; ZWIEB C, 1990, NUCLEIC ACIDS RES, V18, P583, DOI 10.1093/nar/18.3.583	39	43	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15773	15780		10.1074/jbc.M200109200	http://dx.doi.org/10.1074/jbc.M200109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877409	hybrid			2022-12-25	WOS:000175510400075
J	Lee, SF; Ko, CY; Wang, CT; Chen, SSL				Lee, SF; Ko, CY; Wang, CT; Chen, SSL			Effect of point mutations in the N terminus of the lentivirus lytic peptide-1 sequence of human immunodeficiency virus type 1 transmembrane protein gp41 Env stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 ENVELOPE GLYCOPROTEIN; POLYMERASE CHAIN-REACTION; AMINO-ACID SUBSTITUTIONS; FAS-MEDIATED APOPTOSIS; CYTOPLASMIC DOMAIN; CALMODULIN-BINDING; CLATHRIN ADAPTER; MATRIX PROTEIN; LIPID BILAYERS; MATURE VIRIONS	To understand the role of the lentivirus lytic peptide-1 region of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp) 41 in viral infection, we examined the effects on virus replication of single amino acid deletions spanning this region in an infectious provirus of the HXB2 strain. Among the mutants analyzed, only the deletion of one of the two adjacent valine residues located at positions 832 and 833 (termed the Delta833 mutant for simplicity) greatly reduced the steady-state, cell-associated levels of the Env precursor and gp120, as opposed to the wild-type virus. The altered Env phenotype resulted in severely impaired virus infectivity and gp120 incorporation into this mutant virion. Analyses of additional mutants with deletions at Ile-830, Ala-836, and He-840 demonstrated that the Delta830 mutant exhibited the most significant inhibitory effect on Env steady-state expression. These results indicate that the N terminus of the lentivirus lytic peptide-1 region is critical for Env steady-state expression. Among the mutant viruses encoding Env proteins in which residues Val-832 and Val-833 were individually substituted by nonconserved amino acids Ala, Ser, or Pro, which were expected to disrupt the a-helical structure in the increasingly severe manner of Pro > Ser > Ala, only the 833P mutant exhibited significantly reduced steady-state Env expression. Pulse labeling and pulse-chase studies demonstrated that the Delta830, Delta833, and 833P mutants of Env proteins degraded more rapidly in a time-dependent manner after biosynthesis than did the wildtype Env. The results indicate that residue 830 and 833 mutations are likely to induce a conformational change in Env that targets the mutant protein for cellular degradation. Our study has implications about the structural determinants located at the N terminus of the lentivirus lytic peptide-1 sequence of gp41 that affect the fate of Env in virus-infected cells.	Acad Sinica, Inst Biomed Sci, Div Infect Dis, Taipei 11529, Taiwan; Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan; Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 11217, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Chen, SSL (corresponding author), Acad Sinica, Inst Biomed Sci, Div Infect Dis, 128 Sect,2 Yen Chiu Yuan Rd, Taipei 11529, Taiwan.							Akari H, 2000, J VIROL, V74, P4891, DOI 10.1128/JVI.74.10.4891-4893.2000; ARROYO J, 1995, J VIROL, V69, P4095, DOI 10.1128/JVI.69.7.4095-4102.1995; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Berlioz-Torrent C, 1999, J VIROL, V73, P1350, DOI 10.1128/JVI.73.2.1350-1361.1999; Boge M, 1998, J BIOL CHEM, V273, P15773, DOI 10.1074/jbc.273.25.15773; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; Chen SSL, 1999, J VIROL, V73, P8290, DOI 10.1128/JVI.73.10.8290-8302.1999; Chen SSL, 1996, VIROLOGY, V226, P260, DOI 10.1006/viro.1996.0654; Chen SSL, 1998, J VIROL, V72, P4765, DOI 10.1128/JVI.72.6.4765-4774.1998; Chen SSL, 2001, J VIROL, V75, P9925, DOI 10.1128/JVI.75.20.9925-9938.2001; CHERNOMORDIK L, 1994, J VIROL, V68, P7115, DOI 10.1128/JVI.68.11.7115-7123.1994; Comardelle AM, 1997, AIDS RES HUM RETROV, V13, P1525, DOI 10.1089/aid.1997.13.1525; DORFMAN T, 1994, J VIROL, V68, P1689, DOI 10.1128/JVI.68.3.1689-1696.1994; DUBAY JW, 1992, J VIROL, V66, P6616, DOI 10.1128/JVI.66.11.6616-6625.1992; EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991; EISENBERG D, 1990, BIOPOLYMERS, V29, P171, DOI 10.1002/bip.360290122; FISHER AG, 1986, SCIENCE, V233, P655, DOI 10.1126/science.3014663; FREED EO, 1995, J VIROL, V69, P1984, DOI 10.1128/JVI.69.3.1984-1989.1995; Freed EO, 1996, J VIROL, V70, P341, DOI 10.1128/JVI.70.1.341-351.1996; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; GAWRISCH K, 1993, BIOCHEMISTRY-US, V32, P3112, DOI 10.1021/bi00063a024; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Kliger Y, 1997, BIOCHEMISTRY-US, V36, P5157, DOI 10.1021/bi962935r; KORBER B, 1998, HUMAN RETROVIRUSES A, pA1; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Lee SF, 2000, J BIOL CHEM, V275, P15809, DOI 10.1074/jbc.M000601200; LEE SJ, 1989, AIDS RES HUM RETROV, V5, P441, DOI 10.1089/aid.1989.5.441; Lodge R, 1997, EMBO J, V16, P695, DOI 10.1093/emboj/16.4.695; LODGE R, 1994, J VIROL, V68, P4857, DOI 10.1128/JVI.68.8.4857-4861.1994; MANNANO F, 1995, J VIROL, V69, P3824; Micoli KJ, 2000, J BIOL CHEM, V275, P1233, DOI 10.1074/jbc.275.2.1233; MILLER MA, 1993, AIDS RES HUM RETROV, V9, P1057, DOI 10.1089/aid.1993.9.1057; MILLER RK, 1992, TROPHOBLAST RES, V6, P351; Murakami T, 2000, J VIROL, V74, P3548, DOI 10.1128/JVI.74.8.3548-3554.2000; Murakami T, 2000, P NATL ACAD SCI USA, V97, P343, DOI 10.1073/pnas.97.1.343; Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839; Pan ZG, 1996, AM J PATHOL, V149, P903; Piller SC, 2000, J VIROL, V74, P11717, DOI 10.1128/JVI.74.24.11717-11723.2000; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; ROWELL JF, 1995, J IMMUNOL, V155, P473; SPIES CP, 1994, J VIROL, V68, P585, DOI 10.1128/JVI.68.2.585-591.1994; SRINIVAS SK, 1993, J BIOL CHEM, V268, P22895; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; Tencza SB, 1997, AIDS RES HUM RETROV, V13, P263, DOI 10.1089/aid.1997.13.263; TENCZA SB, 1995, J VIROL, V69, P5199, DOI 10.1128/JVI.69.8.5199-5202.1995; TERWILLIGER E, 1986, J VIROL, V60, P754, DOI 10.1128/JVI.60.2.754-760.1986; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VENABLE RM, 1989, AIDS RES HUM RETROV, V5, P7, DOI 10.1089/aid.1989.5.7; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; YU XF, 1992, J VIROL, V66, P4966, DOI 10.1128/JVI.66.8.4966-4971.1992; YU XF, 1993, J VIROL, V67, P213, DOI 10.1128/JVI.67.1.213-221.1993	54	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15363	15375		10.1074/jbc.M201479200	http://dx.doi.org/10.1074/jbc.M201479200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859090	hybrid			2022-12-25	WOS:000175510400020
J	Park, JK; Wang, LX; Roseman, S				Park, JK; Wang, LX; Roseman, S			Isolation of a glucosamine-specific kinase, a unique enzyme of Vibrio cholerae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHITIN CATABOLIC CASCADE; MOLECULAR-CLONING; MARINE-BACTERIA; SUGAR-TRANSPORT; NAG REGULON; FURNISSII; IDENTIFICATION; SEQUENCE	We showed previously that chitin catabolism by the marine bacterium Vibrio furnissii involves at least three signal transduction systems and many genes, several of which were molecularly cloned, and the corresponding proteins were characterized. The predicted amino acid sequences of these proteins showed a high degree of identity to the corresponding proteins from Vibrio cholerae, whose complete genomic sequence has recently been determined. We have therefore initiated studies with V. cholerae. We report here a novel ATP-dependent glucosamine kinase of V. cholerae encoded by a gene designated gspK. The protein, GspK (31.6 kDa), was purified to apparent homogeneity from recombinant Escherichia coli. The product of the reaction was shown to be GlcN-6-P by matrix-assisted laser desorption/ionization-time of flight (MALDI mass spectrometry) and NAIR. The K(m) values for GlcN, ATP, and MgCl(2) were 0.45, 2.4, and 2.2 mM, respectively, and the V(max) values were in the range 180-200 nmol/mug/min (similar to6 nmol/pmol/min). Kinase activity was not observed with any other sugar, including: galactosamine, mannosamine, Glc, GlcNAc, GalNAc, mannose, 2-deoxyglucose, and oligosaccharides of chitosan. The enzyme is also ATP-specific. The kinase can be used to specifically determine micro quantities of GlcN in acid hydrolysates of glycoconjugates. The physiological function of this enzyme remains to be determined.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA; Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Wang, Lai-Xi/E-8755-2019; Wang, Lai-Xi/E-8790-2019; wang, xl/Y-8251-2019	Wang, Lai-Xi/0000-0003-4293-5819; 	NIGMS NIH HHS [GM51215] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asensio C., 1966, METHODS ENZYMOL, V9, P421; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; Bouma CL, 1996, J BIOL CHEM, V271, P33468, DOI 10.1074/jbc.271.52.33468; BUEDING E, 1954, P NATL ACAD SCI USA, V40, P773, DOI 10.1073/pnas.40.9.773; Carlson DM., 1966, METHOD ENZYMOL, V8, P179; COMB DG, 1958, J BIOL CHEM, V232, P807; DAVIDSON EA, 1957, J BIOL CHEM, V226, P125; DISTLER JJ, 1958, J BIOL CHEM, V230, P497; FERNANDE.A, 1971, J BIOL CHEM, V246, P3485; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; JOURDIAN GW, 1962, BIOCHEM PREP, V9, P44; Keyhani NO, 1999, BBA-GEN SUBJECTS, V1473, P108, DOI 10.1016/S0304-4165(99)00172-5; Keyhani NO, 2000, J BIOL CHEM, V275, P33068, DOI 10.1074/jbc.M001041200; Keyhani NO, 1996, J BIOL CHEM, V271, P33425, DOI 10.1074/jbc.271.52.33425; Keyhani NO, 1996, J BIOL CHEM, V271, P33414, DOI 10.1074/jbc.271.52.33414; Keyhani NO, 1996, J BIOL CHEM, V271, P33409, DOI 10.1074/jbc.271.52.33409; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; NALIN DR, 1979, INFECT IMMUN, V25, P768, DOI 10.1128/IAI.25.2.768-770.1979; NALIN DR, 1976, LANCET, V2, P958; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; PLUMBRIDGE J, 2001, NUCLEIC ACIDS RES, V29, P1; PLUMBRIDGE JA, 1989, MOL MICROBIOL, V3, P505, DOI 10.1111/j.1365-2958.1989.tb00197.x; PLUMBRIDGE JA, 1991, MOL MICROBIOL, V5, P2053, DOI 10.1111/j.1365-2958.1991.tb00828.x; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; REISSIG JL, 1956, J BIOL CHEM, V219, P753; ROSEMAN S, 1957, J BIOL CHEM, V226, P115; Segel I.H., 1976, BIOCH CALCULATIONS, V2nd ed., P236	29	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15573	15578		10.1074/jbc.M107953200	http://dx.doi.org/10.1074/jbc.M107953200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11850417	hybrid			2022-12-25	WOS:000175510400048
J	Rajas, F; Gautier, A; Bady, I; Montano, S; Mithieux, G				Rajas, F; Gautier, A; Bady, I; Montano, S; Mithieux, G			Polyunsaturated fatty acyl coenzyme A suppress the glucose-6-phosphatase promoter activity by modulating the DNA binding of hepatocyte nuclear factor 4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-6 PHOSPHATASE GENE; TRANSCRIPTION FACTOR HNF-4; MUSCLE INSULIN-RESISTANCE; RAT SMALL-INTESTINE; DIABETIC RATS; DIETARY-FAT; LIVER GLUCOSE-6-PHOSPHATASE; REGULATORY ELEMENT; ACCESSORY FACTOR; FACTOR-IV	Glucose-6-phosphatase confers on gluconeogenic tissues the capacity to release endogenous glucose in blood. The expression of its gene is modulated by nutritional mechanisms dependent on dietary fatty acids, with specific inhibitory effects of polyunsaturated fatty acids (PUFA). The presence of consensus binding sites of hepatocyte nuclear factor 4 (HNF4) in the -1640/+60 bp region of the rat glucose-6-phosphatase gene has led us to consider the hypothesis that HNF4alpha could be involved in the regulation of glucose-6-phosphatase gene transcription by long chain fatty acid (LCFA). Our results have shown that the glucose-6-phosphatase promoter activity is specifically inhibited in the presence of PUFA in HepG2 hepatoma cells, whereas saturated LCFA have no effect. In HeLa cells, the glucose-6-phosphatase promoter activity is induced by the co-expression of HNF4alpha or HNF1alpha. PUFA repress the promoter activity only in HNF4alpha-cotransfected HeLa cells, whereas they have no effects on the promoter activity in HNF1alpha-cotransfected HeLa cells. From gel shift mobility assays, deletion, and mutagenesis experiments, two specific binding sequences have been identified that appear able to account for both transactivation by HNF4alpha and regulation by LCFA in cells. The binding of HNF4alpha to its cognate sites is specifically inhibited by polyunsaturated fatty acyl coenzyme A in vitro. These data strongly suggest that the mechanism by which PUFA suppress the glucose-6-phosphatase gene transcription involves an inhibition of the binding of HNF4alpha to its cognate sites in the presence of polyunsaturated fatty acyl-CoA thioesters.	Fac Med Laennec, INSERM, U449, F-69372 Lyon 08, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Rajas, F (corresponding author), Fac Med Laennec, INSERM, U449, Rue Guillaume Paradin, F-69372 Lyon 08, France.		RAJAS, Fabienne/P-4091-2016	RAJAS, Fabienne/0000-0002-9233-7633; Gilles, Mithieux/0000-0003-3579-8529; Gautier-Stein, Amandine/0000-0002-6003-1891				Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; AUSABEL FM, 1999, CURRENT PROTOCOLS MO; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; Clarke SD, 2001, AM J PHYSIOL-GASTR L, V281, pG865, DOI 10.1152/ajpgi.2001.281.4.G865; Clore JN, 2000, DIABETES, V49, P969, DOI 10.2337/diabetes.49.6.969; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Croset M, 2001, DIABETES, V50, P740, DOI 10.2337/diabetes.50.4.740; Daniele N, 1997, J NUTR, V127, P2289, DOI 10.1093/jn/127.12.2289; EFENDIC S, 1988, J CLIN INVEST, V81, P1953, DOI 10.1172/JCI113543; EFENDIC S, 1985, P NATL ACAD SCI USA, V82, P2965, DOI 10.1073/pnas.82.9.2965; Foretz M, 1999, BIOCHEM J, V341, P371, DOI 10.1042/0264-6021:3410371; Fourel G, 1996, J VIROL, V70, P8571, DOI 10.1128/JVI.70.12.8571-8583.1996; GARG ML, 1985, BIOCHEM INT, V10, P585; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hu CB, 1999, AM J PHYSIOL-GASTR L, V276, pG1181, DOI 10.1152/ajpgi.1999.276.5.G1181; Hung HL, 1996, J BIOL CHEM, V271, P2323, DOI 10.1074/jbc.271.4.2323; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; LEFF T, 1989, J BIOL CHEM, V264, P16132; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; Lin BC, 1998, DNA CELL BIOL, V17, P967, DOI 10.1089/dna.1998.17.967; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; METZGER S, 1993, J BIOL CHEM, V268, P16831; MITHIEUX G, 1993, EUR J BIOCHEM, V213, P461, DOI 10.1111/j.1432-1033.1993.tb17782.x; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; Mithieux G, 2002, DIABETES, V51, P139, DOI 10.2337/diabetes.51.1.139; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; NEWMANN JR, 1987, BIOTECHNIQUES, V5, P444; Oakes ND, 1997, DIABETES, V46, P1768, DOI 10.2337/diabetes.46.11.1768; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Rouet P, 1998, BIOCHEM J, V334, P577, DOI 10.1042/bj3340577; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; VENKATRAMAN JT, 1991, LIPIDS, V26, P441, DOI 10.1007/BF02536070; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Waltz SE, 1996, J BIOL CHEM, V271, P9024, DOI 10.1074/jbc.271.15.9024; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Yamada K, 1997, BIOCHEM J, V324, P917, DOI 10.1042/bj3240917; Yanai K, 1999, J BIOL CHEM, V274, P34605, DOI 10.1074/jbc.274.49.34605; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	50	69	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15736	15744		10.1074/jbc.M200971200	http://dx.doi.org/10.1074/jbc.M200971200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864989	hybrid			2022-12-25	WOS:000175510400070
J	Knox, S; Merry, C; Stringer, S; Melrose, J; Whitelock, J				Knox, S; Merry, C; Stringer, S; Melrose, J; Whitelock, J			Not all perlecans are created equal - Interactions with fibroblast growth factor (FGF) 2 and FGF receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; FACTOR-BINDING; CELL-SURFACE; STRUCTURAL REQUIREMENTS; MITOGENIC ACTIVITY; ENDOTHELIAL-CELLS; LIGAND-BINDING; SPECIFICITY; AFFINITY; IDENTIFICATION	Human basement membrane heparan sulfate proteoglycan (HSPG) perlecan binds and activates fibroblast growth factor (FGF)-2 through its heparan sulfate (HS) chains. Here we show that perlecans immunopurified from three cellular sources possess different HS structures and subsequently different FGF-2 binding and activating capabilities. Perlecan isolated from human umbilical arterial endothelial cells (HUAEC) and a continuous endothelial cell line (C11 STH) bound similar amounts of FGF-2 either alone or complexed with FGFRalpha1-IIIc or FGFR3alpha-IIIc. Both perlecans stimulated the growth of BaF3 cell lines expressing FGFR1b/c; however, only HUAEC perlecan stimulated those cells expressing FGFR3c, suggesting that the source of perlecan confers FGF and FGFR binding specificity. Despite these differences in FGF-2 activation, the level of 2-O- and 6-O-sulfation was similar for both perlecans. Interestingly, perlecan isolated from a colon carcinoma cell line that was capable of binding FGF-2 was incapable of activating any BaF3 cell line unless the HS was removed from the protein core. The HS chains also exhibited greater bioactivity after digestion with heparinase III. Collectively, these data clearly demonstrate that the bioactivity of HS decorating a single PG is dependent on its cell source and that subtle changes in structure including secondary interactions have a profound effect on biological activity.	CSIRO Mol Sci, N Ryde, NSW 2113, Australia; Christie Hosp, Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England; Royal N Shore Hosp, Inst Bone & Joint Res, Raymond Purves Labs, St Leonards, NSW 2065, Australia; Univ New S Wales, Grad Sch Biomed Engn, Kensington, NSW 2052, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Royal North Shore Hospital; University of New South Wales Sydney	Whitelock, J (corresponding author), CSIRO Mol Sci, POB 184, N Ryde, NSW 1670, Australia.	john.whitelock@csiro.au	Melrose, James/AAG-5445-2019	Melrose, James/0000-0001-9237-0524; Whitelock, John/0000-0003-1835-802X; merry, catherine/0000-0002-3490-2809				Adatia R, 1997, ANN ONCOL, V8, P1257, DOI 10.1023/A:1008243115385; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Barillari G, 1998, AM J PATHOL, V152, P1161; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; COCKERILL GW, 1994, LAB INVEST, V71, P497; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Cotman SL, 1999, EXP CELL RES, V249, P54, DOI 10.1006/excr.1999.4463; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; Ebara T, 2000, J CLIN INVEST, V105, P1807, DOI 10.1172/JCI8283; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Feitsma K, 2000, J BIOL CHEM, V275, P9396, DOI 10.1074/jbc.275.13.9396; Fernig DG, 2000, BIOCHEM BIOPH RES CO, V267, P770, DOI 10.1006/bbrc.1999.2028; FRANSSON LA, 1982, CARBOHYD RES, V110, P135, DOI 10.1016/0008-6215(82)85032-5; French MM, 1999, J CELL BIOL, V145, P1103, DOI 10.1083/jcb.145.5.1103; Friedl A, 1997, AM J PATHOL, V150, P1443; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; IOZZO RV, 1994, MATRIX BIOL, V14, P203, DOI 10.1016/0945-053X(94)90183-X; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KATO M, 1994, J BIOL CHEM, V269, P18881; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; LaRochelle WJ, 1999, BIOCHEMISTRY-US, V38, P1765, DOI 10.1021/bi982092z; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MELROSE J, 1993, J CHROMATOGR, V637, P91, DOI 10.1016/0021-9673(93)83102-X; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Molist A, 1998, EUR J BIOCHEM, V254, P371, DOI 10.1046/j.1432-1327.1998.2540371.x; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Pye DA, 2000, GLYCOBIOLOGY, V10, P1183, DOI 10.1093/glycob/10.11.1183; Pye DA, 1998, BIOCHEM BIOPH RES CO, V248, P889, DOI 10.1006/bbrc.1998.9081; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; Safran M, 2000, BIOCHEM J, V345, P107, DOI 10.1042/0264-6021:3450107; SCOTT JE, 1982, BIOCHEM J, V207, P139, DOI 10.1042/bj2070139; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Tapanadechopone P, 2001, BIOCHEM J, V355, P517, DOI 10.1042/0264-6021:3550517; TESSLER S, 1994, J BIOL CHEM, V269, P12456; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Uematsu F, 2000, BIOCHEM BIOPH RES CO, V272, P830, DOI 10.1006/bbrc.2000.2872; Whitelock J, 1997, CELL BIOL INT, V21, P181, DOI 10.1006/cbir.1996.0125; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Whitelock JM, 1999, MATRIX BIOL, V18, P163, DOI 10.1016/S0945-053X(99)00014-1; Wu XC, 2001, CANCER RES, V61, P5295; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zhang Z, 2001, J BIOL CHEM, V276, P41921, DOI 10.1074/jbc.M106608200	61	131	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14657	14665		10.1074/jbc.M111826200	http://dx.doi.org/10.1074/jbc.M111826200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847221	hybrid			2022-12-25	WOS:000175203000040
J	Morohashi, Y; Hatano, N; Ohya, S; Takikawa, R; Watabiki, T; Takasugi, N; Imaizumi, Y; Tomita, T; Iwatsubo, T				Morohashi, Y; Hatano, N; Ohya, S; Takikawa, R; Watabiki, T; Takasugi, N; Imaizumi, Y; Tomita, T; Iwatsubo, T			Molecular cloning and characterization of CALP/KChIP4, a novel EF-hand protein interacting with presenilin 2 and voltage-gated potassium channel subunit Kv4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; GAMMA-SECRETASE ACTIVITY; CAPACITATIVE CALCIUM-ENTRY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; PREFERENTIALLY INTERACTS; MUTANT PRESENILIN-1; TRANSFECTED CELLS; BINDING PROTEIN; C-TERMINUS	Presenilin (PS) genes linked to early-onset familial Alzheimer's disease encode polytopic membrane proteins that are presumed to constitute the catalytic subunit of gamma-secretase, forming a high molecular weight complex with other proteins. During our attempts to identify binding partners of PS2, we cloned CALP (calsenilin-like protein)/KChIP4, a novel member of calsenilin/ KChIP protein family that interacts with the C-terminal region of PS. Upon co-expression in cultured cells, CALP was directly bound to and co-localized with PS2 in endoplasmic reticulum. Overexpression of CALP did not affect the metabolism or stability of PS complex, and gamma-cleavage of betaAPP or Notch site 3 cleavage was not altered. However, co-expression of CALP and a voltage-gated potassium channel subunit Kv4.2 reconstituted the features of A-type K+ currents and CALP directly bound Kv4.2, indicating that CALP functions as KChIPs that are known as components of native Kv4 channel complex. Taken together, CALP/KChIP4 is a novel EF-hand protein interacting with PS as well as with Kv4 that may modulate functions of a subset of membrane proteins in brain.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol & Cellular Pharmacol, Nagoya, Aichi 4678603, Japan	University of Tokyo; Nagoya City University	Iwatsubo, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Ohya, Susumu/AAB-3618-2020; Imaizumi, Yuji/AAF-6585-2020; Tomita, Taisuke/L-5427-2015	Ohya, Susumu/0000-0002-5765-0667; Tomita, Taisuke/0000-0002-0075-5943; TAKASUGI, NOBUMASA/0000-0002-6059-2082				An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Choi EK, 2001, J BIOL CHEM, V276, P19197, DOI 10.1074/jbc.M008597200; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fukumoto H, 1999, NEUROREPORT, V10, P2965, DOI 10.1097/00001756-199909290-00017; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Holmqvist MH, 2001, J NEUROSCI, V21, P4154, DOI 10.1523/JNEUROSCI.21-12-04154.2001; IMAIZUMI Y, 1990, J PHYSIOL-LONDON, V427, P301, DOI 10.1113/jphysiol.1990.sp018173; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Leissring MA, 2000, P NATL ACAD SCI USA, V97, P8590, DOI 10.1073/pnas.97.15.8590; Leissring MA, 1999, J BIOL CHEM, V274, P32535, DOI 10.1074/jbc.274.46.32535; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Murata T, 1999, J BIOL CHEM, V274, P1277, DOI 10.1074/jbc.274.3.1277; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Ohya S, 1997, FEBS LETT, V420, P47, DOI 10.1016/S0014-5793(97)01483-X; Ohya S, 2001, BIOCHEM BIOPH RES CO, V282, P96, DOI 10.1006/bbrc.2001.4558; Pack-Chung E, 2000, J BIOL CHEM, V275, P14440, DOI 10.1074/jbc.M909882199; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shinozaki K, 1998, INT J MOL MED, V1, P797; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	53	130	141	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14965	14975		10.1074/jbc.M200897200	http://dx.doi.org/10.1074/jbc.M200897200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847232	hybrid			2022-12-25	WOS:000175203000078
J	Saito, S; Goodarzi, AA; Higashimoto, Y; Noda, Y; Lees-Miller, SP; Appella, E; Anderson, CW				Saito, S; Goodarzi, AA; Higashimoto, Y; Noda, Y; Lees-Miller, SP; Appella, E; Anderson, CW			ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; KINASE; ACTIVATION; TRANSACTIVATION; CHECKPOINT; INHIBITION; CASCADE	The p53 tumor suppressor protein preserves genome integrity by regulating growth arrest and apoptosis in response to DNA damage. In response to ionizing radiation (111), ATM, the gene product mutated in ataxia telangiectasia, stabilizes and activates p53 through phosphorylation of Ser(15) and (indirectly) Ser(20). Here we show that phosphorylation of p53 on Ser(46), a residue important for p53 apoptotic activity, as well as on Ser(9), in response to IR also is dependent on the ATM protein kinase. IR-induced phosphorylation at Ser(46) was inhibited by wortmannin, a phosphatidylinositol 3-kinase inhibitor, but not PD169316, a p38 MAPK inhibitor. p53 C-terminal acetylation at Lys(320) and Lys(382), which may stabilize p53 and activate sequence-specific DNA binding, required Ser15 phosphorylation by ATM and was enhanced by phosphorylation at nearby residues including Ser(6), Ser(9), and Thr(18). These observations, together with the proposed role of Ser(46) phosphorylation in mediating apoptosis, suggest that ATM is involved in the initiation of p53-dependent apoptosis after IR in human lymphoblastoid cells.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; NCI, NIH, Cell Biol Lab, Bethesda, MD 20892 USA; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 1N4, Canada	United States Department of Energy (DOE); Brookhaven National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Calgary	Anderson, CW (corresponding author), Brookhaven Natl Lab, Dept Biol, 50 Bell Ave, Upton, NY 11973 USA.	cwa@bnl.gov		Higashimoto, Yuichiro/0000-0003-1382-8598; Lees-Miller, Susan/0000-0001-5809-2516				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Gallagher TF, 1997, BIOORGAN MED CHEM, V5, P49, DOI 10.1016/S0968-0896(96)00212-X; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; Jabbur JR, 2000, ONCOGENE, V19, P6203, DOI 10.1038/sj.onc.1204017; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277	35	200	204	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12491	12494		10.1074/jbc.C200093200	http://dx.doi.org/10.1074/jbc.C200093200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11875057	hybrid			2022-12-25	WOS:000175036300002
J	Arentson, E; Faloon, P; Seo, J; Moon, E; Studts, JM; Fremont, DH; Choi, KH				Arentson, E; Faloon, P; Seo, J; Moon, E; Studts, JM; Fremont, DH; Choi, KH			Oncogenic potential of the DNA replication licensing protein CDT1	ONCOGENE			English	Article						CDT1; retroviral insertional activation; oncogene	APRT LOCUS; CELL-CYCLE; COILED COILS; GENE; HETEROZYGOSITY; SEQUENCES; MUTATION; CANCER; YEAST; RETINOBLASTOMA	The expression of a gene, designated as Retroviral insertion site (Ris)2, was activated by retroviral DNA integration in an immortalized primitive erythroid cell line, EB-PE. Ris2 was also expressed at high levels in all human tumor cell lines analysed. Consistently, NIH3T3 fibroblasts overexpressing Ris2 formed tumors in Rag2(-/-) mice when injected subcutaneously. The putative RIS2 protein shows a high sequence similarity to Xenopus CDT1, Drosophila DUP, and human CDT1, a newly identified DNA replication licensing protein, suggesting that Ris2 is a mouse homologue of CDT1. Cells overexpressing Ris2/Cdt1 exhibited a quicker entry into S phase when released from serum starvation compared to controls. Our results suggest that CDT1, an essential licensing protein for DNA replication, can function as an oncogene in mammals.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Ajou Univ, Dept Biol Sci, Suwon 441749, South Korea	Washington University (WUSTL); Ajou University	Choi, KH (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	kchoi@pathology.wustl.edu		Fremont, Daved/0000-0002-8544-2689				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; Blow JJ, 2000, NATURE, V404, P560, DOI 10.1038/35007187; Choi K, 1998, DEVELOPMENT, V125, P725; DEWYSE P, 1989, SOMAT CELL MOLEC GEN, V15, P19, DOI 10.1007/BF01534666; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fujita Masatoshi, 1999, Frontiers in Bioscience, V4, pd816, DOI 10.2741/Fujita; GUPTA PK, 1994, ADV EXP MED BIOL, V370, P653; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HARWOOD J, 1995, SOMAT CELL MOLEC GEN, V21, P151, DOI 10.1007/BF02254767; HIRAMA T, 1995, BLOOD, V86, P841; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lygerou Z, 2000, SCIENCE, V290, P2271; Madine M, 2001, NAT CELL BIOL, V3, pE49, DOI 10.1038/35055158; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; MOIR D, 1982, GENETICS, V100, P547; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PHEAR G, 1989, J MOL BIOL, V209, P577, DOI 10.1016/0022-2836(89)90595-0; QUINTANA DG, 1999, FRONT BIOSCI, V4, P805, DOI DOI 10.2741/QUINTANA; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Stambrook PJ, 1996, ENVIRON MOL MUTAGEN, V28, P471; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Van Sloun PPH, 1998, NUCLEIC ACIDS RES, V26, P4888, DOI 10.1093/nar/26.21.4888; Whittaker AJ, 2000, GENE DEV, V14, P1765; Wijnhoven SWP, 1998, P NATL ACAD SCI USA, V95, P13759, DOI 10.1073/pnas.95.23.13759; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Yuen D, 1998, BLOOD, V91, P3202, DOI 10.1182/blood.V91.9.3202.3202_3202_3209; ZHU Y, 1993, MOL CARCINOGEN, V8, P138, DOI 10.1002/mc.2940080304	45	106	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1150	1158		10.1038/sj.onc.1205175	http://dx.doi.org/10.1038/sj.onc.1205175			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850834				2022-12-25	WOS:000173729400002
J	Moll, F; Katsaros, D; Lazennec, G; Hellio, N; Roger, P; Giacalone, PL; Chalbos, D; Maudelonde, T; Rochefort, H; Pujol, P				Moll, F; Katsaros, D; Lazennec, G; Hellio, N; Roger, P; Giacalone, PL; Chalbos, D; Maudelonde, T; Rochefort, H; Pujol, P			Estrogen induction and overexpression of fibutin-1C mRNA in ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; fibulin-1C; fibulin-1D; estrogen; competitive PCR	EXON-INTRON ORGANIZATION; RECEPTOR-ALPHA; EXTRACELLULAR-MATRIX; CARCINOMA CELLS; HUMAN FIBULIN-1; IN-VITRO; EXPRESSION; GROWTH; PROTEIN; BETA	Fibulin-1 is an extracellular matrix protein induced by estradiol in estrogen receptor (ER) positive ovarian cancer cell lines. Alternative splicing of fibulin-1 mRNA results in four different variants named A, B, C and D that may have distinct biological functions. We studied the relative expression of fibulin-1 mRNA variants and their estrogen regulation in human ovarian cancer cells. In ovarian tissues and cancer cell lines, fibulin-1C and -1D are the predominant forms, whereas fibulin-1A and -1B are weakly expressed. We developed a competitive PCR assay based on coamplification of fibulin-1C and -1D to study the relative expression of these fibulin-1 variants in human ovarian samples. In ovarian cancer cell lines and ovarian cancer samples, there was a marked increase in the fibutin-1C:1D and fibulin-1C:HPRT mRNA ratios as compared to normal ovaries. In the BG1 estrogen receptor positive ovarian cancer cell line, fibulin-1C mRNA was induced by estradiol in a dose- and time-dependent manner. Since others and we have previously shown an increased expression of ERalpha as compared to ERbeta in ovarian cancer cells, we investigated whether ERalpha or ERbeta is involved in this induction. For this aim, MDA-MB-231 breast cancer cell line, which expresses both low basal levels of ERs and fibulin-1, was infected with recombinant ERalpha or ERbeta encoding adenovirus and treated with estradiol. Fibulin-1C was induced by estradiol in ERalpha- but not ERbeta-infected cells, suggesting that fibulin-1C induction is mediated through ERa. In ovarian tumors, a trend towards a correlation between fibulin-1C and ERalpha expression levels was noted. In conclusion, this study showed an increased fibulin-1C: -1D mRNA ratio in ovarian cancer cells as compared to normal ovaries. This finding suggests that the C variant may be involved in ovarian carcinogenesis. Fibulin-1C overexpression may thus be a clue for the understanding of a putative role of estrogens in ERalpha promoted ovarian tumor progression.	Hop Arnaud de Villeneuve, Serv Biol Cellulaire, F-34295 Montpellier, France; Hop Arnaud de Villeneuve, Serv Hormonale, F-34295 Montpellier, France; INSERM, U540, F-34095 Montpellier, France; Dept Obstet & Gynecol, I-10126 Turin, Italy; CHU Montpellier, Hop Arnaud de Villeneuve, F-34295 Montpellier, France	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Pujol, P (corresponding author), Hop Arnaud de Villeneuve, Serv Biol Cellulaire, 271 Av G Giraud, F-34295 Montpellier, France.	p-pujol@chu-montpellier.fr		Lazennec, Gwendal/0000-0002-8522-1763; ROGER, Pascal/0000-0002-4040-5892				Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244; AHLGREN JD, 1993, J CLIN ONCOL, V11, P1957, DOI 10.1200/JCO.1993.11.10.1957; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; BALBONA K, 1992, J BIOL CHEM, V267, P20120; Brandenberger AW, 1998, J CLIN ENDOCR METAB, V83, P1025, DOI 10.1210/jc.83.3.1025; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; CHIEN CH, 1994, MOL CELL ENDOCRINOL, V99, P11; Clinton GM, 1996, P NATL ACAD SCI USA, V93, P316, DOI 10.1073/pnas.93.1.316; GALTIERDEREURE F, 1992, J CLIN ENDOCR METAB, V75, P1497, DOI 10.1210/jc.75.6.1497; GEISINGER KR, 1989, CANCER-AM CANCER SOC, V63, P280, DOI 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N; Grassel S, 1999, EUR J BIOCHEM, V263, P471, DOI 10.1046/j.1432-1327.1999.00523.x; Greenwood M, 2000, HIST TODAY, V50, P3; Hamilton TC, 1999, ANN ONCOL, V10, P69, DOI 10.1023/A:1008367620240; HATCH KD, 1991, CANCER, V68, P269, DOI 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O; Havrilesky LJ, 2001, J SOC GYNECOL INVEST, V8, P104, DOI 10.1016/S1071-5576(01)00093-4; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; Hillier SG, 1998, MOL HUM REPROD, V4, P811, DOI 10.1093/molehr/4.8.811; JABARA AG, 1962, AUST J EXP BIOL MED, V40, P139, DOI 10.1038/icb.1962.17; KORENBERG JR, 1995, CYTOGENET CELL GENET, V68, P192, DOI 10.1159/000133911; KRYWICKI RF, 1993, EUR J CANCER, V29A, P2015, DOI 10.1016/0959-8049(93)90464-Q; LANGDON SP, 1990, BRIT J CANCER, V62, P213, DOI 10.1038/bjc.1990.263; LANGDON SP, 1993, INT J CANCER, V55, P459, DOI 10.1002/ijc.2910550323; LANGDON SP, 1994, EUR J CANCER, V30A, P682, DOI 10.1016/0959-8049(94)90545-2; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Makar AP, 2000, ENDOCR-RELAT CANCER, V7, P85, DOI 10.1677/erc.0.0070085; MAZARS R, 1991, ONCOGENE, V6, P1685; NASH JD, 1989, OBSTET GYNECOL, V73, P1009; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; Pan TC, 1999, FEBS LETT, V444, P38, DOI 10.1016/S0014-5793(99)00024-1; PAVLIK EJ, 1991, GYNECOL ONCOL, V42, P245, DOI 10.1016/0090-8258(91)90353-7; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Pujol P, 1998, CANCER RES, V58, P5367; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; Rey JM, 2000, J MOL ENDOCRINOL, V24, P433, DOI 10.1677/jme.0.0240433; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; ROCHEFORT H, 1984, RECENT RESULTS CANC, V91, P289; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Roger P, 1998, AM J PATHOL, V153, P1579, DOI 10.1016/S0002-9440(10)65746-X; Romagnolo D, 1998, MOL CARCINOGEN, V22, P102, DOI 10.1002/(SICI)1098-2744(199806)22:2<102::AID-MC5>3.0.CO;2-O; Rutherford T, 2000, OBSTET GYNECOL, V96, P417, DOI 10.1016/S0029-7844(00)00917-0; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4	47	87	93	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1097	1107		10.1038/sj.onc.1205171	http://dx.doi.org/10.1038/sj.onc.1205171			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850827				2022-12-25	WOS:000173580100013
J	Leem, SH; Londono-Vallejo, JA; Kim, JH; Bui, H; Tubacher, E; Solomon, G; Park, JE; Horikawa, I; Kouprina, N; Barrett, JC; Larionov, V				Leem, SH; Londono-Vallejo, JA; Kim, JH; Bui, H; Tubacher, E; Solomon, G; Park, JE; Horikawa, I; Kouprina, N; Barrett, JC; Larionov, V			The human telomerase gene: complete genomic sequence and analysis of tandem repeat polymorphisms in intronic regions	ONCOGENE			English	Article						hTERT; VNTR; polymorphism	REVERSE-TRANSCRIPTASE HTERT; EMBRYONIC STEM-CELLS; CATALYTIC SUBUNIT; AFFECTIVE-DISORDERS; VARIABLE NUMBER; C-MYC; PROMOTER; IDENTIFICATION; MINISATELLITE; CLONING	In this work, the full-length hTERT gene was isolated and the sequence of the previously unknown region in intron 6 as well as that of upstream and downstream hTERT regions was determined. We have shown that intron 6 includes a variable number of tandem repeats (VNTR) of a 38 bp sequence, (hTERT-VNTR 6-1). Eight alleles of hTERT-VNTR 6-1 were identified among 103 unrelated individuals, ranging front 27 to 47 repeats. hTERT-VNTR 2-2 is another new 61 bp minisatellite repeat found in intron 2 of hTERT. At least four alleles of hTERT-VNTR 2-2 can be distinguished. Previous studies have described polymorphisms for minisatellites hTERT-VNTR 2-1, a 42 bp repeat in intron 2, and hTERT-VNTR 6-2, a 36 bp repeat in intron 6. These, together with another minisatellite found in intron 12, add up to five such structures within the hTERT gene. The segregation of hTERT minisatellites was analysed in families, revealing that the VNTRs are transmitted through meiosis following a Mendelian inheritance. Minisatellites in hTERT were also analysed in matching normal and cancer tissues from patients with tumors; in one patient with a kidney tumor, the two VNTRs in intron 6 had undergone concomitant rearrangements. This observation suggests that chromosomal rearrangements implicating these VNTRs may be associated with the activation of telomerase expression in cancer cells.	NCI, Lab Biosyst & Canc, NIH, Bethesda, MD 20892 USA; DongA Univ, Dept Biol, Pusan 604714, South Korea; NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Dong A University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Larionov, V (corresponding author), NCI, Lab Biosyst & Canc, NIH, Bldg 49,Room 4A56, Bethesda, MD 20892 USA.		Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Alakurtti K, 2000, GENE, V242, P65, DOI 10.1016/S0378-1119(99)00550-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Armstrong L, 2000, MECH DEVELOP, V97, P109, DOI 10.1016/S0925-4773(00)00423-8; Avilion AA, 1996, CANCER RES, V56, P645; Bailly S, 1996, MOL IMMUNOL, V33, P999, DOI 10.1016/S0161-5890(96)00042-9; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Blackburn EH, 2000, NAT STRUCT BIOL, V7, P847, DOI 10.1038/79594; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Choi YM, 2000, J HUM GENET, V45, P218, DOI 10.1007/s100380070030; Chowdhury MR, 2000, HAEMOPHILIA, V6, P625, DOI 10.1046/j.1365-2516.2000.00442.x; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Desseyn JL, 1999, ELECTROPHORESIS, V20, P493, DOI 10.1002/(SICI)1522-2683(19990301)20:3<493::AID-ELPS493>3.0.CO;2-7; FAIK P, 1994, GENOMICS, V21, P122, DOI 10.1006/geno.1994.1233; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fiskerstrand CE, 1999, FEBS LETT, V458, P171, DOI 10.1016/S0014-5793(99)01150-3; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Horikawa I, 1999, CANCER RES, V59, P826; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kouprina N, 1998, P NATL ACAD SCI USA, V95, P4469, DOI 10.1073/pnas.95.8.4469; KOUPRINA N, 1999, CURRENT PROTOCOLS HU, V1; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; MacKenzie A, 1999, P NATL ACAD SCI USA, V96, P15251, DOI 10.1073/pnas.96.26.15251; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakamura Y, 1998, J HUM GENET, V43, P149, DOI 10.1007/s100380050059; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; ROYLE NJ, 1988, GENOMICS, V3, P352, DOI 10.1016/0888-7543(88)90127-9; Shay JW, 1999, SCIENCE, V286, P2284, DOI 10.1126/science.286.5448.2284; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; Takakura M, 1999, CANCER RES, V59, P551; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; TREPICCHIO WL, 1992, NUCLEIC ACIDS RES, V20, P2427, DOI 10.1093/nar/20.10.2427; TURRI MG, 1995, NUCLEIC ACIDS RES, V23, P1854, DOI 10.1093/nar/23.11.1854; Tzukerman M, 2000, MOL BIOL CELL, V11, P4381, DOI 10.1091/mbc.11.12.4381; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yang F, 2000, AM J MED GENET, V95, P385, DOI 10.1002/1096-8628(20001211)95:4<385::AID-AJMG16>3.0.CO;2-V; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200	46	61	69	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					769	777		10.1038/sj.onc.1205122	http://dx.doi.org/10.1038/sj.onc.1205122			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850805				2022-12-25	WOS:000173427000008
J	Yamaguchi-Iwai, Y; Ueta, R; Fukunaka, A; Sasaki, R				Yamaguchi-Iwai, Y; Ueta, R; Fukunaka, A; Sasaki, R			Subcellular localization of Aft1 transcription factor responds to iron status in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; DNA-BINDING DOMAIN; OXIDATIVE STRESS; NUCLEOCYTOPLASMIC TRANSPORT; REGULATORY PROTEIN-2; ACTIVATION DOMAIN; GENE-EXPRESSION; MESSENGER-RNA; FACTOR PHO4; FACTOR PAP1	The Aft1 transcription factor regulates the iron regulon in response to iron availability in Saccharomyces cerevisiae. Aft1 activates a battery of genes required for iron uptake under iron-starved conditions, whereas Aft1 function is inactivated under iron-replete conditions. Previously, we have shown that iron-regulated DNA binding by Aft1 is responsible for the controlled expression of target genes. Here we show that this iron-regulated DNA binding by Aft1 is not due to the change in the total expression level of Aft1 or alteration of DNA binding activity. Rather, nuclear localization of Aft1 responds to iron status, leading to iron-regulated expression of the target genes. We identified the nuclear export signal (NES)-like sequence in the AFT1 open reading frame. Mutation of the NES-like sequence causes nuclear retention of Aft1 and the constitutive activation of Aft1 function independent of the iron status of the cells. These results suggest that the nuclear export of Aft1 is critical for ensuring iron-responsive transcriptional activation of the Aft1 regulon and that the nuclear import/export systems are involved in iron sensing by Aft1 in S. cerevisiae.	Kyoto Univ, Grad Sch Biostudies, Dept Appl Mol Biol, Sakyo Ku, Kyoto 6068502, Japan; Univ Shiga Prefecture, Sch Human Cultures, Dept Life Style Studies, Shiga 5228533, Japan	Kyoto University; University Shiga Prefecture	Yamaguchi-Iwai, Y (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Appl Mol Biol, Sakyo Ku, Kyoto 6068502, Japan.	yukoiwai@kais.kyoto-u.ac.jp						Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Brittenham GM, 2000, HEMATOLOGY BASIC PRI, P397; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; Dancis A, 1998, J PEDIATR-US, V132, pS24, DOI 10.1016/S0022-3476(98)70524-4; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Halliwell B., 1991, FREE RADICALS BIOL M; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PANTOPOULOS K, 1995, RNA, V1, P155; PANTOPOULOS K, 1999, IRON METABOLISM, P131; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; TANG CK, 1992, J BIOL CHEM, V267, P24466; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Winge DR, 1998, CURR OPIN CHEM BIOL, V2, P216, DOI 10.1016/S1367-5931(98)80063-X; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044	58	134	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18914	18918		10.1074/jbc.M200949200	http://dx.doi.org/10.1074/jbc.M200949200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877447	hybrid			2022-12-25	WOS:000175975800087
J	Seo, YW; Sanyal, S; Kim, HJ; Won, DH; An, JY; Amano, T; Zavacki, AM; Kwon, HB; Shi, YB; Kim, WS; Kang, H; Moore, DD; Choi, HS				Seo, YW; Sanyal, S; Kim, HJ; Won, DH; An, JY; Amano, T; Zavacki, AM; Kwon, HB; Shi, YB; Kim, WS; Kang, H; Moore, DD; Choi, HS			FOR, a novel orphan nuclear receptor related to farnesoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RECEPTOR; RETINOIC ACID; BILE-ACIDS; GENE; IDENTIFICATION; BINDING; SUPERFAMILY; TRANSCRIPTION; MEMBER; SPECIFICITY	We have identified and characterized a new amphibian orphan member of the nuclear receptor superfamily and termed it FOR1 (farnesoid X receptor (EXR)-like Orphan Receptor) because it shares the highest amino acid identity with the mammalian FXR. We also identified a variant of FOR1, called FOR2, which has 15 additional C-terminal amino acids. Both variants include an unusual insertion of 33 amino acids in the helix 7 region of the canonical ligand binding domain sequence, suggesting a unique structure for FOR. Northern blot analysis demonstrates that the FOR gene is highly expressed in adult and tadpole liver, kidney, and tail bud stage of the embryo. Detailed expression analysis using in situ hybridization indicates that FOR expression is first detectable at stage 30/31 in the presumptive liver region lasting until stage 41 with a peak level evident at stage 35/36. FOR forms heterodimeric complexes with retinoid X receptor (RXR) as demonstrated by biochemical and mammalian two-hybrid approaches. Gel mobility shift assays demonstrate that FORs form specific DNA-protein complexes on an FXR binding element consisting of an inverted repeat DNA element with 1 nucleotide spacing (IR1) from the phospholipid transfer protein gene promoter. Finally, although FORs do not exhibit constitutive transcriptional activity, frog gallbladder extract significantly augments the transcriptional activities of FORs.	Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Sogang Univ, Dept Life Sci, Seoul 121742, South Korea; Seoul Natl Univ, Sch Earth & Environm Sci, Marine Biotechnol Lab, Seoul 151, South Korea; NICHHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thyroid, Boston, MA 02115 USA; Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA	Chonnam National University; Chonnam National University; Sogang University; Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Baylor College of Medicine	Choi, HS (corresponding author), Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea.		Sanyal, Sabyasachi/E-8034-2010	Sanyal, Sabyasachi/0000-0002-8603-3828; Shi, Yun-Bo/0000-0002-6330-0639	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001901] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; DUMAS B, 1994, MOL ENDOCRINOL, V8, P996, DOI 10.1210/me.8.8.996; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; JONES BB, 1995, MOL CELL BIOL, V15, P5226; KOSTROUCH Z, 1995, P NATL ACAD SCI USA, V92, P156, DOI 10.1073/pnas.92.1.156; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Liang V C, 1997, Cell Res, V7, P179; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; NIEWKOOP P.D., 1994, NORMAL TABLE XENOPUS; NOMA Y, 1980, J LIPID RES, V21, P339; Parker KL, 1998, MOL CELL ENDOCRINOL, V145, P15, DOI 10.1016/S0303-7207(98)00164-6; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; UBBELS GA, 1983, J EMBRYOL EXP MORPH, V77, P15; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UNE M, 1980, J LIPID RES, V21, P269; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	35	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17836	17844		10.1074/jbc.M111795200	http://dx.doi.org/10.1074/jbc.M111795200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11867625	hybrid			2022-12-25	WOS:000175685100058
J	Anzai, N; Deval, E; Schaefer, L; Friend, V; Lazdunski, M; Lingueglia, E				Anzai, N; Deval, E; Schaefer, L; Friend, V; Lazdunski, M; Lingueglia, E			The multivalent PDZ domain-containing protein CIPP is a partner of acid-sensing ion channel 3 in sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED NA+ CHANNEL; MUTATIONS CAUSING NEURODEGENERATION; MAMMALIAN DEGENERIN MDEG; CATION CHANNEL; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; FAMILY; EXPRESSION; RECEPTOR; ISCHEMIA	Acid-sensing ion channels (ASICs) are cationic channels activated by extracellular pH. They are present in the brain, where they are thought to participate in signal transduction associated with local pH variations, and in sensory neurons, where they have been involved in pain perception associated with tissue acidosis and in mechanoperception. The ASIC3 subunit is mainly expressed in dorsal root ganglion neurons. Its expression is associated with a rapidly inactivating current followed by a slowly activating sustained current thought to be required for the tonic sensation of pain caused by acids. We report here the interaction of this channel subunit with the multivalent PDZ (PSD-95 Drosophila discs-large protein, Zonula occludens protein 1) domain-containing protein CIPP. This interaction requires the C-terminal region of ASIC3 and the fourth PDZ domain of CIPP. Co-expression of CIPP and ASIC3 in COS cells increases the maximal ASIC3 peak current density by a factor of 5 and slightly shifts the pH(0.5) for activation from pH 6.2 to pH 6.4. CIPP mRNA is found at a significant level in the same dorsal root ganglion neuronal cell population that expresses the ASIC3 subunit, i.e. mainly in the small nociceptive neurons. CIPP is thus a scaffolding protein that could both enhance the surface expression of ASIC3 and bring together ASIC3 and functionally related proteins in the membrane of sensory neurons.	Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, 660 Route Lucioles, F-06560 Valbonne, France.		LINGUEGLIA, Eric/F-5509-2013; ANZAI, NAOHIKO/K-9492-2017; DEVAL, Emmanuel/N-6280-2016	LINGUEGLIA, Eric/0000-0003-3902-3405; ANZAI, NAOHIKO/0000-0003-0605-0458; DEVAL, Emmanuel/0000-0002-0215-9379				Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Babinski K, 2000, J BIOL CHEM, V275, P28519, DOI 10.1074/jbc.M004114200; BARON A, 2002, J PHYSL, P485; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Benson CJ, 1999, CIRC RES, V84, P921; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Weille JR, 1998, FEBS LETT, V433, P257, DOI 10.1016/S0014-5793(98)00916-8; DeVries SH, 2001, NEURON, V32, P1107, DOI 10.1016/S0896-6273(01)00535-9; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GOLEMIS EA, 1997, YEAST 2 HYBRID SYSTE; Grunder S, 2000, NEUROREPORT, V11, P1607; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Pan HL, 1999, J PHYSIOL-LONDON, V518, P857, DOI 10.1111/j.1469-7793.1999.0857p.x; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Reeh PW, 1996, PROG BRAIN RES, V113, P143, DOI 10.1016/S0079-6123(08)61085-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Traynelis SF, 2001, NEURON, V32, P960, DOI 10.1016/S0896-6273(01)00549-9; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6	38	61	62	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16655	16661		10.1074/jbc.M201087200	http://dx.doi.org/10.1074/jbc.M201087200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872753	hybrid			2022-12-25	WOS:000175564500043
J	Han, ZY; Wei, WY; Dunaway, S; Darnowski, JW; Calabresi, P; Sedivy, J; Hendrickson, EA; Balan, KV; Pantazis, P; Wyche, JH				Han, ZY; Wei, WY; Dunaway, S; Darnowski, JW; Calabresi, P; Sedivy, J; Hendrickson, EA; Balan, KV; Pantazis, P; Wyche, JH			Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; BCL-2 FAMILY PROTEINS; DNA-DAMAGE; REPLICATIVE SENESCENCE; ANTICANCER AGENTS; GENE-EXPRESSION; IN-VIVO; CELLULAR SENESCENCE; DRUG DEVELOPMENT; GROWTH ARREST	Treatment of cells with the anti-cancer drug camptothecin (CPT) induces topoisomerase I (Top1)-mediated DNA damage, which in turn affects cell proliferation and survival. In this report, we demonstrate that treatment of the wild-type HCT116 (wt HCT116) human colon cancer cell line and the isogenic p53(-/-) HCT116 and p21(-/-) HCT116 cell lines with a high concentration (250 nM) of CPT resulted in apoptosis, indicating that apoptosis occurred by a p53- and p21-independent mechanism. In contrast, treatment with a low concentration (20 nM) of CPT induced cell cycle arrest and senescence of the wt HCT116 cells, but apoptosis of the p53(-/-) HCT116 and p21(-/-) HCT116 cells. Further investigations indicated that p53-dependent expression of p21 blocked apoptosis of wt HCT116 cells treated with 20 nM, but not 250 nM CPT. Interestingly, blocking of the apoptotic pathway, by Z-VAD-FMK, in p21(-/-) HCT116 cells following treatment with 20 nM CPT did not permit the cells to develop properties of senescence. These observations demonstrated that p21 was required for senescence development of HCT116 cells following treatment with low concentrations of CPT.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Rhode Isl Hosp, Dept Clin Pharmacol, Providence, RI 02903 USA; Univ Minnesota, Sch Med, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	Brown University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Lifespan Health Rhode Island; Rhode Island Hospital; University of Minnesota System; University of Minnesota Twin Cities	Han, ZY (corresponding author), Brown Univ, Dept MCB, Rm 130,69 Brown St, Providence, RI 02912 USA.		Balan, Kannan/P-8892-2015		NIAID NIH HHS [AI35763] Funding Source: Medline; NIA NIH HHS [AG16694] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG016694, R01AG016694] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; BAYREUTHER K, 1988, P NATL ACAD SCI USA, V85, P5112, DOI 10.1073/pnas.85.14.5112; Brown JM, 1999, CANCER RES, V59, P1391; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; Cristofalo VJ, 1996, EXP GERONTOL, V31, P111, DOI 10.1016/0531-5565(95)02018-7; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Eisenhauer EA, 1997, ANN ONCOL, V8, P963, DOI 10.1023/A:1008240421028; Gelmon KA, 1999, J NATL CANCER I, V91, P1281, DOI 10.1093/jnci/91.15.1281; Gerrits CJH, 1997, BRIT J CANCER, V76, P952, DOI 10.1038/bjc.1997.491; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Good LF, 1996, J CELL PHYSIOL, V168, P580, DOI 10.1002/(SICI)1097-4652(199609)168:3<580::AID-JCP10>3.0.CO;2-3; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; Han ZY, 1996, CANCER RES, V56, P1621; Herben VMM, 1997, BRIT J CANCER, V76, P1500, DOI 10.1038/bjc.1997.585; HICKMAN JA, 1994, PHILOS T ROY SOC B, V345, P319, DOI 10.1098/rstb.1994.0112; HOCHSTER H, 1994, J CLIN ONCOL, V12, P553, DOI 10.1200/JCO.1994.12.3.553; Huang YY, 1997, CANCER RES, V57, P3640; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; ISHIZAKI Y, 1993, J CELL BIOL, V121, P899, DOI 10.1083/jcb.121.4.899; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; JACOBSON MD, 1994, BIOCHEM SOC T, V22, P600, DOI 10.1042/bst0220600; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVIN MF, 1999, INT J RADIAT BIOL, V75, P1201; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin WC, 2001, GENE DEV, V15, P1833; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; McGill G., 1997, FRONT BIOSCI, V2, P353; Mohamood AS, 1997, J SUBMICR CYTOL PATH, V29, P1; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Mullauer L, 2001, MUTAT RES-REV MUTAT, V488, P211, DOI 10.1016/S1383-5742(01)00057-6; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; O'Leary J, 1998, EUR J CANCER, V34, P1500, DOI 10.1016/S0959-8049(98)00229-9; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; PANTAZIS P, 1994, CANCER RES, V54, P771; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Preston TJ, 2001, ADV DRUG DELIVER REV, V49, P45, DOI 10.1016/S0169-409X(01)00127-2; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Reed JC, 2000, CURR OPIN BIOTECH, V11, P586, DOI 10.1016/S0958-1669(00)00148-8; RICHTER KH, 1991, CANCER RES, V51, P6010; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Sarraj S, 2001, EXP CELL RES, V270, P268, DOI 10.1006/excr.2001.5352; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Severino J, 2000, EXP CELL RES, V257, P162, DOI 10.1006/excr.2000.4875; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Stein GH, 1999, MOL CELL BIOL, V19, P2109; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2; TAHARA H, 1995, ONCOGENE, V10, P835; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vaziri H, 1999, ONCOGENE, V18, P7676, DOI 10.1038/sj.onc.1203016; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Wei WY, 1999, EXP CELL RES, V253, P519, DOI 10.1006/excr.1999.4665; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; WynfordThomas D, 1996, J PATHOL, V180, P118, DOI 10.1002/(SICI)1096-9896(199610)180:2<118::AID-PATH673>3.0.CO;2-I; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	78	209	221	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17154	17160		10.1074/jbc.M112401200	http://dx.doi.org/10.1074/jbc.M112401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877436	hybrid			2022-12-25	WOS:000175564500108
J	Moriguchi, T; Sakurai, T; Takahashi, S; Goto, K; Yamamoto, M				Moriguchi, T; Sakurai, T; Takahashi, S; Goto, K; Yamamoto, M			The human prepro-orexin gene regulatory region that activates gene expression in the lateral region and represses it in the medial regions of the hypothalamus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; POU-DOMAIN; INSULIN GENE; TRANSCRIPTION; PROTEIN; NARCOLEPSY; NEURONS; PITUITARY; REVEALS; SYSTEM	Prepro-orexin is a precursor of the neuropeptides orexin-A and -B, which are localized in the neuronal population of the lateral hypothalamic area (LHA). We wished to elucidate the mechanisms by which the prepro-orexin gene is specifically activated in orexin neurons in the LHA. The 3.2-kb 5'-flanking region of the human prepro-orexin gene is sufficient for the specific expression of an Escherichia coli lacZ reporter gene in orexin neurons. Therefore, we examined a series of reporter constructs harboring this 3.2-kb regulatory region or its deletion in a reporter transgenic mouse assay. There are two phylogenetically conserved regions located 287 bp (orexin regulatory element (OE) 1) and 2.5 kb (OE2) upstream of the transcription initiation site of the human prepro-orexin gene. In transgenic mice, both OE1 and OE2 are necessary for expressing the human prepro-orexin gene in the LHA and for repressing its expression in the medial regions of the hypothalamus. Through serial deletion analysis of OE1, we found that the 57-bp core region of OE1 is critical for its spatial gene regulatory function in vivo. Mutation analysis further demonstrated that without contribution from the OE1 core region, the lacZ reporter is expressed ectopically in the medial regions of the hypothalamus. Thus, OE1 contains crucial cis-acting elements regulating prepro-orexin gene expression specifically in the LHA.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Pharmacol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Anat & Embryol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Mol & Dev Biol, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba	Yamamoto, M (corresponding author), Univ Tsukuba, Ctr TARA, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058577, Japan.	masi@tara.tsukuba.ac.jp	Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436				ANAND BK, 1951, YALE J BIOL MED, V24, P123; Bernardis LL, 1996, NEUROSCI BIOBEHAV R, V20, P189, DOI 10.1016/0149-7634(95)00015-1; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Chiocchetti A, 1997, BBA-GENE STRUCT EXPR, V1352, P193, DOI 10.1016/S0167-4781(97)00010-9; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Eraly SA, 1998, MOL ENDOCRINOL, V12, P469, DOI 10.1210/me.12.4.469; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HE X, 1989, NATURE, V340, P34; HOGAN B, 1986, MANIPULATING MOUSE E; Horvath TL, 1999, J NEUROSCI, V19, P1072; JUAN IY, 1998, J NEUROSCI, V18, P6631; Lau S, 1999, DEV DYNAM, V215, P126, DOI 10.1002/(SICI)1097-0177(199906)215:2<126::AID-DVDY5>3.3.CO;2-#; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; Nambu T, 1999, BRAIN RES, V827, P243, DOI 10.1016/S0006-8993(99)01336-0; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; Sakurai T, 1999, J BIOL CHEM, V274, P17771, DOI 10.1074/jbc.274.25.17771; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; Shibahara M, 1999, PEPTIDES, V20, P1169, DOI 10.1016/S0196-9781(99)00120-5; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STRACHAN T, 1996, HUM MOL GENET, P198; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; Vuillaumier S, 1997, BIOCHEM J, V327, P651, DOI 10.1042/bj3270651; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Yamamoto Y, 1999, MOL BRAIN RES, V65, P14, DOI 10.1016/S0169-328X(98)00320-9; Yamamoto Y, 2000, MOL BRAIN RES, V78, P108, DOI 10.1016/S0169-328X(00)00080-2	39	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16985	16992		10.1074/jbc.M107962200	http://dx.doi.org/10.1074/jbc.M107962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11854267	hybrid			2022-12-25	WOS:000175564500086
J	Khan, NA; Wang, Y; Kim, KJ; Chung, JW; Wass, CA; Kim, KS				Khan, NA; Wang, Y; Kim, KJ; Chung, JW; Wass, CA; Kim, KS			Cytotoxic necrotizing factor-1 contributes to Escherichia coli K1 invasion of the central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; FOCAL ADHESION KINASE; MEMBRANE PROTEIN-A; FACTOR-I; ACTIN CYTOSKELETON; EXTRAINTESTINAL INFECTIONS; INDUCED ACTIVATION; FACTOR TYPE-1; GENE LOCUS; RHO	Escherichia coli K1 invasion of brain microvascular endothelial cells (BMECs) is a prerequisite for penetration into the central nervous system and requires actin cytoskeletal rearrangements. Here, we demonstrate that E. coli K1 invasion of BMECs requires RhoA activation. In addition, we show that cytotoxic necrotizing factor-1 (CNF1) contributes to E. coli K1 invasion of brain endothelial cells in vitro and traversal of the blood-brain barrier in the experimental hematogenous meningitis animal model. These in vitro and in vivo effects of CNF1 were dependent upon RhoA activation as shown by (a) decreased invasion and RhoA activation with the Deltacnf1 mutant of E. coli K1 and (b) restoration of invasion frequency of the Deltacnf1 mutant to the level of the parent E. coli K1 strain in BMECs with constitutively active RhoA. In addition, CNF1-enhanced E. coli invasion of brain endothelial cells and stress fiber formation were independent of focal adhesion kinase and phosphatidylinositol 3-kinase activation. This is the first demonstration that CNF1 contributes to E. coli K1 invasion of BMECs.	Johns Hopkins Univ, Sch Med, Div Pediat Infect Dis, Baltimore, MD 21287 USA; Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Infect Dis, Los Angeles, CA 90027 USA	Johns Hopkins University; Children's Hospital Los Angeles; University of Southern California	Kim, KS (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Infect Dis, 600 N Wolfe St,Pk 256, Baltimore, MD 21287 USA.	kwangkim@jhmi.edu	khan, Naveed Ahmed/F-2478-2015; Khan, Naveed/AAM-2892-2021; Khan, Naveed/AAJ-5377-2020	Khan, Naveed/0000-0001-7667-8553; Khan, Naveed/0000-0001-7667-8553	NHLBI NIH HHS [HL 61951] Funding Source: Medline; NIAID NIH HHS [AI 47225] Funding Source: Medline; NINDS NIH HHS [NS 26310] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026310, R56NS026310] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badger JL, 2000, INFECT IMMUN, V68, P5056, DOI 10.1128/IAI.68.9.5056-5061.2000; Badger JL, 1999, INFECT IMMUN, V67, P4208, DOI 10.1128/IAI.67.8.4208-4215.1999; Bodie SL, 2001, BIOCHEM BIOPH RES CO, V287, P71, DOI 10.1006/bbrc.2001.5547; Cantrell DA, 2001, J CELL SCI, V114, P1439; CAPRIOLI A, 1987, J CLIN MICROBIOL, V25, P146, DOI 10.1128/JCM.25.1.146-149.1987; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; FALBO V, 1992, INFECT IMMUN, V60, P2182, DOI 10.1128/IAI.60.6.2182-2187.1992; FALBO V, 1993, INFECT IMMUN, V61, P4909, DOI 10.1128/IAI.61.11.4909-4914.1993; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; Fiorentini C, 1997, BIOCHEM BIOPH RES CO, V241, P341, DOI 10.1006/bbrc.1997.7723; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Fournout S, 2000, INFECT IMMUN, V68, P839, DOI 10.1128/IAI.68.2.839-847.2000; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hoffman JA, 2000, INFECT IMMUN, V68, P5062, DOI 10.1128/IAI.68.9.5062-5067.2000; HUANG SH, 1995, INFECT IMMUN, V63, P4470, DOI 10.1128/IAI.63.11.4470-4475.1995; Huang SH, 1999, INFECT IMMUN, V67, P2103, DOI 10.1128/IAI.67.5.2103-2109.1999; Jin SH, 2000, BIOCHEM BIOPH RES CO, V277, P718, DOI 10.1006/bbrc.2000.3744; Johnson DE, 2000, FEMS IMMUNOL MED MIC, V28, P37, DOI 10.1111/j.1574-695X.2000.tb01454.x; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kim K S, 2000, Subcell Biochem, V33, P47; KIM KS, 1992, J CLIN INVEST, V90, P897, DOI 10.1172/JCI115965; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nizet V, 1997, INFECT IMMUN, V65, P5074, DOI 10.1128/IAI.65.12.5074-5081.1997; Prasadarao NV, 1999, INFECT IMMUN, V67, P5775, DOI 10.1128/IAI.67.11.5775-5783.1999; Prasadarao NV, 1999, INFECT IMMUN, V67, P1131, DOI 10.1128/IAI.67.3.1131-1138.1999; Prasadarao NV, 1996, INFECT IMMUN, V64, P146, DOI 10.1128/IAI.64.1.146-153.1996; Reddy MA, 2000, INFECT IMMUN, V68, P6423, DOI 10.1128/IAI.68.11.6423-6430.2000; Reddy MA, 2000, J BIOL CHEM, V275, P36769, DOI 10.1074/jbc.M007382200; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Rippere-Lampe KE, 2001, INFECT IMMUN, V69, P3954, DOI 10.1128/IAI.69.6.3954-3964.2001; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; TAYLOR RK, 1989, J BACTERIOL, V171, P1870, DOI 10.1128/jb.171.4.1870-1878.1989; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Vouret-Craviari V, 1999, INFECT IMMUN, V67, P3002, DOI 10.1128/IAI.67.6.3002-3008.1999; Wang Y, 1999, INFECT IMMUN, V67, P4751, DOI 10.1128/IAI.67.9.4751-4756.1999; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	39	123	128	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15607	15612		10.1074/jbc.M112224200	http://dx.doi.org/10.1074/jbc.M112224200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877402	hybrid			2022-12-25	WOS:000175510400053
J	Petropoulos, H; Skerjanc, IS				Petropoulos, H; Skerjanc, IS			beta-catenin is essential and sufficient for skeletal Myogenesis in P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; DORSAL NEURAL-TUBE; PARAXIAL MESODERM; MUSCLE DEVELOPMENT; AXIS FORMATION; SIGNAL-TRANSDUCTION; WNT/BETA-CATENIN; GENE-EXPRESSION; MOUSE EMBRYOS; INDUCTION	Wnt1 and Wnt3a are signaling factors known to play a role in the induction of myogenesis in the myotome of the differentiating somite. Both factors may transduce their signal by a conserved pathway that leads to transcriptional regulation by beta-catenin/Lef1. beta-Catenin and Lef1 are found in the myotome prior to MyoD expression. We have utilized the P19 cell system to study the mechanisms by which Wnt3a may activate MyoD expression and subsequent skeletal muscle development. We have isolated P19 cell lines that stably express either Wnt3a or activated beta-catenin and found that aggregation of these cells results in the induction of myogenesis compared with control cells. Pax3, Gli2, Mox1, and Six1 were expressed during Wnt3a and beta-catenin-induced differentiation prior to MyoD expression. Furthermore, we have shown that the nuclear function of beta-catenin was essential for skeletal myogenesis in P19 cells by overexpression of a dominant negative beta-catenin/engrailed chimera. Primitive streak factors were present, but expression of Pax3, Mox1, Gli2, and Six1 was lost in these cells, indicating that nuclear beta-catenin is essential for specification of mesodermal precursors to the myogenic lineage. Therefore, Wnt signaling, acting via beta-catenin, is necessary and sufficient for skeletal myogenesis in P19 cells.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Skerjanc, IS (corresponding author), Univ Western Ontario, Dept Biochem, Med Sci Bldg, London, ON N6A 5C1, Canada.		Skerjanc, Ilona/AAN-3318-2020					ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Angello JC, 1997, DEV BIOL, V192, P93, DOI 10.1006/dbio.1997.8722; Arnold SJ, 2000, MECH DEVELOP, V91, P249, DOI 10.1016/S0925-4773(99)00309-3; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Bailey P, 2001, CURR OPIN CELL BIOL, V13, P679, DOI 10.1016/S0955-0674(00)00271-4; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Borello U, 1999, DEVELOPMENT, V126, P4247; Borycki AG, 2000, DEVELOPMENT, V127, P2075; Borycki AG, 2000, CURR TOP DEV BIOL, V48, P165; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Capdevila J, 1998, DEV BIOL, V193, P182, DOI 10.1006/dbio.1997.8806; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; Fan CM, 1997, DEV BIOL, V191, P160, DOI 10.1006/dbio.1997.8713; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Galceran J, 2001, P NATL ACAD SCI USA, V98, P8668, DOI 10.1073/pnas.151258098; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Goichberg P, 2001, J CELL SCI, V114, P1309; Goichberg P, 1998, MOL BIOL CELL, V9, P3119, DOI 10.1091/mbc.9.11.3119; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Ikeya M, 1998, DEVELOPMENT, V125, P4969; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCBURNEY MW, 1994, SOMAT CELL MOLEC GEN, V20, P515, DOI 10.1007/BF02255842; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Montross WT, 2000, J CELL SCI, V113, P1759; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PARR BA, 1993, DEVELOPMENT, V119, P247; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200; Ridgeway AG, 2000, J BIOL CHEM, V275, P32398, DOI 10.1074/jbc.M004349200; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Schmidt M, 2000, DEVELOPMENT, V127, P4105; Seghatoleslami MR, 2000, J CELL BIOCHEM, V77, P252, DOI 10.1002/(SICI)1097-4644(20000501)77:2<252::AID-JCB8>3.0.CO;2-J; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Smith ST, 1996, DEVELOPMENT, V122, P3141; STERN HM, 1995, DEVELOPMENT, V121, P3675; Tada M, 2000, DEVELOPMENT, V127, P2227; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Wagner J, 2000, DEV BIOL, V228, P86, DOI 10.1006/dbio.2000.9921; Wang SW, 1997, BIOCHEM BIOPH RES CO, V236, P502, DOI 10.1006/bbrc.1997.6995; Wilton S, 1999, IN VITRO CELL DEV-AN, V35, P175; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Yamaguchi TP, 1999, GENE DEV, V13, P3185, DOI 10.1101/gad.13.24.3185; Zhurinsky J, 2000, J CELL SCI, V113, P3127	60	115	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15393	15399		10.1074/jbc.M112141200	http://dx.doi.org/10.1074/jbc.M112141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856745	hybrid			2022-12-25	WOS:000175510400023
J	Schneider, S; Hotz, HR; Schwer, B				Schneider, S; Hotz, HR; Schwer, B			Characterization of dominant-negative mutants of the DEAH-box splicing factors Prp22 and Prp16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; RNA-DEPENDENT ATPASE; MESSENGER-RNA; MUTATIONAL ANALYSIS; SACCHAROMYCES-CEREVISIAE; HELICASE DOMAIN; NUCLEOSIDE TRIPHOSPHATASE; CRYSTAL-STRUCTURE; PROTEIN PRP22; NS3 PROTEIN	Saccharomyces cerevisiae Prp22 and Prp16 are RNA-dependent ATPases required for pre-mRNA splicing. Both proteins are members of the DEXH-box family of nucleic acid-dependent NTPases. Prior mutational analysis of Prp22 and Prp16 identified residues within conserved motifs I (GYGKT), II (DEAH), and VI (QRXGRXGR) that are required for their biological activity. Nonfunctional Prp22 and Prp16 mutants exerted a dominant negative effect on cell growth. Here we show that overexpression of lethal Prp22 mutants leads to accumulation of unspliced pre-mRNAs and excised introns in vivo. The biochemical basis for the lethality and inhibition of splicing in vivo was determined by purifying and characterizing recombinant mutant proteins. The lethal Prp22 mutants D603A and E604A in motif II and Q804A and R808A in motif VI were defective for ATP hydrolysis and mRNA release from the spliceosome, but were active in promoting step 2 transesterification. Lethal Prp16 mutants G378A and K379A in motif I; D473A and E474A in motif II; and Q685A, G688A, R689A, and R692A in motif VI were defective for ATP hydrolysis and step 2 transesterification chemistry. The ATPase-defective mutants of Prp16 and Prp22 bound to spliceosomes in vitro and blocked the function of the respective wild-type proteins in trans. Comparing the mutational effects in Prp16 and Prp22 highlights common as well as distinct structural requirements for the ATP-dependent steps in pre-mRNA splicing.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Cornell University	Schwer, B (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.				NIGMS NIH HHS [GM50288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050288] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; BURGESS SM, 1993, CELL, V73, P1377, DOI 10.1016/0092-8674(93)90363-U; Campodonico E, 2002, GENETICS, V160, P407; Chanfreau G, 1999, RNA, V5, P876, DOI 10.1017/S1355838299990544; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Edwalds-Gilbert G, 2000, RNA, V6, P1106, DOI 10.1017/S1355838200992483; Gross CH, 1998, J VIROL, V72, P4729, DOI 10.1128/JVI.72.6.4729-4736.1998; Gross CH, 1996, J VIROL, V70, P1706, DOI 10.1128/JVI.70.3.1706-1713.1996; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; Hotz HR, 1998, GENETICS, V149, P807; Kim DH, 1999, RNA, V5, P959, DOI 10.1017/S135583829999012X; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Lee CG, 1997, EMBO J, V16, P2671, DOI 10.1093/emboj/16.10.2671; Linder P, 2000, YEAST, V16, P507, DOI 10.1002/(SICI)1097-0061(200004)16:6<507::AID-YEA549>3.0.CO;2-N; Martins A, 1999, J VIROL, V73, P1302, DOI 10.1128/JVI.73.2.1302-1308.1999; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PLUMPTON M, 1994, EMBO J, V13, P879, DOI 10.1002/j.1460-2075.1994.tb06331.x; Schneider S, 2001, J BIOL CHEM, V276, P21184, DOI 10.1074/jbc.M101964200; SCHWER B, 1992, MOL CELL BIOL, V12, P3540, DOI 10.1128/MCB.12.8.3540; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Schwer B, 2001, NAT STRUCT BIOL, V8, P113, DOI 10.1038/84091; Schwer B, 2000, EMBO J, V19, P6582, DOI 10.1093/emboj/19.23.6582; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wardell AD, 1999, J GEN VIROL, V80, P701, DOI 10.1099/0022-1317-80-3-701; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701; Zhang XP, 1997, NUCLEIC ACIDS RES, V25, P2146, DOI 10.1093/nar/25.11.2146	38	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15452	15458		10.1074/jbc.M112473200	http://dx.doi.org/10.1074/jbc.M112473200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856747	hybrid			2022-12-25	WOS:000175510400032
J	Shi, YY; Hsu, JH; Hu, LP; Gera, J; Lichtenstein, A				Shi, YY; Hsu, JH; Hu, LP; Gera, J; Lichtenstein, A			Signal pathways involved in activation of p70(S6K) and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; AKT KINASE; PROTEIN-SYNTHESIS; IN-VIVO; RAPAMYCIN; APOPTOSIS; SURVIVAL; GROWTH; INSULIN; IDENTIFICATION	Interleukin-6 (IL-6) is a prominent tumor growth factor for malignant multiple myeloma cells. In addition to its known activation of the Janus tyrosine kinase-STAT and RAS-MEK-ERK pathways, recent work suggests that IL-6 can also activate the phosphatidylinositol 3-kinase (PI3-K)/AKT kinase pathway in myeloma cells. Because activation of the PI3-K/AKT as well as RAS-MEK-ERK pathways may result in downstream stimulation of the p70(S6K) (p70) and phosphorylation of the 4E-BP1 translational repressor, we assessed these potential molecular targets in IL-6-treated myeloma cells. IL-6 rapidly activated p70 kinase activity and p70 phosphorylation. Activation was inhibited by wortmannin, rapamycin, and the ERK inhibitors PD98059 and UO126, as well as by a dominant negative mutant of AKT. The concurrent requirements for both ERK and PI3-K/AKT appeared to be a result of their ability to phosphorylate p70 on different residues. In contrast, IL-6-induced phosphorylation of 4E-BP1 was inhibited by rapamycin, wortmannin, and dominant negative ART but ERK inhibitors had no effect, indicating ERK function was dispensable. In keeping with these data, a dominant active AKT mutant was sufficient to induce 4E-BP1 phosphorylation but could not by itself activate p70 kinase activity. Prevention of IL-6-induced p70 activation and 4E-BP1 phosphorylation by the mammalian target of rapamycin inhibitors rapamycin and CCI-779 resulted in inhibition of IL-6-induced myeloma cell growth. These results indicate that both ERK and PI3-K/AKT pathways are required for optimal IL-6-induced p70 activity, but PI3-K/AKT is sufficient for 4E-BP1 phosphorylation. Both effects are mediated via mammalian target of rapamycin function, and, furthermore, these effects are critical for IL-6-induced tumor cell growth.	Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA; Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; UCLA Jonsson Comprehensive Cancer Center	Lichtenstein, A (corresponding author), Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA.	alichten@ucla.edu		Gera, Joseph/0000-0002-2908-6894				ANDERSON KC, 1989, BLOOD, V73, P1915; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; DEL PL, 1997, SCIENCE, V278, P687; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Geoerger B, 2001, CANCER RES, V61, P1527; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hsu JH, 2002, ONCOGENE, V21, P1391, DOI 10.1038/sj/onc/1205194; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P75; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; MURAGUCHI A, 1988, J EXP MED, V167, P332, DOI 10.1084/jem.167.2.332; Ogata A, 1997, J IMMUNOL, V159, P2212; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; SOONYANG Z, 1997, P NATL ACAD SCI USA, V94, P11345; Tu YP, 2000, CANCER RES, V60, P6763; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200	45	89	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15712	15720		10.1074/jbc.M200043200	http://dx.doi.org/10.1074/jbc.M200043200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11872747	hybrid			2022-12-25	WOS:000175510400067
J	Westling, J; Fosang, AJ; Last, K; Thompson, VP; Tomkinson, KN; Hebert, T; McDonagh, T; Collins-Racie, LA; LaVallie, ER; Morris, EA; Sandy, JD				Westling, J; Fosang, AJ; Last, K; Thompson, VP; Tomkinson, KN; Hebert, T; McDonagh, T; Collins-Racie, LA; LaVallie, ER; Morris, EA; Sandy, JD			ADAMTS4 cleaves at the aggrecanase site (Glu(373)-Ala(374)) and secondarily at the matrix metalloproteinase site (Asn(341)-Phe(342)) in the aggrecan interglobular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL COLLAGENASE MMP-8; HUMAN SYNOVIAL-FLUID; AGE-RELATED-CHANGES; CARTILAGE AGGRECAN; ARTICULAR-CARTILAGE; MAMMALIAN-CELLS; PROTEOGLYCAN; DEGRADATION; CATABOLISM; FRAGMENTS	Two major proteolytic cleavages, one at NITEGE(373) down arrowA(374)RGSVI and the other at VDIPEN341 down arrow F(342)FGVGG, have been shown to occur in vivo within the interglobular domain of aggrecan. The Glu(373)-Ala(374) site is cleaved in vitro by aggrecanase-1 (ADAMTS4) and aggrecanase-2 (ADAMTS5), whereas the other site, at Asn(341)-Phe(342), is efficiently cleaved by matrix metalloproteinases (MMPs) and by cathepsin B at low pH. Accordingly, the presence of the cleavage products globular domain 1 (G1)-NITEGE(373) and G1-VDIPEN341 in vivo has been widely interpreted as evidence for the specific involvement of ADAMTS enzymes and MMPs/cathepsin B, respectively, in aggrecan proteolysis in situ. We show here, in digests with native human aggrecan, that purified ADAMTS4 cleaves primarily at the Glu(373)-Ala(374) site, but also, albeit slowly and secondarily, at the Asn(341)-Phe(342) site. Cleavage at the Asn(341)-Phe(342) site in these incubations was due to bona fide ADAMTS4 activity (and not a contaminating MMP) because the cleavage was inhibited by TIMP-3 (a potent inhibitor of ADAMTS4), but not by TIMP-1 and TIMP-2, at concentrations that totally blocked MMP-3-mediated cleavage at this site. Digestion of recombinant human G1-G2 (wild-type and cleavage site mutants) confirmed the dual activity of ADAMTS4 and supported the idea that the enzyme cleaves primarily at the Glu(373)-Ala(374) site and secondarily generates G1-VDIPEN341 by removal of the Phe(342) -Glu(373) peptide from G1-NITEGE(373). These results show that G1-VDIPEN341 is a product of both MMP and ADAMTS4 activities and challenge the widely held assumption that this product represents a specific indicator of MMP- or cathepsin B-mediated aggrecan degradation.	Shriners Hosp Children, Ctr Skeletal Dev & Pediat Orthoped Res, Tampa, FL 33612 USA; Univ S Florida, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA; Univ Melbourne, Dept Paediat, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Wyeth Ayerst Res, Genet Inst, Cambridge, MA 02140 USA	State University System of Florida; University of South Florida; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Pfizer	Westling, J (corresponding author), Shriners Hosp Children, Ctr Skeletal Dev & Pediat Orthoped Res, 12502 N Pine Dr, Tampa, FL 33612 USA.			Fosang, Amanda/0000-0002-5523-5427; Last, Karena/0000-0002-4396-8404				Arner EC, 1997, J BIOL CHEM, V272, P9294; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; BUCKWALTER JA, 1994, MICROSC RES TECHNIQ, V28, P398, DOI 10.1002/jemt.1070280506; Buttner FH, 1998, BIOCHEM J, V333, P159, DOI 10.1042/bj3330159; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; Chambers MG, 2001, ARTHRITIS RHEUM-US, V44, P1455, DOI 10.1002/1529-0131(200106)44:6<1455::AID-ART241>3.0.CO;2-J; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; Fosang AJ, 2000, J BIOL CHEM, V275, P33027, DOI 10.1074/jbc.M910207199; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Hashimoto G, 2001, FEBS LETT, V494, P192, DOI 10.1016/S0014-5793(01)02323-7; Horber C, 2000, MATRIX BIOL, V19, P533, DOI 10.1016/S0945-053X(00)00113-X; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; Kozaci LD, 1997, ARTHRITIS RHEUM-US, V40, P164, DOI 10.1002/art.1780400121; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Lee ER, 2001, DEV DYNAM, V222, P52, DOI 10.1002/dvdy.1168; Lemons ML, 2001, J NEUROSCI, V21, P4772, DOI 10.1523/JNEUROSCI.21-13-04772.2001; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; Lohmander LS, 1999, ARTHRITIS RHEUM, V42, P534, DOI 10.1002/1529-0131(199904)42:3<534::AID-ANR19>3.0.CO;2-J; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Mercuri FA, 1999, J BIOL CHEM, V274, P32387, DOI 10.1074/jbc.274.45.32387; Mercuri FA, 2000, J BIOL CHEM, V275, P33038, DOI 10.1074/jbc.275.42.33038; MORGELIN M, 1994, BIOPHYS CHEM, V50, P113, DOI 10.1016/0301-4622(94)85024-0; Mort JS, 1998, BIOCHEM J, V335, P491, DOI 10.1042/bj3350491; Mort JS, 1999, J CLIN PATHOL-MOL PA, V52, P11, DOI 10.1136/mp.52.1.11; OEGEMA TR, 1979, J BIOL CHEM, V254, P1312; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Patwari P, 2000, ARCH BIOCHEM BIOPHYS, V374, P79, DOI 10.1006/abbi.1999.1538; Pratta MA, 2000, J BIOL CHEM, V275, P39096, DOI 10.1074/jbc.M006201200; Quinn TM, 1999, ANN NY ACAD SCI, V878, P420, DOI 10.1111/j.1749-6632.1999.tb07700.x; Quinn TM, 1998, J ORTHOP RES, V16, P490, DOI 10.1002/jor.1100160415; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Sandy JD, 2001, BIOCHEM J, V358, P615, DOI 10.1042/0264-6021:3580615; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1998, J BIOL CHEM, V273, P5846, DOI 10.1074/jbc.273.10.5846; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; van Meurs JBJ, 1999, ARTHRITIS RHEUM, V42, P1128, DOI 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2	49	66	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16059	16066		10.1074/jbc.M108607200	http://dx.doi.org/10.1074/jbc.M108607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11854269	hybrid			2022-12-25	WOS:000175510400112
J	Deng, HB; Parekh, HK; Chow, KC; Simpkins, H				Deng, HB; Parekh, HK; Chow, KC; Simpkins, H			Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-DIAMMINEDICHLOROPLATINUM(II) ACCUMULATION; ACQUIRED-RESISTANCE; CONFERS RESISTANCE; LUNG-CANCER; DNA-REPAIR; SENSITIVITY; OVEREXPRESSION; MODULATION; GENES; LINES	We employed cDNA microarrays to identify the differentially expressed genes in a cisplatin-sensitive parental (2008) human ovarian carcinoma cell line and its cisplatin-resistant variant (2008/C13*). Differential expression of five genes was found in the 2008/C13* cells, a result confirmed by semi-quantitative reverse transcription-PCR. The five genes were identified as fibroblast muscle-type tropomyosin and skeletal muscle-type tropomyosin, dihydrodiol dehydrogenase, apolipoprotein J and glucose-6-phosphate dehydrogenase variant-A. Treatment of the 2008 cells with cisplatin (at its IC50. concentration of 2 muM) induced expression of these genes, as determined by semi-quantitative reverse transcription-PCR analysis using gene-specific primers. In contrast, treatment of the drug-resistant 200S/C13* cells with cisplatin (at its IC50 concentration of 20 muM) did not lead to the induction of any of the aforementioned genes. Most importantly, constitutive overexpression of dihydrodiol dehydrogenase (but not the other genes) in the 2008 cells led to induction of cisplatin resistance, clearly indicating its role in the development of the resistance phenotype in the 2008/C13* cells. The development of cisplatin resistance in the transfected cells was associated with an increase in the dihydrodiol dehydrogenase enzyme activity. Although at present it is not clear how dihydrodiol dehydrogenase is involved in cisplatin resistance, the identification of this gene as a causal factor suggests the existence of a hitherto undefined pathway resulting in cisplatin resistance.	Temple Univ, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; China Med Coll Hosp, Dept Med Res, Taichung 404, Taiwan	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; China Medical University Taiwan	Simpkins, H (corresponding author), Temple Univ, Sch Med, Dept Pathol & Lab Med, Rm 206,OMS,3400 N Broad St, Philadelphia, PA 19140 USA.			Chow, Kuan-Chih/0000-0002-0611-0337				ANDREWS PA, 1992, CANCER RES, V52, P1895; ANDREWS PA, 1988, CANCER RES, V48, P68; Ax W, 2000, BIOCHEM PHARMACOL, V59, P293, DOI 10.1016/S0006-2952(99)00322-6; BEUTLER E, 1994, BLOOD, V84, P3613, DOI 10.1182/blood.V84.11.3613.bloodjournal84113613; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Burger H, 2000, BIOCHEM BIOPH RES CO, V269, P767, DOI 10.1006/bbrc.2000.2361; CHATTERJEE D, 1995, CANCER CHEMOTH PHARM, V35, P423, DOI 10.1007/s002800050257; CHRISTEN RD, 1993, J CLIN INVEST, V92, P431, DOI 10.1172/JCI116585; Chung YM, 2001, ANTICANCER RES, V21, P1129; CIACCIO PJ, 1994, J BIOL CHEM, V269, P15558; CIACCIO PJ, 1993, MOL PHARMACOL, V43, P845; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; Dempke W, 2000, ANTI-CANCER DRUG, V11, P225, DOI 10.1097/00001813-200004000-00001; Fink D, 1998, CLIN CANCER RES, V4, P1; Gebauer G, 2000, INT J ONCOL, V16, P321; Hsu NY, 2001, CANCER RES, V61, P2727; ISONISHI S, 1992, J CLIN INVEST, V90, P1436, DOI 10.1172/JCI116010; Johnsson A, 2000, BRIT J CANCER, V83, P1047, DOI 10.1054/bjoc.2000.1420; KASAHARA K, 1991, CANCER RES, V51, P3237; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; KOU WY, 1998, FREE RADICAL BIO MED, V24, P1130; Kudoh K, 2000, CANCER RES, V60, P4161; LAI GM, 1988, BIOCHEM PHARMACOL, V37, P4597, DOI 10.1016/0006-2952(88)90325-5; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; LOH SY, 1992, BRIT J CANCER, V66, P1109, DOI 10.1038/bjc.1992.419; MAMENTA EL, 1994, CANCER RES, V54, P3500; MANN SC, 1991, INT J CANCER, V48, P866, DOI 10.1002/ijc.2910480613; MASUDA H, 1988, CANCER RES, V48, P5713; MATH C, 1997, BRIT J CANCER, V76, P1328; MEIJER C, 1992, CANCER RES, V52, P6885; Miyake H, 2000, CANCER RES, V60, P2547; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; Moorehead RA, 2000, BIOCHEM PHARMACOL, V59, P337, DOI 10.1016/S0006-2952(99)00333-0; OHARA H, 1995, BIOCHEM PHARMACOL, V50, P221, DOI 10.1016/0006-2952(95)00124-I; Parekh H, 1996, CANCER CHEMOTH PHARM, V37, P457, DOI 10.1007/s002800050412; PAREKH HK, 1995, CANCER RES, V55, P5203; PINTO A L, 1985, Biochimica et Biophysica Acta, V780, P167, DOI 10.1016/0304-419X(85)90001-0; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; STRYER L, 1981, BIOCHEMISTRY-US, P427; TIMMERBOSSCHA H, 1992, BRIT J CANCER, V66, P227, DOI 10.1038/bjc.1992.249; Tsukamoto N, 1998, BLOOD CELL MOL DIS, V24, P231, DOI 10.1006/bcmd.1998.0188; Wang FL, 1996, CANCER RES, V56, P3634; ZINKEWICHPEOTTI K, 1992, CANCER RES, V52, P1902	45	80	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15035	15043		10.1074/jbc.M112028200	http://dx.doi.org/10.1074/jbc.M112028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11842089	hybrid			2022-12-25	WOS:000175203000087
J	Rice, NA; Nadeau, OW; Yang, Q; Carlson, GM				Rice, NA; Nadeau, OW; Yang, Q; Carlson, GM			The calmodulin-binding domain of the catalytic gamma subunit of phosphorylase kinase interacts with its inhibitory subunit - Evidence for a Ca2+-sensitive network of quaternary interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-SKELETAL-MUSCLE; REGULATORY ALPHA-SUBUNIT; YEAST CALMODULIN; CROSS-LINKING; BETA-SUBUNITS; MOLECULAR-BASIS; TROPONIN-I; PROTEIN; ACTIVATION; PURIFICATION	Chemical cross-linking as a probe of conformation has consistently shown that activators, including Ca2+ ions, of the (alphabetagammadelta)(4) phosphorylase kinase holoenzyme (PhK) alter the interactions between its regulatory alpha and catalytic gamma subunits. The gamma subunit is also known to interact with the delta subunit, an endogenous molecule of calmodulin that mediates the activation of PhK by Ca2+ ions. In this study, we have used two-hybrid screening and chemical cross-linking to dissect the regulatory quaternary interactions involving these subunits. The yeast two-hybrid system indicated that regions near the C termini of the gamma (residues 343-386) and alpha (residues 10601237) subunits interact. The association of this region of a with gamma was corroborated by the isolation of a cross-linked fragment of alpha containing residues 1015-1237 from an alpha-gamma dimer that had been formed within the PhK holoenzyme by formaldehyde, a nearly zero-length cross-linker. Because the region of gamma that we found to interact with alpha has previously been shown to contain a high affinity binding site for calmodulin (Dasgupta, M., Honeycutt, T., and Blumenthal, D. K. (1989) J. Biol. Chem. 264,17156-17163), we tested the influence of Ca2+ on the conformation of the alpha subunit and found that the region of alpha that interacts with gamma was, in fact, perturbed by Ca2+. The results herein support the existence of a Ca2+-sensitive communication network among the delta, gamma, and alpha subunits, with the regulatory domain of gamma being the primary mediator. The similarity of such a Ca2+-dependent network to the interactions among troponin C, troponin I, and actin is discussed in light of the known structural and functional similarities between troponin I and the gamma subunit of PhK.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Carlson, GM (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, 503 Biol Sci Bldg,5100 Rockhill Rd, Kansas City, MO 64110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032953, R56DK032953] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32953] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSEMBEL FM, 1996, CURRENT PROTOCOLS MO; Ayers NA, 1998, BIOCHEM J, V331, P137, DOI 10.1042/bj3310137; Ayers NA, 1999, J BIOL CHEM, V274, P35583, DOI 10.1074/jbc.274.50.35583; BROSTROM CO, 1971, J BIOL CHEM, V246, P1961; Brushia Robert J., 1999, Frontiers in Bioscience, V4, pd618, DOI 10.2741/Brushia; CHAN KFJ, 1982, J BIOL CHEM, V257, P5956; CHAN KFJ, 1982, J BIOL CHEM, V257, P5948; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; COHEN P, 1980, EUR J BIOCHEM, V111, P563, DOI 10.1111/j.1432-1033.1980.tb04972.x; COX S, 1992, PROTEIN ENG, V5, P811, DOI 10.1093/protein/5.8.811; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P10274, DOI 10.1021/bi00106a027; FARRAR YJK, 1993, J BIOL CHEM, V268, P4120; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; GEITZ D, 1992, NUCLEIC ACIDS RES, V20, P1425; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARMANN B, 1991, J BIOL CHEM, V266, P15631; HARRIS WR, 1990, J BIOL CHEM, V265, P11740; HEILMEYER LMG, 1991, BIOCHIM BIOPHYS ACTA, V1094, P168, DOI 10.1016/0167-4889(91)90005-I; HERRERA JE, 1986, THESIS U MISSISSIPPI; JAMES P, 1991, J BIOL CHEM, V266, P7087; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KEE SM, 1986, J BIOL CHEM, V261, P4732; KILIMANN MW, 1988, P NATL ACAD SCI USA, V85, P9381, DOI 10.1073/pnas.85.24.9381; KING MM, 1981, J BIOL CHEM, V256, P1058; Kobayashi T, 2000, BIOCHEMISTRY-US, V39, P86, DOI 10.1021/bi991903b; LAW DJ, 1994, J CELL SCI, V107, P1477; LUAN Y, 1987, J BIOCHEM-TOKYO, V102, P1531, DOI 10.1093/oxfordjournals.jbchem.a122201; LUKAS TJ, 1994, BBA-MOL CELL RES, V1223, P341, DOI 10.1016/0167-4889(94)90093-0; MATSUURA I, 1993, J BIOL CHEM, V268, P13267; Miller J.H., 1972, EXPT MOL GENETICS; Nadeau OW, 1998, BIOCHEM BIOPH RES CO, V251, P637, DOI 10.1006/bbrc.1998.9507; Nadeau OW, 1997, J BIOL CHEM, V272, P26202, DOI 10.1074/jbc.272.42.26202; Nadeau OW, 2002, STRUCTURE, V10, P23, DOI 10.1016/S0969-2126(01)00678-5; Nadeau OW, 1997, J BIOL CHEM, V272, P26196, DOI 10.1074/jbc.272.42.26196; Nadeau OW, 1999, BIOCHEMISTRY-US, V38, P2551, DOI 10.1021/bi982060b; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PAUDEL HK, 1987, J BIOL CHEM, V262, P11912; PAUDEL HK, 1990, P NATL ACAD SCI USA, V87, P7285, DOI 10.1073/pnas.87.18.7285; Pickett-Gies CA., 1986, ENZYMES, V17, P395; PINE HK, 1980, ORGANIC CHEM, P86; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; Sambrook J., 2002, MOL CLONING LAB MANU; STAOVASNIK MA, 1993, BIOCHEMISTRY-US, V32, P2361; Traxler KW, 2001, J STRUCT BIOL, V135, P231, DOI 10.1006/jsbi.2001.4411; TREMPE MR, 1987, J BIOL CHEM, V262, P4333; Wilkinson DA, 1997, J MOL BIOL, V265, P319, DOI 10.1006/jmbi.1996.0739; WILKINSON DA, 1994, J MOL BIOL, V235, P974, DOI 10.1006/jmbi.1994.1051; WU FC, 1956, BIOCHIM BIOPHYS ACTA, V19, P110, DOI 10.1016/0006-3002(56)90391-2	52	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14681	14687		10.1074/jbc.M201229200	http://dx.doi.org/10.1074/jbc.M201229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11847235	hybrid			2022-12-25	WOS:000175203000043
J	Gunther, EJ; Belka, GK; Wertheim, GBW; Wang, J; Hartman, JL; Boxer, RB; Chodosh, LA				Gunther, EJ; Belka, GK; Wertheim, GBW; Wang, J; Hartman, JL; Boxer, RB; Chodosh, LA			A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology	FASEB JOURNAL			English	Article						transgenic mice; MMTV; transgene induction	BREAST-CANCER RISK; GENE-EXPRESSION; NEU ONCOGENE; TUMOR VIRUS; HA-RAS; MICE; TUMORIGENESIS; SINGLE; CELLS; TIME	Normal developmental events such as puberty, pregnancy, and parity influence the susceptibility of the mammary gland to tumorigenesis in both humans and rodent model systems. Unfortunately, constitutive transgenic mouse models that rely on mammary- specific promoters to control transgene expression have limited utility for studying the effect of developmental events on breast cancer risk since the hormonal signals governing these events also markedly influence transgene expression levels. A novel transgenic mouse system is described that uses the MMTV-LTR to drive expression of the reverse tetracycline-dependent transactivator rtTA. Transgenic mice expressing rtTA in the mammary epithelium were crossed with reporter lines bearing tet operator- controlled transgenes. We tested the ability to spatially, temporally, and quantitatively control reporter gene expression after administration of doxycycline to bi-transgenic mice. Transgene expression using this system can be rapidly induced and deinduced, is highly mammary specific, can be reproducibly titrated over a wide range of expression levels, and is essentially undetectable in the uninduced state. Homogeneous transgene expression throughout the mammary epithelium can be achieved. This system permits transgene expression to be restricted to any desired stage of postnatal mammary gland development. We have developed a mammary- specific, doxycycline- inducible transgenic mouse model for studying the effect of mammary gland development on transgene- mediated phenotypes. Unlike other mammary- specific, transgenic systems that have been described, this system combines spatially homogeneous transgene expression in the mammary epithelium during puberty, pregnancy, lactation, and involution with the use of an orally administered, inexpensive, and widely available inducing agent. This system offers new opportunities for the transgenic analysis of mammary gland biology in vivo.	Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Chodosh, LA (corresponding author), Univ Penn, Sch Med, Dept Canc Biol, 612 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	chodosh@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [P01CA077596, K08CA079682, R01CA092190, R01CA078410, P30CA016520, R01CA083849] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA77596, K08 CA79682, CA92190, CA83849, CA78410, CA16520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanese C, 2000, FASEB J, V14, P877, DOI 10.1096/fasebj.14.7.877; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Gardner HP, 2000, DEVELOPMENT, V127, P4493; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOULD MN, 1995, SEMIN CANCER BIOL, V6, P147, DOI 10.1006/scbi.1995.0023; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; Hennighausen L, 1999, NAT BIOTECHNOL, V17, P1062, DOI 10.1038/15046; HENNIGHAUSEN LG, 1982, EUR J BIOCHEM, V125, P131, DOI 10.1111/j.1432-1033.1982.tb06660.x; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; MARCHANT J, 1955, J PATHOL BACTERIOL, V70, P415, DOI 10.1002/path.1700700218; Medina D, 1999, J NATL CANCER I, V91, P967, DOI 10.1093/jnci/91.11.967; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUNOZ B, 1989, MOL CELL ENDOCRINOL, V62, P23, DOI 10.1016/0303-7207(89)90109-3; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; ROSS SR, 1990, MOL CELL BIOL, V10, P5822, DOI 10.1128/MCB.10.11.5822; Rossant J, 1999, GENE DEV, V13, P142, DOI 10.1101/gad.13.2.142; RUSSO J, 1990, LAB INVEST, V62, P244; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; Utomo ARH, 1999, NAT BIOTECHNOL, V17, P1091, DOI 10.1038/15073; VARLEY JM, 1987, ONCOGENE, V1, P423; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511	31	160	162	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2002	16	3							UNSP 0892-6638/02/0016-0283	10.1096/fj.01-0551com	http://dx.doi.org/10.1096/fj.01-0551com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	537JV	11874978				2022-12-25	WOS:000174755900021
J	Chano, T; Ikegawa, S; Kontani, K; Okabe, H; Baldini, N; Saeki, Y				Chano, T; Ikegawa, S; Kontani, K; Okabe, H; Baldini, N; Saeki, Y			Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells	ONCOGENE			English	Article						RB1CC1 (RB1-inducible coiled-coil 1); RB1 (retinoblastoma 1); MDR (multidrug resistance); neoplasm	P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; HUMAN OSTEOSARCOMA; EXPRESSION; CHILDHOOD; PROTEIN	Multidrug resistance to anti-cancer agents (MDR) is a major barrier to successful cancer treatment. Current knowledge about genes that contribute to MDR is limited, however, and its mechanisms remain unclear. To identify genes involved in MDR, we performed differential display analysis and isolated a novel human gene, RB1CC1 (RBI-inducible Coiled-Coil 1). The 6.6-kb RB1CC1 cDNA encodes a putative 1594-amino-acid protein that contains a nuclear localization signal, a leucine zipper motif and a coiled-coil structure. Western blot analysis and immunocytochemical staining with anti-RB1CC1 antibody showed that endogenously expressed RB1CC1 protein localized to the nucleus. In MDR variants of human osteosarcoma cells, RB1CC1 expression increased in response to doxorubicin-induced cytotoxic stress and remained elevated for the duration of drug treatment. RB1CC1 expression levels correlated closely with those of RB1 (retinoblastoma 1) in cancer cell lines as well as in various normal human tissues. Moreover, introduction of wild-type RB1CC1 significantly induced RB1 expression in human leukemic cells. These data suggest that RB1CC1 may be a key regulator of RB1 gene expression.	Shiga Univ Med Sci, Dept Basic Sci Hlth & Nursing, Otsu, Shiga 5202192, Japan; Shiga Univ Med Sci, Dept Clin Lab Med, Shiga 5202192, Japan; RIKEN, SNP Res Ctr, Lab Bone & Joint Dis, Tokyo 1088639, Japan; Rizzoli Inst, Lab Onc Res, I-40136 Bologna, Italy; Shiga Univ Med Sci, Dept Surg 2, Otsu, Shiga 5202192, Japan	Shiga University of Medical Science; Shiga University of Medical Science; RIKEN; Shiga University of Medical Science	Chano, T (corresponding author), Shiga Univ Med Sci, Dept Basic Sci Hlth & Nursing, Tsukinowa Cho, Otsu, Shiga 5202192, Japan.		Baldini, Nicola/J-4806-2016; Chano, Tokuhiro/F-5816-2018; Ikegawa, Shiro/N-6895-2015	Baldini, Nicola/0000-0003-2228-3833; Chano, Tokuhiro/0000-0002-9959-1183; Ikegawa, Shiro/0000-0003-0316-2147				Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; BIEDLER JL, 1994, CANCER METAST REV, V13, P191, DOI 10.1007/BF00689636; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; Chano T, 2000, OSTEOARTHR CARTILAGE, V8, P115, DOI 10.1053/joca.1999.0279; FERRACINI R, 1995, ONCOGENE, V10, P739; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; PINEDO HM, 1995, NEW ENGL J MED, V333, P1417, DOI 10.1056/NEJM199511233332111; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; Sauerbrey A, 1996, BRIT J HAEMATOL, V94, P99, DOI 10.1046/j.1365-2141.1996.d01-1753.x; Scotlandi K, 1996, CANCER RES, V56, P2434; Scotlandi K, 1999, ONCOGENE, V18, P739, DOI 10.1038/sj.onc.1202330; TANG A, 1989, ONCOGENE, V4, P401; TAYA Y, 1997, TIBS, V21, P14; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343	20	61	67	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1295	1298		10.1038/sj.onc.1205178	http://dx.doi.org/10.1038/sj.onc.1205178			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850849				2022-12-25	WOS:000173729400017
